WO2013151663A1

Modified polynucleotides for the production of membrane proteins

Abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides. More specifically, the disclosure provides compositions, methods, processes, kits and devices for the design, preparation, manufacture and/or formulation of modified mRNA (mmRNA) molecules from primary transcripts. Methods of using mmRNA for treating conditions or diseases are also disclosed.

WO2013151663A1, drawing sheet 1 — Sheet 1 of 359

Term

No projected expiry on record.

92 claims: 25 independent, 67 dependent

1
Claims We claim:1. An isolated polynucleotide comprising;(a) a first region of linked nucleosides, said first region encoding a polypeptide of interest, said polypeptide of interest selected from the group consisting of SEQ ID NOs 8144- 16131 ;(b) a first flanking region located at the 5' terminus of said first region comprising;(i) a sequence of linked nucleosides selected from the group consisting of the native 5' UTR of any of the nucleic acids that encode any of SEQ ID NOs 8144-16131, SEQ ID NOs: 1-4 and functional variants thereof;and (ii) at least one 5' terminal cap;(c) a second flanking region located at the 3' terminus of said first region comprising;(i') a sequence of linked nucleosides selected from the group consisting of the native 3' UTR of any of the nucleic acids that encode any of SEQ ID NOs 8144-16131, SEQ ID NOs 5-21 and functional variants thereof;and (ϋ') a 3' tailing sequence of linked nucleosides.
4
The isolated polynucleotide of any one of claims 1-3 which is purified.
5
The isolated polynucleotide of any one of claims 1-4, wherein the at least one 5' terminal cap is selected from the group consisting of CapO, Capl, ARC A, inosine, Nl- methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino- guanosine, LNA-guanosine, and 2-azido-guanosine.
6
The isolated polynucleotide of any preceding claim, wherein at least one of said linked nucleosides comprises at least one modification as compared to the chemical structure of an A, G, U or C ribonucleotide.
8
The isolated polynucleotide of any one of claims 1-7, wherein said first region comprises n number of linked nucleosides having Formula (la):), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein U is O, S, N(R u ) nu , or C(R u ) nu , wherein nu is an integer from 0 to 2 and each R u is, independently, H, halo, or optionally substituted alkyl;is a single or double bond;— is a single bond or absent;1 ' 2' 1 " 2" 3 4 5 each of R , R , R , R , R , R , and R is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, or absent;wherein the combination of R 3 with one or more of R^ R^ R^ R 2 ' , or R 5 can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl;wherein the combination of R 5 with one or more of R 1 , R 1 , R 2 , or R 2 can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl;and wherein the combination of R 4 and one or more of R 1 ' , R 1" , R 2' , R 2" , R 3 , or R 5 can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl;each of Y 1 , Y 2 , and Y 3 , is, independently, O, S, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent;each Y 4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;each Y 5 is, independently, O, S, optionally substituted alkylene, or optionally substituted heteroalkylene;n is an integer from 1 to 100,000;and B is a nucleobase, wherein the combination of B and R 1 , the combination of B and R 2 , the combination of B and R 1 , or the combination of B and R 2 can, taken together with the carbons to which they are attached, optionally form a bicyclic group or wherein the combination of B, R 1 , and R 3 or the combination of B, R 2 , and R 3 can optionally form a tricyclic or tetracyclic group.
10
The isolated polynucleotide of any one of claims 8-9, wherein U is O or C(R u ) nu , wherein nu is an integer from 1 to 2 and each R u is, independently, H, halo, or optionally substituted alkyl;each of R 1 , R 1 , R 1 , R 2 , R 2 , and R 2 , if present, is, independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, or optionally substituted aminoalkyl;each of R 3 and R 4 is, independently, H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxyalkoxy;each of Y 1 , Y 2 , and Y 3 , is, independently, O, S, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;each Y 4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, or optionally substituted amino;each Y 5 is, independently, O or optionally substituted alkylene;and n is an integer from 10 to 10,000.
23
The isolated polynucleotide of any one of claims 11-22, wherein U is O or C(R u ) nu , wherein nu is an integer from 1 to 2 and each R u is, independently, H, halo, or optionally substituted alkyl;each of R 1 and R 2 is, independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, or optionally substituted aminoalkyl;each of R 3 and R 4 is, independently, H or optionally substituted alkyl;each of Y 1 , Y 2 , and Y 3 , is, independently, O, S, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;each Y 4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, or optionally substituted amino;each Y 5 is, independently, O or optionally substituted alkylene;and n is an integer from 10 to 10,000.
25
The isolated polynucleotide of any one of claims 8-24, wherein in said n number of B has, each B independently has a formula selected from Formula (bl)-(b5):or "" T ™" (b5), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein ^ connecting V 1 and V 2 in formula (bl) is a single or double bond;each of T 1 , T 1 , T 2 , and T 2 is, independently, H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or the combination of T 1 and T 1 or the combination of T 2 and T 2 join together to form O (oxo), S (thio), or Se (seleno);each of V 1 and V 2 is, independently, O, S, N(R vb ) nv , or C(R vb ) nv , wherein nv is an integer from 0 to 2 and each R^ is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy;R 10 is H, halo, optionally substituted amino acid, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aminoalkyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl;R 11 is H or optionally substituted alkyl;R 12a is H, optionally substituted alkyl, or optionally substituted aminoalkyl;and R 12c is H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, or optionally substituted aminoalkyl.
26
The isolated polynucleotide of any one of claims 8-25, wherein n number of B has Formula (b6)-(b9):(b9), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein ^ is a single or double bond;each of T 1 , T 1 , T 2 , and T 2 is, independently, H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or the combination of T 1 and T 1 or the combination of T 2 and T 2 join together to form O (oxo), S (thio), or Se (seleno);each of W 1 and W 2 is, independently, N(R Wa ) nw or C(R Wa ) nw , wherein nw is an integer from 0 to 2 and each R Wa is, independently, H, optionally substituted alkyl, or optionally substituted alkoxy;each V 3 is, independently, O, S, N(R Va ) nv , or C(R Va ) nv , wherein nv is an integer from 0 to 2 and each R Va is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy, and wherein R Va and R 12c taken together with the carbon atoms to which they are attached can form optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heterocyclyl;R 12a is H, optionally substituted alkyl, optionally substituted aminoalkyl, or absent;R 12b is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkaryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, or optionally substituted amino acid, wherein the combination of R 12b and T 1 or the combination of R 12b and R 12c can join together to form optionally substituted heterocyclyl;and R 12c is H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, or optionally substituted aminoalkyl.
28
The isolated polynucleotide of any one of claims 8-27, wherein n number of B has Formula (bl0)-(bl4):acceptable salt or stereoisomer thereof, wherein each of T 3 and T 3 is, independently, H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or the combination of T 3 and T 3 join together to form O (oxo), S (thio), or Se (seleno);each V 4 is, independently, O, S, N(R Vc ) nv , or C(R Vc ) nv , wherein nv is an integer from 0 to 2 and each R Vc is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, or optionally substituted alkynyloxy, wherein the combination of R 13b and R Vc can be taken together to form optionally substituted heterocyclyl;each of R 13a and R 13b is, independently, H, optionally substituted acyl, optionally substituted alkyl, or optionally substituted alkoxy, wherein the combination of R 13b and R 14 can be taken together to form optionally substituted heterocyclyl;each R 14 is, independently, H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, or optionally substituted aminoalkyl;and each of R 15 and R 16 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.
29
The isolated polynucleotide of any one of claims 7-27, wherein n number of B has Formula (bl5)-(b 17):stereoisomer thereof, wherein each of T 4 , T 4 , T 5 , T 5 , T 6 , and T 6 is, independently, H, optionally substituted alkyl, or optionally substituted alkoxy, and wherein the combination of T 4 and T 4 or the combination of T 5 and T 5 or the combination of T 6 and T 6 together form O, S, or Se;each of V 5 and V 6 is, independently, O, S, N(R vd ) nv , or C(R vd ) nv , wherein nv is an integer from 0 to 2 and each R vd is, independently, H, halo, optionally substituted amino acid, cyano, amidine, optionally substituted aminoalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy;and each of R 17 , R 18 , R 19a , R 19b , R 21 , R 22 , R 23 , and R 24 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted amino acid.
30
The polynucleotide of any one of claims 8-29, wherein n number of B has Formula (bl8)-(b20):alt or stereoisomer thereof, wherein each V 7 is, independently, O, S, N(R Ve ) nv , or C(R Ve ) nv , wherein nv is an integer from 0 to 2 and each R Ve is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy;each R 25 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;each of R 26a and R 26b is, independently, H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, or optionally substituted alkoxy;each R 27 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, or optionally substituted amino;each R 28 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;and each R 29 is, independently, H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted alkoxy, or optionally substituted amino.
32
The isolated polynucleotide of any one of claims 8-31 , wherein n number of B has F rmula (b21):(b21), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 12 is, independently, O, S, optionally substituted alkylene, or optionally substituted heteroalkylene;xa is an integer from 0 to 3;R 12a is H, optionally substituted alkyl, optionally substituted aminoalkyl, or absent;and T 2 is O, S, or Se.
33
The isolated polynucleotide of any one of claims 8-32, wherein n number of B has Formul (b22), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10 is, independently, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted aminoalkyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl;R 11 is H or optionally substituted alkyl;R 12a is H, optionally substituted alkyl, optionally substituted aminoalkyl, or absent;and each of T 1 and T 2 is, independently, O, S, or Se.
34
The isolated polynucleotide of any one of claims 8-33, wherein n number of B has Formula (b23):(b23), wherein R is optionally substituted heterocyclyl or optionally substituted aryl;R 11 is H or optionally substituted alkyl;R 12a is H, optionally substituted alkyl, optionally substituted aminoalkyl, or absent;and each of T 1 and T 2 is, independently, O, S, or Se.
35
The isolated polynucleotide of any one of claims 8-34, wherein n number of B has Formula (b24):(b24), wherein T 3 is O, S, or Se;each of R 13a and R 13b is, independently, H, optionally substituted acyl, optionally substituted alkyl, or optionally substituted alkoxy, wherein the combination of R 13b and R 14 can be taken together to form optionally substituted heterocyclyl;R 14 is, independently, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted alkaryl, optionally substituted aminoalkyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl;and each R 15 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.
36
The isolated polynucleotide of any one of claims 1-35, further comprising a targeting moiety, wherein said targeting moiety is covalently bound to said polynucleotide.
38
A pharmaceutical composition comprising the isolated polynucleotide of any one of claims 1-37.
39
A pharmaceutical composition comprising the isolated polynucleotide of any one of claims 1-37 and a pharmaceutically acceptable excipient.
42
A method of producing a polypeptide of interest in a mammalian cell, tissue or organism comprising administering to said cell, tissue or organism the isolated polynucleotide of any one of claims 1-37 or the pharmaceutical composition of any of claims 38-41.
52
A method for producing an increased level of a polypeptide of interest selected from the group consisting of SEQ ID NOs 8144-16131in a mammalian cell, tissue or organism, comprising administering to said cell, tissue or organism a total daily dose of the isolated polynucleotide of any one of claims 4-37 or the pharmaceutical composition of any one of claims 38-41 in two or more equal or unequal split doses.
78
A method of preparing a lipid nanopartical formulation of a polynucleotide encoding a polypeptide of interest comprising rapidly injecting a first ethanolic solution into a second aqueous solution wherein, (a) said first ethanolic solution comprises a mixture of lipid:DSPC: Cholesterol: PEG-c-DOMG to yield a molar ratio of 50: 10:38.5: 1.5 and having a final lipid concentration of approximately 25mM, and (b) said second aqueous solution comprises a sodium citrate buffered solution of the polynucleotide encoding the polypeptide of interest having a concentration of 1-2 mg/mL and a pH of approximately 3, wherein the rapid injection results in a suspension containing 33% ethanol and a total lipid to polynucleotide weight ratio of at least 10: 1.
83
The method of any of claims 78-82, wherein the lipid is selected from the group consisting of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, CI 2-200, DLin- MC3-DMA, DODMA, DSDMA, DLenDMA, reLNPs, PLGA and PEGylated lipids.
84
The method of any of claims 78-83, wherein the polynucleotide is selected from the polynucleotide of any of claims 1-37.
85
A lipid nanopartical formulation of a polynucleotide encoding a polypeptide of interest produced by the method of any of claims 78-84 and having a particle size of 80 nm-160 nm, a PDI of between 0.02 and 0.20 and a lipid to polnucleotide ratio (wt/wt) of between 10-30.
87
A reLNP formulation of a polynucleotide said polynucleotide encoding a polypeptide of interest.
89
A sustained release formulation of a polynucleotide said polynucleotide encoding a polypeptide of interest.
91
A polynucleotide encoding a fusion protein said fusion protein comprising a first polypeptide and a second polypeptide.

Independent claims28

15,554 paragraphs in 713 sections, as filed

MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE

PROTEINS

REFERENCE TO SEQUENCE LISTING

0004[0001] The instant application contains a "lengthy" Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. This contains a sequence listing text file as part of the originally filed subject matter as follows: File name: M305.20-2030.1305PCT_SL.txt; File size: 129,495,040 Bytes; Date created: March 4, 2013. These CD-Rs are labeled "CRF," "Copy 1," and "Copy 2," respectively, and each contain only one identical file, as identified immediately above. The machine -readable format of each CD-R is IBM-PC and the operating system of each compact disc is MS-Windows.

0006[0002] This application claims priority to U.S. Provisional Patent Application No 61/681,742, filed, August 10, 2012, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, U.S. Provisional Patent Application No 61/737,224, filed December 14, 2012, entitled Terminally Optimized Modified RNAs, International Application No PCT/US2012/069610, filed December 14, 2012, entitled Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions, U.S. Provisional Patent Application No 61/618,862, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/681,645, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/737,130, filed December 14, 2012, entitled

0007Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/618,866, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/681,647, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/737,134, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/618,868, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/681,648, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/737,135, filed December 14, 2012, entitled

0008Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/618,870, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/681,649, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No

000961/737,139, filed December 14, 2012, Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/618,873, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S. Provisional Patent Application No 61/681,650, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S.

0010Provisional Patent Application No 61/737,147, filed December 14, 2012, entitled

0011Modified Polynucleotides for the Production of Secreted Proteins, U.S. Provisional Patent Application No 61/618,878, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, U.S. Provisional Patent Application No 61/681,654, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, U.S. Provisional Patent Application No 61/737,152, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, U.S. Provisional Patent Application No 61/618,885, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Cytoplasmic and

0012Cytoskeletal Proteins, U.S. Provisional Patent Application No 61/681,658, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, U.S. Provisional Patent Application No 61/737,155, filed

0013December 14, 2012, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, U.S. Provisional Patent Application No 61/618,896, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins, U.S. Provisional Patent Application No 61/668,157, filed July 5, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins, U.S. Provisional Patent Application No 61/681,661, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins, U.S. Provisional Patent Application No 61/737,160, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins, U.S. Provisional Patent Application No 61/618,911, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Nuclear Proteins, U.S. Provisional Patent Application No 61/681,667, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Nuclear Proteins, U.S. Provisional Patent Application No 61/737,168, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Nuclear Proteins, U.S. Provisional Patent Application No 61/618,922, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins, U.S. Provisional Patent Application No 61/681,675, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins, U.S. Provisional Patent Application No 61/737,174, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Proteins, U.S. Provisional Patent Application No 61/618,935, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/681,687, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/737,184, filed December 14, 2012, entitled

0014Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/618,945, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/681,696, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/737,191, filed December 14, 2012, entitled

0015Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/618,953, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/681,704, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/737,203, filed December 14, 2012, entitled

0016Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No 61/618,961, filed April 2, 2012, entitled Dosing Methods for Modified mRNA, U.S. Provisional Patent Application No 61/648,286, filed May 17, 2012, entitled Dosing Methods for Modified mRNA, the contents of each of which are herein incorporated by reference in its entirety.

0017[0003] This application is also related to International Publication No.

0018PCT/US2012/58519, filed October 3, 2012, entitled Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof and International Publication No.

0019PCT/US2012/69610, filed December 14, 2012, entitled Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions.

0020[0004] The instant application is also related to co-pending applications, each filed concurrently herewith on March 9, 2013 and having Attorney Docket Number M300.20, (PCT/US 13/XXXXX) entitled Modified Polynucleotides for the Production of Biologies and Proteins Associated with Human Disease; Attorney Docket Number M304.20 (PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of Secreted Proteins; Attorney Docket Number M301.20 (PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of Proteins; Attorney Docket Number M306.20 (PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of

0021Cytoplasmic and Cytoskeletal Proteins; Attorney Docket Number M308.20

0022(PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of Nuclear Proteins; Attorney Docket Number M309.20 (PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of Proteins; Attorney Docket Number M310.20 (PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease; Attorney Docket Number MNC1.20

0023(PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides and Attorney Docket Number MNC2.20 (PCT/US 13/XXXXX), entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, the contents of each of which are herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

0025[0005] The invention relates to compositions, methods, processes, kits and devices for the design, preparation, manufacture and/or formulation of polynucleotides, primary constructs and modified mRNA molecules (mmRNA). BACKGROUND OF THE INVENTION

0026[0006] There are multiple problems with prior methodologies of effecting protein expression. For example, introduced DNA can integrate into host cell genomic DNA at some frequency, resulting in alterations and/or damage to the host cell genomic DNA. Alternatively, the heterologous deoxyribonucleic acid (DNA) introduced into a cell can be inherited by daughter cells (whether or not the heterologous DNA has integrated into the chromosome) or by offspring.

0027[0007] In addition, assuming proper delivery and no damage or integration into the host genome, there are multiple steps which must occur before the encoded protein is made. Once inside the cell, DNA must be transported into the nucleus where it is transcribed into RNA. The RNA transcribed from DNA must then enter the cytoplasm where it is translated into protein. Not only do the multiple processing steps from administered DNA to protein create lag times before the generation of the functional protein, each step represents an opportunity for error and damage to the cell. Further, it is known to be difficult to obtain DNA expression in cells as DNA frequently enters a cell but is not expressed or not expressed at reasonable rates or concentrations. This can be a particular problem when DNA is introduced into primary cells or modified cell lines.

0028[0008] In the early 1990's Bloom and colleagues successfully rescued vasopressin- deficient rats by injecting in vitro-transcribed vasopressin mRNA into the hypothalamus (Science 255: 996-998; 1992). However, the low levels of translation and the immunogenicity of the molecules hampered the development of mRNA as a therapeutic and efforts have since focused on alternative applications that could instead exploit these pitfalls, i.e. immunization with mRNAs coding for cancer antigens.

0029[0009] Others have investigated the use of mRNA to deliver a polypeptide of interest and shown that certain chemical modifications of mRNA molecules, particularly pseudouridine and 5-methyl-cytosine, have reduced immunostimulatory effect.

0030[00010] These studies are disclosed in, for example, Ribostem Limited in United Kingdom patent application serial number 0316089.2 filed on July 9, 2003 now abandoned, PCT application number PCT/GB2004/002981 filed on July 9, 2004 published as WO2005005622, United States patent application national phase entry serial number 10/563,897 filed on June 8, 2006 published as US20060247195 now abandoned, and European patent application national phase entry serial number EP2004743322 filed on July 9, 2004 published as EP 1646714 now withdrawn; Novozymes, Inc. in PCT application number PCT/US2007/88060 filed on December 19, 2007 published as WO2008140615, United States patent application national phase entry serial number 12/520,072 filed on July 2, 2009 published as US20100028943 and European patent application national phase entry serial number EP2007874376 filed on July 7, 2009 published as EP2104739; University of Rochester in PCT application number

0031PCT/US2006/46120 filed on December 4, 2006 published as WO2007064952 and United States patent application serial number 11/606,995 filed on December 1, 2006 published as US20070141030; BioNTech AG in European patent application serial number EP2007024312 filed December 14, 2007 now abandoned, PCT application number PCT/EP2008/01059 filed on December 12, 2008 published as WO2009077134, European patent application national phase entry serial number EP2008861423 filed on June 2, 2010 published as EP2240572, United States patent application national phase entry serial number 12/,735,060 filed November 24, 2010 published as US20110065103, German patent application serial number DE 10 2005 046 490 filed September 28, 2005, PCT application PCT/EP2006/0448 filed September 28, 2006 published as

0032WO2007036366, national phase European patent EP1934345 published March, 21, 2012 and national phase US patent application serial number 11/992,638 filed August 14, 2009 published as 20100129877; Immune Disease Institute Inc. in United States patent application serial number 13/088,009 filed April 15, 2011 published as US20120046346 and PCT application PCT/US2011/32679 filed April 15, 2011 published as

0033WO20110130624; Shire Human Genetic Therapeutics in United States patent application serial number 12/957,340 filed on November 20, 2010 published as US20110244026; Sequitur Inc. in PCT application PCT/US 1998/019492 filed on September 18, 1998 published as WO 1999014346; The Scripps Research Institute in PCT application number PCT/US2010/00567 filed on February 24, 2010 published as WO2010098861, and United States patent application national phase entry serial number 13/203,229 filed November 3, 2011 published as US20120053333; Ludwig-Maximillians University in PCT application number PCT/EP2010/004681 filed on July 30, 2010 published as WO2011012316; Cellscript Inc. in United States patent number 8,039,214 filed June 30, 2008 and granted October 18, 2011, United States patent application serial numbers 12/962,498 filed on December 7, 2010 published as US20110143436, 12/962,468 filed on December 7, 2010 published as US20110143397, 13/237,451 filed on September 20, 2011 published as US20120009649, and PCT applications PCT/US2010/59305 filed December 7, 2010 published as WO2011071931 and PCT/US2010/59317 filed on December 7, 2010 published as WO2011071936; The Trustees of the University of Pennsylvania in PCT application number PCT/US2006/32372 filed on August 21, 2006 published as WO2007024708, and United States patent application national phase entry serial number 11/990,646 filed on March 27, 2009 published as US20090286852;

0034Curevac GMBH in German patent application serial numbers DE10 2001 027 283.9 filed June 5, 2001, DE10 2001 062 480.8 filed December 19, 2001, and DE 20 2006 051 516 filed October 31, 2006 all abandoned, European patent numbers EP 1392341 granted March 30, 2005 and EP1458410 granted January 2, 2008, PCT application numbers PCT/EP2002/06180 filed June 5, 2002 published as WO2002098443,

0035PCT/EP2002/14577 filed on December 19, 2002 published as WO2003051401,

0036PCT/EP2007/09469 filed on December 31, 2007 published as WO2008052770,

0037PCT/EP2008/03033 filed on April 16, 2008 published as WO2009127230,

0038PCT/EP2006/004784 filed on May 19, 2005 published as WO2006122828,

0039PCT/EP2008/00081 filed on January 9, 2007 published as WO2008083949, and United States patent application serial numbers 10/729,830 filed on December 5, 2003 published as US20050032730, 10/870,110 filed on June 18, 2004 published as US20050059624, 11/914,945 filed on July 7, 2008 published as US20080267873, 12/446,912 filed on October 27, 2009 published as US2010047261 now abandoned, 12/522,214 filed on January 4, 2010 published as US20100189729, 12/787,566 filed on May 26, 2010 published as US20110077287, 12/787,755 filed on May 26, 2010 published as

0040US20100239608, 13/185,119 filed on July 18, 2011 published as US20110269950, and 13/106,548 filed on May 12, 2011 published as US20110311472 all of which are herein incorporated by reference in their entirety.

0041[00011] Notwithstanding these reports which are limited to a selection of chemical modifications including pseudouridine and 5-methyl-cytosine, there remains a need in the art for therapeutic modalities to address the myriad of barriers surrounding the efficacious modulation of intracellular translation and processing of nucleic acids encoding polypeptides or fragments thereof.

0042[00012] To this end, the inventors have shown that certain modified mRNA sequences have the potential as therapeutics with benefits beyond just evading, avoiding or diminishing the immune response. Such studies are detailed in published co-pending applications International Application PCT/US2011/046861 filed August 5, 2011 and PCT/US2011/054636 filed October 3, 2011, International Application number

0043PCT/US2011/054617 filed October 3, 2011, the contents of which are incorporated herein by reference in their entirety.

0044[00013] The present invention addresses this need by providing nucleic acid based compounds or polynucleotides which encode a polypeptide of interest (e.g., modified mRNA or mmRNA) and which have structural and/or chemical features that avoid one or more of the problems in the art, for example, features which are useful for optimizing formulation and delivery of nucleic acid-based therapeutics while retaining structural and functional integrity, overcoming the threshold of expression, improving expression rates, half life and/or protein concentrations, optimizing protein localization, and avoiding deleterious bio-responses such as the immune response and/or degradation pathways.

SUMMARY OF THE INVENTION

0046[00014] Described herein are compositions, methods, processes, kits and devices for the design, preparation, manufacture and/or formulation of modified mRNA (mmRNA) molecules.

0047[00015] The details of various embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and the drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

0049[00016] The foregoing and other objects, features and advantages will be apparent from the following description of particular embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of various embodiments of the invention. [00017] FIG. 1 is a schematic of a primary construct of the present invention.

0050[00018] FIG. 2 illustrates lipid structures in the prior art useful in the present invention. Shown are the structures for 98N12-5 (TETA5-LAP), DLin-DMA, DLin-K- DMA (2,2-Dilinoleyl-4-dimethylaminomethyl-[ 1 ,3]-dioxolane), DLin-KC2-DMA, DLin-MC3-DMA and C12-200.

0051[00019] FIG. 3 is a representative plasmid useful in the IVT reactions taught herein. The plasmid contains Insert 64818, designed by the instant inventors.

0052[00020] FIG. 4 is a gel profile of modified mRNA encapsulated in PLGA

0053microspheres.

0054[00021] FIG. 5 is a histogram of Factor IX protein production PLGA formulation Factor IX modified mRNA.

0055[00022] FIG. 6 is a histogram showing VEGF protein production in human keratinocyte cells after transfection of modified mRNA at a range of doses. Figure 6 A shows protein production after transfection of modified mRNA comprising natural nucleoside triphosphate (NTP). Figure 6B shows protein production after transfection of modified mRNA fully modified with pseudouridine (Pseudo-U) and 5-methylcytosine (5mC). Figure 6C shows protein production after transfection of modified mRNA fully modified with Nl-methyl-pseudouridine (Nl-methyl-Pseudo-U) and 5-methylcytosine (5mC).

0056[00023] FIG. 7 is a histogram of VEGF protein production in HEK293 cells.

0057[00024] FIG. 8 is a histogram of VEGF expression and IFN-alpha induction after transfection of VEGF modified mRNA in peripheral blood mononuclear cells (PBMC). Figure 8A shows VEGF expression. Figure 8B shows IFN-alpha induction.

0058[00025] FIG. 9 is a histogram of VEGF protein production in HeLa cells from VEGF modified mRNA.

0059[00026] FIG. 10 is a histogram of VEGF protein production from lipoplexed VEGF modified mRNA in mice.

0060[00027] FIG. 11 is a histogram of G-CSF protein production in HeLa cells from G- CSF modified mRNA.

0061[00028] FIG. 12 is a histogram of Factor IX protein production in HeLa cell supernatant from Factor IX modified mRNA. DETAILED DESCRIPTION

0062[00029] It is of great interest in the fields of therapeutics, diagnostics, reagents and for biological assays to be able to deliver a nucleic acid, e.g., a ribonucleic acid (RNA) inside a cell, whether in vitro, in vivo, in situ or ex vivo, such as to cause intracellular translation of the nucleic acid and production of an encoded polypeptide of interest. Of particular importance is the delivery and function of a non-integrative polynucleotide.

0063[00030] Described herein are compositions (including pharmaceutical compositions) and methods for the design, preparation, manufacture and/or formulation of

0064polynucleotides encoding one or more polypeptides of interest. Also provided are systems, processes, devices and kits for the selection, design and/or utilization of the polynucleotides encoding the polypeptides of interest described herein.

0065[00031] According to the present invention, these polynucleotides are preferably modified as to avoid the deficiencies of other polypeptide-encoding molecules of the art. Hence these polynucleotides are referred to as modified mRNA or mmRNA.

0066[00032] The use of modified polynucleotides in the fields of antibodies, viruses, veterinary applications and a variety of in vivo settings has been explored by the inventors and these studies are disclosed in for example, co-pending and co-owned United States provisional patent application serial numbers 61/470,451 filed March 31, 2011 teaching in vivo applications of mmRNA; 61/517,784 filed on April 26, 2011 teaching engineered nucleic acids for the production of antibody polypeptides;

006761/519,158 filed May 17, 2011 teaching veterinary applications of mmRNA technology; 61/533, 537 filed on September 12, 2011 teaching antimicrobial applications of mmRNA technology; 61/533,554 filed on September 12, 2011 teaching viral applications of mmRNA technology, 61/542,533 filed on October 3, 2011 teaching various chemical modifications for use in mmRNA technology; 61/570,690 filed on December 14, 2011 teaching mobile devices for use in making or using mmRNA technology; 61/570,708 filed on December 14, 2011 teaching the use of mmRNA in acute care situations;

006861/576,651 filed on December 16, 2011 teaching terminal modification architecture for mmRNA; 61/576,705 filed on December 16, 2011 teaching delivery methods using lipidoids for mmRNA; 61/578,271 filed on December 21, 2011 teaching methods to increase the viability of organs or tissues using mmRNA; 61/581,322 filed on December 29, 2011 teaching mmRNA encoding cell penetrating peptides; 61/581,352 filed on December 29, 2011 teaching the incorporation of cytotoxic nucleosides in mmRNA and 61/631,729 filed on January 10, 2012 teaching methods of using mmRNA for crossing the blood brain barrier; all of which are herein incorporated by reference in their entirety.

0069[00033] Provided herein, in part, are polynucleotides, primary constructs and/or mmRNA encoding polypeptides of interest which have been designed to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency (when applicable), accessibility to circulation, protein half-life and/or modulation of a cell's status, function and/or activity.

0070I. Compositions of the Invention (mmRNA)

0071[00034] The present invention provides nucleic acid molecules, specifically polynucleotides, primary constructs and/or mmRNA which encode one or more polypeptides of interest. The term "nucleic acid," in its broadest sense, includes any compound and/or substance that comprise a polymer of nucleotides. These polymers are often referred to as polynucleotides. Exemplary nucleic acids or polynucleotides of the invention include, but are not limited to, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a β- D-ribo configuration, a-LNA having an a-L-ribo configuration (a diastereomer of LNA), 2'- amino-LNA having a 2'-amino functionalization, and 2'-amino- a-LNA having a 2'- amino functionalization) or hybrids thereof.

0072[00035] In preferred embodiments, the nucleic acid molecule is a messenger RNA (mRNA). As used herein, the term "messenger RNA" (mRNA) refers to any

0073polynucleotide which encodes a polypeptide of interest and which is capable of being translated to produce the encoded polypeptide of interest in vitro, in vivo, in situ or ex vivo.

0074[00036] Traditionally, the basic components of an mRNA molecule include at least a coding region, a 5'UTR, a 3'UTR, a 5' cap and a poly-A tail. Building on this wild type modular structure, the present invention expands the scope of functionality of traditional mR A molecules by providing polynucleotides or primary RNA constructs which maintain a modular organization, but which comprise one or more structural and/or chemical modifications or alterations which impart useful properties to the

0075polynucleotide including, in some embodiments, the lack of a substantial induction of the innate immune response of a cell into which the polynucleotide is introduced. As such, modified mRNA molecules of the present invention are termed "mmRNA." As used herein, a "structural" feature or modification is one in which two or more linked nucleotides are inserted, deleted, duplicated, inverted or randomized in a polynucleotide, primary construct or mmRNA without significant chemical modification to the nucleotides themselves. Because chemical bonds will necessarily be broken and reformed to effect a structural modification, structural modifications are of a chemical nature and hence are chemical modifications. However, structural modifications will result in a different sequence of nucleotides. For example, the polynucleotide "ATCG" may be chemically modified to "AT-5meC-G". The same polynucleotide may be structurally modified from "ATCG" to "ATCCCG". Here, the dinucleotide "CC" has been inserted, resulting in a structural modification to the polynucleotide.

0076mmRNA Architecture

0077[00037] The mmRNA of the present invention are distinguished from wild type mRNA in their functional and/or structural design features which serve to, as evidenced herein, overcome existing problems of effective polypeptide production using nucleic acid-based therapeutics.

0078[00038] Figure 1 shows a representative polynucleotide primary construct 100 of the present invention. As used herein, the term "primary construct" or "primary mRNA construct" refers to a polynucleotide transcript which encodes one or more polypeptides of interest and which retains sufficient structural and/or chemical features to allow the polypeptide of interest encoded therein to be translated. Primary constructs may be polynucleotides of the invention. When structurally or chemically modified, the primary construct may be referred to as an mmRNA.

0079[00039] Returning to FIG. 1, the primary construct 100 here contains a first region of linked nucleotides 102 that is flanked by a first flanking region 104 and a second flaking region 106. As used herein, the "first region" may be referred to as a "coding region" or "region encoding" or simply the "first region." This first region may include, but is not limited to, the encoded polypeptide of interest. The polypeptide of interest may comprise at its 5' terminus one or more signal sequences encoded by a signal sequence region 103. The flanking region 104 may comprise a region of linked nucleotides comprising one or more complete or incomplete 5' UTRs sequences. The flanking region 104 may also comprise a 5' terminal cap 108. The second flanking region 106 may comprise a region of linked nucleotides comprising one or more complete or incomplete 3' UTRs. The flanking region 106 may also comprise a 3' tailing sequence 110.

0080[00040] Bridging the 5' terminus of the first region 102 and the first flanking region 104 is a first operational region 105. Traditionally this operational region comprises a Start codon. The operational region may alternatively comprise any translation initiation sequence or signal including a Start codon.

0081[00041] Bridging the 3' terminus of the first region 102 and the second flanking region 106 is a second operational region 107. Traditionally this operational region comprises a Stop codon. The operational region may alternatively comprise any translation initiation sequence or signal including a Stop codon. According to the present invention, multiple serial stop codons may also be used.

0082[00042] Generally, the shortest length of the first region of the primary construct of the present invention can be the length of a nucleic acid sequence that is sufficient to encode for a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, a hexapeptide, a heptapeptide, an octapeptide, a nonapeptide, or a decapeptide. In another embodiment, the length may be sufficient to encode a peptide of 2-30 amino acids, e.g. 5-30, 10-30, 2-25, 5-25, 10-25, or 10-20 amino acids. The length may be sufficient to encode for a peptide of at least 11, 12, 13, 14, 15, 17, 20, 25 or 30 amino acids, or a peptide that is no longer than 40 amino acids, e.g. no longer than 35, 30, 25, 20, 17, 15, 14, 13, 12, 11 or 10 amino acids.

0083Examples of dipeptides that the polynucleotide sequences can encode or include, but are not limited to, carnosine and anserine.

0084[00043] Generally, the length of the first region encoding the polypeptide of interest of the present invention is greater than about 30 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, and 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000 or up to and including 100,000 nucleotides). As used herein, the "first region" may be referred to as a "coding region" or "region encoding" or simply the "first region."

0085[00044] In some embodiments, the polynucleotide, primary construct, or mmRNA includes from about 30 to about 100,000 nucleotides (e.g., from 30 to 50, from 30 to 100, from 30 to 250, from 30 to 500, from 30 to 1,000, from 30 to 1,500, from 30 to 3,000, from 30 to 5,000, from 30 to 7,000, from 30 to 10,000, from 30 to 25,000, from 30 to 50,000, from 30 to 70,000, from 100 to 250, from 100 to 500, from 100 to 1,000, from 100 to 1,500, from 100 to 3,000, from 100 to 5,000, from 100 to 7,000, from 100 to 10,000, from 100 to 25,000, from 100 to 50,000, from 100 to 70,000, from 100 to 100,000, from 500 to 1,000, from 500 to 1,500, from 500 to 2,000, from 500 to 3,000, from 500 to 5,000, from 500 to 7,000, from 500 to 10,000, from 500 to 25,000, from 500 to 50,000, from 500 to 70,000, from 500 to 100,000, from 1,000 to 1,500, from 1,000 to 2,000, from 1,000 to 3,000, from 1,000 to 5,000, from 1,000 to 7,000, from 1,000 to 10,000, from 1 ,000 to 25,000, from 1,000 to 50,000, from 1,000 to 70,000, from 1,000 to 100,000, from 1,500 to 3,000, from 1,500 to 5,000, from 1,500 to 7,000, from 1,500 to 10,000, from 1 ,500 to 25,000, from 1,500 to 50,000, from 1,500 to 70,000, from 1,500 to 100,000, from 2,000 to 3,000, from 2,000 to 5,000, from 2,000 to 7,000, from 2,000 to 10,000, from 2,000 to 25,000, from 2,000 to 50,000, from 2,000 to 70,000, and from 2,000 to 100,000).

0086[00045] According to the present invention, the first and second flanking regions may range independently from 15-1,000 nucleotides in length (e.g., greater than 30, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, and 900 nucleotides or at least 30, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, and 1,000 nucleotides).

0087[00046] According to the present invention, the tailing sequence may range from absent to 500 nucleotides in length (e.g., at least 60, 70, 80, 90, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 nucleotides). Where the tailing region is a polyA tail, the length may be determined in units of or as a function of polyA Binding Protein binding. In this embodiment, the polyA tail is long enough to bind at least 4 monomers of PolyA Binding Protein. PolyA Binding Protein monomers bind to stretches of approximately 38 nucleotides. As such, it has been observed that polyA tails of about 80 nucleotides and 160 nucleotides are functional.

0088[00047] According to the present invention, the capping region may comprise a single cap or a series of nucleotides forming the cap. In this embodiment the capping region may be from 1 to 10, e.g. 2-9, 3-8, 4-7, 1-5, 5-10, or at least 2, or 10 or fewer nucleotides in length. In some embodiments, the cap is absent.

0089[00048] According to the present invention, the first and second operational regions may range from 3 to 40, e.g., 5-30, 10-20, 15, or at least 4, or 30 or fewer nucleotides in length and may comprise, in addition to a Start and/or Stop codon, one or more signal and/or restriction sequences.

0090Cyclic mmRNA

0091[00049] According to the present invention, a primary construct or mmRNA may be cyclized, or concatemerized, to generate a translation competent molecule to assist interactions between poly-A binding proteins and 5 '-end binding proteins. The mechanism of cyclization or concatemerization may occur through at least 3 different routes: 1) chemical, 2) enzymatic, and 3) ribozyme catalyzed. The newly formed 5'-/3'- linkage may be intramolecular or intermolecular.

0092[00050] In the first route, the 5'-end and the 3'-end of the nucleic acid contain chemically reactive groups that, when close together, form a new covalent linkage between the 5 '-end and the 3 '-end of the molecule. The 5 '-end may contain an NHS-ester reactive group and the 3 '-end may contain a 3'-amino-terminated nucleotide such that in an organic solvent the 3'-amino-terminated nucleotide on the 3 '-end of a synthetic mRNA molecule will undergo a nucleophilic attack on the 5 '-NHS-ester moiety forming a new 5 '-/3 '-amide bond.

0093[00051] In the second route, T4 RNA ligase may be used to enzymatically link a 5'- phosphorylated nucleic acid molecule to the 3'-hydroxyl group of a nucleic acid forming a new phosphorodiester linkage. In an example reaction, ^g of a nucleic acid molecule is incubated at 37°C for 1 hour with 1-10 units of T4 RNA ligase (New England Biolabs, Ipswich, MA) according to the manufacturer's protocol. The ligation reaction may occur in the presence of a split oligonucleotide capable of base-pairing with both the 5'- and 3'- region in juxtaposition to assist the enzymatic ligation reaction.

0094[00052] In the third route, either the 5 '-or 3 '-end of the cDNA template encodes a ligase ribozyme sequence such that during in vitro transcription, the resultant nucleic acid molecule can contain an active ribozyme sequence capable of ligating the 5 '-end of a nucleic acid molecule to the 3 '-end of a nucleic acid molecule. The ligase ribozyme may be derived from the Group I Intron, Group I Intron, Hepatitis Delta Virus, Hairpin ribozyme or may be selected by SELEX (systematic evolution of ligands by exponential enrichment). The ribozyme ligase reaction may take 1 to 24 hours at temperatures between 0 and 37°C.

0095mmRNA Multimers

0096[00053] According to the present invention, multiple distinct polynucleotides, primary constructs or mmRNA may be linked together through the 3 '-end using nucleotides which are modified at the 3 '-terminus. Chemical conjugation may be used to control the stoichiometry of delivery into cells. For example, the glyoxylate cycle enzymes, isocitrate lyase and malate synthase, may be supplied into HepG2 cells at a 1 : 1 ratio to alter cellular fatty acid metabolism. This ratio may be controlled by chemically linking polynucleotides, primary constructs or mmRNA using a 3'-azido terminated nucleotide on one polynucleotide, primary construct or mmRNA species and a C5-ethynyl or alkynyl-containing nucleotide on the opposite polynucleotide, primary construct or mmRNA species. The modified nucleotide is added post-transcriptionally using terminal transferase (New England Biolabs, Ipswich, MA) according to the manufacturer's protocol. After the addition of the 3 '-modified nucleotide, the two polynucleotide, primary construct or mmRNA species may be combined in an aqueous solution, in the presence or absence of copper, to form a new covalent linkage via a click chemistry mechanism as described in the literature.

0097[00054] In another example, more than two polynucleotides may be linked together using a functionalized linker molecule. For example, a functionalized saccharide molecule may be chemically modified to contain multiple chemical reactive groups (SH-, NH2-, N3, etc...) to react with the cognate moiety on a 3 '-functionalized mRNA molecule (i.e., a 3'-maleimide ester, 3'-NHS-ester, alkynyl). The number of reactive groups on the modified saccharide can be controlled in a stoichiometric fashion to directly control the stoichiometric ratio of conjugated polynucleotide, primary construct or mmRNA.

0098mmRNA Conjugates and Combinations

0099[00055] In order to further enhance protein production, primary constructs or mmRNA of the present invention can be designed to be conjugated to other polynucleotides, dyes, intercalating agents {e.g. acridines), cross-linkers {e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons {e.g., phenazine, dihydrophenazine), artificial endonucleases {e.g. EDTA), alkylating agents, phosphate, amino, mercapto, PEG {e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens {e.g. biotin),

0100transport/absorption facilitators {e.g., aspirin, vitamin E, folic acid), synthetic

0101ribonucleases, proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell, hormones and hormone receptors, non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, or a drug.

0102[00056] Conjugation may result in increased stability and/or half life and may be particularly useful in targeting the polynucleotides, primary constructs or mmRNA to specific sites in the cell, tissue or organism.

0103[00057] According to the present invention, the mmRNA or primary constructs may be administered with, or further encode one or more of RNAi agents, siRNAs, shRNAs, miRNAs, miRNA binding sites, antisense RNAs, ribozymes, catalytic DNA, tRNA, RNAs that induce triple helix formation, aptamers or vectors, and the like.

0104Bifunctional mmRNA

0105[00058] In one embodiment of the invention are bifunctional polynucleotides (e.g., bifunctional primary constructs or bifunctional mmRNA). As the name implies, bifunctional polynucleotides are those having or capable of at least two functions. These molecules may also by convention be referred to as multi-functional.

0106[00059] The multiple functionalities of bifunctional polynucleotides may be encoded by the RNA (the function may not manifest until the encoded product is translated) or may be a property of the polynucleotide itself. It may be structural or chemical.

0107Bifunctional modified polynucleotides may comprise a function that is covalently or electrostatically associated with the polynucleotides. Further, the two functions may be provided in the context of a complex of a mmR A and another molecule.

0108[00060] Bifunctional polynucleotides may encode peptides which are antiproliferative. These peptides may be linear, cyclic, constrained or random coil. They may function as aptamers, signaling molecules, ligands or mimics or mimetics thereof. Anti-proliferative peptides may, as translated, be from 3 to 50 amino acids in length. They may be 5-40, 10-30, or approximately 15 amino acids long. They may be single chain, multichain or branched and may form complexes, aggregates or any multi-unit structure once translated.

0109Noncoding polynucleotides and primary constructs

0110[00061] As described herein, provided are polynucleotides and primary constructs having sequences that are partially or substantially not translatable, e.g., having a noncoding region. Such noncoding region may be the "first region" of the primary construct. Alternatively, the noncoding region may be a region other than the first region. Such molecules are generally not translated, but can exert an effect on protein production by one or more of binding to and sequestering one or more translational machinery components such as a ribosomal protein or a transfer R A (tRNA), thereby effectively reducing protein expression in the cell or modulating one or more pathways or cascades in a cell which in turn alters protein levels. The polynucleotide or primary construct may contain or encode one or more long noncoding RNA (IncRNA, or lincRNA) or portion thereof, a small nucleolar RNA (sno-RNA), micro RNA (miRNA), small interfering RNA (siRNA) or Piwi-interacting RNA (piRNA).

0111Polypeptides of interest

0112[00062] According to the present invention, the primary construct is designed to encode one or more polypeptides of interest or fragments thereof. A polypeptide of interest may include, but is not limited to, whole polypeptides, a plurality of polypeptides or fragments of polypeptides, which independently may be encoded by one or more nucleic acids, a plurality of nucleic acids, fragments of nucleic acids or variants of any of the aforementioned. As used herein, the term "polypeptides of interest" refer to any polypeptide which is selected to be encoded in the primary construct of the present invention. As used herein, "polypeptide" means a polymer of amino acid residues (natural or unnatural) linked together most often by peptide bonds. The term, as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function. In some instances the polypeptide encoded is smaller than about 50 amino acids and the polypeptide is then termed a peptide. If the polypeptide is a peptide, it will be at least about 2, 3, 4, or at least 5 amino acid residues long. Thus, polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing. A polypeptide may be a single molecule or may be a multi-molecular complex such as a dimer, trimer or tetramer. They may also comprise single chain or multichain

0113polypeptides such as antibodies or insulin and may be associated or linked. Most commonly disulfide linkages are found in multichain polypeptides. The term polypeptide may also apply to amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid.

0114[00063] The term "polypeptide variant" refers to molecules which differ in their amino acid sequence from a native or reference sequence. The amino acid sequence variants may possess substitutions, deletions, and/or insertions at certain positions within the amino acid sequence, as compared to a native or reference sequence. Ordinarily, variants will possess at least about 50% identity (homology) to a native or reference sequence, and preferably, they will be at least about 80%, more preferably at least about 90% identical (homologous) to a native or reference sequence.

0115[00064] In some embodiments "variant mimics" are provided. As used herein, the term "variant mimic" is one which contains one or more amino acids which would mimic an activated sequence. For example, glutamate may serve as a mimic for phosphoro- threonine and/or phosphoro-serine. Alternatively, variant mimics may result in deactivation or in an inactivated product containing the mimic, e.g., phenylalanine may act as an inactivating substitution for tyrosine; or alanine may act as an inactivating substitution for serine.

0116[00065] "Homology" as it applies to amino acid sequences is defined as the percentage of residues in the candidate amino acid sequence that are identical with the residues in the amino acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Methods and computer programs for the alignment are well known in the art. It is understood that homology depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation.

0117[00066] By "homologs" as it applies to polypeptide sequences means the

0118corresponding sequence of other species having substantial identity to a second sequence of a second species.

0119[00067] "Analogs" is meant to include polypeptide variants which differ by one or more amino acid alterations, e.g., substitutions, additions or deletions of amino acid residues that still maintain one or more of the properties of the parent or starting polypeptide.

0120[00068] The present invention contemplates several types of compositions which are polypeptide based including variants and derivatives. These include substitutional, insertional, deletion and covalent variants and derivatives. The term "derivative" is used synonymously with the term "variant" but generally refers to a molecule that has been modified and/or changed in any way relative to a reference molecule or starting molecule.

0121[00069] As such, mmR A encoding polypeptides containing substitutions, insertions and/or additions, deletions and covalent modifications with respect to reference sequences, in particular the polypeptide sequences disclosed herein, are included within the scope of this invention. For example, sequence tags or amino acids, such as one or more lysines, can be added to the peptide sequences of the invention (e.g., at the N- terminal or C-terminal ends). Sequence tags can be used for peptide purification or localization. Lysines can be used to increase peptide solubility or to allow for

0122biotinylation. Alternatively, amino acid residues located at the carboxy and amino terminal regions of the amino acid sequence of a peptide or protein may optionally be deleted providing for truncated sequences. Certain amino acids (e.g., C-terminal or N- terminal residues) may alternatively be deleted depending on the use of the sequence, as for example, expression of the sequence as part of a larger sequence which is soluble, or linked to a solid support.

0123[00070] "Substitutional variants" when referring to polypeptides are those that have at least one amino acid residue in a native or starting sequence removed and a different amino acid inserted in its place at the same position. The substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more amino acids have been substituted in the same molecule.

0124[00071] As used herein the term "conservative amino acid substitution" refers to the substitution of an amino acid that is normally present in the sequence with a different amino acid of similar size, charge, or polarity. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as isoleucine, valine and leucine for another non-polar residue. Likewise, examples of conservative substitutions include the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, and between glycine and serine. Additionally, the substitution of a basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue such as aspartic acid or glutamic acid for another acidic residue are additional examples of conservative substitutions. Examples of non-conservative substitutions include the substitution of a non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine, alanine, methionine for a polar (hydrophilic) residue such as cysteine, glutamine, glutamic acid or lysine and/or a polar residue for a non-polar residue.

0125[00072] "Insertional variants" when referring to polypeptides are those with one or more amino acids inserted immediately adjacent to an amino acid at a particular position in a native or starting sequence. "Immediately adjacent" to an amino acid means connected to either the alpha-carboxy or alpha-amino functional group of the amino acid.

0126[00073] "Deletional variants" when referring to polypeptides are those with one or more amino acids in the native or starting amino acid sequence removed. Ordinarily, deletional variants will have one or more amino acids deleted in a particular region of the molecule.

0127[00074] "Covalent derivatives" when referring to polypeptides include modifications of a native or starting protein with an organic proteinaceous or non-proteinaceous derivatizing agent, and/or post-translational modifications. Covalent modifications are traditionally introduced by reacting targeted amino acid residues of the protein with an organic derivatizing agent that is capable of reacting with selected side-chains or terminal residues, or by harnessing mechanisms of post-translational modifications that function in selected recombinant host cells. The resultant covalent derivatives are useful in programs directed at identifying residues important for biological activity, for immunoassays, or for the preparation of anti-protein antibodies for immunoaffinity purification of the recombinant glycoprotein. Such modifications are within the ordinary skill in the art and are performed without undue experimentation.

0128[00075] Certain post-translational modifications are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues may be present in the polypeptides produced in accordance with the present invention.

0129[00076] Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains (T. E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)).

0130[00077] "Features" when referring to polypeptides are defined as distinct amino acid sequence-based components of a molecule. Features of the polypeptides encoded by the mmRNA of the present invention include surface manifestations, local conformational shape, folds, loops, half-loops, domains, half-domains, sites, termini or any combination thereof.

0131[00078] As used herein when referring to polypeptides the term "surface

0132manifestation" refers to a polypeptide based component of a protein appearing on an outermost surface.

0133[00079] As used herein when referring to polypeptides the term "local conformational shape" means a polypeptide based structural manifestation of a protein which is located within a definable space of the protein.

0134[00080] As used herein when referring to polypeptides the term "fold" refers to the resultant conformation of an amino acid sequence upon energy minimization. A fold may occur at the secondary or tertiary level of the folding process. Examples of secondary level folds include beta sheets and alpha helices. Examples of tertiary folds include domains and regions formed due to aggregation or separation of energetic forces.

0135Regions formed in this way include hydrophobic and hydrophilic pockets, and the like.

0136[00081] As used herein the term "turn" as it relates to protein conformation means a bend which alters the direction of the backbone of a peptide or polypeptide and may involve one, two, three or more amino acid residues.

0137[00082] As used herein when referring to polypeptides the term "loop" refers to a structural feature of a polypeptide which may serve to reverse the direction of the backbone of a peptide or polypeptide. Where the loop is found in a polypeptide and only alters the direction of the backbone, it may comprise four or more amino acid residues. Oliva et al. have identified at least 5 classes of protein loops (J. Mol Biol 266 (4): 814- 830; 1997). Loops may be open or closed. Closed loops or "cyclic" loops may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids between the bridging moieties. Such bridging moieties may comprise a cysteine-cysteine bridge (Cys-Cys) typical in polypeptides having disulfide bridges or alternatively bridging moieties may be non-protein based such as the dibromozylyl agents used herein.

0138[00083] As used herein when referring to polypeptides the term "half-loop" refers to a portion of an identified loop having at least half the number of amino acid resides as the loop from which it is derived. It is understood that loops may not always contain an even number of amino acid residues. Therefore, in those cases where a loop contains or is identified to comprise an odd number of amino acids, a half-loop of the odd-numbered loop will comprise the whole number portion or next whole number portion of the loop (number of amino acids of the loop/2+/-0.5 amino acids). For example, a loop identified as a 7 amino acid loop could produce half-loops of 3 amino acids or 4 amino acids (7/2=3.5+/-0.5 being 3 or 4).

0139[00084] As used herein when referring to polypeptides the term "domain" refers to a motif of a polypeptide having one or more identifiable structural or functional characteristics or properties (e.g., binding capacity, serving as a site for protein-protein interactions).

0140[00085] As used herein when referring to polypeptides the term "half-domain" means a portion of an identified domain having at least half the number of amino acid resides as the domain from which it is derived. It is understood that domains may not always contain an even number of amino acid residues. Therefore, in those cases where a domain contains or is identified to comprise an odd number of amino acids, a half-domain of the odd-numbered domain will comprise the whole number portion or next whole number portion of the domain (number of amino acids of the domain/2+/-0.5 amino acids). For example, a domain identified as a 7 amino acid domain could produce half-domains of 3 amino acids or 4 amino acids (7/2=3.5+/-0.5 being 3 or 4). It is also understood that sub- domains may be identified within domains or half-domains, these subdomains possessing less than all of the structural or functional properties identified in the domains or half domains from which they were derived. It is also understood that the amino acids that comprise any of the domain types herein need not be contiguous along the backbone of the polypeptide (i.e., nonadjacent amino acids may fold structurally to produce a domain, half-domain or subdomain).

0141[00086] As used herein when referring to polypeptides the terms "site" as it pertains to amino acid based embodiments is used synonymously with "amino acid residue" and "amino acid side chain." A site represents a position within a peptide or polypeptide that may be modified, manipulated, altered, derivatized or varied within the polypeptide based molecules of the present invention.

0142[00087] As used herein the terms "termini" or "terminus" when referring to polypeptides refers to an extremity of a peptide or polypeptide. Such extremity is not limited only to the first or final site of the peptide or polypeptide but may include additional amino acids in the terminal regions. The polypeptide based molecules of the present invention may be characterized as having both an N-terminus (terminated by an amino acid with a free amino group (NH2)) and a C -terminus (terminated by an amino acid with a free carboxyl group (COOH)). Proteins of the invention are in some cases made up of multiple polypeptide chains brought together by disulfide bonds or by non- covalent forces (multimers, oligomers). These sorts of proteins will have multiple N- and C-termini. Alternatively, the termini of the polypeptides may be modified such that they begin or end, as the case may be, with a non-polypeptide based moiety such as an organic conjugate.

0143[00088] Once any of the features have been identified or defined as a desired component of a polypeptide to be encoded by the primary construct or mmR A of the invention, any of several manipulations and/or modifications of these features may be performed by moving, swapping, inverting, deleting, randomizing or duplicating.

0144Furthermore, it is understood that manipulation of features may result in the same outcome as a modification to the molecules of the invention. For example, a manipulation which involved deleting a domain would result in the alteration of the length of a molecule just as modification of a nucleic acid to encode less than a full length molecule would.

0145[00089] Modifications and manipulations can be accomplished by methods known in the art such as, but not limited to, site directed mutagenesis. The resulting modified molecules may then be tested for activity using in vitro or in vivo assays such as those described herein or any other suitable screening assay known in the art.

0146[00090] According to the present invention, the polypeptides may comprise a consensus sequence which is discovered through rounds of experimentation. As used herein a "consensus" sequence is a single sequence which represents a collective population of sequences allowing for variability at one or more sites.

0147[00091] As recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered to be within the scope of polypeptides of interest of this invention. For example, provided herein is any protein fragment (meaning a polypeptide sequence at least one amino acid residue shorter than a reference polypeptide sequence but otherwise identical) of a reference protein 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or greater than 100 amino acids in length. In another example, any protein that includes a stretch of about 20, about 30, about 40, about 50, or about 100 amino acids which are about 40%, about 50%>, about 60%>, about 70%>, about 80%>, about 90%), about 95%o, or about 100% identical to any of the sequences described herein can be utilized in accordance with the invention. In certain embodiments, a polypeptide to be utilized in accordance with the invention includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations as shown in any of the sequences provided or referenced herein.

0148Encoded Polypeptides

0149[00092] The primary constructs or mmRNA of the present invention may be designed to encode polypeptides of interest selected from any of several target categories including, but not limited to, biologies, antibodies, vaccines, therapeutic proteins or peptides, cell penetrating peptides, secreted proteins, plasma membrane proteins, cytoplasmic or cytoskeletal proteins, intracellular membrane bound proteins, nuclear proteins, proteins associated with human disease, targeting moieties or those proteins encoded by the human genome for which no therapeutic indication has been identified but which nonetheless have utility in areas of research and discovery.

0150[00093] In one embodiment primary constructs or mmRNA may encode variant polypeptides which have a certain identity with a reference polypeptide sequence. As used herein, a "reference polypeptide sequence" refers to a starting polypeptide sequence. Reference sequences may be wild type sequences or any sequence to which reference is made in the design of another sequence. A "reference polypeptide sequence" may, e.g., be any one of SEQ ID NOs: 8144-16131 as disclosed herein, e.g., any of SEQ ID NOs

0151<img file="WO2013151663A1_D0001.tif" />8424, 8425, 8426, 8427, 8428, 8429, 8430 8431, 8432, 8433, 8434, 8435, 8436, 8437

01528438, 8439, 8440, 8441, 8442, 8443, 8444 8445, 8446, 8447, 8448, 8449, 8450, 8451

01538452, 8453, 8454, 8455, 8456, 8457, 8458 8459, 8460, 8461, 8462, 8463, 8464, 8465

01548466, 8467, 8468, 8469, 8470, 8471, 8472 8473, 8474, 8475, 8476, 8477, 8478, 8479

01558480, 8481, 8482, 8483, 8484, 8485, 8486 8487, 8488, 8489, 8490, 8491, 8492, 8493

01568494, 8495, 8496, 8497, 8498, 8499, 8500 8501, 8502, 8503, 8504, 8505, 8506, 8507

01578508, 8509, 8510, 8511, 8512, 8513, 8514 8515, 8516, 8517, 8518, 8519, 8520, 8521

01588522, 8523, 8524, 8525, 8526, 8527, 8528 8529, 8530, 8531, 8532, 8533, 8534, 8535

01598536, 8537, 8538, 8539, 8540, 8541, 8542 8543, 8544, 8545, 8546, 8547, 8548, 8549

01608550, 8551, 8552, 8553, 8554, 8555, 8556 8557, 8558, 8559, 8560, 8561, 8562, 8563

01618564, 8565, 8566, 8567, 8568, 8569, 8570 8571, 8572, 8573, 8574, 8575, 8576, 8577

01628578, 8579, 8580, 8581, 8582, 8583, 8584 8585, 8586, 8587, 8588, 8589, 8590, 8591

01638592, 8593, 8594, 8595, 8596, 8597, 8598 8599, 8600, 8601, 8602, 8603, 8604, 8605

01648606, 8607, 8608, 8609, 8610, 8611, 8612 8613, 8614, 8615, 8616, 8617, 8618, 8619

01658620, 8621, 8622, 8623, 8624, 8625, 8626 8627, 8628, 8629, 8630, 8631, 8632, 8633

01668634, 8635, 8636, 8637, 8638, 8639, 8640 8641, 8642, 8643, 8644, 8645, 8646, 8647

01678648, 8649, 8650, 8651, 8652, 8653, 8654 8655, 8656, 8657, 8658, 8659, 8660, 8661

01688662, 8663, 8664, 8665, 8666, 8667, 8668 8669, 8670, 8671, 8672, 8673, 8674, 8675

01698676, 8677, 8678, 8679, 8680, 8681, 8682 8683, 8684, 8685, 8686, 8687, 8688, 8689

01708690, 8691, 8692, 8693, 8694, 8695, 8696 8697, 8698, 8699, 8700, 8701, 8702, 8703

01718704, 8705, 8706, 8707, 8708, 8709, 8710 8711, 8712, 8713, 8714, 8715, 8716, 8717

01728718, 8719, 8720, 8721, 8722, 8723, 8724 8725, 8726, 8727, 8728, 8729, 8730, 8731

01738732, 8733, 8734, 8735, 8736, 8737, 8738 8739, 8740, 8741, 8742, 8743, 8744, 8745

01748746, 8747, 8748, 8749, 8750, 8751, 8752 8753, 8754, 8755, 8756, 8757, 8758, 8759

01758760, 8761, 8762, 8763, 8764, 8765, 8766 8767, 8768, 8769, 8770, 8771, 8772, 8773

01768774, 8775, 8776, 8777, 8778, 8779, 8780 8781, 8782, 8783, 8784, 8785, 8786, 8787

01778788, 8789, 8790, 8791, 8792, 8793, 8794 8795, 8796, 8797, 8798, 8799, 8800, 8801

01788802, 8803, 8804, 8805, 8806, 8807, 8808 8809, 8810, 8811, 8812, 8813, 8814, 8815

01798816, 8817, 8818, 8819, 8820, 8821, 8822 8823, 8824, 8825, 8826, 8827, 8828, 8829

01808830, 8831, 8832, 8833, 8834, 8835, 8836 8837, 8838, 8839, 8840, 8841, 8842, 8843

01818844, 8845, 8846, 8847, 8848, 8849, 8850 8851, 8852, 8853, 8854, 8855, 8856, 8857 8858, 8859, 8860, 8861, 8862, 8863, 8864 8865, 8866, 8867, 8868, 8869, 8870, 8871

01828872, 8873, 8874, 8875, 8876, 8877, 8878 8879, 8880, 8881, 8882, 8883, 8884, 8885

01838886, 8887, 8888, 8889, 8890, 8891, 8892 8893, 8894, 8895, 8896, 8897, 8898, 8899

01848900, 8901, 8902, 8903, 8904, 8905, 8906 8907, 8908, 8909, 8910, 8911, 8912, 8913

01858914, 8915, 8916, 8917, 8918, 8919, 8920 8921, 8922, 8923, 8924, 8925, 8926, 8927

01868928, 8929, 8930, 8931, 8932, 8933, 8934 8935, 8936, 8937, 8938, 8939, 8940, 8941

01878942, 8943, 8944, 8945, 8946, 8947, 8948 8949, 8950, 8951, 8952, 8953, 8954, 8955

01888956, 8957, 8958, 8959, 8960, 8961, 8962 8963, 8964, 8965, 8966, 8967, 8968, 8969

01898970, 8971, 8972, 8973, 8974, 8975, 8976 8977, 8978, 8979, 8980, 8981, 8982, 8983

01908984, 8985, 8986, 8987, 8988, 8989, 8990 8991, 8992, 8993, 8994, 8995, 8996, 8997

01918998, 8999, 9000, 9001, 9002, 9003, 9004 9005, 9006, 9007, 9008, 9009, 9010, 9011

01929012, 9013, 9014, 9015, 9016, 9017, 9018 9019, 9020, 9021, 9022, 9023, 9024, 9025

01939026, 9027, 9028, 9029, 9030, 9031, 9032 9033, 9034, 9035, 9036, 9037, 9038, 9039

01949040, 9041, 9042, 9043, 9044, 9045, 9046 9047, 9048, 9049, 9050, 9051, 9052, 9053

01959054, 9055, 9056, 9057, 9058, 9059, 9060 9061, 9062, 9063, 9064, 9065, 9066, 9067

01969068, 9069, 9070, 9071, 9072, 9073, 9074 9075, 9076, 9077, 9078, 9079, 9080, 9081

01979082, 9083, 9084, 9085, 9086, 9087, 9088 9089, 9090, 9091, 9092, 9093, 9094, 9095

01989096, 9097, 9098, 9099, 9100, 9101, 9102 9103, 9104, 9105, 9106, 9107, 9108, 9109

01999110, 9111, 9112, 9113, 9114, 9115, 9116 9117, 9118, 9119, 9120, 9121, 9122, 9123

02009124, 9125, 9126, 9127, 9128, 9129, 9130 9131, 9132, 9133, 9134, 9135, 9136, 9137

02019138, 9139, 9140, 9141, 9142, 9143, 9144 9145, 9146, 9147, 9148, 9149, 9150, 9151

02029152, 9153, 9154, 9155, 9156, 9157, 9158 9159, 9160, 9161, 9162, 9163, 9164, 9165

02039166, 9167, 9168, 9169, 9170, 9171, 9172 9173, 9174, 9175, 9176, 9177, 9178, 9179

02049180, 9181, 9182, 9183, 9184, 9185, 9186 9187, 9188, 9189, 9190, 9191, 9192, 9193

02059194, 9195, 9196, 9197, 9198, 9199, 9200 9201, 9202, 9203, 9204, 9205, 9206, 9207

02069208, 9209, 9210, 9211, 9212, 9213, 9214 9215, 9216, 9217, 9218, 9219, 9220, 9221

02079222, 9223, 9224, 9225, 9226, 9227, 9228 9229, 9230, 9231, 9232, 9233, 9234, 9235

02089236, 9237, 9238, 9239, 9240, 9241, 9242 9243, 9244, 9245, 9246, 9247, 9248, 9249

02099250, 9251, 9252, 9253, 9254, 9255, 9256 9257, 9258, 9259, 9260, 9261, 9262, 9263

02109264, 9265, 9266, 9267, 9268, 9269, 9270 9271, 9272, 9273, 9274, 9275, 9276, 9277

02119278, 9279, 9280, 9281, 9282, 9283, 9284 9285, 9286, 9287, 9288, 9289, 9290, 9291 9292, 9293, 9294, 9295, 9296, 9297, 9298, 9299, 9300, 9301, 9302, 9303, 9304, 9305,

02129306, 9307, 9308, 9309, 9310, 9311, 9312, 9313, 9314, 9315, 9316, 9317, 9318, 9319,

02139320, 9321, 9322, 9323, 9324, 9325, 9326, 9327, 9328, 9329, 9330, 9331, 9332, 9333,

02149334, 9335, 9336, 9337, 9338, 9339, 9340, 9341, 9342, 9343, 9344, 9345, 9346, 9347,

02159348, 9349, 9350, 9351, 9352, 9353, 9354, 9355, 9356, 9357, 9358, 9359, 9360, 9361,

02169362, 9363, 9364, 9365, 9366, 9367, 9368, 9369, 9370, 9371, 9372, 9373, 9374, 9375,

02179376, 9377, 9378, 9379, 9380, 9381, 9382, 9383, 9384, 9385, 9386, 9387, 9388, 9389,

02189390, 9391, 9392, 9393, 9394, 9395, 9396, 9397, 9398, 9399, 9400, 9401, 9402, 9403,

02199404, 9405, 9406, 9407, 9408, 9409, 9410, 9411, 9412, 9413, 9414, 9415, 9416, 9417,

02209418, 9419, 9420, 9421, 9422, 9423, 9424, 9425, 9426, 9427, 9428, 9429, 9430, 9431,

02219432, 9433, 9434, 9435, 9436, 9437, 9438, 9439, 9440, 9441, 9442, 9443, 9444, 9445,

02229446, 9447, 9448, 9449, 9450, 9451, 9452, 9453, 9454, 9455, 9456, 9457, 9458, 9459,

02239460, 9461, 9462, 9463, 9464, 9465, 9466, 9467, 9468, 9469, 9470, 9471, 9472, 9473,

02249474, 9475, 9476, 9477, 9478, 9479, 9480, 9481, 9482, 9483, 9484, 9485, 9486, 9487,

02259488, 9489, 9490, 9491, 9492, 9493, 9494, 9495, 9496, 9497, 9498, 9499, 9500, 9501,

02269502, 9503, 9504, 9505, 9506, 9507, 9508, 9509, 9510, 9511, 9512, 9513, 9514, 9515,

02279516, 9517, 9518, 9519, 9520, 9521, 9522, 9523, 9524, 9525, 9526, 9527, 9528, 9529,

02289530, 9531, 9532, 9533, 9534, 9535, 9536, 9537, 9538, 9539, 9540, 9541, 9542, 9543,

02299544, 9545, 9546, 9547, 9548, 9549, 9550, 9551, 9552, 9553, 9554, 9555, 9556, 9557,

02309558, 9559, 9560, 9561, 9562, 9563, 9564, 9565, 9566, 9567, 9568, 9569, 9570, 9571,

02319572, 9573, 9574, 9575, 9576, 9577, 9578, 9579, 9580, 9581, 9582, 9583, 9584, 9585,

02329586, 9587, 9588, 9589, 9590, 9591, 9592, 9593, 9594, 9595, 9596, 9597, 9598, 9599,

02339600, 9601, 9602, 9603, 9604, 9605, 9606, 9607, 9608, 9609, 9610, 9611, 9612, 9613,

02349614, 9615, 9616, 9617, 9618, 9619, 9620, 9621, 9622, 9623, 9624, 9625, 9626, 9627,

02359628, 9629, 9630, 9631, 9632, 9633, 9634, 9635, 9636, 9637, 9638, 9639, 9640, 9641,

02369642, 9643, 9644, 9645, 9646, 9647, 9648, 9649, 9650, 9651, 9652, 9653, 9654, 9655,

02379656, 9657, 9658, 9659, 9660, 9661, 9662, 9663, 9664, 9665, 9666, 9667, 9668, 9669,

02389670, 9671, 9672, 9673, 9674, 9675, 9676, 9677, 9678, 9679, 9680, 9681, 9682, 9683,

02399684, 9685, 9686, 9687, 9688, 9689, 9690, 9691, 9692, 9693, 9694, 9695, 9696, 9697,

02409698, 9699, 9700, 9701, 9702, 9703, 9704, 9705, 9706, 9707, 9708, 9709, 9710, 9711,

02419712, 9713, 9714, 9715, 9716, 9717, 9718, 9719, 9720, 9721, 9722, 9723, 9724, 9725, 9726 9727 9728 9729 9730 9731 9732 9733 9734, 9735, 9736, 9737 9738, 9739, 9740 9741 9742 9743 9744 9745 9746 9747 9748, 9749, 9750, 9751 9752 9753, 9754 9755 9756 9757 9758 9759 9760 9761 9762, 9763, 9764, 9765 9766 9767, 9768 9769 9770 9771 9772 9773 9774 9775 9776, 9777, 9778, 9779 9780 9781, 9782 9783 9784 9785 9786 9787 9788 9789 9790, 9791, 9792, 9793 9794 9795, 9796 9797 9798 9799 9800 9801 9802 9803 9804, 9805, 9806, 9807 9808 9809, 9810 9811 9812 9813 9814 9815 9816 9817 9818, 9819, 9820, 9821 9822 9823, 9824 9825 9826 9827 9828 9829 9830 9831 9832, 9833, 9834, 9835 9836 9837, 9838 9839 9840 9841 9842 9843 9844 9845 9846, 9847, 9848, 9849 9850 9851, 9852 9853 9854 9855 9856 9857 9858 9859 9860, 9861, 9862, 9863 9864 9865, 9866 9867 9868 9869 9870 9871 9872 9873 9874, 9875, 9876, 9877 9878 9879, 9880 9881 9882 9883 9884 9885 9886 9887 9888, 9889, 9890, 9891 9892 9893, 9894 9895 9896 9897 9898 9899 9900 9901 9902, 9903, 9904, 9905 9906 9907, 9908 9909 9910 9911 9912 9913 9914 9915 9916, 9917, 9918, 9919 9920 9921, 9922 9923 9924 9925 9926 9927 9928 9929 9930, 9931, 9932, 9933 9934 9935, 9936 9937 9938 9939 9940 9941 9942 9943 9944, 9945, 9946, 9947 9948 9949, 9950 9951 9952 9953 9954 9955 9956 9957 9958, 9959, 9960, 9961 9962 9963, 9964 9965 9966 9967 9968 9969 9970 9971 9972, 9973, 9974, 9975 9976 9977, 9978 9979 9980 9981 9982 9983 9984 9985 9986, 9987, 9988, 9989 9990 9991, 9992 9993 9994 9995 9996 9997 9998 9999 10000, 10001, 10002 10003 10004,

024210005, 10006, 10007, 10008, 10009 10010, 10011, 10012, 10013, 10014 10015, 10016, 10017, 10018, 10019, 10020, 10021 10022, 10023, 10024, 10025, 10026 10027, 10028, 10029, 10030, 10031, 10032, 10033 10034, 10035, 10036, 10037, 10038 10039, 10040, 10041, 10042, 10043, 10044, 10045 10046, 10047, 10048, 10049, 10050 10051, 10052, 10053, 10054, 10055, 10056, 10057 10058, 10059, 10060, 10061, 10062 10063, 10064, 10065, 10066, 10067, 10068, 10069 10070, 10071, 10072, 10073, 10074 10075, 10076, 10077, 10078, 10079, 10080, 10081 10082, 10083, 10084, 10085, 10086 10087, 10088, 10089, 10090, 10091, 10092, 10093 10094, 10095, 10096, 10097, 10098 10099, 10100, 10101, 10102, 10103, 10104, 10105 10106, 10107, 10108, 10109, 10110 10111, 10112, 10113, 10114, 10115, 10116, 10117 10118, 10119, 10120, 10121, 10122 10123, 10124, 10125, 10126, 10127, 10128, 10129 10130, 10131, 10132, 10133, 10134 10135, 10136, 10137, 10138, 10139 10140, 10141, 10142, 10143, 10144, 10145 10146, 10147, 10148,

024310149, 10150, 10151 10152, 10153, 10154, 10155, 10156, 10157 10158, 10159, 10160,

024410161, 10162, 10163 10164, 10165, 10166, 10167, 10168, 10169 10170, 10171, 10172,

024510173, 10174, 10175 10176, 10177, 10178, 10179, 10180, 10181 10182, 10183, 10184,

024610185, 10186, 10187 10188, 10189, 10190, 10191, 10192, 10193 10194, 10195, 10196,

024710197, 10198, 10199 10200, 10201, 10202, 10203, 10204, 10205 10206, 10207, 10208,

024810209, 10210, 10211 10212, 10213, 10214, 10215, 10216, 10217 10218, 10219, 10220,

024910221, 10222, 10223 10224, 10225, 10226, 10227, 10228, 10229 10230, 10231, 10232,

025010233, 10234, 10235 10236, 10237, 10238, 10239, 10240, 10241 10242, 10243, 10244,

025110245, 10246, 10247 10248, 10249, 10250, 10251, 10252, 10253 10254, 10255, 10256,

025210257, 10258, 10259 10260, 10261, 10262, 10263, 10264, 10265 10266, 10267, 10268,

025310269, 10270, 10271 10272, 10273, 10274, 10275, 10276, 10277 10278, 10279, 10280,

025410281, 10282, 10283 10284, 10285, 10286, 10287, 10288, 10289 10290, 10291, 10292,

025510293, 10294, 10295 10296, 10297, 10298, 10299, 10300, 10301 10302, 10303, 10304,

025610305, 10306, 10307 10308, 10309, 10310, 10311, 10312, 10313 10314, 10315, 10316,

025710317, 10318, 10319 10320, 10321, 10322, 10323, 10324, 10325 10326, 10327, 10328,

025810329, 10330, 10331 10332, 10333, 10334, 10335, 10336, 10337 10338, 10339, 10340,

025910341, 10342, 10343 10344, 10345, 10346, 10347, 10348, 10349 10350, 10351, 10352,

026010353, 10354, 10355 10356, 10357, 10358, 10359, 10360, 10361 10362, 10363, 10364,

026110365, 10366, 10367 10368, 10369, 10370, 10371, 10372, 10373 10374, 10375, 10376,

026210377, 10378, 10379 10380, 10381, 10382, 10383, 10384, 10385 10386, 10387, 10388,

026310389, 10390, 10391 10392, 10393, 10394, 10395, 10396, 10397 10398, 10399, 10400,

026410401, 10402, 10403 10404, 10405, 10406, 10407, 10408, 10409 10410, 10411, 10412,

026510413, 10414, 10415 10416, 10417, 10418, 10419, 10420, 10421 10422, 10423, 10424,

026610425, 10426, 10427 10428, 10429, 10430, 10431, 10432, 10433 10434, 10435, 10436,

026710437, 10438, 10439 10440, 10441, 10442, 10443, 10444, 10445 10446, 10447, 10448,

026810449, 10450, 10451 10452, 10453, 10454, 10455, 10456, 10457 10458, 10459, 10460,

026910461, 10462, 10463 10464, 10465, 10466, 10467, 10468, 10469 10470, 10471, 10472,

027010473, 10474, 10475 10476, 10477, 10478, 10479, 10480, 10481 10482, 10483, 10484,

027110485, 10486, 10487 10488, 10489, 10490, 10491, 10492, 10493 10494, 10495, 10496,

027210497, 10498, 10499 10500, 10501, 10502, 10503, 10504, 10505 10506, 10507, 10508, 10509, 10510, 10511 10512, 10513, 10514, 10515, 10516, 10517 10518, 10519, 10520,

027310521, 10522, 10523 10524, 10525, 10526, 10527, 10528, 10529 10530, 10531, 10532,

027410533, 10534, 10535 10536, 10537, 10538, 10539, 10540, 10541 10542, 10543, 10544,

027510545, 10546, 10547 10548, 10549, 10550, 10551, 10552, 10553 10554, 10555, 10556,

027610557, 10558, 10559 10560, 10561, 10562, 10563, 10564, 10565 10566, 10567, 10568,

027710569, 10570, 10571 10572, 10573, 10574, 10575, 10576, 10577 10578, 10579, 10580,

027810581, 10582, 10583 10584, 10585, 10586, 10587, 10588, 10589 10590, 10591, 10592,

027910593, 10594, 10595 10596, 10597, 10598, 10599, 10600, 10601 10602, 10603, 10604,

028010605, 10606, 10607 10608, 10609, 10610, 10611, 10612, 10613 10614, 10615, 10616,

028110617, 10618, 10619 10620, 10621, 10622, 10623, 10624, 10625 10626, 10627, 10628,

028210629, 10630, 10631 10632, 10633, 10634, 10635, 10636, 10637 10638, 10639, 10640,

028310641, 10642, 10643 10644, 10645, 10646, 10647, 10648, 10649 10650, 10651, 10652,

028410653, 10654, 10655 10656, 10657, 10658, 10659, 10660, 10661 10662, 10663, 10664,

028510665, 10666, 10667 10668, 10669, 10670, 10671, 10672, 10673 10674, 10675, 10676,

028610677, 10678, 10679 10680, 10681, 10682, 10683, 10684, 10685 10686, 10687, 10688,

028710689, 10690, 10691 10692, 10693, 10694, 10695, 10696, 10697 10698, 10699, 10700,

028810701, 10702, 10703 10704, 10705, 10706, 10707, 10708, 10709 10710, 10711, 10712,

028910713, 10714, 10715 10716, 10717, 10718, 10719, 10720, 10721 10722, 10723, 10724,

029010725, 10726, 10727 10728, 10729, 10730, 10731, 10732, 10733 10734, 10735, 10736,

029110737, 10738, 10739 10740, 10741, 10742, 10743, 10744, 10745 10746, 10747, 10748,

029210749, 10750, 10751 10752, 10753, 10754, 10755, 10756, 10757 10758, 10759, 10760,

029310761, 10762, 10763 10764, 10765, 10766, 10767, 10768, 10769 10770, 10771, 10772,

029410773, 10774, 10775 10776, 10777, 10778, 10779, 10780, 10781 10782, 10783, 10784,

029510785, 10786, 10787 10788, 10789, 10790, 10791, 10792, 10793 10794, 10795, 10796,

029610797, 10798, 10799 10800, 10801, 10802, 10803, 10804, 10805 10806, 10807, 10808,

029710809, 10810, 10811 10812, 10813, 10814, 10815, 10816, 10817 10818, 10819, 10820,

029810821, 10822, 10823 10824, 10825, 10826, 10827, 10828, 10829 10830, 10831, 10832,

029910833, 10834, 10835 10836, 10837, 10838, 10839, 10840, 10841 10842, 10843, 10844,

030010845, 10846, 10847 10848, 10849, 10850, 10851, 10852, 10853 10854, 10855, 10856,

030110857, 10858, 10859 10860, 10861, 10862, 10863, 10864, 10865 10866, 10867, 10868,

030210869, 10870, 10871 10872, 10873, 10874, 10875, 10876, 10877 10878, 10879, 10880, 10881, 10882, 10883 10884, 10885, 10886, 10887, 10888, 10889 10890, 10891, 10892, 10893, 10894, 10895 10896, 10897, 10898, 10899, 10900, 10901 10902, 10903, 10904, 10905, 10906, 10907 10908, 10909, 10910, 10911, 10912, 10913 10914, 10915, 10916, 10917, 10918, 10919 10920, 10921, 10922, 10923, 10924, 10925 10926, 10927, 10928, 10929, 10930, 10931 10932, 10933, 10934, 10935, 10936, 10937 10938, 10939, 10940, 10941, 10942, 10943 10944, 10945, 10946, 10947, 10948, 10949 10950, 10951, 10952, 10953, 10954, 10955 10956, 10957, 10958, 10959, 10960, 10961 10962, 10963, 10964, 10965, 10966, 10967 10968, 10969, 10970, 10971, 10972, 10973 10974, 10975, 10976, 10977, 10978, 10979 10980, 10981, 10982, 10983, 10984, 10985 10986, 10987, 10988, 10989, 10990, 10991 10992, 10993, 10994, 10995, 10996, 10997 10998, 10999, 11000, 11001, 11002, 11003 11004, 11005, 11006, 11007, 11008, 11009 11010, 11011, 11012, 11013, 11014, 11015 11016, 11017, 11018, 11019, 11020, 11021 11022, 11023, 11024, 11025, 11026, 11027 11028, 11029, 11030, 11031, 11032, 11033 11034, 11035, 11036, 11037, 11038, 11039 11040, 11041, 11042, 11043, 11044, 11045 11046, 11047, 11048, 11049, 11050, 11051 11052, 11053, 11054, 11055, 11056, 11057 11058, 11059, 11060, 11061, 11062, 11063 11064, 11065, 11066, 11067, 11068, 11069 11070, 11071, 11072, 11073, 11074, 11075 11076, 11077, 11078, 11079, 11080, 11081 11082, 11083, 11084, 11085, 11086, 11087 11088, 11089, 11090, 11091, 11092, 11093 11094, 11095, 11096, 11097, 11098, 11099 11100, 11101, 11102, 11103, 11104, 11105 11106, 11107, 11108, 11109, 11110, 11111 11112, 11113, 11114, 11115, 11116, 11117 11118, 11119, 11120, 11121, 11122, 11123 11124, 11125, 11126, 11127, 11128, 11129 11130, 11131, 11132, 11133, 11134, 11135 11136, 11137, 11138, 11139, 11140, 11141 11142, 11143, 11144, 11145, 11146, 11147 11148, 11149, 11150, 11151, 11152, 11153 11154, 11155, 11156, 11157, 11158, 11159 11160, 11161, 11162, 11163, 11164, 11165 11166, 11167, 11168, 11169, 11170, 11171 11172, 11173, 11174, 11175, 11176, 11177 11178, 11179, 11180, 11181, 11182, 11183 11184, 11185, 11186, 11187, 11188, 11189 11190, 11191, 11192, 11193, 11194, 11195 11196, 11197, 11198, 11199, 11200, 11201 11202, 11203, 11204, 11205, 11206, 11207 11208, 11209, 11210, 11211, 11212, 11213 11214, 11215, 11216, 11217, 11218, 11219 11220, 11221, 11222, 11223, 11224, 11225 11226, 11227, 11228, 11229, 11230, 11231 11232, 11233, 11234, 11235, 11236, 11237 11238, 11239, 11240, 11241, 11242, 11243 11244, 11245, 11246, 11247, 11248, 11249 11250, 11251, 11252, 11253, 11254, 11255 11256, 11257, 11258, 11259, 11260, 11261 11262, 11263, 11264, 11265, 11266, 11267 11268, 11269, 11270, 11271, 11272, 11273 11274, 11275, 11276, 11277, 11278, 11279 11280, 11281, 11282, 11283, 11284, 11285 11286, 11287, 11288, 11289, 11290, 11291 11292, 11293, 11294, 11295, 11296, 11297 11298, 11299, 11300, 11301, 11302, 11303 11304, 11305, 11306, 11307, 11308, 11309 11310, 11311, 11312, 11313, 11314, 11315 11316, 11317, 11318, 11319, 11320, 11321 11322, 11323, 11324, 11325, 11326, 11327 11328, 11329, 11330, 11331, 11332, 11333 11334, 11335, 11336, 11337, 11338, 11339 11340, 11341, 11342, 11343, 11344, 11345 11346, 11347, 11348, 11349, 11350, 11351 11352, 11353, 11354, 11355, 11356, 11357 11358, 11359, 11360, 11361, 11362, 11363 11364, 11365, 11366, 11367, 11368, 11369 11370, 11371, 11372, 11373, 11374, 11375 11376, 11377, 11378, 11379, 11380, 11381 11382, 11383, 11384, 11385, 11386, 11387 11388, 11389, 11390, 11391, 11392, 11393 11394, 11395, 11396, 11397, 11398, 11399 11400, 11401, 11402, 11403, 11404, 11405 11406, 11407, 11408, 11409, 11410, 11411 11412, 11413, 11414, 11415, 11416, 11417 11418, 11419, 11420, 11421, 11422, 11423 11424, 11425, 11426, 11427, 11428, 11429 11430, 11431, 11432, 11433, 11434, 11435 11436, 11437, 11438, 11439, 11440, 11441 11442, 11443, 11444, 11445, 11446, 11447 11448, 11449, 11450, 11451, 11452, 11453 11454, 11455, 11456, 11457, 11458, 11459 11460, 11461, 11462, 11463, 11464, 11465 11466, 11467, 11468, 11469, 11470, 11471 11472, 11473, 11474, 11475, 11476, 11477 11478, 11479, 11480, 11481, 11482, 11483 11484, 11485, 11486, 11487, 11488, 11489 11490, 11491, 11492, 11493, 11494, 11495 11496, 11497, 11498, 11499, 11500, 11501 11502, 11503, 11504, 11505, 11506, 11507 11508, 11509, 11510, 11511, 11512, 11513 11514, 11515, 11516, 11517, 11518, 11519 11520, 11521, 11522, 11523, 11524, 11525 11526, 11527, 11528, 11529, 11530, 11531 11532, 11533, 11534, 11535, 11536, 11537 11538, 11539, 11540, 11541, 11542, 11543 11544, 11545, 11546, 11547, 11548, 11549 11550, 11551, 11552, 11553, 11554, 11555 11556, 11557, 11558, 11559, 11560, 11561 11562, 11563, 11564, 11565, 11566, 11567 11568, 11569, 11570, 11571, 11572, 11573 11574, 11575, 11576, 11577, 11578, 11579 11580, 11581, 11582, 11583, 11584, 11585 11586, 11587, 11588, 11589, 11590, 11591 11592, 11593, 11594, 11595, 11596, 11597 11598, 11599, 11600, 11601, 11602, 11603 11604, 11605, 11606, 11607, 11608, 11609 11610, 11611, 11612, 11613, 11614, 11615 11616, 11617, 11618, 11619, 11620, 11621 11622, 11623, 11624, 11625, 11626, 11627 11628, 11629, 11630, 11631, 11632, 11633 11634, 11635, 11636, 11637, 11638, 11639 11640, 11641, 11642, 11643, 11644, 11645 11646, 11647, 11648, 11649, 11650, 11651 11652, 11653, 11654, 11655, 11656, 11657 11658, 11659, 11660, 11661, 11662, 11663 11664, 11665, 11666, 11667, 11668, 11669 11670, 11671, 11672, 11673, 11674, 11675 11676, 11677, 11678, 11679, 11680, 11681 11682, 11683, 11684, 11685, 11686, 11687 11688, 11689, 11690, 11691, 11692, 11693 11694, 11695, 11696, 11697, 11698, 11699 11700, 11701, 11702, 11703, 11704, 11705 11706, 11707, 11708, 11709, 11710, 11711 11712, 11713, 11714, 11715, 11716, 11717 11718, 11719, 11720, 11721, 11722, 11723 11724, 11725, 11726, 11727, 11728, 11729 11730, 11731, 11732, 11733, 11734, 11735 11736, 11737, 11738, 11739, 11740, 11741 11742, 11743, 11744, 11745, 11746, 11747 11748, 11749, 11750, 11751, 11752, 11753 11754, 11755, 11756, 11757, 11758, 11759 11760, 11761, 11762, 11763, 11764, 11765 11766, 11767, 11768, 11769, 11770, 11771 11772, 11773, 11774, 11775, 11776, 11777 11778, 11779, 11780, 11781, 11782, 11783 11784, 11785, 11786, 11787, 11788, 11789 11790, 11791, 11792, 11793, 11794, 11795 11796, 11797, 11798, 11799, 11800, 11801 11802, 11803, 11804, 11805, 11806, 11807 11808, 11809, 11810, 11811, 11812, 11813 11814, 11815, 11816, 11817, 11818, 11819 11820, 11821, 11822, 11823, 11824, 11825 11826, 11827, 11828, 11829, 11830, 11831 11832, 11833, 11834, 11835, 11836, 11837 11838, 11839, 11840, 11841, 11842, 11843 11844, 11845, 11846, 11847, 11848, 11849 11850, 11851, 11852, 11853, 11854, 11855 11856, 11857, 11858, 11859, 11860, 11861 11862, 11863, 11864, 11865, 11866, 11867 11868, 11869, 11870, 11871, 11872, 11873 11874, 11875, 11876, 11877, 11878, 11879 11880, 11881, 11882, 11883, 11884, 11885 11886, 11887, 11888, 11889, 11890, 11891 11892, 11893, 11894, 11895, 11896, 11897 11898, 11899, 11900, 11901, 11902, 11903 11904, 11905, 11906, 11907, 11908, 11909 11910, 11911, 11912, 11913, 11914, 11915 11916, 11917, 11918, 11919, 11920, 11921 11922, 11923, 11924, 11925, 11926, 11927 11928, 11929, 11930, 11931, 11932, 11933 11934, 11935, 11936, 11937, 11938, 11939 11940, 11941, 11942, 11943, 11944, 11945 11946, 11947, 11948, 11949, 11950, 11951 11952, 11953, 11954, 11955, 11956, 11957 11958, 11959, 11960, 11961, 11962, 11963 11964, 11965, 11966, 11967, 11968, 11969 11970, 11971, 11972, 11973, 11974, 11975 11976, 11977, 11978, 11979, 11980, 11981 11982, 11983, 11984, 11985, 11986, 11987 11988, 11989, 11990, 11991, 11992, 11993 11994, 11995, 11996, 11997, 11998, 11999 12000, 12001, 12002, 12003, 12004, 12005 12006, 12007, 12008,

030312009, 12010, 12011 12012, 12013, 12014, 12015, 12016, 12017 12018, 12019, 12020,

030412021, 12022, 12023 12024, 12025, 12026, 12027, 12028, 12029 12030, 12031, 12032,

030512033, 12034, 12035 12036, 12037, 12038, 12039, 12040, 12041 12042, 12043, 12044,

030612045, 12046, 12047 12048, 12049, 12050, 12051, 12052, 12053 12054, 12055, 12056,

030712057, 12058, 12059 12060, 12061, 12062, 12063, 12064, 12065 12066, 12067, 12068,

030812069, 12070, 12071 12072, 12073, 12074, 12075, 12076, 12077 12078, 12079, 12080,

030912081, 12082, 12083 12084, 12085, 12086, 12087, 12088, 12089 12090, 12091, 12092,

031012093, 12094, 12095 12096, 12097, 12098, 12099, 12100, 12101 12102, 12103, 12104,

031112105, 12106, 12107 12108, 12109, 12110, 12111, 12112, 12113 12114, 12115, 12116,

031212117, 12118, 12119 12120, 12121, 12122, 12123, 12124, 12125 12126, 12127, 12128,

031312129, 12130, 12131 12132, 12133, 12134, 12135, 12136, 12137 12138, 12139, 12140,

031412141, 12142, 12143 12144, 12145, 12146, 12147, 12148, 12149 12150, 12151, 12152,

031512153, 12154, 12155 12156, 12157, 12158, 12159, 12160, 12161 12162, 12163, 12164,

031612165, 12166, 12167 12168, 12169, 12170, 12171, 12172, 12173 12174, 12175, 12176,

031712177, 12178, 12179 12180, 12181, 12182, 12183, 12184, 12185 12186, 12187, 12188,

031812189, 12190, 12191 12192, 12193, 12194, 12195, 12196, 12197 12198, 12199, 12200,

031912201, 12202, 12203 12204, 12205, 12206, 12207, 12208, 12209 12210, 12211, 12212,

032012213, 12214, 12215 12216, 12217, 12218, 12219, 12220, 12221 12222, 12223, 12224,

032112225, 12226, 12227 12228, 12229, 12230, 12231, 12232, 12233 12234, 12235, 12236,

032212237, 12238, 12239 12240, 12241, 12242, 12243, 12244, 12245 12246, 12247, 12248,

032312249, 12250, 12251 12252, 12253, 12254, 12255, 12256, 12257 12258, 12259, 12260,

032412261, 12262, 12263 12264, 12265, 12266, 12267, 12268, 12269 12270, 12271, 12272,

032512273, 12274, 12275 12276, 12277, 12278, 12279, 12280, 12281 12282, 12283, 12284,

032612285, 12286, 12287 12288, 12289, 12290, 12291, 12292, 12293 12294, 12295, 12296,

032712297, 12298, 12299 12300, 12301, 12302, 12303, 12304, 12305 12306, 12307, 12308,

032812309, 12310, 12311 12312, 12313, 12314, 12315, 12316, 12317 12318, 12319, 12320,

032912321, 12322, 12323 12324, 12325, 12326, 12327, 12328, 12329 12330, 12331, 12332,

033012333, 12334, 12335 12336, 12337, 12338, 12339, 12340, 12341 12342, 12343, 12344,

033112345, 12346, 12347 12348, 12349, 12350, 12351, 12352, 12353 12354, 12355, 12356,

033212357, 12358, 12359 12360, 12361, 12362, 12363, 12364, 12365 12366, 12367, 12368, 12369, 12370, 12371 12372, 12373, 12374, 12375, 12376, 12377 12378, 12379, 12380,

033312381, 12382, 12383 12384, 12385, 12386, 12387, 12388, 12389 12390, 12391, 12392,

033412393, 12394, 12395 12396, 12397, 12398, 12399, 12400, 12401 12402, 12403, 12404,

033512405, 12406, 12407 12408, 12409, 12410, 12411, 12412, 12413 12414, 12415, 12416,

033612417, 12418, 12419 12420, 12421, 12422, 12423, 12424, 12425 12426, 12427, 12428,

033712429, 12430, 12431 12432, 12433, 12434, 12435, 12436, 12437 12438, 12439, 12440,

033812441, 12442, 12443 12444, 12445, 12446, 12447, 12448, 12449 12450, 12451, 12452,

033912453, 12454, 12455 12456, 12457, 12458, 12459, 12460, 12461 12462, 12463, 12464,

034012465, 12466, 12467 12468, 12469, 12470, 12471, 12472, 12473 12474, 12475, 12476,

034112477, 12478, 12479 12480, 12481, 12482, 12483, 12484, 12485 12486, 12487, 12488,

034212489, 12490, 12491 12492, 12493, 12494, 12495, 12496, 12497 12498, 12499, 12500,

034312501, 12502, 12503 12504, 12505, 12506, 12507, 12508, 12509 12510, 12511, 12512,

034412513, 12514, 12515 12516, 12517, 12518, 12519, 12520, 12521 12522, 12523, 12524,

034512525, 12526, 12527 12528, 12529, 12530, 12531, 12532, 12533 12534, 12535, 12536,

034612537, 12538, 12539 12540, 12541, 12542, 12543, 12544, 12545 12546, 12547, 12548,

034712549, 12550, 12551 12552, 12553, 12554, 12555, 12556, 12557 12558, 12559, 12560,

034812561, 12562, 12563 12564, 12565, 12566, 12567, 12568, 12569 12570, 12571, 12572,

034912573, 12574, 12575 12576, 12577, 12578, 12579, 12580, 12581 12582, 12583, 12584,

035012585, 12586, 12587 12588, 12589, 12590, 12591, 12592, 12593 12594, 12595, 12596,

035112597, 12598, 12599 12600, 12601, 12602, 12603, 12604, 12605 12606, 12607, 12608,

035212609, 12610, 12611 12612, 12613, 12614, 12615, 12616, 12617 12618, 12619, 12620,

035312621, 12622, 12623 12624, 12625, 12626, 12627, 12628, 12629 12630, 12631, 12632,

035412633, 12634, 12635 12636, 12637, 12638, 12639, 12640, 12641 12642, 12643, 12644,

035512645, 12646, 12647 12648, 12649, 12650, 12651, 12652, 12653 12654, 12655, 12656,

035612657, 12658, 12659 12660, 12661, 12662, 12663, 12664, 12665 12666, 12667, 12668,

035712669, 12670, 12671 12672, 12673, 12674, 12675, 12676, 12677 12678, 12679, 12680,

035812681, 12682, 12683 12684, 12685, 12686, 12687, 12688, 12689 12690, 12691, 12692,

035912693, 12694, 12695 12696, 12697, 12698, 12699, 12700, 12701 12702, 12703, 12704,

036012705, 12706, 12707 12708, 12709, 12710, 12711, 12712, 12713 12714, 12715, 12716,

036112717, 12718, 12719 12720, 12721, 12722, 12723, 12724, 12725 12726, 12727, 12728,

036212729, 12730, 12731 12732, 12733, 12734, 12735, 12736, 12737 12738, 12739, 12740, 12741, 12742, 12743 12744, 12745, 12746, 12747, 12748, 12749 12750, 12751, 12752,

036312753, 12754, 12755 12756, 12757, 12758, 12759, 12760, 12761 12762, 12763, 12764,

036412765, 12766, 12767 12768, 12769, 12770, 12771, 12772, 12773 12774, 12775, 12776,

036512777, 12778, 12779 12780, 12781, 12782, 12783, 12784, 12785 12786, 12787, 12788,

036612789, 12790, 12791 12792, 12793, 12794, 12795, 12796, 12797 12798, 12799, 12800,

036712801, 12802, 12803 12804, 12805, 12806, 12807, 12808, 12809 12810, 12811, 12812,

036812813, 12814, 12815 12816, 12817, 12818, 12819, 12820, 12821 12822, 12823, 12824,

036912825, 12826, 12827 12828, 12829, 12830, 12831, 12832, 12833 12834, 12835, 12836,

037012837, 12838, 12839 12840, 12841, 12842, 12843, 12844, 12845 12846, 12847, 12848,

037112849, 12850, 12851 12852, 12853, 12854, 12855, 12856, 12857 12858, 12859, 12860,

037212861, 12862, 12863 12864, 12865, 12866, 12867, 12868, 12869 12870, 12871, 12872,

037312873, 12874, 12875 12876, 12877, 12878, 12879, 12880, 12881 12882, 12883, 12884,

037412885, 12886, 12887 12888, 12889, 12890, 12891, 12892, 12893 12894, 12895, 12896,

037512897, 12898, 12899 12900, 12901, 12902, 12903, 12904, 12905 12906, 12907, 12908,

037612909, 12910, 12911 12912, 12913, 12914, 12915, 12916, 12917 12918, 12919, 12920,

037712921, 12922, 12923 12924, 12925, 12926, 12927, 12928, 12929 12930, 12931, 12932,

037812933, 12934, 12935 12936, 12937, 12938, 12939, 12940, 12941 12942, 12943, 12944,

037912945, 12946, 12947 12948, 12949, 12950, 12951, 12952, 12953 12954, 12955, 12956,

038012957, 12958, 12959 12960, 12961, 12962, 12963, 12964, 12965 12966, 12967, 12968,

038112969, 12970, 12971 12972, 12973, 12974, 12975, 12976, 12977 12978, 12979, 12980,

038212981, 12982, 12983 12984, 12985, 12986, 12987, 12988, 12989 12990, 12991, 12992,

038312993, 12994, 12995 12996, 12997, 12998, 12999, 13000, 13001 13002, 13003, 13004,

038413005, 13006, 13007 13008, 13009, 13010, 13011, 13012, 13013 13014, 13015, 13016,

038513017, 13018, 13019 13020, 13021, 13022, 13023, 13024, 13025 13026, 13027, 13028,

038613029, 13030, 13031 13032, 13033, 13034, 13035, 13036, 13037 13038, 13039, 13040,

038713041, 13042, 13043 13044, 13045, 13046, 13047, 13048, 13049 13050, 13051, 13052,

038813053, 13054, 13055 13056, 13057, 13058, 13059, 13060, 13061 13062, 13063, 13064,

038913065, 13066, 13067 13068, 13069, 13070, 13071, 13072, 13073 13074, 13075, 13076,

039013077, 13078, 13079 13080, 13081, 13082, 13083, 13084, 13085 13086, 13087, 13088,

039113089, 13090, 13091 13092, 13093, 13094, 13095, 13096, 13097 13098, 13099, 13100,

039213101, 13102, 13103 13104, 13105, 13106, 13107, 13108, 13109 13110, 13111, 13112, 13113, 13114, 13115 13116, 13117, 13118, 13119, 13120, 13121 13122, 13123, 13124,

039313125, 13126, 13127 13128, 13129, 13130, 13131, 13132, 13133 13134, 13135, 13136,

039413137, 13138, 13139 13140, 13141, 13142, 13143, 13144, 13145 13146, 13147, 13148,

039513149, 13150, 13151 13152, 13153, 13154, 13155, 13156, 13157 13158, 13159, 13160,

039613161, 13162, 13163 13164, 13165, 13166, 13167, 13168, 13169 13170, 13171, 13172,

039713173, 13174, 13175 13176, 13177, 13178, 13179, 13180, 13181 13182, 13183, 13184,

039813185, 13186, 13187 13188, 13189, 13190, 13191, 13192, 13193 13194, 13195, 13196,

039913197, 13198, 13199 13200, 13201, 13202, 13203, 13204, 13205 13206, 13207, 13208,

040013209, 13210, 13211 13212, 13213, 13214, 13215, 13216, 13217 13218, 13219, 13220,

040113221, 13222, 13223 13224, 13225, 13226, 13227, 13228, 13229 13230, 13231, 13232,

040213233, 13234, 13235 13236, 13237, 13238, 13239, 13240, 13241 13242, 13243, 13244,

040313245, 13246, 13247 13248, 13249, 13250, 13251, 13252, 13253 13254, 13255, 13256,

040413257, 13258, 13259 13260, 13261, 13262, 13263, 13264, 13265 13266, 13267, 13268,

040513269, 13270, 13271 13272, 13273, 13274, 13275, 13276, 13277 13278, 13279, 13280,

040613281, 13282, 13283 13284, 13285, 13286, 13287, 13288, 13289 13290, 13291, 13292,

040713293, 13294, 13295 13296, 13297, 13298, 13299, 13300, 13301 13302, 13303, 13304,

040813305, 13306, 13307 13308, 13309, 13310, 13311, 13312, 13313 13314, 13315, 13316,

040913317, 13318, 13319 13320, 13321, 13322, 13323, 13324, 13325 13326, 13327, 13328,

041013329, 13330, 13331 13332, 13333, 13334, 13335, 13336, 13337 13338, 13339, 13340,

041113341, 13342, 13343 13344, 13345, 13346, 13347, 13348, 13349 13350, 13351, 13352,

041213353, 13354, 13355 13356, 13357, 13358, 13359, 13360, 13361 13362, 13363, 13364,

041313365, 13366, 13367 13368, 13369, 13370, 13371, 13372, 13373 13374, 13375, 13376,

041413377, 13378, 13379 13380, 13381, 13382, 13383, 13384, 13385 13386, 13387, 13388,

041513389, 13390, 13391 13392, 13393, 13394, 13395, 13396, 13397 13398, 13399, 13400,

041613401, 13402, 13403 13404, 13405, 13406, 13407, 13408, 13409 13410, 13411, 13412,

041713413, 13414, 13415 13416, 13417, 13418, 13419, 13420, 13421 13422, 13423, 13424,

041813425, 13426, 13427 13428, 13429, 13430, 13431, 13432, 13433 13434, 13435, 13436,

041913437, 13438, 13439 13440, 13441, 13442, 13443, 13444, 13445 13446, 13447, 13448,

042013449, 13450, 13451 13452, 13453, 13454, 13455, 13456, 13457 13458, 13459, 13460,

042113461, 13462, 13463 13464, 13465, 13466, 13467, 13468, 13469 13470, 13471, 13472,

042213473, 13474, 13475 13476, 13477, 13478, 13479, 13480, 13481 13482, 13483, 13484, 13485, 13486, 13487 13488, 13489, 13490, 13491, 13492, 13493 13494, 13495, 13496,

042313497, 13498, 13499 13500, 13501, 13502, 13503, 13504, 13505 13506, 13507, 13508,

042413509, 13510, 13511 13512, 13513, 13514, 13515, 13516, 13517 13518, 13519, 13520,

042513521, 13522, 13523 13524, 13525, 13526, 13527, 13528, 13529 13530, 13531, 13532,

042613533, 13534, 13535 13536, 13537, 13538, 13539, 13540, 13541 13542, 13543, 13544,

042713545, 13546, 13547 13548, 13549, 13550, 13551, 13552, 13553 13554, 13555, 13556,

042813557, 13558, 13559 13560, 13561, 13562, 13563, 13564, 13565 13566, 13567, 13568,

042913569, 13570, 13571 13572, 13573, 13574, 13575, 13576, 13577 13578, 13579, 13580,

043013581, 13582, 13583 13584, 13585, 13586, 13587, 13588, 13589 13590, 13591, 13592,

043113593, 13594, 13595 13596, 13597, 13598, 13599, 13600, 13601 13602, 13603, 13604,

043213605, 13606, 13607 13608, 13609, 13610, 13611, 13612, 13613 13614, 13615, 13616,

043313617, 13618, 13619 13620, 13621, 13622, 13623, 13624, 13625 13626, 13627, 13628,

043413629, 13630, 13631 13632, 13633, 13634, 13635, 13636, 13637 13638, 13639, 13640,

043513641, 13642, 13643 13644, 13645, 13646, 13647, 13648, 13649 13650, 13651, 13652,

043613653, 13654, 13655 13656, 13657, 13658, 13659, 13660, 13661 13662, 13663, 13664,

043713665, 13666, 13667 13668, 13669, 13670, 13671, 13672, 13673 13674, 13675, 13676,

043813677, 13678, 13679 13680, 13681, 13682, 13683, 13684, 13685 13686, 13687, 13688,

043913689, 13690, 13691 13692, 13693, 13694, 13695, 13696, 13697 13698, 13699, 13700,

044013701, 13702, 13703 13704, 13705, 13706, 13707, 13708, 13709 13710, 13711, 13712,

044113713, 13714, 13715 13716, 13717, 13718, 13719, 13720, 13721 13722, 13723, 13724,

044213725, 13726, 13727 13728, 13729, 13730, 13731, 13732, 13733 13734, 13735, 13736,

044313737, 13738, 13739 13740, 13741, 13742, 13743, 13744, 13745 13746, 13747, 13748,

044413749, 13750, 13751 13752, 13753, 13754, 13755, 13756, 13757 13758, 13759, 13760,

044513761, 13762, 13763 13764, 13765, 13766, 13767, 13768, 13769 13770, 13771, 13772,

044613773, 13774, 13775 13776, 13777, 13778, 13779, 13780, 13781 13782, 13783, 13784,

044713785, 13786, 13787 13788, 13789, 13790, 13791, 13792, 13793 13794, 13795, 13796,

044813797, 13798, 13799 13800, 13801, 13802, 13803, 13804, 13805 13806, 13807, 13808,

044913809, 13810, 13811 13812, 13813, 13814, 13815, 13816, 13817 13818, 13819, 13820,

045013821, 13822, 13823 13824, 13825, 13826, 13827, 13828, 13829 13830, 13831, 13832,

045113833, 13834, 13835 13836, 13837, 13838, 13839, 13840, 13841 13842, 13843, 13844,

045213845, 13846, 13847 13848, 13849, 13850, 13851, 13852, 13853 13854, 13855, 13856, 13857, 13858, 13859 13860, 13861, 13862, 13863, 13864, 13865 13866, 13867, 13868,

045313869, 13870, 13871 13872, 13873, 13874, 13875, 13876, 13877 13878, 13879, 13880,

045413881, 13882, 13883 13884, 13885, 13886, 13887, 13888, 13889 13890, 13891, 13892,

045513893, 13894, 13895 13896, 13897, 13898, 13899, 13900, 13901 13902, 13903, 13904,

045613905, 13906, 13907 13908, 13909, 13910, 13911, 13912, 13913 13914, 13915, 13916,

045713917, 13918, 13919 13920, 13921, 13922, 13923, 13924, 13925 13926, 13927, 13928,

045813929, 13930, 13931 13932, 13933, 13934, 13935, 13936, 13937 13938, 13939, 13940,

045913941, 13942, 13943 13944, 13945, 13946, 13947, 13948, 13949 13950, 13951, 13952,

046013953, 13954, 13955 13956, 13957, 13958, 13959, 13960, 13961 13962, 13963, 13964,

046113965, 13966, 13967 13968, 13969, 13970, 13971, 13972, 13973 13974, 13975, 13976,

046213977, 13978, 13979 13980, 13981, 13982, 13983, 13984, 13985 13986, 13987, 13988,

046313989, 13990, 13991 13992, 13993, 13994, 13995, 13996, 13997 13998, 13999, 14000,

046414001, 14002, 14003 14004, 14005, 14006, 14007, 14008, 14009 14010, 14011, 14012,

046514013, 14014, 14015 14016, 14017, 14018, 14019, 14020, 14021 14022, 14023, 14024,

046614025, 14026, 14027 14028, 14029, 14030, 14031, 14032, 14033 14034, 14035, 14036,

046714037, 14038, 14039 14040, 14041, 14042, 14043, 14044, 14045 14046, 14047, 14048,

046814049, 14050, 14051 14052, 14053, 14054, 14055, 14056, 14057 14058, 14059, 14060,

046914061, 14062, 14063 14064, 14065, 14066, 14067, 14068, 14069 14070, 14071, 14072,

047014073, 14074, 14075 14076, 14077, 14078, 14079, 14080, 14081 14082, 14083, 14084,

047114085, 14086, 14087 14088, 14089, 14090, 14091, 14092, 14093 14094, 14095, 14096,

047214097, 14098, 14099 14100, 14101, 14102, 14103, 14104, 14105 14106, 14107, 14108,

047314109, 14110, 14111 14112, 14113, 14114, 14115, 14116, 14117 14118, 14119, 14120,

047414121, 14122, 14123 14124, 14125, 14126, 14127, 14128, 14129 14130, 14131, 14132,

047514133, 14134, 14135 14136, 14137, 14138, 14139, 14140, 14141 14142, 14143, 14144,

047614145, 14146, 14147 14148, 14149, 14150, 14151, 14152, 14153 14154, 14155, 14156,

047714157, 14158, 14159 14160, 14161, 14162, 14163, 14164, 14165 14166, 14167, 14168,

047814169, 14170, 14171 14172, 14173, 14174, 14175, 14176, 14177 14178, 14179, 14180,

047914181, 14182, 14183 14184, 14185, 14186, 14187, 14188, 14189 14190, 14191, 14192,

048014193, 14194, 14195 14196, 14197, 14198, 14199, 14200, 14201 14202, 14203, 14204,

048114205, 14206, 14207 14208, 14209, 14210, 14211, 14212, 14213 14214, 14215, 14216,

048214217, 14218, 14219 14220, 14221, 14222, 14223, 14224, 14225 14226, 14227, 14228, 14229, 14230, 14231 14232, 14233, 14234, 14235, 14236, 14237 14238, 14239, 14240,

048314241, 14242, 14243 14244, 14245, 14246, 14247, 14248, 14249 14250, 14251, 14252,

048414253, 14254, 14255 14256, 14257, 14258, 14259, 14260, 14261 14262, 14263, 14264,

048514265, 14266, 14267 14268, 14269, 14270, 14271, 14272, 14273 14274, 14275, 14276,

048614277, 14278, 14279 14280, 14281, 14282, 14283, 14284, 14285 14286, 14287, 14288,

048714289, 14290, 14291 14292, 14293, 14294, 14295, 14296, 14297 14298, 14299, 14300,

048814301, 14302, 14303 14304, 14305, 14306, 14307, 14308, 14309 14310, 14311, 14312,

048914313, 14314, 14315 14316, 14317, 14318, 14319, 14320, 14321 14322, 14323, 14324,

049014325, 14326, 14327 14328, 14329, 14330, 14331, 14332, 14333 14334, 14335, 14336,

049114337, 14338, 14339 14340, 14341, 14342, 14343, 14344, 14345 14346, 14347, 14348,

049214349, 14350, 14351 14352, 14353, 14354, 14355, 14356, 14357 14358, 14359, 14360,

049314361, 14362, 14363 14364, 14365, 14366, 14367, 14368, 14369 14370, 14371, 14372,

049414373, 14374, 14375 14376, 14377, 14378, 14379, 14380, 14381 14382, 14383, 14384,

049514385, 14386, 14387 14388, 14389, 14390, 14391, 14392, 14393 14394, 14395, 14396,

049614397, 14398, 14399 14400, 14401, 14402, 14403, 14404, 14405 14406, 14407, 14408,

049714409, 14410, 14411 14412, 14413, 14414, 14415, 14416, 14417 14418, 14419, 14420,

049814421, 14422, 14423 14424, 14425, 14426, 14427, 14428, 14429 14430, 14431, 14432,

049914433, 14434, 14435 14436, 14437, 14438, 14439, 14440, 14441 14442, 14443, 14444,

050014445, 14446, 14447 14448, 14449, 14450, 14451, 14452, 14453 14454, 14455, 14456,

050114457, 14458, 14459 14460, 14461, 14462, 14463, 14464, 14465 14466, 14467, 14468,

050214469, 14470, 14471 14472, 14473, 14474, 14475, 14476, 14477 14478, 14479, 14480,

050314481, 14482, 14483 14484, 14485, 14486, 14487, 14488, 14489 14490, 14491, 14492,

050414493, 14494, 14495 14496, 14497, 14498, 14499, 14500, 14501 14502, 14503, 14504,

050514505, 14506, 14507 14508, 14509, 14510, 14511, 14512, 14513 14514, 14515, 14516,

050614517, 14518, 14519 14520, 14521, 14522, 14523, 14524, 14525 14526, 14527, 14528,

050714529, 14530, 14531 14532, 14533, 14534, 14535, 14536, 14537 14538, 14539, 14540,

050814541, 14542, 14543 14544, 14545, 14546, 14547, 14548, 14549 14550, 14551, 14552,

050914553, 14554, 14555 14556, 14557, 14558, 14559, 14560, 14561 14562, 14563, 14564,

051014565, 14566, 14567 14568, 14569, 14570, 14571, 14572, 14573 14574, 14575, 14576,

051114577, 14578, 14579 14580, 14581, 14582, 14583, 14584, 14585 14586, 14587, 14588,

051214589, 14590, 14591 14592, 14593, 14594, 14595, 14596, 14597 14598, 14599, 14600, 14601, 14602, 14603 14604, 14605, 14606, 14607, 14608, 14609 14610, 14611, 14612,

051314613, 14614, 14615 14616, 14617, 14618, 14619, 14620, 14621 14622, 14623, 14624,

051414625, 14626, 14627 14628, 14629, 14630, 14631, 14632, 14633 14634, 14635, 14636,

051514637, 14638, 14639 14640, 14641, 14642, 14643, 14644, 14645 14646, 14647, 14648,

051614649, 14650, 14651 14652, 14653, 14654, 14655, 14656, 14657 14658, 14659, 14660,

051714661, 14662, 14663 14664, 14665, 14666, 14667, 14668, 14669 14670, 14671, 14672,

051814673, 14674, 14675 14676, 14677, 14678, 14679, 14680, 14681 14682, 14683, 14684,

051914685, 14686, 14687 14688, 14689, 14690, 14691, 14692, 14693 14694, 14695, 14696,

052014697, 14698, 14699 14700, 14701, 14702, 14703, 14704, 14705 14706, 14707, 14708,

052114709, 14710, 14711 14712, 14713, 14714, 14715, 14716, 14717 14718, 14719, 14720,

052214721, 14722, 14723 14724, 14725, 14726, 14727, 14728, 14729 14730, 14731, 14732,

052314733, 14734, 14735 14736, 14737, 14738, 14739, 14740, 14741 14742, 14743, 14744,

052414745, 14746, 14747 14748, 14749, 14750, 14751, 14752, 14753 14754, 14755, 14756,

052514757, 14758, 14759 14760, 14761, 14762, 14763, 14764, 14765 14766, 14767, 14768,

052614769, 14770, 14771 14772, 14773, 14774, 14775, 14776, 14777 14778, 14779, 14780,

052714781, 14782, 14783 14784, 14785, 14786, 14787, 14788, 14789 14790, 14791, 14792,

052814793, 14794, 14795 14796, 14797, 14798, 14799, 14800, 14801 14802, 14803, 14804,

052914805, 14806, 14807 14808, 14809, 14810, 14811, 14812, 14813 14814, 14815, 14816,

053014817, 14818, 14819 14820, 14821, 14822, 14823, 14824, 14825 14826, 14827, 14828,

053114829, 14830, 14831 14832, 14833, 14834, 14835, 14836, 14837 14838, 14839, 14840,

053214841, 14842, 14843 14844, 14845, 14846, 14847, 14848, 14849 14850, 14851, 14852,

053314853, 14854, 14855 14856, 14857, 14858, 14859, 14860, 14861 14862, 14863, 14864,

053414865, 14866, 14867 14868, 14869, 14870, 14871, 14872, 14873 14874, 14875, 14876,

053514877, 14878, 14879 14880, 14881, 14882, 14883, 14884, 14885 14886, 14887, 14888,

053614889, 14890, 14891 14892, 14893, 14894, 14895, 14896, 14897 14898, 14899, 14900,

053714901, 14902, 14903 14904, 14905, 14906, 14907, 14908, 14909 14910, 14911, 14912,

053814913, 14914, 14915 14916, 14917, 14918, 14919, 14920, 14921 14922, 14923, 14924,

053914925, 14926, 14927 14928, 14929, 14930, 14931, 14932, 14933 14934, 14935, 14936,

054014937, 14938, 14939 14940, 14941, 14942, 14943, 14944, 14945 14946, 14947, 14948,

054114949, 14950, 14951 14952, 14953, 14954, 14955, 14956, 14957 14958, 14959, 14960,

054214961, 14962, 14963 14964, 14965, 14966, 14967, 14968, 14969 14970, 14971, 14972, 14973, 14974, 14975 14976, 14977, 14978, 14979, 14980, 14981 14982, 14983, 14984,

054314985, 14986, 14987 14988, 14989, 14990, 14991, 14992, 14993 14994, 14995, 14996,

054414997, 14998, 14999 15000, 15001, 15002, 15003, 15004, 15005 15006, 15007, 15008,

054515009, 15010, 15011 15012, 15013, 15014, 15015, 15016, 15017 15018, 15019, 15020,

054615021, 15022, 15023 15024, 15025, 15026, 15027, 15028, 15029 15030, 15031, 15032,

054715033, 15034, 15035 15036, 15037, 15038, 15039, 15040, 15041 15042, 15043, 15044,

054815045, 15046, 15047 15048, 15049, 15050, 15051, 15052, 15053 15054, 15055, 15056,

054915057, 15058, 15059 15060, 15061, 15062, 15063, 15064, 15065 15066, 15067, 15068,

055015069, 15070, 15071 15072, 15073, 15074, 15075, 15076, 15077 15078, 15079, 15080,

055115081, 15082, 15083 15084, 15085, 15086, 15087, 15088, 15089 15090, 15091, 15092,

055215093, 15094, 15095 15096, 15097, 15098, 15099, 15100, 15101 15102, 15103, 15104,

055315105, 15106, 15107 15108, 15109, 15110, 15111, 15112, 15113 15114, 15115, 15116,

055415117, 15118, 15119 15120, 15121, 15122, 15123, 15124, 15125 15126, 15127, 15128,

055515129, 15130, 15131 15132, 15133, 15134, 15135, 15136, 15137 15138, 15139, 15140,

055615141, 15142, 15143 15144, 15145, 15146, 15147, 15148, 15149 15150, 15151, 15152,

055715153, 15154, 15155 15156, 15157, 15158, 15159, 15160, 15161 15162, 15163, 15164,

055815165, 15166, 15167 15168, 15169, 15170, 15171, 15172, 15173 15174, 15175, 15176,

055915177, 15178, 15179 15180, 15181, 15182, 15183, 15184, 15185 15186, 15187, 15188,

056015189, 15190, 15191 15192, 15193, 15194, 15195, 15196, 15197 15198, 15199, 15200,

056115201, 15202, 15203 15204, 15205, 15206, 15207, 15208, 15209 15210, 15211, 15212,

056215213, 15214, 15215 15216, 15217, 15218, 15219, 15220, 15221 15222, 15223, 15224,

056315225, 15226, 15227 15228, 15229, 15230, 15231, 15232, 15233 15234, 15235, 15236,

056415237, 15238, 15239 15240, 15241, 15242, 15243, 15244, 15245 15246, 15247, 15248,

056515249, 15250, 15251 15252, 15253, 15254, 15255, 15256, 15257 15258, 15259, 15260,

056615261, 15262, 15263 15264, 15265, 15266, 15267, 15268, 15269 15270, 15271, 15272,

056715273, 15274, 15275 15276, 15277, 15278, 15279, 15280, 15281 15282, 15283, 15284,

056815285, 15286, 15287 15288, 15289, 15290, 15291, 15292, 15293 15294, 15295, 15296,

056915297, 15298, 15299 15300, 15301, 15302, 15303, 15304, 15305 15306, 15307, 15308,

057015309, 15310, 15311 15312, 15313, 15314, 15315, 15316, 15317 15318, 15319, 15320,

057115321, 15322, 15323 15324, 15325, 15326, 15327, 15328, 15329 15330, 15331, 15332,

057215333, 15334, 15335 15336, 15337, 15338, 15339, 15340, 15341 15342, 15343, 15344, 15345, 15346, 15347 15348, 15349, 15350, 15351, 15352, 15353 15354, 15355, 15356,

057315357, 15358, 15359 15360, 15361, 15362, 15363, 15364, 15365 15366, 15367, 15368,

057415369, 15370, 15371 15372, 15373, 15374, 15375, 15376, 15377 15378, 15379, 15380,

057515381, 15382, 15383 15384, 15385, 15386, 15387, 15388, 15389 15390, 15391, 15392,

057615393, 15394, 15395 15396, 15397, 15398, 15399, 15400, 15401 15402, 15403, 15404,

057715405, 15406, 15407 15408, 15409, 15410, 15411, 15412, 15413 15414, 15415, 15416,

057815417, 15418, 15419 15420, 15421, 15422, 15423, 15424, 15425 15426, 15427, 15428,

057915429, 15430, 15431 15432, 15433, 15434, 15435, 15436, 15437 15438, 15439, 15440,

058015441, 15442, 15443 15444, 15445, 15446, 15447, 15448, 15449 15450, 15451, 15452,

058115453, 15454, 15455 15456, 15457, 15458, 15459, 15460, 15461 15462, 15463, 15464,

058215465, 15466, 15467 15468, 15469, 15470, 15471, 15472, 15473 15474, 15475, 15476,

058315477, 15478, 15479 15480, 15481, 15482, 15483, 15484, 15485 15486, 15487, 15488,

058415489, 15490, 15491 15492, 15493, 15494, 15495, 15496, 15497 15498, 15499, 15500,

058515501, 15502, 15503 15504, 15505, 15506, 15507, 15508, 15509 15510, 15511, 15512,

058615513, 15514, 15515 15516, 15517, 15518, 15519, 15520, 15521 15522, 15523, 15524,

058715525, 15526, 15527 15528, 15529, 15530, 15531, 15532, 15533 15534, 15535, 15536,

058815537, 15538, 15539 15540, 15541, 15542, 15543, 15544, 15545 15546, 15547, 15548,

058915549, 15550, 15551 15552, 15553, 15554, 15555, 15556, 15557 15558, 15559, 15560,

059015561, 15562, 15563 15564, 15565, 15566, 15567, 15568, 15569 15570, 15571, 15572,

059115573, 15574, 15575 15576, 15577, 15578, 15579, 15580, 15581 15582, 15583, 15584,

059215585, 15586, 15587 15588, 15589, 15590, 15591, 15592, 15593 15594, 15595, 15596,

059315597, 15598, 15599 15600, 15601, 15602, 15603, 15604, 15605 15606, 15607, 15608,

059415609, 15610, 15611 15612, 15613, 15614, 15615, 15616, 15617 15618, 15619, 15620,

059515621, 15622, 15623 15624, 15625, 15626, 15627, 15628, 15629 15630, 15631, 15632,

059615633, 15634, 15635 15636, 15637, 15638, 15639, 15640, 15641 15642, 15643, 15644,

059715645, 15646, 15647 15648, 15649, 15650, 15651, 15652, 15653 15654, 15655, 15656,

059815657, 15658, 15659 15660, 15661, 15662, 15663, 15664, 15665 15666, 15667, 15668,

059915669, 15670, 15671 15672, 15673, 15674, 15675, 15676, 15677 15678, 15679, 15680,

060015681, 15682, 15683 15684, 15685, 15686, 15687, 15688, 15689 15690, 15691, 15692,

060115693, 15694, 15695 15696, 15697, 15698, 15699, 15700, 15701 15702, 15703, 15704,

060215705, 15706, 15707 15708, 15709, 15710, 15711, 15712, 15713 15714, 15715, 15716, 15717, 15718, 15719 15720, 15721, 15722, 15723, 15724, 15725 15726, 15727, 15728,

060315729, 15730, 15731 15732, 15733, 15734, 15735, 15736, 15737 15738, 15739, 15740,

060415741, 15742, 15743 15744, 15745, 15746, 15747, 15748, 15749 15750, 15751, 15752,

060515753, 15754, 15755 15756, 15757, 15758, 15759, 15760, 15761 15762, 15763, 15764,

060615765, 15766, 15767 15768, 15769, 15770, 15771, 15772, 15773 15774, 15775, 15776,

060715777, 15778, 15779 15780, 15781, 15782, 15783, 15784, 15785 15786, 15787, 15788,

060815789, 15790, 15791 15792, 15793, 15794, 15795, 15796, 15797 15798, 15799, 15800,

060915801, 15802, 15803 15804, 15805, 15806, 15807, 15808, 15809 15810, 15811, 15812,

061015813, 15814, 15815 15816, 15817, 15818, 15819, 15820, 15821 15822, 15823, 15824,

061115825, 15826, 15827 15828, 15829, 15830, 15831, 15832, 15833 15834, 15835, 15836,

061215837, 15838, 15839 15840, 15841, 15842, 15843, 15844, 15845 15846, 15847, 15848,

061315849, 15850, 15851 15852, 15853, 15854, 15855, 15856, 15857 15858, 15859, 15860,

061415861, 15862, 15863 15864, 15865, 15866, 15867, 15868, 15869 15870, 15871, 15872,

061515873, 15874, 15875 15876, 15877, 15878, 15879, 15880, 15881 15882, 15883, 15884,

061615885, 15886, 15887 15888, 15889, 15890, 15891, 15892, 15893 15894, 15895, 15896,

061715897, 15898, 15899 15900, 15901, 15902, 15903, 15904, 15905 15906, 15907, 15908,

061815909, 15910, 15911 15912, 15913, 15914, 15915, 15916, 15917 15918, 15919, 15920,

061915921, 15922, 15923 15924, 15925, 15926, 15927, 15928, 15929 15930, 15931, 15932,

062015933, 15934, 15935 15936, 15937, 15938, 15939, 15940, 15941 15942, 15943, 15944,

062115945, 15946, 15947 15948, 15949, 15950, 15951, 15952, 15953 15954, 15955, 15956,

062215957, 15958, 15959 15960, 15961, 15962, 15963, 15964, 15965 15966, 15967, 15968,

062315969, 15970, 15971 15972, 15973, 15974, 15975, 15976, 15977 15978, 15979, 15980,

062415981, 15982, 15983 15984, 15985, 15986, 15987, 15988, 15989 15990, 15991, 15992,

062515993, 15994, 15995 15996, 15997, 15998, 15999, 16000, 16001 16002, 16003, 16004,

062616005, 16006, 16007 16008, 16009, 16010, 16011, 16012, 16013 16014, 16015, 16016,

062716017, 16018, 16019 16020, 16021, 16022, 16023, 16024, 16025 16026, 16027, 16028,

062816029, 16030, 16031 16032, 16033, 16034, 16035, 16036, 16037 16038, 16039, 16040,

062916041, 16042, 16043 16044, 16045, 16046, 16047, 16048, 16049 16050, 16051, 16052,

063016053, 16054, 16055 16056, 16057, 16058, 16059, 16060, 16061 16062, 16063, 16064,

063116065, 16066, 16067 16068, 16069, 16070, 16071, 16072, 16073 16074, 16075, 16076,

063216077, 16078, 16079 16080, 16081, 16082, 16083, 16084, 16085 16086, 16087, 16088, 16089, 16090, 16091, 16092, 16093, 16094, 16095, 16096, 16097, 16098, 16099, 16100, 16101, 16102, 16103, 16104, 16105, 16106, 16107, 16108, 16109, 16110, 16111, 16112, 16113, 16114, 16115, 16116, 16117, 16118, 16119, 16120, 16121, 16122, 16123, 16124, 16125, 16126, 16127, 16128, 16129, 16130, 16131.

0633[00094] The term "identity" as known in the art, refers to a relationship between the sequences of two or more peptides, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between peptides, as determined by the number of matches between strings of two or more amino acid residues. Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., "algorithms"). Identity of related peptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in

0634Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al, SIAM J. Applied Math. 48, 1073 (1988).

0635[00095] In some embodiments, the polypeptide variant may have the same or a similar activity as the reference polypeptide. Alternatively, the variant may have an altered activity (e.g., increased or decreased) relative to a reference polypeptide. Generally, variants of a particular polynucleotide or polypeptide of the invention will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity to that particular reference polynucleotide or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul, Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.) Other tools are described herein, specifically in the definition of "Identity."

0636[00096] Default parameters in the BLAST algorithm include, for example, an expect threshold of 10, Word size of 28, Match/Mismatch Scores 1, -2, Gap costs Linear. Any filter can be applied as well as a selection for species specific repeats, e.g., Homo sapiens. Biologies

0637[00097] The polynucleotides, primary constructs or mmRNA disclosed herein, may encode one or more biologies. As used herein, a "biologic" is a polypeptide-based molecule produced by the methods provided herein and which may be used to treat, cure, mitigate, prevent, or diagnose a serious or life-threatening disease or medical condition. Biologies, according to the present invention include, but are not limited to, allergenic extracts (e.g. for allergy shots and tests), blood components, gene therapy products, human tissue or cellular products used in transplantation, vaccines, monoclonal antibodies, cytokines, growth factors, enzymes, thrombolytics, and immunomodulators, among others.

0638[00098] According to the present invention, one or more biologies currently being marketed or in development may be encoded by the polynucleotides, primary constructs or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporation of the encoding polynucleotides of a known biologic into the primary constructs or mmRNA of the invention will result in improved therapeutic efficacy due at least in part to the specificity, purity and/or selectivity of the construct designs.

0639Antibodies

0640[00099] The primary constructs or mmRNA disclosed herein, may encode one or more antibodies or fragments thereof. The term "antibody" includes monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, multispecific antibodies (e.g., bispecific antibodies, diabodies, and single-chain molecules), as well as antibody fragments. The term "immunoglobulin" (Ig) is used interchangeably with "antibody" herein. As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations and/or post- translation modifications (e.g., isomerizations, amidations) that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site.

0641[000100] The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. Chimeric antibodies of interest herein include, but are not limited to, "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non- human primate (e.g., Old World Monkey, Ape etc.) and human constant region sequences.

0642[000101] An "antibody fragment" comprises a portion of an intact antibody, preferably the antigen binding and/or the variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2 and Fv fragments; diabodies; linear antibodies; nanobodies; single-chain antibody molecules and multispecific antibodies formed from antibody fragments.

0643[000102] Any of the five classes of immunoglobulins, IgA, IgD, IgE, IgG and IgM, may be encoded by the mmRNA of the invention, including the heavy chains designated alpha, delta, epsilon, gamma and mu, respectively. Also included are polynucleotide sequences encoding the subclasses, gamma and mu. Hence any of the subclasses of antibodies may be encoded in part or in whole and include the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl and IgA2.

0644[000103] According to the present invention, one or more antibodies or fragments currently being marketed or in development may be encoded by the polynucleotides, primary constructs or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporation into the primary constructs of the invention will result in improved therapeutic efficacy due at least in part to the specificity, purity and selectivity of the mmRNA designs.

0645[000104] Antibodies encoded in the polynucleotides, primary constructs or mmRNA of the invention may be utilized to treat conditions or diseases in many therapeutic areas such as, but not limited to, blood, cardiovascular, CNS, poisoning (including

0646antivenoms), dermatology, endocrinology, gastrointestinal, medical imaging,

0647musculoskeletal, oncology, immunology, respiratory, sensory and anti-infective.

0648[000105] In one embodiment, primary constructs or mmRNA disclosed herein may encode monoclonal antibodies and/or variants thereof. Variants of antibodies may also include, but are not limited to, substitutional variants, conservative amino acid substitution, insertional variants, deletional variants and/or covalent derivatives. In one embodiment, the primary construct and/or mmRNA disclosed herein may encode an immunoglobulin Fc region. In another embodiment, the primary constructs and/or mmRNA may encode a variant immunoglobulin Fc region. As a non-limiting example, the primary constructs and/or mmRNA may encode an antibody having a variant immunoglobulin Fc region as described in U.S. Pat. No. 8,217,147 herein incorporated by reference in its entirety.

0649Vaccines

0650[000106] The primary constructs or mmRNA disclosed herein, may encode one or more vaccines. As used herein, a "vaccine" is a biological preparation that improves immunity to a particular disease or infectious agent. According to the present invention, one or more vaccines currently being marketed or in development may be encoded by the polynucleotides, primary constructs or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporation into the primary constructs or mmRNA of the invention will result in improved therapeutic efficacy due at least in part to the specificity, purity and selectivity of the construct designs.

0651[000107] Vaccines encoded in the polynucleotides, primary constructs or mmRNA of the invention may be utilized to treat conditions or diseases in many therapeutic areas such as, but not limited to, cardiovascular, CNS, dermatology, endocrinology, oncology, immunology, respiratory, and anti-infective.

0652Therapeutic proteins or peptides [000108] The primary constructs or mmRNA disclosed herein, may encode one or more validated or "in testing" therapeutic proteins or peptides.

0653[000109] According to the present invention, one or more therapeutic proteins or peptides currently being marketed or in development may be encoded by the

0654polynucleotides, primary constructs or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporation into the primary constructs or mmRNA of the invention will result in improved therapeutic efficacy due at least in part to the specificity, purity and selectivity of the construct designs.

0655[000110] Therapeutic proteins and peptides encoded in the polynucleotides, primary constructs or mmRNA of the invention may be utilized to treat conditions or diseases in many therapeutic areas such as, but not limited to, blood, cardiovascular, CNS, poisoning (including antivenoms), dermatology, endocrinology, genetic, genitourinary,

0656gastrointestinal, musculoskeletal, oncology, and immunology, respiratory, sensory and anti-infective.

0657Cell-Penetrating Polypeptides

0658[000111] The primary constructs or mmRNA disclosed herein, may encode one or more cell-penetrating polypeptides. As used herein, "cell-penetrating polypeptide" or CPP refers to a polypeptide which may facilitate the cellular uptake of molecules. A cell- penetrating polypeptide of the present invention may contain one or more detectable labels. The polypeptides may be partially labeled or completely labeled throughout. The polynucleotide, primary construct or mmRNA may encode the detectable label completely, partially or not at all. The cell-penetrating peptide may also include a signal sequence. As used herein, a "signal sequence" refers to a sequence of amino acid residues bound at the amino terminus of a nascent protein during protein translation. The signal sequence may be used to signal the secretion of the cell-penetrating polypeptide.

0659[000112] In one embodiment, the polynucleotides, primary constructs or mmRNA may also encode a fusion protein. The fusion protein may be created by operably linking a charged protein to a therapeutic protein. As used herein, "operably linked" refers to the therapeutic protein and the charged protein being connected in such a way to permit the expression of the complex when introduced into the cell. As used herein, "charged protein" refers to a protein that carries a positive, negative or overall neutral electrical charge. Preferably, the therapeutic protein may be covalently linked to the charged protein in the formation of the fusion protein. The ratio of surface charge to total or surface amino acids may be approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9.

0660[000113] The cell-penetrating polypeptide encoded by the polynucleotides, primary constructs or mmRNA may form a complex after being translated. The complex may comprise a charged protein linked, e.g. covalently linked, to the cell-penetrating polypeptide. "Therapeutic protein" refers to a protein that, when administered to a cell has a therapeutic, diagnostic, and/or prophylactic effect and/or elicits a desired biological and/or pharmacological effect.

0661[000114] In one embodiment, the cell-penetrating polypeptide may comprise a first domain and a second domain. The first domain may comprise a supercharged

0662polypeptide. The second domain may comprise a protein-binding partner. As used herein, "protein-binding partner" includes, but is not limited to, antibodies and functional fragments thereof, scaffold proteins, or peptides. The cell-penetrating polypeptide may further comprise an intracellular binding partner for the protein-binding partner. The cell-penetrating polypeptide may be capable of being secreted from a cell where the polynucleotide, primary construct or mmRNA may be introduced. The cell-penetrating polypeptide may also be capable of penetrating the first cell.

0663[000115] In a further embodiment, the cell-penetrating polypeptide is capable of penetrating a second cell. The second cell may be from the same area as the first cell, or it may be from a different area. The area may include, but is not limited to, tissues and organs. The second cell may also be proximal or distal to the first cell.

0664[000116] In one embodiment, the polynucleotides, primary constructs or mmRNA may encode a cell-penetrating polypeptide which may comprise a protein-binding partner. The protein binding partner may include, but is not limited to, an antibody, a

0665supercharged antibody or a functional fragment. The polynucleotides, primary constructs or mmRNA may be introduced into the cell where a cell-penetrating polypeptide comprising the protein-binding partner is introduced.

0666Secreted proteins

0667[000117] Human and other eukaryotic cells are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

0668[000118] One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER).

0669[000119] Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane. While not wishing to be bound by theory, the molecules of the present invention may be used to exploit the cellular trafficking described above. As such, in some embodiments of the invention, polynucleotides, primary constructs or mrnRNA are provided to express a secreted protein. The secreted proteins may be selected from those described herein or those in US Patent Publication, 20100255574, the contents of which are incorporated herein by reference in their entirety.

0670[000120] In one embodiment, these may be used in the manufacture of large quantities of valuable human gene products.

0671Plasma membrane proteins

0672[000121] In some embodiments of the invention, polynucleotides, primary constructs or mrnRNA are provided to express a protein of the plasma membrane.

0673Cytoplasmic or cytoskeletal proteins

0674[000122] In some embodiments of the invention, polynucleotides, primary constructs or mrnRNA are provided to express a cytoplasmic or cytoskeletal protein.

0675Intracellular membrane bound proteins

0676[000123] In some embodiments of the invention, polynucleotides, primary constructs or mrnRNA are provided to express an intracellular membrane bound protein.

0677Nuclear proteins

0678[000124] In some embodiments of the invention, polynucleotides, primary constructs or mrnRNA are provided to express a nuclear protein. Proteins associated with human disease

0679[000125] In some embodiments of the invention, polynucleotides, primary constructs or mmRNA are provided to express a protein associated with human disease.

0680Miscellaneous proteins

0681[000126] In some embodiments of the invention, polynucleotides, primary constructs or mmRNA are provided to express a protein with a presently unknown therapeutic function.

0682Targeting Moieties

0683[000127] In some embodiments of the invention, polynucleotides, primary constructs or mmRNA are provided to express a targeting moiety. These include a protein-binding partner or a receptor on the surface of the cell, which functions to target the cell to a specific tissue space or to interact with a specific moiety, either in vivo or in vitro.

0684Suitable protein-binding partners include, but are not limited to, antibodies and functional fragments thereof, scaffold proteins, or peptides. Additionally, polynucleotide, primary construct or mmRNA can be employed to direct the synthesis and extracellular localization of lipids, carbohydrates, or other biological moieties or biomolecules.

0685Polypeptide Libraries

0686[000128] In one embodiment, the polynucleotides, primary constructs or mmRNA may be used to produce polypeptide libraries. These libraries may arise from the production of a population of polynucleotides, primary constructs or mmRNA, each containing various structural or chemical modification designs. In this embodiment, a population of polynucleotides, primary constructs or mmRNA may comprise a plurality of encoded polypeptides, including but not limited to, an antibody or antibody fragment, protein binding partner, scaffold protein, and other polypeptides taught herein or known in the art. In a preferred embodiment, the polynucleotides are primary constructs of the present invention, including mmRNA which may be suitable for direct introduction into a target cell or culture which in turn may synthesize the encoded polypeptides.

0687[000129] In certain embodiments, multiple variants of a protein, each with different amino acid modification(s), may be produced and tested to determine the best variant in terms of pharmacokinetics, stability, biocompatibility, and/or biological activity, or a biophysical property such as expression level. Such a library may contain 10, 102, 103, 104, 105, 106, 107, 108, 109, or over 109 possible variants (including, but not limited to, substitutions, deletions of one or more residues, and insertion of one or more residues). Anti-Microbial and Anti-viral Polypeptides

0688[000130] The polynucleotides, primary constructs and mmRNA of the present invention may be designed to encode on or more antimicrobial peptides (AMP) or antiviral peptides (A VP). AMPs and AVPs have been isolated and described from a wide range of animals such as, but not limited to, microorganisms, invertebrates, plants, amphibians, birds, fish, and mammals (Wang et ah, Nucleic Acids Res. 2009; 37 (Database issue):D933-7). For example, anti-microbial polypeptides are described in Antimicrobial Peptide Database (http://aps.unmc.edu/AP/main.php; Wang et ah, Nucleic Acids Res. 2009; 37 (Database issue):D933-7), CAMP: Collection of Anti-Microbial Peptides

0689(http://www.bicnirrh.res.in/antimicrobial/); Thomas et ah, Nucleic Acids Res. 2010; 38 (Database issue) :D774-80), US 5221732, US 5447914, US 5519115, US 5607914, US 5714577, US 5734015, US 5798336, US 5821224, US 5849490, US 5856127, US 5905187, US 5994308, US 5998374, US 6107460, US 6191254, US 6211148, US 6300489, US 6329504, US 6399370, US 6476189, US 6478825, US 6492328, US 6514701, US 6573361, US 6573361, US 6576755, US 6605698, US 6624140, US 6638531, US 6642203, US 6653280, US 6696238, US 6727066, US 6730659, US 6743598, US 6743769, US 6747007, US 6790833, US 6794490, US 6818407, US 6835536, US 6835713, US 6838435, US 6872705, US 6875907, US 6884776, US 6887847, US 6906035, US 6911524, US 6936432, US 7001924, US 7071293, US 7078380, US 7091185, US 7094759, US 7166769, US 7244710, US 7314858, and US 7582301, the contents of which are incorporated by reference in their entirety.

0690[000131] The anti-microbial polypeptides described herein may block cell fusion and/or viral entry by one or more enveloped viruses {e.g., HIV, HCV). For example, the antimicrobial polypeptide can comprise or consist of a synthetic peptide corresponding to a region, e.g., a consecutive sequence of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 amino acids of the transmembrane subunit of a viral envelope protein, e.g., HIV-1 gpl20 or gp41. The amino acid and nucleotide sequences of HIV- 1 gpl20 or gp41 are described in, e.g., Kuiken et ah, (2008). "HIV Sequence Compendium, " Los Alamos National Laboratory. [000132] In some embodiments, the anti-microbial polypeptide may have at least about 75%, 80%o, 85%), 90%), 95%, 100% sequence homology to the corresponding viral protein sequence. In some embodiments, the anti-microbial polypeptide may have at least about 75%o, 80%o, 85%o, 90%), 95%, or 100% sequence homology to the corresponding viral protein sequence.

0691[000133] In other embodiments, the anti-microbial polypeptide may comprise or consist of a synthetic peptide corresponding to a region, e.g. , a consecutive sequence of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 amino acids of the binding domain of a capsid binding protein. In some embodiments, the anti-microbial polypeptide may have at least about 75%, 80%, 85%, 90%, 95%, or 100% sequence homology to the corresponding sequence of the capsid binding protein.

0692[000134] The anti-microbial polypeptides described herein may block protease dimerization and inhibit cleavage of viral proproteins {e.g. , HIV Gag-pol processing) into functional proteins thereby preventing release of one or more enveloped viruses {e.g., HIV, HCV). In some embodiments, the anti-microbial polypeptide may have at least about 75%o, 80%o, 85%, 90%>, 95%, 100% sequence homology to the corresponding viral protein sequence.

0693[000135] In other embodiments, the anti-microbial polypeptide can comprise or consist of a synthetic peptide corresponding to a region, e.g. , a consecutive sequence of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 amino acids of the binding domain of a protease binding protein. In some embodiments, the anti-microbial polypeptide may have at least about 75%, 80%, 85%, 90%, 95%, 100% sequence homology to the corresponding sequence of the protease binding protein.

0694[000136] The anti-microbial polypeptides described herein can include an in vitro- evolved polypeptide directed against a viral pathogen.

0695Anti-Microbial Polypeptides

0696[000137] Anti-microbial polypeptides (AMPs) are small peptides of variable length, sequence and structure with broad spectrum activity against a wide range of

0697microorganisms including, but not limited to, bacteria, viruses, fungi, protozoa, parasites, prions, and tumor/cancer cells. (See, e.g., Zaiou, J Mol Med, 2007; 85:317; herein incorporated by reference in its entirety). It has been shown that AMPs have broad- spectrum of rapid onset of killing activities, with potentially low levels of induced resistance and concomitant broad anti-inflammatory effects.

0698[000138] In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) may be under lOkDa, e.g., under 8kDa, 6kDa, 4kDa, 2kDa, or lkDa. In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) consists of from about 6 to about 100 amino acids, e.g., from about 6 to about 75 amino acids, about 6 to about 50 amino acids, about 6 to about 25 amino acids, about 25 to about 100 amino acids, about 50 to about 100 amino acids, or about 75 to about 100 amino acids. In certain embodiments, the anti-microbial polypeptide (e.g., an antibacterial polypeptide) may consist of from about 15 to about 45 amino acids. In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) is substantially cationic.

0699[000139] In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) may be substantially amphipathic. In certain embodiments, the antimicrobial polypeptide (e.g. , an anti-bacterial polypeptide) may be substantially cationic and amphipathic. In some embodiments, the anti-microbial polypeptide (e.g., an antibacterial polypeptide) may be cytostatic to a Gram-positive bacterium. In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) may be cytotoxic to a Gram-positive bacterium. In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) may be cytostatic and cytotoxic to a Gram-positive bacterium. In some embodiments, the anti-microbial polypeptide (e.g. , an anti-bacterial polypeptide) may be cytostatic to a Gram-negative bacterium. In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) may be cytotoxic to a Gram-negative bacterium. In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) may be cytostatic and cytotoxic to a Gram-positive bacterium. In some embodiments, the anti-microbial polypeptide may be cytostatic to a virus, fungus, protozoan, parasite, prion, or a combination thereof. In some embodiments, the anti-microbial polypeptide may be cytotoxic to a virus, fungus, protozoan, parasite, prion, or a combination thereof. In certain embodiments, the antimicrobial polypeptide may be cytostatic and cytotoxic to a virus, fungus, protozoan, parasite, prion, or a combination thereof. In some embodiments, the anti-microbial polypeptide may be cytotoxic to a tumor or cancer cell (e.g., a human tumor and/or cancer cell). In some embodiments, the anti-microbial polypeptide may be cytostatic to a tumor or cancer cell (e.g., a human tumor and/or cancer cell). In certain embodiments, the anti-microbial polypeptide may be cytotoxic and cytostatic to a tumor or cancer cell (e.g., a human tumor or cancer cell). In some embodiments, the anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) may be a secreted polypeptide.

0700[000140] In some embodiments, the anti-microbial polypeptide comprises or consists of a defensin. Exemplary defensins include, but are not limited to, a-defensins (e.g., neutrophil defensin 1, defensin alpha 1, neutrophil defensin 3, neutrophil defensin 4, defensin 5, defensin 6), β-defensins (e.g., beta-defensin 1, beta-defensin 2, beta-defensin 103, beta-defensin 107, beta-defensin 110, beta-defensin 136), and θ-defensins. In other embodiments, the anti-microbial polypeptide comprises or consists of a cathelicidin (e.g., hCAP18).

0701Anti-Viral Polypeptides

0702[000141] Anti-viral polypeptides (A VPs) are small peptides of variable length, sequence and structure with broad spectrum activity against a wide range of viruses. See, e.g., Zaiou, J Mol Med, 2007; 85:317. It has been shown that AVPs have a broad- spectrum of rapid onset of killing activities, with potentially low levels of induced resistance and concomitant broad anti-inflammatory effects. In some embodiments, the anti-viral polypeptide is under lOkDa, e.g., under 8kDa, 6kDa, 4kDa, 2kDa, or lkDa. In some embodiments, the anti-viral polypeptide comprises or consists of from about 6 to about 100 amino acids, e.g., from about 6 to about 75 amino acids, about 6 to about 50 amino acids, about 6 to about 25 amino acids, about 25 to about 100 amino acids, about 50 to about 100 amino acids, or about 75 to about 100 amino acids. In certain

0703embodiments, the anti-viral polypeptide comprises or consists of from about 15 to about 45 amino acids. In some embodiments, the anti-viral polypeptide is substantially cationic. In some embodiments, the anti-viral polypeptide is substantially amphipathic. In certain embodiments, the anti-viral polypeptide is substantially cationic and amphipathic. In some embodiments, the anti-viral polypeptide is cytostatic to a virus. In some embodiments, the anti-viral polypeptide is cytotoxic to a virus. In some

0704embodiments, the anti-viral polypeptide is cytostatic and cytotoxic to a virus. In some embodiments, the anti-viral polypeptide is cytostatic to a bacterium, fungus, protozoan, parasite, prion, or a combination thereof. In some embodiments, the anti-viral polypeptide is cytotoxic to a bacterium, fungus, protozoan, parasite, prion or a combination thereof. In certain embodiments, the anti-viral polypeptide is cytostatic and cytotoxic to a bacterium, fungus, protozoan, parasite, prion, or a combination thereof. In some embodiments, the anti-viral polypeptide is cytotoxic to a tumor or cancer cell (e.g., a human cancer cell). In some embodiments, the anti-viral polypeptide is cytostatic to a tumor or cancer cell (e.g., a human cancer cell). In certain embodiments, the anti-viral polypeptide is cytotoxic and cytostatic to a tumor or cancer cell (e.g., a human cancer cell). In some embodiments, the anti-viral polypeptide is a secreted polypeptide.

0705Cytotoxic Nucleosides

0706[000142] In one embodiment, the polynucleotides, primary constructs or mmR A of the present invention may incorporate one or more cytotoxic nucleosides. For example, cytotoxic nucleosides may be incorporated into polynucleotides, primary constructs or mmRNA such as bifunctional modified RNAs or mRNAs. Cytotoxic nucleoside anticancer agents include, but are not limited to, adenosine arabinoside, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, FTORAFUR® (a combination of tegafur and uracil), tegafur ((RS)-5-fluoro-l-(tetrahydrofuran-2-yl)pyrimidine- 2,4(lH,3H)-dione), and 6-mercaptopurine.

0707[000143] A number of cytotoxic nucleoside analogues are in clinical use, or have been the subject of clinical trials, as anticancer agents. Examples of such analogues include, but are not limited to, cytarabine, gemcitabine, troxacitabine, decitabine, tezacitabine, 2'- deoxy-2'-methylidenecytidine (DMDC), cladribine, clofarabine, 5-azacytidine, 4'-thio- aracytidine, cyclopentenylcytosine and l-(2-C-cyano-2-deoxy-beta-D-arabino- pentofuranosyl)-cytosine. Another example of such a compound is fludarabine phosphate. These compounds may be administered systemically and may have side effects which are typical of cytotoxic agents such as, but not limited to, little or no specificity for tumor cells over proliferating normal cells.

0708[000144] A number of prodrugs of cytotoxic nucleoside analogues are also reported in the art. Examples include, but are not limited to, N4-behenoyl-l-beta-D- arabinofuranosylcytosine, N4-octadecyl- 1 -beta-D-arabinofuranosylcytosine, N4- palmitoyl-l-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine, and P-4055 (cytarabine 5'-elaidic acid ester). In general, these prodrugs may be converted into the active drugs mainly in the liver and systemic circulation and display little or no selective release of active drug in the tumor tissue. For example, capecitabine, a prodrug of 5'- deoxy-5-fluorocytidine (and eventually of 5-fluorouracil), is metabolized both in the liver and in the tumor tissue. A series of capecitabine analogues containing "an easily hydrolysable radical under physiological conditions" has been claimed by Fujiu et al. (U.S. Pat. No. 4,966,891) and is herein incorporated by reference. The series described by Fujiu includes N4 alkyl and aralkyl carbamates of 5'-deoxy-5-fluorocytidine and the implication that these compounds will be activated by hydrolysis under normal physiological conditions to provide 5'-deoxy-5-fluorocytidine.

0709[000145] A series of cytarabine N4-carbamates has been by reported by Fadl et al (Pharmazie. 1995, 50, 382-7, herein incorporated by reference) in which compounds were designed to convert into cytarabine in the liver and plasma. WO 2004/041203, herein incorporated by reference, discloses prodrugs of gemcitabine, where some of the prodrugs are N4-carbamates. These compounds were designed to overcome the gastrointestinal toxicity of gemcitabine and were intended to provide gemcitabine by hydrolytic release in the liver and plasma after absorption of the intact prodrug from the gastrointestinal tract. Nomura et al (Bioorg Med. Chem. 2003, 11, 2453-61, herein incorporated by reference) have described acetal derivatives of l-(3-C-ethynyl-P-D-ribo- pentofaranosyl) cytosine which, on bioreduction, produced an intermediate that required further hydrolysis under acidic conditions to produce a cytotoxic nucleoside compound.

0710[000146] Cytotoxic nucleotides which may be chemotherapeutic also include, but are not limited to, pyrazolo [3,4-D]-pyrimidines, allopurinol, azathioprine, capecitabine, cytosine arabinoside, fluorouracil, mercaptopurine, 6-thioguanine, acyclovir, ara- adenosine, ribavirin, 7-deaza-adenosine, 7-deaza-guanosine, 6-aza-uracil, 6-aza-cytidine, thymidine ribonucleotide, 5-bromodeoxyuridine, 2-chloro-purine, and inosine, or combinations thereof.

0711Flanking Regions: Untranslated Regions (UTRs)

0712[000147] Untranslated regions (UTRs) of a gene are transcribed but not translated. The 5'UTR starts at the transcription start site and continues to the start codon but does not include the start codon; whereas, the 3 'UTR starts immediately following the stop codon and continues until the transcriptional termination signal. There is growing body of evidence about the regulatory roles played by the UTRs in terms of stability of the nucleic acid molecule and translation. The regulatory features of a UTR can be incorporated into the polynucleotides, primary constructs and/or mmRNA of the present invention to enhance the stability of the molecule. The specific features can also be incorporated to ensure controlled down-regulation of the transcript in case they are misdirected to undesired organs sites.

07135' UTR and Translation Initiation

0714[000148] Natural 5'UTRs bear features which play roles in for translation initiation. They harbor signatures like Kozak sequences which are commonly known to be involved in the process by which the ribosome initiates translation of many genes. Kozak sequences have the consensus CCR(A/G)CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), which is followed by another 'G'. 5 'UTR also have been known to form secondary structures which are involved in elongation factor binding.

0715[000149] By engineering the features typically found in abundantly expressed genes of specific target organs, one can enhance the stability and protein production of the polynucleotides, primary constructs or mmRNA of the invention. For example, introduction of 5' UTR of liver-expressed mRNA, such as albumin, serum amyloid A, Apolipoprotein A/B/E, transferrin, alpha fetoprotein, erythropoietin, or Factor VIII, could be used to enhance expression of a nucleic acid molecule, such as a mmRNA, in hepatic cell lines or liver. Likewise, use of 5' UTR from other tissue-specific mRNA to improve expression in that tissue is possible for muscle (MyoD, Myosin, Myoglobin, Myogenin, Herculin), for endothelial cells (Tie-1, CD36), for myeloid cells (C/EBP, AML1, G-CSF, GM-CSF, CD1 lb, MSR, Fr-1, i-NOS), for leukocytes (CD45, CD18), for adipose tissue (CD36, GLUT4, ACRP30, adiponectin) and for lung epithelial cells (SP-A/B/C/D).

0716[000150] Other non-UTR sequences may be incorporated into the 5' (or 3' UTR) UTRs. For example, introns or portions of introns sequences may be incorporated into the flanking regions of the polynucleotides, primary constructs or mmRNA of the invention. Incorporation of intronic sequences may increase protein production as well as mRNA levels.

07173' UTR and the AU Rich Elements

0718[000151] 3' UTRs are known to have stretches of Adenosines and Uridines embedded in them. These AU rich signatures are particularly prevalent in genes with high rates of turnover. Based on their sequence features and functional properties, the AU rich elements (AREs) can be separated into three classes (Chen et al, 1995): Class I AREs contain several dispersed copies of an AUUUA motif within U-rich regions. C-Myc and MyoD contain class I AREs. Class II AREs possess two or more overlapping

0719UUAUUUA(U/A)(U/A) nonamers. Molecules containing this type of AREs include GM-CSF and TNF-a. Class III ARES are less well defined. These U rich regions do not contain an AUUUA motif. c-Jun and Myogenin are two well-studied examples of this class. Most proteins binding to the AREs are known to destabilize the messenger, whereas members of the ELAV family, most notably HuR, have been documented to increase the stability of mRNA. HuR binds to AREs of all the three classes. Engineering the HuR specific binding sites into the 3' UTR of nucleic acid molecules will lead to HuR binding and thus, stabilization of the message in vivo.

0720[000152] Introduction, removal or modification of 3' UTR AU rich elements (AREs) can be used to modulate the stability of polynucleotides, primary constructs or mmRNA of the invention. When engineering specific polynucleotides, primary constructs or mmRNA, one or more copies of an ARE can be introduced to make polynucleotides, primary constructs or mmRNA of the invention less stable and thereby curtail translation and decrease production of the resultant protein. Likewise, AREs can be identified and removed or mutated to increase the intracellular stability and thus increase translation and production of the resultant protein. Transfection experiments can be conducted in relevant cell lines, using polynucleotides, primary constructs or mmRNA of the invention and protein production can be assayed at various time points post-transfection. For example, cells can be transfected with different ARE-engineering molecules and by using an ELISA kit to the relevant protein and assaying protein produced at 6 hour, 12 hour, 24 hour, 48 hour, and 7 days post-transfection.

0721Incorporating microRNA Binding Sites [000153] microRNAs (or miRNA) are 19-25 nucleotide long noncoding RNAs that bind to the 3'UTR of nucleic acid molecules and down-regulate gene expression either by reducing nucleic acid molecule stability or by inhibiting translation. The

0722polynucleotides, primary constructs or mmRNA of the invention may comprise one or more microRNA target sequences, microRNA seqences, or microRNA seeds. Such sequences may correspond to any known microRNA such as those taught in US

0723Publication US2005/0261218 and US Publication US2005/0059005, the contents of which are incorporated herein by reference in their entirety.

0724[000154] A microRNA sequence comprises a "seed" region, i.e., a sequence in the region of positions 2-8 of the mature microRNA, which sequence has perfect Watson- Crick complementarity to the miRNA target sequence. A microRNA seed may comprise positions 2-8 or 2-7 of the mature microRNA. In some embodiments, a microRNA seed may comprise 7 nucleotides (e.g., nucleotides 2-8 of the mature microRNA), wherein the seed-complementary site in the corresponding miRNA target is flanked by an adenine (A) opposed to microRNA position 1. In some embodiments, a microRNA seed may comprise 6 nucleotides (e.g., nucleotides 2-7 of the mature microRNA), wherein the seed-complementary site in the corresponding miRNA target is flanked byan adenine (A) opposed to microRNA position 1. See for example, Grimson A, Farh K , Johnston WK, Garrett-Engele P, Lim LP, Barrel DP; Mol Cell. 2007 Jul 6;27(1):91-105; each of which is herein incorporated by reference in their entirety. The bases of the microRNA seed have complete complementarity with the target sequence. By engineering microRNA target sequences into the 3'UTR of polynucleotides, primary constructs or mmRNA of the invention one can target the molecule for degradation or reduced translation, provided the microRNA in question is available. This process will reduce the hazard of off target effects upon nucleic acid molecule delivery. Identification of microRNA, microRNA target regions, and their expression patterns and role in biology have been reported (Bonauer et al., Curr Drug Targets 2010 11 :943-949; Anand and Cheresh Curr Opin Hematol 2011 18: 171-176; Contreras and Rao Leukemia 2012 26:404-413 (2011 Dec 20. doi: 10.1038/leu.2011.356); Barrel Cell 2009 136:215-233; Landgraf et al, Cell, 2007 129: 1401-1414; each of which is herein incorporated by reference in its entirety). [000155] For example, if the nucleic acid molecule is an mRNA and is not intended to be delivered to the liver but ends up there, then miR-122, a microRNA abundant in liver, can inhibit the expression of the gene of interest if one or multiple target sites of miR-122 are engineered into the 3' UTR of the polynucleotides, primary constructs or mmRNA. Introduction of one or multiple binding sites for different microRNA can be engineered to further decrease the longevity, stability, and protein translation of a polynucleotides, primary constructs or mmRNA.

0725[000156] As used herein, the term "microRNA site" refers to a microRNA target site or a microRNA recognition site, or any nucleotide sequence to which a microRNA binds or associates. It should be understood that "binding" may follow traditional Watson-Crick hybridization rules or may reflect any stable association of the microRNA with the target sequence at or adjacent to the microRNA site.

0726[000157] Conversely, for the purposes of the polynucleotides, primary constructs or mmRNA of the present invention, microRNA binding sites can be engineered out of (i.e. removed from) sequences in which they naturally occur in order to increase protein expression in specific tissues. For example, miR-122 binding sites may be removed to improve protein expression in the liver. Regulation of expression in multiple tissues can be accomplished through introduction or removal or one or several microRNA binding sites.

0727[000158] Examples of tissues where microRNA are known to regulate mRNA, and thereby protein expression, include, but are not limited to, liver (miR-122), muscle (miR- 133, miR-206, miR-208), endothelial cells (miR-17-92, miR-126), myeloid cells (miR- 142-3p, miR-142-5p, miR-16, miR-21, miR-223, miR-24, miR-27), adipose tissue (let-7, miR-30c), heart (miR-ld, miR-149), kidney (miR-192, miR-194, miR-204), and lung epithelial cells (let-7, miR-133, miR-126). MicroRNA can also regulate complex biological processes such as angiogenesis (miR-132) (Anand and Cheresh Curr Opin Hematol 2011 18: 171-176; herein incorporated by reference in its entirety). In the polynucleotides, primary constructs or mmRNA of the present invention, binding sites for microRNAs that are involved in such processes may be removed or introduced, in order to tailor the expression of the polynucleotides, primary constructs or mmRNA expression to biologically relevant cell types or to the context of relevant biological processes. A listing of MicroRNA, miR sequences and miR binding sites is listed in Table 9 of U.S. Provisional Application No. 61/753,661 filed January 17, 2013, in Table 9 of U.S. Provisional Application No. 61/754,159 filed January 18, 2013, and in Table 7 of U.S. Provisional Application No. 61/758,921 filed January 31, 2013, each of which are herein incorporated by reference in their entireties.

0728[000159] Examples of use of microRNA to drive tissue or disease-specific gene expression are listed (Getner and Naldini, Tissue Antigens. 2012, 80:393-403; herein incoroporated by reference in its entirety). In addition, microRNA seed sites can be incorporated into mRNA to decrease expression in certain cells which results in a biological improvement. An example of this is incorporation of miR- 142 sites into a UGT1A1 -expressing lentiviral vector. The presence of miR- 142 seed sites reduced expression in hematopoietic cells, and as a consequence reduced expression in antigen- presentating cells, leading to the absence of an immune response against the virally expressed UGT1A1 (Schmitt et al, Gastroenterology 2010; 139:999-1007; Gonzalez- Asequinolaza et al. Gastroenterology 2010, 139:726-729; both herein incorporated by reference in its entirety) . Incorporation of miR- 142 sites into modified mRNA could not only reduce expression of the encoded protein in hematopoietic cells, but could also reduce or abolish immune responses to the mRNA-encoded protein. Incorporation of miR- 142 seed sites (one or multiple) into mRNA would be important in the case of treatment of patients with complete protein deficiencies (UGT1A1 type I, LDLR- deficient patients, CRIM-negative Pompe patients, etc.) .

0729[000160] Lastly, through an understanding of the expression patterns of microRNA in different cell types, polynucleotides, primary constructs or mmRNA can be engineered for more targeted expression in specific cell types or only under specific biological conditions. Through introduction of tissue-specific microRNA binding sites,

0730polynucleotides, primary constructs or mmRNA could be designed that would be optimal for protein expression in a tissue or in the context of a biological condition.

0731[000161] Transfection experiments can be conducted in relevant cell lines, using engineered polynucleotides, primary constructs or mmRNA and protein production can be assayed at various time points post-transfection. For example, cells can be transfected with different microRNA binding site-engineering polynucleotides, primary constructs or mmRNA and by using an ELISA kit to the relevant protein and assaying protein produced at 6 hour, 12 hour, 24 hour, 48 hour, 72 hour and 7 days post-transfection. In vivo experiments can also be conducted using microRNA-binding site-engineered molecules to examine changes in tissue-specific expression of formulated

0732polynucleotides, primary constructs or mmRNA.

07335' Capping

0734[000162] The 5' cap structure of an mRNA is involved in nuclear export, increasing mRNA stability and binds the mRNA Cap Binding Protein (CBP), which is responsibile for mRNA stability in the cell and translation competency through the association of CBP with poly(A) binding protein to form the mature cyclic mRNA species. The cap further assists the removal of 5' proximal introns removal during mRNA splicing.

0735[000163] Endogenous mRNA molecules may be 5'-end capped generating a 5'-ppp-5'- triphosphate linkage between a terminal guanosine cap residue and the 5 '-terminal transcribed sense nucleotide of the mRNA molecule. This 5'-guanylate cap may then be methylated to generate an N7-methyl-guanylate residue. The ribose sugars of the terminal and/or anteterminal transcribed nucleotides of the 5' end of the mRNA may optionally also be 2'-0-methylated. 5'-decapping through hydrolysis and cleavage of the guanylate cap structure may target a nucleic acid molecule, such as an mRNA molecule, for degradation.

0736[000164] Modifications to the polynucleotides, primary constructs, and mmRNA of the present invention may generate a non-hydrolyzable cap structure preventing decapping and thus increasing mRNA half-life. Because cap structure hydrolysis requires cleavage of 5'-ppp-5' phosphorodiester linkages, modified nucleotides may be used during the capping reaction. For example, a Vaccinia Capping Enzyme from New England Biolabs (Ipswich, MA) may be used with a-thio-guanosine nucleotides according to the manufacturer's instructions to create a phosphorothioate linkage in the 5'-ppp-5' cap. Additional modified guanosine nucleotides may be used such as a-methyl-phosphonate and seleno-phosphate nucleotides.

0737[000165] Additional modifications include, but are not limited to, 2'-0-methylation of the ribose sugars of 5 '-terminal and/or 5 '-anteterminal nucleotides of the mRNA (as mentioned above) on the 2'-hydroxyl group of the sugar ring. Multiple distinct 5 '-cap structures can be used to generate the 5 '-cap of a nucleic acid molecule, such as an mRNA molecule.

0738[000166] Cap analogs, which herein are also referred to as synthetic cap analogs, chemical caps, chemical cap analogs, or structural or functional cap analogs, differ from natural (i.e. endogenous, wild-type or physiological) 5'-caps in their chemical structure, while retaining cap function. Cap analogs may be chemically (i.e. non-enzymatically) or enzymatically synthesized and/or linked to a nucleic acid molecule.

0739[000167] For example, the Anti-Reverse Cap Analog (ARC A) cap contains two guanines linked by a 5 '-5 '-triphosphate group, wherein one guanine contains an N7 methyl group as well as a 3'-0-methyl group (i.e., N7,3'-0-dimethyl-guanosine-5'- triphosphate-5'-guanosine (m7G-3'mppp-G; which may equivaliently be designated 3' O- Me-m7G(5')ppp(5')G). The 3'-0 atom of the other, unmodified, guanine becomes linked to the 5'-terminal nucleotide of the capped nucleic acid molecule (e.g. an mRNA or mmRNA). The N7- and 3'-0-methlyated guanine provides the terminal moiety of the capped nucleic acid molecule (e.g. mRNA or mmRNA).

0740[000168] Another exemplary cap is mCAP, which is similar to ARCA but has a 2'-0- methyl group on guanosine (i.e., N7,2'-0-dimethyl-guanosine-5'-triphosphate-5'- guanosine, m7Gm-ppp-G).

0741[000169] While cap analogs allow for the concomitant capping of a nucleic acid molecule in an in vitro transcription reaction, up to 20% of transcripts can remain uncapped. This, as well as the structural differences of a cap analog from an endogenous 5 '-cap structures of nucleic acids produced by the endogenous, cellular transcription machinery, may lead to reduced translational competency and reduced cellular stability.

0742[000170] Polynucleotides, primary constructs and mmRNA of the invention may also be capped post-transcriptionally, using enzymes, in order to generate more authentic 5'- cap structures. As used herein, the phrase "more authentic" refers to a feature that closely mirrors or mimics, either structurally or functionally, an endogenous or wild type feature. That is, a "more authentic" feature is better representative of an endogenous, wild-type, natural or physiological cellular function and/or structure as compared to synthetic features or analogs, etc., of the prior art, or which outperforms the

0743corresponding endogenous, wild-type, natural or physiological feature in one or more respects. Non- limiting examples of more authentic 5 'cap structures of the present invention are those which, among other things, have enhanced binding of cap binding proteins, increased half life, reduced susceptibility to 5' endonucleases and/or reduced 5'decapping, as compared to synthetic 5 'cap structures known in the art (or to a wild-type, natural or physiological 5 'cap structure). For example, recombinant Vaccinia Virus Capping Enzyme and recombinant 2'-0-methyltransferase enzyme can create a canonical 5 '-5 '-triphosphate linkage between the 5 '-terminal nucleotide of an mRNA and a guanine cap nucleotide wherein the cap guanine contains an N7 methylation and the 5 '-terminal nucleotide of the mRNA contains a 2'-0-methyl. Such a structure is termed the Capl structure. This cap results in a higher translational-competency and cellular stability and a reduced activation of cellular pro-inflammatory cytokines, as compared, e.g., to other 5 'cap analog structures known in the art. Cap structures include, but are not limited to, 7mG(5*)ppp(5*)N,pN2p (cap 0), 7mG(5*)ppp(5*)NlmpNp (cap 1), and 7mG(5*)- ppp(5')NlmpN2mp (cap 2).

0744[000171] Because the polynucleotides, primary constructs or mmRNA may be capped post-transcriptionally, and because this process is more efficient, nearly 100% of the polynucleotides, primary constructs or mmRNA may be capped. This is in contrast to -80% when a cap analog is linked to an mRNA in the course of an in vitro transcription reaction.

0745[000172] According to the present invention, 5' terminal caps may include endogenous caps or cap analogs. According to the present invention, a 5' terminal cap may comprise a guanine analog. Useful guanine analogs include, but are not limited to, inosine, Nl- methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino- guanosine, LNA-guanosine, and 2-azido-guanosine.

0746Viral Sequences

0747[000173] Additional viral sequences such as, but not limited to, the translation enhancer sequence of the barley yellow dwarf virus (BYDV-PAV), the Jaagsiekte sheep retrovirus (JSRV) and/or the Enzootic nasal tumor virus (See e.g., International Pub. No.

0748WO2012129648; herein incorporated by reference in its entirety) can be engineered and inserted in the 3' UTR of the polynucleotides, primary constructs or mmRNA of the invention and can stimulate the translation of the construct in vitro and in vivo. Transfection experiments can be conducted in relevant cell lines at and protein production can be assayed by ELISA at 12hr, 24hr, 48hr, 72 hr and day 7 post- transfection.

0749IRES Sequences

0750[000174] Further, provided are polynucleotides, primary constructs or mmRNA which may contain an internal ribosome entry site (IRES). First identified as a feature Picorna virus RNA, IRES plays an important role in initiating protein synthesis in absence of the 5' cap structure. An IRES may act as the sole ribosome binding site, or may serve as one of multiple ribosome binding sites of an mRNA. Polynucleotides, primary constructs or mmRNA containing more than one functional ribosome binding site may encode several peptides or polypeptides that are translated independently by the ribosomes

0751("multicistronic nucleic acid molecules"). When polynucleotides, primary constructs or mmRNA are provided with an IRES, further optionally provided is a second translatable region. Examples of IRES sequences that can be used according to the invention include without limitation, those from picornaviruses (e.g. FMDV), pest viruses (CFFV), polio viruses (PV), encephalomyocarditis viruses (ECMV), foot-and-mouth disease viruses (FMDV), hepatitis C viruses (HCV), classical swine fever viruses (CSFV), murine leukemia virus (MLV), simian immune deficiency viruses (SIV) or cricket paralysis viruses (CrPV).

0752Poly-A tails

0753[000175] During RNA processing, a long chain of adenine nucleotides (poly- A tail) may be added to a polynucleotide such as an mRNA molecules in order to increase stability. Immediately after transcription, the 3' end of the transcript may be cleaved to free a 3' hydroxyl. Then poly-A polymerase adds a chain of adenine nucleotides to the RNA. The process, called polyadenylation, adds a poly-A tail that can be between, for example, approximately 100 and 250 residues long.

0754[000176] It has been discovered that unique poly-A tail lengths provide certain advantages to the polynucleotides, primary constructs or mmRNA of the present invention.

0755[000177] Generally, the length of a poly-A tail of the present invention is greater than 30 nucleotides in length. In another embodiment, the poly-A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, and 3,000 nucleotides). In some embodiments, the polynucleotide, primary construct, or mmR A includes from about 30 to about 3,000 nucleotides (e.g., from 30 to 50, from 30 to 100, from 30 to 250, from 30 to 500, from 30 to 750, from 30 to 1,000, from 30 to 1,500, from 30 to 2,000, from 30 to 2,500, from 50 to 100, from 50 to 250, from 50 to 500, from 50 to 750, from 50 to 1 ,000, from 50 to 1,500, from 50 to 2,000, from 50 to 2,500, from 50 to 3,000, from 100 to 500, from 100 to 750, from 100 to 1,000, from 100 to 1,500, from 100 to 2,000, from 100 to 2,500, from 100 to 3,000, from 500 to 750, from 500 to 1,000, from 500 to 1,500, from 500 to 2,000, from 500 to 2,500, from 500 to 3,000, from 1,000 to 1,500, from 1,000 to 2,000, from 1,000 to 2,500, from 1,000 to 3,000, from 1,500 to 2,000, from 1,500 to 2,500, from 1,500 to 3,000, from 2,000 to 3,000, from 2,000 to 2,500, and from 2,500 to 3,000).

0756[000178] In one embodiment, the poly- A tail is designed relative to the length of the overall polynucleotides, primary constructs or mmRNA. This design may be based on the length of the coding region, the length of a particular feature or region (such as the first or flanking regions), or based on the length of the ultimate product expressed from the polynucleotides, primary constructs or mmRNA.

0757[000179] In this context the poly-A tail may be 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% greater in length than the polynucleotides, primary constructs or mmRNA or feature thereof. The poly-A tail may also be designed as a fraction of polynucleotides, primary constructs or mmRNA to which it belongs. In this context, the poly-A tail may be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the construct or the total length of the construct minus the poly-A tail. Further, engineered binding sites and conjugation of polynucleotides, primary constructs or mmRNA for Poly-A binding protein may enhance expression.

0758[000180] Additionally, multiple distinct polynucleotides, primary constructs or mmRNA may be linked together to the PABP (Poly-A binding protein) through the 3'- end using modified nucleotides at the 3 '-terminus of the poly-A tail. Transfection experiments can be conducted in relevant cell lines at and protein production can be assayed by ELISA at 12hr, 24hr, 48hr, 72 hr and day 7 post-trans fection.

0759[000181] In one embodiment, the polynucleotide primary constructs of the present invention are designed to include a polyA-G Quartet. The G-quartet is a cyclic hydrogen bonded array of four guanine nucleotides that can be formed by G-rich sequences in both DNA and RNA. In this embodiment, the G-quartet is incorporated at the end of the poly- A tail. The resultant mmR A construct is assayed for stability, protein production and other parameters including half- life at various time points. It has been discovered that the polyA-G quartet results in protein production equivalent to at least 75% of that seen using a poly-A tail of 120 nucleotides alone.

0760Quantification

0761[000182] In one embodiment, the polynucleotides, primary constructs or mmRNA of the present invention may be quantified in exosomes derived from one or more bodily fluid. As used herein "bodily fluids" include peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, and umbilical cord blood. Alternatively, exosomes may be retrieved from an organ selected from the group consisting of lung, heart, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colon, breast, prostate, brain, esophagus, liver, and placenta.

0762[000183] In the quantification method, a sample of not more than 2mL is obtained from the subject and the exosomes isolated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration,

0763immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof. In the analysis, the level or concentration of a polynucleotide, primary construct or mmRNA may be an expression level, presence, absence, truncation or alteration of the administered construct. It is advantageous to correlate the level with one or more clinical phenotypes or with an assay for a human disease biomarker. The assay may be performed using construct specific probes, cytometry, qRT-PCR, real-time PCR, PCR, flow cytometry, electrophoresis, mass spectrometry, or combinations thereof while the exosomes may be isolated using immunohistochemical methods such as enzyme linked immunosorbent assay (ELISA) methods. Exosomes may also be isolated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.

0764[000184] These methods afford the investigator the ability to monitor, in real time, the level of polynucleotides, primary constructs or mmRNA remaining or delivered. This is possible because the polynucleotides, primary constructs or mmRNA of the present invention differ from the endogenous forms due to the structural or chemical

0765modifications.

0766II. Design and synthesis of mmRNA

0767[000185] Polynucleotides, primary constructs or mmRNA for use in accordance with the invention may be prepared according to any available technique including, but not limited to chemical synthesis, enzymatic synthesis, which is generally termed in vitro transcription (IVT) or enzymatic or chemical cleavage of a longer precursor, etc.

0768Methods of synthesizing RNAs are known in the art (see, e.g., Gait, M.J. (ed.)

0769Oligonucleotide synthesis: a practical approach, Oxford [Oxfordshire], Washington, DC: IRL Press, 1984; and Herdewijn, P. (ed.) Oligonucleotide synthesis: methods and applications, Methods in Molecular Biology, v. 288 (Clifton, N.J.) Totowa, N.J.: Humana Press, 2005; both of which are incorporated herein by reference).

0770[000186] The process of design and synthesis of the primary constructs of the invention generally includes the steps of gene construction, mRNA production (either with or without modifications) and purification. In the enzymatic synthesis method, a target polynucleotide sequence encoding the polypeptide of interest is first selected for incorporation into a vector which will be amplified to produce a cDNA template.

0771Optionally, the target polynucleotide sequence and/or any flanking sequences may be codon optimized. The cDNA template is then used to produce mRNA through in vitro transcription (IVT). After production, the mRNA may undergo purification and clean-up processes. The steps of which are provided in more detail below.

0772Gene Construction

0773[000187] The step of gene construction may include, but is not limited to gene synthesis, vector amplification, plasmid purification, plasmid linearization and clean-up, and cDNA template synthesis and clean-up.

0774Gene Synthesis

0775[000188] Once a polypeptide of interest, or target, is selected for production, a primary construct is designed. Within the primary construct, a first region of linked nucleosides encoding the polypeptide of interest may be constructed using an open reading frame (ORF) of a selected nucleic acid (DNA or RNA) transcript. The ORF may comprise the wild type ORF, an isoform, variant or a fragment thereof. As used herein, an "open reading frame" or "ORF" is meant to refer to a nucleic acid sequence (DNA or RNA) which is capable of encoding a polypeptide of interest. ORFs often begin with the start codon, ATG and end with a nonsense or termination codon or signal.

0776[000189] Further, the nucleotide sequence of the first region may be codon optimized. Codon optimization methods are known in the art and may be useful in efforts to achieve one or more of several goals. These goals include to match codon frequencies in target and host organisms to ensure proper folding, bias GC content to increase mRNA stability or reduce secondary structures, minimize tandem repeat codons or base runs that may impair gene construction or expression, customize transcriptional and translational control regions, insert or remove protein trafficking sequences, remove/add post translation modification sites in encoded protein (e.g. glycosylation sites), add, remove or shuffle protein domains, insert or delete restriction sites, modify ribosome binding sites and mRNA degradation sites, to adjust translational rates to allow the various domains of the protein to fold properly, or to reduce or eliminate problem secondary structures within the mRNA. Codon optimization tools, algorithms and services are known in the art, non- limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park CA) and/or proprietary methods. In one embodiment, the ORF sequence is optimized using optimization algorithms. Codon options for each amino acid are given in Table 1. Table 1. Codon Options

0777<img file="WO2013151663A1_D0002.tif" />

0778[000190] Features, which may be considered beneficial in some embodiments of the present invention, may be encoded by the primary construct and may flank the ORF as a first or second flanking region. The flanking regions may be incorporated into the primary construct before and/or after optimization of the ORF. It is not required that a primary construct contain both a 5' and 3' flanking region. Examples of such features include, but are not limited to, untranslated regions (UTRs), Kozak sequences, an oligo(dT) sequence, and detectable tags and may include multiple cloning sites which may have Xbal recognition.

0779[000191] In some embodiments, a 5' UTR and/or a 3' UTR may be provided as flanking regions. Multiple 5 ' or 3' UTRs may be included in the flanking regions and may be the same or of different sequences. Any portion of the flanking regions, including none, may be codon optimized and any may independently contain one or more different structural or chemical modifications, before and/or after codon optimization. Combinations of features may be included in the first and second flanking regions and may be contained within other features. For example, the ORF may be flanked by a 5' UTR which may contain a strong Kozak translational initiation signal and/or a 3' UTR which may include an oligo(dT) sequence for templated addition of a poly-A tail. 5 'UTR may comprise a first polynucleotide fragment and a second polynucleotide fragment from the same and/or different genes such as the 5 'UTRs described in US Patent Application Publication No. 20100293625, herein incorporated by reference in its entirety.

0780[000192] Tables 2 and 3 provide a listing of exemplary UTRs which may be utilized in the primary construct of the present invention as flanking regions. Shown in Table 2 is a listing of a 5 '-untranslated region of the invention. Variants of 5' UTRs may be utilized wherein one or more nucleotides are added or removed to the termini, including A, T, C or G.

0781Table 2. 5 '-Untranslated Regions

0782<img file="WO2013151663A1_D0003.tif" />

0783[000193] Shown in Table 3 is a representative listing of 3 '-untranslated regions of the invention. Variants of 3 ' UTRs may be utilized wherein one or more nucleotides are added or removed to the termini, including A, T, C or G.

0784Table 3. 3 '-Untranslated Regions

0785<img file="WO2013151663A1_D0004.tif" /> TGGCAGGGTCCTCTTCTTTTCCCAGAGCTC

CACCCCAACCAGGAGCTCTAGTTAATGGA

GAGCTCCCAGCACACTCGGAGCTTGTGCT

TTGTCTCCACGCAAAGCGATAAATAAAAG

CATTGGTGGCCTTTGGTCTTTGAATAAAGC

CTGAGTAGGAAGTCTAGA

GCCCCTGCCGCTCCCACCCCCACCCATCTG

GGCCCCGGGTTCAAGAGAGAGCGGGGTCT

GATCTCGTGTAGCCATATAGAGTTTGCTTC

TGAGTGTCTGCTTTGTTTAGTAGAGGTGG

GCAGGAGGAGCTGAGGGGCTGGGGCTGG

GGTGTTGAAGTTGGCTTTGCATGCCCAGC

GATGCGCCTCCCTGTGGGATGTCATCACC

CTGGGAACCGGGAGTGGCCCTTGGCTCAC

TGTGTTCTGCATGGTTTGGATCTGAATTAA

0800TTGTCCTTTCTTCTAAATCCCAACCGAACTUTR-002 Myoglobin 6

TCTTCCAACCTCCAAACTGGCTGTAACCCC

AAATCCAAGCCATTAACTACACCTGACAG

TAGCAATTGTCTGATTAATCACTGGCCCCT

TGAAGACAGCAGAATGTCCCTTTGCAATG

AGGAGGAGATCTGGGCTGGGCGGGCCAG

CTGGGGAAGCATTTGACTATCTGGAACTT

GTGTGTGCCTCCTCAGGTATGGCAGTGAC

TCACCTGGTTTTAATAAAACAACCTGCAA

CATCTCATGGTCTTTGAATAAAGCCTGAG

TAGGAAGTCTAGA

ACACACTCCACCTCCAGCACGCGACTTCT

CAGGACGACGAATCTTCTCAATGGGGGGG

CGGCTGAGCTCCAGCCACCCCGCAGTCAC

TTTCTTTGTAACAACTTCCGTTGCTGCCAT

0815α-actin CGTAAACTGACACAGTGTTTATAACGTGTUTR-003 7

ACATACATTAACTTATTACCTCATTTTGTT

0817AATGGAAAACTTGAAGAAGCATTAAAGTC ATTCTGTTAAGCTGCGTAAATGGTCTTTGA ATAAAGCCTGAGTAGGAAGTCTAGA

CATCACATTTAAAAGCATCTCAGCCTACC ATGAGAATAAGAGAAAGAAAATGAAGAT

GTTGGTGTAAAGCCAACACCCTGTCTAAA

AAACATAAATTTCTTTAATCATTTTGCCTC

TTTTCTCTGTGCTTCAATTAATAAAAAATG

0822Albumin

UTR-004 GAAAGAATCTAATAGAGTGGTACAGCACT 8

GTTATTTTTCAAAGATGTGTTGCTATCCTG

AAAATTCTGTAGGTTCTGTGGAAGTTCCA

GTGTTCTCTCTTATTCCACTTCGGTAGAGG

ATTTCTAGTTTCTTGTGGGCTAATTAAATA

AATCATTAATACTCTTCTAATGGTCTTTGA

0829ATAAAGCCTGAGTAGGAAGTCTAGAUTR-005 a-globin GCTGCCTTCTGCGGGGCTTGCCTTCTGGCC 9 ATGCCCTTCTTCTCTCCCTTGCACCTGTAC

CTCTTGGTCTTTGAATAAAGCCTGAGTAG GAAGGCGGCCGCTCGAGCATGCATCTAGA

GCCAAGCCCTCCCCATCCCATGTATTTATC

TCTATTTAATATTTATGTCTATTTAAGCCT

CATATTTAAAGACAGGGAAGAGCAGAAC

GGAGCCCCAGGCCTCTGTGTCCTTCCCTGC

ATTTCTGAGTTTCATTCTCCTGCCTGTAGC

AGTGAGAAAAAGCTCCTGTCCTCCCATCC

CCTGGACTGGGAGGTAGATAGGTAAATAC

CAAGTATTTATTACTATGACTGCTCCCCAG

CCCTGGCTCTGCAATGGGCACTGGGATGA

GCCGCTGTGAGCCCCTGGTCCTGAGGGTC

CCCACCTGGGACCCTTGAGAGTATCAGGT

CTCCCACGTGGGAGACAAGAAATCCCTGT

TTAATATTTAAACAGCAGTGTTCCCCATCT

GGGTCCTTGCACCCCTCACTCTGGCCTCAG

CCGACTGCACAGCGGCCCCTGCATCCCCTUTR-006 G-CSF TGGCTGTGAGGCCCCTGGACAAGCAGAGG 10

TGGCCAGAGCTGGGAGGCATGGCCCTGGG

GTCCCACGAATTTGCTGGGGAATCTCGTTT

TTCTTCTTAAGACTTTTGGGACATGGTTTG

ACTCCCGAACATCACCGACGCGTCTCCTG

TGCCCCCACGAGGGTCAGGACTGTGACTC

TTGCCTTGCTGGACGGGGACTGGGGATGT

GGGAGGGAGCAGACAGGAGGAATCATGT

CAGGCCTGTGTGTGAAAGGAAGCTCCACT

GTCACCCTCCACCTCTTCACCCCCCACTCA

CCAGTGTCCCCTCCACTGTCACATTGTAAC

TGAACTTCAGGATAATAAAGTGTTTGCCT

CCATGGTCTTTGAATAAAGCCTGAGTAGG

AAGGCGGCCGCTCGAGCATGCATCTAGA

ACTCAATCTAAATTAAAAAAGAAAGAAAT

TTGAAAAAACTTTCTCTTTGCCATTTCTTC

TTCTTCTTTTTTAACTGAAAGCTGAATCCT

TCCATTTCTTCTGCACATCTACTTGCTTAA

ATTGTGGGCAAAAGAGAAAAAGAAGGAT

TGATCAGAGCATTGTGCAATACAGTTTCA

TTAACTCCTTCCCCCGCTCCCCCAAAAATT

0866Colla2; TGAATTTTTTTTTCAACACTCTTACACCTG

0867UTR-007 collagen, type TTATGGAAAATGTCAACCTTTGTAAGAAA 1 1

0868I, alpha 2 ACCAAAATAAAAATTGAAAAATAAAAAC

CATAAACATTTGCACCACTTGTGGCTTTTG

AATATCTTCCACAGAGGGAAGTTTAAAAC

CCAAACTTCCAAAGGTTTAAACTACCTCA

AAACACTTTCCCATGAGTGTGATCCACAT

TGTTAGGTGCTGACCTAGACAGAGATGAA

CTGAGGTCCTTGTTTTGTTTTGTTCATAAT

ACAAAGGTGCTAATTAATAGTATTTCAGA TACTTGAAGAATGTTGATGGTGCTAGAAG

AATTTGAGAAGAAATACTCCTGTATTGAG

TTGTATCGTGTGGTGTATTTTTTAAAAAAT

TTGATTTAGCATTCATATTTTCCATCTTAT

TCCCAATTAAAAGTATGCAGATTATTTGC

CCAAATCTTCTTCAGATTCAGCATTTGTTC

TTTGCCAGTCTCATTTTCATCTTCTTCCAT

GGTTCCACAGAAGCTTTGTTTCTTGGGCA

AGCAGAAAAATTAAATTGTACCTATTTTG

TATATGTGAGATGTTTAAATAAATTGTGA

AAAAAATGAAATAAAGCATGTTTGGTTTT

CCAAAAGAACATAT

CGCCGCCGCCCGGGCCCCGCAGTCGAGGG

TCGTGAGCCCACCCCGTCCATGGTGCTAA

GCGGGCCCGGGTCCCACACGGCCAGCACC

GCTGCTCACTCGGACGACGCCCTGGGCCT

0891Col6a2; GCACCTCTCCAGCTCCTCCCACGGGGTCC

0892UTR-008 collagen, type CCGTAGCCCCGGCCCCCGCCCAGCCCCAG 12

0893VI, alpha 2 GTCTCCCCAGGCCCTCCGCAGGCTGCCCG

GCCTCCCTCCCCCTGCAGCCATCCCAAGG

CTCCTGACCTACCTGGCCCCTGAGCTCTGG

AGCAAGCCCTGACCCAATAAAGGCTTTGA

ACCCAT

GGGGCTAGAGCCCTCTCCGCACAGCGTGG

AGACGGGGCAAGGAGGGGGGTTATTAGG

ATTGGTGGTTTTGTTTTGCTTTGTTTAAAG

CCGTGGGAAAATGGCACAACTTTACCTCT

GTGGGAGATGCAACACTGAGAGCCAAGG

GGTGGGAGTTGGGATAATTTTTATATAAA

AGAAGTTTTTCCACTTTGAATTGCTAAAA

CTCATTTCTAAAATAGGGACGTGGCCAGG

CACGGTGGCTCATGCCTGTAATCCCAGCA

RPN1;

0908UTR-009 CTTTGGGAGGCCGAGGCAGGCGGCTCACG 13 ribophorin I

AGGTCAGGAGATCGAGACTATCCTGGCTA

ACACGGTAAAACCCTGTCTCTACTAAAAG

TACAAAAAATTAGCTGGGCGTGGTGGTGG

GCACCTGTAGTCCCAGCTACTCGGGAGGC

TGAGGCAGGAGAAAGGCATGAATCCAAG

AGGCAGAGCTTGCAGTGAGCTGAGATCAC

GCCATTGCACTCCAGCCTGGGCAACAGTG

TTAAGACTCTGTCTCAAATATAAATAAAT

AAATAAATAAATAAATAAATAAATAAAA

ATAAAGCGAGATGTTGCCCTCAAA

GGCCCTGCCCCGTCGGACTGCCCCCAGAA

0920LRP1 ; low

AGCCTCCTGCCCCCTGCCAGTGAAGTCCTT

0922density

0923CAGTGAGCCCCTCCCCAGCCAGCCCTTCCUTR-010 lipoprotein 14

CTGGCCCCGCCGGATGTATAAATGTAAAA

0925receptor-related

ATGAAGGAATTACATTTTATATGTGAGCG

0927protein 1

AGCAAGCCGGCAAGCGAGCACAGTATTAT TTCTCCATCCCCTCCCTGCCTGCTCCTTGG

CACCCCCATGCTGCCTTCAGGGAGACAGG

CAGGGAGGGCTTGGGGCTGCACCTCCTAC

CCTCCCACCAGAACGCACCCCACTGGGAG

AGCTGGTGGTGCAGCCTTCCCCTCCCTGTA

TAAGACACTTTGCCAAGGCTCTCCCCTCTC

GCCCCATCCCTGCTTGCCCGCTCCCACAGC

TTCCTGAGGGCTAATTCTGGGAAGGGAGA

GTTCTTTGCTGCCCCTGTCTGGAAGACGTG

GCTCTGGGTGAGGTAGGCGGGAAAGGAT

GGAGTGTTTTAGTTCTTGGGGGAGGCCAC

CCCAAACCCCAGCCCCAACTCCAGGGGCA

CCTATGAGATGGCCATGCTCAACCCCCCT

CCCAGACAGGCCCTCCCTGTCTCCAGGGC

CCCCACCGAGGTTCCCAGGGCTGGAGACT

TCCTCTGGTAAACATTCCTCCAGCCTCCCC

TCCCCTGGGGACGCCAAGGAGGTGGGCCA

CACCCAGGAAGGGAAAGCGGGCAGCCCC

GTTTTGGGGACGTGAACGTTTTAATAATTT

TTGCTGAATTCCTTTACAACTAAATAACAC

AGATATTGTTATAAATAAAATTGT

ATATTAAGGATCAAGCTGTTAGCTAATAA

TGCCACCTCTGCAGTTTTGGGAACAGGCA

AATAAAGTATCAGTATACATGGTGATGTA

CATCTGTAGCAAAGCTCTTGGAGAAAATG

AAGACTGAAGAAAGCAAAGCAAAAACTG

TATAGAGAGATTTTTCAAAAGCAGTAATC

CCTCAATTTTAAAAAAGGATTGAAAATTC

TAAATGTCTTTCTGTGCATATTTTTTGTGT

TAGGAATCAAAAGTATTTTATAAAAGGAG

AAAGAACAGCCTCATTTTAGATGTAGTCC

TGTTGGATTTTTTATGCCTCCTCAGTAACC

AGAAATGTTTTAAAAAACTAAGTGTTTAG

GATTTCAAGACAACATTATACATGGCTCT

0962Nntl; GAAATATCTGACACAATGTAAACATTGCA cardiotrophin- GGCACCTGCATTTTATGTTTTTTTTTTCAAUTR-01 1 15 like cytokine CAAATGTGACTAATTTGAAACTTTTATGA

0963factor 1 ACTTCTGAGCTGTCCCCTTGCAATTCAACC

GCAGTTTGAATTAATCATATCAAATCAGT

ATATTTCAAGGGCACATTTTCTCACTACTA

TTTTAATACATTAAAGGACTAAATAATCTT

TCAGAGATGCTGGAAACAAATCATTTGCT

TTATATGTTTCATTAGAATACCAATGAAA

CATACAACTTGAAAATTAGTAATAGTATT

TTTGAAGATCCCATTTCTAATTGGAGATCT

CTTTAATTTCGATCAACTTATAATGTGTAG

TACTATATTAAGTGCACTTGAGTGGAATT

CAACATTTGACTAATAAAATGAGTTCATC

ATGTTGGCAAGTGATGTGGCAATTATCTC

0975TGGTGACAAAAGAGTAAAATCAAATATTT CTGCCTGTTACAAATATCAAGGAAGACCT GCTACTATGAAATAGATGACATTAATCTG TCTTCACTGTTTATAATACGGATGGATTTT TTTTCAAATCAGTGTGTGTTTTGAGGTCTT ATGTAATTGATGACATTTGAGAGAAATGG TGGCTTTTTTTAGCTACCTCTTTGTTCATTT

AGAAGTGTAGATTTTCTTTGTGACTTTGCT

ATCGTGCCTAAAGCTCTAAATATAGGTGA

ATGTGTGATGAATACTCAGATTATTTGTCT

CTCTATATAATTAGTTTGGTACTAAGTTTC

TCAAAAAATTATTAACACATGAAAGACAA

TCTCTAAACCAGAAAAAGAAGTAGTACAA

ATTTTGTTACTGTAATGCTCGCGTTTAGTG

AGTTTAAAACACACAGTATCTTTTGGTTTT

ATAATCAGTTTCTATTTTGCTGTGCCTGAG

ATTAAGATCTGTGTATGTGTGTGTGTGTGT

GTGTGCGTTTGTGTGTTAAAGCAGAAAAG

ACTTTTTTAAAAGTTTTAAGTGATAAATGC

AATTTGTTAATTGATCTTAGATCACTAGTA

AACTCAGGGCTGAATTATACCATGTATAT

TCTATTAGAAGAAAGTAAACACCATCTTT

TTGTAGTTATATCTAGAAAGAAGCAATTT

TGATTTCTTGAAAAGGTAGTTCCTGCACTC

AGTTTAAACTAAAAATAATCATACTTGGA

0994TAATTTATATATATTTTTATTTAGTATTAT CTTATTCTTTGCTATTTGCCAATCCTTTGTC ATCAATTGTGTTAAATGAATTGAAAATTC ATGCCCTGTTCATTTTATTTTACTTTATTG

0995TAATTTCTTAAATTAATATTCCAAAAGGTT <img file="WO2013151663A1_D0005.tif" />

TAAGTCATACAATTGGTAGATATGACTTA

TTTTATTTTTGTATTATTCACTATATCTTTA

TGATATTTAAGTATAAATAATTAAAAAAA

TTTATTGTACCTTATAGTCTGTCACCAAAA

AAAAAAAATTATCTGTAGGTAGTGAAATG

CTAATGTTGATTTGTCTTTAAGGGCTTGTT

AACTATCCTTTATTTTCTCATTTGTCTTAA

ATTAGGAGTTTGTGTTTAAATTACTCATCT

AAGCAAAAAATGTATATAAATCCCATTAC

TGGGTATATACCCAAAGGATTATAAATCA

TGCTGCTATAAAGACACATGCACACGTAT

GTTTATTGCAGCACTATTCACAATAGCAA

AGACTTGGAACCAACCCAAATGTCCATCA

ATGATAGACTTGATTAAGAAAATGTGCAC

ATATACACCATGGAATACTATGCAGCCAT AAAAAAGGATGAGTTCATGTCCTTTGTAG

GGACATGGATAAAGCTGGAAACCATCATT

CTGAGCAAACTATTGCAAGGACAGAAAAC

CAAACACTGCATGTTCTCACTCATAGGTG

GGAATTGAACAATGAGAACACTTGGACAC

AAGGTGGGGAACACCACACACCAGGGCC

TGTCATGGGGTGGGGGGAGTGGGGAGGG

ATAGCATTAGGAGATATACCTAATGTAAA

TGATGAGTTAATGGGTGCAGCACACCAAC

ATGGCACATGTATACATATGTAGCAAACC

TGCACGTTGTGCACATGTACCCTAGAACT

TAAAGTATAATTAAAAAAAAAAAGAAAA

CAGAAGCTATTTATAAAGAAGTTATTTGC

TGAAATAAATGTGATCTTTCCCATTAAAA

AAATAAAGAAATTTTGGGGTAAAAAAAC

ACAATATATTGTATTCTTGAAAAATTCTAA

GAGAGTGGATGTGAAGTGTTCTCACCACA

AAAGTGATAACTAATTGAGGTAATGCACA

TATTAATTAGAAAGATTTTGTCATTCCACA

ATGTATATATACTTAAAAATATGTTATAC

ACAATAAATACATACATTAAAAAATAAGT

AAATGTA

1032CCCACCCTGCACGCCGGCACCAAACCCTG TCCTCCCACCCCTCCCCACTCATCACTAAA CAGAGTAAAATGTGATGCGAATTTTCCCG

GAAAAGCTTGGAAAGCCAGGACACAACG

CTGCTGCCTGCTTTGTGCAGGGTCCTCCGG

GGCTCAGCCCTGAGTTGGCATCACCTGCG

CAGGGCCCTCTGGGGCTCAGCCCTGAGCT

AGTGTCACCTGCACAGGGCCCTCTGAGGC

TCAGCCCTGAGCTGGCGTCACCTGTGCAG

GGCCCTCTGGGGCTCAGCCCTGAGCTGGC

CTCACCTGGGTTCCCCACCCCGGGCTCTCC

TGCCCTGCCCTCCTGCCCGCCCTCCCTCCT

1042Col6al ; GCCTGCGCAGCTCCTTCCCTAGGCACCTCTUTR-012 collagen, type GTGCTGCATCCCACCAGCCTGAGCAAGAC 16

1043VI, alpha 1 GCCCTCTCGGGGCCTGTGCCGCACTAGCC

TCCCTCTCCTCTGTCCCCATAGCTGGTTTT

TCCCACCAATCCTCACCTAACAGTTACTTT

ACAATTAAACTCAAAGCAAGCTCTTCTCC

TCAGCTTGGGGCAGCCATTGGCCTCTGTCT

CGTTTTGGGAAACCAAGGTCAGGAGGCCG

TTGCAGACATAAATCTCGGCGACTCGGCC

CCGTCTCCTGAGGGTCCTGCTGGTGACCG

GCCTGGACCTTGGCCCTACAGCCCTGGAG

GCCGCTGCTGACCAGCACTGACCCCGACC

TCAGAGAGTACTCGCAGGGGCGCTGGCTG

CACTCAAGACCCTCGAGATTAACGGTGCT

AACCCCGTCTGCTCCTCCCTCCCGCAGAG

ACTGGGGCCTGGACTGGACATGAGAGCCC CTTGGTGCCACAGAGGGCTGTGTCTTACT

1057AGAAACAACGCAAACCTCTCCTTCCTCAG AATAGTGATGTGTTCGACGTTTTATCAAA GGCCCCCTTTCTATGTTCATGTTAGTTTTG

CATGTTGCTGACTTTTCCAAATAAAGGTTT TCACTCCTCTC

1059AGAGGCCTGCCTCCAGGGCTGGACTGAGG CCTGAGCGCTCCTGCCGCAGAGCTGGCCG CGCCAAATAATGTCTCTGTGAGACTCGAG

TTTGGGGTGGATTTTGGTTTTGTTCCCCTC CTCCACTCTCCCCCACCCCCTCCCCGCCCT

TCTTTGATTCTCCTTCAGCCCTCACCCCTG

GTTCTCATCTTTCTTGATCAACATCTTTTCT

1063Calr; TGCCTCTGTCCCCTTCTCTCATCTCTTAGC

1064UTR-013 17 calreticulin TCCCCTCCAACCTGGGGGGCAGTGGTGTG

GAGAAGCCACAGGCCTGAGATTTCATCTG

CTCTCCTTCCTGGAGCCCAGAGGAGGGCA

GCAGAAGGGGGTGGTGTCTCCAACCCCCC

AGCACTGAGGAAGAACGGGGCTCTTCTCA

TTTCACCCCTCCCTTTCTCCCCTGCCCCCA

GGACTGGGCCACTTCTGGGTGGGGCAGTG

GGTCCCAGATTGGCTCACACTGAGAATGT

AAGAACTACAAACAAAATTTCTATTAAAT

TAAATTTTGTGTCTCC

1074CTCCCTCCATCCCAACCTGGCTCCCTCCCA CCCAACCAACTTTCCCCCCAACCCGGAAA CAGACAAGCAACCCAAACTGAACCCCCTC AAAAGCCAAAAAATGGGAGACAATTTCA

GCATTCATCTCTCAAACTTAGTTTTTATCT

TTGACCAACCGAACATGACCAAAAACCAA

AAGTGCATTCAACCTTACCAAAAAAAAAA

AAAAAAAAAGAATAAATAAATAACTTTTT

AAAAAAGGAAGCTTGGTCCACTTGCTTGA

AGACCCATGCGGGGGTAAGTCCCTTTCTG

1081Collal ;

1082CCCGTTGGGCTTATGAAACCCCAATGCTGUTR-014 collagen, type 18

CCCTTTCTGCTCCTTTCTCCACACCCCCCT

1084I, alpha 1

TGGGGCCTCCCCTCCACTCCTTCCCAAATC

TGTCTCCCCAGAAGACACAGGAAACAATG

TATTGTCTGCCCAGCAATCAAAGGCAATG

CTCAAACACCCAAGTGGCCCCCACCCTCA

GCCCGCTCCTGCCCGCCCAGCACCCCCAG

GCCCTGGGGGACCTGGGGTTCTCAGACTG

CCAAAGAAGCCTTGCCATCTGGCGCTCCC

ATGGCTCTTGCAACATCTCCCCTTCGTTTT

TGAGGGGGTCATGCCGGGGGAGCCACCA

GCCCCTCACTGGGTTCGGAGGAGAGTCAG

GAAGGGCCACGACAAAGCAGAAACATCG GATTTGGGGAACGCGTGTCAATCCCTTGT

GCCGCAGGGCTGGGCGGGAGAGACTGTTC

TGTTCCTTGTGTAACTGTGTTGCTGAAAGA

CTACCTCGTTCTTGTCTTGATGTGTCACCG

GGGCAACTGCCTGGGGGCGGGGATGGGG

GCAGGGTGGAAGCGGCTCCCCATTTTATA

CCAAAGGTGCTACATCTATGTGATGGGTG

1102GGGTGGGGAGGGAATCACTGGTGCTATAG <img file="WO2013151663A1_D0006.tif" />

TGTGGATGGGGACTTGTGAATTTTTCTAA

AGGTGCTATTTAACATGGGAGGAGAGCGT

GTGCGGCTCCAGCCCAGCCCGCTGCTCAC

TTTCCACCCTCTCTCCACCTGCCTCTGGCT

TCTCAGGCCTCTGCTCTCCGACCTCTCTCC

TCTGAAACCCTCCTCCACAGCTGCAGCCC

ATCCTCCCGGCTCCCTCCTAGTCTGTCCTG

CGTCCTCTGTCCCCGGGTTTCAGAGACAA

CTTCCCAAAGCACAAAGCAGTTTTTCCCC

CTAGGGGTGGGAGGAAGCAAAAGACTCT

GTACCTATTTTGTATGTGTATAATAATTTG

TAAAGCATGTGGAAATGACCCAAACATAA

TCCGCAGTGGCCTCCTAATTTCCTTCTTTG

GAGTTGGGGGAGGGGTAGACATGGGGAA

GGGGCTTTGGGGTGATGGGCTTGCCTTCC

ATTCCTGCCCTTTCCCTCCCCACTATTCTC

TTCTAGATCCCTCCATAACCCCACTCCCCT

TTCTCTCACCCTTCTTATACCGCAAACCTT

TCTACTTCCTCTTTCATTTTCTATTCTTGCA

ATTTCCTTGCACCTTTTCCAAATCCTCTTC

TCCCCTGCAATACCATACAGGCAATCCAC

GTGCACAACACACACACACACTCTTCACA

TCTGGGGTTGTCCAAACCTCATACCCACTC

CCCTTCAAGCCCATCCACTCTCCACCCCCT

GGATGCCCTGCACTTGGTGGCGGTGGGAT

GCTCATGGATACTGGGAGGGTGAGGGGA

GTGGAACCCGTGAGGAGGACCTGGGGGC

CTCTCCTTGAACTGACATGAAGGGTCATC

TGGCCTCTGCTCCCTTCTCACCCACGCTGA

CCTCCTGCCGAAGGAGCAACGCAACAGGA

GAGGGGTCTGCTGAGCCTGGCGAGGGTCT

GGGAGGGACCAGGAGGAAGGCGTGCTCC

CTGCTCGCTGTCCTGGCCCTGGGGGAGTG

AGGGAGACAGACACCTGGGAGAGCTGTG

GGGAAGGCACTCGCACCGTGCTCTTGGGA

AGGAAGGAGACCTGGCCCTGCTCACCACG

GACTGGGTGCCTCGACCTCCTGAATCCCC

AGAACACAACCCCCCTGGGCTGGGGTGGT

CTGGGGAACCATCGTGCCCCCGCCTCCCG CCTACTCCTTTTTAAGCTT

TTGGCCAGGCCTGACCCTCTTGGACCTTTC

TTCTTTGCCGACAACCACTGCCCAGCAGC

CTCTGGGACCTCGGGGTCCCAGGGAACCC

AGTCCAGCCTCCTGGCTGTTGACTTCCCAT

TGCTCTTGGAGCCACCAATCAAAGAGATT

CAAAGAGATTCCTGCAGGCCAGAGGCGG

AACACACCTTTATGGCTGGGGCTCTCCGT

GGTGTTCTGGACCCAGCCCCTGGAGACAC

CATTCACTTTTACTGCTTTGTAGTGACTCG

TGCTCTCCAACCTGTCTTCCTGAAAAACCA

1152Plodl ; AGGCCCCCTTCCCCCACCTCTTCCATGGGG procollagen- TGAGACTTGAGCAGAACAGGGGCTTCCCCUTR-015 lysine, 2- AAGTTGCCCAGAAAGACTGTCTGGGTGAG 19 oxoglutarate 5- AAGCCATGGCCAGAGCTTCTCCCAGGCAC dioxygenase 1 AGGTGTTGCACCAGGGACTTCTGCTTCAA

GTTTTGGGGTAAAGACACCTGGATCAGAC

TCCAAGGGCTGCCCTGAGTCTGGGACTTC

TGCCTCCATGGCTGGTCATGAGAGCAAAC

CGTAGTCCCCTGGAGACAGCGACTCCAGA

GAACCTCTTGGGAGACAGAAGAGGCATCT

GTGCACAGCTCGATCTTCTACTTGCCTGTG

GGGAGGGGAGTGACAGGTCCACACACCA

CACTGGGTCACCCTGTCCTGGATGCCTCTG

AAGAGAGGGACAGACCGTCAGAAACTGG

AGAGTTTCTATTAAAGGTCATTTAAACCA

TCCTCCGGGACCCCAGCCCTCAGGATTCC

TGATGCTCCAAGGCGACTGATGGGCGCTG

GATGAAGTGGCACAGTCAGCTTCCCTGGG

GGCTGGTGTCATGTTGGGCTCCTGGGGCG

GGGGCACGGCCTGGCATTTCACGCATTGC

TGCCACCCCAGGTCCACCTGTCTCCACTTT

CACAGCCTCCAAGTCTGTGGCTCTTCCCTT

CTGTCCTCCGAGGGGCTTGCCTTCTCTCGT

GTCCAGTGAGGTGCTCAGTGATCGGCTTA

ACTTAGAGAAGCCCGCCCCCTCCCCTTCTC

CGTCTGTCCCAAGAGGGTCTGCTCTGAGC

CTGCGTTCCTAGGTGGCTCGGCCTCAGCT

1175Nucbl ;

1176UTR-016 GCCTGGGTTGTGGCCGCCCTAGCATCCTG 20 nucleobindin 1

TATGCCCACAGCTACTGGAATCCCCGCTG

CTGCTCCGGGCCAAGCTTCTGGTTGATTA

ATGAGGGCATGGGGTGGTCCCTCAAGACC

TTCCCCTACCTTTTGTGGAACCAGTGATGC

CTCAAAGACAGTGTCCCCTCCACAGCTGG

GTGCCAGGGGCAGGGGATCCTCAGTATAG

CCGGTGAACCCTGATACCAGGAGCCTGGG

CCTCCCTGAACCCCTGGCTTCCAGCCATCT

CATCGCCAGCCTCCTCCTGGACCTCTTGGC

CCCCAGCCCCTTCCCCACACAGCCCCAGA

AGGGTCCCAGAGCTGACCCCACTCCAGGA

CCTAGGCCCAGCCCCTCAGCCTCATCTGG AGCCCCTGAAGACCAGTCCCACCCACCTT

1189TCTGGCCTCATCTGACACTGCTCCGCATCC TGCTGTGTGTCCTGTTCCATGTTCCGGTTC CATCCAAATACACTTTCTGGAACAAA

GCTGGAGCCTCGGTGGCCATGCTTCTTGC

1191α-globin CCCTTGGGCCTCCCCCCAGCCCCTCCTCCC

3UTR-017 21

CTTCCTGCACCCGTACCCCCGTGGTCTTTG AATAAAGTCTGAGTGGGCGGC

1194[000194] It should be understood that those listed in the previous tables are examples and that any UTR from any gene may be incorporated into the respective first or second flanking region of the primary construct. Furthermore, multiple wild-type UTRs of any known gene may be utilized. It is also within the scope of the present invention to provide artificial UTRs which are not variants of wild type genes. These UTRs or portions thereof may be placed in the same orientation as in the transcript from which they were selected or may be altered in orientation or location. Hence a 5 ' or 3' UTR may be inverted, shortened, lengthened, made chimeric with one or more other 5' UTRs or 3' UTRs. As used herein, the term "altered" as it relates to a UTR sequence, means that the UTR has been changed in some way in relation to a reference sequence. For example, a 3' or 5' UTR may be altered relative to a wild type or native UTR by the change in orientation or location as taught above or may be altered by the inclusion of additional nucleotides, deletion of nucleotides, swapping or transposition of nucleotides. Any of these changes producing an "altered" UTR (whether 3' or 5') comprise a variant UTR.

1195[000195] In one embodiment, a double, triple or quadruple UTR such as a 5' or 3' UTR may be used. As used herein, a "double" UTR is one in which two copies of the same UTR are encoded either in series or substantially in series. For example, a double beta- globin 3' UTR may be used as described in US Patent publication 20100129877, the contents of which are incorporated herein by reference in its entirety.

1196[000196] It is also within the scope of the present invention to have patterned UTRs. As used herein "patterned UTRs" are those UTRs which reflect a repeating or alternating pattern, such as ABABAB or AABBAABBAABB or ABCABCABC or variants thereof repeated once, twice, or more than 3 times. In these patterns, each letter, A, B, or C represent a different UTR at the nucleotide level. [000197] In one embodiment, flanking regions are selected from a family of transcripts whose proteins share a common function, structure, feature of property. For example, polypeptides of interest may belong to a family of proteins which are expressed in a particular cell, tissue or at some time during development. The UTRs from any of these genes may be swapped for any other UTR of the same or different family of proteins to create a new chimeric primary transcript. As used herein, a "family of proteins" is used in the broadest sense to refer to a group of two or more polypeptides of interest which share at least one function, structure, feature, localization, origin, or expression pattern.

1197[000198] After optimization (if desired), the primary construct components are reconstituted and transformed into a vector such as, but not limited to, plasmids, viruses, cosmids, and artificial chromosomes. For example, the optimized construct may be reconstituted and transformed into chemically competent E. coli, yeast, neurospora, maize, drosophila, etc. where high copy plasmid-like or chromosome structures occur by methods described herein.

1198[000199] The untranslated region may also include translation enhancer elements (TEE). As a non-limiting example, the TEE may include those described in US

1199Application No. 20090226470, herein incorporated by reference in its entirety, and those known in the art.

1200Stop Codons

1201[000200] In one embodiment, the primary constructs of the present invention may include at least two stop codons before the 3' untranslated region (UTR). The stop codon may be selected from TGA, TAA and TAG. In one embodiment, the primary constructs of the present invention include the stop codon TGA and one additional stop codon. In a further embodiment the addition stop codon may be TAA. In another embodiment, the primary constructs of the present invention include three stop codons.

1202Vector Amplification

1203[000201] The vector containing the primary construct is then amplified and the plasmid isolated and purified using methods known in the art such as, but not limited to, a maxi prep using the Invitrogen PURELINK™ HiPure Maxiprep Kit (Carlsbad, CA).

1204Plasmid Linearization [000202] The plasmid may then be linearized using methods known in the art such as, but not limited to, the use of restriction enzymes and buffers. The linearization reaction may be purified using methods including, for example Invitrogen's PURELINK™ PCR Micro Kit (Carlsbad, CA), and HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP- HPLC), and hydrophobic interaction HPLC (HIC-HPLC) and Invitrogen's standard PURELINK™ PCR Kit (Carlsbad, CA). The purification method may be modified depending on the size of the linearization reaction which was conducted. The linearized plasmid is then used to generate cDNA for in vitro transcription (IVT) reactions.

1205cDNA Template Synthesis

1206[000203] A cDNA template may be synthesized by having a linearized plasmid undergo polymerase chain reaction (PCR). Table 4 is a listing of primers and probes that may be usefully in the PCR reactions of the present invention. It should be understood that the listing is not exhaustive and that primer-probe design for any amplification is within the skill of those in the art. Probes may also contain chemically modified bases to increase base-pairing fidelity to the target molecule and base-pairing strength. Such modifications may include 5-methyl-Cytidine, 2, 6-di-amino-purine, 2'-fluoro, phosphoro-thioate, or locked nucleic acids.

1207Table 4. Primers and Probes

1208<img file="WO2013151663A1_D0007.tif" /> GCSF2 GCAGTCCCTGATACAAGAAC G-CSF 30

GCSF3 GATTGAAGGTGGCTCGCTAC G-CSF 31

1210*UFP is universal forward primer; URP is universal reverse primer.

1211[000204] In one embodiment, the cDNA may be submitted for sequencing analysis before undergoing transcription.

1212mRNA Production

1213[000205] The process of mRNA or mmRNA production may include, but is not limited to, in vitro transcription, cDNA template removal and RNA clean-up, and mRNA capping and/or tailing reactions.

1214In Vitro Transcription

1215[000206] The cDNA produced in the previous step may be transcribed using an in vitro transcription (IVT) system. The system typically comprises a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor and a polymerase. The NTPs may be manufactured in house, may be selected from a supplier, or may be synthesized as described herein. The NTPs may be selected from, but are not limited to, those described herein including natural and unnatural (modified) NTPs. The polymerase may be selected from, but is not limited to, T7 RNA polymerase, T3 RNA polymerase and mutant polymerases such as, but not limited to, polymerases able to incorporate modified nucleic acids.

1216RNA Polymerases

1217[000207] Any number of RNA polymerases or variants may be used in the design of the primary constructs of the present invention.

1218[000208] RNA polymerases may be modified by inserting or deleting amino acids of the RNA polymerase sequence. As a non-limiting example, the RNA polymerase may be modified to exhibit an increased ability to incorporate a 2 '-modified nucleotide triphosphate compared to an unmodified RNA polymerase (see International Publication WO2008078180 and U.S. Patent 8,101,385; herein incorporated by reference in their entireties).

1219[000209] Variants may be obtained by evolving an RNA polymerase, optimizing the RNA polymerase amino acid and/or nucleic acid sequence and/or by using other methods known in the art. As a non-limiting example, T7 R A polymerase variants may be evolved using the continuous directed evolution system set out by Esvelt et al. (Nature (2011) 472(7344):499-503; herein incorporated by reference in its entirety) where clones of T7 RNA polymerase may encode at least one mutation such as, but not limited to, lysine at position 93 substituted for threonine (K93T), I4M, A7T, E63V, V64D, A65E, D66Y, T76N, C125R, S128R, A136T, N165S, G175R, H176L, Y178H, F182L, L196F, G198V, D208Y, E222K, S228A, Q239R, T243N, G259D, M267I, G280C, H300R, D351A, A354S, E356D, L360P, A383V, Y385C, D388Y, S397R, M401T, N410S, K450R, P451T, G452V, E484A, H523L, H524N, G542V, E565K, K577E, K577M, N601S, S684Y, L699I, K713E, N748D, Q754R, E775K, A827V, D851N or L864F. As another non-limiting example, T7 RNA polymerase variants may encode at least mutation as described in U.S. Pub. Nos. 20100120024 and 20070117112; herein incorporated by reference in their entireties. Variants of RNA polymerase may also include, but are not limited to, substitutional variants, conservative amino acid substitution, insertional variants, deletional variants and/or covalent derivatives.

1220[000210] In one embodiment, the primary construct may be designed to be recognized by the wild type or variant RNA polymerases. In doing so, the primary construct may be modified to contain sites or regions of sequence changes from the wild type or parent primary construct.

1221[000211] In one embodiment, the primary construct may be designed to include at least one substitution and/or insertion upstream of an RNA polymerase binding or recognition site, downstream of the RNA polymerase binding or recognition site, upstream of the TATA box sequence, downstream of the TATA box sequence of the primary construct but upstream of the coding region of the primary construct, within the 5'UTR, before the 5'UTR and/or after the 5'UTR.

1222[000212] In one embodiment, the 5 'UTR of the primary construct may be replaced by the insertion of at least one region and/or string of nucleotides of the same base. The region and/or string of nucleotides may include, but is not limited to, at least 3, at least 4, at least 5, at least 6, at least 7 or at least 8 nucleotides and the nucleotides may be natural and/or unnatural. As a non-limiting example, the group of nucleotides may include 5-8 adenine, cytosine, thymine, a string of any of the other nucleotides disclosed herein and/or combinations thereof.

1223[000213] In one embodiment, the 5 'UTR of the primary construct may be replaced by the insertion of at least two regions and/or strings of nucleotides of two different bases such as, but not limited to, adenine, cytosine, thymine, any of the other nucleotides disclosed herein and/or combinations thereof. For example, the 5 'UTR may be replaced by inserting 5-8 adenine bases followed by the insertion of 5-8 cytosine bases. In another example, the 5 'UTR may be replaced by inserting 5-8 cytosine bases followed by the insertion of 5-8 adenine bases.

1224[000214] In one embodiment, the primary construct may include at least one substitution and/or insertion downstream of the transcription start site which may be recognized by an RNA polymerase. As a non-limiting example, at least one substitution and/or insertion may occur downstream the transcription start site by substituting at least one nucleic acid in the region just downstream of the transcription start site (such as, but not limited to, +1 to +6). Changes to region of nucleotides just downstream of the transcription start site may affect initiation rates, increase apparent nucleotide

1225triphosphate (NTP) reaction constant values, and increase the dissociation of short transcripts from the transcription complex curing initial transcription (Brieba et al, Biochemistry (2002) 41 : 5144-5149; herein incorporated by reference in its entirety). The modification, substitution and/or insertion of at least one nucleic acid may cause a silent mutation of the nucleic acid sequence or may cause a mutation in the amino acid sequence.

1226[000215] In one embodiment, the primary construct may include the substitution of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12 or at least 13 guanine bases downstream of the transcription start site.

1227[000216] In one embodiment, the primary construct may include the substitution of at least 1, at least 2, at least 3, at least 4, at least 5 or at least 6 guanine bases in the region just downstream of the transcription start site. As a non-limiting example, if the nucleotides in the region are GGGAGA the guanine bases may be substituted by at least 1, at least 2, at least 3 or at least 4 adenine nucleotides. In another non-limiting example, if the nucleotides in the region are GGGAGA the guanine bases may be substituted by at least 1, at least 2, at least 3 or at least 4 cytosine bases. In another non-limiting example, if the nucleotides in the region are GGGAGA the guanine bases may be substituted by at least 1, at least 2, at least 3 or at least 4 thymine, and/or any of the nucleotides described herein.

1228[000217] In one embodiment, the primary construct may include at least one substitution and/or insertion upstream of the start codon. For the purpose of clarity, one of skill in the art would appreciate that the start codon is the first codon of the protein coding region whereas the transcription start site is the site where transcription begins. The primary construct may include, but is not limited to, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 or at least 8 substitutions and/or insertions of nucleotide bases. The nucleotide bases may be inserted or substituted at 1, at least 1, at least 2, at least 3, at least 4 or at least 5 locations upstream of the start codon. The nucleotides inserted and/or substituted may be the same base (e.g., all A or all C or all T or all G), two different bases (e.g., A and C, A and T, or C and T), three different bases (e.g., A, C and T or A, C and T) or at least four different bases. As a non-limiting example, the guanine base upstream of the coding region in the primary construct may be substituted with adenine, cytosine, thymine, or any of the nucleotides described herein. In another non-limiting example the substitution of guanine bases in the primary construct may be designed so as to leave one guanine base in the region downstream of the transcription start site and before the start codon (see Esvelt et al. Nature (2011) 472(7344):499-503; herein incorporated by reference in its entirety). As a non-limiting example, at least 5 nucleotides may be inserted at 1 location downstream of the transcription start site but upstream of the start codon and the at least 5 nucleotides may be the same base type.

1229cDNA Template Removal and Clean-Up

1230[000218] The cDNA template may be removed using methods known in the art such as, but not limited to, treatment with Deoxyribonuclease I (DNase I). RNA clean-up may also include a purification method such as, but not limited to, AGENCOURT®

1231CLEANSEQ® system from Beckman Coulter (Danvers, MA), HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC- HPLC) .

1232Capping and/or Tailing Reactions

1233[000219] The primary construct or mmRNA may also undergo capping and/or tailing reactions. A capping reaction may be performed by methods known in the art to add a 5' cap to the 5' end of the primary construct. Methods for capping include, but are not limited to, using a Vaccinia Capping enzyme (New England Biolabs, Ipswich, MA).

1234[000220] A poly-A tailing reaction may be performed by methods known in the art, such as, but not limited to, 2' O-methyltransferase and by methods as described herein. If the primary construct generated from cDNA does not include a poly-T, it may be beneficial to perform the poly-A-tailing reaction before the primary construct is cleaned. mRNA Purification

1235[000221] Primary construct or mmRNA purification may include, but is not limited to, mRNA or mmRNA clean-up, quality assurance and quality control. mRNA or mmRNA clean-up may be performed by methods known in the arts such as, but not limited to, AGENCOURT® beads (Beckman Coulter Genomics, Danvers, MA), poly-T beads, LNA™ oligo-T capture probes (EXIQON® Inc, Vedbaek, Denmark) or HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC). The term "purified" when used in relation to a polynucleotide such as a "purified mRNA or mmRNA" refers to one that is separated from at least one contaminant. As used herein, a "contaminant" is any substance which makes another unfit, impure or inferior. Thus, a purified polynucleotide (e.g., DNA and RNA) is present in a form or setting different from that in which it is found in nature, or a form or setting different from that which existed prior to subjecting it to a treatment or purification method.

1236[000222] A quality assurance and/or quality control check may be conducted using methods such as, but not limited to, gel electrophoresis, UV absorbance, or analytical HPLC.

1237[000223] In another embodiment, the mRNA or mmRNA may be sequenced by methods including, but not limited to reverse-transcriptase-PCR. [000224] In one embodiment, the mRNA or mmRNA may be quantified using methods such as, but not limited to, ultraviolet visible spectroscopy (UV/Vis). A non-limiting example of a UV/Vis spectrometer is a NANODROP® spectrometer (ThermoFisher, Waltham, MA). The quantified mRNA or mmRNA may be analyzed in order to determine if the mRNA or mmRNA may be of proper size, check that no degradation of the mRNA or mmRNA has occurred. Degradation of the mRNA and/or mmRNA may be checked by methods such as, but not limited to, agarose gel electrophoresis, HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC), liquid chromatography-mass spectrometry (LCMS), capillary electrophoresis (CE) and capillary gel electrophoresis (CGE).

1238Signal Sequences

1239[000225] The primary constructs or mmRNA may also encode additional features which facilitate trafficking of the polypeptides to therapeutically relevant sites. One such feature which aids in protein trafficking is the signal sequence. As used herein, a "signal sequence" or "signal peptide" is a polynucleotide or polypeptide, respectively, which is from about 9 to 200 nucleotides (3-60 amino acids) in length which is incorporated at the 5' (or N-terminus) of the coding region or polypeptide encoded, respectively. Addition of these sequences result in trafficking of the encoded polypeptide to the endoplasmic reticulum through one or more secretory pathways. Some signal peptides are cleaved from the protein by signal peptidase after the proteins are transported.

1240[000226] Table 5 is a representative listing of protein signal sequences which may be incorporated for encoding by the polynucleotides, primary constructs or mmRNA of the invention.

1241Table 5. Signal Sequences

1242<img file="WO2013151663A1_D0008.tif" /> SS-002 G-CSF ATGGCCGGACCGGCGAC 33 MAGPATQSP 95

TCAGTCGCCCATGAAACT MKLMALQLL

CATGGCCCTGCAGTTGTT LWHSALWTV

GCTTTGGCACTCAGCCCT QEA

CTGGACCGTCCAAGAGG

CG

1248SS-003 Factor IX ATGCAGAGAGTGAACAT 34 MQRVNMIMA 96

GATTATGGCCGAGTCCCC ESPSLITICLLG

ATCGCTCATCACAATCTG YLLSAECTVF

CCTGCTTGGTACCTGCTT LDHENANKIL

TCCGCCGAATGCACTGTC NRPKR

TTTCTGGATCACGAGAAT

GCGAATAAGATCTTGAAC

CGACCCAAACGG

1256SS-004 Prolactin ATGAAAGGATCATTGCTG 35 MKGSLLLLLV 97

TTGCTCCTCGTGTCGAAC SNLLLCQSVA CTTCTGCTTTGCCAGTCC P GTAGCCCCC

1258SS-005 Albumin ATGAAATGGGTGACGTTC 36 MKWVTFISLL 98

ATCTCACTGTTGTTTTTGT FLFSSAYSRG TCTCGTCCGCCTACTCCA VFRR GGGGAGTATTCCGCCGA

SS-006 HMMSP38 ATGTGGTGGCGGCTCTGG 37 MWWRLWWL 99

TGGCTGCTCCTGTTGCTC LLLLLLLPMW CTCTTGCTGTGGCCCATG A GTGTGGGCA

1262MLS- ornithine TGCTCTTTAACCTCCGCA 38 MLFNLRILLN 100 001 carbamoyltr TCCTGTTGAATAACGCTG NAAFRNGHN

1263ansferase CGTTCCGAAATGGGCATA FMVRNFRCG

ACTTCATGGTACGCAACT QPLQ

TCAGATGCGGCCAGCCAC

TCCAG

1267MLS- Cytochrome ATGTCCGTCTTGACACCC 39 MSVLTPLLLR 101 002 C Oxidase CTGCTCTTGAGAGGGCTG GLTGSARRLP

1268subunit 8A ACGGGGTCCGCTAGACG VPRAKIHSL

CCTGCCGGTACCGCGAGC

GAAGATCCACTCCCTG

1271MLS- Cytochrome ATGAGCGTGCTCACTCCG 40 MSVLTPLLLR 102 003 C Oxidase TTGCTTCTTCGAGGGCTT GLTGSARRLP

1272subunit 8A ACGGGATCGGCTCGGAG VPRAKIHSL

GTTGCCCGTCCCGAGAGC

GAAGATCCATTCGTTG

1275SS-007 Type III, TGACAAAAATAACTTTAT 41 MVTKITLSPQ 103 bacterial CTCCCCAGAATTTTAGAA NFRIQKQETT

TCCAAAAACAGGAAACC LLKEKSTEKN

ACACTACTAAAAGAAAA SLAKSILAVK

ATCAACCGAGAAAAATT NHFIELRSKLS

CTTTAGCAAAAAGTATTC ERFISHKNT

TCGCAGTAAAAATCACTT

CATCGAATTAAGGTCAAA ATTATCGGAACGTTTTAT

TTCGCATAAGAACACT

1283SS-008 Viral ATGCTGAGCTTTGTGGAT 42 MLSFVDTRTL 104

ACCCGCACCCTGCTGCTG LLLAVTSCLA CTGGCGGTGACCAGCTGC TCQ CTGGCGACCTGCCAG

1285SS-009 viral ATGGGCAGCAGCCAGGC 43 MGSSQAPRM 105

GCCGCGCATGGGCAGCG GSVGGHGLM

TGGGCGGCCATGGCCTGA ALLMAGLILP

TGGCGCTGCTGATGGCGG GILA

GCCTGATTCTGCCGGGCA

TTCTGGCG

1291SS-010 Viral ATGGCGGGCATTTTTTAT 44 MAGIFYFLFSF 106

TTTCTGTTTAGCTTTCTGT LFGICD TTGGCATTTGCGAT

1293SS-01 1 Viral ATGGAAAACCGCCTGCTG 45 MENRLLRVFL 107

CGCGTGTTTCTGGTGTGG VWAALTMDG GCGGCGCTGACCATGGAT ASA GGCGCGAGCGCG

1295SS-012 Viral ATGGCGCGCCAGGGCTG 46 MARQGCFGS 108

CTTTGGCAGCTATCAGGT YQVISLFTFAI

GATTAGCCTGTTTACCTT GVNLCLG

TGCGATTGGCGTGAACCT

GTGCCTGGGC

1300SS-013 Bacillus ATGAGCCGCCTGCCGGTG 47 MSRLPVLLLL 109

CTGCTGCTGCTGCAGCTG QLLVRPGLQ CTGGTGCGCCCGGGCCTG CAG

1302SS-014 Bacillus ATGAAACAGCAGAAACG 48 MKQQKRLYA 1 10

1303CCTGTATGCGCGCCTGCT RLLTLLFALIF GACCCTGCTGTTTGCGCT LLPHSSASA GATTTTTCTGCTGCCGCA TAGCAGCGCGAGCGCG

1304SS-015 Secretion ATGGCGACGCCGCTGCCT 49 MATPLPPPSP 1 1 1 signal CCGCCCTCCCCGCGGCAC RHLRLLRLLL

CTGCGGCTGCTGCGGCTG SG

CTGCTCTCCGCCCTCGTC

CTCGGC

1308SS-016 Secretion ATGAAGGCTCCGGGTCG 50 MKAPGRLVLI 1 12 signal GCTCGTGCTCATCATCCT ILCSVVFS

GTGCTCCGTGGTCTTCTC T

1310SS-017 Secretion ATGCTTCAGCTTTGGAAA 51 MLQLWKLLC 1 13 signal CTTGTTCTCCTGTGCGGC GVLT

GTGCTCACT

1312SS-018 Secretion ATGCTTTATCTCCAGGGT 52 MLYLQGWSM 1 14 signal TGGAGCATGCCTGCTGTG PAVA

GCA

1314SS-019 Secretion ATGGATAACGTGCAGCC 53 MDNVQPKIK 1 15 signal GAAAATAAAACATCGCC HRPFCFSVKG CCTTCTGCTTCAGTGTGA HVKMLRLDII

AAGGCCACGTGAAGATG NSLVTTVFML

CTGCGGCTGGATATTATC IVSVLALIP

AACTCACTGGTAACAACA

GTATTCATGCTCATCGTA

TCTGTGTTGGCACTGATA

CCA

1321SS-020 Secretion ATGCCCTGCCTAGACCAA 54 MPCLDQQLT 1 16 signal CAGCTCACTGTTCATGCC VHALPCPAQP

CTACCCTGCCCTGCCCAG SSLAFCQVGF

CCCTCCTCTCTGGCCTTCT LTA

GCCAAGTGGGGTTCTTAA

CAGCA

1326SS-021 Secretion ATGAAAACCTTGTTCAAT 55 MKTLFNPAPA 1 17 signal CCAGCCCCTGCCATTGCT IADLDPQFYT

GACCTGGATCCCCAGTTC LSDVFCCNES

TACACCCTCTCAGATGTG EAEILTGLTV

TTCTGCTGCAATGAAAGT GSAADA

GAGGCTGAGATTTTAACT

GGCCTCACGGTGGGCAG

CGCTGCAGATGCT

1333SS-022 Secretion ATGAAGCCTCTCCTTGTT 56 MKPLLVVFVF 1 18 signal GTGTTTGTCTTTCTTTTCC LFLWDPVLA

TTTGGGATCCAGTGCTGG CA

1335SS-023 Secretion ATGTCCTGTTCCCTAAAG 57 MSCSLKFTLI 1 19 signal TTTACTTTGATTGTAATTT VIFFTCTLSSS

ATCCAGC

1337SS-024 Secretion ATGGTTCTTACTAAACCT 58 MVLTKPLQR 120 signal CTTCAAAGAAATGGCAG NGSMMSFEN

CATGATGAGCTTTGAAAA VKEKSREGGP

TGTGAAAGAAAAGAGCA HAHTPEEELC

GAGAAGGAGGGCCCCAT FVVTHTPQVQ

GCACACACACCCGAAGA TTLNLFFHIFK

AGAATTGTGTTTCGTGGT VLTQPLSLLW

AACACACTACCCTCAGGT G

TCAGACCACACTCAACCT

GGTTCTTACTCAACCACT TTCCCTTCTGTGGGGT

1346SS-025 Secretion ATGGCCACCCCGCCATTC 59 MATPPFRLIR 121 signal CGGCTGATAAGGAAGAT KMFSFKVSR

GTTTTCCTTCAAGGTGAG WMGLACFRS

CAGATGGATGGGGCTTGC LAAS

CTGCTTCCGGTCCCTGGC

GGCATCC

1351SS-026 Secretion 60 MSFFQLLMKR 122 signal CTGATGAAAAGGAAGGA KELIPLVVFM

ACTCATTCCCTTGGTGGT TVAAGGASS GTTCATGACTGTGGCGGC

GGGTGGAGCCTCATCT

1354SS-027 Secretion ATGGTCTCAGCTCTGCGG 61 MVSALRGAPL 123 signal GGAGCACCCCTGATCAG IRVHSSPVSSP

GGTGCACTCAAGCCCTGT SVSGPAALVS

TTCTTCTCCTTCTGTGAGT CLSSQSSALS

GGACCACGGAGGCTGGT

GAGCTGCCTGTCATCCCA

AAGCTCAGCTCTGAGC

1360SS-028 Secretion ATGATGGGGTCCCCAGTG 62 MMGSPVSHL 124 signal AGTCATCTGCTGGCCGGC LAGFCVWVV

TTCTGTGTGTGGGTCGTC LG TTGGGC

1362SS-029 Secretion ATGGCAAGCATGGCTGCC 63 MASMAAVLT 125 signal GTGCTCACCTGGGCTCTG WALALLSAFS

GCTCTTCTTTCAGCGTTTT ATQA CGGCCACCCAGGCA

1364SS-030 Secretion ATGGTGCTCATGTGGACC 64 MVLMWTSGD 126 signal AGTGGTGACGCCTTCAAG AFKTAYFLLK

ACGGCCTACTTCCTGCTG GAPLQFSVCG

AAGGGTGCCCCTCTGCAG LLQVLVDLAI

TTCTCCGTGTGCGGCCTG LGQATA

CTGCAGGTGCTGGTGGAC

CTGGCCATCCTGGGGCAG

GCCTACGCC

1371SS-031 Secretion ATGGATTTTGTCGCTGGA 65 MDFVAGAIG 127 signal GCCATCGGAGGCGTCTGC GVCGVAVGY

GGTGTTGCTGTGGGCTAC PLDTVKVRIQ

CCCCTGGACACGGTGAA TEPLYTGIWH

GGTCAGGATCCAGACGG CVRDTYHRER

AGCCAAAGTACACAGGC VWGFYRGLS

ATCTGGCACTGCGTCCGG LPVCTVSLVS

GATACGTATCACCGAGA S

GCGCGTGTGGG

GCTTCTACCGGGGCCTCT

CGCTGCCCGTGTGCACGG

TGTCCCTGGTATCTTCC

1382SS-032 Secretion ATGGAGAAGCCCCTCTTC 66 MEKPLFPLVP 128 signal CCATTAGTGCCTTTGCAT LHWFGFGYT

TGGTTTGGCTTTGGCTAC ALVVSGGIVG

ACAGCACTGGTTGTTTCT YVKTGSVPSL

GGTGGGATCGTTGGCTAT AAGLLFGSLA

GTAAAAACAGGCAGCGT

GCCGTCCCTGGCTGCAGG

GCTGCTCTTCGGCAGTCT

AGCC

1390SS-033 Secretion ATGGGTCTGCTCCTTCCC 67 MGLLLPLALC 129 signal CTGGCACTCTGCATCCTA ILVLC

1391GTCCTGTGC SS-034 Secretion ATGGGGATCCAGACGAG 68 MGIQTSPVLL 130 signal CCCCGTCCTGCTGGCCTC ASLGVGLVTL

CCTGGGGGTGGGGCTGGT LGLAVG

CACTCTGCTCGGCCTGGC

TGTGGGC

1395SS-035 Secretion ATGTCGGACCTGCTACTA 69 MSDLLLLGLI 131 signal CTGGGCCTGATTGGGGGC GGLTLLLLLT

CTGACTCTCTTACTGCTG LLAFA

CTGACGCTGCTAGCCTTT

GCC

1399SS-036 Secretion ATGGAGACTGTGGTGATT 70 METVVIVAIG 132 signal GTTGCCATAGGTGTGCTG VLATIFLASFA

GCCACCATGTTTCTGGCT ALVLVCRQ

TCGTTTGCAGCCTTGGTG

CTGGTTTGCAGGCAG

1403SS-037 Secretion ATGCGCGGCTCTGTGGAG 71 MAGSVECTW 133 signal TGCACCTGGGGTTGGGGG GWGHCAPSPL

CACTGTGCCCCCAGCCCC LLWTLLLFAA

CTGCTCCTTTGGACTCTA PFGLLG

CTTCTGTTTGCAGCCCCA

TTTGGCCTGCTGGGG

1408SS-038 Secretion ATGATGCCGTCCCGTACC 72 MMPSPvTNLA 134 signal AACCTGGCTACTGGAATC TGIPSSKVKYS

CCCAGTAGTAAAGTGAA RLSSTDDGYI

ATATTCAAGGCTCTCCAG DLQFKKTPPK

CACAGACGATGGCTACAT IPYKAIALATV

TGACCTTCAGTTTAAGAA LFLIGA

AACCCCTCCTAAGATCCC

TTATAAGGCCATCGCACT

TGCCACTGTGCTGTTTTT

GATTGGCGCC

1417SS-039 Secretion ATGGCCCTGCCCCAGATG 73 MALPQMCDG 135 signal TGTGACGGGAGCCACTTG SHLASTLRYC

GCCTCCACCCTCCGCTAT MTVSGTVVL

TGCATGACAGTCAGCGGC VAGTLCFA

ACAGTGGTTCTGGTGGCC

GGGACGCTCTGCTTCGCT

1422SS-041 Vrg-6 TGAAAAAGTGGTTCGTTG 74 MKKWFVAAG 136

CTGCCGGCATCGGCGCTG IGAGLLMLSS CCGGACTCATGCTCTCCA AA GCGCCGCCA

1424SS-042 PhoA ATGAAACAGAGCACCAT 75 MKQSTIALAL 137

TGCGCTGGCGCTGCTGCC LPLLFTPVTK GCTGCTGTTTACCCCGGT A GACCAAAGCG

1426SS-043 OmpA ATGAAAAAAACCGCGAT 76 MKKTAIAIAV 138

1427TGCGATTGCGGTGGCGCT ALAGFATVA GGCGGGCTTTGCGACCGT QA GGCGCAGGCG SS-044 STI ATGAAAAAACTGATGCT 77 MKKLMLAIFF 139

SVLSFPSFSQS

GCTGAGCTTTCCGAGCTT TAGCCAGAGC

SS-045 STII ATGAAAAAAAACATTGC 78 MKKNIAFLLA 140

GTTTCTGCTGGCGAGCAT SMFVFSIATN GTTTGTGTTTAGCATTGC AYA GACCAACGCGTATGCG

1432SS-046 Amylase ATGTTTGCGAAACGCTTT 79 MFAKRFKTSL 141

AAAACCAGCCTGCTGCCG LPLFAGFLLLF

CTGTTTGCGGGCTTTCTG HLVLAGPAA

CTGCTGTTTCATCTGGTG AS

CTGGCGGGCCCGGCGGC

GGCGAGC

1438SS-047 Alpha ATGCGCTTTCCGAGCATT 80 MRFP SIFTAVL 142

1439Factor TTTACCGCGGTGCTGTTT FAASSALA

GCGGCGAGCAGCGCGCT GGCG

1441SS-048 Alpha ATGCGCTTTCCGAGCATT 81 MRFPSIFTTVL 143

1442Factor TTTACCACCGTGCTGTTT FAASSALA

GCGGCGAGCAGCGCGCT GGCG

1444SS-049 Alpha ATGCGCTTTCCGAGCATT 82 MRFPSIFTSVL 144

1445Factor TTTACCAGCGTGCTGTTT FAASSALA

GCGGCGAGCAGCGCGCT GGCG

1447SS-050 Alpha ATGCGCTTTCCGAGCATT 83 MRFP SIFTHVL 145

1448Factor TTTACCCATGTGCTGTTT FAASSALA

GCGGCGAGCAGCGCGCT GGCG

1450SS-051 Alpha ATGCGCTTTCCGAGCATT 84 MRFPSIFTIVL 146

1451Factor TTTACCATTGTGCTGTTT FAASSALA

GCGGCGAGCAGCGCGCT GGCG

1453SS-052 Alpha ATGCGCTTTCCGAGCATT 85 MRFPSIFTFVL 147

1454Factor TTTACCTTTGTGCTGTTTG FAASSALA

CGGCGAGCAGCGCGCTG GCG

1456SS-053 Alpha ATGCGCTTTCCGAGCATT 86 MRFPSIFTEVL 148

1457Factor TTTACCGAAGTGCTGTTT FAASSALA

GCGGCGAGCAGCGCGCT GGCG

1459SS-054 Alpha ATGCGCTTTCCGAGCATT 87 MRFPSIFTGVL 149

1460Factor TTTACCGGCGTGCTGTTT FAASSALA

GCGGCGAGCAGCGCGCT GGCG

1462SS-055 Endoglucan ATGCGTTCCTCCCCCCTC 88 MRSSPLLRSA 150 ase V CTCCGCTCCGCCGTTGTG VVAALPVLAL

1463GCCGCCCTGCCGGTGTTG A GCCCTTGCC SS-056 Secretion ATGGGCGCGGCGGCCGT 89 MGAAAVRW 151 signal GCGCTGGCACTTGTGCGT HLCVLLALGT

GCTGCTGGCCCTGGGCAC RGRL ACGCGGGCGGCTG

1465SS-057 Fungal ATGAGGAGCTCCCTTGTG 90 MRSSLVLFFV 152

CTGTTCTTTGTCTCTGCGT SAWTALA GGACGGCCTTGGCCAG

1467SS-058 Fibronectin ATGCTCAGGGGTCCGGG 91 MLRGPGPGRL 153

ACCCGGGCGGCTGCTGCT LLLAVLCLGT

GCTAGCAGTCCTGTGCCT SVRCTETGKS

GGGGACATCGGTGCGCT KR

GCACCGAAACCGGGAAG

AGCAAGAGG

1473SS-059 Fibronectin ATGCTTAGGGGTCCGGGG 92 MLRGPGPGLL 154

CCCGGGCTGCTGCTGCTG LLAVQCLGTA GCCGTCCAGCTGGGGAC VPSTGA AGCGGTGCCCTCCACG

1475SS-060 Fibronectin ATGCGCCGGGGGGCCCT 93 MRRGALTGL 155

GACCGGGCTGCTCCTGGT LLVLCLSVVL

CCTGTGCCTGAGTGTTGT RAAPSATSKK

GCTACGTGCAGCCCCCTC RR

TGCAACAAGCAAGAAGC

GCAGG

1481[000227] In the table, SS is secretion signal and MLS is mitochondrial leader signal. The primary constructs or mmRNA of the present invention may be designed to encode any of the signal sequences of SEQ ID NOs 94-155, or fragments or variants thereof. These sequences may be included at the beginning of the polypeptide coding region, in the middle or at the terminus or alternatively into a flanking region. Further, any of the polynucleotide primary constructs of the present invention may also comprise one or more of the sequences defined by SEQ ID NOs 32-93. These may be in the first region or either flanking region.

1482[000228] Additional signal sequences which may be utilized in the present invention include those taught in, for example, databases such as those found at

1483http://www.signalpeptide.de/ or http://proline.bic.nus.edu.sg/spdb/. Those described in US Patents 8,124,379; 7,413,875 and 7,385,034 are also within the scope of the invention and the contents of each are incorporated herein by reference in their entirety.

1484Target Selection

1485[000229] According to the present invention, the primary constructs comprise at least a first region of linked nucleosides encoding at least one polypeptide of interest. The polypeptides of interest or "Targets" of the present invention are listed in Table 6. Shown in Table 6, in addition to the name and description of the gene encoding the polypeptide of interest (Target Description) are the ENSEMBL Transcript ID (ENST), the

1486ENSEMBL Protein ID (ENSP) and when available the optimized open reading frame sequence ID (Optimized ORF SEQ ID). For any particular gene there may exist one or more variants or isoforms. Where these exist, they are shown in the table as well. It will be appreciated by those of skill in the art that disclosed in the Table are potential flanking regions. These are encoded in each ENST transcript either to the 5' (upstream) or 3' (downstream) of the ORF or coding region. The coding region is definitively and specifically disclosed by teaching the ENSP sequence. Consequently, the sequences taught flanking that encoding the protein are considered flanking regions. It is also possible to further characterize the 5' and 3' flanking regions by utilizing one or more available databases or algorithms. Databases have annotated the features contained in the flanking regions of the ENST transcripts and these are available in the art.

1487Table 6. Membrane Protein Targets

1488<img file="WO2013151663A1_D0009.tif" /> l-acylglycerol-3- 448287 164 389318 8152 16140, 24128, phosphate O- 32116, 40104, acyltransferase 3 48092 l-acylglycerol-3- 448845 165 394102 8153 16141, 24129, phosphate O- 32117, 40105, acyltransferase 3 48093 l-acylglycerol-3- 457068 166 413906 8154 16142, 24130, phosphate O- 32118, 40106, acyltransferase 3 48094 l-acylglycerol-3- 546158 167 443510 8155 16143, 24131, phosphate O- 32119, 40107, acyltransferase 3 48095 l-acylglycerol-3- 320285 168 314036 8156 16144, 24132, phosphate O- 32120, 40108, acyltransferase 4 48096 (lysophosphatidic

1489acid acyltransferase,

1490delta)

1491l-acylglycerol-3- 366905 169 355872 8157 16145, 24133, phosphate O- 32121, 40109, acyltransferase 4 48097 (lysophosphatidic

1492acid acyltransferase,

1493delta)

1494l-acylglycerol-3- 366906 170 355873 8158 16146, 24134, phosphate O- 32122, 40110, acyltransferase 4 48098 (lysophosphatidic

1495acid acyltransferase,

1496delta)

1497l-acylglycerol-3- 366908 171 355875 8159 16147, 24135, phosphate O- 32123, 40111, acyltransferase 4 48099 (lysophosphatidic

1498acid acyltransferase,

1499delta)

1500l-acylglycerol-3- 366911 172 355878 8160 16148, 24136, phosphate O- 32124, 40112, acyltransferase 4 48100 (lysophosphatidic

1501acid acyltransferase,

1502delta)

1503l-acylglycerol-3- 437165 173 400211 8161 16149, 24137, phosphate O- 32125, 40113, acyltransferase 4 48101 (lysophosphatidic

1504acid acyltransferase,

1505delta)

1506l-acylglycerol-3- 457520 174 407007 8162 16150, 24138, phosphate O- 32126, 40114, acyltransferase 4 48102 (lysophosphatidic

1507acid acyltransferase,

1508delta) l-acylglycerol-3- 285518 175 285518 8163 16151, 24139, phosphate O- 32127, 40115, acyltransferase 5 48103 (lysophosphatidic

1509acid acyltransferase,

1510epsilon)

15112,4-dienoyl CoA 219481 176 219481 8164 16152, 24140, reductase 2, 32128, 40116, peroxisomal 48104

15122,4-dienoyl CoA 397710 177 380822 8165 16153, 24141, reductase 2, 32129, 40117, peroxisomal 48105

15132 - aminoethanethiol 373783 178 362888 8166 16154, 24142,

1514(cysteamine) 32130, 40118, dioxygenase 48106

15153 -hydroxybutyrate 358186 179 350914 8167 16155, 24143, dehydrogenase, type 32131, 40119, 1 48107

15163 -hydroxybutyrate 392378 180 376183 8168 16156, 24144, dehydrogenase, type 32132, 40120, 1 48108

15173 -hydroxybutyrate 392379 181 376184 8169 16157, 24145, dehydrogenase, type 32133, 40121, 1 48109

15183 -hydroxybutyrate 431056 182 396149 8170 16158, 24146, dehydrogenase, type 32134, 40122, 1 48110

15193 -hydroxybutyrate 441275 183 411014 8171 16159, 24147, dehydrogenase, type 32135, 40123, 1 48111

15203 -hydroxybutyrate 445160 184 405462 8172 16160, 24148, dehydrogenase, type 32136, 40124, 1 48112

15213- 265395 185 265395 8173 16161, 24149, hydroxyisobutyrate 32137, 40125, dehydrogenase 48113

15223-oxoacid CoA 327582 186 361914 8174 16162, 24150, transferase 2 32138, 40126,

152348114

15243-oxoacid CoA 542949 187 438055 8175 16163, 24151, transferase 2 32139, 40127,

152548115

15264-hydroxy-2- 370646 188 359680 8176 16164, 24152, oxoglutarate 32140, 40128, aldolase 1 48116

15274-hydroxy-2- 370647 189 359681 8177 16165, 24153, oxoglutarate 32141, 40129, aldolase 1 48117

15285, 10- 258874 190 258874 8178 16166, 24154, methenyltetrahydrof 32142, 40130, olate synthetase (5- 48118 formyltetrahydrofola

1529te cyclo-ligase) 5- 299961 191 299961 8179 16167, 24155, hydroxytryptamine 32143, 40131, (serotonin) receptor 48119 3A

15305- 355556 192 347754 8180 16168, 24156, hydroxytryptamine 32144, 40132, (serotonin) receptor 48120 3A

15315- 375498 193 364648 8181 16169, 24157, hydroxytryptamine 32145, 40133, (serotonin) receptor 48121 3A

15325- 504030 194 424189 8182 16170, 24158, hydroxytryptamine 32146, 40134, (serotonin) receptor 48122 3A

15335- 506841 195 424776 8183 16171, 24159, hydroxytryptamine 32147, 40135, (serotonin) receptor 48123 3A

15345- 510849 196 423653 8184 16172, 24160, hydroxytryptamine 32148, 40136, (serotonin) receptor 48124 3A

15355- 535865 197 437776 8185 16173, 24161, hydroxytryptamine 32149, 40137, (serotonin) receptor 48125 3A

1536A kinase (PRKA) 253332 198 253332 8186 16174, 24162, anchor protein 12 32150, 40138,

153748126

1538A kinase (PRKA) 354675 199 346702 8187 16175, 24163, anchor protein 12 32151, 40139,

153948127

1540A kinase (PRKA) 359755 200 352794 8188 16176, 24164, anchor protein 12 32152, 40140,

154148128

1542A kinase (PRKA) 402676 201 384537 8189 16177, 24165, anchor protein 12 32153, 40141,

154348129

1544A kinase (PRKA) 320636 202 315615 8190 16178, 24166, anchor protein 5 32154, 40142,

154548130

1546A kinase (PRKA) 394718 203 378207 8191 16179, 24167, anchor protein 5 32155, 40143,

154748131

1548A kinase (PRKA) 280979 204 280979 8192 16180, 24168, anchor protein 6 32156, 40144,

154948132

1550A kinase (PRKA) 557102 205 451146 8193 16181, 24169, anchor protein 6 32157, 40145,

155148133

1552A kinase (PRKA) 342266 206 345149 8194 16182, 24170, anchor protein 7 32158, 40146,

155348134 A kinase (PRKA) 368123 207 357105 8195 16183, 24171, anchor protein 7 32159, 40147,

155448135

1555A kinase (PRKA) 431975 208 405252 8196 16184, 24172, anchor protein 7 32160, 40148,

155648136

1557A kinase (PRKA) 474850 209 418208 8197 16185, 24173, anchor protein 7 32161, 40149,

155848137

1559A kinase (PRKA) 537303 210 442114 8198 16186, 24174, anchor protein 8 32162, 40150,

156048138

1561A kinase (PRKA) 269701 211 269701 8199 16187, 24175, anchor protein 8 32163, 40151,

156248139 aarF domain 72869 212 72869 8200 16188, 24176, containing kinase 2 32164, 40152,

156348140, 56072, 56105 aarF domain 243583 213 243583 8201 16189, 24177, containing kinase 4 32165, 40153,

156448141 aarF domain 324464 214 315118 8202 16190, 24178, containing kinase 4 32166, 40154,

156548142 aarF domain 450541 215 412839 8203 16191, 24179, containing kinase 4 32167, 40155,

156648143 aarF domain 308860 216 310547 8204 16192, 24180, containing kinase 5 32168, 40156,

156748144 abhydrolase domain 273359 217 273359 8205 16193, 24181, containing 10 32169, 40157,

156848145 abhydrolase domain 534857 218 442932 8206 16194, 24182, containing 10 32170, 40158,

156948146 abhydrolase domain 222800 219 222800 8207 16195, 24183, containing 11 32171, 40159,

157048147 abhydrolase domain 322862 220 317293 8208 16196, 24184, containing 11 32172, 40160,

157148148 abhydrolase domain 395147 221 378579 8209 16197, 24185, containing 11 32173, 40161,

157248149 abhydrolase domain 437775 222 416970 8210 16198, 24186, containing 11 32174, 40162,

157348150 abhydrolase domain 375898 223 365063 8211 16199, 24187, containing 13 32175, 40163,

157448151 abhydrolase domain 273596 224 273596 8212 16200, 24188, containing 14A 32176, 40164,

157548152 abhydrolase domain 360889 225 354140 8213 16201, 24189, containing 14A 32177, 40165,

157648153 abhydrolase domain 452452 226 395914 8214 16202, 24190, containing 14A 32178, 40166,

157748154 abhydrolase domain 538216 227 439603 8215 16203, 24191, containing 14A 32179, 40167,

157848155 abhydrolase domain 295962 228 295962 8216 16204, 24192, containing 6 32180, 40168,

157948156 abhydrolase domain 463756 229 420408 8217 16205, 24193, containing 6 32181, 40169,

158048157 abhydrolase domain 478253 230 420315 8218 16206, 24194, containing 6 32182, 40170,

158148158 abhydrolase domain 485900 231 418934 8219 16207, 24195, containing 6 32183, 40171,

158248159 abhydrolase domain 511761 232 442448 8220 16208, 24196, containing 6 32184, 40172,

158348160 acetyl-CoA 285093 233 285093 8221 16209, 24197, acyltransferase 2 32185, 40173,

158448161

1585ACN9 homolog (S. 432641 234 414066 8222 16210, 24198, cerevisiae) 32186, 40174,

158648162 acyl-CoA binding 375888 235 365049 8223 16211, 24199, domain containing 5 32187, 40175,

158748163 acyl-CoA binding 375889 236 365050 8224 16212, 24200, domain containing 5 32188, 40176,

158848164 acyl-CoA binding 375897 237 365062 8225 16213, 24201, domain containing 5 32189, 40177,

158948165 acyl-CoA binding 375901 238 365066 8226 16214, 24202, domain containing 5 32190, 40178,

159048166 acyl-CoA binding 375905 239 365070 8227 16215, 24203, domain containing 5 32191, 40179,

159148167 acyl-CoA binding 396271 240 379568 8228 16216, 24204, domain containing 5 32192, 40180,

159248168 acyl-CoA binding 412279 241 393398 8229 16217, 24205, domain containing 5 32193, 40181,

159348169 acyl-CoA binding 426079 242 401591 8230 16218, 24206, domain containing 5 32194, 40182,

159448170 88 acyl-CoA wax 374521 243 363645 8231 16219, 24207, alcohol 32195, 40183, acyltransferase 1 48171

159589 acyl-CoA wax 276101 244 421172 8232 16220, 24208, alcohol 32196, 40184, acyltransferase 2 48172

159690 ADAM 265707 245 265707 8233 16221, 24209, metallopeptidase 32197, 40185, domain 18 48173

159791 ADAM 379866 246 369195 8234 16222, 24210, metallopeptidase 32198, 40186, domain 18 48174

159892 ADAM 541111 247 444729 8235 16223, 24211, metallopeptidase 32199, 40187, domain 18 48175

159993 ADAM 520772 248 429908 8236 16224, 24212, metallopeptidase 32200, 40188, domain 18 48176

160094 ADAM 379907 249 369238 8237 16225, 24213, metallopeptidase 32201, 40189, domain 32 48177

160195 ADAM 399826 250 382722 8238 16226, 24214, metallopeptidase 32202, 40190, domain 32 48178

160296 adaptor-related 308724 251 312442 8239 16227, 24215, protein complex 1, 32203, 40191, gamma 2 subunit 48179

160397 adaptor-related 397120 252 380309 8240 16228, 24216, protein complex 1, 32204, 40192, gamma 2 subunit 48180

160498 adaptor-related 535852 253 445313 8241 16229, 24217, protein complex 1, 32205, 40193, gamma 2 subunit 48181

160599 adaptor-related 545295 254 442716 8242 16230, 24218, protein complex 1, 32206, 40194, gamma 2 subunit 48182

1606100 adaptor-related 556843 255 451504 8243 16231, 24219, protein complex 1, 32207, 40195, gamma 2 subunit 48183

1607101 adaptor-related 557189 256 452153 8244 16232, 24220, protein complex 1, 32208, 40196, gamma 2 subunit 48184

1608102 adaptor-related 396654 257 379891 8245 16233, 24221, protein complex 1, 32209, 40197, sigma 3 subunit 48185

1609103 adaptor-related 423110 258 406686 8246 16234, 24222, protein complex 1, 32210, 40198, sigma 3 subunit 48186

1610104 adaptor-related 443700 259 397155 8247 16235, 24223, protein complex 1, 32211, 40199, sigma 3 subunit 48187

1611105 adaptor-related 446015 260 388738 8248 16236, 24224, protein complex 1, 32212, 40200, sigma 3 subunit 48188 106 adaptor-related 261722 261 261722 8249 16237, 24225, protein complex 3, 32213, 40201, beta 2 subunit 48189

1612107 adaptor-related 535348 262 438721 8250 16238, 24226, protein complex 3, 32214, 40202, beta 2 subunit 48190

1613108 adaptor-related 535359 263 440984 8251 16239, 24227, protein complex 3, 32215, 40203, beta 2 subunit 48191

1614109 adaptor-related 343722 264 341579 8252 16240, 24228, protein complex 3, 32216, 40204, delta 1 subunit 48192

1615110 adaptor-related 345016 265 344055 8253 16241, 24229, protein complex 3, 32217, 40205, delta 1 subunit 48193

1616111 adaptor-related 350812 266 342321 8254 16242, 24230, protein complex 3, 32218, 40206, delta 1 subunit 48194

1617112 adaptor-related 355272 267 347416 8255 16243, 24231, protein complex 3, 32219, 40207, delta 1 subunit 48195

1618113 adaptor-related 356926 268 349398 8256 16244, 24232, protein complex 3, 32220, 40208, delta 1 subunit 48196

1619114 adaptor-related 355264 269 347408 8257 16245, 24233, protein complex 3, 32221, 40209, mu 1 subunit 48197

1620115 adaptor-related 372745 270 361831 8258 16246, 24234, protein complex 3, 32222, 40210, mu 1 subunit 48198

1621116 adaptor-related 174653 271 174653 8259 16247, 24235, protein complex 3, 32223, 40211, mu 2 subunit 48199

1622117 adaptor-related 396926 272 380132 8260 16248, 24236, protein complex 3, 32224, 40212, mu 2 subunit 48200

1623118 adaptor-related 517969 273 430538 8261 16249, 24237, protein complex 3, 32225, 40213, mu 2 subunit 48201

1624119 adaptor-related 518421 274 428787 8262 16250, 24238, protein complex 3, 32226, 40214, mu 2 subunit 48202

1625120 adaptor-related 522288 275 429515 8263 16251, 24239, protein complex 3, 32227, 40215, mu 2 subunit 48203

1626121 adaptor-related 530375 276 431918 8264 16252, 24240, protein complex 3, 32228, 40216, mu 2 subunit 48204

1627122 adaptor-related 336418 277 338777 8265 16253, 24241, protein complex 3, 32229, 40217, sigma 2 subunit 48205

1628123 adaptor-related 423566 278 394170 8266 16254, 24242, protein complex 3, 32230, 40218, sigma 2 subunit 48206 124 adaptor-related 560251 279 453288 8267 16255, 24243, protein complex 3, 32231, 40219, sigma 2 subunit 48207

1629125 adenomatosis 371149 280 360191 8268 16256, 24244, polyposis coli down- 32232, 40220, regulated 1 -like 48208

1630126 adenomatosis 439429 281 413261 8269 16257, 24245, polyposis coli down- 32233, 40221, regulated 1 -like 48209

1631127 adenosylhomocystei 359172 282 352092 8270 16258, 24246, nase-like 1 32234, 40222,

163248210

1633128 adenosylhomocystei 369799 283 358814 8271 16259, 24247, nase-like 1 32235, 40223,

163448211

1635129 adenosylhomocystei 393614 284 377238 8272 16260, 24248, nase-like 1 32236, 40224,

163648212

1637130 adenylate cyclase 10 271426 285 271426 8273 16261, 24249, (soluble) 32237, 40225,

163848213

1639131 adenylate cyclase 10 367848 286 356822 8274 16262, 24250, (soluble) 32238, 40226,

164048214

1641132 adenylate cyclase 10 367851 287 356825 8275 16263, 24251, (soluble) 32239, 40227,

164248215

1643133 adenylate cyclase 10 545172 288 441992 8276 16264, 24252, (soluble) 32240, 40228,

164448216

1645134 adenylate kinase 4 327299 289 322175 8277 16265, 24253,

164632241, 40229, 48217

1647135 adenylate kinase 4 395334 290 378743 8278 16266, 24254,

164832242, 40230, 48218

1649136 adenylate kinase 4 545314 291 445912 8279 16267, 24255,

165032243, 40231, 48219

1651137 adhesion molecule 369862 292 358878 8280 16268, 24256, with Ig-like domain 32244, 40232, 1 48220

1652138 adhesion molecule 369864 293 358880 8281 16269, 24257, with Ig-like domain 32245, 40233, 1 48221

1653139 adhesion molecule 266581 294 266581 8282 16270, 24258, with Ig-like domain 32246, 40234, 2 48222

1654140 adhesion molecule 321382 295 320848 8283 16271, 24259, with Ig-like domain 32247, 40235, 2 48223

1655141 adhesion molecule 429635 296 406020 8284 16272, 24260, with Ig-like domain 32248, 40236, 2 48224 142 adhesion molecule 550413 297 449034 8285 16273, 24261, with Ig-like domain 32249, 40237, 2 48225

1656143 adhesion molecule 320431 298 323096 8286 16274, 24262, with Ig-like domain 32250, 40238, 3 48226

1657144 adhesion molecule 535833 299 439268 8287 16275, 24263, with Ig-like domain 32251, 40239, 3 48227

1658145 adhesion regulating 253003 300 253003 8288 16276, 24264, molecule 1 32252, 40240,

165948228

1660146 adhesion regulating 370744 301 359780 8289 16277, 24265, molecule 1 32253, 40241,

166148229

1662147 adipogenin 470147 302 434385 8290 16278, 24266,

166332254, 40242, 48230

1664148 adipogenin 537425 303 440331 8291 16279, 24267,

166532255, 40243, 48231

1666149 ADP-ribosylation 254584 304 254584 8292 16280, 24268, factor interacting 32256, 40244, protein 2 48232

1667150 ADP-ribosylation 396777 305 379998 8293 16281, 24269, factor interacting 32257, 40245, protein 2 48233

1668151 ADP-ribosylation 423813 306 398375 8294 16282, 24270, factor interacting 32258, 40246, protein 2 48234

1669152 ADP-ribosylation 445086 307 391427 8295 16283, 24271, factor interacting 32259, 40247, protein 2 48235

1670153 ADP-ribosylation 329240 308 331563 8296 16284, 24272, factor-like 17A 32260, 40248,

167148236

1672154 ADP-ribosylation 336125 309 337478 8297 16285, 24273, factor-like 17A 32261, 40249,

167348237

1674155 ADP-ribosylation 337845 310 338611 8298 16286, 24274, factor-like 17A 32262, 40250,

167548238

1676156 ADP-ribosylation 358484 311 351272 8299 16287, 24275, factor-like 17A 32263, 40251,

167748239

1678157 ADP-ribosylation 445552 312 416535 8300 16288, 24276, factor-like 17A 32264, 40252,

167948240

1680158 ADP-ribosylation 434041 313 391751 8301 16289, 24277, factor-like 17B 32265, 40253,

168148241

1682159 ADP-ribosylation 448026 314 395866 8302 16290, 24278, factor-like 17B 32266, 40254,

168348242 160 ADP-ribosylation 450673 315 404247 8303 16291, 24279, factor-like 17B 32267, 40255,

168448243

1685161 ADP-ribosylation 549665 316 446857 8304 16292, 24280, factor-like 17-like 32268, 40256, isoform a 48244

1686162 ADP-ribosylation 549904 317 449445 8305 16293, 24281, factor-like 17-like 32269, 40257, isoform a 48245

1687163 ADP-ribosylation 550273 318 449219 8306 16294, 24282, factor-like 17-like 32270, 40258, isoform a 48246

1688164 ADP-ribosylation 553155 319 447187 8307 16295, 24283, factor-like 17-like 32271, 40259, isoform a 48247

1689165 ADP-ribosylation 356797 320 349250 8308 16296, 24284, factor-like 4A 32272, 40260,

169048248

1691166 ADP-ribosylation 396662 321 379897 8309 16297, 24285, factor-like 4A 32273, 40261,

169248249

1693167 ADP-ribosylation 396663 322 379898 8310 16298, 24286, factor-like 4A 32274, 40262,

169448250

1695168 ADP-ribosylation 396664 323 379899 8311 16299, 24287, factor-like 4A 32275, 40263,

169648251

1697169 ADP-ribosylation 404894 324 385236 8312 16300, 24288, factor-like 4A 32276, 40264,

169848252

1699170 ADP-ribosylation 439721 325 397651 8313 16301, 24289, factor-like 4A 32277, 40265,

170048253

1701171 ADP-ribosylation 339728 326 339754 8314 16302, 24290, factor-like 4C 32278, 40266,

170248254

1703172 ADP-ribosylation 390645 327 375057 8315 16303, 24291, factor-like 4C 32279, 40267,

170448255

1705173 ADP-ribosylation 304414 328 306788 8316 16304, 24292, factor-like 6 32280, 40268, interacting protein 1 48256

1706174 ADP-ribosylation 545430 329 440010 8317 16305, 24293, factor-like 6 32281, 40269, interacting protein 1 48257

1707175 ADP-ribosylation 546206 330 440048 8318 16306, 24294, factor-like 6 32282, 40270, interacting protein 1 48258

1708176 ADP-ribosylation 272217 331 272217 8319 16307, 24295, factor-like 8A 32283, 40271,

170948259

1710177 ADP-ribosylation 256496 332 256496 8320 16308, 24296, factor-like 8B 32284, 40272,

171148260 178 ADP-ribosylation 419534 333 402996 8321 16309, 24297, factor-like 8B 32285, 40273,

171248261

1713179 ADP-ribosylation 438743 334 414192 8322 16310, 24298, factor-like 8B 32286, 40274,

171448262

1715180 ADP-ribosylation- 326446 335 315357 8323 16311, 24299, like factor 6 32287, 40275, interacting protein 6 48263

1716181 AF4/FMR2 family, 265343 336 265343 8324 16312, 24300, member 4 32288, 40276,

171748264

1718182 AF4/FMR2 family, 421773 337 395268 8325 16313, 24301, member 4 32289, 40277,

171948265

1720183 agmatine 375826 338 364986 8326 16314, 24302, ureohydrolase 32290, 40278,

1721(agmatinase) 48266

1722184 ajuba LIM protein 262713 339 262713 8327 16315, 24303,

172332291, 40279, 48267

1724185 ajuba LIM protein 361265 340 354491 8328 16316, 24304,

172532292, 40280, 48268

1726186 ajuba LIM protein 397388 341 380543 8329 16317, 24305,

172732293, 40281, 48269

1728187 ajuba LIM protein 553592 342 452369 8330 16318, 24306,

172932294, 40282, 48270

1730188 ajuba LIM protein 553911 343 452325 8331 16319, 24307,

173132295, 40283, 48271

1732189 ajuba LIM protein 556731 344 451649 8332 16320, 24308,

173332296, 40284, 48272

190 AL138831.1 356722 345 369622 8333 16321, 24309,

173532297, 40285, 48273

1736191 alanine-glyoxylate 296486 346 296486 8334 16322, 24310, aminotransferase 2- 32298, 40286, like 1 48274

1737192 alanine-glyoxylate 411864 347 392269 8335 16323, 24311, aminotransferase 2- 32299, 40287, like 1 48275

1738193 alanine-glyoxylate 512646 348 427065 8336 16324, 24312, aminotransferase 2- 32300, 40288, like 1 48276

1739194 alanine-glyoxylate 308158 349 310978 8337 16325, 24313, aminotransferase 2- 32301, 40289, like 2 48277

1740195 alkaline ceramidase 526597 350 431149 8338 16326, 24314, 3 32302, 40290,

174148278 196 alkaline ceramidase 532485 351 434480 8339 16327, 24315, 3 32303, 40291,

174248279

1743197 alkaline ceramidase 533873 352 436252 8340 16328, 24316, 3 32304, 40292,

174448280

1745198 alkaline ceramidase 538157 353 440916 8341 16329, 24317, 3 32305, 40293,

174648281

1747199 alkaline ceramidase 544113 354 440663 8342 16330, 24318, 3 32306, 40294,

174848282

1749200 allograft 247291 355 247291 8343 16331, 24319, inflammatory factor 32307, 40295, 1 -like 48283

1750201 allograft 372300 356 361374 8344 16332, 24320, inflammatory factor 32308, 40296, 1 -like 48284

1751202 allograft 372301 357 361375 8345 16333, 24321, inflammatory factor 32309, 40297, 1 -like 48285

1752203 allograft 372302 358 361376 8346 16334, 24322, inflammatory factor 32310, 40298, 1 -like 48286

1753204 allograft 372309 359 361383 8347 16335, 24323, inflammatory factor 32311, 40299, 1 -like 48287

1754205 allograft 372312 360 361386 8348 16336, 24324, inflammatory factor 32312, 40300, 1 -like 48288

1755206 alpha- 1,4-N- 236709 361 236709 8349 16337, 24325, acetylglucosaminyltr 32313, 40301, ansferase 48289

1756207 amiloride-sensitive 537611 362 442477 8350 16338, 24326, cation channel 5, 32314, 40302, intestinal 48290

1757208 Aminopeptidase Q 357872 363 350541 8351 16339, 24327,

175832315, 40303, 48291

1759209 Aminopeptidase Q 379578 364 368897 8352 16340, 24328,

176032316, 40304, 48292

1761210 Aminopeptidase Q 395528 365 378899 8353 16341, 24329,

176232317, 40305, 48293

1763211 amyloid beta (A4) 356785 366 349237 8354 16342, 24330, precursor protein- 32318, 40306, binding, family B, 48294 member 1

1764interacting protein

1765212 amyloid beta (A4) 376236 367 365411 8355 16343, 24331, precursor protein- 32319, 40307, binding, family B, 48295 member 1

1766interacting protein 213 amyloid beta (A4) 445780 368 412699 8356 16344, 24332, precursor protein- 32320, 40308, binding, family B, 48296 member 1

1767interacting protein

1768214 androgen-induced 1 275235 369 275235 8357 16345, 24333,

176932321, 40309, 48297

1770215 androgen-induced 1 344492 370 340090 8358 16346, 24334,

177132322, 40310, 48298

1772216 androgen-induced 1 357847 371 350509 8359 16347, 24335,

177332323, 40311, 48299

1774217 androgen-induced 1 367596 372 356568 8360 16348, 24336,

177532324, 40312, 48300

1776218 androgen-induced 1 367598 373 356570 8361 16349, 24337,

177732325, 40313, 48301

1778219 androgen-induced 1 367601 374 356573 8362 16350, 24338,

177932326, 40314, 48302

1780220 androgen-induced 1 419072 375 398080 8363 16351, 24339,

178132327, 40315, 48303

1782221 androgen-induced 1 447498 376 405048 8364 16352, 24340,

178332328, 40316, 48304

1784222 androgen-induced 1 458219 377 407817 8365 16353, 24341,

178532329, 40317, 48305

1786223 angio-associated, 248450 378 248450 8366 16354, 24342, migratory cell 32330, 40318, protein 48306

1787224 angiomotin like 1 317829 379 320968 8367 16355, 24343,

178832331, 40319, 48307

1789225 angiomotin like 1 317837 380 323474 8368 16356, 24344,

179032332, 40320, 48308

1791226 angiomotin like 1 433060 381 387739 8369 16357, 24345,

179232333, 40321, 48309

1793227 angiomotin like 1 542840 382 442286 8370 16358, 24346,

179432334, 40322, 48310

1795228 angiomotin like 2 249883 383 249883 8371 16359, 24347,

179632335, 40323, 48311

1797229 angiomotin like 2 422605 384 409999 8372 16360, 24348,

179832336, 40324, 48312 230 angiomotin like 2 502491 385 421521 8373 16361, 24349,

179932337, 40325, 48313

1800231 angiomotin like 2 504234 386 424910 8374 16362, 24350,

180132338, 40326, 48314

1802232 angiomotin like 2 505596 387 427292 8375 16363, 24351,

180332339, 40327, 48315

1804233 angiomotin like 2 506107 388 422658 8376 16364, 24352,

180532340, 40328, 48316

1806234 angiomotin like 2 510560 389 427184 8377 16365, 24353,

180732341, 40329, 48317

1808235 angiomotin like 2 513145 390 425475 8378 16366, 24354,

180932342, 40330, 48318

1810236 angiomotin like 2 514516 391 424765 8379 16367, 24355,

181132343, 40331, 48319

1812237 angiomotin like 2 515172 392 427482 8380 16368, 24356,

181332344, 40332, 48320

1814238 angiotensin II 314340 393 319713 8381 16369, 24357, receptor-associated 32345, 40333, protein 48321

1815239 angiotensin II 376629 394 365816 8382 16370, 24358, receptor-associated 32346, 40334, protein 48322

1816240 angiotensin II 376637 395 365824 8383 16371, 24359, receptor-associated 32347, 40335, protein 48323

1817241 angiotensin II 400895 396 383688 8384 16372, 24360, receptor-associated 32348, 40336, protein 48324

1818242 angiotensin II 452018 397 408505 8385 16373, 24361, receptor-associated 32349, 40337, protein 48325

1819243 ankyrin and 281412 398 281412 8386 16374, 24362, armadillo repeat 32350, 40338, containing 48326

1820244 ankyrin and 313581 399 313513 8387 16375, 24363, armadillo repeat 32351, 40339, containing 48327

1821245 ankyrin and 374838 400 363971 8388 16376, 24364, armadillo repeat 32352, 40340, containing 48328

1822246 ankyrin and 431575 401 393043 8389 16377, 24365, armadillo repeat 32353, 40341, containing 48329

1823247 ankyrin and 438402 402 397243 8390 16378, 24366, armadillo repeat 32354, 40342, containing 48330 248 ankyrin and 520309 403 427882 8391 16379, 24367, armadillo repeat 32355, 40343, containing 48331

1824249 ankyrin repeat and 341657 404 343362 8392 16380, 24368, FYVE domain 32356, 40344, containing 1 48332

1825250 ankyrin repeat and 433651 405 416005 8393 16381, 24369, FYVE domain 32357, 40345, containing 1 48333

1826251 ankyrin repeat and 535427 406 442785 8394 16382, 24370, FYVE domain 32358, 40346, containing 1 48334

1827252 ankyrin repeat and 574367 407 459775 8395 16383, 24371, FYVE domain 32359, 40347, containing 1 48335

1828253 ankyrin repeat 377477 408 366697 8396 16384, 24372, domain 20 family, 32360, 40348, member Al 48336

1829254 ankyrin repeat 301190 409 301190 8397 16385, 24373, domain 33 32361, 40349,

183048337

1831255 ankyrin repeat 335659 410 335287 8398 16386, 24374, domain 46 32362, 40350,

183248338

1833256 ankyrin repeat 358990 411 351881 8399 16387, 24375, domain 46 32363, 40351,

183448339

1835257 ankyrin repeat 519597 412 430056 8400 16388, 24376, domain 46 32364, 40352,

183648340

1837258 ankyrin repeat 520311 413 428388 8401 16389, 24377, domain 46 32365, 40353,

183848341

1839259 ankyrin repeat 520552 414 429015 8402 16390, 24378, domain 46 32366, 40354,

184048342

1841260 ankyrin repeat 521345 415 429647 8403 16391, 24379, domain 46 32367, 40355,

184248343

1843261 ankyrin repeat 523000 416 430800 8404 16392, 24380, domain 46 32368, 40356,

184448344

1845262 ankyrin repeat 524072 417 430357 8405 16393, 24381, domain 46 32369, 40357,

184648345

1847263 annexin A13 262219 418 262219 8406 16394, 24382,

184832370, 40358, 48346

1849264 annexin A13 419625 419 390809 8407 16395, 24383,

185032371, 40359, 48347

1851265 anoctamin 3 256737 420 256737 8408 16396, 24384,

185232372, 40360, 48348 266 anoctamin 3 525139 421 432576 8409 16397, 24385,

185332373, 40361, 48349

1854267 anoctamin 3 531568 422 432394 8410 16398, 24386,

185532374, 40362, 48350

1856268 anoctamin 3 537978 423 440737 8411 16399, 24387,

185732375, 40363, 48351

1858269 anoctamin 3 538001 424 442241 8412 16400, 24388,

185932376, 40364, 48352

1860270 anoctamin 4 299222 425 299222 8413 16401, 24389,

186132377, 40365, 48353

1862271 anoctamin 4 392977 426 376703 8414 16402, 24390,

186332378, 40366, 48354

1864272 anoctamin 4 392979 427 376705 8415 16403, 24391,

186532379, 40367, 48355

1866273 anoctamin 4 538618 428 443751 8416 16404, 24392,

186732380, 40368, 48356

1868274 anoctamin 4 546991 429 447867 8417 16405, 24393,

186932381, 40369, 48357

1870275 anoctamin 4 550015 430 450192 8418 16406, 24394,

187132382, 40370, 48358

1872276 anoctamin 7 274979 431 274979 8419 16407, 24395,

187332383, 40371, 48359

1874277 anoctamin 7 402430 432 385418 8420 16408, 24396,

187532384, 40372, 48360

1876278 anoctamin 7 402530 433 383985 8421 16409, 24397,

187732385, 40373, 48361

1878279 anoctamin 8 159087 434 159087 8422 16410, 24398,

187932386, 40374, 48362, 56073, 56106

1880280 anoctamin 9 332826 435 332788 8423 16411, 24399,

188132387, 40375, 48363

1882281 AP2 associated 406297 436 385181 8424 16412, 24400, kinase 1 32388, 40376,

188348364

1884282 AP2 associated 409085 437 386456 8425 16413, 24401, kinase 1 32389, 40377,

188548365

1886283 apelin receptor 257254 438 257254 8426 16414, 24402,

188732390, 40378, 48366 284 apelin receptor 326830 439 322708 8427 16415, 24403,

188832391, 40379, 48367

1889285 apelin receptor 444275 440 399748 8428 16416, 24404,

189032392, 40380, 48368

1891286 apoptogenic 1 409074 441 386485 8429 16417, 24405,

189232393, 40381, 48369

1893287 apoptosis-inducing 307864 442 312370 8430 16418, 24406, factor, 32394, 40382, mitochondrion- 48370 associated, 2

1894288 apoptosis-inducing 373248 443 362345 8431 16419, 24407, factor, 32395, 40383, mitochondrion- 48371 associated, 2

1895289 apoptosis-inducing 395039 444 378480 8432 16420, 24408, factor, 32396, 40384, mitochondrion- 48372 associated, 2

1896290 aquaporin 10 324978 445 318355 8433 16421, 24409,

189732397, 40385, 48373

1898291 aquaporin 10 484864 446 420341 8434 16422, 24410,

189932398, 40386, 48374

1900292 ArfGAP with dual 265846 447 265846 8435 16423, 24411, PH domains 1 32399, 40387,

190148375

1902293 ArfGAP with dual 449296 448 407267 8436 16424, 24412, PH domains 1 32400, 40388,

190348376

1904294 ArfGAP with dual 449929 449 392174 8437 16425, 24413, PH domains 1 32401, 40389,

190548377

1906295 ArfGAP with dual 538188 450 442254 8438 16426, 24414, PH domains 1 32402, 40390,

190748378

1908296 ArfGAP with dual 539900 451 442682 8439 16427, 24415, PH domains 1 32403, 40391,

190948379

1910297 ArfGAP with dual 330889 452 329468 8440 16428, 24416, PH domains 2 32404, 40392,

191148380

1912298 ArfGAP with SH3 281419 453 281419 8441 16429, 24417, domain, ankyrin 32405, 40393, repeat and PH 48381 domain 2

1913299 ArfGAP with SH3 315273 454 316404 8442 16430, 24418, domain, ankyrin 32406, 40394, repeat and PH 48382 domain 2 300 armadillo repeat 276569 455 276569 8443 16431, 24419, containing 1 32407, 40395,

191448383

1915301 armadillo repeat 458464 456 388572 8444 16432, 24420, containing 1 32408, 40396,

191648384

1917302 armadillo repeat 423738 457 404304 8445 16433, 24421, containing X-linked 32409, 40397, 4 48385

1918303 armadillo repeat 433011 458 424452 8446 16434, 24422, containing, X-linked 32410, 40398, 4 48386

1919304 armadillo repeat 452188 459 425302 8447 16435, 24423, containing, X-linked 32411, 40399, 4 48387

1920305 armadillo repeat 361910 460 354708 8448 16436, 24424, containing, X-linked 32412, 40400, 6 48388

1921306 armadillo repeat 538627 461 440648 8449 16437, 24425, containing, X-linked 32413, 40401, 6 48389

1922307 armadillo repeat 539247 462 444537 8450 16438, 24426, containing, X-linked 32414, 40402, 6 48390

1923308 arrestin domain 371421 463 360475 8451 16439, 24427, containing 1 32415, 40403,

192448391

1925309 arrestin domain 419386 464 406833 8452 16440, 24428, containing 1 32416, 40404,

192648392

1927310 arrestin domain 431925 465 406247 8453 16441, 24429, containing 1 32417, 40405,

192848393

1929311 arylacetamide 376221 466 365395 8454 16442, 24430, deacetylase-like 4 32418, 40406,

193048394

1931312 ashl (absent, small, 368346 467 357330 8455 16443, 24431, or homeotic)-like 32419, 40407, (Drosophila) 48395

1932313 ashl (absent, small, 392403 468 376204 8456 16444, 24432, or homeotic)-like 32420, 40408, (Drosophila) 48396

1933314 asialoglycoprotein 254850 469 254850 8457 16445, 24433, receptor 2 32421, 40409,

193448397

1935315 asialoglycoprotein 355035 470 347140 8458 16446, 24434, receptor 2 32422, 40410,

193648398

1937316 asialoglycoprotein 380952 471 370339 8459 16447, 24435, receptor 2 32423, 40411,

193848399

1939317 asialoglycoprotein 446679 472 405844 8460 16448, 24436, receptor 2 32424, 40412,

194048400 318 asialoglycoprotein 450034 473 411881 8461 16449, 24437, receptor 2 32425, 40413,

194148401

1942319 asparagine-linked 308742 474 310120 8462 16450, 24438, glycosylation 10, 32426, 40414, alpha- 1,2- 48402 glucosyltransferase

1943homolog B (yeast)

1944320 asparagine-linked 445626 475 402744 8463 16451, 24439, glycosylation 3, 32427, 40415, alpha- 1,3- 48403 mannosyltransferase

1945homolog (S.

1946cerevisiae)

1947321 asparagine-linked 239891 476 239891 8464 16452, 24440, glycosylation 5, 32428, 40416, dolichyl-phosphate 48404 beta- glucosyltransferase

1948homolog (S.

1949cerevisiae)

1950322 asparagine-linked 413537 477 389647 8465 16453, 24441, glycosylation 5, 32429, 40417, dolichyl-phosphate 48405 beta- glucosyltransferase

1951homolog (S.

1952cerevisiae)

1953323 asparagine-linked 443765 478 390533 8466 16454, 24442, glycosylation 5, 32430, 40418, dolichyl-phosphate 48406 beta- glucosyltransferase

1954homolog (S.

1955cerevisiae)

1956324 aspartate beta- 308748 479 311447 8467 16455, 24443, hydroxylase domain 32431, 40419, containing 1 48407

1957325 aspartate beta- 414952 480 388036 8468 16456, 24444, hydroxylase domain 32432, 40420, containing 1 48408

1958326 aspartate beta- 215906 481 215906 8469 16457, 24445, hydroxylase domain 32433, 40421, containing 2 48409

1959327 aspartyl-tRNA 264161 482 264161 8470 16458, 24446, synthetase 32434, 40422,

196048410

1961328 aspartyl-tRNA 537273 483 444192 8471 16459, 24447, synthetase 32435, 40423,

196248411

1963329 ATG12 autophagy 274459 484 274459 8472 16460, 24448, related 12 homolog 32436, 40424, (S. cerevisiae) 48412

1964330 ATG12 autophagy 500945 485 425164 8473 16461, 24449, related 12 homolog 32437, 40425, (S. cerevisiae) 48413

1965331 ATG12 autophagy 509910 486 425107 8474 16462, 24450, related 12 homolog 32438, 40426, (S. cerevisiae) 48414

1966332 ATG14 autophagy 247178 487 247178 8475 16463, 24451, related 14 homolog 32439, 40427, (S. cerevisiae) 48415

1967333 ATG5 autophagy 343245 488 343313 8476 16464, 24452, related 5 homolog 32440, 40428, (S. cerevisiae) 48416

1968334 ATG5 autophagy 360666 489 353884 8477 16465, 24453, related 5 homolog 32441, 40429, (S. cerevisiae) 48417

1969335 ATG5 autophagy 369070 490 358066 8478 16466, 24454, related 5 homolog 32442, 40430, (S. cerevisiae) 48418

1970336 ATG5 autophagy 369076 491 358072 8479 16467, 24455, related 5 homolog 32443, 40431, (S. cerevisiae) 48419

1971337 ATP synthase H+ 245448 492 245448 8480 16468, 24456, transporting 32444, 40432, mitochondrial Fo 48420 complex subunit s

1972(factor B)

1973338 ATP synthase H+ 426751 493 389246 8481 16469, 24457, transporting 32445, 40433, mitochondrial Fo 48421 complex subunit s

1974(factor B)

1975339 ATP synthase 329231 494 330685 8482 16470, 24458, mitochondrial F 1 32446, 40434, complex assembly 48422 factor 1

1976340 ATP synthase 371937 495 361005 8483 16471, 24459, mitochondrial F 1 32447, 40435, complex assembly 48423 factor 1

1977341 ATP synthase 532925 496 435732 8484 16472, 24460, mitochondrial F 1 32448, 40436, complex assembly 48424 factor 1

1978342 ATP synthase 542495 497 443588 8485 16473, 24461, mitochondrial F 1 32449, 40437, complex assembly 48425 factor 1

1979343 ATP synthase 529214 498 436267 8486 16474, 24462, mitochondrial F 1 32450, 40438, complex assembly 48426 factor 1

1980344 ATP synthase 574428 499 459167 8487 16475, 24463, mitochondrial F 1 32451, 40439, complex assembly 48427 factor 1 345 ATP synthase 361851 500 355265 8488 16476, 24464, protein 8 32452, 40440,

198148428

1982346 ATP synthase, H+ 215375 501 215375 8489 16477, 24465, transporting, 32453, 40441, mitochondrial F 1 48429 complex, delta

1983subunit

1984347 ATP synthase, H+ 395633 502 378995 8490 16478, 24466, transporting, 32454, 40442, mitochondrial F 1 48430 complex, delta

1985subunit

1986348 ATP synthase, H+ 381026 503 370414 8491 16479, 24467, transporting, 32455, 40443, mitochondrial F 1 48431 complex, epsilon

1987subunit pseudogene

19882

1989349 ATP synthase, H+ 369722 504 358737 8492 16480, 24468, transporting, 32456, 40444, mitochondrial Fo 48432 complex, subunit Bl

1990350 ATP synthase, H+ 483994 505 420366 8493 16481, 24469, transporting, 32457, 40445, mitochondrial Fo 48433 complex, subunit Bl

1991351 ATP synthase, H+ 301587 506 301587 8494 16482, 24470, transporting, 32458, 40446, mitochondrial Fo 48434 complex, subunit d

1992352 ATP synthase, H+ 344546 507 344230 8495 16483, 24471, transporting, 32459, 40447, mitochondrial Fo 48435 complex, subunit d

1993353 ATP synthase, H+ 538432 508 437996 8496 16484, 24472, transporting, 32460, 40448, mitochondrial Fo 48436 complex, subunit d

1994354 ATP synthase, H+ 292475 509 292475 8497 16485, 24473, transporting, 32461, 40449, mitochondrial Fo 48437 complex, subunit F2

1995355 ATP synthase, H+ 359832 510 352890 8498 16486, 24474, transporting, 32462, 40450, mitochondrial Fo 48438 complex, subunit F2

1996356 ATP synthase, H+ 394186 511 377740 8499 16487, 24475, transporting, 32463, 40451, mitochondrial Fo 48439 complex, subunit F2

1997357 ATP synthase, H+ 488775 512 418197 8500 16488, 24476, transporting, 32464, 40452, mitochondrial Fo 48440 complex, subunit F2 358 ATP synthase, H+ 544611 513 444922 8501 16489, 24477, transporting, 32465, 40453, mitochondrial Fo 48441 complex, subunit F2

1998359 ATP synthase, H+ 300688 514 300688 8502 16490, 24478, transporting, 32466, 40454, mitochondrial Fo 48442 complex, subunit G

1999360 ATP synthase, H+ 505920 515 421076 8503 16491, 24479, transporting, 32467, 40455, mitochondrial Fo 48443 complex, subunit G2

2000361 ATP synthase, H+ 311459 516 308334 8504 16492, 24480, transporting, 32468, 40456, mitochondrial Fo 48444 complex, subunit s

2001(factor B)

2002362 ATP synthase, H+ 358473 517 351258 8505 16493, 24481, transporting, 32469, 40457, mitochondrial Fo 48445 complex, subunit s

2003(factor B)

2004363 ATPase H+ 492758 518 417378 8506 16494, 24482, transporting 32470, 40458, lysosomal 14kDa VI 48446 subunit F

2005364 ATPase inhibitory 335514 519 335203 8507 16495, 24483, factor 1 32471, 40459,

200648447

2007365 ATPase inhibitory 465645 520 437337 8508 16496, 24484, factor 1 32472, 40460,

200848448

2009366 ATPase inhibitory 497986 521 435579 8509 16497, 24485, factor 1 32473, 40461,

201048449

2011367 ATPase type 13A1 291503 522 291503 8510 16498, 24486,

201232474, 40462, 48450

2013368 ATPase type 13A1 357324 523 349877 8511 16499, 24487,

201432475, 40463, 48451

2015369 ATPase type 13 A3 256031 524 256031 8512 16500, 24488,

201632476, 40464, 48452

2017370 ATPase type 13 A3 310773 525 311019 8513 16501, 24489,

201832477, 40465, 48453

2019371 ATPase type 13 A3 439040 526 416508 8514 16502, 24490,

202032478, 40466, 48454

2021372 ATPase type 13 A3 446356 527 410767 8515 16503, 24491,

202232479, 40467, 48455 373 ATPase type 13 A3 457986 528 406234 8516 16504, 24492,

202332480, 40468, 48456

2024374 ATPase type 13A4 295548 529 295548 8517 16505, 24493,

202532481, 40469, 48457

2026375 ATPase type 13A4 342695 530 339182 8518 16506, 24494,

202732482, 40470, 48458

2028376 ATPase type 13A4 400270 531 383129 8519 16507, 24495,

202932483, 40471, 48459

2030377 ATPase type 13A5 342358 532 341942 8520 16508, 24496,

203132484, 40472, 48460

2032378 ATPase, 264449 533 264449 8521 16509, 24497, aminophospholipid 32485, 40473, transporter (APLT), 48461 class I, type 8A,

2033member 1

2034379 ATPase, 381668 534 371084 8522 16510, 24498, aminophospholipid 32486, 40474, transporter (APLT), 48462 class I, type 8A,

2035member 1

2036380 ATPase, class I, type 284509 535 284509 8523 16511, 24499, 8B, member 4 32487, 40475,

203748463

2038381 ATPase, class I, type 558829 536 453539 8524 16512, 24500, 8B, member 4 32488, 40476,

203948464

2040382 ATPase, class I, type 559829 537 453169 8525 16513, 24501, 8B, member 4 32489, 40477,

204148465

2042383 ATPase, class II, 311637 538 309086 8526 16514, 24502, type 9A 32490, 40478,

204348466

2044384 ATPase, class II, 338821 539 342481 8527 16515, 24503, type 9A 32491, 40479,

204548467

2046385 ATPase, class II, 402822 540 385875 8528 16516, 24504, type 9A 32492, 40480,

204748468

2048386 ATPase, class V, 327245 541 313600 8529 16517, 24505, type 10B 32493, 40481,

204948469

2050387 ATPase, class V, 273859 542 273859 8530 16518, 24506, type 10D 32494, 40482,

205148470

2052388 ATPase, class V, 504445 543 420909 8531 16519, 24507, type 10D 32495, 40483,

205348471

2054389 ATPase, class VI, 327569 544 332756 8532 16520, 24508, type l lC 32496, 40484,

205548472 390 ATPase, class VI, 359686 545 352715 8533 16521, 24509, type l lC 32497, 40485,

205648473

2057391 ATPase, class VI, 361648 546 355165 8534 16522, 24510, type l lC 32498, 40486,

205848474

2059392 ATPase, class VI, 370543 547 359574 8535 16523, 24511, type l lC 32499, 40487,

206048475

2061393 ATPase, class VI, 370557 548 359588 8536 16524, 24512, type l lC 32500, 40488,

206248476

2063394 ATPase, class VI, 422228 549 394573 8537 16525, 24513, type l lC 32501, 40489,

206448477

2065395 ATPase, class VI, 433868 550 397923 8538 16526, 24514, type l lC 32502, 40490,

206648478

2067396 ATPase, class VI, 450801 551 391259 8539 16527, 24515, type l lC 32503, 40491,

206848479

2069397 ATPase, H+ 281087 552 281087 8540 16528, 24516, transporting, 32504, 40492, lysosomal 13kDa, 48480 VI subunit G3

2070398 ATPase, H+ 309309 553 309574 8541 16529, 24517, transporting, 32505, 40493, lysosomal 13kDa, 48481 VI subunit G3

2071399 ATPase, H+ 367381 554 356351 8542 16530, 24518, transporting, 32506, 40494, lysosomal 13kDa, 48482 VI subunit G3

2072400 ATPase, H+ 367382 555 356352 8543 16531, 24519, transporting, 32507, 40495, lysosomal 13kDa, 48483 VI subunit G3

2073401 ATPase, H+ 489986 556 417171 8544 16532, 24520, transporting, 32508, 40496, lysosomal 13kDa, 48484 VI subunit G3

2074402 ATPase, H+ 249289 557 249289 8545 16533, 24521, transporting, 32509, 40497, lysosomal 14kDa, 48485 VI subunit F

2075403 ATPase, H+ 306448 558 304891 8546 16534, 24522, transporting, 32510, 40498, lysosomal 31kDa, 48486 VI subunit E2

2076404 ATPase, H+ 522587 559 428141 8547 16535, 24523, transporting, 32511, 40499, lysosomal 31kDa, 48487 VI subunit E2 405 ATPase, H+ 216442 560 216442 8548 16536, 24524, transporting, 32512, 40500, lysosomal 34kDa, 48488 VI subunit D

2077406 ATPase, H+ 554087 561 451167 8549 16537, 24525, transporting, 32513, 40501, lysosomal 34kDa, 48489 VI subunit D

2078407 ATPase, H+ 555012 562 451031 8550 16538, 24526, transporting, 32514, 40502, lysosomal 34kDa, 48490 VI subunit D

2079408 ATPase, H+ 285393 563 285393 8551 16539, 24527, transporting, 32515, 40503, lysosomal 38kDa, 48491 V0 subunit d2

2080409 ATPase, H+ 521564 564 429731 8552 16540, 24528, transporting, 32516, 40504, lysosomal 38kDa, 48492 V0 subunit d2

2081410 ATPase, H+ 523635 565 428382 8553 16541, 24529, transporting, 32517, 40505, lysosomal 38kDa, 48493 V0 subunit d2

2082411 ATPase, H+ 272238 566 272238 8554 16542, 24530, transporting, 32518, 40506, lysosomal 42kDa, 48494 VI subunit C2

2083412 ATPase, H+ 381661 567 371077 8555 16543, 24531, transporting, 32519, 40507, lysosomal 42kDa, 48495 VI subunit C2

2084413 ATPase, H+ 355221 568 347359 8556 16544, 24532, transporting, 32520, 40508, lysosomal 48496 50/57kDa, VI

2085subunit H

2086414 ATPase, H+ 359530 569 352522 8557 16545, 24533, transporting, 32521, 40509, lysosomal 48497 50/57kDa, VI

2087subunit H

2088415 ATPase, H+ 396774 570 379995 8558 16546, 24534, transporting, 32522, 40510, lysosomal 48498 50/57kDa, VI

2089subunit H

2090416 ATPase, H+ 521275 571 429786 8559 16547, 24535, transporting, 32523, 40511, lysosomal 48499 50/57kDa, VI

2091subunit H

2092417 ATPase, H+ 524234 572 427835 8560 16548, 24536, transporting, 32524, 40512, lysosomal 48500 50/57kDa, VI

2093subunit H

2094418 ATPase, H+ 234396 573 234396 8561 16549, 24537, transporting, 32525, 40513, lysosomal 48501 56/58kDa, VI

2095subunit Bl

2096419 ATPase, H+ 412314 574 388353 8562 16550, 24538, transporting, 32526, 40514, lysosomal 48502 56/58kDa, VI

2097subunit Bl

2098420 ATPase, H+ 483246 575 443856 8563 16551, 24539, transporting, 32527, 40515, lysosomal 48503 56/58kDa, VI

2099subunit Bl

2100421 ATPase, H+ 276390 576 276390 8564 16552, 24540, transporting, 32528, 40516, lysosomal 48504 56/58kDa, VI

2101subunit B2

2102422 ATPase, H+ 542368 577 439953 8565 16553, 24541, transporting, 32529, 40517, lysosomal 48505 56/58kDa, VI

2103subunit B2

2104423 ATPase, H+ 273398 578 273398 8566 16554, 24542, transporting, 32530, 40518, lysosomal 70kDa, 48506 VI subunit A

2105424 ATPase, H+ 475322 579 419294 8567 16555, 24543, transporting, 32531, 40519, lysosomal 70kDa, 48507 VI subunit A

2106425 ATPase, H+ 538620 580 439874 8568 16556, 24544, transporting, 32532, 40520, lysosomal 70kDa, 48508 VI subunit A

2107426 ATPase, H+ 545842 581 441031 8569 16557, 24545, transporting, 32533, 40521, lysosomal 70kDa, 48509 VI subunit A

2108427 ATPase, H+ 517669 582 427941 8570 16558, 24546, transporting, 32534, 40522, lysosomal 9kDa, VO 48510 subunit el

2109428 ATPase, H+ 519374 583 429690 8571 16559, 24547, transporting, 32535, 40523, lysosomal 9kDa, VO 48511 subunit el

2110429 ATPase, H+ 369762 584 358777 8572 16560, 24548, transporting, 32536, 40524, lysosomal accessory 48512 protein 1 430 ATPase, H+ 422890 585 398511 8573 16561, 24549, transporting, 32537, 40525, lysosomal accessory 48513 protein 1

2111431 ATPase, H+ 445849 586 388546 8574 16562, 24550, transporting, 32538, 40526, lysosomal accessory 48514 protein 1

2112432 ATPase, H+ 449556 587 392375 8575 16563, 24551, transporting, 32539, 40527, lysosomal accessory 48515 protein 1

2113433 ATPase, H+ 380167 588 369513 8576 16564, 24552, transporting, 32540, 40528, lysosomal accessory 48516 protein 1-like

2114434 ATPase, H+ 439350 589 391381 8577 16565, 24553, transporting, 32541, 40529, lysosomal accessory 48517 protein 1-like

2115435 ATPase, Na+/K+ 218008 590 218008 8578 16566, 24554, transporting, beta 4 32542, 40530, polypeptide 48518

2116436 ATPase, Na+/K+ 361319 591 355346 8579 16567, 24555, transporting, beta 4 32543, 40531, polypeptide 48519

2117437 ATPase, Na+/K+ 539306 592 443334 8580 16568, 24556, transporting, beta 4 32544, 40532, polypeptide 48520

2118438 ATP-binding 406935 593 383899 8581 16569, 24557, cassette sub-family 32545, 40533, B (MDR/TAP) 48521 member 5

2119439 ATP-binding 258738 594 258738 8582 16570, 24558, cassette, sub-family 32546, 40534, B (MDR/TAP), 48522 member 5

2120440 ATP-binding 404938 595 384881 8583 16571, 24559, cassette, sub-family 32547, 40535, B (MDR/TAP), 48523 member 5

2121441 ATP-binding 443026 596 406730 8584 16572, 24560, cassette, sub-family 32548, 40536, B (MDR/TAP), 48524 member 5

2122442 ATP-binding 302539 597 303960 8585 16573, 24561, cassette, sub-family 32549, 40537, C (CFTR/MRP), 48525 member 8

2123443 ATP-binding 379493 598 368807 8586 16574, 24562, cassette, sub-family 32550, 40538, C (CFTR/MRP), 48526 member 8 444 ATP-binding 389817 599 374467 8587 16575, 24563, cassette, sub-family 32551, 40539, C (CFTR/MRP), 48527 member 8

2124445 ATP-binding 527905 600 431653 8588 16576, 24564, cassette, sub-family 32552, 40540, C (CFTR/MRP), 48528 member 8

2125446 ATP-binding 546162 601 443361 8589 16577, 24565, cassette, sub-family 32553, 40541, C, member 6 48529 pseudogene 1

2126447 aurora kinase A 321751 602 319778 8590 16578, 24566, interacting protein 1 32554, 40542,

212748530

2128448 aurora kinase A 338338 603 340656 8591 16579, 24567, interacting protein 1 32555, 40543,

212948531

2130449 aurora kinase A 338370 604 342676 8592 16580, 24568, interacting protein 1 32556, 40544,

213148532

2132450 aurora kinase A 378853 605 368130 8593 16581, 24569, interacting protein 1 32557, 40545,

213348533

2134451 B and T lymphocyte 334529 606 333919 8594 16582, 24570, associated 32558, 40546,

213548534

2136452 B and T lymphocyte 383680 607 373178 8595 16583, 24571, associated 32559, 40547,

213748535

2138453 B7 homolog 6 338965 608 341637 8596 16584, 24572,

213932560, 40548, 48536

2140454 B7 homolog 6 530403 609 434394 8597 16585, 24573,

214132561, 40549, 48537

2142455 BAI1 -associated 332536 610 328876 8598 16586, 24574, protein 2-like 2 32562, 40550,

214348538

2144456 BAI1 -associated 381669 611 371085 8599 16587, 24575, protein 2-like 2 32563, 40551,

214548539

2146457 BAI1 -associated 402500 612 384877 8600 16588, 24576, protein 2-like 2 32564, 40552,

214748540

2148458 B-cell receptor- 5259 613 5259 8601 16589, 24577, associated protein 29 32565, 40553,

214948541, 56074, 56107

2150459 B-cell receptor- 379117 614 368412 8602 16590, 24578, associated protein 29 32566, 40554,

215148542

2152460 B-cell receptor- 379119 615 368414 8603 16591, 24579, associated protein 29 32567, 40555,

215348543 461 B-cell receptor- 379121 616 368416 8604 16592, 24580, associated protein 29 32568, 40556,

215448544

2155462 B-cell receptor- 421217 617 395828 8605 16593, 24581, associated protein 29 32569, 40557,

215648545

2157463 B-cell receptor- 436699 618 414164 8606 16594, 24582, associated protein 29 32570, 40558,

215848546

2159464 B-cell receptor- 445771 619 400718 8607 16595, 24583, associated protein 29 32571, 40559,

216048547

2161465 B-cell receptor- 457837 620 409350 8608 16596, 24584, associated protein 29 32572, 40560,

216248548

2163466 B-cell receptor- 465919 621 418993 8609 16597, 24585, associated protein 29 32573, 40561,

216448549

2165467 B-cell receptor- 473124 622 420313 8610 16598, 24586, associated protein 29 32574, 40562,

216648550

2167468 B-cell receptor- 479917 623 418816 8611 16599, 24587, associated protein 29 32575, 40563,

216848551

2169469 B-cell receptor- 345046 624 343458 8612 16600, 24588, associated protein 31 32576, 40564,

217048552

2171470 B-cell receptor- 416815 625 394270 8613 16601, 24589, associated protein 31 32577, 40565,

217248553

2173471 B-cell receptor- 423827 626 389740 8614 16602, 24590, associated protein 31 32578, 40566,

217448554

2175472 B-cell receptor- 426131 627 387751 8615 16603, 24591, associated protein 31 32579, 40567,

217648555

2177473 B-cell receptor- 429550 628 409888 8616 16604, 24592, associated protein 31 32580, 40568,

217848556

2179474 B-cell receptor- 430088 629 402342 8617 16605, 24593, associated protein 31 32581, 40569,

218048557

2181475 B-cell receptor- 441714 630 405417 8618 16606, 24594, associated protein 31 32582, 40570,

218248558

2183476 B-cell receptor- 442093 631 400345 8619 16607, 24595, associated protein 31 32583, 40571,

218448559

2185477 B-cell receptor- 458587 632 392330 8620 16608, 24596, associated protein 31 32584, 40572,

218648560

2187478 BCL2/ adenovirus 231668 633 231668 8621 16609, 24597, E1B 19kDa 32585, 40573, interacting protein 1 48561 <img file="WO2013151663A1_D0010.tif" />

2188group) 495 beta- 1,3 -N- 392780 650 376531 8638 16626, 24614, acetylgalactosaminyl 32602, 40590, transferase 1 48578 (globoside blood

2189group)

2190496 beta- 1,3 -N- 392781 651 376532 8639 16627, 24615, acetylgalactosaminyl 32603, 40591, transferase 1 48579 (globoside blood

2191group)

2192497 beta- 1,3 -N- 417187 652 407027 8640 16628, 24616, acetylgalactosaminyl 32604, 40592, transferase 1 48580 (globoside blood

2193group)

2194498 beta- 1,3 -N- 468268 653 419476 8641 16629, 24617, acetylgalactosaminyl 32605, 40593, transferase 1 48581 (globoside blood

2195group)

2196499 beta- 1,3 -N- 473142 654 420604 8642 16630, 24618, acetylgalactosaminyl 32606, 40594, transferase 1 48582 (globoside blood

2197group)

2198500 beta- 1,3 -N- 473285 655 418226 8643 16631, 24619, acetylgalactosaminyl 32607, 40595, transferase 1 48583 (globoside blood

2199group)

2200501 beta- 1,3 -N- 484127 656 420059 8644 16632, 24620, acetylgalactosaminyl 32608, 40596, transferase 1 48584 (globoside blood

2201group)

2202502 beta- 1,3 -N- 488170 657 420163 8645 16633, 24621, acetylgalactosaminyl 32609, 40597, transferase 1 48585 (globoside blood

2203group)

2204503 beta- 1,3 -N- 492353 658 418567 8646 16634, 24622, acetylgalactosaminyl 32610, 40598, transferase 1 48586 (globoside blood

2205group)

2206504 beta- 1,3 -N- 494173 659 419127 8647 16635, 24623, acetylgalactosaminyl 32611, 40599, transferase 1 48587 (globoside blood

2207group)

2208505 beta- 1,3 -N- 498216 660 417643 8648 16636, 24624, acetylgalactosaminyl 32612, 40600, transferase 1 48588 (globoside blood

2209group) 506 beta- 1,3 -N- 313984 661 315678 8649 16637, 24625, acetylgalactosaminyl 32613, 40601, transferase 2 48589

2210507 beta- 1,3 -N- 366599 662 355558 8650 16638, 24626, acetylgalactosaminyl 32614, 40602, transferase 2 48590

2211508 beta- 1,3 -N- 366600 663 355559 8651 16639, 24627, acetylgalactosaminyl 32615, 40603, transferase 2 48591

2212509 beta- 1 ,4-N-acetyl- 341156 664 341562 8652 16640, 24628, galactosaminyl 32616, 40604, transferase 1 48592

2213510 beta- 1 ,4-N-acetyl- 548888 665 447945 8653 16641, 24629, galactosaminyl 32617, 40605, transferase 1 48593

2214511 beta- 1 ,4-N-acetyl- 551220 666 446566 8654 16642, 24630, galactosaminyl 32618, 40606, transferase 1 48594

2215512 beta- 1 ,4-N-acetyl- 300404 667 300404 8655 16643, 24631, galactosaminyl 32619, 40607, transferase 2 48595

2216513 beta- 1 ,4-N-acetyl- 393354 668 377022 8656 16644, 24632, galactosaminyl 32620, 40608, transferase 2 48596

2217514 beta- 1 ,4-N-acetyl- 504681 669 425510 8657 16645, 24633, galactosaminyl 32621, 40609, transferase 2 48597

2218515 beta- 1 ,4-N-acetyl- 329962 670 328277 8658 16646, 24634, galactosaminyl 32622, 40610, transferase 4 48598

2219516 blocked early in 222547 671 222547 8659 16647, 24635, transport 1 homolog 32623, 40611, (S. cerevisiae) 48599

2220517 blocked early in 325147 672 339093 8660 16648, 24636, transport 1 homolog 32624, 40612, (S. cerevisiae)-like 48600

2221518 blocked early in 382762 673 372210 8661 16649, 24637, transport 1 homolog 32625, 40613, (S. cerevisiae)-like 48601

2222519 Boc homolog 273395 674 273395 8662 16650, 24638, (mouse) 32626, 40614,

222348602

2224520 Boc homolog 355385 675 347546 8663 16651, 24639, (mouse) 32627, 40615,

222548603

2226521 Boc homolog 462425 676 418118 8664 16652, 24640, (mouse) 32628, 40616,

222748604

2228522 Boc homolog 464546 677 417362 8665 16653, 24641, (mouse) 32629, 40617,

222948605

2230523 Boc homolog 484034 678 417337 8666 16654, 24642, (mouse) 32630, 40618,

223148606 <img file="WO2013151663A1_D0011.tif" />541 BROl domain and 340934 696 343742 8684 16672, 24660, CAAX motif 32648, 40636, containing 48624

2232542 BROl domain and 426638 697 398862 8685 16673, 24661, CAAX motif 32649, 40637, containing 48625

2233543 BROl domain and 537020 698 440041 8686 16674, 24662, CAAX motif 32650, 40638, containing 48626

2234544 BROl domain and 539697 699 441080 8687 16675, 24663, CAAX motif 32651, 40639, containing 48627

2235545 bromodomain 230901 700 230901 8688 16676, 24664, containing 8 32652, 40640,

223648628

2237546 bromodomain 239899 701 239899 8689 16677, 24665, containing 8 32653, 40641,

223848629

2239547 bromodomain 254900 702 254900 8690 16678, 24666, containing 8 32654, 40642,

224048630

2241548 bromodomain 411594 703 394330 8691 16679, 24667, containing 8 32655, 40643,

224248631

2243549 bromodomain 418329 704 398873 8692 16680, 24668, containing 8 32656, 40644,

224448632

2245550 bromodomain 454473 705 398067 8693 16681, 24669, containing 8 32657, 40645,

224648633

2247551 bromodomain 455658 706 408396 8694 16682, 24670, containing 8 32658, 40646,

224848634

2249552 BTB (POZ) domain 280758 707 280758 8695 16683, 24671, containing 11 32659, 40647,

225048635

2251553 BTB (POZ) domain 357167 708 349690 8696 16684, 24672, containing 11 32660, 40648,

225248636

2253554 BTB (POZ) domain 420571 709 413889 8697 16685, 24673, containing 11 32661, 40649,

225448637

2255555 BTB (POZ) domain 490090 710 447319 8698 16686, 24674, containing 11 32662, 40650,

225648638

2257556 BTB (POZ) domain 494235 711 448322 8699 16687, 24675, containing 11 32663, 40651,

225848639

2259557 butyrophilin-like 8 231229 712 231229 8700 16688, 24676,

226032664, 40652, 48640

2261558 butyrophilin-like 8 340184 713 342197 8701 16689, 24677,

226232665, 40653, 48641 559 butyrophilin-like 8 533815 714 435098 8702 16690, 24678,

226332666, 40654, 48642

2264560 butyrophilin-like 8 400707 715 383543 8703 16691, 24679,

226532667, 40655, 48643

2266561 butyrophilin-like 8 508408 716 424585 8704 16692, 24680,

226732668, 40656, 48644

2268562 butyrophilin-like 8 511704 717 425207 8705 16693, 24681,

226932669, 40657, 48645

2270563 butyrophilin-like 9 327705 718 330200 8706 16694, 24682,

227132670, 40658, 48646

2272564 butyrophilin-like 9 376841 719 366037 8707 16695, 24683,

227332671, 40659, 48647

2274565 butyrophilin-like 9 376842 720 366038 8708 16696, 24684,

227532672, 40660, 48648

2276566 butyrophilin-like 9 376850 721 366046 8709 16697, 24685,

227732673, 40661, 48649

2278567 cache domain 290039 722 290039 8710 16698, 24686, containing 1 32674, 40662,

227948650

2280568 cache domain 371073 723 360113 8711 16699, 24687, containing 1 32675, 40663,

228148651

2282569 cadherin 24, type 2 267383 724 267383 8712 16700, 24688,

228332676, 40664, 48652

2284570 cadherin 24, type 2 397359 725 380517 8713 16701, 24689,

228532677, 40665, 48653

2286571 cadherin 24, type 2 422751 726 392742 8714 16702, 24690,

228732678, 40666, 48654

2288572 cadherin 24, type 2 487137 727 434821 8715 16703, 24691,

228932679, 40667, 48655

2290573 cadherin 24, type 2 554034 728 452493 8716 16704, 24692,

229132680, 40668, 48656

2292574 cadherin 26 244047 729 244047 8717 16705, 24693,

229332681, 40669, 48657

2294575 cadherin 26 244049 730 244049 8718 16706, 24694,

229532682, 40670, 48658

2296576 cadherin 26 348616 731 339390 8719 16707, 24695,

229732683, 40671, 48659 577 cadherin 26 350849 732 310845 8720 16708, 24696,

229832684, 40672, 48660

2299578 cadherin 26 370991 733 360030 8721 16709, 24697,

230032685, 40673, 48661

2301579 cadherin-related 261944 734 261944 8722 16710, 24698, family member 2 32686, 40674,

230248662

2303580 cadherin-related 506348 735 421078 8723 16711, 24699, family member 2 32687, 40675,

230448663

2305581 cadherin-related 510636 736 424565 8724 16712, 24700, family member 2 32688, 40676,

230648664

2307582 cadherin-related 317716 737 325954 8725 16713, 24701, family member 3 32689, 40677,

230848665

2309583 cadherin-related 343366 738 341302 8726 16714, 24702, family member 4 32690, 40678,

231048666

2311584 cadherin-related 412678 739 391409 8727 16715, 24703, family member 4 32691, 40679,

231248667

2313585 calcium binding 288616 740 288616 8728 16716, 24704, protein 1 32692, 40680,

231448668

2315586 calcium binding 316803 741 317310 8729 16717, 24705, protein 1 32693, 40681,

231648669

2317587 calcium binding 351200 742 288615 8730 16718, 24706, protein 1 32694, 40682,

231848670

2319588 calcium binding 216144 743 216144 8731 16719, 24707, protein 7 32695, 40683,

232048671

2321589 calcium channel, 284088 744 284088 8732 16720, 24708, voltage-dependent, 32696, 40684, alpha 2/delta subunit 48672 1

2322590 calcium channel, 356253 745 348589 8733 16721, 24709, voltage-dependent, 32697, 40685, alpha 2/delta subunit 48673 1

2323591 calcium channel, 356860 746 349320 8734 16722, 24710, voltage-dependent, 32698, 40686, alpha 2/delta subunit 48674 1

2324592 calcium channel, 535308 747 443124 8735 16723, 24711, voltage-dependent, 32699, 40687, alpha 2/delta subunit 48675 1

2325593 calcium channel, 262138 748 262138 8736 16724, 24712, voltage-dependent, 32700, 40688, gamma subunit 4 48676 594 calcium channel, 322367 749 323129 8737 16725, 24713, voltage-dependent, 32701, 40689, L type, alpha 1C 48677 subunit

2326595 calcium channel, 327702 750 329877 8738 16726, 24714, voltage-dependent, 32702, 40690, L type, alpha 1C 48678 subunit

2327596 calcium channel, 335762 751 336982 8739 16727, 24715, voltage-dependent, 32703, 40691, L type, alpha 1C 48679 subunit

2328597 calcium channel, 352832 752 339302 8740 16728, 24716, voltage-dependent, 32704, 40692, T type, alpha 1G 48680 subunit

2329598 calcium channel, 354983 753 347078 8741 16729, 24717, voltage-dependent, 32705, 40693, T type, alpha 1G 48681 subunit

2330599 calcium channel, 358244 754 350979 8742 16730, 24718, voltage-dependent, 32706, 40694, T type, alpha 1G 48682 subunit

2331600 calcium channel, 359106 755 352011 8743 16731, 24719, voltage-dependent, 32707, 40695, T type, alpha 1G 48683 subunit

2332601 calcium channel, 360761 756 353990 8744 16732, 24720, voltage-dependent, 32708, 40696, T type, alpha 1G 48684 subunit

2333602 calcium channel, 416767 757 392390 8745 16733, 24721, voltage-dependent, 32709, 40697, T type, alpha 1G 48685 subunit

2334603 calcium channel, 429973 758 414388 8746 16734, 24722, voltage-dependent, 32710, 40698, T type, alpha 1G 48686 subunit

2335604 calcium channel, 442258 759 409759 8747 16735, 24723, voltage-dependent, 32711, 40699, T type, alpha 1G 48687 subunit

2336605 calcium channel, 502264 760 425522 8748 16736, 24724, voltage-dependent, 32712, 40700, T type, alpha 1G 48688 subunit

2337606 calcium channel, 503436 761 427231 8749 16737, 24725, voltage-dependent, 32713, 40701, T type, alpha 1G 48689 subunit 607 calcium channel, 503485 762 427238 8750 16738, 24726, voltage-dependent, 32714, 40702, T type, alpha 1G 48690 subunit

2338608 calcium channel, 503607 763 426558 8751 16739, 24727, voltage-dependent, 32715, 40703, T type, alpha 1G 48691 subunit

2339609 calcium channel, 504076 764 425153 8752 16740, 24728, voltage-dependent, 32716, 40704, T type, alpha 1G 48692 subunit

2340610 calcium channel, 505165 765 422268 8753 16741, 24729, voltage-dependent, 32717, 40705, T type, alpha 1G 48693 subunit

2341611 calcium channel, 506406 766 426313 8754 16742, 24730, voltage-dependent, 32718, 40706, T type, alpha 1G 48694 subunit

2342612 calcium channel, 507336 767 420918 8755 16743, 24731, voltage-dependent, 32719, 40707, T type, alpha 1G 48695 subunit

2343613 calcium channel, 507510 768 423112 8756 16744, 24732, voltage-dependent, 32720, 40708, T type, alpha 1G 48696 subunit

2344614 calcium channel, 507609 769 423045 8757 16745, 24733, voltage-dependent, 32721, 40709, T type, alpha 1G 48697 subunit

2345615 calcium channel, 507896 770 421518 8758 16746, 24734, voltage-dependent, 32722, 40710, T type, alpha 1G 48698 subunit

2346616 calcium channel, 510115 771 427173 8759 16747, 24735, voltage-dependent, 32723, 40711, T type, alpha 1G 48699 subunit

2347617 calcium channel, 510366 772 426814 8760 16748, 24736, voltage-dependent, 32724, 40712, T type, alpha 1G 48700 subunit

2348618 calcium channel, 511765 773 427247 8761 16749, 24737, voltage-dependent, 32725, 40713, T type, alpha 1G 48701 subunit

2349619 calcium channel, 511768 774 424664 8762 16750, 24738, voltage-dependent, 32726, 40714, T type, alpha 1G 48702 subunit 620 calcium channel, 512389 775 426261 8763 16751, 24739, voltage-dependent, 32727, 40715, T type, alpha 1G 48703 subunit

2350621 calcium channel, 513689 776 426172 8764 16752, 24740, voltage-dependent, 32728, 40716, T type, alpha 1G 48704 subunit

2351622 calcium channel, 513964 777 425451 8765 16753, 24741, voltage-dependent, 32729, 40717, T type, alpha 1G 48705 subunit

2352623 calcium channel, 514079 778 423317 8766 16754, 24742, voltage-dependent, 32730, 40718, T type, alpha 1G 48706 subunit

2353624 calcium channel, 514181 779 425698 8767 16755, 24743, voltage-dependent, 32731, 40719, T type, alpha 1G 48707 subunit

2354625 calcium channel, 514717 780 422407 8768 16756, 24744, voltage-dependent, 32732, 40720, T type, alpha 1G 48708 subunit

2355626 calcium channel, 515165 781 426098 8769 16757, 24745, voltage-dependent, 32733, 40721, T type, alpha 1G 48709 subunit

2356627 calcium channel, 515411 782 423155 8770 16758, 24746, voltage-dependent, 32734, 40722, T type, alpha 1G 48710 subunit

2357628 calcium channel, 515765 783 426232 8771 16759, 24747, voltage-dependent, 32735, 40723, T type, alpha 1G 48711 subunit

2358629 calcium homeostasis 369783 784 358798 8772 16760, 24748, modulator 3 32736, 40724,

235948712

2360630 calcium/calmodulin- 9105 785 9105 8773 16761, 24749, dependent protein 32737, 40725, kinase IG 48713, 56075,

236156108

2362631 calcium/calmodulin- 361322 786 354861 8774 16762, 24750, dependent protein 32738, 40726, kinase IG 48714

2363632 calcyon neuron- 252939 787 252939 8775 16763, 24751, specific vesicular 32739, 40727, protein 48715

2364633 calcyon neuron- 368555 788 357543 8776 16764, 24752, specific vesicular 32740, 40728, protein 48716

2365634 calcyon neuron- 368556 789 357544 8777 16765, 24753, specific vesicular 32741, 40729, protein 48717 635 calcyon neuron- 368558 790 357546 8778 16766, 24754, specific vesicular 32742, 40730, protein 48718

2366636 calmegin 325617 791 326699 8779 16767, 24755,

236732743, 40731, 48719

2368637 calmegin 414773 792 392782 8780 16768, 24756,

236932744, 40732, 48720

2370638 calmegin 509477 793 424593 8781 16769, 24757,

237132745, 40733, 48721

2372639 calmegin 537281 794 439381 8782 16770, 24758,

237332746, 40734, 48722

2374640 calmegin 545667 795 445139 8783 16771, 24759,

237532747, 40735, 48723

2376641 calmodulin 160298 796 160298 8784 16772, 24760, regulated spectrin- 32748, 40736, associated protein 48724, 56076, family, member 3 56109

2377642 calmodulin 446248 797 416797 8785 16773, 24761, regulated spectrin- 32749, 40737, associated protein 48725 family, member 3

2378643 calneuron 1 329008 798 332498 8786 16774, 24762,

237932750, 40738, 48726

2380644 calneuron 1 395275 799 378690 8787 16775, 24763,

238132751, 40739, 48727

2382645 calneuron 1 395276 800 378691 8788 16776, 24764,

238332752, 40740, 48728

2384646 calneuron 1 405452 801 384354 8789 16777, 24765,

238532753, 40741, 48729

2386647 calneuron 1 412588 802 391882 8790 16778, 24766,

238732754, 40742, 48730

2388648 calneuron 1 431984 803 410704 8791 16779, 24767,

238932755, 40743, 48731

2390649 calneuron 1 446128 804 411806 8792 16780, 24768,

239132756, 40744, 48732

2392650 calpain, small 457326 805 400882 8793 16781, 24769, subunit 2 32757, 40745,

239348733

2394651 calsyntenin 2 458420 806 402460 8794 16782, 24770,

239532758, 40746, 48734 652 calsyntenin 3 266546 807 266546 8795 16783, 24771,

239632759, 40747, 48735

2397653 calsyntenin 3 537408 808 440679 8796 16784, 24772,

239832760, 40748, 48736

2399654 calsyntenin 3 541953 809 443959 8797 16785, 24773,

240032761, 40749, 48737

2401655 CaM kinase-like 296471 810 296471 8798 16786, 24774, vesicle-associated 32762, 40750,

240248738

2403656 CaM kinase-like 477224 811 419195 8799 16787, 24775, vesicle-associated 32763, 40751,

240448739

2405657 CaM kinase-like 488336 812 418809 8800 16788, 24776, vesicle-associated 32764, 40752,

240648740

2407658 cAMP responsive 288400 813 288400 8801 16789, 24777, element binding 32765, 40753, protein 3 -like 1 48741

2408659 cAMP responsive 446415 814 407420 8802 16790, 24778, element binding 32766, 40754, protein 3 -like 1 48742

2409660 cAMP responsive 529193 815 434939 8803 16791, 24779, element binding 32767, 40755, protein 3 -like 1 48743

2410661 cAMP responsive 330387 816 329140 8804 16792, 24780, element binding 32768, 40756, protein 3 -like 2 48744

2411662 cAMP responsive 417785 817 414123 8805 16793, 24781, element binding 32769, 40757, protein 3 -like 2 48745

2412663 cAMP responsive 452463 818 410314 8806 16794, 24782, element binding 32770, 40758, protein 3 -like 2 48746

2413664 cAMP responsive 456390 819 403550 8807 16795, 24783, element binding 32771, 40759, protein 3 -like 2 48747

2414665 cAMP responsive 544877 820 443915 8808 16796, 24784, element binding 32772, 40760, protein 3 -like 2 48748

2415666 cancer susceptibility 299957 821 299957 8809 16797, 24785, candidate 4 32773, 40761,

241648749

2417667 cancer susceptibility 345795 822 335063 8810 16798, 24786, candidate 4 32774, 40762,

241848750

2419668 cancer susceptibility 360824 823 354067 8811 16799, 24787, candidate 4 32775, 40763,

242048751

2421669 cancer susceptibility 416522 824 411192 8812 16800, 24788, candidate 4 32776, 40764,

242248752 670 cancer susceptibility 561305 825 452833 8813 16801, 24789, candidate 4 32777, 40765,

242348753

2424671 cancer susceptibility 561459 826 452807 8814 16802, 24790, candidate 4 32778, 40766,

242548754

2426672 canopy 2 homolog 273308 827 273308 8815 16803, 24791, (zebralish) 32779, 40767,

242748755

2428673 canopy 2 homolog 551475 828 448809 8816 16804, 24792, (zebrafish) 32780, 40768,

242948756

2430674 CAP-GLY domain 360535 829 353732 8817 16805, 24793, containing linker 32781, 40769, protein 3 48757

2431675 CAP-GLY domain 534959 830 445491 8818 16806, 24794, containing linker 32782, 40770, protein 3 48758

2432676 CAP-GLY domain 544037 831 438218 8819 16807, 24795, containing linker 32783, 40771, protein 3 48759

2433677 carbohydrate 303694 832 305725 8820 16808, 24796, (chondroitin 4) 32784, 40772, sulfotransferase 11 48760

2434678 carbohydrate 549260 833 450004 8821 16809, 24797, (chondroitin 4) 32785, 40773, sulfotransferase 11 48761

2435679 carbohydrate 258711 834 258711 8822 16810, 24798, (chondroitin 4) 32786, 40774, sulfotransferase 12 48762

2436680 carbohydrate 432336 835 411207 8823 16811, 24799, (chondroitin 4) 32787, 40775, sulfotransferase 12 48763

2437681 carbohydrate 319340 836 317404 8824 16812, 24800, (chondroitin 4) 32788, 40776, sulfotransferase 13 48764

2438682 carbohydrate 383575 837 373069 8825 16813, 24801, (chondroitin 4) 32789, 40777, sulfotransferase 13 48765

2439683 carbohydrate (N- 338482 838 341206 8826 16814, 24802, acetylglucosamine 32790, 40778,

24406-0) 48766 sulfotransferase 4

2441684 carbohydrate (N- 539698 839 441204 8827 16815, 24803, acetylglucosamine 32791, 40779,

24426-0) 48767 sulfotransferase 4

2443685 carbonic anhydrase 309893 840 309649 8828 16816, 24804, VA, mitochondrial 32792, 40780,

244448768

2445686 carbonyl reductase 4 306193 841 303525 8829 16817, 24805,

244632793, 40781, 48769 687 carbonyl reductase 4 504480 842 427615 8830 16818, 24806,

244732794, 40782, 48770

2448688 carboxylesterase 2 317091 843 317842 8831 16819, 24807,

244932795, 40783, 48771

2450689 carboxylesterase 2 417689 844 394452 8832 16820, 24808,

245132796, 40784, 48772

2452690 carcinoembryonic 403660 845 384887 8833 16821, 24809, antigen-related cell 32797, 40785, adhesion molecule 48773 19

2453691 carcinoembryonic 358777 846 351627 8834 16822, 24810, antigen-related cell 32798, 40786, adhesion molecule 48774 19

2454692 carcinoembryonic 187608 847 187608 8835 16823, 24811, antigen-related cell 32799, 40787, adhesion molecule 48775 21

2455693 carcinoembryonic 401445 848 385739 8836 16824, 24812, antigen-related cell 32800, 40788, adhesion molecule 48776 21

2456694 carcinoembryonic 221999 849 221999 8837 16825, 24813, antigen-related cell 32801, 40789, adhesion molecule 3 48777

2457695 carcinoembryonic 344550 850 341725 8838 16826, 24814, antigen-related cell 32802, 40790, adhesion molecule 3 48778

2458696 carcinoembryonic 357396 851 349971 8839 16827, 24815, antigen-related cell 32803, 40791, adhesion molecule 3 48779

2459697 carcinoembryonic 389667 852 374318 8840 16828, 24816, antigen-related cell 32804, 40792, adhesion molecule 3 48780

2460698 carcinoembryonic 221954 853 221954 8841 16829, 24817, antigen-related cell 32805, 40793, adhesion molecule 4 48781

2461699 carcinoembryonic 6724 854 6724 8842 16830, 24818, antigen-related cell 32806, 40794, adhesion molecule 7 48782, 56077,

246256110

2463700 carcinoembryonic 338196 855 343286 8843 16831, 24819, antigen-related cell 32807, 40795, adhesion molecule 7 48783

2464701 carcinoembryonic 401731 856 385932 8844 16832, 24820, antigen-related cell 32808, 40796, adhesion molecule 7 48784

2465702 carcinoembryonic 412062 857 399253 8845 16833, 24821, antigen-related cell 32809, 40797, adhesion molecule 7 48785 703 Cas scaffolding 360314 858 353462 8846 16834, 24822, protein family 32810, 40798, member 4 48786

2466704 Cas scaffolding 371336 859 360387 8847 16835, 24823, protein family 32811, 40799, member 4 48787

2467705 Cas scaffolding 434344 860 410027 8848 16836, 24824, protein family 32812, 40800, member 4 48788

2468706 casein kinase 2, beta 375880 861 365040 8849 16837, 24825, polypeptide 32813, 40801,

246948789

2470707 cat eye syndrome 155674 862 155674 8850 16838, 24826, chromosome region, 32814, 40802, candidate 5 48790, 56078,

247156111

2472708 cat eye syndrome 336737 863 337358 8851 16839, 24827, chromosome region, 32815, 40803, candidate 5 48791

2473709 catechol-O- 372538 864 361616 8852 16840, 24828, methyltransferase 32816, 40804, domain containing 1 48792

2474710 catechol-O- 536650 865 444168 8853 16841, 24829, methyltransferase 32817, 40805, domain containing 1 48793

2475711 cathepsin O 433477 866 414904 8854 16842, 24830,

247632818, 40806, 48794

2477712 cation channel, 299989 867 299989 8855 16843, 24831, sperm associated 2 32819, 40807,

247848795

2479713 cation channel, 321596 868 321463 8856 16844, 24832, sperm associated 2 32820, 40808,

248048796

2481714 cation channel, 354127 869 339137 8857 16845, 24833, sperm associated 2 32821, 40809,

248248797

2483715 cation channel, 355438 870 347613 8858 16846, 24834, sperm associated 2 32822, 40810,

248448798

2485716 cation channel, 396879 871 380088 8859 16847, 24835, sperm associated 2 32823, 40811,

248648799

2487717 cation channel, 409481 872 386595 8860 16848, 24836, sperm associated 2 32824, 40812,

248848800

2489718 cation channel, 419473 873 399035 8861 16849, 24837, sperm associated 2 32825, 40813,

249048801

2491719 cation channel, 432420 874 407694 8862 16850, 24838, sperm associated 2 32826, 40814,

249248802 720 CCZ1 vacuolar 325974 875 325681 8863 16851, 24839, protein trafficking 32827, 40815, and biogenesis 48803 associated homolog

2493(S. cerevisiae)

2494721 CCZ1 vacuolar 537980 876 444661 8864 16852, 24840, protein trafficking 32828, 40816, and biogenesis 48804 associated homolog

2495(S. cerevisiae)

2496722 CCZ1 vacuolar 316731 877 314544 8865 16853, 24841, protein trafficking 32829, 40817, and biogenesis 48805 associated homolog

2497B (S. cerevisiae)

2498723 CCZ1 vacuolar 538180 878 444720 8866 16854, 24842, protein trafficking 32830, 40818, and biogenesis 48806 associated homolog

2499B (S. cerevisiae)

2500724 CD 101 molecule 256652 879 256652 8867 16855, 24843,

250132831, 40819, 48807

2502725 CD 101 molecule 369470 880 358482 8868 16856, 24844,

250332832, 40820, 48808

2504726 CD 160 molecule 235933 881 235933 8869 16857, 24845,

250532833, 40821, 48809

2506727 CD 160 molecule 369288 882 358294 8870 16858, 24846,

250732834, 40822, 48810

2508728 CD 160 molecule 369290 883 358296 8871 16859, 24847,

250932835, 40823, 48811

2510729 CD 160 molecule 401557 884 385199 8872 16860, 24848,

251132836, 40824, 48812

2512730 CD 164 sialomucin- 374025 885 363137 8873 16861, 24849, like 2 32837, 40825,

251348813

2514731 CD 164 sialomucin- 374027 886 363139 8874 16862, 24850, like 2 32838, 40826,

251548814

2516732 CD 164 sialomucin- 374030 887 363142 8875 16863, 24851, like 2 32839, 40827,

251748815

2518733 CD 180 molecule 256447 888 256447 8876 16864, 24852,

251932840, 40828, 48816

2520734 CD200 receptor 1- 398214 889 381272 8877 16865, 24853, like 32841, 40829,

252148817 <img file="WO2013151663A1_D0012.tif" /> 753 CD 36 molecule 441034 908 396258 8896 16884, 24872,

2522(thrombospondin 32860, 40848, receptor) 48836

2523754 CD52 molecule 374213 909 363330 8897 16885, 24873,

252432861, 40849, 48837

2525755 CD84 molecule 311224 910 312367 8898 16886, 24874,

252632862, 40850, 48838

2527756 CD84 molecule 360056 911 353163 8899 16887, 24875,

252832863, 40851, 48839

2529757 CD84 molecule 368047 912 357026 8900 16888, 24876,

253032864, 40852, 48840

2531758 CD84 molecule 368048 913 357027 8901 16889, 24877,

253232865, 40853, 48841

2533759 CD84 molecule 368051 914 357030 8902 16890, 24878,

253432866, 40854, 48842

2535760 CD84 molecule 368054 915 357033 8903 16891, 24879,

253632867, 40855, 48843

2537761 CD84 molecule 534968 916 442845 8904 16892, 24880,

253832868, 40856, 48844

2539762 CD93 molecule 246006 917 246006 8905 16893, 24881,

254032869, 40857, 48845

2541763 CD93 molecule 413585 918 414935 8906 16894, 24882,

254232870, 40858, 48846

2543764 CDC42 effector 301200 919 301200 8907 16895, 24883, protein (Rho 32871, 40859, GTPase binding) 5 48847

2544765 CDC42 small 357235 920 349773 8908 16896, 24884, effector 1 32872, 40860,

254548848

2546766 CDC42 small 540998 921 445647 8909 16897, 24885, effector 1 32873, 40861,

254748849

2548767 CDC42 small 360515 922 353706 8910 16898, 24886, effector 2 32874, 40862,

254948850

2550768 CDC42 small 395246 923 378667 8911 16899, 24887, effector 2 32875, 40863,

255148851

2552769 CDC42 small 505065 924 427421 8912 16900, 24888, effector 2 32876, 40864,

255348852

2554770 CDP-diacylglycerol- 219789 925 219789 8913 16901, 24889, -inositol 3- 32877, 40865, phosphatidyltransfer 48853 ase 771 CDP-diacylglycerol- 403894 926 386065 8914 16902, 24890, -inositol 3- 32878, 40866, phosphatidyltransfer 48854 ase

2555772 cell adhesion 383699 927 373200 8915 16903, 24891, molecule 2 32879, 40867,

255648855

2557773 cell adhesion 405615 928 384193 8916 16904, 24892, molecule 2 32880, 40868,

255848856

2559774 cell adhesion 407528 929 384575 8917 16905, 24893, molecule 2 32881, 40869,

256048857

2561775 cell adhesion 368124 930 357106 8918 16906, 24894, molecule 3 32882, 40870,

256248858

2563776 cell adhesion 368125 931 357107 8919 16907, 24895, molecule 3 32883, 40871,

256448859

2565777 cell adhesion 416746 932 387802 8920 16908, 24896, molecule 3 32884, 40872,

256648860

2567778 cell cycle associated 341394 933 340329 8921 16909, 24897, protein 1 32885, 40873,

256848861

2569779 cell cycle associated 532820 934 434150 8922 16910, 24898, protein 1 32886, 40874,

257048862

2571780 cell cycle associated 389645 935 374296 8923 16911, 24899, protein 1 32887, 40875,

257248863

2573781 cell cycle 310958 936 311656 8924 16912, 24900, progression 1 32888, 40876,

257448864

2575782 cell cycle 425574 937 415128 8925 16913, 24901, progression 1 32889, 40877,

257648865

2577783 cell cycle 442196 938 403400 8926 16914, 24902, progression 1 32890, 40878,

257848866

2579784 cell death-inducing 336832 939 338642 8927 16915, 24903, DFFA-like effector c 32891, 40879,

258048867

2581785 cell death-inducing 383817 940 373328 8928 16916, 24904, DFFA-like effector c 32892, 40880,

258248868

2583786 cell death-inducing 423850 941 400649 8929 16917, 24905, DFFA-like effector c 32893, 40881,

258448869

2585787 cell death-inducing 455015 942 392975 8930 16918, 24906, DFFA-like effector c 32894, 40882,

258648870

2587788 cell death-inducing 430427 943 408631 8931 16919, 24907, DFFA-like effector c 32895, 40883,

258848871 cell wall biogenesis 226432 944 226432 8932 16920, 24908, 43 C -terminal 32896, 40884, homolog (S. 48872 cerevisiae)

2589centrin, EF-hand 283122 945 283122 8933 16921, 24909, protein, 3 32897, 40885,

259048873 ceramide kinase 216264 946 216264 8934 16922, 24910,

259132898, 40886, 48874 ceramide kinase 541677 947 438659 8935 16923, 24911,

259232899, 40887, 48875 ceramide synthase 1 427170 948 402697 8936 16924, 24912,

259332900, 40888, 48876 ceramide synthase 1 429504 949 389044 8937 16925, 24913,

259432901, 40889, 48877 ceramide synthase 1 542296 950 437648 8938 16926, 24914,

259532902, 40890, 48878 ceramide synthase 2 271688 951 271688 8939 16927, 24915,

259632903, 40891, 48879 ceramide synthase 2 345896 952 337842 8940 16928, 24916,

259732904, 40892, 48880 ceramide synthase 2 361419 953 355020 8941 16929, 24917,

259832905, 40893, 48881 ceramide synthase 2 368949 954 357945 8942 16930, 24918,

259932906, 40894, 48882 ceramide synthase 2 368954 955 357950 8943 16931, 24919,

260032907, 40895, 48883 ceramide synthase 2 421609 956 393239 8944 16932, 24920,

260132908, 40896, 48884 ceramide synthase 2 457392 957 394012 8945 16933, 24921,

260232909, 40897, 48885 ceramide synthase 2 558062 958 452810 8946 16934, 24922,

260332910, 40898, 48886 ceramide synthase 3 284382 959 284382 8947 16935, 24923,

260432911, 40899, 48887 ceramide synthase 3 394113 960 377672 8948 16936, 24924,

260532912, 40900, 48888 ceramide synthase 3 538112 961 437640 8949 16937, 24925,

260632913, 40901, 48889 807 ceramide synthase 3 558884 962 453816 8950 16938, 24926,

260732914, 40902, 48890

2608808 ceramide synthase 3 559639 963 453598 8951 16939, 24927,

260932915, 40903, 48891

2610809 ceramide synthase 3 560233 964 452661 8952 16940, 24928,

261132916, 40904, 48892

2612810 ceramide synthase 4 251363 965 251363 8953 16941, 24929,

261332917, 40905, 48893

2614811 ceramide synthase 4 558268 966 453388 8954 16942, 24930,

261532918, 40906, 48894

2616812 ceramide synthase 4 558877 967 454122 8955 16943, 24931,

261732919, 40907, 48895

2618813 ceramide synthase 4 559450 968 453509 8956 16944, 24932,

261932920, 40908, 48896

2620814 ceramide synthase 4 560412 969 452920 8957 16945, 24933,

262132921, 40909, 48897

2622815 ceramide synthase 4 561008 970 453796 8958 16946, 24934,

262332922, 40910, 48898

2624816 ceramide synthase 5 317551 971 325485 8959 16947, 24935,

262532923, 40911, 48899

2626817 ceramide synthase 5 380189 972 369536 8960 16948, 24936,

262732924, 40912, 48900

2628818 ceramide synthase 5 422340 973 389050 8961 16949, 24937,

262932925, 40913, 48901

2630819 ceramide synthase 5 542320 974 442918 8962 16950, 24938,

263132926, 40914, 48902

2632820 ceramide synthase 6 305747 975 306579 8963 16951, 24939,

263332927, 40915, 48903

2634821 ceramide synthase 6 392687 976 376453 8964 16952, 24940,

263532928, 40916, 48904

2636822 cerebellin 2 269503 977 269503 8965 16953, 24941, precursor 32929, 40917,

263748905

2638823 cerebral endothelial 372838 978 361929 8966 16954, 24942, cell adhesion 32930, 40918, molecule 48906

2639824 cerebral endothelial 372842 979 361933 8967 16955, 24943, cell adhesion 32931, 40919, molecule 48907 825 cerebral endothelial 411852 980 403766 8968 16956, 24944, cell adhesion 32932, 40920, molecule 48908

2640826 cerebral endothelial 413863 981 388593 8969 16957, 24945, cell adhesion 32933, 40921, molecule 48909

2641827 cerebral endothelial 420034 982 402508 8970 16958, 24946, cell adhesion 32934, 40922, molecule 48910

2642828 cerebral endothelial 420512 983 416676 8971 16959, 24947, cell adhesion 32935, 40923, molecule 48911

2643829 cerebral endothelial 447915 984 402928 8972 16960, 24948, cell adhesion 32936, 40924, molecule 48912

2644830 CGRP receptor 338592 985 340044 8973 16961, 24949, component 32937, 40925,

264548913

2646831 CGRP receptor 395326 986 378736 8974 16962, 24950, component 32938, 40926,

264748914

2648832 CGRP receptor 398684 987 381674 8975 16963, 24951, component 32939, 40927,

264948915

2650833 CGRP receptor 415001 988 398605 8976 16964, 24952, component 32940, 40928,

265148916

2652834 CGRP receptor 431089 989 388653 8977 16965, 24953, component 32941, 40929,

265348917

2654835 charged 297265 990 297265 8978 16966, 24954, multivesicular body 32942, 40930, protein 4C 48918

2655836 chloride channel 302500 991 306552 8979 16967, 24955, CLIC-like 1 32943, 40931,

265648919

2657837 chloride channel 348264 992 337243 8980 16968, 24956, CLIC-like 1 32944, 40932,

265848920

2659838 chloride channel 356970 993 349456 8981 16969, 24957, CLIC-like 1 32945, 40933,

266048921

2661839 chloride channel 369968 994 358985 8982 16970, 24958, CLIC-like 1 32946, 40934,

266248922

2663840 chloride channel 369969 995 358986 8983 16971, 24959, CLIC-like 1 32947, 40935,

266448923

2665841 chloride channel 369970 996 358987 8984 16972, 24960, CLIC-like 1 32948, 40936,

266648924

2667842 chloride channel 369971 997 358988 8985 16973, 24961, CLIC-like 1 32949, 40937,

266848925 843 chloride channel 369976 998 358993 8986 16974, 24962, CLIC-like 1 32950, 40938,

266948926

2670844 chloride channel 415331 999 411591 8987 16975, 24963, CLIC-like 1 32951, 40939,

267148927

2672845 chloride intracellular 375779 1000 364934 8988 16976, 24964, channel 1 32952, 40940,

267348928

2674846 chloride intracellular 375780 1001 364935 8989 16977, 24965, channel 1 32953, 40941,

267548929

2676847 chloride intracellular 375784 1002 364940 8990 16978, 24966, channel 1 32954, 40942,

267748930

2678848 chloride intracellular 383404 1003 372896 8991 16979, 24967, channel 1 32955, 40943,

267948931

2680849 chloride intracellular 383405 1004 372897 8992 16980, 24968, channel 1 32956, 40944,

268148932

2682850 chloride intracellular 395892 1005 379229 8993 16981, 24969, channel 1 32957, 40945,

268348933

2684851 chloride intracellular 400052 1006 382926 8994 16982, 24970, channel 1 32958, 40946,

268548934

2686852 chloride intracellular 400058 1007 382931 8995 16983, 24971, channel 1 32959, 40947,

268748935

2688853 chloride intracellular 415179 1008 409247 8996 16984, 24972, channel 1 32960, 40948,

268948936

2690854 chloride intracellular 418285 1009 407791 8997 16985, 24973, channel 1 32961, 40949,

269148937

2692855 chloride intracellular 420458 1010 410965 8998 16986, 24974, channel 1 32962, 40950,

269348938

2694856 chloride intracellular 422167 1011 407429 8999 16987, 24975, channel 1 32963, 40951,

269548939

2696857 chloride intracellular 423055 1012 406968 9000 16988, 24976, channel 1 32964, 40952,

269748940

2698858 chloride intracellular 423143 1013 404589 9001 16989, 24977, channel 1 32965, 40953,

269948941

2700859 chloride intracellular 423804 1014 409979 9002 16990, 24978, channel 1 32966, 40954,

270148942

2702860 chloride intracellular 425464 1015 401292 9003 16991, 24979, channel 1 32967, 40955,

270348943 861 chloride intracellular 431921 1016 408357 9004 16992, 24980, channel 1 32968, 40956,

270448944

2705862 chloride intracellular 433916 1017 391395 9005 16993, 24981, channel 1 32969, 40957,

270648945

2707863 chloride intracellular 434202 1018 400532 9006 16994, 24982, channel 1 32970, 40958,

270848946

2709864 chloride intracellular 435242 1019 412217 9007 16995, 24983, channel 1 32971, 40959,

271048947

2711865 chloride intracellular 438708 1020 406088 9008 16996, 24984, channel 1 32972, 40960,

271248948

2713866 chloride intracellular 442045 1021 400280 9009 16997, 24985, channel 1 32973, 40961,

271448949

2715867 chloride intracellular 447338 1022 413330 9010 16998, 24986, channel 1 32974, 40962,

271648950

2717868 chloride intracellular 447369 1023 408094 9011 16999, 24987, channel 1 32975, 40963,

271848951

2719869 chloride intracellular 451546 1024 416211 9012 17000, 24988, channel 1 32976, 40964,

272048952

2721870 chloride intracellular 456863 1025 406335 9013 17001, 24989, channel 1 32977, 40965,

272248953

2723871 chloride intracellular 457485 1026 398056 9014 17002, 24990, channel 1 32978, 40966,

272448954

2725872 chloride intracellular 369449 1027 358460 9015 17003, 24991, channel 2 32979, 40967,

272648955

2727873 chloride intracellular 374379 1028 363500 9016 17004, 24992, channel 4 32980, 40968,

272848956

2729874 chloride intracellular 444041 1029 445699 9017 17005, 24993, channel 4 32981, 40969,

273048957

2731875 chloride intracellular 488683 1030 436538 9018 17006, 24994, channel 4 32982, 40970,

273248958

2733876 chloride intracellular 349499 1031 290332 9019 17007, 24995, channel 6 32983, 40971,

273448959

2735877 chloride intracellular 360731 1032 353959 9020 17008, 24996, channel 6 32984, 40972,

273648960

2737878 choline 315251 1033 319851 9021 17009, 24997, dehydrogenase 32985, 40973,

273848961 879 choline 467802 1034 419863 9022 17010, 24998, dehydrogenase 32986, 40974,

273948962

2740880 choline 481668 1035 418273 9023 17011, 24999, dehydrogenase 32987, 40975,

274148963

2742881 choline 229266 1036 229266 9024 17012, 25000, phosphotransferase 32988, 40976, 1 48964

2743882 choline 543999 1037 444102 9025 17013, 25001, phosphotransferase 32989, 40977, 1 48965

2744883 choline/ ethanolamin 357172 1038 349696 9026 17014, 25002, e phosphotransferase 32990, 40978, 1 48966

2745884 choline/ ethanolamin 545121 1039 441980 9027 17015, 25003, e phosphotransferase 32991, 40979, 1 48967

2746885 chondroitin sulfate 311540 1040 310891 9028 17016, 25004, N- 32992, 40980, acetylgalactosaminyl 48968 transferase 1

2747886 chondroitin sulfate 332246 1041 330805 9029 17017, 25005, N- 32993, 40981, acetylgalactosaminyl 48969 transferase 1

2748887 chondroitin sulfate 454498 1042 411816 9030 17018, 25006, N- 32994, 40982, acetylgalactosaminyl 48970 transferase 1

2749888 chondroitin sulfate 517494 1043 429130 9031 17019, 25007, N- 32995, 40983, acetylgalactosaminyl 48971 transferase 1

2750889 chondroitin sulfate 520003 1044 428774 9032 17020, 25008, N- 32996, 40984, acetylgalactosaminyl 48972 transferase 1

2751890 chondroitin sulfate 522854 1045 429809 9033 17021, 25009, N- 32997, 40985, acetylgalactosaminyl 48973 transferase 1

2752891 chondroitin sulfate 523262 1046 428089 9034 17022, 25010, N- 32998, 40986, acetylgalactosaminyl 48974 transferase 1

2753892 chondroitin sulfate 524213 1047 427740 9035 17023, 25011, N- 32999, 40987, acetylgalactosaminyl 48975 transferase 1

2754893 chondroitin sulfate 544602 1048 442155 9036 17024, 25012, N- 33000, 40988, acetylgalactosaminyl 48976 transferase 1 894 chondroitin sulfate 374464 1049 363588 9037 17025, 25013, N- 33001, 40989, acetylgalactosaminyl 48977 transferase 2

2755895 chondroitin sulfate 374466 1050 363590 9038 17026, 25014, N- 33002, 40990, acetylgalactosaminyl 48978 transferase 2

2756896 chondroitin sulfate 264723 1051 264723 9039 17027, 25015, proteoglycan 5 33003, 40991, (neuroglycan C) 48979

2757897 chondroitin sulfate 383738 1052 373244 9040 17028, 25016, proteoglycan 5 33004, 40992, (neuroglycan C) 48980

2758898 chondroitin sulfate 456150 1053 392096 9041 17029, 25017, proteoglycan 5 33005, 40993, (neuroglycan C) 48981

2759899 chondrolectin 299295 1054 299295 9042 17030, 25018,

276033006, 40994, 48982

2761900 chondrolectin 338326 1055 339975 9043 17031, 25019,

276233007, 40995, 48983

2763901 chondrolectin 400127 1056 382992 9044 17032, 25020,

276433008, 40996, 48984

2765902 chondrolectin 400128 1057 382993 9045 17033, 25021,

276633009, 40997, 48985

2767903 chondrolectin 400131 1058 382996 9046 17034, 25022,

276833010, 40998, 48986

2769904 chondrolectin 400135 1059 383001 9047 17035, 25023,

277033011, 40999, 48987

2771905 chondrolectin 427223 1060 390957 9048 17036, 25024,

277233012, 41000, 48988

2773906 chondrolectin 452759 1061 415566 9049 17037, 25025,

277433013, 41001, 48989

2775907 chondrolectin 465099 1062 417423 9050 17038, 25026,

277633014, 41002, 48990

2777908 chondrolectin 543733 1063 443566 9051 17039, 25027,

277833015, 41003, 48991

2779909 CHRNA7 299847 1064 299847 9052 17040, 25028, (cholinergic 33016, 41004, receptor, nicotinic, 48992 alpha 7, exons 5-10)

2780and FAM7A (family

2781with sequence

2782similarity 7A, exons

2783A-E) fusion 910 CHRNA7 397827 1065 380927 9053 17041, 25029, (cholinergic 33017, 41005, receptor, nicotinic, 48993 alpha 7, exons 5-10)

2784and FAM7A (family

2785with sequence

2786similarity 7A, exons

2787A-E) fusion

2788911 CHRNA7 401522 1066 385389 9054 17042, 25030, (cholinergic 33018, 41006, receptor, nicotinic, 48994 alpha 7, exons 5-10)

2789and FAM7A (family

2790with sequence

2791similarity 7A, exons

2792A-E) fusion

2793912 chromodomain 250838 1067 250838 9055 17043, 25031, protein, Y-linked, 33019, 41007, 2A 48995

2794913 chromodomain 426790 1068 402280 9056 17044, 25032, protein, Y-linked, 33020, 41008, 2A 48996

2795914 chromosome 1 open 366531 1069 355489 9057 17045, 25033, reading frame 101 33021, 41009,

279648997

2797915 chromosome 1 open 366533 1070 355491 9058 17046, 25034, reading frame 101 33022, 41010,

279848998

2799916 chromosome 1 open 366534 1071 355492 9059 17047, 25035, reading frame 101 33023, 41011,

280048999

2801917 chromosome 1 open 391841 1072 375716 9060 17048, 25036, reading frame 101 33024, 41012,

280249000

2803918 chromosome 1 open 428042 1073 395796 9061 17049, 25037, reading frame 101 33025, 41013,

280449001

2805919 chromosome 1 open 374392 1074 363513 9062 17050, 25038, reading frame 130 33026, 41014,

280649002

2807920 chromosome 1 open 294576 1075 294576 9063 17051, 25039, reading frame 159 33027, 41015,

280849003

2809921 chromosome 1 open 379319 1076 368623 9064 17052, 25040, reading frame 159 33028, 41016,

281049004

2811922 chromosome 1 open 379339 1077 368644 9065 17053, 25041, reading frame 159 33029, 41017,

281249005

2813923 chromosome 1 open 421241 1078 400736 9066 17054, 25042, reading frame 159 33030, 41018,

281449006

2815924 chromosome 1 open 437760 1079 399027 9067 17055, 25043, reading frame 159 33031, 41019,

281649007 925 chromosome 1 open 442117 1080 416740 9068 17056, 25044, reading frame 159 33032, 41020,

281749008

2818926 chromosome 1 open 448924 1081 392290 9069 17057, 25045, reading frame 159 33033, 41021,

281949009

2820927 chromosome 1 open 457999 1082 414929 9070 17058, 25046, reading frame 159 33034, 41022,

282149010

2822928 chromosome 1 open 343534 1083 344218 9071 17059, 25047, reading frame 162 33035, 41023,

282349011

2824929 chromosome 1 open 369718 1084 358732 9072 17060, 25048, reading frame 162 33036, 41024,

282549012

2826930 chromosome 1 open 371759 1085 360824 9073 17061, 25049, reading frame 185 33037, 41025,

282749013

2828931 chromosome 1 open 331555 1086 356093 9074 17062, 25050, reading frame 186 33038, 41026,

282949014

2830932 chromosome 1 open 423420 1087 429399 9075 17063, 25051, reading frame 210 33039, 41027,

283149015

2832933 chromosome 1 open 523677 1088 430918 9076 17064, 25052, reading frame 210 33040, 41028,

283349016

2834934 chromosome 1 open 287859 1089 287859 9077 17065, 25053, reading frame 27 33041, 41029,

283549017

2836935 chromosome 1 open 367470 1090 356440 9078 17066, 25054, reading frame 27 33042, 41030,

283749018

2838936 chromosome 1 open 419367 1091 395084 9079 17067, 25055, reading frame 27 33043, 41031,

283949019

2840937 chromosome 1 open 432021 1092 402029 9080 17068, 25056, reading frame 27 33044, 41032,

284149020

2842938 chromosome 1 open 366612 1093 355571 9081 17069, 25057, reading frame 31 33045, 41033,

284349021

2844939 chromosome 1 open 366613 1094 355572 9082 17070, 25058, reading frame 31 33046, 41034,

284549022

2846940 chromosome 1 open 366615 1095 355574 9083 17071, 25059, reading frame 31 33047, 41035,

284749023

2848941 chromosome 1 open 424237 1096 392376 9084 17072, 25060, reading frame 31 33048, 41036,

284949024

2850942 chromosome 1 open 350592 1097 271925 9085 17073, 25061, reading frame 43 33049, 41037,

285149025 943 chromosome 1 open 362076 1098 354496 9086 17074, 25062, reading frame 43 33050, 41038,

285249026

2853944 chromosome 1 open 368516 1099 357502 9087 17075, 25063, reading frame 43 33051, 41039,

285449027

2855945 chromosome 1 open 368518 1100 357504 9088 17076, 25064, reading frame 43 33052, 41040,

285649028

2857946 chromosome 1 open 368519 1101 357505 9089 17077, 25065, reading frame 43 33053, 41041,

285849029

2859947 chromosome 1 open 368521 1102 357507 9090 17078, 25066, reading frame 43 33054, 41042,

286049030

2861948 chromosome 1 open 362007 1103 354553 9091 17079, 25067, reading frame 85 33055, 41043,

286249031

2863949 chromosome 1 open 263688 1104 263688 9092 17080, 25068, reading frame 9 33056, 41044,

286449032

2865950 chromosome 1 open 367723 1105 356696 9093 17081, 25069, reading frame 9 33057, 41045,

286649033

2867951 chromosome 1 open 373374 1106 362472 9094 17082, 25070, reading frame 94 33058, 41046,

286849034

2869952 chromosome 1 open 488417 1107 435634 9095 17083, 25071, reading frame 94 33059, 41047,

287049035

2871953 chromosome 1 open 366788 1108 355752 9096 17084, 25072, reading frame 95 33060, 41048,

287249036

2873954 chromosome 1 open 366789 1109 355753 9097 17085, 25073, reading frame 95 33061, 41049,

287449037

2875955 chromosome 10 298295 1110 298295 9098 17086, 25074, open reading frame 33062, 41050, 10 49038

2876956 chromosome 10 432283 1111 392803 9099 17087, 25075, open reading frame 33063, 41051, 10 49039

2877957 chromosome 10 448778 1112 414494 9100 17088, 25076, open reading frame 33064, 41052, 10 49040

2878958 chromosome 10 398786 1113 381766 9101 17089, 25077, open reading frame 33065, 41053, 105 49041

2879959 chromosome 10 441508 1114 403151 9102 17090, 25078, open reading frame 33066, 41054, 105 49042

2880960 chromosome 10 545760 1115 440187 9103 17091, 25079, open reading frame 33067, 41055, 105 49043 chromosome 10 378207 1116 367449 9104 17092, 25080, open reading frame 33068, 41056, 1 11 49044 chromosome 10 377265 1117 366476 9105 17093, 25081, open reading frame 33069, 41057, 1 12 49045 chromosome 10 377266 1118 366477 9106 17094, 25082, open reading frame 33070, 41058, 1 12 49046 chromosome 10 441070 1119 404330 9107 17095, 25083, open reading frame 33071, 41059, 1 12 49047 chromosome 10 454679 1120 412763 9108 17096, 25084, open reading frame 33072, 41060, 1 12 49048 chromosome 10 455457 1121 391253 9109 17097, 25085, open reading frame 33073, 41061, 1 12 49049 chromosome 10 474718 1122 417246 9110 17098, 25086, open reading frame 33074, 41062, 128 49050 chromosome 10 341686 1123 340296 9111 17099, 25087, open reading frame 33075, 41063, 129 49051 chromosome 10 394005 1124 377573 9112 17100, 25088, open reading frame 33076, 41064, 129 49052 chromosome 10 430183 1125 400368 9113 17101, 25089, open reading frame 33077, 41065, 129 49053 chromosome 10 539707 1126 438774 9114 17102, 25090, open reading frame 33078, 41066, 129 49054 chromosome 10 373279 1127 362376 9115 17103, 25091, open reading frame 33079, 41067, 35 49055 chromosome 10 421716 1128 398621 9116 17104, 25092, open reading frame 33080, 41068, 35 49056 chromosome 10 263569 1129 263569 9117 17105, 25093, open reading frame 33081, 41069, 54 49057 chromosome 10 394957 1130 378409 9118 17106, 25094, open reading frame 33082, 41070, 54 49058 chromosome 10 372273 1131 361347 9119 17107, 25095, open reading frame 33083, 41071, 57 49059 chromosome 10 372274 1132 361348 9120 17108, 25096, open reading frame 33084, 41072, 57 49060 chromosome 10 372275 1133 361349 9121 17109, 25097, open reading frame 33085, 41073, 57 49061 chromosome 10 372277 1134 361351 9122 17110, 25098, open reading frame 33086, 41074, 57 49062 chromosome 10 372281 1135 361355 9123 17111, 25099, open reading frame 33087, 41075, 57 49063 chromosome 10 450179 1136 393450 9124 17112, 25100, open reading frame 33088, 41076, 57 49064 chromosome 10 263485 1137 263485 9125 17113, 25101, open reading frame 33089, 41077, 76 49065 chromosome 10 311122 1138 312408 9126 17114, 25102, open reading frame 33090, 41078, 76 49066 chromosome 10 370033 1139 359050 9127 17115, 25103, open reading frame 33091, 41079, 76 49067 chromosome 10 456149 1140 413473 9128 17116, 25104, open reading frame 33092, 41080, 76 49068 chromosome 11 257262 1141 257262 9129 17117, 25105, open reading frame 33093, 41081, 10 49069 chromosome 11 537328 1142 443216 9130 17118, 25106, open reading frame 33094, 41082, 10 49070 chromosome 11 279281 1143 279281 9131 17119, 25107, open reading frame 33095, 41083, 2 49071 chromosome 11 327419 1144 331581 9132 17120, 25108, open reading frame 33096, 41084, 87 49072 chromosome 12 267103 1145 267103 9133 17121, 25109, open reading frame 33097, 41085, 10 49073 chromosome 12 545214 1146 437921 9134 17122, 25110, open reading frame 33098, 41086, 10 49074 chromosome 12 280756 1147 280756 9135 17123, 25111, open reading frame 33099, 41087, 23 49075 chromosome 12 547081 1148 449106 9136 17124, 25112, open reading frame 33100, 41088, 23 49076 chromosome 12 547242 1149 446537 9137 17125, 25113, open reading frame 33101, 41089, 23 49077 chromosome 12 548125 1150 449785 9138 17126, 25114, open reading frame 33102, 41090, 23 49078 chromosome 12 550344 1151 446717 9139 17127, 25115, open reading frame 33103, 41091, 23 49079 997 chromosome 12 551813 1152 450350 9140 17128, 25116, open reading frame 33104, 41092, 23 49080

2881998 chromosome 12 377560 1153 366783 9141 17129, 25117, open reading frame 33105, 41093, 51 49081

2882999 chromosome 12 430131 1154 404379 9142 17130, 25118, open reading frame 33106, 41094, 51 49082

28831000 chromosome 12 320591 1155 317818 9143 17131, 25119, open reading frame 33107, 41095, 53 49083

28841001 chromosome 12 439553 1156 391992 9144 17132, 25120, open reading frame 33108, 41096, 53 49084

28851002 chromosome 12 534837 1157 443919 9145 17133, 25121, open reading frame 33109, 41097, 53 49085

28861003 chromosome 12 540656 1158 442157 9146 17134, 25122, open reading frame 33110, 41098, 53 49086

28871004 chromosome 12 298530 1159 298530 9147 17135, 25123, open reading frame 33111, 41099, 59 49087

28881005 chromosome 12 381923 1160 371348 9148 17136, 25124, open reading frame 33112, 41100, 59 49088

28891006 chromosome 12 536952 1161 446102 9149 17137, 25125, open reading frame 33113, 41101, 59 49089

28901007 chromosome 12 543484 1162 445582 9150 17138, 25126, open reading frame 33114, 41102, 59 49090

28911008 chromosome 12 317943 1163 326052 9151 17139, 25127, open reading frame 33115, 41103, 62 49091

28921009 chromosome 12 548985 1164 447776 9152 17140, 25128, open reading frame 33116, 41104, 62 49092

28931010 chromosome 12 550487 1165 446524 9153 17141, 25129, open reading frame 33117, 41105, 62 49093

28941011 chromosome 12 550654 1166 450331 9154 17142, 25130, open reading frame 33118, 41106, 62 49094

28951012 chromosome 12 316048 1167 381895 9155 17143, 25131, open reading frame 33119, 41107, 69 49095

28961013 chromosome 13 283547 1168 283547 9156 17144, 25132, open reading frame 33120, 41108, 16 49096

28971014 chromosome 13 400419 1169 383270 9157 17145, 25133, open reading frame 33121, 41109, 44 49097 1015 chromosome 14 261556 1170 261556 9158 17146, 25134, open reading frame 33122, 41110, 101 49098

28981016 chromosome 14 536419 1171 438742 9159 17147, 25135, open reading frame 33123, 41111, 101 49099

28991017 chromosome 14 538838 1172 441934 9160 17148, 25136, open reading frame 33124, 41112, 101 49100

29001018 chromosome 14 283534 1173 283534 9161 17149, 25137, open reading frame 33125, 41113, 109 49101

29011019 chromosome 14 415050 1174 388431 9162 17150, 25138, open reading frame 33126, 41114, 109 49102

29021020 chromosome 14 421193 1175 440920 9163 17151, 25139, open reading frame 33127, 41115, 132 49103

29031021 chromosome 14 555004 1176 451731 9164 17152, 25140, open reading frame 33128, 41116, 132 49104

29041022 chromosome 14 317623 1177 317396 9165 17153, 25141, open reading frame 33129, 41117, 135 49105

29051023 chromosome 14 404681 1178 385713 9166 17154, 25142, open reading frame 33130, 41118, 135 49106

29061024 chromosome 14 406854 1179 384801 9167 17155, 25143, open reading frame 33131, 41119, 135 49107

29071025 chromosome 14 535349 1180 445644 9168 17156, 25144, open reading frame 33132, 41120, 135 49108

29081026 chromosome 14 555740 1181 450441 9169 17157, 25145, open reading frame 33133, 41121, 135 49109

29091027 chromosome 14 256324 1182 256324 9170 17158, 25146, open reading frame 33134, 41122, 159 49110

29101028 chromosome 14 298858 1183 298858 9171 17159, 25147, open reading frame 33135, 41123, 159 49111

29111029 chromosome 14 412671 1184 404196 9172 17160, 25148, open reading frame 33136, 41124, 159 49112

29121030 chromosome 14 428926 1185 404343 9173 17161, 25149, open reading frame 33137, 41125, 159 49113

29131031 chromosome 14 517362 1186 429806 9174 17162, 25150, open reading frame 33138, 41126, 159 49114

29141032 chromosome 14 517518 1187 428652 9175 17163, 25151, open reading frame 33139, 41127, 159 49115 1033 chromosome 14 518665 1188 429098 9176 17164, 25152, open reading frame 33140, 41128, 159 49116

29151034 chromosome 14 518868 1189 428263 9177 17165, 25153, open reading frame 33141, 41129, 159 49117

29161035 chromosome 14 518871 1190 429189 9178 17166, 25154, open reading frame 33142, 41130, 159 49118

29171036 chromosome 14 519950 1191 428296 9179 17167, 25155, open reading frame 33143, 41131, 159 49119

29181037 chromosome 14 520328 1192 429453 9180 17168, 25156, open reading frame 33144, 41132, 159 49120

29191038 chromosome 14 521064 1193 429392 9181 17169, 25157, open reading frame 33145, 41133, 159 49121

29201039 chromosome 14 521077 1194 430137 9182 17170, 25158, open reading frame 33146, 41134, 159 49122

29211040 chromosome 14 521081 1195 428997 9183 17171, 25159, open reading frame 33147, 41135, 159 49123

29221041 chromosome 14 521334 1196 430022 9184 17172, 25160, open reading frame 33148, 41136, 159 49124

29231042 chromosome 14 522170 1197 430666 9185 17173, 25161, open reading frame 33149, 41137, 159 49125

29241043 chromosome 14 522322 1198 427953 9186 17174, 25162, open reading frame 33150, 41138, 159 49126

29251044 chromosome 14 522837 1199 427971 9187 17175, 25163, open reading frame 33151, 41139, 159 49127

29261045 chromosome 14 523771 1200 429655 9188 17176, 25164, open reading frame 33152, 41140, 159 49128

29271046 chromosome 14 523816 1201 428974 9189 17177, 25165, open reading frame 33153, 41141, 159 49129

29281047 chromosome 14 523879 1202 428122 9190 17178, 25166, open reading frame 33154, 41142, 159 49130

29291048 chromosome 14 523894 1203 429459 9191 17179, 25167, open reading frame 33155, 41143, 159 49131

29301049 chromosome 14 524232 1204 429097 9192 17180, 25168, open reading frame 33156, 41144, 159 49132

29311050 chromosome 14 525393 1205 435459 9193 17181, 25169, open reading frame 33157, 41145, 159 49133 1051 chromosome 14 410013 1206 386487 9194 17182, 25170, open reading frame 33158, 41146, 180 49134

29321052 chromosome 14 557649 1207 452502 9195 17183, 25171, open reading frame 33159, 41147, 180 49135

29331053 chromosome 14 267485 1208 267485 9196 17184, 25172, open reading frame 33160, 41148, 37 49136

29341054 chromosome 15 256545 1209 256545 9197 17185, 25173, open reading frame 33161, 41149, 24 49137

29351055 chromosome 15 388942 1210 373594 9198 17186, 25174, open reading frame 33162, 41150, 27 49138

29361056 chromosome 15 344300 1211 341610 9199 17187, 25175, open reading frame 33163, 41151, 48 49139

29371057 chromosome 15 396650 1212 379887 9200 17188, 25176, open reading frame 33164, 41152, 48 49140

29381058 chromosome 15 344320 1213 341178 9201 17189, 25177, open reading frame 33165, 41153, 62 49141

29391059 chromosome 15 559319 1214 453366 9202 17190, 25178, open reading frame 33166, 41154, 62 49142

29401060 chromosome 16 329410 1215 327506 9203 17191, 25179, open reading frame 33167, 41155, 54 49143

29411061 chromosome 16 327237 1216 317579 9204 17192, 25180, open reading frame 33168, 41156, 58 49144

29421062 chromosome 16 430477 1217 398074 9205 17193, 25181, open reading frame 33169, 41157, 58 49145

29431063 chromosome 16 452223 1218 414614 9206 17194, 25182, open reading frame 33170, 41158, 58 49146

29441064 chromosome 16 541442 1219 440050 9207 17195, 25183, open reading frame 33171, 41159, 58 49147

29451065 chromosome 16 251143 1220 251143 9208 17196, 25184, open reading frame 33172, 41160, 62 49148

29461066 chromosome 16 417362 1221 395973 9209 17197, 25185, open reading frame 33173, 41161, 62 49149

29471067 chromosome 16 438132 1222 400815 9210 17198, 25186, open reading frame 33174, 41162, 62 49150

29481068 chromosome 16 448695 1223 398009 9211 17199, 25187, open reading frame 33175, 41163, 62 49151 1069 chromosome 16 538853 1224 444363 9212 17200, 25188, open reading frame 33176, 41164, 62 49152

29491070 chromosome 16 542263 1225 442468 9213 17201, 25189, open reading frame 33177, 41165, 62 49153

29501071 chromosome 16 219139 1226 219139 9214 17202, 25190, open reading frame 33178, 41166, 70 49154

29511072 chromosome 16 310355 1227 311390 9215 17203, 25191, open reading frame 33179, 41167, 91 49155

29521073 chromosome 16 442039 1228 413100 9216 17204, 25192, open reading frame 33180, 41168, 91 49156

29531074 chromosome 16 300575 1229 300575 9217 17205, 25193, open reading frame 33181, 41169, 92 49157

29541075 chromosome 17 313056 1230 320116 9218 17206, 25194, open reading frame 33182, 41170, 101 49158

29551076 chromosome 17 329197 1231 330075 9219 17207, 25195, open reading frame 33183, 41171, 101 49159

29561077 chromosome 17 375215 1232 364363 9220 17208, 25196, open reading frame 33184, 41172, 109 49160

29571078 chromosome 17 300714 1233 300714 9221 17209, 25197, open reading frame 33185, 41173, 56 49161

29581079 chromosome 17 374769 1234 363901 9222 17210, 25198, open reading frame 33186, 41174, 56 49162

29591080 chromosome 17 389017 1235 373669 9223 17211, 25199, open reading frame 33187, 41175, 59 49163

29601081 chromosome 17 302422 1236 301939 9224 17212, 25200, open reading frame 33188, 41176, 61 49164

29611082 chromosome 17 306645 1237 307765 9225 17213, 25201, open reading frame 33189, 41177, 62 49165

29621083 chromosome 17 336995 1238 337560 9226 17214, 25202, open reading frame 33190, 41178, 62 49166

29631084 chromosome 17 342572 1239 342228 9227 17215, 25203, open reading frame 33191, 41179, 62 49167

29641085 chromosome 17 434650 1240 401626 9228 17216, 25204, open reading frame 33192, 41180, 62 49168

29651086 chromosome 17 437807 1241 388909 9229 17217, 25205, open reading frame 33193, 41181, 62 49169 1087 chromosome 17 536759 1242 439100 9230 17218, 25206, open reading frame 33194, 41182, 62 49170

29661088 chromosome 17 300618 1243 300618 9231 17219, 25207, open reading frame 33195, 41183, 78 49171

29671089 chromosome 17 321564 1244 318689 9232 17220, 25208, open reading frame 33196, 41184, 78 49172

29681090 chromosome 17 255557 1245 255557 9233 17221, 25209, open reading frame 33197, 41185, 80 49173

29691091 chromosome 17 268942 1246 268942 9234 17222, 25210, open reading frame 33198, 41186, 80 49174

29701092 chromosome 17 359042 1247 351937 9235 17223, 25211, open reading frame 33199, 41187, 80 49175

29711093 chromosome 17 426147 1248 396970 9236 17224, 25212, open reading frame 33200, 41188, 80 49176

29721094 chromosome 17 535032 1249 440551 9237 17225, 25213, open reading frame 33201, 41189, 80 49177

29731095 chromosome 17 431388 1250 400184 9238 17226, 25214, open reading frame 33202, 41190, 89 49178

29741096 chromosome 17 374741 1251 363873 9239 17227, 25215, open reading frame 33203, 41191, 90 49179

29751097 chromosome 18 321600 1252 315265 9240 17228, 25216, open reading frame 33204, 41192, 26 49180

29761098 chromosome 18 382638 1253 372083 9241 17229, 25217, open reading frame 33205, 41193, 62 49181

29771099 chromosome 18 579022 1254 462106 9242 17230, 25218, open reading frame 33206, 41194, 62 49182

29781100 chromosome 19 314391 1255 321519 9243 17231, 25219, open reading frame 33207, 41195, 18 49183

29791101 chromosome 19 382477 1256 371917 9244 17232, 25220, open reading frame 33208, 41196, 26 49184

29801102 chromosome 19 397820 1257 380920 9245 17233, 25221, open reading frame 33209, 41197, 38 49185

29811103 chromosome 19 324444 1258 316130 9246 17234, 25222, open reading frame 33210, 41198, 46 49186

29821104 chromosome 19 340477 1259 343152 9247 17235, 25223, open reading frame 33211, 41199, 46 49187 1105 chromosome 19 333598 1260 329920 9248 17236, 25224, open reading frame 33212, 41200, 59 49188

29831106 chromosome 19 309324 1261 309561 9249 17237, 25225, open reading frame 33213, 41201, 70 49189

29841107 chromosome 19 316401 1262 321249 9250 17238, 25226, open reading frame 33214, 41202, 75 49190

29851108 chromosome 19 215531 1263 215531 9251 17239, 25227, open reading frame 33215, 41203, 77 49191

29861109 chromosome 2 open 344420 1264 345528 9252 17240, 25228, reading frame 18 33216, 41204,

298749192

29881110 chromosome 2 open 416475 1265 413413 9253 17241, 25229, reading frame 18 33217, 41205,

298949193

29901111 chromosome 2 open 380171 1266 369518 9254 17242, 25230, reading frame 28 33218, 41206,

299149194

29921112 chromosome 2 open 405489 1267 384033 9255 17243, 25231, reading frame 28 33219, 41207,

299349195

29941113 chromosome 2 open 419744 1268 397319 9256 17244, 25232, reading frame 28 33220, 41208,

299549196

29961114 chromosome 2 open 295079 1269 295079 9257 17245, 25233, reading frame 47 33221, 41209,

299749197

29981115 chromosome 2 open 392290 1270 376111 9258 17246, 25234, reading frame 47 33222, 41210,

299949198

30001116 chromosome 2 open 2125 1271 2125 9259 17247, 25235, reading frame 56 33223, 41211,

300149199, 56079, 56112

30021117 chromosome 2 open 290536 1272 290536 9260 17248, 25236, reading frame 65 33224, 41212,

300349200

30041118 chromosome 2 open 358434 1273 351213 9261 17249, 25237, reading frame 65 33225, 41213,

300549201

30061119 chromosome 2 open 421985 1274 414882 9262 17250, 25238, reading frame 65 33226, 41214,

300749202

30081120 chromosome 2 open 536235 1275 445662 9263 17251, 25239, reading frame 65 33227, 41215,

300949203

30101121 chromosome 2 open 398634 1276 381631 9264 17252, 25240, reading frame 73 33228, 41216,

301149204

30121122 chromosome 2 open 331342 1277 333208 9265 17253, 25241, reading frame 82 33229, 41217,

301349205 1123 chromosome 2 open 409230 1278 386804 9266 17254, 25242, reading frame 82 33230, 41218,

301449206

30151124 chromosome 2 open 409533 1279 387130 9267 17255, 25243, reading frame 82 33231, 41219,

301649207

30171125 chromosome 2 open 335459 1280 335004 9268 17256, 25244, reading frame 89 33232, 41220,

301849208

30191126 chromosome 2 open 409520 1281 387075 9269 17257, 25245, reading frame 89 33233, 41221,

302049209

30211127 chromosome 20 217320 1282 217320 9270 17258, 25246, open reading frame 33234, 41222, 118 49210

30221128 chromosome 20 279028 1283 279028 9271 17259, 25247, open reading frame 33235, 41223, 123 49211

30231129 chromosome 20 342422 1284 341213 9272 17260, 25248, open reading frame 33236, 41224, 24 49212

30241130 chromosome 20 344795 1285 340164 9273 17261, 25249, open reading frame 33237, 41225, 24 49213

30251131 chromosome 20 373852 1286 362958 9274 17262, 25250, open reading frame 33238, 41226, 24 49214

30261132 chromosome 20 217456 1287 217456 9275 17263, 25251, open reading frame 33239, 41227, 3 49215

30271133 chromosome 20 447138 1288 415373 9276 17264, 25252, open reading frame 33240, 41228, 3 49216

30281134 chromosome 20 451442 1289 395874 9277 17265, 25253, open reading frame 33241, 41229, 3 49217

30291135 chromosome 20 202834 1290 202834 9278 17266, 25254, open reading frame 33242, 41230, 30 49218

30301136 chromosome 20 342308 1291 341364 9279 17267, 25255, open reading frame 33243, 41231, 30 49219

30311137 chromosome 20 379276 1292 368578 9280 17268, 25256, open reading frame 33244, 41232, 30 49220

30321138 chromosome 20 379277 1293 368579 9281 17269, 25257, open reading frame 33245, 41233, 30 49221

30331139 chromosome 20 379279 1294 368581 9282 17270, 25258, open reading frame 33246, 41234, 30 49222

30341140 chromosome 20 379283 1295 368585 9283 17271, 25259, open reading frame 33247, 41235, 30 49223 1141 chromosome 20 379286 1296 368588 9284 17272, 25260, open reading frame 33248, 41236, 30 49224

30351142 chromosome 20 379299 1297 368601 9285 17273, 25261, open reading frame 33249, 41237, 30 49225

30361143 chromosome 20 377704 1298 366933 9286 17274, 25262, open reading frame 33250, 41238, 72 49226

30371144 chromosome 20 377709 1299 366938 9287 17275, 25263, open reading frame 33251, 41239, 72 49227

30381145 chromosome 20 377710 1300 366939 9288 17276, 25264, open reading frame 33252, 41240, 72 49228

30391146 chromosome 21 300255 1301 300255 9289 17277, 25265, open reading frame 33253, 41241, 63 49229

30401147 chromosome 21 330551 1302 331610 9290 17278, 25266, open reading frame 33254, 41242, 67 49230

30411148 chromosome 21 380070 1303 369410 9291 17279, 25267, open reading frame 33255, 41243, 67 49231

30421149 chromosome 22 248984 1304 248984 9292 17280, 25268, open reading frame 33256, 41244, 24 49232

30431150 chromosome 22 543051 1305 437643 9293 17281, 25269, open reading frame 33257, 41245, 24 49233

30441151 chromosome 22 327374 1306 332721 9294 17282, 25270, open reading frame 33258, 41246, 25 49234

30451152 chromosome 22 398042 1307 381122 9295 17283, 25271, open reading frame 33259, 41247, 25 49235

30461153 chromosome 22 401886 1308 385662 9296 17284, 25272, open reading frame 33260, 41248, 25 49236

30471154 chromosome 22 420290 1309 396182 9297 17285, 25273, open reading frame 33261, 41249, 25 49237

30481155 chromosome 22 432198 1310 413850 9298 17286, 25274, open reading frame 33262, 41250, 25 49238

30491156 chromosome 22 432883 1311 402926 9299 17287, 25275, open reading frame 33263, 41251, 25 49239

30501157 chromosome 22 434168 1312 411602 9300 17288, 25276, open reading frame 33264, 41252, 25 49240

30511158 chromosome 22 434570 1313 391262 9301 17289, 25277, open reading frame 33265, 41253, 25 49241 1159 chromosome 22 447208 1314 389797 9302 17290, 25278, open reading frame 33266, 41254, 25 49242

30521160 chromosome 22 450664 1315 415450 9303 17291, 25279, open reading frame 33267, 41255, 25 49243

30531161 chromosome 22 456048 1316 403645 9304 17292, 25280, open reading frame 33268, 41256, 25 49244

30541162 chromosome 22 331479 1317 327467 9305 17293, 25281, open reading frame 33269, 41257, 32 49245

30551163 chromosome 3 open 314400 1318 320251 9306 17294, 25282, reading frame 17 33270, 41258,

305649246

30571164 chromosome 3 open 383675 1319 373173 9307 17295, 25283, reading frame 17 33271, 41259,

305849247

30591165 chromosome 3 open 393857 1320 377438 9308 17296, 25284, reading frame 17 33272, 41260,

306049248

30611166 chromosome 3 open 412848 1321 411150 9309 17297, 25285, reading frame 17 33273, 41261,

306249249

30631167 chromosome 3 open 357203 1322 349732 9310 17298, 25286, reading frame 18 33274, 41262,

306449250

30651168 chromosome 3 open 426034 1323 387606 9311 17299, 25287, reading frame 18 33275, 41263,

306649251

30671169 chromosome 3 open 441239 1324 414124 9312 17300, 25288, reading frame 18 33276, 41264,

306849252

30691170 chromosome 3 open 449241 1325 404913 9313 17301, 25289, reading frame 18 33277, 41265,

307049253

30711171 chromosome 3 open 253697 1326 253697 9314 17302, 25290, reading frame 20 33278, 41266,

307249254

30731172 chromosome 3 open 412910 1327 396081 9315 17303, 25291, reading frame 20 33279, 41267,

307449255

30751173 chromosome 3 open 435614 1328 402933 9316 17304, 25292, reading frame 20 33280, 41268,

307649256

30771174 chromosome 3 open 342649 1329 341539 9317 17305, 25293, reading frame 23 33281, 41269,

307849257

30791175 chromosome 3 open 383746 1330 373252 9318 17306, 25294, reading frame 23 33282, 41270,

308049258

30811176 chromosome 3 open 396078 1331 379388 9319 17307, 25295, reading frame 23 33283, 41271,

308249259 1177 chromosome 3 open 417237 1332 402581 9320 17308, 25296, reading frame 23 33284, 41272,

308349260

30841178 chromosome 3 open 340171 1333 342512 9321 17309, 25297, reading frame 33 33285, 41273,

308549261

30861179 chromosome 3 open 534941 1334 445446 9322 17310, 25298, reading frame 33 33286, 41274,

308749262

30881180 chromosome 3 open 537385 1335 444116 9323 17311, 25299, reading frame 33 33287, 41275,

308949263

30901181 chromosome 3 open 328376 1336 331625 9324 17312, 25300, reading frame 35 33288, 41276,

309149264

30921182 chromosome 3 open 425564 1337 414104 9325 17313, 25301, reading frame 35 33289, 41277,

309349265

30941183 chromosome 3 open 425932 1338 395513 9326 17314, 25302, reading frame 35 33290, 41278,

309549266

30961184 chromosome 3 open 426078 1339 392399 9327 17315, 25303, reading frame 35 33291, 41279,

309749267

30981185 chromosome 3 open 452017 1340 413537 9328 17316, 25304, reading frame 35 33292, 41280,

309949268

31001186 chromosome 3 open 397537 1341 380671 9329 17317, 25305, reading frame 43 33293, 41281,

310149269

31021187 chromosome 3 open 316436 1342 315081 9330 17318, 25306, reading frame 45 33294, 41282,

310349270

31041188 chromosome 3 open 459838 1343 420317 9331 17319, 25307, reading frame 55 33295, 41283,

310549271

31061189 chromosome 3 open 408959 1344 386193 9332 17320, 25308, reading frame 71 33296, 41284,

310749272

31081190 chromosome 3 open 477703 1345 417806 9333 17321, 25309, reading frame 78 33297, 41285,

310949273

31101191 chromosome 4 open 309071 1346 309095 9334 17322, 25310, reading frame 21 33298, 41286,

311149274

31121192 chromosome 4 open 445203 1347 390505 9335 17323, 25311, reading frame 21 33299, 41287,

311349275

31141193 chromosome 4 open 503172 1348 424995 9336 17324, 25312, reading frame 21 33300, 41288,

311549276

31161194 chromosome 4 open 399075 1349 382026 9337 17325, 25313, reading frame 3 33301, 41289,

311749277 1195 chromosome 4 open 504110 1350 427214 9338 17326, 25314, reading frame 3 33302, 41290,

311849278

31191196 chromosome 4 open 309733 1351 310182 9339 17327, 25315, reading frame 32 33303, 41291,

312049279

31211197 chromosome 4 open 295958 1352 295958 9340 17328, 25316, reading frame 34 33304, 41292,

312249280

31231198 chromosome 4 open 505729 1353 422904 9341 17329, 25317, reading frame 34 33305, 41293,

312449281

31251199 chromosome 4 open 398955 1354 381928 9342 17330, 25318, reading frame 49 33306, 41294,

312649282

31271200 chromosome 5 open 231512 1355 231512 9343 17331, 25319, reading frame 15 33307, 41295,

312849283

31291201 chromosome 5 open 451255 1356 389086 9344 17332, 25320, reading frame 15 33308, 41296,

313049284

31311202 chromosome 5 open 397080 1357 380270 9345 17333, 25321, reading frame 28 33309, 41297,

313249285

31331203 chromosome 5 open 500337 1358 426067 9346 17334, 25322, reading frame 28 33310, 41298,

313449286

31351204 chromosome 5 open 506860 1359 424720 9347 17335, 25323, reading frame 28 33311, 41299,

313649287

31371205 chromosome 5 open 512085 1360 422881 9348 17336, 25324, reading frame 28 33312, 41300,

313849288

31391206 chromosome 5 open 537319 1361 443629 9349 17337, 25325, reading frame 28 33313, 41301,

314049289

31411207 chromosome 5 open 326080 1362 320604 9350 17338, 25326, reading frame 4 33314, 41302,

314249290

31431208 chromosome 5 open 517938 1363 430286 9351 17339, 25327, reading frame 4 33315, 41303,

314449291

31451209 chromosome 5 open 519501 1364 429837 9352 17340, 25328, reading frame 4 33316, 41304,

314649292

31471210 chromosome 5 open 520461 1365 431015 9353 17341, 25329, reading frame 4 33317, 41305,

314849293

31491211 chromosome 5 open 339020 1366 339324 9354 17342, 25330, reading frame 43 33318, 41306,

315049294

31511212 chromosome 5 open 507416 1367 421336 9355 17343, 25331, reading frame 43 33319, 41307,

315249295 1213 chromosome 5 open 526627 1368 436897 9356 17344, 25332, reading frame 62 33320, 41308,

315349296

31541214 chromosome 6 open 305725 1369 303292 9357 17345, 25333, reading frame 10 33321, 41309,

315549297

31561215 chromosome 6 open 375002 1370 364141 9358 17346, 25334, reading frame 10 33322, 41310,

315749298

31581216 chromosome 6 open 375007 1371 364146 9359 17347, 25335, reading frame 10 33323, 41311,

315949299

31601217 chromosome 6 open 383130 1372 372611 9360 17348, 25336, reading frame 10 33324, 41312,

316149300

31621218 chromosome 6 open 447241 1373 415517 9361 17349, 25337, reading frame 10 33325, 41313,

316349301

31641219 chromosome 6 open 448986 1374 410514 9362 17350, 25338, reading frame 10 33326, 41314,

316549302

31661220 chromosome 6 open 547550 1375 449235 9363 17351, 25339, reading frame 10 33327, 41315,

316749303

31681221 chromosome 6 open 548927 1376 448472 9364 17352, 25340, reading frame 10 33328, 41316,

316949304

31701222 chromosome 6 open 548975 1377 449655 9365 17353, 25341, reading frame 10 33329, 41317,

317149305

31721223 chromosome 6 open 551961 1378 447564 9366 17354, 25342, reading frame 10 33330, 41318,

317349306

31741224 chromosome 6 open 374214 1379 363331 9367 17355, 25343, reading frame 125 33331, 41319,

317549307

31761225 chromosome 6 open 374231 1380 363348 9368 17356, 25344, reading frame 125 33332, 41320,

317749308

31781226 chromosome 6 open 293604 1381 293604 9369 17357, 25345, reading frame 136 33333, 41321,

317949309

31801227 chromosome 6 open 376471 1382 365654 9370 17358, 25346, reading frame 136 33334, 41322,

318149310

31821228 chromosome 6 open 376473 1383 365656 9371 17359, 25347, reading frame 136 33335, 41323,

318349311

31841229 chromosome 6 open 528347 1384 431811 9372 17360, 25348, reading frame 136 33336, 41324,

318549312

31861230 chromosome 6 open 339488 1385 341914 9373 17361, 25349, reading frame 138 33337, 41325,

318749313 1231 chromosome 6 open 398738 1386 381722 9374 17362, 25350, reading frame 138 33338, 41326,

318849314

31891232 chromosome 6 open 543600 1387 439864 9375 17363, 25351, reading frame 138 33339, 41327,

319049315

31911233 chromosome 6 open 229570 1388 229570 9376 17364, 25352, reading frame 162 33340, 41328,

319249316

31931234 chromosome 6 open 392863 1389 376603 9377 17365, 25353, reading frame 162 33341, 41329,

319449317

31951235 chromosome 6 open 368268 1390 357251 9378 17366, 25354, reading frame 174 33342, 41330,

319649318

31971236 chromosome 6 open 467753 1391 431662 9379 17367, 25355, reading frame 174 33343, 41331,

319849319

31991237 chromosome 6 open 525778 1392 434570 9380 17368, 25356, reading frame 174 33344, 41332,

320049320

32011238 chromosome 6 open 556132 1393 451768 9381 17369, 25357, reading frame 174 33345, 41333,

320249321

32031239 chromosome 6 open 368143 1394 357125 9382 17370, 25358, reading frame 191 33346, 41334,

320449322

32051240 chromosome 6 open 438392 1395 403755 9383 17371, 25359, reading frame 191 33347, 41335,

320649323

32071241 chromosome 6 open 311381 1396 310951 9384 17372, 25360, reading frame 203 33348, 41336,

320849324

32091242 chromosome 6 open 405204 1397 384867 9385 17373, 25361, reading frame 203 33349, 41337,

321049325

32111243 chromosome 6 open 443043 1398 390153 9386 17374, 25362, reading frame 203 33350, 41338,

321249326

32131244 chromosome 6 open 375804 1399 364962 9387 17375, 25363, reading frame 25 33351, 41339,

321449327

32151245 chromosome 6 open 375805 1400 364963 9388 17376, 25364, reading frame 25 33352, 41340,

321649328

32171246 chromosome 6 open 375806 1401 364964 9389 17377, 25365, reading frame 25 33353, 41341,

321849329

32191247 chromosome 6 open 375809 1402 364967 9390 17378, 25366, reading frame 25 33354, 41342,

322049330

32211248 chromosome 6 open 375810 1403 364968 9391 17379, 25367, reading frame 25 33355, 41343,

322249331 1249 chromosome 6 open 375814 1404 364972 9392 17380, 25368, reading frame 25 33356, 41344,

322349332

32241250 chromosome 6 open 383410 1405 372902 9393 17381, 25369, reading frame 25 33357, 41345,

322549333

32261251 chromosome 6 open 383411 1406 372903 9394 17382, 25370, reading frame 25 33358, 41346,

322749334

32281252 chromosome 6 open 383412 1407 372904 9395 17383, 25371, reading frame 25 33359, 41347,

322949335

32301253 chromosome 6 open 400067 1408 382940 9396 17384, 25372, reading frame 25 33360, 41348,

323149336

32321254 chromosome 6 open 400071 1409 382944 9397 17385, 25373, reading frame 25 33361, 41349,

323349337

32341255 chromosome 6 open 415728 1410 408430 9398 17386, 25374, reading frame 25 33362, 41350,

323549338

32361256 chromosome 6 open 415984 1411 394082 9399 17387, 25375, reading frame 25 33363, 41351,

323749339

32381257 chromosome 6 open 417610 1412 412747 9400 17388, 25376, reading frame 25 33364, 41352,

323949340

32401258 chromosome 6 open 422012 1413 398061 9401 17389, 25377, reading frame 25 33365, 41353,

324149341

32421259 chromosome 6 open 425998 1414 392917 9402 17390, 25378, reading frame 25 33366, 41354,

324349342

32441260 chromosome 6 open 426729 1415 390272 9403 17391, 25379, reading frame 25 33367, 41355,

324549343

32461261 chromosome 6 open 428302 1416 404519 9404 17392, 25380, reading frame 25 33368, 41356,

324749344

32481262 chromosome 6 open 431888 1417 390821 9405 17393, 25381, reading frame 25 33369, 41357,

324949345

32501263 chromosome 6 open 435007 1418 401892 9406 17394, 25382, reading frame 25 33370, 41358,

325149346

32521264 chromosome 6 open 436030 1419 406706 9407 17395, 25383, reading frame 25 33371, 41359,

325349347

32541265 chromosome 6 open 437153 1420 412937 9408 17396, 25384, reading frame 25 33372, 41360,

325549348

32561266 chromosome 6 open 440063 1421 388982 9409 17397, 25385, reading frame 25 33373, 41361,

325749349 1267 chromosome 6 open 444404 1422 415282 9410 17398, 25386, reading frame 25 33374, 41362,

325849350

32591268 chromosome 6 open 445381 1423 396823 9411 17399, 25387, reading frame 25 33375, 41363,

326049351

32611269 chromosome 6 open 447587 1424 416447 9412 17400, 25388, reading frame 25 33376, 41364,

326249352

32631270 chromosome 6 open 449633 1425 388484 9413 17401, 25389, reading frame 25 33377, 41365,

326449353

32651271 chromosome 6 open 451549 1426 395801 9414 17402, 25390, reading frame 25 33378, 41366,

326649354

32671272 chromosome 6 open 455185 1427 414824 9415 17403, 25391, reading frame 25 33379, 41367,

326849355

32691273 chromosome 6 open 457450 1428 395279 9416 17404, 25392, reading frame 25 33380, 41368,

327049356

32711274 chromosome 6 open 457884 1429 391097 9417 17405, 25393, reading frame 25 33381, 41369,

327249357

32731275 chromosome 6 open 366771 1430 355733 9418 17406, 25394, reading frame 70 33382, 41370,

327449358

32751276 chromosome 6 open 366772 1431 355734 9419 17407, 25395, reading frame 70 33383, 41371,

327649359

32771277 chromosome 6 open 366773 1432 355735 9420 17408, 25396, reading frame 70 33384, 41372,

327849360

32791278 chromosome 6 open 392095 1433 375945 9421 17409, 25397, reading frame 70 33385, 41373,

328049361

32811279 chromosome 6 open 418781 1434 397661 9422 17410, 25398, reading frame 70 33386, 41374,

328249362

32831280 chromosome 6 open 367419 1435 356389 9423 17411, 25399, reading frame 72 33387, 41375,

328449363

32851281 chromosome 6 open 367423 1436 356393 9424 17412, 25400, reading frame 72 33388, 41376,

328649364

32871282 chromosome 6 open 433539 1437 407343 9425 17413, 25401, reading frame 72 33389, 41377,

328849365

32891283 chromosome 6 open 355190 1438 347322 9426 17414, 25402, reading frame 89 33390, 41378,

329049366

32911284 chromosome 6 open 359359 1439 352316 9427 17415, 25403, reading frame 89 33391, 41379,

329249367 1285 chromosome 6 open 373685 1440 362789 9428 17416, 25404, reading frame 89 33392, 41380,

329349368

32941286 chromosome 6 open 416621 1441 387562 9429 17417, 25405, reading frame 89 33393, 41381,

329549369

32961287 chromosome 6 open 510325 1442 445655 9430 17418, 25406, reading frame 89 33394, 41382,

329749370

32981288 chromosome 6 open 540072 1443 443462 9431 17419, 25407, reading frame 89 33395, 41383,

329949371

33001289 chromosome 7 open 333319 1444 331784 9432 17420, 25408, reading frame 13 33396, 41384,

330149372

33021290 chromosome 7 open 257637 1445 257637 9433 17421, 25409, reading frame 23 33397, 41385,

330349373

33041291 chromosome 7 open 433078 1446 398083 9434 17422, 25410, reading frame 23 33398, 41386,

330549374

33061292 chromosome 7 open 455575 1447 401897 9435 17423, 25411, reading frame 23 33399, 41387,

330749375

33081293 chromosome 7 open 466681 1448 419370 9436 17424, 25412, reading frame 30 33400, 41388,

330949376

33101294 chromosome 7 open 341567 1449 340668 9437 17425, 25413, reading frame 42 33401, 41389,

331149377

33121295 chromosome 7 open 413593 1450 410505 9438 17426, 25414, reading frame 42 33402, 41390,

331349378

33141296 chromosome 7 open 418375 1451 413824 9439 17427, 25415, reading frame 42 33403, 41391,

331549379

33161297 chromosome 7 open 424964 1452 394507 9440 17428, 25416, reading frame 42 33404, 41392,

331749380

33181298 chromosome 7 open 223336 1453 223336 9441 17429, 25417, reading frame 44 33405, 41393,

331949381

33201299 chromosome 7 open 310564 1454 312100 9442 17430, 25418, reading frame 44 33406, 41394,

332149382

33221300 chromosome 7 open 395879 1455 379218 9443 17431, 25419, reading frame 44 33407, 41395,

332349383

33241301 chromosome 7 open 395880 1456 379219 9444 17432, 25420, reading frame 44 33408, 41396,

332549384

33261302 chromosome 7 open 415076 1457 400759 9445 17433, 25421, reading frame 44 33409, 41397,

332749385 1303 chromosome 7 open 415798 1458 405582 9446 17434, 25422, reading frame 44 33410, 41398,

332849386

33291304 chromosome 7 open 431651 1459 417046 9447 17435, 25423, reading frame 44 33411, 41399,

333049387

33311305 chromosome 7 open 438444 1460 395586 9448 17436, 25424, reading frame 44 33412, 41400,

333249388

33331306 chromosome 7 open 446330 1461 416406 9449 17437, 25425, reading frame 44 33413, 41401,

333449389

33351307 chromosome 7 open 446564 1462 413777 9450 17438, 25426, reading frame 44 33414, 41402,

333649390

33371308 chromosome 7 open 297819 1463 297819 9451 17439, 25427, reading frame 45 33415, 41403,

333849391

33391309 chromosome 7 open 312849 1464 323304 9452 17440, 25428, reading frame 53 33416, 41404,

334049392

33411310 chromosome 7 open 429049 1465 415047 9453 17441, 25429, reading frame 53 33417, 41405,

334249393

33431311 chromosome 7 open 439068 1466 389278 9454 17442, 25430, reading frame 53 33418, 41406,

334449394

33451312 chromosome 7 open 297534 1467 297534 9455 17443, 25431, reading frame 55 33419, 41407,

334649395

33471313 chromosome 7 open 310396 1468 309772 9456 17444, 25432, reading frame 58 33420, 41408,

334849396

33491314 chromosome 7 open 340646 1469 345235 9457 17445, 25433, reading frame 58 33421, 41409,

335049397

33511315 chromosome 7 open 428526 1470 398082 9458 17446, 25434, reading frame 58 33422, 41410,

335249398

33531316 chromosome 7 open 450913 1471 406122 9459 17447, 25435, reading frame 58 33423, 41411,

335449399

33551317 chromosome 7 open 379007 1472 368292 9460 17448, 25436, reading frame 66 33424, 41412,

335649400

33571318 chromosome 8 open 507535 1473 428230 9461 17449, 25437, reading frame 17 33425, 41413,

335849401

33591319 chromosome 8 open 414154 1474 408997 9462 17450, 25438, reading frame 40 33426, 41414,

336049402

33611320 chromosome 8 open 416469 1475 390750 9463 17451, 25439, reading frame 40 33427, 41415,

336249403 1321 chromosome 8 open 417410 1476 405694 9464 17452, 25440, reading frame 40 33428, 41416,

336349404

33641322 chromosome 8 open 438528 1477 391549 9465 17453, 25441, reading frame 40 33429, 41417,

336549405

33661323 chromosome 8 open 490331 1478 429586 9466 17454, 25442, reading frame 40 33430, 41418,

336749406

33681324 chromosome 8 open 524821 1479 436621 9467 17455, 25443, reading frame 82 33431, 41419,

336949407

33701325 chromosome 8 open 378861 1480 368138 9468 17456, 25444, reading frame 83 33432, 41420,

337149408

33721326 chromosome 8 open 517751 1481 430683 9469 17457, 25445, reading frame 83 33433, 41421,

337349409

33741327 chromosome 8 open 518748 1482 430837 9470 17458, 25446, reading frame 83 33434, 41422,

337549410

33761328 chromosome 8 open 519969 1483 429381 9471 17459, 25447, reading frame 83 33435, 41423,

337749411

33781329 chromosome 8 open 520430 1484 428822 9472 17460, 25448, reading frame 83 33436, 41424,

337949412

33801330 chromosome 8 open 520686 1485 429822 9473 17461, 25449, reading frame 83 33437, 41425,

338149413

33821331 chromosome 8 open 521617 1486 430992 9474 17462, 25450, reading frame 83 33438, 41426,

338349414

33841332 chromosome 8 open 521988 1487 429517 9475 17463, 25451, reading frame 83 33439, 41427,

338549415

33861333 chromosome 8 open 522903 1488 429302 9476 17464, 25452, reading frame 83 33440, 41428,

338749416

33881334 chromosome 8 open 524107 1489 429742 9477 17465, 25453, reading frame 83 33441, 41429,

338949417

33901335 chromosome 8 open 537541 1490 442030 9478 17466, 25454, reading frame 83 33442, 41430,

339149418

33921336 chromosome 9 open 380031 1491 369370 9479 17467, 25455, reading frame 11 33443, 41431,

339349419

33941337 chromosome 9 open 380032 1492 369371 9480 17468, 25456, reading frame 11 33444, 41432,

339549420

33961338 chromosome 9 open 537675 1493 441630 9481 17469, 25457, reading frame 11 33445, 41433,

339749421 1339 chromosome 9 open 358227 1494 350961 9482 17470, 25458, reading frame 123 33446, 41434,

339849422

33991340 chromosome 9 open 374847 1495 363980 9483 17471, 25459, reading frame 125 33447, 41435,

340049423

34011341 chromosome 9 open 374848 1496 363981 9484 17472, 25460, reading frame 125 33448, 41436,

340249424

34031342 chromosome 9 open 374851 1497 363984 9485 17473, 25461, reading frame 125 33449, 41437,

340449425

34051343 chromosome 9 open 377197 1498 366402 9486 17474, 25462, reading frame 135 33450, 41438,

340649426

34071344 chromosome 9 open 357503 1499 350102 9487 17475, 25463, reading frame 167 33451, 41439,

340849427

34091345 chromosome 9 open 357054 1500 349562 9488 17476, 25464, reading frame 174 33452, 41440,

341049428

34111346 chromosome 9 open 375202 1501 364348 9489 17477, 25465, reading frame 174 33453, 41441,

341249429

34131347 chromosome 9 open 375205 1502 364351 9490 17478, 25466, reading frame 174 33454, 41442,

341449430

34151348 chromosome 9 open 395220 1503 378646 9491 17479, 25467, reading frame 174 33455, 41443,

341649431

34171349 chromosome 9 open 411667 1504 414000 9492 17480, 25468, reading frame 174 33456, 41444,

341849432

34191350 chromosome 9 open 529487 1505 434727 9493 17481, 25469, reading frame 174 33457, 41445,

342049433

34211351 chromosome 9 open 541524 1506 437666 9494 17482, 25470, reading frame 174 33458, 41446,

342249434

34231352 chromosome 9 open 376854 1507 366050 9495 17483, 25471, reading frame 40 33459, 41447,

342449435

34251353 chromosome 9 open 223864 1508 223864 9496 17484, 25472, reading frame 46 33460, 41448,

342649436

34271354 chromosome 9 open 377024 1509 366223 9497 17485, 25473, reading frame 57 33461, 41449,

342849437

34291355 chromosome 9 open 424431 1510 412956 9498 17486, 25474, reading frame 57 33462, 41450,

343049438

34311356 chromosome 9 open 377311 1511 366528 9499 17487, 25475, reading frame 71 33463, 41451,

343249439 1357 chromosome 9 open 325643 1512 322640 9500 17488, 25476, reading frame 79 33464, 41452,

343349440

34341358 chromosome 9 open 539327 1513 443171 9501 17489, 25477, reading frame 79 33465, 41453,

343549441

34361359 chromosome 9 open 288502 1514 288502 9502 17490, 25478, reading frame 91 33466, 41454,

343749442

34381360 chromosome 9 open 374049 1515 363161 9503 17491, 25479, reading frame 91 33467, 41455,

343949443

34401361 chromosome X open 379682 1516 369004 9504 17492, 25480, reading frame 23 33468, 41456,

344149444

34421362 chromosome X open 313548 1517 324767 9505 17493, 25481, reading frame 59 33469, 41457,

344349445

34441363 chromosome X open 378660 1518 367929 9506 17494, 25482, reading frame 59 33470, 41458,

344549446

34461364 chromosome X open 397458 1519 380599 9507 17495, 25483, reading frame 59 33471, 41459,

344749447

34481365 chromosome X open 449698 1520 414151 9508 17496, 25484, reading frame 59 33472, 41460,

344949448

34501366 chromosome X open 370540 1521 359571 9509 17497, 25485, reading frame 66 33473, 41461,

345149449

34521367 chromosome X open 369529 1522 358542 9510 17498, 25486, reading frame 68 33474, 41462,

345349450

34541368 ciliary rootlet coiled- 375541 1523 364691 9511 17499, 25487, coil, rootletin 33475, 41463,

345549451

34561369 ciliary rootlet coiled- 445545 1524 402626 9512 17500, 25488, coil, rootletin 33476, 41464,

345749452

34581370 cingulin 271636 1525 271636 9513 17501, 25489,

345933477, 41465, 49453

34601371 cingulin 427934 1526 410836 9514 17502, 25490,

346133478, 41466, 49454

34621372 cingulin 502442 1527 422299 9515 17503, 25491,

346333479, 41467, 49455

34641373 cingulin 505188 1528 425532 9516 17504, 25492,

346533480, 41468, 49456

34661374 clarin 2 511148 1529 424711 9517 17505, 25493,

346733481, 41469, 49457 1375 clarin 3 368671 1530 357660 9518 17506, 25494,

346833482, 41470, 49458

34691376 claudin 10 299339 1531 299339 9519 17507, 25495,

347033483, 41471, 49459

34711377 claudin 10 376855 1532 366051 9520 17508, 25496,

347233484, 41472, 49460

34731378 claudin 10 376873 1533 366069 9521 17509, 25497,

347433485, 41473, 49461

34751379 claudin 12 287916 1534 287916 9522 17510, 25498,

347633486, 41474, 49462

34771380 claudin 12 394604 1535 378102 9523 17511, 25499,

347833487, 41475, 49463

34791381 claudin 12 394605 1536 378103 9524 17512, 25500,

348033488, 41476, 49464

34811382 claudin 12 416322 1537 411399 9525 17513, 25501,

348233489, 41477, 49465

34831383 claudin 12 422604 1538 394444 9526 17514, 25502,

348433490, 41478, 49466

34851384 claudin 12 427904 1539 391062 9527 17515, 25503,

348633491, 41479, 49467

34871385 claudin 12 496677 1540 419053 9528 17516, 25504,

348833492, 41480, 49468

34891386 claudin 12 535571 1541 443476 9529 17517, 25505,

349033493, 41481, 49469

34911387 claudin 15 308344 1542 308870 9530 17518, 25506,

349233494, 41482, 49470

34931388 claudin 15 401528 1543 385300 9531 17519, 25507,

349433495, 41483, 49471

34951389 claudin 17 286808 1544 286808 9532 17520, 25508,

349633496, 41484, 49472

34971390 claudin 2 336803 1545 336571 9533 17521, 25509,

349833497, 41485, 49473

34991391 claudin 2 540876 1546 443230 9534 17522, 25510,

350033498, 41486, 49474

35011392 claudin 2 541806 1547 441283 9535 17523, 25511,

350233499, 41487, 49475 1393 claudin 20 367165 1548 356133 9536 17524, 25512,

350333500, 41488, 49476

35041394 claudin 22 323319 1549 318113 9537 17525, 25513,

350533501, 41489, 49477

35061395 claudin 23 519106 1550 428780 9538 17526, 25514,

350733502, 41490, 49478

35081396 claudin 25 453129 1551 396304 9539 17527, 25515,

350933503, 41491, 49479

35101397 claudin 6 328796 1552 328674 9540 17528, 25516,

351133504, 41492, 49480

35121398 claudin 6 396925 1553 380131 9541 17529, 25517,

351333505, 41493, 49481

35141399 claudin 7 360325 1554 353475 9542 17530, 25518,

351533506, 41494, 49482

35161400 claudin 7 397317 1555 396638 9543 17531, 25519,

351733507, 41495, 49483

35181401 claudin 7 538261 1556 445131 9544 17532, 25520,

351933508, 41496, 49484

35201402 claudin 8 286809 1557 286809 9545 17533, 25521,

352133509, 41497, 49485

35221403 claudin 8 399899 1558 382783 9546 17534, 25522,

352333510, 41498, 49486

35241404 claudin 8 536721 1559 439258 9547 17535, 25523,

352533511, 41499, 49487

35261405 claudin 9 445369 1560 398017 9548 17536, 25524,

352733512, 41500, 49488

35281406 claudin domain 341181 1561 340247 9549 17537, 25525, containing 1 33513, 41501,

352949489

35301407 claudin domain 394180 1562 377734 9550 17538, 25526, containing 1 33514, 41502,

353149490

35321408 claudin domain 394181 1563 377735 9551 17539, 25527, containing 1 33515, 41503,

353349491

35341409 claudin domain 394185 1564 377739 9552 17540, 25528, containing 1 33516, 41504,

353549492

35361410 claudin domain 437922 1565 388457 9553 17541, 25529, containing 1 33517, 41505,

353749493 1411 claudin domain 502299 1566 420913 9554 17542, 25530, containing 1 33518, 41506,

353849494

35391412 claudin domain 503004 1567 421226 9555 17543, 25531, containing 1 33519, 41507,

354049495

35411413 claudin domain 506575 1568 427042 9556 17544, 25532, containing 1 33520, 41508,

354249496

35431414 claudin domain 507944 1569 425204 9557 17545, 25533, containing 1 33521, 41509,

354449497

35451415 claudin domain 508071 1570 425256 9558 17546, 25534, containing 1 33522, 41510,

354649498

35471416 claudin domain 508659 1571 427658 9559 17547, 25535, containing 1 33523, 41511,

354849499

35491417 claudin domain 508902 1572 421413 9560 17548, 25536, containing 1 33524, 41512,

355049500

35511418 claudin domain 510545 1573 423590 9561 17549, 25537, containing 1 33525, 41513,

355249501

35531419 claudin domain 511081 1574 424669 9562 17550, 25538, containing 1 33526, 41514,

355449502

35551420 claudin domain 513130 1575 426079 9563 17551, 25539, containing 1 33527, 41515,

355649503

35571421 claudin domain 513287 1576 426869 9564 17552, 25540, containing 1 33528, 41516,

355849504

35591422 claudin domain 513452 1577 425539 9565 17553, 25541, containing 1 33529, 41517,

356049505

35611423 claudin domain 514537 1578 423151 9566 17554, 25542, containing 1 33530, 41518,

356249506

35631424 claudin domain 515620 1579 423093 9567 17555, 25543, containing 1 33531, 41519,

356449507

35651425 claudin domain 291715 1580 291715 9568 17556, 25544, containing 2 33532, 41520,

356649508

35671426 clavesin 1 325897 1581 325506 9569 17557, 25545,

356833533, 41521, 49509

35691427 clavesin 1 519846 1582 428402 9570 17558, 25546,

357033534, 41522, 49510

35711428 clavesin 1 522621 1583 428986 9571 17559, 25547,

357233535, 41523, 49511 1429 clavesin 2 275162 1584 275162 9572 17560, 25548,

357333536, 41524, 49512

35741430 clavesin 2 368438 1585 357423 9573 17561, 25549,

357533537, 41525, 49513

35761431 cleft lip and palate 337392 1586 336994 9574 17562, 25550, associated 33538, 41526, transmembrane 49514 protein 1

35771432 cleft lip and palate 347493 1587 270281 9575 17563, 25551, associated 33539, 41527, transmembrane 49515 protein 1

35781433 cleft lip and palate 541297 1588 442011 9576 17564, 25552, associated 33540, 41528, transmembrane 49516 protein 1

35791434 cleft lip and palate 546079 1589 443192 9577 17565, 25553, associated 33541, 41529, transmembrane 49517 protein 1

35801435 ClpB caseinolytic 294053 1590 294053 9578 17566, 25554, peptidase B 33542, 41530, homolog (E. coli) 49518

35811436 ClpB caseinolytic 437826 1591 407296 9579 17567, 25555, peptidase B 33543, 41531, homolog (E. coli) 49519

35821437 ClpB caseinolytic 538039 1592 441518 9580 17568, 25556, peptidase B 33544, 41532, homolog (E. coli) 49520

35831438 ClpB caseinolytic 543042 1593 439746 9581 17569, 25557, peptidase B 33545, 41533, homolog (E. coli) 49521

35841439 ClpX caseinolytic 300107 1594 300107 9582 17570, 25558, peptidase X 33546, 41534, homolog (E. coli) 49522

35851440 ClpX caseinolytic 546194 1595 440853 9583 17571, 25559, peptidase X 33547, 41535, homolog (E. coli) 49523

35861441 coatomer protein 314797 1596 325002 9584 17572, 25560, complex, subunit 33548, 41536, gamma 49524

35871442 coatomer protein 262061 1597 262061 9585 17573, 25561, complex, subunit 33549, 41537, zeta 1 49525

35881443 coatomer protein 416254 1598 388141 9586 17574, 25562, complex, subunit 33550, 41538, zeta 1 49526

35891444 coatomer protein 455864 1599 410620 9587 17575, 25563, complex, subunit 33551, 41539, zeta 1 49527

35901445 coatomer protein 552848 1600 449414 9588 17576, 25564, complex, subunit 33552, 41540, zeta 1 49528 1446 coenzyme Q10 308197 1601 312587 9589 17577, 25565, homolog A (S. 33553, 41541, cerevisiae) 49529

35911447 coenzyme Q10 433805 1602 407843 9590 17578, 25566, homolog A (S. 33554, 41542, cerevisiae) 49530

35921448 coenzyme Q10 546544 1603 446723 9591 17579, 25567, homolog A (S. 33555, 41543, cerevisiae) 49531

35931449 coenzyme Q10 551814 1604 447964 9592 17580, 25568, homolog A (S. 33556, 41544, cerevisiae) 49532

35941450 coenzyme Q10 263960 1605 263960 9593 17581, 25569, homolog B (S. 33557, 41545, cerevisiae) 49533

35951451 coenzyme Q10 409010 1606 387223 9594 17582, 25570, homolog B (S. 33558, 41546, cerevisiae) 49534

35961452 coenzyme Q10 545340 1607 442520 9595 17583, 25571, homolog B (S. 33559, 41547, cerevisiae) 49535

35971453 coenzyme Q5 288532 1608 288532 9596 17584, 25572, homolog, 33560, 41548, methyltransferase 49536 (S. cerevisiae)

35981454 coenzyme Q5 302223 1609 302233 9597 17585, 25573, homolog, 33561, 41549, methyltransferase 49537 (S. cerevisiae)

35991455 coenzyme Q6 238709 1610 238709 9598 17586, 25574, homolog, 33562, 41550, monooxygenase (S. 49538 cerevisiae)

36001456 coenzyme Q6 334571 1611 333946 9599 17587, 25575, homolog, 33563, 41551, monooxygenase (S. 49539 cerevisiae)

36011457 coenzyme Q6 394026 1612 377594 9600 17588, 25576, homolog, 33564, 41552, monooxygenase (S. 49540 cerevisiae)

36021458 coenzyme Q6 545052 1613 439592 9601 17589, 25577, homolog, 33565, 41553, monooxygenase (S. 49541 cerevisiae)

36031459 coenzyme Q6 554153 1614 451685 9602 17590, 25578, homolog, 33566, 41554, monooxygenase (S. 49542 cerevisiae)

36041460 coenzyme Q6 554320 1615 451123 9603 17591, 25579, homolog, 33567, 41555, monooxygenase (S. 49543 cerevisiae) 1461 coenzyme Q6 555376 1616 450526 9604 17592, 25580, homolog, 33568, 41556, monooxygenase (S. 49544 cerevisiae)

36051462 coiled-coil domain 327351 1617 330327 9605 17593, 25581, containing 107 33569, 41557,

360649545

36071463 coiled-coil domain 378406 1618 367661 9606 17594, 25582, containing 107 33570, 41558,

360849546

36091464 coiled-coil domain 378407 1619 367662 9607 17595, 25583, containing 107 33571, 41559,

361049547

36111465 coiled-coil domain 378409 1620 367665 9608 17596, 25584, containing 107 33572, 41560,

361249548

36131466 coiled-coil domain 421582 1621 413003 9609 17597, 25585, containing 107 33573, 41561,

361449549

36151467 coiled-coil domain 426546 1622 414964 9610 17598, 25586, containing 107 33574, 41562,

361649550

36171468 coiled-coil domain 394650 1623 378145 9611 17599, 25587, containing 109B 33575, 41563,

361849551

36191469 coiled-coil domain 447857 1624 404220 9612 17600, 25588, containing 155 33576, 41564,

362049552

36211470 coiled-coil domain 373405 1625 362504 9613 17601, 25589, containing 167 33577, 41565,

362249553

36231471 coiled-coil domain 373408 1626 362507 9614 17602, 25590, containing 167 33578, 41566,

362449554

36251472 coiled-coil domain 411755 1627 407966 9615 17603, 25591, containing 167 33579, 41567,

362649555

36271473 coiled-coil domain 225726 1628 225726 9616 17604, 25592, containing 47 33580, 41568,

362849556

36291474 coiled-coil domain 403162 1629 384888 9617 17605, 25593, containing 47 33581, 41569,

363049557

36311475 coiled-coil domain 395694 1630 379047 9618 17606, 25594, containing 51 33582, 41570,

363249558

36331476 coiled-coil domain 395696 1631 379049 9619 17607, 25595, containing 51 33583, 41571,

363449559

36351477 coiled-coil domain 412398 1632 401194 9620 17608, 25596, containing 51 33584, 41572,

363649560

36371478 coiled-coil domain 438370 1633 408197 9621 17609, 25597, containing 51 33585, 41573,

363849561 1479 coiled-coil domain 442740 1634 392898 9622 17610, 25598, containing 51 33586, 41574,

363949562

36401480 coiled-coil domain 446140 1635 409494 9623 17611, 25599, containing 51 33587, 41575,

364149563

36421481 coiled-coil domain 447018 1636 412300 9624 17612, 25600, containing 51 33588, 41576,

364349564

36441482 coiled-coil domain 328434 1637 354762 9625 17613, 25601, containing 56 33589, 41577,

364549565

36461483 coiled-coil domain 291458 1638 291458 9626 17614, 25602, containing 58 33590, 41578,

364749566

36481484 coiled-coil domain 359495 1639 352475 9627 17615, 25603, containing 90 A 33591, 41579,

364949567

36501485 coiled-coil domain 379170 1640 368468 9628 17616, 25604, containing 90 A 33592, 41580,

365149568

36521486 coiled-coil domain 455220 1641 390990 9629 17617, 25605, containing 90B 33593, 41581,

365349569

36541487 coiled-coil domain 525503 1642 431424 9630 17618, 25606, containing 90B 33594, 41582,

365549570

36561488 coiled-coil domain 529611 1643 431345 9631 17619, 25607, containing 90B 33595, 41583,

365749571

36581489 coiled-coil domain 529689 1644 434724 9632 17620, 25608, containing 90B 33596, 41584,

365949572

36601490 coiled-coil domain 306172 1645 305075 9633 17621, 25609, containing 91 33597, 41585,

366149573

36621491 coiled-coil domain 381256 1646 370655 9634 17622, 25610, containing 91 33598, 41586,

366349574

36641492 coiled-coil domain 381259 1647 370658 9635 17623, 25611, containing 91 33599, 41587,

366549575

36661493 coiled-coil domain 536442 1648 445660 9636 17624, 25612, containing 91 33600, 41588,

366749576

36681494 coiled-coil domain 538586 1649 440194 9637 17625, 25613, containing 91 33601, 41589,

366949577

36701495 coiled-coil domain 539107 1650 440513 9638 17626, 25614, containing 91 33602, 41590,

367149578

36721496 coiled-coil domain 543534 1651 446045 9639 17627, 25615, containing 91 33603, 41591,

367349579 1497 coiled-coil domain 545336 1652 438040 9640 17628, 25616, containing 91 33604, 41592,

367449580

36751498 coiled-coil-helix- 372833 1653 361923 9641 17629, 25617, coiled-coil-helix 33605, 41593, domain containing 1 49581

36761499 coiled-coil-helix- 372837 1654 361928 9642 17630, 25618, coiled-coil-helix 33606, 41594, domain containing 1 49582

36771500 coiled-coil-helix- 484558 1655 418428 9643 17631, 25619, coiled-coil-helix 33607, 41595, domain containing 49583 10

36781501 coiled-coil-helix- 395422 1656 378812 9644 17632, 25620, coiled-coil-helix 33608, 41596, domain containing 2 49584

36791502 coiled-coil-helix- 295767 1657 295767 9645 17633, 25621, coiled-coil-helix 33609, 41597, domain containing 4 49585

36801503 coiled-coil-helix- 396914 1658 380122 9646 17634, 25622, coiled-coil-helix 33610, 41598, domain containing 4 49586

36811504 complement 307637 1659 302079 9647 17635, 25623, component 3 a 33611, 41599, receptor 1 49587

36821505 complement 546241 1660 444500 9648 17636, 25624, component 3 a 33612, 41600, receptor 1 49588

36831506 complement 355085 1661 347197 9649 17637, 25625, component 5 a 33613, 41601, receptor 1 49589

36841507 complexin 3 395018 1662 378464 9650 17638, 25626,

368533614, 41602, 49590

36861508 connector enhancer 361530 1663 354609 9651 17639, 25627, of kinase suppressor 33615, 41603, of Ras 1 49591

36871509 connector enhancer 374253 1664 363371 9652 17640, 25628, of kinase suppressor 33616, 41604, of Ras 1 49592

36881510 connector enhancer 422547 1665 390945 9653 17641, 25629, of kinase suppressor 33617, 41605, of Ras 1 49593

36891511 contactin associated 264638 1666 264638 9654 17642, 25630, protein 1 33618, 41606,

369049594

36911512 contactin associated 276974 1667 276974 9655 17643, 25631, protein-like 3B 33619, 41607,

369249595

36931513 contactin associated 341990 1668 340890 9656 17644, 25632, protein-like 3B 33620, 41608,

369449596

36951514 contactin associated 377555 1669 366778 9657 17645, 25633, protein-like 3B 33621, 41609,

369649597 1515 contactin associated 377561 1670 366784 9658 17646, 25634, protein-like 3B 33622, 41610,

369749598

36981516 contactin associated 377564 1671 366787 9659 17647, 25635, protein-like 3B 33623, 41611,

369949599

37001517 contactin associated 403166 1672 385153 9660 17648, 25636, protein-like 3B 33624, 41612,

370149600

37021518 contactin associated 431078 1673 399013 9661 17649, 25637, protein-like 5 33625, 41613,

370349601

37041519 corin, serine 273857 1674 273857 9662 17650, 25638, peptidase 33626, 41614,

370549602

37061520 corin, serine 502252 1675 424212 9663 17651, 25639, peptidase 33627, 41615,

370749603

37081521 corin, serine 505909 1676 425401 9664 17652, 25640, peptidase 33628, 41616,

370949604

37101522 cornichon homolog 216416 1677 216416 9665 17653, 25641, (Drosophila) 33629, 41617,

371149605

37121523 cornichon homolog 395573 1678 378940 9666 17654, 25642, (Drosophila) 33630, 41618,

371349606

37141524 cornichon homolog 311445 1679 310003 9667 17655, 25643, 2 (Drosophila) 33631, 41619,

371549607

37161525 cornichon homolog 272133 1680 272133 9668 17656, 25644, 3 (Drosophila) 33632, 41620,

371749608

37181526 cornichon homolog 366856 1681 355821 9669 17657, 25645, 4 (Drosophila) 33633, 41621,

371949609

37201527 cornichon homolog 366857 1682 355822 9670 17658, 25646, 4 (Drosophila) 33634, 41622,

372149610

37221528 cornichon homolog 366858 1683 355823 9671 17659, 25647, 4 (Drosophila) 33635, 41623,

372349611

37241529 cornichon homolog 465271 1684 420443 9672 17660, 25648, 4 (Drosophila) 33636, 41624,

372549612

37261530 cortexin 3 379445 1685 368758 9673 17661, 25649,

372733637, 41625, 49613

37281531 cortexin 3 395322 1686 378732 9674 17662, 25650,

372933638, 41626, 49614

37301532 corticotropin- 547258 1687 448155 9675 17663, 25651, releasing factor 33639, 41627, receptor 1 isoform 1 49615 precursor 1533 corticotropin- 548394 1688 449671 9676 17664, 25652, releasing factor 33640, 41628, receptor 1 isoform 1 49616 precursor

37311534 corticotropin- 548791 1689 448783 9677 17665, 25653, releasing factor 33641, 41629, receptor 1 isoform 1 49617 precursor

37321535 corticotropin- 550606 1690 448894 9678 17666, 25654, releasing factor 33642, 41630, receptor 1 isoform 1 49618 precursor

37331536 corticotropin- 551221 1691 446568 9679 17667, 25655, releasing factor 33643, 41631, receptor 1 isoform 1 49619 precursor

37341537 corticotropin- 551817 1692 447617 9680 17668, 25656, releasing factor 33644, 41632, receptor 1 isoform 1 49620 precursor

37351538 corticotropin- 552616 1693 448216 9681 17669, 25657, releasing factor 33645, 41633, receptor 1 isoform 1 49621 precursor

37361539 corticotropin- 552724 1694 448734 9682 17670, 25658, releasing factor 33646, 41634, receptor 1 isoform 1 49622 precursor

37371540 COX assembly 466830 1695 418348 9683 17671, 25659, mitochondrial 33647, 41635, protein homolog (S. 49623 cerevisiae)

37381541 COX 16 cytochrome 389912 1696 374562 9684 17672, 25660, c oxidase assembly 33648, 41636, homolog (S. 49624 cerevisiae)

37391542 COX 18 cytochrome 295890 1697 295890 9685 17673, 25661, c oxidase assembly 33649, 41637, homolog (S. 49625 cerevisiae)

37401543 COX 18 cytochrome 507544 1698 425261 9686 17674, 25662, c oxidase assembly 33650, 41638, homolog (S. 49626 cerevisiae)

37411544 CTAGE family, 486333 1699 419539 9687 17675, 25663, member 4 33651, 41639,

374249627

37431545 CTAGE family, 487179 1700 417289 9688 17676, 25664, member 8 33652, 41640,

374449628

37451546 CTAGE family, 314099 1701 395587 9689 17677, 25665, member 9 33653, 41641,

374649629 1547 CTD nuclear 318988 1702 321732 9690 17678, 25666, envelope 33654, 41642, phosphatase 1 49630

37471548 CTD nuclear 574322 1703 460683 9691 17679, 25667, envelope 33655, 41643, phosphatase 1 49631

37481549 C-type lectin domain 298527 1704 298527 9692 17680, 25668, family 1 , member B 33656, 41644,

374949632

37501550 C-type lectin domain 348658 1705 327169 9693 17681, 25669, family 1 , member B 33657, 41645,

375149633

37521551 C-type lectin domain 398939 1706 381912 9694 17682, 25670, family 1 , member B 33658, 41646,

375349634

37541552 C-type lectin domain 428126 1707 406338 9695 17683, 25671, family 1 , member B 33659, 41647,

375549635

37561553 C-type lectin domain 338896 1708 344563 9696 17684, 25672, family 12, member 33660, 41648, B 49636

37571554 C-type lectin domain 396502 1709 379759 9697 17685, 25673, family 12, member 33661, 41649, B 49637

37581555 C-type lectin domain 342213 1710 353013 9698 17686, 25674, family 14, member 33662, 41650, A 49638

37591556 C-type lectin domain 546356 1711 443662 9699 17687, 25675, family 14, member 33663, 41651, A 49639

37601557 C-type lectin domain 397439 1712 380581 9700 17688, 25676, family 17, member 33664, 41652, A 49640

37611558 C-type lectin domain 417570 1713 393719 9701 17689, 25677, family 17, member 33665, 41653, A 49641

37621559 C-type lectin domain 547437 1714 450065 9702 17690, 25678, family 17, member 33666, 41654, A 49642

37631560 C-type lectin domain 272367 1715 272367 9703 17691, 25679, family 4, member F 33667, 41655,

376449643

37651561 C-type lectin domain 328853 1716 327599 9704 17692, 25680, family 4, member G 33668, 41656,

376649644

37671562 C-type lectin domain 381308 1717 370709 9705 17693, 25681, family 4, member G 33669, 41657,

376849645

37691563 C-type lectin domain 355819 1718 348074 9706 17694, 25682, family 9, member A 33670, 41658,

377049646

37711564 C-type lectin-like 1 327839 1719 331766 9707 17695, 25683,

377233671, 41659, 49647 1565 C-type lectin-like 1 540988 1720 444947 9708 17696, 25684,

377333672, 41660, 49648

37741566 CUB and zona 338948 1721 340905 9709 17697, 25685, pellucida-like 33673, 41661, domains 1 49649

37751567 CUB and zona 368899 1722 357895 9710 17698, 25686, pellucida-like 33674, 41662, domains 1 49650

37761568 CUB and zona 368900 1723 357896 9711 17699, 25687, pellucida-like 33675, 41663, domains 1 49651

37771569 CUB and zona 368901 1724 357897 9712 17700, 25688, pellucida-like 33676, 41664, domains 1 49652

37781570 CUB and zona 368904 1725 357900 9713 17701, 25689, pellucida-like 33677, 41665, domains 1 49653

37791571 cutaneous T-cell 391403 1726 375220 9714 17702, 25690, lymphoma- 33678, 41666, associated antigen 1 49654

37801572 Cutaneous T-cell 525417 1727 436900 9715 17703, 25691, lymphoma- 33679, 41667, associated antigen 1 49655

37811573 cut-like homeobox 1 292535 1728 292535 9716 17704, 25692,

378233680, 41668, 49656

37831574 cut-like homeobox 1 292538 1729 292538 9717 17705, 25693,

378433681, 41669, 49657

37851575 cut-like homeobox 1 360264 1730 353401 9718 17706, 25694,

378633682, 41670, 49658

37871576 cut-like homeobox 1 393824 1731 377410 9719 17707, 25695,

378833683, 41671, 49659

37891577 cut-like homeobox 1 425244 1732 409745 9720 17708, 25696,

379033684, 41672, 49660

37911578 cut-like homeobox 1 437600 1733 414091 9721 17709, 25697,

379233685, 41673, 49661

37931579 cut-like homeobox 1 546411 1734 450125 9722 17710, 25698,

379433686, 41674, 49662

37951580 cut-like homeobox 1 547394 1735 449371 9723 17711, 25699,

379633687, 41675, 49663

37971581 cut-like homeobox 1 549414 1736 446630 9724 17712, 25700,

379833688, 41676, 49664

37991582 cut-like homeobox 1 550008 1737 447373 9725 17713, 25701,

380033689, 41677, 49665 1583 cut-like homeobox 1 556210 1738 451558 9726 17714, 25702,

380133690, 41678, 49666

38021584 cut-like homeobox 1 558836 1739 453088 9727 17715, 25703,

380333691, 41679, 49667

38041585 cut-like homeobox 1 560541 1740 453533 9728 17716, 25704,

380533692, 41680, 49668

38061586 CXXC finger 343216 1741 345374 9729 17717, 25705, protein 11 33693, 41681,

380749669

38081587 cyclic nucleotide 379936 1742 369268 9730 17718, 25706, gated channel alpha 33694, 41682, 4 49670

38091588 cyclin J-like 257536 1743 257536 9731 17719, 25707,

381033695, 41683, 49671

38111589 cyclin J-like 393977 1744 377547 9732 17720, 25708,

381233696, 41684, 49672

38131590 cyclin J-like 505287 1745 444778 9733 17721, 25709,

381433697, 41685, 49673

38151591 cyclin J-like 519673 1746 427960 9734 17722, 25710,

381633698, 41686, 49674

38171592 cyclin J-like 541762 1747 446367 9735 17723, 25711,

381833699, 41687, 49675

38191593 cyclin Pas 1/PHO80 360507 1748 353698 9736 17724, 25712, domain containing 1 33700, 41688,

382049676

38211594 cyclin Pas 1/PHO80 409789 1749 386277 9737 17725, 25713, domain containing 1 33701, 41689,

382249677

38231595 cyclin Pas 1/PHO80 453038 1750 410109 9738 17726, 25714, domain containing 1 33702, 41690,

382449678

38251596 cyclin-dependent 265741 1751 265741 9739 17727, 25715, kinase 14 33703, 41691,

382649679

38271597 cyclin-dependent 380050 1752 369390 9740 17728, 25716, kinase 14 33704, 41692,

382849680

38291598 cyclin-dependent 436577 1753 398936 9741 17729, 25717, kinase 14 33705, 41693,

383049681

38311599 cyclin-dependent 286878 1754 286878 9742 17730, 25718, kinase 20 33706, 41694,

383249682

38331600 cyclin-dependent 325303 1755 322343 9743 17731, 25719, kinase 20 33707, 41695,

383449683 1601 cyclin-dependent 336654 1756 338975 9744 17732, 25720, kinase 20 33708, 41696,

383549684

38361602 cyclin-dependent 375871 1757 365031 9745 17733, 25721, kinase 20 33709, 41697,

383749685

38381603 cyclin-dependent 375883 1758 365043 9746 17734, 25722, kinase 20 33710, 41698,

383949686

38401604 cysteine/tyrosine- 299340 1759 299340 9747 17735, 25723, rich 1 33711, 41699,

384149687

38421605 cysteine/tyrosine- 435845 1760 401313 9748 17736, 25724, rich 1 33712, 41700,

384349688

38441606 cysteine -rich 373502 1761 362601 9749 17737, 25725, hydrophobic domain 33713, 41701, 1 49689

38451607 cysteine -rich 373504 1762 362603 9750 17738, 25726, hydrophobic domain 33714, 41702, 1 49690

38461608 cysteine -rich PAK1 324803 1763 323978 9751 17739, 25727, inhibitor 33715, 41703,

384749691

38481609 cysteine -rich PAK1 382944 1764 372402 9752 17740, 25728, inhibitor 33716, 41704,

384949692

38501610 cytochrome b 321348 1765 319141 9753 17741, 25729, reductase 1 33717, 41705,

385149693

38521611 cytochrome b 375252 1766 364401 9754 17742, 25730, reductase 1 33718, 41706,

385349694

38541612 cytochrome b 409484 1767 386739 9755 17743, 25731, reductase 1 33719, 41707,

385549695

38561613 cytochrome b, 294072 1768 294072 9756 17744, 25732, ascorbate dependent 33720, 41708, 3 49696

38571614 cytochrome b, 426130 1769 398979 9757 17745, 25733, ascorbate dependent 33721, 41709, 3 49697

38581615 cytochrome b, 536915 1770 437390 9758 17746, 25734, ascorbate dependent 33722, 41710, 3 49698

38591616 cytochrome b, 537364 1771 438725 9759 17747, 25735, ascorbate dependent 33723, 41711, 3 49699

38601617 cytochrome b, 537680 1772 439702 9760 17748, 25736, ascorbate dependent 33724, 41712, 3 49700

38611618 cytochrome b, 539128 1773 443005 9761 17749, 25737, ascorbate dependent 33725, 41713, 3 49701 1619 cytochrome b, 542361 1774 443321 9762 17750, 25738, ascorbate dependent 33726, 41714, 3 49702

38621620 cytochrome b, 545361 1775 437819 9763 17751, 25739, ascorbate dependent 33727, 41715, 3 49703

38631621 cytochrome b5 367249 1776 356218 9764 17752, 25740, reductase 1 33728, 41716,

386449704

38651622 cytochrome b5 446185 1777 396382 9765 17753, 25741, reductase 1 33729, 41717,

386649705

38671623 cytochrome b-561 310611 1778 309324 9766 17754, 25742, domain containing 1 33730, 41718,

386849706

38691624 cytochrome b-561 369868 1779 358884 9767 17755, 25743, domain containing 1 33731, 41719,

387049707

38711625 cytochrome b-561 393709 1780 377312 9768 17756, 25744, domain containing 1 33732, 41720,

387249708

38731626 cytochrome b-561 420578 1781 413530 9769 17757, 25745, domain containing 1 33733, 41721,

387449709

38751627 cytochrome b-561 430195 1782 416898 9770 17758, 25746, domain containing 1 33734, 41722,

387649710

38771628 cytochrome C 328709 1783 330730 9771 17759, 25747, oxidase assembly 33735, 41723, factor 5 49711

38781629 cytochrome c 423336 1784 404078 9772 17760, 25748, oxidase subunit Via 33736, 41724, polypeptide 1 49712 pseudogene 2

38791630 cytochrome c 287490 1785 287490 9773 17761, 25749, oxidase subunit Via 33737, 41725, polypeptide 2 49713

38801631 cytochrome c 326529 1786 320672 9774 17762, 25750, oxidase subunit VIb 33738, 41726, polypeptide 2 (testis) 49714

38811632 cytochrome c 481445 1787 417656 9775 17763, 25751, oxidase subunit Vllb 33739, 41727,

388249715

38831633 cytochrome c 314133 1788 321260 9776 17764, 25752, oxidase subunit 33740, 41728, VIIIA (ubiquitous) 49716

38841634 cytochrome c 342144 1789 340568 9777 17765, 25753, oxidase subunit 33741, 41729, vine 49717

38851635 cytochrome P450 358632 1790 351455 9778 17766, 25754, family 11 subfamily 33742, 41730, A polypeptide 1 49718

38861636 cytochrome P450, 268053 1791 268053 9779 17767, 25755, family 11 , subfamily 33743, 41731, A, polypeptide 1 49719 1637 cytochrome P450, 419019 1792 405488 9780 17768, 25756, family 11 , subfamily 33744, 41732, A, polypeptide 1 49720

38871638 cytochrome P450, 435365 1793 391081 9781 17769, 25757, family 11 , subfamily 33745, 41733, A, polypeptide 1 49721

38881639 cytochrome P450, 452422 1794 391041 9782 17770, 25758, family 11 , subfamily 33746, 41734, A, polypeptide 1 49722

38891640 cytochrome P450, 541301 1795 439750 9783 17771, 25759, family 11 , subfamily 33747, 41735, A, polypeptide 1 49723

38901641 cytochrome P450, 285979 1796 285979 9784 17772, 25760, family 2, subfamily 33748, 41736, C, polypeptide 18 49724

38911642 cytochrome P450, 339022 1797 341293 9785 17773, 25761, family 2, subfamily 33749, 41737, C, polypeptide 18 49725

38921643 cytochrome P450, 308919 1798 310149 9786 17774, 25762, family 2, subfamily 33750, 41738, W, polypeptide 1 49726

38931644 cytochrome P450, 356079 1799 348380 9787 17775, 25763, family 20, subfamily 33751, 41739, A, polypeptide 1 49727

38941645 cytochrome P450, 421618 1800 397114 9788 17776, 25764, family 20, subfamily 33752, 41740, A, polypeptide 1 49728

38951646 cytochrome P450, 1146 1801 1146 9789 17777, 25765, family 26, subfamily 33753, 41741, B, polypeptide 1 49729, 56080,

389656113

38971647 cytochrome P450, 546307 1802 443304 9790 17778, 25766, family 26, subfamily 33754, 41742, B, polypeptide 1 49730

38981648 cytochrome P450, 294337 1803 294337 9791 17779, 25767, family 4, subfamily 33755, 41743, A, polypeptide 22 49731

38991649 cytochrome P450, 371890 1804 360957 9792 17780, 25768, family 4, subfamily 33756, 41744, A, polypeptide 22 49732

39001650 cytochrome P450, 371891 1805 360958 9793 17781, 25769, family 4, subfamily 33757, 41745, A, polypeptide 22 49733

39011651 cytochrome P450, 271153 1806 271153 9794 17782, 25770, family 4, subfamily 33758, 41746, B, polypeptide 1 49734

39021652 cytochrome P450, 371919 1807 360987 9795 17783, 25771, family 4, subfamily 33759, 41747, B, polypeptide 1 49735

39031653 cytochrome P450, 371923 1808 360991 9796 17784, 25772, family 4, subfamily 33760, 41748, B, polypeptide 1 49736 1654 cytochrome P450, 11989 1809 11989 9797 17785, 25773, family 4, subfamily 33761, 41749, F, polypeptide 2 49737, 56081,

390456114

39051655 cytochrome P450, 221700 1810 221700 9798 17786, 25774, family 4, subfamily 33762, 41750, F, polypeptide 2 49738

39061656 cytochrome P450, 392846 1811 376588 9799 17787, 25775, family 4, subfamily 33763, 41751, F, polypeptide 2 49739

39071657 cytochrome P450, 371901 1812 360968 9800 17788, 25776, family 4, subfamily 33764, 41752, X, polypeptide 1 49740

39081658 cytochrome P450, 538609 1813 445965 9801 17789, 25777, family 4, subfamily 33765, 41753, X, polypeptide 1 49741

39091659 cytochrome P450, 334194 1814 334246 9802 17790, 25778, family 4, subfamily 33766, 41754, Z, polypeptide 1 49742

39101660 cytoskeleton- 378026 1815 367265 9803 17791, 25779, associated protein 4 33767, 41755,

391149743

39121661 dachsous 1 299441 1816 299441 9804 17792, 25780, (Drosophila) 33768, 41756,

391349744

39141662 dachsous 1 442153 1817 390601 9805 17793, 25781, (Drosophila) 33769, 41757,

391549745

39161663 DC-STAMP domain 295542 1818 295542 9806 17794, 25782, containing 1 33770, 41758,

391749746

39181664 DC-STAMP domain 368419 1819 357404 9807 17795, 25783, containing 1 33771, 41759,

391949747

39201665 DC-STAMP domain 392480 1820 376271 9808 17796, 25784, containing 1 33772, 41760,

392149748

39221666 DC-STAMP domain 423025 1821 387369 9809 17797, 25785, containing 1 33773, 41761,

392349749

39241667 DC-STAMP domain 295536 1822 295536 9810 17798, 25786, containing 2 33774, 41762,

392549750

39261668 DC-STAMP domain 368424 1823 357409 9811 17799, 25787, containing 2 33775, 41763,

392749751

39281669 DDB1 and CUL4 375255 1824 364404 9812 17800, 25788, associated factor 17 33776, 41764,

392949752

39301670 DDB1 and CUL4 429466 1825 389290 9813 17801, 25789, associated factor 17 33777, 41765,

393149753

39321671 DDB1 and CUL4 539783 1826 442238 9814 17802, 25790, associated factor 17 33778, 41766,

393349754 1672 DDRGK domain 354488 1827 346483 9815 17803, 25791, containing 1 33779, 41767,

393449755

39351673 DDRGK domain 380201 1828 369548 9816 17804, 25792, containing 1 33780, 41768,

393649756

39371674 DDRGK domain 380213 1829 369561 9817 17805, 25793, containing 1 33781, 41769,

393849757

39391675 death associated 309950 1830 309538 9818 17806, 25794, protein-like 1 33782, 41770,

394049758

39411676 dehydrogenase El 263035 1831 263035 9819 17807, 25795, and transketolase 33783, 41771, domain containing 1 49759

39421677 dehydrogenase El 415935 1832 400625 9820 17808, 25796, and transketolase 33784, 41772, domain containing 1 49760

39431678 dehydrogenase El 437298 1833 388163 9821 17809, 25797, and transketolase 33785, 41773, domain containing 1 49761

39441679 dehydrogenase El 448829 1834 398482 9822 17810, 25798, and transketolase 33786, 41774, domain containing 1 49762

39451680 dehydrogenase/redu 288111 1835 288111 9823 17811, 25799, ctase (SDR family) 33787, 41775, member 1 49763

39461681 dehydrogenase/redu 396813 1836 380027 9824 17812, 25800, ctase (SDR family) 33788, 41776, member 1 49764

39471682 dehydrogenase/redu 346603 1837 320352 9825 17813, 25801, ctase (SDR family) 33789, 41777, member 7B 49765

39481683 dehydrogenase/redu 395511 1838 378887 9826 17814, 25802, ctase (SDR family) 33790, 41778, member 7B 49766

39491684 deleted in liver 276297 1839 276297 9827 17815, 25803, cancer 1 33791, 41779,

395049767

39511685 deleted in liver 316609 1840 321034 9828 17816, 25804, cancer 1 33792, 41780,

395249768

39531686 deleted in liver 358919 1841 351797 9829 17817, 25805, cancer 1 33793, 41781,

395449769

39551687 delta(4)-desaturase, 323699 1842 316476 9830 17818, 25806, sphingolipid 1 33794, 41782,

395649770

39571688 delta(4)-desaturase, 391877 1843 375749 9831 17819, 25807, sphingolipid 1 33795, 41783,

395849771

39591689 delta(4)-desaturase, 415210 1844 400545 9832 17820, 25808, sphingolipid 1 33796, 41784,

396049772 1690 delta-like 2 homolog 357338 1845 349893 9833 17821, 25809, (Drosophila) 33797, 41785,

396149773

39621691 delta-like 2 homolog 372485 1846 361563 9834 17822, 25810, (Drosophila) 33798, 41786,

396349774

39641692 delta-like 2 homolog 372488 1847 361566 9835 17823, 25811, (Drosophila) 33799, 41787,

396549775

39661693 delta-like 2 homolog 372496 1848 361574 9836 17824, 25812, (Drosophila) 33800, 41788,

396749776

39681694 delta-like 2 homolog 414245 1849 398906 9837 17825, 25813, (Drosophila) 33801, 41789,

396949777

39701695 delta-like 2 homolog 430324 1850 399829 9838 17826, 25814, (Drosophila) 33802, 41790,

397149778

39721696 DE N/MADD 307015 1851 305795 9839 17827, 25815, domain containing 33803, 41791, 4C 49779

39731697 DENN/MADD 361024 1852 354301 9840 17828, 25816, domain containing 33804, 41792, 4C 49780

39741698 DENN/MADD 380424 1853 369789 9841 17829, 25817, domain containing 33805, 41793, 4C 49781

39751699 DENN/MADD 380427 1854 369792 9842 17830, 25818, domain containing 33806, 41794, 4C 49782

39761700 DENN/MADD 380432 1855 369797 9843 17831, 25819, domain containing 33807, 41795, 4C 49783

39771701 DENN/MADD 380437 1856 369802 9844 17832, 25820, domain containing 33808, 41796, 4C 49784

39781702 DENN/MADD 453857 1857 394407 9845 17833, 25821, domain containing 33809, 41797, 4C 49785

39791703 DENN/MADD 540671 1858 443804 9846 17834, 25822, domain containing 33810, 41798, 4C 49786

39801704 DENN/MADD 328194 1859 328524 9847 17835, 25823, domain containing 33811, 41799, 5A 49787

39811705 DENN/MADD 527700 1860 432549 9848 17836, 25824, domain containing 33812, 41800, 5A 49788

39821706 DENN/MADD 530044 1861 435866 9849 17837, 25825, domain containing 33813, 41801, 5A 49789

39831707 DENN/MADD 306833 1862 306482 9850 17838, 25826, domain containing 33814, 41802, 5B 49790 1708 DE N/MADD 354285 1863 346238 9851 17839, 25827, domain containing 33815, 41803, 5B 49791

39841709 DENN/MADD 389082 1864 373734 9852 17840, 25828, domain containing 33816, 41804, 5B 49792

39851710 DENN/MADD 536562 1865 444889 9853 17841, 25829, domain containing 33817, 41805, 5B 49793

39861711 dephospho-CoA 310604 1866 308515 9854 17842, 25830, kinase domain 33818, 41806, containing 49794

39871712 dephospho-CoA 342350 1867 341504 9855 17843, 25831, kinase domain 33819, 41807, containing 49795

39881713 dephospho-CoA 452796 1868 413483 9856 17844, 25832, kinase domain 33820, 41808, containing 49796

39891714 Deri -like domain 259512 1869 259512 9857 17845, 25833, family, member 1 33821, 41809,

399049797

39911715 Deri -like domain 405944 1870 384289 9858 17846, 25834, family, member 1 33822, 41810,

399249798

39931716 Deri -like domain 419562 1871 389965 9859 17847, 25835, family, member 1 33823, 41811,

399449799

39951717 Deri -like domain 158771 1872 158771 9860 17848, 25836, family, member 2 33824, 41812,

399649800, 56082, 56115

39971718 Deri -like domain 318109 1873 315303 9861 17849, 25837, family, member 3 33825, 41813,

399849801

39991719 Deri -like domain 476077 1874 419399 9862 17850, 25838, family, member 3 33826, 41814,

400049802

40011720 derlin 3 406855 1875 384744 9863 17851, 25839,

400233827, 41815, 49803

40031721 diacylglycerol 343674 1876 343065 9864 17852, 25840, kinase zeta 33828, 41816,

400449804

40051722 diacylglycerol 527911 1877 436291 9865 17853, 25841, kinase zeta 33829, 41817,

400649805

40071723 diacylglycerol 261491 1878 261491 9866 17854, 25842, kinase, eta 33830, 41818,

400849806

40091724 diacylglycerol 337343 1879 337572 9867 17855, 25843, kinase, eta 33831, 41819,

401049807

40111725 diacylglycerol 379274 1880 368576 9868 17856, 25844, kinase, eta 33832, 41820,

401249808 1726 diacylglycerol 536612 1881 445114 9869 17857, 25845, kinase, eta 33833, 41821,

401349809

40141727 diacylglycerol 538674 1882 441308 9870 17858, 25846, kinase, eta 33834, 41822,

401549810

40161728 diacylglycerol 540693 1883 440823 9871 17859, 25847, kinase, eta 33835, 41823,

401749811

40181729 diacylglycerol 318201 1884 320340 9872 17860, 25848, kinase, zeta 33836, 41824,

401949812

40201730 diacylglycerol 395574 1885 378941 9873 17861, 25849, kinase, zeta 33837, 41825,

402149813

40221731 diacylglycerol 421244 1886 391021 9874 17862, 25850, kinase, zeta 33838, 41826,

402349814

40241732 diacylglycerol 454345 1887 412178 9875 17863, 25851, kinase, zeta 33839, 41827,

402549815

40261733 diacylglycerol 456247 1888 395684 9876 17864, 25852, kinase, zeta 33840, 41828,

402749816

40281734 diacylglycerol 543978 1889 438417 9877 17865, 25853, kinase, zeta 33841, 41829,

402949817

40301735 diacylglycerol O- 333026 1890 328036 9878 17866, 25854, acyltransferase 2- 33842, 41830, like 6 49818

40311736 diazepam binding 393103 1891 376815 9879 17867, 25855, inhibitor (GABA 33843, 41831, receptor modulator 49819 acyl-CoA binding

4032protein)

40331737 diazepam binding 311521 1892 311117 9880 17868, 25856, inhibitor (GABA 33844, 41832, receptor modulator, 49820 acyl-CoA binding

4034protein)

40351738 diazepam binding 355857 1893 348116 9881 17869, 25857, inhibitor (GABA 33845, 41833, receptor modulator, 49821 acyl-CoA binding

4036protein)

40371739 diazepam binding 409094 1894 386486 9882 17870, 25858, inhibitor (GABA 33846, 41834, receptor modulator, 49822 acyl-CoA binding

4038protein)

40391740 diazepam binding 535617 1895 442917 9883 17871, 25859, inhibitor (GABA 33847, 41835, receptor modulator, 49823 acyl-CoA binding

4040protein) 1741 diazepam binding 535757 1896 439012 9884 17872, 25860, inhibitor (GABA 33848, 41836, receptor modulator, 49824 acyl-CoA binding

4041protein)

40421742 diazepam binding 542275 1897 440698 9885 17873, 25861, inhibitor (GABA 33849, 41837, receptor modulator, 49825 acyl-CoA binding

4043protein)

40441743 dihydrofolate 314636 1898 319170 9886 17874, 25862, reductase-like 1 33850, 41838,

404549826

40461744 dihydrofolate 394221 1899 377768 9887 17875, 25863, reductase-like 1 33851, 41839,

404749827

40481745 dihydrofolate 461173 1900 418415 9888 17876, 25864, reductase-like 1 33852, 41840,

404949828

40501746 dihydrofolate 496983 1901 420810 9889 17877, 25865, reductase-like 1 33853, 41841,

405149829

40521747 DIRAS family, 323469 1902 325836 9890 17878, 25866, GTP-binding RAS- 33854, 41842, like 1 49830

40531748 DIRAS family, 375765 1903 364919 9891 17879, 25867, GTP-binding RAS- 33855, 41843, like 2 49831

40541749 DIRAS family, 370981 1904 360020 9892 17880, 25868, GTP-binding RAS- 33856, 41844, like 3 49832

40551750 DIRAS family, 395201 1905 378627 9893 17881, 25869, GTP-binding RAS- 33857, 41845, like 3 49833

40561751 discoidin domain 413044 1906 396609 9894 17882, 25870, receptor tyrosine 33858, 41846, kinase 1 49834

40571752 discoidin domain 413115 1907 414878 9895 17883, 25871, receptor tyrosine 33859, 41847, kinase 1 49835

40581753 discoidin domain 414077 1908 395405 9896 17884, 25872, receptor tyrosine 33860, 41848, kinase 1 49836

40591754 discoidin domain 421499 1909 402013 9897 17885, 25873, receptor tyrosine 33861, 41849, kinase 1 49837

40601755 discoidin domain 421672 1910 403454 9898 17886, 25874, receptor tyrosine 33862, 41850, kinase 1 49838

40611756 discoidin domain 422275 1911 393056 9899 17887, 25875, receptor tyrosine 33863, 41851, kinase 1 49839

40621757 discoidin domain 422628 1912 396187 9900 17888, 25876, receptor tyrosine 33864, 41852, kinase 1 49840 1758 discoidin domain 426303 1913 401304 9901 17889, 25877, receptor tyrosine 33865, 41853, kinase 1 49841

40631759 discoidin domain 429955 1914 402647 9902 17890, 25878, receptor tyrosine 33866, 41854, kinase 1 49842

40641760 discoidin domain 430486 1915 404054 9903 17891, 25879, receptor tyrosine 33867, 41855, kinase 1 49843

40651761 discoidin domain 433322 1916 398904 9904 17892, 25880, receptor tyrosine 33868, 41856, kinase 1 49844

40661762 discoidin domain 433393 1917 389085 9905 17893, 25881, receptor tyrosine 33869, 41857, kinase 1 49845

40671763 discoidin domain 434428 1918 388866 9906 17894, 25882, receptor tyrosine 33870, 41858, kinase 1 49846

40681764 discoidin domain 439604 1919 398343 9907 17895, 25883, receptor tyrosine 33871, 41859, kinase 1 49847

40691765 discoidin domain 439772 1920 402992 9908 17896, 25884, receptor tyrosine 33872, 41860, kinase 1 49848

40701766 discoidin domain 440427 1921 414928 9909 17897, 25885, receptor tyrosine 33873, 41861, kinase 1 49849

40711767 discoidin domain 444160 1922 391895 9910 17898, 25886, receptor tyrosine 33874, 41862, kinase 1 49850

40721768 discoidin domain 445749 1923 395136 9911 17899, 25887, receptor tyrosine 33875, 41863, kinase 1 49851

40731769 discoidin domain 448537 1924 412396 9912 17900, 25888, receptor tyrosine 33876, 41864, kinase 1 49852

40741770 discoidin domain 454377 1925 406865 9913 17901, 25889, receptor tyrosine 33877, 41865, kinase 1 49853

40751771 discoidin domain 458576 1926 406688 9914 17902, 25890, receptor tyrosine 33878, 41866, kinase 1 49854

40761772 discoidin domain 549169 1927 447523 9915 17903, 25891, receptor tyrosine 33879, 41867, kinase 1 49855

40771773 discoidin, CUB and 296955 1928 296955 9916 17904, 25892, LCCL domain 33880, 41868, containing 1 49856

40781774 discoidin, CUB and 338728 1929 342422 9917 17905, 25893, LCCL domain 33881, 41869, containing 1 49857

40791775 discoidin, CUB and 368503 1930 357489 9918 17906, 25894, LCCL domain 33882, 41870, containing 1 49858 1776 discoidin, CUB and 392504 1931 376292 9919 17907, 25895, LCCL domain 33883, 41871, containing 1 49859

40801777 discoidin, CUB and 326840 1932 321573 9920 17908, 25896, LCCL domain 33884, 41872, containing 2 49860

40811778 discoidin, CUB and 326857 1933 321646 9921 17909, 25897, LCCL domain 33885, 41873, containing 2 49861

40821779 discoidin, CUB and 404023 1934 385656 9922 17910, 25898, LCCL domain 33886, 41874, containing 2 49862

40831780 discs large 400145 1935 383010 9923 17911, 25899, (Drosophila) 33887, 41875, homolog-associated 49863 protein 1

40841781 discs large 400150 1936 383014 9924 17912, 25900, (Drosophila) 33888, 41876, homolog-associated 49864 protein 1

40851782 discs large 400155 1937 383019 9925 17913, 25901, (Drosophila) 33889, 41877, homolog-associated 49865 protein 1

40861783 discs large 581527 1938 463864 9926 17914, 25902, (Drosophila) 33890, 41878, homolog-associated 49866 protein 1

40871784 discs, large 315677 1939 316377 9927 17915, 25903, (Drosophila) 33891, 41879, homolog-associated 49867 protein 1

40881785 discs, large 400147 1940 383011 9928 17916, 25904, (Drosophila) 33892, 41880, homolog-associated 49868 protein 1

40891786 discs, large 515196 1941 445973 9929 17917, 25905, (Drosophila) 33893, 41881, homolog-associated 49869 protein 1

40901787 discs, large 534970 1942 437817 9930 17918, 25906, (Drosophila) 33894, 41882, homolog-associated 49870 protein 1

40911788 discs, large 539435 1943 446312 9931 17919, 25907, (Drosophila) 33895, 41883, homolog-associated 49871 protein 1

40921789 discs, large 235180 1944 235180 9932 17920, 25908, (Drosophila) 33896, 41884, homolog-associated 49872 protein 3

40931790 discs, large 373347 1945 362444 9933 17921, 25909,

4094(Drosophila) 33897, 41885, homolog-associated 49873 protein 3

40951791 discs, large 542913 1946 445209 9934 17922, 25910, (Drosophila) 33898, 41886, homolog-associated 49874 protein 3

40961792 dishevelled, dsh 5340 1947 5340 9935 17923, 25911, homolog 2 33899, 41887, (Drosophila) 49875, 56083,

409756116

40981793 dispatched homolog 284476 1948 284476 9936 17924, 25912, 1 (Drosophila) 33900, 41888,

409949876

41001794 dispatched homolog 360254 1949 355848 9937 17925, 25913, 1 (Drosophila) 33901, 41889,

410149877

41021795 dispatched homolog 267889 1950 267889 9938 17926, 25914, 2 (Drosophila) 33902, 41890,

410349878

41041796 DIX domain 315253 1951 314068 9939 17927, 25915, containing 1 33903, 41891,

410549879

41061797 DIX domain 440460 1952 394352 9940 17928, 25916, containing 1 33904, 41892,

410749880

41081798 DIX domain 531396 1953 432959 9941 17929, 25917, containing 1 33905, 41893,

410949881

41101799 DnaJ (Hsp40) 442697 1954 404381 9942 17930, 25918, homolog, subfamily 33906, 41894, B, member 14 49882

41111800 DnaJ (Hsp40) 370763 1955 359799 9943 17931, 25919, homolog, subfamily 33907, 41895, B, member 4 49883

41121801 DnaJ (Hsp40) 426517 1956 399494 9944 17932, 25920, homolog, subfamily 33908, 41896, B, member 4 49884

41131802 DnaJ (Hsp40) 313525 1957 320650 9945 17933, 25921, homolog, subfamily 33909, 41897, C , member 25 49885

41141803 DnaJ (Hsp40) 556107 1958 451984 9946 17934, 25922, homolog, subfamily 33910, 41898, C , member 25 49886

41151804 DnaJ (Hsp40) 376946 1959 366145 9947 17935, 25923, homolog, subfamily 33911, 41899, C, member 1 49887

41161805 DnaJ (Hsp40) 376980 1960 366179 9948 17936, 25924, homolog, subfamily 33912, 41900, C, member 1 49888

41171806 DnaJ (Hsp40) 447548 1961 398185 9949 17937, 25925, homolog, subfamily 33913, 41901, C, member 1 49889

41181807 DnaJ (Hsp40) 294401 1962 294401 9950 17938, 25926, homolog, subfamily 33914, 41902, C, member 11 49890

41191808 DnaJ (Hsp40) 349363 1963 326304 9951 17939, 25927, homolog, subfamily 33915, 41903, C, member 11 49891

41201809 DnaJ (Hsp40) 377573 1964 366796 9952 17940, 25928, homolog, subfamily 33916, 41904, C, member 11 49892

41211810 DnaJ (Hsp40) 377577 1965 366800 9953 17941, 25929, homolog, subfamily 33917, 41905, C, member 11 49893

41221811 DnaJ (Hsp40) 426784 1966 410194 9954 17942, 25930, homolog, subfamily 33918, 41906, C, member 11 49894

41231812 DnaJ (Hsp40) 451196 1967 415871 9955 17943, 25931, homolog, subfamily 33919, 41907, C, member 11 49895

41241813 DnaJ (Hsp40) 542246 1968 444020 9956 17944, 25932, homolog, subfamily 33920, 41908, C, member 11 49896

41251814 DnaJ (Hsp40) 317269 1969 316240 9957 17945, 25933, homolog, subfamily 33921, 41909, C, member 14 49897

41261815 DnaJ (Hsp40) 317287 1970 317500 9958 17946, 25934, homolog, subfamily 33922, 41910, C, member 14 49898

41271816 DnaJ (Hsp40) 357606 1971 350223 9959 17947, 25935, homolog, subfamily 33923, 41911, C, member 14 49899

41281817 DnaJ (Hsp40) 537962 1972 443945 9960 17948, 25936, homolog, subfamily 33924, 41912, C, member 14 49900

41291818 DnaJ (Hsp40) 540330 1973 441495 9961 17949, 25937, homolog, subfamily 33925, 41913, C, member 14 49901

41301819 DnaJ (Hsp40) 546957 1974 448876 9962 17950, 25938, homolog, subfamily 33926, 41914, C, member 14 49902

41311820 DnaJ (Hsp40) 547445 1975 450196 9963 17951, 25939, homolog, subfamily 33927, 41915, C, member 14 49903

41321821 DnaJ (Hsp40) 379221 1976 368523 9964 17952, 25940, homolog, subfamily 33928, 41916, C, member 15 49904

41331822 DnaJ (Hsp40) 375838 1977 364998 9965 17953, 25941, homolog, subfamily 33929, 41917, C, member 16 49905

41341823 DnaJ (Hsp40) 375847 1978 365007 9966 17954, 25942, homolog, subfamily 33930, 41918, C, member 16 49906

41351824 DnaJ (Hsp40) 375849 1979 365009 9967 17955, 25943, homolog, subfamily 33931, 41919, C, member 16 49907 1825 DnaJ (Hsp40) 546230 1980 440636 9968 17956, 25944, homolog, subfamily 33932, 41920, C, member 16 49908

41361826 DnaJ (Hsp40) 302060 1981 302843 9969 17957, 25945, homolog, subfamily 33933, 41921, C, member 18 49909

41371827 DnaJ (Hsp40) 512473 1982 426819 9970 17958, 25946, homolog, subfamily 33934, 41922, C, member 18 49910

41381828 DnaJ (Hsp40) 515277 1983 425523 9971 17959, 25947, homolog, subfamily 33935, 41923, C, member 18 49911

41391829 DnaJ (Hsp40) 515581 1984 424572 9972 17960, 25948, homolog, subfamily 33936, 41924, C, member 18 49912

41401830 DnaJ (Hsp40) 395069 1985 378508 9973 17961, 25949, homolog, subfamily 33937, 41925, C, member 22 49913

41411831 DnaJ (Hsp40) 549441 1986 446830 9974 17962, 25950, homolog, subfamily 33938, 41926, C, member 22 49914

41421832 DnaJ (Hsp40) 395176 1987 378605 9975 17963, 25951, homolog, subfamily 33939, 41927, C, member 30 49915

41431833 DnaJ (Hsp40) 539255 1988 443739 9976 17964, 25952, homolog, subfamily 33940, 41928, C, member 30 49916

41441834 DnaJ (Hsp40) 321685 1989 396896 9977 17965, 25953, homolog, subfamily 33941, 41929, C, member 4 49917

41451835 DNL-type zinc 371738 1990 360803 9978 17966, 25954, finger 33942, 41930,

414649918

41471836 dolichol kinase 372586 1991 361667 9979 17967, 25955,

414833943, 41931, 49919

41491837 dolichol kinase 515348 1992 445830 9980 17968, 25956,

415033944, 41932, 49920

41511838 dolichyl 372546 1993 361625 9981 17969, 25957, pyrophosphate 33945, 41933, phosphatase 1 49921

41521839 dolichyl 406974 1994 384043 9982 17970, 25958, pyrophosphate 33946, 41934, phosphatase 1 49922

41531840 dolichyl 540102 1995 440218 9983 17971, 25959, pyrophosphate 33947, 41935, phosphatase 1 49923

41541841 dolichyl-phosphate 354202 1996 346142 9984 17972, 25960, (UDP-N- 33948, 41936, acetylglucosamine) 49924 N- acetylglucosamineph

4155osphotransferase 1

4156(GlcNAc-l-P transferase)

41571842 dolichyl-phosphate 409993 1997 386597 9985 17973, 25961, (UDP-N- 33949, 41937, acetylglucosamine) 49925 N- acetylglucosamineph

4158osphotransferase 1

4159(GlcNAc-l-P

4160transferase)

41611843 dolichyl-phosphate 432443 1998 404036 9986 17974, 25962, (UDP-N- 33950, 41938, acetylglucosamine) 49926 N- acetylglucosamineph

4162osphotransferase 1

4163(GlcNAc-l-P

4164transferase)

41651844 dolichyl-phosphate 314392 1999 322181 9987 17975, 25963, mannosyltransferase 33951, 41939, polypeptide 2, 49927 regulatory subunit

41661845 dolichyl-phosphate 373110 2000 362202 9988 17976, 25964, mannosyltransferase 33952, 41940, polypeptide 2, 49928 regulatory subunit

41671846 dopey family 237163 2001 237163 9989 17977, 25965, member 1 33953, 41941,

416849929

41691847 dopey family 349129 2002 195654 9990 17978, 25966, member 1 33954, 41942,

417049930

41711848 dopey family 369739 2003 358754 9991 17979, 25967, member 1 33955, 41943,

417249931

41731849 dopey family 536812 2004 439675 9992 17980, 25968, member 1 33956, 41944,

417449932

41751850 dual specificity 323825 2005 322015 9993 17981, 25969, phosphatase 10 33957, 41945,

417649933

41771851 dual specificity 366899 2006 355866 9994 17982, 25970, phosphatase 10 33958, 41946,

417849934

41791852 dual specificity 418487 2007 390238 9995 17983, 25971, phosphatase 10 33959, 41947,

418049935

41811853 dual specificity 544095 2008 441302 9996 17984, 25972, phosphatase 10 33960, 41948,

418249936 1854 dual specificity 278979 2009 278979 9997 17985, 25973, phosphatase 15 33961, 41949,

418349937

41841855 dual specificity 339738 2010 341658 9998 17986, 25974, phosphatase 15 33962, 41950,

418549938

41861856 dual specificity 375953 2011 365120 9999 17987, 25975, phosphatase 15 33963, 41951,

418749939

41881857 dual specificity 375966 2012 365133 10000 17988, 25976, phosphatase 15 33964, 41952,

418949940

41901858 dual specificity 398083 2013 381157 10001 17989, 25977, phosphatase 15 33965, 41953,

419149941

41921859 dual specificity 398084 2014 381158 10002 17990, 25978, phosphatase 15 33966, 41954,

419349942

41941860 dual specificity 447647 2015 397486 10003 17991, 25979, phosphatase 15 33967, 41955,

419549943

41961861 dual specificity 486996 2016 419818 10004 17992, 25980, phosphatase 15 33968, 41956,

419749944

41981862 dynein, axonemal, 298292 2017 298292 10005 17993, 25981, assembly factor 2 33969, 41957,

419949945

42001863 dynein, axonemal, 406043 2018 384862 10006 17994, 25982, assembly factor 2 33970, 41958,

420149946

42021864 dynein, axonemal, 216068 2019 216068 10007 17995, 25983, light chain 4 33971, 41959,

420349947

42041865 dynein, cytoplasmic 273130 2020 273130 10008 17996, 25984, 1 , light intermediate 33972, 41960, chain 1 49948

42051866 dynein, light chain, 378578 2021 367841 10009 17997, 25985, Tctex-type 3 33973, 41961,

420649949

42071867 dynein, light chain, 378581 2022 367844 10010 17998, 25986, Tctex-type 3 33974, 41962,

420849950

42091868 dynein, light chain, 432389 2023 402695 10011 17999, 25987, Tctex-type 3 33975, 41963,

421049951

42111869 dystrotelin 452335 2024 396593 10012 18000, 25988,

421233976, 41964, 49952

42131870 E2F-associated 250454 2025 250454 10013 18001, 25989, phosphoprotein 33977, 41965,

421449953

42151871 early endosome 322349 2026 317955 10014 18002, 25990, antigen 1 33978, 41966,

421649954 1872 early endosome 540777 2027 441243 10015 18003, 25991, antigen 1 33979, 41967,

421749955

42181873 ectonucleoside 356206 2028 348536 10016 18004, 25992, triphosphate 33980, 41968, diphosphohydrolase 49956 4

42191874 ectonucleoside 358689 2029 351520 10017 18005, 25993, triphosphate 33981, 41969, diphosphohydrolase 49957 4

42201875 ectonucleoside 417069 2030 408573 10018 18006, 25994, triphosphate 33982, 41970, diphosphohydrolase 49958 4

42211876 ectonucleoside 370489 2031 359520 10019 18007, 25995, triphosphate 33983, 41971, diphosphohydrolase 49959 7

42221877 ectonucleoside 344119 2032 344089 10020 18008, 25996, triphosphate 33984, 41972, diphosphohydrolase 49960 8

42231878 ectonucleoside 371506 2033 360561 10021 18009, 25997, triphosphate 33985, 41973, diphosphohydrolase 49961 8

42241879 ectonucleoside 472938 2034 420531 10022 18010, 25998, triphosphate 33986, 41974, diphosphohydrolase 49962 8

42251880 ectonucleotide 321037 2035 318066 10023 18011, 25999, pyrophosphatase/ph 33987, 41975, osphodiesterase 4 49963 (putative)

42261881 ectonucleotide 371401 2036 360454 10024 18012, 26000, pyrophosphatase/ph 33988, 41976, osphodiesterase 4 49964 (putative)

42271882 ectonucleotide 328313 2037 332656 10025 18013, 26001, pyrophosphatase/ph 33989, 41977, osphodiesterase 7 49965

42281883 EF-hand domain 382374 2038 371811 10026 18014, 26002, family, member Al 33990, 41978,

422949966

42301884 EF-hand domain 318063 2039 321455 10027 18015, 26003, family, member A2 33991, 41979,

423149967

42321885 EF-hand domain 375975 2040 365142 10028 18016, 26004, family, member D2 33992, 41980,

423349968

42341886 EF-hand domain 375980 2041 365147 10029 18017, 26005, family, member D2 33993, 41981,

423549969 1887 EF-hand domain 445566 2042 395153 10030 18018, 26006, family, member D2 33994, 41982,

423649970

42371888 EGF, latrophilin and 370742 2043 359778 10031 18019, 26007, seven 33995, 41983, transmembrane 49971 domain containing 1

42381889 EGF, latrophilin and 401034 2044 383813 10032 18020, 26008, seven 33996, 41984, transmembrane 49972 domain containing 1

42391890 egf-like module 596991 2045 472280 10033 18021, 26009, containing mucin- 33997, 41985, like hormone 49973 receptor-like 2

42401891 egf-like module 315576 2046 319883 10034 18022, 26010, containing, mucin- 33998, 41986, like, hormone 49974 receptor-like 2

42411892 egf-like module 346057 2047 263380 10035 18023, 26011, containing, mucin- 33999, 41987, like, hormone 49975 receptor-like 2

42421893 egf-like module 353005 2048 319838 10036 18024, 26012, containing, mucin- 34000, 41988, like, hormone 49976 receptor-like 2

42431894 egf-like module 353876 2049 319454 10037 18025, 26013, containing, mucin- 34001, 41989, like, hormone 49977 receptor-like 2

42441895 egf-like module 360222 2050 353356 10038 18026, 26014, containing, mucin- 34002, 41990, like, hormone 49978 receptor-like 2

42451896 egf-like module 392962 2051 376689 10039 18027, 26015, containing, mucin- 34003, 41991, like, hormone 49979 receptor-like 2

42461897 egf-like module 392964 2052 376691 10040 18028, 26016, containing, mucin- 34004, 41992, like, hormone 49980 receptor-like 2

42471898 egf-like module 392965 2053 376692 10041 18029, 26017, containing, mucin- 34005, 41993, like, hormone 49981 receptor-like 2

42481899 egf-like module 392967 2054 376694 10042 18030, 26018, containing, mucin- 34006, 41994, like, hormone 49982 receptor-like 2

42491900 ELKS/RAB6- 288221 2055 288221 10043 18031, 26019, interacting/ CAST 34007, 41995, family member 2 49983 1901 ELKS/RAB6- 460849 2056 417445 10044 18032, 26020, interacting/ CAST 34008, 41996, family member 2 49984

42501902 ELKS/RAB6- 492584 2057 417280 10045 18033, 26021, interacting/ CAST 34009, 41997, family member 2 49985

42511903 embigin 303221 2058 302289 10046 18034, 26022,

425234010, 41998, 49986

42531904 emopamil binding 242827 2059 242827 10047 18035, 26023, protein-like 34011, 41999,

425449987

42551905 emopamil binding 378274 2060 367523 10048 18036, 26024, protein-like 34012, 42000,

425649988

42571906 Enah/Vasp-like 392920 2061 376652 10049 18037, 26025,

425834013, 42001, 49989

42591907 Enah/Vasp-like 402714 2062 384720 10050 18038, 26026,

426034014, 42002, 49990

42611908 Enah/Vasp-like 539470 2063 440743 10051 18039, 26027,

426234015, 42003, 49991

42631909 Enah/Vasp-like 544450 2064 437904 10052 18040, 26028,

426434016, 42004, 49992

42651910 Enah/Vasp-like 554695 2065 451821 10053 18041, 26029,

426634017, 42005, 49993

42671911 endogenous 472091 2066 420174 10054 18042, 26030, retrovirus group 34018, 42006, FRD, member 1 49994

42681912 endogenous 542862 2067 444461 10055 18043, 26031, retrovirus group 34019, 42007, FRD, member 1 49995

42691913 endogenous 493463 2068 419945 10056 18044, 26032, retrovirus group W, 34020, 42008, member 1 49996

42701914 endonuclease/exonu 242108 2069 242108 10057 18045, 26033, clease/phosphatase 34021, 42009, family domain 49997 containing 1

42711915 endonuclease/exonu 534978 2070 442692 10058 18046, 26034, clease/phosphatase 34022, 42010, family domain 49998 containing 1

42721916 endoplasmic 266397 2071 266397 10059 18047, 26035, reticulum protein 27 34023, 42011,

427349999

42741917 endoplasmic 433197 2072 401445 10060 18048, 26036, reticulum to nucleus 34024, 42012, signaling 1 50000 1918 endoplasmic 393784 2073 377374 10061 18049, 26037, reticulum-golgi 34025, 42013, intermediate 50001 compartment

(ERGIC) 1

42761919 endothelial cell- 510908 2074 421010 10062 18050, 26038, specific chemotaxis 34026, 42014, regulator 50002

42771920 endothelial cell- 515823 2075 421364 10063 18051, 26039, specific chemotaxis 34027, 42015, regulator 50003

42781921 endothelin 324557 2076 314295 10064 18052, 26040, converting enzyme 2 34028, 42016,

427950004

42801922 endothelin 359140 2077 352052 10065 18053, 26041, converting enzyme 2 34029, 42017,

428150005

42821923 endothelin 402825 2078 384223 10066 18054, 26042, converting enzyme 2 34030, 42018,

428350006

42841924 endothelin 404464 2079 385846 10067 18055, 26043, converting enzyme 2 34031, 42019,

428550007

42861925 endothelin 357474 2080 350066 10068 18056, 26044, converting enzyme 2 34032, 42020,

428750008

42881926 enoyl CoA hydratase 358358 2081 351125 10069 18057, 26045, domain containing 2 34033, 42021,

428950009

42901927 enoyl CoA hydratase 371522 2082 360577 10070 18058, 26046, domain containing 2 34034, 42022,

429150010

42921928 enoyl CoA hydratase 536120 2083 439264 10071 18059, 26047, domain containing 2 34035, 42023,

429350011

42941929 enoyl CoA hydratase 541281 2084 445358 10072 18060, 26048, domain containing 2 34036, 42024,

429550012

42961930 enoyl CoA hydratase 467988 2085 441962 10073 18061, 26049, domain containing 2 34037, 42025,

429750013

42981931 enoyl CoA hydratase 379215 2086 368517 10074 18062, 26050, domain containing 3 34038, 42026,

429950014

43001932 enoyl CoA hydratase 420401 2087 405584 10075 18063, 26051, domain containing 3 34039, 42027,

430150015

43021933 enoyl CoA hydratase 422887 2088 398429 10076 18064, 26052, domain containing 3 34040, 42028,

430350016

43041934 enoyl-CoA delta 301729 2089 301729 10077 18065, 26053, isomerase 1 34041, 42029,

430550017 1935 enoyl-CoA delta 562238 2090 456319 10078 18066, 26054, isomerase 1 34042, 42030,

430650018

43071936 enoyl-CoA delta 361538 2091 354737 10079 18067, 26055, isomerase 2 34043, 42031,

430850019

43091937 enoyl-CoA delta 380118 2092 369461 10080 18068, 26056, isomerase 2 34044, 42032,

431050020

43111938 enoyl-CoA delta 380125 2093 369468 10081 18069, 26057, isomerase 2 34045, 42033,

431250021

43131939 enoyl-CoA delta 413766 2094 406969 10082 18070, 26058, isomerase 2 34046, 42034,

431450022

43151940 enoyl-CoA delta 465828 2095 420309 10083 18071, 26059, isomerase 2 34047, 42035,

431650023

43171941 EPH receptor A4 281821 2096 281821 10084 18072, 26060,

431834048, 42036, 50024

43191942 EPH receptor A4 392071 2097 375923 10085 18073, 26061,

432034049, 42037, 50025

43211943 EPH receptor A4 409854 2098 386276 10086 18074, 26062,

432234050, 42038, 50026

43231944 EPH receptor A4 409938 2099 386829 10087 18075, 26063,

432434051, 42039, 50027

43251945 EPH receptor A4 434266 2100 404089 10088 18076, 26064,

432634052, 42040, 50028

43271946 EPH receptor A4 541600 2101 444085 10089 18077, 26065,

432834053, 42041, 50029

43291947 EPH receptor A7 369297 2102 358303 10090 18078, 26066,

433034054, 42042, 50030

43311948 EPH receptor A7 369303 2103 358309 10091 18079, 26067,

433234055, 42043, 50031

43331949 ephrin-A5 333274 2104 328777 10092 18080, 26068,

433434056, 42044, 50032

43351950 epidermal growth 248070 2105 248070 10093 18081, 26069, factor receptor 34057, 42045, pathway substrate 50033 15-like 1

43361951 epidermal growth 455140 2106 393313 10094 18082, 26070, factor receptor 34058, 42046, pathway substrate 50034 15-like 1 1952 epidermal growth 535753 2107 440103 10095 18083, 26071, factor receptor 34059, 42047, pathway substrate 50035 15-like 1

43371953 epidermal growth 597937 2108 472267 10096 18084, 26072, factor receptor 34060, 42048, pathway substrate 50036 15-like 1

43381954 EPM2A (laforin) 322716 2109 406027 10097 18085, 26073, interacting protein 1 34061, 42049,

433950037

43401955 epoxide hydrolase 4 370383 2110 359410 10098 18086, 26074,

434134062, 42050, 50038

43421956 ER degradation 256497 2111 256497 10099 18087, 26075, enhancer, 34063, 42051, mannosidase alpha50039 like 1

43431957 ER degradation 419550 2112 402075 10100 18088, 26076, enhancer, 34064, 42052, mannosidase alpha50040 like 1

43441958 ER degradation 445686 2113 394099 10101 18089, 26077, enhancer, 34065, 42053, mannosidase alpha50041 like 1

43451959 ER degradation 318130 2114 318147 10102 18090, 26078, enhancer, 34066, 42054, mannosidase alpha50042 like 3

43461960 ER degradation 367512 2115 356482 10103 18091, 26079, enhancer, 34067, 42055, mannosidase alpha50043 like 3

43471961 Era G-protein-like 1 254928 2116 254928 10104 18092, 26080, (E. coli) 34068, 42056,

434850044

43491962 Era G-protein-like 1 412138 2117 396125 10105 18093, 26081, (E. coli) 34069, 42057,

435050045

43511963 ERGIC and golgi 3 279052 2118 279052 10106 18094, 26082,

435234070, 42058, 50046

43531964 ERGIC and golgi 3 348547 2119 341358 10107 18095, 26083,

435434071, 42059, 50047

43551965 ERGIC and golgi 3 355563 2120 347762 10108 18096, 26084,

435634072, 42060, 50048

43571966 ERGIC and golgi 3 357394 2121 349970 10109 18097, 26085,

435834073, 42061, 50049

43591967 ERGIC and golgi 3 447986 2122 392341 10110 18098, 26086,

436034074, 42062, 50050 1968 ER01-like (S. 395686 2123 379042 10111 18099, 26087, cerevisiae) 34075, 42063,

436150051

43621969 EROl-like beta (S. 264181 2124 264181 10112 18100, 26088, cerevisiae) 34076, 42064,

436350052

43641970 EROl-like beta (S. 327333 2125 377574 10113 18101, 26089, cerevisiae) 34077, 42065,

436550053

43661971 EROl-like beta (S. 354619 2126 346635 10114 18102, 26090, cerevisiae) 34078, 42066,

436750054

43681972 EROl-like beta (S. 366589 2127 355548 10115 18103, 26091, cerevisiae) 34079, 42067,

436950055

43701973 ES cell expressed 338270 2128 339136 10116 18104, 26092, Ras 34080, 42068,

437150056

43721974 exocyst complex 360394 2129 353564 10117 18105, 26093, component 8 34081, 42069,

437350057

43741975 exocyst complex 366645 2130 355605 10118 18106, 26094, component 8 34082, 42070,

437550058

43761976 extended 267113 2131 267113 10119 18107, 26095, synaptotagmin-like 34083, 42071, protein 1 50059

43771977 extended 394048 2132 377612 10120 18108, 26096, synaptotagmin-like 34084, 42072, protein 1 50060

43781978 extended 402331 2133 386045 10121 18109, 26097, synaptotagmin-like 34085, 42073, protein 1 50061

43791979 extended 541590 2134 445952 10122 18110, 26098, synaptotagmin-like 34086, 42074, protein 1 50062

43801980 extended 389567 2135 374218 10123 18111, 26099, synaptotagmin-like 34087, 42075, protein 3 50063

43811981 extracellular 349653 2136 300147 10124 18112, 26100, leucine -rich repeat 34088, 42076, and fibronectin type 50064 III domain

4382containing 2

43831982 extracellular 402918 2137 385277 10125 18113, 26101, leucine -rich repeat 34089, 42077, and fibronectin type 50065 III domain

4384containing 2

43851983 FAM 18B2-CDRT4 557349 2138 450826 10126 18114, 26102, readthrough 34090, 42078,

438650066

43871984 family with 216214 2139 216214 10127 18115, 26103, sequence similarity 34091, 42079, 118, member A 50067 1985 family with 405548 2140 384836 10128 18116, 26104, sequence similarity 34092, 42080, 118, member A 50068

43881986 family with 427777 2141 395194 10129 18117, 26105, sequence similarity 34093, 42081, 118, member A 50069

43891987 family with 441876 2142 395892 10130 18118, 26106, sequence similarity 34094, 42082, 118, member A 50070

43901988 family with 317040 2143 324810 10131 18119, 26107, sequence similarity 34095, 42083, 125, member A 50071

43911989 family with 392702 2144 376466 10132 18120, 26108, sequence similarity 34096, 42084, 125, member A 50072

43921990 family with 543795 2145 444653 10133 18121, 26109, sequence similarity 34097, 42085, 125, member A 50073

43931991 family with 361171 2146 354772 10134 18122, 26110, sequence similarity 34098, 42086, 125, member B 50074

43941992 family with 402437 2147 384751 10135 18123, 26111, sequence similarity 34099, 42087, 125, member B 50075

43951993 family with 436593 2148 401379 10136 18124, 26112, sequence similarity 34100, 42088, 125, member B 50076

43961994 family with 535766 2149 442846 10137 18125, 26113, sequence similarity 34101, 42089, 125, member B 50077

43971995 family with 545391 2150 441988 10138 18126, 26114, sequence similarity 34102, 42090, 125, member B 50078

43981996 family with 367511 2151 356481 10139 18127, 26115, sequence similarity 34103, 42091, 129, member A 50079

43991997 family with 417056 2152 414039 10140 18128, 26116, sequence similarity 34104, 42092, 129, member A 50080

44001998 family with 430297 2153 395249 10141 18129, 26117, sequence similarity 34105, 42093, 134, member A 50081

44011999 family with 443518 2154 398910 10142 18130, 26118, sequence similarity 34106, 42094, 134, member A 50082

44022000 family with 309428 2155 309432 10143 18131, 26119, sequence similarity 34107, 42095, 134, member C 50083

44032001 family with 543197 2156 446235 10144 18132, 26120, sequence similarity 34108, 42096, 134, member C 50084

44042002 family with 361499 2157 354913 10145 18133, 26121, sequence similarity 34109, 42097, 135, member A 50085 2003 family with 370479 2158 359510 10146 18134, 26122, sequence similarity 34110, 42098, 135, member A 50086

44052004 family with 418814 2159 410768 10147 18135, 26123, sequence similarity 34111, 42099, 135, member A 50087

44062005 family with 457062 2160 409201 10148 18136, 26124, sequence similarity 34112, 42100, 135, member A 50088

44072006 family with 507085 2161 425101 10149 18137, 26125, sequence similarity 34113, 42101, 135, member A 50089

44082007 family with 515280 2162 421505 10150 18138, 26126, sequence similarity 34114, 42102, 135, member A 50090

44092008 family with 515323 2163 422406 10151 18139, 26127, sequence similarity 34115, 42103, 135, member A 50091

44102009 family with 160713 2164 160713 10152 18140, 26128, sequence similarity 34116, 42104, 135, member B 50092, 56084,

441156117

44122010 family with 395297 2165 378710 10153 18141, 26129, sequence similarity 34117, 42105, 135, member B 50093

44132011 family with 520380 2166 428017 10154 18142, 26130, sequence similarity 34118, 42106, 135, member B 50094

44142012 family with 294370 2167 294370 10155 18143, 26131, sequence similarity 34119, 42107, 151, member A 50095

44152013 family with 302250 2168 306888 10156 18144, 26132, sequence similarity 34120, 42108, 151, member A 50096

44162014 family with 371304 2169 360353 10157 18145, 26133, sequence similarity 34121, 42109, 151, member A 50097

44172015 family with 375915 2170 365080 10158 18146, 26134, sequence similarity 34122, 42110, 155, member A 50098

44182016 family with 252338 2171 252338 10159 18147, 26135, sequence similarity 34123, 42111, 155, member B 50099

44192017 family with 316310 2172 318182 10160 18148, 26136, sequence similarity 34124, 42112, 156, member A 50100

44202018 family with 330025 2173 328443 10161 18149, 26137, sequence similarity 34125, 42113, 156, member A 50101

44212019 family with 356333 2174 348687 10162 18150, 26138, sequence similarity 34126, 42114, 156, member A 50102

44222020 family with 375473 2175 364622 10163 18151, 26139, sequence similarity 34127, 42115, 156, member A 50103 2021 family with 411516 2176 427693 10164 18152, 26140, sequence similarity 34128, 42116, 156, member A 50104

44232022 family with 414076 2177 405771 10165 18153, 26141, sequence similarity 34129, 42117, 156, member A 50105

44242023 family with 416923 2178 412234 10166 18154, 26142, sequence similarity 34130, 42118, 156, member A 50106

44252024 family with 438003 2179 398565 10167 18155, 26143, sequence similarity 34131, 42119, 156, member A 50107

44262025 family with 447562 2180 414701 10168 18156, 26144, sequence similarity 34132, 42120, 156, member A 50108

44272026 family with 451084 2181 412585 10169 18157, 26145, sequence similarity 34133, 42121, 156, member A 50109

44282027 family with 503775 2182 421939 10170 18158, 26146, sequence similarity 34134, 42122, 156, member A 50110

44292028 family with 505988 2183 424378 10171 18159, 26147, sequence similarity 34135, 42123, 156, member A 50111

44302029 family with 510517 2184 425216 10172 18160, 26148, sequence similarity 34136, 42124, 156, member A 50112

44312030 family with 512364 2185 426868 10173 18161, 26149, sequence similarity 34137, 42125, 156, member A 50113

44322031 family with 412319 2186 422884 10174 18162, 26150, sequence similarity 34138, 42126, 156, member B 50114

44332032 family with 416841 2187 424864 10175 18163, 26151, sequence similarity 34139, 42127, 156, member B 50115

44342033 family with 430150 2188 425174 10176 18164, 26152, sequence similarity 34140, 42128, 156, member B 50116

44352034 family with 452021 2189 426113 10177 18165, 26153, sequence similarity 34141, 42129, 156, member B 50117

44362035 family with 452154 2190 420954 10178 18166, 26154, sequence similarity 34142, 42130, 156, member B 50118

44372036 family with 509613 2191 422411 10179 18167, 26155, sequence similarity 34143, 42131, 156, member B 50119

44382037 family with 517870 2192 429726 10180 18168, 26156, sequence similarity 34144, 42132, 159, member A 50120

44392038 family with 440333 2193 405770 10181 18169, 26157, sequence similarity 34145, 42133, 162, member A 50121 2039 family with 477892 2194 419088 10182 18170, 26158, sequence similarity 34146, 42134, 162, member A 50122

44402040 family with 368557 2195 357545 10183 18171, 26159, sequence similarity 34147, 42135, 162, member B 50123

44412041 family with 341785 2196 354891 10184 18172, 26160, sequence similarity 34148, 42136, 163, member A 50124

44422042 family with 356873 2197 349336 10185 18173, 26161, sequence similarity 34149, 42137, 163, member B 50125

44432043 family with 496132 2198 419867 10186 18174, 26162, sequence similarity 34150, 42138, 163, member B 50126

44442044 family with 369586 2199 358599 10187 18175, 26163, sequence similarity 34151, 42139, 165, member A 50127

44452045 family with 399292 2200 382231 10188 18176, 26164, sequence similarity 34152, 42140, 165, member B 50128

44462046 family with 399295 2201 382234 10189 18177, 26165, sequence similarity 34153, 42141, 165, member B 50129

44472047 family with 378114 2202 367354 10190 18178, 26166, sequence similarity 34154, 42142, 171, member Al 50130

44482048 family with 378116 2203 367356 10191 18179, 26167, sequence similarity 34155, 42143, 171, member Al 50131

44492049 family with 396781 2204 380001 10192 18180, 26168, sequence similarity 34156, 42144, 171, member Al 50132

44502050 family with 455654 2205 407796 10193 18181, 26169, sequence similarity 34157, 42145, 171, member Al 50133

44512051 family with 293443 2206 293443 10194 18182, 26170, sequence similarity 34158, 42146, 171, member A2 50134

44522052 family with 272804 2207 272804 10195 18183, 26171, sequence similarity 34159, 42147, 171, member B 50135

44532053 family with 304698 2208 304108 10196 18184, 26172, sequence similarity 34160, 42148, 171, member B 50136

44542054 family with 569529 2209 454380 10197 18185, 26173, sequence similarity 34161, 42149, 173 member A 50137

44552055 family with 219535 2210 219535 10198 18186, 26174, sequence similarity 34162, 42150, 173, member A 50138

44562056 family with 511437 2211 422338 10199 18187, 26175, sequence similarity 34163, 42151, 173, member B 50139 2057 family with 312637 2212 307954 10200 18188, 26176, sequence similarity 34164, 42152, 174, member A 50140

44572058 family with 327355 2213 329040 10201 18189, 26177, sequence similarity 34165, 42153, 174, member B 50141

44582059 family with 233712 2214 233712 10202 18190, 26178, sequence similarity 34166, 42154, 176, member A 50142

44592060 family with 393913 2215 377490 10203 18191, 26179, sequence similarity 34167, 42155, 176, member A 50143

44602061 family with 410071 2216 386930 10204 18192, 26180, sequence similarity 34168, 42156, 176, member A 50144

44612062 family with 410113 2217 386435 10205 18193, 26181, sequence similarity 34169, 42157, 176, member A 50145

44622063 family with 432649 2218 398249 10206 18194, 26182, sequence similarity 34170, 42158, 176, member A 50146

44632064 family with 452003 2219 388105 10207 18195, 26183, sequence similarity 34171, 42159, 176, member A 50147

44642065 family with 518321 2220 464052 10208 18196, 26184, sequence similarity 34172, 42160, 18 member B2 50148

44652066 family with 299866 2221 299866 10209 18197, 26185, sequence similarity 34173, 42161, 18, member A 50149

44662067 family with 456096 2222 411972 10210 18198, 26186, sequence similarity 34174, 42162, 18, member A 50150

44672068 family with 307767 2223 305654 10211 18199, 26187, sequence similarity 34175, 42163, 18, member B 1 50151

44682069 family with 225576 2224 225576 10212 18200, 26188, sequence similarity 34176, 42164, 18, member B2 50152

44692070 family with 428082 2225 406387 10213 18201, 26189, sequence similarity 34177, 42165, 18, member B2 50153

44702071 family with 519970 2226 428961 10214 18202, 26190, sequence similarity 34178, 42166, 18, member B2 50154

44712072 family with 324675 2227 323355 10215 18203, 26191, sequence similarity 34179, 42167, 187, member B 50155

44722073 family with 261275 2228 261275 10216 18204, 26192, sequence similarity 34180, 42168, 189, member Al 50156

44732074 family with 257515 2229 257515 10217 18205, 26193, sequence similarity 34181, 42169, 189, member A2 50157 2075 family with 303068 2230 304435 10218 18206, 26194, sequence similarity 34182, 42170, 189, member A2 50158

44742076 family with 377216 2231 366422 10219 18207, 26195, sequence similarity 34183, 42171, 189, member A2 50159

44752077 family with 377225 2232 366432 10220 18208, 26196, sequence similarity 34184, 42172, 189, member A2 50160

44762078 family with 455972 2233 395675 10221 18209, 26197, sequence similarity 34185, 42173, 189, member A2 50161

44772079 family with 323361 2234 323164 10222 18210, 26198, sequence similarity 34186, 42174, 189, member B 50162

44782080 family with 333966 2235 333944 10223 18211, 26199, sequence similarity 34187, 42175, 189, member B 50163

44792081 family with 350210 2236 307128 10224 18212, 26200, sequence similarity 34188, 42176, 189, member B 50164

44802082 family with 361361 2237 354958 10225 18213, 26201, sequence similarity 34189, 42177, 189, member B 50165

44812083 family with 368368 2238 357352 10226 18214, 26202, sequence similarity 34190, 42178, 189, member B 50166

44822084 family with 487649 2239 427520 10227 18215, 26203, sequence similarity 34191, 42179, 189, member B 50167

44832085 family with 585682 2240 465976 10228 18216, 26204, sequence similarity 34192, 42180, 198 member B 50168

44842086 family with 296530 2241 296530 10229 18217, 26205, sequence similarity 34193, 42181, 198, member B 50169

44852087 family with 337222 2242 338886 10230 18218, 26206, sequence similarity 34194, 42182, 198, member B 50170

44862088 family with 393807 2243 377396 10231 18219, 26207, sequence similarity 34195, 42183, 198, member B 50171

44872089 family with 417442 2244 409135 10232 18220, 26208, sequence similarity 34196, 42184, 198, member B 50172

44882090 family with 408938 2245 386191 10233 18221, 26209, sequence similarity 34197, 42185, 200, member A 50173

44892091 family with 449309 2246 411372 10234 18222, 26210, sequence similarity 34198, 42186, 200, member A 50174

44902092 family with 378788 2247 417711 10235 18223, 26211, sequence similarity 34199, 42187, 205, member A 50175 2093 family with 371328 2248 360379 10236 18224, 26212, sequence similarity 34200, 42188, 209, member A 50176

44912094 family with 371325 2249 360376 10237 18225, 26213, sequence similarity 34201, 42189, 209, member B 50177

44922095 family with 282633 2250 282633 10238 18226, 26214, sequence similarity 34202, 42190, 21, member A 50178

44932096 family with 314664 2251 314417 10239 18227, 26215, sequence similarity 34203, 42191, 21, member A 50179

44942097 family with 351071 2252 344037 10240 18228, 26216, sequence similarity 34204, 42192, 21, member A 50180

44952098 family with 399339 2253 382277 10241 18229, 26217, sequence similarity 34205, 42193, 21, member A 50181

44962099 family with 434114 2254 403781 10242 18230, 26218, sequence similarity 34206, 42194, 21, member A 50182

44972100 family with 454806 2255 398095 10243 18231, 26219, sequence similarity 34207, 42195, 21, member A 50183

44982101 family with 355876 2256 348138 10244 18232, 26220, sequence similarity 34208, 42196, 21, member B 50184

44992102 family with 358474 2257 351259 10245 18233, 26221, sequence similarity 34209, 42197, 21, member B 50185

45002103 family with 430074 2258 416073 10246 18234, 26222, sequence similarity 34210, 42198, 21, member B 50186

45012104 family with 535219 2259 438386 10247 18235, 26223, sequence similarity 34211, 42199, 21, member B 50187

45022105 family with 543972 2260 440306 10248 18236, 26224, sequence similarity 34212, 42200, 21, member B 50188

45032106 family with 322247 2261 323635 10249 18237, 26225, sequence similarity 34213, 42201, 210, member A 50189

45042107 family with 402563 2262 386115 10250 18238, 26226, sequence similarity 34214, 42202, 210, member A 50190

45052108 family with 371384 2263 360437 10251 18239, 26227, sequence similarity 34215, 42203, 210, member B 50191

45062109 family with 368596 2264 357585 10252 18240, 26228, sequence similarity 34216, 42204, 26, member D 50192

45072110 family with 368597 2265 357586 10253 18241, 26229, sequence similarity 34217, 42205, 26, member D 50193 2111 family with 405399 2266 385836 10254 18242, 26230, sequence similarity 34218, 42206, 26, member D 50194

45082112 family with 416171 2267 416976 10255 18243, 26231, sequence similarity 34219, 42207, 26, member D 50195

45092113 family with 452373 2268 409556 10256 18244, 26232, sequence similarity 34220, 42208, 26, member D 50196

45102114 family with 368599 2269 357588 10257 18245, 26233, sequence similarity 34221, 42209, 26, member E 50197

45112115 family with 368605 2270 357594 10258 18246, 26234, sequence similarity 34222, 42210, 26, member F 50198

45122116 family with 377542 2271 366765 10259 18247, 26235, sequence similarity 34223, 42211, 27, member C 50199

45132117 family with 366528 2272 355486 10260 18248, 26236, sequence similarity 34224, 42212, 36, member A 50200

45142118 family with 411948 2273 406327 10261 18249, 26237, sequence similarity 34225, 42213, 36, member A 50201

45152119 family with 389586 2274 374237 10262 18250, 26238, sequence similarity 34226, 42214, 55, member B 50202

45162120 family with 505358 2275 439889 10263 18251, 26239, sequence similarity 34227, 42215, 55, member B 50203

45172121 family with 279389 2276 279389 10264 18252, 26240, sequence similarity 34228, 42216, 57, member B 50204

45182122 family with 380495 2277 369863 10265 18253, 26241, sequence similarity 34229, 42217, 57, member B 50205

45192123 family with 370310 2278 359333 10266 18254, 26242, sequence similarity 34230, 42218, 69, member A 50206

45202124 family with 401027 2279 383809 10267 18255, 26243, sequence similarity 34231, 42219, 69, member A 50207

45212125 family with 371691 2280 360756 10268 18256, 26244, sequence similarity 34232, 42220, 69, member B 50208

45222126 family with 371692 2281 360757 10269 18257, 26245, sequence similarity 34233, 42221, 69, member B 50209

45232127 family with 343998 2282 344331 10270 18258, 26246, sequence similarity 34234, 42222, 69, member C 50210

45242128 family with 309720 2283 310110 10271 18259, 26247, sequence similarity 34235, 42223, 70, member A 50211 2129 family with 371352 2284 360403 10272 18260, 26248, sequence similarity 34236, 42224, 70, member A 50212

45252130 family with 371369 2285 360420 10273 18261, 26249, sequence similarity 34237, 42225, 70, member A 50213

45262131 family with 440464 2286 405781 10274 18262, 26250, sequence similarity 34238, 42226, 70, member A 50214

45272132 family with 375353 2287 364502 10275 18263, 26251, sequence similarity 34239, 42227, 70, member B 50215

45282133 family with 370791 2288 359827 10276 18264, 26252, sequence similarity 34240, 42228, 73, member A 50216

45292134 family with 443751 2289 393675 10277 18265, 26253, sequence similarity 34241, 42229, 73, member A 50217

45302135 family with 277475 2290 277475 10278 18266, 26254, sequence similarity 34242, 42230, 73, member B 50218

45312136 family with 358369 2291 351138 10279 18267, 26255, sequence similarity 34243, 42231, 73, member B 50219

45322137 family with 406926 2292 384662 10280 18268, 26256, sequence similarity 34244, 42232, 73, member B 50220

45332138 family with 450073 2293 409348 10281 18269, 26257, sequence similarity 34245, 42233, 73, member B 50221

45342139 family with 434519 2294 388519 10282 18270, 26258, sequence similarity 34246, 42234, 74, member Al 50222

45352140 family with 427006 2295 415978 10283 18271, 26259, sequence similarity 34247, 42235, 74, member A2 50223

45362141 family with 377647 2296 366875 10284 18272, 26260, sequence similarity 34248, 42236, 75, member Al 50224

45372142 family with 456183 2297 406957 10285 18273, 26261, sequence similarity 34249, 42237, 75, member A2 50225

45382143 family with 356699 2298 349132 10286 18274, 26262, sequence similarity 34250, 42238, 75, member A3 50226

45392144 family with 377509 2299 366731 10287 18275, 26263, sequence similarity 34251, 42239, 75, member A4 50227

45402145 family with 429767 2300 411237 10288 18276, 26264, sequence similarity 34252, 42240, 75, member A4 50228

45412146 family with 377621 2301 366847 10289 18277, 26265, sequence similarity 34253, 42241, 75, member A5 50229 2147 family with 332857 2302 329825 10290 18278, 26266, sequence similarity 34254, 42242, 75, member A6 50230

45422148 family with 355045 2303 347153 10291 18279, 26267, sequence similarity 34255, 42243, 75, member A7 50231

45432149 family with 344803 2304 341988 10292 18280, 26268, sequence similarity 34256, 42244, 75, member Dl 50232

45442150 family with 259963 2305 259963 10293 18281, 26269, sequence similarity 34257, 42245, 8, member Al 50233

45452151 family with 542476 2306 446393 10294 18282, 26270, sequence similarity 34258, 42246, 8, member Al 50234

45462152 family with 393246 2307 376937 10295 18283, 26271, sequence similarity 34259, 42247, 92, member B 50235

45472153 family with 539556 2308 443411 10296 18284, 26272, sequence similarity 34260, 42248, 92, member B 50236

45482154 Fas (TNFRSF6) 319129 2309 324292 10297 18285, 26273, binding factor 1 34261, 42249,

454950237

45502155 Fas (TNFRSF6) 337792 2310 337039 10298 18286, 26274, binding factor 1 34262, 42250,

455150238

45522156 Fas (TNFRSF6) 389570 2311 374221 10299 18287, 26275, binding factor 1 34263, 42251,

455350239

45542157 Fas (TNFRSF6) 427433 2312 401215 10300 18288, 26276, binding factor 1 34264, 42252,

455550240

45562158 FAST kinase 445210 2313 399551 10301 18289, 26277, domains 1 34265, 42253,

455750241

45582159 FAST kinase 453153 2314 400513 10302 18290, 26278, domains 1 34266, 42254,

455950242

45602160 FAST kinase 453929 2315 403229 10303 18291, 26279, domains 1 34267, 42255,

456150243

45622161 FAST kinase 264669 2316 264669 10304 18292, 26280, domains 3 34268, 42256,

456350244

45642162 FAST kinase 504695 2317 426008 10305 18293, 26281, domains 3 34269, 42257,

456550245

45662163 fat storage-inducing 267426 2318 267426 10306 18294, 26282, transmembrane 34270, 42258, protein 1 50246

45672164 fat storage-inducing 396825 2319 380037 10307 18295, 26283, transmembrane 34271, 42259, protein 2 50247 2165 fatty acid desaturase 310226 2320 307821 10308 18296, 26284, domain family, 34272, 42260, member 6 50248

45682166 fatty acid desaturase 413142 2321 396743 10309 18297, 26285, domain family, 34273, 42261, member 6 50249

45692167 fatty acyl CoA 354817 2322 346874 10310 18298, 26286, reductase 1 34274, 42262,

457050250

45712168 fatty acyl CoA 355107 2323 347226 10311 18299, 26287, reductase 1 34275, 42263,

457250251

45732169 fatty acyl CoA 182377 2324 182377 10312 18300, 26288, reductase 2 34276, 42264,

457450252

45752170 fatty acyl CoA 536681 2325 443291 10313 18301, 26289, reductase 2 34277, 42265,

457650253

45772171 Fc receptor-like 2 292389 2326 292389 10314 18302, 26290,

457834278, 42266, 50254

45792172 Fc receptor-like 2 361516 2327 355157 10315 18303, 26291,

458034279, 42267, 50255

45812173 Fc receptor-like 2 368181 2328 357163 10316 18304, 26292,

458234280, 42268, 50256

45832174 Fc receptor-like 2 392274 2329 376100 10317 18305, 26293,

458434281, 42269, 50257

45852175 Fc receptor-like 2 469986 2330 417393 10318 18306, 26294,

458634282, 42270, 50258

45872176 Fc receptor-like 3 292392 2331 292392 10319 18307, 26295,

458834283, 42271, 50259

45892177 Fc receptor-like 3 368184 2332 357167 10320 18308, 26296,

459034284, 42272, 50260

45912178 Fc receptor-like 3 368186 2333 357169 10321 18309, 26297,

459234285, 42273, 50261

45932179 Fc receptor-like 3 485028 2334 434331 10322 18310, 26298,

459434286, 42274, 50262

45952180 Fc receptor-like 4 271532 2335 271532 10323 18311, 26299,

459634287, 42275, 50263

45972181 Fc receptor-like 5 356953 2336 349434 10324 18312, 26300,

459834288, 42276, 50264

45992182 Fc receptor-like 5 361835 2337 354691 10325 18313, 26301,

460034289, 42277, 50265 2183 Fc receptor-like 5 368188 2338 357171 10326 18314, 26302,

460134290, 42278, 50266

46022184 Fc receptor-like 5 368189 2339 357172 10327 18315, 26303,

460334291, 42279, 50267

46042185 Fc receptor-like 5 368190 2340 357173 10328 18316, 26304,

460534292, 42280, 50268

46062186 Fc receptor-like 5 368191 2341 357174 10329 18317, 26305,

460734293, 42281, 50269

46082187 Fc receptor-like 6 339348 2342 340949 10330 18318, 26306,

460934294, 42282, 50270

46102188 Fc receptor-like 6 368106 2343 357086 10331 18319, 26307,

461134295, 42283, 50271

46122189 Fc receptor-like 6 392235 2344 376068 10332 18320, 26308,

461334296, 42284, 50272

46142190 Feline leukemia 238667 2345 238667 10333 18321, 26309, virus subgroup C 34297, 42285, receptor-related 50273 protein 2

46152191 Feline leukemia 539311 2346 443439 10334 18322, 26310, virus subgroup C 34298, 42286, receptor-related 50274 protein 2

46162192 fer-l-like 6 (C. 399018 2347 381982 10335 18323, 26311, elegans) 34299, 42287,

461750275

46182193 fer-l-like 6 (C. 522917 2348 428280 10336 18324, 26312, elegans) 34300, 42288,

461950276

46202194 FERM and PDZ 359927 2349 439868 10337 18325, 26313, domain containing 1 34301, 42289,

462150277

46222195 FERM and PDZ 377765 2350 366995 10338 18326, 26314, domain containing 1 34302, 42290,

462350278

46242196 FERM and PDZ 536622 2351 437762 10339 18327, 26315, domain containing 1 34303, 42291,

462550279

46262197 FERM and PDZ 539465 2352 444411 10340 18328, 26316, domain containing 1 34304, 42292,

462750280

46282198 FERM and PDZ 541302 2353 444804 10341 18329, 26317, domain containing 1 34305, 42293,

462950281

46302199 FERM domain 417257 2354 403067 10342 18330, 26318, containing 5 34306, 42294,

463150282 2200 FERM domain 484674 2355 452968 10343 18331, 26319, containing 5 34307, 42295,

463250283

46332201 FERM domain 344768 2356 343899 10344 18332, 26320, containing 6 34308, 42296,

463450284

46352202 FERM domain 356218 2357 348550 10345 18333, 26321, containing 6 34309, 42297,

463650285

46372203 FERM domain 395718 2358 379068 10346 18334, 26322, containing 6 34310, 42298,

463850286

46392204 FERM domain 553556 2359 452529 10347 18335, 26323, containing 6 34311, 42299,

464050287

46412205 FERM domain 554778 2360 452122 10348 18336, 26324, containing 6 34312, 42300,

464250288

46432206 FERM, RhoGEF 319562 2361 322926 10349 18337, 26325, (ARHGEF) and 34313, 42301, pleckstrin domain 50289 protein 1

4644(chondrocyte- derived)

46452207 FERM, RhoGEF 376581 2362 365765 10350 18338, 26326, (ARHGEF) and 34314, 42302, pleckstrin domain 50290 protein 1

4646(chondrocyte- derived)

46472208 FERM, RhoGEF 376584 2363 365768 10351 18339, 26327, (ARHGEF) and 34315, 42303, pleckstrin domain 50291 protein 1

4648(chondrocyte- derived)

46492209 FERM, RhoGEF 376586 2364 365771 10352 18340, 26328, (ARHGEF) and 34316, 42304, pleckstrin domain 50292 protein 1

4650(chondrocyte- derived)

46512210 FERM, RhoGEF 423063 2365 410930 10353 18341, 26329, (ARHGEF) and 34317, 42305, pleckstrin domain 50293 protein 1

4652(chondrocyte- derived)

46532211 FERM, RhoGEF 457029 2366 406623 10354 18342, 26330, (ARHGEF) and 34318, 42306, pleckstrin domain 50294 protein 1

4654(chondrocyte- derived) 2212 FERM, RhoGEF 264042 2367 264042 10355 18343, 26331, and pleckstrin 34319, 42307, domain protein 2 50295

46552213 FERM, RhoGEF 373287 2368 362384 10356 18344, 26332, and pleckstrin 34320, 42308, domain protein 2 50296

46562214 FERM, RhoGEF 412332 2369 403437 10357 18345, 26333, and pleckstrin 34321, 42309, domain protein 2 50297

46572215 FERM, RhoGEF 418082 2370 393376 10358 18346, 26334, and pleckstrin 34322, 42310, domain protein 2 50298

46582216 FERM, RhoGEF 445489 2371 388167 10359 18347, 26335, and pleckstrin 34323, 42311, domain protein 2 50299

46592217 FERM, RhoGEF 545004 2372 443876 10360 18348, 26336, and pleckstrin 34324, 42312, domain protein 2 50300

46602218 fermitin family 217289 2373 217289 10361 18349, 26337, member 1 34325, 42313,

466150301

46622219 fermitin family 339538 2374 342074 10362 18350, 26338, member 1 34326, 42314,

466350302

46642220 fermitin family 378844 2375 368121 10363 18351, 26339, member 1 34327, 42315,

466550303

46662221 fermitin family 536936 2376 441063 10364 18352, 26340, member 1 34328, 42316,

466750304

46682222 ferredoxin 1-like 393708 2377 377311 10365 18353, 26341,

466934329, 42317, 50305

46702223 ferredoxin 1-like 541276 2378 441093 10366 18354, 26342,

467134330, 42318, 50306

46722224 fetal and adult testis 370350 2379 359375 10367 18355, 26343, expressed 1 34331, 42319,

467350307

46742225 fibroblast growth 299293 2380 299293 10368 18356, 26344, factor receptor 34332, 42320, substrate 2 50308

46752226 fibroblast growth 397997 2381 381083 10369 18357, 26345, factor receptor 34333, 42321, substrate 2 50309

46762227 fibroblast growth 547219 2382 447724 10370 18358, 26346, factor receptor 34334, 42322, substrate 2 50310

46772228 fibroblast growth 548154 2383 449105 10371 18359, 26347, factor receptor 34335, 42323, substrate 2 50311

46782229 fibroblast growth 549092 2384 449111 10372 18360, 26348, factor receptor 34336, 42324, substrate 2 50312 2230 fibroblast growth 549921 2385 450048 10373 18361, 26349, factor receptor 34337, 42325, substrate 2 50313

46792231 fibroblast growth 550169 2386 447978 10374 18362, 26350, factor receptor 34338, 42326, substrate 2 50314

46802232 fibroblast growth 550316 2387 450000 10375 18363, 26351, factor receptor 34339, 42327, substrate 2 50315

46812233 fibroblast growth 550389 2388 447241 10376 18364, 26352, factor receptor 34340, 42328, substrate 2 50316

46822234 fibroblast growth 550937 2389 447804 10377 18365, 26353, factor receptor 34341, 42329, substrate 2 50317

46832235 fibroblast growth 551325 2390 449432 10378 18366, 26354, factor receptor 34342, 42330, substrate 2 50318

46842236 fibroblast growth 259748 2391 259748 10379 18367, 26355, factor receptor 34343, 42331, substrate 3 50319

46852237 fibroblast growth 373018 2392 362109 10380 18368, 26356, factor receptor 34344, 42332, substrate 3 50320

46862238 fibroblast growth 422888 2393 413214 10381 18369, 26357, factor receptor 34345, 42333, substrate 3 50321

46872239 fibroblast growth 426290 2394 396715 10382 18370, 26358, factor receptor 34346, 42334, substrate 3 50322

46882240 fibronectin type III 337156 2395 338579 10383 18371, 26359, domain containing 34347, 42335, 3A 50323

46892241 fibronectin type III 398316 2396 381362 10384 18372, 26360, domain containing 34348, 42336, 3A 50324

46902242 fibronectin type III 492622 2397 417257 10385 18373, 26361, domain containing 34349, 42337, 3A 50325

46912243 fibronectin type III 541916 2398 441831 10386 18374, 26362, domain containing 34350, 42338, 3A 50326

46922244 fibronectin type III 484074 2399 420275 10387 18375, 26363, domain containing 34351, 42339, 3A 50327

46932245 fibronectin type III 312349 2400 310594 10388 18376, 26364, domain containing 9 34352, 42340,

469450328

46952246 fibronectin type III 520782 2401 429434 10389 18377, 26365, domain containing 9 34353, 42341,

469650329

46972247 fibrous sheath 326147 2402 321903 10390 18378, 26366, interacting protein 2 34354, 42342,

469850330 2248 fibrous sheath 343098 2403 344403 10391 18379, 26367, interacting protein 2 34355, 42343,

469950331

47002249 fibrous sheath 424728 2404 401306 10392 18380, 26368, interacting protein 2 34356, 42344,

470150332

47022250 fibrous sheath 429412 2405 395888 10393 18381, 26369, interacting protein 2 34357, 42345,

470350333

47042251 fibrous sheath 546113 2406 439530 10394 18382, 26370, interacting protein 2 34358, 42346,

470550334

47062252 FIC domain 552695 2407 446479 10395 18383, 26371, containing 34359, 42347,

470750335

47082253 filamin binding LIM 332305 2408 364920 10396 18384, 26372, protein 1 34360, 42348,

470950336

47102254 filamin binding LIM 375766 2409 364921 10397 18385, 26373, protein 1 34361, 42349,

471150337

47122255 filamin binding LIM 375771 2410 364926 10398 18386, 26374, protein 1 34362, 42350,

471350338

47142256 filamin binding LIM 400773 2411 383584 10399 18387, 26375, protein 1 34363, 42351,

471550339

47162257 filamin binding LIM 430076 2412 387595 10400 18388, 26376, protein 1 34364, 42352,

471750340

47182258 filamin binding LIM 431771 2413 402401 10401 18389, 26377, protein 1 34365, 42353,

471950341

47202259 filamin binding LIM 441801 2414 416387 10402 18390, 26378, protein 1 34366, 42354,

472150342

47222260 filamin binding LIM 483633 2415 427052 10403 18391, 26379, protein 1 34367, 42355,

472350343

47242261 filamin binding LIM 496928 2416 422862 10404 18392, 26380, protein 1 34368, 42356,

472550344

47262262 filamin binding LIM 502638 2417 422075 10405 18393, 26381, protein 1 34369, 42357,

472750345

47282263 filamin binding LIM 502739 2418 424920 10406 18394, 26382, protein 1 34370, 42358,

472950346

47302264 filamin binding LIM 508310 2419 423471 10407 18395, 26383, protein 1 34371, 42359,

473150347

47322265 filamin binding LIM 510393 2420 421885 10408 18396, 26384, protein 1 34372, 42360,

473350348 2266 filamin binding LIM 510929 2421 421764 10409 18397, 26385, protein 1 34373, 42361,

473450349

47352267 FK506 binding 444214 2422 412403 10410 18398, 26386, protein 11, 19 kDa 34374, 42362,

473650350

47372268 FK506 binding 453172 2423 396874 10411 18399, 26387, protein 11, 19 kDa 34375, 42363,

473850351

47392269 FK506 binding 550765 2424 449751 10412 18400, 26388, protein 11, 19 kDa 34376, 42364,

474050352

47412270 FK506 binding 222803 2425 222803 10413 18401, 26389, protein 14, 22 kDa 34377, 42365,

474250353

47432271 FK506 binding 242209 2426 242209 10414 18402, 26390, protein 9, 63 kDa 34378, 42366,

474450354

47452272 FK506 binding 490776 2427 441317 10415 18403, 26391, protein 9, 63 kDa 34379, 42367,

474650355

47472273 FK506 binding 538336 2428 439250 10416 18404, 26392, protein 9, 63 kDa 34380, 42368,

474850356

47492274 FK506 binding 538443 2429 437504 10417 18405, 26393, protein 9, 63 kDa 34381, 42369,

475050357

47512275 formin 1 320930 2430 325166 10418 18406, 26394,

475234382, 42370, 50358

47532276 formin 1 334528 2431 333950 10419 18407, 26395,

475434383, 42371, 50359

47552277 formin 1 558197 2432 452984 10420 18408, 26396,

475634384, 42372, 50360

47572278 formin 1 559047 2433 454047 10421 18409, 26397,

475834385, 42373, 50361

47592279 fragile X mental 370467 2434 359498 10422 18410, 26398, retardation 1 34386, 42374, neighbor 50362

47602280 free fatty acid 246553 2435 246553 10423 18411, 26399, receptor 1 34387, 42375,

476150363

47622281 free fatty acid 246549 2436 246549 10424 18412, 26400, receptor 2 34388, 42376,

476350364

47642282 free fatty acid 327809 2437 328230 10425 18413, 26401, receptor 3 34389, 42377,

476550365

47662283 frizzled family 295417 2438 354607 10426 18414, 26402, receptor 5 34390, 42378,

476750366 2284 FtsJ 338099 2439 337512 10427 18415, 26403, methyltransferase 34391, 42379, domain containing 1 50367

47682285 FtsJ 434935 2440 411148 10428 18416, 26404, methyltransferase 34392, 42380, domain containing 1 50368

47692286 fucosyltransferase 327671 2441 332757 10429 18417, 26405, 10 (alpha (1,3) 34393, 42381, fucosyltransferase) 50369

47702287 fucosyltransferase 335589 2442 334997 10430 18418, 26406, 10 (alpha (1,3) 34394, 42382, fucosyltransferase) 50370

47712288 fucosyltransferase 380081 2443 369421 10431 18419, 26407, 10 (alpha (1,3) 34395, 42383, fucosyltransferase) 50371

47722289 fucosyltransferase 372841 2444 361932 10432 18420, 26408, 11 (alpha (1,3) 34396, 42384, fucosyltransferase) 50372

47732290 fucosyltransferase 394790 2445 378270 10433 18421, 26409, 11 (alpha (1,3) 34397, 42385, fucosyltransferase) 50373

47742291 FUN 14 domain 369498 2446 358510 10434 18422, 26410, containing 2 34398, 42386,

477550374

47762292 furry homolog 267067 2447 267067 10435 18423, 26411, (Drosophila) 34399, 42387,

477750375

47782293 furry homolog 380217 2448 369565 10436 18424, 26412, (Drosophila) 34400, 42388,

477950376

47802294 furry homolog 380235 2449 369584 10437 18425, 26413, (Drosophila) 34401, 42389,

478150377

47822295 furry homolog 380250 2450 369600 10438 18426, 26414, (Drosophila) 34402, 42390,

478350378

47842296 furry homolog 380257 2451 369607 10439 18427, 26415, (Drosophila) 34403, 42391,

478550379

47862297 furry homolog 436046 2452 398010 10440 18428, 26416, (Drosophila) 34404, 42392,

478750380

47882298 furry homolog 542859 2453 445043 10441 18429, 26417, (Drosophila) 34405, 42393,

478950381

47902299 FXYD domain 374451 2454 363575 10442 18430, 26418, containing ion 34406, 42394, transport regulator 4 50382

47912300 FXYD domain 458363 2455 388004 10443 18431, 26419, containing ion 34407, 42395, transport regulator 4 50383

47922301 G elongation factor, 296805 2456 296805 10444 18432, 26420, mitochondrial 2 34408, 42396,

479350384 2302 G elongation factor, 345239 2457 296804 10445 18433, 26421, mitochondrial 2 34409, 42397,

479450385

47952303 G elongation factor, 427854 2458 405808 10446 18434, 26422, mitochondrial 2 34410, 42398,

479650386

47972304 G elongation factor, 509430 2459 427004 10447 18435, 26423, mitochondrial 2 34411, 42399,

479850387

47992305 G elongation factor, 546082 2460 437810 10448 18436, 26424, mitochondrial 2 34412, 42400,

480050388

48012306 G kinase anchoring 376365 2461 365544 10449 18437, 26425, protein 1 34413, 42401,

480250389

48032307 G kinase anchoring 376371 2462 365550 10450 18438, 26426, protein 1 34414, 42402,

480450390

48052308 G kinase anchoring 388782 2463 373434 10451 18439, 26427, protein 1 34415, 42403,

480650391

48072309 G kinase anchoring 485742 2464 417621 10452 18440, 26428, protein 1 34416, 42404,

480850392

48092310 G protein regulated 303991 2465 305839 10453 18441, 26429, inducer of neurite 34417, 42405, outgrowth 1 50393

48102311 G protein regulated 335532 2466 335279 10454 18442, 26430, inducer of neurite 34418, 42406, outgrowth 1 50394

48112312 G protein-coupled 347136 2467 336988 10455 18443, 26431, receptor 107 34419, 42407,

481250395

48132313 G protein-coupled 372406 2468 361483 10456 18444, 26432, receptor 107 34420, 42408,

481450396

48152314 G protein-coupled 372410 2469 361487 10457 18445, 26433, receptor 107 34421, 42409,

481650397

48172315 G protein-coupled 455412 2470 402109 10458 18446, 26434, receptor 107 34422, 42410,

481850398

48192316 G protein-coupled 264080 2471 264080 10459 18447, 26435, receptor 108 34423, 42411,

482050399

48212317 G protein-coupled 430424 2472 401284 10460 18448, 26436, receptor 108 34424, 42412,

482250400

48232318 G protein-coupled 283297 2473 283297 10461 18449, 26437, receptor 110 34425, 42413,

482450401

48252319 G protein-coupled 371243 2474 360289 10462 18450, 26438, receptor 110 34426, 42414,

482650402 2320 G protein-coupled 371252 2475 360298 10463 18451, 26439, receptor 110 34427, 42415,

482750403

48282321 G protein-coupled 371253 2476 360299 10464 18452, 26440, receptor 110 34428, 42416,

482950404

48302322 G protein-coupled 296862 2477 296862 10465 18453, 26441, receptor 111 34429, 42417,

483150405

48322323 G protein-coupled 398742 2478 381727 10466 18454, 26442, receptor 111 34430, 42418,

483350406

48342324 G protein-coupled 467205 2479 425269 10467 18455, 26443, receptor 111 34431, 42419,

483550407

48362325 G protein-coupled 287534 2480 287534 10468 18456, 26444, receptor 112 34432, 42420,

483750408

48382326 G protein-coupled 370652 2481 359686 10469 18457, 26445, receptor 112 34433, 42421,

483950409

48402327 G protein-coupled 394143 2482 377699 10470 18458, 26446, receptor 112 34434, 42422,

484150410

48422328 G protein-coupled 412101 2483 416526 10471 18459, 26447, receptor 112 34435, 42423,

484350411

48442329 G protein-coupled 311519 2484 307831 10472 18460, 26448, receptor 113 34436, 42424,

484550412

48462330 G protein-coupled 333478 2485 327396 10473 18461, 26449, receptor 113 34437, 42425,

484750413

48482331 G protein-coupled 541401 2486 445729 10474 18462, 26450, receptor 113 34438, 42426,

484950414

48502332 G protein-coupled 421160 2487 388537 10475 18463, 26451, receptor 113 34439, 42427,

485150415

48522333 G protein-coupled 340339 2488 342981 10476 18464, 26452, receptor 114 34440, 42428,

485350416

48542334 G protein-coupled 349457 2489 290823 10477 18465, 26453, receptor 114 34441, 42429,

485550417

48562335 G protein-coupled 394361 2490 377888 10478 18466, 26454, receptor 114 34442, 42430,

485750418

48582336 G protein-coupled 265417 2491 265417 10479 18467, 26455, receptor 116 34443, 42431,

485950419

48602337 G protein-coupled 283296 2492 283296 10480 18468, 26456, receptor 116 34444, 42432,

486150420 2338 G protein-coupled 362015 2493 354563 10481 18469, 26457, receptor 116 34445, 42433,

486250421

48632339 G protein-coupled 452370 2494 394590 10482 18470, 26458, receptor 116 34446, 42434,

486450422

48652340 G protein-coupled 456426 2495 412866 10483 18471, 26459, receptor 116 34447, 42435,

486650423

48672341 G protein-coupled 545557 2496 440867 10484 18472, 26460, receptor 116 34448, 42436,

486850424

48692342 G protein-coupled 545669 2497 441581 10485 18473, 26461, receptor 116 34449, 42437,

487050425

48712343 G protein-coupled 276218 2498 276218 10486 18474, 26462, receptor 119 34450, 42438,

487250426

48732344 G protein-coupled 395116 2499 378548 10487 18475, 26463, receptor 135 34451, 42439,

487450427

48752345 G protein-coupled 481661 2500 432696 10488 18476, 26464, receptor 135 34452, 42440,

487650428

48772346 G protein-coupled 539022 2501 444314 10489 18477, 26465, receptor 135 34453, 42441,

487850429

48792347 G protein-coupled 313074 2502 321698 10490 18478, 26466, receptor 137 34454, 42442,

488050430

48812348 G protein-coupled 377702 2503 366931 10491 18479, 26467, receptor 137 34455, 42443,

488250431

48832349 G protein-coupled 411458 2504 411827 10492 18480, 26468, receptor 137 34456, 42444,

488450432

48852350 G protein-coupled 438980 2505 415698 10493 18481, 26469, receptor 137 34457, 42445,

488650433

48872351 G protein-coupled 535675 2506 446342 10494 18482, 26470, receptor 137 34458, 42446,

488850434

48892352 G protein-coupled 538032 2507 445000 10495 18483, 26471, receptor 137 34459, 42447,

489050435

48912353 G protein-coupled 538244 2508 442322 10496 18484, 26472, receptor 137 34460, 42448,

489250436

48932354 G protein-coupled 539833 2509 438716 10497 18485, 26473, receptor 137 34461, 42449,

489450437

48952355 G protein-coupled 539851 2510 442792 10498 18486, 26474, receptor 137 34462, 42450,

489650438 2356 G protein-coupled 540370 2511 446387 10499 18487, 26475, receptor 137 34463, 42451,

489750439

48982357 G protein-coupled 540969 2512 437739 10500 18488, 26476, receptor 137 34464, 42452,

489950440

49002358 G protein-coupled 543383 2513 441003 10501 18489, 26477, receptor 137 34465, 42453,

490150441

49022359 G protein-coupled 366591 2514 355550 10502 18490, 26478, receptor 137B 34466, 42454,

490350442

49042360 G protein-coupled 366592 2515 355551 10503 18491, 26479, receptor 137B 34467, 42455,

490550443

49062361 G protein-coupled 391852 2516 375725 10504 18492, 26480, receptor 137B 34468, 42456,

490750444

49082362 G protein-coupled 419162 2517 401841 10505 18493, 26481, receptor 137B 34469, 42457,

490950445

49102363 G protein-coupled 454895 2518 395814 10506 18494, 26482, receptor 137B 34470, 42458,

491150446

49122364 G protein-coupled 321662 2519 315106 10507 18495, 26483, receptor 137C 34471, 42459,

491350447

49142365 G protein-coupled 326571 2520 370779 10508 18496, 26484, receptor 139 34472, 42460,

491550448

49162366 G protein-coupled 570682 2521 458791 10509 18497, 26485, receptor 139 34473, 42461,

491750449

49182367 G protein-coupled 334425 2522 334540 10510 18498, 26486, receptor 141 34474, 42462,

491950450

49202368 G protein-coupled 447769 2523 390410 10511 18499, 26487, receptor 141 34475, 42463,

492150451

49222369 G protein-coupled 450180 2524 396300 10512 18500, 26488, receptor 141 34476, 42464,

492350452

49242370 G protein-coupled 335666 2525 335158 10513 18501, 26489, receptor 142 34477, 42465,

492550453

49262371 G protein-coupled 334810 2526 335156 10514 18502, 26490, receptor 144 34478, 42466,

492750454

49282372 G protein-coupled 439837 2527 405734 10515 18503, 26491, receptor 144 34479, 42467,

492950455

49302373 G protein-coupled 446588 2528 414478 10516 18504, 26492, receptor 144 34480, 42468,

493150456 2374 G protein-coupled 536897 2529 443708 10517 18505, 26493, receptor 144 34481, 42469,

493250457

49332375 G protein-coupled 297468 2530 297468 10518 18506, 26494, receptor 146 34482, 42470,

493450458

49352376 G protein-coupled 397095 2531 380283 10519 18507, 26495, receptor 146 34483, 42471,

493650459

49372377 G protein-coupled 444847 2532 410743 10520 18508, 26496, receptor 146 34484, 42472,

493850460

49392378 G protein-coupled 500070 2533 444126 10521 18509, 26497, receptor 146 34485, 42473,

494050461

49412379 G protein-coupled 309926 2534 308908 10522 18510, 26498, receptor 148 34486, 42474,

494250462

49432380 G protein-coupled 389740 2535 374390 10523 18511, 26499, receptor 149 34487, 42475,

494450463

49452381 G protein-coupled 380007 2536 369344 10524 18512, 26500, receptor 150 34488, 42476,

494650464

49472382 G protein-coupled 311104 2537 308733 10525 18513, 26501, receptor 151 34489, 42477,

494850465

49492383 G protein-coupled 312457 2538 310255 10526 18514, 26502, receptor 152 34490, 42478,

495050466

49512384 G protein-coupled 295500 2539 295500 10527 18515, 26503, receptor 155 34491, 42479,

495250467

49532385 G protein-coupled 392551 2540 376334 10528 18516, 26504, receptor 155 34492, 42480,

495450468

49552386 G protein-coupled 392552 2541 376335 10529 18517, 26505, receptor 155 34493, 42481,

495650469

49572387 G protein-coupled 510236 2542 446160 10530 18518, 26506, receptor 155 34494, 42482,

495850470

49592388 G protein-coupled 377408 2543 366625 10531 18519, 26507, receptor 157 34495, 42483,

496050471

49612389 G protein-coupled 377411 2544 366628 10532 18520, 26508, receptor 157 34496, 42484,

496250472

49632390 G protein-coupled 414642 2545 411172 10533 18521, 26509, receptor 157 34497, 42485,

496450473

49652391 G protein-coupled 376351 2546 365529 10534 18522, 26510, receptor 158 34498, 42486,

496650474 2392 G protein-coupled 355897 2547 348161 10535 18523, 26511, receptor 160 34499, 42487,

496750475

49682393 G protein-coupled 473675 2548 420751 10536 18524, 26512, receptor 160 34500, 42488,

496950476

49702394 G protein-coupled 482710 2549 419400 10537 18525, 26513, receptor 160 34501, 42489,

497150477

49722395 G protein-coupled 492492 2550 418531 10538 18526, 26514, receptor 160 34502, 42490,

497350478

49742396 G protein-coupled 311268 2551 311528 10539 18527, 26515, receptor 162 34503, 42491,

497550479

49762397 G protein-coupled 428545 2552 399670 10540 18528, 26516, receptor 162 34504, 42492,

497750480

49782398 G protein-coupled 309180 2553 308479 10541 18529, 26517, receptor 171 34505, 42493,

497950481

49802399 G protein-coupled 480322 2554 420109 10542 18530, 26518, receptor 171 34506, 42494,

498150482

49822400 G protein-coupled 332582 2555 331600 10543 18531, 26519, receptor 173 34507, 42495,

498350483

49842401 G protein-coupled 375466 2556 364615 10544 18532, 26520, receptor 173 34508, 42496,

498550484

49862402 G protein-coupled 276077 2557 276077 10545 18533, 26521, receptor 174 34509, 42497,

498750485

49882403 G protein-coupled 342292 2558 345060 10546 18534, 26522, receptor 179 34510, 42498,

498950486

49902404 G protein-coupled 376958 2559 366157 10547 18535, 26523, receptor 180 34511, 42499,

499150487

49922405 G protein-coupled 300098 2560 300098 10548 18536, 26524, receptor 182 34512, 42500,

499350488

49942406 G protein-coupled 367282 2561 356251 10549 18537, 26525, receptor 37 like 1 34513, 42501,

499550489

49962407 G protein-coupled 541334 2562 439451 10550 18538, 26526, receptor 37 like 1 34514, 42502,

499750490

49982408 G protein-coupled 257267 2563 257267 10551 18539, 26527, receptor 77 34515, 42503,

499950491

50002409 G protein-coupled 600626 2564 471184 10552 18540, 26528, receptor 77 34516, 42504,

500150492 2410 G protein-coupled 315033 2565 314223 10553 18541, 26529, receptor 88 34517, 42505,

500250493

50032411 G protein-coupled 447947 2566 399563 10554 18542, 26530, receptor 89C 34518, 42506,

500450494

50052412 G protein-coupled 327655 2567 331199 10555 18543, 26531, receptor 97 34519, 42507,

500650495

50072413 G protein-coupled 333493 2568 332900 10556 18544, 26532, receptor 97 34520, 42508,

500850496

50092414 G protein-coupled 450388 2569 404803 10557 18545, 26533, receptor 97 34521, 42509,

501050497

50112415 G protein-coupled 14914 2570 14914 10558 18546, 26534, receptor, family C, 34522, 42510, group 5, member A 50498, 56085,

501256118

50132416 G protein-coupled 534831 2571 441627 10559 18547, 26535, receptor, family C, 34523, 42511, group 5, member A 50499

50142417 G protein-coupled 310357 2572 309493 10560 18548, 26536, receptor, family C, 34524, 42512, group 6, member A 50500

50152418 G protein-coupled 368549 2573 357537 10561 18549, 26537, receptor, family C, 34525, 42513, group 6, member A 50501

50162419 G protein-coupled 530250 2574 433465 10562 18550, 26538, receptor, family C, 34526, 42514, group 6, member A 50502

50172420 gametogenetin 374458 2575 363582 10563 18551, 26539, binding protein 1 34527, 42515,

501850503

50192421 gamma- 418225 2576 416731 10564 18552, 26540, aminobutyric acid 34528, 42516, (GABA) B receptor, 50504 1

50202422 gamma- 440316 2577 412044 10565 18553, 26541, aminobutyric acid 34529, 42517, (GABA) B receptor, 50505 1

50212423 gamma- 448754 2578 405709 10566 18554, 26542, aminobutyric acid 34530, 42518, (GABA) B receptor, 50506 1

50222424 gamma- 458612 2579 416903 10567 18555, 26543, aminobutyric acid 34531, 42519, (GABA) B receptor, 50507 1

50232425 gamma- 550820 2580 448763 10568 18556, 26544, aminobutyric acid 34532, 42520, (GABA) B receptor, 50508 1 2426 gamma- 336431 2581 338964 10569 18557, 26545, glutamyltransferase 34533, 42521, 7 50509

50242427 GDNF family 340465 2582 343636 10570 18558, 26546, receptor alpha like 34534, 42522,

502550510

50262428 GH3 domain 301671 2583 301671 10571 18559, 26547, containing 34535, 42523,

502750511

50282429 GH3 domain 393854 2584 377436 10572 18560, 26548, containing 34536, 42524,

502950512

50302430 GH3 domain 414034 2585 399952 10573 18561, 26549, containing 34537, 42525,

503150513

50322431 GH3 domain 428494 2586 410945 10574 18562, 26550, containing 34538, 42526,

503350514

50342432 GH3 domain 436923 2587 402654 10575 18563, 26551, containing 34539, 42527,

503550515

50362433 GH3 domain 587427 2588 467585 10576 18564, 26552, containing 34540, 42528,

503750516

50382434 GIPC PDZ domain 345425 2589 340698 10577 18565, 26553, containing family, 34541, 42529, member 1 50517

50392435 GIPC PDZ domain 351277 2590 341425 10578 18566, 26554, containing family, 34542, 42530, member 1 50518

50402436 GIPC PDZ domain 393028 2591 376748 10579 18567, 26555, containing family, 34543, 42531, member 1 50519

50412437 GIPC PDZ domain 393029 2592 376749 10580 18568, 26556, containing family, 34544, 42532, member 1 50520

50422438 GIPC PDZ domain 393033 2593 376753 10581 18569, 26557, containing family, 34545, 42533, member 1 50521

50432439 GLI pathogenesis- 320460 2594 317385 10582 18570, 26558, related 1 like 2 34546, 42534,

504450522

50452440 GLI pathogenesis- 378689 2595 367960 10583 18571, 26559, related 1 like 2 34547, 42535,

504650523

50472441 GLI pathogenesis- 378692 2596 367963 10584 18572, 26560, related 1 like 2 34548, 42536,

504850524

50492442 GLI pathogenesis- 435775 2597 398328 10585 18573, 26561, related 1 like 2 34549, 42537,

505050525

50512443 GLI pathogenesis- 441218 2598 405273 10586 18574, 26562, related 1 like 2 34550, 42538,

505250526 2444 GLI pathogenesis- 550916 2599 448248 10587 18575, 26563, related 1 like 2 34551, 42539,

505350527

50542445 glucosamine- 216410 2600 216410 10588 18576, 26564, phosphate N- 34552, 42540, acetyltransferase 1 50528

50552446 glucosamine- 557604 2601 452032 10589 18577, 26565, phosphate N- 34553, 42541, acetyltransferase 1 50529

50562447 glucosaminyl (N- 322348 2602 317027 10590 18578, 26566, acetyl) transferase 4, 34554, 42542, core 2 50530

50572448 glucosaminyl (N- 243913 2603 243913 10591 18579, 26567, acetyl) transferase 34555, 42543, family member 7 50531

50582449 glucosidase, beta 378088 2604 367328 10592 18580, 26568, (bile acid) 2 34556, 42544,

505950532

50602450 glucosidase, beta 378094 2605 367334 10593 18581, 26569, (bile acid) 2 34557, 42545,

506150533

50622451 glucosidase, beta 378103 2606 367343 10594 18582, 26570, (bile acid) 2 34558, 42546,

506350534

50642452 glucosidase, beta 545786 2607 442372 10595 18583, 26571, (bile acid) 2 34559, 42547,

506550535

50662453 glutamate receptor, 457091 2608 397351 10596 18584, 26572, ionotropic, delta 2 34560, 42548, (Grid2) interacting 50536 protein

50672454 glutamate receptor, 234389 2609 234389 10597 18585, 26573, ionotropic, N- 34561, 42549, methyl-D-aspartate 50537 3B

50682455 glutamate receptor, 305432 2610 305905 10598 18586, 26574, metabotropic 5 34562, 42550,

506950538

50702456 glutamate receptor, 305447 2611 306138 10599 18587, 26575, metabotropic 5 34563, 42551,

507150539

50722457 glutamate receptor, 393297 2612 376975 10600 18588, 26576, metabotropic 5 34564, 42552,

507350540

50742458 glutamate receptor, 418177 2613 402912 10601 18589, 26577, metabotropic 5 34565, 42553,

507550541

50762459 glutamate receptor, 455756 2614 405690 10602 18590, 26578, metabotropic 5 34566, 42554,

507750542

50782460 glutaminyl-peptide 12049 2615 12049 10603 18591, 26579, cyclotransferase-like 34567, 42555,

507950543, 56086, 56119 2461 glutaminyl-peptide 366382 2616 387944 10604 18592, 26580, cyclotransferase-like 34568, 42556,

508050544

50812462 glutaminyl-tRNA 369044 2617 358040 10605 18593, 26581, synthase (glutamine- 34569, 42557, hydrolyzing)-like 1 50545

50822463 glutaminyl-tRNA 369046 2618 358042 10606 18594, 26582, synthase (glutamine- 34570, 42558, hydrolyzing)-like 1 50546

50832464 Glutamyl- 551765 2619 446872 10607 18595, 26583, tRNA(Gln) 34571, 42559, amidotransferase 50547 subunit C,

5084mitochondrial

50852465 glutathione 503787 2620 423822 10608 18596, 26584, peroxidase 8 34572, 42560, (putative) 50548

50862466 glycerol- 3- 359548 2621 352547 10609 18597, 26585, phosphate 34573, 42561, acyltransferase 2, 50549 mitochondrial

50872467 glycerol- 3- 377137 2622 366341 10610 18598, 26586, phosphate 34574, 42562, acyltransferase 2, 50550 mitochondrial

50882468 glycerol- 3- 434632 2623 389395 10611 18599, 26587, phosphate 34575, 42563, acyltransferase 2, 50551 mitochondrial

50892469 glycerol- 3- 439254 2624 401334 10612 18600, 26588, phosphate 34576, 42564, acyltransferase 2, 50552 mitochondrial

50902470 glycerol- 3- 348367 2625 265276 10613 18601, 26589, phosphate 34577, 42565, acyltransferase, 50553 mitochondrial

50912471 glycerol- 3- 369425 2626 358433 10614 18602, 26590, phosphate 34578, 42566, acyltransferase, 50554 mitochondrial

50922472 glycerol- 3- 423155 2627 409242 10615 18603, 26591, phosphate 34579, 42567, acyltransferase, 50555 mitochondrial

50932473 glycerophosphodiest 284116 2628 284116 10616 18604, 26592, er phosphodiesterase 34580, 42568, domain containing 1 50556

50942474 glycerophosphodiest 581140 2629 463273 10617 18605, 26593, er phosphodiesterase 34581, 42569, domain containing 1 50557 2475 glycerophosphodiest 581276 2630 464690 10618 18606, 26594, er phosphodiesterase 34582, 42570, domain containing 1 50558

50952476 glycerophosphodiest 374382 2631 363503 10619 18607, 26595, er phosphodiesterase 34583, 42571, domain containing 2 50559

50962477 glycerophosphodiest 453994 2632 414019 10620 18608, 26596, er phosphodiesterase 34584, 42572, domain containing 2 50560

50972478 glycerophosphodiest 536730 2633 445982 10621 18609, 26597, er phosphodiesterase 34585, 42573, domain containing 2 50561

50982479 glycerophosphodiest 538649 2634 444601 10622 18610, 26598, er phosphodiesterase 34586, 42574, domain containing 2 50562

50992480 glycerophosphodiest 360688 2635 353909 10623 18611, 26599, er phosphodiesterase 34587, 42575, domain containing 3 50563

51002481 glycerophosphodiest 406256 2636 384363 10624 18612, 26600, er phosphodiesterase 34588, 42576, domain containing 3 50564

51012482 glycerophosphodiest 315938 2637 320815 10625 18613, 26601, er phosphodiesterase 34589, 42577, domain containing 4 50565

51022483 glycerophosphodiest 376217 2638 365390 10626 18614, 26602, er phosphodiesterase 34590, 42578, domain containing 4 50566

51032484 glycine receptor, 372617 2639 361700 10627 18615, 26603, alpha 4 34591, 42579,

510450567

51052485 glycine -N- 300079 2640 300079 10628 18616, 26604, acyltransferase-like 34592, 42580,

51061 50568

51072486 glycine -N- 317391 2641 322223 10629 18617, 26605, acyltransferase-like 34593, 42581,

51081 50569

51092487 glycine -N- 444580 2642 401353 10630 18618, 26606, acyltransferase-like 34594, 42582,

51101 50570

51112488 glycine -N- 525608 2643 433716 10631 18619, 26607, acyltransferase-like 34595, 42583,

51121 50571

51132489 glycine -N- 532726 2644 436116 10632 18620, 26608, acyltransferase-like 34596, 42584,

51141 50572 2490 glycine -N- 287275 2645 287275 10633 18621, 26609, acyltransferase-like 34597, 42585,

51152 50573

51162491 glycine -N- 532258 2646 434277 10634 18622, 26610, acyltransferase-like 34598, 42586,

51172 50574

51182492 glycine -N- 371197 2647 360240 10635 18623, 26611, acyltransferase-like 34599, 42587,

51193 50575

51202493 glycine -N- 545705 2648 440029 10636 18624, 26612, acyltransferase-like 34600, 42588,

51213 50576

51222494 glycoprotein 258733 2649 258733 10637 18625, 26613,

5123(transmembrane) 34601, 42589, nmb 50577

51242495 glycoprotein 381990 2650 371420 10638 18626, 26614,

5125(transmembrane) 34602, 42590, nmb 50578

51262496 glycoprotein 409458 2651 386476 10639 18627, 26615,

5127(transmembrane) 34603, 42591, nmb 50579

51282497 glycoprotein 425903 2652 396994 10640 18628, 26616,

5129(transmembrane) 34604, 42592, nmb 50580

51302498 glycoprotein 435486 2653 409199 10641 18629, 26617,

5131(transmembrane) 34605, 42593, nmb 50581

51322499 glycoprotein 453162 2654 405586 10642 18630, 26618,

5133(transmembrane) 34606, 42594, nmb 50582

51342500 glycoprotein 539136 2655 445266 10643 18631, 26619,

5135(transmembrane) 34607, 42595, nmb 50583

51362501 glycoprotein A33 367868 2656 356842 10644 18632, 26620, (transmembrane) 34608, 42596,

513750584

51382502 glycoprotein V 323007 2657 319286 10645 18633, 26621, (platelet) 34609, 42597,

513950585

51402503 glycoprotein V 401815 2658 383931 10646 18634, 26622, (platelet) 34610, 42598,

514150586

51422504 glycosyltransferase 252599 2659 252599 10647 18635, 26623, 25 domain 34611, 42599, containing 1 50587

51432505 glycosyltransferase 379714 2660 369036 10648 18636, 26624, 25 domain 34612, 42600, containing 1 50588

51442506 glycosyltransferase 361927 2661 354960 10649 18637, 26625, 25 domain 34613, 42601, containing 2 50589

51452507 glycosyltransferase 367520 2662 356490 10650 18638, 26626, 25 domain 34614, 42602, containing 2 50590 2508 glycosyltransferase 367521 2663 356491 10651 18639, 26627, 25 domain 34615, 42603, containing 2 50591

51462509 glycosyltransferase 546159 2664 439112 10652 18640, 26628, 25 domain 34616, 42604, containing 2 50592

51472510 glycosyltransferase 360814 2665 354053 10653 18641, 26629, 8 domain containing 34617, 42605, 2 50593

51482511 glycosyltransferase 546436 2666 449750 10654 18642, 26630, 8 domain containing 34618, 42606, 2 50594

51492512 glycosyltransferase 548660 2667 447450 10655 18643, 26631, 8 domain containing 34619, 42607, 2 50595

51502513 glyoxalase domain 301328 2668 301328 10656 18644, 26632, containing 4 34620, 42608,

515150596

51522514 glyoxalase domain 301329 2669 301329 10657 18645, 26633, containing 4 34621, 42609,

515350597

51542515 glyoxalase domain 397393 2670 380548 10658 18646, 26634, containing 4 34622, 42610,

515550598

51562516 glyoxalase domain 536578 2671 444315 10659 18647, 26635, containing 4 34623, 42611,

515750599

51582517 golgi reassembly 234160 2672 234160 10660 18648, 26636, stacking protein 2, 34624, 42612, 55kDa 50600

51592518 golgi reassembly 452526 2673 410208 10661 18649, 26637, stacking protein 2, 34625, 42613, 55kDa 50601

51602519 golgi transport 1A 308302 2674 308535 10662 18650, 26638,

516134626, 42614, 50602

51622520 golgi transport IB 229314 2675 229314 10663 18651, 26639,

516334627, 42615, 50603

51642521 golgi-associated, 309859 2676 311962 10664 18652, 26640, gamma adaptin ear 34628, 42616, containing, ARF 50604 binding protein 2

51652522 golgi-associated, 498959 2677 442062 10665 18653, 26641, gamma adaptin ear 34629, 42617, containing, ARF 50605 binding protein 2

51662523 golgin A2 342583 2678 342692 10666 18654, 26642,

516734630, 42618, 50606

51682524 golgin A2 421699 2679 416097 10667 18655, 26643,

516934631, 42619, 50607 2525 golgin A2 450617 2680 409271 10668 18656, 26644,

517034632, 42620, 50608

51712526 golgin A7 357743 2681 350378 10669 18657, 26645,

517234633, 42621, 50609

51732527 golgin A7 405786 2682 386030 10670 18658, 26646,

517434634, 42622, 50610

51752528 golgin A7 518270 2683 429329 10671 18659, 26647,

517634635, 42623, 50611

51772529 golgin A7 520817 2684 429480 10672 18660, 26648,

517834636, 42624, 50612

51792530 G-protein signaling 291775 2685 291775 10673 18661, 26649, modulator 1 34637, 42625,

518050613

51812531 G-protein signaling 354753 2686 346797 10674 18662, 26650, modulator 1 34638, 42626,

518250614

51832532 G-protein signaling 392944 2687 376673 10675 18663, 26651, modulator 1 34639, 42627,

518450615

51852533 G-protein signaling 392945 2688 376674 10676 18664, 26652, modulator 1 34640, 42628,

518650616

51872534 G-protein signaling 429455 2689 390705 10677 18665, 26653, modulator 1 34641, 42629,

518850617

51892535 G-protein signaling 440944 2690 392828 10678 18666, 26654, modulator 1 34642, 42630,

519050618

51912536 GRAM domain 317991 2691 441032 10679 18667, 26655, containing 1A 34643, 42631,

519250619

51932537 GRAM domain 411896 2692 439267 10680 18668, 26656, containing 1A 34644, 42632,

519450620

51952538 GRAM domain 453966 2693 441346 10681 18669, 26657, containing 1A 34645, 42633,

519650621

51972539 GRAM domain 504615 2694 423728 10682 18670, 26658, containing 1A 34646, 42634,

519850622

51992540 GRAM domain 322282 2695 325628 10683 18671, 26659, containing IB 34647, 42635,

520050623

52012541 GRAM domain 529750 2696 436500 10684 18672, 26660, containing IB 34648, 42636,

520250624

52032542 GRAM domain 539133 2697 444667 10685 18673, 26661, containing IB 34649, 42637,

520450625 2543 GRAM domain 358160 2698 350881 10686 18674, 26662, containing 1C 34650, 42638,

520550626

52062544 GRAM domain 440446 2699 408135 10687 18675, 26663, containing 1C 34651, 42639,

520750627

52082545 GRAM domain 452134 2700 399844 10688 18676, 26664, containing 1C 34652, 42640,

520950628

52102546 GRAM domain 462838 2701 418302 10689 18677, 26665, containing 1C 34653, 42641,

521150629

52122547 GRAM domain 309731 2702 311657 10690 18678, 26666, containing 2 34654, 42642,

521350630

52142548 GRB2-binding 318469 2703 323075 10691 18679, 26667, adaptor protein, 34655, 42643, transmembrane 50631

52152549 GRB2-binding 396776 2704 379997 10692 18680, 26668, adaptor protein, 34656, 42644, transmembrane 50632

52162550 GRB2-binding 502276 2705 423113 10693 18681, 26669, adaptor protein, 34657, 42645, transmembrane 50633

52172551 GRB2-binding 511930 2706 422645 10694 18682, 26670, adaptor protein, 34658, 42646, transmembrane 50634

52182552 growth 374375 2707 363495 10695 18683, 26671, differentiation factor 34659, 42647, 5 opposite strand 50635

52192553 growth hormone 339736 2708 342214 10696 18684, 26672, inducible 34660, 42648, transmembrane 50636 protein

52202554 growth hormone 372134 2709 361207 10697 18685, 26673, inducible 34661, 42649, transmembrane 50637 protein

52212555 growth hormone 436406 2710 397663 10698 18686, 26674, inducible 34662, 42650, transmembrane 50638 protein

52222556 growth hormone 538477 2711 444366 10699 18687, 26675, inducible 34663, 42651, transmembrane 50639 protein

52232557 growth regulation by 269218 2712 269218 10700 18688, 26676, estrogen in breast 34664, 42652, cancer-like 50640

52242558 growth regulation by 400483 2713 383331 10701 18689, 26677, estrogen in breast 34665, 42653, cancer-like 50641

52252559 growth regulation by 424526 2714 412060 10702 18690, 26678, estrogen in breast 34666, 42654, cancer-like 50642 2560 growth regulation by 431264 2715 393125 10703 18691, 26679, estrogen in breast 34667, 42655, cancer-like 50643

52262561 GSGl-like 380897 2716 370282 10704 18692, 26680,

522734668, 42656, 50644

52282562 GSGl-like 380898 2717 370283 10705 18693, 26681,

522934669, 42657, 50645

52302563 GSGl-like 395724 2718 379074 10706 18694, 26682,

523134670, 42658, 50646

52322564 GSGl-like 447459 2719 394954 10707 18695, 26683,

523334671, 42659, 50647

52342565 GTP binding protein 324894 2720 313818 10708 18696, 26684, 3 (mitochondrial) 34672, 42660,

523550648

52362566 GTP binding protein 358792 2721 351644 10709 18697, 26685, 3 (mitochondrial) 34673, 42661,

523750649

52382567 GTP binding protein 361619 2722 354598 10710 18698, 26686, 3 (mitochondrial) 34674, 42662,

523950650

52402568 GTP binding protein 546035 2723 438301 10711 18699, 26687, 3 (mitochondrial) 34675, 42663,

524150651

52422569 GTP binding protein 600625 2724 473150 10712 18700, 26688, 3 (mitochondrial) 34676, 42664,

524350652

52442570 GTP binding protein 360059 2725 353168 10713 18701, 26689, 4 34677, 42665,

524550653

52462571 GTP binding protein 360803 2726 354040 10714 18702, 26690, 4 34678, 42666,

524750654

52482572 GTP binding protein 538293 2727 444277 10715 18703, 26691, 4 34679, 42667,

524950655

52502573 GTP binding protein 545048 2728 445473 10716 18704, 26692, 4 34680, 42668,

525150656

52522574 GTPase, IMAP 307271 2729 305107 10717 18705, 26693, family member 8 34681, 42669,

525350657

52542575 GTP-binding protein 305485 2730 303802 10718 18706, 26694, 8 (putative) 34682, 42670,

525550658

52562576 GTP-binding protein 383677 2731 373175 10719 18707, 26695, 8 (putative) 34683, 42671,

525750659

52582577 GTP-binding protein 383678 2732 373176 10720 18708, 26696, 8 (putative) 34684, 42672,

525950660 2578 GTP-binding protein 467752 2733 417632 10721 18709, 26697, 8 (putative) 34685, 42673,

526050661

52612579 GTP-binding protein 473129 2734 418514 10722 18710, 26698, 8 (putative) 34686, 42674,

526250662

52632580 GTP-binding protein 485330 2735 418877 10723 18711, 26699, 8 (putative) 34687, 42675,

526450663

52652581 guanine nucleotide 456394 2736 394470 10724 18712, 26700, binding protein (G 34688, 42676, protein), beta 50664 polypeptide 2-like 1

52662582 guanine nucleotide 512805 2737 426909 10725 18713, 26701, binding protein (G 34689, 42677, protein), beta 50665 polypeptide 2-like 1

52672583 guanine nucleotide 374293 2738 363411 10726 18714, 26702, binding protein (G 34690, 42678, protein), gamma 10 50666

52682584 guanine nucleotide 370982 2739 360021 10727 18715, 26703, binding protein (G 34691, 42679, protein), gamma 12 50667

52692585 guanine nucleotide 294117 2740 294117 10728 18716, 26704, binding protein (G 34692, 42680, protein), gamma 3 50668

52702586 guanine nucleotide 366597 2741 355556 10729 18717, 26705, binding protein (G 34693, 42681, protein), gamma 4 50669

52712587 guanine nucleotide 366598 2742 355557 10730 18718, 26706, binding protein (G 34694, 42682, protein), gamma 4 50670

52722588 guanine nucleotide 391854 2743 375727 10731 18719, 26707, binding protein (G 34695, 42683, protein), gamma 4 50671

52732589 guanine nucleotide 450593 2744 398629 10732 18720, 26708, binding protein (G 34696, 42684, protein), gamma 4 50672

52742590 guanine nucleotide 382159 2745 371594 10733 18721, 26709, binding protein (G 34697, 42685, protein), gamma 7 50673

52752591 guanine nucleotide 428834 2746 401781 10734 18722, 26710, binding protein (G 34698, 42686, protein), gamma 50674 transducing activity

5276polypeptide 1

52772592 guanine nucleotide 430875 2747 395756 10735 18723, 26711, binding protein (G 34699, 42687, protein), gamma 50675 transducing activity

5278polypeptide 1

52792593 guanine nucleotide 455502 2748 395857 10736 18724, 26712, binding protein (G 34700, 42688, protein), gamma 50676 transducing activity polypeptide 1

52802594 guanine nucleotide 398291 2749 381339 10737 18725, 26713, binding protein, 34701, 42689, alpha transducing 3 50677

52812595 guanine nucleotide 336470 2750 338573 10738 18726, 26714, binding protein-like 34702, 42690, 3 (nucleolar)-like 50678

52822596 guanine nucleotide 360845 2751 354091 10739 18727, 26715, binding protein-like 34703, 42691, 3 (nucleolar)-like 50679

52832597 GUF1 GTPase 281543 2752 281543 10740 18728, 26716, homolog (S. 34704, 42692, cerevisiae) 50680

52842598 haloacid 238379 2753 238379 10741 18729, 26717, dehalogenase-like 34705, 42693, hydrolase domain 50681 containing 3

52852599 haloacid 374180 2754 363295 10742 18730, 26718, dehalogenase-like 34706, 42694, hydrolase domain 50682 containing 3

52862600 HCG2044188Seven 316517 2755 321173 10743 18731, 26719, transmembrane helix 34707, 42695, receptorUncharacteri 50683 zed protein

52872601 HD domain 318787 2756 316242 10744 18732, 26720, containing 2 34708, 42696,

528850684

52892602 HD domain 398153 2757 381220 10745 18733, 26721, containing 2 34709, 42697,

529050685

52912603 HEAT repeat 339553 2758 343211 10746 18734, 26722, containing 8 34710, 42698,

529250686

52932604 HEAT repeat 371287 2759 360336 10747 18735, 26723, containing 8 34711, 42699,

529450687

52952605 HEAT repeat 395690 2760 379044 10748 18736, 26724, containing 8 34712, 42700,

529650688

52972606 HEAT repeat 414867 2761 403054 10749 18737, 26725, containing 8 34713, 42701,

529850689

52992607 HEAT repeat 421030 2762 396622 10750 18738, 26726, containing 8 34714, 42702,

530050690

53012608 HEAT repeat 454855 2763 401130 10751 18739, 26727, containing 8 34715, 42703,

530250691

53032609 HEAT repeat 545244 2764 442333 10752 18740, 26728, containing 8 34716, 42704,

530450692 2610 heat shock protein 285667 2765 285667 10753 18741, 26729, 70kDa family, 34717, 42705, member 13 50693

53052611 heat shock protein 544452 2766 441986 10754 18742, 26730, 70kDa family, 34718, 42706, member 13 50694

53062612 hedgehog 310417 2767 310621 10755 18743, 26731, acyltransferase-like 34719, 42707,

530750695

53082613 hedgehog 341477 2768 341177 10756 18744, 26732, acyltransferase-like 34720, 42708,

530950696

53102614 hedgehog 416756 2769 395779 10757 18745, 26733, acyltransferase-like 34721, 42709,

531150697

53122615 hedgehog 441594 2770 405423 10758 18746, 26734, acyltransferase-like 34722, 42710,

531350698

53142616 hematopoietic cell 246551 2771 246551 10759 18747, 26735, signal transducer 34723, 42711,

531550699

53162617 hematopoietic cell 437550 2772 400516 10760 18748, 26736, signal transducer 34724, 42712,

531750700

53182618 heparan sulfate 2596 2773 2596 10761 18749, 26737, (glucosamine) 3-0- 34725, 42713, sulfotransferase 1 50701, 56087,

531956120

53202619 heparan sulfate 510712 2774 422629 10762 18750, 26738, (glucosamine) 3-0- 34726, 42714, sulfotransferase 1 50702

53212620 heparan sulfate 514690 2775 425673 10763 18751, 26739, (glucosamine) 3-0- 34727, 42715, sulfotransferase 1 50703

53222621 heparan sulfate 293937 2776 293937 10764 18752, 26740, (glucosamine) 3-0- 34728, 42716, sulfotransferase 6 50704

53232622 heparan sulfate 443547 2777 390354 10765 18753, 26741, (glucosamine) 3-0- 34729, 42717, sulfotransferase 6 50705

53242623 heparan sulfate 454677 2778 416741 10766 18754, 26742, (glucosamine) 3-0- 34730, 42718, sulfotransferase 6 50706

53252624 hepatitis A virus 307851 2779 312002 10767 18755, 26743, cellular receptor 2 34731, 42719,

532650707

53272625 hephaestin-like 1 315765 2780 313699 10768 18756, 26744,

532834732, 42720, 50708

53292626 HERPUD family 311350 2781 310729 10769 18757, 26745, member 2 34733, 42721,

533050709

53312627 HERPUD family 396081 2782 379390 10770 18758, 26746, member 2 34734, 42722,

533250710 2628 HERV-H LTR- 357759 2783 350402 10771 18759, 26747, associating 2 34735, 42723,

533350711

53342629 HERV-H LTR- 462629 2784 419911 10772 18760, 26748, associating 2 34736, 42724,

533550712

53362630 HERV-H LTR- 463019 2785 419940 10773 18761, 26749, associating 2 34737, 42725,

533750713

53382631 HERV-H LTR- 467761 2786 419207 10774 18762, 26750, associating 2 34738, 42726,

533950714

53402632 HERV-H LTR- 482430 2787 418174 10775 18763, 26751, associating 2 34739, 42727,

534150715

53422633 HERV-H LTR- 489514 2788 417856 10776 18764, 26752, associating 2 34740, 42728,

534350716

53442634 heterogeneous 325495 2789 325376 10777 18765, 26753, nuclear 34741, 42729, ribonucleoprotein M 50717

53452635 heterogeneous 348943 2790 325732 10778 18766, 26754, nuclear 34742, 42730, ribonucleoprotein M 50718

53462636 heterogeneous 539473 2791 443840 10779 18767, 26755, nuclear 34743, 42731, ribonucleoprotein M 50719

53472637 heterogeneous 544159 2792 442876 10780 18768, 26756, nuclear 34744, 42732, ribonucleoprotein M 50720

53482638 hexokinase domain 354624 2793 346643 10781 18769, 26757, containing 1 34745, 42733,

534950721

53502639 hexokinase domain 395086 2794 378521 10782 18770, 26758, containing 1 34746, 42734,

535150722

53522640 hexokinase domain 395087 2795 378522 10783 18771, 26759, containing 1 34747, 42735,

535350723

53542641 HIG1 hypoxia 321331 2796 319393 10784 18772, 26760, inducible domain 34748, 42736, family, member 1A 50724

53552642 HIG1 hypoxia 418900 2797 402160 10785 18773, 26761, inducible domain 34749, 42737, family, member 1A 50725

53562643 HIG1 hypoxia 452906 2798 398064 10786 18774, 26762, inducible domain 34750, 42738, family, member 1A 50726

53572644 HIG1 hypoxia 253410 2799 253410 10787 18775, 26763, inducible domain 34751, 42739, family, member IB 50727

53582645 HIG1 hypoxia 274787 2800 274787 10788 18776, 26764, inducible domain 34752, 42740, family, member 2A 50728 2646 HIG1 hypoxia 311755 2801 307951 10789 18777, 26765, inducible domain 34753, 42741, family, member 2B 50729

53592647 hippocampus 370152 2802 359171 10790 18778, 26766, abundant transcript 1 34754, 42742,

536050730

53612648 hippocampus 421661 2803 411185 10791 18779, 26767, abundant transcript 1 34755, 42743,

536250731

53632649 hippocampus 277183 2804 277183 10792 18780, 26768, abundant transcript34756, 42744, like 1 50732

53642650 hippocampus 375344 2805 364493 10793 18781, 26769, abundant transcript34757, 42745, like 1 50733

53652651 hippocampus 428393 2806 405909 10794 18782, 26770, abundant transcript34758, 42746, like 1 50734

53662652 hippocampus 375223 2807 364371 10795 18783, 26771, abundant transcript34759, 42747, like 2 50735

53672653 histidine rich 354323 2808 346283 10796 18784, 26772, carboxyl terminus 1 34760, 42748,

536850736

53692654 hydroxycarboxylic 356987 2809 349478 10797 18785, 26773, acid receptor 1 34761, 42749,

537050737

53712655 hydroxycarboxylic 432564 2810 389255 10798 18786, 26774, acid receptor 1 34762, 42750,

537250738

53732656 hydroxycarboxylic 436083 2811 409980 10799 18787, 26775, acid receptor 1 34763, 42751,

537450739

53752657 hydroxycarboxylic 328880 2812 375066 10800 18788, 26776, acid receptor 2 34764, 42752,

537650740

53772658 hydroxycarboxylic 536970 2813 443556 10801 18789, 26777, acid receptor 2 34765, 42753,

537850741

53792659 hydroxy steroid (17- 322165 2814 318631 10802 18790, 26778, beta) dehydrogenase 34766, 42754, 6 homolog (mouse) 50742

53802660 hydroxy steroid (17- 554150 2815 452273 10803 18791, 26779, beta) dehydrogenase 34767, 42755, 6 homolog (mouse) 50743

53812661 hydroxy steroid (17- 554155 2816 451497 10804 18792, 26780, beta) dehydrogenase 34768, 42756, 6 homolog (mouse) 50744

53822662 hydroxy steroid (17- 554643 2817 451406 10805 18793, 26781, beta) dehydrogenase 34769, 42757, 6 homolog (mouse) 50745

53832663 hydroxy steroid (17- 555159 2818 450698 10806 18794, 26782, beta) dehydrogenase 34770, 42758, 6 homolog (mouse) 50746 2664 hydroxy steroid (17- 555805 2819 451753 10807 18795, 26783, beta) dehydrogenase 34771, 42759, 6 homolog (mouse) 50747

53842665 hydroxy steroid (17- 556650 2820 452103 10808 18796, 26784, beta) dehydrogenase 34772, 42760, 6 homolog (mouse) 50748

53852666 hydroxysteroid 219439 2821 219439 10809 18797, 26785, dehydrogenase like 34773, 42761, 1 50749

53862667 hydroxysteroid 434463 2822 407437 10810 18798, 26786, dehydrogenase like 34774, 42762, 1 50750

53872668 hyperpolarization 303230 2823 307342 10811 18799, 26787, activated cyclic 34775, 42763, nucleotide-gated 50751 potassium channel 1

53882669 hypocretin (orexin) 373705 2824 362809 10812 18800, 26788, receptor 1 34776, 42764,

538950752

53902670 hypocretin (orexin) 373706 2825 362810 10813 18801, 26789, receptor 1 34777, 42765,

539150753

53922671 hypocretin (orexin) 403528 2826 384387 10814 18802, 26790, receptor 1 34778, 42766,

539350754

53942672 hypocretin (orexin) 370862 2827 359899 10815 18803, 26791, receptor 2 34779, 42767,

539550755

53962673 IKBKB interacting 299157 2828 299157 10816 18804, 26792, protein 34780, 42768,

539750756

53982674 IKBKB interacting 342502 2829 343471 10817 18805, 26793, protein 34781, 42769,

539950757

54002675 IKBKB interacting 393042 2830 376762 10818 18806, 26794, protein 34782, 42770,

540150758

54022676 IKBKB interacting 420861 2831 398023 10819 18807, 26795, protein 34783, 42771,

540350759

54042677 immunoglobulin 327987 2832 332773 10820 18808, 26796, superfamily, DCC 34784, 42772, subclass, member 3 50760

54052678 immunoglobulin 443278 2833 388643 10821 18809, 26797, superfamily, DCC 34785, 42773, subclass, member 3 50761

54062679 immunoglobulin 352385 2834 319623 10822 18810, 26798, superfamily, DCC 34786, 42774, subclass, member 4 50762

54072680 immunoglobulin 356152 2835 348473 10823 18811, 26799, superfamily, DCC 34787, 42775, subclass, member 4 50763

54082681 immunoglobulin 354673 2836 346700 10824 18812, 26800, superfamily, 34788, 42776, member 11 50764 2682 immunoglobulin 393775 2837 377370 10825 18813, 26801, superfamily, 34789, 42777, member 11 50765

54092683 immunoglobulin 425327 2838 406092 10826 18814, 26802, superfamily, 34790, 42778, member 11 50766

54102684 immunoglobulin 402988 2839 385592 10827 18815, 26803, superfamily, 34791, 42779, member 23 50767

54112685 immunoglobulin 380588 2840 369962 10828 18816, 26804, superfamily, 34792, 42780, member 5 50768

54122686 immunoglobulin- 271417 2841 271417 10829 18817, 26805, like domain 34793, 42781, containing receptor 50769 2

54132687 inositol 1,4,5- 278071 2842 278071 10830 18818, 26806, trisphosphate 34794, 42782, receptor interacting 50770 protein

54142688 inositol 1,4,5- 337478 2843 337178 10831 18819, 26807, trisphosphate 34795, 42783, receptor interacting 50771 protein

54152689 inositol 1,4,5- 358187 2844 350915 10832 18820, 26808, trisphosphate 34796, 42784, receptor interacting 50772 protein

54162690 inositol 1,4,5- 458723 2845 414141 10833 18821, 26809, trisphosphate 34797, 42785, receptor interacting 50773 protein

54172691 inositol 1,4,5- 361124 2846 355121 10834 18822, 26810, trisphosphate 34798, 42786, receptor interacting 50774 protein-like 1

54182692 inositol 1,4,5- 439118 2847 389308 10835 18823, 26811, trisphosphate 34799, 42787, receptor interacting 50775 protein-like 1

54192693 inositol 1,4,5- 536814 2848 439566 10836 18824, 26812, trisphosphate 34800, 42788, receptor interacting 50776 protein-like 1

54202694 inositol 1,4,5- 542887 2849 438212 10837 18825, 26813, trisphosphate 34801, 42789, receptor interacting 50777 protein-like 1

54212695 inositol 1,4,5- 381440 2850 370849 10838 18826, 26814, trisphosphate 34802, 42790, receptor interacting 50778 protein-like 2

54222696 insulin receptor 372129 2851 361202 10839 18827, 26815, substrate 4 34803, 42791,

542350779 2697 integrator complex 389470 2852 374121 10840 18828, 26816, subunit 1 34804, 42792,

542450780

54252698 integrator complex 404767 2853 385722 10841 18829, 26817, subunit 1 34805, 42793,

542650781

54272699 integrator complex 251334 2854 251334 10842 18830, 26818, subunit 2 34806, 42794,

542850782

54292700 integrator complex 444766 2855 414237 10843 18831, 26819, subunit 2 34807, 42795,

543050783

54312701 integrator complex 330574 2856 327889 10844 18832, 26820, subunit 5 34808, 42796,

543250784

54332702 integrin alpha FG- 301678 2857 301678 10845 18833, 26821, GAP repeat 34809, 42797, containing 3 50785

54342703 integrin alpha FG- 399932 2858 382814 10846 18834, 26822, GAP repeat 34810, 42798, containing 3 50786

54352704 integrin alpha FG- 417499 2859 405659 10847 18835, 26823, GAP repeat 34811, 42799, containing 3 50787

54362705 integrin alpha FG- 419173 2860 388726 10848 18836, 26824, GAP repeat 34812, 42800, containing 3 50788

54372706 integrin alpha FG- 420046 2861 398433 10849 18837, 26825, GAP repeat 34813, 42801, containing 3 50789

54382707 integrin alpha FG- 426695 2862 392612 10850 18838, 26826, GAP repeat 34814, 42802, containing 3 50790

54392708 integrin alpha FG- 442458 2863 397477 10851 18839, 26827, GAP repeat 34815, 42803, containing 3 50791

54402709 integrin alpha FG- 447499 2864 395334 10852 18840, 26828, GAP repeat 34816, 42804, containing 3 50792

54412710 integrin alpha FG- 450082 2865 411394 10853 18841, 26829, GAP repeat 34817, 42805, containing 3 50793

54422711 integrin alpha FG- 453430 2866 399150 10854 18842, 26830, GAP repeat 34818, 42806, containing 3 50794

54432712 integrin, alpha 10 369304 2867 358310 10855 18843, 26831,

544434819, 42807, 50795

54452713 integrin, alpha 10 538811 2868 440011 10856 18844, 26832,

544634820, 42808, 50796

54472714 integrin, alpha 10 539363 2869 439894 10857 18845, 26833,

544834821, 42809, 50797 2715 integrin, alpha 10 543043 2870 439105 10858 18846, 26834,

544934822, 42810, 50798

54502716 integrin, alpha 8 378076 2871 367316 10859 18847, 26835,

545134823, 42811, 50799

54522717 integrin, alpha 8 538044 2872 443785 10860 18848, 26836,

545334824, 42812, 50800

54542718 integrin, alpha E 263087 2873 263087 10861 18849, 26837, (antigen CD 103, 34825, 42813, human mucosal 50801 lymphocyte antigen

54551; alpha

5456polypeptide)

54572719 integrin, beta 5 296181 2874 296181 10862 18850, 26838,

545834826, 42814, 50802

54592720 integrin, beta 8 222573 2875 222573 10863 18851, 26839,

546034827, 42815, 50803

54612721 integrin, beta 8 537992 2876 441561 10864 18852, 26840,

546234828, 42816, 50804

54632722 interaction protein 265198 2877 265198 10865 18853, 26841, for cytohesin 34829, 42817, exchange factors 1 50805

54642723 interaction protein 367220 2878 356189 10866 18854, 26842, for cytohesin 34830, 42818, exchange factors 1 50806

54652724 interaction protein 422970 2879 394751 10867 18855, 26843, for cytohesin 34831, 42819, exchange factors 1 50807

54662725 interaction protein 520261 2880 431004 10868 18856, 26844, for cytohesin 34832, 42820, exchange factors 1 50808

54672726 interferon alpha 553856 2881 452581 10869 18857, 26845, responsive protein 34833, 42821, isoform a 50809

54682727 interferon induced 340134 2882 344430 10870 18858, 26846, transmembrane 34834, 42822, protein 10 50810

54692728 interferon induced 382614 2883 372059 10871 18859, 26847, transmembrane 34835, 42823, protein 5 50811

54702729 interferon regulatory 330243 2884 329411 10872 18860, 26848, factor 7 34836, 42824,

547150812

54722730 interferon regulatory 348655 2885 331803 10873 18861, 26849, factor 7 34837, 42825,

547350813

54742731 interferon regulatory 397562 2886 380693 10874 18862, 26850, factor 7 34838, 42826,

547550814 2732 interferon regulatory 397566 2887 380697 10875 18863, 26851, factor 7 34839, 42827,

547650815

54772733 interferon regulatory 397570 2888 380700 10876 18864, 26852, factor 7 34840, 42828,

547850816

54792734 interferon regulatory 397574 2889 380704 10877 18865, 26853, factor 7 34841, 42829,

548050817

54812735 interferon, alpha- 393115 2890 376824 10878 18866, 26854, inducible protein 27- 34842, 42830, like 1 50818

54822736 interferon, alpha- 555523 2891 451851 10879 18867, 26855, inducible protein 27- 34843, 42831, like 1 50819

54832737 interferon, alpha- 238609 2892 238609 10880 18868, 26856, inducible protein 27- 34844, 42832, like 2 50820

54842738 interferon, alpha- 339145 2893 342513 10881 18869, 26857, inducible protein 6 34845, 42833,

548550821

54862739 interferon, alpha- 361157 2894 354736 10882 18870, 26858, inducible protein 6 34846, 42834,

548750822

54882740 interferon, alpha- 362020 2895 355152 10883 18871, 26859, inducible protein 6 34847, 42835,

548950823

54902741 interleukin 10 290200 2896 290200 10884 18872, 26860, receptor, beta 34848, 42836,

549150824

54922742 interleukin 10 539894 2897 442753 10885 18873, 26861, receptor, beta 34849, 42837,

549350825

54942743 interleukin 20 309741 2898 311979 10886 18874, 26862, receptor beta 34850, 42838,

549550826

54962744 interleukin 20 329582 2899 328133 10887 18875, 26863, receptor beta 34851, 42839,

549750827

54982745 interleukin 22 270800 2900 270800 10888 18876, 26864, receptor, alpha 1 34852, 42840,

549950828

55002746 interleukin 27 263379 2901 263379 10889 18877, 26865, receptor, alpha 34853, 42841,

550150829

55022747 interleukin 7 511982 2902 425309 10890 18878, 26866, receptor 34854, 42842,

550350830

55042748 interleukin 7 514217 2903 427688 10891 18879, 26867, receptor 34855, 42843,

550550831

55062749 IQ motif containing 325979 2904 313772 10892 18880, 26868, E 34856, 42844,

550750832 2750 IQ motif containing 402050 2905 385597 10893 18881, 26869, E 34857, 42845,

550850833

55092751 IQ motif containing 404984 2906 385945 10894 18882, 26870, E 34858, 42846,

551050834

55112752 IQ motif containing 422276 2907 402108 10895 18883, 26871, E 34859, 42847,

551250835

55132753 IQ motif containing 423395 2908 413570 10896 18884, 26872, E 34860, 42848,

551450836

55152754 IQ motif containing 438376 2909 396178 10897 18885, 26873, E 34861, 42849,

551650837

55172755 IQ motif containing 361170 2910 354451 10898 18886, 26874, GTPase activating 34862, 42850, protein 3 50838

55182756 iron-sulfur cluster 556816 2911 452007 10899 18887, 26875, assembly 2 homolog 34863, 42851, (S. cerevisiae) 50839

55192757 IZUMO family 293405 2912 293405 10900 18888, 26876, member 2 34864, 42852,

552050840

55212758 IZUMO family 377000 2913 366199 10901 18889, 26877, member 2 34865, 42853,

552250841

55232759 IZUMO family 543880 2914 438895 10902 18890, 26878, member 3 34866, 42854,

552450842

55252760 izumo sperm-egg 332955 2915 327786 10903 18891, 26879, fusion 1 34867, 42855,

552650843

55272761 jagunal homolog 1 307768 2916 306106 10904 18892, 26880, (Drosophila) 34868, 42856,

552850844

55292762 jagunal homolog 1 543379 2917 442889 10905 18893, 26881, (Drosophila) 34869, 42857,

553050845

55312763 janus kinase and 282924 2918 282924 10906 18894, 26882, microtubule 34870, 42858, interacting protein 1 50846

55322764 janus kinase and 409021 2919 386711 10907 18895, 26883, microtubule 34871, 42859, interacting protein 1 50847

55332765 janus kinase and 409371 2920 387042 10908 18896, 26884, microtubule 34872, 42860, interacting protein 1 50848

55342766 janus kinase and 409831 2921 386925 10909 18897, 26885, microtubule 34873, 42861, interacting protein 1 50849

55352767 janus kinase and 418227 2922 406526 10910 18898, 26886, microtubule 34874, 42862, interacting protein 1 50850 2768 janus kinase and 425341 2923 401449 10911 18899, 26887, microtubule 34875, 42863, interacting protein 1 50851

55362769 janus kinase and 429819 2924 398750 10912 18900, 26888, microtubule 34876, 42864, interacting protein 1 50852

55372770 janus kinase and 265272 2925 265272 10913 18901, 26889, microtubule 34877, 42865, interacting protein 2 50853

55382771 janus kinase and 333010 2926 328989 10914 18902, 26890, microtubule 34878, 42866, interacting protein 2 50854

55392772 janus kinase and 507386 2927 421398 10915 18903, 26891, microtubule 34879, 42867, interacting protein 2 50855

55402773 janus kinase and 539401 2928 439220 10916 18904, 26892, microtubule 34880, 42868, interacting protein 2 50856

55412774 Janus kinase and 298622 2929 298622 10917 18905, 26893, microtubule 34881, 42869, interacting protein 3 50857

55422775 junctional 300961 2930 300961 10918 18906, 26894, sarcoplasmic 34882, 42870, reticulum protein 1 50858

55432776 junctophilin 4 356300 2931 348648 10919 18907, 26895,

554434883, 42871, 50859

55452777 junctophilin 4 397118 2932 380307 10920 18908, 26896,

554634884, 42872, 50860

55472778 junctophilin 4 543864 2933 445800 10921 18909, 26897,

554834885, 42873, 50861

55492779 KDEL (Lys-Asp- 323468 2934 315386 10922 18910, 26898, Glu-Leu) containing 34886, 42874, 2 50862

55502780 KDEL (Lys-Asp- 375648 2935 364799 10923 18911, 26899, Glu-Leu) containing 34887, 42875, 2 50863

55512781 KDEL (Lys-Asp- 434945 2936 413429 10924 18912, 26900, Glu-Leu) containing 34888, 42876, 2 50864

55522782 KDEL (Lys-Asp- 330720 2937 329471 10925 18913, 26901, Glu-Leu) 34889, 42877, endoplasmic 50865 reticulum protein

5553retention receptor 1

55542783 KDEL (Lys-Asp- 258739 2938 258739 10926 18914, 26902, Glu-Leu) 34890, 42878, endoplasmic 50866 reticulum protein

5555retention receptor 2 2784 KDEL (Lys-Asp- 490996 2939 420501 10927 18915, 26903, Glu-Leu) 34891, 42879, endoplasmic 50867 reticulum protein

5556retention receptor 2

55572785 KDEL (Lys-Asp- 216014 2940 216014 10928 18916, 26904, Glu-Leu) 34892, 42880, endoplasmic 50868 reticulum protein

5558retention receptor 3

55592786 KDEL (Lys-Asp- 409006 2941 386918 10929 18917, 26905, Glu-Leu) 34893, 42881, endoplasmic 50869 reticulum protein

5560retention receptor 3

55612787 kelch domain 400664 2942 383505 10930 18918, 26906, containing 7A 34894, 42882,

556250870

55632788 kelch domain 540290 2943 439465 10931 18919, 26907, containing 7A 34895, 42883,

556450871

55652789 kelch-like 17 338591 2944 343930 10932 18920, 26908, (Drosophila) 34896, 42884,

556650872

55672790 kelch-like 17 455747 2945 389373 10933 18921, 26909, (Drosophila) 34897, 42885,

556850873

55692791 kelch-like 17 540863 2946 439107 10934 18922, 26910, (Drosophila) 34898, 42886,

557050874

55712792 keratinocyte 295682 2947 295682 10935 18923, 26911, associated protein 2 34899, 42887,

557250875

55732793 keratinocyte 288873 2948 288873 10936 18924, 26912, associated protein 3 34900, 42888,

557450876

55752794 keratinocyte 407293 2949 384689 10937 18925, 26913, associated protein 3 34901, 42889,

557650877

55772795 keratinocyte 452499 2950 388115 10938 18926, 26914, associated protein 3 34902, 42890,

557850878

55792796 keratinocyte 543753 2951 442400 10939 18927, 26915, associated protein 3 34903, 42891,

558050879

2797 KIAA0090 477853 2952 420608 10940 18928, 26916,

558234904, 42892, 50880

2798 KIAA0195 314256 2953 313885 10941 18929, 26917,

558434905, 42893, 50881

2799 KIAA0247 342745 2954 344424 10942 18930, 26918,

34906, 42894, 50882 2800 KIAA0317 356357 2955 348714 10943 18931, 26919,

558734907, 42895, 50883

55882801 KIAA0319-like 325722 2956 318406 10944 18932, 26920,

558934908, 42896, 50884

2802 KIAA0922 409663 2957 386574 10945 18933, 26921,

559134909, 42897, 50885

2803 KIAA1009 403245 2958 385215 10946 18934, 26922,

559334910, 42898, 50886

2804 KIAA1024 305428 2959 307461 10947 18935, 26923,

559534911, 42899, 50887

2805 KIAA1244 251691 2960 251691 10948 18936, 26924,

559734912, 42900, 50888

2806 KIAA1324 369939 2961 358955 10949 18937, 26925,

559934913, 42901, 50889

2807 KIAA1467 197268 2962 197268 10950 18938, 26926,

560134914, 42902, 50890

2808 KIAA1467 416494 2963 394063 10951 18939, 26927,

560334915, 42903, 50891

2809 KIAA1644 381176 2964 370568 10952 18940, 26928,

560534916, 42904, 50892

2810 KIAA1683 359737 2965 352774 10953 18941, 26929,

560734917, 42905, 50893

2811 KIAA1797 338382 2966 344307 10954 18942, 26930,

560934918, 42906, 50894

2812 KIAA1797 380249 2967 369599 10955 18943, 26931,

561134919, 42907, 50895

2813 KIAA1919 368847 2968 357840 10956 18944, 26932,

561334920, 42908, 50896

2814 KIAA2013 376572 2969 365756 10957 18945, 26933,

561534921, 42909, 50897

56162815 killer cell 291860 2970 291860 10958 18946, 26934, immunoglobulin- 34922, 42910, like receptor, three 50898 domains, long

5617cytoplasmic tail, 3

56182816 killer cell lectin-like 535540 2971 438244 10959 18947, 26935, receptor subfamily 34923, 42911, F, member 2 50899 2817 killer cell lectin-like 340940 2972 339356 10960 18948, 26936, receptor subfamily 34924, 42912, G, member 2 50900

56192818 killer cell lectin-like 393039 2973 376759 10961 18949, 26937, receptor subfamily 34925, 42913, G, member 2 50901

56202819 kin of lRRE like 359209 2974 352138 10962 18950, 26938, (Drosophila) 34926, 42914,

562150902

56222820 kin of lRRE like 360089 2975 353202 10963 18951, 26939, (Drosophila) 34927, 42915,

562350903

56242821 kin of lRRE like 368173 2976 357155 10964 18952, 26940, (Drosophila) 34928, 42916,

562550904

56262822 kin of lRRE like 392272 2977 376098 10965 18953, 26941, (Drosophila) 34929, 42917,

562750905

56282823 kin of lRRE like 416935 2978 389674 10966 18954, 26942, (Drosophila) 34930, 42918,

562950906

56302824 kinase D-interacting 256707 2979 256707 10967 18955, 26943, substrate, 220kDa 34931, 42919,

563150907

56322825 kinase D-interacting 319688 2980 319947 10968 18956, 26944, substrate, 220kDa 34932, 42920,

563350908

56342826 kinase D-interacting 418530 2981 414923 10969 18957, 26945, substrate, 220kDa 34933, 42921,

563550909

56362827 kinase D-interacting 427284 2982 411849 10970 18958, 26946, substrate, 220kDa 34934, 42922,

563750910

56382828 kinase D-interacting 473731 2983 418974 10971 18959, 26947, substrate, 220kDa 34935, 42923,

563950911

56402829 kinase D-interacting 541927 2984 446229 10972 18960, 26948, substrate, 220kDa 34936, 42924,

564150912

56422830 kinesin family 354981 2985 347076 10973 18961, 26949, member 16B 34937, 42925,

564350913

56442831 kinesin family 355755 2986 347995 10974 18962, 26950, member 16B 34938, 42926,

564550914

56462832 kinesin family 377997 2987 367236 10975 18963, 26951, member 16B 34939, 42927,

564750915

56482833 kinesin family 378003 2988 367242 10976 18964, 26952, member 16B 34940, 42928,

564950916

56502834 kinesin family 408042 2989 384164 10977 18965, 26953, member 16B 34941, 42929,

565150917 2835 kinesin family 263181 2990 263181 10978 18966, 26954, member 18A 34942, 42930,

565250918

56532836 kringle containing 327813 2991 331242 10979 18967, 26955, transmembrane 34943, 42931, protein 1 50919

56542837 kringle containing 400335 2992 383189 10980 18968, 26956, transmembrane 34944, 42932, protein 1 50920

56552838 kringle containing 400338 2993 383192 10981 18969, 26957, transmembrane 34945, 42933, protein 1 50921

56562839 kringle containing 407188 2994 385431 10982 18970, 26958, transmembrane 34946, 42934, protein 1 50922

56572840 lactamase, beta 2 276590 2995 276590 10983 18971, 26959,

565834947, 42935, 50923

56592841 lactamase, beta 2 522447 2996 428801 10984 18972, 26960,

566034948, 42936, 50924

56612842 lactase-like 341509 2997 343490 10985 18973, 26961,

566234949, 42937, 50925

56632843 lactase-like 537670 2998 445419 10986 18974, 26962,

566434950, 42938, 50926

56652844 lactation elevated 1 368977 2999 357973 10987 18975, 26963,

566634951, 42939, 50927

56672845 late 278671 3000 278671 10988 18976, 26964, endosomal/lysosoma 34952, 42940, 1 adaptor, MAPK 50928 and MTOR activator

56681

56692846 late 368302 3001 357285 10989 18977, 26965, endosomal/lysosoma 34953, 42941, 1 adaptor, MAPK 50929 and MTOR activator

56702

56712847 late 368304 3002 357287 10990 18978, 26966, endosomal/lysosoma 34954, 42942, 1 adaptor, MAPK 50930 and MTOR activator

56722

56732848 late 368305 3003 357288 10991 18979, 26967, endosomal/lysosoma 34955, 42943, 1 adaptor, MAPK 50931 and MTOR activator

56742

56752849 late 499666 3004 424183 10992 18980, 26968, endosomal/lysosoma 34956, 42944, 1 adaptor, MAPK 50932 and MTOR activator

56763 2850 latrophilin 1 340736 3005 340688 10993 18981, 26969,

567734957, 42945, 50933

56782851 latrophilin 1 361434 3006 355328 10994 18982, 26970,

567934958, 42946, 50934

56802852 latrophilin 2 271029 3007 271029 10995 18983, 26971,

568134959, 42947, 50935

56822853 latrophilin 2 319517 3008 322270 10996 18984, 26972,

568334960, 42948, 50936

56842854 latrophilin 2 335786 3009 337306 10997 18985, 26973,

568534961, 42949, 50937

56862855 latrophilin 2 359929 3010 353006 10998 18986, 26974,

568734962, 42950, 50938

56882856 latrophilin 2 370713 3011 359748 10999 18987, 26975,

568934963, 42951, 50939

56902857 latrophilin 2 370715 3012 359750 11000 18988, 26976,

569134964, 42952, 50940

56922858 latrophilin 2 370717 3013 359752 11001 18989, 26977,

569334965, 42953, 50941

56942859 latrophilin 2 370721 3014 359756 11002 18990, 26978,

569534966, 42954, 50942

56962860 latrophilin 2 370723 3015 359758 11003 18991, 26979,

569734967, 42955, 50943

56982861 latrophilin 2 370725 3016 359760 11004 18992, 26980,

569934968, 42956, 50944

57002862 latrophilin 2 370727 3017 359762 11005 18993, 26981,

570134969, 42957, 50945

57022863 latrophilin 2 370728 3018 359763 11006 18994, 26982,

570334970, 42958, 50946

57042864 latrophilin 2 370730 3019 359765 11007 18995, 26983,

570534971, 42959, 50947

57062865 latrophilin 2 394879 3020 378344 11008 18996, 26984,

570734972, 42960, 50948

57082866 latrophilin 2 402328 3021 385853 11009 18997, 26985,

570934973, 42961, 50949

57102867 latrophilin 2 449420 3022 397740 11010 18998, 26986,

571134974, 42962, 50950 2868 latrophilin 3 280009 3023 280009 11011 18999, 26987,

571234975, 42963, 50951

57132869 latrophilin 3 295349 3024 295349 11012 19000, 26988,

571434976, 42964, 50952

57152870 latrophilin 3 502815 3025 424402 11013 19001, 26989,

571634977, 42965, 50953

57172871 latrophilin 3 504896 3026 423434 11014 19002, 26990,

571834978, 42966, 50954

57192872 latrophilin 3 506700 3027 424120 11015 19003, 26991,

572034979, 42967, 50955

57212873 latrophilin 3 506720 3028 420931 11016 19004, 26992,

572234980, 42968, 50956

57232874 latrophilin 3 506746 3029 425884 11017 19005, 26993,

572434981, 42969, 50957

57252875 latrophilin 3 507164 3030 421476 11018 19006, 26994,

572634982, 42970, 50958

57272876 latrophilin 3 507625 3031 421372 11019 19007, 26995,

572834983, 42971, 50959

57292877 latrophilin 3 508693 3032 424030 11020 19008, 26996,

573034984, 42972, 50960

57312878 latrophilin 3 508946 3033 421627 11021 19009, 26997,

573234985, 42973, 50961

57332879 latrophilin 3 509896 3034 423787 11022 19010, 26998,

573434986, 42974, 50962

57352880 latrophilin 3 511324 3035 425033 11023 19011, 26999,

573634987, 42975, 50963

57372881 latrophilin 3 512091 3036 423388 11024 19012, 27000,

573834988, 42976, 50964

57392882 latrophilin 3 514157 3037 425201 11025 19013, 27001,

574034989, 42977, 50965

57412883 latrophilin 3 514591 3038 422533 11026 19014, 27002,

574234990, 42978, 50966

57432884 latrophilin 3 514996 3039 424258 11027 19015, 27003,

574434991, 42979, 50967

57452885 latrophilin 3 534975 3040 437800 11028 19016, 27004,

574634992, 42980, 50968 2886 latrophilin 3 545650 3041 439831 11029 19017, 27005,

574734993, 42981, 50969

57482887 layilin 375614 3042 364764 11030 19018, 27006,

574934994, 42982, 50970

57502888 layilin 375615 3043 364765 11031 19019, 27007,

575134995, 42983, 50971

57522889 layilin 436913 3044 392942 11032 19020, 27008,

575334996, 42984, 50972

57542890 layilin 541011 3045 439524 11033 19021, 27009,

575534997, 42985, 50973

57562891 layilin 525866 3046 434300 11034 19022, 27010,

575734998, 42986, 50974

57582892 lectin, mannose- 303127 3047 303366 11035 19023, 27011, binding 2 34999, 42987,

575950975

57602893 lectin, mannose- 539488 3048 445179 11036 19024, 27012, binding 2 35000, 42988,

576150976

57622894 lectin, mannose- 264963 3049 264963 11037 19025, 27013, binding 2-like 35001, 42989,

576350977

57642895 lectin, mannose- 377079 3050 366280 11038 19026, 27014, binding 2-like 35002, 42990,

576550978

57662896 lectin, mannose- 426463 3051 396391 11039 19027, 27015, binding 2-like 35003, 42991,

576750979

57682897 lectin, mannose- 534882 3052 438501 11040 19028, 27016, binding 2-like 35004, 42992,

576950980

57702898 lectin, mannose- 537039 3053 441701 11041 19029, 27017, binding 2-like 35005, 42993,

577150981

57722899 lectin, mannose- 309664 3054 310431 11042 19030, 27018, binding, 1 like 35006, 42994,

577350982

57742900 lectin, mannose- 379709 3055 369031 11043 19031, 27019, binding, 1 like 35007, 42995,

577550983

57762901 lectin, mannose- 456603 3056 407216 11044 19032, 27020, binding, 1 like 35008, 42996,

577750984

57782902 LEM domain 367149 3057 356117 11045 19033, 27021, containing 1 35009, 42997,

577950985

57802903 LEM domain 367151 3058 356119 11046 19034, 27022, containing 1 35010, 42998,

578150986 2904 LEM domain 367152 3059 356120 11047 19035, 27023, containing 1 35011, 42999,

578250987

57832905 LEM domain 367153 3060 356121 11048 19036, 27024, containing 1 35012, 43000,

578450988

57852906 LEM domain 367154 3061 356122 11049 19037, 27025, containing 1 35013, 43001,

578650989

57872907 LEM domain 391936 3062 375801 11050 19038, 27026, containing 1 35014, 43002,

578850990

57892908 LEM domain 293760 3063 293760 11051 19039, 27027, containing 2 35015, 43003,

579050991

57912909 LEM domain 508327 3064 421704 11052 19040, 27028, containing 2 35016, 43004,

579250992

57932910 LEM domain 513701 3065 423619 11053 19041, 27029, containing 2 35017, 43005,

579450993

57952911 lemur tyrosine 270238 3066 270238 11054 19042, 27030, kinase 3 35018, 43006,

579650994

57972912 leprecan-like 2 290510 3067 290510 11055 19043, 27031,

579835019, 43007, 50995

57992913 leprecan-like 2 396725 3068 379951 11056 19044, 27032,

580035020, 43008, 50996

58012914 leprecan-like 2 451242 3069 410202 11057 19045, 27033,

580235021, 43009, 50997

58032915 LETM1 domain 262055 3070 262055 11058 19046, 27034, containing 1 35022, 43010,

580450998

58052916 LETM1 domain 380123 3071 369466 11059 19047, 27035, containing 1 35023, 43011,

580650999

58072917 LETM1 domain 448283 3072 397107 11060 19048, 27036, containing 1 35024, 43012,

580851000

58092918 LETM1 domain 550929 3073 450163 11061 19049, 27037, containing 1 35025, 43013,

581051001

58112919 LETM1 domain 418425 3074 389903 11062 19050, 27038, containing 1 35026, 43014,

581251002

58132920 leucine rich repeat 368820 3075 357810 11063 19051, 27039, and Ig domain 35027, 43015, containing 4 51003

58142921 leucine rich repeat 347624 3076 306276 11064 19052, 27040, containing 15 35028, 43016,

581551004 2922 leucine rich repeat 428839 3077 413707 11065 19053, 27041, containing 15 35029, 43017,

581651005

58172923 leucine rich repeat 439944 3078 389128 11066 19054, 27042, containing 15 35030, 43018,

581851006

58192924 leucine rich repeat 380055 3079 369395 11067 19055, 27043, containing 19 35031, 43019,

582051007

58212925 leucine rich repeat 529415 3080 434849 11068 19056, 27044, containing 24 35032, 43020,

582251008

58232926 leucine rich repeat 291592 3081 291592 11069 19057, 27045, containing 3 35033, 43021,

582451009

58252927 leucine rich repeat 471776 3082 441142 11070 19058, 27046, containing 3 35034, 43022,

582651010

58272928 leucine rich repeat 260061 3083 260061 11071 19059, 27047, containing 32 35035, 43023,

582851011

58292929 leucine rich repeat 404995 3084 385766 11072 19060, 27048, containing 32 35036, 43024,

583051012

58312930 leucine rich repeat 407242 3085 384126 11073 19061, 27049, containing 32 35037, 43025,

583251013

58332931 leucine rich repeat 421973 3086 413331 11074 19062, 27050, containing 32 35038, 43026,

583451014

58352932 leucine rich repeat 328557 3087 328625 11075 19063, 27051, containing 33 35039, 43027,

583651015

58372933 leucine rich repeat 584306 3088 464535 11076 19064, 27052, containing 37 35040, 43028, member A3 51016

58382934 leucine rich repeat 319651 3089 325713 11077 19065, 27053, containing 37, 35041, 43029, member A3 51017

58392935 leucine rich repeat 334962 3090 335617 11078 19066, 27054, containing 37, 35042, 43030, member A3 51018

58402936 leucine rich repeat 339474 3091 344298 11079 19067, 27055, containing 37, 35043, 43031, member A3 51019

58412937 leucine rich repeat 400877 3092 383674 11080 19068, 27056, containing 37, 35044, 43032, member A3 51020

58422938 leucine rich repeat 320254 3093 326324 11081 19069, 27057, containing 37A 35045, 43033,

584351021

58442939 leucine rich repeat 393466 3094 377109 11082 19070, 27058, containing 37A 35046, 43034,

584551022 2940 leucine rich repeat 327564 3095 332536 11083 19071, 27059, containing 37B 35047, 43035,

584651023

58472941 leucine rich repeat 341671 3096 340519 11084 19072, 27060, containing 37B 35048, 43036,

584851024

58492942 leucine rich repeat 394713 3097 378202 11085 19073, 27061, containing 37B 35049, 43037,

585051025

58512943 leucine rich repeat 543378 3098 443345 11086 19074, 27062, containing 37B 35050, 43038,

585251026

58532944 leucine rich repeat 376085 3099 365253 11087 19075, 27063, containing 38 35051, 43039,

585451027

58552945 leucine rich repeat 396641 3100 379880 11088 19076, 27064, containing 3B 35052, 43040,

585651028

58572946 leucine rich repeat 414619 3101 389764 11089 19077, 27065, containing 3B 35053, 43041,

585851029

58592947 leucine rich repeat 417744 3102 406370 11090 19078, 27066, containing 3B 35054, 43042,

586051030

58612948 leucine rich repeat 432040 3103 398184 11091 19079, 27067, containing 3B 35055, 43043,

586251031

58632949 leucine rich repeat 456208 3104 394940 11092 19080, 27068, containing 3B 35056, 43044,

586451032

58652950 leucine rich repeat 377924 3105 367157 11093 19081, 27069, containing 3C 35057, 43045,

586651033

58672951 leucine rich repeat 249363 3106 249363 11094 19082, 27070, containing 4 35058, 43046,

586851034

58692952 leucine rich repeat 476782 3107 418093 11095 19083, 27071, containing 4 35059, 43047,

587051035

58712953 leucine rich repeat 478726 3108 417795 11096 19084, 27072, containing 4 35060, 43048,

587251036

58732954 leucine rich repeat 389201 3109 373853 11097 19085, 27073, containing 4B 35061, 43049,

587451037

58752955 leucine rich repeat 535879 3110 440583 11098 19086, 27074, containing 4B 35062, 43050,

587651038

58772956 leucine rich repeat 294818 3111 294818 11099 19087, 27075, containing 52 35063, 43051,

587851039

58792957 leucine rich repeat 497933 3112 419542 11100 19088, 27076, containing 55 35064, 43052,

588051040 2958 leucine rich repeat 225972 3113 225972 11101 19089, 27077, containing 59 35065, 43053,

588151041

58822959 leucine rich repeat 343457 3114 341944 11102 19090, 27078, containing 66 35066, 43054,

588351042

58842960 leucine rich repeat 334994 3115 399441 11103 19091, 27079, containing 70 35067, 43055,

588551043

58862961 leucine rich repeat 319331 3116 314901 11104 19092, 27080, neuronal 1 35068, 43056,

588751044

58882962 leucine rich repeat 367175 3117 356143 11105 19093, 27081, neuronal 2 35069, 43057,

588951045

58902963 leucine rich repeat 367176 3118 356144 11106 19094, 27082, neuronal 2 35070, 43058,

589151046

58922964 leucine rich repeat 367177 3119 356145 11107 19095, 27083, neuronal 2 35071, 43059,

589351047

58942965 leucine rich repeat 308478 3120 312001 11108 19096, 27084, neuronal 3 35072, 43060,

589551048

58962966 leucine rich repeat 422987 3121 412417 11109 19097, 27085, neuronal 3 35073, 43061,

589751049

58982967 leucine rich repeat 451085 3122 397312 11110 19098, 27086, neuronal 3 35074, 43062,

589951050

59002968 leucine rich repeat 378858 3123 368135 11111 19099, 27087, neuronal 4 35075, 43063,

590151051

59022969 leucine zipper-EF- 297720 3124 297720 11112 19100, 27088, hand containing 35076, 43064, transmembrane 51052 protein 2

59032970 leucine zipper-EF- 379957 3125 369291 11113 19101, 27089, hand containing 35077, 43065, transmembrane 51053 protein 2

59042971 leucine zipper-EF- 524874 3126 431211 11114 19102, 27090, hand containing 35078, 43066, transmembrane 51054 protein 2

59052972 leucine zipper-EF- 526356 3127 432955 11115 19103, 27091, hand containing 35079, 43067, transmembrane 51055 protein 2

59062973 leucine zipper-EF- 527334 3128 432080 11116 19104, 27092, hand containing 35080, 43068, transmembrane 51056 protein 2 2974 leucine zipper-EF- 527710 3129 434867 11117 19105, 27093, hand containing 35081, 43069, transmembrane 51057 protein 2

59072975 leucine zipper-EF- 518883 3130 429019 11118 19106, 27094, hand containing 35082, 43070, transmembrane 51058 protein 2

59082976 leucine zipper-EF- 523983 3131 428765 11119 19107, 27095, hand containing 35083, 43071, transmembrane 51059 protein 2

59092977 leucine-rich repeat, 372105 3132 361177 11120 19108, 27096, immunoglobulin- 35084, 43072, like and 51060 transmembrane

5910domains 1

59112978 leucine-rich repeat, 327908 3133 328222 11121 19109, 27097, immunoglobulin- 35085, 43073, like and 51061 transmembrane

5912domains 3

59132979 leucine-rich repeat, 379920 3134 369252 11122 19110, 27098, immunoglobulin- 35086, 43074, like and 51062 transmembrane

5914domains 3

59152980 leucine-rich repeat, 409621 3135 386734 11123 19111, 27099, immunoglobulin- 35087, 43075, like and 51063 transmembrane

5916domains 3

59172981 leucine-rich repeats 320743 3136 326759 11124 19112, 27100, and 35088, 43076, immunoglobulin- 51064 like domains 3

59182982 leucine-rich repeats 379141 3137 368436 11125 19113, 27101, and 35089, 43077, immunoglobulin- 51065 like domains 3

59192983 leucine-rich repeats 273286 3138 273286 11126 19114, 27102, and transmembrane 35090, 43078, domains 1 51066

59202984 leucine-rich repeats 493075 3139 419772 11127 19115, 27103, and transmembrane 35091, 43079, domains 1 51067

59212985 leucine-rich repeats 299194 3140 299194 11128 19116, 27104, and transmembrane 35092, 43080, domains 2 51068

59222986 leucine-rich repeats 424079 3141 394967 11129 19117, 27105, and transmembrane 35093, 43081, domains 2 51069

59232987 leucine-rich repeats 535041 3142 444737 11130 19118, 27106, and transmembrane 35094, 43082, domains 2 51070 2988 leucine-rich repeats 543818 3143 446278 11131 19119, 27107, and transmembrane 35095, 43083, domains 2 51071

59242989 leukocyte 291759 3144 291759 11132 19120, 27108, immunoglobulin- 35096, 43084, like receptor, 51072 subfamily A (with

5925TM domain),

5926member 4

59272990 LIM and senescent 332345 3145 331775 11133 19121, 27109, cell antigen-like 35097, 43085, domains 1 51073

59282991 LIM and senescent 338045 3146 337598 11134 19122, 27110, cell antigen-like 35098, 43086, domains 1 51074

59292992 LIM and senescent 393310 3147 376987 11135 19123, 27111, cell antigen-like 35099, 43087, domains 1 51075

59302993 LIM and senescent 393314 3148 376990 11136 19124, 27112, cell antigen-like 35100, 43088, domains 1 51076

59312994 LIM and senescent 409441 3149 387264 11137 19125, 27113, cell antigen-like 35101, 43089, domains 1 51077

59322995 LIM and senescent 410093 3150 386926 11138 19126, 27114, cell antigen-like 35102, 43090, domains 1 51078

59332996 LIM and senescent 542845 3151 446121 11139 19127, 27115, cell antigen-like 35103, 43091, domains 1 51079

59342997 LIM and senescent 544547 3152 437912 11140 19128, 27116, cell antigen-like 35104, 43092, domains 1 51080

59352998 LIM and senescent 324938 3153 326888 11141 19129, 27117, cell antigen-like 35105, 43093, domains 2 51081

59362999 LIM and senescent 342067 3154 339689 11142 19130, 27118, cell antigen-like 35106, 43094, domains 2 51082

59373000 LIM and senescent 355119 3155 347240 11143 19131, 27119, cell antigen-like 35107, 43095, domains 2 51083

59383001 LIM and senescent 409254 3156 386907 11144 19132, 27120, cell antigen-like 35108, 43096, domains 2 51084

59393002 LIM and senescent 409286 3157 386252 11145 19133, 27121, cell antigen-like 35109, 43097, domains 2 51085

59403003 LIM and senescent 409455 3158 386383 11146 19134, 27122, cell antigen-like 35110, 43098, domains 2 51086

59413004 LIM and senescent 409754 3159 386345 11147 19135, 27123, cell antigen-like 35111, 43099, domains 2 51087 3005 LIM and senescent 409808 3160 386637 11148 19136, 27124, cell antigen-like 35112, 43100, domains 2 51088

59423006 LIM and senescent 410011 3161 387002 11149 19137, 27125, cell antigen-like 35113, 43101, domains 2 51089

59433007 LIM and senescent 410038 3162 386570 11150 19138, 27126, cell antigen-like 35114, 43102, domains 2 51090

59443008 LIM and senescent 410109 3163 386240 11151 19139, 27127, cell antigen-like 35115, 43103, domains 2 51091

59453009 LIM and senescent 422034 3164 416224 11152 19140, 27128, cell antigen-like 35116, 43104, domains 2 51092

59463010 LIM and senescent 537572 3165 446212 11153 19141, 27129, cell antigen-like 35117, 43105, domains 2 51093

59473011 LIM and senescent 544917 3166 437681 11154 19142, 27130, cell antigen-like 35118, 43106, domains 2 51094

59483012 LIM and senescent 545738 3167 443794 11155 19143, 27131, cell antigen-like 35119, 43107, domains 2 51095

59493013 lin-7 homolog A (C. 552864 3168 447488 11156 19144, 27132, elegans) 35120, 43108,

595051096

59513014 lipase maturation 216080 3169 216080 11157 19145, 27133, factor 2 35121, 43109,

595251097

59533015 lipase maturation 380796 3170 370173 11158 19146, 27134, factor 2 35122, 43110,

595451098

59553016 lipase maturation 474879 3171 424381 11159 19147, 27135, factor 2 35123, 43111,

595651099

59573017 Lipid phosphate 374871 3172 364005 11160 19148, 27136, phosphatase-related 35124, 43112, protein type 1 51100

59583018 Lipid phosphate 374874 3173 364008 11161 19149, 27137, phosphatase-related 35125, 43113, protein type 1 51101

59593019 Lipid phosphate 395056 3174 378496 11162 19150, 27138, phosphatase-related 35126, 43114, protein type 1 51102

59603020 Lipid phosphate 456287 3175 410223 11163 19151, 27139, phosphatase-related 35127, 43115, protein type 1 51103

59613021 Lipid phosphate 251473 3176 251473 11164 19152, 27140, phosphatase-related 35128, 43116, protein type 2 51104

59623022 Lipid phosphate 591608 3177 466898 11165 19153, 27141, phosphatase-related 35129, 43117, protein type 2 51105 3023 Lipid phosphate 300947 3178 300947 11166 19154, 27142, phosphatase-related 35130, 43118, protein type 3 51106

59633024 Lipid phosphate 359894 3179 352962 11167 19155, 27143, phosphatase-related 35131, 43119, protein type 3 51107

59643025 Lipid phosphate 520876 3180 430297 11168 19156, 27144, phosphatase-related 35132, 43120, protein type 3 51108

59653026 Lipid phosphate 263178 3181 263178 11169 19157, 27145, phosphatase-related 35133, 43121, protein type 4 51109

59663027 Lipid phosphate 370184 3182 359203 11170 19158, 27146, phosphatase-related 35134, 43122, protein type 4 51110

59673028 Lipid phosphate 370185 3183 359204 11171 19159, 27147, phosphatase-related 35135, 43123, protein type 4 51111

59683029 Lipid phosphate 457765 3184 394913 11172 19160, 27148, phosphatase-related 35136, 43124, protein type 4 51112

59693030 Lipid phosphate 263177 3185 263177 11173 19161, 27149, phosphatase-related 35137, 43125, protein type 5 51113

59703031 Lipid phosphate 370188 3186 359207 11174 19162, 27150, phosphatase-related 35138, 43126, protein type 5 51114

59713032 lipoma HMGIC 287585 3187 287585 11175 19163, 27151, fusion partner-like 4 35139, 43127,

597251115

59733033 LMBR1 domain 296603 3188 296603 11176 19164, 27152, containing 2 35140, 43128,

597451116

59753034 LMBR1 domain 546130 3189 444863 11177 19165, 27153, containing 2 35141, 43129,

597651117

59773035 low density 371360 3190 360411 11178 19166, 27154, lipoprotein receptor 35142, 43130, class A domain 51118 containing 1

59783036 low density 371362 3191 360413 11179 19167, 27155, lipoprotein receptor 35143, 43131, class A domain 51119 containing 1

59793037 low density 344642 3192 340988 11180 19168, 27156, lipoprotein receptor 35144, 43132, class A domain 51120 containing 2

59803038 low density 543870 3193 444097 11181 19169, 27157, lipoprotein receptor 35145, 43133, class A domain 51121 containing 2

59813039 low density 315571 3194 318607 11182 19170, 27158, lipoprotein receptor 35146, 43134, class A domain 51122 containing 3

59823040 low density 545142 3195 438737 11183 19171, 27159, lipoprotein receptor 35147, 43135, class A domain 51123 containing 3

59833041 low density 239367 3196 239367 11184 19172, 27160, lipoprotein receptor- 35148, 43136, related protein 11 51124

59843042 low density 367368 3197 356338 11185 19173, 27161, lipoprotein receptor- 35149, 43137, related protein 11 51125

59853043 low density 546019 3198 440196 11186 19174, 27162, lipoprotein receptor- 35150, 43138, related protein 11 51126

59863044 low density 276654 3199 276654 11187 19175, 27163, lipoprotein receptor- 35151, 43139, related protein 12 51127

59873045 low density 424843 3200 399148 11188 19176, 27164, lipoprotein receptor- 35152, 43140, related protein 12 51128

59883046 LPS -responsive 357115 3201 349629 11189 19177, 27165, vesicle trafficking, 35153, 43141, beach and anchor 51129 containing

59893047 LPS -responsive 535741 3202 446299 11190 19178, 27166, vesicle trafficking, 35154, 43142, beach and anchor 51130 containing

59903048 LRRN4 C-terminal 317449 3203 325808 11191 19179, 27167, like 35155, 43143,

599151131

59923049 LY6/PLAUR 345008 3204 340563 11192 19180, 27168, domain containing 1 35156, 43144,

599351132

59943050 LY6/PLAUR 397463 3205 380605 11193 19181, 27169, domain containing 1 35157, 43145,

599551133

59963051 LY6/PLAUR 409034 3206 386311 11194 19182, 27170, domain containing 1 35158, 43146,

599751134

59983052 LY6/PLAUR 359228 3207 352163 11195 19183, 27171, domain containing 2 35159, 43147,

599951135

60003053 LY6/PLAUR 330743 3208 328737 11196 19184, 27172, domain containing 4 35160, 43148,

600151136

60023054 LY6/PLAUR 343055 3209 339568 11197 19185, 27173, domain containing 4 35161, 43149,

600351137

60043055 LY6/PLAUR 377950 3210 367185 11198 19186, 27174, domain containing 5 35162, 43150,

600551138 3056 LY6/PLAUR 414615 3211 408433 11199 19187, 27175, domain containing 5 35163, 43151,

600651139

60073057 LY6/PLAUR 280115 3212 280115 11200 19188, 27176, domain containing 35164, 43152, 6B 51140

60083058 LY6/PLAUR 409029 3213 386650 11201 19189, 27177, domain containing 35165, 43153, 6B 51141

60093059 LY6/PLAUR 409642 3214 387077 11202 19190, 27178, domain containing 35166, 43154, 6B 51142

60103060 LY6/PLAUR 409876 3215 386479 11203 19191, 27179, domain containing 35167, 43155, 6B 51143

60113061 lymphocyte antigen 375819 3216 364978 11204 19192, 27180, 6 complex, locus 35168, 43156, G6C 51144

60123062 lymphocyte antigen 383413 3217 372905 11205 19193, 27181, 6 complex, locus 35169, 43157, G6C 51145

60133063 lymphocyte antigen 419939 3218 388591 11206 19194, 27182, 6 complex, locus 35170, 43158, G6C 51146

60143064 lymphocyte antigen 428121 3219 411365 11207 19195, 27183, 6 complex, locus 35171, 43159, G6C 51147

60153065 lymphocyte antigen 428498 3220 410398 11208 19196, 27184, 6 complex, locus 35172, 43160, G6C 51148

60163066 lymphocyte antigen 434915 3221 415732 11209 19197, 27185, 6 complex, locus 35173, 43161, G6C 51149

60173067 lymphocyte antigen 448386 3222 409428 11210 19198, 27186, 6 complex, locus 35174, 43162, G6C 51150

60183068 lymphocyte antigen 495859 3223 433207 11211 19199, 27187, 6 complex, locus 35175, 43163, G6C 51151

60193069 lymphocyte antigen 497123 3224 431133 11212 19200, 27188, 6 complex, locus 35176, 43164, G6C 51152

60203070 lymphocyte antigen 375832 3225 364992 11213 19201, 27189, 6 complex, locus 35177, 43165, G6F 51153

60213071 lymphocyte antigen 446062 3226 404884 11214 19202, 27190, 6 complex, locus 35178, 43166, G6F 51154

60223072 lymphocyte antigen 447811 3227 409959 11215 19203, 27191, 6 complex, locus 35179, 43167, G6F 51155

60233073 lymphocyte antigen 453044 3228 389102 11216 19204, 27192, 6 complex, locus 35180, 43168, G6F 51156 3074 lymphocyte antigen 455632 3229 407535 11217 19205, 27193, 6 complex, locus 35181, 43169, G6F 51157

60243075 lymphocyte antigen 554860 3230 451668 11218 19206, 27194, 6 complex, locus 35182, 43170, G6F 51158

60253076 lymphocyte antigen 556581 3231 452432 11219 19207, 27195, 6 complex, locus 35183, 43171, G6F 51159

60263077 lymphocyte antigen 557698 3232 452228 11220 19208, 27196, 6 complex, locus 35184, 43172, G6F 51160

60273078 lymphocyte antigen 263636 3233 263636 11221 19209, 27197, 75 35185, 43173,

602851161

60293079 lymphocyte antigen 553424 3234 451446 11222 19210, 27198, 75 35186, 43174,

603051162

60313080 lymphocyte antigen 554112 3235 451511 11223 19211, 27199, 75 35187, 43175,

603251163

60333081 lymphocyte 367217 3236 356186 11224 19212, 27200, transmembrane 35188, 43176, adaptor 1 51164

60343082 lymphocyte 442561 3237 406970 11225 19213, 27201, transmembrane 35189, 43177, adaptor 1 51165

60353083 LYR motif 219168 3238 219168 11226 19214, 27202, containing 1 35190, 43178,

603651166

60373084 LYR motif 396052 3239 379367 11227 19215, 27203, containing 1 35191, 43179,

603851167

60393085 LYR motif 412082 3240 396868 11228 19216, 27204, containing 1 35192, 43180,

604051168

60413086 LYR motif 439021 3241 407883 11229 19217, 27205, containing 1 35193, 43181,

604251169

60433087 LYR motif 523377 3242 430025 11230 19218, 27206, containing 2 35194, 43182,

604451170

60453088 LYR motif 381356 3243 370761 11231 19219, 27207, containing 5 35195, 43183,

604651171

60473089 LYR motif 556198 3244 452130 11232 19220, 27208, containing 5 35196, 43184,

604851172

60493090 LYR motif 556351 3245 452146 11233 19221, 27209, containing 5 35197, 43185,

605051173

60513091 LYR motif 556885 3246 451494 11234 19222, 27210, containing 5 35198, 43186,

605251174 3092 LYR motif 556927 3247 450443 11235 19223, 27211, containing 5 35199, 43187,

605351175

60543093 LYR motif 557540 3248 450584 11236 19224, 27212, containing 5 35200, 43188,

605551176

60563094 Lyrm7 homolog 379380 3249 368688 11237 19225, 27213, (mouse) 35201, 43189,

605751177

60583095 lysM and putative 554351 3250 451382 11238 19226, 27214, peptidoglycan- 35202, 43190, binding domain- 51178 containing protein 3

60593096 LysM, putative 315948 3251 314518 11239 19227, 27215, peptidoglycan- 35203, 43191, binding, domain 51179 containing 3

60603097 LysM, putative 509384 3252 427683 11240 19228, 27216, peptidoglycan- 35204, 43192, binding, domain 51180 containing 3

60613098 LysM, putative 332728 3253 333008 11241 19229, 27217, peptidoglycan- 35205, 43193, binding, domain 51181 containing 4

60623099 LysM, putative 344791 3254 342840 11242 19230, 27218, peptidoglycan- 35206, 43194, binding, domain 51182 containing 4

60633100 LysM, putative 409796 3255 386283 11243 19231, 27219, peptidoglycan- 35207, 43195, binding, domain 51183 containing 4

60643101 LysM, putative 545021 3256 445357 11244 19232, 27220, peptidoglycan- 35208, 43196, binding, domain 51184 containing 4

60653102 lysophosphatidylcho 262134 3257 262134 11245 19233, 27221, line acyltransferase 35209, 43197, 2 51185

60663103 lysophosphatidylgly 366996 3258 355963 11246 19234, 27222, cerol acyltransferase 35210, 43198, 1 51186

60673104 lysophosphatidylgly 366997 3259 355964 11247 19235, 27223, cerol acyltransferase 35211, 43199, 1 51187

60683105 lysosomal protein 175091 3260 175091 11248 19236, 27224, transmembrane 4 35212, 43200, alpha 51188

60693106 lysosomal- 265598 3261 265598 11249 19237, 27225, associated 35213, 43201, membrane protein 3 51189

60703107 lysosomal- 476015 3262 419059 11250 19238, 27226, associated 35214, 43202, membrane protein 3 51190 3108 lysosomal- 246070 3263 246070 11251 19239, 27227, associated 35215, 43203, membrane protein 51191 family, member 5

60713109 lysosomal- 427562 3264 406360 11252 19240, 27228, associated 35216, 43204, membrane protein 51192 family, member 5

60723110 MACRO domain 255681 3265 255681 11253 19241, 27229, containing 1 35217, 43205,

607351193

60743111 macrophage 361050 3266 354335 11254 19242, 27230, expressed 1 35218, 43206,

607551194

60763112 macrophage 545098 3267 444560 11255 19243, 27231, expressed 1 35219, 43207,

607751195

60783113 major facilitator 264266 3268 264266 11256 19244, 27232, superfamily domain 35220, 43208, containing 1 51196

60793114 major facilitator 361159 3269 355227 11257 19245, 27233, superfamily domain 35221, 43209, containing 1 51197

60803115 major facilitator 392813 3270 376560 11258 19246, 27234, superfamily domain 35222, 43210, containing 1 51198

60813116 major facilitator 415822 3271 403117 11259 19247, 27235, superfamily domain 35223, 43211, containing 1 51199

60823117 major facilitator 329687 3272 332646 11260 19248, 27236, superfamily domain 35224, 43212, containing 10 51200

60833118 major facilitator 355443 3273 347619 11261 19249, 27237, superfamily domain 35225, 43213, containing 10 51201

60843119 major facilitator 336509 3274 337240 11262 19250, 27238, superfamily domain 35226, 43214, containing 11 51202

60853120 major facilitator 355954 3275 348225 11263 19251, 27239, superfamily domain 35227, 43215, containing 11 51203

60863121 major facilitator 355415 3276 347583 11264 19252, 27240, superfamily domain 35228, 43216, containing 12 51204

60873122 major facilitator 389395 3277 374046 11265 19253, 27241, superfamily domain 35229, 43217, containing 12 51205

60883123 major facilitator 398558 3278 381566 11266 19254, 27242, superfamily domain 35230, 43218, containing 12 51206

60893124 major facilitator 301327 3279 301327 11267 19255, 27243, superfamily domain 35231, 43219, containing 3 51207 3125 major facilitator 367147 3280 356115 11268 19256, 27244, superfamily domain 35232, 43220, containing 4 51208

60903126 major facilitator 536357 3281 440183 11269 19257, 27245, superfamily domain 35233, 43221, containing 4 51209

60913127 major facilitator 539267 3282 445329 11270 19258, 27246, superfamily domain 35234, 43222, containing 4 51210

60923128 major facilitator 328704 3283 331231 11271 19259, 27247, superfamily domain 35235, 43223, containing 5 51211

60933129 major facilitator 329548 3284 332624 11272 19260, 27248, superfamily domain 35236, 43224, containing 5 51212

60943130 major facilitator 534842 3285 442688 11273 19261, 27249, superfamily domain 35237, 43225, containing 5 51213

60953131 major facilitator 551660 3286 449354 11274 19262, 27250, superfamily domain 35238, 43226, containing 5 51214

60963132 major facilitator 329805 3287 330051 11275 19263, 27251, superfamily domain 35239, 43227, containing 6-like 51215

60973133 major facilitator 322224 3288 320234 11276 19264, 27252, superfamily domain 35240, 43228, containing 7 51216

60983134 major facilitator 347950 3289 307545 11277 19265, 27253, superfamily domain 35241, 43229, containing 7 51217

60993135 major facilitator 404286 3290 384616 11278 19266, 27254, superfamily domain 35242, 43230, containing 7 51218

61003136 major facilitator 258436 3291 258436 11279 19267, 27255, superfamily domain 35243, 43231, containing 9 51219

61013137 major 355767 3292 348012 11280 19268, 27256, histocompatibility 35244, 43232, complex, class I, A 51220

61023138 major 376802 3293 365998 11281 19269, 27257, histocompatibility 35245, 43233, complex, class I, A 51221

61033139 major 376806 3294 366002 11282 19270, 27258, histocompatibility 35246, 43234, complex, class I, A 51222

61043140 major 376809 3295 366005 11283 19271, 27259, histocompatibility 35247, 43235, complex, class I, A 51223

61053141 major 376822 3296 366018 11284 19272, 27260, histocompatibility 35248, 43236, complex, class I, A 51224

61063142 major 383605 3297 373100 11285 19273, 27261, histocompatibility 35249, 43237, complex, class I, A 51225 3143 major 383619 3298 373114 11286 19274, 27262, histocompatibility 35250, 43238, complex, class I, A 51226

61073144 major 396634 3299 379873 11287 19275, 27263, histocompatibility 35251, 43239, complex, class I, A 51227

61083145 major 413609 3300 390225 11288 19276, 27264, histocompatibility 35252, 43240, complex, class I, A 51228

61093146 major 414592 3301 394582 11289 19277, 27265, histocompatibility 35253, 43241, complex, class I, A 51229

61103147 major 416096 3302 394889 11290 19278, 27266, histocompatibility 35254, 43242, complex, class I, A 51230

61113148 major 417978 3303 388724 11291 19279, 27267, histocompatibility 35255, 43243, complex, class I, A 51231

61123149 major 431930 3304 406366 11292 19280, 27268, histocompatibility 35256, 43244, complex, class I, A 51232

61133150 major 438861 3305 388526 11293 19281, 27269, histocompatibility 35257, 43245, complex, class I, A 51233

61143151 major 442939 3306 397962 11294 19282, 27270, histocompatibility 35258, 43246, complex, class I, A 51234

61153152 major 443552 3307 404678 11295 19283, 27271, histocompatibility 35259, 43247, complex, class I, A 51235

61163153 major 444289 3308 398188 11296 19284, 27272, histocompatibility 35260, 43248, complex, class I, A 51236

61173154 major 450342 3309 391738 11297 19285, 27273, histocompatibility 35261, 43249, complex, class I, A 51237

61183155 major 453057 3310 403922 11298 19286, 27274, histocompatibility 35262, 43250, complex, class I, A 51238

61193156 major 453975 3311 392547 11299 19287, 27275, histocompatibility 35263, 43251, complex, class I, A 51239

61203157 major 454091 3312 410645 11300 19288, 27276, histocompatibility 35264, 43252, complex, class I, A 51240

61213158 major 455882 3313 416233 11301 19289, 27277, histocompatibility 35265, 43253, complex, class I, A 51241

61223159 major 456012 3314 408986 11302 19290, 27278, histocompatibility 35266, 43254, complex, class I, A 51242

61233160 major 457879 3315 403575 11303 19291, 27279, histocompatibility 35267, 43255, complex, class I, A 51243 3161 major 470780 3316 432736 11304 19292, 27280, histocompatibility 35268, 43256, complex, class I, A 51244

61243162 major 536480 3317 440033 11305 19293, 27281, histocompatibility 35269, 43257, complex, class I, A 51245

61253163 major 547112 3318 448887 11306 19294, 27282, histocompatibility 35270, 43258, complex, class I, A 51246

61263164 major 547271 3319 447962 11307 19295, 27283, histocompatibility 35271, 43259, complex, class I, A 51247

61273165 major 547522 3320 448077 11308 19296, 27284, histocompatibility 35272, 43260, complex, class I, A 51248

61283166 major 549224 3321 447990 11309 19297, 27285, histocompatibility 35273, 43261, complex, class I, A 51249

61293167 major 549835 3322 446814 11310 19298, 27286, histocompatibility 35274, 43262, complex, class I, A 51250

61303168 major 549869 3323 447635 11311 19299, 27287, histocompatibility 35275, 43263, complex, class I, A 51251

61313169 major 550707 3324 450284 11312 19300, 27288, histocompatibility 35276, 43264, complex, class I, A 51252

61323170 major 550728 3325 450169 11313 19301, 27289, histocompatibility 35277, 43265, complex, class I, A 51253

61333171 major 551120 3326 449453 11314 19302, 27290, histocompatibility 35278, 43266, complex, class I, A 51254

61343172 major 551190 3327 450314 11315 19303, 27291, histocompatibility 35279, 43267, complex, class I, A 51255

61353173 major 551578 3328 448239 11316 19304, 27292, histocompatibility 35280, 43268, complex, class I, A 51256

61363174 major 552193 3329 447614 11317 19305, 27293, histocompatibility 35281, 43269, complex, class I, A 51257

61373175 major 552493 3330 448992 11318 19306, 27294, histocompatibility 35282, 43270, complex, class I, A 51258

61383176 major 552498 3331 448516 11319 19307, 27295, histocompatibility 35283, 43271, complex, class I, A 51259

61393177 major 359635 3332 352656 11320 19308, 27296, histocompatibility 35284, 43272, complex, class I, B 51260

61403178 major 412585 3333 399168 11321 19309, 27297, histocompatibility 35285, 43273, complex, class I, B 51261 3179 major 416726 3334 392099 11322 19310, 27298, histocompatibility 35286, 43274, complex, class I, B 51262

61413180 major 418147 3335 411954 11323 19311, 27299, histocompatibility 35287, 43275, complex, class I, B 51263

61423181 major 421349 3336 405365 11324 19312, 27300, histocompatibility 35288, 43276, complex, class I, B 51264

61433182 major 425798 3337 401443 11325 19313, 27301, histocompatibility 35289, 43277, complex, class I, B 51265

61443183 major 425848 3338 400842 11326 19314, 27302, histocompatibility 35290, 43278, complex, class I, B 51266

61453184 major 426590 3339 392626 11327 19315, 27303, histocompatibility 35291, 43279, complex, class I, B 51267

61463185 major 428231 3340 401183 11328 19316, 27304, histocompatibility 35292, 43280, complex, class I, B 51268

61473186 major 430299 3341 416672 11329 19317, 27305, histocompatibility 35293, 43281, complex, class I, B 51269

61483187 major 434333 3342 405931 11330 19318, 27306, histocompatibility 35294, 43282, complex, class I, B 51270

61493188 major 435618 3343 405178 11331 19319, 27307, histocompatibility 35295, 43283, complex, class I, B 51271

61503189 major 436729 3344 403471 11332 19320, 27308, histocompatibility 35296, 43284, complex, class I, B 51272

61513190 major 437265 3345 398100 11333 19321, 27309, histocompatibility 35297, 43285, complex, class I, B 51273

61523191 major 437866 3346 392235 11334 19322, 27310, histocompatibility 35298, 43286, complex, class I, B 51274

61533192 major 445222 3347 399675 11335 19323, 27311, histocompatibility 35299, 43287, complex, class I, B 51275

61543193 major 445610 3348 396397 11336 19324, 27312, histocompatibility 35300, 43288, complex, class I, B 51276

61553194 major 450871 3349 388208 11337 19325, 27313, histocompatibility 35301, 43289, complex, class I, B 51277

61563195 major 452596 3350 396980 11338 19326, 27314, histocompatibility 35302, 43290, complex, class I, B 51278

61573196 major 461583 3351 436637 11339 19327, 27315, histocompatibility 35303, 43291, complex, class I, B 51279 3197 major 471639 3352 435221 11340 19328, 27316, histocompatibility 35304, 43292, complex, class I, B 51280

61583198 major 479203 3353 433363 11341 19329, 27317, histocompatibility 35305, 43293, complex, class I, B 51281

61593199 major 481283 3354 435817 11342 19330, 27318, histocompatibility 35306, 43294, complex, class I, B 51282

61603200 major 498484 3355 435083 11343 19331, 27319, histocompatibility 35307, 43295, complex, class I, B 51283

61613201 major 546599 3356 446558 11344 19332, 27320, histocompatibility 35308, 43296, complex, class I, B 51284

61623202 major 550965 3357 449246 11345 19333, 27321, histocompatibility 35309, 43297, complex, class I, B 51285

61633203 major 553172 3358 447662 11346 19334, 27322, histocompatibility 35310, 43298, complex, class I, B 51286

61643204 major 376630 3359 365817 11347 19335, 27323, histocompatibility 35311, 43299, complex, class I, E 51287

61653205 major 383597 3360 373091 11348 19336, 27324, histocompatibility 35312, 43300, complex, class I, E 51288

61663206 major 415289 3361 409910 11349 19337, 27325, histocompatibility 35313, 43301, complex, class I, E 51289

61673207 major 415649 3362 390707 11350 19338, 27326, histocompatibility 35314, 43302, complex, class I, E 51290

61683208 major 425603 3363 402694 11351 19339, 27327, histocompatibility 35315, 43303, complex, class I, E 51291

61693209 major 427936 3364 397420 11352 19340, 27328, histocompatibility 35316, 43304, complex, class I, E 51292

61703210 major 444683 3365 400458 11353 19341, 27329, histocompatibility 35317, 43305, complex, class I, E 51293

61713211 major 547304 3366 450038 11354 19342, 27330, histocompatibility 35318, 43306, complex, class I, E 51294

61723212 major 259951 3367 259951 11355 19343, 27331, histocompatibility 35319, 43307, complex, class I, F 51295

61733213 major 334668 3368 334263 11356 19344, 27332, histocompatibility 35320, 43308, complex, class I, F 51296

61743214 major 342322 3369 345828 11357 19345, 27333, histocompatibility 35321, 43309, complex, class I, F 51297 3215 major 359076 3370 351977 11358 19346, 27334, histocompatibility 35322, 43310, complex, class I, F 51298

61753216 major 376844 3371 366040 11359 19347, 27335, histocompatibility 35323, 43311, complex, class I, F 51299

61763217 major 376848 3372 366044 11360 19348, 27336, histocompatibility 35324, 43312, complex, class I, F 51300

61773218 major 376861 3373 366057 11361 19349, 27337, histocompatibility 35325, 43313, complex, class I, F 51301

61783219 major 383515 3374 373007 11362 19350, 27338, histocompatibility 35326, 43314, complex, class I, F 51302

61793220 major 383516 3375 373008 11363 19351, 27339, histocompatibility 35327, 43315, complex, class I, F 51303

61803221 major 383626 3376 373121 11364 19352, 27340, histocompatibility 35328, 43316, complex, class I, F 51304

61813222 major 383627 3377 373123 11365 19353, 27341, histocompatibility 35329, 43317, complex, class I, F 51305

61823223 major 399258 3378 382201 11366 19354, 27342, histocompatibility 35330, 43318, complex, class I, F 51306

61833224 major 414333 3379 389590 11367 19355, 27343, histocompatibility 35331, 43319, complex, class I, F 51307

61843225 major 414958 3380 409934 11368 19356, 27344, histocompatibility 35332, 43320, complex, class I, F 51308

61853226 major 418017 3381 405190 11369 19357, 27345, histocompatibility 35333, 43321, complex, class I, F 51309

61863227 major 420024 3382 416426 11370 19358, 27346, histocompatibility 35334, 43322, complex, class I, F 51310

61873228 major 420067 3383 393535 11371 19359, 27347, histocompatibility 35335, 43323, complex, class I, F 51311

61883229 major 420414 3384 407836 11372 19360, 27348, histocompatibility 35336, 43324, complex, class I, F 51312

61893230 major 420923 3385 400112 11373 19361, 27349, histocompatibility 35337, 43325, complex, class I, F 51313

61903231 major 422439 3386 414318 11374 19362, 27350, histocompatibility 35338, 43326, complex, class I, F 51314

61913232 major 422711 3387 395853 11375 19363, 27351, histocompatibility 35339, 43327, complex, class I, F 51315 3233 major 425139 3388 412140 11376 19364, 27352, histocompatibility 35340, 43328, complex, class I, F 51316

61923234 major 426470 3389 404395 11377 19365, 27353, histocompatibility 35341, 43329, complex, class I, F 51317

61933235 major 426675 3390 415401 11378 19366, 27354, histocompatibility 35342, 43330, complex, class I, F 51318

61943236 major 428296 3391 387786 11379 19367, 27355, histocompatibility 35343, 43331, complex, class I, F 51319

61953237 major 429294 3392 416998 11380 19368, 27356, histocompatibility 35344, 43332, complex, class I, F 51320

61963238 major 430472 3393 397705 11381 19369, 27357, histocompatibility 35345, 43333, complex, class I, F 51321

61973239 major 433515 3394 398913 11382 19370, 27358, histocompatibility 35346, 43334, complex, class I, F 51322

61983240 major 434407 3395 397376 11383 19371, 27359, histocompatibility 35347, 43335, complex, class I, F 51323

61993241 major 435058 3396 408540 11384 19372, 27360, histocompatibility 35348, 43336, complex, class I, F 51324

62003242 major 437020 3397 396776 11385 19373, 27361, histocompatibility 35349, 43337, complex, class I, F 51325

62013243 major 437226 3398 400299 11386 19374, 27362, histocompatibility 35350, 43338, complex, class I, F 51326

62023244 major 440587 3399 404130 11387 19375, 27363, histocompatibility 35351, 43339, complex, class I, F 51327

62033245 major 440590 3400 399835 11388 19376, 27364, histocompatibility 35352, 43340, complex, class I, F 51328

62043246 major 441200 3401 405198 11389 19377, 27365, histocompatibility 35353, 43341, complex, class I, F 51329

62053247 major 444057 3402 389555 11390 19378, 27366, histocompatibility 35354, 43342, complex, class I, F 51330

62063248 major 444621 3403 392251 11391 19379, 27367, histocompatibility 35355, 43343, complex, class I, F 51331

62073249 major 444891 3404 402853 11392 19380, 27368, histocompatibility 35356, 43344, complex, class I, F 51332

62083250 major 445657 3405 414905 11393 19381, 27369, histocompatibility 35357, 43345, complex, class I, F 51333 3251 major 447400 3406 388133 11394 19382, 27370, histocompatibility 35358, 43346, complex, class I, F 51334

62093252 major 448064 3407 399120 11395 19383, 27371, histocompatibility 35359, 43347, complex, class I, F 51335

62103253 major 449921 3408 415312 11396 19384, 27372, histocompatibility 35360, 43348, complex, class I, F 51336

62113254 major 452916 3409 415017 11397 19385, 27373, histocompatibility 35361, 43349, complex, class I, F 51337

62123255 major 454646 3410 414500 11398 19386, 27374, histocompatibility 35362, 43350, complex, class I, F 51338

62133256 major 454779 3411 390887 11399 19387, 27375, histocompatibility 35363, 43351, complex, class I, F 51339

62143257 major 458026 3412 399043 11400 19388, 27376, histocompatibility 35364, 43352, complex, class I, F 51340

62153258 major 547126 3413 450176 11401 19389, 27377, histocompatibility 35365, 43353, complex, class I, F 51341

62163259 major 547128 3414 450179 11402 19390, 27378, histocompatibility 35366, 43354, complex, class I, F 51342

62173260 major 547132 3415 446947 11403 19391, 27379, histocompatibility 35367, 43355, complex, class I, F 51343

62183261 major 547503 3416 450111 11404 19392, 27380, histocompatibility 35368, 43356, complex, class I, F 51344

62193262 major 547953 3417 449390 11405 19393, 27381, histocompatibility 35369, 43357, complex, class I, F 51345

62203263 major 548879 3418 446526 11406 19394, 27382, histocompatibility 35370, 43358, complex, class I, F 51346

62213264 major 549067 3419 450053 11407 19395, 27383, histocompatibility 35371, 43359, complex, class I, F 51347

62223265 major 549166 3420 450301 11408 19396, 27384, histocompatibility 35372, 43360, complex, class I, F 51348

62233266 major 549254 3421 446505 11409 19397, 27385, histocompatibility 35373, 43361, complex, class I, F 51349

62243267 major 549422 3422 450119 11410 19398, 27386, histocompatibility 35374, 43362, complex, class I, F 51350

62253268 major 550237 3423 448113 11411 19399, 27387, histocompatibility 35375, 43363, complex, class I, F 51351 3269 major 550932 3424 450300 11412 19400, 27388, histocompatibility 35376, 43364, complex, class I, F 51352

62263270 major 550980 3425 447195 11413 19401, 27389, histocompatibility 35377, 43365, complex, class I, F 51353

62273271 major 551026 3426 450148 11414 19402, 27390, histocompatibility 35378, 43366, complex, class I, F 51354

62283272 major 551205 3427 449164 11415 19403, 27391, histocompatibility 35379, 43367, complex, class I, F 51355

62293273 major 551347 3428 447078 11416 19404, 27392, histocompatibility 35380, 43368, complex, class I, F 51356

62303274 major 551780 3429 447401 11417 19405, 27393, histocompatibility 35381, 43369, complex, class I, F 51357

62313275 major 552082 3430 447228 11418 19406, 27394, histocompatibility 35382, 43370, complex, class I, F 51358

62323276 major 552732 3431 448096 11419 19407, 27395, histocompatibility 35383, 43371, complex, class I, F 51359

62333277 major 552880 3432 448638 11420 19408, 27396, histocompatibility 35384, 43372, complex, class I, F 51360

62343278 major 360323 3433 353472 11421 19409, 27397, histocompatibility 35385, 43373, complex, class I, G 51361

62353279 major 376815 3434 366011 11422 19410, 27398, histocompatibility 35386, 43374, complex, class I, G 51362

62363280 major 376818 3435 366014 11423 19411, 27399, histocompatibility 35387, 43375, complex, class I, G 51363

62373281 major 376828 3436 366024 11424 19412, 27400, histocompatibility 35388, 43376, complex, class I, G 51364

62383282 major 383621 3437 373116 11425 19413, 27401, histocompatibility 35389, 43377, complex, class I, G 51365

62393283 major 383622 3438 373117 11426 19414, 27402, histocompatibility 35390, 43378, complex, class I, G 51366

62403284 major 383623 3439 373118 11427 19415, 27403, histocompatibility 35391, 43379, complex, class I, G 51367

62413285 major 400665 3440 383506 11428 19416, 27404, histocompatibility 35392, 43380, complex, class I, G 51368

62423286 major 400682 3441 383521 11429 19417, 27405, histocompatibility 35393, 43381, complex, class I, G 51369 3287 major 412263 3442 397733 11430 19418, 27406, histocompatibility 35394, 43382, complex, class I, G 51370

62433288 major 415687 3443 389969 11431 19419, 27407, histocompatibility 35395, 43383, complex, class I, G 51371

62443289 major 420559 3444 397331 11432 19420, 27408, histocompatibility 35396, 43384, complex, class I, G 51372

62453290 major 422371 3445 387624 11433 19421, 27409, histocompatibility 35397, 43385, complex, class I, G 51373

62463291 major 423011 3446 389522 11434 19422, 27410, histocompatibility 35398, 43386, complex, class I, G 51374

62473292 major 423373 3447 405238 11435 19423, 27411, histocompatibility 35399, 43387, complex, class I, G 51375

62483293 major 426863 3448 392075 11436 19424, 27412, histocompatibility 35400, 43388, complex, class I, G 51376

62493294 major 428701 3449 412927 11437 19425, 27413, histocompatibility 35401, 43389, complex, class I, G 51377

62503295 major 428952 3450 388176 11438 19426, 27414, histocompatibility 35402, 43390, complex, class I, G 51378

62513296 major 429890 3451 401326 11439 19427, 27415, histocompatibility 35403, 43391, complex, class I, G 51379

62523297 major 430253 3452 396594 11440 19428, 27416, histocompatibility 35404, 43392, complex, class I, G 51380

62533298 major 434881 3453 392347 11441 19429, 27417, histocompatibility 35405, 43393, complex, class I, G 51381

62543299 major 434907 3454 408461 11442 19430, 27418, histocompatibility 35406, 43394, complex, class I, G 51382

62553300 major 444098 3455 398200 11443 19431, 27419, histocompatibility 35407, 43395, complex, class I, G 51383

62563301 major 445373 3456 416408 11444 19432, 27420, histocompatibility 35408, 43396, complex, class I, G 51384

62573302 major 448306 3457 413926 11445 19433, 27421, histocompatibility 35409, 43397, complex, class I, G 51385

62583303 major 449127 3458 408773 11446 19434, 27422, histocompatibility 35410, 43398, complex, class I, G 51386

62593304 major 450984 3459 409132 11447 19435, 27423, histocompatibility 35411, 43399, complex, class I, G 51387 3305 major 452577 3460 415905 11448 19436, 27424, histocompatibility 35412, 43400, complex, class I, G 51388

62603306 major 452715 3461 390678 11449 19437, 27425, histocompatibility 35413, 43401, complex, class I, G 51389

62613307 major 457132 3462 410247 11450 19438, 27426, histocompatibility 35414, 43402, complex, class I, G 51390

62623308 major 466488 3463 433426 11451 19439, 27427, histocompatibility 35415, 43403, complex, class I, G 51391

62633309 major 467814 3464 434622 11452 19440, 27428, histocompatibility 35416, 43404, complex, class I, G 51392

62643310 major 469347 3465 437036 11453 19441, 27429, histocompatibility 35417, 43405, complex, class I, G 51393

62653311 major 469472 3466 432220 11454 19442, 27430, histocompatibility 35418, 43406, complex, class I, G 51394

62663312 major 478519 3467 436375 11455 19443, 27431, histocompatibility 35419, 43407, complex, class I, G 51395

62673313 major 486553 3468 432239 11456 19444, 27432, histocompatibility 35420, 43408, complex, class I, G 51396

62683314 major 546545 3469 447762 11457 19445, 27433, histocompatibility 35421, 43409, complex, class I, G 51397

62693315 major 546634 3470 447780 11458 19446, 27434, histocompatibility 35422, 43410, complex, class I, G 51398

62703316 major 547241 3471 448085 11459 19447, 27435, histocompatibility 35423, 43411, complex, class I, G 51399

62713317 major 547931 3472 448363 11460 19448, 27436, histocompatibility 35424, 43412, complex, class I, G 51400

62723318 major 550897 3473 449903 11461 19449, 27437, histocompatibility 35425, 43413, complex, class I, G 51401

62733319 major 553052 3474 449291 11462 19450, 27438, histocompatibility 35426, 43414, complex, class I, G 51402

62743320 major 341486 3475 345804 11463 19451, 27439, histocompatibility 35427, 43415, complex, class II, 51403 DM alpha

62753321 major 374843 3476 363976 11464 19452, 27440, histocompatibility 35428, 43416, complex, class II, 51404 DM alpha 3322 major 383227 3477 372714 11465 19453, 27441, histocompatibility 35429, 43417, complex, class II, 51405 DM alpha

62763323 major 383228 3478 372715 11466 19454, 27442, histocompatibility 35430, 43418, complex, class II, 51406 DM alpha

62773324 major 383230 3479 372717 11467 19455, 27443, histocompatibility 35431, 43419, complex, class II, 51407 DM alpha

62783325 major 395303 3480 378714 11468 19456, 27444, histocompatibility 35432, 43420, complex, class II, 51408 DM alpha

62793326 major 395305 3481 378716 11469 19457, 27445, histocompatibility 35433, 43421, complex, class II, 51409 DM alpha

62803327 major 412394 3482 412550 11470 19458, 27446, histocompatibility 35434, 43422, complex, class II, 51410 DM alpha

62813328 major 416297 3483 398728 11471 19459, 27447, histocompatibility 35435, 43423, complex, class II, 51411 DM alpha

62823329 major 416806 3484 405637 11472 19460, 27448, histocompatibility 35436, 43424, complex, class II, 51412 DM alpha

62833330 major 418042 3485 395579 11473 19461, 27449, histocompatibility 35437, 43425, complex, class II, 51413 DM alpha

62843331 major 419041 3486 394366 11474 19462, 27450, histocompatibility 35438, 43426, complex, class II, 51414 DM alpha

62853332 major 419231 3487 407671 11475 19463, 27451, histocompatibility 35439, 43427, complex, class II, 51415 DM alpha

62863333 major 420299 3488 414945 11476 19464, 27452, histocompatibility 35440, 43428, complex, class II, 51416 DM alpha

62873334 major 420931 3489 402739 11477 19465, 27453, histocompatibility 35441, 43429, complex, class II, 51417 DM alpha

62883335 major 422196 3490 409144 11478 19466, 27454, histocompatibility 35442, 43430, complex, class II, 51418 DM alpha

62893336 major 422832 3491 403122 11479 19467, 27455, histocompatibility 35443, 43431, complex, class II, 51419 DM alpha

62903337 major 426176 3492 395056 11480 19468, 27456, histocompatibility 35444, 43432, complex, class II, 51420 DM alpha

62913338 major 432991 3493 389962 11481 19469, 27457, histocompatibility 35445, 43433, complex, class II, 51421 DM alpha

62923339 major 433630 3494 411774 11482 19470, 27458, histocompatibility 35446, 43434, complex, class II, 51422 DM alpha

62933340 major 434337 3495 407198 11483 19471, 27459, histocompatibility 35447, 43435, complex, class II, 51423 DM alpha

62943341 major 435503 3496 390001 11484 19472, 27460, histocompatibility 35448, 43436, complex, class II, 51424 DM alpha

62953342 major 437285 3497 399386 11485 19473, 27461, histocompatibility 35449, 43437, complex, class II, 51425 DM alpha

62963343 major 439054 3498 403906 11486 19474, 27462, histocompatibility 35450, 43438, complex, class II, 51426 DM alpha

62973344 major 440717 3499 415844 11487 19475, 27463, histocompatibility 35451, 43439, complex, class II, 51427 DM alpha

62983345 major 441171 3500 400783 11488 19476, 27464, histocompatibility 35452, 43440, complex, class II, 51428 DM alpha

62993346 major 441375 3501 410591 11489 19477, 27465, histocompatibility 35453, 43441, complex, class II, 51429 DM alpha

63003347 major 443447 3502 398951 11490 19478, 27466, histocompatibility 35454, 43442, complex, class II, 51430 DM alpha

63013348 major 450601 3503 392842 11491 19479, 27467, histocompatibility 35455, 43443, complex, class II, 51431 DM alpha 3349 major 451148 3504 414016 11492 19480, 27468, histocompatibility 35456, 43444, complex, class II, 51432 DM alpha

63023350 major 451753 3505 409734 11493 19481, 27469, histocompatibility 35457, 43445, complex, class II, 51433 DM alpha

63033351 major 452330 3506 398742 11494 19482, 27470, histocompatibility 35458, 43446, complex, class II, 51434 DM alpha

63043352 major 452434 3507 412100 11495 19483, 27471, histocompatibility 35459, 43447, complex, class II, 51435 DM alpha

63053353 major 452615 3508 395349 11496 19484, 27472, histocompatibility 35460, 43448, complex, class II, 51436 DM alpha

63063354 major 452703 3509 405208 11497 19485, 27473, histocompatibility 35461, 43449, complex, class II, 51437 DM alpha

63073355 major 453490 3510 404018 11498 19486, 27474, histocompatibility 35462, 43450, complex, class II, 51438 DM alpha

63083356 major 454298 3511 414631 11499 19487, 27475, histocompatibility 35463, 43451, complex, class II, 51439 DM alpha

63093357 major 456486 3512 408520 11500 19488, 27476, histocompatibility 35464, 43452, complex, class II, 51440 DM alpha

63103358 major 456800 3513 409668 11501 19489, 27477, histocompatibility 35465, 43453, complex, class II, 51441 DM alpha

63113359 major 457285 3514 399032 11502 19490, 27478, histocompatibility 35466, 43454, complex, class II, 51442 DM alpha

63123360 major 458066 3515 408141 11503 19491, 27479, histocompatibility 35467, 43455, complex, class II, 51443 DM alpha

63133361 major 383231 3516 372718 11504 19492, 27480, histocompatibility 35468, 43456, complex, class II, 51444 DM beta

63143362 major 395312 3517 378723 11505 19493, 27481, histocompatibility 35469, 43457, complex, class II, 51445 DM beta

63153363 major 412948 3518 413471 11506 19494, 27482, histocompatibility 35470, 43458, complex, class II, 51446 DM beta

63163364 major 413038 3519 410077 11507 19495, 27483, histocompatibility 35471, 43459, complex, class II, 51447 DM beta

63173365 major 413617 3520 394789 11508 19496, 27484, histocompatibility 35472, 43460, complex, class II, 51448 DM beta

63183366 major 413696 3521 405790 11509 19497, 27485, histocompatibility 35473, 43461, complex, class II, 51449 DM beta

63193367 major 414017 3522 411276 11510 19498, 27486, histocompatibility 35474, 43462, complex, class II, 51450 DM beta

63203368 major 415090 3523 398843 11511 19499, 27487, histocompatibility 35475, 43463, complex, class II, 51451 DM beta

63213369 major 415927 3524 414153 11512 19500, 27488, histocompatibility 35476, 43464, complex, class II, 51452 DM beta

63223370 major 416244 3525 391010 11513 19501, 27489, histocompatibility 35477, 43465, complex, class II, 51453 DM beta

63233371 major 418107 3526 398890 11514 19502, 27490, histocompatibility 35478, 43466, complex, class II, 51454 DM beta

63243372 major 418759 3527 394997 11515 19503, 27491, histocompatibility 35479, 43467, complex, class II, 51455 DM beta

63253373 major 421456 3528 410609 11516 19504, 27492, histocompatibility 35480, 43468, complex, class II, 51456 DM beta

63263374 major 424822 3529 414817 11517 19505, 27493, histocompatibility 35481, 43469, complex, class II, 51457 DM beta

63273375 major 424874 3530 394737 11518 19506, 27494, histocompatibility 35482, 43470, complex, class II, 51458 DM beta 3376 major 428420 3531 393646 11519 19507, 27495, histocompatibility 35483, 43471, complex, class II, 51459 DM beta

63283377 major 428864 3532 402800 11520 19508, 27496, histocompatibility 35484, 43472, complex, class II, 51460 DM beta

63293378 Major 429234 3533 412457 11521 19509, 27497, histocompatibility 35485, 43473, complex, class II, 51461 DM beta

63303379 major 430099 3534 412415 11522 19510, 27498, histocompatibility 35486, 43474, complex, class II, 51462 DM beta

63313380 major 430115 3535 401587 11523 19511, 27499, histocompatibility 35487, 43475, complex, class II, 51463 DM beta

63323381 major 433242 3536 401238 11524 19512, 27500, histocompatibility 35488, 43476, complex, class II, 51464 DM beta

63333382 major 435056 3537 410908 11525 19513, 27501, histocompatibility 35489, 43477, complex, class II, 51465 DM beta

63343383 major 435204 3538 391679 11526 19514, 27502, histocompatibility 35490, 43478, complex, class II, 51466 DM beta

63353384 major 437382 3539 391352 11527 19515, 27503, histocompatibility 35491, 43479, complex, class II, 51467 DM beta

63363385 major 437583 3540 405746 11528 19516, 27504, histocompatibility 35492, 43480, complex, class II, 51468 DM beta

63373386 major 438310 3541 399634 11529 19517, 27505, histocompatibility 35493, 43481, complex, class II, 51469 DM beta

63383387 major 438510 3542 390848 11530 19518, 27506, histocompatibility 35494, 43482, complex, class II, 51470 DM beta

63393388 major 439344 3543 413062 11531 19519, 27507, histocompatibility 35495, 43483, complex, class II, 51471 DM beta

63403389 major 440078 3544 411321 11532 19520, 27508, histocompatibility 35496, 43484, complex, class II, 51472 DM beta

63413390 major 440269 3545 406776 11533 19521, 27509, histocompatibility 35497, 43485, complex, class II, 51473 DM beta

63423391 major 441177 3546 393285 11534 19522, 27510, histocompatibility 35498, 43486, complex, class II, 51474 DM beta

63433392 major 446948 3547 393569 11535 19523, 27511, histocompatibility 35499, 43487, complex, class II, 51475 DM beta

63443393 major 447454 3548 396075 11536 19524, 27512, histocompatibility 35500, 43488, complex, class II, 51476 DM beta

63453394 major 448590 3549 389736 11537 19525, 27513, histocompatibility 35501, 43489, complex, class II, 51477 DM beta

63463395 major 448798 3550 398332 11538 19526, 27514, histocompatibility 35502, 43490, complex, class II, 51478 DM beta

63473396 major 449417 3551 410329 11539 19527, 27515, histocompatibility 35503, 43491, complex, class II, 51479 DM beta

63483397 major 449679 3552 404072 11540 19528, 27516, histocompatibility 35504, 43492, complex, class II, 51480 DM beta

63493398 major 450897 3553 408453 11541 19529, 27517, histocompatibility 35505, 43493, complex, class II, 51481 DM beta

63503399 major 451921 3554 399759 11542 19530, 27518, histocompatibility 35506, 43494, complex, class II, 51482 DM beta

63513400 major 452407 3555 399130 11543 19531, 27519, histocompatibility 35507, 43495, complex, class II, 51483 DM beta

63523401 major 456428 3556 416157 11544 19532, 27520, histocompatibility 35508, 43496, complex, class II, 51484 DM beta

63533402 major 546470 3557 447781 11545 19533, 27521, histocompatibility 35509, 43497, complex, class II, 51485 DM beta 3403 major 546855 3558 450237 11546 19534, 27522, histocompatibility 35510, 43498, complex, class II, 51486 DM beta

63543404 major 547313 3559 449487 11547 19535, 27523, histocompatibility 35511, 43499, complex, class II, 51487 DM beta

63553405 major 547391 3560 449127 11548 19536, 27524, histocompatibility 35512, 43500, complex, class II, 51488 DM beta

63563406 major 547478 3561 448541 11549 19537, 27525, histocompatibility 35513, 43501, complex, class II, 51489 DM beta

63573407 major 548183 3562 450057 11550 19538, 27526, histocompatibility 35514, 43502, complex, class II, 51490 DM beta

63583408 major 548290 3563 446674 11551 19539, 27527, histocompatibility 35515, 43503, complex, class II, 51491 DM beta

63593409 major 548611 3564 448875 11552 19540, 27528, histocompatibility 35516, 43504, complex, class II, 51492 DM beta

63603410 major 549152 3565 449375 11553 19541, 27529, histocompatibility 35517, 43505, complex, class II, 51493 DM beta

63613411 major 549556 3566 446912 11554 19542, 27530, histocompatibility 35518, 43506, complex, class II, 51494 DM beta

63623412 major 549676 3567 448564 11555 19543, 27531, histocompatibility 35519, 43507, complex, class II, 51495 DM beta

63633413 major 550052 3568 450287 11556 19544, 27532, histocompatibility 35520, 43508, complex, class II, 51496 DM beta

63643414 major 550933 3569 447570 11557 19545, 27533, histocompatibility 35521, 43509, complex, class II, 51497 DM beta

63653415 major 551036 3570 446547 11558 19546, 27534, histocompatibility 35522, 43510, complex, class II, 51498 DM beta

63663416 major 551481 3571 447325 11559 19547, 27535, histocompatibility 35523, 43511, complex, class II, 51499 DM beta

63673417 major 551515 3572 446560 11560 19548, 27536, histocompatibility 35524, 43512, complex, class II, 51500 DM beta

63683418 major 552299 3573 449810 11561 19549, 27537, histocompatibility 35525, 43513, complex, class II, 51501 DM beta

63693419 major 552389 3574 447573 11562 19550, 27538, histocompatibility 35526, 43514, complex, class II, 51502 DM beta

63703420 major 553199 3575 449606 11563 19551, 27539, histocompatibility 35527, 43515, complex, class II, 51503 DM beta

63713421 major 229829 3576 229829 11564 19552, 27540, histocompatibility 35528, 43516, complex, class II, 51504 DO alpha

63723422 major 374813 3577 363946 11565 19553, 27541, histocompatibility 35529, 43517, complex, class II, 51505 DO alpha

63733423 major 383225 3578 372712 11566 19554, 27542, histocompatibility 35530, 43518, complex, class II, 51506 DO alpha

63743424 major 383226 3579 372713 11567 19555, 27543, histocompatibility 35531, 43519, complex, class II, 51507 DO alpha

63753425 major 416763 3580 402076 11568 19556, 27544, histocompatibility 35532, 43520, complex, class II, 51508 DO alpha

63763426 major 418857 3581 405153 11569 19557, 27545, histocompatibility 35533, 43521, complex, class II, 51509 DO alpha

63773427 major 426070 3582 401504 11570 19558, 27546, histocompatibility 35534, 43522, complex, class II, 51510 DO alpha

63783428 major 426685 3583 397945 11571 19559, 27547, histocompatibility 35535, 43523, complex, class II, 51511 DO alpha

63793429 major 432150 3584 412819 11572 19560, 27548, histocompatibility 35536, 43524, complex, class II, 51512 DO alpha 3430 major 434335 3585 416448 11573 19561, 27549, histocompatibility 35537, 43525, complex, class II, 51513 DO alpha

63803431 major 438987 3586 395737 11574 19562, 27550, histocompatibility 35538, 43526, complex, class II, 51514 DO alpha

63813432 major 444109 3587 402347 11575 19563, 27551, histocompatibility 35539, 43527, complex, class II, 51515 DO alpha

63823433 major 450833 3588 403896 11576 19564, 27552, histocompatibility 35540, 43528, complex, class II, 51516 DO alpha

63833434 major 452598 3589 398819 11577 19565, 27553, histocompatibility 35541, 43529, complex, class II, 51517 DO alpha

63843435 major 455325 3590 402487 11578 19566, 27554, histocompatibility 35542, 43530, complex, class II, 51518 DO alpha

63853436 major 457663 3591 409491 11579 19567, 27555, histocompatibility 35543, 43531, complex, class II, 51519 DO alpha

63863437 major 546375 3592 447202 11580 19568, 27556, histocompatibility 35544, 43532, complex, class II, 51520 DO alpha

63873438 major 547284 3593 446715 11581 19569, 27557, histocompatibility 35545, 43533, complex, class II, 51521 DO alpha

63883439 major 547661 3594 449987 11582 19570, 27558, histocompatibility 35546, 43534, complex, class II, 51522 DO alpha

63893440 major 548708 3595 448280 11583 19571, 27559, histocompatibility 35547, 43535, complex, class II, 51523 DO alpha

63903441 major 549720 3596 446832 11584 19572, 27560, histocompatibility 35548, 43536, complex, class II, 51524 DO alpha

63913442 major 549845 3597 449183 11585 19573, 27561, histocompatibility 35549, 43537, complex, class II, 51525 DO alpha

63923443 major 549849 3598 449760 11586 19574, 27562, histocompatibility 35550, 43538, complex, class II, 51526 DO alpha

63933444 major 549880 3599 448865 11587 19575, 27563, histocompatibility 35551, 43539, complex, class II, 51527 DO alpha

63943445 major 549881 3600 446500 11588 19576, 27564, histocompatibility 35552, 43540, complex, class II, 51528 DO alpha

63953446 major 550072 3601 449395 11589 19577, 27565, histocompatibility 35553, 43541, complex, class II, 51529 DO alpha

63963447 major 552368 3602 449656 11590 19578, 27566, histocompatibility 35554, 43542, complex, class II, 51530 DO alpha

63973448 major 553212 3603 449347 11591 19579, 27567, histocompatibility 35555, 43543, complex, class II, 51531 DO alpha

63983449 major 413252 3604 390574 11592 19580, 27568, histocompatibility 35556, 43544, complex, class II, 51532 DO beta

63993450 major 426644 3605 395780 11593 19581, 27569, histocompatibility 35557, 43545, complex, class II, 51533 DO beta

64003451 major 438763 3606 390020 11594 19582, 27570, histocompatibility 35558, 43546, complex, class II, 51534 DO beta

64013452 major 439310 3607 401290 11595 19583, 27571, histocompatibility 35559, 43547, complex, class II, 51535 DO beta

64023453 major 447178 3608 405108 11596 19584, 27572, histocompatibility 35560, 43548, complex, class II, 51536 DO beta

64033454 major 447394 3609 394860 11597 19585, 27573, histocompatibility 35561, 43549, complex, class II, 51537 DO beta

64043455 major 448690 3610 413915 11598 19586, 27574, histocompatibility 35562, 43550, complex, class II, 51538 DO beta

64053456 major 453971 3611 391708 11599 19587, 27575, histocompatibility 35563, 43551, complex, class II, 51539 DO beta <img file="WO2013151663A1_D0013.tif" /><img file="WO2013151663A1_D0014.tif" /><img file="WO2013151663A1_D0015.tif" /><img file="WO2013151663A1_D0016.tif" /> ap a 3511 major 411524 3666 405295 11654 19642, 27630, histocompatibility 35618, 43606, complex, class II, 51594 DR alpha

64063512 major 414698 3667 402951 11655 19643, 27631, histocompatibility 35619, 43607, complex, class II, 51595 DR alpha

64073513 major 415767 3668 392789 11656 19644, 27632, histocompatibility 35620, 43608, complex, class II, 51596 DR alpha

64083514 major 416883 3669 410443 11657 19645, 27633, histocompatibility 35621, 43609, complex, class II, 51597 DR alpha

64093515 major 418111 3670 412562 11658 19646, 27634, histocompatibility 35622, 43610, complex, class II, 51598 DR alpha

64103516 major 427753 3671 398838 11659 19647, 27635, histocompatibility 35623, 43611, complex, class II, 51599 DR alpha

64113517 major 434866 3672 403385 11660 19648, 27636, histocompatibility 35624, 43612, complex, class II, 51600 DR alpha

64123518 major 442960 3673 404533 11661 19649, 27637, histocompatibility 35625, 43613, complex, class II, 51601 DR alpha

64133519 major 542549 3674 443327 11662 19650, 27638, histocompatibility 35626, 43614, complex, class II, 51602 DR alpha

64143520 major 546379 3675 447577 11663 19651, 27639, histocompatibility 35627, 43615, complex, class II, 51603 DR alpha

64153521 major 546550 3676 447027 11664 19652, 27640, histocompatibility 35628, 43616, complex, class II, 51604 DR alpha

64163522 major 546589 3677 448422 11665 19653, 27641, histocompatibility 35629, 43617, complex, class II, 51605 DR alpha

64173523 major 547499 3678 446911 11666 19654, 27642, histocompatibility 35630, 43618, complex, class II, 51606 DR alpha

64183524 major 547909 3679 449599 11667 19655, 27643, histocompatibility 35631, 43619, complex, class II, 51607 DR alpha

64193525 major 548099 3680 448765 11668 19656, 27644, histocompatibility 35632, 43620, complex, class II, 51608 DR alpha

64203526 major 548168 3681 447052 11669 19657, 27645, histocompatibility 35633, 43621, complex, class II, 51609 DR alpha

64213527 major 549449 3682 447849 11670 19658, 27646, histocompatibility 35634, 43622, complex, class II, 51610 DR alpha

64223528 major 549531 3683 449251 11671 19659, 27647, histocompatibility 35635, 43623, complex, class II, 51611 DR alpha

64233529 major 550055 3684 450200 11672 19660, 27648, histocompatibility 35636, 43624, complex, class II, 51612 DR alpha

64243530 major 550966 3685 450172 11673 19661, 27649, histocompatibility 35637, 43625, complex, class II, 51613 DR alpha

64253531 major 551689 3686 446751 11674 19662, 27650, histocompatibility 35638, 43626, complex, class II, 51614 DR alpha

64263532 major 551750 3687 447755 11675 19663, 27651, histocompatibility 35639, 43627, complex, class II, 51615 DR alpha

64273533 major 552078 3688 446742 11676 19664, 27652, histocompatibility 35640, 43628, complex, class II, 51616 DR alpha

64283534 major 552804 3689 447375 11677 19665, 27653, histocompatibility 35641, 43629, complex, class II, 51617 DR alpha

64293535 major 553193 3690 446750 11678 19666, 27654, histocompatibility 35642, 43630, complex, class II, 51618 DR alpha

64303536 major 411565 3691 410857 11679 19667, 27655, histocompatibility 35643, 43631, complex, class II, 51619 DR beta 4

64313537 major 411959 3692 410046 11680 19668, 27656, histocompatibility 35644, 43632, complex, class II, 51620 DR beta 4 3538 major 457451 3693 412031 11681 19669, 27657, histocompatibility 35645, 43633, complex, class II, 51621 DR beta 4

64323539 malonyl CoA:ACP 290429 3694 290429 11682 19670, 27658, acyltransferase 35646, 43634,

6433(mitochondrial) 51622

64343540 malonyl CoA:ACP 327555 3695 331306 11683 19671, 27659, acyltransferase 35647, 43635,

6435(mitochondrial) 51623

64363541 MAM domain 317446 3696 319388 11684 19672, 27660, containing 4 35648, 43636,

643751624

64383542 MAM domain 413647 3697 400009 11685 19673, 27661, containing 4 35649, 43637,

643951625

64403543 MAM domain 445819 3698 411339 11686 19674, 27662, containing 4 35650, 43638,

644151626

64423544 mannosidase, alpha, 263979 3699 263979 11687 19675, 27663, class IC, member 1 35651, 43639,

644351627

64443545 mannosidase, alpha, 374329 3700 363449 11688 19676, 27664, class IC, member 1 35652, 43640,

644551628

64463546 mannosidase, alpha, 374331 3701 363451 11689 19677, 27665, class IC, member 1 35653, 43641,

644751629

64483547 mannosidase, alpha, 374332 3702 363452 11690 19678, 27666, class IC, member 1 35654, 43642,

644951630

64503548 mannosidase, beta 373605 3703 362707 11691 19679, 27667, A, lysosomal-like 35655, 43643,

645151631

64523549 mannosidase, beta 373606 3704 362708 11692 19680, 27668, A, lysosomal-like 35656, 43644,

645351632

64543550 mannosidase, beta 397150 3705 380337 11693 19681, 27669, A, lysosomal-like 35657, 43645,

645551633

64563551 mannosidase, beta 397151 3706 380338 11694 19682, 27670, A, lysosomal-like 35658, 43646,

645751634

64583552 mannosidase, beta 397152 3707 380339 11695 19683, 27671, A, lysosomal-like 35659, 43647,

645951635

64603553 mannosidase, beta 397156 3708 380342 11696 19684, 27672, A, lysosomal-like 35660, 43648,

646151636

64623554 mannosidase, endo- 329006 3709 328770 11697 19685, 27673, alpha-like 35661, 43649,

646351637

64643555 mannosidase, endo- 373045 3710 362136 11698 19686, 27674, alpha-like 35662, 43650,

646551638 3556 mannosidase, endo- 397631 3711 380755 11699 19687, 27675, alpha-like 35663, 43651,

646651639

64673557 mannosyl (alpha- 332156 3712 331664 11700 19688, 27676, l,3-)-glycoprotein 35664, 43652, beta-l,4-N- 51640 acetylglucosaminyltr

6468ansferase, isozyme

6469C (putative)

64703558 mannosyl (alpha- 393205 3713 376900 11701 19689, 27677, l,3-)-glycoprotein 35665, 43653, beta-l,4-N- 51641 acetylglucosaminyltr

6471ansferase, isozyme

6472C (putative)

64733559 mannosyl (alpha- 547225 3714 449172 11702 19690, 27678, l,3-)-glycoprotein 35666, 43654, beta-l,4-N- 51642 acetylglucosaminyltr

6474ansferase, isozyme

6475C (putative)

64763560 mannosyl (alpha- 548651 3715 447253 11703 19691, 27679, l,3-)-glycoprotein 35667, 43655, beta-l,4-N- 51643 acetylglucosaminyltr

6477ansferase, isozyme

6478C (putative)

64793561 mannosyl (alpha- 549405 3716 449022 11704 19692, 27680, l,3-)-glycoprotein 35668, 43656, beta-l,4-N- 51644 acetylglucosaminyltr

6480ansferase, isozyme

6481C (putative)

64823562 mannosyl (alpha- 550460 3717 448690 11705 19693, 27681, l,3-)-glycoprotein 35669, 43657, beta-l,4-N- 51645 acetylglucosaminyltr

6483ansferase, isozyme

6484C (putative)

64853563 mannosyl (alpha- 552808 3718 446647 11706 19694, 27682, l,3-)-glycoprotein 35670, 43658, beta-l,4-N- 51646 acetylglucosaminyltr

6486ansferase, isozyme

6487C (putative)

64883564 mannosyl- 233616 3719 233616 11707 19695, 27683, oligosaccharide 35671, 43659, glucosidase 51647

64893565 mannosyl- 452063 3720 388201 11708 19696, 27684, oligosaccharide 35672, 43660, glucosidase 51648

64903566 mannosyl- 535045 3721 439971 11709 19697, 27685, oligosaccharide 35673, 43661, glucosidase 51649 3567 MANSC domain 535902 3722 438205 11710 19698, 27686, containing 1 35674, 43662,

649151650

64923568 MANSC domain 543314 3723 437624 11711 19699, 27687, containing 1 35675, 43663,

649351651

64943569 matrix-remodelling 355797 3724 348050 11712 19700, 27688, associated 7 35676, 43664,

649551652

64963570 matrix-remodelling 375036 3725 364176 11713 19701, 27689, associated 7 35677, 43665,

649751653

64983571 matrix-remodelling 392488 3726 376279 11714 19702, 27690, associated 7 35678, 43666,

649951654

65003572 matrix-remodelling 449428 3727 391466 11715 19703, 27691, associated 7 35679, 43667,

650151655

65023573 matrix-remodelling 309212 3728 307887 11716 19704, 27692, associated 8 35680, 43668,

650351656

65043574 matrix-remodelling 342753 3729 344998 11717 19705, 27693, associated 8 35681, 43669,

650551657

65063575 matrix-remodelling 378864 3730 368141 11718 19706, 27694, associated 8 35682, 43670,

650751658

65083576 matrix-remodelling 445648 3731 399229 11719 19707, 27695, associated 8 35683, 43671,

650951659

65103577 mature T-cell 369479 3732 358491 11720 19708, 27696, proliferation 1 35684, 43672, neighbor 51660

65113578 mature T-cell 369484 3733 358496 11721 19709, 27697, proliferation 1 35685, 43673, neighbor 51661

65123579 melanocortin 2 257776 3734 257776 11722 19710, 27698, receptor accessory 35686, 43674, protein 2 51662

65133580 melanoma antigen 356661 3735 349085 11723 19711, 27699, family A, 1 (directs 35687, 43675, expression of 51663 antigen MZ2-E)

65143581 membrane 354212 3736 346151 11724 19712, 27700, associated guanylate 35688, 43676, kinase, WW and 51664 PDZ domain

6515containing 2

65163582 membrane 419488 3737 405766 11725 19713, 27701, associated guanylate 35689, 43677, kinase, WW and 51665 PDZ domain

6517containing 2 3583 membrane 535697 3738 441603 11726 19714, 27702, associated guanylate 35690, 43678, kinase, WW and 51666 PDZ domain

6518containing 2

65193584 membrane 536298 3739 445041 11727 19715, 27703, associated guanylate 35691, 43679, kinase, WW and 51667 PDZ domain

6520containing 2

65213585 membrane 536571 3740 441584 11728 19716, 27704, associated guanylate 35692, 43680, kinase, WW and 51668 PDZ domain

6522containing 2

65233586 membrane bound O- 245615 3741 245615 11729 19717, 27705, acyltransferase 35693, 43681, domain containing 7 51669

65243587 membrane bound O- 338624 3742 344377 11730 19718, 27706, acyltransferase 35694, 43682, domain containing 7 51670

65253588 membrane bound O- 391754 3743 375634 11731 19719, 27707, acyltransferase 35695, 43683, domain containing 7 51671

65263589 membrane bound O- 414665 3744 388250 11732 19720, 27708, acyltransferase 35696, 43684, domain containing 7 51672

65273590 membrane bound O- 431666 3745 410503 11733 19721, 27709, acyltransferase 35697, 43685, domain containing 7 51673

65283591 membrane bound O- 453320 3746 410320 11734 19722, 27710, acyltransferase 35698, 43686, domain containing 7 51674

65293592 Membrane frizzled- 449574 3747 391664 11735 19723, 27711, related protein 35699, 43687,

653051675

65313593 Membrane frizzled- 555262 3748 450509 11736 19724, 27712, related protein 35700, 43688,

653251676

65333594 membrane 305963 3749 306220 11737 19725, 27713, magnesium 35701, 43689, transporter 1 51677

65343595 membrane 433339 3750 411359 11738 19726, 27714, magnesium 35702, 43690, transporter 1 51678

65353596 membrane-spanning 531783 3751 433761 11739 19727, 27715, 4-domains 35703, 43691, subfamily A 51679 member 14 3597 membrane-spanning 378185 3752 367427 11740 19728, 27716, 4-domains, 35704, 43692, subfamily A, 51680 member 13

65363598 membrane-spanning 378186 3753 367428 11741 19729, 27717, 4-domains, 35705, 43693, subfamily A, 51681 member 13

65373599 membrane-spanning 437058 3754 415535 11742 19730, 27718, 4-domains, 35706, 43694, subfamily A, 51682 member 13

65383600 membrane-spanning 300187 3755 300187 11743 19731, 27719, 4-domains, 35707, 43695, subfamily A, 51683 member 14

65393601 membrane-spanning 395001 3756 378449 11744 19732, 27720, 4-domains, 35708, 43696, subfamily A, 51684 member 14

65403602 membrane-spanning 395005 3757 378453 11745 19733, 27721, 4-domains, 35709, 43697, subfamily A, 51685 member 14

65413603 membrane-spanning 531787 3758 437222 11746 19734, 27722, 4-domains, 35710, 43698, subfamily A, 51686 member 14

65423604 membrane-spanning 337911 3759 338692 11747 19735, 27723, 4-domains, 35711, 43699, subfamily A, 51687 member 15

65433605 membrane-spanning 405633 3760 386022 11748 19736, 27724, 4-domains, 35712, 43700, subfamily A, 51688 member 15

65443606 mesothelin-like 293892 3761 293892 11749 19737, 27725,

654535713, 43701, 51689

65463607 mesothelin-like 442466 3762 415767 11750 19738, 27726,

654735714, 43702, 51690

65483608 metaxin 2 249442 3763 249442 11751 19739, 27727,

654935715, 43703, 51691

65503609 metaxin 2 392529 3764 376314 11752 19740, 27728,

655135716, 43704, 51692

65523610 metaxin 3 328496 3765 331672 11753 19741, 27729,

655335717, 43705, 51693

65543611 metaxin 3 418095 3766 392181 11754 19742, 27730,

655535718, 43706, 51694 3612 metaxin 3 509852 3767 423302 11755 19743, 27731,

655635719, 43707, 51695

65573613 metaxin 3 512528 3768 424798 11756 19744, 27732,

655835720, 43708, 51696

65593614 metaxin 3 512560 3769 423600 11757 19745, 27733,

656035721, 43709, 51697

65613615 methionyl 315796 3770 315152 11758 19746, 27734, aminopeptidase type 35722, 43710, ID (mitochondrial) 51698

65623616 methylenetetrahydro 264090 3771 264090 11759 19747, 27735, folate 35723, 43711, dehydrogenase 51699 (NADP+ dependent)

65632,

6564methenyltetrahydrof

6565olate cyclohydrolase

65663617 methylenetetrahydro 394050 3772 377614 11760 19748, 27736, folate 35724, 43712, dehydrogenase 51700 (NADP+ dependent)

65672,

6568methenyltetrahydrof

6569olate cyclohydrolase

65703618 methylenetetrahydro 394053 3773 377617 11761 19749, 27737, folate 35725, 43713, dehydrogenase 51701 (NADP+ dependent)

65712,

6572methenyltetrahydrof

6573olate cyclohydrolase

65743619 methylsterol 261507 3774 261507 11762 19750, 27738, monooxygenase 1 35726, 43714,

657551702

65763620 methylsterol 393766 3775 377361 11763 19751, 27739, monooxygenase 1 35727, 43715,

657751703

65783621 methylsterol 505270 3776 425112 11764 19752, 27740, monooxygenase 1 35728, 43716,

657951704

65803622 methylsterol 507013 3777 425241 11765 19753, 27741, monooxygenase 1 35729, 43717,

658151705

65823623 methyltransferase 532971 3778 431287 11766 19754, 27742, like 12 35730, 43718,

658351706

65843624 methyltransferase 406927 3779 385481 11767 19755, 27743, like 21 A 35731, 43719,

658551707

65863625 methyltransferase 411432 3780 415115 11768 19756, 27744, like 21 A 35732, 43720,

658751708 3626 methyltransferase 425132 3781 400730 11769 19757, 27745, like 21 A 35733, 43721,

658851709

65893627 methyltransferase 426075 3782 403317 11770 19758, 27746, like 21 A 35734, 43722,

659051710

65913628 methyltransferase 442521 3783 392062 11771 19759, 27747, like 21 A 35735, 43723,

659251711

65933629 methyltransferase 448007 3784 407622 11772 19760, 27748, like 21 A 35736, 43724,

659451712

65953630 methyltransferase 458426 3785 389684 11773 19761, 27749, like 21 A 35737, 43725,

659651713

65973631 methyltransferase 300209 3786 300209 11774 19762, 27750, like 2 IB 35738, 43726,

659851714

65993632 methyltransferase 333012 3787 327425 11775 19763, 27751, like 2 IB 35739, 43727,

660051715

66013633 methyltransferase 317409 3788 316862 11776 19764, 27752, like 23 35740, 43728,

660251716

66033634 methyltransferase 341249 3789 341543 11777 19765, 27753, like 23 35741, 43729,

660451717

66053635 methyltransferase 586752 3790 466203 11778 19766, 27754, like 23 35742, 43730,

660651718

66073636 methyltransferase 588822 3791 465430 11779 19767, 27755, like 23 35743, 43731,

660851719

66093637 methyltransferase 590964 3792 465890 11780 19768, 27756, like 23 35744, 43732,

661051720

66113638 MICAL-like 2 297508 3793 297508 11781 19769, 27757,

661235745, 43733, 51721

66133639 MICAL-like 2 405088 3794 385928 11782 19770, 27758,

661435746, 43734, 51722

66153640 microfibrillar- 361618 3795 354583 11783 19771, 27759, associated protein 3- 35747, 43735, like 51723

66163641 microfibrillar- 393704 3796 377307 11784 19772, 27760, associated protein 3- 35748, 43736, like 51724

66173642 microfibrillar- 502832 3797 423722 11785 19773, 27761, associated protein 3- 35749, 43737, like 51725

66183643 microfibrillar- 504999 3798 425303 11786 19774, 27762, associated protein 3- 35750, 43738, like 51726 3644 microfibrillar- 506764 3799 426247 11787 19775, 27763, associated protein 3- 35751, 43739, like 51727

66193645 microfibrillar- 510306 3800 423549 11788 19776, 27764, associated protein 3- 35752, 43740, like 51728

66203646 microfibrillar- 512698 3801 422791 11789 19777, 27765, associated protein 3- 35753, 43741, like 51729

66213647 microtubule- 360668 3802 353886 11790 19778, 27766, associated protein 1 35754, 43742, light chain 3 alpha 51730

66223648 microtubule- 397709 3803 380821 11791 19779, 27767, associated protein 1 35755, 43743, light chain 3 alpha 51731

66233649 microtubule- 374837 3804 363970 11792 19780, 27768, associated protein 1 35756, 43744, light chain 3 alpha 51732

66243650 microtubule- 268607 3805 268607 11793 19781, 27769, associated protein 1 35757, 43745, light chain 3 beta 51733

66253651 microtubule- 534986 3806 441125 11794 19782, 27770, associated protein 1 35758, 43746, light chain 3 beta 51734

66263652 microtubule- 357246 3807 349785 11795 19783, 27771, associated protein 1 35759, 43747, light chain 3 gamma 51735

66273653 microtubule- 345567 3808 344217 11796 19784, 27772, associated protein 7 35760, 43748,

662851736

66293654 microtubule- 354570 3809 346581 11797 19785, 27773, associated protein 7 35761, 43749,

663051737

66313655 microtubule- 432797 3810 414879 11798 19786, 27774, associated protein 7 35762, 43750,

663251738

66333656 microtubule- 438100 3811 400790 11799 19787, 27775, associated protein 7 35763, 43751,

663451739

66353657 microtubule- 454590 3812 414712 11800 19788, 27776, associated protein 7 35764, 43752,

663651740

66373658 microtubule- 544465 3813 445737 11801 19789, 27777, associated protein 7 35765, 43753,

663851741

66393659 mindbomb homolog 261537 3814 261537 11802 19790, 27778, 1 (Drosophila) 35766, 43754,

664051742

66413660 MIT, microtubule 289359 3815 289359 11803 19791, 27779, interacting and 35767, 43755, transport, domain 51743 containing 1

66423661 MIT, microtubule 422537 3816 413371 11804 19792, 27780, interacting and 35768, 43756, transport, domain 51744 containing 1

66433662 mitochondrial 361114 3817 354415 11805 19793, 27781, calcium uptake 1 35769, 43757,

664451745

66453663 mitochondrial 398761 3818 381745 11806 19794, 27782, calcium uptake 1 35770, 43758,

664651746

66473664 mitochondrial 398763 3819 381747 11807 19795, 27783, calcium uptake 1 35771, 43759,

664851747

66493665 mitochondrial 401998 3820 384068 11808 19796, 27784, calcium uptake 1 35772, 43760,

665051748

66513666 mitochondrial 418483 3821 402470 11809 19797, 27785, calcium uptake 1 35773, 43761,

665251749

66533667 mitochondrial 337855 3822 338712 11810 19798, 27786, carrier 1 35774, 43762,

665451750

66553668 mitochondrial 373550 3823 362651 11811 19799, 27787, carrier 1 35775, 43763,

665651751

66573669 mitochondrial 373565 3824 362666 11812 19800, 27788, carrier 1 35776, 43764,

665851752

66593670 mitochondrial 373616 3825 362718 11813 19801, 27789, carrier 1 35777, 43765,

666051753

66613671 mitochondrial 373627 3826 362730 11814 19802, 27790, carrier 1 35778, 43766,

666251754

66633672 mitochondrial 418541 3827 399187 11815 19803, 27791, carrier 1 35779, 43767,

666451755

66653673 mitochondrial 460219 3828 419739 11816 19804, 27792, carrier 1 35780, 43768,

666651756

66673674 mitochondrial 538808 3829 437660 11817 19805, 27793, carrier 1 35781, 43769,

666851757

66693675 mitochondrial 242275 3830 242275 11818 19806, 27794, carrier triple repeat 1 35782, 43770,

667051758

66713676 mitochondrial 377716 3831 366945 11819 19807, 27795, carrier triple repeat 1 35783, 43771,

667251759

66733677 mitochondrial 380590 3832 369964 11820 19808, 27796, carrier triple repeat 1 35784, 43772,

667451760

66753678 mitochondrial 269205 3833 372612 11821 19809, 27797, carrier triple repeat 2 35785, 43773,

667651761 3679 mitochondrial 535708 3834 443889 11822 19810, 27798, carrier triple repeat 2 35786, 43774,

667751762

66783680 mitochondrial 357421 3835 361681 11823 19811, 27799, carrier triple repeat 6 35787, 43775,

667951763

66803681 mitochondrial 304593 3836 304898 11824 19812, 27800, fission factor 35788, 43776,

668151764

66823682 mitochondrial 337110 3837 338412 11825 19813, 27801, fission factor 35789, 43777,

668351765

66843683 mitochondrial 349901 3838 304134 11826 19814, 27802, fission factor 35790, 43778,

668551766

66863684 mitochondrial 353339 3839 302037 11827 19815, 27803, fission factor 35791, 43779,

668751767

66883685 mitochondrial 354503 3840 346498 11828 19816, 27804, fission factor 35792, 43780,

668951768

66903686 mitochondrial 392059 3841 375912 11829 19817, 27805, fission factor 35793, 43781,

669151769

66923687 mitochondrial 409565 3842 386964 11830 19818, 27806, fission factor 35794, 43782,

669351770

66943688 mitochondrial 409616 3843 386641 11831 19819, 27807, fission factor 35795, 43783,

669551771

66963689 mitochondrial 418961 3844 407547 11832 19820, 27808, fission factor 35796, 43784,

669751772

66983690 mitochondrial 423098 3845 390165 11833 19821, 27809, fission factor 35797, 43785,

669951773

67003691 mitochondrial 436237 3846 411386 11834 19822, 27810, fission factor 35798, 43786,

670151774

67023692 mitochondrial 443428 3847 391829 11835 19823, 27811, fission factor 35799, 43787,

670351775

67043693 mitochondrial 452930 3848 415996 11836 19824, 27812, fission factor 35800, 43788,

670551776

67063694 mitochondrial 525195 3849 436920 11837 19825, 27813, fission factor 35801, 43789,

670751777

67083695 mitochondrial 266263 3850 266263 11838 19826, 27814, fission process 1 35802, 43790,

670951778

67103696 mitochondrial 355143 3851 347267 11839 19827, 27815, fission process 1 35803, 43791,

671151779 3697 mitochondrial 262146 3852 262146 11840 19828, 27816, fission regulator 1 35804, 43792,

671251780

67133698 mitochondrial 458689 3853 391502 11841 19829, 27817, fission regulator 1 35805, 43793,

671451781

67153699 Mitochondrial 317502 3854 323047 11842 19830, 27818, GTPase 1 35806, 43794,

671651782

67173700 Mitochondrial 432508 3855 393480 11843 19831, 27819, GTPase 1 35807, 43795,

671851783

67193701 Mitochondrial 537620 3856 438503 11844 19832, 27820, GTPase 1 35808, 43796,

672051784

67213702 mitochondrial inner 322753 3857 325562 11845 19833, 27821, membrane 35809, 43797, organizing system 1 51785

67223703 Mitochondrial 250377 3858 250377 11846 19834, 27822, ribonuclease P 35810, 43798, protein 3 51786

67233704 Mitochondrial 321130 3859 324697 11847 19835, 27823, ribonuclease P 35811, 43799, protein 3 51787

67243705 Mitochondrial 534898 3860 440915 11848 19836, 27824, ribonuclease P 35812, 43800, protein 3 51788

67253706 Mitochondrial 553978 3861 451940 11849 19837, 27825, ribonuclease P 35813, 43801, protein 3 51789

67263707 Mitochondrial 554727 3862 452604 11850 19838, 27826, ribonuclease P 35814, 43802, protein 3 51790

67273708 Mitochondrial 554896 3863 450779 11851 19839, 27827, ribonuclease P 35815, 43803, protein 3 51791

67283709 Mitochondrial 556115 3864 452471 11852 19840, 27828, ribonuclease P 35816, 43804, protein 3 51792

67293710 Mitochondrial 556121 3865 452094 11853 19841, 27829, ribonuclease P 35817, 43805, protein 3 51793

67303711 mitochondrial 556912 3866 451707 11854 19842, 27830, ribonuclease P 35818, 43806, protein 3 isoform 2 51794

67313712 mitochondrial 297908 3867 297908 11855 19843, 27831, ribosome recycling 35819, 43807, factor 51795

67323713 mitochondrial 344641 3868 343867 11856 19844, 27832, ribosome recycling 35820, 43808, factor 51796

67333714 mitochondrial 373723 3869 362828 11857 19845, 27833, ribosome recycling 35821, 43809, factor 51797 3715 mitochondrial 373724 3870 362829 11858 19846, 27834, ribosome recycling 35822, 43810, factor 51798

67343716 mitochondrial 373727 3871 362832 11859 19847, 27835, ribosome recycling 35823, 43811, factor 51799

67353717 mitochondrial 373728 3872 362833 11860 19848, 27836, ribosome recycling 35824, 43812, factor 51800

67363718 mitochondrial 373729 3873 362834 11861 19849, 27837, ribosome recycling 35825, 43813, factor 51801

67373719 mitochondrial 373730 3874 362835 11862 19850, 27838, ribosome recycling 35826, 43814, factor 51802

67383720 mitochondrial 394315 3875 377850 11863 19851, 27839, ribosome recycling 35827, 43815, factor 51803

67393721 mitochondrial 441707 3876 395072 11864 19852, 27840, ribosome recycling 35828, 43816, factor 51804

67403722 mitochondrial 546115 3877 445588 11865 19853, 27841, ribosome recycling 35829, 43817, factor 51805

67413723 mitochondrial rRNA 250156 3878 250156 11866 19854, 27842, methyltransferase 1 35830, 43818, homolog (S. 51806 cerevisiae)

67423724 mitochondrial 381116 3879 370508 11867 19855, 27843, translational 35831, 43819, initiation factor 3 51807

67433725 mitochondrial 381120 3880 370512 11868 19856, 27844, translational 35832, 43820, initiation factor 3 51808

67443726 mitochondrial 405591 3881 384659 11869 19857, 27845, translational 35833, 43821, initiation factor 3 51809

67453727 mitochondrial 431572 3882 400084 11870 19858, 27846, translational 35834, 43822, initiation factor 3 51810

67463728 mitochondrially 361899 3883 354632 11871 19859, 27847, encoded ATP 35835, 43823, synthase 6 51811

67473729 mitochondrially 361789 3884 354554 11872 19860, 27848, encoded cytochrome 35836, 43824, b 51812

67483730 mitochondrially 361624 3885 354499 11873 19861, 27849, encoded cytochrome 35837, 43825, c oxidase I 51813

67493731 mitochondrially 361739 3886 354876 11874 19862, 27850, encoded cytochrome 35838, 43826, c oxidase II 51814

67503732 mitochondrially 362079 3887 354982 11875 19863, 27851, encoded cytochrome 35839, 43827, c oxidase III 51815 3733 mitochondrially 361390 3888 354687 11876 19864, 27852, encoded NADH 35840, 43828, dehydrogenase 1 51816

67513734 mitochondrially 361453 3889 355046 11877 19865, 27853, encoded NADH 35841, 43829, dehydrogenase 2 51817

67523735 mitochondrially 361227 3890 355206 11878 19866, 27854, encoded NADH 35842, 43830, dehydrogenase 3 51818

67533736 mitochondrially 361381 3891 354961 11879 19867, 27855, encoded NADH 35843, 43831, dehydrogenase 4 51819

67543737 mitochondrially 361335 3892 354728 11880 19868, 27856, encoded NADH 35844, 43832, dehydrogenase 4L 51820

67553738 mitochondrially 361567 3893 354813 11881 19869, 27857, encoded NADH 35845, 43833, dehydrogenase 5 51821

67563739 mitochondrially 361681 3894 354665 11882 19870, 27858, encoded NADH 35846, 43834, dehydrogenase 6 51822

67573740 mitofusin 1 263969 3895 263969 11883 19871, 27859,

675835847, 43835, 51823

67593741 mitofusin 1 280653 3896 280653 11884 19872, 27860,

676035848, 43836, 51824

67613742 mitofusin 1 467174 3897 419134 11885 19873, 27861,

676235849, 43837, 51825

67633743 mitofusin 1 471841 3898 420617 11886 19874, 27862,

676435850, 43838, 51826

67653744 mitofusin 1 539169 3899 445566 11887 19875, 27863,

676635851, 43839, 51827

67673745 mitogen-activated 250894 3900 250894 11888 19876, 27864, protein kinase 8 35852, 43840, interacting protein 3 51828

67683746 mitogen-activated 356010 3901 348290 11889 19877, 27865, protein kinase 8 35853, 43841, interacting protein 3 51829

67693747 mitogen-activated 265960 3902 265960 11890 19878, 27866, protein kinase 35854, 43842, associated protein 1 51830

67703748 mitogen-activated 350766 3903 265961 11891 19879, 27867, protein kinase 35855, 43843, associated protein 1 51831

67713749 mitogen-activated 373496 3904 362595 11892 19880, 27868, protein kinase 35856, 43844, associated protein 1 51832

67723750 mitogen-activated 373497 3905 362596 11893 19881, 27869, protein kinase 35857, 43845, associated protein 1 51833 3751 mitogen-activated 373498 3906 362597 11894 19882, 27870, protein kinase 35858, 43846, associated protein 1 51834

67733752 mitogen-activated 373503 3907 362602 11895 19883, 27871, protein kinase 35859, 43847, associated protein 1 51835

67743753 mitogen-activated 373505 3908 362604 11896 19884, 27872, protein kinase 35860, 43848, associated protein 1 51836

67753754 mitogen-activated 373511 3909 362610 11897 19885, 27873, protein kinase 35861, 43849, associated protein 1 51837

67763755 mitogen-activated 394063 3910 377627 11898 19886, 27874, protein kinase 35862, 43850, associated protein 1 51838

67773756 mitogen-activated 433483 3911 390024 11899 19887, 27875, protein kinase 35863, 43851, associated protein 1 51839

67783757 mitogen-activated 444226 3912 412485 11900 19888, 27876, protein kinase 35864, 43852, associated protein 1 51840

67793758 mitogen-activated 394060 3913 377624 11901 19889, 27877, protein kinase 35865, 43853, associated protein 1 51841

67803759 monoacylglycerol 446656 3914 406674 11902 19890, 27878, O-acyltransferase 1 35866, 43854,

678151842

67823760 monoacylglycerol 198801 3915 198801 11903 19891, 27879, O-acyltransferase 2 35867, 43855,

678351843

67843761 monoacylglycerol 526712 3916 436283 11904 19892, 27880, O-acyltransferase 2 35868, 43856,

678551844

67863762 monoacylglycerol 223114 3917 223114 11905 19893, 27881, O-acyltransferase 3 35869, 43857,

678751845

67883763 monoacylglycerol 379423 3918 368734 11906 19894, 27882, O-acyltransferase 3 35870, 43858,

678951846

67903764 monoacylglycerol 440203 3919 403756 11907 19895, 27883, O-acyltransferase 3 35871, 43859,

679151847

67923765 motile sperm 370777 3920 359813 11908 19896, 27884, domain containing 1 35872, 43860,

679351848

67943766 motile sperm 370779 3921 359815 11909 19897, 27885, domain containing 1 35873, 43861,

679551849

67963767 motile sperm 370783 3922 359819 11910 19898, 27886, domain containing 1 35874, 43862,

679751850

67983768 motile sperm 380492 3923 369860 11911 19899, 27887, domain containing 2 35875, 43863,

679951851 3769 motile sperm 223054 3924 223054 11912 19900, 27888, domain containing 3 35876, 43864,

680051852

68013770 motile sperm 379527 3925 368842 11913 19901, 27889, domain containing 3 35877, 43865,

680251853

68033771 motile sperm 393950 3926 377522 11914 19902, 27890, domain containing 3 35878, 43866,

680451854

68053772 motile sperm 393953 3927 377525 11915 19903, 27891, domain containing 3 35879, 43867,

680651855

68073773 motile sperm 424091 3928 404626 11916 19904, 27892, domain containing 3 35880, 43868,

680851856

68093774 MPV17 287594 3929 287594 11917 19905, 27893, mitochondrial 35881, 43869, membrane protein51857 like

68103775 MPV17 396385 3930 379669 11918 19906, 27894, mitochondrial 35882, 43870, membrane protein51858 like

68113776 MPV17 247712 3931 247712 11919 19907, 27895, mitochondrial 35883, 43871, membrane protein51859 like 2

68123777 MRS2 magnesium 274747 3932 274747 11920 19908, 27896, homeostasis factor 35884, 43872, homolog (S. 51860 cerevisiae)

68133778 MRS2 magnesium 378353 3933 367604 11921 19909, 27897, homeostasis factor 35885, 43873, homolog (S. 51861 cerevisiae)

68143779 MRS2 magnesium 378386 3934 367637 11922 19910, 27898, homeostasis factor 35886, 43874, homolog (S. 51862 cerevisiae)

68153780 MRS2 magnesium 443868 3935 399585 11923 19911, 27899, homeostasis factor 35887, 43875, homolog (S. 51863 cerevisiae)

68163781 MRS2 magnesium 446191 3936 387441 11924 19912, 27900, homeostasis factor 35888, 43876, homolog (S. 51864 cerevisiae)

68173782 MRS2 magnesium 535061 3937 441839 11925 19913, 27901, homeostasis factor 35889, 43877, homolog (S. 51865 cerevisiae)

68183783 MRS2 magnesium 543597 3938 438118 11926 19914, 27902, homeostasis factor 35890, 43878, homolog (S. 51866 cerevisiae) 3784 MTERF domain 287025 3939 287025 11927 19915, 27903, containing 1 35891, 43879,

681951867

68203785 MTERF domain 240050 3940 240050 11928 19916, 27904, containing 3 35892, 43880,

682151868

68223786 MTERF domain 392830 3941 376575 11929 19917, 27905, containing 3 35893, 43881,

682351869

68243787 MTERF domain 548101 3942 448343 11930 19918, 27906, containing 3 35894, 43882,

682551870

68263788 MTERF domain 550496 3943 448246 11931 19919, 27907, containing 3 35895, 43883,

682751871

68283789 MTERF domain 550736 3944 448854 11932 19920, 27908, containing 3 35896, 43884,

682951872

68303790 MTERF domain 552029 3945 447651 11933 19921, 27909, containing 3 35897, 43885,

683151873

68323791 mucin 21 , cell 376296 3946 365473 11934 19922, 27910, surface associated 35898, 43886,

683351874

68343792 mucin 21 , cell 450707 3947 402251 11935 19923, 27911, surface associated 35899, 43887,

683551875

68363793 mucosal vascular 215637 3948 215637 11936 19924, 27912, addressin cell 35900, 43888, adhesion molecule 1 51876

68373794 mucosal vascular 346144 3949 304247 11937 19925, 27913, addressin cell 35901, 43889, adhesion molecule 1 51877

68383795 mucosal vascular 382683 3950 372130 11938 19926, 27914, addressin cell 35902, 43890, adhesion molecule 1 51878

68393796 mucosal vascular 537731 3951 444768 11939 19927, 27915, addressin cell 35903, 43891, adhesion molecule 1 51879

68403797 mucosal vascular 542525 3952 438655 11940 19928, 27916, addressin cell 35904, 43892, adhesion molecule 1 51880

68413798 mucosal vascular 543297 3953 443089 11941 19929, 27917, addressin cell 35905, 43893, adhesion molecule 1 51881

68423799 multiple C2 domains 557742 3954 454847 11942 19930, 27918, transmembrane 2 35906, 43894,

684351882

68443800 multiple C2 312216 3955 308957 11943 19931, 27919, domains, 35907, 43895, transmembrane 1 51883

68453801 multiple C2 415885 3956 405735 11944 19932, 27920, domains, 35908, 43896, transmembrane 1 51884 3802 multiple C2 429576 3957 391639 11945 19933, 27921, domains, 35909, 43897, transmembrane 1 51885

68463803 multiple C2 505078 3958 426417 11946 19934, 27922, domains, 35910, 43898, transmembrane 1 51886

68473804 multiple C2 505208 3959 426438 11947 19935, 27923, domains, 35911, 43899, transmembrane 1 51887

68483805 multiple C2 505465 3960 422317 11948 19936, 27924, domains, 35912, 43900, transmembrane 1 51888

68493806 multiple C2 515393 3961 424126 11949 19937, 27925, domains, 35913, 43901, transmembrane 1 51889

68503807 multiple C2 331706 3962 329646 11950 19938, 27926, domains, 35914, 43902, transmembrane 2 51890

68513808 multiple C2 357742 3963 350377 11951 19939, 27927, domains, 35915, 43903, transmembrane 2 51891

68523809 multiple C2 451018 3964 395109 11952 19940, 27928, domains, 35916, 43904, transmembrane 2 51892

68533810 multiple C2 543482 3965 438521 11953 19941, 27929, domains, 35917, 43905, transmembrane 2 51893

68543811 murine retrovirus 308763 3966 307885 11954 19942, 27930, integration site 1 35918, 43906, homolog 51894

68553812 murine retrovirus 421747 3967 414598 11955 19943, 27931, integration site 1 35919, 43907, homolog 51895

68563813 murine retrovirus 424001 3968 401205 11956 19944, 27932, integration site 1 35920, 43908, homolog 51896

68573814 murine retrovirus 436272 3969 412229 11957 19945, 27933, integration site 1 35921, 43909, homolog 51897

68583815 murine retrovirus 527509 3970 432067 11958 19946, 27934, integration site 1 35922, 43910, homolog 51898

68593816 murine retrovirus 545852 3971 441971 11959 19947, 27935, integration site 1 35923, 43911, homolog 51899

68603817 murine retrovirus 547195 3972 448278 11960 19948, 27936, integration site 1 35924, 43912, homolog 51900

68613818 murine retrovirus 552103 3973 446764 11961 19949, 27937, integration site 1 35925, 43913, homolog 51901

68623819 murine retrovirus 558540 3974 453013 11962 19950, 27938, integration site 1 35926, 43914, homolog 51902 3820 murine retrovirus 423302 3975 412130 11963 19951, 27939, integration site 1 35927, 43915, homolog 51903

68633821 murine retrovirus 531107 3976 432436 11964 19952, 27940, integration site 1 35928, 43916, homolog 51904

68643822 murine retrovirus 541483 3977 437784 11965 19953, 27941, integration site 1 35929, 43917, homolog 51905

68653823 myelin expression 267836 3978 267836 11966 19954, 27942, factor 2 35930, 43918,

686651906

68673824 myelin expression 324324 3979 316950 11967 19955, 27943, factor 2 35931, 43919,

686851907

68693825 myelin expression 454655 3980 406195 11968 19956, 27944, factor 2 35932, 43920,

687051908

68713826 myelin expression 560172 3981 452918 11969 19957, 27945, factor 2 35933, 43921,

687251909

68733827 myelin protein zero359523 3982 352513 11970 19958, 27946, like 1 35934, 43922,

687451910

68753828 myelin protein zero474859 3983 420455 11971 19959, 27947, like 1 35935, 43923,

687651911

68773829 myelin protein zero392121 3984 375968 11972 19960, 27948, like 1 35936, 43924,

687851912

68793830 myoferlin 358334 3985 351094 11973 19961, 27949,

688035937, 43925, 51913

68813831 myoferlin 359263 3986 352208 11974 19962, 27950,

688235938, 43926, 51914

68833832 myoferlin 371488 3987 360543 11975 19963, 27951,

688435939, 43927, 51915

68853833 myoferlin 371489 3988 360544 11976 19964, 27952,

688635940, 43928, 51916

68873834 myoferlin 371501 3989 360556 11977 19965, 27953,

688835941, 43929, 51917

68893835 myoferlin 371502 3990 360557 11978 19966, 27954,

689035942, 43930, 51918

68913836 myo-inositol 216075 3991 216075 11979 19967, 27955, oxygenase 35943, 43931,

689251919

68933837 myo-inositol 395732 3992 379081 11980 19968, 27956, oxygenase 35944, 43932,

689451920 3838 myo-inositol 395733 3993 379082 11981 19969, 27957, oxygenase 35945, 43933,

689551921

68963839 myo-inositol 451761 3994 409894 11982 19970, 27958, oxygenase 35946, 43934,

689751922

68983840 myosin XVI 251041 3995 251041 11983 19971, 27959,

689935947, 43935, 51923

69003841 myosin XVI 356711 3996 349145 11984 19972, 27960,

690135948, 43936, 51924

69023842 myosin XVI 357550 3997 350160 11985 19973, 27961,

690335949, 43937, 51925

69043843 myosin XVI 375857 3998 365017 11986 19974, 27962,

690535950, 43938, 51926

69063844 myosin XVI 397258 3999 380429 11987 19975, 27963,

690735951, 43939, 51927

69083845 myosin XVI 457511 4000 401633 11988 19976, 27964,

690935952, 43940, 51928

69103846 myosin, light chain 223167 4001 223167 11989 19977, 27965, 10, regulatory 35953, 43941,

691151929

69123847 myristoylated 368635 4002 357624 11990 19978, 27966, alanine -rich protein 35954, 43942, kinase C substrate 51930

69133848 N(alpha)- 395257 4003 378676 11991 19979, 27967, acetyltransferase 30, 35955, 43943, NatC catalytic 51931 subunit

69143849 N(alpha)- 556492 4004 452521 11992 19980, 27968, acetyltransferase 30, 35956, 43944, NatC catalytic 51932 subunit

69153850 N(alpha)- 361671 4005 354972 11993 19981, 27969, acetyltransferase 35, 35957, 43945, NatC auxiliary 51933 subunit

69163851 N(alpha)- 376040 4006 365208 11994 19982, 27970, acetyltransferase 35, 35958, 43946, NatC auxiliary 51934 subunit

69173852 N(alpha)- 416045 4007 399595 11995 19983, 27971, acetyltransferase 35, 35959, 43947, NatC auxiliary 51935 subunit

69183853 N-acetyltransferase 205194 4008 205194 11996 19984, 27972, 14 (GCN5-related, 35960, 43948, putative) 51936 3854 N-acylsphingosine 329428 4009 329886 11997 19985, 27973, amidohydrolase 35961, 43949, (non-lysosomal 51937 ceramidase) 2

69193855 N-acylsphingosine 374028 4010 363140 11998 19986, 27974, amidohydrolase 35962, 43950, (non-lysosomal 51938 ceramidase) 2

69203856 N-acylsphingosine 395526 4011 378897 11999 19987, 27975, amidohydrolase 35963, 43951, (non-lysosomal 51939 ceramidase) 2

69213857 N-acylsphingosine 443575 4012 392766 12000 19988, 27976, amidohydrolase 35964, 43952, (non-lysosomal 51940 ceramidase) 2

69223858 N-acylsphingosine 447815 4013 388206 12001 19989, 27977, amidohydrolase 35965, 43953, (non-lysosomal 51941 ceramidase) 2

69233859 NAD kinase domain 282512 4014 282512 12002 19990, 27978, containing 1 35966, 43954,

692451942

69253860 NAD kinase domain 381937 4015 371362 12003 19991, 27979, containing 1 35967, 43955,

692651943

69273861 NAD kinase domain 397338 4016 380499 12004 19992, 27980, containing 1 35968, 43956,

692851944

69293862 NAD kinase domain 506945 4017 422250 12005 19993, 27981, containing 1 35969, 43957,

693051945

69313863 NAD kinase domain 514504 4018 421029 12006 19994, 27982, containing 1 35970, 43958,

693251946

69333864 NADH 547986 4019 450130 12007 19995, 27983, dehydrogenase 35971, 43959, (ubiquinone) 1 alpha 51947 subcomplex 12

69343865 NADH 327772 4020 330737 12008 19996, 27984, dehydrogenase 35972, 43960, (ubiquinone) 1 alpha 51948 subcomplex, 12

69353866 NADH 417328 4021 410363 12009 19997, 27985, dehydrogenase 35973, 43961, (ubiquinone) 1 alpha 51949 subcomplex, 3,

69369kDa

69373867 NADH 419113 4022 398290 12010 19998, 27986, dehydrogenase 35974, 43962, (ubiquinone) 1 alpha 51950 subcomplex, 3,

69389kDa 3868 NADH 485876 4023 418438 12011 19999, 27987, dehydrogenase 35975, 43963, (ubiquinone) 1 alpha 51951 subcomplex, 3,

69399kDa

69403869 NADH 339600 4024 339720 12012 20000, 27988, dehydrogenase 35976, 43964, (ubiquinone) 1 alpha 51952 subcomplex, 4,

69419kDa

69423870 NADH 471112 4025 419501 12013 20001, 27989, dehydrogenase 35977, 43965, (ubiquinone) 1 beta 51953 subcomplex 5

694316kDa

69443871 NADH 329559 4026 330787 12014 20002, 27990, dehydrogenase 35978, 43966, (ubiquinone) 1 beta 51954 subcomplex, 1,

69457kDa

69463872 NADH 553377 4027 451293 12015 20003, 27991, dehydrogenase 35979, 43967, (ubiquinone) 1 beta 51955 subcomplex, 1,

69477kDa

69483873 NADH 555441 4028 450776 12016 20004, 27992, dehydrogenase 35980, 43968, (ubiquinone) 1 beta 51956 subcomplex, 1,

69497kDa

69503874 NADH 204307 4029 204307 12017 20005, 27993, dehydrogenase 35981, 43969, (ubiquinone) 1 beta 51957 subcomplex, 2,

69518kDa

69523875 NADH 247866 4030 247866 12018 20006, 27994, dehydrogenase 35982, 43970, (ubiquinone) 1 beta 51958 subcomplex, 2,

69538kDa

69543876 NADH 464566 4031 419479 12019 20007, 27995, dehydrogenase 35983, 43971, (ubiquinone) 1 beta 51959 subcomplex, 2,

69558kDa

69563877 NADH 465506 4032 419357 12020 20008, 27996, dehydrogenase 35984, 43972, (ubiquinone) 1 beta 51960 subcomplex, 2,

69578kDa

69583878 NADH 476279 4033 419087 12021 20009, 27997, dehydrogenase 35985, 43973, (ubiquinone) 1 beta 51961 subcomplex, 2,

69598kDa 3879 NADH 184266 4034 184266 12022 20010, 27998, dehydrogenase 35986, 43974, (ubiquinone) 1 beta 51962 subcomplex, 4,

696015kDa

69613880 NADH 485064 4035 419578 12023 20011, 27999, dehydrogenase 35987, 43975, (ubiquinone) 1 beta 51963 subcomplex, 4,

696215kDa

69633881 NADH 259037 4036 259037 12024 20012, 28000, dehydrogenase 35988, 43976, (ubiquinone) 1 beta 51964 subcomplex, 5,

696416kDa

69653882 NADH 493866 4037 419656 12025 20013, 28001, dehydrogenase 35989, 43977, (ubiquinone) 1 beta 51965 subcomplex, 5,

696616kDa

69673883 NADH 350021 4038 297983 12026 20014, 28002, dehydrogenase 35990, 43978, (ubiquinone) 1 beta 51966 subcomplex, 6,

696817kDa

69693884 NADH 525085 4039 434262 12027 20015, 28003, dehydrogenase 35991, 43979, (ubiquinone) 1 51967 subcomplex

6970unknown 2 14.5kDa

69713885 NADH 527806 4040 432739 12028 20016, 28004, dehydrogenase 35992, 43980, (ubiquinone) 1 51968 subcomplex

6972unknown 2 14.5kDa

69733886 NADH 281031 4041 281031 12029 20017, 28005, dehydrogenase 35993, 43981, (ubiquinone) 1, 51969 subcomplex

6974unknown, 2,

697514.5kDa

69763887 NADH 324742 4042 316370 12030 20018, 28006, dehydrogenase 35994, 43982, (ubiquinone) 1, 51970 subcomplex

6977unknown, 2,

697814.5kDa

69793888 NADH 336237 4043 337431 12031 20019, 28007, dehydrogenase 35995, 43983, (ubiquinone) 51971 complex I assembly

6980factor 7

69813889 NADPH oxidase 341349 4044 342848 12032 20020, 28008, activator 1 35996, 43984,

698251972 3890 NADPH oxidase 392815 4045 376562 12033 20021, 28009, activator 1 35997, 43985,

698351973

69843891 NADPH oxidase 354249 4046 346195 12034 20022, 28010, organizer 1 35998, 43986,

698551974

69863892 NADPH oxidase 356120 4047 348435 12035 20023, 28011, organizer 1 35999, 43987,

698751975

69883893 NADPH oxidase 397280 4048 380450 12036 20024, 28012, organizer 1 36000, 43988,

698951976

69903894 naked cuticle 268459 4049 268459 12037 20025, 28013, homolog 1 36001, 43989, (Drosophila) 51977

69913895 naked cuticle 296849 4050 296849 12038 20026, 28014, homolog 2 36002, 43990, (Drosophila) 51978

69923896 naked cuticle 382730 4051 372177 12039 20027, 28015, homolog 2 36003, 43991, (Drosophila) 51979

69933897 naked cuticle 537972 4052 440925 12040 20028, 28016, homolog 2 36004, 43992, (Drosophila) 51980

69943898 naked cuticle 274150 4053 274150 12041 20029, 28017, homolog 2 36005, 43993, (Drosophila) 51981

69953899 natural killer cell 221978 4054 221978 12042 20030, 28018, group 7 sequence 36006, 43994,

699651982

69973900 NCK adaptor protein 288986 4055 288986 12043 20031, 28019, 1 36007, 43995,

699851983

69993901 NCK adaptor protein 476286 4056 418513 12044 20032, 28020, 1 36008, 43996,

700051984

70013902 NCK adaptor protein 481752 4057 417273 12045 20033, 28021, 1 36009, 43997,

700251985

70033903 NCK adaptor protein 485096 4058 419677 12046 20034, 28022, 1 36010, 43998,

700451986

70053904 NCK adaptor protein 491539 4059 419302 12047 20035, 28023, 1 36011, 43999,

700651987

70073905 NCK adaptor protein 469404 4060 419631 12048 20036, 28024, 1 36012, 44000,

700851988

70093906 NCK-associated 293373 4061 293373 12049 20037, 28025, protein 1-like 36013, 44001,

701051989

70113907 NCK-associated 545638 4062 445596 12050 20038, 28026, protein 1-like 36014, 44002,

701251990 3908 N-deacetylase/N- 296499 4063 296499 12051 20039, 28027, sulfotransferase 36015, 44003, (heparan 51991 glucosaminyl) 3

70133909 N-deacetylase/N- 433996 4064 396625 12052 20040, 28028, sulfotransferase 36016, 44004, (heparan 51992 glucosaminyl) 3

70143910 N-deacetylase/N- 264363 4065 264363 12053 20041, 28029, sulfotransferase 36017, 44005, (heparan 51993 glucosaminyl) 4

70153911 NEDD4 binding 274605 4066 274605 12054 20042, 28030, protein 3 36018, 44006,

701651994

70173912 N-ethylmaleimide- 322897 4067 324628 12055 20043, 28031, sensitive factor 36019, 44007, attachment protein, 51995 gamma

70183913 N-ethylmaleimide- 542979 4068 442849 12056 20044, 28032, sensitive factor 36020, 44008, attachment protein, 51996 gamma

70193914 netrin G2 360670 4069 353888 12057 20045, 28033,

702036021, 44009, 51997

70213915 netrin G2 372179 4070 361252 12058 20046, 28034,

702236022, 44010, 51998

70233916 netrin G2 393228 4071 376920 12059 20047, 28035,

702436023, 44011, 51999

70253917 netrin G2 393229 4072 376921 12060 20048, 28036,

702636024, 44012, 52000

70273918 neuralized homolog 372518 4073 361596 12061 20049, 28037, 2 (Drosophila) 36025, 44013,

702852001

70293919 neurensin 1 378475 4074 367736 12062 20050, 28038,

703036026, 44014, 52002

70313920 neurensin 1 378477 4075 367738 12063 20051, 28039,

703236027, 44015, 52003

70333921 neurensin 1 378478 4076 367739 12064 20052, 28040,

703436028, 44016, 52004

70353922 neurensin 1 378491 4077 367752 12065 20053, 28041,

703636029, 44017, 52005

70373923 neuritin 1-like 339176 4078 342411 12066 20054, 28042,

703836030, 44018, 52006 3924 neuroligin 4, X- 275857 4079 275857 12067 20055, 28043, linked 36031, 44019,

703952007

70403925 neuroligin 4, X- 381092 4080 370482 12068 20056, 28044, linked 36032, 44020,

704152008

70423926 neuroligin 4, X- 381093 4081 370483 12069 20057, 28045, linked 36033, 44021,

704352009

70443927 neuroligin 4, X- 381095 4082 370485 12070 20058, 28046, linked 36034, 44022,

704552010

70463928 neuroligin 4, X- 538097 4083 439203 12071 20059, 28047, linked 36035, 44023,

704752011

70483929 Neuron-specific 397958 4084 381049 12072 20060, 28048, protein family 36036, 44024, member 1 52012

70493930 Neuron-specific 421177 4085 388823 12073 20061, 28049, protein family 36037, 44025, member 1 52013

70503931 Neuron-specific 433139 4086 408833 12074 20062, 28050, protein family 36038, 44026, member 1 52014

70513932 Neuron-specific 504171 4087 425803 12075 20063, 28051, protein family 36039, 44027, member 1 52015

70523933 Neuron-specific 505246 4088 421841 12076 20064, 28052, protein family 36040, 44028, member 1 52016

70533934 Neuron-specific 506380 4089 425423 12077 20065, 28053, protein family 36041, 44029, member 1 52017

70543935 Neuron-specific 513555 4090 426358 12078 20066, 28054, protein family 36042, 44030, member 1 52018

70553936 Neuron-specific 513829 4091 425345 12079 20067, 28055, protein family 36043, 44031, member 1 52019

70563937 Neuron-specific 303177 4092 307722 12080 20068, 28056, protein family 36044, 44032, member 2 52020

70573938 Neuron-specific 519717 4093 431119 12081 20069, 28057, protein family 36045, 44033, member 2 52021

70583939 Neuron-specific 519867 4094 429689 12082 20070, 28058, protein family 36046, 44034, member 2 52022

70593940 Neuron-specific 521278 4095 430208 12083 20071, 28059, protein family 36047, 44035, member 2 52023

70603941 neuropeptide FF 277942 4096 277942 12084 20072, 28060, receptor 1 36048, 44036,

706152024 3942 neuropeptide FF 449957 4097 401171 12085 20073, 28061, receptor 1 36049, 44037,

706252025

70633943 neuropeptide FF 308744 4098 307822 12086 20074, 28062, receptor 2 36050, 44038,

706452026

70653944 neuropeptide FF 344413 4099 340789 12087 20075, 28063, receptor 2 36051, 44039,

706652027

70673945 neuropeptide FF 358749 4100 351599 12088 20076, 28064, receptor 2 36052, 44040,

706852028

70693946 neuropeptide FF 395999 4101 379321 12089 20077, 28065, receptor 2 36053, 44041,

707052029

70713947 neuropeptides B/W 369768 4102 358783 12090 20078, 28066, receptor 2 36054, 44042,

707252030

70733948 neuropilin (NRP) 303155 4103 306726 12091 20079, 28067, and tolloid (TLL)- 36055, 44043, like 2 52031

70743949 neuropilin (NRP) 562435 4104 455169 12092 20080, 28068, and tolloid (TLL)- 36056, 44044, like 2 52032

70753950 neurotensin receptor 306928 4105 303686 12093 20081, 28069, 2 36057, 44045,

707652033

70773951 nicalin 246117 4106 246117 12094 20082, 28070,

707836058, 44046, 52034

70793952 NIPA-like domain 295461 4107 295461 12095 20083, 28071, containing 1 36059, 44047,

708052035

70813953 NIPA-like domain 341166 4108 339256 12096 20084, 28072, containing 2 36060, 44048,

708252036

70833954 NIPA-like domain 3912 4109 3912 12097 20085, 28073, containing 3 36061, 44049,

708452037, 56088, 56121

70853955 NIPA-like domain 339255 4110 343549 12098 20086, 28074, containing 3 36062, 44050,

708652038

70873956 NIPA-like domain 358028 4111 350722 12099 20087, 28075, containing 3 36063, 44051,

708852039

70893957 NIPA-like domain 374399 4112 363520 12100 20088, 28076, containing 3 36064, 44052,

709052040

70913958 NIPA-like domain 428131 4113 406509 12101 20089, 28077, containing 3 36065, 44053,

709252041

70933959 NIPA-like domain 432012 4114 392170 12102 20090, 28078, containing 3 36066, 44054,

709452042 3960 nischarin 345716 4115 339958 12103 20091, 28079,

709536067, 44055, 52043

70963961 nischarin 414197 4116 410462 12104 20092, 28080,

709736068, 44056, 52044

70983962 nischarin 433196 4117 398513 12105 20093, 28081,

709936069, 44057, 52045

71003963 nischarin 479054 4118 418232 12106 20094, 28082,

710136070, 44058, 52046

71023964 nischarin 488380 4119 417812 12107 20095, 28083,

710336071, 44059, 52047

71043965 nitric oxide 264230 4120 264230 12108 20096, 28084, associated 1 36072, 44060,

710552048

71063966 NODAL modulator 287667 4121 287667 12109 20097, 28085, 1 36073, 44061,

710752049

71083967 NODAL modulator 456867 4122 405450 12110 20098, 28086, 1 36074, 44062,

710952050

71103968 NODAL modulator 536948 4123 441154 12111 20099, 28087, 1 36075, 44063,

711152051

71123969 NODAL modulator 330537 4124 331851 12112 20100, 28088, 2 36076, 44064,

711352052

71143970 NODAL modulator 381474 4125 370883 12113 20101, 28089, 2 36077, 44065,

711552053

71163971 NODAL modulator 543392 4126 439970 12114 20102, 28090, 2 36078, 44066,

711752054

71183972 NODAL modulator 263012 4127 263012 12115 20103, 28091, 3 36079, 44067,

711952055

71203973 NODAL modulator 399336 4128 382274 12116 20104, 28092, 3 36080, 44068,

712152056

71223974 NODAL modulator 538468 4129 443768 12117 20105, 28093, 3 36081, 44069,

712352057

71243975 non-SMC condensin 315579 4130 325017 12118 20106, 28094, I complex, subunit 36082, 44070, D2 52058

71253976 non-SMC condensin 535602 4131 445103 12119 20107, 28095, I complex, subunit 36083, 44071, D2 52059

71263977 non-SMC condensin 545962 4132 444417 12120 20108, 28096, I complex, subunit 36084, 44072, D2 52060 3978 NSFL1 (p97) 216879 4133 216879 12121 20109, 28097, cofactor (p47) 36085, 44073,

712752061

71283979 NSFL1 (p97) 350991 4134 202584 12122 20110, 28098, cofactor (p47) 36086, 44074,

712952062

71303980 NSFL1 (p97) 353088 4135 338643 12123 20111, 28099, cofactor (p47) 36087, 44075,

713152063

71323981 NSFL1 (p97) 381658 4136 371074 12124 20112, 28100, cofactor (p47) 36088, 44076,

713352064

71343982 NSFL1 (p97) 476071 4137 418529 12125 20113, 28101, cofactor (p47) 36089, 44077,

713552065

71363983 N-terminal EF-hand 417640 4138 387380 12126 20114, 28102, calcium binding 36090, 44078, protein 1 52066

71373984 N-terminal EF-hand 521366 4139 428632 12127 20115, 28103, calcium binding 36091, 44079, protein 1 52067

71383985 N-terminal EF-hand 522820 4140 428953 12128 20116, 28104, calcium binding 36092, 44080, protein 1 52068

71393986 NTPase, KAP 317951 4141 321976 12129 20117, 28105, family P-loop 36093, 44081, domain containing 1 52069

71403987 NTPase, KAP 429338 4142 404706 12130 20118, 28106, family P-loop 36094, 44082, domain containing 1 52070

71413988 NTPase, KAP 438936 4143 401739 12131 20119, 28107, family P-loop 36095, 44083, domain containing 1 52071

71423989 Nuclear pore 435324 4144 415207 12132 20120, 28108, complex-interacting 36096, 44084, protein-like 1 52072

71433990 nuclear protein 331134 4145 331487 12133 20121, 28109, localization 4 36097, 44085, homolog (S. 52073 cerevisiae)

71443991 nuclear protein 374747 4146 363879 12134 20122, 28110, localization 4 36098, 44086, homolog (S. 52074 cerevisiae)

71453992 nuclear protein 539314 4147 446199 12135 20123, 28111, localization 4 36099, 44087, homolog (S. 52075 cerevisiae)

71463993 nuclear transcription 329043 4148 333113 12136 20124, 28112, factor, X-box 36100, 44088, binding-like 1 52076

71473994 nuclear transcription 381538 4149 370949 12137 20125, 28113, factor, X-box 36101, 44089, binding-like 1 52077 3995 nuclear transcription 507489 4150 422037 12138 20126, 28114, factor, X-box 36102, 44090, binding-like 1 52078

71483996 nucleoporin 271854 4151 271854 12139 20127, 28115, 210kDa-like 36103, 44091,

714952079

71503997 nucleoporin 368553 4152 357541 12140 20128, 28116, 210kDa-like 36104, 44092,

715152080

71523998 nucleoporin 368559 4153 357547 12141 20129, 28117, 210kDa-like 36105, 44093,

715352081

71543999 nucleoredoxin-like 1 301944 4154 305631 12142 20130, 28118,

715536106, 44094, 52082

71564000 nudix (nucleoside 301490 4155 301490 12143 20131, 28119, diphosphate linked 36107, 44095, moiety X)-type 52083 motif 8

71574001 nudix (nucleoside 376693 4156 365883 12144 20132, 28120, diphosphate linked 36108, 44096, moiety X)-type 52084 motif 8

71584002 nudix (nucleoside 302174 4157 303575 12145 20133, 28121, diphosphate linked 36109, 44097, moiety X)-type 52085 motif 9

71594003 nudix (nucleoside 473942 4158 421811 12146 20134, 28122, diphosphate linked 36110, 44098, moiety X)-type 52086 motif 9

71604004 nudix (nucleoside 512216 4159 424702 12147 20135, 28123, diphosphate linked 36111, 44099, moiety X)-type 52087 motif 9

71614005 nurim (nuclear 259953 4160 259953 12148 20136, 28124, envelope membrane 36112, 44100, protein) 52088

71624006 nurim (nuclear 376420 4161 365602 12149 20137, 28125, envelope membrane 36113, 44101, protein) 52089

71634007 nurim (nuclear 376421 4162 365603 12150 20138, 28126, envelope membrane 36114, 44102, protein) 52090

71644008 nurim (nuclear 383570 4163 373064 12151 20139, 28127, envelope membrane 36115, 44103, protein) 52091

71654009 nurim (nuclear 383571 4164 373065 12152 20140, 28128, envelope membrane 36116, 44104, protein) 52092

71664010 nurim (nuclear 411883 4165 407049 12153 20141, 28129, envelope membrane 36117, 44105, protein) 52093 4011 nurim (nuclear 422181 4166 409285 12154 20142, 28130, envelope membrane 36118, 44106, protein) 52094

71674012 nurim (nuclear 422664 4167 394788 12155 20143, 28131, envelope membrane 36119, 44107, protein) 52095

71684013 nurim (nuclear 422747 4168 414927 12156 20144, 28132, envelope membrane 36120, 44108, protein) 52096

71694014 nurim (nuclear 427944 4169 405789 12157 20145, 28133, envelope membrane 36121, 44109, protein) 52097

71704015 nurim (nuclear 430286 4170 408118 12158 20146, 28134, envelope membrane 36122, 44110, protein) 52098

71714016 nurim (nuclear 431322 4171 398752 12159 20147, 28135, envelope membrane 36123, 44111, protein) 52099

71724017 nurim (nuclear 434776 4172 394862 12160 20148, 28136, envelope membrane 36124, 44112, protein) 52100

71734018 nurim (nuclear 436892 4173 412991 12161 20149, 28137, envelope membrane 36125, 44113, protein) 52101

71744019 nurim (nuclear 438502 4174 397755 12162 20150, 28138, envelope membrane 36126, 44114, protein) 52102

71754020 nurim (nuclear 444096 4175 397892 12163 20151, 28139, envelope membrane 36127, 44115, protein) 52103

71764021 nurim (nuclear 444252 4176 407779 12164 20152, 28140, envelope membrane 36128, 44116, protein) 52104

71774022 nurim (nuclear 445058 4177 389958 12165 20153, 28141, envelope membrane 36129, 44117, protein) 52105

71784023 nurim (nuclear 446443 4178 389894 12166 20154, 28142, envelope membrane 36130, 44118, protein) 52106

71794024 nurim (nuclear 449041 4179 399560 12167 20155, 28143, envelope membrane 36131, 44119, protein) 52107

71804025 nurim (nuclear 450138 4180 407111 12168 20156, 28144, envelope membrane 36132, 44120, protein) 52108

71814026 nurim (nuclear 456720 4181 392502 12169 20157, 28145, envelope membrane 36133, 44121, protein) 52109

71824027 YN domain and 206466 4182 206466 12170 20158, 28146, retroviral integrase 36134, 44122, containing 52110

71834028 NYN domain and 382554 4183 371994 12171 20159, 28147, retroviral integrase 36135, 44123, containing 52111 4029 odz, odd Oz/ten-m 403607 4184 384905 12172 20160, 28148, homolog 2 36136, 44124, (Drosophila) 52112

71844030 odz, odd Oz/ten-m 518659 4185 429430 12173 20161, 28149, homolog 2 36137, 44125, (Drosophila) 52113

71854031 odz, odd Oz/ten-m 545108 4186 438635 12174 20162, 28150, homolog 2 36138, 44126, (Drosophila) 52114

71864032 odz, odd Oz/ten-m 406950 4187 385276 12175 20163, 28151, homolog 3 36139, 44127, (Drosophila) 52115

71874033 odz, odd Oz/ten-m 511685 4188 424226 12176 20164, 28152, homolog 3 36140, 44128, (Drosophila) 52116

71884034 odz, odd Oz/ten-m 512480 4189 421320 12177 20165, 28153, homolog 3 36141, 44129, (Drosophila) 52117

71894035 Olfactory receptor 550708 4190 449002 12178 20166, 28154, 11H12 36142, 44130,

719052118

71914036 olfactory receptor 594432 4191 471977 12179 20167, 28155, family 7 subfamily 36143, 44131, A member 5 52119

71924037 olfactory receptor, 304094 4192 305207 12180 20168, 28156, family 1, subfamily 36144, 44132, A, member 1 52120

71934038 olfactory receptor, 381951 4193 371377 12181 20169, 28157, family 1, subfamily 36145, 44133, A, member 2 52121

71944039 olfactory receptor, 304833 4194 303151 12182 20170, 28158, family 1, subfamily 36146, 44134, B, member 1 52122

71954040 olfactory receptor, 408896 4195 386138 12183 20171, 28159, family 1, subfamily 36147, 44135, C, member 1 52123

71964041 olfactory receptor, 322608 4196 313384 12184 20172, 28160, family 1, subfamily 36148, 44136, E, member 1 52124

71974042 olfactory receptor, 248384 4197 248384 12185 20173, 28161, family 1, subfamily 36149, 44137, E, member 2 52125

71984043 olfactory receptor, 328890 4198 331545 12186 20174, 28162, family 1, subfamily 36150, 44138, G, member 1 52126

71994044 olfactory receptor, 209540 4199 209540 12187 20175, 28163, family 1, subfamily 36151, 44139, I, member 1 52127

72004045 olfactory receptor, 259357 4200 259357 12188 20176, 28164, family 1, subfamily 36152, 44140, J, member 1 52128

72014046 olfactory receptor, 335302 4201 335575 12189 20177, 28165, family 1, subfamily 36153, 44141, J, member 2 52129 4047 olfactory receptor, 444856 4202 407987 12190 20178, 28166, family 1, subfamily 36154, 44142, J, member 2 52130

72024048 olfactory receptor, 340750 4203 343521 12191 20179, 28167, family 1, subfamily 36155, 44143, J, member 4 52131

72034049 olfactory receptor, 277309 4204 277309 12192 20180, 28168, family 1, subfamily 36156, 44144, K, member 1 52132

72044050 olfactory receptor, 309623 4205 310773 12193 20181, 28169, family 1, subfamily 36157, 44145, L, member 1 52133

72054051 olfactory receptor, 373686 4206 362790 12194 20182, 28170, family 1, subfamily 36158, 44146, L, member 1 52134

72064052 olfactory receptor, 304820 4207 302863 12195 20183, 28171, family 1, subfamily 36159, 44147, L, member 3 52135

72074053 olfactory receptor, 259466 4208 259466 12196 20184, 28172, family 1, subfamily 36160, 44148, L, member 4 52136

72084054 olfactory receptor, 304720 4209 304235 12197 20185, 28173, family 1, subfamily 36161, 44149, L, member 6 52137

72094055 olfactory receptor, 373684 4210 362788 12198 20186, 28174, family 1, subfamily 36162, 44150, L, member 6 52138

72104056 olfactory receptor, 304865 4211 306607 12199 20187, 28175, family 1, subfamily 36163, 44151, L, member 8 52139

72114057 olfactory receptor, 305465 4212 303195 12200 20188, 28176, family 1, subfamily 36164, 44152, M, member 1 52140

72124058 olfactory receptor, 429566 4213 401966 12201 20189, 28177, family 1, subfamily 36165, 44153, M, member 1 52141

72134059 olfactory receptor, 304880 4214 306974 12202 20190, 28178, family 1, subfamily 36166, 44154, N, member 1 52142

72144060 olfactory receptor, 373688 4215 362792 12203 20191, 28179, family 1, subfamily 36167, 44155, N, member 2 52143

72154061 olfactory receptor, 297913 4216 297913 12204 20192, 28180, family 1, subfamily 36168, 44156, Q, member 1 52144

72164062 olfactory receptor, 309433 4217 311688 12205 20193, 28181, family 1, subfamily 36169, 44157, S, member 1 52145

72174063 olfactory receptor, 302592 4218 305469 12206 20194, 28182, family 1, subfamily 36170, 44158, S, member 2 52146

72184064 olfactory receptor, 307322 4219 303862 12207 20195, 28183, family 10, subfamily 36171, 44159, A, member 2 52147 4065 olfactory receptor, 360759 4220 353988 12208 20196, 28184, family 10, subfamily 36172, 44160, A, member 3 52148

72194066 olfactory receptor, 379829 4221 369157 12209 20197, 28185, family 10, subfamily 36173, 44161, A, member 4 52149

72204067 olfactory receptor, 299454 4222 299454 12210 20198, 28186, family 10, subfamily 36174, 44162, A, member 5 52150

72214068 olfactory receptor, 379831 4223 369159 12211 20199, 28187, family 10, subfamily 36175, 44163, A, member 5 52151

72224069 olfactory receptor, 309838 4224 312470 12212 20200, 28188, family 10, subfamily 36176, 44164, A, member 6 52152

72234070 olfactory receptor, 326258 4225 326718 12213 20201, 28189, family 10, subfamily 36177, 44165, A, member 7 52153

72244071 olfactory receptor, 317359 4226 322295 12214 20202, 28190, family 10, subfamily 36178, 44166, AB, member 1 52154 pseudogene

72254072 olfactory receptor, 310248 4227 308689 12215 20203, 28191, family 10, subfamily 36179, 44167, AD, member 1 52155

72264073 olfactory receptor, 312345 4228 311477 12216 20204, 28192, family 10, subfamily 36180, 44168, AG, member 1 52156

72274074 olfactory receptor, 377138 4229 366343 12217 20205, 28193, family 10, subfamily 36181, 44169, C, member 1 52157

72284075 olfactory receptor, 391549 4230 375393 12218 20206, 28194, family 10, subfamily 36182, 44170, C, member 1 52158

72294076 olfactory receptor, 428644 4231 404869 12219 20207, 28195, family 10, subfamily 36183, 44171, C, member 1 52159

72304077 olfactory receptor, 437403 4232 408961 12220 20208, 28196, family 10, subfamily 36184, 44172, C, member 1 52160

72314078 olfactory receptor, 444197 4233 419119 12221 20209, 28197, family 10, subfamily 36185, 44173, C, member 1 52161

72324079 olfactory receptor, 455234 4234 402486 12222 20210, 28198, family 10, subfamily 36186, 44174, C, member 1 52162

72334080 olfactory receptor, 457403 4235 412512 12223 20211, 28199, family 10, subfamily 36187, 44175, C, member 1 52163

72344081 olfactory receptor, 503212 4236 425554 12224 20212, 28200, family 10, subfamily 36188, 44176, C, member 1 52164

72354082 olfactory receptor, 546473 4237 448774 12225 20213, 28201, family 10, subfamily 36189, 44177, C, member 1 52165 4083 olfactory receptor, 550017 4238 450100 12226 20214, 28202, family 10, subfamily 36190, 44178, C, member 1 52166

72364084 olfactory receptor, 550132 4239 449846 12227 20215, 28203, family 10, subfamily 36191, 44179, C, member 1 52167

72374085 olfactory receptor, 551349 4240 448262 12228 20216, 28204, family 10, subfamily 36192, 44180, C, member 1 52168

72384086 olfactory receptor, 552057 4241 447194 12229 20217, 28205, family 10, subfamily 36193, 44181, C, member 1 52169

72394087 olfactory receptor, 552404 4242 448011 12230 20218, 28206, family 10, subfamily 36194, 44182, C, member 1 52170

72404088 olfactory receptor, 552782 4243 448371 12231 20219, 28207, family 10, subfamily 36195, 44183, C, member 1 52171

72414089 olfactory receptor, 318666 4244 323895 12232 20220, 28208, family 10, subfamily 36196, 44184, D, member 3 (non52172 functional)

72424090 olfactory receptor, 542433 4245 445383 12233 20221, 28209, family 10, subfamily 36197, 44185, G, member 2 52173

72434091 olfactory receptor, 303532 4246 302437 12234 20222, 28210, family 10, subfamily 36198, 44186, G, member 3 52174

72444092 olfactory receptor, 320891 4247 325076 12235 20223, 28211, family 10, subfamily 36199, 44187, G, member 4 52175

72454093 olfactory receptor, 330487 4248 329689 12236 20224, 28212, family 10, subfamily 36200, 44188, G, member 7 52176

72464094 olfactory receptor, 431524 4249 389072 12237 20225, 28213, family 10, subfamily 36201, 44189, G, member 8 52177

72474095 olfactory receptor, 375024 4250 364164 12238 20226, 28214, family 10, subfamily 36202, 44190, G, member 9 52178

72484096 olfactory receptor, 334920 4251 335596 12239 20227, 28215, family 10, subfamily 36203, 44191, H, member 1 52179

72494097 olfactory receptor, 305899 4252 306095 12240 20228, 28216, family 10, subfamily 36204, 44192, H, member 2 52180

72504098 olfactory receptor, 305892 4253 307130 12241 20229, 28217, family 10, subfamily 36205, 44193, H, member 3 52181

72514099 olfactory receptor, 322107 4254 318834 12242 20230, 28218, family 10, subfamily 36206, 44194, H, member 4 52182

72524100 olfactory receptor, 308940 4255 310704 12243 20231, 28219, family 10, subfamily 36207, 44195, H, member 5 52183 4101 olfactory receptor, 423932 4256 399078 12244 20232, 28220, family 10, subfamily 36208, 44196, J, member 1 52184

72534102 olfactory receptor, 332217 4257 331789 12245 20233, 28221, family 10, subfamily 36209, 44197, J, member 3 52185

72544103 olfactory receptor, 334857 4258 334441 12246 20234, 28222, family 10, subfamily 36210, 44198, J, member 5 52186

72554104 olfactory receptor, 289451 4259 289451 12247 20235, 28223, family 10, subfamily 36211, 44199, K, member 1 52187

72564105 olfactory receptor, 314902 4260 324251 12248 20236, 28224, family 10, subfamily 36212, 44200, K, member 2 52188

72574106 olfactory receptor, 309675 4261 308082 12249 20237, 28225, family 10, subfamily 36213, 44201, P, member 1 52189

72584107 olfactory receptor, 316770 4262 314324 12250 20238, 28226, family 10, subfamily 36214, 44202, Q, member 1 52190

72594108 olfactory receptor, 368152 4263 357134 12251 20239, 28227, family 10, subfamily 36215, 44203, R, member 2 52191

72604109 olfactory receptor, 531945 4264 431914 12252 20240, 28228, family 10, subfamily 36216, 44204, S, member 1 52192

72614110 olfactory receptor, 334438 4265 334115 12253 20241, 28229, family 10, subfamily 36217, 44205, T, member 2 52193

72624111 olfactory receptor, 307552 4266 302199 12254 20242, 28230, family 10, subfamily 36218, 44206, V, member 1 52194

72634112 olfactory receptor, 395079 4267 378516 12255 20243, 28231, family 10, subfamily 36219, 44207, W, member 1 52195

72644113 olfactory receptor, 368150 4268 357132 12256 20244, 28232, family 10, subfamily 36220, 44208, X, member 1 52196

72654114 olfactory receptor, 361284 4269 354707 12257 20245, 28233, family 10, subfamily 36221, 44209, Z, member 1 52197

72664115 olfactory receptor, 539185 4270 443651 12258 20246, 28234, family 10, subfamily 36222, 44210, Z, member 1 52198

72674116 olfactory receptor, 377147 4271 366352 12259 20247, 28235, family 11 , subfamily 36223, 44211, A, member 1 52199

72684117 olfactory receptor, 377148 4272 366353 12260 20248, 28236, family 11 , subfamily 36224, 44212, A, member 1 52200

72694118 olfactory receptor, 377149 4273 366354 12261 20249, 28237, family 11 , subfamily 36225, 44213, A, member 1 52201 4119 olfactory receptor, 383551 4274 373043 12262 20250, 28238, family 11 , subfamily 36226, 44214, A, member 1 52202

72704120 olfactory receptor, 383645 4275 373141 12263 20251, 28239, family 11 , subfamily 36227, 44215, A, member 1 52203

72714121 olfactory receptor, 400696 4276 383532 12264 20252, 28240, family 11 , subfamily 36228, 44216, A, member 1 52204

72724122 olfactory receptor, 400715 4277 383550 12265 20253, 28241, family 11 , subfamily 36229, 44217, A, member 1 52205

72734123 olfactory receptor, 418485 4278 400657 12266 20254, 28242, family 11 , subfamily 36230, 44218, A, member 1 52206

72744124 olfactory receptor, 419773 4279 399062 12267 20255, 28243, family 11 , subfamily 36231, 44219, A, member 1 52207

72754125 olfactory receptor, 421634 4280 400331 12268 20256, 28244, family 11 , subfamily 36232, 44220, A, member 1 52208

72764126 olfactory receptor, 427264 4281 403427 12269 20257, 28245, family 11 , subfamily 36233, 44221, A, member 1 52209

72774127 olfactory receptor, 428144 4282 399592 12270 20258, 28246, family 11 , subfamily 36234, 44222, A, member 1 52210

72784128 olfactory receptor, 435232 4283 398659 12271 20259, 28247, family 11 , subfamily 36235, 44223, A, member 1 52211

72794129 olfactory receptor, 440485 4284 392324 12272 20260, 28248, family 11 , subfamily 36236, 44224, A, member 1 52212

72804130 olfactory receptor, 444884 4285 412097 12273 20261, 28249, family 11 , subfamily 36237, 44225, A, member 1 52213

72814131 olfactory receptor, 546665 4286 447956 12274 20262, 28250, family 11 , subfamily 36238, 44226, A, member 1 52214

72824132 olfactory receptor, 547506 4287 447215 12275 20263, 28251, family 11 , subfamily 36239, 44227, A, member 1 52215

72834133 olfactory receptor, 547645 4288 450263 12276 20264, 28252, family 11 , subfamily 36240, 44228, A, member 1 52216

72844134 olfactory receptor, 549749 4289 447745 12277 20265, 28253, family 11 , subfamily 36241, 44229, A, member 1 52217

72854135 olfactory receptor, 551986 4290 447627 12278 20266, 28254, family 11 , subfamily 36242, 44230, A, member 1 52218

72864136 olfactory receptor, 552225 4291 447222 12279 20267, 28255, family 11 , subfamily 36243, 44231, A, member 1 52219 4137 olfactory receptor, 357366 4292 349930 12280 20268, 28256, family 11 , subfamily 36244, 44232, G, member 2 52220

72874138 olfactory receptor, 252835 4293 252835 12281 20269, 28257, family 11 , subfamily 36245, 44233, H, member 1 52221

72884139 olfactory receptor, 315409 4294 318997 12282 20270, 28258, family 11 , subfamily 36246, 44234, H, member 4 52222

72894140 olfactory receptor, 315519 4295 319071 12283 20271, 28259, family 11 , subfamily 36247, 44235, H, member 6 52223

72904141 olfactory receptor, 355784 4296 348033 12284 20272, 28260, family 11 , subfamily 36248, 44236, L, member 1 52224

72914142 olfactory receptor, 383555 4297 373047 12285 20273, 28261, family 12, subfamily 36249, 44237, D, member 2 52225

72924143 olfactory receptor, 432767 4298 390448 12286 20274, 28262, family 12, subfamily 36250, 44238, D, member 2 52226

72934144 olfactory receptor, 443442 4299 400571 12287 20275, 28263, family 12, subfamily 36251, 44239, D, member 2 52227

72944145 olfactory receptor, 377143 4300 366348 12288 20276, 28264, family 12, subfamily 36252, 44240, D, member 3 52228

72954146 olfactory receptor, 383556 4301 373048 12289 20277, 28265, family 12, subfamily 36253, 44241, D, member 3 52229

72964147 olfactory receptor, 396806 4302 380023 12290 20278, 28266, family 12, subfamily 36254, 44242, D, member 3 52230

72974148 olfactory receptor, 430148 4303 393734 12291 20279, 28267, family 12, subfamily 36255, 44243, D, member 3 52231

72984149 olfactory receptor, 505384 4304 421215 12292 20280, 28268, family 12, subfamily 36256, 44244, D, member 3 52232

72994150 olfactory receptor, 550681 4305 449350 12293 20281, 28269, family 12, subfamily 36257, 44245, D, member 3 52233

73004151 olfactory receptor, 550913 4306 447580 12294 20282, 28270, family 12, subfamily 36258, 44246, D, member 3 52234

73014152 olfactory receptor, 552446 4307 447204 12295 20283, 28271, family 12, subfamily 36259, 44247, D, member 3 52235

73024153 olfactory receptor, 374401 4308 363522 12296 20284, 28272, family 13, subfamily 36260, 44248, A, member 1 52236

73034154 olfactory receptor, 536058 4309 438657 12297 20285, 28273, family 13, subfamily 36261, 44249, A, member 1 52237 4155 olfactory receptor, 553795 4310 451950 12298 20286, 28274, family 13, subfamily 36262, 44250, A, member 1 52238

73044156 olfactory receptor, 542196 4311 438815 12299 20287, 28275, family 13, subfamily 36263, 44251, C, member 2 52239

73054157 olfactory receptor, 374781 4312 363913 12300 20288, 28276, family 13, subfamily 36264, 44252, C, member 3 52240

73064158 olfactory receptor, 277216 4313 277216 12301 20289, 28277, family 13, subfamily 36265, 44253, C, member 4 52241

73074159 olfactory receptor, 545903 4314 444047 12302 20290, 28278, family 13, subfamily 36266, 44254, C, member 4 52242

73084160 olfactory receptor, 374779 4315 363911 12303 20291, 28279, family 13, subfamily 36267, 44255, C, member 5 52243

73094161 olfactory receptor, 335040 4316 334068 12304 20292, 28280, family 13, subfamily 36268, 44256, C, member 8 52244

73104162 olfactory receptor, 259362 4317 259362 12305 20293, 28281, family 13, subfamily 36269, 44257, C, member 9 52245

73114163 olfactory receptor, 318763 4318 317357 12306 20294, 28282, family 13, subfamily 36270, 44258, D, member 1 52246

73124164 olfactory receptor, 334726 4319 334452 12307 20295, 28283, family 13, subfamily 36271, 44259, F, member 1 52247

73134165 olfactory receptor, 338616 4320 340748 12308 20296, 28284, family 13, subfamily 36272, 44260, H, member 1 52248

73144166 olfactory receptor, 377981 4321 367219 12309 20297, 28285, family 13, subfamily 36273, 44261, J, member 1 52249

73154167 olfactory receptor, 357627 4322 350248 12310 20298, 28286, family 14, subfamily 36274, 44262, A, member 16 52250

73164168 olfactory receptor, 366485 4323 355441 12311 20299, 28287, family 14, subfamily 36275, 44263, A, member 2 52251

73174169 olfactory receptor, 317861 4324 324534 12312 20300, 28288, family 14, subfamily 36276, 44264, C, member 36 52252

73184170 olfactory receptor, 230221 4325 230221 12313 20301, 28289, family 14, subfamily 36277, 44265, J, member 1 52253

73194171 olfactory receptor, 377160 4326 366365 12314 20302, 28290, family 14, subfamily 36278, 44266, J, member 1 52254

73204172 olfactory receptor, 434778 4327 398851 12315 20303, 28291, family 14, subfamily 36279, 44267, J, member 1 52255 4173 olfactory receptor, 283225 4328 283225 12316 20304, 28292, family 14, subfamily 36280, 44268, K, member 1 52256

73214174 olfactory receptor, 408951 4329 386175 12317 20305, 28293, family 2, subfamily 36281, 44269, A, member 1 52257

73224175 olfactory receptor, 408949 4330 386174 12318 20306, 28294, family 2, subfamily 36282, 44270, A, member 12 52258

73234176 olfactory receptor, 408899 4331 386137 12319 20307, 28295, family 2, subfamily 36283, 44271, A, member 14 52259

73244177 olfactory receptor, 408979 4332 386209 12320 20308, 28296, family 2, subfamily 36284, 44272, A, member 2 52260

73254178 olfactory receptor, 408898 4333 386167 12321 20309, 28297, family 2, subfamily 36285, 44273, A, member 25 52261

73264179 olfactory receptor, 315453 4334 319546 12322 20310, 28298, family 2, subfamily 36286, 44274, A, member 4 52262

73274180 olfactory receptor, 391496 4335 375334 12323 20311, 28299, family 2, subfamily 36287, 44275, A, member 42 52263

73284181 olfactory receptor, 408906 4336 386208 12324 20312, 28300, family 2, subfamily 36288, 44276, A, member 5 52264

73294182 olfactory receptor, 493325 4337 420502 12325 20313, 28301, family 2, subfamily 36289, 44277, A, member 7 52265

73304183 olfactory receptor, 316368 4338 313936 12326 20314, 28302, family 2, subfamily 36290, 44278, AE, member 1 52266

73314184 olfactory receptor, 307401 4339 307447 12327 20315, 28303, family 2, subfamily 36291, 44279, AG, member 1 52267

73324185 olfactory receptor, 318244 4340 325078 12328 20316, 28304, family 2, subfamily 36292, 44280, AJ, member 1 52268

73334186 olfactory receptor, 366480 4341 355436 12329 20317, 28305, family 2, subfamily 36293, 44281, AK, member 2 52269

73344187 olfactory receptor, 321688 4342 323423 12330 20318, 28306, family 2, subfamily 36294, 44282, AP, member 1 52270

73354188 olfactory receptor, 305159 4343 304846 12331 20319, 28307, family 2, subfamily 36295, 44283, AT, member 4 52271

73364189 olfactory receptor, 318749 4344 325682 12332 20320, 28308, family 2, subfamily 36296, 44284, B, member 11 52272

73374190 olfactory receptor, 303324 4345 304419 12333 20321, 28309, family 2, subfamily 36297, 44285, B, member 2 52273 4191 olfactory receptor, 377173 4346 366378 12334 20322, 28310, family 2, subfamily 36298, 44286, B, member 3 52274

73384192 olfactory receptor, 383653 4347 373149 12335 20323, 28311, family 2, subfamily 36299, 44287, B, member 3 52275

73394193 olfactory receptor, 415976 4348 394571 12336 20324, 28312, family 2, subfamily 36300, 44288, B, member 3 52276

73404194 olfactory receptor, 419873 4349 394593 12337 20325, 28313, family 2, subfamily 36301, 44289, B, member 3 52277

73414195 olfactory receptor, 420178 4350 388604 12338 20326, 28314, family 2, subfamily 36302, 44290, B, member 3 52278

73424196 olfactory receptor, 444830 4351 393235 12339 20327, 28315, family 2, subfamily 36303, 44291, B, member 3 52279

73434197 olfactory receptor, 450817 4352 399881 12340 20328, 28316, family 2, subfamily 36304, 44292, B, member 3 52280

73444198 olfactory receptor, 456140 4353 403571 12341 20329, 28317, family 2, subfamily 36305, 44293, B, member 3 52281

73454199 olfactory receptor, 244623 4354 244623 12342 20330, 28318, family 2, subfamily 36306, 44294, B, member 6 52282

73464200 olfactory receptor, 304936 4355 307726 12343 20331, 28319, family 2, subfamily 36307, 44295, C, member 1 52283

73474201 olfactory receptor, 366487 4356 355443 12344 20332, 28320, family 2, subfamily 36308, 44296, C, member 3 52284

73484202 olfactory receptor, 299459 4357 299459 12345 20333, 28321, family 2, subfamily 36309, 44297, D, member 2 52285

73494203 olfactory receptor, 317834 4358 320560 12346 20334, 28322, family 2, subfamily 36310, 44298, D, member 3 52286

73504204 olfactory receptor, 392899 4359 376633 12347 20335, 28323, family 2, subfamily 36311, 44299, F, member 1 52287

73514205 olfactory receptor, 408955 4360 386222 12348 20336, 28324, family 2, subfamily 36312, 44300, F, member 2 52288

73524206 olfactory receptor, 320065 4361 326349 12349 20337, 28325, family 2, subfamily 36313, 44301, G, member 2 52289

73534207 olfactory receptor, 320002 4362 326301 12350 20338, 28326, family 2, subfamily 36314, 44302, G, member 3 52290

73544208 olfactory receptor, 343414 4363 341291 12351 20339, 28327, family 2, subfamily 36315, 44303, G, member 6 52291 4209 olfactory receptor, 377132 4364 366336 12352 20340, 28328, family 2, subfamily 36316, 44304, H, member 1 52292

73554210 olfactory receptor, 377133 4365 366337 12353 20341, 28329, family 2, subfamily 36317, 44305, H, member 1 52293

73564211 olfactory receptor, 377136 4366 366340 12354 20342, 28330, family 2, subfamily 36318, 44306, H, member 1 52294

73574212 olfactory receptor, 383550 4367 373042 12355 20343, 28331, family 2, subfamily 36319, 44307, H, member 1 52295

73584213 olfactory receptor, 383644 4368 373140 12356 20344, 28332, family 2, subfamily 36320, 44308, H, member 1 52296

73594214 olfactory receptor, 396792 4369 380010 12357 20345, 28333, family 2, subfamily 36321, 44309, H, member 1 52297

73604215 olfactory receptor, 400689 4370 383527 12358 20346, 28334, family 2, subfamily 36322, 44310, H, member 1 52298

73614216 olfactory receptor, 400693 4371 383529 12359 20347, 28335, family 2, subfamily 36323, 44311, H, member 1 52299

73624217 olfactory receptor, 400694 4372 383530 12360 20348, 28336, family 2, subfamily 36324, 44312, H, member 1 52300

73634218 olfactory receptor, 400712 4373 383547 12361 20349, 28337, family 2, subfamily 36325, 44313, H, member 1 52301

73644219 olfactory receptor, 400713 4374 383548 12362 20350, 28338, family 2, subfamily 36326, 44314, H, member 1 52302

73654220 olfactory receptor, 400714 4375 383549 12363 20351, 28339, family 2, subfamily 36327, 44315, H, member 1 52303

73664221 olfactory receptor, 412956 4376 407739 12364 20352, 28340, family 2, subfamily 36328, 44316, H, member 1 52304

73674222 olfactory receptor, 415581 4377 396944 12365 20353, 28341, family 2, subfamily 36329, 44317, H, member 1 52305

73684223 olfactory receptor, 416582 4378 395850 12366 20354, 28342, family 2, subfamily 36330, 44318, H, member 1 52306

73694224 olfactory receptor, 418376 4379 395567 12367 20355, 28343, family 2, subfamily 36331, 44319, H, member 1 52307

73704225 olfactory receptor, 421808 4380 410401 12368 20356, 28344, family 2, subfamily 36332, 44320, H, member 1 52308

73714226 olfactory receptor, 431658 4381 394698 12369 20357, 28345, family 2, subfamily 36333, 44321, H, member 1 52309 4227 olfactory receptor, 435958 4382 397171 12370 20358, 28346, family 2, subfamily 36334, 44322, H, member 1 52310

73724228 olfactory receptor, 436167 4383 388844 12371 20359, 28347, family 2, subfamily 36335, 44323, H, member 1 52311

73734229 olfactory receptor, 438840 4384 412463 12372 20360, 28348, family 2, subfamily 36336, 44324, H, member 1 52312

73744230 olfactory receptor, 439879 4385 409651 12373 20361, 28349, family 2, subfamily 36337, 44325, H, member 1 52313

73754231 olfactory receptor, 440557 4386 413910 12374 20362, 28350, family 2, subfamily 36338, 44326, H, member 1 52314

73764232 olfactory receptor, 440672 4387 396414 12375 20363, 28351, family 2, subfamily 36339, 44327, H, member 1 52315

73774233 olfactory receptor, 442615 4388 393254 12376 20364, 28352, family 2, subfamily 36340, 44328, H, member 1 52316

73784234 olfactory receptor, 443407 4389 398695 12377 20365, 28353, family 2, subfamily 36341, 44329, H, member 1 52317

73794235 olfactory receptor, 444920 4390 410659 12378 20366, 28354, family 2, subfamily 36342, 44330, H, member 1 52318

73804236 olfactory receptor, 446161 4391 389230 12379 20367, 28355, family 2, subfamily 36343, 44331, H, member 1 52319

73814237 olfactory receptor, 449826 4392 411617 12380 20368, 28356, family 2, subfamily 36344, 44332, H, member 1 52320

73824238 olfactory receptor, 453467 4393 392619 12381 20369, 28357, family 2, subfamily 36345, 44333, H, member 1 52321

73834239 olfactory receptor, 454071 4394 395934 12382 20370, 28358, family 2, subfamily 36346, 44334, H, member 1 52322

73844240 olfactory receptor, 456657 4395 408584 12383 20371, 28359, family 2, subfamily 36347, 44335, H, member 1 52323

73854241 olfactory receptor, 458051 4396 405714 12384 20372, 28360, family 2, subfamily 36348, 44336, H, member 1 52324

73864242 olfactory receptor, 546418 4397 449206 12385 20373, 28361, family 2, subfamily 36349, 44337, H, member 1 52325

73874243 olfactory receptor, 546570 4398 449512 12386 20374, 28362, family 2, subfamily 36350, 44338, H, member 1 52326

73884244 olfactory receptor, 548244 4399 449029 12387 20375, 28363, family 2, subfamily 36351, 44339, H, member 1 52327 4245 olfactory receptor, 550783 4400 447994 12388 20376, 28364, family 2, subfamily 36352, 44340, H, member 1 52328

73894246 olfactory receptor, 551060 4401 449069 12389 20377, 28365, family 2, subfamily 36353, 44341, H, member 1 52329

73904247 olfactory receptor, 552011 4402 448814 12390 20378, 28366, family 2, subfamily 36354, 44342, H, member 1 52330

73914248 olfactory receptor, 552129 4403 450138 12391 20379, 28367, family 2, subfamily 36355, 44343, H, member 1 52331

73924249 olfactory receptor, 376947 4404 366146 12392 20380, 28368, family 2, subfamily 36356, 44344, H, member 2 52332

73934250 olfactory receptor, 383640 4405 373136 12393 20381, 28369, family 2, subfamily 36357, 44345, H, member 2 52333

73944251 olfactory receptor, 411574 4406 410227 12394 20382, 28370, family 2, subfamily 36358, 44346, H, member 2 52334

73954252 olfactory receptor, 377171 4407 366376 12395 20383, 28371, family 2, subfamily 36359, 44347, J, member 1 52335 (gene/pseudogene)

73964253 olfactory receptor, 415857 4408 392497 12396 20384, 28372, family 2, subfamily 36360, 44348, J, member 2 52336

73974254 olfactory receptor, 419605 4409 408988 12397 20385, 28373, family 2, subfamily 36361, 44349, J, member 2 52337

73984255 olfactory receptor, 427744 4410 403186 12398 20386, 28374, family 2, subfamily 36362, 44350, J, member 2 52338

73994256 olfactory receptor, 440124 4411 398238 12399 20387, 28375, family 2, subfamily 36363, 44351, J, member 2 52339

74004257 olfactory receptor, 457762 4412 416299 12400 20388, 28376, family 2, subfamily 36364, 44352, J, member 2 52340

74014258 olfactory receptor, 383651 4413 373147 12401 20389, 28377, family 2, subfamily 36365, 44353, J, member 3 52341

74024259 olfactory receptor, 414140 4414 390144 12402 20390, 28378, family 2, subfamily 36366, 44354, J, member 3 52342

74034260 olfactory receptor, 418630 4415 400546 12403 20391, 28379, family 2, subfamily 36367, 44355, J, member 3 52343

74044261 olfactory receptor, 419260 4416 408783 12404 20392, 28380, family 2, subfamily 36368, 44356, J, member 3 52344

74054262 olfactory receptor, 422576 4417 393371 12405 20393, 28381, family 2, subfamily 36369, 44357, J, member 3 52345 4263 olfactory receptor, 428081 4418 388392 12406 20394, 28382, family 2, subfamily 36370, 44358, J, member 3 52346

74064264 olfactory receptor, 430478 4419 388205 12407 20395, 28383, family 2, subfamily 36371, 44359, J, member 3 52347

74074265 olfactory receptor, 302681 4420 305055 12408 20396, 28384, family 2, subfamily 36372, 44360, K, member 2 52348

74084266 olfactory receptor, 374428 4421 363550 12409 20397, 28385, family 2, subfamily 36373, 44361, K, member 2 52349

74094267 olfactory receptor, 358120 4422 350836 12410 20398, 28386, family 2, subfamily 36374, 44362, L, member 13 52350

74104268 olfactory receptor, 366478 4423 355434 12411 20399, 28387, family 2, subfamily 36375, 44363, L, member 13 52351

74114269 olfactory receptor, 366479 4424 355435 12412 20400, 28388, family 2, subfamily 36376, 44364, L, member 2 52352

74124270 olfactory receptor, 359959 4425 353044 12413 20401, 28389, family 2, subfamily 36377, 44365, L, member 3 52353

74134271 olfactory receptor, 355281 4426 347428 12414 20402, 28390, family 2, subfamily 36378, 44366, L, member 5 52354

74144272 olfactory receptor, 357191 4427 349719 12415 20403, 28391, family 2, subfamily 36379, 44367, L, member 8 52355

74154273 olfactory receptor, 359682 4428 352710 12416 20404, 28392, family 2, subfamily 36380, 44368, M, member 2 52356

74164274 olfactory receptor, 456743 4429 389625 12417 20405, 28393, family 2, subfamily 36381, 44369, M, member 3 52357

74174275 olfactory receptor, 306687 4430 306688 12418 20406, 28394, family 2, subfamily 36382, 44370, M, member 4 52358

74184276 olfactory receptor, 366476 4431 355432 12419 20407, 28395, family 2, subfamily 36383, 44371, M, member 5 52359

74194277 olfactory receptor, 317965 4432 324557 12420 20408, 28396, family 2, subfamily 36384, 44372, M, member 7 52360

74204278 olfactory receptor, 341959 4433 344040 12421 20409, 28397, family 2, subfamily 36385, 44373, S, member 2 52361

74214279 olfactory receptor, 366474 4434 355430 12422 20410, 28398, family 2, subfamily 36386, 44374, T, member 1 52362

74224280 olfactory receptor, 330500 4435 329210 12423 20411, 28399, family 2, subfamily 36387, 44375, T, member 10 52363 4281 olfactory receptor, 330803 4436 328934 12424 20412, 28400, family 2, subfamily 36388, 44376, T, member 11 52364

74234282 olfactory receptor, 317996 4437 324583 12425 20413, 28401, family 2, subfamily 36389, 44377, T, member 12 52365

74244283 olfactory receptor, 342927 4438 343062 12426 20414, 28402, family 2, subfamily 36390, 44378, T, member 2 52366

74254284 olfactory receptor, 344889 4439 342008 12427 20415, 28403, family 2, subfamily 36391, 44379, T, member 27 52367

74264285 olfactory receptor, 328570 4440 331774 12428 20416, 28404, family 2, subfamily 36392, 44380, T, member 29 52368

74274286 olfactory receptor, 359594 4441 352604 12429 20417, 28405, family 2, subfamily 36393, 44381, T, member 3 52369

74284287 olfactory receptor, 318021 4442 324687 12430 20418, 28406, family 2, subfamily 36394, 44382, T, member 33 52370

74294288 olfactory receptor, 328782 4443 330904 12431 20419, 28407, family 2, subfamily 36395, 44383, T, member 34 52371

74304289 olfactory receptor, 317450 4444 324369 12432 20420, 28408, family 2, subfamily 36396, 44384, T, member 35 52372

74314290 olfactory receptor, 366475 4445 355431 12433 20421, 28409, family 2, subfamily 36397, 44385, T, member 4 52373

74324291 olfactory receptor, 366473 4446 355429 12434 20422, 28410, family 2, subfamily 36398, 44386, T, member 5 52374

74334292 olfactory receptor, 355728 4447 347965 12435 20423, 28411, family 2, subfamily 36399, 44387, T, member 6 52375

74344293 olfactory receptor, 329365 4448 404102 12436 20424, 28412, family 2, subfamily 36400, 44388, V, member 1 52376

74354294 olfactory receptor, 328275 4449 332185 12437 20425, 28413, family 2, subfamily 36401, 44389, V, member 2 52377

74364295 olfactory receptor, 377175 4450 366380 12438 20426, 28414, family 2, subfamily 36402, 44390, W, member 1 52378

74374296 olfactory receptor, 383654 4451 373150 12439 20427, 28415, family 2, subfamily 36403, 44391, W, member 1 52379

74384297 olfactory receptor, 411447 4452 388144 12440 20428, 28416, family 2, subfamily 36404, 44392, W, member 1 52380

74394298 olfactory receptor, 420540 4453 392635 12441 20429, 28417, family 2, subfamily 36405, 44393, W, member 1 52381 4299 olfactory receptor, 421027 4454 412537 12442 20430, 28418, family 2, subfamily 36406, 44394, W, member 1 52382

74404300 olfactory receptor, 421766 4455 389825 12443 20431, 28419, family 2, subfamily 36407, 44395, W, member 1 52383

74414301 olfactory receptor, 439723 4456 401866 12444 20432, 28420, family 2, subfamily 36408, 44396, W, member 1 52384

74424302 olfactory receptor, 446776 4457 405025 12445 20433, 28421, family 2, subfamily 36409, 44397, W, member 1 52385

74434303 olfactory receptor, 360358 4458 353516 12446 20434, 28422, family 2, subfamily 36410, 44398, W, member 3 52386

74444304 olfactory receptor, 537741 4459 445853 12447 20435, 28423, family 2, subfamily 36411, 44399, W, member 3 52387

74454305 olfactory receptor, 307832 4460 312403 12448 20436, 28424, family 2, subfamily 36412, 44400, Y, member 1 52388

74464306 olfactory receptor, 324060 4461 316284 12449 20437, 28425, family 2, subfamily 36413, 44401, Z, member 1 52389

74474307 olfactory receptor, 323404 4462 313803 12450 20438, 28426, family 3, subfamily 36414, 44402, A, member 1 52390

74484308 olfactory receptor, 408891 4463 386180 12451 20439, 28427, family 3, subfamily 36415, 44403, A, member 2 52391

74494309 olfactory receptor, 291231 4464 291231 12452 20440, 28428, family 3, subfamily 36416, 44404, A, member 3 52392

74504310 olfactory receptor, 314706 4465 325065 12453 20441, 28429, family 4, subfamily 36417, 44405, A, member 15 52393

74514311 olfactory receptor, 314721 4466 325128 12454 20442, 28430, family 4, subfamily 36418, 44406, A, member 16 52394

74524312 olfactory receptor, 446524 4467 412752 12455 20443, 28431, family 4, subfamily 36419, 44407, A, member 47 52395

74534313 olfactory receptor, 319760 4468 367664 12456 20444, 28432, family 4, subfamily 36420, 44408, A, member 5 52396

74544314 olfactory receptor, 309562 4469 311605 12457 20445, 28433, family 4, subfamily 36421, 44409, B, member 1 52397

74554315 olfactory receptor, 302231 4470 306651 12458 20446, 28434, family 4, subfamily 36422, 44410, C, member 11 52398

74564316 olfactory receptor, 335238 4471 334418 12459 20447, 28435, family 4, subfamily 36423, 44411, C, member 12 52399 4317 olfactory receptor, 555099 4472 452277 12460 20448, 28436, family 4, subfamily 36424, 44412, C, member 13 52400

74574318 olfactory receptor, 314644 4473 324958 12461 20449, 28437, family 4, subfamily 36425, 44413, C, member 15 52401

74584319 olfactory receptor, 314634 4474 324913 12462 20450, 28438, family 4, subfamily 36426, 44414, C, member 16 52402

74594320 olfactory receptor, 319856 4475 321419 12463 20451, 28439, family 4, subfamily 36427, 44415, C, member 3 52403

74604321 olfactory receptor, 395239 4476 378660 12464 20452, 28440, family 4, subfamily 36428, 44416, C, member 3 52404

74614322 olfactory receptor, 319813 4477 321338 12465 20453, 28441, family 4, subfamily 36429, 44417, C, member 5 52405

74624323 olfactory receptor, 314259 4478 324769 12466 20454, 28442, family 4, subfamily 36430, 44418, C, member 6 52406

74634324 olfactory receptor, 268912 4479 365451 12467 20455, 28443, family 4, subfamily 36431, 44419, D, member 1 52407

74644325 olfactory receptor, 530162 4480 436424 12468 20456, 28444, family 4, subfamily 36432, 44420, D, member 10 52408

74654326 olfactory receptor, 313253 4481 320077 12469 20457, 28445, family 4, subfamily 36433, 44421, D, member 11 52409

74664327 olfactory receptor, 545221 4482 441354 12470 20458, 28446, family 4, subfamily 36434, 44422, D, member 2 52410

74674328 olfactory receptor, 307033 4483 305970 12471 20459, 28447, family 4, subfamily 36435, 44423, D, member 5 52411

74684329 olfactory receptor, 300127 4484 300127 12472 20460, 28448, family 4, subfamily 36436, 44424, D, member 6 52412

74694330 olfactory receptor, 329328 4485 328563 12473 20461, 28449, family 4, subfamily 36437, 44425, D, member 9 52413

74704331 olfactory receptor, 408935 4486 386195 12474 20462, 28450, family 4, subfamily 36438, 44426, E, member 2 52414

74714332 olfactory receptor, 332238 4487 333184 12475 20463, 28451, family 4, subfamily 36439, 44427, F, member 15 52415

74724333 olfactory receptor, 332831 4488 329982 12476 20464, 28452, family 4, subfamily 36440, 44428, F, member 16 52416

74734334 olfactory receptor, 318050 4489 315047 12477 20465, 28453, family 4, subfamily 36441, 44429, F, member 17 52417 4335 olfactory receptor, 442916 4490 400284 12478 20466, 28454, family 4, subfamily 36442, 44430, F, member 17 52418

74744336 olfactory receptor, 320901 4491 318878 12479 20467, 28455, family 4, subfamily 36443, 44431, F, member 21 52419

74754337 olfactory receptor, 426406 4492 409316 12480 20468, 28456, family 4, subfamily 36444, 44432, F, member 29 52420

74764338 olfactory receptor, 456475 4493 394282 12481 20469, 28457, family 4, subfamily 36445, 44433, F, member 3 52421

74774339 olfactory receptor, 326183 4494 317482 12482 20470, 28458, family 4, subfamily 36446, 44434, F, member 4 52422

74784340 olfactory receptor, 335137 4495 334393 12483 20471, 28459, family 4, subfamily 36447, 44435, F, member 5 52423

74794341 olfactory receptor, 328882 4496 327525 12484 20472, 28460, family 4, subfamily 36448, 44436, F, member 6 52424

74804342 olfactory receptor, 285600 4497 285600 12485 20473, 28461, family 4, subfamily 36449, 44437, K, member 1 52425

74814343 olfactory receptor, 315693 4498 319322 12486 20474, 28462, family 4, subfamily 36450, 44438, K, member 13 52426

74824344 olfactory receptor, 305045 4499 305011 12487 20475, 28463, family 4, subfamily 36451, 44439, K, member 14 52427

74834345 olfactory receptor, 305051 4500 304077 12488 20476, 28464, family 4, subfamily 36452, 44440, K, member 15 52428

74844346 olfactory receptor, 315543 4501 319197 12489 20477, 28465, family 4, subfamily 36453, 44441, K, member 17 52429

74854347 olfactory receptor, 298642 4502 298642 12490 20478, 28466, family 4, subfamily 36454, 44442, K, member 2 52430

74864348 olfactory receptor, 315915 4503 319511 12491 20479, 28467, family 4, subfamily 36455, 44443, K, member 5 52431

74874349 olfactory receptor, 315683 4504 319217 12492 20480, 28468, family 4, subfamily 36456, 44444, L, member 1 52432

74884350 olfactory receptor, 315957 4505 319654 12493 20481, 28469, family 4, subfamily 36457, 44445, M, member 1 52433

74894351 olfactory receptor, 332663 4506 329467 12494 20482, 28470, family 4, subfamily 36458, 44446, M, member 2 52434

74904352 olfactory receptor, 315947 4507 319601 12495 20483, 28471, family 4, subfamily 36459, 44447, N, member 2 52435 4353 olfactory receptor, 557414 4508 451462 12496 20484, 28472, family 4, subfamily 36460, 44448, N, member 2 52436

74914354 olfactory receptor, 557677 4509 452022 12497 20485, 28473, family 4, subfamily 36461, 44449, N, member 2 52437

74924355 olfactory receptor, 328795 4510 332500 12498 20486, 28474, family 4, subfamily 36462, 44450, N, member 4 52438

74934356 olfactory receptor, 333629 4511 332110 12499 20487, 28475, family 4, subfamily 36463, 44451, N, member 5 52439

74944357 olfactory receptor, 314612 4512 324831 12500 20488, 28476, family 4, subfamily 36464, 44452, P, member 4 52440

74954358 olfactory receptor, 331723 4513 330049 12501 20489, 28477, family 4, subfamily 36465, 44453, Q, member 3 52441

74964359 olfactory receptor, 319988 4514 321447 12502 20490, 28478, family 4, subfamily 36466, 44454, S, member 1 52442

74974360 olfactory receptor, 312422 4515 310337 12503 20491, 28479, family 4, subfamily 36467, 44455, S, member 2 52443

74984361 olfactory receptor, 320048 4516 321506 12504 20492, 28480, family 4, subfamily 36468, 44456, X, member 1 52444

74994362 olfactory receptor, 302329 4517 307751 12505 20493, 28481, family 4, subfamily 36469, 44457, X, member 2 52445

75004363 olfactory receptor, 302030 4518 303096 12506 20494, 28482, family 5, subfamily 36470, 44458, A, member 1 52446

75014364 olfactory receptor, 302040 4519 303834 12507 20495, 28483, family 5, subfamily 36471, 44459, A, member 2 52447

75024365 olfactory receptor, 358642 4520 351466 12508 20496, 28484, family 5, subfamily 36472, 44460, AC, member 2 52448

75034366 olfactory receptor, 326855 4521 322784 12509 20497, 28485, family 5, subfamily 36473, 44461, AK, member 2 52449

75044367 olfactory receptor, 313940 4522 320302 12510 20498, 28486, family 5, subfamily 36474, 44462, AN, member 1 52450

75054368 olfactory receptor, 302981 4523 303111 12511 20499, 28487, family 5, subfamily 36475, 44463, AP, member 2 52451

75064369 olfactory receptor, 544374 4524 442701 12512 20500, 28488, family 5, subfamily 36476, 44464, AP, member 2 52452

75074370 olfactory receptor, 302969 4525 302639 12513 20501, 28489, family 5, subfamily 36477, 44465, AR, member 1 52453 4371 olfactory receptor, 313555 4526 324111 12514 20502, 28490, family 5, subfamily 36478, 44466, AS, member 1 52454

75084372 olfactory receptor, 304418 4527 302057 12515 20503, 28491, family 5, subfamily 36479, 44467, AU, member 1 52455

75094373 olfactory receptor, 302572 4528 306657 12516 20504, 28492, family 5, subfamily 36480, 44468, B, member 12 52456

75104374 olfactory receptor, 357377 4529 349945 12517 20505, 28493, family 5, subfamily 36481, 44469, B, member 17 52457

75114375 olfactory receptor, 302581 4530 303076 12518 20506, 28494, family 5, subfamily 36482, 44470, B, member 2 52458

75124376 olfactory receptor, 309403 4531 308270 12519 20507, 28495, family 5, subfamily 36483, 44471, B, member 3 52459

75134377 olfactory receptor, 373680 4532 362784 12520 20508, 28496, family 5, subfamily 36484, 44472, C, member 1 52460

75144378 olfactory receptor, 361760 4533 354800 12521 20509, 28497, family 5, subfamily 36485, 44473, D, member 13 52461

75154379 olfactory receptor, 335605 4534 334456 12522 20510, 28498, family 5, subfamily 36486, 44474, D, member 14 52462

75164380 olfactory receptor, 378396 4535 367649 12523 20511, 28499, family 5, subfamily 36487, 44475, D, member 16 52463

75174381 olfactory receptor, 333976 4536 335025 12524 20512, 28500, family 5, subfamily 36488, 44476, D, member 18 52464

75184382 olfactory receptor, 278409 4537 278409 12525 20513, 28501, family 5, subfamily 36489, 44477, F, member 1 52465

75194383 olfactory receptor, 437310 4538 401706 12526 20514, 28502, family 5, subfamily 36490, 44478, H, member 14 52466

75204384 olfactory receptor, 355273 4539 347418 12527 20515, 28503, family 5, subfamily 36491, 44479, H, member 2 52467

75214385 olfactory receptor, 301532 4540 301532 12528 20516, 28504, family 5, subfamily 36492, 44480, I, member 1 52468

75224386 olfactory receptor, 312298 4541 310788 12529 20517, 28505, family 5, subfamily 36493, 44481, J, member 2 52469

75234387 olfactory receptor, 332650 4542 373193 12530 20518, 28506, family 5, subfamily 36494, 44482, K, member 1 52470

75244388 olfactory receptor, 427338 4543 393889 12531 20519, 28507, family 5, subfamily 36495, 44483, K, member 2 52471 4389 olfactory receptor, 354924 4544 347003 12532 20520, 28508, family 5, subfamily 36496, 44484, K, member 4 52472

75254390 olfactory receptor, 333973 4545 335529 12533 20521, 28509, family 5, subfamily 36497, 44485, L, member 1 52473

75264391 olfactory receptor, 378397 4546 367650 12534 20522, 28510, family 5, subfamily 36498, 44486, L, member 2 52474

75274392 olfactory receptor, 526538 4547 435416 12535 20523, 28511, family 5, subfamily 36499, 44487, M, member 1 52475

75284393 olfactory receptor, 526812 4548 436004 12536 20524, 28512, family 5, subfamily 36500, 44488, M, member 10 52476

75294394 olfactory receptor, 528616 4549 432417 12537 20525, 28513, family 5, subfamily 36501, 44489, M, member 11 52477

75304395 olfactory receptor, 312240 4550 312208 12538 20526, 28514, family 5, subfamily 36502, 44490, M, member 3 52478

75314396 olfactory receptor, 327216 4551 323354 12539 20527, 28515, family 5, subfamily 36503, 44491, M, member 8 52479

75324397 olfactory receptor, 279791 4552 279791 12540 20528, 28516, family 5, subfamily 36504, 44492, M, member 9 52480

75334398 olfactory receptor, 329434 4553 331823 12541 20529, 28517, family 5, subfamily 36505, 44493, P, member 2 52481

75344399 olfactory receptor, 328375 4554 332068 12542 20530, 28518, family 5, subfamily 36506, 44494, P, member 3 52482

75354400 olfactory receptor, 312253 4555 308595 12543 20531, 28519, family 5, subfamily 36507, 44495, R, member 1 52483

75364401 olfactory receptor, 313033 4556 323612 12544 20532, 28520, family 5, subfamily 36508, 44496, T, member 1 52484

75374402 olfactory receptor, 313264 4557 323688 12545 20533, 28521, family 5, subfamily 36509, 44497, T, member 2 52485

75384403 olfactory receptor, 303059 4558 305403 12546 20534, 28522, family 5, subfamily 36510, 44498, T, member 3 52486

75394404 olfactory receptor, 377151 4559 366356 12547 20535, 28523, family 5, subfamily 36511, 44499, V, member 1 52487

75404405 olfactory receptor, 377154 4560 366359 12548 20536, 28524, family 5, subfamily 36512, 44500, V, member 1 52488

75414406 olfactory receptor, 441440 4561 404163 12549 20537, 28525, family 5, subfamily 36513, 44501, V, member 1 52489 4407 olfactory receptor, 444009 4562 407363 12550 20538, 28526, family 5, subfamily 36514, 44502, V, member 1 52490

75424408 olfactory receptor, 446761 4563 404109 12551 20539, 28527, family 5, subfamily 36515, 44503, V, member 1 52491

75434409 olfactory receptor, 458372 4564 404990 12552 20540, 28528, family 5, subfamily 36516, 44504, V, member 1 52492

75444410 olfactory receptor, 543825 4565 443309 12553 20541, 28529, family 5, subfamily 36517, 44505, V, member 1 52493

75454411 olfactory receptor, 549299 4566 450230 12554 20542, 28530, family 5, subfamily 36518, 44506, V, member 1 52494

75464412 olfactory receptor, 550240 4567 446579 12555 20543, 28531, family 5, subfamily 36519, 44507, V, member 1 52495

75474413 olfactory receptor, 344514 4568 342448 12556 20544, 28532, family 5, subfamily 36520, 44508, W, member 2 52496

75484414 olfactory receptor, 380371 4569 369729 12557 20545, 28533, family 51 , subfamily 36521, 44509, A, member 2 52497

75494415 olfactory receptor, 380373 4570 369731 12558 20546, 28534, family 51 , subfamily 36522, 44510, A, member 4 52498

75504416 olfactory receptor, 359350 4571 352305 12559 20547, 28535, family 51 , subfamily 36523, 44511, A, member 7 52499

75514417 olfactory receptor, 544684 4572 445796 12560 20548, 28536, family 51 , subfamily 36524, 44512, A, member 7 52500

75524418 olfactory receptor, 545959 4573 439834 12561 20549, 28537, family 51 , subfamily 36525, 44513, A, member 7 52501

75534419 olfactory receptor, 328813 4574 327540 12562 20550, 28538, family 51 , subfamily 36526, 44514, B, member 2 52502

75544420 olfactory receptor, 380224 4575 369573 12563 20551, 28539, family 51 , subfamily 36527, 44515, B, member 4 52503

75554421 olfactory receptor, 300773 4576 300773 12564 20552, 28540, family 51 , subfamily 36528, 44516, B, member 5 52504

75564422 olfactory receptor, 380219 4577 369568 12565 20553, 28541, family 51 , subfamily 36529, 44517, B, member 6 52505

75574423 olfactory receptor, 537299 4578 441886 12566 20554, 28542, family 51 , subfamily 36530, 44518, B, member 6 52506

75584424 olfactory receptor, 357764 4579 350408 12567 20555, 28543, family 51 , subfamily 36531, 44519, C, member 1 52507 pseudogene 4425 olfactory receptor, 357605 4580 350222 12568 20556, 28544, family 51 , subfamily 36532, 44520, D, member 1 52508

75594426 olfactory receptor, 396952 4581 380155 12569 20557, 28545, family 51 , subfamily 36533, 44521, E, member 1 52509

75604427 olfactory receptor, 396950 4582 380153 12570 20558, 28546, family 51 , subfamily 36534, 44522, E, member 2 52510

75614428 olfactory receptor, 532598 4583 432644 12571 20559, 28547, family 51 , subfamily 36535, 44523, E, member 2 52511

75624429 olfactory receptor, 322110 4584 323952 12572 20560, 28548, family 51 , subfamily 36536, 44524, F, member 2 52512

75634430 olfactory receptor, 321961 4585 322546 12573 20561, 28549, family 51 , subfamily 36537, 44525, G, member 1 52513

75644431 olfactory receptor, 322013 4586 322593 12574 20562, 28550, family 51 , subfamily 36538, 44526, G, member 2 52514

75654432 olfactory receptor, 322059 4587 322724 12575 20563, 28551, family 51 , subfamily 36539, 44527, H, member 1 52515 pseudogene

75664433 olfactory receptor, 317283 4588 348350 12576 20564, 28552, family 51 , subfamily 36540, 44528, I, member 1 52516

75674434 olfactory receptor, 321307 4589 439622 12577 20565, 28553, family 51 , subfamily 36541, 44529, I, member 1 52517

75684435 olfactory receptor, 380211 4590 369559 12578 20566, 28554, family 51 , subfamily 36542, 44530, I, member 1 52518

75694436 olfactory receptor, 341449 4591 341987 12579 20567, 28555, family 51 , subfamily 36543, 44531, I, member 2 52519

75704437 olfactory receptor, 332043 4592 332473 12580 20568, 28556, family 51 , subfamily 36544, 44532, J, member 1 52520 (gene/pseudogene)

75714438 olfactory receptor, 321543 4593 322156 12581 20569, 28557, family 51 , subfamily 36545, 44533, L, member 1 52521

75724439 olfactory receptor, 300778 4594 300778 12582 20570, 28558, family 51 , subfamily 36546, 44534, Q, member 1 52522

75734440 olfactory receptor, 322101 4595 322754 12583 20571, 28559, family 51 , subfamily 36547, 44535, S, member 1 52523

75744441 olfactory receptor, 322049 4596 322679 12584 20572, 28560, family 51 , subfamily 36548, 44536, T, member 1 52524 4442 olfactory receptor, 380378 4597 369738 12585 20573, 28561, family 51 , subfamily 36549, 44537, T, member 1 52525

75754443 olfactory receptor, 321255 4598 321729 12586 20574, 28562, family 51 , subfamily 36550, 44538, V, member 1 52526

75764444 olfactory receptor, 328942 4599 333684 12587 20575, 28563, family 52, subfamily 36551, 44539, A, member 1 52527

75774445 olfactory receptor, 380367 4600 369725 12588 20576, 28564, family 52, subfamily 36552, 44540, A, member 1 52528

75784446 olfactory receptor, 307388 4601 303469 12589 20577, 28565, family 52, subfamily 36553, 44541, A, member 5 52529

75794447 olfactory receptor, 530810 4602 432011 12590 20578, 28566, family 52, subfamily 36554, 44542, B, member 2 52530

75804448 olfactory receptor, 408920 4603 386160 12591 20579, 28567, family 52, subfamily 36555, 44543, B, member 4 52531

75814449 olfactory receptor, 345043 4604 341581 12592 20580, 28568, family 52, subfamily 36556, 44544, B, member 6 52532

75824450 olfactory receptor, 322641 4605 326232 12593 20581, 28569, family 52, subfamily 36557, 44545, D, member 1 52533

75834451 olfactory receptor, 321522 4606 322088 12594 20582, 28570, family 52, subfamily 36558, 44546, E, member 2 52534

75844452 olfactory receptor, 316987 4607 321426 12595 20583, 28571, family 52, subfamily 36559, 44547, E, member 4 52535

75854453 olfactory receptor, 329322 4608 328878 12596 20584, 28572, family 52, subfamily 36560, 44548, E, member 6 52536

75864454 olfactory receptor, 379946 4609 369279 12597 20585, 28573, family 52, subfamily 36561, 44549, E, member 6 52537

75874455 olfactory receptor, 537935 4610 444054 12598 20586, 28574, family 52, subfamily 36562, 44550, E, member 8 52538

75884456 olfactory receptor, 322653 4611 326259 12599 20587, 28575, family 52, subfamily 36563, 44551, H, member 1 52539

75894457 olfactory receptor, 450052 4612 409094 12600 20588, 28576, family 52, subfamily 36564, 44552, I, member 1 52540

75904458 olfactory receptor, 530443 4613 436453 12601 20589, 28577, family 52, subfamily 36565, 44553, I, member 1 52541

75914459 olfactory receptor, 312614 4614 308764 12602 20590, 28578, family 52, subfamily 36566, 44554, I, member 2 52542 4460 olfactory receptor, 380370 4615 369728 12603 20591, 28579, family 52, subfamily 36567, 44555, J, member 3 52543

75924461 olfactory receptor, 307632 4616 302422 12604 20592, 28580, family 52, subfamily 36568, 44556, K, member 1 52544

75934462 olfactory receptor, 325719 4617 318956 12605 20593, 28581, family 52, subfamily 36569, 44557, K, member 2 52545

75944463 olfactory receptor, 332249 4618 330338 12606 20594, 28582, family 52, subfamily 36570, 44558, L, member 1 52546

75954464 olfactory receptor, 360213 4619 353343 12607 20595, 28583, family 52, subfamily 36571, 44559, M, member 1 52547

75964465 olfactory receptor, 317078 4620 322823 12608 20596, 28584, family 52, subfamily 36572, 44560, N, member 1 52548

75974466 olfactory receptor, 317037 4621 322801 12609 20597, 28585, family 52, subfamily 36573, 44561, N, member 2 52549

75984467 olfactory receptor, 317254 4622 323224 12610 20598, 28586, family 52, subfamily 36574, 44562, N, member 4 52550

75994468 olfactory receptor, 317093 4623 322866 12611 20599, 28587, family 52, subfamily 36575, 44563, N, member 5 52551

76004469 olfactory receptor, 356069 4624 348368 12612 20600, 28588, family 52, subfamily 36576, 44564, R, member 1 52552

76014470 olfactory receptor, 380382 4625 369742 12613 20601, 28589, family 52, subfamily 36577, 44565, R, member 1 52553

76024471 olfactory receptor, 311352 4626 309673 12614 20602, 28590, family 52, subfamily 36578, 44566, W, member 1 52554

76034472 olfactory receptor, 316650 4627 321246 12615 20603, 28591, family 56, subfamily 36579, 44567, A, member 1 52555

76044473 olfactory receptor, 329564 4628 331572 12616 20604, 28592, family 56, subfamily 36580, 44568, A, member 3 52556

76054474 olfactory receptor, 330728 4629 328215 12617 20605, 28593, family 56, subfamily 36581, 44569, A, member 4 52557

76064475 olfactory receptor, 317121 4630 322939 12618 20606, 28594, family 56, subfamily 36582, 44570, B, member 1 52558

76074476 olfactory receptor, 316529 4631 321196 12619 20607, 28595, family 56, subfamily 36583, 44571, B, member 4 52559

76084477 olfactory receptor, 332601 4632 330384 12620 20608, 28596, family 6, subfamily 36584, 44572, A, member 2 52560 4478 olfactory receptor, 408922 4633 386151 12621 20609, 28597, family 6, subfamily 36585, 44573, B, member 1 52561

76094479 olfactory receptor, 402971 4634 384563 12622 20610, 28598, family 6, subfamily 36586, 44574, B, member 2 52562

76104480 olfactory receptor, 319423 4635 322435 12623 20611, 28599, family 6, subfamily 36587, 44575, B, member 3 52563

76114481 olfactory receptor, 379668 4636 368990 12624 20612, 28600, family 6, subfamily 36588, 44576, C, member 1 52564

76124482 olfactory receptor, 322678 4637 323606 12625 20613, 28601, family 6, subfamily 36589, 44577, C, member 2 52565

76134483 olfactory receptor, 379667 4638 368989 12626 20614, 28602, family 6, subfamily 36590, 44578, C, member 3 52566

76144484 olfactory receptor, 394256 4639 377799 12627 20615, 28603, family 6, subfamily 36591, 44579, C, member 4 52567

76154485 olfactory receptor, 379665 4640 368986 12628 20616, 28604, family 6, subfamily 36592, 44580, C, member 65 52568

76164486 olfactory receptor, 379662 4641 368983 12629 20617, 28605, family 6, subfamily 36593, 44581, C, member 68 52569

76174487 olfactory receptor, 548615 4642 448811 12630 20618, 28606, family 6, subfamily 36594, 44582, C, member 68 52570

76184488 olfactory receptor, 327335 4643 329153 12631 20619, 28607, family 6, subfamily 36595, 44583, C, member 70 52571

76194489 olfactory receptor, 343870 4644 342836 12632 20620, 28608, family 6, subfamily 36596, 44584, C, member 74 52572

76204490 olfactory receptor, 343399 4645 368987 12633 20621, 28609, family 6, subfamily 36597, 44585, C, member 75 52573

76214491 olfactory receptor, 302084 4646 305640 12634 20622, 28610, family 6, subfamily 36598, 44586, F, member 1 52574

76224492 olfactory receptor, 540461 4647 437629 12635 20623, 28611, family 6, subfamily 36599, 44587, J, member 1 52575

76234493 olfactory receptor, 359610 4648 352626 12636 20624, 28612, family 6, subfamily 36600, 44588, K, member 2 52576

76244494 olfactory receptor, 368145 4649 357127 12637 20625, 28613, family 6, subfamily 36601, 44589, K, member 3 52577

76254495 olfactory receptor, 368146 4650 357128 12638 20626, 28614, family 6, subfamily 36602, 44590, K, member 3 52578 4496 olfactory receptor, 368144 4651 357126 12639 20627, 28615, family 6, subfamily 36603, 44591, K, member 6 52579

76264497 olfactory receptor, 309154 4652 311038 12640 20628, 28616, family 6, subfamily 36604, 44592, M, member 1 52580

76274498 olfactory receptor, 335094 4653 335535 12641 20629, 28617, family 6, subfamily 36605, 44593, N, member 1 52581

76284499 olfactory receptor, 339258 4654 344101 12642 20630, 28618, family 6, subfamily 36606, 44594, N, member 2 52582

76294500 olfactory receptor, 334632 4655 334721 12643 20631, 28619, family 6, subfamily 36607, 44595, P, member 1 52583

76304501 olfactory receptor, 302622 4656 307734 12644 20632, 28620, family 6, subfamily 36608, 44596, Q, member 1 52584

76314502 olfactory receptor, 320704 4657 313110 12645 20633, 28621, family 6, subfamily 36609, 44597, S, member 1 52585

76324503 olfactory receptor, 321252 4658 325203 12646 20634, 28622, family 6, subfamily 36610, 44598, T, member 1 52586

76334504 olfactory receptor, 418316 4659 396085 12647 20635, 28623, family 6, subfamily 36611, 44599, V, member 1 52587

76344505 olfactory receptor, 327930 4660 333724 12648 20636, 28624, family 6, subfamily 36612, 44600, X, member 1 52588

76354506 olfactory receptor, 302617 4661 304807 12649 20637, 28625, family 6, subfamily 36613, 44601, Y, member 1 52589

76364507 olfactory receptor, 248058 4662 248058 12650 20638, 28626, family 7, subfamily 36614, 44602, A, member 10 52590

76374508 olfactory receptor, 327462 4663 328144 12651 20639, 28627, family 7, subfamily 36615, 44603, A, member 17 52591

76384509 olfactory receptor, 304105 4664 307397 12652 20640, 28628, family 7, subfamily 36616, 44604, A, member 2 52592 pseudogene

76394510 olfactory receptor, 322301 4665 316955 12653 20641, 28629, family 7, subfamily 36617, 44605, A, member 5 52593

76404511 olfactory receptor, 344248 4666 345563 12654 20642, 28630, family 7, subfamily 36618, 44606, D, member 2 52594

76414512 olfactory receptor, 456448 4667 387523 12655 20643, 28631, family 7, subfamily 36619, 44607, E, member 24 52595

76424513 olfactory receptor, 293614 4668 293614 12656 20644, 28632, family 7, subfamily 36620, 44608, G, member 1 52596 4514 olfactory receptor, 541538 4669 444134 12657 20645, 28633, family 7, subfamily 36621, 44609, G, member 1 52597

76434515 olfactory receptor, 305456 4670 303822 12658 20646, 28634, family 7, subfamily 36622, 44610, G, member 2 52598

76444516 olfactory receptor, 305444 4671 302867 12659 20647, 28635, family 7, subfamily 36623, 44611, G, member 3 52599

76454517 olfactory receptor, 284287 4672 284287 12660 20648, 28636, family 8, subfamily 36624, 44612, A, member 1 52600

76464518 olfactory receptor, 306842 4673 307159 12661 20649, 28637, family 8, subfamily 36625, 44613, B, member 12 52601

76474519 olfactory receptor, 375013 4674 364152 12662 20650, 28638, family 8, subfamily 36626, 44614, B, member 2 52602

76484520 olfactory receptor, 354597 4675 346611 12663 20651, 28639, family 8, subfamily 36627, 44615, B, member 3 52603

76494521 olfactory receptor, 356130 4676 348449 12664 20652, 28640, family 8, subfamily 36628, 44616, B, member 4 52604

76504522 olfactory receptor, 328064 4677 330280 12665 20653, 28641, family 8, subfamily 36629, 44617, B, member 8 52605

76514523 olfactory receptor, 357821 4678 350474 12666 20654, 28642, family 8, subfamily 36630, 44618, D, member 1 52606

76524524 olfactory receptor, 357438 4679 350022 12667 20655, 28643, family 8, subfamily 36631, 44619, D, member 2 52607

76534525 olfactory receptor, 321355 4680 325381 12668 20656, 28644, family 8, subfamily 36632, 44620, D, member 4 52608

76544526 olfactory receptor, 313022 4681 323595 12669 20657, 28645, family 8, subfamily 36633, 44621, H, member 1 52609

76554527 olfactory receptor, 395186 4682 378613 12670 20658, 28646, family 8, subfamily 36634, 44622, H, member 1 52610

76564528 olfactory receptor, 313503 4683 323982 12671 20659, 28647, family 8, subfamily 36635, 44623, H, member 2 52611

76574529 olfactory receptor, 313472 4684 323928 12672 20660, 28648, family 8, subfamily 36636, 44624, H, member 3 52612

76584530 olfactory receptor, 302124 4685 303864 12673 20661, 28649, family 8, subfamily 36637, 44625, I, member 2 52613

76594531 olfactory receptor, 303039 4686 304060 12674 20662, 28650, family 8, subfamily 36638, 44626, J, member 1 52614 4532 olfactory receptor, 301529 4687 301529 12675 20663, 28651, family 8, subfamily 36639, 44627, J, member 3 52615

76604533 olfactory receptor, 279783 4688 279783 12676 20664, 28652, family 8, subfamily 36640, 44628, K, member 1 52616

76614534 olfactory receptor, 312711 4689 323555 12677 20665, 28653, family 8, subfamily 36641, 44629, K, member 3 52617

76624535 olfactory receptor, 313447 4690 323853 12678 20666, 28654, family 8, subfamily 36642, 44630, K, member 5 52618

76634536 olfactory receptor, 310194 4691 310632 12679 20667, 28655, family 8, subfamily 36643, 44631, S, member 1 52619

76644537 olfactory receptor, 302270 4692 304188 12680 20668, 28656, family 8, subfamily 36644, 44632, U, member 1 52620

76654538 olfactory receptor, 350513 4693 316518 12681 20669, 28657, family 9, subfamily 36645, 44633, A, member 2 52621

76664539 olfactory receptor, 548136 4694 448789 12682 20670, 28658, family 9, subfamily 36646, 44634, A, member 4 52622

76674540 olfactory receptor, 312153 4695 309012 12683 20671, 28659, family 9, subfamily 36647, 44635, G, member 1 52623

76684541 olfactory receptor, 302957 4696 307515 12684 20672, 28660, family 9, subfamily 36648, 44636, G, member 4 52624

76694542 olfactory receptor, 302610 4697 302606 12685 20673, 28661, family 9, subfamily 36649, 44637, I, member 1 52625

76704543 olfactory receptor, 305377 4698 307598 12686 20674, 28662, family 9, subfamily 36650, 44638, K, member 2 52626

76714544 olfactory receptor, 335397 4699 334934 12687 20675, 28663, family 9, subfamily 36651, 44639, Q, member 1 52627

76724545 olfactory receptor, 311591 4700 308714 12688 20676, 28664, family 9, subfamily 36652, 44640, Q, member 2 52628

76734546 oligodendrocyte 371172 4701 360214 12689 20677, 28665, myelin paranodal 36653, 44641, and inner loop 52629 protein

76744547 oligodendrocytic 393870 4702 377448 12690 20678, 28666, myelin paranodal 36654, 44642, and inner loop 52630 protein

76754548 oligodendrocytic 393871 4703 377449 12691 20679, 28667, myelin paranodal 36655, 44643, and inner loop 52631 protein 4549 oligodendrocytic 419479 4704 398025 12692 20680, 28668, myelin paranodal 36656, 44644, and inner loop 52632 protein

76764550 oligodendrocytic 536387 4705 445125 12693 20681, 28669, myelin paranodal 36657, 44645, and inner loop 52633 protein

76774551 oligosaccharyltransf 361564 4706 354676 12694 20682, 28670, erase complex 36658, 44646, subunit 52634

76784552 oligosaccharyltransf 512478 4707 426167 12695 20683, 28671, erase complex 36659, 44647, subunit 52635

76794553 OMA1 zinc 358603 4708 351417 12696 20684, 28672, metallopeptidase 36660, 44648, homolog (S. 52636 cerevisiae)

76804554 OMA1 zinc 371226 4709 360270 12697 20685, 28673, metallopeptidase 36661, 44649, homolog (S. 52637 cerevisiae)

76814555 OMA1 zinc 419242 4710 409589 12698 20686, 28674, metallopeptidase 36662, 44650, homolog (S. 52638 cerevisiae)

76824556 OMA1 zinc 421528 4711 391941 12699 20687, 28675, metallopeptidase 36663, 44651, homolog (S. 52639 cerevisiae)

76834557 OMA1 zinc 426139 4712 416495 12700 20688, 28676, metallopeptidase 36664, 44652, homolog (S. 52640 cerevisiae)

76844558 OMA1 zinc 453710 4713 392978 12701 20689, 28677, metallopeptidase 36665, 44653, homolog (S. 52641 cerevisiae)

76854559 OMA1 zinc 456980 4714 395053 12702 20690, 28678, metallopeptidase 36666, 44654, homolog (S. 52642 cerevisiae)

76864560 omega-3 fatty acid 371481 4715 360536 12703 20691, 28679, receptor 1 36667, 44655,

768752643

76884561 omega-3 fatty acid 371483 4716 360538 12704 20692, 28680, receptor 1 36668, 44656,

768952644

76904562 opiate receptor-like 336866 4717 336843 12705 20693, 28681, 1 36669, 44657,

769152645

76924563 opiate receptor-like 349451 4718 336764 12706 20694, 28682, 1 36670, 44658,

769352646 4564 opiate receptor-like 355631 4719 347848 12707 20695, 28683, 1 36671, 44659,

769452647

76954565 opsin 1 (cone 442922 4720 402493 12708 20696, 28684, pigments), long36672, 44660, wave-sensitive 52648

76964566 opsin 1 (cone 369929 4721 358945 12709 20697, 28685, pigments), medium- 36673, 44661, wave-sensitive 2 52649

76974567 opsin 4 241891 4722 241891 12710 20698, 28686,

769836674, 44662, 52650

76994568 opsin 4 372071 4723 361141 12711 20699, 28687,

770036675, 44663, 52651

77014569 opsin 4 443292 4724 393132 12712 20700, 28688,

770236676, 44664, 52652

77034570 opsin 5 371211 4725 360255 12713 20701, 28689,

770436677, 44665, 52653

77054571 organic solute 235532 4726 235532 12714 20702, 28690, carrier partner 1 36678, 44666,

770652654

77074572 organic solute 315643 4727 314541 12715 20703, 28691, carrier partner 1 36679, 44667,

770852655

77094573 organic solute 354267 4728 346216 12716 20704, 28692, carrier partner 1 36680, 44668,

771052656

77114574 organic solute 356637 4729 349052 12717 20705, 28693, carrier partner 1 36681, 44669,

771252657

77134575 Organic solute 296327 4730 296327 12718 20706, 28694, transporter subunit 36682, 44670, alpha 52658

77144576 Organic solute 334287 4731 335292 12719 20707, 28695, transporter subunit 36683, 44671, beta 52659

77154577 O-sialoglycoprotein 264151 4732 264151 12720 20708, 28696, endopeptidase-like 1 36684, 44672,

771652660

77174578 O-sialoglycoprotein 517895 4733 430879 12721 20709, 28697, endopeptidase-like 1 36685, 44673,

771852661

77194579 O-sialoglycoprotein 521630 4734 429385 12722 20710, 28698, endopeptidase-like 1 36686, 44674,

772052662

77214580 O-sialoglycoprotein 522700 4735 429697 12723 20711, 28699, endopeptidase-like 1 36687, 44675,

772252663

77234581 otopetrin 2 331427 4736 332528 12724 20712, 28700,

772436688, 44676, 52664 4582 otopetrin 3 328801 4737 328090 12725 20713, 28701,

772536689, 44677, 52665

77264583 oxidoreductase 285083 4738 285083 12726 20714, 28702, NAD-binding 36690, 44678, domain containing 1 52666

77274584 oxidoreductase 435829 4739 389872 12727 20715, 28703, NAD-binding 36691, 44679, domain containing 1 52667

77284585 oxidoreductase 544043 4740 437967 12728 20716, 28704, NAD-binding 36692, 44680, domain containing 1 52668

77294586 oxoeicosanoid 378661 4741 367930 12729 20717, 28705, (OXE) receptor 1 36693, 44681,

773052669

77314587 oxoglutarate (alpha- 298440 4742 298440 12730 20718, 28706, ketoglutarate) 36694, 44682, receptor 1 52670

77324588 oxoglutarate (alpha- 541038 4743 437356 12731 20719, 28707, ketoglutarate) 36695, 44683, receptor 1 52671

77334589 oxoglutarate (alpha- 541518 4744 445269 12732 20720, 28708, ketoglutarate) 36696, 44684, receptor 1 52672

77344590 oxoglutarate (alpha- 543457 4745 438800 12733 20721, 28709, ketoglutarate) 36697, 44685, receptor 1 52673

77354591 oxoglutarate 374103 4746 363216 12734 20722, 28710, dehydrogenase-like 36698, 44686,

773652674

77374592 oxoglutarate 419399 4747 401356 12735 20723, 28711, dehydrogenase-like 36699, 44687,

773852675

77394593 oxoglutarate 432695 4748 390240 12736 20724, 28712, dehydrogenase-like 36700, 44688,

774052676

77414594 p21 protein 353224 4749 322957 12737 20725, 28713, (Cdc42/Rac)- 36701, 44689, activated kinase 7 52677

77424595 p21 protein 378423 4750 367679 12738 20726, 28714, (Cdc42/Rac)- 36702, 44690, activated kinase 7 52678

77434596 p21 protein 378429 4751 367686 12739 20727, 28715, (Cdc42/Rac)- 36703, 44691, activated kinase 7 52679

77444597 p21 protein 439520 4752 414175 12740 20728, 28716, (Cdc42/Rac)- 36704, 44692, activated kinase 7 52680

77454598 pannexin 1 227638 4753 227638 12741 20729, 28717,

774636705, 44693, 52681

77474599 pannexin 1 436171 4754 411461 12742 20730, 28718,

774836706, 44694, 52682 4600 pannexin 2 395842 4755 379183 12743 20731, 28719,

774936707, 44695, 52683

77504601 pannexin 2 401643 4756 385054 12744 20732, 28720,

775136708, 44696, 52684

77524602 pannexin 3 284288 4757 284288 12745 20733, 28721,

775336709, 44697, 52685

77544603 PAPPA antisense 445861 4758 398729 12746 20734, 28722, RNA 1 (non-protein 36710, 44698, coding) 52686

77554604 par-3 partitioning 349953 4759 340280 12747 20735, 28723, defective 3 homolog 36711, 44699, B (C. elegans) 52687

77564605 par-3 partitioning 351153 4760 317261 12748 20736, 28724, defective 3 homolog 36712, 44700, B (C. elegans) 52688

77574606 par-3 partitioning 358768 4761 351618 12749 20737, 28725, defective 3 homolog 36713, 44701, B (C. elegans) 52689

77584607 par-3 partitioning 406610 4762 385848 12750 20738, 28726, defective 3 homolog 36714, 44702, B (C. elegans) 52690

77594608 par-6 partitioning 219255 4763 219255 12751 20739, 28727, defective 6 homolog 36715, 44703, alpha (C. elegans) 52691

77604609 par-6 partitioning 458121 4764 392388 12752 20740, 28728, defective 6 homolog 36716, 44704, alpha (C. elegans) 52692

77614610 paralemmin 264560 4765 264560 12753 20741, 28729,

776236717, 44705, 52693

77634611 paralemmin 338448 4766 341911 12754 20742, 28730,

776436718, 44706, 52694

77654612 paralemmin 538247 4767 446163 12755 20743, 28731,

776636719, 44707, 52695

77674613 paraneoplastic 316836 4768 318914 12756 20744, 28732, antigen MAI 36720, 44708,

776852696

77694614 parathyroid hormone 313049 4769 321999 12757 20745, 28733, 1 receptor 36721, 44709,

777052697

77714615 parathyroid hormone 418619 4770 411424 12758 20746, 28734, 1 receptor 36722, 44710,

777252698

77734616 parathyroid hormone 427125 4771 400977 12759 20747, 28735, 1 receptor 36723, 44711,

777452699

77754617 parathyroid hormone 428220 4772 389811 12760 20748, 28736, 1 receptor 36724, 44712,

777652700 4618 parathyroid hormone 430002 4773 413774 12761 20749, 28737, 1 receptor 36725, 44713,

777752701

77784619 parathyroid hormone 449590 4774 402723 12762 20750, 28738, 1 receptor 36726, 44714,

777952702

77804620 parathyroid hormone 272847 4775 272847 12763 20751, 28739, 2 receptor 36727, 44715,

778152703

77824621 PDZK1 interacting 294338 4776 294338 12764 20752, 28740, protein 1 36728, 44716,

778352704

77844622 PDZK1 interacting 371885 4777 360952 12765 20753, 28741, protein 1 36729, 44717,

778552705

77864623 pecanex homolog 238570 4778 238570 12766 20754, 28742, (Drosophila) 36730, 44718,

778752706

77884624 pecanex homolog 304743 4779 304192 12767 20755, 28743, (Drosophila) 36731, 44719,

778952707

77904625 pecanex homolog 439984 4780 396617 12768 20756, 28744, (Drosophila) 36732, 44720,

779152708

77924626 pecanex homolog 554691 4781 451016 12769 20757, 28745, (Drosophila) 36733, 44721,

779352709

77944627 pecanex-like 2 258229 4782 258229 12770 20758, 28746, (Drosophila) 36734, 44722,

779552710

77964628 pecanex-like 2 344698 4783 340759 12771 20759, 28747, (Drosophila) 36735, 44723,

779752711

77984629 pecanex-like 2 430153 4784 394703 12772 20760, 28748, (Drosophila) 36736, 44724,

779952712

78004630 pecanex-like 3 355703 4785 347931 12773 20761, 28749, (Drosophila) 36737, 44725,

780152713

78024631 pentatricopeptide 308077 4786 308948 12774 20762, 28750, repeat domain 2 36738, 44726,

780352714

78044632 pentatricopeptide 380639 4787 370013 12775 20763, 28751, repeat domain 2 36739, 44727,

780552715

78064633 pentatricopeptide 536805 4788 444772 12776 20764, 28752, repeat domain 2 36740, 44728,

780752716

78084634 pentatricopeptide 543322 4789 438810 12777 20765, 28753, repeat domain 2 36741, 44729,

780952717

78104635 Pentatricopeptide 254630 4790 254630 12778 20766, 28754, repeat domain 3 36742, 44730,

781152718 4636 Pentatricopeptide 409277 4791 386462 12779 20767, 28755, repeat domain 3 36743, 44731,

781252719

78134637 peptidase 249269 4792 249269 12780 20768, 28756, (mitochondrial 36744, 44732, processing) beta 52720

78144638 peptidase 420236 4793 410393 12781 20769, 28757, (mitochondrial 36745, 44733, processing) beta 52721

78154639 peptidyl-tRNA 419060 4794 418661 12782 20770, 28758, hydrolase 1 homolog 36746, 44734, (S. cerevisiae) 52722

78164640 peptidyl-tRNA 543175 4795 439469 12783 20771, 28759, hydrolase 1 homolog 36747, 44735, (S. cerevisiae) 52723

78174641 perilipin 4 301286 4796 301286 12784 20772, 28760,

781836748, 44736, 52724

78194642 peroxisomal 369306 4797 358312 12785 20773, 28761, biogenesis factor 11 36749, 44737, beta 52725

78204643 peroxisomal 428634 4798 414018 12786 20774, 28762, biogenesis factor 11 36750, 44738, beta 52726

78214644 peroxisomal 537888 4799 437510 12787 20775, 28763, biogenesis factor 11 36751, 44739, beta 52727

78224645 peroxisomal 225873 4800 225873 12788 20776, 28764, biogenesis factor 12 36752, 44740,

782352728

78244646 peroxisomal 424525 4801 399205 12789 20777, 28765, biogenesis factor 12 36753, 44741,

782552729

78264647 peroxisomal 317479 4802 321271 12790 20778, 28766, membrane protein 2, 36754, 44742, 22kDa 52730

78274648 peroxisomal 545677 4803 445782 12791 20779, 28767, membrane protein 2, 36755, 44743, 22kDa 52731

78284649 peroxisomal 344022 4804 343071 12792 20780, 28768, membrane protein 4, 36756, 44744, 24kDa 52732

78294650 peroxisomal 409299 4805 386385 12793 20781, 28769, membrane protein 4, 36757, 44745, 24kDa 52733

78304651 PERP, TP53 265603 4806 265603 12794 20782, 28770, apoptosis effector 36758, 44746,

783152734

78324652 PERP, TP53 421351 4807 397157 12795 20783, 28771, apoptosis effector 36759, 44747,

783352735

78344653 PET 112 homolog 263985 4808 263985 12796 20784, 28772, (yeast) 36760, 44748,

783552736 4654 phosphatide acid 369073 4809 358069 12797 20785, 28773, phosphatase type 2 36761, 44749, domain containing 52737 1A

78364655 phosphatidic acid 398248 4810 381300 12798 20786, 28774, phosphatase type 2 36762, 44750, domain containing 52738 1A

78374656 phosphatidic acid 398250 4811 381302 12799 20787, 28775, phosphatase type 2 36763, 44751, domain containing 52739 1A

78384657 phosphatidic acid 427079 4812 407979 12800 20788, 28776, phosphatase type 2 36764, 44752, domain containing 52740 1A

78394658 phosphatidic acid 439221 4813 403508 12801 20789, 28777, phosphatase type 2 36765, 44753, domain containing 52741 1A

78404659 phosphatidic acid 541332 4814 440493 12802 20790, 28778, phosphatase type 2 36766, 44754, domain containing 52742 1A

78414660 phosphatidic acid 372261 4815 361335 12803 20791, 28779, phosphatase type 2 36767, 44755, domain containing 3 52743

78424661 phosphatidic acid 372264 4816 361338 12804 20792, 28780, phosphatase type 2 36768, 44756, domain containing 3 52744

78434662 phosphatidic acid 264775 4817 264775 12805 20793, 28781, phosphatase type 2A 36769, 44757,

784452745

78454663 phosphatidic acid 307259 4818 302229 12806 20794, 28782, phosphatase type 2A 36770, 44758,

784652746

78474664 phosphatidic acid 371250 4819 360296 12807 20795, 28783, phosphatase type 2B 36771, 44759,

784852747

78494665 phosphatidic acid 269812 4820 269812 12808 20796, 28784, phosphatase type 2C 36772, 44760,

785052748

78514666 phosphatidic acid 327790 4821 329697 12809 20797, 28785, phosphatase type 2C 36773, 44761,

785252749

78534667 phosphatidic acid 434325 4822 388565 12810 20798, 28786, phosphatase type 2C 36774, 44762,

785452750

78554668 phosphatidylethanol 255389 4823 255389 12811 20799, 28787, amine N- 36775, 44763, methyltransferase 52751

78564669 phosphatidylethanol 395781 4824 379127 12812 20800, 28788, amine N- 36776, 44764, methyltransferase 52752 4670 phosphatidylethanol 395782 4825 379128 12813 20801, 28789, amine N- 36777, 44765, methyltransferase 52753

78574671 phosphatidylethanol 395783 4826 379129 12814 20802, 28790, amine N- 36778, 44766, methyltransferase 52754

78584672 phosphatidylethanol 421096 4827 398705 12815 20803, 28791, amine N- 36779, 44767, methyltransferase 52755

78594673 phosphatidylethanol 435340 4828 391288 12816 20804, 28792, amine N- 36780, 44768, methyltransferase 52756

78604674 phosphatidylethanol 256404 4829 256404 12817 20805, 28793, amine-binding 36781, 44769, protein 4 52757

78614675 phosphatidylglycero 262764 4830 262764 12818 20806, 28794, phosphate synthase 36782, 44770, 1 52758

78624676 phosphatidylglycero 329897 4831 330039 12819 20807, 28795, phosphate synthase 36783, 44771, 1 52759

78634677 phosphatidylglycero 335081 4832 334151 12820 20808, 28796, phosphate synthase 36784, 44772, 1 52760

78644678 phosphatidylinositol 296306 4833 296306 12821 20809, 28797, glycan anchor 36785, 44773, biosynthesis, class G 52761

78654679 phosphatidylinositol 310340 4834 311750 12822 20810, 28798, glycan anchor 36786, 44774, biosynthesis, class G 52762

78664680 phosphatidylinositol 383028 4835 372494 12823 20811, 28799, glycan anchor 36787, 44775, biosynthesis, class G 52763

78674681 phosphatidylinositol 453061 4836 415203 12824 20812, 28800, glycan anchor 36788, 44776, biosynthesis, class G 52764

78684682 phosphatidylinositol 453065 4837 394941 12825 20813, 28801, glycan anchor 36789, 44777, biosynthesis, class G 52765

78694683 phosphatidylinositol 503111 4838 426002 12826 20814, 28802, glycan anchor 36790, 44778, biosynthesis, class G 52766

78704684 phosphatidylinositol 536264 4839 439240 12827 20815, 28803, glycan anchor 36791, 44779, biosynthesis, class G 52767

78714685 phosphatidylinositol 298004 4840 298004 12828 20816, 28804, glycan anchor 36792, 44780, biosynthesis, class O 52768

78724686 phosphatidylinositol 341666 4841 339382 12829 20817, 28805, glycan anchor 36793, 44781, biosynthesis, class O 52769

78734687 phosphatidylinositol 361778 4842 354678 12830 20818, 28806, glycan anchor 36794, 44782, biosynthesis, class O 52770 4688 phosphatidylinositol 378617 4843 367880 12831 20819, 28807, glycan anchor 36795, 44783, biosynthesis, class O 52771

78744689 phosphatidylinositol 26218 4844 26218 12832 20820, 28808, glycan anchor 36796, 44784, biosynthesis, class Q 52772, 56089,

787556122

78764690 phosphatidylinositol 293874 4845 293874 12833 20821, 28809, glycan anchor 36797, 44785, biosynthesis, class Q 52773

78774691 phosphatidylinositol 321878 4846 326674 12834 20822, 28810, glycan anchor 36798, 44786, biosynthesis, class Q 52774

78784692 phosphatidylinositol 409439 4847 386554 12835 20823, 28811, glycan anchor 36799, 44787, biosynthesis, class Q 52775

78794693 phosphatidylinositol 409527 4848 386760 12836 20824, 28812, glycan anchor 36800, 44788, biosynthesis, class Q 52776

78804694 phosphatidylinositol 422307 4849 413753 12837 20825, 28813, glycan anchor 36801, 44789, biosynthesis, class Q 52777

78814695 phosphatidylinositol 439574 4850 387820 12838 20826, 28814, glycan anchor 36802, 44790, biosynthesis, class Q 52778

78824696 phosphatidylinositol 443147 4851 410434 12839 20827, 28815, glycan anchor 36803, 44791, biosynthesis, class Q 52779

78834697 phosphatidylinositol 470411 4852 439650 12840 20828, 28816, glycan anchor 36804, 44792, biosynthesis, class Q 52780

78844698 phosphatidylinositol 268758 4853 268758 12841 20829, 28817, glycan anchor 36805, 44793, biosynthesis, class S 52781

78854699 phosphatidylinositol 308360 4854 309430 12842 20830, 28818, glycan anchor 36806, 44794, biosynthesis, class S 52782

78864700 phosphatidylinositol 395346 4855 378755 12843 20831, 28819, glycan anchor 36807, 44795, biosynthesis, class S 52783

78874701 phosphatidylinositol 543734 4856 438447 12844 20832, 28820, glycan anchor 36808, 44796, biosynthesis, class S 52784

78884702 phosphatidylinositol 279035 4857 279035 12845 20833, 28821, glycan anchor 36809, 44797, biosynthesis, class T 52785

78894703 phosphatidylinositol 279036 4858 279036 12846 20834, 28822, glycan anchor 36810, 44798, biosynthesis, class T 52786

78904704 phosphatidylinositol 341555 4859 343783 12847 20835, 28823, glycan anchor 36811, 44799, biosynthesis, class T 52787

78914705 phosphatidylinositol 372689 4860 361774 12848 20836, 28824, glycan anchor 36812, 44800, biosynthesis, class T 52788 4706 phosphatidylinositol 535404 4861 440528 12849 20837, 28825, glycan anchor 36813, 44801, biosynthesis, class T 52789

78924707 phosphatidylinositol 543458 4862 441577 12850 20838, 28826, glycan anchor 36814, 44802, biosynthesis, class T 52790

78934708 phosphatidylinositol 545755 4863 443963 12851 20839, 28827, glycan anchor 36815, 44803, biosynthesis, class T 52791

78944709 phosphatidylinositol 273968 4864 273968 12852 20840, 28828, glycan anchor 36816, 44804, biosynthesis, class Y 52792

78954710 Phosphatidylinositol 527353 4865 432688 12853 20841, 28829, N- 36817, 44805, acetylglucosaminyltr 52793 ansferase subunit Y

78964711 phosphatidylinositol 280562 4866 280562 12854 20842, 28830, transfer protein, 36818, 44806, membrane - 52794 associated 2

78974712 phosphatidylinositol 320201 4867 322218 12855 20843, 28831, transfer protein, 36819, 44807, membrane - 52795 associated 2

78984713 phosphatidylinositol 392428 4868 376223 12856 20844, 28832, transfer protein, 36820, 44808, membrane - 52796 associated 2

78994714 phosphatidylinositol 541244 4869 445399 12857 20845, 28833, transfer protein, 36821, 44809, membrane - 52797 associated 2

79004715 phosphatidylinositol 542210 4870 437869 12858 20846, 28834, transfer protein, 36822, 44810, membrane - 52798 associated 2

79014716 phosphatidylinositol 542749 4871 437611 12859 20847, 28835, transfer protein, 36823, 44811, membrane - 52799 associated 2

79024717 phosphatidylinositol 269554 4872 269554 12860 20848, 28836, -5-phosphate 4- 36824, 44812, kinase, type II, beta 52800

79034718 phosphatidylinositol 311500 4873 311210 12861 20849, 28837, -5-phosphate 4- 36825, 44813, kinase, type II, beta 52801

79044719 phosphodiesterase 311180 4874 309142 12862 20850, 28838, 12 36826, 44814,

790552802

79064720 phosphodiesterase 487257 4875 420626 12863 20851, 28839, 12 36827, 44815,

790752803

79084721 phosphodiesterase 334456 4876 334910 12864 20852, 28840, 2A, cGMP- 36828, 44816, stimulated 52804 4722 phosphodiesterase 376450 4877 365633 12865 20853, 28841, 2A, cGMP- 36829, 44817, stimulated 52805

79094723 phosphodiesterase 429363 4878 401006 12866 20854, 28842, 2A, cGMP- 36830, 44818, stimulated 52806

79104724 phosphodiesterase 444035 4879 411657 12867 20855, 28843, 2A, cGMP- 36831, 44819, stimulated 52807

79114725 phosphodiesterase 544570 4880 442256 12868 20856, 28844, 2A, cGMP- 36832, 44820, stimulated 52808

79124726 phosphodiesterase 359062 4881 351957 12869 20857, 28845, 3A, cGMP-inhibited 36833, 44821,

791352809

79144727 phosphofurin acidic 325438 4882 321834 12870 20858, 28846, cluster sorting 36834, 44822, protein 2 52810

79154728 phosphofurin acidic 447393 4883 393559 12871 20859, 28847, cluster sorting 36835, 44823, protein 2 52811

79164729 phosphofurin acidic 458164 4884 399732 12872 20860, 28848, cluster sorting 36836, 44824, protein 2 52812

79174730 phosphoglycerate 317555 4885 321503 12873 20861, 28849, mutase family 36837, 44825, member 5 52813

79184731 phosphoglycerate 498926 4886 438465 12874 20862, 28850, mutase family 36838, 44826, member 5 52814

79194732 phosphoinositide-3 - 339364 4887 339826 12875 20863, 28851, kinase adaptor 36839, 44827, protein 1 52815

79204733 phosphoinositide-3 - 371109 4888 360150 12876 20864, 28852, kinase adaptor 36840, 44828, protein 1 52816

79214734 phosphoinositide-3 - 371110 4889 360151 12877 20865, 28853, kinase adaptor 36841, 44829, protein 1 52817

79224735 phosphoinositide-3 - 215912 4890 215912 12878 20866, 28854, kinase interacting 36842, 44830, protein 1 52818

79234736 phosphoinositide-3 - 402249 4891 385204 12879 20867, 28855, kinase interacting 36843, 44831, protein 1 52819

79244737 phosphoinositide-3 - 416925 4892 403641 12880 20868, 28856, kinase interacting 36844, 44832, protein 1 52820

79254738 phosphoinositide-3 - 441972 4893 415608 12881 20869, 28857, kinase interacting 36845, 44833, protein 1 52821

79264739 phosphoinositide-3 - 487265 4894 441361 12882 20870, 28858, kinase interacting 36846, 44834, protein 1 52822 4740 phospholipase A2, 290497 4895 290497 12883 20871, 28859, group IVF 36847, 44835,

792752823

79284741 phospholipase A2, 357924 4896 350604 12884 20872, 28860, group IVF 36848, 44836,

792952824

79304742 phospholipase A2, 382396 4897 371833 12885 20873, 28861, group IVF 36849, 44837,

793152825

79324743 phospholipase A2, 397272 4898 380442 12886 20874, 28862, group IVF 36850, 44838,

793352826

79344744 phospholipase A2, 443825 4899 400843 12887 20875, 28863, group IVF 36851, 44839,

793552827

79364745 phospholipase B 280800 4900 280800 12888 20876, 28864, domain containing 2 36852, 44840,

793752828

79384746 phospholipase B 545182 4901 443463 12889 20877, 28865, domain containing 2 36853, 44841,

793952829

79404747 phospholipase D 356508 4902 348901 12890 20878, 28866, family, member 3 36854, 44842,

794152830

79424748 phospholipase D 359274 4903 352220 12891 20879, 28867, family, member 3 36855, 44843,

794352831

79444749 phospholipase D 392032 4904 375886 12892 20880, 28868, family, member 3 36856, 44844,

794552832

79464750 phospholipase D 409281 4905 387022 12893 20881, 28869, family, member 3 36857, 44845,

794752833

79484751 phospholipase D 409419 4906 386293 12894 20882, 28870, family, member 3 36858, 44846,

794952834

79504752 phospholipase D 409587 4907 387050 12895 20883, 28871, family, member 3 36859, 44847,

795152835

79524753 phospholipase D 409735 4908 386938 12896 20884, 28872, family, member 3 36860, 44848,

795352836

79544754 phospholipase D 536031 4909 445216 12897 20885, 28873, family, member 3 36861, 44849,

795552837

79564755 phospholipase D 392593 4910 376372 12898 20886, 28874, family, member 4 36862, 44850,

795752838

79584756 phospholipase D 540372 4911 438677 12899 20887, 28875, family, member 4 36863, 44851,

795952839

79604757 phospholipase D 427495 4912 401285 12900 20888, 28876, family, member 5 36864, 44852,

796152840 4758 phospholipase D 442594 4913 414188 12901 20889, 28877, family, member 5 36865, 44853,

796252841

79634759 phospholipase D 536534 4914 440896 12902 20890, 28878, family, member 5 36866, 44854,

796452842

79654760 phospholipase D 321560 4915 317177 12903 20891, 28879, family, member 6 36867, 44855,

796652843

79674761 phospholipase D 427497 4916 394249 12904 20892, 28880, family, member 6 36868, 44856,

796852844

79694762 phosphoserine 275605 4917 275605 12905 20893, 28881, phosphatase 36869, 44857,

797052845

79714763 phosphoserine 395471 4918 378854 12906 20894, 28882, phosphatase 36870, 44858,

797252846

79734764 phosphoserine 413218 4919 404674 12907 20895, 28883, phosphatase 36871, 44859,

797452847

79754765 phosphoserine 416592 4920 405538 12908 20896, 28884, phosphatase 36872, 44860,

797652848

79774766 phosphoserine 419984 4921 399660 12909 20897, 28885, phosphatase 36873, 44861,

797852849

79794767 phosphoserine 421312 4922 390952 12910 20898, 28886, phosphatase 36874, 44862,

798052850

79814768 phosphoserine 421626 4923 398653 12911 20899, 28887, phosphatase 36875, 44863,

798252851

79834769 phosphoserine 424596 4924 390452 12912 20900, 28888, phosphatase 36876, 44864,

798452852

79854770 phosphoserine 437355 4925 401639 12913 20901, 28889, phosphatase 36877, 44865,

798652853

79874771 phosphoseryl-tRNA 368887 4926 357882 12914 20902, 28890, kinase 36878, 44866,

798852854

79894772 phosphoseryl-tRNA 405485 4927 384764 12915 20903, 28891, kinase 36879, 44867,

799052855

79914773 phosphoseryl-tRNA 406217 4928 384653 12916 20904, 28892, kinase 36880, 44868,

799252856

79934774 piezo-type 301015 4929 301015 12917 20905, 28893, mechanosensitive 36881, 44869, ion channel 52857 component 1

79944775 piezo-type 327397 4930 333704 12918 20906, 28894, mechanosensitive 36882, 44870, ion channel 52858 component 1

79954776 piezo-t pe 451779 4931 408244 12919 20907, 28895, mechanosensitive 36883, 44871, ion channel 52859 component 1

79964777 piggyBac 321327 4932 322530 12920 20908, 28896, transposable element 36884, 44872, derived 5 52860

79974778 piggyBac 525115 4933 431404 12921 20909, 28897, transposable element 36885, 44873, derived 5 52861

79984779 platelet endothelial 292357 4934 292357 12922 20910, 28898, aggregation receptor 36886, 44874, 1 52862

79994780 platelet endothelial 338302 4935 344465 12923 20911, 28899, aggregation receptor 36887, 44875, 1 52863

80004781 platelet endothelial 455314 4936 389742 12924 20912, 28900, aggregation receptor 36888, 44876, 1 52864

80014782 pleckstrin and Sec7 274710 4937 274710 12925 20913, 28901, domain containing 2 36889, 44877,

800252865

80034783 pleckstrin 359729 4938 352764 12926 20914, 28902, homology-like 36890, 44878, domain, family B, 52866 member 2

80044784 pleckstrin 393923 4939 377500 12927 20915, 28903, homology-like 36891, 44879, domain, family B, 52867 member 2

80054785 pleckstrin 393925 4940 377502 12928 20916, 28904, homology-like 36892, 44880, domain, family B, 52868 member 2

80064786 pleckstrin 412622 4941 405292 12929 20917, 28905, homology-like 36893, 44881, domain, family B, 52869 member 2

80074787 pleckstrin 431670 4942 405405 12930 20918, 28906, homology-like 36894, 44882, domain, family B, 52870 member 2

80084788 pleckstrin 481953 4943 418319 12931 20919, 28907, homology-like 36895, 44883, domain, family B, 52871 member 2

80094789 pleckstrin 498699 4944 418296 12932 20920, 28908, homology-like 36896, 44884, domain, family B, 52872 member 2

80104790 plexin A3 369682 4945 358696 12933 20921, 28909,

801136897, 44885, 52873

80124791 plexin C 1 258526 4946 258526 12934 20922, 28910,

801336898, 44886, 52874

80144792 plexin C 1 547057 4947 446720 12935 20923, 28911,

801536899, 44887, 52875

80164793 podocalyxin-like 2 302192 4948 304498 12936 20924, 28912,

801736900, 44888, 52876

80184794 podocalyxin-like 2 342480 4949 345359 12937 20925, 28913,

801936901, 44889, 52877

80204795 podoplanin 294489 4950 294489 12938 20926, 28914,

802136902, 44890, 52878

80224796 podoplanin 376057 4951 365225 12939 20927, 28915,

802336903, 44891, 52879

80244797 podoplanin 376061 4952 365229 12940 20928, 28916,

802536904, 44892, 52880

80264798 podoplanin 475043 4953 426063 12941 20929, 28917,

802736905, 44893, 52881

80284799 podoplanin 487038 4954 427537 12942 20930, 28918,

802936906, 44894, 52882

80304800 podoplanin 513143 4955 425304 12943 20931, 28919,

803136907, 44895, 52883

80324801 poliovirus receptor 317271 4956 316675 12944 20932, 28920, related 36908, 44896, immunoglobulin 52884 domain containing

80334802 poly (ADP-ribose) 261888 4957 261888 12945 20933, 28921, polymerase family, 36909, 44897, member 16 52885

80344803 poly(A)-specific 275275 4958 275275 12946 20934, 28922, ribonuclease 36910, 44898, (PARN)-like domain 52886 containing 1

80354804 polymerase (RNA) 379357 4959 368662 12947 20935, 28923, II (DNA directed) 36911, 44899, polypeptide J3 52887

80364805 polyribonucleotide 415374 4960 393953 12948 20936, 28924, nucleotidyltransferas 36912, 44900, e 1 52888

80374806 polyribonucleotide 447944 4961 400646 12949 20937, 28925, nucleotidyltransferas 36913, 44901, e 1 52889

80384807 POM121 membrane 257622 4962 257622 12950 20938, 28926, glycoprotein 36914, 44902, 52890

80394808 POM121 membrane 358357 4963 351124 12951 20939, 28927, glycoprotein 36915, 44903,

804052891

80414809 POM121 membrane 395270 4964 378687 12952 20940, 28928, glycoprotein 36916, 44904,

804252892

80434810 POM121 membrane 434423 4965 405562 12953 20941, 28929, glycoprotein 36917, 44905,

804452893

80454811 POM121 membrane 446813 4966 393020 12954 20942, 28930, glycoprotein 36918, 44906,

804652894

80474812 POM121 membrane 257665 4967 257665 12955 20943, 28931, glycoprotein C 36919, 44907,

804852895

80494813 POM121 membrane 398379 4968 381415 12956 20944, 28932, glycoprotein C 36920, 44908,

805052896

80514814 POM121 membrane 453279 4969 414208 12957 20945, 28933, glycoprotein C 36921, 44909,

805252897

80534815 post-GPI attachment 278243 4970 278243 12958 20946, 28934, to proteins 2 36922, 44910,

805452898

80554816 post-GPI attachment 300730 4971 300730 12959 20947, 28935, to proteins 2 36923, 44911,

805652899

80574817 post-GPI attachment 396991 4972 380188 12960 20948, 28936, to proteins 2 36924, 44912,

805852900

80594818 post-GPI attachment 396993 4973 380190 12961 20949, 28937, to proteins 2 36925, 44913,

806052901

80614819 post-GPI attachment 463452 4974 435223 12962 20950, 28938, to proteins 2 36926, 44914,

806252902

80634820 post-GPI attachment 464906 4975 434631 12963 20951, 28939, to proteins 2 36927, 44915,

806452903

80654821 post-GPI attachment 502872 4976 445541 12964 20952, 28940, to proteins 2 36928, 44916,

806652904

80674822 post-GPI attachment 396986 4977 380183 12965 20953, 28941, to proteins 2 36929, 44917,

806852905

80694823 post-GPI attachment 493547 4978 431851 12966 20954, 28942, to proteins 2 36930, 44918,

807052906

80714824 post-GPI attachment 528216 4979 432215 12967 20955, 28943, to proteins 2 36931, 44919,

807252907 4825 post-GPI attachment 300658 4980 300658 12968 20956, 28944, to proteins 3 36932, 44920,

807352908

80744826 post-GPI attachment 309862 4981 310218 12969 20957, 28945, to proteins 3 36933, 44921,

807552909

80764827 post-GPI attachment 378011 4982 367250 12970 20958, 28946, to proteins 3 36934, 44922,

807752910

80784828 post-GPI attachment 429199 4983 415765 12971 20959, 28947, to proteins 3 36935, 44923,

807952911

80804829 potassium channel 312942 4984 324191 12972 20960, 28948, regulator 36936, 44924,

808152912

80824830 potassium channel 360473 4985 353661 12973 20961, 28949, regulator 36937, 44925,

808352913

80844831 potassium channel 317765 4986 317141 12974 20962, 28950, tetramerisation 36938, 44926, domain containing 52914 12

80854832 potassium channel 377474 4987 366694 12975 20963, 28951, tetramerisation 36939, 44927, domain containing 52915 12

80864833 potassium channel 353172 4988 316482 12976 20964, 28952, tetramerisation 36940, 44928, domain containing 52916 14

80874834 potassium channel 533144 4989 431155 12977 20965, 28953, tetramerisation 36941, 44929, domain containing 52917 14

80884835 potassium channel 422820 4990 389293 12978 20966, 28954, tetramerisation 36942, 44930, domain containing 52918 15

80894836 potassium channel 430256 4991 394390 12979 20967, 28955, tetramerisation 36943, 44931, domain containing 52919 15

80904837 potassium channel 402077 4992 384391 12980 20968, 28956, tetramerisation 36944, 44932, domain containing 52920 17

80914838 potassium channel 403888 4993 385096 12981 20969, 28957, tetramerisation 36945, 44933, domain containing 52921 17

80924839 potassium channel 431531 4994 402434 12982 20970, 28958, tetramerisation 36946, 44934, domain containing 52922 17 4840 potassium channel 456470 4995 409638 12983 20971, 28959, tetramerisation 36947, 44935, domain containing 52923 17

80934841 potassium channel 359878 4996 352941 12984 20972, 28960, tetramerisation 36948, 44936, domain containing 52924 18

80944842 potassium channel 409157 4997 386751 12985 20973, 28961, tetramerisation 36949, 44937, domain containing 52925 18

80954843 potassium channel 304372 4998 305702 12986 20974, 28962, tetramerisation 36950, 44938, domain containing 52926 19

80964844 potassium channel 373731 4999 362836 12987 20975, 28963, tetramerisation 36951, 44939, domain containing 52927 20

80974845 potassium channel 449081 5000 412205 12988 20976, 28964, tetramerisation 36952, 44940, domain containing 52928 20

80984846 potassium channel 460983 5001 417126 12989 20977, 28965, tetramerisation 36953, 44941, domain containing 52929 20

80994847 potassium channel 483557 5002 419943 12990 20978, 28966, tetramerisation 36954, 44942, domain containing 52930 20

81004848 potassium channel 498267 5003 418459 12991 20979, 28967, tetramerisation 36955, 44943, domain containing 52931 20

81014849 potassium channel 536244 5004 439118 12992 20980, 28968, tetramerisation 36956, 44944, domain containing 52932 20

81024850 potassium channel 544295 5005 440150 12993 20981, 28969, tetramerisation 36957, 44945, domain containing 52933 20

81034851 potassium channel 340067 5006 339340 12994 20982, 28970, tetramerisation 36958, 44946, domain containing 52934 21

81044852 potassium channel 525447 5007 434174 12995 20983, 28971, tetramerisation 36959, 44947, domain containing 52935 21

81054853 potassium channel 379108 5008 368402 12996 20984, 28972, tetramerisation 36960, 44948, domain containing 4 52936 4854 potassium channel 405872 5009 385144 12997 20985, 28973, tetramerisation 36961, 44949, domain containing 4 52937

81064855 potassium channel 301738 5010 301738 12998 20986, 28974, tetramerisation 36962, 44950, domain containing 5 52938

81074856 potassium channel 355076 5011 347188 12999 20987, 28975, tetramerisation 36963, 44951, domain containing 6 52939

81084857 potassium channel 404589 5012 384948 13000 20988, 28976, tetramerisation 36964, 44952, domain containing 6 52940

81094858 potassium channel 479179 5013 418999 13001 20989, 28977, tetramerisation 36965, 44953, domain containing 6 52941

81104859 potassium channel 490264 5014 417490 13002 20990, 28978, tetramerisation 36966, 44954, domain containing 6 52942

81114860 potassium channel 360029 5015 353129 13003 20991, 28979, tetramerisation 36967, 44955, domain containing 8 52943

81124861 potassium channel 221200 5016 221200 13004 20992, 28980, tetramerisation 36968, 44956, domain containing 9 52944

81134862 potassium 222249 5017 222249 13005 20993, 28981, intermediate/ small 36969, 44957, conductance 52945 calcium-activated

8114channel, subfamily

8115N, member 1

81164863 potassium 536713 5018 437873 13006 20994, 28982, intermediate/ small 36970, 44958, conductance 52946 calcium-activated

8117channel, subfamily

8118N, member 1

81194864 potassium inwardly- 342291 5019 341479 13007 20995, 28983, rectifying channel, 36971, 44959, subfamily J, member 52947 14

81204865 potassium inwardly- 391884 5020 375756 13008 20996, 28984, rectifying channel, 36972, 44960, subfamily J, member 52948 14

81214866 potassium inwardly- 368088 5021 357067 13009 20997, 28985, rectifying channel, 36973, 44961, subfamily J, member 52949 9

81224867 potassium large 358316 5022 351068 13010 20998, 28986, conductance 36974, 44962, calcium-activated 52950 channel, subfamily

8123M, beta member 2 4868 potassium large 420517 5023 408252 13011 20999, 28987, conductance 36975, 44963, calcium-activated 52951 channel, subfamily

8124M, beta member 2

81254869 potassium large 432997 5024 407592 13012 21000, 28988, conductance 36976, 44964, calcium-activated 52952 channel, subfamily

8126M, beta member 2

81274870 potassium large 437510 5025 395807 13013 21001, 28989, conductance 36977, 44965, calcium-activated 52953 channel, subfamily

8128M, beta member 2

81294871 potassium large 452583 5026 397483 13014 21002, 28990, conductance 36978, 44966, calcium-activated 52954 channel, subfamily

8130M, beta member 2

81314872 potassium large 455865 5027 399100 13015 21003, 28991, conductance 36979, 44967, calcium-activated 52955 channel, subfamily

8132M, beta member 2

81334873 potassium large 457763 5028 395918 13016 21004, 28992, conductance 36980, 44968, calcium-activated 52956 channel, subfamily

8134M, beta member 2

81354874 potassium voltage- 581784 5029 463830 13017 21005, 28993, gated channel 36981, 44969, subfamily H (eag- 52957 related) member 6

81364875 potassium voltage- 583023 5030 463533 13018 21006, 28994, gated channel 36982, 44970, subfamily H (eag- 52958 related) member 6

81374876 potassium voltage- 306117 5031 307694 13019 21007, 28995, gated channel, 36983, 44971, delayed-rectifier, 52959 subfamily S,

8138member 1

81394877 potassium voltage- 537075 5032 445595 13020 21008, 28996, gated channel, 36984, 44972, delayed-rectifier, 52960 subfamily S,

8140member 1

81414878 potassium voltage- 316361 5033 314520 13021 21009, 28997, gated channel, 36985, 44973, shaker-related 52961 subfamily, member

81422 4879 potassium voltage- 369770 5034 358785 13022 21010, 28998, gated channel, 36986, 44974, shaker-related 52962 subfamily, member

81432

81444880 potassium voltage- 440270 5035 415257 13023 21011, 28999, gated channel, 36987, 44975, shaker-related 52963 subfamily, member

81452

81464881 potassium voltage- 485317 5036 433109 13024 21012, 29000, gated channel, 36988, 44976, shaker-related 52964 subfamily, member

81472

81484882 potassium voltage- 280684 5037 280684 13025 21013, 29001, gated channel, 36989, 44977, shaker-related 52965 subfamily, member

81496

81504883 potassium voltage- 433855 5038 408321 13026 21014, 29002, gated channel, 36990, 44978, shaker-related 52966 subfamily, member

81516

81524884 potassium voltage- 218176 5039 218176 13027 21015, 29003, gated channel, Shal- 36991, 44979, related subfamily, 52967 member 1

81534885 potassium voltage- 376477 5040 365660 13028 21016, 29004, gated channel, Shal- 36992, 44980, related subfamily, 52968 member 1

81544886 potassium voltage- 419374 5041 413989 13029 21017, 29005, gated channel, Shal- 36993, 44981, related subfamily, 52969 member 1

81554887 potassium voltage- 316249 5042 315654 13030 21018, 29006, gated channel, 36994, 44982, subfamily G, 52970 member 2

81564888 potassium voltage- 264661 5043 264661 13031 21019, 29007, gated channel, 36995, 44983, subfamily H (eag- 52971 related), member 4

81574889 potassium voltage- 314672 5044 318212 13032 21020, 29008, gated channel, 36996, 44984, subfamily H (eag- 52972 related), member 6

81584890 potassium voltage- 456941 5045 396900 13033 21021, 29009, gated channel, 36997, 44985, subfamily H (eag- 52973 related), member 6 4891 potassium voltage- 328405 5046 328813 13034 21022, 29010, gated channel, 36998, 44986, subfamily H (eag- 52974 related), member 8

81594892 potassium voltage- 537696 5047 446294 13035 21023, 29011, gated channel, 36999, 44987, subfamily H (eag- 52975 related), member 8

81604893 PQ loop repeat 351365 5048 315627 13036 21024, 29012, containing 1 37000, 44988,

816152976

81624894 PQ loop repeat 357575 5049 350188 13037 21025, 29013, containing 1 37001, 44989,

816352977

81644895 PQ loop repeat 397778 5050 380880 13038 21026, 29014, containing 1 37002, 44990,

816552978

81664896 PQ loop repeat 590381 5051 465546 13039 21027, 29015, containing 1 37003, 44991,

816752979

81684897 PQ loop repeat 375153 5052 364295 13040 21028, 29016, containing 2 37004, 44992,

816952980

81704898 PQ loop repeat 375155 5053 364297 13041 21029, 29017, containing 2 37005, 44993,

817152981

81724899 PQ loop repeat 400548 5054 383395 13042 21030, 29018, containing 2 37006, 44994,

817352982

81744900 PQ loop repeat 295083 5055 295083 13043 21031, 29019, containing 3 37007, 44995,

817552983

81764901 PQ loop repeat 441908 5056 406148 13044 21032, 29020, containing 3 37008, 44996,

817752984

81784902 praja ring finger 2 361189 5057 354775 13045 21033, 29021,

817937009, 44997, 52985

81804903 praja ring finger 2 361557 5058 355284 13046 21034, 29022,

818137010, 44998, 52986

81824904 PRELI domain 334744 5059 335675 13047 21035, 29023, containing 2 37011, 44999,

818352987

81844905 PRELI domain 358004 5060 350694 13048 21036, 29024, containing 2 37012, 45000,

818552988

81864906 PRELI domain 394450 5061 377965 13049 21037, 29025, containing 2 37013, 45001,

818752989

81884907 progestin and 295462 5062 295462 13050 21038, 29026, adipoQ receptor 37014, 45002, family member III 52990 4908 progestin and 380645 5063 370019 13051 21039, 29027, adipoQ receptor 37015, 45003, family member III 52991

81894909 progestin and 511594 5064 425080 13052 21040, 29028, adipoQ receptor 37016, 45004, family member III 52992

81904910 progestin and 512733 5065 421981 13053 21041, 29029, adipoQ receptor 37017, 45005, family member III 52993

81914911 progestin and 293978 5066 293978 13054 21042, 29030, adipoQ receptor 37018, 45006, family member IV 52994

81924912 progestin and 318782 5067 321804 13055 21043, 29031, adipoQ receptor 37019, 45007, family member IV 52995

81934913 progestin and 340634 5068 341564 13056 21044, 29032, adipoQ receptor 37020, 45008, family member IX 52996

81944914 progestin and 340965 5069 343877 13057 21045, 29033, adipoQ receptor 37021, 45009, family member V 52997

81954915 progestin and 395407 5070 378803 13058 21046, 29034, adipoQ receptor 37022, 45010, family member V 52998

81964916 progestin and 561153 5071 453526 13059 21047, 29035, adipoQ receptor 37023, 45011, family member V 52999

81974917 progestin and 292291 5072 292291 13060 21048, 29036, adipoQ receptor 37024, 45012, family member VI 53000

81984918 progestin and 335852 5073 338330 13061 21049, 29037, adipoQ receptor 37025, 45013, family member VI 53001

81994919 progestin and 340183 5074 341926 13062 21050, 29038, adipoQ receptor 37026, 45014, family member VI 53002

82004920 progestin and 356983 5075 349474 13063 21051, 29039, adipoQ receptor 37027, 45015, family member VI 53003

82014921 progestin and 360733 5076 353961 13064 21052, 29040, adipoQ receptor 37028, 45016, family member VI 53004

82024922 progestin and 368270 5077 357253 13065 21053, 29041, adipoQ receptor 37029, 45017, family member VI 53005

82034923 progestin and 368271 5078 357254 13066 21054, 29042, adipoQ receptor 37030, 45018, family member VI 53006

82044924 progestin and 540423 5079 443167 13067 21055, 29043, adipoQ receptor 37031, 45019, family member VI 53007

82054925 progestin and 360726 5080 353953 13068 21056, 29044, adipoQ receptor 37032, 45020, family member VIII 53008 4926 progestin and 442253 5081 406197 13069 21057, 29045, adipoQ receptor 37033, 45021, family member VIII 53009

82064927 progestin and 512121 5082 427161 13070 21058, 29046, adipoQ receptor 37034, 45022, family member VIII 53010

82074928 programmed cell 264933 5083 264933 13071 21059, 29047, death 6 37035, 45023,

820853011

82094929 programmed cell 505221 5084 422085 13072 21060, 29048, death 6 37036, 45024,

821053012

82114930 programmed cell 506909 5085 426003 13073 21061, 29049, death 6 37037, 45025,

821253013

82134931 programmed cell 507528 5086 423815 13074 21062, 29050, death 6 37038, 45026,

821453014

82154932 programmed cell 509581 5087 422691 13075 21063, 29051, death 6 37039, 45027,

821653015

82174933 prokineticin receptor 303786 5088 303775 13076 21064, 29052, 1 37040, 45028,

821853016

82194934 prokineticin receptor 394342 5089 377874 13077 21065, 29053, 1 37041, 45029,

822053017

82214935 prolactin releasing 239032 5090 239032 13078 21066, 29054, hormone receptor 37042, 45030,

822253018

82234936 prolactin releasing 369169 5091 358167 13079 21067, 29055, hormone receptor 37043, 45031,

822453019

82254937 proline rich 18 322583 5092 319590 13080 21068, 29056,

822637044, 45032, 53020

82274938 proline rich 18 529616 5093 433381 13081 21069, 29057,

822837045, 45033, 53021

82294939 proline rich 5 like 311599 5094 310103 13082 21070, 29058,

823037046, 45034, 53022

82314940 proline rich 5 like 378867 5095 368144 13083 21071, 29059,

823237047, 45035, 53023

82334941 proline rich 5 like 524380 5096 433305 13084 21072, 29060,

823437048, 45036, 53024

82354942 proline rich 5 like 526679 5097 436402 13085 21073, 29061,

823637049, 45037, 53025

82374943 proline rich 5 like 526682 5098 436485 13086 21074, 29062,

823837050, 45038, 53026 4944 proline rich 5 like 526728 5099 431610 13087 21075, 29063,

823937051, 45039, 53027

82404945 proline rich 5 like 527172 5100 433708 13088 21076, 29064,

824137052, 45040, 53028

82424946 proline rich 5 like 530050 5101 432203 13089 21077, 29065,

824337053, 45041, 53029

82444947 proline rich 5 like 530252 5102 431475 13090 21078, 29066,

824537054, 45042, 53030

82464948 proline rich 5 like 530639 5103 435050 13091 21079, 29067,

824737055, 45043, 53031

82484949 proline rich 5 like 532121 5104 433893 13092 21080, 29068,

824937056, 45044, 53032

82504950 proline rich 5 like 527487 5105 435241 13093 21081, 29069,

825137057, 45045, 53033

82524951 proline rich 7 323249 5106 327168 13094 21082, 29070, (synaptic) 37058, 45046,

825353034

82544952 proline rich 7 355386 5107 347547 13095 21083, 29071, (synaptic) 37059, 45047,

825553035

82564953 proline rich 7 502922 5108 420872 13096 21084, 29072, (synaptic) 37060, 45048,

825753036

82584954 proline rich 7 507881 5109 426601 13097 21085, 29073, (synaptic) 37061, 45049,

825953037

82604955 proline rich 7 510492 5110 421039 13098 21086, 29074, (synaptic) 37062, 45050,

826153038

82624956 proline -rich coiled- 296666 5111 296666 13099 21087, 29075, coil 1 37063, 45051,

826353039

82644957 proline -rich coiled- 330542 5112 332855 13100 21088, 29076, coil 1 37064, 45052,

826553040

82664958 proline -rich coiled- 414018 5113 414586 13101 21089, 29077, coil 1 37065, 45053,

826753041

82684959 proline -rich coiled- 442138 5114 392873 13102 21090, 29078, coil 1 37066, 45054,

826953042

82704960 proline -rich coiled- 512535 5115 426785 13103 21091, 29079, coil 1 37067, 45055,

827153043

82724961 proline -rich coiled- 512635 5116 421965 13104 21092, 29080, coil 1 37068, 45056,

827353044 4962 proline -rich 211413 5117 211413 13105 21093, 29081, transmembrane 37069, 45057, protein 1 53045

82744963 proline -rich 375150 5118 364292 13106 21094, 29082, transmembrane 37070, 45058, protein 1 53046

82754964 proline -rich 375152 5119 364294 13107 21095, 29083, transmembrane 37071, 45059, protein 1 53047

82764965 proline -rich 383309 5120 372799 13108 21096, 29084, transmembrane 37072, 45060, protein 1 53048

82774966 proline -rich 414687 5121 414711 13109 21097, 29085, transmembrane 37073, 45061, protein 1 53049

82784967 proline -rich 418753 5122 411544 13110 21098, 29086, transmembrane 37074, 45062, protein 1 53050

82794968 proline -rich 419655 5123 396427 13111 21099, 29087, transmembrane 37075, 45063, protein 1 53051

82804969 proline -rich 419839 5124 395695 13112 21100, 29088, transmembrane 37076, 45064, protein 1 53052

82814970 proline -rich 423003 5125 413784 13113 21101, 29089, transmembrane 37077, 45065, protein 1 53053

82824971 proline -rich 423671 5126 411183 13114 21102, 29090, transmembrane 37078, 45066, protein 1 53054

82834972 proline -rich 425067 5127 393852 13115 21103, 29091, transmembrane 37079, 45067, protein 1 53055

82844973 proline -rich 425739 5128 416064 13116 21104, 29092, transmembrane 37080, 45068, protein 1 53056

82854974 proline -rich 428778 5129 396077 13117 21105, 29093, transmembrane 37081, 45069, protein 1 53057

82864975 proline -rich 437574 5130 416602 13118 21106, 29094, transmembrane 37082, 45070, protein 1 53058

82874976 proline -rich 439937 5131 389727 13119 21107, 29095, transmembrane 37083, 45071, protein 1 53059

82884977 proline -rich 441129 5132 411596 13120 21108, 29096, transmembrane 37084, 45072, protein 1 53060

82894978 proline -rich 444218 5133 415611 13121 21109, 29097, transmembrane 37085, 45073, protein 1 53061

82904979 proline -rich 444466 5134 405389 13122 21110, 29098, transmembrane 37086, 45074, protein 1 53062 4980 proline -rich 445122 5135 396426 13123 21111, 29099, transmembrane 37087, 45075, protein 1 53063

82914981 proline -rich 451329 5136 398756 13124 21112, 29100, transmembrane 37088, 45076, protein 1 53064

82924982 proline -rich 452030 5137 394808 13125 21113, 29101, transmembrane 37089, 45077, protein 1 53065

82934983 proline -rich 454112 5138 389058 13126 21114, 29102, transmembrane 37090, 45078, protein 1 53066

82944984 proline -rich 456814 5139 397896 13127 21115, 29103, transmembrane 37091, 45079, protein 1 53067

82954985 proline -rich 457819 5140 390214 13128 21116, 29104, transmembrane 37092, 45080, protein 1 53068

82964986 proline -rich 458719 5141 398252 13129 21117, 29105, transmembrane 37093, 45081, protein 1 53069

82974987 proline -rich 547412 5142 449685 13130 21118, 29106, transmembrane 37094, 45082, protein 1 53070

82984988 proline -rich 548904 5143 449975 13131 21119, 29107, transmembrane 37095, 45083, protein 1 53071

82994989 proline -rich 549696 5144 447380 13132 21120, 29108, transmembrane 37096, 45084, protein 1 53072

83004990 proline -rich 551213 5145 449638 13133 21121, 29109, transmembrane 37097, 45085, protein 1 53073

83014991 proline -rich 551958 5146 450235 13134 21122, 29110, transmembrane 37098, 45086, protein 1 53074

83024992 proline -rich 552325 5147 449065 13135 21123, 29111, transmembrane 37099, 45087, protein 1 53075

83034993 proline -rich 552684 5148 448469 13136 21124, 29112, transmembrane 37100, 45088, protein 1 53076

83044994 proline -rich 295984 5149 295984 13137 21125, 29113, transmembrane 37101, 45089, protein 3 53077

83054995 proline -rich 412055 5150 392511 13138 21126, 29114, transmembrane 37102, 45090, protein 3 53078

83064996 proline -rich 435512 5151 410779 13139 21127, 29115, transmembrane 37103, 45091, protein 4 53079

83074997 proline -rich 446477 5152 415026 13140 21128, 29116, transmembrane 37104, 45092, protein 4 53080 4998 proline -rich 535159 5153 445239 13141 21129, 29117, transmembrane 37105, 45093, protein 4 53081

83084999 proline -rich 489835 5154 419296 13142 21130, 29118, transmembrane 37106, 45094, protein 4 53082

83095000 prolyl 4- 343546 5155 341422 13143 21131, 29119, hydroxylase, 37107, 45095, transmembrane 53083

8310(endoplasmic

8311reticulum)

83125001 prolyl 4- 383729 5156 373235 13144 21132, 29120, hydroxylase, 37108, 45096, transmembrane 53084

8313(endoplasmic

8314reticulum)

83155002 proprotein 320934 5157 325917 13145 21133, 29121, convertase 37109, 45097, subtilisin/kexin type 53085 7

83165003 proprotein 524507 5158 433841 13146 21134, 29122, convertase 37110, 45098, subtilisin/kexin type 53086 7

83175004 proprotein 530269 5159 433252 13147 21135, 29123, convertase 37111, 45099, subtilisin/kexin type 53087 7

83185005 proprotein 532301 5160 436459 13148 21136, 29124, convertase 37112, 45100, subtilisin/kexin type 53088 7

83195006 proprotein 540028 5161 441944 13149 21137, 29125, convertase 37113, 45101, subtilisin/kexin type 53089 7

83205007 proprotein 543900 5162 445538 13150 21138, 29126, convertase 37114, 45102, subtilisin/kexin type 53090 7

83215008 ProSAP-interacting 329152 5163 332123 13151 21139, 29127, protein 1 37115, 45103,

832253091

83235009 ProSAP-interacting 337576 5164 338166 13152 21140, 29128, protein 1 37116, 45104,

832453092

83255010 ProSAP-interacting 360342 5165 353496 13153 21141, 29129, protein 1 37117, 45105,

832653093

83275011 prostaglandin D2 332539 5166 332812 13154 21142, 29130, receptor 2 37118, 45106,

832853094

83295012 prostate androgen- 307428 5167 370224 13155 21143, 29131, regulated mucin-like 37119, 45107, protein 1 53095 5013 prostate tumor 221557 5168 221557 13156 21144, 29132, overexpressed 1 37120, 45108,

833053096

83315014 prostate tumor 391842 5169 375717 13157 21145, 29133, overexpressed 1 37121, 45109,

833253097

83335015 protease serine 55 522210 5170 430459 13158 21146, 29134,

833437122, 45110, 53098

83355016 protease, serine, 55 328655 5171 333003 13159 21147, 29135,

833637123, 45111, 53099

83375017 protein arginine 382622 5172 372067 13160 21148, 29136, methyltransferase 8 37124, 45112,

833853100

83395018 protein arginine 452611 5173 414507 13161 21149, 29137, methyltransferase 8 37125, 45113,

834053101

83415019 Protein Coding 251879 5174 251879 13162 21150, 29138,

834237126, 45114, 53102

83435020 Protein Coding 297625 5175 297625 13163 21151, 29139,

834437127, 45115, 53103

83455021 Protein Coding 356068 5176 364329 13164 21152, 29140,

834637128, 45116, 53104

83475022 Protein Coding 358422 5177 351198 13165 21153, 29141,

834837129, 45117, 53105

83495023 Protein Coding 367706 5178 356679 13166 21154, 29142,

835037130, 45118, 53106

83515024 Protein Coding 373258 5179 362355 13167 21155, 29143,

835237131, 45119, 53107

83535025 Protein Coding 375199 5180 364345 13168 21156, 29144,

835437132, 45120, 53108

83555026 Protein Coding 375208 5181 364354 13169 21157, 29145,

835637133, 45121, 53109

83575027 Protein Coding 375248 5182 364397 13170 21158, 29146,

835837134, 45122, 53110

83595028 Protein Coding 376576 5183 365760 13171 21159, 29147,

836037135, 45123, 53111

83615029 Protein Coding 379142 5184 368437 13172 21160, 29148,

836237136, 45124, 53112

83635030 Protein Coding 381532 5185 370943 13173 21161, 29149,

836437137, 45125, 53113 5031 Protein Coding 392412 5186 376212 13174 21162, 29150,

836537138, 45126, 53114

83665032 Protein Coding 392413 5187 376213 13175 21163, 29151,

836737139, 45127, 53115

83685033 Protein Coding 409959 5188 386787 13176 21164, 29152,

836937140, 45128, 53116

83705034 Protein Coding 411671 5189 393122 13177 21165, 29153,

837137141, 45129, 53117

83725035 Protein Coding 414202 5190 416696 13178 21166, 29154,

837337142, 45130, 53118

83745036 Protein Coding 418622 5191 402240 13179 21167, 29155,

837537143, 45131, 53119

83765037 Protein Coding 426982 5192 395883 13180 21168, 29156,

837737144, 45132, 53120

83785038 Protein Coding 427634 5193 404501 13181 21169, 29157,

837937145, 45133, 53121

83805039 Protein Coding 440579 5194 407576 13182 21170, 29158,

838137146, 45134, 53122

83825040 Protein Coding 440693 5195 409663 13183 21171, 29159,

838337147, 45135, 53123

83845041 Protein Coding 449720 5196 398823 13184 21172, 29160,

838537148, 45136, 53124

83865042 Protein Coding 469892 5197 419396 13185 21173, 29161,

838737149, 45137, 53125

83885043 Protein Coding 494948 5198 420226 13186 21174, 29162,

838937150, 45138, 53126

83905044 Protein Coding 526264 5199 435066 13187 21175, 29163,

839137151, 45139, 53127

83925045 Protein Coding 529753 5200 434595 13188 21176, 29164,

839337152, 45140, 53128

83945046 Protein Coding 531664 5201 431349 13189 21177, 29165,

839537153, 45141, 53129

83965047 Protein Coding 533147 5202 431134 13190 21178, 29166,

839737154, 45142, 53130

83985048 Protein Coding 534476 5203 432164 13191 21179, 29167,

839937155, 45143, 53131 5049 Protein Coding 543377 5204 444648 13192 21180, 29168,

840037156, 45144, 53132

84015050 Protein Coding 555249 5205 450458 13193 21181, 29169,

840237157, 45145, 53133

84035051 Protein coding 194118 5206 194118 13194 21182, 29170,

840437158, 45146, 53134

84055052 Protein coding 432126 5207 396225 13195 21183, 29171,

840637159, 45147, 53135

84075053 Protein Coding 507481 5208 426138 13196 21184, 29172,

840837160, 45148, 53136

84095054 protein disulfide 316218 5209 323313 13197 21185, 29173, isomerase family A, 37161, 45149, member 5 53137

84105055 protein disulfide 302451 5210 305465 13198 21186, 29174, isomerase-like, testis 37162, 45150, expressed 53138

84115056 protein kinase, 254101 5211 254101 13199 21187, 29175, AMP-activated, beta 37163, 45151, 2 non-catalytic 53139 subunit

84125057 protein kinase, 425272 5212 415469 13200 21188, 29176, AMP-activated, beta 37164, 45152, 2 non-catalytic 53140 subunit

84135058 Protein kinase-like 331373 5213 331258 13201 21189, 29177, protein SgK196 37165, 45153,

841453141

84155059 protein O- 375730 5214 364882 13202 21190, 29178, fucosyltransferase 1 37166, 45154,

841653142

84175060 protein O- 375749 5215 364902 13203 21191, 29179, fucosyltransferase 1 37167, 45155,

841853143

84195061 protein O- 539210 5216 446154 13204 21192, 29180, fucosyltransferase 1 37168, 45156,

842053144

84215062 protein O- 331343 5217 329682 13205 21193, 29181, fucosyltransferase 2 37169, 45157,

842253145

84235063 protein O- 349485 5218 339613 13206 21194, 29182, fucosyltransferase 2 37170, 45158,

842453146

84255064 protein O- 295588 5219 295588 13207 21195, 29183, glucosyltransferase 37171, 45159,

84261 53147

84275065 protein phosphatase 202556 5220 202556 13208 21196, 29184, 1, regulatory subunit 37172, 45160, 13B 53148 5066 protein phosphatase 380023 5221 369362 13209 21197, 29185, 1, regulatory subunit 37173, 45161, 13B 53149

84285067 protein phosphatase 423488 5222 395213 13210 21198, 29186, 1, regulatory subunit 37174, 45162, 13B 53150

84295068 protein phosphatase 556597 5223 451739 13211 21199, 29187, 1, regulatory subunit 37175, 45163, 13B 53151

84305069 protein phosphatase 292539 5224 292539 13212 21200, 29188, 1, regulatory subunit 37176, 45164, 16A 53152

84315070 protein phosphatase 435887 5225 391126 13213 21201, 29189, 1, regulatory subunit 37177, 45165, 16A 53153

84325071 protein phosphatase 452015 5226 408288 13214 21202, 29190, 1, regulatory subunit 37178, 45166, 3E 53154

84335072 protein phosphatase 558058 5227 453175 13215 21203, 29191, 1, regulatory subunit 37179, 45167, 3E 53155

84345073 protein phosphatase 559314 5228 454106 13216 21204, 29192, 1, regulatory subunit 37180, 45168, 3E 53156

84355074 protein phosphatase 559942 5229 453437 13217 21205, 29193, 1, regulatory subunit 37181, 45169, 3E 53157

84365075 protein phosphatase 560913 5230 453543 13218 21206, 29194, 1, regulatory subunit 37182, 45170, 3E 53158

84375076 protein phosphatase 561437 5231 453726 13219 21207, 29195, 1, regulatory subunit 37183, 45171, 3E 53159

84385077 protein phosphatase 55335 5232 55335 13220 21208, 29196, 1, regulatory subunit 37184, 45172, 3F 53160, 56090,

843956123

84405078 protein phosphatase 438316 5233 415548 13221 21209, 29197, 1, regulatory subunit 37185, 45173, 3F 53161

84415079 protein phosphatase, 325642 5234 327255 13222 21210, 29198, Mg2+/Mn2+ 37186, 45174, dependent, 1A 53162

84425080 protein phosphatase, 325658 5235 314850 13223 21211, 29199, Mg2+/Mn2+ 37187, 45175, dependent, 1A 53163

84435081 protein phosphatase, 395076 5236 378514 13224 21212, 29200, Mg2+/Mn2+ 37188, 45176, dependent, 1A 53164

84445082 protein phosphatase, 525399 5237 435398 13225 21213, 29201, Mg2+/Mn2+ 37189, 45177, dependent, 1A 53165

84455083 protein phosphatase, 528241 5238 431453 13226 21214, 29202, Mg2+/Mn2+ 37190, 45178, dependent, 1A 53166 5084 protein phosphatase, 529574 5239 432966 13227 21215, 29203, Mg2+/Mn2+ 37191, 45179, dependent, 1A 53167

84465085 protein phosphatase, 531937 5240 435575 13228 21216, 29204, Mg2+/Mn2+ 37192, 45180, dependent, 1A 53168

84475086 Protein transport 239472 5241 239472 13229 21217, 29205, protein Secl6B 37193, 45181,

844853169

84495087 Protein transport 308284 5242 308339 13230 21218, 29206, protein Secl6B 37194, 45182,

845053170

84515088 Protein transport 414025 5243 408171 13231 21219, 29207, protein Secl6B 37195, 45183,

845253171

84535089 protein tyrosine 426530 5244 410272 13232 21220, 29208, phosphatase 37196, 45184, mitochondrial 1 53172

84545090 protein tyrosine 443686 5245 388373 13233 21221, 29209, phosphatase receptor 37197, 45185, type f polypeptide 53173 (PTPRF) interacting

8455protein (liprin) alpha

84562

84575091 protein tyrosine 541570 5246 438337 13234 21222, 29210, phosphatase receptor 37198, 45186, type f polypeptide 53174 (PTPRF) interacting

8458protein (liprin) alpha

84592

84605092 protein tyrosine 548586 5247 449338 13235 21223, 29211, phosphatase receptor 37199, 45187, type f polypeptide 53175 (PTPRF) interacting

8461protein (liprin) alpha

84622

84635093 protein tyrosine 549325 5248 450298 13236 21224, 29212, phosphatase receptor 37200, 45188, type f polypeptide 53176 (PTPRF) interacting

8464protein (liprin) alpha

84652

84665094 protein tyrosine 550584 5249 449558 13237 21225, 29213, phosphatase receptor 37201, 45189, type f polypeptide 53177 (PTPRF) interacting

8467protein (liprin) alpha

84682

84695095 protein tyrosine 552948 5250 447868 13238 21226, 29214, phosphatase receptor 37202, 45190, type f polypeptide 53178 (PTPRF) interacting

8470protein (liprin) alpha

84712 <img file="WO2013151663A1_D0017.tif" />

8472alpha 2 5110 protein tyrosine 541017 5265 445532 13253 21241, 29229, phosphatase, 37217, 45205, receptor type, f 53193 polypeptide

8473(PTPRF), interacting

8474protein (liprin),

8475alpha 2

84765111 protein tyrosine 541501 5266 439748 13254 21242, 29230, phosphatase, 37218, 45206, receptor type, f 53194 polypeptide

8477(PTPRF), interacting

8478protein (liprin),

8479alpha 2

84805112 protein tyrosine 547623 5267 447918 13255 21243, 29231, phosphatase, 37219, 45207, receptor type, f 53195 polypeptide

8481(PTPRF), interacting

8482protein (liprin),

8483alpha 2

84845113 protein tyrosine 549396 5268 450337 13256 21244, 29232, phosphatase, 37220, 45208, receptor type, f 53196 polypeptide

8485(PTPRF), interacting

8486protein (liprin),

8487alpha 2

84885114 protein tyrosine 283228 5269 283228 13257 21245, 29233, phosphatase, 37221, 45209, receptor type, R 53197

84895115 protein tyrosine 378778 5270 368054 13258 21246, 29234, phosphatase, 37222, 45210, receptor type, R 53198

84905116 protein tyrosine 440835 5271 391750 13259 21247, 29235, phosphatase, 37223, 45211, receptor type, R 53199

84915117 protein tyrosine 549308 5272 446943 13260 21248, 29236, phosphatase, 37224, 45212, receptor type, R 53200

84925118 protein tyrosine 550661 5273 449616 13261 21249, 29237, phosphatase, 37225, 45213, receptor type, R 53201

84935119 protein tyrosine 356100 5274 348408 13262 21250, 29238, phosphatase, 37226, 45214, receptor type, T 53202

84945120 protein tyrosine 373184 5275 362280 13263 21251, 29239, phosphatase, 37227, 45215, receptor type, T 53203

84955121 protein tyrosine 373187 5276 362283 13264 21252, 29240, phosphatase, 37228, 45216, receptor type, T 53204

84965122 protein tyrosine 373190 5277 362286 13265 21253, 29241, phosphatase, 37229, 45217, receptor type, T 53205 5123 protein tyrosine 373193 5278 362289 13266 21254, 29242, phosphatase, 37230, 45218, receptor type, T 53206

84975124 protein tyrosine 373198 5279 362294 13267 21255, 29243, phosphatase, 37231, 45219, receptor type, T 53207

84985125 protein tyrosine 373201 5280 362297 13268 21256, 29244, phosphatase, 37232, 45220, receptor type, T 53208

84995126 protein tyrosine 383657 5281 373153 13269 21257, 29245, phosphatase-like 37233, 45221, (proline instead of 53209 catalytic arginine),

8500member b

85015127 protein tyrosine 261875 5282 261875 13270 21258, 29246, phosphatase-like A 37234, 45222, domain containing 1 53210

85025128 protein tyrosine 495827 5283 419503 13271 21259, 29247, phosphatase-like A 37235, 45223, domain containing 2 53211

85035129 protein tyrosine 513293 5284 426475 13272 21260, 29248, phosphatase-like A 37236, 45224, domain containing 2 53212

85045130 protocadherin alpha 356878 5285 349344 13273 21261, 29249, 4 37237, 45225,

850553213

85065131 protocadherin alpha 512229 5286 423470 13274 21262, 29250, 4 37238, 45226,

850753214

85085132 protocadherin alpha 530339 5287 435300 13275 21263, 29251, 4 37239, 45227,

850953215

85105133 protocadherin beta 239446 5288 239446 13276 21264, 29252, 10 37240, 45228,

851153216

85125134 Protocadherin- 539533 5289 438685 13277 21265, 29253, psi 1 Uncharacterized 37241, 45229, protein 53217

85135135 prune homolog 271619 5290 271619 13278 21266, 29254, (Drosophila) 37242, 45230,

851453218

85155136 prune homolog 271620 5291 271620 13279 21267, 29255, (Drosophila) 37243, 45231,

851653219

85175137 prune homolog 302413 5292 302092 13280 21268, 29256, (Drosophila) 37244, 45232,

851853220

85195138 prune homolog 368934 5293 357930 13281 21269, 29257, (Drosophila) 37245, 45233,

852053221

85215139 prune homolog 368935 5294 357931 13282 21270, 29258, (Drosophila) 37246, 45234,

852253222 <img file="WO2013151663A1_D0018.tif" /> 5155 purinergic receptor 345901 5310 342161 13298 21286, 29274, P2X ligand-gated 37262, 45250, ion channel 5 53238

85235156 purinergic receptor 401443 5311 385309 13299 21287, 29275, P2X ligand-gated 37263, 45251, ion channel 6 53239

85245157 purinergic receptor 343948 5312 343339 13300 21288, 29276, P2X, ligand-gated 37264, 45252, ion channel, 2 53240

85255158 purinergic receptor 348800 5313 345095 13301 21289, 29277, P2X, ligand-gated 37265, 45253, ion channel, 2 53241

85265159 purinergic receptor 350048 5314 343904 13302 21290, 29278, P2X, ligand-gated 37266, 45254, ion channel, 2 53242

85275160 purinergic receptor 351222 5315 344502 13303 21291, 29279, P2X, ligand-gated 37267, 45255, ion channel, 2 53243

85285161 purinergic receptor 352418 5316 341419 13304 21292, 29280, P2X, ligand-gated 37268, 45256, ion channel, 2 53244

85295162 purinergic receptor 389110 5317 373762 13305 21293, 29281, P2X, ligand-gated 37269, 45257, ion channel, 2 53245

85305163 purinergic receptor 449132 5318 405531 13306 21294, 29282, P2X, ligand-gated 37270, 45258, ion channel, 2 53246

85315164 purinergic receptor 225328 5319 225328 13307 21295, 29283, P2X, ligand-gated 37271, 45259, ion channel, 5 53247

85325165 purinergic receptor 435558 5320 415370 13308 21296, 29284, P2X, ligand-gated 37272, 45260, ion channel, 5 53248

85335166 purinergic receptor 547178 5321 448355 13309 21297, 29285, P2X, ligand-gated 37273, 45261, ion channel, 5 53249

85345167 purinergic receptor 551178 5322 447545 13310 21298, 29286, P2X, ligand-gated 37274, 45262, ion channel, 5 53250

85355168 purinergic receptor 552050 5323 450006 13311 21299, 29287, P2X, ligand-gated 37275, 45263, ion channel, 5 53251

85365169 purinergic receptor 336296 5324 338797 13312 21300, 29288, P2X, ligand-gated 37276, 45264, ion channel, 6 53252

85375170 purinergic receptor 402329 5325 383997 13313 21301, 29289, P2X, ligand-gated 37277, 45265, ion channel, 6 53253

85385171 purinergic receptor 413302 5326 416193 13314 21302, 29290, P2X, ligand-gated 37278, 45266, ion channel, 6 53254

85395172 purinergic receptor 442475 5327 401192 13315 21303, 29291, P2X, ligand-gated 37279, 45267, ion channel, 6 53255 5173 purinergic receptor 443995 5328 408088 13316 21304, 29292, P2X, ligand-gated 37280, 45268, ion channel, 6 53256

85405174 purinergic receptor 171757 5329 171757 13317 21305, 29293, P2Y, G-protein 37281, 45269, coupled, 10 53257

85415175 purinergic receptor 544091 5330 443138 13318 21306, 29294, P2Y, G-protein 37282, 45270, coupled, 10 53258

85425176 purinergic receptor 325602 5331 320376 13319 21307, 29295, P2Y, G-protein 37283, 45271, coupled, 13 53259

85435177 purinergic receptor 309170 5332 308361 13320 21308, 29296, P2Y, G-protein 37284, 45272, coupled, 14 53260

85445178 purinergic receptor 424796 5333 408733 13321 21309, 29297, P2Y, G-protein 37285, 45273, coupled, 14 53261

85455179 purinergic receptor 494668 5334 418065 13322 21310, 29298, P2Y, G-protein 37286, 45274, coupled, 14 53262

85465180 putative 248550 5335 248550 13323 21311, 29299, homeodomain 37287, 45275, transcription factor 2 53263

85475181 putative 275575 5336 275575 13324 21312, 29300, homeodomain 37288, 45276, transcription factor 2 53264

85485182 putative 307305 5337 307699 13325 21313, 29301, homeodomain 37289, 45277, transcription factor 2 53265

85495183 putative 416283 5338 400958 13326 21314, 29302, homeodomain 37290, 45278, transcription factor 2 53266

85505184 putative 422959 5339 403042 13327 21315, 29303, homeodomain 37291, 45279, transcription factor 2 53267

85515185 putative 427986 5340 415496 13328 21316, 29304, homeodomain 37292, 45280, transcription factor 2 53268

85525186 putative 415251 5341 408035 13329 21317, 29305, homeodomain 37293, 45281, transcription factor 2 53269

85535187 putative 450574 5342 387355 13330 21318, 29306, homeodomain 37294, 45282, transcription factor 2 53270

85545188 Putative maltase- 550469 5343 447431 13331 21319, 29307, glucoamylase-like 37295, 45283, protein LOC93432 53271

85555189 Putative maltase- 550494 5344 448551 13332 21320, 29308, glucoamylase-like 37296, 45284, protein LOC93432 53272

85565190 Putative NPIP-like 342168 5345 441680 13333 21321, 29309, protein 37297, 45285,

8557LOCI 00132247 53273 5191 Putative NPIP-like 344223 5346 440432 13334 21322, 29310, protein 37298, 45286,

LOCI 00132247 53274

85595192 Putative NPIP-like 424340 5347 440703 13335 21323, 29311, protein 37299, 45287,

LOCI 00132247 53275

85615193 Putative NPIP-like 446615 5348 437919 13336 21324, 29312, protein 37300, 45288,

LOCI 00132247 53276

85635194 Putative NPIP-like 457705 5349 446325 13337 21325, 29313, protein 37301, 45289,

LOCI 00132247 53277

85655195 Putative NPIP-like 503072 5350 426452 13338 21326, 29314, protein 37302, 45290,

LOCI 00132247 53278

85675196 Putative NPIP-like 517539 5351 430633 13339 21327, 29315, protein 37303, 45291,

LOCI 00132247 53279

85695197 Putative 398633 5352 381630 13340 21328, 29316, transmembrane 37304, 45292, protein C8orfK29 53280

85705198 Putative 531225 5353 436572 13341 21329, 29317, transmembrane 37305, 45293, protein C8orfK29 53281

85715199 Putative 397764 5354 380871 13342 21330, 29318, transmembrane 37306, 45294, protein LOC401397 53282

85725200 Putative 413744 5355 410731 13343 21331, 29319, transmembrane 37307, 45295, protein LOC401397 53283

85735201 Putative 441359 5356 405021 13344 21332, 29320, transmembrane 37308, 45296, protein LOC401397 53284

85745202 pyridoxal 215904 5357 215904 13345 21333, 29321,

8575(pyridoxine, vitamin 37309, 45297, B6) phosphatase 53285

85765203 pyridoxal 403251 5358 385336 13346 21334, 29322,

8577(pyridoxine, vitamin 37310, 45298, B6) phosphatase 53286

85785204 pyroglutamylated 394427 5359 377948 13347 21335, 29323, PvF amide peptide 37311, 45299, receptor 53287

85795205 pyruvate 430469 5360 415695 13348 21336, 29324, dehydrogenase 37312, 45300, complex component 53288 X

85805206 pyruvate 227868 5361 227868 13349 21337, 29325, dehydrogenase 37313, 45301, complex, component 53289 X

85815207 pyruvate 448838 5362 389404 13350 21338, 29326, dehydrogenase 37314, 45302, complex, component 53290 X 5208 pyruvate 379162 5363 368460 13351 21339, 29327, dehydrogenase 37315, 45303, kinase, isozyme 3 53291

85825209 pyruvate 441463 5364 387536 13352 21340, 29328, dehydrogenase 37316, 45304, kinase, isozyme 3 53292

85835210 pyruvate 311765 5365 309548 13353 21341, 29329, dehyrogenase 37317, 45305, phosphatase 53293 catalytic subunit 2

85845211 QKI, KH domain 275262 5366 275262 13354 21342, 29330, containing, RNA 37318, 45306, binding 53294

85855212 QKI, KH domain 361195 5367 354867 13355 21343, 29331, containing, RNA 37319, 45307, binding 53295

85865213 QKI, KH domain 361752 5368 355094 13356 21344, 29332, containing, RNA 37320, 45308, binding 53296

85875214 QKI, KH domain 392127 5369 375973 13357 21345, 29333, containing, RNA 37321, 45309, binding 53297

85885215 QKI, KH domain 453779 5370 408775 13358 21346, 29334, containing, RNA 37322, 45310, binding 53298

85895216 Rab acceptor 1 222008 5371 222008 13359 21347, 29335, (prenylated) 37323, 45311,

859053299

85915217 RAB11 family 258098 5372 258098 13360 21348, 29336, interacting protein 5 37324, 45312, (class I) 53300

85925218 RABl IB, member 328024 5373 333547 13361 21349, 29337, RAS oncogene 37325, 45313, family 53301

85935219 RAB 15, member 267512 5374 267512 13362 21350, 29338, RAS onocogene 37326, 45314, family 53302

85945220 RAB 15, member 533601 5375 434103 13363 21351, 29339, RAS onocogene 37327, 45315, family 53303

85955221 RAB 19, member 275874 5376 275874 13364 21352, 29340, RAS oncogene 37328, 45316, family 53304

85965222 RAB 19, member 356407 5377 348778 13365 21353, 29341, RAS oncogene 37329, 45317, family 53305

85975223 RAB 19, member 495590 5378 420782 13366 21354, 29342, RAS oncogene 37330, 45318, family 53306

85985224 RAB 19, member 537763 5379 440167 13367 21355, 29343, RAS oncogene 37331, 45319, family 53307

85995225 RAB20, member 267328 5380 267328 13368 21356, 29344, RAS oncogene 37332, 45320, family 53308 5226 RAB27B, member 262094 5381 262094 13369 21357, 29345, RAS oncogene 37333, 45321, family 53309

86005227 RAB39A, member 320578 5382 322594 13370 21358, 29346, RAS oncogene 37334, 45322, family 53310

86015228 RAB3D, member 222120 5383 222120 13371 21359, 29347, RAS oncogene 37335, 45323, family 53311

86025229 RAB40A, member 304236 5384 305648 13372 21360, 29348, RAS oncogene 37336, 45324, family 53312

86035230 RAB40A, member 372633 5385 361716 13373 21361, 29349, RAS oncogene 37337, 45325, family 53313

86045231 RAB40B member 571995 5386 461785 13374 21362, 29350, RAS oncogene 37338, 45326, family 53314

86055232 RAB40B, member 269347 5387 269347 13375 21363, 29351, RAS oncogene 37339, 45327, family 53315

86065233 RAB40B, member 538809 5388 438897 13376 21364, 29352, RAS oncogene 37340, 45328, family 53316

86075234 RAB40C, member 248139 5389 248139 13377 21365, 29353, RAS oncogene 37341, 45329, family 53317

86085235 RAB40C, member 535977 5390 438492 13378 21366, 29354, RAS oncogene 37342, 45330, family 53318

86095236 RAB40C, member 538492 5391 438382 13379 21367, 29355, RAS oncogene 37343, 45331, family 53319

86105237 RAB40C, member 539661 5392 445050 13380 21368, 29356, RAS oncogene 37344, 45332, family 53320

86115238 RAB43 member 476465 5393 427632 13381 21369, 29357, RAS oncogene 37345, 45333, family 53321

86125239 RAB43, member 315150 5394 319781 13382 21370, 29358, RAS oncogene 37346, 45334, family 53322

86135240 RAB43, member 393304 5395 376981 13383 21371, 29359, RAS oncogene 37347, 45335, family 53323

86145241 RAB43, member 393305 5396 376982 13384 21372, 29360, RAS oncogene 37348, 45336, family 53324

86155242 RAB43, member 393307 5397 376984 13385 21373, 29361, RAS oncogene 37349, 45337, family 53325

86165243 RAB43, member 393308 5398 376985 13386 21374, 29362, RAS oncogene 37350, 45338, family 53326 5244 RAB43, member 457077 5399 390782 13387 21375, 29363, RAS oncogene 37351, 45339, family 53327

86175245 RAB8B, member 321437 5400 312734 13388 21376, 29364, RAS oncogene 37352, 45340, family 53328

86185246 RAB8B, member 448330 5401 405463 13389 21377, 29365, RAS oncogene 37353, 45341, family 53329

86195247 Rab9 effector 259460 5402 259460 13390 21378, 29366, protein with kelch 37354, 45342, motifs 53330

86205248 Rab9 effector 373538 5403 362639 13391 21379, 29367, protein with kelch 37355, 45343, motifs 53331

86215249 Rab9 effector 373544 5404 362645 13392 21380, 29368, protein with kelch 37356, 45344, motifs 53332

86225250 Rab9 effector 394124 5405 377682 13393 21381, 29369, protein with kelch 37357, 45345, motifs 53333

86235251 Rab9 effector 394125 5406 377683 13394 21382, 29370, protein with kelch 37358, 45346, motifs 53334

86245252 Rab9 effector 416065 5407 402234 13395 21383, 29371, protein with kelch 37359, 45347, motifs 53335

86255253 RAB9A, member 464506 5408 420127 13396 21384, 29372, RAS oncogene 37360, 45348, family 53336

86265254 raftlin family 295049 5409 295049 13397 21385, 29373, member 2 37361, 45349,

862753337

86285255 raftlin, lipid raft 334133 5410 334153 13398 21386, 29374, linker 1 37362, 45350,

862953338

86305256 raftlin, lipid raft 431547 5411 393216 13399 21387, 29375, linker 1 37363, 45351,

863153339

86325257 raftlin, lipid raft 441460 5412 388718 13400 21388, 29376, linker 1 37364, 45352,

863353340

86345258 raftlin, lipid raft 449415 5413 409427 13401 21389, 29377, linker 1 37365, 45353,

863553341

86365259 raftlin, lipid raft 451036 5414 403997 13402 21390, 29378, linker 1 37366, 45354,

863753342

86385260 Ral GEF with PH 324778 5415 313613 13403 21391, 29379, domain and SH3 37367, 45355, binding motif 2 53343

86395261 Ral GEF with PH 367634 5416 356606 13404 21392, 29380, domain and SH3 37368, 45356, binding motif 2 53344 5262 Ral GEF with PH 367635 5417 356607 13405 21393, 29381, domain and SH3 37369, 45357, binding motif 2 53345

86405263 Ral GEF with PH 535251 5418 445104 13406 21394, 29382, domain and SH3 37370, 45358, binding motif 2 53346

86415264 RALBP1 associated 258062 5419 258062 13407 21395, 29383, Eps domain 37371, 45359, containing 1 53347

86425265 RALBP1 associated 367663 5420 356635 13408 21396, 29384, Eps domain 37372, 45360, containing 1 53348

86435266 RALBP1 associated 367668 5421 356640 13409 21397, 29385, Eps domain 37373, 45361, containing 1 53349

86445267 RALBP1 associated 409812 5422 386699 13410 21398, 29386, Eps domain 37374, 45362, containing 1 53350

86455268 RALBP1 associated 450536 5423 392065 13411 21399, 29387, Eps domain 37375, 45363, containing 1 53351

86465269 RALBP1 associated 530255 5424 435131 13412 21400, 29388, Eps domain 37376, 45364, containing 1 53352

86475270 RAN binding 296604 5425 296604 13413 21401, 29389, protein 3 -like 37377, 45365,

864853353

86495271 RAN binding 505865 5426 427147 13414 21402, 29390, protein 3 -like 37378, 45366,

865053354

86515272 RAN binding 502994 5427 421853 13415 21403, 29391, protein 3 -like 37379, 45367,

865253355

86535273 Rap guanine 264431 5428 264431 13416 21404, 29392, nucleotide exchange 37380, 45368, factor (GEF) 2 53356

86545274 Rap guanine 171000 5429 171000 13417 21405, 29393, nucleotide exchange 37381, 45369, factor (GEF) 3 53357

86555275 Rap guanine 389211 5430 373863 13418 21406, 29394, nucleotide exchange 37382, 45370, factor (GEF) 3 53358

86565276 Rap guanine 389212 5431 373864 13419 21407, 29395, nucleotide exchange 37383, 45371, factor (GEF) 3 53359

86575277 Rap guanine 395358 5432 378764 13420 21408, 29396, nucleotide exchange 37384, 45372, factor (GEF) 3 53360

86585278 Rap guanine 397089 5433 380278 13421 21409, 29397, nucleotide exchange 37385, 45373, factor (GEF) 3 53361

86595279 Rap guanine 405493 5434 384521 13422 21410, 29398, nucleotide exchange 37386, 45374, factor (GEF) 3 53362 5280 Rap guanine 449771 5435 395708 13423 21411, 29399, nucleotide exchange 37387, 45375, factor (GEF) 3 53363

86605281 Rap guanine 466322 5436 446731 13424 21412, 29400, nucleotide exchange 37388, 45376, factor (GEF) 3 53364

86615282 Rap guanine 495953 5437 448804 13425 21413, 29401, nucleotide exchange 37389, 45377, factor (GEF) 3 53365

86625283 Rap guanine 541821 5438 438798 13426 21414, 29402, nucleotide exchange 37390, 45378, factor (GEF) 3 53366

86635284 Rap guanine 549151 5439 448619 13427 21415, 29403, nucleotide exchange 37391, 45379, factor (GEF) 3 53367

86645285 Rap guanine 264111 5440 264111 13428 21416, 29404, nucleotide exchange 37392, 45380, factor (GEF) 4 53368

86655286 Rap guanine 397081 5441 380271 13429 21417, 29405, nucleotide exchange 37393, 45381, factor (GEF) 4 53369

86665287 Rap guanine 397087 5442 380276 13430 21418, 29406, nucleotide exchange 37394, 45382, factor (GEF) 4 53370

86675288 Rap guanine 409036 5443 387104 13431 21419, 29407, nucleotide exchange 37395, 45383, factor (GEF) 4 53371

86685289 Rap guanine 535187 5444 438011 13432 21420, 29408, nucleotide exchange 37396, 45384, factor (GEF) 4 53372

86695290 Rap guanine 538974 5445 440135 13433 21421, 29409, nucleotide exchange 37397, 45385, factor (GEF) 4 53373

86705291 Rap guanine 539331 5446 437384 13434 21422, 29410, nucleotide exchange 37398, 45386, factor (GEF) 4 53374

86715292 Rap guanine 539767 5447 443231 13435 21423, 29411, nucleotide exchange 37399, 45387, factor (GEF) 4 53375

86725293 Rap guanine 540783 5448 440250 13436 21424, 29412, nucleotide exchange 37400, 45388, factor (GEF) 4 53376

86735294 RAP2B, member of 323534 5449 319096 13437 21425, 29413, RAS oncogene 37401, 45389, family 53377

86745295 RAP2C, member of 342983 5450 340274 13438 21426, 29414, RAS oncogene 37402, 45390, family 53378

86755296 RAP2C, member of 370874 5451 359911 13439 21427, 29415, RAS oncogene 37403, 45391, family 53379

86765297 RAS (RAD and 267396 5452 267396 13440 21428, 29416, GEM)-like GTP 37404, 45392, binding 2 53380 5298 RAS (RAD and 536884 5453 442774 13441 21429, 29417, GEM)-like GTP 37405, 45393, binding 2 53381

86775299 RAS (RAD and 201979 5454 201979 13442 21430, 29418, GEM)-like GTP- 37406, 45394, binding 1 53382

86785300 Ras and Rab 311320 5455 310406 13443 21431, 29419, interactor 1 37407, 45395,

867953383

86805301 Ras and Rab 424433 5456 400560 13444 21432, 29420, interactor 1 37408, 45396,

868153384

86825302 Ras association 308091 5457 311293 13445 21433, 29421, (RalGDS/AF-6) and 37409, 45397, pleckstrin homology 53385 domains 1

86835303 Ras association 319170 5458 316543 13446 21434, 29422, (RalGDS/AF-6) and 37410, 45398, pleckstrin homology 53386 domains 1

86845304 Ras association 374488 5459 363612 13447 21435, 29423, (RalGDS/AF-6) and 37411, 45399, pleckstrin homology 53387 domains 1

86855305 Ras association 374489 5460 363613 13448 21436, 29424, (RalGDS/AF-6) and 37412, 45400, pleckstrin homology 53388 domains 1

86865306 Ras association 374493 5461 363617 13449 21437, 29425, (RalGDS/AF-6) and 37413, 45401, pleckstrin homology 53389 domains 1

86875307 Ras association 413201 5462 394454 13450 21438, 29426, (RalGDS/AF-6) and 37414, 45402, pleckstrin homology 53390 domains 1

86885308 Ras association 418114 5463 396711 13451 21439, 29427, (RalGDS/AF-6) and 37415, 45403, pleckstrin homology 53391 domains 1

86895309 Ras association 419464 5464 390578 13452 21440, 29428, (RalGDS/AF-6) and 37416, 45404, pleckstrin homology 53392 domains 1

86905310 Ras association 420371 5465 412241 13453 21441, 29429, (RalGDS/AF-6) and 37417, 45405, pleckstrin homology 53393 domains 1

86915311 Ras association 423104 5466 397751 13454 21442, 29430, (RalGDS/AF-6) and 37418, 45406, pleckstrin homology 53394 domains 1

86925312 Ras association 428637 5467 414430 13455 21443, 29431, (RalGDS/AF-6) and 37419, 45407, pleckstrin homology 53395 domains 1

86935313 Ras association 432342 5468 415364 13456 21444, 29432, (RalGDS/AF-6) and 37420, 45408, pleckstrin homology 53396 domains 1

86945314 Ras association 439222 5469 411138 13457 21445, 29433, (RalGDS/AF-6) and 37421, 45409, pleckstrin homology 53397 domains 1

86955315 Ras association 453034 5470 406662 13458 21446, 29434, (RalGDS/AF-6) and 37422, 45410, pleckstrin homology 53398 domains 1

86965316 RAS guanyl 402538 5471 385886 13459 21447, 29435, releasing protein 3 37423, 45411, (calcium and DAG- 53399 regulated)

86975317 RAS guanyl 403687 5472 384192 13460 21448, 29436, releasing protein 3 37424, 45412, (calcium and DAG- 53400 regulated)

86985318 RAS guanyl 407811 5473 383917 13461 21449, 29437, releasing protein 3 37425, 45413, (calcium and DAG- 53401 regulated)

86995319 RAS guanyl 423159 5474 388139 13462 21450, 29438, releasing protein 3 37426, 45414, (calcium and DAG- 53402 regulated)

87005320 RAS guanyl 425210 5475 401974 13463 21451, 29439, releasing protein 3 37427, 45415, (calcium and DAG- 53403 regulated)

87015321 RAS guanyl 437184 5476 393866 13464 21452, 29440, releasing protein 3 37428, 45416, (calcium and DAG- 53404 regulated)

87025322 RAS guanyl 442390 5477 405648 13465 21453, 29441, releasing protein 3 37429, 45417, (calcium and DAG- 53405 regulated)

87035323 RAS guanyl 444784 5478 400602 13466 21454, 29442, releasing protein 3 37430, 45418, (calcium and DAG- 53406 regulated)

87045324 Ras homolog 301068 5479 301068 13467 21455, 29443, enriched in brain 37431, 45419, like 1 53407

87055325 ras homolog gene 308831 5480 308576 13468 21456, 29444, family, member D 37432, 45420,

870653408

87075326 ras homolog gene 267205 5481 267205 13469 21457, 29445, family, member F 37433, 45421, <img file="WO2013151663A1_D0019.tif" /> 5344 RAS protein 448150 5499 407768 13487 21475, 29463, activator like 2 37451, 45439,

870853427

87095345 RAS protein 462775 5500 420558 13488 21476, 29464, activator like 2 37452, 45440,

871053428

87115346 RAS protein 343625 5501 341905 13489 21477, 29465, activator like 3 37453, 45441,

871253429

87135347 Ras-like without 368322 5502 357305 13490 21478, 29466, CAAX 1 37454, 45442,

871453430

87155348 Ras-like without 368323 5503 357306 13491 21479, 29467, CAAX 1 37455, 45443,

871653431

87175349 Ras-like without 539040 5504 441950 13492 21480, 29468, CAAX 1 37456, 45444,

871853432

87195350 Ras-like without 282028 5505 282028 13493 21481, 29469, CAAX 2 37457, 45445,

872053433

87215351 Ras-like without 326695 5506 321805 13494 21482, 29470, CAAX 2 37458, 45446,

872253434

87235352 reactive oxygen 336695 5507 338293 13495 21483, 29471, species modulator 1 37459, 45447,

872453435

87255353 reactive oxygen 374077 5508 363190 13496 21484, 29472, species modulator 1 37460, 45448,

872653436

87275354 reactive oxygen 374078 5509 363191 13497 21485, 29473, species modulator 1 37461, 45449,

872853437

87295355 reactive oxygen 397416 5510 380561 13498 21486, 29474, species modulator 1 37462, 45450,

873053438

87315356 receptor 312295 5511 311712 13499 21487, 29475, (chemosensory) 37463, 45451, transporter protein 1 53439

87325357 receptor 358241 5512 350976 13500 21488, 29476, (chemosensory) 37464, 45452, transporter protein 2 53440

87335358 receptor (TNFRSF)- 259808 5513 259808 13501 21489, 29477, interacting serine- 37465, 45453, threonine kinase 1 53441

87345359 receptor (TNFRSF)- 380409 5514 369773 13502 21490, 29478, interacting serine- 37466, 45454, threonine kinase 1 53442

87355360 receptor (TNFRSF)- 453483 5515 415981 13503 21491, 29479, interacting serine- 37467, 45455, threonine kinase 1 53443

87365361 receptor (TNFRSF)- 541791 5516 442294 13504 21492, 29480, interacting serine- 37468, 45456, threonine kinase 1 53444 5362 regulator of G- 369101 5517 358097 13505 21493, 29481, protein signaling 10 37469, 45457,

873753445

87385363 regulator of G- 369103 5518 358099 13506 21494, 29482, protein signaling 10 37470, 45458,

873953446

87405364 regulator of G- 392865 5519 376605 13507 21495, 29483, protein signaling 10 37471, 45459,

874153447

87425365 regulator of G- 316163 5520 319069 13508 21496, 29484, protein signaling 11 37472, 45460,

874353448

87445366 regulator of G- 397768 5521 380874 13509 21497, 29485, protein signaling 11 37473, 45461,

874553449

87465367 regulator of G- 397770 5522 380876 13510 21498, 29486, protein signaling 11 37474, 45462,

874753450

87485368 regulator of G- 431291 5523 411215 13511 21499, 29487, protein signaling 11 37475, 45463,

874953451

87505369 regulator of G- 391995 5524 375853 13512 21500, 29488, protein signaling 13 37476, 45464,

875153452

87525370 regulator of G- 543215 5525 442837 13513 21501, 29489, protein signaling 13 37477, 45465,

875353453

87545371 regulator of G- 206262 5526 206262 13514 21502, 29490, protein signaling 17 37478, 45466,

875553454

87565372 regulator of G- 367225 5527 356194 13515 21503, 29491, protein signaling 17 37479, 45467,

875753455

87585373 regulator of G- 367460 5528 356430 13516 21504, 29492, protein signaling 18 37480, 45468,

875953456

87605374 regulator of G- 332298 5529 333194 13517 21505, 29493, protein signaling 19 37481, 45469,

876153457

87625375 regulator of G- 395042 5530 378483 13518 21506, 29494, protein signaling 19 37482, 45470,

876353458

87645376 regulator of G- 276500 5531 276500 13519 21507, 29495, protein signaling 20 37483, 45471,

876553459

87665377 regulator of G- 297313 5532 297313 13520 21508, 29496, protein signaling 20 37484, 45472,

876753460

87685378 regulator of G- 360863 5533 354109 13521 21509, 29497, protein signaling 22 37485, 45473,

876953461

87705379 regulator of G- 427793 5534 389751 13522 21510, 29498, protein signaling 22 37486, 45474,

877153462 5380 regulator of G- 258302 5535 258302 13523 21511, 29499, protein signaling 8 37487, 45475,

877253463

87735381 regulator of G- 367556 5536 356527 13524 21512, 29500, protein signaling 8 37488, 45476,

877453464

87755382 regulator of G- 367557 5537 356528 13525 21513, 29501, protein signaling 8 37489, 45477,

877653465

87775383 regulator of G- 483095 5538 426289 13526 21514, 29502, protein signaling 8 37490, 45478,

877853466

87795384 regulator of G- 508450 5539 427076 13527 21515, 29503, protein signaling 8 37491, 45479,

878053467

87815385 relaxin/insulin-like 307765 5540 303248 13528 21516, 29504, family peptide 37492, 45480, receptor 1 53468

87825386 relaxin/insulin-like 423548 5541 405841 13529 21517, 29505, family peptide 37493, 45481, receptor 1 53469

87835387 relaxin/insulin-like 440678 5542 402226 13530 21518, 29506, family peptide 37494, 45482, receptor 1 53470

87845388 relaxin/insulin-like 448688 5543 414885 13531 21519, 29507, family peptide 37495, 45483, receptor 1 53471

87855389 relaxin/insulin-like 342048 5544 432036 13532 21520, 29508, family peptide 37496, 45484, receptor 1 53472

87865390 relaxin/insulin-like 298386 5545 298386 13533 21521, 29509, family peptide 37497, 45485, receptor 2 53473

87875391 relaxin/insulin-like 380314 5546 369670 13534 21522, 29510, family peptide 37498, 45486, receptor 2 53474

87885392 relaxin/insulin-like 330120 5547 328708 13535 21523, 29511, family peptide 37499, 45487, receptor 3 53475

87895393 relaxin/insulin-like 368318 5548 357301 13536 21524, 29512, family peptide 37500, 45488, receptor 4 53476

87905394 RELT-like 1 314117 5549 313385 13537 21525, 29513,

879137501, 45489, 53477

87925395 RELT-like 1 454158 5550 398778 13538 21526, 29514,

879337502, 45490, 53478

87945396 reprimo-like 322329 5551 318032 13539 21527, 29515,

879537503, 45491, 53479

87965397 required for meiotic 336451 5552 336683 13540 21528, 29516, nuclear division 1 37504, 45492, homolog (S. 53480 cerevisiae) 5398 required for meiotic 367299 5553 356268 13541 21529, 29517, nuclear division 1 37505, 45493, homolog (S. 53481 cerevisiae)

87975399 required for meiotic 367303 5554 356272 13542 21530, 29518, nuclear division 1 37506, 45494, homolog (S. 53482 cerevisiae)

87985400 required for meiotic 444024 5555 412708 13543 21531, 29519, nuclear division 1 37507, 45495, homolog (S. 53483 cerevisiae)

87995401 REM retention in 306256 5556 302088 13544 21532, 29520, endoplasmic 37508, 45496, reticulum 1 homolog 53484 (S. cerevisiae)

88005402 REM retention in 378512 5557 367773 13545 21533, 29521, endoplasmic 37509, 45497, reticulum 1 homolog 53485 (S. cerevisiae)

88015403 RERl retention in 378513 5558 367774 13546 21534, 29522, endoplasmic 37510, 45498, reticulum 1 homolog 53486 (S. cerevisiae)

88025404 RERl retention in 378518 5559 367779 13547 21535, 29523, endoplasmic 37511, 45499, reticulum 1 homolog 53487 (S. cerevisiae)

88035405 RERl retention in 434662 5560 396797 13548 21536, 29524, endoplasmic 37512, 45500, reticulum 1 homolog 53488 (S. cerevisiae)

88045406 RERl retention in 443438 5561 417000 13549 21537, 29525, endoplasmic 37513, 45501, reticulum 1 homolog 53489 (S. cerevisiae)

88055407 resistance to 309737 5562 308820 13550 21538, 29526, inhibitors of 37514, 45502, choline sterase 3 53490 homolog (C.

8806elegans)

88075408 resistance to 335425 5563 333988 13551 21539, 29527, inhibitors of 37515, 45503, choline sterase 3 53491 homolog (C.

8808elegans)

88095409 resistance to 343202 5564 344904 13552 21540, 29528, inhibitors of 37516, 45504, choline sterase 3 53492 homolog (C.

8810elegans)

88115410 resistance to 396677 5565 379910 13553 21541, 29529, inhibitors of 37517, 45505, choline sterase 3 53493 homolog (C. elegans)

88125411 resistance to 419822 5566 404415 13554 21542, 29530, inhibitors of 37518, 45506, choline sterase 3 53494 homolog (C.

8813elegans)

88145412 resistance to 539720 5567 443871 13555 21543, 29531, inhibitors of 37519, 45507, choline sterase 3 53495 homolog (C.

8815elegans)

88165413 resistance to 543346 5568 442352 13556 21544, 29532, inhibitors of 37520, 45508, choline sterase 3 53496 homolog (C.

8817elegans)

88185414 resistance to 425599 5569 395320 13557 21545, 29533, inhibitors of 37521, 45509, choline sterase 3 53497 homolog (C.

8819elegans)

88205415 resistance to 325207 5570 325941 13558 21546, 29534, inhibitors of 37522, 45510, choline sterase 8 53498 homolog A (C.

8821elegans)

88225416 resistance to 526104 5571 432008 13559 21547, 29535, inhibitors of 37523, 45511, choline sterase 8 53499 homolog A (C.

8823elegans)

88245417 resistance to 355478 5572 347662 13560 21548, 29536, inhibitors of 37524, 45512, choline sterase 8 53500 homolog B (C.

8825elegans)

88265418 resistance to 392837 5573 376582 13561 21549, 29537, inhibitors of 37525, 45513, choline sterase 8 53501 homolog B (C.

8827elegans)

88285419 resistance to 392839 5574 376583 13562 21550, 29538, inhibitors of 37526, 45514, choline sterase 8 53502 homolog B (C.

8829elegans)

88305420 reticulocalbin 3, EF- 270645 5575 270645 13563 21551, 29539, hand calcium 37527, 45515, binding domain 53503

88315421 reticulon 4 receptor331238 5576 330631 13564 21552, 29540, like 1 37528, 45516,

883253504 <img file="WO2013151663A1_D0020.tif" /> 5440 Rho family GTPase 550607 5595 447059 13583 21571, 29559, 1 37547, 45535,

883353523

88345441 Rho family GTPase 225973 5596 225973 13584 21572, 29560, 2 37548, 45536,

883553524

88365442 Rho family GTPase 544533 5597 439328 13585 21573, 29561, 2 37549, 45537,

883753525

88385443 Rho family GTPase 587250 5598 466680 13586 21574, 29562, 2 37550, 45538,

883953526

88405444 Rho GTPase 310343 5599 310561 13587 21575, 29563, activating protein 32 37551, 45539,

884153527

88425445 Rho GTPase 356092 5600 348396 13588 21576, 29564, activating protein 32 37552, 45540,

884353528

88445446 Rho GTPase 457677 5601 416571 13589 21577, 29565, activating protein 32 37553, 45541,

884553529

88465447 Rho GTPase 527272 5602 432862 13590 21578, 29566, activating protein 32 37554, 45542,

884753530

88485448 Rho GTPase 350060 5603 203786 13591 21579, 29567, activating protein 4 37555, 45543,

884953531

88505449 Rho GTPase 370016 5604 359033 13592 21580, 29568, activating protein 4 37556, 45544,

885153532

88525450 Rho GTPase 370028 5605 359045 13593 21581, 29569, activating protein 4 37557, 45545,

885353533

88545451 Rho GTPase 393721 5606 377322 13594 21582, 29570, activating protein 4 37558, 45546,

885553534

88565452 Rho GTPase 537206 5607 444169 13595 21583, 29571, activating protein 4 37559, 45547,

885753535

88585453 Rho guanine 315174 5608 313470 13596 21584, 29572, nucleotide exchange 37560, 45548, factor (GEF) 11 53536

88595454 Rho guanine 361409 5609 354644 13597 21585, 29573, nucleotide exchange 37561, 45549, factor (GEF) 11 53537

88605455 Rho guanine 368194 5610 357177 13598 21586, 29574, nucleotide exchange 37562, 45550, factor (GEF) 11 53538

88615456 Rho guanine 286494 5611 286494 13599 21587, 29575, nucleotide exchange 37563, 45551, factor (GEF) 25 53539

88625457 Rho guanine 300189 5612 300189 13600 21588, 29576, nucleotide exchange 37564, 45552, factor (GEF) 25 53540 5458 Rho guanine 333972 5613 335560 13601 21589, 29577, nucleotide exchange 37565, 45553, factor (GEF) 25 53541

88635459 Rho-guanine 287898 5614 287898 13602 21590, 29578, nucleotide exchange 37566, 45554, factor 53542

88645460 Rho-guanine 296794 5615 296794 13603 21591, 29579, nucleotide exchange 37567, 45555, factor 53543

88655461 Rho-guanine 426542 5616 412175 13604 21592, 29580, nucleotide exchange 37568, 45556, factor 53544

88665462 Rho-guanine 509848 5617 421859 13605 21593, 29581, nucleotide exchange 37569, 45557, factor 53545

88675463 Rho-guanine 513042 5618 441436 13606 21594, 29582, nucleotide exchange 37570, 45558, factor 53546

88685464 Rho-guanine 545377 5619 441913 13607 21595, 29583, nucleotide exchange 37571, 45559, factor 53547

88695465 rhomboid domain 341329 5620 344779 13608 21596, 29584, containing 1 37572, 45560,

887053548

88715466 rhomboid domain 392062 5621 375914 13609 21597, 29585, containing 1 37573, 45561,

887253549

88735467 rhomboid domain 423616 5622 399694 13610 21598, 29586, containing 1 37574, 45562,

887453550

88755468 rhomboid domain 424132 5623 400765 13611 21599, 29587, containing 1 37575, 45563,

887653551

88775469 rhomboid domain 436481 5624 397298 13612 21600, 29588, containing 1 37576, 45564,

887853552

88795470 rhomboid domain 437454 5625 410384 13613 21601, 29589, containing 1 37577, 45565,

888053553

88815471 rhomboid domain 443477 5626 414801 13614 21602, 29590, containing 1 37578, 45566,

888253554

88835472 rhomboid domain 448992 5627 388847 13615 21603, 29591, containing 1 37579, 45567,

888453555

88855473 rhomboid domain 6777 5628 6777 13616 21604, 29592, containing 2 37580, 45568,

888653556, 56091, 56124

88875474 rhomboid domain 318622 5629 314144 13617 21605, 29593, containing 2 37581, 45569,

888853557

88895475 rhomboid domain 413229 5630 407074 13618 21606, 29594, containing 2 37582, 45570,

889053558 5476 rhomboid domain 428119 5631 391232 13619 21607, 29595, containing 2 37583, 45571,

889153559

88925477 rhomboid domain 216085 5632 216085 13620 21608, 29596, containing 3 37584, 45572,

889353560

88945478 rhomboid domain 406335 5633 384113 13621 21609, 29597, containing 3 37585, 45573,

889553561

88965479 rhomboid domain 414672 5634 413128 13622 21610, 29598, containing 3 37586, 45574,

889753562

88985480 rhomboid, veinlet- 219551 5635 219551 13623 21611, 29599, like 1 (Drosophila) 37587, 45575,

889953563

89005481 rhomboid, veinlet- 352681 5636 344206 13624 21612, 29600, like 1 (Drosophila) 37588, 45576,

890153564

89025482 rhomboid, veinlet- 450775 5637 401752 13625 21613, 29601, like 1 (Drosophila) 37589, 45577,

890353565

89045483 rhomboid, veinlet- 289248 5638 289248 13626 21614, 29602, like 2 (Drosophila) 37590, 45578,

890553566

89065484 rhomboid, veinlet- 372985 5639 362076 13627 21615, 29603, like 2 (Drosophila) 37591, 45579,

890753567

89085485 rhomboid, veinlet- 372990 5640 362081 13628 21616, 29604, like 2 (Drosophila) 37592, 45580,

890953568

89105486 rhomboid, veinlet- 538156 5641 439227 13629 21617, 29605, like 2 (Drosophila) 37593, 45581,

891153569

89125487 rhomboid, veinlet- 269051 5642 269051 13630 21618, 29606, like 3 (Drosophila) 37594, 45582,

891353570

89145488 rhomboid, veinlet- 431505 5643 394849 13631 21619, 29607, like 3 (Drosophila) 37595, 45583,

891553571

89165489 rhomboid, veinlet- 536287 5644 442289 13632 21620, 29608, like 3 (Drosophila) 37596, 45584,

891753572

89185490 rhomboid, veinlet- 538145 5645 442092 13633 21621, 29609, like 3 (Drosophila) 37597, 45585,

891953573

89205491 rhotekin 2 315289 5646 325379 13634 21622, 29610,

892137598, 45586, 53574

89225492 rhotekin 2 373789 5647 362894 13635 21623, 29611,

892337599, 45587, 53575

89245493 rhotekin 2 395260 5648 378678 13636 21624, 29612,

892537600, 45588, 53576 5494 rhotekin 2 395265 5649 378682 13637 21625, 29613,

892637601, 45589, 53577

89275495 ribonuclease, RNase 402093 5650 385440 13638 21626, 29614, K 37602, 45590,

892853578

89295496 ribonuclease, RNase 548577 5651 449500 13639 21627, 29615, K 37603, 45591,

893053579

89315497 ribosomal protein 272317 5652 272317 13640 21628, 29616, S27a 37604, 45592,

893253580

89335498 ribosomal protein 402285 5653 383981 13641 21629, 29617, S27a 37605, 45593,

893453581

89355499 ribosomal protein 404735 5654 385659 13642 21630, 29618, S27a 37606, 45594,

893653582

89375500 ribosomal protein 449323 5655 408482 13643 21631, 29619, S27a 37607, 45595,

893853583

89395501 ribosomal RNA 368216 5656 357199 13644 21632, 29620, adenine dimethylase 37608, 45596, domain containing 1 53584

89405502 ribosomal RNA 368218 5657 357201 13645 21633, 29621, adenine dimethylase 37609, 45597, domain containing 1 53585

89415503 ribosomal RNA 315563 5658 324315 13646 21634, 29622, processing 12 37610, 45598, homolog (S. 53586 cerevisiae)

89425504 ribosomal RNA 370992 5659 360031 13647 21635, 29623, processing 12 37611, 45599, homolog (S. 53587 cerevisiae)

89435505 ribosomal RNA 414986 5660 414863 13648 21636, 29624, processing 12 37612, 45600, homolog (S. 53588 cerevisiae)

89445506 ribosomal RNA 536831 5661 446184 13649 21637, 29625, processing 12 37613, 45601, homolog (S. 53589 cerevisiae)

89455507 ribosomal RNA 366932 5662 355899 13650 21638, 29626, processing 15 37614, 45602, homolog (S. 53590 cerevisiae)

89465508 ribosome binding 262197 5663 262197 13651 21639, 29627, factor A (putative) 37615, 45603,

894753591

89485509 ribosome binding 306735 5664 305696 13652 21640, 29628, factor A (putative) 37616, 45604,

894953592 5510 ring finger protein 237455 5665 237455 13653 21641, 29629, 103 37617, 45605,

895053593

89515511 ring finger protein 361756 5666 354571 13654 21642, 29630, 121 37618, 45606,

895253594

89535512 ring finger protein 545854 5667 443799 13655 21643, 29631, 121 37619, 45607,

895453595

89555513 ring finger protein 256257 5668 256257 13656 21644, 29632, 122 37620, 45608,

895653596

89575514 ring finger protein 344229 5669 341361 13657 21645, 29633, 13 37621, 45609,

895853597

89595515 ring finger protein 392894 5670 376628 13658 21646, 29634, 13 37622, 45610,

896053598

89615516 ring finger protein 459632 5671 419069 13659 21647, 29635, 13 37623, 45611,

896253599

89635517 ring finger protein 466478 5672 419508 13660 21648, 29636, 13 37624, 45612,

896453600

89655518 ring finger protein 466795 5673 417655 13661 21649, 29637, 13 37625, 45613,

896653601

89675519 ring finger protein 468648 5674 420067 13662 21650, 29638, 13 37626, 45614,

896853602

89695520 ring finger protein 470151 5675 419836 13663 21651, 29639, 13 37627, 45615,

897053603

89715521 ring finger protein 482539 5676 420691 13664 21652, 29640, 13 37628, 45616,

897253604

89735522 ring finger protein 543506 5677 442599 13665 21653, 29641, 13 37629, 45617,

897453605

89755523 ring finger protein 521389 5678 430237 13666 21654, 29642, 130 37630, 45618,

897653606

89775524 ring finger protein 340112 5679 344489 13667 21655, 29643, 133 37631, 45619,

897853607

89795525 ring finger protein 320892 5680 321330 13668 21656, 29644, 144 A 37632, 45620,

898053608

89815526 ring finger protein 416587 5681 414420 13669 21657, 29645, 144 A 37633, 45621,

898253609

89835527 ring finger protein 427092 5682 389017 13670 21658, 29646, 144 A 37634, 45622,

898453610 5528 ring finger protein 433456 5683 402645 13671 21659, 29647, 144 A 37635, 45623,

898553611

89865529 ring finger protein 259939 5684 259939 13672 21660, 29648, 144B 37636, 45624,

898753612

89885530 ring finger protein 429054 5685 411270 13673 21661, 29649, 144B 37637, 45625,

898953613

89905531 ring finger protein 274542 5686 274542 13674 21662, 29650, 145 37638, 45626,

899153614

89925532 ring finger protein 413445 5687 445115 13675 21663, 29651, 145 37639, 45627,

899353615

89945533 ring finger protein 424310 5688 409064 13676 21664, 29652, 145 37640, 45628,

899553616

89965534 ring finger protein 518802 5689 430955 13677 21665, 29653, 145 37641, 45629,

899753617

89985535 ring finger protein 519865 5690 430397 13678 21666, 29654, 145 37642, 45630,

899953618

90005536 ring finger protein 520638 5691 429071 13679 21667, 29655, 145 37643, 45631,

900153619

90025537 ring finger protein 521606 5692 430753 13680 21668, 29656, 145 37644, 45632,

900353620

90045538 ring finger protein 535312 5693 442941 13681 21669, 29657, 145 37645, 45633,

900553621

90065539 ring finger protein 434824 5694 388207 13682 21670, 29658, 148 37646, 45634,

900753622

90085540 ring finger protein 295317 5695 295317 13683 21671, 29659, 149 37647, 45635,

900953623

90105541 ring finger protein 306799 5696 304321 13684 21672, 29660, 150 37648, 45636,

901153624

90125542 ring finger protein 379512 5697 368827 13685 21673, 29661, 150 37649, 45637,

901353625

90145543 ring finger protein 420921 5698 394581 13686 21674, 29662, 150 37650, 45638,

901553626

90165544 ring finger protein 507500 5699 425568 13687 21675, 29663, 150 37651, 45639,

901753627

90185545 ring finger protein 515673 5700 425840 13688 21676, 29664, 150 37652, 45640,

901953628 5546 ring finger protein 312828 5701 316628 13689 21677, 29665, 152 37653, 45641,

902053629

90215547 ring finger protein 262482 5702 262482 13690 21678, 29666, 167 37654, 45642,

902253630

90235548 ring finger protein 319073 5703 325969 13691 21679, 29667, 170 37655, 45643,

902453631

90255549 ring finger protein 319104 5704 326138 13692 21680, 29668, 170 37656, 45644,

902653632

90275550 ring finger protein 524954 5705 437146 13693 21681, 29669, 170 37657, 45645,

902853633

90295551 ring finger protein 527424 5706 434797 13694 21682, 29670, 170 37658, 45646,

903053634

90315552 ring finger protein 531440 5707 436416 13695 21683, 29671, 170 37659, 45647,

903253635

90335553 ring finger protein 534961 5708 445725 13696 21684, 29672, 170 37660, 45648,

903453636

90355554 ring finger protein 526349 5709 435782 13697 21685, 29673, 170 37661, 45649,

903653637

90375555 ring finger protein 274068 5710 274068 13698 21686, 29674, 175 37662, 45650,

903853638

90395556 ring finger protein 347063 5711 340979 13699 21687, 29675, 175 37663, 45651,

904053639

90415557 ring finger protein 296615 5712 296615 13700 21688, 29676, 180 37664, 45652,

904253640

90435558 ring finger protein 381081 5713 370471 13701 21689, 29677, 180 37665, 45653,

904453641

90455559 ring finger protein 389100 5714 373752 13702 21690, 29678, 180 37666, 45654,

904653642

90475560 ring finger protein 504296 5715 426884 13703 21691, 29679, 180 37667, 45655,

904853643

90495561 ring finger protein 420478 5716 419329 13704 21692, 29680, 182 37668, 45656,

905053644

90515562 ring finger protein 423553 5717 418717 13705 21693, 29681, 182 37669, 45657,

905253645

90535563 ring finger protein 471906 5718 417514 13706 21694, 29682, 182 37670, 45658,

905453646 5564 ring finger protein 488300 5719 420465 13707 21695, 29683, 182 37671, 45659,

905553647

90565565 ring finger protein 488763 5720 417500 13708 21696, 29684, 182 37672, 45660,

905753648

90585566 ring finger protein 537388 5721 441271 13709 21697, 29685, 182 37673, 45661,

905953649

90605567 ring finger protein 537663 5722 443228 13710 21698, 29686, 182 37674, 45662,

906153650

90625568 ring finger protein 544682 5723 442021 13711 21699, 29687, 182 37675, 45663,

906353651

90645569 ring finger protein 326132 5724 320508 13712 21700, 29688, 185 37676, 45664,

906553652

90665570 ring finger protein 426256 5725 410916 13713 21701, 29689, 185 37677, 45665,

906753653

90685571 ring finger protein 436825 5726 404601 13714 21702, 29690, 185 37678, 45666,

906953654

90705572 ring finger protein 518626 5727 427755 13715 21703, 29691, 185 37679, 45667,

907153655

90725573 ring finger protein 266252 5728 266252 13716 21704, 29692, 185 37680, 45668,

907353656

90745574 ring finger protein 341084 5729 342667 13717 21705, 29693, 19A 37681, 45669,

907553657

90765575 ring finger protein 432381 5730 397305 13718 21706, 29694, 19A 37682, 45670,

907753658

90785576 ring finger protein 519449 5731 428968 13719 21707, 29695, 19A 37683, 45671,

907953659

90805577 ring finger protein 519527 5732 431077 13720 21708, 29696, 19A 37684, 45672,

908153660

90825578 ring finger protein 522369 5733 429841 13721 21709, 29697, 19A 37685, 45673,

908353661

90845579 ring finger protein 523167 5734 429549 13722 21710, 29698, 19A 37686, 45674,

908553662

90865580 ring finger protein 523481 5735 430553 13723 21711, 29699, 19A 37687, 45675,

908753663

90885581 ring finger protein 235150 5736 235150 13724 21712, 29700, 19B 37688, 45676,

908953664 5582 ring finger protein 356990 5737 349482 13725 21713, 29701, 19B 37689, 45677,

909053665

90915583 ring finger protein 373456 5738 362555 13726 21714, 29702, 19B 37690, 45678,

909253666

90935584 ring finger protein 405457 5739 385924 13727 21715, 29703, 19B 37691, 45679,

909453667

90955585 ring finger protein 382363 5740 371800 13728 21716, 29704, 215 37692, 45680,

909653668

90975586 ring finger protein 275184 5741 275184 13729 21717, 29705, 217 37693, 45681,

909853669

90995587 ring finger protein 359704 5742 352734 13730 21718, 29706, 217 37694, 45682,

910053670

91015588 ring finger protein 519799 5743 427711 13731 21719, 29707, 217 37695, 45683,

910253671

91035589 ring finger protein 560949 5744 452812 13732 21720, 29708, 217 37696, 45684,

910453672

91055590 ring finger protein 453464 5745 410533 13733 21721, 29709, 223 37697, 45685,

910653673

91075591 ring finger protein 324685 5746 325677 13734 21722, 29710, 40 37698, 45686,

910853674

91095592 ring finger protein 357890 5747 350563 13735 21723, 29711, 40 37699, 45687,

911053675

91115593 ring finger protein 402121 5748 384942 13736 21724, 29712, 40 37700, 45688,

911253676

91135594 ring finger protein 452273 5749 397150 13737 21725, 29713, 40 37701, 45689,

911453677

91155595 ring finger protein 538323 5750 445060 13738 21726, 29714, 40 37702, 45690,

911653678

91175596 ring finger protein, 305783 5751 304670 13739 21727, 29715, transmembrane 1 37703, 45691,

911853679

91195597 ring finger protein, 442346 5752 389049 13740 21728, 29716, transmembrane 1 37704, 45692,

912053680

91215598 ring finger protein, 257575 5753 257575 13741 21729, 29717, transmembrane 2 37705, 45693,

912253681

91235599 ring finger protein, 392549 5754 376332 13742 21730, 29718, transmembrane 2 37706, 45694,

912453682 5600 ring finger protein, 407967 5755 385669 13743 21731, 29719, transmembrane 2 37707, 45695,

912553683

91265601 RNA (guanine-9-) 309922 5756 312356 13744 21732, 29720, methyltransferase 37708, 45696, domain containing 1 53684

91275602 RNA (guanine-9-) 495642 5757 419389 13745 21733, 29721, methyltransferase 37709, 45697, domain containing 1 53685

91285603 RNA 298317 5758 298317 13746 21734, 29722, pseudouridylate 37710, 45698, synthase domain 53686 containing 4

91295604 RNA 533628 5759 433065 13747 21735, 29723, pseudouridylate 37711, 45699, synthase domain 53687 containing 4

91305605 RRSl ribosome 320270 5760 322396 13748 21736, 29724, biogenesis regulator 37712, 45700, homolog (S. 53688 cerevisiae)

91315606 RUN and FYVE 319449 5761 325594 13749 21737, 29725, domain containing 1 37713, 45701,

913253689

91335607 RUN and FYVE 360569 5762 353773 13750 21738, 29726, domain containing 1 37714, 45702,

913453690

91355608 RUN and FYVE 377001 5763 366200 13751 21739, 29727, domain containing 1 37715, 45703,

913653691

91375609 RUN and FYVE 393438 5764 377087 13752 21740, 29728, domain containing 1 37716, 45704,

913853692

91395610 RUN and FYVE 437570 5765 390025 13753 21741, 29729, domain containing 1 37717, 45705,

914053693

91415611 RYK receptor-like 296084 5766 296084 13754 21742, 29730, tyrosine kinase 37718, 45706,

914253694

91435612 RYK receptor-like 427044 5767 399527 13755 21743, 29731, tyrosine kinase 37719, 45707,

914453695

91455613 RYK receptor-like 460933 5768 419122 13756 21744, 29732, tyrosine kinase 37720, 45708,

914653696

91475614 SI 00 calcium 380200 5769 369547 13757 21745, 29733, binding protein G 37721, 45709,

914853697

91495615 saccharopine 366509 5770 355466 13758 21746, 29734, dehydrogenase 37722, 45710,

9150(putative) 53698

91515616 saccharopine 366510 5771 355467 13759 21747, 29735, dehydrogenase 37723, 45711, (putative) 53699

91525617 Sadl and UNC84 297325 5772 297325 13760 21748, 29736, domain containing 3 37724, 45712,

915353700

91545618 Sadl and UNC84 395572 5773 378939 13761 21749, 29737, domain containing 3 37725, 45713,

915553701

91565619 Sadl and UNC84 412142 5774 410204 13762 21750, 29738, domain containing 3 37726, 45714,

915753702

91585620 Sadl and UNC84 438771 5775 409077 13763 21751, 29739, domain containing 3 37727, 45715,

915953703

91605621 Sadl and UNC84 453071 5776 388627 13764 21752, 29740, domain containing 3 37728, 45716,

916153704

91625622 Sadl and UNC84 453192 5777 387525 13765 21753, 29741, domain containing 3 37729, 45717,

916353705

91645623 sarcoglycan, zeta 382080 5778 371512 13766 21754, 29742,

916537730, 45718, 53706

91665624 sarcoglycan, zeta 421524 5779 405224 13767 21755, 29743,

916737731, 45719, 53707

91685625 sarcolemma 295951 5780 295951 13768 21756, 29744, associated protein 37732, 45720,

916953708

91705626 sarcolemma 295952 5781 295952 13769 21757, 29745, associated protein 37733, 45721,

917153709

91725627 sarcolemma 383718 5782 373224 13770 21758, 29746, associated protein 37734, 45722,

917353710

91745628 sarcolemma 416870 5783 412342 13771 21759, 29747, associated protein 37735, 45723,

917553711

91765629 sarcolemma 417128 5784 412829 13772 21760, 29748, associated protein 37736, 45724,

917753712

91785630 sarcolemma 428312 5785 398661 13773 21761, 29749, associated protein 37737, 45725,

917953713

91805631 sarcolemma 438794 5786 391886 13774 21762, 29750, associated protein 37738, 45726,

918153714

91825632 sarcolemma 442599 5787 388978 13775 21763, 29751, associated protein 37739, 45727,

918353715

91845633 sarcolemma 449503 5788 412945 13776 21764, 29752, associated protein 37740, 45728,

918553716 5634 sarcolemma 494088 5789 418218 13777 21765, 29753, associated protein 37741, 45729,

918653717

91875635 sarcolemma 495364 5790 419543 13778 21766, 29754, associated protein 37742, 45730,

918853718

91895636 sarcolemma 537224 5791 437995 13779 21767, 29755, associated protein 37743, 45731,

919053719

91915637 SAYSVFN motif 229903 5792 229903 13780 21768, 29756, domain containing 1 37744, 45732,

919253720

91935638 SAYSVFN motif 373249 5793 362346 13781 21769, 29757, domain containing 1 37745, 45733,

919453721

91955639 scavenger receptor 301906 5794 301906 13782 21770, 29758, class A, member 5 37746, 45734, (putative) 53722

91965640 scavenger receptor 354914 5795 346990 13783 21771, 29759, class A, member 5 37747, 45735, (putative) 53723

91975641 scavenger receptor 380385 5796 369746 13784 21772, 29760, class A, member 5 37748, 45736, (putative) 53724

91985642 scavenger receptor 518030 5797 430713 13785 21773, 29761, class A, member 5 37749, 45737, (putative) 53725

91995643 scavenger receptor 524352 5798 428663 13786 21774, 29762, class A, member 5 37750, 45738, (putative) 53726

92005644 SCYl-like 2 (S. 258506 5799 258506 13787 21775, 29763, cerevisiae) 37751, 45739,

920153727

92025645 SCYl-like 2 (S. 360820 5800 354061 13788 21776, 29764, cerevisiae) 37752, 45740,

920353728

92045646 SCYl-like 2 (S. 549687 5801 448366 13789 21777, 29765, cerevisiae) 37753, 45741,

920553729

92065647 sec 1 family domain 396629 5802 379870 13790 21778, 29766, containing 1 37754, 45742,

920753730

92085648 sec 1 family domain 421551 5803 388078 13791 21779, 29767, containing 1 37755, 45743,

920953731

92105649 sec 1 family domain 458591 5804 390783 13792 21780, 29768, containing 1 37756, 45744,

921153732

92125650 sec 1 family domain 541123 5805 443537 13793 21781, 29769, containing 1 37757, 45745,

921353733

92145651 sec 1 family domain 544052 5806 443010 13794 21782, 29770, containing 1 37758, 45746,

921553734 5652 SECl l homolog A 268220 5807 268220 13795 21783, 29771, (S. cerevisiae) 37759, 45747,

921653735

92175653 SECl l homolog A 455959 5808 413121 13796 21784, 29772, (S. cerevisiae) 37760, 45748,

921853736

92195654 SECl l homolog C 299714 5809 299714 13797 21785, 29773, (S. cerevisiae) 37761, 45749,

922053737

92215655 SECl l homolog C 509791 5810 443624 13798 21786, 29774, (S. cerevisiae) 37762, 45750,

922253738

92235656 SECl l homolog C 587834 5811 468633 13799 21787, 29775, (S. cerevisiae) 37763, 45751,

922453739

92255657 SEC 14 and spectrin 428443 5812 415332 13800 21788, 29776, domains 1 37764, 45752,

922653740

92275658 SEC 14 and spectrin 435047 5813 410286 13801 21789, 29777, domains 1 37765, 45753,

922853741

92295659 SEC 14 and spectrin 440010 5814 416164 13802 21790, 29778, domains 1 37766, 45754,

923053742

92315660 SEC14-like 1 (S. 392476 5815 376268 13803 21791, 29779, cerevisiae) 37767, 45755,

923253743

92335661 SEC14-like 1 (S. 413679 5816 394716 13804 21792, 29780, cerevisiae) 37768, 45756,

923453744

92355662 SEC14-like 1 (S. 430767 5817 408169 13805 21793, 29781, cerevisiae) 37769, 45757,

923653745

92375663 SEC14-like 1 (S. 431431 5818 389838 13806 21794, 29782, cerevisiae) 37770, 45758,

923853746

92395664 SEC14-like 1 (S. 436233 5819 390392 13807 21795, 29783, cerevisiae) 37771, 45759,

924053747

92415665 SEC14-like 1 (S. 443798 5820 406030 13808 21796, 29784, cerevisiae) 37772, 45760,

924253748

92435666 SEC14-like 5 (S. 251170 5821 251170 13809 21797, 29785, cerevisiae) 37773, 45761,

924453749

92455667 SEC22 vesicle 264454 5822 264454 13810 21798, 29786, trafficking protein 37774, 45762, homolog C (S. 53750 cerevisiae)

92465668 SEC22 vesicle 273156 5823 273156 13811 21799, 29787, trafficking protein 37775, 45763, homolog C (S. 53751 cerevisiae) 5669 SEC22 vesicle 417572 5824 407564 13812 21800, 29788, trafficking protein 37776, 45764, homolog C (S. 53752 cerevisiae)

92475670 SEC22 vesicle 423701 5825 414576 13813 21801, 29789, trafficking protein 37777, 45765, homolog C (S. 53753 cerevisiae)

92485671 SEC22 vesicle 536332 5826 439845 13814 21802, 29790, trafficking protein 37778, 45766, homolog C (S. 53754 cerevisiae)

92495672 SEC24 family 322887 5827 321749 13815 21803, 29791, member A (S. 37779, 45767, cerevisiae) 53755

92505673 SEC24 family, 398844 5828 381823 13816 21804, 29792, member A (S. 37780, 45768, cerevisiae) 53756

92515674 SEC24 family, 265175 5829 265175 13817 21805, 29793, member B (S. 37781, 45769, cerevisiae) 53757

92525675 SEC24 family, 399100 5830 382051 13818 21806, 29794, member B (S. 37782, 45770, cerevisiae) 53758

92535676 SEC24 family, 504968 5831 428564 13819 21807, 29795, member B (S. 37783, 45771, cerevisiae) 53759

92545677 SEC24 family, 339365 5832 343405 13820 21808, 29796, member C (S. 37784, 45772, cerevisiae) 53760

92555678 SEC24 family, 345254 5833 321845 13821 21809, 29797, member C (S. 37785, 45773, cerevisiae) 53761

92565679 SEC24 family, 411652 5834 402913 13822 21810, 29798, member C (S. 37786, 45774, cerevisiae) 53762

92575680 SEC24 family, 535742 5835 446174 13823 21811, 29799, member C (S. 37787, 45775, cerevisiae) 53763

92585681 SEC24 family, 540668 5836 445023 13824 21812, 29800, member C (S. 37788, 45776, cerevisiae) 53764

92595682 SEC24 family, 280551 5837 280551 13825 21813, 29801, member D (S. 37789, 45777, cerevisiae) 53765

92605683 SEC24 family, 379735 5838 369059 13826 21814, 29802, member D (S. 37790, 45778, cerevisiae) 53766

92615684 SEC24 family, 419654 5839 388324 13827 21815, 29803, member D (S. 37791, 45779, cerevisiae) 53767

92625685 SEC24 family, 429811 5840 409775 13828 21816, 29804, member D (S. 37792, 45780, cerevisiae) 53768 5686 SEC31 homolog A 264405 5841 264405 13829 21817, 29805, (S. cerevisiae) 37793, 45781,

926353769

92645687 SEC31 homolog A 311785 5842 309070 13830 21818, 29806, (S. cerevisiae) 37794, 45782,

926553770

92665688 SEC31 homolog A 326950 5843 325087 13831 21819, 29807, (S. cerevisiae) 37795, 45783,

926753771

92685689 SEC31 homolog A 348405 5844 337602 13832 21820, 29808, (S. cerevisiae) 37796, 45784,

926953772

92705690 SEC31 homolog A 355196 5845 347329 13833 21821, 29809, (S. cerevisiae) 37797, 45785,

927153773

92725691 SEC31 homolog A 395310 5846 378721 13834 21822, 29810, (S. cerevisiae) 37798, 45786,

927353774

92745692 SEC31 homolog A 432794 5847 407944 13835 21823, 29811, (S. cerevisiae) 37799, 45787,

927553775

92765693 SEC31 homolog A 448323 5848 400926 13836 21824, 29812, (S. cerevisiae) 37800, 45788,

927753776

92785694 SEC31 homolog A 500777 5849 421464 13837 21825, 29813, (S. cerevisiae) 37801, 45789,

927953777

92805695 SEC31 homolog A 503210 5850 422563 13838 21826, 29814, (S. cerevisiae) 37802, 45790,

928153778

92825696 SEC31 homolog A 505434 5851 425095 13839 21827, 29815, (S. cerevisiae) 37803, 45791,

928353779

92845697 SEC31 homolog A 505984 5852 424451 13840 21828, 29816, (S. cerevisiae) 37804, 45792,

928553780

92865698 SEC31 homolog A 506495 5853 425064 13841 21829, 29817, (S. cerevisiae) 37805, 45793,

928753781

92885699 SEC31 homolog A 508502 5854 424635 13842 21830, 29818, (S. cerevisiae) 37806, 45794,

928953782

92905700 SEC31 homolog A 509142 5855 426569 13843 21831, 29819, (S. cerevisiae) 37807, 45795,

929153783

92925701 SEC31 homolog A 513323 5856 426950 13844 21832, 29820, (S. cerevisiae) 37808, 45796,

929353784

92945702 SEC31 homolog A 514326 5857 425555 13845 21833, 29821, (S. cerevisiae) 37809, 45797,

929553785

92965703 SEC31 homolog A 443462 5858 408027 13846 21834, 29822, (S. cerevisiae) 37810, 45798,

929753786 5704 Sec61 alpha 1 243253 5859 243253 13847 21835, 29823, subunit (S. 37811, 45799, cerevisiae) 53787

92985705 Sec61 alpha 1 424880 5860 411445 13848 21836, 29824, subunit (S. 37812, 45800, cerevisiae) 53788

92995706 Sec61 alpha 1 464451 5861 418493 13849 21837, 29825, subunit (S. 37813, 45801, cerevisiae) 53789

93005707 Sec61 alpha 2 298428 5862 298428 13850 21838, 29826, subunit (S. 37814, 45802, cerevisiae) 53790

93015708 Sec61 alpha 2 304267 5863 302048 13851 21839, 29827, subunit (S. 37815, 45803, cerevisiae) 53791

93025709 Sec61 alpha 2 379017 5864 368302 13852 21840, 29828, subunit (S. 37816, 45804, cerevisiae) 53792

93035710 Sec61 alpha 2 379020 5865 368306 13853 21841, 29829, subunit (S. 37817, 45805, cerevisiae) 53793

93045711 Sec61 alpha 2 379033 5866 368319 13854 21842, 29830, subunit (S. 37818, 45806, cerevisiae) 53794

93055712 Sec61 alpha 2 379051 5867 368339 13855 21843, 29831, subunit (S. 37819, 45807, cerevisiae) 53795

93065713 Sec61 alpha 2 418772 5868 393214 13856 21844, 29832, subunit (S. 37820, 45808, cerevisiae) 53796

93075714 Sec61 alpha 2 419021 5869 402124 13857 21845, 29833, subunit (S. 37821, 45809, cerevisiae) 53797

93085715 Sec61 alpha 2 426560 5870 404563 13858 21846, 29834, subunit (S. 37822, 45810, cerevisiae) 53798

93095716 Sec61 alpha 2 441368 5871 404959 13859 21847, 29835, subunit (S. 37823, 45811, cerevisiae) 53799

93105717 Sec61 alpha 2 457034 5872 401731 13860 21848, 29836, subunit (S. 37824, 45812, cerevisiae) 53800

93115718 Sec61 alpha 2 475268 5873 436749 13861 21849, 29837, subunit (S. 37825, 45813, cerevisiae) 53801

93125719 Sec61 beta subunit 223641 5874 223641 13862 21850, 29838,

931337826, 45814, 53802

93145720 Sec61 gamma 352861 5875 341538 13863 21851, 29839, subunit 37827, 45815,

931553803

93165721 Sec61 gamma 395535 5876 378906 13864 21852, 29840, subunit 37828, 45816,

931753804 5722 Sec61 gamma 415949 5877 388337 13865 21853, 29841, subunit 37829, 45817,

931853805

93195723 Sec61 gamma 450622 5878 409884 13866 21854, 29842, subunit 37830, 45818,

932053806

93215724 seizure related 6 317338 5879 312942 13867 21855, 29843, homolog (mouse) 37831, 45819,

932253807

93235725 seizure related 6 335960 5880 337407 13868 21856, 29844, homolog (mouse) 37832, 45820,

932453808

93255726 seizure related 6 360295 5881 353440 13869 21857, 29845, homolog (mouse) 37833, 45821,

932653809

93275727 seizure related 6 442608 5882 403784 13870 21858, 29846, homolog (mouse) 37834, 45822,

932853810

93295728 seizure related 6 308713 5883 312550 13871 21859, 29847, homolog (mouse)- 37835, 45823, like 2 53811

93305729 seizure related 6 346932 5884 319215 13872 21860, 29848, homolog (mouse)- 37836, 45824, like 2 53812

93315730 seizure related 6 350527 5885 310206 13873 21861, 29849, homolog (mouse)- 37837, 45825, like 2 53813

93325731 seizure related 6 537485 5886 439412 13874 21862, 29850, homolog (mouse)- 37838, 45826, like 2 53814

93335732 sel-1 suppressor of 264868 5887 264868 13875 21863, 29851, lin-12-like 3 (C. 37839, 45827, elegans) 53815

93345733 sel-1 suppressor of 399878 5888 382767 13876 21864, 29852, lin-12-like 3 (C. 37840, 45828, elegans) 53816

93355734 sel-1 suppressor of 502949 5889 425438 13877 21865, 29853, lin-12-like 3 (C. 37841, 45829, elegans) 53817

93365735 sel-1 suppressor of 510880 5890 423743 13878 21866, 29854, lin-12-like 3 (C. 37842, 45830, elegans) 53818

93375736 sel-1 suppressor of 513691 5891 421567 13879 21867, 29855, lin-12-like 3 (C. 37843, 45831, elegans) 53819

93385737 sel-1 suppressor of 514872 5892 420951 13880 21868, 29856, lin-12-like 3 (C. 37844, 45832, elegans) 53820

93395738 Selenoprotein S 398226 5893 381282 13881 21869, 29857,

934037845, 45833, 53821

93415739 Selenoprotein S 526049 5894 433541 13882 21870, 29858,

934237846, 45834, 53822 5740 Selenoprotein S 537379 5895 437381 13883 21871, 29859,

934337847, 45835, 53823

93445741 sema domain 586582 5896 467290 13884 21872, 29860, transmembrane 37848, 45836, domain (TM) and 53824 cytoplasmic domain

9345(semaphorin) 6B

93465742 sema domain, 2829 5897 2829 13885 21873, 29861, immunoglobulin 37849, 45837, domain (Ig), short 53825, 56092, basic domain, 56125 secreted,

9347(semaphorin) 3F

93485743 sema domain, 414301 5898 392588 13886 21874, 29862, immunoglobulin 37850, 45838, domain (Ig), short 53826 basic domain,

9349secreted,

9350(semaphorin) 3F

93515744 sema domain, 426511 5899 400549 13887 21875, 29863, immunoglobulin 37851, 45839, domain (Ig), short 53827 basic domain,

9352secreted,

9353(semaphorin) 3F

93545745 sema domain, 434342 5900 409859 13888 21876, 29864, immunoglobulin 37852, 45840, domain (Ig), short 53828 basic domain,

9355secreted,

9356(semaphorin) 3F

93575746 sema domain, 450338 5901 398399 13889 21877, 29865, immunoglobulin 37853, 45841, domain (Ig), short 53829 basic domain,

9358secreted,

9359(semaphorin) 3F

93605747 sema domain, 332496 5902 332204 13890 21878, 29866, immunoglobulin 37854, 45842, domain (Ig), 53830 transmembrane

9361domain (TM) and

9362short cytoplasmic

9363domain,

9364(semaphorin) 4B

93655748 sema domain, 379122 5903 368417 13891 21879, 29867, immunoglobulin 37855, 45843, domain (Ig), 53831 transmembrane

9366domain (TM) and

9367short cytoplasmic

9368domain,

9369(semaphorin) 4B 5749 sema domain, 411539 5904 394720 13892 21880, 29868, immunoglobulin 37856, 45844, domain (Ig), 53832 transmembrane

9370domain (TM) and

9371short cytoplasmic

9372domain,

9373(semaphorin) 4B

93745750 sema domain, 558895 5905 453705 13893 21881, 29869, immunoglobulin 37857, 45845, domain (Ig), 53833 transmembrane

9375domain (TM) and

9376short cytoplasmic

9377domain,

9378(semaphorin) 4B

93795751 sema domain, 559322 5906 453272 13894 21882, 29870, immunoglobulin 37858, 45846, domain (Ig), 53834 transmembrane

9380domain (TM) and

9381short cytoplasmic

9382domain,

9383(semaphorin) 4B

93845752 sema domain, 559792 5907 453563 13895 21883, 29871, immunoglobulin 37859, 45847, domain (Ig), 53835 transmembrane

9385domain (TM) and

9386short cytoplasmic

9387domain,

9388(semaphorin) 4B

93895753 sema domain, 305476 5908 306844 13896 21884, 29872, immunoglobulin 37860, 45848, domain (Ig), 53836 transmembrane

9390domain (TM) and

9391short cytoplasmic

9392domain,

9393(semaphorin) 4C

93945754 sema domain, 442264 5909 393498 13897 21885, 29873, immunoglobulin 37861, 45849, domain (Ig), 53837 transmembrane

9395domain (TM) and

9396short cytoplasmic

9397domain,

9398(semaphorin) 4C

93995755 sema domain, 449330 5910 391094 13898 21886, 29874, immunoglobulin 37862, 45850, domain (Ig), 53838 transmembrane

9400domain (TM) and

9401short cytoplasmic

9402domain, (semaphorin) 4C

94035756 sema domain, 343780 5911 343418 13899 21887, 29875, immunoglobulin 37863, 45851, domain (Ig), 53839 transmembrane

9404domain (TM) and

9405short cytoplasmic

9406domain,

9407(semaphorin) 4D

94085757 sema domain, 356444 5912 348822 13900 21888, 29876, immunoglobulin 37864, 45852, domain (Ig), 53840 transmembrane

9409domain (TM) and

9410short cytoplasmic

9411domain,

9412(semaphorin) 4D

94135758 sema domain, 418828 5913 416747 13901 21889, 29877, immunoglobulin 37865, 45853, domain (Ig), 53841 transmembrane

9414domain (TM) and

9415short cytoplasmic

9416domain,

9417(semaphorin) 4D

94185759 sema domain, 420101 5914 399948 13902 21890, 29878, immunoglobulin 37866, 45854, domain (Ig), 53842 transmembrane

9419domain (TM) and

9420short cytoplasmic

9421domain,

9422(semaphorin) 4D

94235760 sema domain, 420670 5915 405652 13903 21891, 29879, immunoglobulin 37867, 45855, domain (Ig), 53843 transmembrane

9424domain (TM) and

9425short cytoplasmic

9426domain,

9427(semaphorin) 4D

94285761 sema domain, 420681 5916 390754 13904 21892, 29880, immunoglobulin 37868, 45856, domain (Ig), 53844 transmembrane

9429domain (TM) and

9430short cytoplasmic

9431domain,

9432(semaphorin) 4D 5762 sema domain, 420987 5917 391733 13905 21893, 29881, immunoglobulin 37869, 45857, domain (Ig), 53845 transmembrane

9433domain (TM) and

9434short cytoplasmic

9435domain,

9436(semaphorin) 4D

94375763 sema domain, 422704 5918 388768 13906 21894, 29882, immunoglobulin 37870, 45858, domain (Ig), 53846 transmembrane

9438domain (TM) and

9439short cytoplasmic

9440domain,

9441(semaphorin) 4D

94425764 sema domain, 433650 5919 413352 13907 21895, 29883, immunoglobulin 37871, 45859, domain (Ig), 53847 transmembrane

9443domain (TM) and

9444short cytoplasmic

9445domain,

9446(semaphorin) 4D

94475765 sema domain, 438547 5920 405102 13908 21896, 29884, immunoglobulin 37872, 45860, domain (Ig), 53848 transmembrane

9448domain (TM) and

9449short cytoplasmic

9450domain,

9451(semaphorin) 4D

94525766 sema domain, 450295 5921 416523 13909 21897, 29885, immunoglobulin 37873, 45861, domain (Ig), 53849 transmembrane

9453domain (TM) and

9454short cytoplasmic

9455domain,

9456(semaphorin) 4D

94575767 sema domain, 540475 5922 438389 13910 21898, 29886, immunoglobulin 37874, 45862, domain (Ig), 53850 transmembrane

9458domain (TM) and

9459short cytoplasmic

9460domain,

9461(semaphorin) 4D

94625768 sema domain, 357877 5923 350547 13911 21899, 29887, immunoglobulin 37875, 45863, domain (Ig), 53851 transmembrane

9463domain (TM) and

9464short cytoplasmic

9465domain, (semaphorin) 4F

94665769 sema domain, 446927 5924 413916 13912 21900, 29888, immunoglobulin 37876, 45864, domain (Ig), 53852 transmembrane

9467domain (TM) and

9468short cytoplasmic

9469domain,

9470(semaphorin) 4F

94715770 sema domain, 210633 5925 210633 13913 21901, 29889, immunoglobulin 37877, 45865, domain (Ig), 53853 transmembrane

9472domain (TM) and

9473short cytoplasmic

9474domain,

9475(semaphorin) 4G

94765771 sema domain, 370250 5926 359270 13914 21902, 29890, immunoglobulin 37878, 45866, domain (Ig), 53854 transmembrane

9477domain (TM) and

9478short cytoplasmic

9479domain,

9480(semaphorin) 4G

94815772 sema domain, 457585 5927 405616 13915 21903, 29891, immunoglobulin 37879, 45867, domain (Ig), 53855 transmembrane

9482domain (TM) and

9483short cytoplasmic

9484domain,

9485(semaphorin) 4G

94865773 sema domain, 517724 5928 430175 13916 21904, 29892, immunoglobulin 37880, 45868, domain (Ig), 53856 transmembrane

9487domain (TM) and

9488short cytoplasmic

9489domain,

9490(semaphorin) 4G

94915774 sema domain, 518124 5929 430103 13917 21905, 29893, immunoglobulin 37881, 45869, domain (Ig), 53857 transmembrane

9492domain (TM) and

9493short cytoplasmic

9494domain,

9495(semaphorin) 4G 5775 sema domain, 519649 5930 428896 13918 21906, 29894, immunoglobulin 37882, 45870, domain (Ig), 53858 transmembrane

9496domain (TM) and

9497short cytoplasmic

9498domain,

9499(semaphorin) 4G

95005776 sema domain, 521006 5931 430881 13919 21907, 29895, immunoglobulin 37883, 45871, domain (Ig), 53859 transmembrane

9501domain (TM) and

9502short cytoplasmic

9503domain,

9504(semaphorin) 4G

95055777 sema domain, seven 195173 5932 195173 13920 21908, 29896, thrombospondin 37884, 45872, repeats (type 1 and 53860 type 1-like),

9506transmembrane

9507domain (TM) and

9508short cytoplasmic

9509domain,

9510(semaphorin) 5B

95115778 sema domain, seven 357599 5933 350215 13921 21909, 29897, thrombospondin 37885, 45873, repeats (type 1 and 53861 type 1-like),

9512transmembrane

9513domain (TM) and

9514short cytoplasmic

9515domain,

9516(semaphorin) 5B

95175779 sema domain, seven 393583 5934 377208 13922 21910, 29898, thrombospondin 37886, 45874, repeats (type 1 and 53862 type 1-like),

9518transmembrane

9519domain (TM) and

9520short cytoplasmic

9521domain,

9522(semaphorin) 5B

95235780 sema domain, seven 418793 5935 413917 13923 21911, 29899, thrombospondin 37887, 45875, repeats (type 1 and 53863 type 1-like),

9524transmembrane

9525domain (TM) and

9526short cytoplasmic

9527domain,

9528(semaphorin) 5B 5781 sema domain, seven 421053 5936 401056 13924 21912, 29900, thrombospondin 37888, 45876, repeats (type 1 and 53864 type 1-like),

9529transmembrane

9530domain (TM) and

9531short cytoplasmic

9532domain,

9533(semaphorin) 5B

95345782 sema domain, seven 449546 5937 401038 13925 21913, 29901, thrombospondin 37889, 45877, repeats (type 1 and 53865 type 1-like),

9535transmembrane

9536domain (TM) and

9537short cytoplasmic

9538domain,

9539(semaphorin) 5B

95405783 sema domain, seven 451055 5938 389588 13926 21914, 29902, thrombospondin 37890, 45878, repeats (type 1 and 53866 type 1-like),

9541transmembrane

9542domain (TM) and

9543short cytoplasmic

9544domain,

9545(semaphorin) 5B

95465784 sema domain, 257414 5939 257414 13927 21915, 29903, transmembrane 37891, 45879, domain (TM), and 53867 cytoplasmic domain,

9547(semaphorin) 6A

95485785 sema domain, 282394 5940 282394 13928 21916, 29904, transmembrane 37892, 45880, domain (TM), and 53868 cytoplasmic domain,

9549(semaphorin) 6A

95505786 sema domain, 343348 5941 345512 13929 21917, 29905, transmembrane 37893, 45881, domain (TM), and 53869 cytoplasmic domain,

9551(semaphorin) 6A

95525787 sema domain, 503865 5942 425364 13930 21918, 29906, transmembrane 37894, 45882, domain (TM), and 53870 cytoplasmic domain,

9553(semaphorin) 6A

95545788 sema domain, 509665 5943 425553 13931 21919, 29907, transmembrane 37895, 45883, domain (TM), and 53871 cytoplasmic domain,

9555(semaphorin) 6A 5789 sema domain, 510263 5944 424388 13932 21920, 29908, transmembrane 37896, 45884, domain (TM), and 53872 cytoplasmic domain,

9556(semaphorin) 6A

95575790 sema domain, 513137 5945 422997 13933 21921, 29909, transmembrane 37897, 45885, domain (TM), and 53873 cytoplasmic domain,

9558(semaphorin) 6A

95595791 sema domain, 515009 5946 421935 13934 21922, 29910, transmembrane 37898, 45886, domain (TM), and 53874 cytoplasmic domain,

9560(semaphorin) 6A

95615792 sema domain, 301292 5947 301292 13935 21923, 29911, transmembrane 37899, 45887, domain (TM), and 53875 cytoplasmic domain,

9562(semaphorin) 6B

95635793 sema domain, 301293 5948 301293 13936 21924, 29912, transmembrane 37900, 45888, domain (TM), and 53876 cytoplasmic domain,

9564(semaphorin) 6B

95655794 sema domain, 341697 5949 344148 13937 21925, 29913, transmembrane 37901, 45889, domain (TM), and 53877 cytoplasmic domain,

9566(semaphorin) 6C

95675795 sema domain, 368912 5950 357908 13938 21926, 29914, transmembrane 37902, 45890, domain (TM), and 53878 cytoplasmic domain,

9568(semaphorin) 6C

95695796 sema domain, 368913 5951 357909 13939 21927, 29915, transmembrane 37903, 45891, domain (TM), and 53879 cytoplasmic domain,

9570(semaphorin) 6C

95715797 sema domain, 368914 5952 357910 13940 21928, 29916, transmembrane 37904, 45892, domain (TM), and 53880 cytoplasmic domain,

9572(semaphorin) 6C

95735798 sema domain, 392792 5953 376542 13941 21929, 29917, transmembrane 37905, 45893, domain (TM), and 53881 cytoplasmic domain,

9574(semaphorin) 6C

95755799 sema domain, 316364 5954 324857 13942 21930, 29918, transmembrane 37906, 45894, domain (TM), and 53882 cytoplasmic domain,

9576(semaphorin) 6D 5800 sema domain, 354744 5955 346786 13943 21931, 29919, transmembrane 37907, 45895, domain (TM), and 53883 cytoplasmic domain,

9577(semaphorin) 6D

95785801 sema domain, 355997 5956 348276 13944 21932, 29920, transmembrane 37908, 45896, domain (TM), and 53884 cytoplasmic domain,

9579(semaphorin) 6D

95805802 sema domain, 358066 5957 350770 13945 21933, 29921, transmembrane 37909, 45897, domain (TM), and 53885 cytoplasmic domain,

9581(semaphorin) 6D

95825803 sema domain, 389425 5958 374076 13946 21934, 29922, transmembrane 37910, 45898, domain (TM), and 53886 cytoplasmic domain,

9583(semaphorin) 6D

95845804 sema domain, 389428 5959 374079 13947 21935, 29923, transmembrane 37911, 45899, domain (TM), and 53887 cytoplasmic domain,

9585(semaphorin) 6D

95865805 sema domain, 389432 5960 374083 13948 21936, 29924, transmembrane 37912, 45900, domain (TM), and 53888 cytoplasmic domain,

9587(semaphorin) 6D

95885806 sema domain, 389433 5961 374084 13949 21937, 29925, transmembrane 37913, 45901, domain (TM), and 53889 cytoplasmic domain,

9589(semaphorin) 6D

95905807 sema domain, 536845 5962 446152 13950 21938, 29926, transmembrane 37914, 45902, domain (TM), and 53890 cytoplasmic domain,

9591(semaphorin) 6D

95925808 sema domain, 537942 5963 442040 13951 21939, 29927, transmembrane 37915, 45903, domain (TM), and 53891 cytoplasmic domain,

9593(semaphorin) 6D

95945809 sema domain, 558014 5964 452815 13952 21940, 29928, transmembrane 37916, 45904, domain (TM), and 53892 cytoplasmic domain,

9595(semaphorin) 6D

95965810 sema domain, 558816 5965 453661 13953 21941, 29929, transmembrane 37917, 45905, domain (TM), and 53893 cytoplasmic domain,

9597(semaphorin) 6D 5811 sema domain, 559184 5966 453097 13954 21942, 29930, transmembrane 37918, 45906, domain (TM), and 53894 cytoplasmic domain,

9598(semaphorin) 6D

95995812 sema domain, 559196 5967 453755 13955 21943, 29931, transmembrane 37919, 45907, domain (TM), and 53895 cytoplasmic domain,

9600(semaphorin) 6D

96015813 sema domain, 560636 5968 453420 13956 21944, 29932, transmembrane 37920, 45908, domain (TM), and 53896 cytoplasmic domain,

9602(semaphorin) 6D

96035814 sema domain, 561133 5969 453530 13957 21945, 29933, transmembrane 37921, 45909, domain (TM), and 53897 cytoplasmic domain,

9604(semaphorin) 6D

96055815 serine dehydratase- 345635 5970 341117 13958 21946, 29934, like 37922, 45910,

960653898

96075816 serine dehydratase- 403593 5971 385790 13959 21947, 29935, like 37923, 45911,

960853899

96095817 serine dehydratase- 547802 5972 446867 13960 21948, 29936, like 37924, 45912,

961053900

96115818 serine incorporator 1 339697 5973 342962 13961 21949, 29937,

961237925, 45913, 53901

96135819 serine incorporator 1 368454 5974 357439 13962 21950, 29938,

961437926, 45914, 53902

96155820 serine incorporator 2 373709 5975 362813 13963 21951, 29939,

961637927, 45915, 53903

96175821 serine incorporator 2 373710 5976 362814 13964 21952, 29940,

961837928, 45916, 53904

96195822 serine incorporator 2 536384 5977 439048 13965 21953, 29941,

962037929, 45917, 53905

96215823 serine incorporator 2 536859 5978 444307 13966 21954, 29942,

962237930, 45918, 53906

96235824 serine incorporator 4 249714 5979 249714 13967 21955, 29943,

962437931, 45919, 53907

96255825 serine incorporator 4 319327 5980 319796 13968 21956, 29944,

962637932, 45920, 53908 5826 serine incorporator 4 457418 5981 402868 13969 21957, 29945,

962737933, 45921, 53909

96285827 serine incorporator 5 329637 5982 327542 13970 21958, 29946,

962937934, 45922, 53910

96305828 serine incorporator 5 507668 5983 426237 13971 21959, 29947,

963137935, 45923, 53911

96325829 serine incorporator 5 509193 5984 426134 13972 21960, 29948,

963337936, 45924, 53912

96345830 serine incorporator 5 512721 5985 420863 13973 21961, 29949,

963537937, 45925, 53913

96365831 serine 298130 5986 298130 13974 21962, 29950, palmitoyltrans ferase , 37938, 45926, small subunit A 53914

96375832 serine 359175 5987 352097 13975 21963, 29951, palmitoyltrans ferase , 37939, 45927, small subunit B 53915

96385833 serine 497137 5988 420115 13976 21964, 29952, palmitoyltrans ferase , 37940, 45928, small subunit B 53916

96395834 serine/threonine 396738 5989 379964 13977 21965, 29953, kinase 16 37941, 45929,

964053917

96415835 serine/threonine 409638 5990 386928 13978 21966, 29954, kinase 16 37942, 45930,

964253918

96435836 serine/threonine/tyro 75503 5991 75503 13979 21967, 29955, sine kinase 1 37943, 45931,

964453919, 56093, 56126

96455837 serine/threonine/tyro 535345 5992 444488 13980 21968, 29956, sine kinase 1 37944, 45932,

964653920

96475838 serine/threonine/tyro 538867 5993 445391 13981 21969, 29957, sine kinase 1 37945, 45933,

964853921

96495839 serine/threonine/tyro 541561 5994 444942 13982 21970, 29958, sine kinase 1 37946, 45934,

965053922

96515840 serine/threonine/tyro 542562 5995 446241 13983 21971, 29959, sine kinase 1 37947, 45935,

965253923

96535841 serine-rich and 315190 5996 325776 13984 21972, 29960, transmembrane 37948, 45936, domain containing 1 53924

96545842 SERPINE1 mRNA 361219 5997 354591 13985 21973, 29961, binding protein 1 37949, 45937,

965553925

96565843 SERPINE1 mRNA 370990 5998 360029 13986 21974, 29962, binding protein 1 37950, 45938,

965753926 5844 SERPINE1 mRNA 370994 5999 360033 13987 21975, 29963, binding protein 1 37951, 45939,

965853927

96595845 SERPINE1 mRNA 370995 6000 360034 13988 21976, 29964, binding protein 1 37952, 45940,

966053928

96615846 Seven 316506 6001 321133 13989 21977, 29965, transmembrane helix 37953, 45941, receptorUncharacteri 53929 zed protein

96625847 Seven 344049 6002 340453 13990 21978, 29966, transmembrane helix 37954, 45942, receptorUncharacteri 53930 zed protein

96635848 SFT2 domain 361731 6003 354590 13991 21979, 29967, containing 1 37955, 45943,

966453931

96655849 SFT2 domain 271375 6004 271375 13992 21980, 29968, containing 2 37956, 45944,

966653932

96675850 SFT2 domain 367825 6005 356799 13993 21981, 29969, containing 2 37957, 45945,

966853933

96695851 SFT2 domain 367829 6006 356803 13994 21982, 29970, containing 2 37958, 45946,

967053934

96715852 SFT2 domain 310981 6007 310803 13995 21983, 29971, containing 3 37959, 45947,

967253935

96735853 SH3 and multiple 293441 6008 293441 13996 21984, 29972, ankyrin repeat 37960, 45948, domains 1 53936

96745854 SH3 and multiple 359082 6009 351984 13997 21985, 29973, ankyrin repeat 37961, 45949, domains 1 53937

96755855 SH3 and multiple 391813 6010 375689 13998 21986, 29974, ankyrin repeat 37962, 45950, domains 1 53938

96765856 SH3 and multiple 391814 6011 375690 13999 21987, 29975, ankyrin repeat 37963, 45951, domains 1 53939

96775857 SH3 -domain GRB2- 212369 6012 212369 14000 21988, 29976, like endophilin B 1 37964, 45952,

967853940

96795858 SH3 -domain GRB2- 482504 6013 418744 14001 21989, 29977, like endophilin B 1 37965, 45953,

968053941

96815859 SH3 -domain GRB2- 535010 6014 441355 14002 21990, 29978, like endophilin B 1 37966, 45954,

968253942

96835860 SH3KBP1 binding 291842 6015 291842 14003 21991, 29979, protein 1 37967, 45955,

968453943 5861 SH3KBP1 binding 446701 6016 410670 14004 21992, 29980, protein 1 37968, 45956,

968553944

96865862 SHC (Src homology 332408 6017 329668 14005 21993, 29981, 2 domain 37969, 45957, containing) family, 53945 member 4

96875863 SHC (Src homology 396535 6018 379786 14006 21994, 29982, 2 domain 37970, 45958, containing) family, 53946 member 4

96885864 shisa homolog 2 319420 6019 313079 14007 21995, 29983, (Xenopus laevis) 37971, 45959,

968953947

96905865 shisa homolog 3 319234 6020 326445 14008 21996, 29984, (Xenopus laevis) 37972, 45960,

969153948

96925866 shisa homolog 4 362011 6021 355064 14009 21997, 29985, (Xenopus laevis) 37973, 45961,

969353949

96945867 shisa homolog 6 409168 6022 387157 14010 21998, 29986, (Xenopus laevis) 37974, 45962,

969553950

96965868 shisa homolog 6 432116 6023 388659 14011 21999, 29987, (Xenopus laevis) 37975, 45963,

969753951

96985869 shisa homolog 6 441885 6024 390084 14012 22000, 29988, (Xenopus laevis) 37976, 45964,

969953952

97005870 short chain 303749 6025 307607 14013 22001, 29989, dehydrogenase/redu 37977, 45965, ctase family 16C, 53953 member 5

97015871 short chain 396721 6026 379947 14014 22002, 29990, dehydrogenase/redu 37978, 45966, ctase family 16C, 53954 member 5

97025872 short chain 538514 6027 440545 14015 22003, 29991, dehydrogenase/redu 37979, 45967, ctase family 16C, 53955 member 5

97035873 short chain 328945 6028 332407 14016 22004, 29992, dehydrogenase/redu 37980, 45968, ctase family 42E, 53956 member 1

97045874 short coiled-coil 338517 6029 345262 14017 22005, 29993, protein 37981, 45969,

970553957

97065875 short coiled-coil 394201 6030 377751 14018 22006, 29994, protein 37982, 45970,

970753958

97085876 short coiled-coil 394203 6031 377753 14019 22007, 29995, protein 37983, 45971,

970953959 5877 short coiled-coil 394205 6032 377755 14020 22008, 29996, protein 37984, 45972,

971053960

97115878 short coiled-coil 506597 6033 426649 14021 22009, 29997, protein 37985, 45973,

971253961

97135879 sialic acid binding 360844 6034 354090 14022 22010, 29998, Ig-like lectin 14 37986, 45974,

971453962

97155880 sialic acid binding 389474 6035 374125 14023 22011, 29999, Ig-like lectin 15 37987, 45975,

971653963

97175881 sialic acid binding 546268 6036 443509 14024 22012, 30000, Ig-like lectin 15 37988, 45976,

971853964

97195882 sialidase 4 325935 6037 320318 14025 22013, 30001,

972037989, 45977, 53965

97215883 sialidase 4 391969 6038 375830 14026 22014, 30002,

972237990, 45978, 53966

97235884 sialidase 4 404257 6039 385149 14027 22015, 30003,

972437991, 45979, 53967

97255885 sialidase 4 405370 6040 384804 14028 22016, 30004,

972637992, 45980, 53968

97275886 sialidase 4 407683 6041 385402 14029 22017, 30005,

972837993, 45981, 53969

97295887 sialidase 4 420288 6042 388707 14030 22018, 30006,

973037994, 45982, 53970

97315888 sialidase 4 423583 6043 397860 14031 22019, 30007,

973237995, 45983, 53971

97335889 sialidase 4 472793 6044 441629 14032 22020, 30008,

973437996, 45984, 53972

97355890 SID1 264852 6045 264852 14033 22021, 30009, transmembrane 37997, 45985, family, member 1 53973

97365891 SID1 393830 6046 377416 14034 22022, 30010, transmembrane 37998, 45986, family, member 1 53974

97375892 SID1 278951 6047 278951 14035 22023, 30011, transmembrane 37999, 45987, family, member 2 53975

97385893 SID1 324225 6048 314023 14036 22024, 30012, transmembrane 38000, 45988, family, member 2 53976

97395894 SID1 392956 6049 376683 14037 22025, 30013, transmembrane 38001, 45989, family, member 2 53977 5895 SID1 431081 6050 399635 14038 22026, 30014, transmembrane 38002, 45990, family, member 2 53978

97405896 SID1 525347 6051 432058 14039 22027, 30015, transmembrane 38003, 45991, family, member 2 53979

97415897 SID1 532960 6052 431176 14040 22028, 30016, transmembrane 38004, 45992, family, member 2 53980

97425898 sidekick cell 404826 6053 385899 14041 22029, 30017, adhesion molecule 1 38005, 45993,

974353981

97445899 sidekick cell 446104 6054 393517 14042 22030, 30018, adhesion molecule 1 38006, 45994,

974553982

97465900 sidekick cell 316893 6055 324967 14043 22031, 30019, adhesion molecule 2 38007, 45995,

974753983

97485901 sidekick cell 388726 6056 373378 14044 22032, 30020, adhesion molecule 2 38008, 45996,

974953984

97505902 sidekick cell 392650 6057 376421 14045 22033, 30021, adhesion molecule 2 38009, 45997,

975153985

97525903 sideroflexin 1 321442 6058 316905 14046 22034, 30022,

975338010, 45998, 53986

97545904 sideroflexin 1 506963 6059 421467 14047 22035, 30023,

975538011, 45999, 53987

97565905 sideroflexin 1 507017 6060 420961 14048 22036, 30024,

975738012, 46000, 53988

97585906 sideroflexin 2 369893 6061 358909 14049 22037, 30025,

975938013, 46001, 53989

97605907 sideroflexin 3 224807 6062 224807 14050 22038, 30026,

976138014, 46002, 53990

97625908 sideroflexin 3 393459 6063 377103 14051 22039, 30027,

976338015, 46003, 53991

97645909 sideroflexin 4 330036 6064 333200 14052 22040, 30028,

976538016, 46004, 53992

97665910 sideroflexin 4 355697 6065 347924 14053 22041, 30029,

976738017, 46005, 53993

97685911 sideroflexin 4 369131 6066 358127 14054 22042, 30030,

976938018, 46006, 53994

97705912 sideroflexin 4 392875 6067 376614 14055 22043, 30031,

977138019, 46007, 53995 5913 sideroflexin 4 419372 6068 414193 14056 22044, 30032,

977238020, 46008, 53996

97735914 sideroflexin 5 272433 6069 272433 14057 22045, 30033,

977438021, 46009, 53997

97755915 signal peptidase 233025 6070 233025 14058 22046, 30034, complex subunit 1 38022, 46010, homolog (S. 53998 cerevisiae)

97765916 signal peptidase 263672 6071 263672 14059 22047, 30035, complex subunit 2 38023, 46011, homolog (S. 53999 cerevisiae)

97775917 signal peptidase 503362 6072 427463 14060 22048, 30036, complex subunit 3 38024, 46012, homolog (S. 54000 cerevisiae)

97785918 Signal peptide 261854 6073 261854 14061 22049, 30037, peptidase-like 2A 38025, 46013,

977954001

97805919 Signal peptide 329196 6074 332488 14062 22050, 30038, peptidase-like 2C 38026, 46014,

978154002

97825920 Signal peptide 353487 6075 288680 14063 22051, 30039, peptidase-like 3 38027, 46015,

978354003

97845921 Signal peptide 405631 6076 385950 14064 22052, 30040, peptidase-like 3 38028, 46016,

978554004

97865922 signal recognition 466490 6077 418401 14065 22053, 30041, particle receptor, B 38029, 46017, subunit 54005

97875923 signal recognition 484684 6078 417096 14066 22054, 30042, particle receptor, B 38030, 46018, subunit 54006

97885924 signal sequence 244763 6079 244763 14067 22055, 30043, receptor, alpha 38031, 46019,

978954007

97905925 signal sequence 534851 6080 443020 14068 22056, 30044, receptor, alpha 38032, 46020,

979154008

97925926 signal sequence 265044 6081 265044 14069 22057, 30045, receptor, gamma 38033, 46021, (translocon- 54009 associated protein

9793gamma)

97945927 signal sequence 467789 6082 420641 14070 22058, 30046, receptor, gamma 38034, 46022, (translocon- 54010 associated protein

9795gamma)

97965928 signal-induced 381232 6083 370630 14071 22059, 30047, proliferation- 38035, 46023, associated 1 like 1 54011 5929 signal-induced 537413 6084 440682 14072 22060, 30048, proliferation- 38036, 46024, associated 1 like 1 54012

97975930 signal-induced 555818 6085 450832 14073 22061, 30049, proliferation- 38037, 46025, associated 1 like 1 54013

97985931 signaling threshold 259608 6086 259608 14074 22062, 30050, regulating 38038, 46026, transmembrane 54014 adaptor 1

97995932 signal-regulatory 356025 6087 348307 14075 22063, 30051, protein alpha 38039, 46027,

980054015

98015933 signal-regulatory 358771 6088 351621 14076 22064, 30052, protein alpha 38040, 46028,

980254016

98035934 signal-regulatory 400068 6089 382941 14077 22065, 30053, protein alpha 38041, 46029,

980454017

98055935 signal-regulatory 262929 6090 262929 14078 22066, 30054, protein beta 1 38042, 46030,

980654018

98075936 signal-regulatory 279477 6091 279477 14079 22067, 30055, protein beta 1 38043, 46031,

980854019

98095937 signal-regulatory 381596 6092 371009 14080 22068, 30056, protein beta 1 38044, 46032,

981054020

98115938 signal-regulatory 381603 6093 371016 14081 22069, 30057, protein beta 1 38045, 46033,

981254021

98135939 signal-regulatory 381605 6094 371018 14082 22070, 30058, protein beta 1 38046, 46034,

981454022

98155940 Sin3A-associated 382533 6095 371973 14083 22071, 30059, protein, 18kDa 38047, 46035,

981654023

98175941 six transmembrane 297205 6096 297205 14084 22072, 30060, epithelial antigen of 38048, 46036, the prostate 1 54024

98185942 SLAM family 368092 6097 357071 14085 22073, 30061, member 9 38049, 46037,

981954025

98205943 SLAM family 368093 6098 357072 14086 22074, 30062, member 9 38050, 46038,

982154026

98225944 slowmo homolog 1 336990 6099 338988 14087 22075, 30063, (Drosophila) 38051, 46039,

982354027

98245945 slowmo homolog 1 440960 6100 404700 14088 22076, 30064, (Drosophila) 38052, 46040,

982554028

98265946 slowmo homolog 2 355937 6101 348206 14089 22077, 30065, (Drosophila) 38053, 46041,

982754029 5947 SMAD specific E3 262435 6102 262435 14090 22078, 30066, ubiquitin protein 38054, 46042, ligase 2 54030

98285948 small cell adhesion 380103 6103 369446 14091 22079, 30067, glycoprotein 38055, 46043,

982954031

98305949 small cell adhesion 398453 6104 381471 14092 22080, 30068, glycoprotein 38056, 46044,

983154032

98325950 small G protein 400358 6105 383211 14093 22081, 30069, signaling modulator 38057, 46045, 1 54033

98335951 small G protein 400359 6106 383212 14094 22082, 30070, signaling modulator 38058, 46046, 1 54034

98345952 small G protein 403206 6107 385854 14095 22083, 30071, signaling modulator 38059, 46047, 1 54035

98355953 small VCP/p97- 354193 6108 346130 14096 22084, 30072, interacting protein 38060, 46048,

983654036

98375954 Smith-Magenis 323019 6109 323591 14097 22085, 30073, syndrome 38061, 46049, chromosome region, 54037 candidate 7

98385955 Smith-Magenis 395703 6110 379055 14098 22086, 30074, syndrome 38062, 46050, chromosome region, 54038 candidate 7

98395956 Smith-Magenis 395704 6111 379056 14099 22087, 30075, syndrome 38063, 46051, chromosome region, 54039 candidate 7

98405957 Smith-Magenis 395706 6112 379057 14100 22088, 30076, syndrome 38064, 46052, chromosome region, 54040 candidate 7

98415958 Smith-Magenis 325301 6113 327124 14101 22089, 30077, syndrome 38065, 46053, chromosome region, 54041 candidate 7-like

98425959 Smith-Magenis 402881 6114 385110 14102 22090, 30078, syndrome 38066, 46054, chromosome region, 54042 candidate 7-like

98435960 Smith-Magenis 404569 6115 385191 14103 22091, 30079, syndrome 38067, 46055, chromosome region, 54043 candidate 7-like

98445961 Smith-Magenis 428069 6116 413730 14104 22092, 30080, syndrome 38068, 46056, chromosome region, 54044 candidate 7-like 5962 Smith-Magenis 433117 6117 404096 14105 22093, 30081, syndrome 38069, 46057, chromosome region, 54045 candidate 7-like

98455963 Smith-Magenis 434364 6118 390029 14106 22094, 30082, syndrome 38070, 46058, chromosome region, 54046 candidate 7-like

98465964 sodium channel and 281142 6119 281142 14107 22095, 30083, clathrin linker 1 38071, 46059,

984754047

98485965 sodium channel and 434680 6120 401539 14108 22096, 30084, clathrin linker 1 38072, 46060,

984954048

98505966 sodium channel and 439369 6121 395292 14109 22097, 30085, clathrin linker 1 38073, 46061,

985154049

98525967 sodium channel and 511426 6122 420861 14110 22098, 30086, clathrin linker 1 38074, 46062,

985354050

98545968 sodium channel, 338748 6123 345028 14111 22099, 30087, nonvoltage -gated 1 38075, 46063, alpha 54051

98555969 sodium channel, 360168 6124 353292 14112 22100, 30088, nonvoltage -gated 1 38076, 46064, alpha 54052

98565970 sodium channel, 543768 6125 438739 14113 22101, 30089, nonvoltage -gated 1 38077, 46065, alpha 54053

98575971 solute carrier family 371491 6126 360546 14114 22102, 30090, 1 (glutamate 38078, 46066, transporter), member 54054 7

98585972 solute carrier family 371494 6127 360549 14115 22103, 30091, 1 (glutamate 38079, 46067, transporter), member 54055 7

98595973 solute carrier family 221742 6128 221742 14116 22104, 30092, 1 (high affinity 38080, 46068, aspartate/glutamate 54056 transporter), member

98606

98615974 solute carrier family 430939 6129 409386 14117 22105, 30093, 1 (high affinity 38081, 46069, aspartate/glutamate 54057 transporter), member

98626

98635975 solute carrier family 542610 6130 442673 14118 22106, 30094, 1 (high affinity 38082, 46070, aspartate/glutamate 54058 transporter), member

98646 5976 solute carrier family 544886 6131 446175 14119 22107, 30095, 1 (high affinity 38083, 46071, aspartate/glutamate 54059 transporter), member

98656

98665977 solute carrier family 518568 6132 428612 14120 22108, 30096, 10 (sodium/bile acid 38084, 46072, cotransporter 54060 family), member 5

98675978 solute carrier family 264986 6133 264986 14121 22109, 30097, 10 (sodium/bile acid 38085, 46073, cotransporter 54061 family), member 7

98685979 solute carrier family 335472 6134 334594 14122 22110, 30098, 10 (sodium/bile acid 38086, 46074, cotransporter 54062 family), member 7

98695980 solute carrier family 394059 6135 377623 14123 22111, 30099, 10 (sodium/bile acid 38087, 46075, cotransporter 54063 family), member 7

98705981 solute carrier family 394062 6136 377626 14124 22112, 30100, 10 (sodium/bile acid 38088, 46076, cotransporter 54064 family), member 7

98715982 solute carrier family 432059 6137 411297 14125 22113, 30101, 10 (sodium/bile acid 38089, 46077, cotransporter 54065 family), member 7

98725983 solute carrier family 502607 6138 422577 14126 22114, 30102, 10 (sodium/bile acid 38090, 46078, cotransporter 54066 family), member 7

98735984 solute carrier family 507030 6139 421275 14127 22115, 30103, 10 (sodium/bile acid 38091, 46079, cotransporter 54067 family), member 7

98745985 solute carrier family 262051 6140 262051 14128 22116, 30104, 11 (proton-coupled 38092, 46080, divalent metal ion 54068 transporters),

9875member 2

98765986 solute carrier family 262052 6141 262052 14129 22117, 30105, 11 (proton-coupled 38093, 46081, divalent metal ion 54069 transporters),

9877member 2

98785987 solute carrier family 394904 6142 378364 14130 22118, 30106, 11 (proton-coupled 38094, 46082, divalent metal ion 54070 transporters),

9879member 2 5988 solute carrier family 541174 6143 444542 14131 22119, 30107, 11 (proton-coupled 38095, 46083, divalent metal ion 54071 transporters),

9880member 2

98815989 solute carrier family 545993 6144 442810 14132 22120, 30108, 11 (proton-coupled 38096, 46084, divalent metal ion 54072 transporters),

9882member 2

98835990 solute carrier family 546636 6145 449008 14133 22121, 30109, 11 (proton-coupled 38097, 46085, divalent metal ion 54073 transporters),

9884member 2

98855991 solute carrier family 546743 6146 446914 14134 22122, 30110, 11 (proton-coupled 38098, 46086, divalent metal ion 54074 transporters),

9886member 2

98875992 solute carrier family 547198 6147 446769 14135 22123, 30111, 11 (proton-coupled 38099, 46087, divalent metal ion 54075 transporters),

9888member 2

98895993 solute carrier family 547688 6148 449200 14136 22124, 30112, 11 (proton-coupled 38100, 46088, divalent metal ion 54076 transporters),

9890member 2

98915994 solute carrier family 548150 6149 448273 14137 22125, 30113, 11 (proton-coupled 38101, 46089, divalent metal ion 54077 transporters),

9892member 2

98935995 solute carrier family 548193 6150 449209 14138 22126, 30114, 11 (proton-coupled 38102, 46090, divalent metal ion 54078 transporters),

9894member 2

98955996 solute carrier family 393469 6151 377112 14139 22127, 30115, 12 38103, 46091,

9896(potassium/ chloride 54079 transporters),

9897member 8

98985997 solute carrier family 469902 6152 418783 14140 22128, 30116, 12 38104, 46092,

9899(potassium/ chloride 54080 transporters),

9900member 8

99015998 solute carrier family 275729 6153 275729 14141 22129, 30117, 12 38105, 46093,

9902(potassium/ chloride 54081 transporters),

9903member 9 5999 solute carrier family 354161 6154 275730 14142 22130, 30118, 12 38106, 46094,

9904(potassium/ chloride 54082 transporters),

9905member 9

99066000 solute carrier family 415287 6155 413796 14143 22131, 30119, 12 38107, 46095,

9907(potassium/ chloride 54083 transporters),

9908member 9

99096001 solute carrier family 428758 6156 408301 14144 22132, 30120, 12 38108, 46096,

9910(potassium/ chloride 54084 transporters),

9911member 9

99126002 solute carrier family 434158 6157 408571 14145 22133, 30121, 12 38109, 46097,

9913(potassium/ chloride 54085 transporters),

9914member 9

99156003 solute carrier family 539308 6158 442859 14146 22134, 30122, 12 38110, 46098,

9916(potassium/ chloride 54086 transporters),

9917member 9

99186004 solute carrier family 540482 6159 443702 14147 22135, 30123, 12 38111, 46099,

9919(potassium/ chloride 54087 transporters),

9920member 9

99216005 solute carrier family 295605 6160 295605 14148 22136, 30124, 15 (H+/peptide 38112, 46100, transporter), member 54088 2

99226006 solute carrier family 489711 6161 417085 14149 22137, 30125, 15 (H+/peptide 38113, 46101, transporter), member 54089 2

99236007 solute carrier family 542599 6162 444920 14150 22138, 30126, 15 (H+/peptide 38114, 46102, transporter), member 54090 2

99246008 solute carrier family 227880 6163 227880 14151 22139, 30127, 15, member 3 38115, 46103,

992554091

99266009 solute carrier family 442626 6164 403318 14152 22140, 30128, 15, member 3 38116, 46104,

992754092

99286010 solute carrier family 266771 6165 266771 14153 22141, 30129, 15, member 4 38117, 46105,

992954093

99306011 solute carrier family 472422 6166 432495 14154 22142, 30130, 16 member 4 38118, 46106, (monocarboxylic 54094 acid transporter 5) 6012 solute carrier family 308009 6167 310490 14155 22143, 30131, 16, member 11 38119, 46107, (monocarboxylic 54095 acid transporter 11)

99316013 solute carrier family 447225 6168 394449 14156 22144, 30132, 16, member 11 38120, 46108, (monocarboxylic 54096 acid transporter 11)

99326014 solute carrier family 308027 6169 309751 14157 22145, 30133, 16, member 13 38121, 46109, (monocarboxylic 54097 acid transporter 13)

99336015 solute carrier family 295190 6170 295190 14158 22146, 30134, 16, member 14 38122, 46110, (monocarboxylic 54098 acid transporter 14)

99346016 solute carrier family 412034 6171 395775 14159 22147, 30135, 16, member 14 38123, 46111, (monocarboxylic 54099 acid transporter 14)

99356017 solute carrier family 425822 6172 389726 14160 22148, 30136, 16, member 14 38124, 46112, (monocarboxylic 54100 acid transporter 14)

99366018 solute carrier family 436869 6173 396834 14161 22149, 30137, 16, member 14 38125, 46113, (monocarboxylic 54101 acid transporter 14)

99376019 solute carrier family 457406 6174 400352 14162 22150, 30138, 16, member 14 38126, 46114, (monocarboxylic 54102 acid transporter 14)

99386020 solute carrier family 369779 6175 358794 14163 22151, 30139, 16, member 4 38127, 46115, (monocarboxylic 54103 acid transporter 5)

99396021 solute carrier family 369781 6176 358796 14164 22152, 30140, 16, member 4 38128, 46116, (monocarboxylic 54104 acid transporter 5)

99406022 solute carrier family 437429 6177 394790 14165 22153, 30141, 16, member 4 38129, 46117, (monocarboxylic 54105 acid transporter 5)

99416023 solute carrier family 541986 6178 446087 14166 22154, 30142, 16, member 4 38130, 46118, (monocarboxylic 54106 acid transporter 5)

99426024 solute carrier family 329783 6179 330141 14167 22155, 30143, 16, member 5 38131, 46119, (monocarboxylic 54107 acid transporter 6) 6025 solute carrier family 450736 6180 390564 14168 22156, 30144, 16, member 5 38132, 46120, (monocarboxylic 54108 acid transporter 6)

99436026 solute carrier family 538213 6181 440212 14169 22157, 30145, 16, member 5 38133, 46121, (monocarboxylic 54109 acid transporter 6)

99446027 solute carrier family 327268 6182 319991 14170 22158, 30146, 16, member 6 38134, 46122, (monocarboxylic 54110 acid transporter 7)

99456028 solute carrier family 320521 6183 321735 14171 22159, 30147, 16, member 8 38135, 46123, (monocarboxylic 54111 acid transporter 3)

99466029 solute carrier family 427592 6184 409547 14172 22160, 30148, 16, member 8 38136, 46124, (monocarboxylic 54112 acid transporter 3)

99476030 solute carrier family 316185 6185 326748 14173 22161, 30149, 2 (facilitated glucose 38137, 46125, transporter), member 54113 11

99486031 solute carrier family 345044 6186 342542 14174 22162, 30150, 2 (facilitated glucose 38138, 46126, transporter), member 54114 11

99496032 solute carrier family 398356 6187 381399 14175 22163, 30151, 2 (facilitated glucose 38139, 46127, transporter), member 54115 11

99506033 solute carrier family 398359 6188 381400 14176 22164, 30152, 2 (facilitated glucose 38140, 46128, transporter), member 54116 11

99516034 solute carrier family 398363 6189 381404 14177 22165, 30153, 2 (facilitated glucose 38141, 46129, transporter), member 54117 11

99526035 solute carrier family 407566 6190 386027 14178 22166, 30154, 2 (facilitated glucose 38142, 46130, transporter), member 54118 11

99536036 solute carrier family 275230 6191 275230 14179 22167, 30155, 2 (facilitated glucose 38143, 46131, transporter), member 54119 12

99546037 solute carrier family 311856 6192 310241 14180 22168, 30156, 22 (organic anion 38144, 46132, transporter), member 54120 13

99556038 solute carrier family 450935 6193 406929 14181 22169, 30157, 22 (organic anion 38145, 46133, transporter), member 54121 13

99566039 solute carrier family 279178 6194 279178 14182 22170, 30158, 22 (organic anion 38146, 46134, transporter), member 54122 9

99576040 solute carrier family 310969 6195 311527 14183 22171, 30159, 22 (organic anion 38147, 46135, transporter), member 54123 9

99586041 solute carrier family 332793 6196 327569 14184 22172, 30160, 22, member 10 38148, 46136,

995954124

99606042 solute carrier family 533483 6197 433048 14185 22173, 30161, 22, member 10 38149, 46137,

996154125

99626043 solute carrier family 535888 6198 444602 14186 22174, 30162, 22, member 10 38150, 46138,

996354126

99646044 solute carrier family 544661 6199 445667 14187 22175, 30163, 22, member 10 38151, 46139,

996554127

99666045 solute carrier family 273173 6200 273173 14188 22176, 30164, 22, member 14 38152, 46140,

996754128

99686046 solute carrier family 448498 6201 396283 14189 22177, 30165, 22, member 14 38153, 46141,

996954129

99706047 solute carrier family 312221 6202 311139 14190 22178, 30166, 22, member 18 38154, 46142,

997154130

99726048 solute carrier family 347936 6203 307859 14191 22179, 30167, 22, member 18 38155, 46143,

997354131

99746049 solute carrier family 380574 6204 369948 14192 22180, 30168, 22, member 18 38156, 46144,

997554132

99766050 solute carrier family 449793 6205 392072 14193 22181, 30169, 22, member 18 38157, 46145,

997754133

99786051 solute carrier family 485423 6206 433019 14194 22182, 30170, 22, member 18 38158, 46146,

997954134

99806052 solute carrier family 306494 6207 307443 14195 22183, 30171, 22, member 25 38159, 46147,

998154135

99826053 solute carrier family 403374 6208 384208 14196 22184, 30172, 22, member 25 38160, 46148,

998354136

99846054 solute carrier family 451441 6209 398848 14197 22185, 30173, 22, member 25 38161, 46149,

998554137

99866055 solute carrier family 527057 6210 432242 14198 22186, 30174, 22, member 25 38162, 46150, 54138

99876056 solute carrier family 295738 6211 295738 14199 22187, 30175, 23 (nucleobase 38163, 46151, transporters), 54139 member 3

99886057 solute carrier family 396775 6212 379996 14200 22188, 30176, 23 (nucleobase 38164, 46152, transporters), 54140 member 3

99896058 solute carrier family 409878 6213 386473 14201 22189, 30177, 23 (nucleobase 38165, 46153, transporters), 54141 member 3

99906059 solute carrier family 455516 6214 406546 14202 22190, 30178, 23 (nucleobase 38166, 46154, transporters), 54142 member 3

99916060 solute carrier family 565488 6215 457733 14203 22191, 30179, 25 (mitochondrial 38167, 46155, carrier; phosphate 54143 carrier) member 24

99926061 solute carrier family 264088 6216 264088 14204 22192, 30180, 25 (mitochondrial 38168, 46156, carrier; phosphate 54144 carrier), member 23

99936062 solute carrier family 301454 6217 301454 14205 22193, 30181, 25 (mitochondrial 38169, 46157, carrier; phosphate 54145 carrier), member 23

99946063 solute carrier family 334510 6218 334537 14206 22194, 30182, 25 (mitochondrial 38170, 46158, carrier; phosphate 54146 carrier), member 23

99956064 solute carrier family 414491 6219 408814 14207 22195, 30183, 25 (mitochondrial 38171, 46159, carrier; phosphate 54147 carrier), member 23

99966065 solute carrier family 422102 6220 390524 14208 22196, 30184, 25 (mitochondrial 38172, 46160, carrier; phosphate 54148 carrier), member 23

99976066 solute carrier family 264128 6221 264128 14209 22197, 30185, 25 (mitochondrial 38173, 46161, carrier; phosphate 54149 carrier), member 24

99986067 solute carrier family 370041 6222 359058 14210 22198, 30186, 25 (mitochondrial 38174, 46162, carrier; phosphate 54150 carrier), member 24

99996068 solute carrier family 373064 6223 362155 14211 22199, 30187, 25 (mitochondrial 38175, 46163, carrier; phosphate 54151 carrier), member 25 6069 solute carrier family 373066 6224 362157 14212 22200, 30188, 25 (mitochondrial 38176, 46164, carrier; phosphate 54152 carrier), member 25

100006070 solute carrier family 373068 6225 362159 14213 22201, 30189, 25 (mitochondrial 38177, 46165, carrier; phosphate 54153 carrier), member 25

100016071 solute carrier family 373069 6226 362160 14214 22202, 30190, 25 (mitochondrial 38178, 46166, carrier; phosphate 54154 carrier), member 25

100026072 solute carrier family 432073 6227 410053 14215 22203, 30191, 25 (mitochondrial 38179, 46167, carrier; phosphate 54155 carrier), member 25

100036073 solute carrier family 433501 6228 401672 14216 22204, 30192, 25 (mitochondrial 38180, 46168, carrier; phosphate 54156 carrier), member 25

100046074 solute carrier family 579441 6229 462754 14217 22205, 30193, 25 member 52 38181, 46169,

1000554157

100066075 solute carrier family 359232 6230 352167 14218 22206, 30194, 25, member 29 38182, 46170,

1000754158

100086076 solute carrier family 539621 6231 442985 14219 22207, 30195, 25, member 29 38183, 46171,

1000954159

100106077 solute carrier family 554912 6232 450913 14220 22208, 30196, 25, member 29 38184, 46172,

1001154160

100126078 solute carrier family 555927 6233 452078 14221 22209, 30197, 25, member 29 38185, 46173,

1001354161

100146079 solute carrier family 556505 6234 452446 14222 22210, 30198, 25, member 29 38186, 46174,

1001554162

100166080 solute carrier family 324194 6235 320688 14223 22211, 30199, 25, member 36 38187, 46175,

1001754163

100186081 solute carrier family 446041 6236 401938 14224 22212, 30200, 25, member 36 38188, 46176,

1001954164

100206082 solute carrier family 361529 6237 354886 14225 22213, 30201, 25, member 47 38189, 46177,

1002154165

100226083 solute carrier family 274513 6238 274513 14226 22214, 30202, 25, member 48 38190, 46178,

1002354166

100246084 solute carrier family 412661 6239 413049 14227 22215, 30203, 25, member 48 38191, 46179,

1002554167 6085 solute carrier family 420621 6240 407973 14228 22216, 30204, 25, member 48 38192, 46180,

1002654168

100276086 solute carrier family 433282 6241 399834 14229 22217, 30205, 25, member 48 38193, 46181,

1002854169

100296087 solute carrier family 361661 6242 354721 14230 22218, 30206, 26 (sulfate 38194, 46182, transporter), member 54170 1

100306088 solute carrier family 398516 6243 381528 14231 22219, 30207, 26 (sulfate 38195, 46183, transporter), member 54171 1

100316089 solute carrier family 398520 6244 381532 14232 22220, 30208, 26 (sulfate 38196, 46184, transporter), member 54172 1

100326090 solute carrier family 379218 6245 368520 14233 22221, 30209, 26, member 10 38197, 46185,

1003354173

100346091 solute carrier family 361193 6246 355384 14234 22222, 30210, 26, member 11 38198, 46186,

1003554174

100366092 solute carrier family 411502 6247 403998 14235 22223, 30211, 26, member 11 38199, 46187,

1003754175

100386093 solute carrier family 546047 6248 440724 14236 22224, 30212, 26, member 11 38200, 46188,

1003954176

100406094 solute carrier family 276609 6249 276609 14237 22225, 30213, 26, member 7 38201, 46189,

1004154177

100426095 solute carrier family 309536 6250 309504 14238 22226, 30214, 26, member 7 38202, 46190,

1004354178

100446096 solute carrier family 522862 6251 428881 14239 22227, 30215, 26, member 7 38203, 46191,

1004554179

100466097 solute carrier family 523719 6252 428849 14240 22228, 30216, 26, member 7 38204, 46192,

1004754180

100486098 solute carrier family 355574 6253 347778 14241 22229, 30217, 26, member 8 38205, 46193,

1004954181

100506099 solute carrier family 394602 6254 378100 14242 22230, 30218, 26, member 8 38206, 46194,

1005154182

100526100 solute carrier family 490799 6255 417638 14243 22231, 30219, 26, member 8 38207, 46195,

1005354183

100546101 solute carrier family 340781 6256 341682 14244 22232, 30220, 26, member 9 38208, 46196,

1005554184 6102 solute carrier family 367134 6257 356102 14245 22233, 30221, 26, member 9 38209, 46197,

1005654185

100576103 solute carrier family 367135 6258 356103 14246 22234, 30222, 26, member 9 38210, 46198,

1005854186

100596104 solute carrier family 262462 6259 262462 14247 22235, 30223, 27 (fatty acid 38211, 46199, transporter), member 54187 6

100606105 solute carrier family 395266 6260 378684 14248 22236, 30224, 27 (fatty acid 38212, 46200, transporter), member 54188 6

100616106 solute carrier family 506176 6261 421024 14249 22237, 30225, 27 (fatty acid 38213, 46201, transporter), member 54189 6

100626107 solute carrier family 297195 6262 297195 14250 22238, 30226, 29 (nucleoside 38214, 46202, transporters), 54190 member 4

100636108 solute carrier family 396872 6263 380081 14251 22239, 30227, 29 (nucleoside 38215, 46203, transporters), 54191 member 4

100646109 solute carrier family 434816 6264 406803 14252 22240, 30228, 29 (nucleoside 38216, 46204, transporters), 54192 member 4

100656110 solute carrier family 264451 6265 264451 14253 22241, 30229, 30 (zinc transporter), 38217, 46205, member 9 54193

100666111 solute carrier family 536881 6266 445151 14254 22242, 30230, 30 (zinc transporter), 38218, 46206, member 9 54194

100676112 solute carrier family 217420 6267 217420 14255 22243, 30231, 32 (GABA vesicular 38219, 46207, transporter), member 54195 1

100686113 solute carrier family 595753 6268 470652 14256 22244, 30232, 35 member El 38220, 46208,

1006954196

100706114 solute carrier family 556826 6269 452086 14257 22245, 30233, 35 member F4 38221, 46209,

1007154197

100726115 solute carrier family 323146 6270 327133 14258 22246, 30234, 35, member A4 38222, 46210,

1007354198

100746116 solute carrier family 432254 6271 415133 14259 22247, 30235, 35, member A4 38223, 46211,

1007554199

100766117 solute carrier family 514199 6272 424566 14260 22248, 30236, 35, member A4 38224, 46212,

1007754200 6118 solute carrier family 468642 6273 418265 14261 22249, 30237, 35, member A5 38225, 46213,

1007854201

100796119 solute carrier family 484995 6274 419958 14262 22250, 30238, 35, member A5 38226, 46214,

1008054202

100816120 solute carrier family 492406 6275 417654 14263 22251, 30239, 35, member A5 38227, 46215,

1008254203

100836121 solute carrier family 243896 6276 243896 14264 22252, 30240, 35, member C2 38228, 46216,

1008454204

100856122 solute carrier family 317734 6277 318960 14265 22253, 30241, 35, member C2 38229, 46217,

1008654205

100876123 solute carrier family 372223 6278 361297 14266 22254, 30242, 35, member C2 38230, 46218,

1008854206

100896124 solute carrier family 372225 6279 361299 14267 22255, 30243, 35, member C2 38231, 46219,

1009054207

100916125 solute carrier family 372227 6280 361301 14268 22256, 30244, 35, member C2 38232, 46220,

1009254208

100936126 solute carrier family 372229 6281 361303 14269 22257, 30245, 35, member C2 38233, 46221,

1009454209

100956127 solute carrier family 372230 6282 361304 14270 22258, 30246, 35, member C2 38234, 46222,

1009654210

100976128 solute carrier family 420518 6283 397142 14271 22259, 30247, 35, member C2 38235, 46223,

1009854211

100996129 solute carrier family 424568 6284 415736 14272 22260, 30248, 35, member C2 38236, 46224,

1010054212

101016130 solute carrier family 543605 6285 439974 14273 22261, 30249, 35, member C2 38237, 46225,

1010254213

101036131 solute carrier family 409648 6286 387152 14274 22262, 30250, 35, member El 38238, 46226,

1010454214

101056132 solute carrier family 431408 6287 397670 14275 22263, 30251, 35, member El 38239, 46227,

1010654215

101076133 solute carrier family 246421 6288 246421 14276 22264, 30252, 35, member E2 38240, 46228,

1010854216

101096134 solute carrier family 355439 6289 347614 14277 22265, 30253, 35, member E2 38241, 46229,

1011054217

101116135 solute carrier family 400924 6290 383714 14278 22266, 30254, 35, member E2 38242, 46230,

1011254218 6136 solute carrier family 234800 6291 234800 14279 22267, 30255, 35, member E2B 38243, 46231,

1011354219

101146137 solute carrier family 378662 6292 367931 14280 22268, 30256, 35, member E2B 38244, 46232,

1011554220

101166138 solute carrier family 398004 6293 381089 14281 22269, 30257, 35, member E3 38245, 46233,

1011754221

101186139 solute carrier family 300385 6294 300385 14282 22270, 30258, 35, member E4 38246, 46234,

1011954222

101206140 solute carrier family 343605 6295 339626 14283 22271, 30259, 35, member E4 38247, 46235,

1012154223

101226141 solute carrier family 406566 6296 384377 14284 22272, 30260, 35, member E4 38248, 46236,

1012354224

101246142 solute carrier family 360388 6297 353557 14285 22273, 30261, 35, member Fl 38249, 46237,

1012554225

101266143 solute carrier family 265836 6298 265836 14286 22274, 30262, 35, member F2 38250, 46238,

1012754226

101286144 solute carrier family 375682 6299 364834 14287 22275, 30263, 35, member F2 38251, 46239,

1012954227

101306145 solute carrier family 429869 6300 393571 14288 22276, 30264, 35, member F2 38252, 46240,

1013154228

101326146 solute carrier family 525071 6301 434307 14289 22277, 30265, 35, member F2 38253, 46241,

1013354229

101346147 solute carrier family 525815 6302 436785 14290 22278, 30266, 35, member F2 38254, 46242,

1013554230

101366148 solute carrier family 366617 6303 355576 14291 22279, 30267, 35, member F3 38255, 46243,

1013754231

101386149 solute carrier family 366618 6304 355577 14292 22280, 30268, 35, member F3 38256, 46244,

1013954232

101406150 solute carrier family 339762 6305 342518 14293 22281, 30269, 35, member F4 38257, 46245,

1014154233

101426151 solute carrier family 245680 6306 245680 14294 22282, 30270, 35, member F5 38258, 46246,

1014354234

101446152 solute carrier family 409106 6307 386754 14295 22283, 30271, 35, member F5 38259, 46247,

1014554235

101466153 solute carrier family 371408 6308 360462 14296 22284, 30272, 35, member Gl 38260, 46248,

1014754236 6154 solute carrier family 427197 6309 400932 14297 22285, 30273, 35, member Gl 38261, 46249,

1014854237

101496155 solute carrier family 297307 6310 297307 14298 22286, 30274, 35, member G3 38262, 46250,

1015054238

101516156 solute carrier family 382435 6311 371872 14299 22287, 30275, 35, member G5 38263, 46251,

1015254239

101536157 solute carrier family 298280 6312 298280 14300 22288, 30276, 37 (glycerol- 3- 38264, 46252, phosphate 54240 transporter), member

101542

101556158 solute carrier family 308074 6313 311833 14301 22289, 30277, 37 (glycerol- 3- 38265, 46253, phosphate 54241 transporter), member

101562

101576159 solute carrier family 403796 6314 384407 14302 22290, 30278, 37 (glycerol- 3- 38266, 46254, phosphate 54242 transporter), member

101582

101596160 solute carrier family 407458 6315 385126 14303 22291, 30279, 37 (glycerol- 3- 38267, 46255, phosphate 54243 transporter), member

101602

101616161 solute carrier family 326232 6316 321498 14304 22292, 30280, 37 (glycerol- 3- 38268, 46256, phosphate 54244 transporter), member

101623

101636162 solute carrier family 340308 6317 343358 14305 22293, 30281, 37 (glycerol- 3- 38269, 46257, phosphate 54245 transporter), member

101643

101656163 solute carrier family 429996 6318 412208 14306 22294, 30282, 37 (glycerol- 3- 38270, 46258, phosphate 54246 transporter), member

101663

101676164 solute carrier family 447932 6319 397481 14307 22295, 30283, 37 (glycerol- 3- 38271, 46259, phosphate 54247 transporter), member

101683

101696165 solute carrier family 491505 6320 417181 14308 22296, 30284, 37 (glycerol- 3- 38272, 46260, phosphate 54248 transporter), member

101703 6166 solute carrier family 539816 6321 442808 14309 22297, 30285, 37 (glycerol- 3- 38273, 46261, phosphate 54249 transporter), member

101713

101726167 solute carrier family 288439 6322 288439 14310 22298, 30286, 38, member 10 38274, 46262,

1017354250

101746168 solute carrier family 374759 6323 363891 14311 22299, 30287, 38, member 10 38275, 46263,

1017554251

101766169 solute carrier family 303735 6324 306178 14312 22300, 30288, 38, member 11 38276, 46264,

1017754252

101786170 solute carrier family 409149 6325 386272 14313 22301, 30289, 38, member 11 38277, 46265,

1017954253

101806171 solute carrier family 409662 6326 386774 14314 22302, 30290, 38, member 11 38278, 46266,

1018154254

101826172 solute carrier family 267488 6327 267488 14315 22303, 30291, 38, member 6 38279, 46267,

1018354255

101846173 solute carrier family 354886 6328 346959 14316 22304, 30292, 38, member 6 38280, 46268,

1018554256

101866174 solute carrier family 451406 6329 395851 14317 22305, 30293, 38, member 6 38281, 46269,

1018754257

101886175 solute carrier family 456840 6330 413863 14318 22306, 30294, 38, member 6 38282, 46270,

1018954258

101906176 solute carrier family 318672 6331 316596 14319 22307, 30295, 38, member 9 38283, 46271,

1019154259

101926177 solute carrier family 396865 6332 380074 14320 22308, 30296, 38, member 9 38284, 46272,

1019354260

101946178 solute carrier family 416547 6333 397429 14321 22309, 30297, 38, member 9 38285, 46273,

1019554261

101966179 solute carrier family 503891 6334 425055 14322 22310, 30298, 38, member 9 38286, 46274,

1019754262

101986180 solute carrier family 506624 6335 425259 14323 22311, 30299, 38, member 9 38287, 46275,

1019954263

102006181 solute carrier family 507109 6336 420950 14324 22312, 30300, 38, member 9 38288, 46276,

1020154264

102026182 solute carrier family 512595 6337 427335 14325 22313, 30301, 38, member 9 38289, 46277,

1020354265 6183 solute carrier family 513275 6338 425842 14326 22314, 30302, 38, member 9 38290, 46278,

1020454266

102056184 solute carrier family 513993 6339 422843 14327 22315, 30303, 38, member 9 38291, 46279,

1020654267

102076185 solute carrier family 515629 6340 420934 14328 22316, 30304, 38, member 9 38292, 46280,

1020854268

102096186 solute carrier family 539768 6341 437771 14329 22317, 30305, 38, member 9 38293, 46281,

1021054269

102116187 solute carrier family 255559 6342 255559 14330 22318, 30306, 39 (metal ion 38294, 46282, transporter), member 54270 11

102126188 solute carrier family 542342 6343 445829 14331 22319, 30307, 39 (metal ion 38295, 46283, transporter), member 54271 11

102136189 solute carrier family 266980 6344 266980 14332 22320, 30308, 39 (metal ion 38296, 46284, transporter), member 54272 5

102146190 solute carrier family 417965 6345 414868 14333 22321, 30309, 39 (metal ion 38297, 46285, transporter), member 54273 5

102156191 solute carrier family 419753 6346 402891 14334 22322, 30310, 39 (metal ion 38298, 46286, transporter), member 54274 5

102166192 solute carrier family 424625 6347 404155 14335 22323, 30311, 39 (metal ion 38299, 46287, transporter), member 54275 5

102176193 solute carrier family 437277 6348 407399 14336 22324, 30312, 39 (metal ion 38300, 46288, transporter), member 54276 5

102186194 solute carrier family 454355 6349 405360 14337 22325, 30313, 39 (metal ion 38301, 46289, transporter), member 54277 5

102196195 solute carrier family 556605 6350 452385 14338 22326, 30314, 39 (zinc transporter) 38302, 46290, member 9 54278

102206196 solute carrier family 359634 6351 352655 14339 22327, 30315, 39 (zinc transporter), 38303, 46291, member 10 54279

102216197 solute carrier family 409086 6352 386766 14340 22328, 30316, 39 (zinc transporter), 38304, 46292, member 10 54280 6198 solute carrier family 412905 6353 406590 14341 22329, 30317, 39 (zinc transporter), 38305, 46293, member 10 54281

102226199 solute carrier family 418005 6354 409272 14342 22330, 30318, 39 (zinc transporter), 38306, 46294, member 10 54282

102236200 solute carrier family 458054 6355 389640 14343 22331, 30319, 39 (zinc transporter), 38307, 46295, member 10 54283

102246201 solute carrier family 541054 6356 437787 14344 22332, 30320, 39 (zinc transporter), 38308, 46296, member 10 54284

102256202 solute carrier family 377369 6357 366586 14345 22333, 30321, 39 (zinc transporter), 38309, 46297, member 12 54285

102266203 solute carrier family 377371 6358 366588 14346 22334, 30322, 39 (zinc transporter), 38310, 46298, member 12 54286

102276204 solute carrier family 377374 6359 366591 14347 22335, 30323, 39 (zinc transporter), 38311, 46299, member 12 54287

102286205 solute carrier family 425219 6360 395382 14348 22336, 30324, 39 (zinc transporter), 38312, 46300, member 12 54288

102296206 solute carrier family 539911 6361 440445 14349 22337, 30325, 39 (zinc transporter), 38313, 46301, member 12 54289

102306207 solute carrier family 240095 6362 240095 14350 22338, 30326, 39 (zinc transporter), 38314, 46302, member 14 54290

102316208 solute carrier family 289952 6363 289952 14351 22339, 30327, 39 (zinc transporter), 38315, 46303, member 14 54291

102326209 solute carrier family 359741 6364 352779 14352 22340, 30328, 39 (zinc transporter), 38316, 46304, member 14 54292

102336210 solute carrier family 381237 6365 370635 14353 22341, 30329, 39 (zinc transporter), 38317, 46305, member 14 54293

102346211 solute carrier family 356736 6366 349174 14354 22342, 30330, 39 (zinc transporter), 38318, 46306, member 8 54294

102356212 solute carrier family 394833 6367 378310 14355 22343, 30331, 39 (zinc transporter), 38319, 46307, member 8 54295

102366213 solute carrier family 424970 6368 394548 14356 22344, 30332, 39 (zinc transporter), 38320, 46308, member 8 54296

102376214 solute carrier family 336643 6369 336887 14357 22345, 30333, 39 (zinc transporter), 38321, 46309, member 9 54297

102386215 solute carrier family 555840 6370 450639 14358 22346, 30334, 39 (zinc transporter), 38322, 46310, member 9 54298 6216 solute carrier family 506545 6371 422855 14359 22347, 30335, 4 sodium 38323, 46311, bicarbonate 54299 cotransporter

10239member 9

102406217 solute carrier family 273063 6372 273063 14360 22348, 30336, 4, anion exchanger, 38324, 46312, member 3 54300

102416218 solute carrier family 317151 6373 314006 14361 22349, 30337, 4, anion exchanger, 38325, 46313, member 3 54301

102426219 solute carrier family 356251 6374 348586 14362 22350, 30338, 4, anion exchanger, 38326, 46314, member 3 54302

102436220 solute carrier family 358055 6375 350756 14363 22351, 30339, 4, anion exchanger, 38327, 46315, member 3 54303

102446221 solute carrier family 373760 6376 362865 14364 22352, 30340, 4, anion exchanger, 38328, 46316, member 3 54304

102456222 solute carrier family 373762 6377 362867 14365 22353, 30341, 4, anion exchanger, 38329, 46317, member 3 54305

102466223 solute carrier family 413743 6378 414722 14366 22354, 30342, 4, anion exchanger, 38330, 46318, member 3 54306

102476224 solute carrier family 230993 6379 230993 14367 22355, 30343, 4, sodium 38331, 46319, bicarbonate 54307 cotransporter,

10248member 9

102496225 solute carrier family 432095 6380 410056 14368 22356, 30344, 4, sodium 38332, 46320, bicarbonate 54308 cotransporter,

10250member 9

102516226 solute carrier family 506757 6381 424424 14369 22357, 30345, 4, sodium 38333, 46321, bicarbonate 54309 cotransporter,

10252member 9

102536227 solute carrier family 507527 6382 427661 14370 22358, 30346, 4, sodium 38334, 46322, bicarbonate 54310 cotransporter,

10254member 9

102556228 solute carrier family 352187 6383 337561 14371 22359, 30347, 43, member 3 38335, 46323,

1025654311

102576229 solute carrier family 395123 6384 378555 14372 22360, 30348, 43, member 3 38336, 46324,

1025854312

102596230 solute carrier family 395124 6385 378556 14373 22361, 30349, 43, member 3 38337, 46325,

1026054313 6231 solute carrier family 524863 6386 434569 14374 22362, 30350, 43, member 3 38338, 46326,

1026154314

102626232 solute carrier family 525474 6387 436055 14375 22363, 30351, 43, member 3 38339, 46327,

1026354315

102646233 solute carrier family 526621 6388 434710 14376 22364, 30352, 43, member 3 38340, 46328,

1026554316

102666234 solute carrier family 529112 6389 434913 14377 22365, 30353, 43, member 3 38341, 46329,

1026754317

102686235 solute carrier family 529494 6390 433974 14378 22366, 30354, 43, member 3 38342, 46330,

1026954318

102706236 solute carrier family 529554 6391 436254 14379 22367, 30355, 43, member 3 38343, 46331,

1027154319

102726237 solute carrier family 529748 6392 433393 14380 22368, 30356, 43, member 3 38344, 46332,

1027354320

102746238 solute carrier family 530005 6393 435893 14381 22369, 30357, 43, member 3 38345, 46333,

1027554321

102766239 solute carrier family 530316 6394 431765 14382 22370, 30358, 43, member 3 38346, 46334,

1027754322

102786240 solute carrier family 532278 6395 434371 14383 22371, 30359, 43, member 3 38347, 46335,

1027954323

102806241 solute carrier family 532795 6396 435109 14384 22372, 30360, 43, member 3 38348, 46336,

1028154324

102826242 solute carrier family 533051 6397 435490 14385 22373, 30361, 43, member 3 38349, 46337,

1028354325

102846243 solute carrier family 533235 6398 435156 14386 22374, 30362, 43, member 3 38350, 46338,

1028554326

102866244 solute carrier family 533245 6399 431762 14387 22375, 30363, 43, member 3 38351, 46339,

1028754327

102886245 solute carrier family 527077 6400 433641 14388 22376, 30364, 44 member 3 38352, 46340,

1028954328

102906246 solute carrier family 529450 6401 431836 14389 22377, 30365, 44 member 3 38353, 46341,

1029154329

102926247 solute carrier family 271227 6402 271227 14390 22378, 30366, 44, member 3 38354, 46342,

1029354330

102946248 solute carrier family 422520 6403 410832 14391 22379, 30367, 44, member 3 38355, 46343,

1029554331 6249 solute carrier family 446120 6404 389143 14392 22380, 30368, 44, member 3 38356, 46344,

1029654332

102976250 solute carrier family 467909 6405 432789 14393 22381, 30369, 44, member 3 38357, 46345,

1029854333

102996251 solute carrier family 370855 6406 359892 14394 22382, 30370, 44, member 5 38358, 46346,

1030054334

103016252 solute carrier family 370859 6407 359896 14395 22383, 30371, 44, member 5 38359, 46347,

1030254335

103036253 solute carrier family 535611 6408 443090 14396 22384, 30372, 44, member 5 38360, 46348,

1030454336

103056254 solute carrier family 535790 6409 442685 14397 22385, 30373, 44, member 5 38361, 46349,

1030654337

103076255 solute carrier family 536707 6410 440581 14398 22386, 30374, 44, member 5 38362, 46350,

1030854338

103096256 solute carrier family 266943 6411 266943 14399 22387, 30375, 46, member 3 38363, 46351,

1031054339

103116257 solute carrier family 380814 6412 370192 14400 22388, 30376, 46, member 3 38364, 46352,

1031254340

103136258 solute carrier family 432662 6413 389956 14401 22389, 30377, 48 (heme 38365, 46353, transporter), member 54341 1

103146259 solute carrier family 442218 6414 415998 14402 22390, 30378, 48 (heme 38366, 46354, transporter), member 54342 1

103156260 solute carrier family 442892 6415 410134 14403 22391, 30379, 48 (heme 38367, 46355, transporter), member 54343 1

103166261 solute carrier family 547002 6416 446739 14404 22392, 30380, 48 (heme 38368, 46356, transporter), member 54344 1

103176262 solute carrier family 548498 6417 450234 14405 22393, 30381, 48 (heme 38369, 46357, transporter), member 54345 1

103186263 solute carrier family 549243 6418 446686 14406 22394, 30382, 48 (heme 38370, 46358, transporter), member 54346 1

103196264 solute carrier family 264047 6419 264047 14407 22395, 30383, 5 (choline 38371, 46359, transporter), member 54347 7 6265 solute carrier family 409059 6420 387346 14408 22396, 30384, 5 (choline 38372, 46360, transporter), member 54348 7

103206266 solute carrier family 540517 6421 445351 14409 22397, 30385, 5 (choline 38373, 46361, transporter), member 54349 7

103216267 solute carrier family 266086 6422 266086 14410 22398, 30386, 5 (low affinity 38374, 46362, glucose 54350 cotransporter),

10322member 4

103236268 solute carrier family 565769 6423 457179 14411 22399, 30387, 5 (sodium/glucose 38375, 46363, cotransporter) 54351 member 11

103246269 solute carrier family 317977 6424 324346 14412 22400, 30388, 5 (sodium/glucose 38376, 46364, cotransporter), 54352 member 10

103256270 solute carrier family 395642 6425 379004 14413 22401, 30389, 5 (sodium/glucose 38377, 46365, cotransporter), 54353 member 10

103266271 solute carrier family 395643 6426 379005 14414 22402, 30390, 5 (sodium/glucose 38378, 46366, cotransporter), 54354 member 10

103276272 solute carrier family 395645 6427 379007 14415 22403, 30391, 5 (sodium/glucose 38379, 46367, cotransporter), 54355 member 10

103286273 solute carrier family 395647 6428 379008 14416 22404, 30392, 5 (sodium/glucose 38380, 46368, cotransporter), 54356 member 10

103296274 solute carrier family 417251 6429 401875 14417 22405, 30393, 5 (sodium/glucose 38381, 46369, cotransporter), 54357 member 10

103306275 solute carrier family 347898 6430 289932 14418 22406, 30394, 5 (sodium/glucose 38382, 46370, cotransporter), 54358 member 11

103316276 solute carrier family 424767 6431 416782 14419 22407, 30395, 5 (sodium/glucose 38383, 46371, cotransporter), 54359 member 11

103326277 solute carrier family 449109 6432 389606 14420 22408, 30396, 5 (sodium/glucose 38384, 46372, cotransporter), 54360 member 11 6278 solute carrier family 539472 6433 441018 14421 22409, 30397, 5 (sodium/glucose 38385, 46373, cotransporter), 54361 member 11

103336279 solute carrier family 545376 6434 441384 14422 22410, 30398, 5 (sodium/glucose 38386, 46374, cotransporter), 54362 member 11

103346280 solute carrier family 236495 6435 236495 14423 22411, 30399, 5 (sodium/glucose 38387, 46375, cotransporter), 54363 member 9

103356281 solute carrier family 420136 6436 408881 14424 22412, 30400, 5 (sodium/glucose 38388, 46376, cotransporter), 54364 member 9

103366282 solute carrier family 438567 6437 401730 14425 22413, 30401, 5 (sodium/glucose 38389, 46377, cotransporter), 54365 member 9

103376283 solute carrier family 441260 6438 399991 14426 22414, 30402, 5 (sodium/glucose 38390, 46378, cotransporter), 54366 member 9

103386284 solute carrier family 310574 6439 310208 14427 22415, 30403, 5 (sodium- 38391, 46379, dependent vitamin 54367 transporter), member

103396

103406285 solute carrier family 401463 6440 384265 14428 22416, 30404, 5 (sodium- 38392, 46380, dependent vitamin 54368 transporter), member

103416

103426286 solute carrier family 408041 6441 384853 14429 22417, 30405, 5 (sodium- 38393, 46381, dependent vitamin 54369 transporter), member

103436

103446287 solute carrier family 412471 6442 403851 14430 22418, 30406, 5 (sodium- 38394, 46382, dependent vitamin 54370 transporter), member

103456

103466288 solute carrier family 414408 6443 404032 14431 22419, 30407, 5 (sodium- 38395, 46383, dependent vitamin 54371 transporter), member

103476

103486289 solute carrier family 426119 6444 401347 14432 22420, 30408, 5 (sodium- 38396, 46384, dependent vitamin 54372 transporter), member

103496 6290 solute carrier family 428518 6445 402903 14433 22421, 30409, 5 (sodium- 38397, 46385, dependent vitamin 54373 transporter), member

103506

103516291 solute carrier family 430186 6446 399299 14434 22422, 30410, 5 (sodium- 38398, 46386, dependent vitamin 54374 transporter), member

103526

103536292 solute carrier family 432106 6447 411536 14435 22423, 30411, 5 (sodium- 38399, 46387, dependent vitamin 54375 transporter), member

103546

103556293 solute carrier family 442731 6448 412115 14436 22424, 30412, 5 (sodium- 38400, 46388, dependent vitamin 54376 transporter), member

103566

103576294 solute carrier family 445802 6449 411361 14437 22425, 30413, 5 (sodium- 38401, 46389, dependent vitamin 54377 transporter), member

103586

103596295 solute carrier family 313154 6450 318097 14438 22426, 30414, 6 (neurotransmitter 38402, 46390, transporter, GAB A), 54378 member 13

103606296 solute carrier family 343164 6451 339260 14439 22427, 30415, 6 (neurotransmitter 38403, 46391, transporter, GAB A), 54379 member 13

103616297 solute carrier family 436453 6452 389316 14440 22428, 30416, 6 (neurotransmitter 38404, 46392, transporter, GAB A), 54380 member 13

103626298 solute carrier family 445055 6453 407104 14441 22429, 30417, 6 (neurotransmitter 38405, 46393, transporter, GAB A), 54381 member 13

103636299 solute carrier family 266682 6454 266682 14442 22430, 30418, 6 (neutral amino 38406, 46394, acid transporter), 54382 member 15

103646300 solute carrier family 318721 6455 317711 14443 22431, 30419, 6 (neutral amino 38407, 46395, acid transporter), 54383 member 15

103656301 solute carrier family 450363 6456 390706 14444 22432, 30420, 6 (neutral amino 38408, 46396, acid transporter), 54384 member 15 6302 solute carrier family 549540 6457 448308 14445 22433, 30421, 6 (neutral amino 38409, 46397, acid transporter), 54385 member 15

103666303 solute carrier family 552192 6458 450145 14446 22434, 30422, 6 (neutral amino 38410, 46398, acid transporter), 54386 member 15

103676304 solute carrier family 335875 6459 338627 14447 22435, 30423, 6, member 16 38411, 46399,

1036854387

103696305 solute carrier family 454748 6460 404022 14448 22436, 30424, 6, member 16 38412, 46400,

1037054388

103716306 solute carrier family 331565 6461 330199 14449 22437, 30425, 6, member 17 38413, 46401,

1037254389

103736307 solute carrier family 450985 6462 405461 14450 22438, 30426, 6, member 17 38414, 46402,

1037454390

103756308 solute carrier family 280612 6463 280612 14451 22439, 30427, 7 (anionic amino 38415, 46403, acid transporter light 54391 chain, xc- system),

10376member 11

103776309 solute carrier family 297524 6464 297524 14452 22440, 30428, 7 (anionic amino 38416, 46404, acid transporter), 54392 member 13

103786310 solute carrier family 419776 6465 410982 14453 22441, 30429, 7 (anionic amino 38417, 46405, acid transporter), 54393 member 13

103796311 solute carrier family 298085 6466 298085 14454 22442, 30430, 7 (cationic amino 38418, 46406, acid transporter, y+ 54394 system), member 3

103806312 solute carrier family 374299 6467 363417 14455 22443, 30431, 7 (cationic amino 38419, 46407, acid transporter, y+ 54395 system), member 3

103816313 solute carrier family 253188 6468 253188 14456 22444, 30432, 7 (neutral amino 38420, 46408, acid transporter light 54396 chain, asc system),

10382member 10

103836314 solute carrier family 231706 6469 231706 14457 22445, 30433, 7 (orphan 38421, 46409, transporter), member 54397 14

103846315 solute carrier family 216568 6470 216568 14458 22446, 30434, 8 (sodium/calcium 38422, 46410, exchanger), member 54398 3 6316 solute carrier family 356921 6471 349392 14459 22447, 30435, 8 (sodium/calcium 38423, 46411, exchanger), member 54399 3

103856317 solute carrier family 357887 6472 350560 14460 22448, 30436, 8 (sodium/calcium 38424, 46412, exchanger), member 54400 3

103866318 solute carrier family 381269 6473 370669 14461 22449, 30437, 8 (sodium/calcium 38425, 46413, exchanger), member 54401 3

103876319 solute carrier family 394330 6474 377863 14462 22450, 30438, 8 (sodium/calcium 38426, 46414, exchanger), member 54402 3

103886320 solute carrier family 494208 6475 436332 14463 22451, 30439, 8 (sodium/calcium 38427, 46415, exchanger), member 54403 3

103896321 solute carrier family 528359 6476 433531 14464 22452, 30440, 8 (sodium/calcium 38428, 46416, exchanger), member 54404 3

103906322 solute carrier family 534137 6477 436688 14465 22453, 30441, 8 (sodium/calcium 38429, 46417, exchanger), member 54405 3

103916323 solute carrier family 367714 6478 356687 14466 22454, 30442, 9, member 11 38430, 46418,

1039254406

103936324 solute carrier family 536496 6479 445437 14467 22455, 30443, 9, member 11 38431, 46419,

1039454407

103956325 solute carrier family 296422 6480 296422 14468 22456, 30444, 9, subfamily B 38432, 46420, (cation proton 54408 antiporter 2),

10396member 1

103976326 solute carrier family 394789 6481 378269 14469 22457, 30445, 9, subfamily B 38433, 46421, (cation proton 54409 antiporter 2),

10398member 1

103996327 solute carrier family 452285 6482 387772 14470 22458, 30446, 9, subfamily B 38434, 46422, (cation proton 54410 antiporter 2),

10400member 1

104016328 solute carrier family 510559 6483 426325 14471 22459, 30447, 9, subfamily B 38435, 46423, (cation proton 54411 antiporter 2),

10402member 1 6329 solute carrier family 339611 6484 345241 14472 22460, 30448, 9, subfamily B 38436, 46424, (cation proton 54412 antiporter 2),

10403member 2

104046330 solute carrier family 362026 6485 354574 14473 22461, 30449, 9, subfamily B 38437, 46425, (cation proton 54413 antiporter 2),

10405member 2

104066331 solute carrier family 394785 6486 378265 14474 22462, 30450, 9, subfamily B 38438, 46426, (cation proton 54414 antiporter 2),

10407member 2

104086332 solute carrier family 503103 6487 425385 14475 22463, 30451, 9, subfamily B 38439, 46427, (cation proton 54415 antiporter 2),

10409member 2

104106333 solute carrier family 503230 6488 422477 14476 22464, 30452, 9, subfamily B 38440, 46428, (cation proton 54416 antiporter 2),

10411member 2

104126334 solute carrier family 503818 6489 426305 14477 22465, 30453, 9, subfamily B 38441, 46429, (cation proton 54417 antiporter 2),

10413member 2

104146335 solute carrier 524945 6490 434422 14478 22466, 30454, organic anion 38442, 46430, transporter family 54418 member 5A1

104156336 solute carrier 307378 6491 305974 14479 22467, 30455, organic anion 38443, 46431, transporter family, 54419 member 1A2

104166337 solute carrier 390670 6492 375088 14480 22468, 30456, organic anion 38444, 46432, transporter family, 54420 member 1A2

104176338 solute carrier 416627 6493 392124 14481 22469, 30457, organic anion 38445, 46433, transporter family, 54421 member 1A2

104186339 solute carrier 421287 6494 390672 14482 22470, 30458, organic anion 38446, 46434, transporter family, 54422 member 1A2

104196340 solute carrier 421294 6495 390572 14483 22471, 30459, organic anion 38447, 46435, transporter family, 54423 member 1A2 6341 solute carrier 422327 6496 416190 14484 22472, 30460, organic anion 38448, 46436, transporter family, 54424 member 1A2

104206342 solute carrier 430803 6497 410338 14485 22473, 30461, organic anion 38449, 46437, transporter family, 54425 member 1A2

104216343 solute carrier 435179 6498 401195 14486 22474, 30462, organic anion 38450, 46438, transporter family, 54426 member 1A2

104226344 solute carrier 450590 6499 407462 14487 22475, 30463, organic anion 38451, 46439, transporter family, 54427 member 1A2

104236345 solute carrier 452078 6500 393973 14488 22476, 30464, organic anion 38452, 46440, transporter family, 54428 member 1A2

104246346 solute carrier 453443 6501 409314 14489 22477, 30465, organic anion 38453, 46441, transporter family, 54429 member 1A2

104256347 solute carrier 458504 6502 394854 14490 22478, 30466, organic anion 38454, 46442, transporter family, 54430 member 1A2

104266348 solute carrier 537524 6503 439401 14491 22479, 30467, organic anion 38455, 46443, transporter family, 54431 member 1A2

104276349 solute carrier 493729 6504 418893 14492 22480, 30468, organic anion 38456, 46444, transporter family, 54432 member 2A1

104286350 solute carrier 289575 6505 289575 14493 22481, 30469, organic anion 38457, 46445, transporter family, 54433 member 2B1

104296351 solute carrier 341411 6506 341286 14494 22482, 30470, organic anion 38458, 46446, transporter family, 54434 member 2B1

104306352 solute carrier 428359 6507 388912 14495 22483, 30471, organic anion 38459, 46447, transporter family, 54435 member 2B1

104316353 solute carrier 454962 6508 389653 14496 22484, 30472, organic anion 38460, 46448, transporter family, 54436 member 2B1

104326354 solute carrier 525650 6509 436324 14497 22485, 30473, organic anion 38461, 46449, transporter family, 54437 member 2B1

104336355 solute carrier 525845 6510 431324 14498 22486, 30474, organic anion 38462, 46450, transporter family, 54438 member 2B1

104346356 solute carrier 527180 6511 436513 14499 22487, 30475, organic anion 38463, 46451, transporter family, 54439 member 2B1

104356357 solute carrier 530556 6512 435384 14500 22488, 30476, organic anion 38464, 46452, transporter family, 54440 member 2B1

104366358 solute carrier 531713 6513 432889 14501 22489, 30477, organic anion 38465, 46453, transporter family, 54441 member 2B1

104376359 solute carrier 532236 6514 434112 14502 22490, 30478, organic anion 38466, 46454, transporter family, 54442 member 2B1

104386360 solute carrier 534004 6515 431192 14503 22491, 30479, organic anion 38467, 46455, transporter family, 54443 member 2B1

104396361 solute carrier 534186 6516 433872 14504 22492, 30480, organic anion 38468, 46456, transporter family, 54444 member 2B1

104406362 solute carrier 310954 6517 309741 14505 22493, 30481, organic anion 38469, 46457, transporter family, 54445 member 4C1

104416363 solute carrier 260126 6518 260126 14506 22494, 30482, organic anion 38470, 46458, transporter family, 54446 member 5A1

104426364 solute carrier 530307 6519 431611 14507 22495, 30483, organic anion 38471, 46459, transporter family, 54447 member 5A1

104436365 sorting nexin 10 338523 6520 343709 14508 22496, 30484,

1044438472, 46460, 54448

104456366 sorting nexin 10 396376 6521 379661 14509 22497, 30485,

1044638473, 46461, 54449

104476367 sorting nexin 10 446848 6522 395474 14510 22498, 30486,

1044838474, 46462, 54450

104496368 sorting nexin 10 409838 6523 386540 14511 22499, 30487,

1045038475, 46463, 54451 6369 sorting nexin 14 314673 6524 313121 14512 22500, 30488,

1045138476, 46464, 54452

104526370 sorting nexin 14 346348 6525 257769 14513 22501, 30489,

1045338477, 46465, 54453

104546371 sorting nexin 14 369627 6526 358641 14514 22502, 30490,

1045538478, 46466, 54454

104566372 sorting nexin 14 369628 6527 358642 14515 22503, 30491,

1045738479, 46467, 54455

104586373 sorting nexin 14 505648 6528 427380 14516 22504, 30492,

1045938480, 46468, 54456

104606374 sorting nexin 16 345957 6529 322652 14517 22505, 30493,

1046138481, 46469, 54457

104626375 sorting nexin 16 353788 6530 322631 14518 22506, 30494,

1046338482, 46470, 54458

104646376 sorting nexin 16 396330 6531 379621 14519 22507, 30495,

1046538483, 46471, 54459

104666377 sorting nexin 16 518183 6532 428289 14520 22508, 30496,

1046738484, 46472, 54460

104686378 sorting nexin 16 519817 6533 428591 14521 22509, 30497,

1046938485, 46473, 54461

104706379 sorting nexin 16 521773 6534 430585 14522 22510, 30498,

1047138486, 46474, 54462

104726380 sorting nexin 16 521810 6535 428734 14523 22511, 30499,

1047338487, 46475, 54463

104746381 sorting nexin 18 326277 6536 317332 14524 22512, 30500,

1047538488, 46476, 54464

104766382 sorting nexin 18 343017 6537 342276 14525 22513, 30501,

1047738489, 46477, 54465

104786383 sorting nexin 18 381410 6538 370817 14526 22514, 30502,

1047938490, 46478, 54466

104806384 sorting nexin 19 265909 6539 265909 14527 22515, 30503,

1048138491, 46479, 54467

104826385 sorting nexin 19 539184 6540 443480 14528 22516, 30504,

1048338492, 46480, 54468

104846386 sorting nexin 19 545537 6541 437982 14529 22517, 30505,

1048538493, 46481, 54469 6387 sorting nexin 22 325881 6542 323435 14530 22518, 30506,

1048638494, 46482, 54470

104876388 sorting nexin 22 380278 6543 369631 14531 22519, 30507,

1048838495, 46483, 54471

104896389 sorting nexin 24 261369 6544 261369 14532 22520, 30508,

1049038496, 46484, 54472

104916390 sorting nexin 24 506996 6545 422535 14533 22521, 30509,

1049238497, 46485, 54473

104936391 sorting nexin 24 513881 6546 424149 14534 22522, 30510,

1049438498, 46486, 54474

104956392 sorting nexin 25 264693 6547 264693 14535 22523, 30511,

1049638499, 46487, 54475

104976393 sorting nexin 25 264694 6548 264694 14536 22524, 30512,

1049838500, 46488, 54476

104996394 sorting nexin 25 504273 6549 426255 14537 22525, 30513,

1050038501, 46489, 54477

105016395 sorting nexin 7 306121 6550 304429 14538 22526, 30514,

1050238502, 46490, 54478

105036396 sorting nexin 7 370189 6551 359208 14539 22527, 30515,

1050438503, 46491, 54479

105056397 sorting nexin 7 529992 6552 434731 14540 22528, 30516,

1050638504, 46492, 54480

105076398 sorting nexin 8 222990 6553 222990 14541 22529, 30517,

1050838505, 46493, 54481

105096399 sorting nexin 8 419693 6554 399127 14542 22530, 30518,

1051038506, 46494, 54482

105116400 sorting nexin 8 457286 6555 406954 14543 22531, 30519,

1051238507, 46495, 54483

105136401 sorting nexin family 342644 6556 344586 14544 22532, 30520, member 21 38508, 46496,

1051454484

105156402 sorting nexin family 372545 6557 361624 14545 22533, 30521, member 21 38509, 46497,

1051654485

105176403 sorting nexin family 462307 6558 420169 14546 22534, 30522, member 21 38510, 46498,

1051854486

105196404 sorting nexin family 491381 6559 418593 14547 22535, 30523, member 21 38511, 46499,

1052054487 <img file="WO2013151663A1_D0021.tif" />

10521sphingomyelinase - 3 ) 6420 sphingomyelin 351288 6575 259217 14563 22551, 30539, phosphodiesterase 4, 38527, 46515, neutral membrane 54503 (neutral

10522sphingomyelinase - 3 )

105236421 sphingomyelin 409031 6576 386531 14564 22552, 30540, phosphodiesterase 4, 38528, 46516, neutral membrane 54504 (neutral

10524sphingomyelinase - 3 )

105256422 sphingomyelin 426662 6577 397479 14565 22553, 30541, phosphodiesterase 4, 38529, 46517, neutral membrane 54505 (neutral

10526sphingomyelinase - 3 )

105276423 sphingomyelin 431183 6578 405187 14566 22554, 30542, phosphodiesterase 4, 38530, 46518, neutral membrane 54506 (neutral

10528sphingomyelinase - 3 )

105296424 sphingomyelin 443958 6579 391896 14567 22555, 30543, phosphodiesterase 4, 38531, 46519, neutral membrane 54507 (neutral

10530sphingomyelinase - 3 )

105316425 sphingomyelin 452225 6580 387762 14568 22556, 30544, phosphodiesterase 4, 38532, 46520, neutral membrane 54508 (neutral

10532sphingomyelinase - 3 )

105336426 sphingomyelin 453750 6581 394313 14569 22557, 30545, phosphodiesterase 4, 38533, 46521, neutral membrane 54509 (neutral

10534sphingomyelinase - 3 )

105356427 sphingosine-1- 299297 6582 299297 14570 22558, 30546, phosphate lyase 1 38534, 46522,

1053654510

105376428 sphingosine-1- 373202 6583 362298 14571 22559, 30547, phosphate lyase 1 38535, 46523,

1053854511

105396429 sphingosine-1- 409118 6584 386549 14572 22560, 30548, phosphate lyase 1 38536, 46524,

1054054512

105416430 spire homolog 1 309836 6585 309661 14573 22561, 30549, (Drosophila) 38537, 46525,

1054254513

105436431 spire homolog 1 383356 6586 372847 14574 22562, 30550, (Drosophila) 38538, 46526,

1054454514

105456432 spire homolog 1 409402 6587 387266 14575 22563, 30551, (Drosophila) 38539, 46527,

1054654515

105476433 spire homolog 1 410092 6588 387226 14576 22564, 30552, (Drosophila) 38540, 46528, 54516

105486434 spire homolog 1 453447 6589 407050 14577 22565, 30553, (Drosophila) 38541, 46529,

1054954517

105506435 SPRY domain 338146 6590 338034 14578 22566, 30554, containing 4 38542, 46530,

1055154518

105526436 SPRY domain 543121 6591 444305 14579 22567, 30555, containing 4 38543, 46531,

1055354519

105546437 ST3 beta-galactoside 377332 6592 366549 14580 22568, 30556, alpha-2,3- 38544, 46532, sialyltransferase 5 54520

105556438 ST3 beta-galactoside 393803 6593 377392 14581 22569, 30557, alpha-2,3- 38545, 46533, sialyltransferase 5 54521

105566439 ST3 beta-galactoside 393805 6594 377394 14582 22570, 30558, alpha-2,3- 38546, 46534, sialyltransferase 5 54522

105576440 ST3 beta-galactoside 393808 6595 377397 14583 22571, 30559, alpha-2,3- 38547, 46535, sialyltransferase 5 54523

105586441 ST3 beta-galactoside 455892 6596 401375 14584 22572, 30560, alpha-2,3- 38548, 46536, sialyltransferase 5 54524

105596442 ST3 beta-galactoside 525834 6597 433607 14585 22573, 30561, alpha-2,3- 38549, 46537, sialyltransferase 5 54525

105606443 ST6 (alpha-N- 156626 6598 156626 14586 22574, 30562, acetyl-neuraminyl- 38550, 46538, 2,3-beta-galactosyl- 54526, 56094, 1,3)-N- 56127 acetylgalactosammid

10561e alpha-2,6- sialyltransferase 1

105626444 ST6 (alpha-N- 359088 6599 351991 14587 22575, 30563, acetyl-neuraminyl- 38551, 46539, 2,3-beta-galactosyl- 54527 1,3)-N- acetylgalactosammid

10563e alpha-2,6- sialyltransferase 1

105646445 ST6 (alpha-N- 225276 6600 225276 14588 22576, 30564, acetyl-neuraminyl- 38552, 46540, 2,3-beta-galactosyl- 54528 1,3)-N- acetylgalactosammid

10565e alpha-2,6- sialyltransferase 2 6446 ST6 (alpha-N- 328299 6601 329214 14589 22577, 30565, acetyl-neuraminyl- 38553, 46541, 2,3-beta-galactosyl- 54529 1,3)-N- acetylgalactosammid

10566e alpha-2,6- sialyltransferase 3

105676447 ST6 (alpha-N- 394993 6602 378444 14590 22578, 30566, acetyl-neuraminyl- 38554, 46542, 2,3-beta-galactosyl- 54530 1,3)-N- acetylgalactosammid

10568e alpha-2,6- sialyltransferase 3

105696448 ST6 (alpha-N- 394994 6603 378445 14591 22579, 30567, acetyl-neuraminyl- 38555, 46543, 2,3-beta-galactosyl- 54531 1,3)-N- acetylgalactosammid

10570e alpha-2,6- sialyltransferase 3

105716449 ST6 (alpha-N- 415813 6604 395887 14592 22580, 30568, acetyl-neuraminyl- 38556, 46544, 2,3-beta-galactosyl- 54532 1,3)-N- acetylgalactosammid

10572e alpha-2,6- sialyltransferase 3

105736450 ST6 (alpha-N- 335791 6605 336733 14593 22581, 30569, acetyl-neuraminyl- 38557, 46545, 2,3-beta-galactosyl- 54533 1,3)-N- acetylgalactosammid

10574e alpha-2,6- sialyltransferase 4

105756451 ST6 (alpha-N- 343609 6606 340382 14594 22582, 30570, acetyl-neuraminyl- 38558, 46546, 2,3-beta-galactosyl- 54534 1,3)-N- acetylgalactosammid

10576e alpha-2,6- sialyltransferase 4

105776452 ST6 (alpha-N- 361444 6607 355130 14595 22583, 30571, acetyl-neuraminyl- 38559, 46547, 2,3-beta-galactosyl- 54535 1,3)-N- acetylgalactosammid

10578e alpha-2,6- sialyltransferase 4

105796453 ST6 (alpha-N- 541933 6608 439786 14596 22584, 30572, acetyl-neuraminyl- 38560, 46548, 2,3-beta-galactosyl- 54536 1,3)-N- acetylgalactosammid

10580e alpha-2,6- sialyltransferase 4

105816454 ST6 (alpha-N- 291839 6609 291839 14597 22585, 30573, acetyl-neuraminyl- 38561, 46549, 2,3-beta-galactosyl- 54537 1,3)-N- acetylgalactosammid

10582e alpha-2,6- sialyltransferase 6

105836455 ST6 (alpha-N- 373141 6610 362234 14598 22586, 30574, acetyl-neuraminyl- 38562, 46550, 2,3-beta-galactosyl- 54538 1,3)-N- acetylgalactosammid

10584e alpha-2,6- sialyltransferase 6

105856456 ST6 (alpha-N- 373142 6611 362235 14599 22587, 30575, acetyl-neuraminyl- 38563, 46551, 2,3-beta-galactosyl- 54539 1,3)-N- acetylgalactosammid

10586e alpha-2,6- sialyltransferase 6

105876457 ST6 (alpha-N- 373144 6612 362237 14600 22588, 30576, acetyl-neuraminyl- 38564, 46552, 2,3-beta-galactosyl- 54540 1,3)-N- acetylgalactosammid

10588e alpha-2,6- sialyltransferase 6

105896458 ST6 (alpha-N- 373146 6613 362239 14601 22589, 30577, acetyl-neuraminyl- 38565, 46553, 2,3-beta-galactosyl- 54541 1,3)-N- acetylgalactosammid

10590e alpha-2,6- sialyltransferase 6

105916459 ST6 (alpha-N- 447681 6614 405326 14602 22590, 30578, acetyl-neuraminyl- 38566, 46554, 2,3-beta-galactosyl- 54542 1,3)-N- acetylgalactosammid

10592e alpha-2,6- sialyltransferase 6

105936460 ST6 (alpha-N- 542456 6615 438109 14603 22591, 30579, acetyl-neuraminyl- 38567, 46555, 2,3-beta-galactosyl- 54543 1,3)-N- acetylgalactosammid

10594e alpha-2,6- sialyltransferase 6 6461 ST6 beta- 361686 6616 355273 14604 22592, 30580, galactosamide 38568, 46556, alpha-2,6- 54544 sialyltranferase 2

105956462 ST6 beta- 361803 6617 355386 14605 22593, 30581, galactosamide 38569, 46557, alpha-2,6- 54545 sialyltranferase 2

105966463 ST6 beta- 409087 6618 387332 14606 22594, 30582, galactosamide 38570, 46558, alpha-2,6- 54546 sialyltranferase 2

105976464 ST6 beta- 409382 6619 386942 14607 22595, 30583, galactosamide 38571, 46559, alpha-2,6- 54547 sialyltranferase 2

105986465 ST6 beta- 419159 6620 395581 14608 22596, 30584, galactosamide 38572, 46560, alpha-2,6- 54548 sialyltranferase 2

105996466 ST8 alpha-N-acetyl- 396037 6621 379353 14609 22597, 30585, neuraminide alpha- 38573, 46561, 2, 8-sialyltransferase 54549 1

106006467 ST8 alpha-N-acetyl- 539510 6622 446363 14610 22598, 30586, neuraminide alpha- 38574, 46562, 2, 8-sialyltransferase 54550 1

106016468 ST8 alpha-N-acetyl- 268164 6623 268164 14611 22599, 30587, neuraminide alpha- 38575, 46563, 2, 8-sialyltransferase 54551 2

106026469 ST8 alpha-N-acetyl- 539113 6624 437382 14612 22600, 30588, neuraminide alpha- 38576, 46564, 2, 8-sialyltransferase 54552 2

106036470 ST8 alpha-N-acetyl- 324000 6625 320431 14613 22601, 30589, neuraminide alpha- 38577, 46565, 2, 8-sialyltransferase 54553 3

106046471 ST8 alpha-N-acetyl- 541833 6626 438901 14614 22602, 30590, neuraminide alpha- 38578, 46566, 2, 8-sialyltransferase 54554 3

106056472 ST8 alpha-N-acetyl- 231461 6627 231461 14615 22603, 30591, neuraminide alpha- 38579, 46567, 2, 8-sialyltransferase 54555 4

106066473 ST8 alpha-N-acetyl- 451528 6628 428914 14616 22604, 30592, neuraminide alpha- 38580, 46568, 2, 8-sialyltransferase 54556 4

106076474 ST8 alpha-N-acetyl- 315087 6629 321343 14617 22605, 30593, neuraminide alpha- 38581, 46569, 2, 8-sialyltransferase 54557 5

106086475 ST8 alpha-N-acetyl- 536490 6630 443683 14618 22606, 30594, neuraminide alpha- 38582, 46570, 2, 8-sialyltransferase 54558 5

106096476 ST8 alpha-N-acetyl- 538168 6631 445492 14619 22607, 30595, neuraminide alpha- 38583, 46571, 2, 8-sialyltransferase 54559 5

106106477 ST8 alpha-N-acetyl- 377602 6632 366827 14620 22608, 30596, neuraminide alpha- 38584, 46572, 2, 8-sialyltransferase 54560 6

106116478 ST8 alpha-N-acetyl- 377610 6633 366835 14621 22609, 30597, neuraminide alpha- 38585, 46573, 2, 8-sialyltransferase 54561 6

106126479 ST8 alpha-N-acetyl- 440449 6634 388343 14622 22610, 30598, neuraminide alpha- 38586, 46574, 2, 8-sialyltransferase 54562 6

106136480 stabilin 1 321725 6635 312946 14623 22611, 30599,

1061438587, 46575, 54563

106156481 stabilin 2 258495 6636 258495 14624 22612, 30600,

1061638588, 46576, 54564

106176482 stabilin 2 388887 6637 373539 14625 22613, 30601,

1061838589, 46577, 54565

106196483 starch binding 237642 6638 237642 14626 22614, 30602, domain 1 38590, 46578,

1062054566

106216484 starch binding 539752 6639 442265 14627 22615, 30603, domain 1 38591, 46579,

1062254567

106236485 StAR-related lipid 337288 6640 338030 14628 22616, 30604, transfer (START) 38592, 46580, domain containing 7 54568

106246486 STEAP family 406890 6641 385239 14629 22617, 30605, member IB 38593, 46581,

1062554569

106266487 STEAP family 424363 6642 416608 14630 22618, 30606, member IB 38594, 46582,

1062754570

106286488 STEAP family 404369 6643 384370 14631 22619, 30607, member IB 38595, 46583,

1062954571

106306489 stearoyl-CoA 273908 6644 273908 14632 22620, 30608, desaturase 5 38596, 46584,

1063154572

106326490 stearoyl-CoA 282709 6645 282709 14633 22621, 30609, desaturase 5 38597, 46585, 54573

106336491 stearoyl-CoA 319540 6646 316329 14634 22622, 30610, desaturase 5 38598, 46586,

1063454574

106356492 stomatin 286713 6647 286713 14635 22623, 30611,

1063638599, 46587, 54575

106376493 stomatin 347359 6648 339607 14636 22624, 30612,

1063838600, 46588, 54576

106396494 stomatin 538954 6649 445764 14637 22625, 30613,

1064038601, 46589, 54577

106416495 STON1-GTF2A1L 309827 6650 311493 14638 22626, 30614, readthrough 38602, 46590,

1064254578

106436496 STON1-GTF2A1L 394749 6651 378232 14639 22627, 30615, readthrough 38603, 46591,

1064454579

106456497 STON1-GTF2A1L 394751 6652 378234 14640 22628, 30616, readthrough 38604, 46592,

1064654580

106476498 STON1-GTF2A1L 394754 6653 378236 14641 22629, 30617, readthrough 38605, 46593,

1064854581

106496499 STON1-GTF2A1L 405008 6654 385499 14642 22630, 30618, readthrough 38606, 46594,

1065054582

106516500 STON1-GTF2A1L 402114 6655 385701 14643 22631, 30619, readthrough 38607, 46595,

1065254583

106536501 stonin 1 309835 6656 310969 14644 22632, 30620,

1065438608, 46596, 54584

106556502 stonin 1 404752 6657 385273 14645 22633, 30621,

1065638609, 46597, 54585

106576503 stonin 1 406226 6658 384615 14646 22634, 30622,

1065838610, 46598, 54586

106596504 stonin 2 267540 6659 267540 14647 22635, 30623,

1066038611, 46599, 54587

106616505 stonin 2 546306 6660 438942 14648 22636, 30624,

1066238612, 46600, 54588

106636506 stonin 2 554710 6661 451383 14649 22637, 30625,

1066438613, 46601, 54589

106656507 stonin 2 557055 6662 450990 14650 22638, 30626,

1066638614, 46602, 54590 6508 stonin 2 555447 6663 450857 14651 22639, 30627,

1066738615, 46603, 54591

106686509 stress responsive 545867 6664 441459 14652 22640, 30628, DNAJB4 interacting 38616, 46604, membrane protein 1 54592

106696510 stress-associated 239944 6665 239944 14653 22641, 30629, endoplasmic 38617, 46605, reticulum protein 1 54593

106706511 stress-associated 479209 6666 420076 14654 22642, 30630, endoplasmic 38618, 46606, reticulum protein 1 54594

106716512 stress-associated 379179 6667 368477 14655 22643, 30631, endoplasmic 38619, 46607, reticulum protein 54595 family member 2

106726513 striatin, calmodulin 263918 6668 263918 14656 22644, 30632, binding protein 38620, 46608,

1067354596

106746514 striatin, calmodulin 379213 6669 368513 14657 22645, 30633, binding protein 38621, 46609,

1067554597

106766515 striatin, calmodulin 538092 6670 442338 14658 22646, 30634, binding protein 38622, 46610,

1067754598

106786516 striatin, calmodulin 355683 6671 347909 14659 22647, 30635, binding protein 3 38623, 46611,

1067954599

106806517 striatin, calmodulin 357479 6672 350071 14660 22648, 30636, binding protein 3 38624, 46612,

1068154600

106826518 STT3, subunit of the 392708 6673 376472 14661 22649, 30637, oligosaccharyltransf 38625, 46613, erase complex, 54601 homolog A (S.

10683cerevisiae)

106846519 STT3, subunit of the 529196 6674 436962 14662 22650, 30638, oligosaccharyltransf 38626, 46614, erase complex, 54602 homolog A (S.

10685cerevisiae)

106866520 STT3, subunit of the 295770 6675 295770 14663 22651, 30639, oligosaccharyltransf 38627, 46615, erase complex, 54603 homolog B (S.

10687cerevisiae)

106886521 succinate receptor 1 362032 6676 355156 14664 22652, 30640,

1068938628, 46616, 54604

106906522 succinate-CoA 493112 6677 419325 14665 22653, 30641, ligase GDP-forming 38629, 46617, beta subunit 54605

106916523 succinate-CoA 307227 6678 307432 14666 22654, 30642, ligase, GDP- 38630, 46618, forming, beta 54606 subunit

106926524 succinate-CoA 541608 6679 439995 14667 22655, 30643, ligase, GDP- 38631, 46619, forming, beta 54607 subunit

106936525 sulfatase modifying 275607 6680 275607 14668 22656, 30644, factor 2 38632, 46620,

1069454608

106956526 sulfatase modifying 342190 6681 341938 14669 22657, 30645, factor 2 38633, 46621,

1069654609

106976527 sulfatase modifying 395435 6682 378823 14670 22658, 30646, factor 2 38634, 46622,

1069854610

106996528 sulfatase modifying 395436 6683 378824 14671 22659, 30647, factor 2 38635, 46623,

1070054611

107016529 sulfatase modifying 413952 6684 414434 14672 22660, 30648, factor 2 38636, 46624,

1070254612

107036530 sulfatase modifying 434526 6685 400922 14673 22661, 30649, factor 2 38637, 46625,

1070454613

107056531 suppressor of cancer 336505 6686 336756 14674 22662, 30650, cell invasion 38638, 46626,

1070654614

107076532 suppressor of cancer 373549 6687 362650 14675 22663, 30651, cell invasion 38639, 46627,

1070854615

107096533 suppressor of 331159 6688 330659 14676 22664, 30652, cytokine signaling 7 38640, 46628,

1071054616

107116534 suppressor of 577233 6689 464034 14677 22665, 30653, cytokine signaling 7 38641, 46629,

1071254617

107136535 sushi domain 374263 6690 363381 14678 22666, 30654, containing 1 38642, 46630,

1071454618

107156536 sushi domain 374264 6691 363382 14679 22667, 30655, containing 1 38643, 46631,

1071654619

107176537 sushi domain 374270 6692 363388 14680 22668, 30656, containing 1 38644, 46632,

1071854620

107196538 sushi domain 358321 6693 351075 14681 22669, 30657, containing 2 38645, 46633,

1072054621

107216539 sushi domain 375469 6694 364618 14682 22670, 30658, containing 3 38646, 46634,

1072254622

107236540 sushi domain 375472 6695 364621 14683 22671, 30659, containing 3 38647, 46635,

1072454623 6541 sushi domain 271787 6696 271787 14684 22672, 30660, containing 4 38648, 46636,

1072554624

107266542 sushi domain 342943 6697 340917 14685 22673, 30661, containing 4 38649, 46637,

1072754625

107286543 sushi domain 343846 6698 344219 14686 22674, 30662, containing 4 38650, 46638,

1072954626

107306544 sushi domain 344029 6699 339926 14687 22675, 30663, containing 4 38651, 46639,

1073154627

107326545 sushi domain 366877 6700 355842 14688 22676, 30664, containing 4 38652, 46640,

1073354628

107346546 sushi domain 366878 6701 355843 14689 22677, 30665, containing 4 38653, 46641,

1073554629

107366547 sushi domain 454695 6702 399288 14690 22678, 30666, containing 4 38654, 46642,

1073754630

107386548 sushi domain 542750 6703 438822 14691 22679, 30667, containing 4 38655, 46643,

1073954631

107406549 sushi domain 309558 6704 308727 14692 22680, 30668, containing 5 38656, 46644,

1074154632

107426550 symplekin 245934 6705 245934 14693 22681, 30669,

1074338657, 46645, 54633

107446551 symplekin 340643 6706 343851 14694 22682, 30670,

1074538658, 46646, 54634

107466552 synaptic Ras 293748 6707 293748 14695 22683, 30671, GTPase activating 38659, 46647, protein 1 54635

107476553 synaptic Ras 355818 6708 348072 14696 22684, 30672, GTPase activating 38660, 46648, protein 1 54636

107486554 synaptic Ras 395071 6709 378509 14697 22685, 30673, GTPase activating 38661, 46649, protein 1 54637

107496555 synaptic Ras 414753 6710 407995 14698 22686, 30674, GTPase activating 38662, 46650, protein 1 54638

107506556 synaptic Ras 418600 6711 403636 14699 22687, 30675, GTPase activating 38663, 46651, protein 1 54639

107516557 synaptic Ras 449372 6712 416519 14700 22688, 30676, GTPase activating 38664, 46652, protein 1 54640

107526558 synaptic Ras 455687 6713 414259 14701 22689, 30677, GTPase activating 38665, 46653, protein 1 54641 6559 synaptic Ras 551507 6714 446753 14702 22690, 30678, GTPase activating 38666, 46654, protein 1 54642

107536560 synaptic vesicle 369145 6715 358141 14703 22691, 30679, glycoprotein 2A 38667, 46655,

1075454643

107556561 synaptic vesicle 369146 6716 358142 14704 22692, 30680, glycoprotein 2A 38668, 46656,

1075654644

107576562 synaptic vesicle 330276 6717 332818 14705 22693, 30681, glycoprotein 2B 38669, 46657,

1075854645

107596563 synaptic vesicle 394232 6718 377779 14706 22694, 30682, glycoprotein 2B 38670, 46658,

1076054646

107616564 synaptic vesicle 545111 6719 443243 14707 22695, 30683, glycoprotein 2B 38671, 46659,

1076254647

107636565 synaptic vesicle 557410 6720 450992 14708 22696, 30684, glycoprotein 2B 38672, 46660,

1076454648

107656566 synaptic vesicle 322285 6721 316983 14709 22697, 30685, glycoprotein 2C 38673, 46661,

1076654649

107676567 synaptic vesicle 502798 6722 423541 14710 22698, 30686, glycoprotein 2C 38674, 46662,

1076854650

107696568 synaptophysin-like 1 11473 6723 11473 14711 22699, 30687,

1077038675, 46663, 54651, 56095, 56128

107716569 synaptophysin-like 1 455385 6724 388336 14712 22700, 30688,

1077238676, 46664, 54652

107736570 synaptophysin-like 2 369872 6725 358888 14713 22701, 30689,

1077438677, 46665, 54653

107756571 synaptophysin-like 2 401021 6726 383805 14714 22702, 30690,

1077638678, 46666, 54654

107776572 synaptoporin 295894 6727 295894 14715 22703, 30691,

1077838679, 46667, 54655

107796573 synaptoporin 460711 6728 418701 14716 22704, 30692,

1078038680, 46668, 54656

107816574 synaptoporin 478300 6729 418994 14717 22705, 30693,

1078238681, 46669, 54657

107836575 synaptosomal- 518312 6730 429937 14718 22706, 30694, associated protein 38682, 46670, 91kDa homolog 54658 (mouse) 6576 synaptosomal- 520302 6731 42851 1 14719 22707, 30695, associated protein 38683, 46671 , 91kDa homolog 54659 (mouse)

107846577 synaptosomal- 195649 6732 195649 14720 22708, 30696, associated protein, 38684, 46672, 91kDa homolog 54660 (mouse)

107856578 synaptosomal- 369690 6733 358704 14721 22709, 30697, associated protein, 38685, 46673, 91kDa homolog 54661 (mouse)

107866579 synaptosomal- 369694 6734 358708 14722 22710, 30698, associated protein, 38686, 46674, 91kDa homolog 54662 (mouse)

107876580 synaptosomal- 428679 6735 412492 14723 22711, 30699, associated protein, 38687, 46675, 91kDa homolog 54663 (mouse)

107886581 synaptosomal- 437520 6736 413277 14724 22712, 30700, associated protein, 38688, 46676, 91kDa homolog 54664 (mouse)

107896582 synaptosomal- 439399 6737 400459 14725 22713, 30701 , associated protein, 38689, 46677, 91kDa homolog 54665 (mouse)

107906583 synaptosomal- 447888 6738 403742 14726 22714, 30702, associated protein, 38690, 46678, 91kDa homolog 54666 (mouse)

107916584 synaptosomal- 518309 6739 430441 14727 22715, 30703, associated protem, 38691 , 46679, 91kDa homolog 54667 (mouse)

107926585 synaptosomal- 519779 6740 429429 14728 22716, 30704, associated protein, 38692, 46680, 91kDa homolog 54668 (mouse)

107936586 synaptosomal- 519825 6741 431055 14729 22717, 30705, associated protein, 38693, 46681, 91kDa homolog 54669 (mouse)

107946587 synaptosomal- 520213 6742 428026 14730 22718, 30706, associated protein, 38694, 46682, 91kDa homolog 54670 (mouse)

107956588 synaptosomal- 521485 6743 429776 14731 22719, 30707, associated protein, 38695, 46683, 91kDa homolog 54671 (mouse)

107966589 synaptosomal- 521743 6744 428215 14732 22720, 30708, associated protein, 38696, 46684, 91kDa homolog 54672 (mouse)

107976590 synaptosomal- 523484 6745 427959 14733 22721, 30709, associated protein, 38697, 46685, 91kDa homolog 54673 (mouse)

107986591 synaptotagmin 355238 6746 347380 14734 22722, 30710, binding, cytoplasmic 38698, 46686, RNA interacting 54674 protein

107996592 synaptotagmin 369622 6747 358635 14735 22723, 30711, binding, cytoplasmic 38699, 46687, RNA interacting 54675 protein

108006593 synaptotagmin 444272 6748 397782 14736 22724, 30712, binding, cytoplasmic 38700, 46688, RNA interacting 54676 protein

108016594 synaptotagmin II 367267 6749 356236 14737 22725, 30713,

1080238701, 46689, 54677

108036595 synaptotagmin II 367268 6750 356237 14738 22726, 30714,

1080438702, 46690, 54678

108056596 synaptotagmin VIII 381968 6751 371394 14739 22727, 30715,

1080638703, 46691, 54679

108076597 synaptotagmin VIII 436964 6752 414626 14740 22728, 30716,

1080838704, 46692, 54680

108096598 synaptotagmin VIII 535046 6753 443325 14741 22729, 30717,

1081038705, 46693, 54681

108116599 synaptotagmin X 228567 6754 228567 14742 22730, 30718,

1081238706, 46694, 54682

108136600 synaptotagmin X 535526 6755 438691 14743 22731, 30719,

1081438707, 46695, 54683

108156601 synaptotagmin XI 368324 6756 357307 14744 22732, 30720,

1081638708, 46696, 54684

108176602 synaptotagmin XI 539162 6757 441657 14745 22733, 30721,

1081838709, 46697, 54685

108196603 synaptotagmin XVII 355377 6758 347538 14746 22734, 30722,

1082038710, 46698, 54686

108216604 syncoilin, 373484 6759 362583 14747 22735, 30723, intermediate 38711, 46699, filament protein 54687

108226605 syncoilin, 409190 6760 386439 14748 22736, 30724, intermediate 38712, 46700, filament protein 54688 6606 syncoilin, 417633 6761 401975 14749 22737, 30725, intermediate 38713, 46701, filament protein 54689

108236607 syncoilin, 426909 6762 387594 14750 22738, 30726, intermediate 38714, 46702, filament protein 54690

108246608 syncoilin 318438 6763 325564 14751 22739, 30727,

1082538715, 46703, 54691

108266609 syndecan binding 260130 6764 260130 14752 22740, 30728, protein (syntenin) 38716, 46704,

1082754692

108286610 syndecan binding 413219 6765 411771 14753 22741, 30729, protein (syntenin) 38717, 46705,

1082954693

108306611 syndecan binding 422546 6766 391687 14754 22742, 30730, protein (syntenin) 38718, 46706,

1083154694

108326612 syndecan binding 424270 6767 395351 14755 22743, 30731, protein (syntenin) 38719, 46707,

1083354695

108346613 syndecan binding 447182 6768 409288 14756 22744, 30732, protein (syntenin) 38720, 46708,

1083554696

108366614 syndecan binding 339987 6769 342935 14757 22745, 30733, protein (syntenin) 2 38721, 46709,

1083754697

108386615 syndecan binding 360779 6770 354013 14758 22746, 30734, protein (syntenin) 2 38722, 46710,

1083954698

108406616 syndecan binding 381808 6771 371229 14759 22747, 30735, protein (syntenin) 2 38723, 46711,

1084154699

108426617 syndecan binding 381812 6772 371233 14760 22748, 30736, protein (syntenin) 2 38724, 46712,

1084354700

108446618 syntaxin 10 242770 6773 242770 14761 22749, 30737,

1084538725, 46713, 54701

108466619 syntaxin 10 343587 6774 339350 14762 22750, 30738,

1084738726, 46714, 54702

108486620 syntaxin 10 440593 6775 415176 14763 22751, 30739,

1084938727, 46715, 54703

108506621 syntaxin 10 587230 6776 466298 14764 22752, 30740,

1085138728, 46716, 54704

108526622 syntaxin 10 589083 6777 465398 14765 22753, 30741,

1085338729, 46717, 54705

108546623 syntaxin 12 373943 6778 363054 14766 22754, 30742,

1085538730, 46718, 54706 6624 syntaxin 12 440806 6779 392577 14767 22755, 30743,

1085638731, 46719, 54707

108576625 syntaxin 18 306200 6780 305810 14768 22756, 30744,

1085838732, 46720, 54708

108596626 syntaxin 6 258301 6781 258301 14769 22757, 30745,

1086038733, 46721, 54709

108616627 syntaxin 6 542060 6782 440188 14770 22758, 30746,

1086238734, 46722, 54710

108636628 syntaxin binding 370008 6783 359025 14771 22759, 30747, protein 3 38735, 46723,

1086454711

108656629 syntrophin, alpha 1 217381 6784 217381 14772 22760, 30748, (dystrophin- 38736, 46724, associated protein 54712 Al, 59kDa, acidic

10866component)

108676630 syntrophin, gamma 308624 6785 311837 14773 22761, 30749, 2 38737, 46725,

1086854713

108696631 T cell receptor beta 466254 6786 417300 14774 22762, 30750, constant 2 38738, 46726,

1087054714

108716632 T cell receptor delta 390477 6787 451468 14775 22763, 30751, constant 38739, 46727,

1087254715

108736633 T cell receptor 390346 6788 374869 14776 22764, 30752, gamma variable 3 38740, 46728,

1087454716

108756634 T cell-interacting, 432826 6789 439454 14777 22765, 30753, activating receptor 38741, 46729, on myeloid cells 1 54717

108766635 T cell-interacting, 446034 6790 441055 14778 22766, 30754, activating receptor 38742, 46730, on myeloid cells 1 54718

108776636 TAM41, 273037 6791 273037 14779 22767, 30755, mitochondrial 38743, 46731, translocator 54719 assembly and

10878maintenance protein,

10879homolog (S.

10880cerevisiae)

108816637 TANK-binding 331710 6792 329967 14780 22768, 30756, kinase 1 38744, 46732,

1088254720

108836638 TANK-binding 538890 6793 445834 14781 22769, 30757, kinase 1 38745, 46733,

1088454721

108856639 TANK-binding 540417 6794 445628 14782 22770, 30758, kinase 1 38746, 46734,

1088654722 6640 TAO kinase 3 359811 6795 352863 14783 22771, 30759,

1088738747, 46735, 54723

108886641 TAO kinase 3 392533 6796 376317 14784 22772, 30760,

1088938748, 46736, 54724

108906642 TAO kinase 3 419821 6797 416374 14785 22773, 30761,

1089138749, 46737, 54725

108926643 TAO kinase 3 535570 6798 443465 14786 22774, 30762,

1089338750, 46738, 54726

108946644 TAO kinase 3 539872 6799 438766 14787 22775, 30763,

1089538751, 46739, 54727

108966645 TAO kinase 3 541186 6800 438820 14788 22776, 30764,

1089738752, 46740, 54728

108986646 TAO kinase 3 541786 6801 442541 14789 22777, 30765,

1089938753, 46741, 54729

109006647 TAO kinase 3 541878 6802 444057 14790 22778, 30766,

1090138754, 46742, 54730

109026648 TAO kinase 3 542532 6803 441071 14791 22779, 30767,

1090338755, 46743, 54731

109046649 TAO kinase 3 542902 6804 440315 14792 22780, 30768,

1090538756, 46744, 54732

109066650 TAP binding 266556 6805 266556 14793 22781, 30769, protein-like 38757, 46745,

1090754733

109086651 target of mybl 348161 6806 343901 14794 22782, 30770, (chicken)-like 1 38758, 46746,

1090954734

109106652 target of mybl 445275 6807 408958 14795 22783, 30771, (chicken)-like 1 38759, 46747,

1091154735

109126653 target of mybl 536554 6808 443099 14796 22784, 30772, (chicken)-like 1 38760, 46748,

1091354736

109146654 target of mybl 540336 6809 441242 14797 22785, 30773, (chicken)-like 1 38761, 46749,

1091554737

109166655 target of mybl 575882 6810 460823 14798 22786, 30774, (chicken)-like 1 38762, 46750,

1091754738

109186656 taste receptor, type 382492 6811 371932 14799 22787, 30775, 2, member 1 38763, 46751,

1091954739

109206657 taste receptor, type 240619 6812 240619 14800 22788, 30776, 2, member 10 38764, 46752,

1092154740 6658 taste receptor, type 390677 6813 375095 14801 22789, 30777, 2, member 13 38765, 46753,

1092254741

109236659 taste receptor, type 537503 6814 441949 14802 22790, 30778, 2, member 14 38766, 46754,

1092454742

109256660 taste receptor, type 446620 6815 405095 14803 22791, 30779, 2, member 39 38767, 46755,

1092654743

109276661 taste receptor, type 240687 6816 240687 14804 22792, 30780, 2, member 7 38768, 46756,

1092854744

109296662 taste receptor, type 240615 6817 240615 14805 22793, 30781, 2, member 8 38769, 46757,

1093054745

109316663 taste receptor, type 240691 6818 240691 14806 22794, 30782, 2, member 9 38770, 46758,

1093254746

109336664 TBC1 domain 355235 6819 347375 14807 22795, 30783, family, member 9B 38771, 46759, (with GRAM 54747 domain)

109346665 TBC1 domain 356834 6820 349291 14808 22796, 30784, family, member 9B 38772, 46760, (with GRAM 54748 domain)

109356666 TBC1 domain 444477 6821 401585 14809 22797, 30785, family, member 9B 38773, 46761, (with GRAM 54749 domain)

109366667 TBC1 domain 544438 6822 443503 14810 22798, 30786, family, member 9B 38774, 46762, (with GRAM 54750 domain)

109376668 T-cell 274532 6823 274532 14811 22799, 30787, immunoglobulin and 38775, 46763, mucin domain 54751 containing 4

109386669 T-cell 407087 6824 385973 14812 22800, 30788, immunoglobulin and 38776, 46764, mucin domain 54752 containing 4

109396670 tectonin beta- 379795 6825 369121 14813 22801, 30789, propeller repeat 38777, 46765, containing 1 54753

109406671 tectonin beta- 423128 6826 407471 14814 22802, 30790, propeller repeat 38778, 46766, containing 1 54754

109416672 tectonin beta- 447648 6827 404923 14815 22803, 30791, propeller repeat 38779, 46767, containing 1 54755

109426673 tectonin beta- 542604 6828 441121 14816 22804, 30792, propeller repeat 38780, 46768, containing 1 54756 6674 tektin 2 (testicular) 207457 6829 207457 14817 22805, 30793,

1094338781, 46769, 54757

109446675 testis expressed 10 374902 6830 364037 14818 22806, 30794,

1094538782, 46770, 54758

109466676 testis expressed 10 429235 6831 399872 14819 22807, 30795,

1094738783, 46771, 54759

109486677 testis expressed 10 444730 6832 413273 14820 22808, 30796,

1094938784, 46772, 54760

109506678 testis expressed 10 535814 6833 444555 14821 22809, 30797,

1095138785, 46773, 54761

109526679 testis expressed 10 537512 6834 438120 14822 22810, 30798,

1095338786, 46774, 54762

109546680 testis expressed 2 258991 6835 258991 14823 22811, 30799,

1095538787, 46775, 54763

109566681 testis expressed 261 272438 6836 272438 14824 22812, 30800,

1095738788, 46776, 54764

109586682 testis expressed 28 369932 6837 358948 14825 22813, 30801, pseudogene 1 38789, 46777,

1095954765

109606683 testis expressed 28 369941 6838 358957 14826 22814, 30802, pseudogene 2 38790, 46778,

1096154766

109626684 tetraspanin 10 328585 6839 331620 14827 22815, 30803,

1096338791, 46779, 54767

109646685 tetraspanin 10 540189 6840 444144 14828 22816, 30804,

1096538792, 46780, 54768

109666686 tetraspanin 11 261177 6841 261177 14829 22817, 30805,

1096738793, 46781, 54769

109686687 tetraspanin 11 544427 6842 439895 14830 22818, 30806,

1096938794, 46782, 54770

109706688 tetraspanin 11 546076 6843 437403 14831 22819, 30807,

1097138795, 46783, 54771

109726689 tetraspanin 14 341863 6844 344076 14832 22820, 30808,

1097338796, 46784, 54772

109746690 tetraspanin 14 372156 6845 361229 14833 22821, 30809,

1097538797, 46785, 54773

109766691 tetraspanin 14 372157 6846 361230 14834 22822, 30810,

1097738798, 46786, 54774 6692 tetraspanin 14 372158 6847 361231 14835 22823, 30811,

1097838799, 46787, 54775

109796693 tetraspanin 14 372160 6848 361233 14836 22824, 30812,

1098038800, 46788, 54776

109816694 tetraspanin 14 372164 6849 361237 14837 22825, 30813,

1098238801, 46789, 54777

109836695 tetraspanin 14 429989 6850 396270 14838 22826, 30814,

1098438802, 46790, 54778

109856696 tetraspanin 14 481124 6851 418195 14839 22827, 30815,

1098638803, 46791, 54779

109876697 tetraspanin 16 316737 6852 319486 14840 22828, 30816,

1098838804, 46792, 54780

109896698 tetraspanin 16 337994 6853 338759 14841 22829, 30817,

1099038805, 46793, 54781

109916699 tetraspanin 17 310032 6854 309036 14842 22830, 30818,

1099238806, 46794, 54782

109936700 tetraspanin 17 405525 6855 385665 14843 22831, 30819,

1099438807, 46795, 54783

109956701 tetraspanin 17 508164 6856 422053 14844 22832, 30820,

1099638808, 46796, 54784

109976702 tetraspanin 17 515708 6857 426650 14845 22833, 30821,

1099838809, 46797, 54785

109996703 tetraspanin 18 340160 6858 339820 14846 22834, 30822,

1100038810, 46798, 54786

110016704 tetraspanin 18 518429 6859 429020 14847 22835, 30823,

1100238811, 46799, 54787

110036705 tetraspanin 18 520358 6860 429993 14848 22836, 30824,

1100438812, 46800, 54788

110056706 tetraspanin 18 533202 6861 434625 14849 22837, 30825,

1100638813, 46801, 54789

110076707 tetraspanin 18 533786 6862 433592 14850 22838, 30826,

1100838814, 46802, 54790

110096708 tetraspanin 33 289407 6863 289407 14851 22839, 30827,

1101038815, 46803, 54791

110116709 tetratricopeptide 220853 6864 220853 14852 22840, 30828, repeat domain 35 38816, 46804,

1101254792 6710 tetratricopeptide 263635 6865 263635 14853 22841, 30829, repeat, ankyrin 38817, 46805, repeat and coiled- 54793 coil containing 1

110136711 tetratricopeptide 454300 6866 396339 14854 22842, 30830, repeat, ankyrin 38818, 46806, repeat and coiled- 54794 coil containing 1

110146712 TGF-beta activated 288422 6867 288422 14855 22843, 30831, kinase 1/MAP3K7 38819, 46807, binding protein 3 54795

110156713 TGF-beta activated 378928 6868 368210 14856 22844, 30832, kinase 1/MAP3K7 38820, 46808, binding protein 3 54796

110166714 TGF-beta activated 378930 6869 368212 14857 22845, 30833, kinase 1/MAP3K7 38821, 46809, binding protein 3 54797

110176715 TGF-beta activated 378932 6870 368214 14858 22846, 30834, kinase 1/MAP3K7 38822, 46810, binding protein 3 54798

110186716 TGF-beta activated 378933 6871 368215 14859 22847, 30835, kinase 1/MAP3K7 38823, 46811, binding protein 3 54799

110196717 thioesterase 368814 6872 357804 14860 22848, 30836, superfamily member 38824, 46812, 4 54800

110206718 thioesterase 368817 6873 357807 14861 22849, 30837, superfamily member 38825, 46813, 5 54801

110216719 thioredoxin 2 216185 6874 216185 14862 22850, 30838,

1102238826, 46814, 54802

110236720 thioredoxin 2 403313 6875 385393 14863 22851, 30839,

1102438827, 46815, 54803

110256721 thioredoxin domain 283033 6876 283033 14864 22852, 30840, containing 11 38828, 46816,

1102654804

110276722 thioredoxin domain 356957 6877 349439 14865 22853, 30841, containing 11 38829, 46817,

1102854805

110296723 thioredoxin domain 436567 6878 397407 14866 22854, 30842, containing 11 38830, 46818,

1103054806

110316724 thioredoxin domain 358387 6879 351157 14867 22855, 30843, containing 15 38831, 46819,

1103254807

110336725 thioredoxin domain 441965 6880 399854 14868 22856, 30844, containing 15 38832, 46820,

1103454808

110356726 thioredoxin domain 546290 6881 443942 14869 22857, 30845, containing 15 38833, 46821,

1103654809 6727 thioredoxin domain 379757 6882 369081 14870 22858, 30846, containing 5 38834, 46822, (endoplasmic 54810 reticulum)

110376728 thioredoxin domain 473453 6883 420784 14871 22859, 30847, containing 5 38835, 46823, (endoplasmic 54811 reticulum)

110386729 thioredoxin domain 539054 6884 442453 14872 22860, 30848, containing 5 38836, 46824, (endoplasmic 54812 reticulum)

110396730 thioredoxin-related 457354 6885 393316 14873 22861, 30849, transmembrane 38837, 46825, protein 1 54813

110406731 thioredoxin-related 278422 6886 278422 14874 22862, 30850, transmembrane 38838, 46826, protein 2 54814

110416732 thioredoxin-related 378312 6887 367562 14875 22863, 30851, transmembrane 38839, 46827, protein 2 54815

110426733 thioredoxin-related 299608 6888 299608 14876 22864, 30852, transmembrane 38840, 46828, protein 3 54816

110436734 thioredoxin-related 443099 6889 402605 14877 22865, 30853, transmembrane 38841, 46829, protein 3 54817

110446735 thioredoxin-related 544714 6890 444954 14878 22866, 30854, transmembrane 38842, 46830, protein 3 54818

110456736 thioredoxin-related 246024 6891 246024 14879 22867, 30855, transmembrane 38843, 46831, protein 4 54819

110466737 thyroid hormone 313244 6892 320117 14880 22868, 30856, receptor interactor 38844, 46832, 10 54820

110476738 thyroid hormone 313285 6893 320493 14881 22869, 30857, receptor interactor 38845, 46833, 10 54821

110486739 thyroid hormone 420690 6894 415493 14882 22870, 30858, receptor interactor 38846, 46834, 10 54822

110496740 thyroid hormone 166345 6895 166345 14883 22871, 30859, receptor interactor 38847, 46835, 13 54823, 56096,

1105056129

110516741 thyroid hormone 354240 6896 346185 14884 22872, 30860, receptor interactor 38848, 46836, 13 54824

110526742 TLC domain 292090 6897 292090 14885 22873, 30861, containing 1 38849, 46837,

1105354825

110546743 TLC domain 394933 6898 378391 14886 22874, 30862, containing 1 38850, 46838,

1105554826 6744 TM2 domain 294613 6899 294613 14887 22875, 30863, containing 1 38851, 46839,

1105654827

110576745 TM2 domain 371177 6900 360219 14888 22876, 30864, containing 1 38852, 46840,

1105854828

110596746 TM2 domain 371178 6901 360220 14889 22877, 30865, containing 1 38853, 46841,

1106054829

110616747 TM2 domain 371180 6902 360222 14890 22878, 30866, containing 1 38854, 46842,

1106254830

110636748 TM2 domain 397070 6903 380260 14891 22879, 30867, containing 2 38855, 46843,

1106454831

110656749 TM2 domain 412303 6904 402964 14892 22880, 30868, containing 2 38856, 46844,

1106654832

110676750 TM2 domain 456397 6905 416050 14893 22881, 30869, containing 2 38857, 46845,

1106854833

110696751 TM2 domain 456845 6906 391674 14894 22882, 30870, containing 2 38858, 46846,

1107054834

110716752 TM2 domain 517872 6907 430685 14895 22883, 30871, containing 2 38859, 46847,

1107254835

110736753 TM2 domain 520152 6908 428203 14896 22884, 30872, containing 2 38860, 46848,

1107454836

110756754 TM2 domain 522142 6909 428394 14897 22885, 30873, containing 2 38861, 46849,

1107654837

110776755 TMED7-TICAM2 282382 6910 282382 14898 22886, 30874, readthrough 38862, 46850,

1107854838

110796756 TMED7-TICAM2 333314 6911 333650 14899 22887, 30875, readthrough 38863, 46851,

1108054839

110816757 TMEM9 domain 309134 6912 311842 14900 22888, 30876, family, member B 38864, 46852,

1108254840

110836758 TMEM9 domain 525069 6913 431487 14901 22889, 30877, family, member B 38865, 46853,

1108454841

110856759 TMEM9 domain 534025 6914 433361 14902 22890, 30878, family, member B 38866, 46854,

1108654842

110876760 TMPRSS11B N 432593 6915 391149 14903 22891, 30879, terminal-like 38867, 46855,

1108854843

110896761 TNF receptor- 262395 6916 262395 14904 22892, 30880, associated factor 4 38868, 46856,

1109054844 6762 TNF receptor- 262396 6917 262396 14905 22893, 30881, associated factor 4 38869, 46857,

1109154845

110926763 TNF receptor- 394924 6918 378382 14906 22894, 30882, associated factor 4 38870, 46858,

1109354846

110946764 TNF receptor- 394925 6919 378383 14907 22895, 30883, associated factor 4 38871, 46859,

1109554847

110966765 TNF receptor- 422344 6920 415789 14908 22896, 30884, associated factor 4 38872, 46860,

1109754848

110986766 TNF receptor- 444415 6921 438154 14909 22897, 30885, associated factor 4 38873, 46861,

1109954849

111006767 TNF receptor- 454852 6922 396602 14910 22898, 30886, associated factor 4 38874, 46862,

1110154850

111026768 toll-like receptor 10 308973 6923 308925 14911 22899, 30887,

1110338875, 46863, 54851

111046769 toll-like receptor 10 361424 6924 354459 14912 22900, 30888,

1110538876, 46864, 54852

111066770 toll-like receptor 10 506111 6925 421483 14913 22901, 30889,

1110738877, 46865, 54853

111086771 toll-like receptor 10 508334 6926 424923 14914 22902, 30890,

1110938878, 46866, 54854

111106772 toll-like receptor 408996 6927 386341 14915 22903, 30891, adaptor molecule 2 38879, 46867,

1111154855

111126773 toll-like receptor 427199 6928 415139 14916 22904, 30892, adaptor molecule 2 38880, 46868,

1111354856

111146774 torsin A interacting 325993 6929 326753 14917 22905, 30893, protein 1 38881, 46869,

1111554857

111166775 torsin A interacting 435319 6930 393292 14918 22906, 30894, protein 1 38882, 46870,

1111754858

111186776 torsin A interacting 367612 6931 356584 14919 22907, 30895, protein 2 38883, 46871,

1111954859

111206777 trace amine 258034 6932 258034 14920 22908, 30896, associated receptor 5 38884, 46872,

1112154860

111226778 trace amine 275200 6933 275200 14921 22909, 30897, associated receptor 8 38885, 46873,

1112354861

111246779 trafficking protein 291574 6934 291574 14922 22910, 30898, particle complex 10 38886, 46874,

1112554862 6780 trafficking protein 542855 6935 438781 14923 22911, 30899, particle complex 10 38887, 46875,

1112654863

111276781 trafficking protein 543226 6936 442778 14924 22912, 30900, particle complex 2 38888, 46876, pseudogene 1 54864

111286782 trafficking protein 317378 6937 316990 14925 22913, 30901, particle complex 5 38889, 46877,

1112954865

111306783 trafficking protein 426877 6938 399025 14926 22914, 30902, particle complex 5 38890, 46878,

1113154866

111326784 trafficking protein 596148 6939 470262 14927 22915, 30903, particle complex 5 38891, 46879,

1113354867

111346785 trafficking protein 6275 6940 6275 14928 22916, 30904, particle complex 6A 38892, 46880,

1113554868, 56097, 56130

111366786 trafficking protein 585934 6941 468612 14929 22917, 30905, particle complex 6A 38893, 46881,

1113754869

111386787 trafficking protein 588062 6942 468363 14930 22918, 30906, particle complex 6A 38894, 46882,

1113954870

111406788 trafficking protein 330149 6943 330289 14931 22919, 30907, particle complex 6B 38895, 46883,

1114154871

111426789 trafficking protein 347691 6944 335171 14932 22920, 30908, particle complex 6B 38896, 46884,

1114354872

111446790 trans-2,3-enoyl-CoA 381210 6945 370607 14933 22921, 30909, reductase-like 38897, 46885,

1114554873

111466791 transcription 332567 6946 331302 14934 22922, 30910, elongation factor B 38898, 46886, polypeptide 3B 54874 (elongin A2)

111476792 transcription 330682 6947 328232 14935 22923, 30911, elongation factor B 38899, 46887, polypeptide 3C 54875 (elongin A3)

111486793 transcription 451265 6948 409932 14936 22924, 30912, elongation factor B 38900, 46888, polypeptide 3C-like 54876

111496794 transcription 581216 6949 462963 14937 22925, 30913, elongation factor 38901, 46889, mitochondrial 54877

111506795 transcription 306049 6950 306574 14938 22926, 30914, elongation factor, 38902, 46890, mitochondrial 54878

111516796 transcription 541382 6951 445311 14939 22927, 30915, elongation factor, 38903, 46891, mitochondrial 54879 6797 transcription factor 366514 6952 355471 14940 22928, 30916, B2, mitochondrial 38904, 46892,

1115254880

111536798 transcription factor 544618 6953 442426 14941 22929, 30917, B2, mitochondrial 38905, 46893,

1115454881

111556799 transforming growth 258770 6954 258770 14942 22930, 30918, factor beta regulator 38906, 46894, 4 54882

111566800 transforming growth 361278 6955 354992 14943 22931, 30919, factor beta regulator 38907, 46895, 4 54883

111576801 transforming growth 395655 6956 379016 14944 22932, 30920, factor beta regulator 38908, 46896, 4 54884

111586802 transforming growth 475893 6957 417324 14945 22933, 30921, factor beta regulator 38909, 46897, 4 54885

111596803 transforming growth 482285 6958 417967 14946 22934, 30922, factor beta regulator 38910, 46898, 4 54886

111606804 transforming growth 494076 6959 420597 14947 22935, 30923, factor beta regulator 38911, 46899, 4 54887

111616805 transforming growth 495078 6960 417071 14948 22936, 30924, factor beta regulator 38912, 46900, 4 54888

111626806 transient receptor 264811 6961 264811 14949 22937, 30925, potential cation 38913, 46901, channel, subfamily 54889 C, member 3

111636807 transient receptor 379645 6962 368966 14950 22938, 30926, potential cation 38914, 46902, channel, subfamily 54890 C, member 3

111646808 transient receptor 502968 6963 422214 14951 22939, 30927, potential cation 38915, 46903, channel, subfamily 54891 C, member 3

111656809 transient receptor 513531 6964 426899 14952 22940, 30928, potential cation 38916, 46904, channel, subfamily 54892 C, member 3

111666810 translocase of inner 169551 6965 169551 14953 22941, 30929, mitochondrial 38917, 46905, membrane 21 54893, 56098, homolog (yeast) 56131

111676811 translocase of inner 374097 6966 363210 14954 22942, 30930, mitochondrial 38918, 46906, membrane 23 54894 homolog B (yeast)

111686812 translocase of inner 374098 6967 363211 14955 22943, 30931, mitochondrial 38919, 46907, membrane 23 54895 homolog B (yeast) 6813 translocase of inner 429265 6968 409439 14956 22944, 30932, mitochondrial 38920, 46908, membrane 23 54896 homolog B (yeast)

111696814 translocase of inner 451577 6969 389331 14957 22945, 30933, mitochondrial 38921, 46909, membrane 23 54897 homolog B (yeast)

111706815 translocase of inner 314349 6970 318115 14958 22946, 30934, mitochondrial 38922, 46910, membrane 50 54898 homolog (S.

11171cerevisiae)

111726816 translocase of inner 544017 6971 445806 14959 22947, 30935, mitochondrial 38923, 46911, membrane 50 54899 homolog (S.

11173cerevisiae)

111746817 translocase of inner 504148 6972 422122 14960 22948, 30936, mitochondrial 38924, 46912, membrane 8 54900 homolog B (yeast)

111756818 translocase of inner 541231 6973 438455 14961 22949, 30937, mitochondrial 38925, 46913, membrane 8 54901 homolog B (yeast)

111766819 translocase of inner 494664 6974 418803 14962 22950, 30938, mitochondrial 38926, 46914, membrane domain 54902 containing 1

111776820 translocase of outer 366607 6975 355566 14963 22951, 30939, mitochondrial 38927, 46915, membrane 20 54903 homolog (yeast)

111786821 translocase of outer 360945 6976 354204 14964 22952, 30940, mitochondrial 38928, 46916, membrane 20 54904 homolog (yeast)-like

111796822 translocase of outer 372813 6977 361900 14965 22953, 30941, mitochondrial 38929, 46917, membrane 34 54905

111806823 translocase of outer 367987 6978 356966 14966 22954, 30942, mitochondrial 38930, 46918, membrane 40 54906 homolog (yeast)-like

111816824 translocase of outer 367988 6979 356967 14967 22955, 30943, mitochondrial 38931, 46919, membrane 40 54907 homolog (yeast)-like

111826825 translocase of outer 542686 6980 438722 14968 22956, 30944, mitochondrial 38932, 46920, membrane 40 54908 homolog (yeast)-like

111836826 translocase of outer 545897 6981 443233 14969 22957, 30945, mitochondrial 38933, 46921, membrane 40 54909 homolog (yeast)-like

111846827 translocase of outer 321301 6982 313584 14970 22958, 30946, mitochondrial 38934, 46922, membrane 5 54910 homolog (yeast)

111856828 translocase of outer 377773 6983 367004 14971 22959, 30947, mitochondrial 38935, 46923, membrane 5 54911 homolog (yeast)

111866829 translocase of outer 544379 6984 438204 14972 22960, 30948, mitochondrial 38936, 46924, membrane 5 54912 homolog (yeast)

111876830 translocase of outer 398881 6985 381856 14973 22961, 30949, mitochondrial 38937, 46925, membrane 6 54913 homolog (yeast)

111886831 translocase of outer 398884 6986 381859 14974 22962, 30950, mitochondrial 38938, 46926, membrane 6 54914 homolog (yeast)

111896832 translocase of outer 358435 6987 351214 14975 22963, 30951, mitochondrial 38939, 46927, membrane 7 54915 homolog (yeast)

111906833 translocase of outer 284320 6988 284320 14976 22964, 30952, mitochondrial 38940, 46928, membrane 70 54916 homolog A (S.

11191cerevisiae)

111926834 translocase of outer 544924 6989 445730 14977 22965, 30953, mitochondrial 38941, 46929, membrane 70 54917 homolog A (S.

11193cerevisiae)

111946835 translocation 262213 6990 262213 14978 22966, 30954, associated 38942, 46930, membrane protein 1 54918

111956836 translocation 536748 6991 439359 14979 22967, 30955, associated 38943, 46931, membrane protein 1 54919

111966837 translocation 310754 6992 309402 14980 22968, 30956, associated 38944, 46932, membrane protein 1 - 54920 like 1

111976838 translocation 182527 6993 182527 14981 22969, 30957, associated 38945, 46933, membrane protein 2 54921

111986839 translocator protein 373161 6994 362255 14982 22970, 30958, 2 38946, 46934,

1119954922

112006840 translocator protein 470917 6995 419985 14983 22971, 30959, 2 38947, 46935, 54923

112016841 transmembrane (C- 398458 6996 381476 14984 22972, 30960, terminal) protease, 38948, 46936, serine 12 54924

112026842 transmembrane 4 L 296059 6997 296059 14985 22973, 30961, six family member 38949, 46937, 18 54925

112036843 transmembrane 4 L 470080 6998 419278 14986 22974, 30962, six family member 38950, 46938, 18 54926

112046844 transmembrane 4 L 474754 6999 418372 14987 22975, 30963, six family member 38951, 46939, 18 54927

112056845 transmembrane 4 L 273695 7000 273695 14988 22976, 30964, six family member 38952, 46940, 19 54928

112066846 transmembrane 4 L 442633 7001 405973 14989 22977, 30965, six family member 38953, 46941, 19 54929

112076847 transmembrane 4 L 454715 7002 387728 14990 22978, 30966, six family member 38954, 46942, 19 54930

112086848 transmembrane 4 L 304568 7003 303028 14991 22979, 30967, six family member 38955, 46943, 20 54931

112096849 transmembrane 4 L 449706 7004 416565 14992 22980, 30968, six family member 38956, 46944, 20 54932

112106850 transmembrane 9 261789 7005 261789 14993 22981, 30969, superfamily member 38957, 46945, 1 54933

112116851 transmembrane 9 396854 7006 380063 14994 22982, 30970, superfamily member 38958, 46946, 1 54934

112126852 transmembrane 9 525592 7007 432435 14995 22983, 30971, superfamily member 38959, 46947, 1 54935

112136853 transmembrane 9 528010 7008 433792 14996 22984, 30972, superfamily member 38960, 46948, 1 54936

112146854 transmembrane 9 528895 7009 431447 14997 22985, 30973, superfamily member 38961, 46949, 1 54937

112156855 transmembrane 9 530468 7010 435857 14998 22986, 30974, superfamily member 38962, 46950, 1 54938

112166856 transmembrane 9 556387 7011 451949 14999 22987, 30975, superfamily member 38963, 46951, 1 54939

112176857 transmembrane 9 530611 7012 433967 15000 22988, 30976, superfamily member 38964, 46952, 1 isoform a 54940 precursor 6858 transmembrane 9 376387 7013 365567 15001 22989, 30977, superfamily member 38965, 46953, 2 54941

112186859 transmembrane 9 371142 7014 360184 15002 22990, 30978, superfamily member 38966, 46954, 3 54942

112196860 transmembrane 9 443638 7015 401152 15003 22991, 30979, superfamily member 38967, 46955, 3 54943

112206861 transmembrane 9 217315 7016 217315 15004 22992, 30980, superfamily protein 38968, 46956, member 4 54944

112216862 transmembrane 9 398022 7017 381104 15005 22993, 30981, superfamily protein 38969, 46957, member 4 54945

112226863 transmembrane 9 421148 7018 403254 15006 22994, 30982, superfamily protein 38970, 46958, member 4 54946

112236864 transmembrane and 329333 7019 327349 15007 22995, 30983, coiled-coil domain 38971, 46959, family 1 54947

112246865 transmembrane and 393238 7020 376930 15008 22996, 30984, coiled-coil domain 38972, 46960, family 1 54948

112256866 transmembrane and 426664 7021 389892 15009 22997, 30985, coiled-coil domain 38973, 46961, family 1 54949

112266867 transmembrane and 432054 7022 404711 15010 22998, 30986, coiled-coil domain 38974, 46962, family 1 54950

112276868 transmembrane and 329800 7023 329436 15011 22999, 30987, coiled-coil domain 38975, 46963, family 2 54951

112286869 transmembrane and 330675 7024 331842 15012 23000, 30988, coiled-coil domain 38976, 46964, family 2 54952

112296870 transmembrane and 358024 7025 350718 15013 23001, 30989, coiled-coil domain 38977, 46965, family 2 54953

112306871 transmembrane and 367159 7026 356127 15014 23002, 30990, coiled-coil domain 38978, 46966, family 2 54954

112316872 transmembrane and 545499 7027 437943 15015 23003, 30991, coiled-coil domain 38979, 46967, family 2 54955

112326873 transmembrane and 261226 7028 261226 15016 23004, 30992, coiled-coil domain 38980, 46968, family 3 54956

112336874 transmembrane and 372766 7029 361852 15017 23005, 30993, coiled-coil domains 38981, 46969, 2 54957

112346875 transmembrane and 434316 7030 389399 15018 23006, 30994, coiled-coil domains 38982, 46970, 3 54958 6876 transmembrane and 294543 7031 294543 15019 23007, 30995, coiled-coil domains 38983, 46971, 4 54959

112356877 transmembrane and 375122 7032 364264 15020 23008, 30996, coiled-coil domains 38984, 46972, 4 54960

112366878 transmembrane and 375127 7033 364269 15021 23009, 30997, coiled-coil domains 38985, 46973, 4 54961

112376879 transmembrane and 319669 7034 327234 15022 23010, 30998, coiled-coil domains 38986, 46974, 5A 54962

112386880 transmembrane and 540944 7035 445914 15023 23011, 30999, coiled-coil domains 38987, 46975, 5A 54963

112396881 transmembrane and 558148 7036 453369 15024 23012, 31000, coiled-coil domains 38988, 46976, 5A 54964

112406882 transmembrane and 558625 7037 453271 15025 23013, 31001, coiled-coil domains 38989, 46977, 5A 54965

112416883 transmembrane and 559502 7038 454112 15026 23014, 31002, coiled-coil domains 38990, 46978, 5A 54966

112426884 transmembrane and 560841 7039 453162 15027 23015, 31003, coiled-coil domains 38991, 46979, 5A 54967

112436885 transmembrane and 261778 7040 261778 15028 23016, 31004, coiled-coil domains 38992, 46980, 7 54968

112446886 transmembrane and 328886 7041 332404 15029 23017, 31005, immunoglobulin 38993, 46981, domain containing 1 54969

112456887 transmembrane and 538566 7042 446118 15030 23018, 31006, immunoglobulin 38994, 46982, domain containing 1 54970

112466888 transmembrane and 301272 7043 301272 15031 23019, 31007, immunoglobulin 38995, 46983, domain containing 2 54971

112476889 transmembrane and 256062 7044 256062 15032 23020, 31008, tetratricopeptide 38996, 46984, repeat containing 1 54972

112486890 transmembrane and 381224 7045 370622 15033 23021, 31009, tetratricopeptide 38997, 46985, repeat containing 1 54973

112496891 transmembrane and 539277 7046 442046 15034 23022, 31010, tetratricopeptide 38998, 46986, repeat containing 1 54974 6892 transmembrane and 540901 7047 446123 15035 23023, 31011, tetratricopeptide 38999, 46987, repeat containing 1 54975

112506893 transmembrane and 551659 7048 448112 15036 23024, 31012, tetratricopeptide 39000, 46988, repeat containing 1 54976

112516894 transmembrane and 321196 7049 322300 15037 23025, 31013, tetratricopeptide 39001, 46989, repeat containing 2 54977

112526895 transmembrane and 266712 7050 266712 15038 23026, 31014, tetratricopeptide 39002, 46990, repeat containing 3 54978

112536896 transmembrane and 549011 7051 447640 15039 23027, 31015, tetratricopeptide 39003, 46991, repeat containing 3 54979

112546897 transmembrane and 328767 7052 365409 15040 23028, 31016, tetratricopeptide 39004, 46992, repeat containing 4 54980

112556898 transmembrane and 342624 7053 343871 15041 23029, 31017, tetratricopeptide 39005, 46993, repeat containing 4 54981

112566899 transmembrane and 376234 7054 365408 15042 23030, 31018, tetratricopeptide 39006, 46994, repeat containing 4 54982

112576900 transmembrane and 423847 7055 398400 15043 23031, 31019, tetratricopeptide 39007, 46995, repeat containing 4 54983

112586901 transmembrane and 475272 7056 419613 15044 23032, 31020, tetratricopeptide 39008, 46996, repeat containing 4 54984

112596902 transmembrane and 297533 7057 297533 15045 23033, 31021, ubiquitin-like 39009, 46997, domain containing 1 54985

112606903 transmembrane and 392818 7058 376565 15046 23034, 31022, ubiquitin-like 39010, 46998, domain containing 1 54986

112616904 transmembrane and 462940 7059 417519 15047 23035, 31023, ubiquitin-like 39011, 46999, domain containing 1 54987

112626905 transmembrane and 476627 7060 419214 15048 23036, 31024, ubiquitin-like 39012, 47000, domain containing 1 54988

112636906 transmembrane and 482202 7061 418709 15049 23037, 31025, ubiquitin-like 39013, 47001, domain containing 1 54989 6907 transmembrane and 488752 7062 420692 15050 23038, 31026, ubiquitin-like 39014, 47002, domain containing 1 54990

112646908 transmembrane and 492838 7063 420516 15051 23039, 31027, ubiquitin-like 39015, 47003, domain containing 1 54991

112656909 transmembrane and 319511 7064 313214 15052 23040, 31028, ubiquitin-like 39016, 47004, domain containing 2 54992

112666910 transmembrane and 357984 7065 350672 15053 23041, 31029, ubiquitin-like 39017, 47005, domain containing 2 54993

112676911 transmembrane and 446571 7066 413127 15054 23042, 31030, ubiquitin-like 39018, 47006, domain containing 2 54994

112686912 transmembrane and 538716 7067 444565 15055 23043, 31031, ubiquitin-like 39019, 47007, domain containing 2 54995

112696913 transmembrane 258412 7068 258412 15056 23044, 31032, BAX inhibitor motif 39020, 47008, containing 1 54996

112706914 transmembrane 396809 7069 380025 15057 23045, 31033, BAX inhibitor motif 39021, 47009, containing 1 54997

112716915 transmembrane 413976 7070 408729 15058 23046, 31034, BAX inhibitor motif 39022, 47010, containing 1 54998

112726916 transmembrane 418569 7071 406744 15059 23047, 31035, BAX inhibitor motif 39023, 47011, containing 1 54999

112736917 transmembrane 420341 7072 413624 15060 23048, 31036, BAX inhibitor motif 39024, 47012, containing 1 55000

112746918 transmembrane 425694 7073 399345 15061 23049, 31037, BAX inhibitor motif 39025, 47013, containing 1 55001

112756919 transmembrane 429501 7074 399987 15062 23050, 31038, BAX inhibitor motif 39026, 47014, containing 1 55002

112766920 transmembrane 434015 7075 405516 15063 23051, 31039, BAX inhibitor motif 39027, 47015, containing 1 55003

112776921 transmembrane 437694 7076 404709 15064 23052, 31040, BAX inhibitor motif 39028, 47016, containing 1 55004

112786922 transmembrane 440422 7077 412518 15065 23053, 31041, BAX inhibitor motif 39029, 47017, containing 1 55005

112796923 transmembrane 444000 7078 403462 15066 23054, 31042, BAX inhibitor motif 39030, 47018, containing 1 55006

112806924 transmembrane 444183 7079 410136 15067 23055, 31043, BAX inhibitor motif 39031, 47019, containing 1 55007 6925 transmembrane 444881 7080 409738 15068 23056, 31044, BAX inhibitor motif 39032, 47020, containing 1 55008

112816926 transmembrane 445635 7081 401491 15069 23057, 31045, BAX inhibitor motif 39033, 47021, containing 1 55009

112826927 transmembrane 451181 7082 394946 15070 23058, 31046, BAX inhibitor motif 39034, 47022, containing 1 55010

112836928 transmembrane 453281 7083 395614 15071 23059, 31047, BAX inhibitor motif 39035, 47023, containing 1 55011

112846929 transmembrane 453776 7084 410771 15072 23060, 31048, BAX inhibitor motif 39036, 47024, containing 1 55012

112856930 transmembrane 543441 7085 437408 15073 23061, 31049, BAX inhibitor motif 39037, 47025, containing 1 55013

112866931 transmembrane 358230 7086 350965 15074 23062, 31050, BAX inhibitor motif 39038, 47026, containing 4 55014

112876932 transmembrane 539043 7087 437888 15075 23063, 31051, BAX inhibitor motif 39039, 47027, containing 4 55015

112886933 transmembrane 539427 7088 444023 15076 23064, 31052, BAX inhibitor motif 39040, 47028, containing 4 55016

112896934 transmembrane 556010 7089 451688 15077 23065, 31053, BAX inhibitor motif 39041, 47029, containing 4 55017

112906935 transmembrane 267115 7090 267115 15078 23066, 31054, BAX inhibitor motif 39042, 47030, containing 6 55018

112916936 transmembrane 395006 7091 378454 15079 23067, 31055, BAX inhibitor motif 39043, 47031, containing 6 55019

112926937 transmembrane 423828 7092 389277 15080 23068, 31056, BAX inhibitor motif 39044, 47032, containing 6 55020

112936938 transmembrane 541612 7093 440808 15081 23069, 31057, BAX inhibitor motif 39045, 47033, containing 6 55021

112946939 transmembrane 542631 7094 445903 15082 23070, 31058, BAX inhibitor motif 39046, 47034, containing 6 55022

112956940 transmembrane 546796 7095 450159 15083 23071, 31059, BAX inhibitor motif 39047, 47035, containing 6 55023

112966941 transmembrane 546914 7096 448612 15084 23072, 31060, BAX inhibitor motif 39048, 47036, containing 6 55024

112976942 transmembrane 547187 7097 447400 15085 23073, 31061, BAX inhibitor motif 39049, 47037, containing 6 55025 6943 transmembrane 547832 7098 448269 15086 23074, 31062, BAX inhibitor motif 39050, 47038, containing 6 55026

112986944 transmembrane 548201 7099 450265 15087 23075, 31063, BAX inhibitor motif 39051, 47039, containing 6 55027

112996945 transmembrane 548713 7100 447888 15088 23076, 31064, BAX inhibitor motif 39052, 47040, containing 6 55028

113006946 transmembrane 548809 7101 449000 15089 23077, 31065, BAX inhibitor motif 39053, 47041, containing 6 55029

113016947 transmembrane 548894 7102 447074 15090 23078, 31066, BAX inhibitor motif 39054, 47042, containing 6 55030

113026948 transmembrane 549130 7103 450305 15091 23079, 31067, BAX inhibitor motif 39055, 47043, containing 6 55031

113036949 transmembrane 549385 7104 448036 15092 23080, 31068, BAX inhibitor motif 39056, 47044, containing 6 55032

113046950 transmembrane 549445 7105 449904 15093 23081, 31069, BAX inhibitor motif 39057, 47045, containing 6 55033

113056951 transmembrane 549966 7106 446668 15094 23082, 31070, BAX inhibitor motif 39058, 47046, containing 6 55034

113066952 transmembrane 550445 7107 449907 15095 23083, 31071, BAX inhibitor motif 39059, 47047, containing 6 55035

113076953 transmembrane 550951 7108 449421 15096 23084, 31072, BAX inhibitor motif 39060, 47048, containing 6 55036

113086954 transmembrane 551154 7109 450417 15097 23085, 31073, BAX inhibitor motif 39061, 47049, containing 6 55037

113096955 transmembrane 552370 7110 450158 15098 23086, 31074, BAX inhibitor motif 39062, 47050, containing 6 55038

113106956 transmembrane 552699 7111 446734 15099 23087, 31075, BAX inhibitor motif 39063, 47051, containing 6 55039

113116957 transmembrane 359440 7112 352413 15100 23088, 31076, channel-like 3 39064, 47052,

1131255040

113136958 transmembrane 558726 7113 452681 15101 23089, 31077, channel-like 3 39065, 47053,

1131455041

113156959 transmembrane 301187 7114 301187 15102 23090, 31078, channel-like 4 39066, 47054,

1131655042

113176960 transmembrane 376591 7115 365776 15103 23091, 31079, channel-like 4 39067, 47055,

1131855043 6961 transmembrane 416963 7116 405023 15104 23092, 31080, channel-like 4 39068, 47056,

1131955044

113206962 transmembrane 219821 7117 219821 15105 23093, 31081, channel-like 5 39069, 47057,

1132155045

113226963 transmembrane 381414 7118 370822 15106 23094, 31082, channel-like 5 39070, 47058,

1132355046

113246964 transmembrane 396229 7119 379531 15107 23095, 31083, channel-like 5 39071, 47059,

1132555047

113266965 transmembrane 440743 7120 395658 15108 23096, 31084, channel-like 5 39072, 47060,

1132755048

113286966 transmembrane 541464 7121 441227 15109 23097, 31085, channel-like 5 39073, 47061,

1132955049

113306967 transmembrane 542583 7122 446274 15110 23098, 31086, channel-like 5 39074, 47062,

1133155050

113326968 transmembrane 304381 7123 304710 15111 23099, 31087, channel-like 7 39075, 47063,

1133355051

113346969 transmembrane 421369 7124 397081 15112 23100, 31088, channel-like 7 39076, 47064,

1133555052

113366970 transmembrane 262225 7125 262225 15113 23101, 31089, emp24 domain 39077, 47065, trafficking protein 2 55053

113376971 transmembrane 432022 7126 388691 15114 23102, 31090, emp24 domain 39078, 47066, trafficking protein 2 55054

113386972 transmembrane 541504 7127 439546 15115 23103, 31091, emp24 domain 39079, 47067, trafficking protein 2 55055

113396973 transmembrane 299705 7128 299705 15116 23104, 31092, emp24 protein 39080, 47068, transport domain 55056 containing 3

113406974 transmembrane 424155 7129 414983 15117 23105, 31093, emp24 protein 39081, 47069, transport domain 55057 containing 3

113416975 transmembrane 370280 7130 359303 15118 23106, 31094, emp24 protein 39082, 47070, transport domain 55058 containing 5

113426976 transmembrane 370282 7131 359305 15119 23107, 31095, emp24 protein 39083, 47071, transport domain 55059 containing 5

113436977 transmembrane 479918 7132 418992 15120 23108, 31096, emp24 protein 39084, 47072, transport domain 55060 containing 5

113446978 transmembrane 535517 7133 438246 15121 23109, 31097, emp24 protein 39085, 47073, transport domain 55061 containing 5

113456979 transmembrane 288025 7134 288025 15122 23110, 31098, emp24 protein 39086, 47074, transport domain 55062 containing 6

113466980 transmembrane 456936 7135 405926 15123 23111, 31099, emp24 protein 39087, 47075, transport domain 55063 containing 7

113476981 transmembrane 508420 7136 450928 15124 23112, 31100, emp24 protein 39088, 47076, transport domain 55064 containing 7

113486982 transmembrane 216468 7137 216468 15125 23113, 31101, emp24 protein 39089, 47077, transport domain 55065 containing 8

113496983 transmembrane 332598 7138 330945 15126 23114, 31102, emp24 protein 39090, 47078, transport domain 55066 containing 9

113506984 transmembrane 367565 7139 356536 15127 23115, 31103, epididymal protein 1 39091, 47079,

1135155067

113526985 transmembrane 255310 7140 255310 15128 23116, 31104, phosphoinositide 3- 39092, 47080, phosphatase and 55068 tensin homolog 2

113536986 transmembrane 343548 7141 343109 15129 23117, 31105, phosphoinositide 3- 39093, 47081, phosphatase and 55069 tensin homolog 2

113546987 transmembrane 382975 7142 372435 15130 23118, 31106, phosphoinositide 3- 39094, 47082, phosphatase and 55070 tensin homolog 2

113556988 transmembrane 382977 7143 372437 15131 23119, 31107, phosphoinositide 3- 39095, 47083, phosphatase and 55071 tensin homolog 2

113566989 transmembrane 390680 7144 375098 15132 23120, 31108, phosphoinositide 3- 39096, 47084, phosphatase and 55072 tensin homolog 2

113576990 transmembrane 400103 7145 382974 15133 23121, 31109, phosphoinositide 3- 39097, 47085, phosphatase and 55073 tensin homolog 2 6991 transmembrane 400230 7146 383089 15134 23122, 31110, phosphoinositide 3- 39098, 47086, phosphatase and 55074 tensin homolog 2

113586992 transmembrane 419256 7147 438339 15135 23123, 31111, phosphoinositide 3- 39099, 47087, phosphatase and 55075 tensin homolog 2

113596993 transmembrane 457266 7148 442218 15136 23124, 31112, phosphoinositide 3- 39100, 47088, phosphatase and 55076 tensin homolog 2

113606994 transmembrane 283916 7149 283916 15137 23125, 31113, protease, serine 11D 39101, 47089,

1136155077, 56099, 56132

113626995 transmembrane 545541 7150 442045 15138 23126, 31114, protease, serine 11D 39102, 47090,

1136355078, 56100, 56133

113646996 transmembrane 284885 7151 284885 15139 23127, 31115, protease, serine 15 39103, 47091,

1136555079

113666997 transmembrane 419127 7152 411645 15140 23128, 31116, protease, serine 7 39104, 47092,

1136755080

113686998 transmembrane 437906 7153 411595 15141 23129, 31117, protease, serine 7 39105, 47093,

1136955081

113706999 transmembrane 443106 7154 389163 15142 23130, 31118, protease, serine 7 39106, 47094,

1137155082

113727000 transmembrane 452346 7155 398236 15143 23131, 31119, protease, serine 7 39107, 47095,

1137355083

113747001 transmembrane 332578 7156 330264 15144 23132, 31120, protease, serine 9 39108, 47096,

1137555084

113767002 transmembrane 395264 7157 378681 15145 23133, 31121, protease, serine 9 39109, 47097,

1137755085

113787003 transmembrane 299377 7158 299377 15146 23134, 31122, protein 100 39110, 47098,

1137955086

113807004 transmembrane 424486 7159 395328 15147 23135, 31123, protein 100 39111, 47099,

1138155087

113827005 transmembrane 575734 7160 465638 15148 23136, 31124, protein 100 39112, 47100,

1138355088

113847006 transmembrane 206380 7161 206380 15149 23137, 31125, protein 101 39113, 47101,

1138555089 7007 transmembrane 542039 7162 442994 15150 23138, 31126, protein 101 39114, 47102,

1138655090

113877008 transmembrane 589334 7163 468025 15151 23139, 31127, protein 101 39115, 47103,

1138855091

113897009 transmembrane 335464 7164 334849 15152 23140, 31128, protein 104 39116, 47104,

1139055092

113917010 transmembrane 417024 7165 397676 15153 23141, 31129, protein 104 39117, 47105,

1139255093

113937011 transmembrane 332900 7166 329795 15154 23142, 31130, protein 105 39118, 47106,

1139455094

113957012 transmembrane 331615 7167 330774 15155 23143, 31131, protein 106 A 39119, 47107,

1139655095

113977013 transmembrane 536052 7168 439835 15156 23144, 31132, protein 106 A 39120, 47108,

1139855096

113997014 transmembrane 541594 7169 439844 15157 23145, 31133, protein 106 A 39121, 47109,

1140055097

114017015 transmembrane 256686 7170 256686 15158 23146, 31134, protein 106C 39122, 47110,

1140255098

114037016 transmembrane 429772 7171 400471 15159 23147, 31135, protein 106C 39123, 47111,

1140455099

114057017 transmembrane 449758 7172 402705 15160 23148, 31136, protein 106C 39124, 47112,

1140655100

114077018 transmembrane 552561 7173 446657 15161 23149, 31137, protein 106C 39125, 47113,

1140855101

114097019 transmembrane 316425 7174 314116 15162 23150, 31138, protein 107 39126, 47114,

1141055102

114117020 transmembrane 415860 7175 392476 15163 23151, 31139, protein 107 39127, 47115,

1141255103

114137021 transmembrane 437139 7176 402732 15164 23152, 31140, protein 107 39128, 47116,

1141455104

114157022 transmembrane 533070 7177 436674 15165 23153, 31141, protein 107 39129, 47117,

1141655105

114177023 transmembrane 321871 7178 324651 15166 23154, 31142, protein 108 39130, 47118,

1141855106

114197024 transmembrane 393130 7179 376838 15167 23155, 31143, protein 108 39131, 47119,

1142055107 7025 transmembrane 508711 7180 424897 15168 23156, 31144, protein 108 39132, 47120,

1142155108

114227026 transmembrane 510183 7181 421486 15169 23157, 31145, protein 108 39133, 47121,

1142355109

114247027 transmembrane 511555 7182 422196 15170 23158, 31146, protein 108 39134, 47122,

1142555110

114267028 transmembrane 512137 7183 426301 15171 23159, 31147, protein 108 39135, 47123,

1142755111

114287029 transmembrane 515826 7184 423338 15172 23160, 31148, protein 108 39136, 47124,

1142955112

114307030 transmembrane 227525 7185 227525 15173 23161, 31149, protein 109 39137, 47125,

1143155113

114327031 transmembrane 446886 7186 403489 15174 23162, 31150, protein 109 39138, 47126,

1143355114

114347032 transmembrane 536171 7187 443990 15175 23163, 31151, protein 109 39139, 47127,

1143555115

114367033 transmembrane 317635 7188 319992 15176 23164, 31152, protein 11 39140, 47128,

1143755116

114387034 transmembrane 355083 7189 347195 15177 23165, 31153, protein 110 39141, 47129,

1143955117

114407035 transmembrane 245046 7190 245046 15178 23166, 31154, protein 111 39142, 47130,

1144155118

114427036 transmembrane 429759 7191 408803 15179 23167, 31155, protein 111 39143, 47131,

1144355119

114447037 transmembrane 266025 7192 266025 15180 23168, 31156, protein 115 39144, 47132,

1144555120

114467038 transmembrane 354825 7193 346883 15181 23169, 31157, protein 116 39145, 47133,

1144755121

114487039 transmembrane 437003 7194 395861 15182 23170, 31158, protein 116 39146, 47134,

1144955122

114507040 transmembrane 546962 7195 446766 15183 23171, 31159, protein 116 39147, 47135,

1145155123

114527041 transmembrane 549425 7196 449774 15184 23172, 31160, protein 116 39148, 47136,

1145355124

114547042 transmembrane 550037 7197 446516 15185 23173, 31161, protein 116 39149, 47137,

1145555125 7043 transmembrane 550233 7198 450060 15186 23174, 31162, protein 116 39150, 47138,

1145655126

114577044 transmembrane 550831 7199 450377 15187 23175, 31163, protein 116 39151, 47139,

1145855127

114597045 transmembrane 552374 7200 447731 15188 23176, 31164, protein 116 39152, 47140,

1146055128

114617046 transmembrane 355445 7201 347620 15189 23177, 31165, protein 116 39153, 47141,

1146255129

114637047 transmembrane 266534 7202 266534 15190 23178, 31166, protein 117 39154, 47142,

1146455130

114657048 transmembrane 417623 7203 405508 15191 23179, 31167, protein 117 39155, 47143,

1146655131

114677049 transmembrane 536799 7204 445243 15192 23180, 31168, protein 117 39156, 47144,

1146855132

114697050 transmembrane 392806 7205 376553 15193 23181, 31169, protein 119 39157, 47145,

1147055133

114717051 transmembrane 433191 7206 409520 15194 23182, 31170, protein 119 39158, 47146,

1147255134

114737052 transmembrane 547567 7207 447345 15195 23183, 31171, protein 119 39159, 47147,

1147455135

114757053 transmembrane 549031 7208 448583 15196 23184, 31172, protein 119 39160, 47148,

1147655136

114777054 transmembrane 549447 7209 447120 15197 23185, 31173, protein 119 39161, 47149,

1147855137

114797055 transmembrane 342607 7210 345152 15198 23186, 31174, protein 120B 39162, 47150,

1148055138

114817056 transmembrane 449592 7211 404991 15199 23187, 31175, protein 120B 39163, 47151,

1148255139

114837057 transmembrane 392519 7212 376304 15200 23188, 31176, protein 121 39164, 47152,

1148455140

114857058 transmembrane 431372 7213 407456 15201 23189, 31177, protein 121 39165, 47153,

1148655141

114877059 transmembrane 432792 7214 429275 15202 23190, 31178, protein 125 39166, 47154,

1148855142

114897060 transmembrane 439858 7215 429775 15203 23191, 31179, protein 125 39167, 47155,

1149055143 7061 transmembrane 456751 7216 428627 15204 23192, 31180, protein 125 39168, 47156,

1149155144

114927062 transmembrane 358867 7217 351737 15205 23193, 31181, protein 126B 39169, 47157,

1149355145

114947063 transmembrane 393375 7218 377039 15206 23194, 31182, protein 126B 39170, 47158,

1149555146

114967064 transmembrane 534341 7219 433471 15207 23195, 31183, protein 126B 39171, 47159,

1149755147

114987065 transmembrane 526822 7220 433449 15208 23196, 31184, protein 126B 39172, 47160,

1149955148

115007066 transmembrane 254742 7221 254742 15209 23197, 31185, protein 128 39173, 47161,

1150155149

115027067 transmembrane 382753 7222 372201 15210 23198, 31186, protein 128 39174, 47162,

1150355150

115047068 transmembrane 538516 7223 442300 15211 23199, 31187, protein 128 39175, 47163,

1150555151

115067069 transmembrane 540397 7224 439174 15212 23200, 31188, protein 128 39176, 47164,

1150755152

115087070 transmembrane 382936 7225 372394 15213 23201, 31189, protein 129 39177, 47165,

1150955153

115107071 transmembrane 536901 7226 441812 15214 23202, 31190, protein 129 39178, 47166,

1151155154

115127072 transmembrane 303277 7227 305243 15215 23203, 31191, protein 129 39179, 47167,

1151355155

115147073 transmembrane 339375 7228 341256 15216 23204, 31192, protein 130 39180, 47168,

1151555156

115167074 transmembrane 345589 7229 330262 15217 23205, 31193, protein 130 39181, 47169,

1151755157

115187075 transmembrane 416379 7230 413163 15218 23206, 31194, protein 130 39182, 47170,

1151955158

115207076 transmembrane 546258 7231 445869 15219 23207, 31195, protein 130 39183, 47171,

1152155159

115227077 transmembrane 186436 7232 186436 15220 23208, 31196, protein 131 39184, 47172,

1152355160

115247078 transmembrane 418629 7233 391566 15221 23209, 31197, protein 131 39185, 47173,

1152555161 7079 transmembrane 425805 7234 401670 15222 23210, 31198, protein 131 39186, 47174,

1152655162

115277080 transmembrane 299308 7235 299308 15223 23211, 31199, protein 132B 39187, 47175,

1152855163

115297081 transmembrane 435159 7236 410852 15224 23212, 31200, protein 132C 39188, 47176,

1153055164

115317082 transmembrane 389441 7237 374092 15225 23213, 31201, protein 132D 39189, 47177,

1153255165

115337083 transmembrane 422113 7238 408581 15226 23214, 31202, protein 132D 39190, 47178,

1153455166

115357084 transmembrane 321639 7239 316532 15227 23215, 31203, protein 132E 39191, 47179,

1153655167

115377085 transmembrane 303130 7240 303999 15228 23216, 31204, protein 133 39192, 47180,

1153855168

115397086 transmembrane 308022 7241 312615 15229 23217, 31205, protein 134 39193, 47181,

1154055169

115417087 transmembrane 393877 7242 377455 15230 23218, 31206, protein 134 39194, 47182,

1154255170

115437088 transmembrane 305494 7243 306344 15231 23219, 31207, protein 135 39195, 47183,

1154455171

115457089 transmembrane 340353 7244 345513 15232 23220, 31208, protein 135 39196, 47184,

1154655172

115477090 transmembrane 355734 7245 347973 15233 23221, 31209, protein 135 39197, 47185,

1154855173

115497091 transmembrane 535167 7246 439525 15234 23222, 31210, protein 135 39198, 47186,

1155055174

115517092 transmembrane 544294 7247 441089 15235 23223, 31211, protein 135 39199, 47187,

1155255175

115537093 transmembrane 314475 7248 312672 15236 23224, 31212, protein 136 39200, 47188,

1155455176

115557094 transmembrane 375095 7249 364236 15237 23225, 31213, protein 136 39201, 47189,

1155655177

115577095 transmembrane 529187 7250 434862 15238 23226, 31214, protein 136 39202, 47190,

1155855178

115597096 transmembrane 359333 7251 352284 15239 23227, 31215, protein 139 39203, 47191,

1156055179 7097 transmembrane 409102 7252 386879 15240 23228, 31216, protein 139 39204, 47192,

1156155180

115627098 transmembrane 409244 7253 386335 15241 23229, 31217, protein 139 39205, 47193,

1156355181

115647099 transmembrane 409541 7254 387044 15242 23230, 31218, protein 139 39206, 47194,

1156555182

115667100 transmembrane 410004 7255 386564 15243 23231, 31219, protein 139 39207, 47195,

1156755183

115687101 transmembrane 275767 7256 275767 15244 23232, 31220, protein 140 39208, 47196,

1156955184

115707102 transmembrane 456488 7257 401207 15245 23233, 31221, protein 140 39209, 47197,

1157155185

115727103 transmembrane 290079 7258 290079 15246 23234, 31222, protein 141 39210, 47198,

1157355186

115747104 transmembrane 293261 7259 293261 15247 23235, 31223, protein 143 39211, 47199,

1157555187

115767105 transmembrane 377431 7260 366649 15248 23236, 31224, protein 143 39212, 47200,

1157755188

115787106 transmembrane 435956 7261 397038 15249 23237, 31225, protein 143 39213, 47201,

1157955189

115807107 transmembrane 436660 7262 390270 15250 23238, 31226, protein 143 39214, 47202,

1158155190

115827108 transmembrane 541566 7263 444275 15251 23239, 31227, protein 143 39215, 47203,

1158355191

115847109 transmembrane 296529 7264 296529 15252 23240, 31228, protein 144 39216, 47204,

1158555192

115867110 transmembrane 502698 7265 425907 15253 23241, 31229, protein 144 39217, 47205,

1158755193

115887111 transmembrane 503200 7266 420990 15254 23242, 31230, protein 144 39218, 47206,

1158955194

115907112 transmembrane 504569 7267 422082 15255 23243, 31231, protein 144 39219, 47207,

1159155195

115927113 transmembrane 505049 7268 425266 15256 23244, 31232, protein 144 39220, 47208,

1159355196

115947114 transmembrane 505189 7269 421289 15257 23245, 31233, protein 144 39221, 47209,

1159555197 7115 transmembrane 508243 7270 422297 15258 23246, 31234, protein 144 39222, 47210,

1159655198

115977116 transmembrane 511038 7271 422255 15259 23247, 31235, protein 144 39223, 47211,

1159855199

115997117 transmembrane 512481 7272 424659 15260 23248, 31236, protein 144 39224, 47212,

1160055200

116017118 transmembrane 514558 7273 426211 15261 23249, 31237, protein 144 39225, 47213,

1160255201

116037119 transmembrane 514971 7274 422899 15262 23250, 31238, protein 144 39226, 47214,

1160455202

116057120 transmembrane 301204 7275 301204 15263 23251, 31239, protein 145 39227, 47215,

1160655203

116077121 transmembrane 381613 7276 371026 15264 23252, 31240, protein 146 39228, 47216,

1160855204

116097122 transmembrane 381614 7277 371027 15265 23253, 31241, protein 146 39229, 47217,

1161055205

116117123 transmembrane 381624 7278 371037 15266 23254, 31242, protein 146 39230, 47218,

1161255206

116137124 transmembrane 222284 7279 222284 15267 23255, 31243, protein 147 39231, 47219,

1161455207

116157125 transmembrane 392204 7280 376040 15268 23256, 31244, protein 147 39232, 47220,

1161655208

116177126 transmembrane 392205 7281 376041 15269 23257, 31245, protein 147 39233, 47221,

1161855209

116197127 transmembrane 593027 7282 466262 15270 23258, 31246, protein 147 39234, 47222,

1162055210

116217128 transmembrane 211314 7283 211314 15271 23259, 31247, protein 14A 39235, 47223,

1162255211

116237129 transmembrane 379530 7284 368845 15272 23260, 31248, protein 14B 39236, 47224,

1162455212

116257130 transmembrane 379542 7285 368858 15273 23261, 31249, protein 14B 39237, 47225,

1162655213

116277131 transmembrane 472062 7286 419375 15274 23262, 31250, protein 14B 39238, 47226,

1162855214

116297132 transmembrane 475942 7287 418730 15275 23263, 31251, protein 14B 39239, 47227,

1163055215 7133 transmembrane 229563 7288 229563 15276 23264, 31252, protein 14C 39240, 47228,

1163155216

116327134 transmembrane 342277 7289 343293 15277 23265, 31253, protein 14C 39241, 47229,

1163355217

116347135 transmembrane 541412 7290 444561 15278 23266, 31254, protein 14C 39242, 47230,

1163555218

116367136 transmembrane 408960 7291 386163 15279 23267, 31255, protein 14E 39243, 47231,

1163755219

116387137 transmembrane 306353 7292 302715 15280 23268, 31256, protein 150A 39244, 47232,

1163955220

116407138 transmembrane 334462 7293 334708 15281 23269, 31257, protein 150A 39245, 47233,

1164155221

116427139 transmembrane 409668 7294 387292 15282 23270, 31258, protein 150A 39246, 47234,

1164355222

116447140 transmembrane 425160 7295 394945 15283 23271, 31259, protein 150A 39247, 47235,

1164555223

116467141 transmembrane 326652 7296 320757 15284 23272, 31260, protein 15 OB 39248, 47236,

1164755224

116487142 transmembrane 438693 7297 412658 15285 23273, 31261, protein 15 OB 39249, 47237,

1164955225

116507143 transmembrane 449862 7298 403438 15286 23274, 31262, protein 150C 39250, 47238,

1165155226

116527144 transmembrane 454948 7299 414988 15287 23275, 31263, protein 150C 39251, 47239,

1165355227

116547145 transmembrane 515780 7300 420919 15288 23276, 31264, protein 150C 39252, 47240,

1165555228

116567146 transmembrane 327259 7301 326244 15289 23277, 31265, protein 151 A 39253, 47241,

1165755229

116587147 transmembrane 430110 7302 410997 15290 23278, 31266, protein 15 IB 39254, 47242,

1165955230

116607148 transmembrane 451188 7303 393161 15291 23279, 31267, protein 15 IB 39255, 47243,

1166155231

116627149 transmembrane 304385 7304 302144 15292 23280, 31268, protein 154 39256, 47244,

1166355232

116647150 transmembrane 504064 7305 422156 15293 23281, 31269, protein 154 39257, 47245,

1166555233 7151 transmembrane 381938 7306 371364 15294 23282, 31270, protein 156 39258, 47246,

1166655234

116677152 transmembrane 253047 7307 253047 15295 23283, 31271, protein 160 39259, 47247,

1166855235

116697153 transmembrane 162044 7308 162044 15296 23284, 31272, protein 161 A 39260, 47248,

1167055236, 56101, 56134

116717154 transmembrane 450333 7309 404208 15297 23285, 31273, protein 161 A 39261, 47249,

1167255237

116737155 transmembrane 296595 7310 296595 15298 23286, 31274, protein 16 IB 39262, 47250,

1167455238

116757156 transmembrane 443393 7311 395621 15299 23287, 31275, protein 16 IB 39263, 47251,

1167655239

116777157 transmembrane 281924 7312 281924 15300 23288, 31276, protein 163 39264, 47252,

1167855240

116797158 transmembrane 537539 7313 445702 15301 23289, 31277, protein 163 39265, 47253,

1168055241

116817159 transmembrane 288381 7314 288381 15302 23290, 31278, protein 164 39266, 47254,

1168255242

116837160 transmembrane 372068 7315 361138 15303 23291, 31279, protein 164 39267, 47255,

1168455243

116857161 transmembrane 372072 7316 384075 15304 23292, 31280, protein 164 39268, 47256,

1168655244

116877162 transmembrane 372073 7317 361143 15305 23293, 31281, protein 164 39269, 47257,

1168855245

116897163 transmembrane 501872 7318 438333 15306 23294, 31282, protein 164 39270, 47258,

1169055246

116917164 transmembrane 381334 7319 370736 15307 23295, 31283, protein 165 39271, 47259,

1169255247

116937165 transmembrane 542052 7320 437816 15308 23296, 31284, protein 165 39272, 47260,

1169455248

116957166 transmembrane 502346 7321 424707 15309 23297, 31285, protein 167 A 39273, 47261,

1169655249

116977167 transmembrane 338272 7322 342148 15310 23298, 31286, protein 167B 39274, 47262,

1169855250

116997168 transmembrane 312814 7323 323068 15311 23299, 31287, protein 168 39275, 47263,

1170055251 7169 transmembrane 447395 7324 410307 15312 23300, 31288, protein 168 39276, 47264,

1170155252

117027170 transmembrane 454074 7325 390696 15313 23301, 31289, protein 168 39277, 47265,

1170355253

117047171 transmembrane 295658 7326 295658 15314 23302, 31290, protein 169 39278, 47266,

1170555254

117067172 transmembrane 406027 7327 384100 15315 23303, 31291, protein 169 39279, 47267,

1170755255

117087173 transmembrane 433112 7328 400798 15316 23304, 31292, protein 169 39280, 47268,

1170955256

117107174 transmembrane 437356 7329 401305 15317 23305, 31293, protein 169 39281, 47269,

1171155257

117127175 transmembrane 454545 7330 412524 15318 23306, 31294, protein 169 39282, 47270,

1171355258

117147176 transmembrane 455479 7331 413257 15319 23307, 31295, protein 169 39283, 47271,

1171555259

117167177 transmembrane 335390 7332 335094 15320 23308, 31296, protein 17 39284, 47272,

1171755260

117187178 transmembrane 357613 7333 350230 15321 23309, 31297, protein 170 A 39285, 47273,

1171955261

117207179 transmembrane 561878 7334 454404 15322 23310, 31298, protein 170 A 39286, 47274,

1172155262

117227180 transmembrane 379426 7335 368737 15323 23311, 31299, protein 170B 39287, 47275,

1172355263

117247181 transmembrane 543875 7336 442131 15324 23312, 31300, protein 170B 39288, 47276,

1172555264

117267182 transmembrane 287773 7337 287773 15325 23313, 31301, protein 171 39289, 47277,

1172755265

117287183 transmembrane 454765 7338 415030 15326 23314, 31302, protein 171 39290, 47278,

1172955266

117307184 transmembrane 296776 7339 296776 15327 23315, 31303, protein 174 39291, 47279,

1173155267

117327185 transmembrane 264771 7340 264771 15328 23316, 31304, protein 175 39292, 47280,

1173355268

117347186 transmembrane 359768 7341 352814 15329 23317, 31305, protein 175 39293, 47281,

1173555269 7187 transmembrane 514546 7342 425763 15330 23318, 31306, protein 175 39294, 47282,

1173655270

117377188 transmembrane 515740 7343 427039 15331 23319, 31307, protein 175 39295, 47283,

1173855271

117397189 transmembrane 4103 7344 4103 15332 23320, 31308, protein 176 A 39296, 47284,

1174055272, 56102, 56135

117417190 transmembrane 484928 7345 417626 15333 23321, 31309, protein 176 A 39297, 47285,

1174255273

117437191 transmembrane 326442 7346 318409 15334 23322, 31310, protein 176B 39298, 47286,

1174455274

117457192 transmembrane 429904 7347 397810 15335 23323, 31311, protein 176B 39299, 47287,

1174655275

117477193 transmembrane 434545 7348 413531 15336 23324, 31312, protein 176B 39300, 47288,

1174855276

117497194 transmembrane 447204 7349 410269 15337 23325, 31313, protein 176B 39301, 47289,

1175055277

117517195 transmembrane 450753 7350 404831 15338 23326, 31314, protein 176B 39302, 47290,

1175255278

117537196 transmembrane 492607 7351 419258 15339 23327, 31315, protein 176B 39303, 47291,

1175455279

117557197 transmembrane 528038 7352 434910 15340 23328, 31316, protein 176B 39304, 47292,

1175655280

117577198 transmembrane 272521 7353 272521 15341 23329, 31317, protein 177 39305, 47293,

1175855281

117597199 transmembrane 401466 7354 385966 15342 23330, 31318, protein 177 39306, 47294,

1176055282

117617200 transmembrane 415646 7355 413982 15343 23331, 31319, protein 177 39307, 47295,

1176255283

117637201 transmembrane 424086 7356 402661 15344 23332, 31320, protein 177 39308, 47296,

1176455284

117657202 transmembrane 445518 7357 405898 15345 23333, 31321, protein 177 39309, 47297,

1176655285

117677203 transmembrane 281961 7358 281961 15346 23334, 31322, protein 178 39310, 47298,

1176855286

117697204 transmembrane 378734 7359 368008 15347 23335, 31323, protein 178 39311, 47299,

1177055287 7205 transmembrane 341595 7360 340477 15348 23336, 31324, protein 179 39312, 47300,

1177155288

117727206 transmembrane 556573 7361 450958 15349 23337, 31325, protein 179 39313, 47301,

1177355289

117747207 transmembrane 333449 7362 333697 15350 23338, 31326, protein 179B 39314, 47302,

1177555290

117767208 transmembrane 238936 7363 238936 15351 23339, 31327, protein 180 39315, 47303,

1177755291

117787209 transmembrane 366277 7364 437572 15352 23340, 31328, protein 180 39316, 47304,

1177955292

117807210 transmembrane 369930 7365 358946 15353 23341, 31329, protein 180 39317, 47305,

1178155293

117827211 transmembrane 369931 7366 358947 15354 23342, 31330, protein 180 39318, 47306,

1178355294

117847212 transmembrane 447593 7367 393816 15355 23343, 31331, protein 180 39319, 47307,

1178555295

117867213 transmembrane 409528 7368 387258 15356 23344, 31332, protein 182 39320, 47308,

1178755296

117887214 transmembrane 412401 7369 394178 15357 23345, 31333, protein 182 39321, 47309,

1178955297

117907215 transmembrane 367242 7370 356211 15358 23346, 31334, protein 183 A 39322, 47310,

1179155298

117927216 transmembrane 297477 7371 297477 15359 23347, 31335, protein 184A 39323, 47311,

1179355299

117947217 transmembrane 414730 7372 398382 15360 23348, 31336, protein 184A 39324, 47312,

1179555300

117967218 transmembrane 431208 7373 403499 15361 23349, 31337, protein 184A 39325, 47313,

1179755301

117987219 transmembrane 441933 7374 389092 15362 23350, 31338, protein 184A 39326, 47314,

1179955302

118007220 transmembrane 361684 7375 354441 15363 23351, 31339, protein 184B 39327, 47315,

1180155303

118027221 transmembrane 361906 7376 355210 15364 23352, 31340, protein 184B 39328, 47316,

1180355304

118047222 transmembrane 403210 7377 385608 15365 23353, 31341, protein 184B 39329, 47317,

1180555305 7223 transmembrane 436674 7378 413085 15366 23354, 31342, protein 184B 39330, 47318,

1180655306

118077224 transmembrane 426077 7379 453399 15367 23355, 31343, protein 185B 39331, 47319,

1180855307

118097225 transmembrane 333050 7380 331640 15368 23356, 31344, protein 186 39332, 47320,

1181055308

118117226 transmembrane 369982 7381 358999 15369 23357, 31345, protein 187 39333, 47321,

1181255309

118137227 transmembrane 425274 7382 390108 15370 23358, 31346, protein 187 39334, 47322,

1181455310

118157228 transmembrane 431598 7383 412872 15371 23359, 31347, protein 187 39335, 47323,

1181655311

118177229 transmembrane 389134 7384 373786 15372 23360, 31348, protein 188 39336, 47324,

1181855312

118197230 transmembrane 427478 7385 394224 15373 23361, 31349, protein 188 39337, 47325,

1182055313

118217231 transmembrane 458059 7386 405635 15374 23362, 31350, protein 188 39338, 47326,

1182255314

118237232 transmembrane 371650 7387 360713 15375 23363, 31351, protein 189 39339, 47327,

1182455315

118257233 transmembrane 371652 7388 360715 15376 23364, 31352, protein 189 39340, 47328,

1182655316

118277234 transmembrane 371656 7389 360719 15377 23365, 31353, protein 189 39341, 47329,

1182855317

118297235 transmembrane 557021 7390 450635 15378 23366, 31354, protein 189 39342, 47330,

1183055318

118317236 transmembrane 266673 7391 266673 15379 23367, 31355, protein 19 39343, 47331,

1183255319

118337237 transmembrane 547816 7392 449176 15380 23368, 31356, protein 19 39344, 47332,

1183455320

118357238 transmembrane 549735 7393 449955 15381 23369, 31357, protein 19 39345, 47333,

1183655321

118377239 transmembrane 550524 7394 448587 15382 23370, 31358, protein 19 39346, 47334,

1183855322

118397240 transmembrane 550787 7395 448069 15383 23371, 31359, protein 19 39347, 47335,

1184055323 7241 transmembrane 291934 7396 291934 15384 23372, 31360, protein 190 39348, 47336,

1184155324

118427242 transmembrane 306480 7397 305069 15385 23373, 31361, protein 192 39349, 47337,

1184355325

118447243 transmembrane 506087 7398 425335 15386 23374, 31362, protein 192 39350, 47338,

1184555326

118467244 transmembrane 300128 7399 300128 15387 23375, 31363, protein 194 A 39351, 47339,

1184755327

118487245 transmembrane 379391 7400 368701 15388 23376, 31364, protein 194 A 39352, 47340,

1184955328

118507246 transmembrane 405764 7401 384234 15389 23377, 31365, protein 196 39353, 47341,

1185155329

118527247 transmembrane 433641 7402 406460 15390 23378, 31366, protein 196 39354, 47342,

1185355330

118547248 transmembrane 344458 7403 343507 15391 23379, 31367, protein 198 39355, 47343,

1185555331

118567249 transmembrane 373883 7404 362990 15392 23380, 31368, protein 198 39356, 47344,

1185755332

118587250 transmembrane 421791 7405 388087 15393 23381, 31369, protein 198 39357, 47345,

1185955333

118607251 transmembrane 292114 7406 292114 15394 23382, 31370, protein 199 39358, 47346,

1186155334

118627252 transmembrane 509083 7407 427614 15395 23383, 31371, protein 199 39359, 47347,

1186355335

118647253 transmembrane 296978 7408 296978 15396 23384, 31372, protein 200 A 39360, 47348,

1186555336

118667254 transmembrane 392429 7409 376224 15397 23385, 31373, protein 200 A 39361, 47349,

1186755337

118687255 transmembrane 545622 7410 438928 15398 23386, 31374, protein 200 A 39362, 47350,

1186955338

118707256 transmembrane 420504 7411 428544 15399 23387, 31375, protein 200B 39363, 47351,

1187155339

118727257 transmembrane 521452 7412 428459 15400 23388, 31376, protein 200B 39364, 47352,

1187355340

118747258 transmembrane 383490 7413 372982 15401 23389, 31377, protein 200C 39365, 47353,

1187555341 7259 transmembrane 581347 7414 463375 15402 23390, 31378, protein 200C 39366, 47354,

1187655342

118777260 transmembrane 340305 7415 344772 15403 23391, 31379, protein 201 39367, 47355,

1187855343

118797261 transmembrane 340381 7416 344503 15404 23392, 31380, protein 201 39368, 47356,

1188055344

118817262 transmembrane 377376 7417 366593 15405 23393, 31381, protein 201 39369, 47357,

1188255345

118837263 transmembrane 343666 7418 375053 15406 23394, 31382, protein 203 39370, 47358,

1188455346

118857264 transmembrane 537254 7419 446302 15407 23395, 31383, protein 203 39371, 47359,

1188655347

118877265 transmembrane 253934 7420 253934 15408 23396, 31384, protein 204 39372, 47360,

1188855348

118897266 transmembrane 566264 7421 454945 15409 23397, 31385, protein 204 39373, 47361,

1189055349

118917267 transmembrane 261455 7422 261455 15410 23398, 31386, protein 206 39374, 47362,

1189255350

118937268 transmembrane 535273 7423 438863 15411 23399, 31387, protein 206 39375, 47363,

1189455351

118957269 transmembrane 354905 7424 346981 15412 23400, 31388, protein 207 39376, 47364,

1189655352

118977270 transmembrane 304800 7425 305892 15413 23401, 31389, protein 208 39377, 47365,

1189855353

118997271 transmembrane 336804 7426 338388 15414 23402, 31390, protein 209 39378, 47366,

1190055354

119017272 transmembrane 397622 7427 380747 15415 23403, 31391, protein 209 39379, 47367,

1190255355

119037273 transmembrane 462753 7428 419697 15416 23404, 31392, protein 209 39380, 47368,

1190455356

119057274 transmembrane 471077 7429 418474 15417 23405, 31393, protein 209 39381, 47369,

1190655357

119077275 transmembrane 473456 7430 417258 15418 23406, 31394, protein 209 39382, 47370,

1190855358

119097276 transmembrane 484249 7431 441312 15419 23407, 31395, protein 209 39383, 47371,

1191055359 7277 transmembrane 382744 7432 372192 15420 23408, 31396, protein 211 39384, 47372,

1191155360

119127278 transmembrane 407886 7433 385494 15421 23409, 31397, protein 211 39385, 47373,

1191355361

119147279 transmembrane 423535 7434 387813 15422 23410, 31398, protein 211 39386, 47374,

1191555362

119167280 transmembrane 422794 7435 402388 15423 23411, 31399, protein 213 39387, 47375,

1191755363

119187281 transmembrane 442682 7436 390407 15424 23412, 31400, protein 213 39388, 47376,

1191955364

119207282 transmembrane 238788 7437 238788 15425 23413, 31401, protein 214 39389, 47377,

1192155365

119227283 transmembrane 321326 7438 319469 15426 23414, 31402, protein 214 39390, 47378,

1192355366

119247284 transmembrane 404032 7439 384417 15427 23415, 31403, protein 214 39391, 47379,

1192555367

119267285 transmembrane 535207 7440 441664 15428 23416, 31404, protein 214 39392, 47380,

1192755368

119287286 transmembrane 537397 7441 445286 15429 23417, 31405, protein 214 39393, 47381,

1192955369

119307287 transmembrane 342743 7442 345468 15430 23418, 31406, protein 215 39394, 47382,

1193155370

119327288 transmembrane 336655 7443 338164 15431 23419, 31407, protein 217 39395, 47383,

1193355371

119347289 transmembrane 356757 7444 349198 15432 23420, 31408, protein 217 39396, 47384,

1193555372

119367290 transmembrane 279968 7445 279968 15433 23421, 31409, protein 218 39397, 47385,

1193755373

119387291 transmembrane 455225 7446 399803 15434 23422, 31410, protein 218 39398, 47386,

1193955374

119407292 transmembrane 526175 7447 436177 15435 23423, 31411, protein 218 39399, 47387,

1194155375

119427293 transmembrane 527271 7448 436162 15436 23424, 31412, protein 218 39400, 47388,

1194355376

119447294 transmembrane 527766 7449 435526 15437 23425, 31413, protein 218 39401, 47389,

1194555377 7295 transmembrane 529583 7450 433374 15438 23426, 31414, protein 218 39402, 47390,

1194655378

119477296 transmembrane 531909 7451 436596 15439 23427, 31415, protein 218 39403, 47391,

1194855379

119497297 transmembrane 532407 7452 434597 15440 23428, 31416, protein 218 39404, 47392,

1195055380

119517298 transmembrane 279396 7453 279396 15441 23429, 31417, protein 219 39405, 47393,

1195255381

119537299 transmembrane 414689 7454 388485 15442 23430, 31418, protein 219 39406, 47394,

1195455382

119557300 transmembrane 393079 7455 376794 15443 23431, 31419, protein 22 39407, 47395,

1195655383

119577301 transmembrane 446465 7456 400839 15444 23432, 31420, protein 22 39408, 47396,

1195855384

119597302 transmembrane 341871 7457 339830 15445 23433, 31421, protein 220 39409, 47397,

1196055385

119617303 transmembrane 455996 7458 396973 15446 23434, 31422, protein 220 39410, 47398,

1196255386

119637304 transmembrane 374073 7459 363186 15447 23435, 31423, protein 222 39411, 47399,

1196455387

119657305 transmembrane 374076 7460 363189 15448 23436, 31424, protein 222 39412, 47400,

1196655388

119677306 transmembrane 307366 7461 303987 15449 23437, 31425, protein 223 39413, 47401,

1196855389

119697307 transmembrane 375026 7462 364166 15450 23438, 31426, protein 225 39414, 47402,

1197055390

119717308 transmembrane 455783 7463 395244 15451 23439, 31427, protein 229A 39415, 47403,

1197255391

119737309 transmembrane 357461 7464 350050 15452 23440, 31428, protein 229B 39416, 47404,

1197455392

119757310 transmembrane 554278 7465 452402 15453 23441, 31429, protein 229B 39417, 47405,

1197655393

119777311 transmembrane 554480 7466 450859 15454 23442, 31430, protein 229B 39418, 47406,

1197855394

119797312 transmembrane 555638 7467 452201 15455 23443, 31431, protein 229B 39419, 47407,

1198055395 7313 transmembrane 555994 7468 452144 15456 23444, 31432, protein 229B 39420, 47408,

1198155396

119827314 transmembrane 557006 7469 451774 15457 23445, 31433, protein 229B 39421, 47409,

1198355397

119847315 transmembrane 557779 7470 452025 15458 23446, 31434, protein 229B 39422, 47410,

1198555398

119867316 transmembrane 258173 7471 258173 15459 23447, 31435, protein 231 39423, 47411,

1198755399

119887317 transmembrane 398114 7472 381184 15460 23448, 31436, protein 231 39424, 47412,

1198955400

119907318 transmembrane 429839 7473 394680 15461 23449, 31437, protein 232 39425, 47413,

1199155401

119927319 transmembrane 455884 7474 401477 15462 23450, 31438, protein 232 39426, 47414,

1199355402

119947320 transmembrane 426426 7475 403130 15463 23451, 31439, protein 233 39427, 47415,

1199555403

119967321 transmembrane 309777 7476 309792 15464 23452, 31440, protein 234 39428, 47416,

1199755404

119987322 transmembrane 344461 7477 344021 15465 23453, 31441, protein 234 39429, 47417,

1199955405

120007323 transmembrane 461402 7478 433020 15466 23454, 31442, protein 234 39430, 47418,

1200155406

120027324 transmembrane 483001 7479 434295 15467 23455, 31443, protein 234 39431, 47419,

1200355407

120047325 transmembrane 489170 7480 436631 15468 23456, 31444, protein 234 39432, 47420,

1200555408

120067326 transmembrane 545122 7481 442664 15469 23457, 31445, protein 234 39433, 47421,

1200755409

120087327 transmembrane 374946 7482 364084 15470 23458, 31446, protein 235 39434, 47422,

1200955410

120107328 transmembrane 421688 7483 402790 15471 23459, 31447, protein 235 39435, 47423,

1201155411

120127329 transmembrane 543327 7484 445762 15472 23460, 31448, protein 235 39436, 47424,

1201355412

120147330 transmembrane 550981 7485 447766 15473 23461, 31449, protein 235 39437, 47425,

1201555413 7331 transmembrane 551068 7486 446514 15474 23462, 31450, protein 235 39438, 47426,

1201655414

120177332 transmembrane 586400 7487 466793 15475 23463, 31451, protein 235 39439, 47427,

1201855415

120197333 transmembrane 338221 7488 348463 15476 23464, 31452, protein 236 39440, 47428,

1202055416

120217334 transmembrane 377495 7489 366715 15477 23465, 31453, protein 236 39441, 47429,

1202255417

120237335 transmembrane 457860 7490 414144 15478 23466, 31454, protein 236 39442, 47430,

1202455418

120257336 transmembrane 480516 7491 417134 15479 23467, 31455, protein 236 39443, 47431,

1202655419

120277337 transmembrane 378733 7492 368007 15480 23468, 31456, protein 240 39444, 47432,

1202855420

120297338 transmembrane 425828 7493 400311 15481 23469, 31457, protein 240 39445, 47433,

1203055421

120317339 transmembrane 383233 7494 372720 15482 23470, 31458, protein 241 39446, 47434,

1203255422

120337340 transmembrane 399707 7495 382615 15483 23471, 31459, protein 241 39447, 47435,

1203455423

120357341 transmembrane 450466 7496 414899 15484 23472, 31460, protein 241 39448, 47436,

1203655424

120377342 transmembrane 542162 7497 440152 15485 23473, 31461, protein 241 39449, 47437,

1203855425

120397343 transmembrane 367144 7498 356112 15486 23474, 31462, protein 242 39450, 47438,

1204055426

120417344 transmembrane 400788 7499 383594 15487 23475, 31463, protein 242 39451, 47439,

1204255427

120437345 transmembrane 526263 7500 435362 15488 23476, 31464, protein 249 39452, 47440,

1204455428

120457346 transmembrane 399293 7501 382232 15489 23477, 31465, protein 26 39453, 47441,

1204655429

120477347 transmembrane 399298 7502 382237 15490 23478, 31466, protein 26 39454, 47442,

1204855430

120497348 transmembrane 503886 7503 425286 15491 23479, 31467, protein 26 39455, 47443,

1205055431 7349 transmembrane 319560 7504 316940 15492 23480, 31468, protein 31 39456, 47444,

1205155432

120527350 transmembrane 325094 7505 441455 15493 23481, 31469, protein 33 39457, 47445,

1205355433

120547351 transmembrane 504986 7506 422473 15494 23482, 31470, protein 33 39458, 47446,

1205555434

120567352 transmembrane 508448 7507 422810 15495 23483, 31471, protein 33 39459, 47447,

1205755435

120587353 transmembrane 513702 7508 427006 15496 23484, 31472, protein 33 39460, 47448,

1205955436

120607354 transmembrane 372930 7509 362021 15497 23485, 31473, protein 35 39461, 47449,

1206155437

120627355 transmembrane 444892 7510 412421 15498 23486, 31474, protein 35 39462, 47450,

1206355438

120647356 transmembrane 306406 7511 303148 15499 23487, 31475, protein 37 39463, 47451,

1206555439

120667357 transmembrane 187762 7512 187762 15500 23488, 31476, protein 38 A 39464, 47452,

1206755440

120687358 transmembrane 374688 7513 363820 15501 23489, 31477, protein 38B 39465, 47453,

1206955441

120707359 transmembrane 374692 7514 363824 15502 23490, 31478, protein 38B 39466, 47454,

1207155442

120727360 transmembrane 434214 7515 403026 15503 23491, 31479, protein 38B 39467, 47455,

1207355443

120747361 transmembrane 435034 7516 410800 15504 23492, 31480, protein 38B 39468, 47456,

1207555444

120767362 transmembrane 451560 7517 416680 15505 23493, 31481, protein 38B 39469, 47457,

1207755445

120787363 transmembrane 319172 7518 326063 15506 23494, 31482, protein 39A 39470, 47458,

1207955446

120807364 transmembrane 461654 7519 419068 15507 23495, 31483, protein 39A 39471, 47459,

1208155447

120827365 transmembrane 468676 7520 418796 15508 23496, 31484, protein 39A 39472, 47460,

1208355448

120847366 transmembrane 497993 7521 419405 15509 23497, 31485, protein 39A 39473, 47461,

1208555449 7367 transmembrane 336294 7522 338165 15510 23498, 31486, protein 39B 39474, 47462,

1208655450

120877368 transmembrane 373633 7523 362736 15511 23499, 31487, protein 39B 39475, 47463,

1208855451

120897369 transmembrane 373634 7524 362737 15512 23500, 31488, protein 39B 39476, 47464,

1209055452

120917370 transmembrane 427288 7525 391719 15513 23501, 31489, protein 39B 39477, 47465,

1209255453

120937371 transmembrane 438825 7526 414616 15514 23502, 31490, protein 39B 39478, 47466,

1209455454

120957372 transmembrane 456834 7527 390057 15515 23503, 31491, protein 39B 39479, 47467,

1209655455

120977373 transmembrane 264728 7528 264728 15516 23504, 31492, protein 40 39480, 47468,

1209855456

120997374 transmembrane 314124 7529 322837 15517 23505, 31493, protein 40 39481, 47469,

1210055457

121017375 transmembrane 431022 7530 407396 15518 23506, 31494, protein 40 39482, 47470,

1210255458

121037376 transmembrane 435218 7531 405740 15519 23507, 31495, protein 40 39483, 47471,

1210455459

121057377 transmembrane 435575 7532 396895 15520 23508, 31496, protein 40 39484, 47472,

1210655460

121077378 transmembrane 421852 7533 406885 15521 23509, 31497, protein 41 A 39485, 47473,

1210855461

121097379 transmembrane 299596 7534 299596 15522 23510, 31498, protein 4 IB 39486, 47474,

1211055462

121117380 transmembrane 528080 7535 433126 15523 23511, 31499, protein 4 IB 39487, 47475,

1211255463

121137381 transmembrane 533723 7536 436480 15524 23512, 31500, protein 4 IB 39488, 47476,

1211455464

121157382 transmembrane 302392 7537 306564 15525 23513, 31501, protein 42 39489, 47477,

1211655465

121177383 transmembrane 323523 7538 319009 15526 23514, 31502, protein 45A 39490, 47478,

1211855466

121197384 transmembrane 403410 7539 385089 15527 23515, 31503, protein 45A 39491, 47479,

1212055467 7385 transmembrane 281441 7540 281441 15528 23516, 31504, protein 45B 39492, 47480,

1212155468

121227386 transmembrane 524567 7541 436293 15529 23517, 31505, protein 45B 39493, 47481,

1212355469

121247387 transmembrane 374358 7542 363478 15530 23518, 31506, protein 50A 39494, 47482,

1212555470

121267388 transmembrane 420455 7543 397773 15531 23519, 31507, protein 50B 39495, 47483,

1212755471

121287389 transmembrane 432504 7544 387622 15532 23520, 31508, protein 50B 39496, 47484,

1212955472

121307390 transmembrane 435619 7545 411248 15533 23521, 31509, protein 50B 39497, 47485,

1213155473

121327391 transmembrane 440644 7546 395003 15534 23522, 31510, protein 50B 39498, 47486,

1213355474

121347392 transmembrane 542230 7547 439768 15535 23523, 31511, protein 50B 39499, 47487,

1213555475

121367393 transmembrane 303840 7548 303666 15536 23524, 31512, protein 51 39500, 47488,

1213755476

121387394 transmembrane 376008 7549 365176 15537 23525, 31513, protein 51 39501, 47489,

1213955477

121407395 transmembrane 376014 7550 365182 15538 23526, 31514, protein 51 39502, 47490,

1214155478

121427396 transmembrane 400796 7551 383600 15539 23527, 31515, protein 51 39503, 47491,

1214355479

121447397 transmembrane 428417 7552 394899 15540 23528, 31516, protein 51 39504, 47492,

1214555480

121467398 transmembrane 434578 7553 409665 15541 23529, 31517, protein 51 39505, 47493,

1214755481

121487399 transmembrane 451326 7554 412298 15542 23530, 31518, protein 51 39506, 47494,

1214955482

121507400 transmembrane 310991 7555 311122 15543 23531, 31519, protein 52 39507, 47495,

1215155483

121527401 transmembrane 378598 7556 367861 15544 23532, 31520, protein 52 39508, 47496,

1215355484

121547402 transmembrane 378602 7557 367865 15545 23533, 31521, protein 52 39509, 47497,

1215555485 7403 transmembrane 416272 7558 409669 15546 23534, 31522, protein 52 39510, 47498,

1215655486

121577404 transmembrane 372235 7559 361309 15547 23535, 31523, protein 53 39511, 47499,

1215855487

121597405 transmembrane 372237 7560 361311 15548 23536, 31524, protein 53 39512, 47500,

1216055488

121617406 transmembrane 372242 7561 361316 15549 23537, 31525, protein 53 39513, 47501,

1216255489

121637407 transmembrane 372243 7562 361317 15550 23538, 31526, protein 53 39514, 47502,

1216455490

121657408 transmembrane 372244 7563 361318 15551 23539, 31527, protein 53 39515, 47503,

1216655491

121677409 transmembrane 420706 7564 391576 15552 23540, 31528, protein 53 39516, 47504,

1216855492

121697410 transmembrane 329151 7565 328630 15553 23541, 31529, protein 54 39517, 47505,

1217055493

121717411 transmembrane 373463 7566 362562 15554 23542, 31530, protein 54 39518, 47506,

1217255494

121737412 transmembrane 250489 7567 250489 15555 23543, 31531, protein 55B 39519, 47507,

1217455495

121757413 transmembrane 398020 7568 381102 15556 23544, 31532, protein 55B 39520, 47508,

1217655496

121777414 transmembrane 370203 7569 359222 15557 23545, 31533, protein 56 39521, 47509,

1217855497

121797415 transmembrane 455656 7570 417043 15558 23546, 31534, protein 56 39522, 47510,

1218055498

121817416 transmembrane 456991 7571 395364 15559 23547, 31535, protein 56 39523, 47511,

1218255499

121837417 transmembrane 374343 7572 363463 15560 23548, 31536, protein 57 39524, 47512,

1218455500

121857418 transmembrane 399763 7573 382666 15561 23549, 31537, protein 57 39525, 47513,

1218655501

121877419 transmembrane 399766 7574 382668 15562 23550, 31538, protein 57 39526, 47514,

1218855502

121897420 transmembrane 234831 7575 234831 15563 23551, 31539, protein 59 39527, 47515,

1219055503 7421 transmembrane 371337 7576 360388 15564 23552, 31540, protein 59 39528, 47516,

1219155504

121927422 transmembrane 371338 7577 360389 15565 23553, 31541, protein 59 39529, 47517,

1219355505

121947423 transmembrane 371341 7578 360392 15566 23554, 31542, protein 59 39530, 47518,

1219555506

121967424 transmembrane 371344 7579 360395 15567 23555, 31543, protein 59 39531, 47519,

1219755507

121987425 transmembrane 371348 7580 360399 15568 23556, 31544, protein 59 39532, 47520,

1219955508

122007426 transmembrane 420738 7581 413792 15569 23557, 31545, protein 59 39533, 47521,

1220155509

122027427 transmembrane 440019 7582 399761 15570 23558, 31546, protein 59 39534, 47522,

1220355510

122047428 transmembrane 452421 7583 397772 15571 23559, 31547, protein 59 39535, 47523,

1220555511

122067429 transmembrane 262817 7584 262817 15572 23560, 31548, protein 59-like 39536, 47524,

1220755512

122087430 transmembrane 600490 7585 470879 15573 23561, 31549, protein 59-like 39537, 47525,

1220955513

122107431 transmembrane 257663 7586 257663 15574 23562, 31550, protein 60 39538, 47526,

1221155514

122127432 transmembrane 371268 7587 360315 15575 23563, 31551, protein 61 39539, 47527,

1221355515

122147433 transmembrane 260403 7588 260403 15576 23564, 31552, protein 62 39540, 47528,

1221555516

122167434 transmembrane 366835 7589 355800 15577 23565, 31553, protein 63 A 39541, 47529,

1221755517

122187435 transmembrane 436966 7590 409002 15578 23566, 31554, protein 63 A 39542, 47530,

1221955518

122207436 transmembrane 537914 7591 445237 15579 23567, 31555, protein 63 A 39543, 47531,

1222155519

122227437 transmembrane 259746 7592 259746 15580 23568, 31556, protein 63 B 39544, 47532,

1222355520

122247438 transmembrane 323267 7593 327154 15581 23569, 31557, protein 63 B 39545, 47533,

1222555521 7439 transmembrane 532634 7594 437163 15582 23570, 31558, protein 63 B 39546, 47534,

1222655522

122277440 transmembrane 298351 7595 298351 15583 23571, 31559, protein 63 C 39547, 47535,

1222855523

122297441 transmembrane 536110 7596 439055 15584 23572, 31560, protein 63 C 39548, 47536,

1223055524

122317442 transmembrane 554346 7597 451237 15585 23573, 31561, protein 63 C 39549, 47537,

1223255525

122337443 transmembrane 554766 7598 451842 15586 23574, 31562, protein 63 C 39550, 47538,

1223455526

122357444 transmembrane 555338 7599 451398 15587 23575, 31563, protein 63 C 39551, 47539,

1223655527

122377445 transmembrane 556514 7600 451404 15588 23576, 31564, protein 63 C 39552, 47540,

1223855528

122397446 transmembrane 557408 7601 450879 15589 23577, 31565, protein 63 C 39553, 47541,

1224055529

122417447 transmembrane 418210 7602 411951 15590 23578, 31566, protein 64 39554, 47542,

1224255530

122437448 transmembrane 458549 7603 414786 15591 23579, 31567, protein 64 39555, 47543,

1224455531

122457449 transmembrane 519519 7604 429832 15592 23580, 31568, protein 64 39556, 47544,

1224655532

122477450 transmembrane 521852 7605 430689 15593 23581, 31569, protein 64 39557, 47545,

1224855533

122497451 transmembrane 297632 7606 297632 15594 23582, 31570, protein 65 39558, 47546,

1225055534

122517452 transmembrane 256255 7607 256255 15595 23583, 31571, protein 66 39559, 47547,

1225255535

122537453 transmembrane 536273 7608 441723 15596 23584, 31572, protein 66 39560, 47548,

1225455536

122557454 transmembrane 541035 7609 445146 15597 23585, 31573, protein 66 39561, 47549,

1225655537

122577455 transmembrane 545648 7610 441351 15598 23586, 31574, protein 66 39562, 47550,

1225855538

122597456 transmembrane 334667 7611 335416 15599 23587, 31575, protein 68 39563, 47551,

1226055539 7457 transmembrane 434581 7612 395204 15600 23588, 31576, protein 68 39564, 47552,

1226155540

122627458 transmembrane 520414 7613 429758 15601 23589, 31577, protein 68 39565, 47553,

1226355541

122647459 transmembrane 521229 7614 429210 15602 23590, 31578, protein 68 39566, 47554,

1226555542

122667460 transmembrane 522090 7615 430542 15603 23591, 31579, protein 68 39567, 47555,

1226755543

122687461 transmembrane 522576 7616 431047 15604 23592, 31580, protein 68 39568, 47556,

1226955544

122707462 transmembrane 523180 7617 427939 15605 23593, 31581, protein 68 39569, 47557,

1227155545

122727463 transmembrane 523423 7618 429175 15606 23594, 31582, protein 68 39570, 47558,

1227355546

122747464 transmembrane 540934 7619 443586 15607 23595, 31583, protein 68 39571, 47559,

1227555547

122767465 transmembrane 372025 7620 361095 15608 23596, 31584, protein 69 39572, 47560,

1227755548

122787466 transmembrane 389583 7621 374234 15609 23597, 31585, protein 72 39573, 47561,

1227955549

122807467 transmembrane 544540 7622 439911 15610 23598, 31586, protein 72 39574, 47562,

1228155550

122827468 transmembrane 381894 7623 371318 15611 23599, 31587, protein 74B 39575, 47563,

1228355551

122847469 transmembrane 429036 7624 400552 15612 23600, 31588, protein 74B 39576, 47564,

1228555552

122867470 transmembrane 539634 7625 446264 15613 23601, 31589, protein 75 39577, 47565,

1228755553

122887471 transmembrane 323223 7626 324799 15614 23602, 31590, protein 78 39578, 47566,

1228955554

122907472 transmembrane 295694 7627 295694 15615 23603, 31591, protein 79 39579, 47567,

1229155555

122927473 transmembrane 357501 7628 350100 15616 23604, 31592, protein 79 39580, 47568,

1229355556

122947474 transmembrane 405535 7629 384748 15617 23605, 31593, protein 79 39581, 47569,

1229555557 7475 transmembrane 456810 7630 394736 15618 23606, 31594, protein 79 39582, 47570,

1229655558

122977476 transmembrane 397510 7631 380646 15619 23607, 31595, protein 80 39583, 47571,

1229855559

122997477 transmembrane 397512 7632 380648 15620 23608, 31596, protein 80 39584, 47572,

1230055560

123017478 transmembrane 367167 7633 356135 15621 23609, 31597, protein 81 39585, 47573,

1230255561

123037479 transmembrane 375782 7634 364938 15622 23610, 31598, protein 82 39586, 47574,

1230455562

123057480 transmembrane 249209 7635 249209 15623 23611, 31599, protein 85 39587, 47575,

1230655563

123077481 transmembrane 267750 7636 267750 15624 23612, 31600, protein 85 39588, 47576,

1230855564

123097482 transmembrane 280734 7637 280734 15625 23613, 31601, protein 86 A 39589, 47577,

1231055565

123117483 transmembrane 535380 7638 441843 15626 23614, 31602, protein 86 A 39590, 47578,

1231255566

123137484 transmembrane 327042 7639 321038 15627 23615, 31603, protein 86B 39591, 47579,

1231455567

123157485 transmembrane 307216 7640 305894 15628 23616, 31604, protein 87 A 39592, 47580,

1231655568

123177486 transmembrane 389834 7641 374484 15629 23617, 31605, protein 87 A 39593, 47581,

1231855569

123197487 transmembrane 448392 7642 405379 15630 23618, 31606, protein 87 A 39594, 47582,

1232055570

123217488 transmembrane 535305 7643 438181 15631 23619, 31607, protein 87 A 39595, 47583,

1232255571

123237489 transmembrane 283206 7644 283206 15632 23620, 31608, protein 87B 39596, 47584,

1232455572

123257490 transmembrane 301599 7645 301599 15633 23621, 31609, protein 88 39597, 47585,

1232655573

123277491 transmembrane 330862 7646 329557 15634 23622, 31610, protein 89 39598, 47586,

1232855574

123297492 transmembrane 382942 7647 372400 15635 23623, 31611, protein 8A 39599, 47587,

1233055575 7493 transmembrane 431232 7648 401338 15636 23624, 31612, protein 8A 39600, 47588,

1233155576

123327494 transmembrane 377988 7649 367227 15637 23625, 31613, protein 8B 39601, 47589,

1233355577

123347495 transmembrane 377991 7650 367230 15638 23626, 31614, protein 8B 39602, 47590,

1233555578

123367496 transmembrane 377996 7651 367235 15639 23627, 31615, protein 8B 39603, 47591,

1233755579

123387497 transmembrane 439587 7652 395810 15640 23628, 31616, protein 8B 39604, 47592,

1233955580

123407498 transmembrane 367329 7653 356298 15641 23629, 31617, protein 9 39605, 47593,

1234155581

123427499 transmembrane 367330 7654 356299 15642 23630, 31618, protein 9 39606, 47594,

1234355582

123447500 transmembrane 367332 7655 356301 15643 23631, 31619, protein 9 39607, 47595,

1234555583

123467501 transmembrane 367333 7656 356302 15644 23632, 31620, protein 9 39608, 47596,

1234755584

123487502 transmembrane 367334 7657 356303 15645 23633, 31621, protein 9 39609, 47597,

1234955585

123507503 transmembrane 414605 7658 398557 15646 23634, 31622, protein 9 39610, 47598,

1235155586

123527504 transmembrane 435310 7659 390184 15647 23635, 31623, protein 9 39611, 47599,

1235355587

123547505 transmembrane 455367 7660 405329 15648 23636, 31624, protein 9 39612, 47600,

1235555588

123567506 transmembrane 342187 7661 345589 15649 23637, 31625, protein 91 39613, 47601,

1235755589

123587507 transmembrane 356385 7662 348750 15650 23638, 31626, protein 91 39614, 47602,

1235955590

123607508 transmembrane 392002 7663 375859 15651 23639, 31627, protein 91 39615, 47603,

1236155591

123627509 transmembrane 413014 7664 413192 15652 23640, 31628, protein 91 39616, 47604,

1236355592

123647510 transmembrane 436170 7665 407003 15653 23641, 31629, protein 91 39617, 47605,

1236555593 7511 transmembrane 447302 7666 405647 15654 23642, 31630, protein 91 39618, 47606,

1236655594

123677512 transmembrane 535712 7667 443375 15655 23643, 31631, protein 91 39619, 47607,

1236855595

123697513 transmembrane 537354 7668 437868 15656 23644, 31632, protein 91 39620, 47608,

1237055596

123717514 transmembrane 544232 7669 437779 15657 23645, 31633, protein 91 39621, 47609,

1237255597

123737515 transmembrane 546362 7670 441729 15658 23646, 31634, protein 91 39622, 47610,

1237455598

123757516 transmembrane 300433 7671 300433 15659 23647, 31635, protein 92 39623, 47611,

1237655599

123777517 transmembrane 507382 7672 425144 15660 23648, 31636, protein 92 39624, 47612,

1237855600

123797518 transmembrane 248378 7673 248378 15661 23649, 31637, protein 93 39625, 47613,

1238055601

123817519 transmembrane 397133 7674 380322 15662 23650, 31638, protein 93 39626, 47614,

1238255602

123837520 transmembrane 261713 7675 261713 15663 23651, 31639, protein 98 39627, 47615,

1238455603

123857521 transmembrane 394642 7676 378138 15664 23652, 31640, protein 98 39628, 47616,

1238655604

123877522 transmembrane 395149 7677 398446 15665 23653, 31641, protein 98 39629, 47617,

1238855605

123897523 transmembrane 439138 7678 406394 15666 23654, 31642, protein 98 39630, 47618,

1239055606

123917524 transmembrane 579849 7679 463245 15667 23655, 31643, protein 98 39631, 47619,

1239255607

123937525 transmembrane 301665 7680 301665 15668 23656, 31644, protein 99 39632, 47620,

1239455608

123957526 transmembrane 436612 7681 390036 15669 23657, 31645, protein 99 39633, 47621,

1239655609

123977527 Transmembrane 358533 7682 351335 15670 23658, 31646, protein FLJ78588 39634, 47622,

1239855610

123997528 transmembrane 342462 7683 343398 15671 23659, 31647, protein with 39635, 47623, metallophosphoester 55611 ase domain 7529 transmembrane 416695 7684 400715 15672 23660, 31648, protein with 39636, 47624, metallophosphoester 55612 ase domain

124007530 transmembrane 296210 7685 296210 15673 23661, 31649, protein, adipocyte 39637, 47625, asscociated 1 55613

124017531 transmembrane 355552 7686 347748 15674 23662, 31650, protein, adipocyte 39638, 47626, asscociated 1 55614

124027532 transmembrane 450633 7687 413428 15675 23663, 31651, protein, adipocyte 39639, 47627, asscociated 1 55615

124037533 transmembrane 462228 7688 419299 15676 23664, 31652, protein, adipocyte 39640, 47628, asscociated 1 55616

124047534 transmembrane 469111 7689 419533 15677 23665, 31653, protein, adipocyte 39641, 47629, asscociated 1 55617

124057535 transmembrane 489960 7690 418298 15678 23666, 31654, protein, adipocyte 39642, 47630, asscociated 1 55618

124067536 transmembrane 490290 7691 417113 15679 23667, 31655, protein, adipocyte 39643, 47631, asscociated 1 55619

124077537 transmembrane 490643 7692 419822 15680 23668, 31656, protein, adipocyte 39644, 47632, asscociated 1 55620

124087538 tribbles homolog 3 217233 7693 217233 15681 23669, 31657, (Drosophila) 39645, 47633,

1240955621

124107539 tribbles homolog 3 422053 7694 415416 15682 23670, 31658, (Drosophila) 39646, 47634,

1241155622

124127540 tribbles homolog 3 449710 7695 391873 15683 23671, 31659, (Drosophila) 39647, 47635,

1241355623

124147541 tripartite motif 259941 7696 259941 15684 23672, 31660, containing 10 39648, 47636,

1241555624

124167542 tripartite motif 354038 7697 343695 15685 23673, 31661, containing 10 39649, 47637,

1241755625

124187543 tripartite motif 548533 7698 448988 15686 23674, 31662, containing 10 39650, 47638,

1241955626

124207544 tripartite motif 336708 7699 338989 15687 23675, 31663, containing 16 39651, 47639,

1242155627

124227545 tripartite motif 578237 7700 463188 15688 23676, 31664, containing 16 39652, 47640,

1242355628

124247546 tripartite motif 349062 7701 275736 15689 23677, 31665, containing 4 39653, 47641,

1242555629 7547 tripartite motif 354241 7702 346186 15690 23678, 31666, containing 4 39654, 47642,

1242655630

124277548 tripartite motif 355947 7703 348216 15691 23679, 31667, containing 4 39655, 47643,

1242855631

124297549 tripartite motif 542799 7704 439655 15692 23680, 31668, containing 4 39656, 47644,

1243055632

124317550 tripartite motif 309784 7705 311219 15693 23681, 31669, containing 59 39657, 47645,

1243255633

124337551 tripartite motif 471155 7706 418699 15694 23682, 31670, containing 59 39658, 47646,

1243455634

124357552 tripartite motif 471396 7707 420520 15695 23683, 31671, containing 59 39659, 47647,

1243655635

124377553 tripartite motif 479460 7708 417081 15696 23684, 31672, containing 59 39660, 47648,

1243855636

124397554 tripartite motif 494486 7709 417605 15697 23685, 31673, containing 59 39661, 47649,

1244055637

124417555 tripartite motif 543469 7710 444313 15698 23686, 31674, containing 59 39662, 47650,

1244255638

124437556 TRM2 tRNA 338687 7711 340970 15699 23687, 31675, methyltransferase 2 39663, 47651, homolog B (S. 55639 cerevisiae)

124447557 TRM2 tRNA 372931 7712 362022 15700 23688, 31676, methyltransferase 2 39664, 47652, homolog B (S. 55640 cerevisiae)

124457558 TRM2 tRNA 372935 7713 362026 15701 23689, 31677, methyltransferase 2 39665, 47653, homolog B (S. 55641 cerevisiae)

124467559 TRM2 tRNA 372936 7714 362027 15702 23690, 31678, methyltransferase 2 39666, 47654, homolog B (S. 55642 cerevisiae)

124477560 TRM2 tRNA 372939 7715 362030 15703 23691, 31679, methyltransferase 2 39667, 47655, homolog B (S. 55643 cerevisiae)

124487561 TRM2 tRNA 545398 7716 438134 15704 23692, 31680, methyltransferase 2 39668, 47656, homolog B (S. 55644 cerevisiae)

124497562 t- SNARE domain 307180 7717 303437 15705 23693, 31681, containing 1 39669, 47657,

1245055645 7563 t- SNARE domain 519651 7718 429679 15706 23694, 31682, containing 1 39670, 47658,

1245155646

124527564 t- SNARE domain 520166 7719 427770 15707 23695, 31683, containing 1 39671, 47659,

1245355647

124547565 t- SNARE domain 520462 7720 429626 15708 23696, 31684, containing 1 39672, 47660,

1245555648

124567566 t- SNARE domain 524325 7721 428763 15709 23697, 31685, containing 1 39673, 47661,

1245755649

124587567 tudor and KH 368822 7722 357812 15710 23698, 31686, domain containing 39674, 47662,

1245955650

124607568 tudor and KH 368823 7723 357813 15711 23699, 31687, domain containing 39675, 47663,

1246155651

124627569 tudor and KH 368824 7724 357815 15712 23700, 31688, domain containing 39676, 47664,

1246355652

124647570 tudor and KH 368825 7725 357817 15713 23701, 31689, domain containing 39677, 47665,

1246555653

124667571 tudor and KH 368827 7726 357819 15714 23702, 31690, domain containing 39678, 47666,

1246755654

124687572 tudor and KH 440583 7727 416645 15715 23703, 31691, domain containing 39679, 47667,

1246955655

124707573 tudor and KH 458431 7728 395718 15716 23704, 31692, domain containing 39680, 47668,

1247155656

124727574 tudor and KH 526378 7729 431557 15717 23705, 31693, domain containing 39681, 47669,

1247355657

124747575 tumor necrosis 248484 7730 248484 15718 23706, 31694, factor receptor 39682, 47670, superfamily, 55658 member 19

124757576 tumor necrosis 382258 7731 371693 15719 23707, 31695, factor receptor 39683, 47671, superfamily, 55659 member 19

124767577 tumor necrosis 382263 7732 371698 15720 23708, 31696, factor receptor 39684, 47672, superfamily, 55660 member 19

124777578 tumor necrosis 403372 7733 385408 15721 23709, 31697, factor receptor 39685, 47673, superfamily, 55661 member 19

124787579 tumor protein p53 308212 7734 309532 15722 23710, 31698, inducible protein 11 39686, 47674,

1247955662 7580 tumor protein p53 308220 7735 309551 15723 23711, 31699, inducible protein 11 39687, 47675,

1248055663

124817581 tumor protein p53 395648 7736 379009 15724 23712, 31700, inducible protein 11 39688, 47676,

1248255664

124837582 tumor protein p53 525680 7737 433474 15725 23713, 31701, inducible protein 11 39689, 47677,

1248455665

124857583 tumor protein p53 525683 7738 434461 15726 23714, 31702, inducible protein 11 39690, 47678,

1248655666

124877584 tumor protein p53 527685 7739 431556 15727 23715, 31703, inducible protein 11 39691, 47679,

1248855667

124897585 tumor protein p53 528473 7740 433454 15728 23716, 31704, inducible protein 11 39692, 47680,

1249055668

124917586 tumor protein p53 530035 7741 432089 15729 23717, 31705, inducible protein 11 39693, 47681,

1249255669

124937587 tumor protein p53 533443 7742 437284 15730 23718, 31706, inducible protein 11 39694, 47682,

1249455670

124957588 tumor protein p53 533937 7743 432926 15731 23719, 31707, inducible protein 11 39695, 47683,

1249655671

124977589 tumor protein p53 533940 7744 436152 15732 23720, 31708, inducible protein 11 39696, 47684,

1249855672

124997590 tumor protein p53 301057 7745 301057 15733 23721, 31709, inducible protein 13 39697, 47685,

1250055673

125017591 tumor protein p53 378818 7746 368095 15734 23722, 31710, inducible protein 13 39698, 47686,

1250255674

125037592 tweety homolog 2 269346 7747 269346 15735 23723, 31711, (Drosophila) 39699, 47687,

1250455675

125057593 tweety homolog 2 441391 7748 394576 15736 23724, 31712, (Drosophila) 39700, 47688,

1250655676

125077594 tweety homolog 3 258796 7749 258796 15737 23725, 31713, (Drosophila) 39701, 47689,

1250855677

125097595 tweety homolog 3 403167 7750 385015 15738 23726, 31714, (Drosophila) 39702, 47690,

1251055678

125117596 tweety homolog 3 407643 7751 385316 15739 23727, 31715, (Drosophila) 39703, 47691,

1251255679

125137597 U2 small nuclear 292879 7752 292879 15740 23728, 31716, RNA auxiliary 39704, 47692, factor 1 -like 4 55680 7598 U2 small nuclear 378975 7753 368258 15741 23729, 31717, RNA auxiliary 39705, 47693, factor 1 -like 4 55681

125147599 U2 small nuclear 392196 7754 376034 15742 23730, 31718, RNA auxiliary 39706, 47694, factor 1 -like 4 55682

125157600 U2 small nuclear 412391 7755 397645 15743 23731, 31719, RNA auxiliary 39707, 47695, factor 1 -like 4 55683

125167601 UBA domain 376440 7756 365623 15744 23732, 31720, containing 2 39708, 47696,

1251755684

125187602 UBA domain 403766 7757 383911 15745 23733, 31721, containing 2 39709, 47697,

1251955685

125207603 ubiquinol- 330029 7758 332887 15746 23734, 31722, cytochrome c 39710, 47698, reductase, complex 55686 III subunit X

125217604 ubiquinol- 332801 7759 333278 15747 23735, 31723, cytochrome c 39711, 47699, reductase, complex 55687 III subunit X

125227605 ubiquinol- 401406 7760 384962 15748 23736, 31724, cytochrome c 39712, 47700, reductase, complex 55688 III subunit X

125237606 ubiquinol- 406782 7761 385696 15749 23737, 31725, cytochrome c 39713, 47701, reductase, complex 55689 III subunit X

125247607 ubiquinol- 262946 7762 262946 15750 23738, 31726, cytochrome c 39714, 47702, reductase, complex 55690 III subunit XI

125257608 ubiquitin protein 375217 7763 364365 15751 23739, 31727, ligase E3 component 39715, 47703, n-recognin 4 55691

125267609 ubiquitin protein 375218 7764 364366 15752 23740, 31728, ligase E3 component 39716, 47704, n-recognin 4 55692

125277610 ubiquitin protein 375224 7765 364372 15753 23741, 31729, ligase E3 component 39717, 47705, n-recognin 4 55693

125287611 ubiquitin protein 375225 7766 364373 15754 23742, 31730, ligase E3 component 39718, 47706, n-recognin 4 55694

125297612 ubiquitin protein 375226 7767 364374 15755 23743, 31731, ligase E3 component 39719, 47707, n-recognin 4 55695

125307613 ubiquitin protein 375254 7768 364403 15756 23744, 31732, ligase E3 component 39720, 47708, n-recognin 4 55696 7614 ubiquitin protein 375267 7769 364416 15757 23745, 31733, ligase E3 component 39721, 47709, n-recognin 4 55697

125317615 ubiquitin protein 417040 7770 404897 15758 23746, 31734, ligase E3 component 39722, 47710, n-recognin 4 55698

125327616 ubiquitin protein 419533 7771 391875 15759 23747, 31735, ligase E3 component 39723, 47711, n-recognin 4 55699

125337617 ubiquitin protein 425413 7772 395313 15760 23748, 31736, ligase E3 component 39724, 47712, n-recognin 4 55700

125347618 ubiquitin protein 429347 7773 394173 15761 23749, 31737, ligase E3 component 39725, 47713, n-recognin 4 55701

125357619 ubiquitin protein 543981 7774 444070 15762 23750, 31738, ligase E3 component 39726, 47714, n-recognin 4 55702

125367620 ubiquitin specific 398888 7775 381863 15763 23751, 31739, peptidase 19 39727, 47715,

1253755703

125387621 ubiquitin specific 425298 7776 412679 15764 23752, 31740, peptidase 19 39728, 47716,

1253955704

125407622 ubiquitin specific 417901 7777 395260 15765 23753, 31741, peptidase 19 39729, 47717,

1254155705

125427623 ubiquitin specific 434032 7778 401197 15766 23754, 31742, peptidase 19 39730, 47718,

1254355706

125447624 ubiquitin specific 453664 7779 400090 15767 23755, 31743, peptidase 19 39731, 47719,

1254555707

125467625 ubiquitin specific 307179 7780 302239 15768 23756, 31744, peptidase 8 39732, 47720,

1254755708

125487626 ubiquitin specific 396440 7781 379717 15769 23757, 31745, peptidase 8 39733, 47721,

1254955709

125507627 ubiquitin specific 396444 7782 379721 15770 23758, 31746, peptidase 8 39734, 47722,

1255155710

125527628 ubiquitin specific 433963 7783 405537 15771 23759, 31747, peptidase 8 39735, 47723,

1255355711

125547629 ubiquitin specific 558091 7784 454059 15772 23760, 31748, peptidase 8 39736, 47724,

1255555712

125567630 ubiquitin specific 560297 7785 453206 15773 23761, 31749, peptidase 8 39737, 47725,

1255755713

125587631 ubiquitin specific 560982 7786 453427 15774 23762, 31750, peptidase 8 39738, 47726,

1255955714 <img file="WO2013151663A1_D0022.tif" />7650 ubiquitin- 357194 7805 349722 15793 23781, 31769, conjugating enzyme 39757, 47745, E2D 3 55733

125607651 ubiquitin- 394801 7806 378280 15794 23782, 31770, conjugating enzyme 39758, 47746, E2D 3 55734

125617652 ubiquitin- 394803 7807 378282 15795 23783, 31771, conjugating enzyme 39759, 47747, E2D 3 55735

125627653 ubiquitin- 394804 7808 378283 15796 23784, 31772, conjugating enzyme 39760, 47748, E2D 3 55736

125637654 ubiquitin- 453744 7809 396901 15797 23785, 31773, conjugating enzyme 39761, 47749, E2D 3 55737

125647655 ubiquitin- 502690 7810 425762 15798 23786, 31774, conjugating enzyme 39762, 47750, E2D 3 55738

125657656 ubiquitin- 508238 7811 423487 15799 23787, 31775, conjugating enzyme 39763, 47751, E2D 3 55739

125667657 ubiquitin- 508249 7812 421310 15800 23788, 31776, conjugating enzyme 39764, 47752, E2D 3 55740

125677658 UBX domain protein 272638 7813 272638 15801 23789, 31777, 4 39765, 47753,

1256855741

125697659 UBX domain protein 430594 7814 400407 15802 23790, 31778, 4 39766, 47754,

1257055742

125717660 UBX domain protein 296328 7815 296328 15803 23791, 31779, 7 39767, 47755,

1257255743

125737661 UBX domain protein 535858 7816 440716 15804 23792, 31780, 7 39768, 47756,

1257455744

125757662 UDP 251566 7817 251566 15805 23793, 31781, glucuronosyltransfer 39769, 47757, ase 2 family, 55745 polypeptide A3

125767663 UDP 420231 7818 440115 15806 23794, 31782, glucuronosyltransfer 39770, 47758, ase 2 family, 55746 polypeptide A3

125777664 UDP 265403 7819 265403 15807 23795, 31783, glucuronosyltransfer 39771, 47759, ase 2 family, 55747 polypeptide BIO

125787665 UDP 274278 7820 274278 15808 23796, 31784, glycosyltransferase 39772, 47760, 3 family, 55748 polypeptide Al

125797666 UDP 333811 7821 328033 15809 23797, 31785, glycosyltransferase 39773, 47761, 3 family, 55749 polypeptide Al

125807667 UDP 310836 7822 311648 15810 23798, 31786, glycosyltransferase 39774, 47762, 8 55750

125817668 UDP 394511 7823 378019 15811 23799, 31787, glycosyltransferase 39775, 47763, 8 55751

125827669 UDP 507710 7824 421446 15812 23800, 31788, glycosyltransferase 39776, 47764, 8 55752

125837670 UDP-Gal:betaGal 379198 7825 368496 15813 23801, 31789, beta 1,3- 39777, 47765, galactosyltransferase 55753 polypeptide 6

7671 UDP- 305861 7826 303740 15814 23802, 31790,

12585GaLbetaGlcNAc 39778, 47766, beta 1,3- 55754 galactosyltransferase

12586, polypeptide 1

7672 UDP- 392690 7827 376456 15815 23803, 31791,

12588GaLbetaGlcNAc 39779, 47767, beta 1,3- 55755 galactosyltransferase

12589, polypeptide 1

7673 UDP- 311181 7828 309096 15816 23804, 31792,

12591GlcNAc:betaGal 39780, 47768, beta- 1,3 -N- 55756 acetylglucosaminyltr

12592ansferase 1

7674 UDP- 538757 7829 440059 15817 23805, 31793,

12594GlcNAc:betaGal 39781, 47769, beta- 1,3 -N- 55757 acetylglucosaminyltr

12595ansferase 1

7675 UDP- 301998 7830 305595 15818 23806, 31794,

12597GlcNAc:betaGal 39782, 47770, beta- 1,3 -N- 55758 acetylglucosaminyltr

12598ansferase 2

7676 UDP- 405767 7831 384692 15819 23807, 31795,

12600GlcNAc:betaGal 39783, 47771, beta- 1,3 -N- 55759 acetylglucosaminyltr

12601ansferase 2

7677 UDP- 326505 7832 316173 15820 23808, 31796,

12603GlcNAc:betaGal 39784, 47772, beta- 1,3 -N- 55760 acetylglucosaminyltr

12604ansferase 5

7678 UDP- 460419 7833 420778 15821 23809, 31797,

12606GlcNAc:betaGal 39785, 47773, beta- 1,3 -N- 55761 acetylglucosaminyltr

12607ansferase 5 7679 UDP- 464191 7834 418785 15822 23810, 31798,

12608GlcNAc:betaGal 39786, 47774, beta- 1,3 -N- 55762 acetylglucosaminyltr

12609ansferase 5

7680 UDP- 464923 7835 418477 15823 23811, 31799,

12611GlcNAc:betaGal 39787, 47775, beta- 1,3 -N- 55763 acetylglucosaminyltr

12612ansferase 5

7681 UDP- 465010 7836 417868 15824 23812, 31800,

12614GlcNAc:betaGal 39788, 47776, beta- 1,3 -N- 55764 acetylglucosaminyltr

12615ansferase 5

7682 UDP- 481531 7837 417301 15825 23813, 31801,

12617GlcNAc:betaGal 39789, 47777, beta- 1,3 -N- 55765 acetylglucosaminyltr

12618ansferase 5

7683 UDP- 287590 7838 287590 15826 23814, 31802,

12620GlcNAc:betaGal 39790, 47778, beta- 1,3 -N- 55766 acetylglucosaminyltr

12621ansferase 7

7684 UDP- 321702 7839 312700 15827 23815, 31803,

12623GlcNAc:betaGal 39791, 47779, beta- 1,3 -N- 55767 acetylglucosaminyltr

12624ansferase 8

7685 UDP- 449549 7840 400157 15828 23816, 31804,

12626GlcNAc:betaGal 39792, 47780, beta- 1,3 -N- 55768 acetylglucosaminyltr

12627ansferase 9

126287686 UDP- 547910 7841 447309 15829 23817, 31805, glucuronosyltransfer 39793, 47781, ase 2 A3 precursor 55769

126297687 UDP- 549931 7842 447700 15830 23818, 31806, glucuronosyltransfer 39794, 47782, ase 2 A3 precursor 55770

126307688 UDP- 549514 7843 449012 15831 23819, 31807, glucuronosyltransfer 39795, 47783, ase 2B 10 isoform 1 55771 precursor

126317689 UDP-N-acetyl- 320311 7844 315835 15832 23820, 31808, alpha-D- 39796, 47784, galactosamine :polyp 55772 eptide N- acetylgalactosaminyl

12632transferase 11

12633(GalNAc-Tl l) 7690 UDP-N-acetyl- 415421 7845 410093 15833 23821, 31809, alpha-D- 39797, 47785, galactosamine :polyp 55773 eptide N- acetylgalactosaminyl

12634transferase 11

12635(GalNAc-Tl l)

126367691 UDP-N-acetyl- 419245 7846 397581 15834 23822, 31810, alpha-D- 39798, 47786, galactosamine :polyp 55774 eptide N- acetylgalactosaminyl

12637transferase 11

12638(GalNAc-Tl l)

126397692 UDP-N-acetyl- 422997 7847 389449 15835 23823, 31811, alpha-D- 39799, 47787, galactosamine :polyp 55775 eptide N- acetylgalactosaminyl

12640transferase 11

12641(GalNAc-Tl l)

126427693 UDP-N-acetyl- 430044 7848 395122 15836 23824, 31812, alpha-D- 39800, 47788, galactosamine :polyp 55776 eptide N- acetylgalactosaminyl

12643transferase 11

12644(GalNAc-Tl l)

126457694 UDP-N-acetyl- 431668 7849 395020 15837 23825, 31813, alpha-D- 39801, 47789, galactosamine :polyp 55777 eptide N- acetylgalactosaminyl

12646transferase 11

12647(GalNAc-Tl l)

126487695 UDP-N-acetyl- 434507 7850 416787 15838 23826, 31814, alpha-D- 39802, 47790, galactosamine :polyp 55778 eptide N- acetylgalactosaminyl

12649transferase 11

12650(GalNAc-Tl l)

126517696 UDP-N-acetyl- 443352 7851 408155 15839 23827, 31815, alpha-D- 39803, 47791, galactosamine :polyp 55779 eptide N- acetylgalactosaminyl

12652transferase 11

12653(GalNAc-Tl l)

126547697 UDP-N-acetyl- 447796 7852 412142 15840 23828, 31816, alpha-D- 39804, 47792, galactosamine :polyp 55780 eptide N- acetylgalactosaminyl

12655transferase 11 (GalNAc-Tl l)

126567698 UDP-N-acetyl- 452146 7853 393399 15841 23829, 31817, alpha-D- 39805, 47793, galactosamine :polyp 55781 eptide N- acetylgalactosaminyl

12657transferase 11

12658(GalNAc-Tl l)

126597699 UDP-N-acetyl- 259056 7854 259056 15842 23830, 31818, alpha-D- 39806, 47794, galactosamine :polyp 55782 eptide N- acetylgalactosaminyl

12660transferase 5

12661(GalNAc-T5)

126627700 UDP-N-acetyl- 337827 7855 336729 15843 23831, 31819, alpha-D- 39807, 47795, galactosamine :polyp 55783 eptide N- acetylgalactosaminyl

12663transferase-like 1

126647701 UDP-N-acetyl- 448469 7856 402970 15844 23832, 31820, alpha-D- 39808, 47796, galactosamine :polyp 55784 eptide N- acetylgalactosaminyl

12665transferase-like 1

126667702 UDP-N-acetyl- 536652 7857 445877 15845 23833, 31821, alpha-D- 39809, 47797, galactosamine :polyp 55785 eptide N- acetylgalactosaminyl

12667transferase-like 1

126687703 UDP-N-acetyl- 553669 7858 451200 15846 23834, 31822, alpha-D- 39810, 47798, galactosamine :polyp 55786 eptide N- acetylgalactosaminyl

12669transferase-like 1

126707704 UDP-N-acetyl- 339732 7859 344260 15847 23835, 31823, alpha-D- 39811, 47799, galactosamine :polyp 55787 eptide N- acetylgalactosaminyl

12671transferase-like 2

126727705 UDP-N-acetyl- 543679 7860 445852 15848 23836, 31824, alpha-D- 39812, 47800, galactosamine :polyp 55788 eptide N- acetylgalactosaminyl

12673transferase-like 2 7706 UDP-N-acetyl- 227756 7861 227756 15849 23837, 31825, alpha-D- 39813, 47801, galactosamine :polyp 55789 eptide N- acetylgalactosaminyl

12674transferase-like 4

126757707 UDP-N-acetyl- 392800 7862 376548 15850 23838, 31826, alpha-D- 39814, 47802, galactosamine :polyp 55790 eptide N- acetylgalactosaminyl

12676transferase-like 5

126777708 UDP-N-acetyl- 431418 7863 392582 15851 23839, 31827, alpha-D- 39815, 47803, galactosamine :polyp 55791 eptide N- acetylgalactosaminyl

12678transferase-like 5

126797709 UDP-N-acetyl- 404275 7864 385382 15852 23840, 31828, alpha-D- 39816, 47804, galactosamine :polyp 55792 eptide N- acetylgalactosaminyl

12680transferase-like 6

126817710 UDP-N-acetyl- 506823 7865 423313 15853 23841, 31829, alpha-D- 39817, 47805, galactosamine :polyp 55793 eptide N- acetylgalactosaminyl

12682transferase-like 6

126837711 UDP-N- 271469 7866 271469 15854 23842, 31830, acteylglucosamine 39818, 47806, pyrophosphorylase 1 55794

126847712 UDP-N- 367924 7867 356901 15855 23843, 31831, acteylglucosamine 39819, 47807, pyrophosphorylase 1 55795

126857713 UDP-N- 367925 7868 356902 15856 23844, 31832, acteylglucosamine 39820, 47808, pyrophosphorylase 1 55796

126867714 UDP-N- 367926 7869 356903 15857 23845, 31833, acteylglucosamine 39821, 47809, pyrophosphorylase 1 55797

126877715 UDP-N- 412525 7870 395648 15858 23846, 31834, acteylglucosamine 39822, 47810, pyrophosphorylase 1 55798

126887716 unc- 13 homolog B 378495 7871 367756 15859 23847, 31835, (C. elegans) 39823, 47811,

1268955799

126907717 unc- 13 homolog B 378496 7872 367757 15860 23848, 31836, (C. elegans) 39824, 47812,

1269155800

126927718 unc- 13 homolog B 396787 7873 380006 15861 23849, 31837, (C. elegans) 39825, 47813,

1269355801 7719 unc- 13 homolog B 535471 7874 441503 15862 23850, 31838, (C. elegans) 39826, 47814,

1269455802

126957720 unc- 13 homolog C 260323 7875 260323 15863 23851, 31839, (C. elegans) 39827, 47815,

1269655803

126977721 unc- 13 homolog C 537900 7876 442569 15864 23852, 31840, (C. elegans) 39828, 47816,

1269855804

126997722 unc- 13 homolog C 545554 7877 438156 15865 23853, 31841, (C. elegans) 39829, 47817,

1270055805

127017723 unc-5 homolog C 244565 7878 244565 15866 23854, 31842, (C. elegans)-like 39830, 47818,

1270255806

127037724 unc-5 homolog C 373164 7879 362258 15867 23855, 31843, (C. elegans)-like 39831, 47819,

1270455807

127057725 unc-5 homolog D 404895 7880 385143 15868 23856, 31844, (C. elegans) 39832, 47820,

1270655808

127077726 unc-5 homolog D 453357 7881 394303 15869 23857, 31845, (C. elegans) 39833, 47821,

1270855809

127097727 unc-50 homolog (C. 357765 7882 350409 15870 23858, 31846, elegans) 39834, 47822,

1271055810

127117728 unc-50 homolog (C. 409347 7883 386466 15871 23859, 31847, elegans) 39835, 47823,

1271255811

127137729 unc-50 homolog (C. 409975 7884 387146 15872 23860, 31848, elegans) 39836, 47824,

1271455812

127157730 unc-51 -like kinase 2 361658 7885 354877 15873 23861, 31849, (C. elegans) 39837, 47825,

1271655813

127177731 unc-51 -like kinase 2 395544 7886 378914 15874 23862, 31850, (C. elegans) 39838, 47826,

1271855814

127197732 Uncharacterized 452392 7887 391806 15875 23863, 31851, protein 39839, 47827,

1272055815

127217733 Uncharacterized 540229 7888 441269 15876 23864, 31852, protein 39840, 47828,

1272255816

127237734 Uncharacterized 546887 7889 447974 15877 23865, 31853, protein 39841, 47829,

1272455817

127257735 Uncharacterized 548145 7890 449195 15878 23866, 31854, protein 39842, 47830,

1272655818

127277736 Uncharacterized 550239 7891 448807 15879 23867, 31855, protein 39843, 47831,

1272855819 7737 Uncharacterized 552745 7892 447257 15880 23868, 31856, protein 39844, 47832,

1272955820

127307738 Uncharacterized 380589 7893 369963 15881 23869, 31857, protein C20orf 141 39845, 47833,

1273155821

127327739 Uncharacterized 517889 7894 431116 15882 23870, 31858, proteincDNA 39846, 47834,

FLJ52651 55822

127347740 unconventional 263897 7895 263897 15883 23871, 31859, SNARE in the ER 1 39847, 47835, homolog (S. 55823 cerevisiae)

127357741 up-regulated during 309579 7896 311245 15884 23872, 31860, skeletal muscle 39848, 47836, growth 5 homolog 55824 (mouse)

127367742 up-regulated during 337003 7897 337705 15885 23873, 31861, skeletal muscle 39849, 47837, growth 5 homolog 55825 (mouse)

127377743 up-regulated during 369811 7898 358826 15886 23874, 31862, skeletal muscle 39850, 47838, growth 5 homolog 55826 (mouse)

127387744 up-regulated during 369815 7899 358830 15887 23875, 31863, skeletal muscle 39851, 47839, growth 5 homolog 55827 (mouse)

127397745 up-regulated during 369825 7900 358840 15888 23876, 31864, skeletal muscle 39852, 47840, growth 5 homolog 55828 (mouse)

127407746 uroplakin 3B-like 340457 7901 342938 15889 23877, 31865,

1274139853, 47841, 55829

127427747 urotensin 2 receptor 313135 7902 323516 15890 23878, 31866,

1274339854, 47842, 55830

127447748 vacuolar protein 380443 7903 369808 15891 23879, 31867, sorting 16 homolog 39855, 47843, (S. cerevisiae) 55831

127457749 vacuolar protein 380445 7904 369810 15892 23880, 31868, sorting 16 homolog 39856, 47844, (S. cerevisiae) 55832

127467750 vacuolar protein 380469 7905 369836 15893 23881, 31869, sorting 16 homolog 39857, 47845, (S. cerevisiae) 55833

127477751 vacuolar protein 417508 7906 409840 15894 23882, 31870, sorting 16 homolog 39858, 47846, (S. cerevisiae) 55834

127487752 vacuolar protein 453689 7907 417031 15895 23883, 31871, sorting 16 homolog 39859, 47847, (S. cerevisiae) 55835 7753 vacuolar protein 220509 7908 220509 15896 23884, 31872, sorting 18 homolog 39860, 47848, (S. cerevisiae) 55836

127497754 vacuolar protein 397678 7909 380795 15897 23885, 31873, sorting 29 homolog 39861, 47849, (S. cerevisiae) 55837

127507755 vacuolar protein 447578 7910 400048 15898 23886, 31874, sorting 29 homolog 39862, 47850, (S. cerevisiae) 55838

127517756 vacuolar protein 549578 7911 447058 15899 23887, 31875, sorting 29 homolog 39863, 47851, (S. cerevisiae) 55839

127527757 vacuolar protein 383210 7912 372697 15900 23888, 31876, sorting 52 homolog 39864, 47852, (S. cerevisiae) 55840

127537758 vacuolar protein 418054 7913 414785 15901 23889, 31877, sorting 52 homolog 39865, 47853, (S. cerevisiae) 55841

127547759 vacuolar protein 428608 7914 406988 15902 23890, 31878, sorting 52 homolog 39866, 47854, (S. cerevisiae) 55842

127557760 vacuolar protein 436044 7915 395282 15903 23891, 31879, sorting 52 homolog 39867, 47855, (S. cerevisiae) 55843

127567761 vacuolar protein 441058 7916 390831 15904 23892, 31880, sorting 52 homolog 39868, 47856, (S. cerevisiae) 55844

127577762 vacuolar protein 443860 7917 404016 15905 23893, 31881, sorting 52 homolog 39869, 47857, (S. cerevisiae) 55845

127587763 vacuolar protein 445902 7918 409952 15906 23894, 31882, sorting 52 homolog 39870, 47858, (S. cerevisiae) 55846

127597764 vacuolar protein 448042 7919 391197 15907 23895, 31883, sorting 52 homolog 39871, 47859, (S. cerevisiae) 55847

127607765 vacuolar protein 548751 7920 446504 15908 23896, 31884, sorting 52 homolog 39872, 47860, (S. cerevisiae) 55848

127617766 vacuolar protein 549522 7921 449313 15909 23897, 31885, sorting 52 homolog 39873, 47861, (S. cerevisiae) 55849

127627767 vacuolar protein 551233 7922 447409 15910 23898, 31886, sorting 52 homolog 39874, 47862, (S. cerevisiae) 55850

127637768 vacuolar protein 552552 7923 448022 15911 23899, 31887, sorting 52 homolog 39875, 47863, (S. cerevisiae) 55851

127647769 v-akt murine 349310 7924 270202 15912 23900, 31888, thymoma viral 39876, 47864, oncogene homolog 1 55852

127657770 Valyl-tRNA 383369 7925 372860 15913 23901, 31889, synthetase, 39877, 47865, mitochondrial 55853 7771 Valyl-tRNA 416187 7926 414807 15914 23902, 31890, synthetase, 39878, 47866, mitochondrial 55854

127667772 Valyl-tRNA 431578 7927 415560 15915 23903, 31891, synthetase, 39879, 47867, mitochondrial 55855

127677773 Valyl-tRNA 548227 7928 448060 15916 23904, 31892, synthetase, 39880, 47868, mitochondrial 55856

127687774 Valyl-tRNA 549900 7929 447763 15917 23905, 31893, synthetase, 39881, 47869, mitochondrial 55857

127697775 Valyl-tRNA 553245 7930 447141 15918 23906, 31894, synthetase, 39882, 47870, mitochondrial 55858

127707776 vesicle transport 554659 7931 450731 15919 23907, 31895, through interaction 39883, 47871, with t-SNAREs 55859 homolog IB (yeast)

127717777 vesicle-associated 236192 7932 236192 15920 23908, 31896, membrane protein 4 39884, 47872,

1277255860

127737778 vesicle-associated 367740 7933 356714 15921 23909, 31897, membrane protein 4 39885, 47873,

1277455861

127757779 vesicle-associated 415773 7934 415627 15922 23910, 31898, membrane protein 4 39886, 47874,

1277655862

127777780 vesicle-associated 474047 7935 435933 15923 23911, 31899, membrane protein 4 39887, 47875,

1277855863

127797781 vesicular, 285279 7936 285279 15924 23912, 31900, overexpressed in 39888, 47876, cancer, prosurvival 55864 protein 1

127807782 vesicular, 545390 7937 446442 15925 23913, 31901, overexpressed in 39889, 47877, cancer, prosurvival 55865 protein 1

127817783 vezatin, adherens 261219 7938 261219 15926 23914, 31902, junctions 39890, 47878, transmembrane 55866 protein

127827784 vezatin, adherens 397796 7939 380898 15927 23915, 31903, junctions 39891, 47879, transmembrane 55867 protein

127837785 vezatin, adherens 436874 7940 410083 15928 23916, 31904, junctions 39892, 47880, transmembrane 55868 protein

127847786 vitamin K epoxide 360768 7941 353998 15929 23917, 31905, reductase complex, 39893, 47881, subunit 1 -like 1 55869 7787 VMA21 vacuolar 330374 7942 333255 15930 23918, 31906, H+-ATPase 39894, 47882, homolog (S. 55870 cerevisiae)

127857788 VMA21 vacuolar 370361 7943 359386 15931 23919, 31907, H+-ATPase 39895, 47883, homolog (S. 55871 cerevisiae)

127867789 vomeronasal 1 341702 7944 351244 15932 23920, 31908, receptor 2 39896, 47884,

1278755872

127887790 V-set and 217957 7945 217957 15933 23921, 31909, immunoglobulin 39897, 47885, domain containing 1 55873, 56103,

1278956136

127907791 V-set and 415430 7946 402219 15934 23922, 31910, immunoglobulin 39898, 47886, domain containing 1 55874

127917792 V-set and 359236 7947 352172 15935 23923, 31911, immunoglobulin 39899, 47887, domain containing 55875 10

127927793 V-set and 335624 7948 335623 15936 23924, 31912, immunoglobulin 39900, 47888, domain containing 55876 10 like

127937794 V-set and 542561 7949 443102 15937 23925, 31913, immunoglobulin 39901, 47889, domain containing 55877 10 like

127947795 V-set and 374737 7950 363869 15938 23926, 31914, immunoglobulin 39902, 47890, domain containing 4 55878

127957796 V-set and 412866 7951 394143 15939 23927, 31915, immunoglobulin 39903, 47891, domain containing 4 55879

127967797 V-set and 423830 7952 414594 15940 23928, 31916, immunoglobulin 39904, 47892, domain containing 4 55880

127977798 V-set and 427538 7953 393108 15941 23929, 31917, immunoglobulin 39905, 47893, domain containing 4 55881

127987799 V-set and 455586 7954 411581 15942 23930, 31918, immunoglobulin 39906, 47894, domain containing 4 55882

127997800 V-set and 368100 7955 357080 15943 23931, 31919, immunoglobulin 39907, 47895, domain containing 8 55883

128007801 V-set and 298454 7956 298454 15944 23932, 31920, transmembrane 39908, 47896, domain containing 4 55884

128017802 V-set and 332853 7957 331062 15945 23933, 31921, transmembrane 39909, 47897, domain containing 4 55885 7803 V-set and 409977 7958 386607 15946 23934, 31922, transmembrane 39910, 47898, domain containing 5 55886

128027804 V-set domain 328189 7959 328168 15947 23935, 31923, containing T cell 39911, 47899, activation inhibitor 1 55887

128037805 V-set domain 359008 7960 351899 15948 23936, 31924, containing T cell 39912, 47900, activation inhibitor 1 55888

128047806 V-set domain 369456 7961 358468 15949 23937, 31925, containing T cell 39913, 47901, activation inhibitor 1 55889

128057807 V-set domain 369458 7962 358470 15950 23938, 31926, containing T cell 39914, 47902, activation inhibitor 1 55890

128067808 V-set domain 539893 7963 444724 15951 23939, 31927, containing T cell 39915, 47903, activation inhibitor 1 55891

128077809 WAS protein family 326592 7964 317542 15952 23940, 31928, homolog 4 39916, 47904, pseudogene 55892

128087810 WAS protein family 538848 7965 441402 15953 23941, 31929, homolog 4 39917, 47905, pseudogene 55893

128097811 WAS protein family 285718 7966 285718 15954 23942, 31930, homolog 6 39918, 47906, pseudogene 55894

128107812 WAS protein family 359512 7967 352498 15955 23943, 31931, homolog 6 39919, 47907, pseudogene 55895

128117813 WD repeat and 295888 7968 295888 15956 23944, 31932, FYVE domain 39920, 47908, containing 3 55896

128127814 WD repeat and 322366 7969 318466 15957 23945, 31933, FYVE domain 39921, 47909, containing 3 55897

128137815 WD repeat and 502713 7970 422741 15958 23946, 31934, FYVE domain 39922, 47910, containing 3 55898

128147816 WD repeat and 509172 7971 425699 15959 23947, 31935, FYVE domain 39923, 47911, containing 3 55899

128157817 WD repeat 272321 7972 272321 15960 23948, 31936, containing planar 39924, 47912, cell polarity effector 55900

128167818 WD repeat domain 254029 7973 254029 15961 23949, 31937, 44 39925, 47913,

1281755901

128187819 WD repeat domain 318919 7974 317678 15962 23950, 31938, 44 39926, 47914,

1281955902

128207820 WD repeat domain 371822 7975 360887 15963 23951, 31939, 44 39927, 47915,

1282155903 7821 WD repeat domain 371825 7976 360890 15964 23952, 31940, 44 39928, 47916,

1282255904

128237822 WD repeat domain 371848 7977 360914 15965 23953, 31941, 44 39929, 47917,

1282455905

128257823 WD repeat domain 322995 7978 365543 15966 23954, 31942, 45 39930, 47918,

1282655906

128277824 WD repeat domain 356463 7979 348848 15967 23955, 31943, 45 39931, 47919,

1282855907

128297825 WD repeat domain 376368 7980 365546 15968 23956, 31944, 45 39932, 47920,

1283055908

128317826 WD repeat domain 376372 7981 365551 15969 23957, 31945, 45 39933, 47921,

1283255909

128337827 WD repeat domain 423215 7982 397657 15970 23958, 31946, 45 39934, 47922,

1283455910

128357828 WD repeat domain 465382 7983 420534 15971 23959, 31947, 45 39935, 47923,

1283655911

128377829 WD repeat domain 553851 7984 451962 15972 23960, 31948, 45 39936, 47924,

1283855912

128397830 WD repeat domain 222190 7985 222190 15973 23961, 31949, 83 opposite strand 39937, 47925,

1284055913

128417831 WD repeat domain 596731 7986 468969 15974 23962, 31950, 83 opposite strand 39938, 47926,

1284255914

128437832 WD repeat domain 268130 7987 268130 15975 23963, 31951, 93 39939, 47927,

1284455915

128457833 WD repeat domain 560294 7988 453971 15976 23964, 31952, 93 39940, 47928,

1284655916

128477834 WD repeat domain, 262139 7989 262139 15977 23965, 31953, phosphoinositide 39941, 47929, interacting 1 55917

128487835 WD repeat domain, 546360 7990 437345 15978 23966, 31954, phosphoinositide 39942, 47930, interacting 1 55918

128497836 WD repeat domain, 288828 7991 288828 15979 23967, 31955, phosphoinositide 39943, 47931, interacting 2 55919

128507837 WD repeat domain, 315176 7992 313532 15980 23968, 31956, phosphoinositide 39944, 47932, interacting 2 55920

128517838 WD repeat domain, 382384 7993 371821 15981 23969, 31957, phosphoinositide 39945, 47933, interacting 2 55921 7839 WD repeat domain, 401525 7994 384945 15982 23970, 31958, phosphoinositide 39946, 47934, interacting 2 55922

128527840 WD repeat domain, 404704 7995 385297 15983 23971, 31959, phosphoinositide 39947, 47935, interacting 2 55923

128537841 WD repeat domain, 484262 7996 429654 15984 23972, 31960, phosphoinositide 39948, 47936, interacting 2 55924

128547842 WDR45-like 392325 7997 376139 15985 23973, 31961,

1285539949, 47937, 55925

128567843 WDR45-like 539012 7998 438383 15986 23974, 31962,

1285739950, 47938, 55926

128587844 Williams-Beuren 329959 7999 333799 15987 23975, 31963, syndrome 39951, 47939, chromosome region 55927 16

128597845 Williams-Beuren 503250 8000 437702 15988 23976, 31964, syndrome 39952, 47940, chromosome region 55928 16

128607846 Williams-Beuren 543840 8001 441127 15989 23977, 31965, syndrome 39953, 47941, chromosome region 55929 16

128617847 Williams-Beuren 333538 8002 329654 15990 23978, 31966, syndrome 39954, 47942, chromosome region 55930 17

128627848 WSC domain 317744 8003 323087 15991 23979, 31967, containing 1 39955, 47943,

1286355931

128647849 WSC domain 539421 8004 446032 15992 23980, 31968, containing 1 39956, 47944,

1286555932

128667850 WSC domain 261400 8005 261400 15993 23981, 31969, containing 2 39957, 47945,

1286755933

128687851 WSC domain 332082 8006 331933 15994 23982, 31970, containing 2 39958, 47946,

1286955934

128707852 WSC domain 547525 8007 448047 15995 23983, 31971, containing 2 39959, 47947,

1287155935

128727853 WSC domain 549903 8008 447272 15996 23984, 31972, containing 2 39960, 47948,

1287355936

128747854 xin actin-binding 340369 8009 343140 15997 23985, 31973, repeat containing 1 39961, 47949,

1287555937

128767855 xin actin-binding 396251 8010 379550 15998 23986, 31974, repeat containing 1 39962, 47950,

1287755938 7856 xin actin-binding 421646 8011 391645 15999 23987, 31975, repeat containing 1 39963, 47951,

1287855939

128797857 XK, Kell blood 327381 8012 328326 16000 23988, 31976, group complex 39964, 47952, subunit-related 55940 family, member 4

128807858 XK, Kell blood 543752 8013 444213 16001 23989, 31977, group complex 39965, 47953, subunit-related 55941 family, member 4

128817859 XK, Kell blood 304437 8014 307120 16002 23990, 31978, group complex 39966, 47954, subunit-related 55942 family, member 6

128827860 XK, Kell blood 416569 8015 416707 16003 23991, 31979, group complex 39967, 47955, subunit-related 55943 family, member 6

128837861 XK, Kell blood 217299 8016 217299 16004 23992, 31980, group complex 39968, 47956, subunit-related 55944 family, member 7

128847862 XK, Kell blood 373884 8017 362991 16005 23993, 31981, group complex 39969, 47957, subunit-related 55945 family, member 8

128857863 XK, Kell blood 408926 8018 386141 16006 23994, 31982, group complex 39970, 47958, subunit-related 55946 family, member 9

128867864 XK, Kell blood 520030 8019 431088 16007 23995, 31983, group complex 39971, 47959, subunit-related 55947 family, member 9

128877865 xyloside 310380 8020 309640 16008 23996, 31984, xylosyltransferase 1 39972, 47960,

1288855948

128897866 xyloside 355729 8021 347967 16009 23997, 31985, xylosyltransferase 1 39973, 47961,

1289055949

128917867 xyloside 356740 8022 349179 16010 23998, 31986, xylosyltransferase 1 39974, 47962,

1289255950

128937868 xyloside 437101 8023 409865 16011 23999, 31987, xylosyltransferase 1 39975, 47963,

1289455951

128957869 xyloside 458652 8024 408351 16012 24000, 31988, xylosyltransferase 1 39976, 47964,

1289655952

128977870 ybeY 329319 8025 329614 16013 24001, 31989, metallopeptidase 39977, 47965, (putative) 55953 7871 ybeY 339195 8026 340675 16014 24002, 31990, metallopeptidase 39978, 47966, (putative) 55954

128987872 ybeY 397691 8027 380805 16015 24003, 31991, metallopeptidase 39979, 47967, (putative) 55955

128997873 ybeY 397692 8028 380806 16016 24004, 31992, metallopeptidase 39980, 47968, (putative) 55956

129007874 ybeY 397694 8029 380808 16017 24005, 31993, metallopeptidase 39981, 47969, (putative) 55957

129017875 ybeY 397701 8030 380813 16018 24006, 31994, metallopeptidase 39982, 47970, (putative) 55958

129027876 Yipl domain family, 72644 8031 72644 16019 24007, 31995, member 1 39983, 47971,

1290355959, 56104, 56137

129047877 Yipl domain family, 371399 8032 360452 16020 24008, 31996, member 1 39984, 47972,

1290555960

129067878 Yipl domain family, 412288 8033 416507 16021 24009, 31997, member 1 39985, 47973,

1290755961

129087879 Yipl domain family, 464950 8034 432266 16022 24010, 31998, member 1 39986, 47974,

1290955962

129107880 Yipl domain family, 539954 8035 439926 16023 24011, 31999, member 1 39987, 47975,

1291155963

129127881 Yipl domain family, 253031 8036 253031 16024 24012, 32000, member 2 39988, 47976,

1291355964

129147882 Yipl domain family, 238831 8037 238831 16025 24013, 32001, member 4 39989, 47977,

1291555965

129167883 Yipl domain family, 374622 8038 363751 16026 24014, 32002, member 6 39990, 47978,

1291755966

129187884 Yipl domain family, 451537 8039 401799 16027 24015, 32003, member 6 39991, 47979,

1291955967

129207885 Yipl domain family, 462683 8040 417573 16028 24016, 32004, member 6 39992, 47980,

1292155968

129227886 Yipl domain family, 332990 8041 332772 16029 24017, 32005, member 7 39993, 47981,

1292355969

129247887 Yipl domain family, 415895 8042 412696 16030 24018, 32006, member 7 39994, 47982,

1292555970

129267888 Yipl interacting 329420 8043 329559 16031 24019, 32007, factor homolog B (S. 39995, 47983, cerevisiae) 55971 7889 Yi l interacting 337679 8044 337411 16032 24020, 32008, factor homolog B (S. 39996, 47984, cerevisiae) 55972

129277890 Yipl interacting 339413 8045 343435 16033 24021, 32009, factor homolog B (S. 39997, 47985, cerevisiae) 55973

129287891 Yipl interacting 392124 8046 375971 16034 24022, 32010, factor homolog B (S. 39998, 47986, cerevisiae) 55974

129297892 YKT6 v-SNARE 223369 8047 223369 16035 24023, 32011, homolog (S. 39999, 47987, cerevisiae) 55975

129307893 YKT6 v-SNARE 496112 8048 420805 16036 24024, 32012, homolog (S. 40000, 47988, cerevisiae) 55976

129317894 YY2 transcription 429584 8049 389381 16037 24025, 32013, factor 40001, 47989,

1293255977

129337895 zer-1 homolog (C. 291900 8050 291900 16038 24026, 32014, elegans) 40002, 47990,

1293455978

129357896 zer-1 homolog (C. 414921 8051 393051 16039 24027, 32015, elegans) 40003, 47991,

1293655979

129377897 zer-1 homolog (C. 427848 8052 389271 16040 24028, 32016, elegans) 40004, 47992,

1293855980

129397898 zinc activated 334586 8053 334854 16041 24029, 32017, ligand-gated ion 40005, 47993, channel 55981

129407899 zinc activated 392503 8054 376291 16042 24030, 32018, ligand-gated ion 40006, 47994, channel 55982

129417900 zinc finger and AT 318135 8055 326997 16043 24031, 32019, hook domain 40007, 47995, containing 55983

129427901 zinc finger and 326544 8056 324450 16044 24032, 32020, SCAN domain 40008, 47996, containing 20 55984

129437902 zinc finger and 361328 8057 355053 16045 24033, 32021, SCAN domain 40009, 47997, containing 20 55985

129447903 zinc finger and 373411 8058 362510 16046 24034, 32022, SCAN domain 40010, 47998, containing 20 55986

129457904 zinc finger and 373413 8059 362512 16047 24035, 32023, SCAN domain 40011, 47999, containing 20 55987

129467905 zinc finger and 401072 8060 383850 16048 24036, 32024, SCAN domain 40012, 48000, containing 20 55988

129477906 zinc finger CCCH- 373082 8061 362174 16049 24037, 32025, type containing 12A 40013, 48001,

1294855989 7907 zinc finger CCCH- 373087 8062 362179 16050 24038, 32026, type containing 12A 40014, 48002,

1294955990

129507908 zinc finger CCCH- 337859 8063 338788 16051 24039, 32027, type containing 15 40015, 48003,

1295155991

129527909 zinc finger CCCH- 536434 8064 439885 16052 24040, 32028, type containing 15 40016, 48004,

1295355992

129547910 zinc finger CCCH- 544130 8065 440525 16053 24041, 32029, type containing 15 40017, 48005,

1295555993

129567911 zinc finger protein 314529 8066 322265 16054 24042, 32030, 620 40018, 48006,

1295755994

129587912 zinc finger protein 420891 8067 406156 16055 24043, 32031, 620 40019, 48007,

1295955995

129607913 zinc finger protein294258 8068 294258 16056 24044, 32032, like 1 40020, 48008,

1296155996

129627914 zinc finger protein526334 8069 434454 16057 24045, 32033, like 1 40021, 48009,

1296355997

129647915 zinc finger protein532200 8070 437090 16058 24046, 32034, like 1 40022, 48010,

1296555998

129667916 zinc finger, DHHC- 348579 8071 340299 16059 24047, 32035, type containing 1 40023, 48011,

1296755999

129687917 zinc finger, DHHC- 283441 8072 283441 16060 24048, 32036, type containing 11 40024, 48012,

1296956000

129707918 zinc finger, DHHC- 424784 8073 397719 16061 24049, 32037, type containing 11 40025, 48013,

1297156001

129727919 zinc finger, DHHC- 372663 8074 361748 16062 24050, 32038, type containing 12 40026, 48014,

1297356002

129747920 zinc finger, DHHC- 372664 8075 361749 16063 24051, 32039, type containing 12 40027, 48015,

1297556003

129767921 zinc finger, DHHC- 372667 8076 361752 16064 24052, 32040, type containing 12 40028, 48016,

1297756004

129787922 zinc finger, DHHC- 372672 8077 361757 16065 24053, 32041, type containing 12 40029, 48017,

1297956005

129807923 zinc finger, DHHC- 406904 8078 384205 16066 24054, 32042, type containing 12 40030, 48018,

1298156006

129827924 zinc finger, DHHC- 452105 8079 387587 16067 24055, 32043, type containing 12 40031, 48019,

1298356007 7925 zinc finger, DHHC- 359775 8080 352821 16068 24056, 32044, type containing 14 40032, 48020,

1298456008

129857926 zinc finger, DHHC- 414563 8081 410713 16069 24057, 32045, type containing 14 40033, 48021,

1298656009

129877927 zinc finger, DHHC- 538483 8082 444176 16070 24058, 32046, type containing 14 40034, 48022,

1298856010

129897928 zinc finger, DHHC- 345745 8083 304487 16071 24059, 32047, type containing 16 40035, 48023,

1299056011

129917929 zinc finger, DHHC- 352634 8084 345383 16072 24060, 32048, type containing 16 40036, 48024,

1299256012

129937930 zinc finger, DHHC- 353979 8085 323360 16073 24061, 32049, type containing 16 40037, 48025,

1299456013

129957931 zinc finger, DHHC- 370842 8086 359879 16074 24062, 32050, type containing 16 40038, 48026,

1299656014

129977932 zinc finger, DHHC- 370846 8087 359883 16075 24063, 32051, type containing 16 40039, 48027,

1299856015

129997933 zinc finger, DHHC- 370854 8088 359891 16076 24064, 32052, type containing 16 40040, 48028,

1300056016

130017934 zinc finger, DHHC- 393760 8089 377357 16077 24065, 32053, type containing 16 40041, 48029,

1300256017

130037935 zinc finger, DHHC- 414567 8090 400719 16078 24066, 32054, type containing 16 40042, 48030,

1300456018

130057936 zinc finger, DHHC- 417044 8091 396286 16079 24067, 32055, type containing 16 40043, 48031,

1300656019

130077937 zinc finger, DHHC- 420089 8092 405240 16080 24068, 32056, type containing 16 40044, 48032,

1300856020

130097938 zinc finger, DHHC- 433086 8093 398532 16081 24069, 32057, type containing 16 40045, 48033,

1301056021

130117939 zinc finger, DHHC- 374142 8094 363257 16082 24070, 32058, type containing 18 40046, 48034,

1301256022

130137940 zinc finger, DHHC- 296326 8095 296326 16083 24071, 32059, type containing 19 40047, 48035,

1301456023

130157941 zinc finger, DHHC- 262096 8096 262096 16084 24072, 32060, type containing 2 40048, 48036,

1301656024

130177942 zinc finger, DHHC- 320220 8097 313583 16085 24073, 32061, type containing 20 40049, 48037,

1301856025 7943 zinc finger, DHHC- 382466 8098 371905 16086 24074, 32062, type containing 20 40050, 48038,

1301956026

130207944 zinc finger, DHHC- 400590 8099 383433 16087 24075, 32063, type containing 20 40051, 48039,

1302156027

130227945 zinc finger, DHHC- 415724 8100 401232 16088 24076, 32064, type containing 20 40052, 48040,

1302356028

130247946 zinc finger, DHHC- 422251 8101 396819 16089 24077, 32065, type containing 20 40053, 48041,

1302556029

130267947 zinc finger, DHHC- 542645 8102 443236 16090 24078, 32066, type containing 20 40054, 48042,

1302756030

130287948 zinc finger, DHHC- 380916 8103 370303 16091 24079, 32067, type containing 21 40055, 48043,

1302956031

130307949 zinc finger, DHHC- 319374 8104 318222 16092 24080, 32068, type containing 22 40056, 48044,

1303156032

130327950 zinc finger, DHHC- 555327 8105 450478 16093 24081, 32069, type containing 22 40057, 48045,

1303356033

130347951 zinc finger, DHHC- 555389 8106 451337 16094 24082, 32070, type containing 22 40058, 48046,

1303556034

130367952 zinc finger, DHHC- 330212 8107 330485 16095 24083, 32071, type containing 23 40059, 48047,

1303756035

130387953 zinc finger, DHHC- 491556 8108 420292 16096 24084, 32072, type containing 23 40060, 48048,

1303956036

130407954 zinc finger, DHHC- 310442 8109 309429 16097 24085, 32073, type containing 24 40061, 48049,

1304156037

130427955 zinc finger, DHHC- 296127 8110 296127 16098 24086, 32074, type containing 3 40062, 48050,

1304356038

130447956 zinc finger, DHHC- 339420 8111 404108 16099 24087, 32075, type containing 3 40063, 48051,

1304556039

130467957 zinc finger, DHHC- 424952 8112 395502 16100 24088, 32076, type containing 3 40064, 48052,

1304756040

130487958 zinc finger, DHHC- 335965 8113 337475 16101 24089, 32077, type containing 4 40065, 48053,

1304956041

130507959 zinc finger, DHHC- 396706 8114 379934 16102 24090, 32078, type containing 4 40066, 48054,

1305156042

130527960 zinc finger, DHHC- 396707 8115 379935 16103 24091, 32079, type containing 4 40067, 48055,

1305356043 7961 zinc finger, DHHC- 396709 8116 379937 16104 24092, 32080, type containing 4 40068, 48056,

1305456044

130557962 zinc finger, DHHC- 396713 8117 379941 16105 24093, 32081, type containing 4 40069, 48057,

1305656045

130577963 zinc finger, DHHC- 405731 8118 385027 16106 24094, 32082, type containing 4 40070, 48058,

1305856046

130597964 zinc finger, DHHC- 483589 8119 418496 16107 24095, 32083, type containing 4 40071, 48059,

1306056047

130617965 zinc finger, DHHC- 287169 8120 287169 16108 24096, 32084, type containing 5 40072, 48060,

1306256048

130637966 zinc finger, DHHC- 527985 8121 432202 16109 24097, 32085, type containing 5 40073, 48061,

1306456049

130657967 zinc finger, DHHC- 369404 8122 358412 16110 24098, 32086, type containing 6 40074, 48062,

1306656050

130677968 zinc finger, DHHC- 369405 8123 358413 16111 24099, 32087, type containing 6 40075, 48063,

1306856051

130697969 zinc finger, DHHC- 313732 8124 315604 16112 24100, 32088, type containing 7 40076, 48064,

1307056052

130717970 zinc finger, DHHC- 344861 8125 341681 16113 24101, 32089, type containing 7 40077, 48065,

1307256053

130737971 zinc finger, FYVE 338008 8126 337159 16114 24102, 32090, domain containing 40078, 48066, 16 56054

130747972 zinc finger, FYVE 505560 8127 426848 16115 24103, 32091, domain containing 40079, 48067, 16 56055

130757973 zinc finger, FYVE 510158 8128 423663 16116 24104, 32092, domain containing 40080, 48068, 16 56056

130767974 zinc finger, FYVE 253699 8129 253699 16117 24105, 32093, domain containing 40081, 48069, 20 56057

130777975 zinc finger, FYVE 418832 8130 389567 16118 24106, 32094, domain containing 40082, 48070, 20 56058

130787976 zinc finger, FYVE 435849 8131 391039 16119 24107, 32095, domain containing 40083, 48071, 20 56059

130797977 zinc finger, FYVE 476527 8132 422551 16120 24108, 32096, domain containing 40084, 48072, 20 56060

130807978 zinc finger, FYVE 507357 8133 427038 16121 24109, 32097, domain containing 40085, 48073, 20 56061 7979 zinc finger, FYVE 287727 8134 287727 16122 24110, 32098, domain containing 9 40086, 48074,

1308156062

130827980 zinc finger, FYVE 357206 8135 349737 16123 24111, 32099, domain containing 9 40087, 48075,

1308356063

130847981 zinc finger, FYVE 361625 8136 355358 16124 24112, 32100, domain containing 9 40088, 48076,

1308556064

130867982 zinc finger, FYVE 371591 8137 360647 16125 24113, 32101, domain containing 9 40089, 48077,

1308756065

130887983 zinc fingers and 314393 8138 314709 16126 24114, 32102, homeoboxes 2 40090, 48078,

1308956066

130907984 zinc fingers and 534247 8139 452720 16127 24115, 32103, homeoboxes 2 40091, 48079,

1309156067

130927985 ZMYM6 neighbor 373337 8140 362435 16128 24116, 32104,

1309340092, 48080, 56068

130947986 zona pellucida-like 306176 8141 307801 16129 24117, 32105, domain containing 1 40093, 48081,

1309556069

130967987 zona pellucida-like 466937 8142 418253 16130 24118, 32106, domain containing 1 40094, 48082,

1309756070

130987988 zona pellucida-like 491959 8143 420265 16131 24119, 32107, domain containing 1 40095, 48083,

1309956071

13100[000230] In one embodiment, the polypeptide of interest is a plasma membrane protein. As a non-limiting example, the polynucleotides, primary constructs and/or mmRNA may encode a plasma membrane protein such as, but not limited to any of SEQ ID NOs: 8144, 8145, 8146, 8147, 8148, 8155, 8156, 8163, 8178, 8179, 8180, 8181, 8182, 8183, 8185, 8186, 8189, 8190, 8191, 8192, 8195, 8196, 8197, 8200, 8202, 8204, 8211, 8212, 8216, 8218, 8223, 8231, 8232, 8233, 8236, 8237, 8239, 8240, 8241, 8242, 8248, 8249, 8250, 8251, 8252, 8253, 8254, 8255, 8256, 8257, 8258, 8259, 8260, 8262, 8264, 8265, 8266, 8267, 8268, 8275, 8280, 8281, 8282, 8283, 8284, 8285, 8286, 8287, 8288, 8290, 8292, 8293, 8308, 8309, 8310, 8311, 8312, 8314, 8315, 8316, 8319, 8320, 8322, 8323, 8327, 8328, 8329, 8333, 8338, 8339, 8340, 8341, 8343, 8349, 8350, 8351, 8355, 8357, 8358, 8359, 8360, 8361, 8362, 8363, 8364, 8365, 8366, 8369, 8371, 8372, 8379, 8381, 8387, 8391, 8392, 8395, 8396, 8402, 8407, 8408, 8409, 8410, 8411, 8412, 8414, 8419, 8422, 8423, 8425, 8426, 8427, 8430, 8431, 8433, 8435, 8440, 8441, 8445, 8446, 8447, 8448, 8449, 8450, 8452, 8453, 8454, 8455, 8458 8459, 8462, 8463, 8464, 8467, 8468, 8469,

131018470, 8472, 8474, 8475, 8476, 8479, 8480 8481, 8488, 8489, 8490, 8497, 8504, 8506,

131028510, 8511, 8512, 8514, 8518, 8520, 8521 8522, 8523, 8525, 8527, 8529, 8530, 8531,

131038532, 8540, 8543, 8545, 8546, 8547, 8548 8549, 8551, 8554, 8557, 8558, 8561, 8563,

131048564, 8565, 8566, 8568, 8569, 8570, 8571 8572, 8573, 8575, 8576, 8577, 8578, 8580,

131058581, 8583, 8588, 8589, 8594, 8596, 8597 8599, 8601, 8602, 8604, 8606, 8609, 8612,

131068615, 8618, 8620, 8622, 8625, 8632, 8635 8636, 8637, 8638, 8639, 8643, 8645, 8651,

131078652, 8655, 8656, 8657, 8658, 8659, 8661 8663, 8669, 8670, 8672, 8683, 8695, 8701,

131088703, 8704, 8705, 8706, 8711, 8712, 8713 8714, 8717, 8722, 8723, 8724, 8725, 8727,

131098729, 8731, 8733, 8734, 8736, 8739, 8749 8750, 8751, 8752, 8753, 8754, 8755, 8757,

131108758, 8760, 8761, 8762, 8764, 8765, 8766 8767, 8768, 8770, 8772, 8773, 8774, 8775,

131118779, 8780, 8782, 8784, 8786, 8787, 8788 8789, 8790, 8791, 8793, 8794, 8795, 8796,

131128799, 8801, 8803, 8804, 8814, 8815, 8817 8818, 8819, 8820, 8822, 8824, 8825, 8826,

131138827, 8833, 8834, 8836, 8839, 8841, 8842 8844, 8846, 8847, 8852, 8855, 8856, 8867,

131148868, 8869, 8870, 8872, 8875, 8876, 8877 8879, 8881, 8882, 8884, 8888, 8891, 8892,

131158893, 8895, 8896, 8897, 8898, 8905, 8907 8908, 8909, 8910, 8911, 8912, 8913, 8917,

131168919, 8921, 8922, 8923, 8924, 8927, 8931 8932, 8934, 8936, 8937, 8938, 8939, 8940,

131178941, 8942, 8943, 8944, 8946, 8947, 8948 8949, 8953, 8956, 8959, 8961, 8963, 8964,

131188965, 8966, 8974, 8977, 8978, 8981, 8985 8988, 8989, 8990, 8991, 8992, 8993, 8994,

131198995, 8996, 8997, 8998, 8999, 9000, 9001 9002, 9003, 9004, 9005, 9006, 9007, 9008,

131209009, 9010, 9011, 9012, 9013, 9014, 9015 9016, 9018, 9020, 9024, 9026, 9027, 9028,

131219029, 9030, 9033, 9036, 9038, 9040, 9042 9052, 9053, 9054, 9059, 9062, 9065, 9069,

131229071, 9073, 9074, 9075, 9076, 9077, 9090 9091, 9092, 9096, 9101, 9102, 9103, 9104,

131239106, 9108, 9110, 9115, 9118, 9123, 9127 9129, 9130, 9131, 9132, 9135, 9136, 9137,

131249138, 9139, 9140, 9141, 9142, 9143, 9146 9148, 9149, 9151, 9152, 9153, 9154, 9155,

131259156, 9157, 9158, 9162, 9163, 9164, 9166 9167, 9168, 9169, 9194, 9195, 9196, 9197,

131269198, 9203, 9204, 9208, 9210, 9216, 9217 9218, 9220, 9221, 9224, 9225, 9229, 9231,

131279235, 9240, 9241, 9242, 9243, 9244, 9245 9246, 9248, 9250, 9251, 9252, 9253, 9254,

131289260, 9265, 9266, 9267, 9269, 9271, 9275 9278, 9279, 9281, 9282, 9283, 9284, 9285,

131299289, 9292, 9293, 9305, 9306, 9310, 9311 9313, 9314, 9321, 9323, 9324, 9329, 9330,

131309332, 9333, 9337, 9338, 9339, 9340, 9342 9343, 9344, 9345, 9346, 9348, 9350, 9351, 9354, 9355, 9356, 9360, 9361, 9373, 9374, 9375, 9376, 9377, 9378, 9380, 9381, 9382,

131319383, 9389, 9397, 9398, 9407, 9412, 9417, 9420, 9423, 9426, 9428, 9432, 9433, 9434,

131329437, 9441, 9442, 9443, 9444, 9445, 9448, 9449, 9450, 9451, 9452, 9454, 9460, 9461,

131339462, 9463, 9464, 9465, 9466, 9468, 9470, 9471, 9472, 9473, 9474, 9475, 9477, 9478,

131349480, 9482, 9483, 9484, 9485, 9486, 9487, 9488, 9496, 9497, 9499, 9500, 9502, 9505,

131359506, 9509, 9510, 9511, 9513, 9514, 9515, 9516, 9517, 9518, 9519, 9520, 9521, 9522,

131369524, 9528, 9529, 9530, 9531, 9532, 9533, 9534, 9535, 9536, 9537, 9538, 9539, 9540,

131379541, 9542, 9543, 9545, 9546, 9548, 9549, 9550, 9551, 9552, 9553, 9555, 9561, 9564,

131389568, 9569, 9570, 9572, 9574, 9576, 9577, 9584, 9585, 9587, 9610, 9611, 9612, 9614,

131399616, 9617, 9618, 9619, 9625, 9628, 9632, 9647, 9649, 9650, 9652, 9654, 9659, 9661,

131409662, 9665, 9667, 9668, 9672, 9673, 9674, 9676, 9678, 9680, 9681, 9682, 9684, 9685,

131419686, 9687, 9688, 9689, 9690, 9691, 9692, 9696, 9698, 9701, 9703, 9704, 9706, 9707,

131429708, 9713, 9714, 9715, 9717, 9729, 9730, 9736, 9737, 9740, 9747, 9749, 9751, 9753,

131439755, 9756, 9757, 9758, 9764, 9767, 9768, 9769, 9775, 9776, 9777, 9784, 9787, 9789,

131449793, 9795, 9798, 9800, 9802, 9803, 9804, 9806, 9807, 9808, 9811, 9812, 9826, 9830,

131459831, 9833, 9835, 9844, 9852, 9857, 9860, 9861, 9863, 9867, 9875, 9878, 9890, 9891,

131469892, 9893, 9894, 9895, 9896, 9897, 9898, 9899, 9900, 9901, 9902, 9903, 9904, 9905,

131479906, 9907, 9908, 9909, 9910, 9911, 9913, 9914, 9915, 9917, 9920, 9923, 9924, 9925,

131489926, 9927, 9932, 9933, 9935, 9936, 9938, 9940, 9942, 9943, 9945, 9948, 9957, 9958,

131499959, 9964, 9966, 9969, 9973, 9974, 9977, 9979, 9980, 9981, 9984, 9985, 9987, 9997,

1315010007, 10008, 10009, 10012, 10013 10014, 10017, 10019, 10021, 10022 10023, 10024, 10025, 10027, 10029, 10031, 10032 10033, 10034, 10043, 10044, 10046 10047, 10048, 10049, 10050, 10054, 10055, 10056 10057, 10058, 10060, 10061, 10063 10066, 10068, 10084, 10085, 10086, 10087, 10091 10092, 10093, 10096, 10098, 10099 10104, 10107, 10111, 10116, 10117, 10120, 10123 10124, 10125, 10126, 10127, 10130 10131, 10133, 10134, 10139, 10141, 10143, 10156 10158, 10159, 10160, 10161, 10162 10165, 10173, 10174, 10175, 10176, 10177, 10178 10179, 10180, 10182, 10183, 10184 10185, 10186, 10187, 10188, 10189, 10191, 10194 10196, 10197, 10198, 10199, 10200 10201, 10202, 10203, 10204, 10205, 10209, 10210 10211, 10212, 10214, 10215, 10216 10217, 10221, 10223, 10225, 10226, 10227, 10228 10229, 10230, 10234, 10235, 10236 10237, 10238, 10245, 10249, 10250, 10251, 10252 10257, 10258, 10261, 10262, 10265 10266, 10269, 10270, 10271, 10275, 10276, 10279, 10282, 10283, 10284, 10285, 10286, 10287, 10288, 10289, 10290, 10291, 10292, 10293, 10299, 10306, 10307, 10308, 10310, 10312, 10313, 10315, 10320, 10322, 10323, 10325, 10331, 10333, 10334, 10335, 10336, 10338, 10340, 10342, 10344, 10349, 10355, 10361, 10362, 10363, 10367, 10368, 10369, 10373, 10376, 10379, 10380, 10381, 10382, 10385, 10386, 10387, 10388, 10395, 10397, 10398, 10412, 10421, 10422, 10423, 10424, 10425, 10426, 10427, 10428, 10429, 10432, 10438, 10442, 10443, 10453, 10455, 10456, 10457, 10458, 10459, 10460, 10464, 10465, 10467, 10469, 10470, 10472, 10475, 10476, 10478, 10479, 10480, 10482, 10486, 10487, 10488, 10490, 10492, 10503, 10507, 10508, 10509, 10510, 10511, 10513, 10514, 10518, 10519, 10521, 10522, 10523, 10524, 10525, 10526, 10527, 10528, 10529, 10532, 10534, 10535, 10539, 10540, 10541, 10543, 10545, 10546, 10547, 10548, 10549, 10551, 10552, 10553, 10554, 10556, 10558, 10560, 10563, 10565, 10566, 10567, 10569, 10570, 10577, 10578, 10579, 10580, 10581, 10587, 10588, 10590, 10591, 10594, 10596, 10597, 10598, 10599, 10600, 10601, 10602, 10603, 10608, 10609, 10611, 10613, 10615, 10616, 10617, 10618, 10619, 10624, 10626, 10627, 10637, 10638, 10639, 10640, 10641, 10643, 10644, 10645, 10646, 10653, 10654, 10655, 10662, 10663, 10664, 10678, 10679, 10684, 10686, 10690, 10691, 10692, 10696, 10697, 10698, 10699, 10702, 10707, 10714, 10715, 10716, 10720, 10721, 10725, 10726, 10727, 10728, 10729, 10730, 10731, 10732, 10733, 10734, 10735, 10736, 10737, 10738, 10739, 10743, 10750, 10753, 10755, 10758, 10759, 10761, 10764, 10766, 10767, 10768, 10769, 10770, 10771, 10774, 10776, 10777, 10784, 10785, 10786, 10787, 10788, 10789, 10790, 10793, 10794, 10795, 10796, 10797, 10798, 10799, 10800, 10802, 10803, 10805, 10806, 10807, 10811, 10813, 10814, 10815, 10817, 10820, 10822, 10825, 10827, 10828, 10829, 10830, 10831, 10832, 10835, 10838, 10839, 10841, 10843, 10844, 10845, 10846, 10855, 10857, 10859, 10861, 10862, 10863, 10864, 10865, 10870, 10871, 10877, 10878, 10879, 10880, 10882, 10883, 10884, 10887, 10888, 10889, 10890, 10891, 10898, 10900, 10902, 10903, 10904, 10906, 10909, 10919, 10920, 10921, 10925, 10926, 10928, 10930, 10932, 10935, 10936, 10939, 10940, 10941, 10942, 10943, 10944, 10945, 10946, 10947, 10948, 10949, 10950, 10951, 10952, 10954, 10955, 10956, 10957, 10958, 10959, 10960, 10962, 10967, 10973, 10978, 10981, 10982, 10985, 10988, 10991, 10992, 10993, 10995, 10997, 11001, 11002, 11003, 11004, 11005, 11006, 11007, 11008, 11009, 11010, 11011, 11012, 11014, 11015, 11016, 11017, 11018, 11019, 11020, 11021, 11022, 11023, 11024, 11025, 1026, 11027, 11029, 11031, 11034, 11035 11037, 11042, 11048, 11051, 11054, 11058, 1062, 11063, 11064, 11065, 11066, 11067 11068, 11069, 11071, 11072, 11073, 11075, 1076, 11077, 11081, 11082, 11083, 11084 11087, 11088, 11090, 11092, 11093, 11094, 1097, 11099, 11100, 11101, 11102, 11103 11104, 11105, 11106, 11107, 11108, 11109, 1110, 11111, 11113, 11118, 11119, 11120 11122, 11124, 11126, 11128, 11130, 11131, 1132, 11133, 11134, 11135, 11137, 11138 11139, 11140, 11141, 11142, 11143, 11144, 1145, 11146, 11147, 11148, 11149, 11150 11151, 11153, 11154, 11155, 11156, 11159, 1160, 11161, 11162, 11164, 11165, 11168 11171, 11173, 11175, 11176, 11178, 11180, 1181, 11182, 11184, 11187, 11189, 11191 11193, 11194, 11195, 11196, 11198, 11201, 1203, 11204, 11205, 11206, 11207, 11208 11209, 11210, 11213, 11214, 11215, 11216, 1217, 11221, 11225, 11238, 11239, 11241 11243, 11245, 11246, 11247, 11248, 11249, 1251, 11254, 11256, 11259, 11260, 11261 11262, 11264, 11267, 11268, 11269, 11272, 1273, 11275, 11278, 11279, 11280, 11281 11282, 11283, 11284, 11285, 11286, 11287, 1288, 11289, 11290, 11291, 11292, 11293 11294, 11295, 11296, 11297, 11298, 11299, 1300, 11301, 11302, 11303, 11304, 11306 11307, 11308, 11309, 11311, 11313, 11315, 1316, 11317, 11318, 11320, 11321, 11322 11323, 11324, 11325, 11326, 11327, 11328, 1329, 11330, 11331, 11332, 11333, 11334 11335, 11336, 11337, 11338, 11339, 11340, 1341, 11342, 11343, 11344, 11345, 11346 11347, 11348, 11349, 11350, 11351, 11352, 1353, 11354, 11355, 11356, 11357, 11358 11359, 11360, 11361, 11362, 11363, 11364, 1365, 11367, 11368, 11369, 11370, 11371 11372, 11373, 11374, 11375, 11378, 11379, 1380, 11381, 11382, 11383, 11384, 11385 11388, 11389, 11390, 11392, 11393, 11394, 1398, 11399, 11401, 11402, 11404, 11408 11409, 11410, 11412, 11417, 11418, 11419, 1421, 11422, 11423, 11424, 11425, 11426 11427, 11428, 11429, 11430, 11431, 11432, 1433, 11434, 11435, 11436, 11437, 11438 11439, 11440, 11441, 11442, 11443, 11444, 1445, 11446, 11447, 11448, 11449, 11450 11451, 11452, 11453, 11454, 11455, 11456, 1457, 11458, 11459, 11460, 11461, 11462 11463, 11464, 11465, 11467, 11468, 11470, 1471, 11472, 11473, 11474, 11475, 11477 11478, 11479, 11480, 11481, 11482, 11483, 1485, 11486, 11487, 11488, 11489, 11491 11492, 11494, 11495, 11496, 11498, 11499, 1500, 11501, 11503, 11504, 11505, 11506 11508, 11511, 11512, 11513, 11514, 11515, 1517, 11519, 11520, 11521, 11522, 11525 11531, 11532, 11535, 11536, 11537, 11539, 1540, 11541, 11543, 11544, 11545, 11548 11555, 11557, 11558, 11560, 11563, 11564, 11567, 11570, 11571 11573, 11574, 11576, 11577, 11582 11583, 11584, 11586, 11587, 11591, 11592, 11593 11594, 11595, 11596, 11597, 11598 11599, 11601, 11602, 11603, 11604, 11605, 11606 11607, 11608, 11609, 11610, 11611 11612, 11613, 11614, 11615, 11616, 11617, 11618 11619, 11620, 11621, 11622, 11623 11624, 11625, 11626, 11627, 11628, 11629, 11630 11631, 11632, 11633, 11634, 11635 11636, 11648, 11649, 11650, 11651, 11652, 11653 11654, 11655, 11656, 11657, 11658 11659, 11660, 11661, 11662, 11665, 11666, 11667 11669, 11672, 11676, 11679, 11680 11681, 11686, 11690, 11691, 11692, 11693, 11694 11695, 11696, 11698, 11700, 11701 11703, 11704, 11705, 11706, 11707, 11710, 11712 11716, 11722, 11723, 11724, 11729 11731, 11732, 11735, 11736, 11737, 11738, 11741 11743, 11748, 11750, 11762, 11767 11768, 11770, 11771, 11772, 11774, 11777, 11778 11779, 11780, 11781, 11783, 11790 11791, 11792, 11793, 11795, 11797, 11798, 11800 11801, 11802, 11803, 11805, 11811 11814, 11816, 11817, 11818, 11819, 11820, 11821 11822, 11823, 11827, 11829, 11838 11839, 11840, 11845, 11871, 11873, 11874, 11875 11876, 11878, 11879, 11880, 11881 11882, 11883, 11886, 11888, 11890, 11894, 11901 11902, 11903, 11905, 11910, 11911 11912, 11913, 11914, 11916, 11918, 11919, 11922 11934, 11936, 11949, 11951, 11957 11963, 11964, 11965, 11970, 11972, 11974, 11984 11985, 11990, 11993, 11996, 11999 12007, 12008, 12009, 12010, 12011, 12012, 12014 12015, 12016, 12018, 12020, 12021 12022, 12024, 12027, 12028, 12029, 12032, 12036 12037, 12038, 12041, 12042, 12043 12045, 12048, 12049, 12051, 12053, 12054, 12060 12061, 12065, 12066, 12067, 12068 12070, 12071, 12072, 12073, 12074, 12075, 12076 12077, 12078, 12079, 12080, 12081 12084, 12085, 12086, 12088, 12089, 12090, 12091 12092, 12093, 12094, 12095, 12096 12100, 12103, 12106, 12109, 12110, 12113, 12115 12116, 12118, 12129, 12131, 12133 12137, 12138, 12141, 12148, 12150, 12152, 12154 12156, 12157, 12159, 12162, 12171 12173, 12175, 12176, 12178, 12179, 12180, 12181 12182, 12183, 12184, 12185, 12186 12187, 12188, 12189, 12191, 12192, 12194, 12195 12196, 12198, 12199, 12200, 12201 12202, 12203, 12204, 12205, 12206, 12207, 12208 12209, 12210, 12211, 12212, 12213 12214, 12215, 12216, 12217, 12218, 12219, 12220 12221, 12222, 12223, 12224, 12232, 12233, 12234, 12235, 12236, 12237, 12238, 12239 12240, 12241, 12242, 12243, 12244 12245, 12246, 12247, 12248, 12249, 12250, 12251 12252, 12253, 12254, 12255, 12256 12257, 12259, 12260, 12261, 12262, 12263, 12264 12265, 12266, 12267, 12268, 12269 12270, 12271, 12272, 12273, 12274, 12275, 12276, 12277, 12278, 12279, 12280, 12281, 12282, 12283, 12284, 12285, 12286, 12287, 12288, 12289, 12290, 12291, 12292, 12293, 12294, 12295, 12296, 12297, 12298, 12299, 12300, 12301, 12303, 12304, 12305, 12306, 12307, 12308, 12309, 12310, 12311, 12312, 12313, 12314, 12315, 12316, 12317, 12318, 12319, 12320, 12321, 12322, 12323, 12324, 12325, 12326, 12327, 12328, 12329, 12330, 12331, 12332, 12333, 12334, 12335, 12336, 12337, 12338, 12339, 12340, 12341, 12342, 12343, 12344, 12345, 12346, 12347, 12348, 12349, 12350, 12351, 12352, 12353, 12354, 12355, 12356, 12357, 12358, 12359, 12360, 12361, 12362, 12363, 12364, 12365, 12366, 12367, 12368, 12369, 12370, 12371, 12372, 12373, 12374, 12375, 12376, 12377, 12378, 12379, 12380, 12381, 12382, 12383, 12384, 12385, 12386, 12387, 12388, 12389, 12390, 12391, 12392, 12393, 12394, 12395, 12396, 12397, 12398, 12399, 12400, 12401, 12402, 12403, 12404, 12405, 12406, 12407, 12409, 12410, 12411, 12412, 12413, 12414, 12415, 12416, 12417, 12418, 12419, 12420, 12421, 12422, 12423, 12424, 12425, 12426, 12427, 12428, 12429, 12430, 12431, 12432, 12433, 12434, 12435, 12436, 12437, 12438, 12439, 12440, 12441, 12442, 12443, 12444, 12445, 12446, 12447, 12448, 12449, 12450, 12451, 12452, 12453, 12454, 12455, 12456, 12457, 12458, 12459, 12460, 12461, 12462, 12463, 12465, 12466, 12467, 12468, 12469, 12470, 12471, 12472, 12473, 12474, 12475, 12476, 12477, 12479, 12480, 12481, 12482, 12483, 12484, 12485, 12486, 12487, 12488, 12489, 12490, 12491, 12492, 12493, 12494, 12495, 12498, 12499, 12500, 12501, 12502, 12503, 12504, 12505, 12506, 12507, 12508, 12509, 12510, 12511, 12512, 12513, 12514, 12515, 12516, 12517, 12518, 12519, 12520, 12521, 12522, 12523, 12524, 12525, 12526, 12527, 12528, 12529, 12530, 12531, 12532, 12533, 12534, 12535, 12536, 12537, 12538, 12539, 12540, 12541, 12542, 12543, 12544, 12545, 12546, 12547, 12548, 12549, 12550, 12551, 12552, 12553, 12554, 12555, 12556, 12557, 12558, 12559, 12562, 12563, 12564, 12565, 12567, 12568, 12569, 12570, 12572, 12573, 12574, 12575, 12578, 12579, 12580, 12581, 12582, 12583, 12584, 12585, 12586, 12587, 12588, 12589, 12590, 12591, 12592, 12593, 12594, 12595, 12596, 12597, 12598, 12599, 12600, 12601, 12602, 12603, 12604, 12605, 12606, 12607, 12608, 12609, 12610, 12611, 12612, 12613, 12614, 12615, 12616, 12617, 12618, 12619, 12620, 12621, 12622, 12623, 12624, 12625, 12626, 12627, 12628, 12629, 12630, 12631, 12632, 12633, 12634, 12635, 12636, 12638, 12639, 12640, 12641, 12642, 12643, 12644, 12645, 12646, 12647, 12648, 12649, 12650, 12651, 12652, 12653, 12654, 12655, 12657, 12658, 12659, 12660, 12661, 12662, 12663, 12664, 12665, 12666, 12667, 12668 12669, 12671, 12672, 12673, 12674, 12675, 12676, 12677, 12678, 12679, 12680, 12681 12682, 12683, 12684, 12685, 12686, 12687, 12688, 12689, 12690, 12692, 12693, 12694 12695, 12697, 12704, 12705, 12706, 12707, 12708, 12709, 12710, 12713, 12717, 12718 12719, 12724, 12725, 12729, 12730, 12733, 12741, 12743, 12745, 12746, 12750, 12751 12754, 12755, 12756, 12757, 12758, 12759, 12760, 12761, 12762, 12763, 12764, 12765 12766, 12767, 12768, 12769, 12770, 12773, 12784, 12785, 12787, 12788, 12790, 12793, 12795, 12799, 12804, 12806, 12807, 12808, 12811, 12813, 12814, 12824, 12829, 12831 12832, 12834, 12836, 12839, 12842, 12845, 12846, 12847, 12849, 12850, 12851, 12853 12855, 12859, 12860, 12864, 12865, 12869, 12874, 12875, 12878, 12885, 12890, 12893 12894, 12895, 12896, 12898, 12899, 12902, 12903, 12905, 12906, 12913, 12917, 12921 12922, 12923, 12924, 12925, 12928, 12930, 12933, 12934, 12937, 12938, 12944, 12945 12946, 12947, 12948, 12949, 12953, 12955, 12958, 12960, 12963, 12965, 12966, 12967 12968, 12972, 12973, 12974, 12975, 12976, 12977, 12978, 12979, 12981, 12982, 12983 12984, 12985, 12986, 12987, 12994, 12996, 12997, 12998, 12999, 13000, 13002, 13003 13004, 13006, 13007, 13008, 13009, 13010, 13011, 13012, 13014, 13019, 13020, 13021 13022, 13023, 13024, 13025, 13026, 13027, 13028, 13030, 13031, 13032, 13034, 13038 13039, 13040, 13041, 13043, 13045, 13046, 13052, 13053, 13055, 13056, 13057, 13058 13059, 13060, 13062, 13065, 13067, 13068, 13069, 13071, 13072, 13073, 13074, 13075 13076, 13077, 13078, 13079, 13094, 13096, 13098, 13105, 13106, 13107, 13108, 13109 13110, 13111, 13112, 13113, 13114, 13115, 13116, 13117, 13118, 13119, 13120, 13121 13122, 13123, 13124, 13125, 13126, 13127, 13128, 13129, 13130, 13131, 13132, 13133 13134, 13135, 13136, 13137, 13138, 13140, 13141, 13142, 13144, 13145, 13151, 13154 13155, 13157, 13158, 13159, 13160, 13163, 13178, 13199, 13201, 13208, 13210, 13211 13212, 13213, 13220, 13222, 13224, 13227, 13242, 13244, 13247, 13252, 13257, 13264 13269, 13270, 13271, 13272, 13274, 13276, 13277, 13279, 13287, 13288, 13290, 13305 13307, 13311, 13314, 13316, 13317, 13318, 13319, 13320, 13321, 13331, 13335, 13339 13340, 13341, 13342, 13343, 13344, 13345, 13347, 13356, 13359, 13360, 13361, 13363 13365, 13367, 13369, 13370, 13371, 13372, 13373, 13374, 13375, 13377, 13378, 13379, 13380, 13381, 13382, 13383, 13384, 13385, 13386, 13388, 13391, 13394, 13396, 13397 13398, 13405, 13411, 13416, 13419, 13423, 13428, 13429, 13430, 13432, 13433, 13434 13436, 13437, 13438, 13439, 13440, 13442, 13443, 13446, 13449, 13459, 13460, 13467, 13468, 13469, 13471, 13472, 13473, 13474, 13475, 13477, 13481, 13482, 13483, 13488, 13489, 13490, 13491, 13492, 13494, 13495, 13496, 13497, 13498, 13499, 13500, 13501, 13502, 13505, 13508, 13510, 13512, 13513, 13514, 13515, 13516, 13517, 13518, 13520, 13521, 13524, 13525, 13526, 13528, 13531, 13532, 13533, 13534, 13535, 13536, 13537, 13538, 13539, 13544, 13545, 13546, 13547, 13548, 13549, 13550, 13557, 13559, 13562, 13564, 13565, 13566, 13567, 13570, 13573, 13578, 13582, 13584, 13586, 13587, 13591, 13593, 13597, 13598, 13599, 13604, 13606, 13608, 13609, 13616, 13620, 13621, 13622, 13623, 13625, 13626, 13627, 13628, 13629, 13630, 13631, 13632, 13633, 13635, 13638, 13639, 13640, 13641, 13642, 13644, 13647, 13653, 13654, 13656, 13657, 13658, 13666, 13667, 13668, 13672, 13674, 13675, 13676, 13677, 13678, 13679, 13680, 13681, 13682, 13683, 13688, 13689, 13690, 13694, 13696, 13697, 13699, 13702, 13707, 13709, 13710, 13711, 13712, 13715, 13716, 13717, 13719, 13726, 13728, 13730, 13733, 13734, 13739, 13741, 13742, 13749, 13754, 13755, 13757, 13760, 13761, 13766, 13767, 13768, 13769, 13773, 13776, 13778, 13780, 13783, 13788, 13790, 13791, 13792, 13793, 13794, 13795, 13796, 13797, 13798, 13799, 13800, 13803, 13804, 13805, 13806, 13807, 13808, 13809, 13810, 13815, 13816, 13817, 13818, 13819, 13820, 13821, 13822, 13823, 13824, 13825, 13826, 13827, 13828, 13833, 13834, 13836, 13846, 13847, 13849, 13850, 13861, 13862, 13863, 13864, 13865, 13866, 13869, 13871, 13876, 13890, 13892, 13896, 13900, 13906, 13908, 13909, 13911, 13912, 13914, 13916, 13919, 13921, 13926, 13929, 13932, 13936, 13937, 13940, 13942, 13944, 13950, 13953, 13961, 13962, 13963, 13968, 13969, 13971, 13974, 13975, 13976, 13979, 13984, 13988, 13989, 13990, 13991, 13992, 13993, 13994, 13995, 13996, 14000, 14002, 14003, 14005, 14007, 14008, 14009, 14010, 14013, 14016, 14022, 14023, 14025, 14026, 14027, 14028, 14029, 14033, 14035, 14036, 14041, 14045, 14046, 14049, 14050, 14053, 14057, 14058, 14059, 14060, 14061, 14062, 14063, 14065, 14067, 14069, 14073, 14074, 14075, 14076, 14079, 14082, 14083, 14084, 14086, 14090, 14091, 14092, 14096, 14097, 14100, 14101, 14103, 14107, 14111, 14112, 14113, 14115, 14116, 14120, 14124, 14127, 14128, 14130, 14133, 14135, 14139, 14140, 14142, 14148, 14149, 14151, 14153, 14155, 14157, 14158, 14159, 14162, 14163, 14164, 14166, 14167, 14168, 14169, 14170, 14171, 14172, 14173, 14174, 14175, 14176, 14178, 14179, 14180, 14182, 14184, 14185, 14186, 14187, 14188, 14189, 14190, 14191, 14192, 14193, 14195, 14198, 14201 14205, 14208, 14209, 14211, 14217, 14218, 14219, 14220, 14221, 14222, 14223, 14225 14228, 14230, 14231, 14234, 14235, 14236, 14237, 14240, 14241, 14243, 14244, 14245 14246, 14247, 14248, 14249, 14250, 14251, 14253, 14254, 14255, 14257, 14258, 14260 14263, 14264, 14268, 14269, 14270, 14273, 14274, 14276, 14279, 14280, 14281, 14283 14285, 14288, 14290, 14291, 14293, 14294, 14297, 14298, 14299, 14301, 14302, 14303 14304, 14311, 14313, 14314, 14315, 14319, 14320, 14321, 14325, 14328, 14331, 14332 14337, 14338, 14339, 14340, 14345, 14351, 14352, 14353, 14354, 14355, 14357, 14358 14361, 14363, 14364, 14366, 14367, 14370, 14371, 14372, 14373, 14379, 14388, 14389 14390, 14394, 14396, 14397, 14399, 14400, 14402, 14407, 14408, 14409, 14410, 14415 14417, 14418, 14420, 14422, 14424, 14425, 14426, 14427, 14428, 14429, 14430, 14431 14432, 14433, 14434, 14435, 14436, 14437, 14439, 14440, 14441, 14442, 14444, 14446 14447, 14448, 14449, 14450, 14451, 14452, 14454, 14455, 14456, 14457, 14458, 14459 14460, 14461, 14462, 14463, 14464, 14465, 14466, 14468, 14473, 14474, 14475, 14476 14478, 14479, 14488, 14490, 14491, 14492, 14493, 14494, 14495, 14496, 14497, 14498 14499, 14500, 14501, 14502, 14503, 14504, 14505, 14506, 14507, 14508, 14509, 14511 14512, 14517, 14519, 14524, 14527, 14530, 14532, 14536, 14537, 14538, 14541, 14547 14551, 14553, 14556, 14557, 14558, 14560, 14561, 14564, 14571, 14580, 14581, 14586 14588, 14589, 14593, 14594, 14595, 14596, 14597, 14601, 14603, 14604, 14607, 14609 14611, 14612, 14613, 14614, 14615, 14617, 14618, 14619, 14620, 14621, 14623, 14625 14626, 14629, 14630, 14631, 14634, 14635, 14638, 14641, 14642, 14643, 14644, 14645 14646, 14647, 14651, 14652, 14653, 14654, 14655, 14656, 14660, 14661, 14662, 14663 14664, 14674, 14676, 14677, 14680, 14681, 14683, 14686, 14689, 14692, 14693, 14699 14701, 14704, 14705, 14706, 14707, 14708, 14709, 14710, 14711, 14713, 14714, 14715 14716, 14718, 14719, 14720, 14722, 14723, 14725, 14731, 14732, 14735, 14737, 14738 14739, 14742, 14744, 14745, 14748, 14751, 14752, 14753, 14757, 14758, 14760, 14761 14764, 14765, 14766, 14768, 14769, 14770, 14771, 14772, 14773, 14774, 14775, 14776 14777, 14780, 14784, 14785, 14793, 14795, 14798, 14799, 14800, 14801, 14802, 14803 14804, 14805, 14806, 14808, 14811, 14812, 14815, 14817, 14818, 14823, 14824, 14825 14826, 14828, 14829, 14831, 14833, 14835, 14838, 14839, 14840, 14841, 14844, 14846 14847, 14848, 14851, 14853, 14855, 14857, 14859, 14860, 14865, 14867, 14873, 14874 14876, 14879, 14880, 14885, 14886, 14887, 14890, 14893, 14898, 14899, 14900, 14901, 14902, 14903, 14904, 14911, 14912, 14913, 14914, 14915, 14916, 14918, 14919, 14920, 14921, 14922, 14923, 14933, 14934, 14935, 14936, 14949, 14950, 14952, 14953, 14955, 14958, 14962, 14963, 14964, 14965, 14966, 14967, 14970, 14975, 14976, 14978, 14979, 14980, 14981, 14982, 14983, 14984, 14985, 14986, 14988, 14989, 14990, 14991, 14993, 14994, 14999, 15000, 15001, 15002, 15003, 15004, 15005, 15007, 15008, 15009, 15010, 15013, 15015, 15016, 15017, 15018, 15019, 15022, 15028, 15029, 15031, 15032, 15034, 15035, 15036, 15037, 15038, 15040, 15041, 15042, 15045, 15046, 15047, 15048, 15049, 15055, 15056, 15057, 15064, 15068, 15069, 15073, 15074, 15078, 15079, 15080, 15081, 15082, 15092, 15099, 15100, 15102, 15103, 15107, 15110, 15111, 15113, 15114, 15116, 15117, 15118, 15119, 15120, 15122, 15123, 15125, 15126, 15127, 15131, 15134, 15138, 15139, 15143, 15144, 15146, 15147, 15148, 15149, 15150, 15151, 15152, 15154, 15155, 15156, 15157, 15159, 15161, 15164, 15166, 15167, 15168, 15173, 15175, 15176, 15177, 15178, 15180, 15181, 15182, 15187, 15188, 15189, 15190, 15193, 15198, 15199, 15200, 15201, 15202, 15203, 15205, 15208, 15210, 15212, 15213, 15214, 15215, 15218, 15219, 15220, 15221, 15222, 15223, 15224, 15226, 15227, 15228, 15229, 15231, 15236, 15237, 15239, 15240, 15241, 15242, 15243, 15244, 15246, 15247, 15252, 15263, 15266, 15267, 15270, 15271, 15272, 15273, 15274, 15275, 15276, 15278, 15279, 15281, 15282, 15284, 15285, 15286, 15288, 15289, 15291, 15292, 15294, 15295, 15296, 15298, 15300, 15302, 15303, 15305, 15306, 15307, 15308, 15309, 15310, 15311, 15313, 15314, 15315, 15317, 15318, 15320, 15321, 15322, 15323, 15324, 15326, 15327, 15328, 15332, 15333, 15334, 15335, 15336, 15337, 15339, 15340, 15341, 15342, 15344, 15346, 15349, 15350, 15351, 15357, 15358, 15359, 15363, 15364, 15365, 15366, 15367, 15368, 15369, 15373, 15375, 15376, 15377, 15379, 15380, 15384, 15385, 15387, 15389, 15391, 15392, 15394, 15396, 15397, 15398, 15399, 15400, 15401, 15402, 15404, 15406, 15407, 15408, 15409, 15410, 15412, 15413, 15415, 15422, 15424, 15425, 15426, 15430, 15431, 15433, 15434, 15435, 15436, 15437, 15438, 15439, 15440, 15441, 15442, 15443, 15444, 15445, 15448, 15449, 15450, 15451, 15452, 15455, 15457, 15459, 15462, 15463, 15465, 15466, 15467, 15468, 15474, 15475, 15476, 15477, 15478, 15479, 15480, 15481, 15482, 15487, 15488, 15490, 15491, 15492, 15493, 15494, 15496, 15497, 15498, 15499, 15500, 15502, 15506, 15510, 15511, 15512, 15513, 15514, 15515, 15516, 15517, 15518, 15520, 15521, 15522, 15523, 15524, 15525, 15526, 15527, 15528, 15529, 15530, 15531, 15535, 15536, 15537, 15538, 15539, 15540, 15541, 15542, 15543, 15546, 15547, 15548, 15549, 15550, 15551, 15552, 15554, 15555, 15557, 15560, 15561, 15562, 15563, 15564, 15566, 15567, 15568, 15569, 15570, 15571, 15572, 15573, 15574, 15575, 15576, 15577, 15580, 15581, 15583, 15591, 15594, 15595, 15596, 15597, 15598, 15600, 15608, 15609, 15611, 15613, 15614, 15615, 15616, 15617, 15618, 15619, 15621, 15622, 15624, 15625, 15626, 15627, 15629, 15631, 15632, 15633, 15634, 15636, 15637, 15638, 15641, 15642, 15643, 15644, 15645, 15646, 15647, 15648, 15650, 15651, 15659, 15660, 15661, 15662, 15663, 15664, 15667, 15668, 15670, 15671, 15672, 15674, 15675, 15678, 15681, 15682, 15687, 15688, 15691, 15693, 15705, 15719, 15722, 15724, 15725, 15732, 15733, 15735, 15737, 15745, 15746, 15750, 15756, 15763, 15765, 15766, 15767, 15768, 15770, 15771, 15776, 15781, 15782, 15789, 15790, 15792, 15794, 15795, 15796, 15797, 15805, 15807, 15808, 15810, 15811, 15813, 15814, 15815, 15816, 15818, 15819, 15820, 15821, 15824, 15826, 15827, 15828, 15829, 15831, 15832, 15836, 15838, 15839, 15841, 15842, 15843, 15844, 15847, 15849, 15850, 15851, 15853, 15854, 15855, 15856, 15857, 15858, 15859, 15863, 15866, 15867, 15868, 15870, 15871, 15872, 15873, 15874, 15875, 15876, 15877, 15878, 15879, 15880, 15881, 15883, 15884, 15885, 15886, 15887, 15888, 15889, 15890, 15892, 15896, 15899, 15900, 15902, 15904, 15905, 15906, 15907, 15919, 15920, 15923, 15924, 15928, 15929, 15930, 15932, 15933, 15935, 15936, 15938, 15943, 15945, 15946, 15950, 15952, 15954, 15956, 15960, 15961, 15969, 15973, 15974, 15977, 15979, 15985, 15990, 15991, 15992, 15994, 15995, 15997, 16000, 16001, 16003, 16004, 16005, 16006, 16007, 16008, 16019, 16022, 16023, 16024, 16025, 16028, 16029, 16033, 16035, 16036, 16037, 16041, 16049, 16050, 16051, 16056, 16059, 16060, 16061, 16062, 16068, 16076, 16077, 16082, 16083, 16084, 16087, 16088, 16091, 16092, 16095, 16097, 16098, 16101, 16102, 16103, 16104, 16105, 16106, 16108, 16111, 16112, 16114, 16115, 16116, 16117, 16120, 16122, 16125, 16126, 16128, 16129, 16130, 16131.

13151[000231] In one embodiment, the polypeptide of interest is an intracellular membrane protein. As a non-limiting example, the polynucleotides, primary constructs and/or mmR A may encode an intracellular membrane bound protein such as, but not limited to, any of SEQ ID NOs: 8166, 8167, 8168, 8169, 8171, 8173, 8174, 8176, 8199, 8205, 8206, 8207, 8210, 8220, 8221, 8222, 8271, 8277, 8278, 8279, 8297, 8303, 8306, 8324, 8326, 8334, 8336, 8337, 8429, 8443, 8483, 8484, 8485, 8486, 8487, 8491, 8492, 8493, 8494, 8502, 8503, 8507, 8590, 8591 8592, 8593, 8626, 8630, 8631, 8634 8673, 8674, 8675, 8677, 8679, 8681, 8682, 8690 8783, 8828, 8829, 8831, 8851, 8854 8863, 8865, 8935, 8945, 8986, 9021, 9082, 9098 9111, 9112, 9133, 9173, 9186, 9188 9189, 9199, 9200, 9201, 9202, 9214, 9238, 9239 9249, 9257, 9258, 9259, 9272, 9290 9302, 9317, 9320, 9368, 9369, 9384, 9385, 9386 9436, 9455, 9456, 9467, 9504, 9578 9582, 9589, 9593, 9594, 9595, 9596, 9599, 9626 9629, 9630, 9631, 9635, 9640, 9641 9643, 9644, 9646, 9683, 9719, 9720, 9721, 9723 9727, 9728, 9744, 9771, 9772, 9773 9774, 9778, 9779, 9781, 9786, 9819, 9823, 9824 9847, 9848, 9849, 9855, 9856, 9859 9879, 9885, 9886, 9887, 9888, 9889, 9953, 9956 9975, 9978, 9988, 9989, 9990, 9991 9992, 9995, 10026, 10059, 10070, 10073, 10074 10076, 10077, 10078, 10097, 10102 10103, 10112, 10113, 10114, 10115, 10147, 10153 10302, 10304, 10365, 10391, 10392 10413, 10414, 10416, 10417, 10434, 10444, 10447 10449, 10450, 10451, 10606, 10607 10629, 10630, 10633, 10634, 10635, 10636, 10647 10649, 10656, 10657, 10660, 10667 10668, 10669, 10671, 10672, 10695, 10708, 10712 10717, 10719, 10722, 10723, 10740 10741, 10742, 10745, 10781, 10809, 10869, 10893 10899, 10913, 10917, 10918, 10922 10953, 10984, 10986, 10987, 11056, 11226, 11227 11228, 11229, 11230, 11231, 11233 11234, 11235, 11236, 11237, 11253, 11682, 11683 11720, 11721, 11751, 11752, 11756 11757, 11758, 11759, 11760, 11761, 11766, 11813 11842, 11848, 11854, 11856, 11866 11867, 11868, 11869, 11870, 11872, 11877, 11923 11925, 11926, 11927, 11928, 11929 11933, 11989, 12002, 12003, 12004, 12005, 12006 12013, 12017, 12023, 12025, 12031 12055, 12108, 12142, 12144, 12145, 12720, 12723 12726, 12728, 12734, 12737, 12738 12739, 12740, 12774, 12775, 12776, 12777, 12778, 12780, 12782, 12783, 12796, 12817 12833, 12835, 12837, 12838, 12840, 12852, 12862 12870, 12888, 12889, 12914, 13047 13049, 13080, 13099, 13162, 13194, 13195, 13196 13197, 13198, 13202, 13203, 13204 13206, 13207, 13230, 13232, 13240, 13323, 13329 13330, 13348, 13349, 13351, 13352 13353, 13368, 13542, 13543, 13563, 13576, 13577 13650, 13651, 13652, 13744, 13746 13747, 13748, 13759, 13881, 13882, 13883, 13958 13959, 13973, 13978, 14018, 14021 14052, 14054, 14056, 14070, 14087, 14088, 14089 14094, 14102, 14104, 14105, 14106 14575, 14576, 14577, 14578, 14606, 14622, 14628 14665, 14666, 14669, 14673, 14746 14779, 14852, 14861, 14862, 14863, 14870, 14871 14872, 14924, 14925, 14926, 14927 14928, 14929, 14930, 14931, 14937, 14938, 14940 14942, 14943, 14944, 14947, 14960 14961, 14969, 14973, 14974, 14977, 15704, 15710, 15711, 15712, 15713, 15714, 15715, 15716, 15749, 15775, 15778, 15779, 15780, 15783, 15784, 15785, 15786, 15801, 15803, 15882, 15914, 15975, 15987, 16013, 16015, 16018, 16038, 16044, 16099.

13152[000232] In one embodiment, the polypeptide of interest is a plasma membrane protein or an intracellular membrane protein. As a non-limiting example, the polynucleotides, primary constructs and/or mmR A may encode a plasma membrane protein or an intracellular membrane protein such as, but not limited to, any of SEQ ID NOs: 8144- 16131.

13153Protein Cleavage Signals and Sites

13154[000233] In one embodiment, the polypeptides of the present invention may include at least one protein cleavage signal containing at least one protein cleavage site. The protein cleavage site may be located at the N-terminus, the C-terminus, at any space between the N- and the C- termini such as, but not limited to, half-way between the N- and C-termini, between the N-terminus and the half way point, between the half way point and the C-terminus, and combinations thereof.

13155[000234] The polypeptides of the present invention may include, but is not limited to, a proprotein convertase (or prohormone convertase), thrombin or Factor Xa protein cleavage signal. Proprotein convertases are a family of nine proteinases, comprising seven basic amino acid-specific subtilisin-like serine proteinases related to yeast kexin, known as prohormone convertase 1/3 (PC 1/3), PC2, furin, PC4, PC5/6, paired basic amino-acid cleaving enzyme 4 (PACE4) and PC7, and two other subtilases that cleave at non-basic residues, called subtilisin kexin isozyme 1 (SKI-1) and proprotein convertase subtilisin kexin 9 (PCSK9). Non-limiting examples of protein cleavage signal amino acid sequences are listing in Table 7. In Table 7, "X" refers to any amino acid, "n" may be 0, 2, 4 or 6 amino acids and "*" refers to the protein cleavage site. In Table 7, SEQ ID NO: 56140 refers to when n=4 and SEQ ID NO: 56141 refers to when n=6.

13156Table 7. Protein Cleavage Site Sequences

13157<img file="WO2013151663A1_D0023.tif" /> Thrombin L-V-P-R*-G-S 56142

13158L-V-P-R* 56143

13159A/F/G/I/L/TA^/M-A/F/G/I/L/TA^/W-P-R* 56144

13160Factor Xa I-E-G-R* 56145

13161I-D-G-R* 56146

13162A-E-G-R* 56147

13163A/F/G/I/L/T/V/M-D/E-G-R* 56148

13164[000235] In one embodiment, the primary constructs and the mmRNA of the present invention may be engineered such that the primary construct or mmRNA contains at least one encoded protein cleavage signal. The encoded protein cleavage signal may be located before the start codon, after the start codon, before the coding region, within the coding region such as, but not limited to, half way in the coding region, between the start codon and the half way point, between the half way point and the stop codon, after the coding region, before the stop codon, between two stop codons, after the stop codon and combinations thereof.

13165[000236] In one embodiment, the primary constructs or mmRNA of the present invention may include at least one encoded protein cleavage signal containing at least one protein cleavage site. The encoded protein cleavage signal may include, but is not limited to, a proprotein convertase (or prohormone convertase), thrombin and/or Factor Xa protein cleavage signal. One of skill in the art may use Table 1 above or other known methods to determine the appropriate encoded protein cleavage signal to include in the primary constructs or mmRNA of the present invention. For example, starting with the signal of Table 7 and considering the codons of Table 1 one can design a signal for the primary construct which can produce a protein signal in the resulting polypeptide.

13166[000237] In one embodiment, the polypeptides of the present invention include at least one protein cleavage signal and/or site.

13167[000238] As a non-limiting example, U.S. Pat. No. 7,374,930 and U.S. Pub. No.

1316820090227660, herein incorporated by reference in their entireties, use a furin cleavage site to cleave the N-terminal methionine of GLP-1 in the expression product from the Golgi apparatus of the cells. In one embodiment, the polypeptides of the present invention include at least one protein cleavage signal and/or site with the proviso that the polypeptide is not GLP-1.

13169[000239] In one embodiment, the primary constructs or mmRNA of the present invention includes at least one encoded protein cleavage signal and/or site.

13170[000240] In one embodiment, the primary constructs or mmRNA of the present invention includes at least one encoded protein cleavage signal and/or site with the proviso that the primary construct or mmRNA does not encode GLP-1.

13171[000241] In one embodiment, the primary constructs or mmRNA of the present invention may include more than one coding region. Where multiple coding regions are present in the primary construct or mmRNA of the present invention, the multiple coding regions may be separated by encoded protein cleavage sites. As a non-limiting example, the primary construct or mmRNA may be signed in an ordered pattern. On such pattern follows AXBY form where A and B are coding regions which may be the same or different coding regions and/or may encode the same or different polypeptides, and X and

13172Y are encoded protein cleavage signals which may encode the same or different protein cleavage signals. A second such pattern follows the form AXYBZ where A and B are coding regions which may be the same or different coding regions and/or may encode the same or different polypeptides, and X, Y and Z are encoded protein cleavage signals which may encode the same or different protein cleavage signals. A third pattern follows the form ABXCY where A, B and C are coding regions which may be the same or different coding regions and/or may encode the same or different polypeptides, and X and

13173Y are encoded protein cleavage signals which may encode the same or different protein cleavage signals.

13174[000242] In one embodiment, the polypeptides, primary constructs and mmRNA can also contain sequences that encode protein cleavage sites so that the polypeptides, primary constructs and mmRNA can be released from a carrier region or a fusion partner by treatment with a specific protease for said protein cleavage site.

13175[000243] In one embodiment, the polypeptides, primary constructs and mmRNA of the present invention may include a sequence encoding the 2A peptide. In one embodiment, this sequence may be used to separate the coding region of two or more polypeptides of interest. As a non-limiting example, the sequence encoding the 2A peptide may be between coding region A and coding region B (A-2Apep-B). The presence of the 2A peptide would result in the cleavage of one long protein into protein A, protein B and the 2A peptide. Protein A and protein B may be the same or different polypeptides of interest. In another embodiment, the 2A peptide may be used in the polynucleotides, primary constructs and/or mmR A of the present invention to produce two, three, four, five, six, seven, eight, nine, ten or more proteins.

13176Incorporating Post Transcriptional Control Modulators

13177[000244] In one embodiment, the polynucleotides, primary constructs and/or mmRNA of the present invention may include at least one post transcriptional control modulator. These post transcriptional control modulators may be, but are not limited to, small molecules, compounds and regulatory sequences. As a non-limiting example, post transcriptional control may be achieved using small molecules identified by PTC

13178Therapeutics Inc. (South Plainfield, NJ) using their GEMS™ (Gene Expression

13179Modulation by Small-Moleclues) screening technology.

13180[000245] The post transcriptional control modulator may be a gene expression modulator which is screened by the method detailed in or a gene expression modulator described in International Publication No. WO2006022712, herein incorporated by reference in its entirety. Methods identifying RNA regulatory sequences involved in translational control are described in International Publication No. WO2004067728, herein incorporated by reference in its entirety; methods identifying compounds that modulate untranslated region dependent expression of a gene are described in

13181International Publication No. WO2004065561, herein incorporated by reference in its entirety.

13182[000246] In one embodiment, the polynucleotides, primary constructs and/or mmRNA of the present invention may include at least one post transcriptional control modulator is located in the 5' and/or the 3' untranslated region of the polynucleotides, primary constructs and/or mmRNA of the present invention

13183[000247] In another embodiment, the polynucleotides, primary constructs and/or mmRNA of the present invention may include at least one post transcription control modulator to modulate premature translation termination. The post transcription control modulators may be compounds described in or a compound found by methods outlined in International Publication Nso. WO2004010106, WO2006044456, WO2006044682, WO2006044503 and WO2006044505, each of which is herein incorporated by reference in its entirety. As a non-limiting example, the compound may bind to a region of the 28S ribosomal RNA in order to modulate premature translation termination (See e.g., WO2004010106, herein incorporated by reference in its entirety).

13184[000248] In one embodiment, polynucleotides, primary constructs and/or mmRNA of the present invention may include at least one post transcription control modulator to alter protein expression. As a non-limiting example, the expression of VEGF may be regulated using the compounds described in or a compound found by the methods described in International Publication Nos. WO2005118857, WO2006065480,

13185WO2006065479 and WO2006058088, each of which is herein incorporated by reference in its entirety.

13186[000249] The polynucleotides, primary constructs and/or mmRNA of the present invention may include at least one post transcription control modulator to control translation. In one embodiment, the post transcription control modulator may be a RNA regulatory sequence. As a non-limiting example, the RNA regulatory sequence may be identified by the methods described in International Publication No. WO2006071903, herein incorporated by reference in its entirety.

13187III. Modifications

13188[000250] Herein, in a polynucleotide (such as a primary construct or an mRNA molecule), the terms "modification" or, as appropriate, "modified" refer to modification with respect to A, G, U or C ribonucleotides. Generally, herein, these terms are not intended to refer to the ribonucleotide modifications in naturally occurring 5 '-terminal mRNA cap moieties. In a polypeptide, the term "modification" refers to a modification as compared to the canonical set of 20 amino acids, moiety)

13189[000251] The modifications may be various distinct modifications. In some

13190embodiments, the coding region, the flanking regions and/or the terminal regions may contain one, two, or more (optionally different) nucleoside or nucleotide modifications. In some embodiments, a modified polynucleotide, primary construct, or mmRNA introduced to a cell may exhibit reduced degradation in the cell, as compared to an unmodified polynucleotide, primary construct, or mmRNA. [000252] The polynucleotides, primary constructs, and mmRNA can include any useful modification, such as to the sugar, the nucleobase, or the internucleoside linkage (e.g. to a linking phosphate / to a phosphodiester linkage / to the phosphodiester backbone). One or more atoms of a pyrimidine nucleobase may be replaced or substituted with optionally substituted amino, optionally substituted thiol, optionally substituted alkyl (e.g., methyl or ethyl), or halo (e.g., chloro or fluoro). In certain embodiments, modifications (e.g., one or more modifications) are present in each of the sugar and the internucleoside linkage. Modifications according to the present invention may be modifications of ribonucleic acids (RNAs) to deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs) or hybrids thereof). Additional modifications are described herein.

13191[000253] As described herein, the polynucleotides, primary constructs, and mmRNA of the invention do not substantially induce an innate immune response of a cell into which the mRNA is introduced. Featues of an induced innate immune response include 1) increased expression of pro-inflammatory cytokines, 2) activation of intracellular PRRs (RIG-I, MDA5, etc, and/or 3) termination or reduction in protein translation.

13192[000254] In certain embodiments, it may desirable to intracellularly degrade a modified nucleic acid molecule introduced into the cell. For example, degradation of a modified nucleic acid molecule may be preferable if precise timing of protein production is desired. Thus, in some embodiments, the invention provides a modified nucleic acid molecule containing a degradation domain, which is capable of being acted on in a directed manner within a cell. In another aspect, the present disclosure provides polynucleotides comprising a nucleoside or nucleotide that can disrupt the binding of a major groove interacting, e.g. binding, partner with the polynucleotide (e.g., where the modified nucleotide has decreased binding affinity to major groove interacting partner, as compared to an unmodified nucleotide).

13193[000255] The polynucleotides, primary constructs, and mmRNA can optionally include other agents (e.g., RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNA, tRNA, RNAs that induce triple helix formation, aptamers, vectors, etc.). In some embodiments, the polynucleotides, primary constructs, or mmRNA may include one or more messenger RNAs (mRNAs) and one or more modified nucleoside or nucleotides (e.g., mmR A molecules). Details for these polynucleotides, primary constructs, and mmRNA follow.

13194Polynucleotides and Primary Constructs

13195[000256] The polynucleotides, primary constructs, and mmRNA of the invention includes a first region of linked nucleosides encoding a polypeptide of interest, a first flanking region located at the 5' terminus of the first region, and a second flanking region located at the 3' terminus of the first region.

13196[000257] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (la) or Formula (Ia-1):

13197<img file="WO2013151663A1_D0024.tif" /> a) or a pharmaceutically acceptable salt or stereoisomer thereof,

13198[000258] wherein

13199[000259] U is O, S, N(Ru)nu, or C(Ru)nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl;

13200[000260] — is a single bond or absent;

13201[000261] each of R1', R2 , R1", R2", R1, R2, R3, R4, and R5 is, independently, if present, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl,or absent; wherein the combination of R3 with one or more of Rl ', Rl", R2', R2", or R5 (e.g., the combination of Rl ' and R3, the combination of Rl" and R3, the combination of R2' and R3, the combination of R2" and R3, or the combination of R5 and R3) can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); wherein the combination of R5 with one or more of Rl ', Rl", R2', or R2" (e.g., the combination of Rl ' and R5, the combination of Rl" and R5, the combination of R2' and R5, or the combination of R2" and R5) can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); and wherein the

132024 1 ' 1" 2' 2" 3 5

13203combination of R and one or more of R , R , R , R , R , or R can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl);each of m' and m" is, independently, an integer from 0 to 3 (e.g., from 0 to 2, from 0 to 1, from 1 to 3, or from 1 to 2);

13204[000262] each of Y1, Y2, and Y3, is, independently, O, S, Se, -NRN1-, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent;

13205[000263] each Y4 is, independently, H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

13206[000264] each Y5 is, independently, O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

13207[000265] n is an integer from 1 to 100,000; and

13208[000266] B is a nucleobase (e.g., a purine, a pyrimidine, or derivatives thereof), wherein the combination of B and R1 , the combination of B and R2 , the combination of B and R1 , or the combination of B and R2 can, taken together with the carbons to which they are attached, optionally form a bicyclic group (e.g., a bicyclic heterocyclyl) or wherein the combination of B, R1 , and R3 or the combination of B, R2 , and R3 can optionally form a tricyclic or tetracyclic group (e.g., a tricyclic or tetracyclic heterocyclyl, such as in Formula (IIo)-(IIp) herein). In some embodiments, the polynucleotide, primary construct, or mmRNA includes a modified ribose. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (Ia-2)- -5) or a pharmaceutically acceptable salt or stereoisomer thereof.

13209<img file="WO2013151663A1_D0025.tif" />

13210[000267] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (lb) or Formula (Ib-1):

13211<img file="WO2013151663A1_D0026.tif" /> ) or a pharmaceutically acceptable salt or stereoisomer thereof,

13212[000268] wherein [000269] U is O, S, N(R )nu, or C(R )nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl;

13213[000270] — is a single bond or absent;

13214[000271] each of R1, R3 , R3 , and R4 is, independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; and wherein the combination of R1 and R3 or the combination of R1 and R3 can be taken together to form optionally substituted alkylene or optionally substituted heteroalkylene (e.g., to produce a locked nucleic acid);

13215[000272] each R5 is, independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, or absent;

13216[000273] each of Y1, Y2, and Y3 is, independently, O, S, Se, -NRN1-, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl;

13217[000274] each Y4 is, independently, H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

13218[000275] n is an integer from 1 to 100,000; and

13219[000276] B is a nucleobase.

13220[000277] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (Ic):

13221<img file="WO2013151663A1_D0027.tif" /> (Ic), or a pharmaceutically acceptable salt or stereoisomer thereof,

13222[000278] wherein

13223[000279] U is O, S, N(Ru)nu, or C(Ru)nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl;

13224[000280] — is a single bond or absent;

13225[000281] each of B1, B2, and B3 is, independently, a nucleobase (e.g., a purine, a pyrimidine, or derivatives thereof, as described herein), H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl, wherein one and only one of B1, B2, and B3 is a nucleobase;

13226[000282] each of Rbl, Rb2, Rb3, R3, and R5 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl or optionally substituted aminoalkynyl;

13227[000283] each of Y1, Y2, and Y3, is, independently, O, S, Se, -NRN1-, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl;

13228[000284] each Y4 is, independently, H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted ammo;

13229[000285] each Y5 is, independently, O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

13230[000286] n is an integer from 1 to 100,000; and

13231[000287] wherein the ring including U can include one or more double bonds.

13232[000288] In particular embodiments, the ring including U does not have a double bond between U-CB3Rb3 or between CB3Rb3-CB2Rb2.

13233[000289] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number f linked nucleosides having Formula (Id):

13234<img file="WO2013151663A1_D0028.tif" /> (Id), or a pharmaceutically acceptable salt or stereoisomer thereof,

13235[000290] wherein

13236[000291] U is O, S, N(Ru)nu, or C(Ru)nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl;

13237[000292] each R3 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl;

13238[000293] each of Y1, Y2, and Y3, is, independently, O, S, Se, -NRN1-, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl; [000294] each Y4 is, independently, H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

13239[000295] each Y5 is, independently, O, S, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

13240[000296] n is an integer from 1 to 100,000; and

13241[000297] B is a nucleobase (e.g., a purine, a pyrimidine, or derivatives thereof).

13242[000298] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (Ie):

13243<img file="WO2013151663A1_D0029.tif" /> (Ie), or a pharmaceutically acceptable salt or stereoisomer thereof,

13244[000299] wherein

13245[000300] each of U' and U" is, independently, O, S, N(Ru)nu, or C(Ru)nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl;

13246[000301] each R6 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl;

13247[000302] each Y5 is, independently, O, S, optionally substituted alkylene (e.g., methylene or ethylene), or optionally substituted heteroalkylene;

13248[000303] n is an integer from 1 to 100,000; and

13249[000304] B is a nucleobase (e.g., a purine, a pyrimidine, or derivatives thereof). [000305] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (If) or (If- 1):

13250<img file="WO2013151663A1_D0030.tif" /> or a pharmaceutically acceptable salt or stereoisomer thereof,

13251[000306] wherein

13252[000307] each of U' and U" is, independently, O, S, N, N(Ru)nu, or C(Ru)nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl (e.g., U' is O and U" is N);

13253[000308] — is a single bond or absent;

13254[000309] each of R1', R2 , R1", R2", R3, and R4 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; and wherein the combination of R1 and R3, the combination of R1 and R3, the combination of R2 and R3, or the combination of R2 and R3 can be taken together to form optionally substituted alkylene or optionally substituted heteroalkylene (e.g., to produce a locked nucleic acid);each of m' and m" is, independently, an integer from 0 to 3 (e.g., from 0 to 2, from 0 to 1, from 1 to 3, or from 1 to 2);

13255[000310] each of Y1, Y2, and Y3, is, independently, O, S, Se, -NRN1-, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent; [000311] each Y4 is, independently, H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

13256[000312] each Y5 is, independently, O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

13257[000313] n is an integer from 1 to 100,000; and

13258[000314] B is a nucleobase (e.g., a purine, a pyrimidine, or derivatives thereof).

13259[000315] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (la), (Ia-l)-(Ia-3), (Ib)-(If), and (Ila)-(IIp)), the ring including U has one or two double bonds.

13260[000316] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), each of R1, R1', and R1", if present, is H. In further embodiments, each of R2, R2 , and R2 , if present, is, independently, H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In particular embodiments, alkoxyalkoxy is - (CH2)s2(OCH2CH2)si(CH2)s30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl). In some embodiments, s2 is 0, si is 1 or 2, s3 is 0 or 1, and R' is Ci_6 alkyl.

13261[000317] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), each of R2, R2', and R2", if present, is H. In further embodiments, each of R1, R1 , and R1 , if present, is, independently, H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In particular embodiments, alkoxyalkoxy is - (CH2)s2(OCH2CH2)si(CH2)s30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl). In some embodiments, s2 is 0, si is 1 or 2, s3 is 0 or 1 , and R' is Ci_6 alkyl.

13262[000318] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), each of R3, R4, and R5 is, independently, H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In particular embodiments, R3 is H, R4 is H, R5 is H, or R3, R4, and R5 are all H. In particular embodiments, R is Ci_ 6 alkyl, R4 is Ci_6 alkyl, R5 is Ci_6 alkyl, or R3, R4, and R5 are all Ci_6 alkyl. In particular embodiments, R3 and R4 are both H, and R5 is Ci_6 alkyl.

13263[000319] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), R3 and R5 join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl, such as trans-3',4' analogs, wherein R3 and R5 join together to form heteroalkylene (e.g., -(CH2)biO(CH2)b20(CH2)b3-, wherein each of bl , b2, and b3 are, independently, an integer from 0 to 3).

13264[000320] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), R3 and one or more of R1 ', R1", R2 , R2", or R5 join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl, R3 and one or more of R1 , R1 , R2 , R2 , or R5 join together to form heteroalkylene (e.g., - (CH2)biO(CH2)b20(CH2)b3-, wherein each of bl , b2, and b3 are, independently, an integer from 0 to 3).

13265[000321] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), R5 and one or more of R1 ', R1", R2', or R2" join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl, R5 and one or more of R1 , R1 , R2 , or R2 join together to form heteroalkylene (e.g., - (CH2)biO(CH2)b20(CH2)b3-, wherein each of bl, b2, and b3 are, independently, an integer from 0 to 3).

13266[000322] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), each Y2 is, independently, O, S, or -NRN1-, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl. In particular embodiments, Y2 is NRN1-, wherein RN1 is H or optionally substituted alkyl (e.g., Ci_6 alkyl, such as methyl, ethyl, isopropyl, or n-propyl).

13267[000323] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), each Y3 is, independently, O or S.

13268[000324] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), R1 is H; each R2 is, independently, H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy (e.g., -(CH2)s2(OCH2CH2)si(CH2)S30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, such as wherein s2 is 0, si is 1 or 2, s3 is 0 or 1, and R' is Ci_6 alkyl); each Y2 is, independently, O or -NRN1-, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein RN1 is H or optionally substituted alkyl (e.g., Ci_ 6 alkyl, such as methyl, ethyl, isopropyl, or n-propyl)); and each Y3 is, independently, O or S (e.g., S). In further embodiments, R3 is H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In yet further embodiments, each Y1 is , independently, O or - NRN1-, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein R is H or optionally substituted alkyl (e.g., Ci_6 alkyl, such as methyl, ethyl, isopropyl, or n- propyl)); and each Y4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino.

13269[000325] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), each R1 is, independently, H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy (e.g., -(CH2)s2(OCH2CH2)si(CH2)s30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, such as wherein s2 is 0, si is 1 or 2, s3 is 0 or 1, and R' is Ci_6 alkyl); R2 is H; each Y2 is, independently, O or -NRN1-, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein RN1 is H or optionally substituted alkyl (e.g., Ci_ 6 alkyl, such as methyl, ethyl, isopropyl, or n-propyl)); and each Y3 is, independently, O or S (e.g., S). In further embodiments, R3 is H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In yet further embodiments, each Y1 is , independently, O or - NRN1-, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein RN1 is H or optionally substituted alkyl (e.g., Ci_6 alkyl, such as methyl, ethyl, isopropyl, or n- propyl)); and each Y4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino.

13270[000326] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), the ring including U is in the β-D (e.g., β-D-ribo) configuration. [000327] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), the ring including U is in the a-L (e.g., a-L-ribo) configuration.

13271[000328] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), one or more B is not pseudouridine (ψ) or 5- methyl-cytidine (m5C). In some embodiments, about 10% to about 100% of n number of B nucleobases is not ψ or m5C (e.g., from 10%> to 20%>, from 10%> to 35%, from 10%> to 50%, from 10% to 60%, from 10% to 75%, from 10% to 90%, from 10% to 95%, from 10% to 98%, from 10% to 99%, from 20% to 35%, from 20% to 50%, from 20% to 60%, from 20% to 75%, from 20% to 90%, from 20% to 95%, from 20% to 98%, from 20% to 99%, from 20% to 100%, from 50% to 60%, from 50% to 75%, from 50% to 90%, from 50% to 95%, from 50% to 98%, from 50% to 99%, from 50% to 100%, from 75% to 90%, from 75% to 95%, from 75% to 98%, from 75% to 99%, and from 75% to 100% of n number of B is not ψ or m5C). In some embodiments, B is not ψ or m5C.

13272[000329] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-l), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), when B is an unmodified nucleobase selected from cytosine, guanine, uracil and adenine, then at least one of Y1, Y2, or Y3 is not O.

13273[000330] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a modified ribose. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (Ila)-(IIc):

13274<img file="WO2013151663A1_D0031.tif" /> (He), or a pharmaceutically acceptable salt or stereoisomer thereof. In particular embodiments, U is O or C(R )nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl (e.g., U is -CH2- or -CH-). In other embodiments, each of R1, R2, R3, R4, and R5 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R1 and R2 is, independently, H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy; each R3 and R4 is, independently, H or optionally substituted alkyl; and R5 is H or hydroxy), and is a single bond or double bond.

13275[000331] In particular embodiments, the polynucleotidesor mmRNA includes n number of linked nucleosides having Formula (lib- 1 )-(IIb -2) : <img file="WO2013151663A1_D0032.tif" /> or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, U is O or C(R )nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl (e.g., U is -CH2- or -CH-). In other embodiments, each of R1 and R2 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R1 and R2 is, independently, H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy, e.g., H, halo, hydroxy, alkyl, or alkoxy). In particular embodiments, R2 is hydroxy or optionally substituted alkoxy (e.g., methoxy, ethoxy, or any described herein).

13276[000332] In particular embodiments, the polynucleotide, primary construct, or mmRNA includes n number of linked nucleosides having Formula (IIc-l)-(IIc-4):

13277<img file="WO2013151663A1_D0033.tif" /> (IIc-3), or (IIc-4), or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, U is O or C(Ru)nu, wherein nu is an integer from 0 to 2 and each Ru is, independently, H, halo, or optionally substituted alkyl (e.g., U is -CH2- or -CH-). In some embodiments, each of R1, R2, and R3 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R1 and R2 is, independently, H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy, e.g., H, halo, hydroxy, alkyl, or alkoxy; and each R3 is, independently, H or optionally substituted alkyl)). In particular embodiments, R2 is optionally substituted alkoxy (e.g., methoxy or ethoxy, or any described herein). In particular embodiments, R1 is optionally substituted alkyl, and R2 is hydroxy. In other embodiments, R1 is hydroxy, and R2 is optionally substituted alkyl. In further embodiments, R3 is optionally substituted alkyl.

13278[000333] In some embodiments, the polynucleotide, primary construct, or mmRNA includes an acyclic modified ribose. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (Ild)-(IIf): <img file="WO2013151663A1_D0034.tif" />

13279(Ilf), or a pharmaceutically acceptable salt or stereoisomer thereof.

13280[000334] In some embodiments, the polynucleotide, primary construct, or mmRNA includes an acyclic modified hexitol. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flankin re ion includes n number of linked nucleosides Formula Il - IIj):

13281<img file="WO2013151663A1_D0035.tif" /> pharmaceutically acceptable salt or stereoisomer thereof.

13282[000335] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a sugar moiety having a contracted or an expanded ribose ring. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula

13283(Ilk)-(IIm):

13284<img file="WO2013151663A1_D0036.tif" /> (IIm),or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each of R1 , R1 , R2 , and R2 is, independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, or absent; and wherein the combination of R2 and R3 or the combination of R2 and R3 can be taken together to form optionally substituted alkylene or optionally substituted heteroalkylene.

13285[000336] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a locked modified ribose. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flankin region) includes n number of linked nucleosides having Formula (Iln):

13286<img file="WO2013151663A1_D0037.tif" /> (Iln), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R3 is O, S, or -NRN1-, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl and R is optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-) or optionally substituted heteroalkylene (e.g., -CH2NH-, -CH2CH2NH-, -CH2OCH2-, or - CH2CH2OCH2-)(e.g., R3 is O and R3 is optionally substituted alkylene (e.g., -CH2-, - CH2CH2-, or -CH2CH2CH2-)).

13287[000337] In some embodiments, the polynucleotide, primary construct, or mmRNA in ludes n number of linked nucleo ides having Formula (IIn-l)-(II-n2):

13288<img file="WO2013151663A1_D0038.tif" />

13289pharmaceutically acceptable salt or stereoisomer thereof, wherein R3 is O, S, or -NRN1- wherein R is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl and R3 is optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-) or optionally substituted

13290heteroalkylene (e.g., -CH2NH-, -CH2CH2NH-, -CH2OCH2-, or -CH2CH2OCH2-) (e.g., R3' is O and R3 is optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-

13291))·

13292[000338] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a locked modified ribose that forms a tetracyclic heterocyclyl. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (Ho):

13293<img file="WO2013151663A1_D0039.tif" />

13294pharmaceutically acceptable salt or stereoisomer thereof, wherein R12a, R12c, T1 , T1 ,T2 , T2", V1, and V3 are as described herein.

13295[000339] Any of the formulas for the polynucleotides, primary constructs, or mmRNA can include one or more nucleobases described herein (e.g., Formulas (bl)-(b43)).

13296[000340] In one embodiment, the present invention provides methods of preparing a polynucleotide, primary construct, or mmRNA, wherein the polynucleotide comprises n number of nucleosides h

13297the method comprising r as defined herein:

13298<img file="WO2013151663A1_D0040.tif" /> , with an RNA polymerase, and a cDNA template. [000341] In a further embodiment, the present invention provides methods of amplifying a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., mmRNA molecule), the method comprising: reacting a compound of Formula (Ilia), as defined herein, with a primer, a cDNA template, and an RNA polymerase.

13299[000342] In one embodiment, the present invention provides methods of preparing a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., mmRNA molecule), wherein the polynucleotide comprises n number of nucleosides having Formula (la), as defined herein:

13300<img file="WO2013151663A1_D0041.tif" /> (Ia-l),

13301the method comprising reacting a compound of Formula (IIIa-1), as defined herein:

13302<img file="WO2013151663A1_D0042.tif" /> with an RNA polymerase, and a cDNA template.

13303[000343] In a further embodiment, the present invention provides methods of amplifying a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., mmRNA molecule), the method comprising:

13304[000344] reacting a compound of Formula (IIIa-1), as defined herein, with a primer, a cDNA template, and an RNA polymerase. [000345] In one embodiment, the present invention provides methods of preparing a modified mRNA comprising at least one nucleotide (e.g., mmRNA molecule), wherein the polynucleotide comprises n number of nucleosides having Formula (Ia-2), as defined herein:

13305<img file="WO2013151663A1_D0043.tif" />

13306the method comprising reacting a compound of Formula (IIIa-2), as defined herein:

13307<img file="WO2013151663A1_D0044.tif" /> (IIIa-2),

13308with an RNA polymerase, and a cDNA template.

13309[000346] In a further embodiment, the present invention provides methods of amplifying a modified mRNA comprising at least one nucleotide (e.g., mmRNA molecule), the method comprising:

13310[000347] reacting a compound of Formula (IIIa-2), as defined herein, with a primer, a cDNA template, and an RNA polymerase.

13311[000348] In some embodiments, the reaction may be repeated from 1 to about 7,000 times. In any of the embodiments herein, B may be a nucleobase of Formula (bl)-(b43).

13312[000349] The polynucleotides, primary constructs, and mmRNA can optionally include 5' and/or 3' flanking regions, which are described herein. Modified RNA (mmRNA) Molecules

13313[000350] The present invention also includes building blocks, e.g., modified ribonucleosides, modified ribonucleotides, of modified RNA (mmRNA) molecules. For example, these building blocks can be useful for preparing the polynucleotides, primary constructs, or mmRNA of the invention.

13314In some embodiments, the building block molecule has Formula (Ilia) or (IIIa-1):

13315<img file="WO2013151663A1_D0045.tif" />

13316pharmaceutically acceptable salt or stereoisomer thereof, wherein the substituents are as described herein (e.g., for Formula (la) and (Ia-1)), and wherein when B is an unmodified nucleobase selected from cytosine, guanine, uracil and adenine, then at least one of Y1,

13317Y2, or Y3 is not O.

13318[000351] In some embodiments, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, has Formula (IVa)-

13319<img file="WO2013151663A1_D0046.tif" /> (IVa) or (IVb), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (bl)-(b43)). In particular embodiments, Formula (IVa) or (IVb) is combined with a modified uracil (e.g., any one of formulas (bl)-(b9), (b21)-(b23), and (b28)-(b31), such as formula (bl), (b8), (b28), (b29), or (b30)). In particular embodiments, Formula (IVa) or (IVb) is combined with a modified cytosine (e.g., any one of formulas (bl0)-(bl4), (b24), (b25), and (b32)-(b36), such as formula (blO) or (b32)). In particular

13320embodiments, Formula (IVa) or (IVb) is combined with a modified guanine (e.g., any one of formulas (bl5)-(bl7) and (b37)-(b40)). In particular embodiments, Formula (IVa) or (IVb) is combined with a modified adenine (e.g., any one of formulas (bl8)-(b20) and (b41)-(b43)).

13321[000352] In some embodiments, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, has Formula (IVc)-

13322<img file="WO2013151663A1_D0047.tif" /><img file="WO2013151663A1_D0048.tif" />

13323HO CI (IVk), or HO I (IVl), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (bl)-(b43)). In particular embodiments, one of Formulas (IVc)-(IVk) is combined with a modified uracil (e.g., any one of formulas (bl)-(b9), (b21)-(b23), and (b28)-(b31), such as formula (bl), (b8), (b28), (b29), or (b30)). In particular

13324embodiments, one of Formulas (IVc)-(IVk) is combined with a modified cytosine (e.g., any one of formulas (M0)-(bl4), (b24), (b25), and (b32)-(b36), such as formula (blO) or (b32)). In particular embodiments, one of Formulas (IVc)-(IVk) is combined with a modified guanine (e.g., any one of formulas (bl5)-(bl7) and (b37)-(b40)). In particular embodiments, one of Formulas (IVc)-(IVk) is combined with a modified adenine (e.g., any one of formulas (M8)-(b20) and (b41)-(b43)).

13325[000353] In other embodiments, the building block molecule, which may be

13326incorporated into a polynucleotide, primary construct, or mmR A, has Formula (Va) or

13327<img file="WO2013151663A1_D0049.tif" />

13328pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (bl)-(b43)).

13329[000354] In other embodiments, the building block molecule, which may be

13330incorporated into a polynucleotide, primary construct, or mmRNA, has Formula (IXa)- (IXd): <img file="WO2013151663A1_D0050.tif" /> , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (bl)-(b43)). In particular embodiments, one of Formulas (IXa)-(IXd) is combined with a modified uracil (e.g., any one of formulas (bl)-(b9), (b21)-(b23), and (b28)-(b31), such as formula (bl), (b8), (b28), (b29), or (b30)). In particular embodiments, one of Formulas (IXa)-(IXd) is combined with a modified cytosine (e.g., any one of formulas (M0)-(bl4), (b24), (b25), and (b32)-(b36), such as formula (blO) or (b32)). In particular embodiments, one of Formulas (IXa)-(IXd) is combined with a modified guanine (e.g., any one of formulas (bl5)-(bl7) and (b37)-(b40)). In particular embodiments, one of Formulas (IXa)-(IXd) is combined with a modified adenine (e.g., any one of formulas (M8)-(b20) and (b41)-(b43)).

13331[000355] In other embodiments, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmR A, has Formula (IXe)-

13332(IXg):

13333<img file="WO2013151663A1_D0051.tif" /> (IXg), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (bl)-(b43)). In particular embodiments, one of Formulas (IXe)-(IXg) is combined with a modified uracil (e.g., any one of formulas (bl)-(b9), (b21)-(b23), and (b28)-(b31), such as formula (bl), (b8), (b28), (b29), or (b30)). In particular embodiments, one of Formulas (IXe)-(IXg) is combined with a modified cytosine (e.g., any one of formulas (M0)-(bl4), (b24), (b25), and (b32)-(b36), such as formula (blO) or (b32)). In particular embodiments, one of Formulas (IXe)-(IXg) is combined with a modified guanine (e.g., any one of formulas (bl5)-(bl7) and (b37)-(b40)). In particular embodiments, one of Formulas (IXe)-(IXg) is combined with a modified adenine (e.g., any one of formulas (M8)-(b20) and (b41)-

13334(b43)).

13335[000356] In other embodiments, the building block molecule, which may be

13336incorporated into a polynucleotide, primary construct, or mmRNA, has Formula (IXh)-

13337(IXk):

13338<img file="WO2013151663A1_D0052.tif" /> or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (bl)-(b43)). In particular embodiments, one of Formulas (IXh)-(IXk) is combined with a modified uracil (e.g., any one of formulas (bl)-(b9), (b21)-(b23), and (b28)-(b31), such as formula (bl), (b8), (b28), (b29), or (b30)). In particular

13339embodiments, one of Formulas (IXh)-(IXk) is combined with a modified cytosine (e.g., any one of formulas (M0)-(bl4), (b24), (b25), and (b32)-(b36), such as formula (blO) or (b32)). In particular embodiments, one of Formulas (IXh)-(IXk) is combined with a modified guanine (e.g., any one of formulas (bl5)-(bl7) and (b37)-(b40)). In particular embodiments, one of Formulas (IXh)-(IXk) is combined with a modified adenine (e.g., any one of formulas (M8)-(b20) and (b41)-(b43)).

13340[000357] In other embodiments, the building block molecule, which may be

13341incorporated into a polynucleotide, primary construct, or mmRNA, has Formula (1X1)-

13342(IXr):

13343<img file="WO2013151663A1_D0053.tif" />

13344<img file="WO2013151663A1_D0054.tif" />

13345(IXr) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each rl and r2 is, independently, an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5) and B is as described herein (e.g., any one of (bl)-(b43)). In particular embodiments, one of Formulas (IXl)-(IXr) is combined with a modified uracil (e.g., any one of formulas (bl)-(b9), (b21)-(b23), and (b28)-(b31), such as formula (bl), (b8), (b28), (b29), or (b30)). In particular embodiments, one of Formulas (IXl)-(IXr) is combined with a modified cytosine (e.g., any one of formulas (M0)-(bl4), (b24), (b25), and (b32)-(b36), such as formula (blO) or (b32)). In particular embodiments, one of Formulas (IXl)-(IXr) is combined with a modified guanine (e.g., any one of formulas (bl5)-(bl7) and (b37)- (b40)). In particular embodiments, one of Formulas (IXl)-(IXr) is combined with a modified adenine (e.g., any one of formulas (M8)-(b20) and (b41)-(b43)).

13346[000358] In some embodiments, the building block molecule, which may be

13347incorporated into a polynucleotide, primary construct, or mmR A, can be selected from the group consisting of: <img file="WO2013151663A1_D0055.tif" /> B<img file="WO2013151663A1_D0056.tif" /> (BB- 3), HO OH (BB- 4),<img file="WO2013151663A1_D0057.tif" /> (BB- 1 1), and

13348<img file="WO2013151663A1_D0058.tif" /> ), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is, independently, an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5).

13349[000359] In some embodiments, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, can be selected from the group consisting of:

13350<img file="WO2013151663A1_D0059.tif" /> stereoisomer thereof, wherein each r is, independently, an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5) and si is as described herein.

13351[000360] In some embodiments, the building block molecule, which may be

13352incorporated into a nucleic acid (e.g., RNA, mRNA, polynucleotide, primary construct, or

13353),

13354<img file="WO2013151663A1_D0060.tif" /> 7),

13355<img file="WO2013151663A1_D0061.tif" />

13356<img file="WO2013151663A1_D0062.tif" /><img file="WO2013151663A1_D0063.tif" />

13357<img file="WO2013151663A1_D0064.tif" /><img file="WO2013151663A1_D0065.tif" />

13358<img file="WO2013151663A1_D0066.tif" />

13359642

13360<img file="WO2013151663A1_D0067.tif" />

13361HO OH (BB- 65),<img file="WO2013151663A1_D0068.tif" />

HO OH (BB- 67),

13363<img file="WO2013151663A1_D0069.tif" />

13364644 - <img file="WO2013151663A1_D0070.tif" />

74), HO OH (BB- 75), HO OH

13366<img file="WO2013151663A1_D0071.tif" />

(BB- 76), HO OH (BB- 77),

13368<img file="WO2013151663A1_D0072.tif" />

(BB-81), HO OH (BB-82),

13370<img file="WO2013151663A1_D0073.tif" /> (BB-

13371<img file="WO2013151663A1_D0074.tif" />

13372<img file="WO2013151663A1_D0075.tif" />

13373HO Br (BB- 91), HO I (BB- 92), <img file="WO2013151663A1_D0076.tif" />

13374HO CH3 (BB- HO OCH3 (BB.<img file="WO2013151663A1_D0077.tif" />

13375HO OH (BB- 99), HO OH (BB- 100), <img file="WO2013151663A1_D0078.tif" />

HO OH (BB- 101),

13377<img file="WO2013151663A1_D0079.tif" />

13378HO OH (BB- 104), <img file="WO2013151663A1_D0080.tif" />

13379HO OH (BB- 106),<img file="WO2013151663A1_D0081.tif" /><img file="WO2013151663A1_D0082.tif" />

13380<img file="WO2013151663A1_D0083.tif" />

13381- 116), HO CI (BB- 117),<img file="WO2013151663A1_D0084.tif" />

13382<img file="WO2013151663A1_D0085.tif" />

13383125), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y1, Y3, Y4, Y6, and r are as described herein (e.g., each r is, independently, an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5)).

13384[000361] In some embodiments, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, is a modified cytidine (e.g., selected from the group consisting of:

13385<img file="WO2013151663A1_D0086.tif" />

-128), HO OH (BB-129),

13387-<img file="WO2013151663A1_D0087.tif" /> (BB- 133), <img file="WO2013151663A1_D0088.tif" />

13388HO OCH3 (BB- 134), HO OH (BB- 135), <img file="WO2013151663A1_D0089.tif" />

HO OCH3 (BB-136), HO OH (BB-137),

13390(BB- 139),<img file="WO2013151663A1_D0090.tif" />

13391HO OH (BB- 140), HO CH3 (BB- 141), <img file="WO2013151663A1_D0091.tif" />

13392HO Br (BB- 146), HO OH (BB- 147),<img file="WO2013151663A1_D0092.tif" />

HO CH 3 (BB- 148), HO OH (BB- 149),

13394<img file="WO2013151663A1_D0093.tif" /> (BB- 158), and

13395<img file="WO2013151663A1_D0094.tif" /> B- 159), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y1, Y3, Y4, Y6, and r are as described herein (e.g., each r is, independently, an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5)). For example, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, can be:

13396<img file="WO2013151663A1_D0095.tif" /> B- 161), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is, independently, an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5).

13397[000362] In some embodiments, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, is a modified adenosine (e.g., selected from the group consisting of:

13398<img file="WO2013151663A1_D0096.tif" />

13399659

13400<img file="WO2013151663A1_D0097.tif" />

(BB- 175),

13402<img file="WO2013151663A1_D0098.tif" />

180), HO OH (BB-181), HO OH

13404<img file="WO2013151663A1_D0099.tif" /><img file="WO2013151663A1_D0100.tif" />

13405-184), HO OH (BB- <img file="WO2013151663A1_D0101.tif" />

185), HO OH (BB-186), HO OH

13407<img file="WO2013151663A1_D0102.tif" />

(BB- 187), HO OH (BB- 188),

13409<img file="WO2013151663A1_D0103.tif" />

13410663

13411<img file="WO2013151663A1_D0104.tif" />

13412664

13413<img file="WO2013151663A1_D0105.tif" />

13414HO OH (BB- 200) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y1, Y3, Y4, Y6, and r are as described herein (e.g., each r is, independently, an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5)).

13415[000363] In some embodiments, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, is a modified guanosine (e.g., selected from the group consisting of:

13416<img file="WO2013151663A1_D0106.tif" /> -

13417<img file="WO2013151663A1_D0107.tif" /> B-

13418<img file="WO2013151663A1_D0108.tif" /> - -

13419<img file="WO2013151663A1_D0109.tif" />

13420<img file="WO2013151663A1_D0110.tif" />

13421(BB- 237), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y1, Y3, Y4, Y6, and r are as described herein (e.g., each r is, independently, an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5)).

13422[000364] In some embodiments, the chemical modification can include replacement of C group at C-5 of the ring (e.g., for a pyrimidine nucleoside, such as cytosine or uracil) with N (e.g., replacement of the >CH group at C-5 with >NRN1 group, wherein RN1 is H or optionally substituted alkyl). For example, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, can be:

13423<img file="WO2013151663A1_D0111.tif" />

13424HO OH (BB- 238) or HO OH (BB- 239)

13425<img file="WO2013151663A1_D0112.tif" />

13426(BB- 241), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is, independently, an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5).

13427[000365] In another embodiment, the chemical modification can include replacement of the hydrogen at C-5 of cytosine with halo (e.g., Br, CI, F, or I) or optionally substituted alkyl (e.g., methyl). For example, the building block molecule, which may be

13428incorporated into a polynucleotide, primary construct, or mmRNA, can be: - 242) or HO OH (BB- 243)

13429<img file="WO2013151663A1_D0113.tif" />

13430or HO OH (BB- 244) or HO OH (BB-

13431245), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is, independently, an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5).

13432[000366] In yet a further embodiment, the chemical modification can include a fused ring that is formed by the NH2 at the C-4 position and the carbon atom at the C-5 position. For example, the building block molecule, which may be incorporated into a polynucleotide, primary construct, or mmRNA, can be:

13433<img file="WO2013151663A1_D0114.tif" /> B- 246), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is, independently, an integer from 0 to 5 (e

134340 to 3, from 1 to 3, or from 1 to 5).

13435Modifications on the Sugar [000367] The modified nucleosides and nucleotides (e.g., building block molecules), which may be incorporated into a polynucleotide, primary construct, or mmRNA (e.g., R A or mRNA, as described herein), can be modified on the sugar of the ribonucleic acid. For example, the 2' hydroxyl group (OH) can be modified or replaced with a number of different substituents. Exemplary substitutions at the 2'-position include, but are not limited to, H, halo, optionally substituted Ci_6 alkyl; optionally substituted Ci_6 alkoxy; optionally substituted C6-1o aryloxy; optionally substituted C3-8 cycloalkyl;

13436optionally substituted C3-8 cycloalkoxy; optionally substituted C6-io aryloxy; optionally substituted C6_io aryl-Ci_6 alkoxy, optionally substituted C1-12 (heterocyclyl)oxy; a sugar (e.g., ribose, pentose, or any described herein); a polyethyleneglycol (PEG), - 0(CH2CH20)nCH2CH2OR, where R is H or optionally substituted alkyl, and n is an integer from 0 to 20 (e.g., from 0 to 4, from 0 to 8, from 0 to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from 1 to 16, from 1 to 20, from 2 to 4, from 2 to 8, from 2 to 10, from 2 to 16, from 2 to 20, from 4 to 8, from 4 to 10, from 4 to 16, and from 4 to 20); "locked" nucleic acids (LNA) in which the 2'-hydroxyl is connected by a Ci_6 alkylene or Ci_6 heteroalkylene bridge to the 4'-carbon of the same ribose sugar, where exemplary bridges included methylene, propylene, ether, or amino bridges; aminoalkyl, as defined herein; aminoalkoxy, as defined herein; amino as defined herein; and amino acid, as defined herein

13437Generally, RNA includes the sugar group ribose, which is a 5-membered ring having an oxygen. Exemplary, non-limiting modified nucleotides include replacement of the oxygen in ribose (e.g., with S, Se, or alkylene, such as methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a 4-membered ring of cyclobutane or oxetane); ring expansion of ribose (e.g., to form a 6- or 7-membered ring having an additional carbon or heteroatom, such as for anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino that also has a phosphoramidate backbone); multicyclic forms (e.g., tricyclo; and "unlocked" forms, such as glycol nucleic acid (GNA) (e.g., R-GNA or S- GNA, where ribose is replaced by glycol units attached to phosphodiester bonds), threose nucleic acid (TNA, where ribose is replace with a-L-threofuranosyl-(3'→2')) , and peptide nucleic acid (PNA, where 2-amino-ethyl-glycine linkages replace the ribose and phosphodiester backbone). The sugar group can also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose. Thus, a polynucleotide, primary construct, or mmRNA molecule can include nucleotides containing, e.g., arabinose, as the sugar.

13438Modifications on the Nucleobase

13439[000368] The present disclosure provides for modified nucleosides and nucleotides. As described herein "nucleoside" is defined as a compound containing a sugar molecule (e.g., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as

13440"nucleobase"). As described herein, "nucleotide" is defined as a nucleoside including a phosphate group. The modified nucleotides may by synthesized by any useful method, as described herein (e.g., chemically, enzymatically, or recombinantly to include one or more modified or non-natural nucleosides).

13441[000369] The modified nucleotide base pairing encompasses not only the standard adenosine-thymine, adenosine -uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and/or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. One example of such nonstandard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil.

13442[000370] The modified nucleosides and nucleotides can include a modified nucleobase. Examples of nucleobases found in RNA include, but are not limited to, adenine, guanine, cytosine, and uracil. Examples of nucleobase found in DNA include, but are not limited to, adenine, guanine, cytosine, and thymine. These nucleobases can be modified or wholly replaced to provide polynucleotides, primary constructs, or mmRNA molecules having enhanced properties, e.g., resistance to nucleases through disruption of the binding of a major groove binding partner. Table 8 below identifies the chemical faces of each canonical nucleotide. Circles identify the atoms comprising the respective chemical regions. Table 8

13443Watson-Crick

13444Major Groove Minor Groove Base-pairing

13445Pyri idines

13446Purines <img file="WO2013151663A1_D0115.tif" />

13447[000371] In some embodiments, B is a modified uracil. Exemplary modified uracils

13448<img file="WO2013151663A1_D0116.tif" />

13449[000372] wherein

13450[000373] is a single or double bond; [000374] each of T1 , T1 , T2 , and T2 is, independently, H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or the combination of T1 and T1 or the combination of T2 and T2 join together (e.g., as in T2) to form O (oxo), S (thio), or Se (seleno);

13451[000375] each of V1 and V2 is, independently, O, S, N(Rvb)nv, or C(Rvb)nv, wherein nv is an integer from 0 to 2 and each R^ is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl), optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1)-(21) for alkyl);

13452[000376] R10 is H, halo, optionally substituted amino acid, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aminoalkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted

13453aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted

13454alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl;

13455[000377] R11 is H or optionally substituted alkyl;

13456[000378] R12a is H, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy), optionally substituted carboxyalkoxy, optionally substituted

13457carboxyaminoalkyl, or optionally substituted carbamoylalkyl; and

13458[000379] R12c is H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted

13459hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl.

13460[000380] Other exemplary modified uracils include those having Formula (b6)-(b9):

13461<img file="WO2013151663A1_D0117.tif" />

13462(b9), or a pharmaceutically acceptable salt or stereoisomer thereof,

13463[000381] wherein

13464[000382] is a single or double bond;

13465[000383] each of T1 , T1 , T2 , and T2 is, independently, H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or the combination of T1 and T1 join together (e.g., as in T1) or the combination of T2 and T2 join together (e.g., as in T2) to form O (oxo), S (thio), or Se (seleno), or each T1 and T2 is,

13466independently, O (oxo), S (thio), or Se (seleno);

13467[000384] each of W1 and W2 is, independently, N(RWa)nw or C(RWa)nw, wherein nw is an integer from 0 to 2 and each RWa is, independently, H, optionally substituted alkyl, or optionally substituted alkoxy;

13468[000385] each V3 is, independently, O, S, N(RVa)nv, or C(RVa)nv, wherein nv is an integer from 0 to 2 and each RVa is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy , optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl, or sulfoalkyl), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl), optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted

13469alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and/or an O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl (e.g., optionally substituted with any substituent described herein, such as those selected from (1)-(21) for alkyl), and wherein RVa and R12c taken together with the carbon atoms to which they are attached can form optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heterocyclyl (e.g., a 5- or 6-membered ring);

13470[000386] R12a is H, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and/or an O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, optionally substituted carbamoylalkyl, or absent;

13471[000387] R12b is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted

13472aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkaryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted amino acid, optionally substituted

13473alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and/or an O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl,

13474[000388] wherein the combination of R12b and T1 or the combination of R12b and R12c can join together to form optionally substituted heterocyclyl; and

13475[000389] R12c is H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl.

13476[000390] Further exemplary modified uracils include those having Formula (b28)-

13477<img file="WO2013151663A1_D0118.tif" /> f,

13478[000391] wherein

13479[000392] each of T1 and T2 is, independently, O (oxo), S (thio), or Se (seleno);

13480[000393] each R^ and R^ is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted

13481hydroxyalkynyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl, or sulfoalkyl), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl), optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and/or an O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl (e.g., optionally substituted with any substituent described herein, such as those selected from (1)-(21) for alkyl) (e.g., R^ is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted aminoalkyl, e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl, or sulfoalkyl);

13482[000394] R12a is H, optionally substituted alkyl, optionally substituted

13483carboxyaminoalkyl, optionally substituted aminoalkyl (e.g., e.g., substituted with an N- protecting group, such as any described herein, e.g., trifluoroacetyl, or sulfoalkyl), optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; and

13484[000395] R12b is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted

13485aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl (e.g., e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl, or sulfoalkyl),

13486[000396] optionally substituted alkoxycarbonylacyl, optionally substituted

13487alkoxycarbonylalkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl.

13488[000397] In particular embodiments, T1 is O (oxo), and T2 is S (thio) or Se (seleno). In other embodiments, T1 is S (thio), and T2 is O (oxo) or Se (seleno). In some

13489embodiments, R^ is H, optionally substituted alkyl, or optionally substituted alkoxy.

13490[000398] In other embodiments, each R12a and R12b is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted hydroxyalkyl. In particular embodiments, R12a is H. In other embodiments, both R12a and R12b are H. [000399] In some embodiments, each R^ of R12b is, independently, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g., trifluoroacetyl, or sulfoalkyl), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group, such as any described herein, e.g.,

13491trifluoroacetyl). In some embodiments, the amino and/or alkyl of the optionally substituted aminoalkyl is substituted with one or more of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted sulfoalkyl, optionally substituted carboxy (e.g., substituted with an O-protecting group), optionally substituted hydroxy (e.g., substituted with an O-protecting group), optionally substituted carboxyalkyl (e.g., substituted with an O-protecting group), optionally substituted alkoxycarbonylalkyl (e.g., substituted with an O-protecting group), or N-protecting group. In some embodiments, optionally substituted aminoalkyl is substituted with an optionally substituted sulfoalkyl or optionally substituted alkenyl. In particular embodiments, R12a and R^ are both H. In particular embodiments, T1 is O (oxo), and T2 is S (thio) or Se (seleno).

13492[000400] In some embodiments, R^ is optionally substituted alkoxycarbonylalkyl or optionally substituted carbamoylalkyl.

13493[000401] In particular embodiments, the optional substituent for R12a, R12b, R12c, or RVa is a polyethylene glycol group (e.g., -(CH2)s2(OCH2CH2)si(CH2)s30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl); or an amino-polyethylene glycol group (e.g., - NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl).

13494[000402] In some embodiments, B is a modified cytosine. Exemplary modified cytosines include compounds of Formula (bl0)-(bl4):

13495<img file="WO2013151663A1_D0119.tif" />

13496thereof,

13497wherein

13498[000403] each of T3 and T3 is, independently, H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or the combination of T3 and T3 join together (e.g., as in T3) to form O (oxo), S (thio), or Se (seleno);

13499[000404] each V4 is, independently, O, S, N(RVc)nv, or C(RVc)nv, wherein nv is an integer from 0 to 2 and each RVc is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1)-(21) for alkyl), wherein the combination of R13b and RVc can be taken together to form optionally substituted heterocyclyl;

13500[000405] each V5 is, independently, N(Rvd)nv, or C(Rvd)nv, wherein nv is an integer from 0 to 2 and each Rvd is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1)-(21) for alkyl) (e.g., V5 is -CH or N);

13501[000406] each of R13a and R13b is, independently, H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl, or optionally substituted alkoxy, wherein the combination of R and R can be taken together to form optionally substituted heterocyclyl;

13502[000407] each R14 is, independently, H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., -NHR, wherein R is H, alkyl, aryl, or phosphoryl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkyl; and

13503[000408] each of R15 and R16 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

13504[000409] Further exemplary modified cytosines include those having Formula (b32)-

13505<img file="WO2013151663A1_D0120.tif" /> ereof,

13506[000410] wherein

13507[000411] each of T1 and T3 is, independently, O (oxo), S (thio), or Se (seleno);

13508[000412] each of R13a and R13b is, independently, H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl, or optionally substituted alkoxy, wherein the combination of R and R can be taken together to form optionally substituted heterocyclyl;

13509[000413] each R14 is, independently, H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., -NHR, wherein R is H, alkyl, aryl, or phosphoryl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl (e.g., hydroxyalkyl, alkyl, alkenyl, or alkynyl), optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; and

13510[000414] each of R15 and R16 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl (e.g., R15 is H, and R16 is H or optionally substituted alkyl).

13511[000415] In some embodiments, R15 is H, and R16 is H or optionally substituted alkyl. In particular embodiments, R14 is H, acyl, or hydroxyalkyl. In some embodiments, R14 is halo. In some embodiments, both R14 and R15 are H. In some embodiments, both R15 and R16 are H. In some embodiments, each of R14 and R15 and R16 is H. In further embodiments, each of R13a and R13b is independently, H or optionally substituted alkyl.

13512[000416] Further non- limiting examples of modified cytosines include compounds of Formula (b36):

13513<img file="WO2013151663A1_D0121.tif" /> (b36) or a pharmaceutically acceptable salt or stereoisomer thereof,

13514[000417] wherein

13515[000418] each R13b is, independently, H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl, or optionally substituted alkoxy, wherein the combination of R and R can be taken together to form optionally substituted heterocyclyl;

13516[000419] each R14a and R14b is, independently, H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., -NHR, wherein R is H, alkyl, aryl, phosphoryl, optionally substituted aminoalkyl, or optionally substituted carboxyaminoalkyl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; and

13517[000420] each of R15 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

13518[000421] In particular embodiments, R14b is an optionally substituted amino acid (e.g., optionally substituted lysine). In some embodiments, R14a is H.

13519[000422] In some embodiments, B is a modified guanine. Exemplary modified guanines include compounds of Formula (bl5)-(bl7):

13520(bl6), or

13521<img file="WO2013151663A1_D0122.tif" /> (bl7), or a pharmaceutically acceptable salt or stereoisomer thereof,

13522[000423] wherein [000424] each of T4', T4", T5 , T5", T6', and T6" is, independently, H, optionally substituted alkyl, or optionally substituted alkoxy, and wherein the combination of T4 and T4 (e.g., as in T4) or the combination of T5 and T5 (e.g., as in T5) or the combination of T6 and T6 (e.g., as in T6) join together form O (oxo), S (thio), or Se (seleno);

13523[000425] each of V5 and V6 is, independently, O, S, N(Rvd)nv, or C(Rvd)nv, wherein nv is an integer from 0 to 2 and each Rvd is, independently, H, halo, thiol, optionally substituted amino acid, cyano, amidine, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1)-(21) for alkyl) , optionally substituted thioalkoxy, or optionally substituted amino; and

13524[000426] each of R17, R18, R19a, R19b, R21, R22, R23, and R24 is, independently, H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, optionally substituted amino, or optionally substituted amino acid.

13525[000427] Exemplary modified guanosines include compounds of Formula (b37)-(b40):

13526<img file="WO2013151663A1_D0123.tif" />

13527stereoisomer thereof,

13528[000428] wherein

13529[000429] each of T4 is, independently, H, optionally substituted alkyl, or optionally substituted alkoxy, and each T4 is, independently, O (oxo), S (thio), or Se (seleno); [000430] each of R18, R19a, R19b, and R21 is, independently, H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, optionally substituted amino, or optionally substituted amino acid.

13530[000431] In some embodiments, R18 is H or optionally substituted alkyl. In further embodiments, T4 is oxo. In some embodiments, each of R19a and R19b is, independently, H or optionally substituted alkyl.

13531[000432] In some embodiments, B is a modified adenine. Exemplary modified adenines include compounds of Formula (M8)-(b20):

13532<img file="WO2013151663A1_D0124.tif" /> alt or stereoisomer thereof,

13533[000433] wherein

13534[000434] each V7 is, independently, O, S, N(RVe)nv, or C(RVe)nv, wherein nv is an integer from 0 to 2 and each RVe is, independently, H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1)-(21) for alkyl);

13535[000435] each R25 is, independently, H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, or optionally substituted amino;

13536[000436] each of R26a and R26b is, independently, H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, or polyethylene glycol group (e.g., - (CH2)s2(OCH2CH2)si(CH2)s30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl); or an amino-polyethylene glycol group (e.g., -NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl);

13537[000437] each R27 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted thioalkoxy or optionally substituted amino;

13538[000438] each R28 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; and

13539[000439] each R29 is, independently, H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted alkoxy, or optionally substituted amino.

13540[000440] Exemplary modified adenines include compounds of Formula (b41)-(b43):

13541<img file="WO2013151663A1_D0125.tif" />

13542(b43), or a pharmaceutically acceptable salt or stereoisomer thereof,

13543[000442] wherein

13544[000443] each R25 is, independently, H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, or optionally substituted amino; [000444] each of R a and R is, independently, H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, or polyethylene glycol group (e.g., - (CH2)s2(OCH2CH2)si(CH2)s30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl); or an amino-polyethylene glycol group (e.g., -NRN1(CH2)S2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl); and

13545[000445] each R27 is, independently, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted thioalkoxy, or optionally substituted amino.

13546[000446] In some embodiments, R26a is H, and R26b is optionally substituted alkyl. In some embodiments, each of R26a and R26b is, independently, optionally substituted alkyl. In particular embodiments, R27 is optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy. In other embodiments, R25 is optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy.

13547[000447] In particular embodiments, the optional substituent for R26a, R26b, or R29 is a polyethylene glycol group (e.g., -(CH2)S2(OCH2CH2)si(CH2)s3OR', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl); or an amino-polyethylene glycol group (e.g., - NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl).

13548[000448] In some embodiments, B may have Formula (b21): <img file="WO2013151663A1_D0126.tif" /> (b21), wherein X is, independently, O, S, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene, xa is an integer from

13549O to 3, and R12a and T2 are as described herein.

13550odiments, B may have Formula (b22):

13551<img file="WO2013151663A1_D0127.tif" /> (b22), wherein R10 is, independently, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted

13552alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl, and R11, R12a, T1, and T2 are as described herein.

13553[000450] In some embodiments, B may have Formula (b23):

13554<img file="WO2013151663A1_D0128.tif" /> (b23), wherein R is optionally substituted heterocyclyl (e.g., optionally substituted furyl, optionally substitued thienyl, or optionally substitued pyrrolyl), optionally substituted aryl (e.g., optionally substituted phenyl or optionally substituted naphthyl), or any substituent described herein (e.g., for R10) ;and wherein R11 (e.g., H or any substituent described herein), R12a (e.g., H or any substituent described herein), T1 (e.g., oxo or any substituent described herein), and T2 (e.g., oxo or any substituent described herein) are as described herein.

13555In some embodiments, B may have Formula (b24):

13556<img file="WO2013151663A1_D0129.tif" /> (b24), wherein R14 is, independently, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkaryl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl, and R13a, R13b, R15, and T3 are as described herein.

13557[000451] In some embodiments, B may have Formula (b25):

13558<img file="WO2013151663A1_D0130.tif" /> (b25), wherein R14 is optionally substituted heterocyclyl (e.g., optionally substituted furyl, optionally substitued thienyl, or optionally substitued pyrrolyl), optionally substituted aryl (e.g., optionally substituted phenyl or optionally substituted naphthyl), or any substituent described herein (e.g., for R14 or R14 ); and wherein R13a (e.g., H or any substituent described herein), R13b (e.g., H or any substituent described herein), R15 (e.g., H or any substituent described herein), and T3 (e.g., oxo or any substituent described herein) are as described herein.

13559[000452] In some embodiments, B is a nucleobase selected from the group consisting of cytosine, guanine, adenine, and uracil. In some embodiments, B may be: <img file="WO2013151663A1_D0131.tif" />

13560[000453] In some embodiments, the modified nucleobase is a modified uracil.

13561Exemplary nucleobases and nucleosides having a modified uracil include pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2- thio-uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5- hydroxy-uridine (ho5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5- bromo-uridine), 3-methyl-uridine (m3U), 5-methoxy-uridine (mo5U), uridine 5-oxyacetic acid (cmo5U), uridine 5-oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm5U), 5- carboxyhydroxymethyl-uridine methyl ester (mchm5U), 5-methoxycarbonylmethyl- uridine (mcm5U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm5s2U), 5-aminomethyl- 2-thio-uridine (nmVU), 5-methylaminomethyl-uridine (mnm5U), 5-methylaminomethyl- 2-thio-uridine (mnm5s2U), 5-methylaminomethyl-2-seleno-uridine (mnm5se2U), 5- carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm5U), 5- carboxymethylaminomethyl-2-thio-uridine (cmnm5s2U), 5-propynyl-uridine, 1-propynyl- pseudouridine, 5-taurinomethyl-uridine (xm5U), 1-taurinomethyl-pseudouridine, 5- taurinomethyl-2-thio-uridine(Tm5s2U), 1 -taurinomethyl-4-thio-pseudouridine, 5-methyl- uridine (m5U, i.e., having the nucleobase deoxythymine), 1-methylpseudouridine (m^), 5-methyl-2-thio-uridine (m5s2U), l-methyl-4-thio-pseudouridine (mVxi/), 4-thio-l- methyl-pseudouridine, 3-methyl-pseudouridine ^3ψ), 2-thio-l-methyl-pseudouridine, 1- methyl- 1 -deaza-pseudouridine, 2-thio- 1 -methyl- 1 -deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m5D), 2-thio- dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio- uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N 1-methylpseudouridine (also known as 1-methylpseudouridine (m^)), 3-(3-amino-3- carboxypropyl)uridine (acp3U), 1 -methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3 ψ), 5-(isopentenylaminomethyl)uridine (inm5U), 5-(isopentenylaminomethyl)-2- thio-uridine (inm5s2U), a-thio-uridine, 2'-0-methyl-uridine (Um), 5,2'-0-dimethyl- uridine (m5Um), 2'-0-methyl-pseudouridine (ψηι), 2-thio-2'-0-methyl-uridine (s2Um), 5- methoxycarbonylmethyl-2'-0-methyl-uridine (mcm5Um), 5-carbamoylmethyl-2'-0- methyl-uridine (ncm5Um), 5-carboxymethylaminomethyl-2'-0-methyl-uridine

13562(cmnm5Um), 3,2'-0-dimethyl-uridine (m3Um), 5-(isopentenylaminomethyl)-2'-0- methyl-uridine (inm5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, and 5-[3-(l-E- propenylamino)uridine.

13563[000454] In some embodiments, the modified nucleobase is a modified cytosine.

13564Exemplary nucleobases and nucleosides having a modified cytosine include 5-aza- cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m3C), N4-acetyl-cytidine (ac4C), 5-formyl-cytidine (f5C), N4-methyl-cytidine (m4C), 5-methyl-cytidine (m5C), 5- halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl- pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s2C), 2- thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4- thio- 1 -methyl- 1 -deaza-pseudoisocytidine, 1 -methyl- 1 -deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio- zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy- pseudoisocytidine, 4-methoxy-l-methyl-pseudoisocytidine, lysidine (k2C), a-thio- cytidine, 2'-0-methyl-cytidine (Cm), 5,2'-0-dimethyl-cytidine (m5Cm), N4-acetyl-2'-0- methyl-cytidine (ac4Cm), N4,2'-0-dimethyl-cytidine (m4Cm), 5-formyl-2'-0-methyl- cytidine (f5Cm), N4,N4,2'-0-trimethyl-cytidine (m42Cm), 1-thio-cytidine, 2'-F-ara- cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.

13565[000455] In some embodiments, the modified nucleobase is a modified adenine.

13566Exemplary nucleobases and nucleosides having a modified adenine include 2-amino- purine, 2, 6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6- halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7- deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino- purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl- adenosine (mxA), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), 2-methylthio- N6-methyl-adenosine (ms2m6A), N6-isopentenyl-adenosine (i6A), 2-methylthio-N6- isopentenyl-adenosine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenosine (io6A), 2- methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms2io6A), N6-glycinylcarbamoyl- adenosine (g6A), N6-threonylcarbamoyl-adenosine (t6A), N6-methyl-N6- threonylcarbamoyl-adenosine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms2g6A), N6,N6-dimethyl-adenosine (m62A), N6-hydroxynorvalylcarbamoyl-adenosine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms2hn6A), N6-acetyl- adenosine (ac6A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, a-thio- adenosine, 2'-0-methyl-adenosine (Am), N6,2'-0-dimethyl-adenosine (m6Am),

13567N6,N6,2'-0-trimethyl-adenosine (m62Am), l,2'-0-dimethyl-adenosine (rr^Am), 2'-0- ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8- azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine, and N6-(19- amino-pentaoxanonadecyl)-adenosine.

13568[000456] In some embodiments, the modified nucleobase is a modified guanine.

13569Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1- methyl-inosine (m1!), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o2yW),

13570hydroxywybutosine (OHyW), undermodified hydroxywybutosine (OHyW*), 7-deaza- guanosine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl- queuosine (manQ), 7-cyano-7-deaza-guanosine (preQo), 7-aminomethyl-7-deaza- guanosine (preQi), archaeosine (G+), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio- 7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m7G), 6-thio-

135717- methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (n^G), N2-methyl-guanosine (m2G), N2,N2-dimethyl-guanosine (m22G), N2,7-dimethyl-

135722 7 2 2 7

13573guanosine (m ' G), N2, N2,7-dimethyl-guanosine (m ' ' G), 8-oxo-guanosine, 7-methyl-

135748- oxo-guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2- dimethyl-6-thio-guanosine, a-thio-guanosine, 2'-0-methyl-guanosine (Gm), N2-methyl- 2'-0-methyl-guanosine (m2Gm), N2,N2-dimethyl-2'-0-methyl-guanosine (m22Gm), 1- methyl-2'-0-methyl-guanosine (m^m), N2,7-dimethyl-2'-0-methyl-guanosine

13575(m2'7Gm), 2'-0-methyl-inosine (Im), l,2'-0-dimethyl-inosine (m^m), and 2'-0- ribosylguanosine (phosphate) (Gr(p)).

13576[000457] The nucleobase of the nucleotide can be independently selected from a purine, a pyrimidine, a purine or pyrimidine analog. For example, the nucleobase can each be independently selected from adenine, cytosine, guanine, uracil, or hypoxanthine. In another embodiment, the nucleobase can also include, for example, naturally-occurring and synthetic derivatives of a base, including pyrazolo[3,4-d]pyrimidines, 5- methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2- aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2- thiocytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5 -uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thioalkyl, 8- hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5- trifluoromethyl and other 5 -substituted uracils and cytosines, 7-methylguanine and 7- methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3- deazaguanine, deazaadenine, 7-deazaadenine, 3-deazaadenine, pyrazolo[3,4- d]pyrimidine, imidazo[l,5-a] l,3,5 triazinones, 9-deazapurines, imidazo[4,5-d]pyrazines, thiazolo[4,5-d]pyrimidines, pyrazin-2-ones, 1,2,4-triazine, pyridazine; and 1,3,5 triazine. When the nucleotides are depicted using the shorthand A, G, C, T or U, each letter refers to the representative base and/or derivatives thereof, e.g., A includes adenine or adenine analogs, e.g., 7-deaza adenine).

13577Modifications on the Internucleoside Linkage

13578[000458] The modified nucleotides, which may be incorporated into a polynucleotide, primary construct, or mmRNA molecule, can be modified on the internucleoside linkage (e.g., phosphate backbone). Herein, in the context of the polynucleotide backbone, the phrases "phosphate" and "phosphodiester" are used interchangeably. Backbone phosphate groups can be modified by replacing one or more of the oxygen atoms with a different substituent. Further, the modified nucleosides and nucleotides can include the wholesale replacement of an unmodified phosphate moiety with another internucleoside linkage as described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioate, phosphoroselenates, boranophosphates,boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linking oxygens replaced by sulfur. The phosphate linker can also be modified by the replacement of a linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene -phosphonates).

13579[000459] The a-thio substituted phosphate moiety is provided to confer stability to R A and DNA polymers through the unnatural phosphorothioate backbone linkages. Phosphorothioate DNA and RNA have increased nuclease resistance and subsequently a longer half-life in a cellular environment. Phosphorothioate linked polynucleotides, primary constructs, or mmRNA molecules are expected to also reduce the innate immune response through weaker binding/activation of cellular innate immune molecules.

13580[000460] In specific embodiments, a modified nucleoside includes an alpha-thio- nucleoside (e.g., 5'-0-(l-thiophosphate)-adenosine, 5'-0-(l-thiophosphate)-cytidine (a- thio-cytidine), 5'-0-(l-thiophosphate)-guanosine, 5'-0-(l-thiophosphate)-uridine, or 5'-0- ( 1 -thiophosphate)-pseudouridine).

13581[000461] Other internucleoside linkages that may be employed according to the present invention, including internucleoside linkages which do not contain a phosphorous atom, are described herein below.

13582Combinations of Modified Sugars, Nucleobases, and Internucleoside Linkages

13583[000462] The polynucleotides, primary constructs, and mmRNA of the invention can include a combination of modifications to the sugar, the nucleobase, and/or the internucleoside linkage. These combinations can include any one or more modifications described herein. For examples, any of the nucleotides described herein in Formulas (la), (Ia-l)-(Ia-3), (Ib)-(If), (Ila)-(IIp), (IIb-1), (IIb-2), (IIc-l)-(IIc-2), (IIn-1), (IIn-2), (IVa)- (IV1), and (IXa)-(IXr) can be combined with any of the nucleobases described herein (e.g., in Formulas (bl)-(b43) or any other described herein).

13584Synthesis of Polypeptides, Primary Constructs, and mmRNA Molecules

13585[000463] The polypeptides, primary constructs, and mmRNA molecules for use in accordance with the invention may be prepared according to any useful technique, as described herein. The modified nucleosides and nucleotides used in the synthesis of polynucleotides, primary constructs, and mmRNA molecules disclosed herein can be prepared from readily available starting materials using the following general methods and procedures. Where typical or preferred process conditions (e.g., reaction

13586temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are provided, a skilled artisan would be able to optimize and develop additional process conditions. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

13587[000464] The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

13588[000465] Preparation of polypeptides, primary constructs, and mmRNA molecules of the present invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al, Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety.

13589[000466] The reactions of the processes described herein can be carried out in suitable solvents, which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.

13590[000467] Resolution of racemic mixtures of modified nucleosides and nucleotides can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallization using a "chiral resolving acid" which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.

13591Modified nucleosides and nucleotides (e.g., building block molecules) can be prepared according to the synthetic methods described in Ogata et al, J. Org. Chem. 74:2585-2588 (2009); Purmal et al, Nucl. Acids Res. 22(1): 72-78, (1994); Fukuhara et al,

13592Biochemistry, 1(4): 563-568 (1962); and Xu et al, Tetrahedron, 48(9): 1729-1740 (1992), each of which are incorporated by reference in their entirety.

13593[000468] The polypeptides, primary constructs, and mmRNA of the invention may or may not be uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotide (e.g., purine or pyrimidine, or any one or more or all of A, G, U, C) may or may not be uniformly modified in a polynucleotide of the invention, or in a given predetermined sequence region thereof (e.g. one or more of the sequence regions represented in Figure 1). In some embodiments, all nucleotides X in a polynucleotide of the invention (or in a given sequence region thereof) are modified, wherein X may any one of nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.

13594[000469] Different sugar modifications, nucleotide modifications, and/or

13595internucleoside linkages (e.g., backbone structures) may exist at various positions in the polynucleotide, primary construct, or mmRNA. One of ordinary skill in the art will appreciate that the nucleotide analogs or other modification(s) may be located at any position(s) of a polynucleotide, primary construct, or mmRNA such that the function of the polynucleotide, primary construct, or mmRNA is not substantially decreased. A modification may also be a 5 ' or 3' terminal modification. The polynucleotide, primary construct, or mmRNA may contain from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e. any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100%).

13596[000470] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a modified pyrimidine (e.g., a modified uracil/uridine/U or modified

13597cytosine/cytidine/C). In some embodiments, the uracil or uridine (generally: U) in the polynucleotide, primary construct, or mmRNA molecule may be replaced with from about 1%) to about 100% of a modified uracil or modified uridine (e.g., from 1% to 20%>, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100% of a modified uracil or modified uridine). The modified uracil or uridine can be replaced by a compound having a single unique structure or by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures, as described herein). In some embodiments, the cytosine or cytidine (generally: C) in the polynucleotide, primary construct, or mmRNA molecule may be replaced with from about 1% to about 100% of a modified cytosine or modified cytidine (e.g., from 1% to 20%>, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90%) to 100%), and from 95% to 100%) of a modified cytosine or modified cytidine). The modified cytosine or cytidine can be replaced by a compound having a single unique structure or by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures, as described herein).

13598In some embodiments, the present disclosure provides methods of synthesizing a polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) including n number of linked nucleosides having Formula (la-

135991 :

13600<img file="WO2013151663A1_D0132.tif" /> (Ia-1), comprising:

13601a) reacting a nucleotide of Formula (IV- 1):

13602<img file="WO2013151663A1_D0133.tif" />

13603with a phosphoramidite compound of Formula (V-1):

13604<img file="WO2013151663A1_D0134.tif" /> wherein Y9 is H, hydroxy, phosphoryl, pyrophosphate, sulfate, amino, thiol, optionally substituted amino acid, or a peptide (e.g., including from 2 to 12 amino acids); and each

13605P1, P2, and P3 is, independently, a suitable protecting group; and @ denotes a solid support;

13606to provide a polynucleotide, primary construct, or mmRNA of Formula (VI- 1):

13607<img file="WO2013151663A1_D0135.tif" />

13608b) oxidizing or sulfurizing the polynucleotide, primary construct, or mmRNA of Formula (V) to yield a polynucleotide, primary construct, or mmRNA of Formula (VII- 1):

13609<img file="WO2013151663A1_D0136.tif" /> (VII- 1), and

13610c) removing the protecting groups to yield the polynucleotide, primary construct, or mmRNA of Formula (la).

13611[000471] In some embodiments, steps a) and b) are repeated from 1 to about 10,000 times. In some embodiments, the methods further comprise a nucleotide (e.g., mmRNA molecule) selected from the group consisting of A, C, G and U adenosine, cytosine, guanosine, and uracil. In some embodiments, the nucleobase may be a pyrimidine or derivative thereof. In some embodiments, the polynucleotide, primary construct, or mmRNA is translatable. [000472] Other components of polynucleotides, primary constructs, and mmRNA are optional, and are beneficial in some embodiments. For example, a 5' untranslated region (UTR) and/or a 3'UTR are provided, wherein either or both may independently contain one or more different nucleotide modifications. In such embodiments, nucleotide modifications may also be present in the translatable region. Also provided are polynucleotides, primary constructs, and mmRNA containing a Kozak sequence.

13612[000473] Exemplary syntheses of modified nucleotides, which are incorporated into a modified nucleic acid or mmRNA, e.g., RNA or mRNA, are provided below in Scheme 1 through Scheme 11. Scheme 1 provides a general method for phosphorylation of nucleosides, including modified nucleosides.

13613Scheme 1

13614<img file="WO2013151663A1_D0137.tif" />

13615[000474] Various protecting groups may be used to control the reaction. For example, Scheme 2 provides the use of multiple protecting and deprotecting steps to promote phosphorylation at the 5' position of the sugar, rather than the 2' and 3' hydroxyl groups.

13616Scheme 2

13617<img file="WO2013151663A1_D0138.tif" />

13618<img file="WO2013151663A1_D0139.tif" />

13619[000475] Modified nucleotides can be synthesized in any useful manner. Schemes 3, 4, and 7 provide exemplary methods for synthesizing modified nucleotides having a modified purine nucleobase; and Schemes 5 and 6 provide exemplary methods for synthesizing modified nucleotides having a modified pseudouridine or pseudoisocytidine, respectively.

13620Scheme 3<img file="WO2013151663A1_D0140.tif" />

13621<img file="WO2013151663A1_D0141.tif" />

13622Scheme 5

13623<img file="WO2013151663A1_D0142.tif" />

136241) POCl,

136252) Pyrophosphate

13626<img file="WO2013151663A1_D0143.tif" />

13627<img file="WO2013151663A1_D0144.tif" />

13628705

13629<img file="WO2013151663A1_D0145.tif" />

13630[000476] Schemes 8 and 9 provide exemplary syntheses of modified nucleotides. Scheme 10 provides a non- limiting biocatalytic method for producing nucleotides.

13631Scheme 8 <img file="WO2013151663A1_D0146.tif" />

13632<img file="WO2013151663A1_D0147.tif" />

13633Scheme 9

13634<img file="WO2013151663A1_D0148.tif" />

136351) H"

136362) "OH, heat

H

13638<img file="WO2013151663A1_D0149.tif" />

13639Scheme 10

13640<img file="WO2013151663A1_D0150.tif" />

13641[000477] Scheme 11 provides an exemplary synthesis of a modified uracil, where the Nl position is modified with R12b, as provided elsewhere, and the 5 '-position of ribose is phosphorylated. T1, T2, R12a, R12b, and r are as provided herein. This synthesis, as well as optimized versions thereof, can be used to modify other pyrimidine nucleobases and purine nucleobases (see e.g., Formulas (bl)-(b43)) and/or to install one or more phosphate groups (e.g., at the 5' position of the sugar). This alkylating reaction can also be used to include one or more optionally substituted alkyl group at any reactive group (e.g., amino group) in any nucleobase described herein (e.g., the amino groups in the

13642Watson-Crick base-pairing face for cytosine, uracil, adenine, and guanine).

13643Scheme 11

13644<img file="WO2013151663A1_D0151.tif" />

13645Combinations of Nucleotides in mmRNA

13646[000478] Further examples of modified nucleotides and modified nucleotide combinations are provided below in Table 9. These combinations of modified nucleotides can be used to form the polypeptides, primary constructs, or mmRNA of the invention. Unless otherwise noted, the modified nucleotides may be completely substituted for the natural nucleotides of the modified nucleic acids or mmRNA of the invention. As a non-limiting example, the natural nucleotide uridine may be substituted with a modified nucleoside described herein. In another non-limiting example, the natural nucleotide uridine may be partially substituted (e.g., about 0.1%, 1%, 5%, 10%>, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%), 95% or 99.9%) with at least one of the modified nucleoside disclosed herein.

13647Table 9

13648<img file="WO2013151663A1_D0152.tif" /> pseudouridine

13649pseudoisocytidine/about 25% of uridines are Nl - methyl-pseudouridine and about 25% of uridines are pseudouridine

13650pyrrolo-cytidine pyrrolo-cytidine/5-iodo-uridine

13651pyrrolo-cytidine/N 1 -methyl-pseudouridine

13652pyrrolo-cytidine/ a-thio-uridine

13653pyrrolo-cytidine/5-methyl-uridine

13654pyrrolo-cytidine/pseudouridine

13655about 50% of the cytosines are pyrrolo-cytidine

136565 -methyl-cytidine 5-methyl-cytidine/5-iodo-uridine

136575-methyl-cytidine/N 1 -methyl-pseudouridine

136585-methyl-cytidine/a-thio-uridine

136595 -methyl-cytidine/ 5 -methyl-uridine

136605-methyl-cytidine/pseudouridine

13661about 25% of cytosines are 5 -methyl-cytidine

13662about 50% of cytosines are 5 -methyl-cytidine

136635 -methyl-cytidine/ 5 -methoxy-uridine

136645 -methyl-cytidine/ 5 -bromo-uridine

136655-methyl-cytidine/2-thio-uridine

136665-methyl-cytidine/about 50% of uridines are 2-thio- uridine

13667about 50% of uridines are 5 -methyl-cytidine/ about 50% of uridines are 2-thio-uridine

13668N4-acetyl-cytidine N4-acetyl-cytidine /5-iodo-uridine

13669N4-acetyl-cytidine /N 1 -methyl-pseudouridine

13670N4-acetyl-cytidine /a-thio-uridine

13671N4-acetyl-cytidine 15 -methyl-uridine

13672N4-acetyl-cytidine /pseudouridine

13673about 50% of cytosines are N4-acetyl-cytidine about 25% of cytosines are N4-acetyl-cytidine

13674N4-acetyl-cytidine 15 -methoxy-uridine

13675N4-acetyl-cytidine /5-bromo-uridine

13676N4-acetyl-cytidine /2-thio-uridine

13677about 50% of cytosines are N4-acetyl-cytidine/ about 50% of uridines are 2-thio-uridine

13678[000479] Further examples of modified nucleotide combinations are provided below in Table 10. These combinations of modified nucleotides can be used to form the polypeptides, primary constructs, or mmRNA of the invention.

13679Table 10

13680<img file="WO2013151663A1_D0153.tif" /> Formula (b 10) modified cytidine with (bl0)/5-methyl-uridine

13681modified cytidine with (bl0)/5-bromo-uridine

13682modified cytidine with (b 10)/2-thio-uridine

13683about 50% of cytidine substituted with modified cytidine (blO)/ about 50% of uridines are 2-thio-uridine

13684modified cytidine modified cytidine with (b32)/pseudouridine

13685having one or more modified cytidine with (b32)/Nl-methyl-pseudouridine

13686nucleobases of modified cytidine with (b32)/5-methoxy-uridine

13687Formula (b32) modified cytidine with (b32)/5-methyl-uridine

13688modified cytidine with (b32)/5-bromo-uridine

13689modified cytidine with (b32)/2-thio-uridine

13690about 50% of cytidine substituted with modified cytidine (b32)/ about 50% of uridines are 2-thio-uridine

13691modified uridine modified uridine with (bl)/ N4-acetyl-cytidine

13692having one or more modified uridine with (bl)/ 5-methyl-cytidine

13693nucleobases of

13694Formula (bl)

13695modified uridine modified uridine with (b8)/ N4-acetyl-cytidine

13696having one or more modified uridine with (b8)/ 5-methyl-cytidine

13697nucleobases of

13698Formula (b8)

13699modified uridine modified uridine with (b28)/ N4-acetyl-cytidine

13700having one or more modified uridine with (b28)/ 5-methyl-cytidine

13701nucleobases of

13702Formula (b28)

13703modified uridine modified uridine with (b29)/ N4-acetyl-cytidine

13704having one or more modified uridine with (b29)/ 5-methyl-cytidine

13705nucleobases of

13706Formula (b29)

13707modified uridine modified uridine with (b30)/ N4-acetyl-cytidine

13708having one or more modified uridine with (b30)/ 5-methyl-cytidine

13709nucleobases of

13710Formula (b30)

13711[000480] In some embodiments, at least 25 %> of the cytosines are replaced by a compound of Formula (M0)-(bl4) (e.g., at least about 30%>, at least about 35%>, at least about 40%), at least about 45%>, at least about 50%>, at least about 55%>, at least about 60%>, at least about 65%>, at least about 70%>, at least about 75%>, at least about 80%>, at least about 85%o, at least about 90%>, at least about 95%>, or about 100%).

13712[000481] In some embodiments, at least 25 %> of the uracils are replaced by a compound of Formula (bl)-(b9) (e.g., at least about 30%>, at least about 35%>, at least about 40%>, at least about 45%>, at least about 50%>, at least about 55%>, at least about 60%>, at least about 65%o, at least about 70%>, at least about 75%>, at least about 80%>, at least about 85%>, at least about 90%, at least about 95%, or about 100%). [000482] In some embodiments, at least 25% of the cytosines are replaced by a compound of Formula (M0)-(bl4), and at least 25% of the uracils are replaced by a compound of Formula (bl)-(b9) (e.g., at least about 30%>, at least about 35%, at least about 40%), at least about 45%, at least about 50%>, at least about 55%, at least about 60%>, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%), at least about 90%, at least about 95%, or about 100%).

13713IV. Pharmaceutical Compositions

13714Formulation, Administration, Delivery and Dosing

13715[000483] The present invention provides polynucleotides, primary constructs and mmRNA compositions and complexes in combination with one or more pharmaceutically acceptable excipients. Pharmaceutical compositions may optionally comprise one or more additional active substances, e.g. therapeutically and/or prophylactically active substances. General considerations in the formulation and/or manufacture of

13716pharmaceutical agents may be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference).

13717[000484] In some embodiments, compositions are administered to humans, human patients or subjects. For the purposes of the present disclosure, the phrase "active ingredient" generally refers to polynucleotides, primary constructs and mmRNA to be delivered as described herein.

13718[000485] Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to any other animal, e.g., to non-human animals, e.g. non-human mammals. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary

13719pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical

13720compositions is contemplated include, but are not limited to, humans and/or other primates; mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice, and/or rats; and/or birds, including commercially relevant birds such as poultry, chickens, ducks, geese, and/or turkeys.

13721[000486] Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.

13722[000487] A pharmaceutical composition in accordance with the invention may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a "unit dose" is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one -third of such a dosage.

13723[000488] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100%, e.g., between .5 and 50%, between 1-30%, between 5-80%, at least 80%) (w/w) active ingredient.

13724Formulations

13725[000489] The polynucleotide, primary construct, and mmRNA of the invention can be formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection; (3) permit the sustained or delayed release (e.g., from a depot formulation of the polynucleotide, primary construct, or mmRNA); (4) alter the biodistribution (e.g., target the polynucleotide, primary construct, or mmRNA to specific tissues or cell types); (5) increase the translation of encoded protein in vivo; and/or (6) alter the release profile of encoded protein in vivo. In addition to traditional excipients such as any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents,

13726preservatives, excipients of the present invention can include, without limitation, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with polynucleotide, primary construct, or mmRNA (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics and combinations thereof. Accordingly, the formulations of the invention can include one or more excipients, each in an amount that together increases the stability of the

13727polynucleotide, primary construct, or mmRNA, increases cell transfection by the polynucleotide, primary construct, or mmRNA, increases the expression of

13728polynucleotide, primary construct, or mmRNA encoded protein, and/or alters the release profile of polynucleotide, primary construct, or mmRNA encoded proteins. Further, the primary construct and mmRNA of the present invention may be formulated using self- assembled nucleic acid nanoparticles.

13729[000490] Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of associating the active ingredient with an excipient and/or one or more other accessory ingredients.

13730[000491] A pharmaceutical composition in accordance with the present disclosure may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a "unit dose" refers to a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient may generally be equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage including, but not limited to, one-half or one-third of such a dosage.

13731[000492] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w/w) of the active ingredient. [000493] In some embodiments, the formulations described herein may contain at least one mmRNA. As a non-limiting example, the formulations may contain 1, 2, 3, 4 or 5 mmRNA. In one embodiment the formulation may contain modified mRNA encoding proteins selected from categories such as, but not limited to, human proteins, veterinary proteins, bacterial proteins, biological proteins, antibodies, immunogenic proteins, therapeutic peptides and proteins, secreted proteins, plasma membrane proteins, cytoplasmic and cytoskeletal proteins, intrancellular membrane bound proteins, nuclear proteins, proteins associated with human disease and/or proteins associated with non- human diseases. In one embodiment, the formulation contains at least three modified mRNA encoding proteins. In one embodiment, the formulation contains at least five modified mRNA encoding proteins.

13732[000494] Pharmaceutical formulations may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes, but is not limited to, any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents,

13733preservatives, and the like, as suited to the particular dosage form desired. Various excipients for formulating pharmaceutical compositions and techniques for preparing the composition are known in the art (see Remington: The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro, Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety). The use of a conventional excipient medium may be contemplated within the scope of the present disclosure, except insofar as any conventional excipient medium may be incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition.

13734[000495] In some embodiments, the particle size of the lipid nanoparticle may be increased and/or decreased. The change in particle size may be able to help counter biological reaction such as, but not limited to, inflammation or may increase the biological effect of the modified mRNA delivered to mammals.

13735[000496] Pharmaceutically acceptable excipients used in the manufacture of

13736pharmaceutical compositions include, but are not limited to, inert diluents, surface active agents and/or emulsifiers, preservatives, buffering agents, lubricating agents, and/or oils. Such excipients may optionally be included in the pharmaceutical formulations of the invention.

13737Lipidoids

13738[000497] The synthesis of lipidoids has been extensively described and formulations containing these compounds are particularly suited for delivery of polynucleotides, primary constructs or mmRNA (see Mahon et al., Bioconjug Chem. 2010 21 : 1448-1454; Schroeder et al, J Intern Med. 2010 267:9-21; Akinc et al, Nat Biotechnol. 2008 26:561- 569; Love et al, Proc Natl Acad Sci U S A. 2010 107: 1864-1869; Siegwart et al, Proc Natl Acad Sci U S A. 2011 108: 12996-3001; all of which are incorporated herein in their entireties).

13739[000498] While these lipidoids have been used to effectively deliver double stranded small interfering RNA molecules in rodents and non-human primates (see Akinc et al., Nat Biotechnol. 2008 26:561-569; Frank-Kamenetsky et al, Proc Natl Acad Sci U S A. 2008 105:11915-11920; Akinc et al, Mol Ther. 2009 17:872-879; Love et al, Proc Natl Acad Sci U S A. 2010 107: 1864-1869; Leuschner et al, Nat Biotechnol. 2011 29: 1005- 1010; all of which is incorporated herein in their entirety), the present disclosure describes their formulation and use in delivering single stranded polynucleotides, primary constructs, or mmRNA. Complexes, micelles, liposomes or particles can be prepared containing these lipidoids and therefore, can result in an effective delivery of the polynucleotide, primary construct, or mmRNA, as judged by the production of an encoded protein, following the injection of a lipidoid formulation via localized and/or systemic routes of administration. Lipidoid complexes of polynucleotides, primary constructs, or mmRNA can be administered by various means including, but not limited to, intravenous, intramuscular, or subcutaneous routes.

13740[000499] In vivo delivery of nucleic acids may be affected by many parameters, including, but not limited to, the formulation composition, nature of particle PEGylation, degree of loading, oligonucleotide to lipid ratio, and biophysical parameters such as, but not limited to, particle size (Akinc et al., Mol Ther. 2009 17:872-879; herein incorporated by reference in its entirety). As an example, small changes in the anchor chain length of poly(ethylene glycol) (PEG) lipids may result in significant effects on in vivo efficacy. Formulations with the different lipidoids, including, but not limited to penta[3-(l- laurylaminopropionyl)]-triethylenetetramine hydrochloride (TETA-5LAP; aka 98N12-5, see Murugaiah et al., Analytical Biochemistry, 401 :61 (2010); herein incorporated by reference in its entirety), CI 2-200 (including derivatives and variants), and MD1, can be tested for in vivo activity.

13741[000500] The lipidoid referred to herein as "98N12-5" is disclosed by Akinc et al, Mol Ther. 2009 17:872-879 and is incorporated by reference in its entirety. (See Figure 2)

13742[000501] The lipidoid referred to herein as "C12-200" is disclosed by Love et al, Proc Natl Acad Sci U S A. 2010 107: 1864-1869 (see Figure 2) and Liu and Huang, Molecular Therapy. 2010 669-670 (see Figure 2); both of which are herein incorporated by reference in their entirety. The lipidoid formulations can include particles comprising either 3 or 4 or more components in addition to polynucleotide, primary construct, or mmRNA. As an example, formulations with certain lipidoids, include, but are not limited to, 98N12-5 and may contain 42% lipidoid, 48% cholesterol and 10% PEG (CI 4 alkyl chain length). As another example, formulations with certain lipidoids, include, but are not limited to, C12-200 and may contain 50%> lipidoid, 10%> disteroylphosphatidyl choline, 38.5% cholesterol, and 1.5% PEG-DMG.

13743[000502] In one embodiment, a polynucleotide, primary construct, or mmRNA formulated with a lipidoid for systemic intravenous administration can target the liver. For example, a final optimized intravenous formulation using polynucleotide, primary construct, or mmRNA, and comprising a lipid molar composition of 42% 98N12-5, 48% cholesterol, and 10% PEG-lipid with a final weight ratio of about 7.5 to 1 total lipid to polynucleotide, primary construct, or mmRNA, and a C14 alkyl chain length on the PEG lipid, with a mean particle size of roughly 50-60 nm, can result in the distribution of the formulation to be greater than 90% to the liver.(see, Akinc et al, Mol Ther. 2009 17:872- 879; herein incorporated by reference in its entirety). In another example, an intravenous formulation using a C12-200 (see US provisional application 61/175,770 and published international application WO2010129709, each of which is herein incorporated by reference in their entirety) lipidoid may have a molar ratio of 50/10/38.5/1.5 of C12- 200/disteroylphosphatidyl choline/cholesterol/PEG-DMG, with a weight ratio of 7 to 1 total lipid to polynucleotide, primary construct, or mmRNA, and a mean particle size of 80 nm may be effective to deliver polynucleotide, primary construct, or mmRNA to hepatocytes (see, Love et al, Proc Natl Acad Sci U S A. 2010 107: 1864-1869 herein incorporated by reference in its entirety). In another embodiment, an MD1 lipidoid- containing formulation may be used to effectively deliver polynucleotide, primary construct, or mmRNA to hepatocytes in vivo. The characteristics of optimized lipidoid formulations for intramuscular or subcutaneous routes may vary significantly depending on the target cell type and the ability of formulations to diffuse through the extracellular matrix into the blood stream. While a particle size of less than 150 nm may be desired for effective hepatocyte delivery due to the size of the endothelial fenestrae (see, Akinc et al., Mol Ther. 2009 17:872-879 herein incorporated by reference in its entirety), use of a lipidoid-formulated polynucleotide, primary construct, or mmRNA to deliver the formulation to other cells types including, but not limited to, endothelial cells, myeloid cells, and muscle cells may not be similarly size-limited. Use of lipidoid formulations to deliver siRNA in vivo to other non-hepatocyte cells such as myeloid cells and

13744endothelium has been reported (see Akinc et al., Nat Biotechnol. 2008 26:561-569;

13745Leuschner et al, Nat Biotechnol. 2011 29: 1005-1010; Cho et al. Adv. Funct. Mater. 2009 19:3112-3118; 8th International Judah Folkman Conference, Cambridge, MA October 8- 9, 2010; each of which is herein incorporated by reference in its entirety). Effective delivery to myeloid cells, such as monocytes, lipidoid formulations may have a similar component molar ratio. Different ratios of lipidoids and other components including, but not limited to, disteroylphosphatidyl choline, cholesterol and PEG-DMG, may be used to optimize the formulation of the polynucleotide, primary construct, or mmRNA for delivery to different cell types including, but not limited to, hepatocytes, myeloid cells, muscle cells, etc. For example, the component molar ratio may include, but is not limited to, 50% C12-200, 10% disteroylphosphatidyl choline, 38.5% cholesterol, and %1.5 PEG- DMG (see Leuschner et al., Nat Biotechnol 2011 29: 1005-1010; herein incorporated by reference in its entirety). The use of lipidoid formulations for the localized delivery of nucleic acids to cells (such as, but not limited to, adipose cells and muscle cells) via either subcutaneous or intramuscular delivery, may not require all of the formulation components desired for systemic delivery, and as such may comprise only the lipidoid and the polynucleotide, primary construct, or mmRNA. [000503] Combinations of different lipidoids may be used to improve the efficacy of polynucleotide, primary construct, or mmRNA directed protein production as the lipidoids may be able to increase cell transfection by the polynucleotide, primary construct, or mmRNA; and/or increase the translation of encoded protein (see Whitehead et al., Mol. Ther. 2011, 19: 1688-1694, herein incorporated by reference in its entirety). Liposomes, Lipoplexes, and Lipid Nanoparticles

13746[000504] The polynucleotide, primary construct, and mmRNA of the invention can be formulated using one or more liposomes, lipoplexes, or lipid nanoparticles. In one embodiment, pharmaceutical compositions of polynucleotide, primary construct, or mmRNA include liposomes. Liposomes are artificially-prepared vesicles which may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of nutrients and pharmaceutical formulations. Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV) which may be hundreds of nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV) which may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) which may be between 50 and 500 nm in diameter. Liposome design may include, but is not limited to, opsonins or ligands in order to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH in order to improve the delivery of the pharmaceutical formulations.

13747[000505] The formation of liposomes may depend on the physicochemical

13748characteristics such as, but not limited to, the pharmaceutical formulation entrapped and the liposomal ingredients , the nature of the medium in which the lipid vesicles are dispersed, the effective concentration of the entrapped substance and its potential toxicity, any additional processes involved during the application and/or delivery of the vesicles, the optimization size, polydispersity and the shelf-life of the vesicles for the intended application, and the batch-to-batch reproducibility and possibility of large-scale production of safe and efficient liposomal products.

13749[000506] In one embodiment, pharmaceutical compositions described herein may include, without limitation, liposomes such as those formed from 1,2-dioleyloxy-NN- dimethylaminopropane (DODMA) liposomes, DiLa2 liposomes from Marina Biotech (Bothell, WA), 1 ,2-dilinoleyloxy-3 -dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl- 4-(2-dimethylaminoethyl)-[l,3]-dioxolane (DLin-KC2-DMA), and MC3

13750(US20100324120; herein incorporated by reference in its entirety) and liposomes which may deliver small molecule drugs such as, but not limited to, DOXIL® from Janssen Biotech, Inc. (Horsham, PA).

13751[000507] In one embodiment, pharmaceutical compositions described herein may include, without limitation, liposomes such as those formed from the synthesis of stabilized plasmid-lipid particles (SPLP) or stabilized nucleic acid lipid particle (SNALP) that have been previously described and shown to be suitable for oligonucleotide delivery in vitro and in vivo (see Wheeler et al. Gene Therapy. 1999 6:271-281; Zhang et al. Gene Therapy. 1999 6: 1438-1447; Jeffs et al. Pharm Res. 2005 22:362-372; Morrissey et al, Nat Biotechnol. 2005 2: 1002-1007; Zimmermann et al, Nature. 2006 441 : 111-114; Heyes et al. J Contr Rel. 2005 107:276-287; Semple et al. Nature Biotech. 2010 28: 172- 176; Judge et al. J Clin Invest. 2009 1 19:661-673; deFougerolles Hum Gene Ther. 2008 19: 125-132; all of which are incorporated herein in their entireties). The original manufacture method by Wheeler et al. was a detergent dialysis method, which was later improved by Jeffs et al. and is referred to as the spontaneous vesicle formation method. The liposome formulations are composed of 3 to 4 lipid components in addition to the polynucleotide, primary construct, or mmRNA. As an example a liposome can contain, but is not limited to, 55% cholesterol, 20% disteroylphosphatidyl choline (DSPC), 10%> PEG-S-DSG, and 15% l,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), as described by Jeffs et al. As another example, certain liposome formulations may contain, but are not limited to, 48% cholesterol, 20% DSPC, 2% PEG-c-DMA, and 30% cationic lipid, where the cationic lipid can be 1 ,2-distearloxy-N,N-dimethylaminopropane

13752(DSDMA), DODMA, DLin-DMA, or 1 ,2-dilinolenyloxy-3 -dimethylaminopropane (DLenDMA), as described by Heyes et al.

13753[000508] In one embodiment, pharmaceutical compositions may include liposomes which may be formed to deliver mmRNA which may encode at least one immunogen. The mmRNA may be encapsulated by the liposome and/or it may be contained in an aqueous core which may then be encapsulated by the liposome (see International Pub. Nos. WO2012031046, WO2012031043, WO2012030901 and WO2012006378; each of which is herein incorporated by reference in their entirety). In another embodiment, the mmRNA which may encode an immunogen may be formulated in a cationic oil-in-water emulsion where the emulsion particle comprises an oil core and a cationic lipid which can interact with the mmRNA anchoring the molecule to the emulsion particle (see

13754International Pub. No. WO2012006380; herein incorporated by reference in its entirety). In yet another embodiment, the lipid formulation may include at least cationic lipid, a lipid which may enhance transfection and a least one lipid which contains a hydrophilic head group linked to a lipid moiety (International Pub. No. WO2011076807 and U.S. Pub. No. 20110200582; each of which is herein incorporated by reference in their entirety). In another embodiment, the polynucleotides, primary constructs and/or mmRNA encoding an immunogen may be formulated in a lipid vesicle which may have crosslinks between functionalized lipid bilayers (see U.S. Pub. No. 20120177724, herein incorporated by reference in its entirety).

13755[000509] In one embodiment, the polynucleotides, primary constructs and/or mmRNA may be formulated in a lipid vesicle which may have crosslinks between functionalized lipid bilayers.

13756[000510] In one embodiment, the polynucleotides, primary constructs and/or mmRNA may be formulated in a liposome comprising a cationic lipid. The liposome may have a molar ratio of nitrogen atoms in the cationic lipid to the phophates in the RNA (N:P ratio) of between 1 : 1 and 20: 1 as described in International Publication No. WO2013006825, herein incorporated by reference in its entirety. In another embodiment, the liposome may have a N:P ratio of greater than 20: 1 or less than 1 : 1.

13757[000511] In one embodiment, the polynucleotides, primary constructs and/or mmRNA may be formulated in a lipid-polycation complex. The formation of the lipid-polycation complex may be accomplished by methods known in the art and/or as described in U.S. Pub. No. 20120178702, herein incorporated by reference in its entirety. As a non- limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine and the cationic peptides described in International Pub. No. WO2012013326; herein incorporated by reference in its entirety. In another embodiment, the polynucleotides, primary constructs and/or mmR A may be formulated in a lipid-polycation complex which may further include a neutral lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamme (DOPE).

13758[000512] The liposome formulation may be influenced by, but not limited to, the selection of the cationic lipid component, the degree of cationic lipid saturation, the nature of the PEGylation, ratio of all components and biophysical parameters such as size. In one example by Semple et al. (Semple et al. Nature Biotech. 2010 28: 172-176; herein incorporated by reference in its entirety), the liposome formulation was composed of 57.1 % cationic lipid, 7.1% dipalmitoylphosphatidylcholine, 34.3 % cholesterol, and 1.4% PEG-c-DMA. As another example, changing the composition of the cationic lipid could more effectively deliver siRNA to various antigen presenting cells (Basha et al. Mol Ther. 2011 19:2186-2200; herein incorporated by reference in its entirety).

13759[000513] In some embodiments, the ratio of PEG in the lipid nanoparticle (LNP) formulations may be increased or decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or

13760biodistribution of the LNP formulations. As a non-limiting example, LNP formulations may contain 1-5% of the lipid molar ratio of PEG-c-DOMG as compared to the cationic lipid, DSPC and cholesterol. In another embodiment the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG- DSG (1,2-Distearoyl-sn-glycerol, methoxypoly ethylene glycol) or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol,

13761methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, DLin-MC3 -DMA, DLin-DMA, C 12-200 and DLin- KC2-DMA.

13762[000514] In one embodiment, the polynucleotides, primary constructs or mmRNA may be formulated in a lipid nanoparticle such as those described in International Publication

13763No. WO2012170930, herein incorporated by reference in its entirety.

13764[000515] In one embodiment, the cationic lipid may be selected from, but not limited to, a cationic lipid described in International Publication Nos. WO2012040184,

WO2011153120, WO2011149733, WO2011090965, WO2011043913, WO2011022460,

13766WO2012061259, WO2012054365, WO2012044638, WO2010080724, WO201021865 and WO2008103276, US Patent Nos. 7,893,302, 7,404,969 and 8,283,333 and US Patent Publication No. US20100036115 and US20120202871; each of which is herein incorporated by reference in their entirety. In another embodiment, the cationic lipid may be selected from, but not limited to, formula A described in International Publication Nos. WO2012040184, WO2011153120, WO2011149733, WO2011090965,

13767WO2011043913, WO2011022460, WO2012061259, WO2012054365 and

13768WO2012044638; each of which is herein incorporated by reference in their entirety. In yet another embodiment, the cationic lipid may be selected from, but not limited to, formula CLI-CLXXIX of International Publication No. WO2008103276, formula CLI- CLXXIX of US Patent No. 7,893,302, formula CLI-CLXXXXII of US Patent No.

137697,404,969 and formula I-VI of US Patent Publication No. US20100036115; each of which is herein incorporated by reference in their entirety. As a non-limiting example, the cationic lipid may be selected from (20Z,23Z)-N,N-dimethylnonacosa-20,23-dien-10- amine, ( 17Z,20Z)-N,N-dimemylhexacosa- 17,20-dien-9-amine, ( 1 Z, 19Z)-N5N- dimethylpentacosa-1 6, 19-dien-8-amine, (13Z,16Z)-N,N-dimethyldocosa-13,16-dien-5- amine, ( 12Z, 15Z)-N,N-dimethylhenicosa- 12, 15-dien-4-amine, (14Z, 17Z)-N,N- dimethyltricosa- 14,17-dien-6-amine, (15Z, 18Z)-N,N-dimethyltetracosa- 15,18-dien-7- amine, ( 18Z,21 Z)-N,N-dimethylheptacosa- 18 ,21 -dien- 10-amine, ( 15Z, 18Z)-N,N- dimethyltetracosa- 15,18-dien-5-amine, ( 14Z, 17Z)-N,N-dimethyltricosa- 14,17-dien-4- amine, (19Z,22Z)-N,N-dimeihyloctacosa-19,22-dien-9-amine, (18Z,21 Z)-N,N- dimethylheptacosa- 18 ,21 -dien-8 -amine, (17Z,20Z)-N,N-dimethylhexacosa- 17,20- dien-7-amine, ( 16Z, 19Z)-N,N-dimethylpentacosa- 16,19-dien-6-amine, (22Z,25Z)-N,N- dimethylhentriaconta-22,25-dien-10-amine, (21 Z ,24Z)-N,N-dimethyltriaconta-21,24- dien-9-amine, (18Z)-N,N-dimetylheptacos- 18-en- 10-amine, ( 17Z)-N,N-dimethylhexacos- 17-en-9-amine, ( 19Z,22Z)-N,N-dimethyloctacosa- 19,22-dien-7-amine, N,N- dimethylheptacosan- 10-amine, (20Z,23Z)-N-ethyl-N-methylnonacosa-20,23-dien-10- amine, 1-[(1 lZ,14Z)-l-nonylicosa-l 1,14-dien-l-yl] pyrrolidine, (20Z)-N,N- dimethylheptacos-20-en-l 0-amine, (15Z)-N,N-dimethyl eptacos-15-en-l 0-amine, (14Z)- Ν,Ν-dimethylnonacos- 14-en-10-amine, ( 17Z)-N,N-dimethylnonacos- 17-en-10-amine, (24Z)-N,N-dimethyltritriacont-24-en-10-amine, (20Z)-N,N-dimethylnonacos-20-en-l 0- amine, (22Z)-N,N-dimethylhentriacont-22-en-10-amine, ( 16Z)-N,N-dimethylpentacos- 16- en-8-amine, (12Z, 15Z)-N,N-dimethyl-2-nonylhenicosa- 12, 15 -dien- 1 -amine, ( 13Z, 16Z)- N,N-dimethyl-3-nonyldocosa-13,16-dien-l-amine, N,N-dimethyl-l-[(lS,2R)-2- octylcyclopropyl] eptadecan-8-amine, 1 -[(1 S,2R)-2-hexylcyclopropyl]-N,N- dimethylnonadecan-10-amine, N,N-dimethyl-l-[(lS ,2R)-2-octylcyclopropyl]nonadecan- 10-amine, N,N-dimethyl-21 -[(lS,2R)-2-octylcyclopropyl]henicosan-10-amine,N,N- dimethyl-l-[(lS,2S)-2-{[(lR,2R)-2-pentylcycIopropyl]methyl}cyclopropyl]nonadecan- 10-amine,N,N-dimethyl-l-[(lS,2R)-2-octylcyclopropyl]hexadecan-8-amine, N,N- dimethyl-[(lR,2S)-2-undecyIcyclopropyl]tetradecan-5-amine, N,N-dimethyl-3-{7- [(lS,2R)-2-octylcyclopropyl]heptyl} dodecan-1 -amine, l-[(lR,2S)-2-hepty

13770lcyclopropyl]-N,N-dimethyloctadecan-9-amine, l-[(lS,2R)-2-decylcyclopropyl]-N,N- dimethylpentadecan-6-amine, N,N-dimethyl-l-[(lS,2R)-2-octylcyclopropyl]pentadecan-8- amine, R-N,N-dimethyl-l-[(9Z,12Z)-octadeca-9,12-dien-l-yloxy]-3-(octyloxy)propan-2- amine, S-N,N-dimethyl- 1 -[(9Z, 12Z)-octadeca-9, 12-dien- 1 -yloxy]-3-(octyloxy)propan-2- amine, 1 - {2-[(9Z, 12Z)-octadeca-9, 12-dien- 1 -yloxy]- 1 -

13771[(octyloxy)methyl]ethyl}pyrrolidine, (2S)-N,N-dimethyl-l-[(9Z,12Z)-octadeca-9,12- dien-l-yloxy]-3-[(5Z)-oct-5-en-l-yloxy]propan-2-amine, l-{2-[(9Z,12Z)-octadeca-9,12- dien- 1 -yloxy]- 1 -[(octyloxy)methyl]ethyl} azetidine, (2S)- 1 -(hexyloxy)-N,N-dimethyl-3- [(9Z, 12Z)-octadeca-9, 12-dien- 1 -yloxy]propan-2-amine, (2S)- 1 -(heptyloxy)-N,N- dimethyl-3-[(9Z, 12Z)-octadeca-9, 12-dien- 1 -yloxy]propan-2-amine, Ν,Ν-dimethyl- 1 - (nonyloxy)-3 - [(9Z, 12Z)-octadeca-9, 12-dien- 1 -yloxy]propan-2-amine, Ν,Ν-dimethyl- 1 - [(9Z)-octadec-9-en- 1 -yloxy]-3-(octyloxy)propan-2-amine; (2S)-N,N-dimethyl- 1 - [(6Z,9Z, 12Z)-octadeca-6,9, 12-trien- 1 -yloxy]-3-(octyloxy)propan-2-amine, (2S)- 1 - [(1 lZ,14Z)-icosa-l l,14-dien-l-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine, (2S)- l-(hexyloxy)-3-[(l lZ,14Z)-icosa-l l,14-dien-l-yloxy]-N,N-dimethylpropan-2-amine, 1- [(1 lZ,14Z)-icosa-l l,14-dien-l-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1- [(13Z, 16Z)-docosa-13, 16-dien-l-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2S)- 1 - [( 13Z, 16Z)-docosa- 13,16-dien- 1 -yloxy] -3 -(hexyloxy)-N,N-dimethylpropan-2-amine, (2S)- 1 -[(13Z)-docos- 13-en- 1 -yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine, 1 - [(13Z)-docos- 13-en- 1 -yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1 -[(9Z)- hexadec-9-en- 1 -yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2R)-N,N-dimethyl- H( 1 -metoylo ctyl)oxy ]-3 - [(9Z, 12Z)-octadeca-9, 12-dien- 1 -yloxy]propan-2-amine, (2R)- 1 - [(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-l-yloxy]propan- 2-amine, Ν,Ν-dimethyl- 1 - (octyloxy)-3 -( { 8-[( 1 S ,2S)-2- { [( 1 R,2R)-2- pentylcyclopropyl]methyl} cyclopropyl]octyl} oxy)propan-2-amine, Ν,Ν-dimethyl- 1 - { [8- (2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-amine and (11E,20Z,23Z)-N,N- dimethylnonacosa-ll ,20,2-trien-10-amine or a pharmaceutically acceptable salt or stereoisomer thereof.

13772[000516] In one embodiment, the lipid may be a cleavable lipid such as those described in International Publication No. WO2012170889, herein incorporated by reference in its entirety.

13773[000517] In one embodiment, the cationic lipid may be synthesized by methods known in the art and/or as described in International Publication Nos. WO2012040184,

13774WO2011153120, WO2011149733, WO2011090965, WO2011043913, WO2011022460, WO2012061259, WO2012054365, WO2012044638, WO2010080724 and

13775WO201021865; each of which is herein incorporated by reference in their entirety.

13776[000518] In one embodiment, the LNP formulations of the polynucleotides, primary constructs and/or mmRNA may contain PEG-c-DOMG at 3% lipid molar ratio. In another embodiment, the LNP formulations polynucleotides, primary constructs and/or mmRNA may contain PEG-c-DOMG at 1.5% lipid molar ratio.

13777[000519] In one embodiment, the pharmaceutical compositions of the polynucleotides, primary constructs and/or mmRNA may include at least one of the PEGylated lipids described in International Publication No. 2012099755, herein incorporated by reference.

13778[000520] In one embodiment, the LNP formulation may contain PEG-DMG 2000 (1 ,2- dimyristoyl-sn-glycero-3 -phophoethanolamine-N- [methoxy(poly ethylene glycol)-2000) . In one embodiment, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art and at least one other component. In another embodiment, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art, DSPC and cholesterol. As a non-limiting example, the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol. As another non-limiting example the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol in a molar ratio of 2:40: 10:48 (see e.g., Geall et al., Nonviral delivery of self-amplifying RNA vaccines, PNAS 2012; PMID: 22908294; herein incorporated by reference in its entirety). . As another non-limiting example, modified RNA described herein may be formulated in a nanoparticle to be delivered by a parenteral route as described in U.S. Pub. No. 20120207845; herein incorporated by reference in its entirety.

13779In one embodiment, the LNP formulation may be formulated by the methods described in International Publication Nos. WO2011127255 or WO2008103276, each of which is herein incorporated by reference in their entirety. As a non-limiting example, modified RNA described herein may be encapsulated in LNP formulations as described in

13780WO2011127255 and/or WO2008103276; each of which is herein incorporated by reference in their entirety.

13781In one embodiment, LNP formulations described herein may comprise a polycationic composition. As a non-limiting example, the polycationic composition may be selected from formula 1-60 of US Patent Publication No. US20050222064; herein incorporated by reference in its entirety. In another embodiment, the LNP formulations comprising a polycationic composition may be used for the delivery of the modified RNA described herein in vivo and/or in vitro.

13782[000521] In one embodiment, the LNP formulations described herein may additionally comprise a permeability enhancer molecule. Non-limiting permeability enhancer molecules are described in US Patent Publication No. US20050222064; herein incorporated by reference in its entirety.

13783[000522] In one embodiment, the pharmaceutical compositions may be formulated in liposomes such as, but not limited to, DiLa2 liposomes (Marina Biotech, Bothell, WA), SMARTICLES® (Marina Biotech, Bothell, WA), neutral DOPC (1,2-dioleoyl-sn- glycero-3-phosphocholine) based liposomes (e.g., siRNA delivery for ovarian cancer (Landen et al. Cancer Biology & Therapy 2006 5(12)1708-1713); herein incorporated by reference in its entirety) and hyaluronan-coated liposomes (Quiet Therapeutics, Israel).

13784[000523] The nanoparticle formulations may be a carbohydrate nanoparticle comprising a carbohydrate carrier and a modified nucleic acid molecule (e.g., mmRNA). As a non- limiting example, the carbohydrate carrier may include, but is not limited to, an anhydride-modified phytoglycogen or glycogen-type material, phtoglycogen octenyl succinate, phytoglycogen beta-dextrin, anhydride-modified phytoglycogen beta-dextrin. (See e.g., International Publication No. WO2012109121; herein incorporated by reference in its entirety). [000524] Lipid nanoparticle formulations may be improved by replacing the cationic lipid with a biodegradable cationic lipid which is known as a rapidly eliminated lipid nanoparticle (reLNP). Ionizable cationic lipids, such as, but not limited to, DLinDMA, DLin-KC2-DMA, and DLin-MC3-DMA, have been shown to accumulate in plasma and tissues over time and may be a potential source of toxicity. The rapid metabolism of the rapidly eliminated lipids can improve the tolerability and therapeutic index of the lipid nanoparticles by an order of magnitude from a 1 mg/kg dose to a 10 mg/kg dose in rat. Inclusion of an enzymatically degraded ester linkage can improve the degradation and metabolism profile of the cationic component, while still maintaining the activity of the reLNP formulation. The ester linkage can be internally located within the lipid chain or it may be terminally located at the terminal end of the lipid chain. The internal ester linkage may replace any carbon in the lipid chain.

13785[000525] In one embodiment, the internal ester linkage may be located on either side of the saturated carbon. Non-limitin examples of reLNPs include,

13786<img file="WO2013151663A1_D0154.tif" />

13787[000526] In one embodiment, an immune response may be elicited by delivering a lipid nanoparticle which may include a nanospecies, a polymer and an immunogen. (U.S. Publication No. 20120189700 and International Publication No. WO2012099805; each of which is herein incorporated by reference in their entirety). The polymer may

13788encapsulate the nanospecies or partially encapsulate the nanospecies. The immunogen may be a recombinant protein, a modified RNA and/or a primary construct described herein. In one embodiment, the lipid nanoparticle may be formulated for use in a vaccine such as, but not limited to, against a pathogen.

13789[000527] Lipid nanoparticles may be engineered to alter the surface properties of particles so the lipid nanoparticles may penetrate the mucosal barrier. Mucus is located on mucosal tissue such as, but not limted to, oral (e.g., the buccal and esophageal membranes and tonsil tissue), ophthalmic, gastrointestinal (e.g., stomach, small intestine, large intestine, colon, rectum), nasal, respiratory (e.g., nasal, pharyngeal, tracheal and bronchial membranes), genital (e.g., vaginal, cervical and urethral membranes).

13790Nanoparticles larger than 10-200 nm which are preferred for higher drug encapsulation efficiency and the ability to provide the sustained delivery of a wide array of drugs have been thought to be too large to rapidly diffuse through mucosal barriers. Mucus is continuously secreted, shed, discarded or digested and recycled so most of the trapped particles may be removed from the mucosla tissue within seconds or within a few hours. Large polymeric nanoparticles (200nm -500nm in diameter) which have been coated densely with a low molecular weight polyethylene glycol (PEG) diffused through mucus only 4 to 6-fold lower than the same particles diffusing in water (Lai et al. PNAS 2007 104(5): 1482-487; Lai et al. Adv Drug Deliv Rev. 2009 61(2): 158-171; each of which is herein incorporated by reference in their entirety). The transport of nanoparticles may be determined using rates of permeation and/or fluorescent microscopy techniques including, but not limited to, fluorescence recovery after photobleaching (FRAP) and high resolution multiple particle tracking (MPT). As a non- limiting example, compositions which can penetrate a mucosal barrier may be made as described in U.S. Pat. No. 8,241,670, herein incorporated by reference in its entirety.

13791[000528] The lipid nanoparticle engineered to penetrate mucus may comprise a polymeric material (i.e. a polymeric core) and/or a polymer-vitamin conjugate and/or a tri-block co-polymer. The polymeric material may include, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas,

13792polycarbonates, poly(styrenes), polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyeneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. The polymeric material may be biodegradable and/or biocompatible. The polymeric material may additionally be irradiated. As a non-limiting example, the polymeric material may be gamma irradiated (See e.g., International App. No. WO201282165, herein incorporated by reference in its entirety). Non-limiting examples of specific polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co- caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co- PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacralate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA),

13793polyethyleneglycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA),

13794poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate),

13795poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene, poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), and trimethylene carbonate, polyvinylpyrrolidone. The lipid nanoparticle may be coated or associated with a co-polymer such as, but not limited to, a block co-polymer (such as a branched polyether-polyamide block copolymer described in International Publication No. WO2013012476, herein incorporated by reference in its entirety), and (poly(ethylene glycol))-(poly(propylene oxide))- (poly(ethylene glycol)) triblock copolymer (see e.g., US Publication 20120121718 and US Publication 20100003337 and U.S. Pat. No. 8,263,665; each of which is herein incorporated by reference in their entirety). The co-polymer may be a polymer that is generally regarded as safe (GRAS) and the formation of the lipid nanoparticle may be in such a way that no new chemical entities are created. For example, the lipid nanoparticle may comprise poloxamers coating PLGA nanoparticles without forming new chemical entities which are still able to rapidly penetrate human mucus (Yang et al. Angew. Chem. Int. Ed. 2011 50:2597-2600; herein incorporated by reference in its entirety).

13796[000529] The vitamin of the polymer- vitamin conjugate may be vitamin E. The vitamin portion of the conjugate may be substituted with other suitable components such as, but not limited to, vitamin A, vitamin E, other vitamins, cholesterol, a hydrophobic moiety, or a hydrophobic component of other surfactants (e.g., sterol chains, fatty acids, hydrocarbon chains and alkylene oxide chains).

13797[000530] The lipid nanoparticle engineered to penetrate mucus may include surface altering agents such as, but not limited to, mmRNA, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as for example dimethyldioctadecyl- ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol and poloxamer), mucolytic agents (e.g., N- acetylcysteine, mugwort, bromelain, papain, clerodendrum, acetylcysteine, bromhexine, carbocisteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin β4 dornase alfa, neltenexine, erdosteine) and various DNases including rhDNase.. The surface altering agent may be embedded or enmeshed in the particle's surface or disposed (e.g., by coating, adsorption, covalent linkage, or other process) on the surface of the lipid nanoparticle. (see e.g., US Publication 20100215580 and US Publication 20080166414; each of which is herein incorporated by reference in their entirety).

13798[000531] The mucus penetrating lipid nanoparticles may comprise at least one mmRNA described herein. The mmRNA may be encapsulated in the lipid nanoparticle and/or disposed on the surface of the paricle. The mmRNA may be covalently coupled to the lipid nanoparticle. Formulations of mucus penetrating lipid nanoparticles may comprise a plurality of nanoparticles. Further, the formulations may contain particles which may interact with the mucus and alter the structural and/or adhesive properties of the surrounding mucus to decrease mucoadhesion which may increase the delivery of the mucus penetrating lipid nanoparticles to the mucosal tissue.

13799[000532] In one embodiment, the polynucleotide, primary construct, or mmRNA is formulated as a lipoplex, such as, without limitation, the ATUPLEX™ system, the DACC system, the DBTC system and other siRNA-lipoplex technology from Silence Therapeutics (London, United Kingdom), STEMFECT™ from STEMGENT®

13800(Cambridge, MA), and polyethylenimine (PEI) or protamine -based targeted and non- targeted delivery of nucleic acids acids (Aleku et al. Cancer Res. 2008 68:9788-9798; Strumberg et al. Int J Clin Pharmacol Ther 2012 50:76-78; Santel et al, Gene Ther 2006 13: 1222-1234; Santel et al, Gene Ther 2006 13: 1360-1370; Gutbier et al, Pulm

13801Pharmacol. Ther. 2010 23:334-344; Kaufmann et al. Microvasc Res 2010 80:286- 293Weide et al. J Immunother. 2009 32:498-507; Weide et al. J Immunother. 2008 31 : 180-188; Pascolo Expert Opin. Biol. Ther. 4: 1285-1294; Fotin-Mleczek et al, 2011 J. Immunother. 34: 1-15; Song et al, Nature Biotechnol. 2005, 23:709-717; Peer et al, Proc Natl Acad Sci U S A. 2007 6;104:4095-4100; deFougerolles Hum Gene Ther. 2008 19: 125-132; all of which are incorporated herein by reference in its entirety).

13802[000533] In one embodiment such formulations may also be constructed or

13803compositions altered such that they passively or actively are directed to different cell types in vivo, including but not limited to hepatocytes, immune cells, tumor cells, endothelial cells, antigen presenting cells, and leukocytes (Akinc et al. Mol Ther. 2010 18: 1357-1364; Song et al, Nat Biotechnol. 2005 23:709-717; Judge et al, J Clin Invest. 2009 119:661-673; Kaufmann et al, Microvasc Res 2010 80:286-293; Santel et al, Gene Ther 2006 13: 1222-1234; Santel et al, Gene Ther 2006 13: 1360-1370; Gutbier et al, Pulm Pharmacol. Ther. 2010 23:334-344; Basha et al, Mol. Ther. 2011 19:2186-2200; Fenske and Cullis, Expert Opin Drug Deliv. 2008 5:25-44; Peer et al, Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 2011 18: 1127-1133; all of which are incorporated herein by reference in its entirety). One example of passive targeting of formulations to liver cells includes the DLin-DMA, DLin-KC2-DMA and DLin-MC3- DMA-based lipid nanoparticle formulations which have been shown to bind to apolipoprotein E and promote binding and uptake of these formulations into hepatocytes in vivo (Akinc et al. Mol Ther. 2010 18:1357-1364; herein incorporated by reference in its entirety). Formulations can also be selectively targeted through expression of different ligands on their surface as exemplified by, but not limited by, folate, transferrin, N-acetylgalactosamine (GalNAc), and antibody targeted approaches (Kolhatkar et al., Curr Drug Discov Technol. 2011 8: 197-206; Musacchio and Torchilin, Front Biosci. 2011 16:1388-1412; Yu et al, Mol Membr Biol. 2010 27:286-298; Patil et al, Crit Rev Ther Drug Carrier Syst. 2008 25: 1-61; Benoit et al, Biomacromolecules. 2011 12:2708- 2714; Zhao et al, Expert Opin Drug Deliv. 2008 5:309-319; Akinc et al, Mol Ther. 2010 18: 1357-1364; Srinivasan et al, Methods Mol Biol. 2012 820: 105-116; Ben-Arie et al, Methods Mol Biol. 2012 757:497-507; Peer 2010 J Control Release. 20:63-68; Peer et al, Proc Natl Acad Sci U S A. 2007 104:4095-4100; Kim et al, Methods Mol Biol. 2011 721 :339-353; Subramanya et al, Mol Ther. 2010 18:2028-2037; Song et al, Nat

13804Biotechnol. 2005 23:709-717; Peer et al, Science. 2008 319:627-630; Peer and

13805Lieberman, Gene Ther. 2011 18: 1127-1133; all of which are incorporated herein by reference in its entirety)..

13806[000534] In one embodiment, the polynucleotide, primary construct, or mmRNA is formulated as a solid lipid nanoparticle. A solid lipid nanoparticle (SLN) may be spherical with an average diameter between 10 to 1000 nm. SLN possess a solid lipid core matrix that can solubilize lipophilic molecules and may be stabilized with

13807surfactants and/or emulsifiers. In a further embodiment, the lipid nanoparticle may be a self-assembly lipid-polymer nanoparticle (see Zhang et al, ACS Nano, 2008, 2 (8), pp 1696-1702; herein incorporated by reference in its entirety).

13808[000535] Liposomes, lipoplexes, or lipid nanoparticles may be used to improve the efficacy of polynucleotide, primary construct, or mmRNA directed protein production as these formulations may be able to increase cell transfection by the polynucleotide, primary construct, or mmRNA; and/or increase the translation of encoded protein. One such example involves the use of lipid encapsulation to enable the effective systemic delivery of polyplex plasmid DNA (Heyes et al, Mol Ther. 2007 15:713-720; herein incorporated by reference in its entirety). The liposomes, lipoplexes, or lipid

13809nanoparticles may also be used to increase the stability of the polynucleotide, primary construct, or mmRNA. [000536] In one embodiment, the the polynucleotides, primary constructs, and/or the mmRNA of the present invention can be formulated for controlled release and/or targeted delivery. As used herein, "controlled release" refers to a pharmaceutical composition or compound release profile that conforms to a particular pattern of release to effect a therapeutic outcome. In one embodiment, the polynucleotides, primary constructs or the mmRNA may be encapsulated into a delivery agent described herein and/or known in the art for controlled release and/or targeted delivery. As used herein, the term "encapsulate" means to enclose, surround or encase. As it relates to the formulation of the compounds of the invention, encapsulation may be substantial, complete or partial. The term

13810"substantially encapsulated" means that at least greater than 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.9 or greater than 99.999% of the pharmaceutical composition or compound of the invention may be enclosed, surrounded or encased within the delivery agent. "Partially encapsulation" means that less than 10, 10, 20, 30, 40 50 or less of the pharmaceutical composition or compound of the invention may be enclosed, surrounded or encased within the delivery agent. Advantageously, encapsulation may be determined by measuring the escape or the activity of the pharmaceutical composition or compound of the invention using fluorescence and/or electron micrograph. For example, at least 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of the pharmaceutical composition or compound of the invention are

13811encapsulated in the delivery agent.

13812[000537] In one embodiment, the controlled release formulation may include, but is not limited to, tri-block co-polymers. As a non-limiting example, the formulation may include two different types of tri-block co-polymers (International Pub. No.

13813WO2012131104 and WO2012131106; each of which is herein incorporated by reference in its entirety).

13814[000538] In another embodiment, the the polynucleotides, primary constructs, or the mmRNA may be encapsulated into a lipid nanoparticle or a rapidly eliminated lipid nanoparticle and the lipid nanoparticles or a rapidly eliminated lipid nanoparticle may then be encapsulated into a polymer, hydrogel and/or surgical sealant described herein and/or known in the art. As a non-limiting example, the polymer, hydrogel or surgical sealant may be PLGA, ethylene vinyl acetate (EVAc), poloxamer, GELSITE® (Nanotherapeutics, Inc. Alachua, FL), HYLENEX® (Halozyme Therapeutics, San Diego CA), surgical sealants such as fibrinogen polymers (Ethicon Inc. Cornelia, GA), TISSELL® (Baxter International, Inc Deerfield, IL), PEG-based sealants, and

13815COSEAL® (Baxter International, Inc Deerfield, IL).

13816[000539] In another embodiment, the lipid nanoparticle may be encapsulated into any polymer known in the art which may form a gel when injected into a subject. As another non-limiting example, the lipid nanoparticle may be encapsulated into a polymer matrix which may be biodegradable.

13817[000540] In one embodiment, the the polynucleotide, primary construct, or mmRNA formulation for controlled release and/or targeted delivery may also include at least one controlled release coating. Controlled release coatings include, but are not limited to, OPADRY®, polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, EUDRAGIT RL®, EUDRAGIT RS® and cellulose derivatives such as ethylcellulose aqueous dispersions (AQUACOAT® and SURELEASE®).

13818[000541] In one embodiment, the controlled release and/or targeted delivery formulation may comprise at least one degradable polyester which may contain polycationic side chains. Degradeable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In another embodiment, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.

13819[000542] In one embodiment, the the polynucleotides, primary constructs, and/or the mmRNA of the present invention may be encapsulated in a therapeutic nanoparticle. Therapeutic nanoparticles may be formulated by methods described herein and known in the art such as, but not limited to, International Pub Nos. WO2010005740,

13820WO2010030763, WO2010005721, WO2010005723, WO2012054923, US Pub. Nos. US20110262491, US20100104645, US20100087337, US20100068285,

13821US20110274759, US20100068286 and US20120288541 and US Pat No. 8,206,747, 8,293,276, 8,318,208 and 8,318,211 each of which is herein incorporated by reference in their entirety. In another embodiment, therapeutic polymer nanoparticles may be identified by the methods described in US Pub No. US20120140790, herein incorporated by reference in its entirety.

13822[000543] In one embodiment, the therapeutic nanoparticle may be formulated for sustained release. As used herein, "sustained release" refers to a pharmaceutical composition or compound that conforms to a release rate over a specific period of time. The period of time may include, but is not limited to, hours, days, weeks, months and years. As a non-limiting example, the sustained release nanoparticle may comprise a polymer and a therapeutic agent such as, but not limited to, the the polynucleotides, primary constructs, and mmRNA of the present invention (see International Pub No. 2010075072 and US Pub No. US20100216804, US20110217377 and US20120201859, each of which is herein incorporated by reference in their entirety).

13823[000544] In one embodiment, the therapeutic nanoparticles may be formulated to be target specific. As a non-limiting example, the thereapeutic nanoparticles may include a corticosteroid (see International Pub. No. WO2011084518; herein incorporated by reference in its entirety). In one embodiment, the therapeutic nanoparticles may be formulated to be cancer specific. As a non-limiting example, the therapeutic

13824nanoparticles may be formulated in nanoparticles described in International Pub No. WO2008121949, WO2010005726, WO2010005725, WO2011084521 and US Pub No. US20100069426, US20120004293 and US20100104655, each of which is herein incorporated by reference in their entirety.

13825[000545] In one embodiment, the nanoparticles of the present invention may comprise a polymeric matrix. As a non-limiting example, the nanoparticle may comprise two or more polymers such as, but not limited to, polyethylenes, polycarbonates,

13826polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof.

13827[000546] In one embodiment, the therapeutic nanoparticle comprises a diblock copolymer. In one embodiment, the diblock copolymer may include PEG in combination with a polymer such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof.

13828[000547] As a non-limiting example the therapeutic nanoparticle comprises a PLGA- PEG block copolymer (see US Pub. No. US20120004293 and US Pat No. 8,236,330, each of which is herein incorporated by reference in their entirety). In another non- limiting example, the therapeutic nanoparticle is a stealth nanoparticle comprising a diblock copolymer of PEG and PLA or PEG and PLGA (see US Pat No 8,246,968 and International Publication No. WO2012166923, each of which is herein incorporated by reference in its entirety).

13829[000548] In one embodiment, the therapeutic nanoparticle may comprise a multiblock copolymer (See e.g., U.S. Pat. No. 8,263,665 and 8,287,910; each of which is herein incorporated by reference in its entirety).

13830[000549] In one embodiment, the block copolymers described herein may be included in a polyion complex comprising a non-polymeric micelle and the block copolymer. (See e.g., U.S. Pub. No. 20120076836; herein incorporated by reference in its entirety).

13831[000550] In one embodiment, the therapeutic nanoparticle may comprise at least one acrylic polymer. Acrylic polymers include but are not limited to, acrylic acid, methacrylic acid, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, amino alkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), polycyanoacrylates and combinations thereof.

13832[000551] In one embodiment, the therapeutic nanoparticles may comprise at least one cationic polymer described herein and/or known in the art.

13833[000552] In one embodiment, the therapeutic nanoparticles may comprise at least one amine-containing polymer such as, but not limited to polylysine, polyethylene imine, poly(amidoamine) dendrimers, poly(beta-amino esters) (See e.g., U.S. Pat. No.

138348,287,849; herein incorporated by reference in its entirety) and combinations thereof.

13835[000553] In one embodiment, the therapeutic nanoparticles may comprise at least one degradable polyester which may contain polycationic side chains. Degradeable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In another embodiment, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.

13836[000554] In another embodiment, the therapeutic nanoparticle may include a conjugation of at least one targeting ligand. The targeting ligand may be any ligand known in the art such as, but not limited to, a monoclonal antibody. (Kirpotin et al, Cancer Res. 2006 66:6732-6740; herein incorporated by reference in its entirety).

13837[000555] In one embodiment, the therapeutic nanoparticle may be formulated in an aqueous solution which may be used to target cancer (see International Pub No.

13838WO2011084513 and US Pub No. US20110294717, each of which is herein incorporated by reference in their entirety).

13839[000556] In one embodiment, the polynucleotides, primary constructs, or mmRNA may be encapsulated in, linked to and/or associated with synthetic nanocarriers. . Synthetic nanocarriers include, but are not limited to, those described in International Pub. Nos. WO2010005740, WO2010030763, WO201213501, WO2012149252, WO2012149255, WO2012149259, WO2012149265, WO2012149268, WO2012149282, WO2012149301, WO2012149393, WO2012149405, WO2012149411, WO2012149454 and

13840WO2013019669, and US Pub. Nos. US20110262491, US20100104645, US20100087337 and US20120244222, each of which is herein incorporated by reference in their entirety. The synthetic nanocarriers may be formulated using methods known in the art and/or described herein. As a non-limiting example, the synthetic nanocarriers may be formulated by the methods described in International Pub Nos. WO2010005740, WO2010030763 and WO201213501 and US Pub. Nos. US20110262491 ,

13841US20100104645, US20100087337 and US2012024422, each of which is herein incorporated by reference in their entirety. In another embodiment, the synthetic nanocarrier formulations may be lyophilized by methods described in International Pub. No. WO2011072218 and US Pat No. 8,211,473; each of which is herein incorporated by reference in their entirety.

13842[000557] In one embodiment, the synthetic nanocarriers may contain reactive groups to release the polynucleotides, primary constructs and/or mmRNA described herein (see International Pub. No. WO20120952552 and US Pub No. US20120171229, each of which is herein incorporated by reference in their entirety).

13843[000558] In one embodiment, the synthetic nanocarriers may contain an

13844immunostimulatory agent to enhance the immune response from delivery of the synthetic nanocarrier. As a non- limiting example, the synthetic nanocarrier may comprise a Thl immunostimulatory agent which may enhance a Thl -based response of the immune system (see International Pub No. WO2010123569 and US Pub. No. US20110223201, each of which is herein incorporated by reference in its entirety).

13845[000559] In one embodiment, the synthetic nanocarriers may be formulated for targeted release. In one embodiment, the synthetic nanocarrier is formulated to release the polynucleotides, primary constructs and/or mmRNA at a specified pH and/or after a desired time interval. As a non-limiting example, the synthetic nanoparticle may be formulated to release the polynucleotides, primary constructs and/or mmRNA after 24 hours and/or at a pH of 4.5 (see International Pub. Nos. WO2010138193 and

13846WO2010138194 and US Pub Nos. US20110020388 and US20110027217, each of which is herein incorporated by reference in their entireties).

13847[000560] In one embodiment, the synthetic nanocarriers may be formulated for controlled and/or sustained release of the polynucleotides, primary constructs and/or mmRNA described herein. As a non-limiting example, the synthetic nanocarriers for sustained release may be formulated by methods known in the art, described herein and/or as described in International Pub No. WO2010138192 and US Pub No.

1384820100303850, each of which is herein incorporated by reference in their entirety.

13849[000561] In one embodiment, the synthetic nanocarrier may be formulated for use as a vaccine. In one embodiment, the synthetic nanocarrier may encapsulate at least one polynucleotide, primary construct and/or mmRNA which encode at least one antigen. As a non-limiting example, the synthetic nanocarrier may include at least one antigen and an excipient for a vaccine dosage form (see International Pub No. WO2011150264 and US Pub No. US20110293723, each of which is herein incorporated by reference in their entirety). As another non-limiting example, a vaccine dosage form may include at least two synthetic nanocarriers with the same or different antigens and an excipient (see International Pub No. WO2011150249 and US Pub No. US20110293701, each of which is herein incorporated by reference in their entirety). The vaccine dosage form may be selected by methods described herein, known in the art and/or described in International Pub No. WO2011150258 and US Pub No. US20120027806, each of which is herein incorporated by reference in their entirety).

13850[000562] In one embodiment, the synthetic nanocarrier may comprise at least one polynucleotide, primary construct and/or mmRNA which encodes at least one adjuvant. As non-limiting example, the adjuvant may comprise dimethyldioctadecylammonium- bromide, dimethyldioctadecylammonium-chloride, dimethyldioctadecylammonium- phosphate or dimethyldioctadecylammonium-acetate (DDA) and an apolar fraction or part of said apolar fraction of a total lipid extract of a mycobacterium (See e.g, U.S. Pat. No. 8,241,610; herein incorporated by reference in its entirety). In another embodiment, the synthetic nanocarrier may comprise at least one polynucleotide, primary construct and/or mmRNA and an adjuvant. As a non-limiting example, the synthetic nanocarrier comprising and adjuvant may be formulated by the methods described in International Pub No. WO2011150240 and US Pub No. US20110293700, each of which is herein incorporated by reference in its entirety.

13851[000563] In one embodiment, the synthetic nanocarrier may encapsulate at least one polynucleotide, primary construct and/or mmRNA which encodes a peptide, fragment or region from a virus. As a non-limiting example, the synthetic nanocarrier may include, but is not limited to, the nanocarriers described in International Pub No. WO2012024621, WO201202629, WO2012024632 and US Pub No. US20120064110, US20120058153 and US20120058154, each of which is herein incorporated by reference in their entirety.

13852[000564] In one embodiment, the synthetic nanocarrier may be coupled to a

13853polynucleotide, primary construct or mmRNA which may be able to trigger a humoral and/or cytotoxic T lymphocyte (CTL) response (See e.g., International Publication No. WO2013019669, herein incorporated by reference in its entirety). [000565] In one embodiment, the nanoparticle may be optimized for oral administration. The nanoparticle may comprise at least one cationic biopolymer such as, but not limited to, chitosan or a derivative thereof. As a non-limiting example, the nanoparticle may be formulated by the methods described in U.S. Pub. No.

1385420120282343; herein incorporated by reference in its entirety.

13855Polymers, Biodegradable Nanoparticles, and Core-Shell Nanoparticles

13856[000566] The polynucleotide, primary construct, and mmRNA of the invention can be formulated using natural and/or synthetic polymers. Non-limiting examples of polymers which may be used for delivery include, but are not limited to, DYNAMIC

13857POLYCON JUGATE® (Arrowhead Reasearch Corp., Pasadena, CA) formulations from MIRUS® Bio (Madison, WI) and Roche Madison (Madison, WI), PHASERX™ polymer formulations such as, without limitation, SMARTT POLYMER TECHNOLOGY™ (PHASERX®, Seattle, WA), DMRI/DOPE, poloxamer, VAXFECTIN® adjuvant from Vical (San Diego, CA), chitosan, cyclodextrin from Calando Pharmaceuticals (Pasadena, CA), dendrimers and poly(lactic-co-glycolic acid) (PLGA) polymers. RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymers (Arrowhead Research

13858Corporation, Pasadena, CA) and pH responsive co-block polymers such as, but not limited to, PHASERX® (Seattle, WA).

13859[000567] A non-limiting example of chitosan formulation includes a core of positively charged chitosan and an outer portion of negatively charged substrate (U.S. Pub. No. 20120258176; herein incorporated by reference in its entirety). Chitosan includes, but is not limited to N-trimethyl chitosan, mono-N-carboxymethyl chitosan (MCC), N- palmitoyl chitosan (NPCS), EDTA-chitosan, low molecular weight chitosan, chitosan derivatives, or combinations thereof.

13860[000568] In one embodiment, the polymers used in the present invention have undergone processing to reduce and/or inhibit the attachement of unwanted substances such as, but not limited to, bacteria, to the surface of the polymer. The polymer may be processed by methods known and/or described in the art and/or described in International Pub. No. WO2012150467, herein incorporated by reference in its entirety.

13861[000569] A non-limiting example of PLGA formulations include, but are not limited to, PLGA injectable depots (e.g., ELIGARD® which is formed by dissolving PLGA in 66% N-methyl-2-pyrrolidone (NMP) and the remainder being aqueous solvent and leuprolide. Once injected, the PLGA and leuprolide peptide precipitates into the subcutaneous space).

13862[000570] Many of these polymer approaches have demonstrated efficacy in delivering oligonucleotides in vivo into the cell cytoplasm (reviewed in deFougerolles Hum Gene Ther. 2008 19: 125-132; herein incorporated by reference in its entirety). Two polymer approaches that have yielded robust in vivo delivery of nucleic acids, in this case with small interfering RNA (siRNA), are dynamic polyconjugates and cyclodextrin-based nanoparticles. The first of these delivery approaches uses dynamic polyconjugates and has been shown in vivo in mice to effectively deliver siRNA and silence endogenous target mRNA in hepatocytes (Rozema et al, Proc Natl Acad Sci U S A. 2007 104: 12982- 12887; herein incorporated by reference in its entirety). This particular approach is a multicomponent polymer system whose key features include a membrane-active polymer to which nucleic acid, in this case siRNA, is covalently coupled via a disulfide bond and where both PEG (for charge masking) and ^-acetylgalactosamine (for hepatocyte targeting) groups are linked via pH-sensitive bonds (Rozema et al., Proc Natl Acad Sci U S A. 2007 104: 12982-12887; herein incorporated by reference in its entirety). On binding to the hepatocyte and entry into the endosome, the polymer complex disassembles in the low-pH environment, with the polymer exposing its positive charge, leading to endosomal escape and cytoplasmic release of the siRNA from the polymer. Through replacement of the ^-acetylgalactosamine group with a mannose group, it was shown one could alter targeting from asialoglycoprotein receptor-expressing hepatocytes to sinusoidal endothelium and Kupffer cells. Another polymer approach involves using transferrin-targeted cyclodextrin-containing polycation nanoparticles. These

13863nanoparticles have demonstrated targeted silencing of the EWS-FLI1 gene product in transferrin receptor-expressing Ewing's sarcoma tumor cells (Hu-Lieskovan et al., Cancer Res.2005 65: 8984-8982; herein incorporated by reference in its entirety) and siRNA formulated in these nanoparticles was well tolerated in non-human primates (Heidel et al, Proc Natl Acad Sci USA 2007 104:5715-21; herein incorporated by reference in its entirety). Both of these delivery strategies incorporate rational approaches using both targeted delivery and endosomal escape mechanisms. [000571] The polymer formulation can permit the sustained or delayed release of polynucleotide, primary construct, or mmRNA (e.g., following intramuscular or subcutaneous injection). The altered release profile for the polynucleotide, primary construct, or mmRNA can result in, for example, translation of an encoded protein over an extended period of time. The polymer formulation may also be used to increase the stability of the polynucleotide, primary construct, or mmRNA. Biodegradable polymers have been previously used to protect nucleic acids other than mmRNA from degradation and been shown to result in sustained release of payloads in vivo (Rozema et al., Proc Natl Acad Sci U S A. 2007 104: 12982-12887; Sullivan et al, Expert Opin Drug Deliv. 2010 7:1433-1446; Convertine et al, Biomacromolecules. 2010 Oct 1; Chu et al, Acc Chem Res. 2012 Jan 13; Manganiello et al., Biomaterials. 2012 33:2301-2309; Benoit et al., Biomacromolecules. 2011 12:2708-2714; Singha et al., Nucleic Acid Ther. 2011 2: 133-147; deFougerolles Hum Gene Ther. 2008 19: 125-132; Schaffert and Wagner, Gene Ther. 2008 16: 1131-1138; Chaturvedi et al, Expert Opin Drug Deliv. 2011 8: 1455- 1468; Davis, Mol Pharm. 2009 6:659-668; Davis, Nature 2010 464: 1067-1070; each of which is herein incorporated by reference in its entirety).

13864[000572] In one embodiment, the pharmaceutical compositions may be sustained release formulations. In a further embodiment, the sustained release formulations may be for subcutaneous delivery. Sustained release formulations may include, but are not limited to, PLGA microspheres, ethylene vinyl acetate (EVAc), poloxamer, GELSITE® (Nanotherapeutics, Inc. Alachua, FL), HYLENEX® (Halozyme Therapeutics, San Diego CA), surgical sealants such as fibrinogen polymers (Ethicon Inc. Cornelia, GA), TISSELL® (Baxter International, Inc Deerfield, IL), PEG-based sealants, and

13865COSEAL® (Baxter International, Inc Deerfield, IL).

13866[000573] As a non-limiting example modified mRNA may be formulated in PLGA microspheres by preparing the PLGA microspheres with tunable release rates (e.g., days and weeks) and encapsulating the modified mRNA in the PLGA microspheres while maintaining the integrity of the modified mRNA during the encapsulation process.

13867EVAc are non-biodegradeable, biocompatible polymers which are used extensively in pre-clinical sustained release implant applications (e.g., extended release products Ocusert a pilocarpine ophthalmic insert for glaucoma or progestasert a sustained release progesterone intrauterine deivce; transdermal delivery systems Testoderm, Duragesic and Selegiline; catheters). Poloxamer F-407 NF is a hydrophilic, non-ionic surfactant triblock copolymer of polyoxyethylene-polyoxypropylene-polyoxyethylene having a low viscosity at temperatures less than 5°C and forms a solid gel at temperatures greater than 15°C. PEG-based surgical sealants comprise two synthetic PEG components mixed in a delivery device which can be prepared in one minute, seals in 3 minutes and is reabsorbed within 30 days. GELSITE® and natural polymers are capable of in-situ gelation at the site of administration. They have been shown to interact with protein and peptide therapeutic candidates through ionic ineraction to provide a stabilizing effect.

13868[000574] Polymer formulations can also be selectively targeted through expression of different ligands as exemplified by, but not limited by, folate, transferrin, and N- acetylgalactosamine (GalNAc) (Benoit et al., Biomacromolecules. 2011 12:2708-2714; Rozema et al, Proc Natl Acad Sci U S A. 2007 104: 12982-12887; Davis, Mol Pharm. 2009 6:659-668; Davis, Nature 2010 464: 1067-1070; each of which is herein

13869incorporated by reference in its entirety).

13870[000575] The modified nucleic acid, and mmRNA of the invention may be formulated with or in a polymeric compound. The polymer may include at least one polymer such as, but not limited to, polyethenes, polyethylene glycol (PEG), poly(l-lysine)(PLL), PEG grafted to PLL, cationic lipopolymer, biodegradable cationic lipopolymer,

13871polyethyleneimine (PEI), cross-linked branched poly(alkylene imines), a polyamine derivative, a modified poloxamer, a biodegradable polymer, elastic biodegradable polymer, biodegradable block copolymer, biodegradable random copolymer,

13872biodegradable polyester copolymer, biodegradable polyester block copolymer, biodegradable polyester block random copolymer, multiblock copolymers, linear biodegradable copolymer, poly[a-(4-aminobutyl)-L-glycolic acid) (PAGA),

13873biodegradable cross-linked cationic multi-block copolymers, polycarbonates,

13874polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), acrylic polymers, amine-containing polymers, dextran polymers, dextran polymer derivatives or or combinations thereof .

13875[000576] As a non-limiting example, the modified nucleic acid or mmRNA of the invention may be formulated with the polymeric compound of PEG grafted with PLL as described in U.S. Pat. No. 6,177,274; herein incorporated by reference in its entirety. The formulation may be used for transfecting cells in vitro or for in vivo delivery of the modified nucleic acid and mmRNA. In another example, the modified nucleic acid and mmRNA may be suspended in a solution or medium with a cationic polymer, in a dry pharmaceutical composition or in a solution that is capable of being dried as described in U.S. Pub. Nos. 20090042829 and 20090042825; each of which are herein incorporated by reference in their entireties.

13876[000577] As another non-limiting example the polynucleotides, primary constructs or mmRNA of the invention may be formulated with a PLGA-PEG block copolymer (see US Pub. No. US20120004293 and US Pat No. 8,236,330, herein incorporated by reference in their entireties) or PLGA-PEG-PLGA block copolymers (See U.S. Pat. No. 6,004,573, herein incorporated by reference in its entirety). As a non-limiting example, the polynucleotides, primary constructs or mmRNA of the invention may be formulated with a diblock copolymer of PEG and PLA or PEG and PLGA (see US Pat No 8,246,968, herein incorporated by reference in its entirety).

13877[000578] A polyamine derivative may be used to deliver nucleic acids or to treat and/or prevent a disease or to be included in an implantable or injectable device (U.S. Pub. No. 20100260817 herein incorporated by reference in its entirety). As a non-limiting example, a pharmaceutical composition may include the modified nucleic acids and mmRNA and the polyamine derivative described in U.S. Pub. No. 20100260817 (the contents of which are incorporated herein by reference in its entirety. As a non-limiting example the polynucleotides, primary constructs and mmRNA of the present invention may be delivered using a polyaminde polymer such as, but not limited to, a polymer comprising a 1,3-dipolar addition polymer prepared by combining a carbohydrate diazide monomer with a dilkyne unite comprising oligoamines (U.S. Pat. No. 8,236,280; herein incorporated by reference in its entirety). [000579] In one embodiment, the polynucleotides, primary constructs or mmRNA of the present invention may be formulated with at least one polymer and/or derivatives thereof described in International Publication Nos. WO2011115862, WO2012082574 and WO2012068187 and U.S. Pub. No. 20120283427, each of which are herein incorporated by reference in their entireties. In another embodiment, the modified nucleic acid or mmRNA of the present invention may be formulated with a polymer of formula Z as described in WO2011115862, herein incorporated by reference in its entirety. In yet another embodiment, the modified nucleic acid or mmRNA may be formulated with a polymer of formula Z, Z' or Z" as described in International Pub. Nos. WO2012082574 or WO2012068187 and U.S. Pub. No. 2012028342, each of which are herein

13878incorporated by reference in their entireties. The polymers formulated with the modified RNA of the present invention may be synthesized by the methods described in

13879International Pub. Nos. WO2012082574 or WO2012068187, each of which are herein incorporated by reference in their entireties.

13880[000580] The polynucleotides, primary constructs or mmRNA of the invention may be formulated with at least one acrylic polymer. Acrylic polymers include but are not limited to, acrylic acid, methacrylic acid, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, amino alkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), polycyanoacrylates and combinations thereof.

13881[000581] Formulations of polynucleotides, primary constructs or mmRNA of the invention may include at least one amine-containing polymer such as, but not limited to polylysine, polyethylene imine, poly(amidoamine) dendrimers or combinations thereof.

13882[000582] For example, the modified nucleic acid or mmRNA of the invention may be formulated in a pharmaceutical compound including a poly(alkylene imine), a biodegradable cationic lipopolymer, a biodegradable block copolymer, a biodegradable polymer, or a biodegradable random copolymer, a biodegradable polyester block copolymer, a biodegradable polyester polymer, a biodegradable polyester random copolymer, a linear biodegradable copolymer, PAGA, a biodegradable cross-linked cationic multi-block copolymer or combinations thereof. The biodegradable cationic lipopolymer may be made by methods known in the art and/or described in U.S. Pat. No. 6,696,038, U.S. App. Nos. 20030073619 and 20040142474 each of which is herein incorporated by reference in their entireties. The poly(alkylene imine) may be made using methods known in the art and/or as described in U.S. Pub. No. 20100004315, herein incorporated by reference in its entirety. The biodegradabale polymer, biodegradable block copolymer, the biodegradable random copolymer, biodegradable polyester block copolymer, biodegradable polyester polymer, or biodegradable polyester random copolymer may be made using methods known in the art and/or as described in U.S. Pat. Nos. 6,517,869 and 6,267,987, the contents of which are each incorporated herein by reference in their entirety. The linear biodegradable copolymer may be made using methods known in the art and/or as described in U.S. Pat. No. 6,652,886. The PAGA polymer may be made using methods known in the art and/or as described in U.S. Pat. No. 6,217,912 herein incorporated by reference in its entirety. The PAGA polymer may be copolymerized to form a copolymer or block copolymer with polymers such as but not limited to, poly-L-lysine, polyargine, polyornithine, histones, avidin, protamines, polylactides and poly(lactide-co-glycolides). The biodegradable cross-linked cationic multi-block copolymers may be made my methods known in the art and/or as described in U.S. Pat. No. 8,057,821 or U.S. Pub. No. 2012009145 each of which are herein incorporated by reference in their entireties. For example, the multi-block copolymers may be synthesized using linear polyethyleneimine (LPEI) blocks which have distinct patterns as compared to branched polyethyleneimines. Further, the composition or pharmaceutical composition may be made by the methods known in the art, described herein, or as described in U.S. Pub. No. 20100004315 or U.S. Pat. Nos. 6,267,987 and 6,217,912 each of which are herein incorporated by reference in their entireties.

13883[000583] The polynucleotides, primary constructs, and mmRNA of the invention may be formulated with at least one degradable polyester which may contain polycationic side chains. Degradeable polyesters include, but are not limited to, poly(serine ester), poly(L- lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In another embodiment, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.

13884[000584] The polynucleotides, primary construct, mmRNA of the invention may be formulated with at least one crosslinkable polyester. Crosslinkable polyesters include those known in the art and described in US Pub. No. 20120269761, herein incorporated by reference in its entirety.

13885[000585] In one embodiment, the polymers described herein may be conjugated to a lipid-terminating PEG. As a non-limiting example, PLGA may be conjugated to a lipid- terminating PEG forming PLGA-DSPE-PEG. As another non-limiting example, PEG conjugates for use with the present invention are described in International Publication No. WO2008103276, herein incorporated by reference in its entirety. The polymers may be conjugated using a ligand conjugate such as, but not limited to, the conjugates described in U.S. Pat. No. 8,273,363, herein incorporated by reference in its entirety.

13886[000586] In one embodiment, the modified RNA described herein may be conjugated with another compound. Non-limiting examples of conjugates are described in US Patent Nos. 7,964,578 and 7,833,992, each of which are herein incorporated by reference in their entireties. In another embodiment, modified RNA of the present invention may be conjugated with conjugates of formula 1-122 as described in US Patent Nos. 7,964,578 and 7,833,992, each of which are herein incorporated by reference in their entireties. The polynucleotides, primary constructs and/or mmRNA described herein may be conjugated with a metal such as, but not limited to, gold. (See e.g., Giljohann et al. Journ. Amer. Chem. Soc. 2009 131(6): 2072-2073; herein incorporated by reference in its entirety). In another embodiment, the polynucleotides, primary constructs and/or mmRNA described herein may be conjugated and/or encapsulated in gold-nanoparticles. (Interantional Pub. No. WO201216269 and U.S. Pub. No. 20120302940; each of which is herein

13887incorporated by reference in its entirety).

13888[000587] As described in U.S. Pub. No. 20100004313, herein incorporated by reference in its entirety, a gene delivery composition may include a nucleotide sequence and a poloxamer. For example, the modified nucleic acid and mmRNA of the present inveition may be used in a gene delivery composition with the poloxamer described in U.S. Pub. No. 20100004313.

13889[000588] In one embodiment, the polymer formulation of the present invention may be stabilized by contacting the polymer formulation, which may include a cationic carrier, with a cationic lipopolymer which may be covalently linked to cholesterol and polyethylene glycol groups. The polymer formulation may be contacted with a cationic lipopolymer using the methods described in U.S. Pub. No. 20090042829 herein incorporated by reference in its entirety. The cationic carrier may include, but is not limited to, polyethylenimine, poly(trimethylenimine), poly(tetramethylenimine), polypropylenimine, aminoglycoside-polyamine, dideoxy-diamino-b-cyclodextrin, spermine, spermidine, poly(2-dimethylamino)ethyl methacrylate, poly(lysine), poly(histidine), poly(arginine), cationized gelatin, dendrimers, chitosan, l,2-Dioleoyl-3- Trimethylammonium-Propane(DOTAP), N-[ 1 -(2,3-dioleoyloxy)propyl]-N,N,N- trimethylammonium chloride (DOTMA), l-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2- hydroxyethyl)imidazolinium chloride (DOTIM), 2,3-dioleyloxy-N- [2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminium trifluoroacetate (DOSPA), 3B-[N— (N',N'-Dimethylaminoethane)-carbamoyl]Cholesterol Hydrochloride (DC-Cholesterol HC1) diheptadecylamidoglycyl spermidine (DOGS), N,N-distearyl-N,N- dimethylammonium bromide (DDAB), N-(l,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N- hydroxyethyl ammonium bromide (DMRIE), N,N-dioleyl-N,N-dimethylammonium chloride DODAC) and combinations thereof.

13890[000589] The polynucleotides, primary constructs and/or mmRNA of the invention may be formulated in a polyp lex of one or more polymers (U.S. Pub. No. 20120237565 and 20120270927; each of which is herein incorporated by reference in its entirety). In one embodiment, the polyplex comprises two or more cationic polymers. The catioinic polymer may comprise a poly(ethylene imine) (PEI) such as linear PEL

13891[000590] The polynucleotide, primary construct, and mmRNA of the invention can also be formulated as a nanoparticle using a combination of polymers, lipids, and/or other biodegradable agents, such as, but not limited to, calcium phosphate. Components may be combined in a core-shell, hybrid, and/or layer-by-layer architecture, to allow for fine- tuning of the nanoparticle so to delivery of the polynucleotide, primary construct and mmRNA may be enhanced (Wang et al, Nat Mater. 2006 5:791-796; Fuller et al, Biomaterials. 2008 29: 1526-1532; DeKoker et al, Adv Drug Deliv Rev. 2011 63:748- 761; Endres et al, Biomaterials. 2011 32:7721-7731; Su et al, Mol Pharm. 2011 Jun 6;8(3):774-87; herein incorporated by reference in its entirety). As a non-limiting example, the nanoparticle may comprise a plurality of polymers such as, but not limited to hydrophilic-hydrophobic polymers (e.g., PEG-PLGA), hydrophobic polymers (e.g., PEG) and/or hydrophilic polymers (International Pub. No. WO20120225129; herein incorporated by reference in its entirety).

13892[000591] Biodegradable calcium phosphate nanoparticles in combination with lipids and/or polymers have been shown to deliver polynucleotides, primary constructs and mmRNA in vivo. In one embodiment, a lipid coated calcium phosphate nanoparticle, which may also contain a targeting ligand such as anisamide, may be used to deliver the polynucleotide, primary construct and mmRNA of the present invention. For example, to effectively deliver siRNA in a mouse metastatic lung model a lipid coated calcium phosphate nanoparticle was used (Li et al, J Contr Rel. 2010 142: 416-421; Li et al., J Contr Rel. 2012 158: 108-114; Yang et al, Mol Ther. 2012 20:609-615; herein incorporated by reference in its entirety). This delivery system combines both a targeted nanoparticle and a component to enhance the endosomal escape, calcium phosphate, in order to improve delivery of the siRNA.

13893[000592] In one embodiment, calcium phosphate with a PEG-polyanion block copolymer may be used to delivery polynucleotides, primary constructs and mmRNA (Kazikawa et al, J Contr Rel. 2004 97:345-356; Kazikawa et al, J Contr Rel. 2006 111 :368-370; herein incorporated by reference in its entirety).

13894[000593] In one embodiment, a PEG-charge-conversional polymer (Pitella et al., Biomaterials. 2011 32:3106-3114) may be used to form a nanoparticle to deliver the polynucleotides, primary constructs and mmRNA of the present invention. The PEG- charge-conversional polymer may improve upon the PEG-polyanion block copolymers by being cleaved into a polycation at acidic pH, thus enhancing endosomal escape.

13895[000594] The use of core-shell nanoparticles has additionally focused on a high- throughput approach to synthesize cationic cross-linked nanogel cores and various shells (Siegwart et al, Proc Natl Acad Sci U S A. 2011 108: 12996-13001). The complexation, delivery, and internalization of the polymeric nanoparticles can be precisely controlled by altering the chemical composition in both the core and shell components of the nanoparticle. For example, the core-shell nanoparticles may efficiently deliver siRNA to mouse hepatocytes after they covalently attach cholesterol to the nanoparticle.

13896[000595] In one embodiment, a hollow lipid core comprising a middle PLGA layer and an outer neutral lipid layer containg PEG may be used to delivery of the polynucleotide, primary construct and mmRNA of the present invention. As a non-limiting example, in mice bearing a luciferease-expressing tumor, it was determined that the lipid-polymer- lipid hybrid nanoparticle significantly suppressed luciferase expression, as compared to a conventional lipoplex (Shi et al, Angew Chem Int Ed. 2011 50:7027-7031; herein incorporated by reference in its entirety).

13897[000596] In one embodiment, the lipid nanoparticles may comprise a core of the modified nucleic acid molecules disclosed herein and a polymer shell. The polymer shell may be any of the polymers described herein and are known in the art. In an additional embodiment, the polymer shell may be used to protect the modified nucleic acids in the core.

13898[000597] Core-shell nanoparticles for use with the modified nucleic acid molecules of the present invention are described and may be formed by the methods described in U.S. Pat. No. 8,313,777 herein incorporated by reference in its entirety.

13899[000598] In one embodiment, the core-shell nanoparticles may comprise a core of the modified nucleic acid molecules disclosed herein and a polymer shell. The polymer shell may be any of the polymers described herein and are known in the art. In an additional embodiment, the polymer shell may be used to protect the modified nucleic acid molecules in the core. As a non-limiting example, the core-shell nanoparticle may be used to treat an eye disease or disorder (See e.g. US Publication No. 20120321719, herein incorporated by reference in its entirety).

13900[000599] In one embodiment, the polymer used with the formulations described herein may be a modified polymer (such as, but not limited to, a modified polyacetal) as described in International Publication No. WO2011120053, herein incorporated by reference in its entirety.

13901Peptides and Proteins

13902[000600] The polynucleotide, primary construct, and mmRNA of the invention can be formulated with peptides and/or proteins in order to increase transfection of cells by the polynucleotide, primary construct, or mmRNA. In one embodiment, peptides such as, but not limited to, cell penetrating peptides and proteins and peptides that enable intracellular delivery may be used to deliver pharmaceutical formulations. A non-limiting example of a cell penetrating peptide which may be used with the pharmaceutical formulations of the present invention includes a cell-penetrating peptide sequence attached to polycations that facilitates delivery to the intracellular space, e.g., HIV-derived TAT peptide, penetratins, transportans, or hCT derived cell-penetrating peptides (see, e.g., Caron et al, Mol. Ther. 3(3):310-8 (2001); Langel, Cell-Penetrating Peptides: Processes and

13903Applications (CRC Press, Boca Raton FL, 2002); El-Andaloussi et al., Curr. Pharm. Des. 11(28):3597-611 (2003); and Deshayes et al, Cell. Mol. Life Sci. 62(16): 1839-49 (2005), all of which are incorporated herein by reference in their entirety). The compositions can also be formulated to include a cell penetrating agent, e.g., liposomes, which enhance delivery of the compositions to the intracellular space. Polynucleotides, primary constructs, and mmRNA of the invention may be complexed to peptides and/or proteins such as, but not limited to, peptides and/or proteins from Aileron Therapeutics

13904(Cambridge, MA) and Permeon Biologies (Cambridge, MA) in order to enable intracellular delivery (Cronican et al, ACS Chem. Biol. 2010 5:747-752; McNaughton et al, Proc. Natl. Acad. Sci. USA 2009 106:6111-6116; Sawyer, Chem Biol Drug Des. 2009 73:3-6; Verdine and Hilinski, Methods Enzymol. 2012;503:3-33; all of which are herein incorporated by reference in its entirety).

13905[000601] In one embodiment, the cell-penetrating polypeptide may comprise a first domain and a second domain. The first domain may comprise a supercharged

13906polypeptide. The second domain may comprise a protein-binding partner. As used herein, "protein-binding partner" includes, but are not limited to, antibodies and functional fragments thereof, scaffold proteins, or peptides. The cell-penetrating polypeptide may further comprise an intracellular binding partner for the protein-binding partner. The cell- penetrating polypeptide may be capable of being secreted from a cell where the polynucleotide, primary construct, or mmRNA may be introduced.

13907[000602] Formulations of the including peptides or proteins may be used to increase cell transfection by the polynucleotide, primary construct, or mmRNA, alter the biodistribution of the polynucleotide, primary construct, or mmRNA (e.g., by targeting specific tissues or cell types), and/or increase the translation of encoded protein. (See e.g., International Pub. No. WO2012110636; herein incorporated by reference in its entirety). Cells

13908[000603] The polynucleotide, primary construct, and mmRNA of the invention can be transfected ex vivo into cells, which are subsequently transplanted into a subject. As non- limiting examples, the pharmaceutical compositions may include red blood cells to deliver modified RNA to liver and myeloid cells, virosomes to deliver modified RNA in virus-like particles (VLPs), and electroporated cells such as, but not limited to, from MAXCYTE® (Gaithersburg, MD) and from ERYTECH® (Lyon, France) to deliver modified RNA. Examples of use of red blood cells, viral particles and electroporated cells to deliver payloads other than mmRNA have been documented (Godfrin et al., Expert Opin Biol Ther. 2012 12: 127-133; Fang et al., Expert Opin Biol Ther. 2012 12:385-389; Hu et al, Proc Natl Acad Sci U S A. 2011 108: 10980-10985; Lund et al, Pharm Res. 2010 27:400-420; Huckriede et al, J Liposome Res. 2007;17:39-47; Cusi, Hum Vaccin. 2006 2: 1-7; de Jonge et al, Gene Ther. 2006 13:400-411; all of which are herein incorporated by reference in its entirety).

13909[000604] The polynucleotides, primary constructs and mmRNA may be delivered in synthetic VLPs synthesized by the methods described in International Pub No.

13910WO2011085231 and US Pub No. 20110171248, each of which are herein incorporated by reference in their entireties.

13911[000605] Cell-based formulations of the polynucleotide, primary construct, and mmRNA of the invention may be used to ensure cell transfection (e.g., in the cellular carrier), alter the biodistribution of the polynucleotide, primary construct, or mmRNA (e.g., by targeting the cell carrier to specific tissues or cell types), and/or increase the translation of encoded protein.

13912[000606] A variety of methods are known in the art and suitable for introduction of nucleic acid into a cell, including viral and non- viral mediated techniques. Examples of typical non-viral mediated techniques include, but are not limited to, electroporation, calcium phosphate mediated transfer, nucleofection, sonoporation, heat shock, magnetofection, liposome mediated transfer, microinjection, microprojectile mediated transfer (nanoparticles), cationic polymer mediated transfer (DEAE-dextran,

13913polyethylenimine, polyethylene glycol (PEG) and the like) or cell fusion. [000607] The technique of sonoporation, or cellular sonication, is the use of sound (e.g., ultrasonic frequencies) for modifying the permeability of the cell plasma membrane. Sonoporation methods are known to those in the art and are used to deliver nucleic acids in vivo (Yoon and Park, Expert Opin Drug Deliv. 2010 7:321-330; Postema and Gilja, Curr Pharm Biotechnol. 2007 8:355-361; Newman and Bettinger, Gene Ther. 2007 14:465-475; all herein incorporated by reference in their entirety). Sonoporation methods are known in the art and are also taught for example as it relates to bacteria in US Patent Publication 20100196983 and as it relates to other cell types in, for example, US Patent Publication 20100009424, each of which are incorporated herein by reference in their entirety.

13914[000608] Electroporation techniques are also well known in the art and are used to deliver nucleic acids in vivo and clinically (Andre et al., Curr Gene Ther. 2010 10:267- 280; Chiarella et al, Curr Gene Ther. 2010 10:281-286; Hojman, Curr Gene Ther. 2010 10: 128-138; all herein incorporated by reference in their entirety). In one embodiment, polynucleotides, primary constructs or mmRNA may be delivered by electroporation as described in Example 8.

13915Hyaluronidase

13916[000609] The intramuscular or subcutaneous localized injection of polynucleotide, primary construct, or mmRNA of the invention can include hyaluronidase, which catalyzes the hydrolysis of hyaluronan. By catalyzing the hydrolysis of hyaluronan, a constituent of the interstitial barrier, hyaluronidase lowers the viscosity of hyaluronan, thereby increasing tissue permeability (Frost, Expert Opin. Drug Deliv. (2007) 4:427- 440; herein incorporated by reference in its entirety). It is useful to speed their dispersion and systemic distribution of encoded proteins produced by transfected cells.

13917Alternatively, the hyaluronidase can be used to increase the number of cells exposed to a polynucleotide, primary construct, or mmRNA of the invention administered

13918intramuscularly or subcutaneously.

13919Nanoparticle Mimics

13920[000610] The polynucleotide, primary construct or mmRNA of the invention may be encapsulated within and/or absorbed to a nanoparticle mimic. A nanoparticle mimic can mimic the delivery function organisms or particles such as, but not limited to, pathogens, viruses, bacteria, fungus, parasites, prions and cells. As a non-limiting example the polynucleotide, primary construct or mmRNA of the invention may be encapsulated in a non-viron particle which can mimic the delivery function of a virus (see International Pub. No. WO2012006376 herein incorporated by reference in its entirety).

13921Nanotubes

13922[000611] The polynucleotides, primary constructs or mmRNA of the invention can be attached or otherwise bound to at least one nanotube such as, but not limited to, rosette nanotubes, rosette nanotubes having twin bases with a linker, carbon nanotubes and/or single-walled carbon nanotubes, The polynucleotides, primary constructs or mmRNA may be bound to the nanotubes through forces such as, but not limited to, steric, ionic, covalent and/or other forces.

13923[000612] In one embodiment, the nanotube can release one or more polynucleotides, primary constructs or mmRNA into cells. The size and/or the surface structure of at least one nanotube may be altered so as to govern the interaction of the nanotubes within the body and/or to attach or bind to the polynucleotides, primary constructs or mmRNA disclosed herein. In one embodiment, the building block and/or the functional groups attached to the building block of the at least one nanotube may be altered to adjust the dimensions and/or properties of the nanotube. As a non-limiting example, the length of the nanotubes may be altered to hinder the nanotubes from passing through the holes in the walls of normal blood vessels but still small enough to pass through the larger holes in the blood vessels of tumor tissue.

13924[000613] In one embodiment, at least one nanotube may also be coated with delivery enhancing compounds including polymers, such as, but not limited to, polyethylene glycol. In another embodiment, at least one nanotube and/or the polynucleotides, primary constructs or mmRNA may be mixed with pharmaceutically acceptable excipients and/or delivery vehicles.

13925[000614] In one embodiment, the polynucleotides, primary constructs or mmRNA are attached and/or otherwise bound to at least one rosette nanotube. The rosette nanotubes may be formed by a process known in the art and/or by the process described in

13926International Publication No. WO2012094304, herein incorporated by reference in its entirety. At least one polynucleotide, primary construct and/or mmRNA may be attached and/or otherwise bound to at least one rosette nanotube by a process as described in International Publication No. WO2012094304, herein incorporated by reference in its entirety, where rosette nanotubes or modules forming rosette nanotubes are mixed in aqueous media with at least one polynucleotide, primary construct and/or mmRNA under conditions which may cause at least one polynucleotide, primary construct or mmRNA to attach or otherwise bind to the rosette nanotubes.

13927[000615] In one embodiment, the polynucleotides, primary constructs or mmRNA may be attached to and/or otherwise bound to at least one carbon nanotube. As a non-limiting example, the polynucleotides, primary constructs or mmRNA may be bound to a linking agent and the linked agent may be bound to the carbon nanotube (See e.g., U.S. Pat No. 8,246,995; herein incorporated by reference in its entirety). The carbon nanotube may be a single-walled nanotube (See e.g., U.S. Pat No. 8,246,995; herein incorporated by reference in its entirety).

13928Conjugates

13929[000616] The polynucleotides, primary constructs, and mmRNA of the invention include conjugates, such as a polynucleotide, primary construct, or mmRNA covalently linked to a carrier or targeting group, or including two encoding regions that together produce a fusion protein (e.g., bearing a targeting group and therapeutic protein or peptide).

13930[000617] The conjugates of the invention include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), high- density lipoprotein (HDL), or globulin); an carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); or a lipid. The ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid, an oligonucleotide (e.g. an aptamer). Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine.

13931Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

13932[000618] Representative U.S. patents that teach the preparation of polynucleotide conjugates, particularly to RNA, include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371 ; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; each of which is herein incorporated by reference in their entireties.

13933[000619] In one embodiment, the conjugate of the present invention may function as a carrier for the modified nucleic acids and mmRNA of the present invention. The conjugate may comprise a cationic polymer such as, but not limited to, polyamine, polylysine, polyalkylenimine, and polyethylenimine which may be grafted to with poly(ethylene glycol). As a non-limiting example, the conjugate may be similar to the polymeric conjugate and the method of synthesizing the polymeric conjugate described in U.S. Pat. No. 6,586,524 herein incorporated by reference in its entirety.

13934[000620] The conjugates can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, an RGD peptide, an RGD peptide mimetic or an aptamer. [000621] Targeting groups can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell.

13935Targeting groups may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl- gulucosamine multivalent mannose, multivalent fucose, or aptamers. The ligand can be, for example, a lipopolysaccharide, or an activator of p38 MAP kinase.

13936[000622] The targeting group can be any ligand that is capable of targeting a specific receptor. Examples include, without limitation, folate, GalNAc, galactose, mannose, mannose-6P, apatamers, integrin receptor ligands, chemokine receptor ligands, transferrin, biotin, serotonin receptor ligands, PSMA, endothelin, GCPII, somatostatin, LDL, and HDL ligands. In particular embodiments, the targeting group is an aptamer. The aptamer can be unmodified or have any combination of modifications disclosed herein.

13937[000623] In one embodiment, pharmaceutical compositions of the present invention may include chemical modifications such as, but not limited to, modifications similar to locked nucleic acids.

13938[000624] Representative U.S. Patents that teach the preparation of locked nucleic acid (LNA) such as those from Santaris, include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,670,461; 6,794,499; 6,998,484; 7,053,207; 7,084,125; and 7,399,845, each of which is herein incorporated by reference in its entirety.

13939[000625] Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.

13940[000626] Some embodiments featured in the invention include polynucleotides, primary constructs or mmRNA with phosphorothioate backbones and oligonucleosides with other modified backbones, and in particular -CH2-NH-CH2-, -CH2-N(CH3)-0-CH2- [known as a methylene (methylimino) or MMI backbone],— CH2— O— N(CH3)— CH2— ,— CH2--N(CH3)--N(CH3)-CH2-- and -N(CH3)-CH2--CH2- [wherein the native phosphodiester backbone is represented as— O— P(0)2— O— CH2— ] of the above- referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the polynucletotides featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

13941[000627] Modifications at the 2' position may also aid in delivery. Preferably, modifications at the 2' position are not located in a polypeptide-coding sequence, i.e., not in a translatable region. Modifications at the 2' position may be located in a 5'UTR, a 3'UTPv and/or a tailing region. Modifications at the 2' position can include one of the following at the 2' position: H (i.e., 2'-deoxy); F; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted Ci to Cio alkyl or C2 to Cio alkenyl and alkynyl. Exemplary suitable modifications include 0[(CH2)nO] mCH3, 0(CH2).nOCH3, 0(CH2)nNH2, 0(CH2) nCH3, 0(CH2)nONH2, and 0(CH2)nON[(CH2)nCH3)]2, where n and m are from 1 to about 10. In other embodiments, the polynucleotides, primary constructs or mmRNA include one of the following at the 2' position: Ci to Cio lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, CI, Br, CN, CF3, OCF3, SOCH3, S02CH3, ON02, N02, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties, or a group for improving the pharmacodynamic properties, and other substituents having similar properties. In some embodiments, the modification includes a 2'-methoxyethoxy (2'-0— CH2CH2OCH3, also known as 2'-0-(2-methoxy ethyl) or 2'-MOE) (Martin et al, Helv. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2'-dimethylaminooxyethoxy, i.e., a 0(CH2)2ON(CH3)2 group, also known as 2'-DMAOE, as described in examples herein below, and 2'- dimethylaminoethoxyethoxy (also known in the art as 2'-0-dimethylaminoethoxyethyl or 2*-DMAEOE), i.e., 2*-0-CH2-0-CH2-N(CH2)2, also described in examples herein below. Other modifications include 2'-methoxy (2'-OCH3), 2'-aminopropoxy (2'- OCH2CH2CH2NH2) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNAs and the 5' position of 5' terminal nucleotide. Polynucleotides of the invention may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957;

139425,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920 and each of which is herein incorporated by reference.

13943[000628] In still other embodiments, the polynucleotide, primary construct, or mmRNA is covalently conjugated to a cell penetrating polypeptide. The cell-penetrating peptide may also include a signal sequence. The conjugates of the invention can be designed to have increased stability; increased cell transfection; and/or altered the biodistribution (e.g., targeted to specific tissues or cell types).

13944[000629] In one embodiment, the polynucleotides, primary constructs or mmRNA may be conjugated to an agent to enhance delivery. As a non-limiting example, the agent may be a monomer or polymer such as a targeting monomer or a polymer having targeting blocks as described in International Publication No. WO2011062965, herein incorporated by reference in its entirety. In another non-limiting example, the agent may be a transport agent covalently coupled to the polynucleotides, primary constructs or mmRNA of the present invention (See e.g., U.S. Pat. Nos. 6,835.393 and 7,374,778, each of which is herein incorporated by reference in its entirety). In yet another non- limiting example, the agent may be a membrane barrier transport enhancing agent such as those described in U.S. Pat. Nos. 7,737,108 and 8,003,129, each of which is herein incorporated by reference in its entirety.

13945[000630] In another embodiment, polynucleotides, primary constructs or mmRNA may be conjugated to SMARTT POLYMER TECHNOLOGY® (PHASERX®, Inc. Seattle, WA).

13946Self-Assembled Nanoparticles

13947Nucleic Acid Self-Assembled Nanoparticles

13948[000631] Self-assembled nanoparticles have a well-defined size which may be precisely controlled as the nucleic acid strands may be easily reprogrammable. For example, the optimal particle size for a cancer-targeting nanodelivery carrier is 20-100 nm as a diameter greater than 20 nm avoids renal clearance and enhances delivery to certain tumors through enhanced permeability and retention effect. Using self-assembled nucleic acid nanoparticles a single uniform population in size and shape having a precisely controlled spatial orientation and density of cancer-targeting ligands for enhanced delivery. As a non-limiting example, oligonucleotide nanoparticles were prepared using programmable self-assembly of short DNA fragments and therapeutic siRNAs. These nanoparticles are molecularly identical with controllable particle size and target ligand location and density. The DNA fragments and siRNAs self-assembled into a one-step reaction to generate DNA/siRNA tetrahedral nanoparticles for targeted in vivo delivery. (Lee et al, Nature Nanotechnology 2012 7:389-393; herein incorporated by reference in its entirety).

13949[000632] In one embodiment, the polynucleotides, primary constructs and/or mmRNA disclosed herein may be formulated as self-assembled nanoparticles. As a non-limiting example, nucleic acids may be used to make nanoparticles which may be used in a delivery system for the polynucleotides, primary constructs and/or mmRNA of the present invention (See e.g., International Pub. No. WO2012125987; herein incorporated by reference in its entirety).

13950[000633] In one embodiment, the nucleic acid self-assembled nanoparticles may comprise a core of the polynucleotides, primary constructs or mmRNA disclosed herein and a polymer shell. The polymer shell may be any of the polymers described herein and are known in the art. In an additional embodiment, the polymer shell may be used to protect the polynucleotides, primary contructs and mmRNA in the core.

13951Polymer-Based Self-Assembled Nanoparticles

13952[000634] Polymers may be used to form sheets which self-assembled into nanoparticles. These nanoparticles may be used to deliver the polynucleotides, primary constructs and mmRNA of the present invention. In one embodiment, these self-assembled

13953nanoparticles may be microsponges formed of long polymers of RNA hairpins which form into crystalline 'pleated' sheets before self-assembling into microsponges. These microsponges are densely-packed sponge like microparticles which may function as an efficient carrier and may be able to deliver cargo to a cell. The microsponges may be from lum to 300 nm in diameter. The microsponges may be complexed with other agents known in the art to form larger microsponges. As a non-limiting example, the microsponge may be complexed with an agent to form an outer layer to promote cellular uptake such as polycation polyethyleneime (PEI). This complex can form a 250-nm diameter particle that can remain stable at high temperatures (150°C) (Grabow and Jaegar, Nature Materials 2012, 11 :269-269; herein incorporated by reference in its entirety). Additionally these microsponges may be able to exhibit an extraordinary degree of protection from degradation by ribonucleases.

13954[000635] In another embodiment, the polymer-based self-assembled nanoparticles such as, but not limited to, microsponges, may be fully programmable nanoparticles. The geometry, size and stoichiometry of the nanoparticle may be precisely controlled to create the optimal nanoparticle for delivery of cargo such as, but not limited to, polynucleotides, primary constructs and/or mmRNA.

13955[000636] In one embodiment, the polymer based nanoparticles may comprise a core of the polynucleotides, primary constructs and/or mmRNA disclosed herein and a polymer shell. The polymer shell may be any of the polymers described herein and are known in the art. In an additional embodiment, the polymer shell may be used to protect the polynucleotides, primary construct and/or mmRNA in the core.

13956[000637] In yet another embodiment, the polymer based nanoparticle may comprise a non-nucleic acid polymer comprising a plurality of heterogenous monomers such as those described in Interantional Publication No. WO2013009736, herein incorporated by reference in its entirety.

13957Inorganic Nanoparticles

13958[000638] The polynucleotides, primary constructs and/or mmRNAs of the present invention may be formulated in inorganic nanoparticles (U.S. Pat. No. 8,257,745, herein incorporated by reference in its entirety). The inorganic nanoparticles may include, but are not limited to, clay substances that are water swellable. As a non-limiting example, the inorganic nanoparticle may include synthetic smectite clays which are made from simple silicates (See e.g., U.S. Pat. No. 5,585,108 and 8,257,745 each of which are herein incorporated by reference in their entirety).

13959[000639] In one embodiment, the inorganic nanoparticles may comprise a core of the modified nucleic acids disclosed herein and a polymer shell. The polymer shell may be any of the polymers described herein and are known in the art. In an additional embodiment, the polymer shell may be used to protect the modified nucleic acids in the core.

13960Semi-conductive and Metallic Nanoparticles

13961[000640] The polynucleotides, primary constructs and/or mmRNAs of the present invention may be formulated in water-dispersible nanoparticle comprising a

13962semiconductive or metallic material (U.S. Pub. No. 20120228565; herein incorporated by reference in its entirety) or formed in a magnetic nanoparticle (U.S. Pub. No.

1396320120265001 and 20120283503; each of which is herein incorporated by reference in its entirety). The water-dispersible nanoparticles may be hydrophobic nanoparticles or hydrophilic nanoparticles.

13964[000641] In one embodiment, the semi-conductive and/or metallic nanoparticles may comprise a core of the polynucleotides, primary constructs and/or mmRNA disclosed herein and a polymer shell. The polymer shell may be any of the polymers described herein and are known in the art. In an additional embodiment, the polymer shell may be used to protect the polynucleotides, primary constructs and/or mmRNA in the core. Gels and Hydrogels

13965[000642] In one embodiment, the polynucleotides, primary constructs and/or mmRNA disclosed herein may be encapsulated into any hydrogel known in the art which may form a gel when injected into a subject. Hydrogels are a network of polymer chains that are hydrophilic, and are sometimes found as a colloidal gel in which water is the dispersion medium. Hydrogels are highly absorbent (they can contain over 99% water) natural or synthetic polymers. Hydrogels also possess a degree of flexibility very similar to natural tissue, due to their significant water content. The hydrogel described herein may used to encapsulate lipid nanoparticles which are biocompatible, biodegradable and/or porous.

13966[000643] As a non-limiting example, the hydrogel may be an aptamer-functionalized hydrogel. The aptamer-functionalized hydrogel may be programmed to release one or more polynucleotides, primary constructs and/or mmRNA using nucleic acid

13967hybridization. (Battig et al, J. Am. Chem. Society. 2012 134: 12410-12413; herein incorporated by reference in its entirety). [000644] As another non-limiting example, the hydrogel may be a shaped as an inverted opal.

13968The opal hydrogels exhibit higher swelling ratios and the swelling kinetics is an order of magnitude faster as well. Methods of producing opal hydrogels and description of opal hydrogels are described in International Pub. No. WO2012148684, herein incorporated by reference in its entirety.

13969[000645] In yet another non-limiting example, the hydrogel may be an antibacterial hydrogel. The antibacterial hydrogel may comprise a pharmaceutical acceptable salt or organic material such as, but not limited to pharmaceutical grade and/or medical grade silver salt and aloe vera gel or extract. (International Pub. No. WO2012151438, herein incorporated by reference in its entirety).

13970[000646] In one embodiment, the modified mRNA may be encapsulated in a lipid nanoparticle and then the lipid nanoparticle may be encapsulated into a hyrdogel.

13971[000647] In one embodiment, the polynucleotides, primary constructs and/or mmRNA disclosed herein may be encapsulated into any gel known in the art. As a non-limiting example the gel may be a fluorouracil injectable gel or a fluorouracil injectable gel containing a chemical compound and/or drug known in the art. As another example, the polynucleotides, primary constructs and/or mmRNA may be encapsulated in a fluorouracil gel containing epinephrine (See e.g., Smith et al. Cancer Chemotherapty and Pharmacology, 1999 44(4):267-274; herein incorporated by reference in its entirety).

13972[000648] In one embodiment, the polynucleotides, primary constructs and/or mmRNA disclosed herein may be encapsulated into a fibrin gel, fibrin hydrogel or fibrin glue. In another embodiment, the polynucleotides, primary constructs and/or mmRNA may be formulated in a lipid nanoparticle or a rapidly eliminated lipid nanoparticle prior to being encapsulated into a fibrin gel, fibrin hydrogel or a fibrin glue. In yet another

13973embodiment, the polynucleotides, primary constructs and/or mmRNA may be formulated as a lipoplex prior to being encapsulated into a fibrin gel, hydrogel or a fibrin glue.

13974Fibrin gels, hydrogels and glues comprise two components, a fibrinogen solution and a thrombin solution which is rich in calcium (See e.g., Spicer and Mikos, Journal of Controlled Release 2010. 148: 49-55; Kidd et al. Journal of Controlled Release 2012. 157:80-85; each of which is herein incorporated by reference in its entirety). The concentration of the components of the fibrin gel, hydrogel and/or glue can be altered to change the characteristics, the network mesh size, and/or the degradation characteristics of the gel, hydrogel and/or glue such as, but not limited to changing the release characteristics of the fibrin gel, hydrogel and/or glue. (See e.g., Spicer and Mikos, Journal of Controlled Release 2010. 148: 49-55; Kidd et al. Journal of Controlled Release 2012. 157:80-85; Catelas et al. Tissue Engineering 2008. 14: 119-128; each of which is herein incorporated by reference in its entirety). This feature may be advantageous when used to deliver the modified mRNA disclosed herein. (See e.g., Kidd et al. Journal of Controlled Release 2012. 157:80-85; Catelas et al. Tissue Engineering 2008. 14: 119-128; each of which is herein incorporated by reference in its entirety).

13975Cations and Anions

13976[000649] Formulations of polynucleotides, primary constructs and/or mmRNA disclosed herein may include cations or anions. In one embodiment, the formulations include metal cations such as, but not limited to, Zn2+, Ca2+, Cu2+, Mg+ and combinations thereof. As a non-limiting example, formulations may include polymers and a polynucleotides, primary constructs and/or mmRNA complexed with a metal cation (See e.g., U.S. Pat. Nos. 6,265,389 and 6,555,525, each of which is herein incorporated by reference in its entirety).

13977Molded Nanoparticles and Microparticles

13978[000650] The polynucleotides, primary constructs and/or mmRNA disclosed herein may be formulated in nanoparticles and/or microparticles. These nanoparticles and/or microparticles may be molded into any size shape and chemistry. As an example, the nanoparticles and/or microparticles may be made using the PRINT® technology by LIQUIDA TECHNOLOGIES® (Morrisville, NC) (See e.g., International Pub. No.

13979WO2007024323; herein incorporated by reference in its entirety).

13980[000651] In one embodiment, the molded nanoparticles may comprise a core of the polynucleotides, primary constructs and/or mmRNA disclosed herein and a polymer shell. The polymer shell may be any of the polymers described herein and are known in the art. In an additional embodiment, the polymer shell may be used to protect the polynucleotides, primary construct and/or mmRNA in the core.

13981NanoJackets and NanoLiposomes [000652] The polynucleotides, primary constructs and/or mmRNA disclosed herein may be formulated in NanoJackets and NanoLiposomes by Keystone Nano (State College, PA). NanoJackets are made of compounds that are naturally found in the body including calcium, phosphate and may also include a small amount of silicates.

13982Nanojackets may range in size from 5 to 50 nm and may be used to deliver hydrophilic and hydrophobic compounds such as, but not limited to, polynucleotides, primary constructs and/or mmRNA.

13983[000653] NanoLiposomes are made of lipids such as, but not limited to, lipids which naturally occur in the body. NanoLiposomes may range in size from 60-80 nm and may be used to deliver hydrophilic and hydrophobic compounds such as, but not limited to, polynucleotides, primary constructs and/or mmRNA. In one aspect, the polynucleotides, primary constructs and/or mmRNA disclosed herein are formulated in a NanoLiposome such as, but not limited to, Ceramide NanoLiposomes.

13984Excipients

13985[000654] Pharmaceutical formulations may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety) discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional excipient medium is incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.

13986[000655] In some embodiments, a pharmaceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, an excipient is approved for use in humans and for veterinary use. In some embodiments, an excipient is approved by United States Food and Drug Administration. In some embodiments, an excipient is pharmaceutical grade. In some embodiments, an excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.

13987[000656] Pharmaceutically acceptable excipients used in the manufacture of

13988pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Such excipients may optionally be included in pharmaceutical compositions.

13989[000657] Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and/or combinations thereof.

13990[000658] Exemplary granulating and/or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (VEEGUM®), sodium lauryl sulfate, quaternary ammonium compounds, etc., and/or combinations thereof.

13991[000659] Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and VEEGUM® [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.

13992carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [TWEEN®20], polyoxy ethylene sorbitan [TWEENn®60], polyoxyethylene sorbitan monooleate [TWEEN®80], sorbitan monopalmitate [SPAN®40], sorbitan monostearate [SPAN®60], sorbitan tristearate

13993[SPAN®65], glyceryl monooleate, sorbitan monooleate [SPAN®80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [MYRJ®45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. CREMOPHOR®), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [BRIJ®30]), polyvinylpyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate,

13994PLUORINC®F 68, POLOXAMER®188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.

13995[000660] Exemplary binding agents include, but are not limited to, starch (e.g.

13996cornstarch and starch paste); gelatin; sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol,); natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; etc.; and

13997combinations thereof.

13998[000661] Exemplary preservatives may include, but are not limited to, antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and/or other preservatives. Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and/or sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and/or trisodium edetate. Exemplary antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and/or thimerosal. Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and/or sorbic acid. Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol,

13999hydroxybenzoate, and/or phenylethyl alcohol. Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and/or phytic acid. Other

14000preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS®, PHENONIP®, methylparaben, GERM ALL® 115, GERM ABEN®II , NEOLONE™, KATHON™, and/or EUXYL®.

14001[000662] Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and/or combinations thereof.

14002[000663] Exemplary lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.

14003[000664] Exemplary oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, saffiower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and/or combinations thereof.

14004[000665] Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and/or perfuming agents can be present in the composition, according to the judgment of the formulator.

14005Delivery

14006[000666] The present disclosure encompasses the delivery of polynucleotides, primary constructs or mmRNA for any of therapeutic, pharmaceutical, diagnostic or imaging by any appropriate route taking into consideration likely advances in the sciences of drug delivery. Delivery may be naked or formulated.

14007Naked Delivery

14008[000667] The polynucleotides, primary constructs or mmRNA of the present invention may be delivered to a cell naked. As used herein in, "naked" refers to delivering polynucleotides, primary constructs or mmRNA free from agents which promote transfection. For example, the polynucleotides, primary constructs or mmRNA delivered to the cell may contain no modifications. The naked polynucleotides, primary constructs or mmRNA may be delivered to the cell using routes of administration known in the art and described herein.

14009Formulated Delivery

14010[000668] The polynucleotides, primary constructs or mmRNA of the present invention may be formulated, using the methods described herein. The formulations may contain polynucleotides, primary constructs or mmRNA which may be modified and/or unmodified. The formulations may further include, but are not limited to, cell penetration agents, a pharmaceutically acceptable carrier, a delivery agent, a bioerodible or biocompatible polymer, a solvent, and a sustained-release delivery depot. The formulated polynucleotides, primary constructs or mmRNA may be delivered to the cell using routes of administration known in the art and described herein.

14011[000669] The compositions may also be formulated for direct delivery to an organ or tissue in any of several ways in the art including, but not limited to, direct soaking or bathing, via a catheter, by gels, powder, ointments, creams, gels, lotions, and/or drops, by using substrates such as fabric or biodegradable materials coated or impregnated with the compositions, and the like.

14012Administration

14013[000670] The polynucleotides, primary constructs or mmRNA of the present invention may be administered by any route which results in a therapeutically effective outcome. These include, but are not limited to enteral, gastroenteral, epidural, oral, transdermal, epidural (peridural), intracerebral (into the cerebrum), intracerebroventricular (into the cerebral ventricles), epicutaneous (application onto the skin), intradermal, (into the skin itself), subcutaneous (under the skin), nasal administration (through the nose), intravenous (into a vein), intraarterial (into an artery), intramuscular (into a muscle), intracardiac (into the heart), intraosseous infusion (into the bone marrow), intrathecal (into the spinal canal), intraperitoneal, (infusion or injection into the peritoneum), intravesical infusion, intravitreal, (through the eye), intracavernous injection, ( into the base of the penis), intravaginal administration, intrauterine, extra-amniotic administration, transdermal (diffusion through the intact skin for systemic distribution), transmucosal (diffusion through a mucous membrane), insufflation (snorting), sublingual, sublabial, enema, eye drops (onto the conjunctiva), or in ear drops. In specific embodiments, compositions may be administered in a way which allows them cross the blood-brain barrier, vascular barrier, or other epithelial barrier .Non-limiting routes of administration for the polynucleotides, primary constructs or mmRNA of the present invention are described below.

14014Parenteral and Injectible Administration

14015[000671] Liquid dosage forms for parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and/or elixirs. In addition to active ingredients, liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents. In certain embodiments for parenteral administration, compositions are mixed with solubilizing agents such as CREMOPHOR®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof.

14016[000672] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing agents, wetting agents, and/or suspending agents. Sterile injectable preparations may be sterile injectable solutions, suspensions, and/or emulsions in nontoxic parenterally acceptable diluents and/or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P., and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injectables.

14017[000673] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, and/or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

14018[000674] In order to prolong the effect of an active ingredient, it is often desirable to slow the absorption of the active ingredient from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is

14019accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

14020Rectal and Vaginal Administration

14021[000675] Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing compositions with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.

14022Oral Administration

14023[000676] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and/or elixirs. In addition to active ingredients, liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, oral

14024compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents. In certain embodiments for parenteral administration, compositions are mixed with solubilizing agents such as CREMOPHOR®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof.

14025[000677] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, an active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient such as sodium citrate or dicalcium phosphate and/or fillers or extenders (e.g. starches, lactose, sucrose, glucose, mannitol, and silicic acid), binders (e.g. carboxymethylcellulose, alginates, gelatin,

14026polyvinylpyrrolidinone, sucrose, and acacia), humectants (e.g. glycerol), disintegrating agents (e.g. agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarding agents (e.g. paraffin), absorption accelerators (e.g. quaternary ammonium compounds), wetting agents (e.g. cetyl alcohol and glycerol monostearate), absorbents (e.g. kaolin and bentonite clay), and lubricants (e.g. talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate), and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.

14027Topical or Transdermal Administration

14028[000678] As described herein, compositions containing the polynucleotides, primary constructs or mmRNA of the invention may be formulated for administration topically. The skin may be an ideal target site for delivery as it is readily accessible. Gene expression may be restricted not only to the skin, potentially avoiding nonspecific toxicity, but also to specific layers and cell types within the skin.

14029[000679] The site of cutaneous expression of the delivered compositions will depend on the route of nucleic acid delivery. Three routes are commonly considered to deliver polynucleotides, primary constructs or mmRNA to the skin: (i) topical application (e.g. for local/regional treatment and/or cosmetic applications); (ii) intradermal injection (e.g. for local/regional treatment and/or cosmetic applications); and (iii) systemic delivery (e.g. for treatment of dermatologic diseases that affect both cutaneous and extracutaneous regions). Polynucleotides, primary constructs or mmRNA can be delivered to the skin by several different approaches known in the art. Most topical delivery approaches have been shown to work for delivery of DNA, such as but not limited to, topical application of non-cationic liposome-DNA complex, cationic liposome-DNA complex, particle- mediated (gene gun), puncture-mediated gene transfections, and viral delivery

14030approaches. After delivery of the nucleic acid, gene products have been detected in a number of different skin cell types, including, but not limited to, basal keratinocytes, sebaceous gland cells, dermal fibroblasts and dermal macrophages.

14031[000680] In one embodiment, the invention provides for a variety of dressings (e.g., wound dressings) or bandages (e.g., adhesive bandages) for conveniently and/or effectively carrying out methods of the present invention. Typically dressing or bandages may comprise sufficient amounts of pharmaceutical compositions and/or polynucleotides, primary constructs or mmRNA described herein to allow a user to perform multiple treatments of a subject(s).

14032[000681] In one embodiment, the invention provides for the polynucleotides, primary constructs or mmRNA compositions to be delivered in more than one injection.

14033[000682] In one embodiment, before topical and/or transdermal administration at least one area of tissue, such as skin, may be subjected to a device and/or solution which may increase permeability. In one embodiment, the tissue may be subjected to an abrasion device to increase the permeability of the skin (see U.S. Patent Publication No.

1403420080275468, herein incorporated by reference in its entirety). In another embodiment, the tissue may be subjected to an ultrasound enhancement device. An ultrasound enhancement device may include, but is not limited to, the devices described in U.S. Publication No. 20040236268 and U.S. Patent Nos. 6,491,657 and 6,234,990; each of which are herein incorporated by reference in their entireties. Methods of enhancing the permeability of tissue are described in U.S. Publication Nos. 20040171980 and

1403520040236268 and U.S. Pat. No. 6,190,315; each of which are herein incorporated by reference in their entireties. [000683] In one embodiment, a device may be used to increase permeability of tissue before delivering formulations of modified mRNA described herein. The permeability of skin may be measured by methods known in the art and/or described in U.S. Patent No. 6,190,315, herein incorporated by reference in its entirety. As a non- limiting example, a modified mRNA formulation may be delivered by the drug delivery methods described in U.S. Patent No. 6,190,315, herein incorporated by reference in its entirety.

14036[000684] In another non-limiting example tissue may be treated with a eutectic mixture of local anesthetics (EMLA) cream before, during and/or after the tissue may be subjected to a device which may increase permeability. Katz et al. (Anesth Analg (2004); 98:371-76; herein incorporated by reference in its entirety) showed that using the EMLA cream in combination with a low energy, an onset of superficial cutaneous analgesia was seen as fast as 5 minutes after a pretreatment with a low energy ultrasound.

14037[000685] In one embodiment, enhancers may be applied to the tissue before, during, and/or after the tissue has been treated to increase permeability. Enhancers include, but are not limited to, transport enhancers, physical enhancers, and cavitation enhancers. Non-limiting examples of enhancers are described in U.S. Patent No. 6,190,315, herein incorporated by reference in its entirety.

14038[000686] In one embodiment, a device may be used to increase permeability of tissue before delivering formulations of modified mRNA described herein, which may further contain a substance that invokes an immune response. In another non-limiting example, a formulation containing a substance to invoke an immune response may be delivered by the methods described in U.S. Publication Nos. 20040171980 and 20040236268; each of which are herein incorporated by reference in their entireties.

14039[000687] Dosage forms for topical and/or transdermal administration of a composition may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. Generally, an active ingredient is admixed under sterile conditions with a pharmaceutically acceptable excipient and/or any needed preservatives and/or buffers as may be required.

14040[000688] Additionally, the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms may be prepared, for example, by dissolving and/or dispensing the compound in the proper medium. Alternatively or additionally, rate may be controlled by either providing a rate controlling membrane and/or by dispersing the compound in a polymer matrix and/or gel.

14041[000689] Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions.

14042[000690] Topically-administrable formulations may, for example, comprise from about 0.1% to about 10% (w/w) active ingredient, although the concentration of active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.

14043Depot Administration

14044[000691] As described herein, in some embodiments, the composition is formulated in depots for extended release. Generally, a specific organ or tissue (a "target tissue") is targeted for administration.

14045[000692] In some aspects of the invention, the polynucleotides, primary constructs or mmRNA are spatially retained within or proximal to a target tissue. Provided are method of providing a composition to a target tissue of a mammalian subject by contacting the target tissue (which contains one or more target cells) with the composition under conditions such that the composition, in particular the nucleic acid component(s) of the composition, is substantially retained in the target tissue, meaning that at least 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of the composition is retained in the target tissue. Advantageously, retention is determined by measuring the amount of the nucleic acid present in the composition that enters one or more target cells. For example, at least 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of the nucleic acids administered to the subject are present intracellularly at a period of time following administration. For example, intramuscular injection to a mammalian subject is performed using an aqueous composition containing a ribonucleic acid and a transfection reagent, and retention of the composition is determined by measuring the amount of the ribonucleic acid present in the muscle cells.

14046[000693] Aspects of the invention are directed to methods of providing a composition to a target tissue of a mammalian subject, by contacting the target tissue (containing one or more target cells) with the composition under conditions such that the composition is substantially retained in the target tissue. The composition contains an effective amount of a polynucleotides, primary constructs or mmRNA such that the polypeptide of interest is produced in at least one target cell. The compositions generally contain a cell penetration agent, although "naked" nucleic acid (such as nucleic acids without a cell penetration agent or other agent) is also contemplated, and a pharmaceutically acceptable carrier.

14047[000694] In some circumstances, the amount of a protein produced by cells in a tissue is desirably increased. Preferably, this increase in protein production is spatially restricted to cells within the target tissue. Thus, provided are methods of increasing production of a protein of interest in a tissue of a mammalian subject. A composition is provided that contains polynucleotides, primary constructs or mmRNA characterized in that a unit quantity of composition has been determined to produce the polypeptide of interest in a substantial percentage of cells contained within a predetermined volume of the target tissue.

14048[000695] In some embodiments, the composition includes a plurality of different polynucleotides, primary constructs or mmRNA, where one or more than one of the polynucleotides, primary constructs or mmRNA encodes a polypeptide of interest.

14049Optionally, the composition also contains a cell penetration agent to assist in the intracellular delivery of the composition. A determination is made of the dose of the composition required to produce the polypeptide of interest in a substantial percentage of cells contained within the predetermined volume of the target tissue (generally, without inducing significant production of the polypeptide of interest in tissue adjacent to the predetermined volume, or distally to the target tissue). Subsequent to this determination, the determined dose is introduced directly into the tissue of the mammalian subject. [000696] In one embodiment, the invention provides for the polynucleotides, primary constructs or mmRNA to be delivered in more than one injection or by split dose injections.

14050[000697] In one embodiment, the invention may be retained near target tissue using a small disposable drug reservoir, patch pump or osmotic pump. Non-limiting examples of patch pumps include those manufactured and/or sold by BD® (Franklin Lakes, NJ), Insulet Corporation (Bedford, MA), SteadyMed Therapeutics (San Francisco, CA), Medtronic (Minneapolis, MN) (e.g., MiniMed), UniLife (York, PA), Valeritas

14051(Bridgewater, NJ), and SpringLeaf Therapeutics (Boston, MA). A non-limiting example of an osmotic pump include those manufactured by DURECT® (Cupertino, CA) (e.g., DUROS® and ALZET ®).

14052Pulmonary Administration

14053[000698] A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 nm to about 7 nm or from about 1 nm to about 6 nm. Such compositions are suitably in the form of dry powders for

14054administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nm and at least 95% of the particles by number have a diameter less than 7 nm. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nm and at least 90% of the particles by number have a diameter less than 6 nm. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.

14055[000699] Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure. Generally the propellant may constitute 50%) to 99.9%) (w/w) of the composition, and active ingredient may constitute 0.1 %> to 20% (w/w) of the composition. A propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).

14056[000700] As a non-limiting example, the polynucleotides, primary constructs and/or mmR A described herein may be formulated for pulmonary delivery by the methods described in U.S. Pat. No. 8,257,685; herein incorporated by reference in its entirety.

14057[000701] Pharmaceutical compositions formulated for pulmonary delivery may provide an active ingredient in the form of droplets of a solution and/or suspension. Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate. Droplets provided by this route of administration may have an average diameter in the range from about 0.1 nm to about 200 nm.

14058Intranasal, nasal and buccal Administration

14059[000702] Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 μιη to 500 μιη. Such a formulation is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nose.

14060[000703] Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100%) (w/w) of active ingredient, and may comprise one or more of the additional ingredients described herein. A

14061pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1% to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising active ingredient. Such powdered, aerosolized, and/or aerosolized

14062formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 nm to about 200 nm, and may further comprise one or more of any additional ingredients described herein.

14063Ophthalmic Administration

14064[000704] A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid excipient. Such drops may further comprise buffering agents, salts, and/or one or more other of any additional ingredients described herein. Other ophthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this invention. A multilayer thin film device may be prepared to contain a pharmaceutical composition for delivery to the eye and/or surrounding tissue.

14065Payload Administration: Detectable Agents and Therapeutic Agents

14066[000705] The polynucleotides, primary constructs or mmR A described herein can be used in a number of different scenarios in which delivery of a substance (the "payload") to a biological target is desired, for example delivery of detectable substances for detection of the target, or delivery of a therapeutic agent. Detection methods can include, but are not limited to, both imaging in vitro and in vivo imaging methods, e.g., immunohistochemistry, bioluminescence imaging (BLI), Magnetic Resonance Imaging (MRI), positron emission tomography (PET), electron microscopy, X-ray computed tomography, Raman imaging, optical coherence tomography, absorption imaging, thermal imaging, fluorescence reflectance imaging, fluorescence microscopy,

14067fluorescence molecular tomographic imaging, nuclear magnetic resonance imaging, X- ray imaging, ultrasound imaging, photoacoustic imaging, lab assays, or in any situation where tagging/staining/imaging is required.

14068[000706] The polynucleotides, primary constructs or mmRNA can be designed to include both a linker and a payload in any useful orientation. For example, a linker having two ends is used to attach one end to the payload and the other end to the nucleobase, such as at the C-7 or C-8 positions of the deaza-adenosine or deaza- guanosine or to the N-3 or C-5 positions of cytosine or uracil. The polynucleotide of the invention can include more than one payload (e.g., a label and a transcription inhibitor), as well as a cleavable linker. In one embodiment, the modified nucleotide is a modified 7-deaza-adenosine triphosphate, where one end of a cleavable linker is attached to the C7 position of 7-deaza-adenine, the other end of the linker is attached to an inhibitor (e.g., to the C5 position of the nucleobase on a cytidine), and a label (e.g., Cy5) is attached to the center of the linker (see, e.g., compound 1 of A*pCp C5 Parg Capless in Fig. 5 and columns 9 and 10 of U.S. Pat. No. 7,994,304, incorporated herein by reference). Upon incorporation of the modified 7-deaza-adenosine triphosphate to an encoding region, the resulting polynucleotide having a cleavable linker attached to a label and an inhibitor (e.g., a polymerase inhibitor). Upon cleavage of the linker (e.g., with reductive conditions to reduce a linker having a cleavable disulfide moiety), the label and inhibitor are released. Additional linkers and payloads (e.g., therapeutic agents, detectable labels, and cell penetrating payloads) are described herein.

14069[000707] Scheme 12 below depicts an exemplary modified nucleotide wherein the nucleobase, adenine, is attached to a linker at the C-7 carbon of 7-deaza adenine. In addition, Scheme 12 depicts the modified nucleotide with the linker and payload, e.g., a detectable agent, incorporated onto the 3' end of the mRNA. Disulfide cleavage and 1,2- addition of the thiol group onto the propargyl ester releases the detectable agent. The remaining structure (depicted, for example, as pApC5Parg in Scheme 12) is the inhibitor. The rationale for the structure of the modified nucleotides is that the tethered inhibitor sterically interferes with the ability of the polymerase to incorporate a second base. Thus, it is critical that the tether be long enough to affect this function and that the inhibiter be in a stereochemical orientation that inhibits or prohibits second and follow on nucleotides into the growing polynucleotide strand.

14070Scheme 12

14071<img file="WO2013151663A1_D0155.tif" />

14072[000708] For example, the polynucleotides, primary constructs or mmRNA described herein can be used in reprogramming induced pluripotent stem cells (iPS cells), which can directly track cells that are transfected compared to total cells in the cluster. In another example, a drug that may be attached to the polynucleotides, primary constructs or mmRNA via a linker and may be fluorescently labeled can be used to track the drug in vivo, e.g. intracellularly. Other examples include, but are not limited to, the use of a polynucleotides, primary constructs or mmRNA in reversible drug delivery into cells.

14073[000709] The polynucleotides, primary constructs or mmRNA described herein can be used in intracellular targeting of a payload, e.g., detectable or therapeutic agent, to specific organelle. Exemplary intracellular targets can include, but are not limited to, the nuclear localization for advanced mRNA processing, or a nuclear localization sequence (NLS) linked to the mRNA containing an inhibitor.

14074[000710] In addition, the polynucleotides, primary constructs or mmRNA described herein can be used to deliver therapeutic agents to cells or tissues, e.g., in living animals. For example, the polynucleotides, primary constructs or mmRNA described herein can be used to deliver highly polar chemotherapeutics agents to kill cancer cells. The polynucleotides, primary constructs or mmRNA attached to the therapeutic agent through a linker can facilitate member permeation allowing the therapeutic agent to travel into a cell to reach an intracellular target.

14075[000711] In one example, the linker is attached at the 2'-position of the ribose ring and/or at the 3' and/or 5' positionof the polynucleotides, primary constructs mmRNA (See e.g., International Pub. No. WO2012030683, herein incorporated by reference in its entirety). The linker may be any linker disclosed herein, known in the art and/or disclosed in International Pub. No. WO2012030683, herein incorporated by reference in its entirety.

14076[000712] In another example, the polynucleotides, primary constructs or mmRNA can be attached to the polynucleotides, primary constructs or mmRNA a viral inhibitory peptide (VIP) through a cleavable linker. The cleavable linker can release the VIP and dye into the cell. In another example, the polynucleotides, primary constructs or mmRNA can be attached through the linker to an ADP-ribosylate, which is responsible for the actions of some bacterial toxins, such as cholera toxin, diphtheria toxin, and pertussis toxin. These toxin proteins are ADP-ribosyltransferases that modify target proteins in human cells. For example, cholera toxin ADP-ribosylates G proteins modifies human cells by causing massive fluid secretion from the lining of the small intestine, which results in life-threatening diarrhea.

14077[000713] In some embodiments, the payload may be a therapeutic agent such as a cytotoxin, radioactive ion, chemotherapeutic, or other therapeutic agent. A cytotoxin or cytotoxic agent includes any agent that may be detrimental to cells. Examples include, but are not limited to, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracmedione, mitoxantrone, mithramycin, actinomycin D, 1- dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids, e.g., maytansinol (see U.S. Pat. No. 5,208,020 incorporated herein in its entirety), rachelmycin (CC-1065, see U.S. Pat. Nos. 5,475,092, 5,585,499, and 5,846,545, all of which are incorporated herein by reference), and analogs or homo logs thereof. Radioactive ions include, but are not limited to iodine {e.g., iodine 125 or iodine 131), strontium 89, phosphorous, palladium, cesium, iridium, phosphate, cobalt, yttrium 90, samarium 153, and praseodymium. Other therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6- thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g.,

14078mechlorethamine, thiotepa chlorambucil, rachelmycin (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine, vinblastine, taxol and maytansinoids).

14079[000714] In some embodiments, the payload may be a detectable agent, such as various organic small molecules, inorganic compounds, nanoparticles, enzymes or enzyme substrates, fluorescent materials, luminescent materials (e.g., luminol), bioluminescent materials (e.g., luciferase, luciferin, and aequorin), chemiluminescent materials, radioactive materials (e.g., 18F, 67Ga, 81mKr, 82Rb, mIn, 123I, 133Xe, 201T1, 125I, 35S, 14C, 3H, or 99mTc (e.g., as pertechnetate (technetate(VII), Tc04~)), and contrast agents (e.g., gold {e.g., gold nanoparticles), gadolinium (e.g., chelated Gd), iron oxides (e.g., superparamagnetic iron oxide (SPIO), monocrystalline iron oxide nanoparticles (MIONs), and ultrasmall superparamagnetic iron oxide (USPIO)), manganese chelates (e.g., Mn-DPDP), barium sulfate, iodinated contrast media (iohexol), microbubbles, or perfiuorocarbons). Such optically-detectable labels include for example, without limitation, 4-acetamido-4'-isothiocyanatostilbene-2,2'disulfonic acid; acridine and derivatives (e.g., acridine and acridine isothiocyanate); 5-(2'- aminoethyl)aminonaphthalene-l -sulfonic acid (EDANS); 4-amino-N-[3- vinylsulfonyl)phenyl]naphthalimide-3 ,5 disulfonate; N-(4-anilino-l-naphthyl)maleimide; anthranilamide; BODIPY; Brilliant Yellow; coumarin and derivatives (e.g., coumarin, 7- amino-4-methylcoumarin (AMC, Coumarin 120), and 7-amino-4- trifluoromethylcoumarin (Coumarin 151)); cyanine dyes; cyanosine; 4',6-diaminidino-2- phenylindole (DAPI); 5' 5"-dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red); 7-diethylamino-3 -(4 ' -isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid; 4,4'- diisothiocyanatostilbene-2,2'-disulfonic acid; 5-[dimethylamino]-naphthalene-l-sulfonyl chloride (DNS, dansylchloride); 4-dimethylaminophenylazophenyl-4' -isothiocyanate (DABITC); eosin and derivatives (e.g., eosin and eosin isothiocyanate); erythrosin and derivatives (e.g., erythrosin B and erythrosin isothiocyanate); ethidium; fluorescein and derivatives (e.g., 5-carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2- yl)amino fluorescein (DTAF), 2',7 ' -dimethoxy-4 ' 5 '-dichloro-6-carboxyfluorescein, fluorescein, fluorescein isothiocyanate, X-rhodamine-5-(and-6)-isothiocyanate (QFITC or XRITC), and fluorescamine); 2-[2-[3-[[l,3-dihydro-l,l-dimethyl-3-(3-sulfopropyl)- 2H-benz[e]indol-2-ylidene]ethylidene]-2-[4-(ethoxycarbonyl)-l-piperazinyl]-l- cyclopenten-1 -yljethenyl]- 1 , 1 -dimethyl-3-(3-sulforpropyl)- lH-benz[e]indolium hydroxide, inner salt, compound with n,n-diethylethanamine(l : l) (IR144); 5-chloro-2-[2- [3-[(5-chloro-3-ethyl-2(3H)-benzothiazol- ylidene)ethylidene]-2-(diphenylamino)-l- cyclopenten-l-yl]ethenyl]-3-ethyl benzothiazolium perchlorate (IR140); Malachite Green isothiocyanate; 4-methylumbelliferone orthocresolphthalein; nitrotyrosine;

14080pararosaniline; Phenol Red; B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives(e.g., pyrene, pyrene butyrate, and succinimidyl 1 -pyrene); butyrate quantum dots; Reactive Red 4 (CIBACRON™ Brilliant Red 3B-A); rhodamine and derivatives (e.g., 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride rhodarnine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101, sulfonyl chloride derivative of sulforhodamine 101 (Texas Red), Ν,Ν,Ν ',Ν 'tetramethyl-6-carboxyrhodamine (TAMRA) tetramethyl rhodamine, and tetramethyl rhodamine isothiocyanate (TRITC)); riboflavin; rosolic acid; terbium chelate derivatives; Cyanine-3 (Cy3); Cyanine-5 (Cy5); cyanine-5.5 (Cy5.5), Cyanine-7 (Cy7); IRD 700; IRD 800; Alexa 647; La Jolta Blue; phthalo cyanine; and naphthalo cyanine.

14081[000715] In some embodiments, the detectable agent may be a non-detectable precursor that becomes detectable upon activation (e.g., fluorogenic tetrazine-fluorophore constructs (e.g., tetrazine-BODIPY FL, tetrazine-Oregon Green 488, or tetrazine- BODIPY TMR-X) or enzyme activatable fluorogenic agents (e.g., PROSENSE® (VisEn Medical))). In vitro assays in which the enzyme labeled compositions can be used include, but are not limited to, enzyme linked immunosorbent assays (ELISAs), immunoprecipitation assays, immunofluorescence, enzyme immunoassays (EIA), radioimmunoassays (RIA), and Western blot analysis.

14082Combinations

14083[000716] The polynucleotides, primary constructs or mmRNA may be used in combination with one or more other therapeutic, prophylactic, diagnostic, or imaging agents. By "in combination with," it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope of the present disclosure. Compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In some embodiments, the present disclosure encompasses the delivery of pharmaceutical, prophylactic, diagnostic, or imaging compositions in combination with agents that may improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. As a non-limiting example, the nucleic acids or mmRNA may be used in combination with a pharmaceutical agent for the treatment of cancer or to control hyperproliferative cells. In U.S. Pat. No. 7,964,571, herein incorporated by reference in its entirety, a combination therapy for the treatment of solid primary or metastasized tumor is described using a pharmaceutical composition including a DNA plasmid encoding for interleukin-12 with a lipopolymer and also administering at least one anticancer agent or chemotherapeutic. Further, the nucleic acids and mmRNA of the present invention that encodes anti-proliferative molecules may be in a pharmaceutical composition with a lipopolymer (see e.g., U.S. Pub. No. 201 10218231 , herein incorporated by reference in its entirety, claiming a pharmaceutical composition comprising a DNA plasmid encoding an anti-proliferative molecule and a lipopolymer) which may be administered with at least one chemotherapeutic or anticancer agent.

14084[000717] It will further be appreciated that therapeutically, prophylactically, diagnostically, or imaging active agents utilized in combination may be administered together in a single composition or administered separately in different compositions. In general, it is expected that agents utilized in combination with be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually. In one embodiment, the combinations, each or together may be administered according to the split dosing regimens described herein.

14085Dosing

14086[000718] The present invention provides methods comprising administering modified mRNAs and their encoded proteins or complexes in accordance with the invention to a subject in need thereof. Nucleic acids, proteins or complexes, or pharmaceutical, imaging, diagnostic, or prophylactic compositions thereof, may be administered to a subject using any amount and any route of administration effective for preventing, treating, diagnosing, or imaging a disease, disorder, and/or condition (e.g., a disease, disorder, and/or condition relating to working memory deficits). The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular composition, its mode of administration, its mode of activity, and the like. Compositions in accordance with the invention are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention may be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective, prophylactically effective, or appropriate imaging dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

14087[000719] In certain embodiments, compositions in accordance with the present invention may be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg, from about 0.001 mg/kg to about 0.05 mg/kg, from about 0.005 mg/kg to about 0.05 mg/kg, from about 0.001 mg/kg to about 0.005 mg/kg, from about 0.05 mg/kg to about 0.5 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic, prophylactic, or imaging effect. The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered using multiple

14088administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). When multiple administrations are employed, split dosing regimens such as those described herein may be used.

14089[000720] According to the present invention, it has been discovered that administration of mmR A in split-dose regimens produce higher levels of proteins in mammalian subjects. As used herein, a "split dose" is the division of single unit dose or total daily dose into two or more doses, e.g, two or more administrations of the single unit dose. As used herein, a "single unit dose" is a dose of any therapeutic administed in one dose/at one time/single route/single point of contact, i.e., single administration event. As used herein, a "total daily dose" is an amount given or prescribed in 24 hr period. It may be administered as a single unit dose. In one embodiment, the mmRNA of the present invention are administed to a subject in split doses. The mmR A may be formulated in buffer only or in a formulation described herein.

14090Dosage Forms

14091[000721] A pharmaceutical composition described herein can be formulated into a dosage form described herein, such as a topical, intranasal, intratracheal, or injectable (e.g., intravenous, intraocular, intravitreal, intramuscular, intracardiac, intraperitoneal, subcutaneous).

14092Liquid dosage forms

14093[000722] Liquid dosage forms for parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and/or elixirs. In addition to active ingredients, liquid dosage forms may comprise inert diluents commonly used in the art including, but not limited to, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. In certain embodiments for parenteral administration, compositions may be mixed with solubilizing agents such as CREMOPHOR®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof.

14094Injectable

14095[000723] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art and may include suitable dispersing agents, wetting agents, and/or suspending agents. Sterile injectable

14096preparations may be sterile injectable solutions, suspensions, and/or emulsions in nontoxic parenterally acceptable diluents and/or solvents, for example, a solution in 1,3- butanediol. Among the acceptable vehicles and solvents that may be employed include, but are not limited to, water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injectables.

14097Injectable formulations can be sterilized, for example, by filtration through a bacterial- retaining filter, and/or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

14098In order to prolong the effect of an active ingredient, it may be desirable to slow the absorption of the active ingredient from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the polynucleotide, primary construct or mmRNA then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered polynucleotide, primary construct or mmRNA may be accomplished by dissolving or suspending the polynucleotide, primary construct or mmRNA in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the polynucleotide, primary construct or mmRNA in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of polynucleotide, primary construct or mmRNA to polymer and the nature of the particular polymer employed, the rate of polynucleotide, primary construct or mmRNA release can be controlled. Examples of other biodegradable polymers include, but are not limited to, poly(orthoesters) and poly(anhydrides). Depot injectable formulations may be prepared by entrapping the polynucleotide, primary construct or mmRNA in liposomes or microemulsions which are compatible with body tissues.

14099Pulmonary

14100[000724] Formulations described herein as being useful for pulmonary delivery may also be used for intranasal delivery of a pharmaceutical composition. Another

14101formulation suitable for intranasal administration may be a coarse powder comprising the active ingredient and having an average particle from about 0.2 μιη to 500 μιη. Such a formulation may be administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nose. [000725] Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of active ingredient, and may comprise one or more of the additional ingredients described herein. A

14102pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, contain about 0.1% to 20% (w/w) active ingredient, where the balance may comprise an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 nm to about 200 nm, and may further comprise one or more of any additional ingredients described herein.

14103[000726] General considerations in the formulation and/or manufacture of

14104pharmaceutical agents may be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).

14105Coatings or Shells

14106[000727] Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or

14107preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

14108Properties of Pharmaceutical Compositions

14109[000728] The pharmaceutical compositions described herein can be characterized by one or more of bioavailability, therapeutic window and/or volume of distribution. Bioavailability

14110[000729] The polynucleotides, primary constructs or mmR A, when formulated into a composition with a delivery agent as described herein, can exhibit an increase in bioavailability as compared to a composition lacking a delivery agent as described herein. As used herein, the term "bioavailability" refers to the systemic availability of a given amount of polynucleotides, primary constructs or mmRNA administered to a mammal. Bioavailability can be assessed by measuring the area under the curve (AUC) or the maximum serum or plasma concentration (Cmax) of the unchanged form of a compound following administration of the compound to a mammal. AUC is a determination of the area under the curve plotting the serum or plasma concentration of a compound along the ordinate (Y-axis) against time along the abscissa (X-axis). Generally, the AUC for a particular compound can be calculated using methods known to those of ordinary skill in the art and as described in G. S. Banker, Modern Pharmaceutics, Drugs and the

14111Pharmaceutical Sciences, v. 72, Marcel Dekker, New York, Inc., 1996, herein

14112incorporated by reference in its entirety.

14113[000730] The Cmax value is the maximum concentration of the compound achieved in the serum or plasma of a mammal following administration of the compound to the mammal. The Cmax value of a particular compound can be measured using methods known to those of ordinary skill in the art. The phrases "increasing bioavailability" or "improving the pharmacokinetics," as used herein mean that the systemic availability of a first polynucleotide, primary construct or mmRNA, measured as AUC, Cmax, or Cmin in a mammal is greater, when co-administered with a delivery agent as described herein, than when such co-administration does not take place. In some embodiments, the

14114bioavailability of the polynucleotide, primary construct or mmRNA can increase by at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%), at least about 25%, at least about 30%>, at least about 35%, at least about 40%>, at least about 45%, at least about 50%>, at least about 55%, at least about 60%, at least about 65%o, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%).

14115Therapeutic Window [000731] The polynucleotides, primary constructs or mmR A, when formulated into a composition with a delivery agent as described herein, can exhibit an increase in the therapeutic window of the administered polynucleotide, primary construct or mmRNA composition as compared to the therapeutic window of the administered polynucleotide, primary construct or mmRNA composition lacking a delivery agent as described herein. As used herein "therapeutic window" refers to the range of plasma concentrations, or the range of levels of therapeutically active substance at the site of action, with a high probability of eliciting a therapeutic effect. In some embodiments, the therapeutic window of the polynucleotide, primary construct or mmRNA when co-administered with a delivery agent as described herein can increase by at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%), at least about 35%, at least about 40%>, at least about 45%, at least about 50%>, at least about 55%, at least about 60%>, at least about 65%, at least about 70%, at least about 75%o, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%.

14116Volume of Distribution

14117[000732] The polynucleotides, primary constructs or mmRNA, when formulated into a composition with a delivery agent as described herein, can exhibit an improved volume of distribution (Vdist), e.g., reduced or targeted, relative to a composition lacking a delivery agent as described herein. The volume of distribution (Vdist) relates the amount of the drug in the body to the concentration of the drug in the blood or plasma. As used herein, the term "volume of distribution" refers to the fluid volume that would be required to contain the total amount of the drug in the body at the same concentration as in the blood or plasma: Vdist equals the amount of drug in the body/concentration of drug in blood or plasma. For example, for a 10 mg dose and a plasma concentration of 10 mg/L, the volume of distribution would be 1 liter. The volume of distribution reflects the extent to which the drug is present in the extravascular tissue. A large volume of distribution reflects the tendency of a compound to bind to the tissue components compared with plasma protein binding. In a clinical setting, Vdist can be used to determine a loading dose to achieve a steady state concentration. In some embodiments, the volume of distribution of the polynucleotide, primary construct or mmRNA when co- administered with a delivery agent as described herein can decrease at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%o, at least about 30%>, at least about 35%, at least about 40%>, at least about 45%, at least about 50%>, at least about 55%, at least about 60%>, at least about 65%, at least about 70%.

14118Biological Effect

14119[000733] In one embodiment, the biological effect of the modified mR A delivered to the animals may be categorized by analyzing the protein expression in the animals. The protein expression may be determined from analyzing a biological sample collected from a mammal administered the modified mRNA of the present invention. In one

14120embodiment, the expression protein encoded by the modified mRNA administered to the mammal of at least 50 pg/ml may be preferred. For example, a protein expression of 50- 200 pg/ml for the protein encoded by the modified mRNA delivered to the mammal may be seen as a therapeutically effective amount of protein in the mammal.

14121Detection of Modified Nucleic Acids by Mass Spectrometry

14122[000734] Mass spectrometry (MS) is an analytical technique that can provide structural and molecular mass/concentration information on molecules after their conversion to ions. The molecules are first ionized to acquire positive or negative charges and then they travel through the mass analyzer to arrive at different areas of the detector according to their mass/charge (m/z) ratio.

14123[000735] Mass spectrometry is performed using a mass spectrometer which includes an ion source for ionizing the fractionated sample and creating charged molecules for further analysis. For example ionization of the sample may be performed by electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), photoionization, electron ionization, fast atom bombardment (FAB)/liquid secondary ionization (LSIMS), matrix assisted laser desorption/ionization (MALDI), field ionization, field desorption, thermospray/plasmaspray ionization, and particle beam ionization. The skilled artisan will understand that the choice of ionization method can be determined based on the analyte to be measured, type of sample, the type of detector, the choice of positive versus negative mode, etc. [000736] After the sample has been ionized, the positively charged or negatively charged ions thereby created may be analyzed to determine a mass-to-charge ratio (i.e., m/z). Suitable analyzers for determining mass-to-charge ratios include quadropole analyzers, ion traps analyzers, and time-of-flight analyzers. The ions may be detected using several detection modes. For example, selected ions may be detected (i.e., using a selective ion monitoring mode (SIM)), or alternatively, ions may be detected using a scanning mode, e.g., multiple reaction monitoring (MRM) or selected reaction monitoring (SRM).

14124[000737] Liquid chromatography-multiple reaction monitoring (LC-MS/MRM) coupled with stable isotope labeled dilution of peptide standards has been shown to be an effective method for protein verification (e.g., Keshishian et al., Mol Cell Proteomics

141252009 8: 2339-2349; Kuhn et al, Clin Chem 2009 55: 1108-1117; Lopez et al, Clin Chem

141262010 56:281-290; each of which are herein incorporated by reference in its entirety). Unlike untargeted mass spectrometry frequently used in biomarker discovery studies, targeted MS methods are peptide sequence-based modes of MS that focus the full analytical capacity of the instrument on tens to hundreds of selected peptides in a complex mixture. By restricting detection and fragmentation to only those peptides derived from proteins of interest, sensitivity and reproducibility are improved

14127dramatically compared to discovery-mode MS methods. This method of mass spectrometry-based multiple reaction monitoring (MRM) quantitation of proteins can dramatically impact the discovery and quantitation of biomarkers via rapid, targeted, multiplexed protein expression profiling of clinical samples.

14128[000738] In one embodiment, a biological sample which may contain at least one protein encoded by at least one modified mRNA of the present invention may be analyzed by the method of MRM-MS. The quantification of the biological sample may further include, but is not limited to, isotopically labeled peptides or proteins as internal standards.

14129[000739] According to the present invention, the biological sample, once obtained from the subject, may be subjected to enzyme digestion. As used herein, the term "digest" means to break apart into shorter peptides. As used herein, the phrase "treating a sample to digest proteins" means manipulating a sample in such a way as to break down proteins in a sample. These enzymes include, but are not limited to, trypsin, endoproteinase Glu- C and chymotrypsin. In one embodiment, a biological sample which may contain at least one protein encoded by at least one modified mRNA of the present invention may be digested using enzymes.

14130[000740] In one embodiment, a biological sample which may contain protein encoded by modified mRNA of the present invention may be analyzed for protein using electrospray ionization. Electrospray ionization (ESI) mass spectrometry (ESIMS) uses electrical energy to aid in the transfer of ions from the solution to the gaseous phase before they are analyzed by mass spectrometry. Samples may be analyzed using methods known in the art (e.g., Ho et al., Clin Biochem Rev. 2003 24(1):3-12; herein incorporated by reference in its entirety). The ionic species contained in solution may be transferred into the gas phase by dispersing a fine spray of charge droplets, evaporating the solvent and ejecting the ions from the charged droplets to generate a mist of highly charged droplets. The mist of highly charged droplets may be analyzed using at least 1, at least 2, at least 3 or at least 4 mass analyzers such as, but not limited to, a quadropole mass analyzer. Further, the mass spectrometry method may include a purification step. As a non-limiting example, the first quadrapole may be set to select a single m/z ratio so it may filter out other molecular ions having a different m/z ratio which may eliminate complicated and time-consuming sample purification procedures prior to MS analysis.

14131[000741] In one embodiment, a biological sample which may contain protein encoded by modified mRNA of the present invention may be analyzed for protein in a tandem ESIMS system (e.g., MS/MS). As non-limiting examples, the droplets may be analyzed using a product scan (or daughter scan) a precursor scan (parent scan) a neutral loss or a multiple reaction monitoring.

14132[000742] In one embodiment, a biological sample which may contain protein encoded by modified mRNA of the present invention may be analyzed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MALDIMS). MALDI provides for the nondestructive vaporization and ionization of both large and small molecules, such as proteins. In MALDI analysis, the analyte is first co-crystallized with a large molar excess of a matrix compound, which may also include, but is not limited to, an ultraviolet absorbing weak organic acid. Non-limiting examples of matrices used in MALDI are a- cyano-4-hydroxycinnamic acid, 3,5-dimethoxy-4-hydroxycinnamic acid and 2,5- dihydroxybenzoic acid. Laser radiation of the analyte -matrix mixture may result in the vaporization of the matrix and the analyte. The laser induced desorption provides high ion yields of the intact analyte and allows for measurement of compounds with high accuracy. Samples may be analyzed using methods known in the art (e.g., Lewis, Wei and Siuzdak, Encyclopedia of Analytical Chemistry 2000:5880-5894; herein incorporated by reference in its entirety). As non-limiting examples, mass analyzers used in the MALDI analysis may include a linear time-of-flight (TOF), a TOF reflectron or a Fourier transform mass analyzer.

14133[000743] In one embodiment, the analyte-matrix mixture may be formed using the dried-droplet method. A biologic sample is mixed with a matrix to create a saturated matrix solution where the matrix-to-sample ratio is approximately 5000: 1. An aliquot (approximately 0.5-2.0 uL) of the saturated matrix solution is then allowed to dry to form the analyte-matrix mixture.

14134[000744] In one embodiment, the analyte-matrix mixture may be formed using the thin-layer method. A matrix homogeneous film is first formed and then the sample is then applied and may be absorbed by the matrix to form the analyte-matrix mixture.

14135[000745] In one embodiment, the analyte-matrix mixture may be formed using the thick-layer method. A matrix homogeneous film is formed with a nitro-cellulose matrix additive. Once the uniform nitro-cellulose matrix layer is obtained the sample is applied and absorbed into the matrix to form the analyte-matrix mixture.

14136[000746] In one embodiment, the analyte-matrix mixture may be formed using the sandwich method. A thin layer of matrix crystals is prepared as in the thin-layer method followed by the addition of droplets of aqueous trifluoroacetic acid, the sample and matrix. The sample is then absorbed into the matrix to form the analyte-matrix mixture.

14137V. Uses of Polynucleotides, primary constructs and mmRNA of the Invention

14138[000747] The polynucleotides, primary constructs and mmRNA of the present invention are designed, in preferred embodiments, to provide for avoidance or evasion of deleterious bio-responses such as the immune response and/or degradation pathways, overcoming the threshold of expression and/or improving protein production capacity, improved expression rates or translation efficiency, improved drug or protein half life and/or protein concentrations, optimized protein localization, to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, secretion efficiency (when applicable), accessibility to circulation, and/or modulation of a cell's status, function and/or activity.

14139Therapeutics

14140Therapeutic Agents

14141[000748] The polynucleotides, primary constructs or mmR A of the present invention, such as modified nucleic acids and modified RNAs, and the proteins translated from them described herein can be used as therapeutic or prophylactic agents. They are provided for use in medicine. For example, a polynucleotide, primary construct or mmRNA described herein can be administered to a subject, wherein the polynucleotide, primary construct or mmRNA is translated in vivo to produce a therapeutic or prophylactic polypeptide in the subject. Provided are compositions, methods, kits, and reagents for diagnosis, treatment or prevention of a disease or condition in humans and other mammals. The active therapeutic agents of the invention include polynucleotides, primary constructs or mmRNA, cells containing polynucleotides, primary constructs or mmRNA or

14142polypeptides translated from the polynucleotides, primary constructs or mmRNA.

14143[000749] In certain embodiments, provided herein are combination therapeutics containing one or more polynucleotide, primary construct or mmRNA containing translatable regions that encode for a protein or proteins that boost a mammalian subject's immunity along with a protein that induces antibody-dependent cellular toxicity. For example, provided herein are therapeutics containing one or more nucleic acids that encode trastuzumab and granulocyte-colony stimulating factor (G-CSF). In particular, such combination therapeutics are useful in Her2+ breast cancer patients who develop induced resistance to trastuzumab. (See, e.g., Albrecht, Immunotherapy.

141442(6):795-8 (2010)).

14145[000750] Provided herein are methods of inducing translation of a recombinant polypeptide in a cell population using the polynucleotide, primary construct or mmRNA described herein. Such translation can be in vivo, ex vivo, in culture, or in vitro. The cell population is contacted with an effective amount of a composition containing a nucleic acid that has at least one nucleoside modification, and a translatable region encoding the recombinant polypeptide. The population is contacted under conditions such that the nucleic acid is localized into one or more cells of the cell population and the recombinant polypeptide is translated in the cell from the nucleic acid.

14146[000751] An "effective amount" of the composition is provided based, at least in part, on the target tissue, target cell type, means of administration, physical characteristics of the nucleic acid (e.g., size, and extent of modified nucleosides), and other determinants. In general, an effective amount of the composition provides efficient protein production in the cell, preferably more efficient than a composition containing a corresponding unmodified nucleic acid. Increased efficiency may be demonstrated by increased cell transfection (i.e., the percentage of cells transfected with the nucleic acid), increased protein translation from the nucleic acid, decreased nucleic acid degradation (as demonstrated, e.g., by increased duration of protein translation from a modified nucleic acid), or reduced innate immune response of the host cell.

14147[000752] Aspects of the invention are directed to methods of inducing in vivo translation of a recombinant polypeptide in a mammalian subject in need thereof.

14148Therein, an effective amount of a composition containing a nucleic acid that has at least one structural or chemical modification and a translatable region encoding the

14149recombinant polypeptide is administered to the subject using the delivery methods described herein. The nucleic acid is provided in an amount and under other conditions such that the nucleic acid is localized into a cell of the subject and the recombinant polypeptide is translated in the cell from the nucleic acid. The cell in which the nucleic acid is localized, or the tissue in which the cell is present, may be targeted with one or more than one rounds of nucleic acid administration.

14150[000753] In certain embodiments, the administered polynucleotide, primary construct or mmRNA directs production of one or more recombinant polypeptides that provide a functional activity which is substantially absent in the cell, tissue or organism in which the recombinant polypeptide is translated. For example, the missing functional activity may be enzymatic, structural, or gene regulatory in nature. In related embodiments, the administered polynucleotide, primary construct or mmRNA directs production of one or more recombinant polypeptides that increases (e.g., synergistically) a functional activity which is present but substantially deficient in the cell in which the recombinant polypeptide is translated.

14151[000754] In other embodiments, the administered polynucleotide, primary construct or mmR A directs production of one or more recombinant polypeptides that replace a polypeptide (or multiple polypeptides) that is substantially absent in the cell in which the recombinant polypeptide is translated. Such absence may be due to genetic mutation of the encoding gene or regulatory pathway thereof. In some embodiments, the recombinant polypeptide increases the level of an endogenous protein in the cell to a desirable level; such an increase may bring the level of the endogenous protein from a subnormal level to a normal level or from a normal level to a super-normal level.

14152[000755] Alternatively, the recombinant polypeptide functions to antagonize the activity of an endogenous protein present in, on the surface of, or secreted from the cell. Usually, the activity of the endogenous protein is deleterious to the subject; for example, due to mutation of the endogenous protein resulting in altered activity or localization. Additionally, the recombinant polypeptide antagonizes, directly or indirectly, the activity of a biological moiety present in, on the surface of, or secreted from the cell. Examples of antagonized biological moieties include lipids (e.g., cholesterol), a lipoprotein (e.g., low density lipoprotein), a nucleic acid, a carbohydrate, a protein toxin such as shiga and tetanus toxins, or a small molecule toxin such as botulinum, cholera, and diphtheria toxins. Additionally, the antagonized biological molecule may be an endogenous protein that exhibits an undesirable activity, such as a cytotoxic or cytostatic activity.

14153[000756] The recombinant proteins described herein may be engineered for localization within the cell, potentially within a specific compartment such as the nucleus, or are engineered for secretion from the cell or translocation to the plasma membrane of the cell.

14154[000757] In some embodiments, modified mRNAs and their encoded polypeptides in accordance with the present invention may be used for treatment of any of a variety of diseases, disorders, and/or conditions, including but not limited to one or more of the following: autoimmune disorders (e.g. diabetes, lupus, multiple sclerosis, psoriasis, rheumatoid arthritis); inflammatory disorders (e.g. arthritis, pelvic inflammatory disease); infectious diseases (e.g. viral infections (e.g. , HIV, HCV, RSV), bacterial infections, fungal infections, sepsis); neurological disorders (e.g. Alzheimer's disease, Huntington's disease; autism; Duchenne muscular dystrophy); cardiovascular disorders (e.g.

14155atherosclerosis, hypercholesterolemia, thrombosis, clotting disorders, angiogenic disorders such as macular degeneration); proliferative disorders (e.g. cancer, benign neoplasms); respiratory disorders (e.g. chronic obstructive pulmonary disease); digestive disorders (e.g. inflammatory bowel disease, ulcers); musculoskeletal disorders (e.g.

14156fibromyalgia, arthritis); endocrine, metabolic, and nutritional disorders (e.g. diabetes, osteoporosis); urological disorders (e.g. renal disease); psychological disorders (e.g. depression, schizophrenia); skin disorders (e.g. wounds, eczema); blood and lymphatic disorders (e.g. anemia, hemophilia); etc.

14157[000758] Diseases characterized by dysfunctional or aberrant protein activity include cystic fibrosis, sickle cell anemia, epidermolysis bullosa, amyotrophic lateral sclerosis, and glucose-6-phosphate dehydrogenase deficiency. The present invention provides a method for treating such conditions or diseases in a subject by introducing nucleic acid or cell-based therapeutics containing the polynucleotide, primary construct or mmRNA provided herein, wherein the polynucleotide, primary construct or mmRNA encode for a protein that antagonizes or otherwise overcomes the aberrant protein activity present in the cell of the subject. Specific examples of a dysfunctional protein are the missense mutation variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which produce a dysfunctional protein variant of CFTR protein, which causes cystic fibrosis.

14158[000759] Diseases characterized by missing (or substantially diminished such that proper (normal or physiological protein function does not occur) protein activity include cystic fibrosis, Niemann-Pick type C, β thalassemia major, Duchenne muscular dystrophy, Hurler Syndrome, Hunter Syndrome, and Hemophilia A. Such proteins may not be present, or are essentially non-functional. The present invention provides a method for treating such conditions or diseases in a subject by introducing nucleic acid or cell-based therapeutics containing the polynucleotide, primary construct or mmRNA provided herein, wherein the polynucleotide, primary construct or mmRNA encode for a protein that replaces the protein activity missing from the target cells of the subject. Specific examples of a dysfunctional protein are the nonsense mutation variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which produce a nonfunctional protein variant of CFTR protein, which causes cystic fibrosis.

14159[000760] Thus, provided are methods of treating cystic fibrosis in a mammalian subject by contacting a cell of the subject with a polynucleotide, primary construct or mmRNA having a translatable region that encodes a functional CFTR polypeptide, under conditions such that an effective amount of the CTFR polypeptide is present in the cell. Preferred target cells are epithelial, endothelial and mesothelial cells, such as the lung, and methods of administration are determined in view of the target tissue; i.e., for lung delivery, the RNA molecules are formulated for administration by inhalation.

14160[000761] In another embodiment, the present invention provides a method for treating hyperlipidemia in a subject, by introducing into a cell population of the subject with a modified mRNA molecule encoding Sortilin, a protein recently characterized by genomic studies, thereby ameliorating the hyperlipidemia in a subject. The SORTI gene encodes a trans-Golgi network (TGN) transmembrane protein called Sortilin. Genetic studies have shown that one of five individuals has a single nucleotide polymorphism, rsl2740374, in the lpl3 locus of the SORTI gene that predisposes them to having low levels of low- density lipoprotein (LDL) and very- low-density lipoprotein (VLDL). Each copy of the minor allele, present in about 30% of people, alters LDL cholesterol by 8 mg/dL, while two copies of the minor allele, present in about 5% of the population, lowers LDL cholesterol 16 mg/dL. Carriers of the minor allele have also been shown to have a 40% decreased risk of myocardial infarction. Functional in vivo studies in mice describes that overexpression of SORTI in mouse liver tissue led to significantly lower LDL-cholesterol levels, as much as 80%> lower, and that silencing SORTI increased LDL cholesterol approximately 200% (Musunuru K et al. From noncoding variant to phenotype via SORTI at the lpl3 cholesterol locus. Nature 2010; 466: 714-721).

14161[000762] In another embodiment, the present invention provides a method for treating hematopoietic disorders, cardiovascular disease, oncology, diabetes, cystic fibrosis, neurological diseases, inborn errors of metabolism, skin and systemic disorders, and blindness. The identity of molecular targets to treat these specific diseases has been described (Templeton ed., Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 3r Edition, Bota Raton, FL:CRC Press; herein incorporated by reference in its entirety).

14162[000763] Provided herein, are methods to prevent infection and/or sepsis in a subject at risk of developing infection and/or sepsis, the method comprising administering to a subject in need of such prevention a composition comprising a polynucleotide, primary construct or mrnRNA precursor encoding an anti-microbial polypeptide (e.g. , an antibacterial polypeptide), or a partially or fully processed form thereof in an amount sufficient to prevent infection and/or sepsis. In certain embodiments, the subject at risk of developing infection and/or sepsis may be a cancer patient. In certain embodiments, the cancer patient may have undergone a conditioning regimen. In some embodiments, the conditioning regiment may include, but is not limited to, chemotherapy, radiation therapy, or both. As a non-limiting example, a polynucleotide, primary construct or mrnRNA can encode Protein C, its zymogen or prepro-protein, the activated form of Protein C (APC) or variants of Protein C which are known in the art. The

14163polynucleotides, primary constructs or mrnRNA may be chemically modified and delivered to cells. Non- limiting examples of polypeptides which may be encoded within the chemically modified mRNAs of the present invention include those taught in US Patents 7,226,999; 7,498,305; 6,630, 138 each of which is incorporated herein by reference in its entirety. These patents teach Protein C like molecules, variants and derivatives, any of which may be encoded within the chemically modified molecules of the present invention.

14164[000764] Further provided herein, are methods to treat infection and/or sepsis in a subject, the method comprising administering to a subject in need of such treatment a composition comprising a polynucleotide, primary construct or mrnRNA precursor encoding an anti-microbial polypeptide (e.g., an anti-bacterial polypeptide), e.g., an antimicrobial polypeptide described herein, or a partially or fully processed form thereof in an amount sufficient to treat an infection and/or sepsis. In certain embodiments, the subject in need of treatment is a cancer patient. In certain embodiments, the cancer patient has undergone a conditioning regimen. In some embodiments, the conditioning regiment may include, but is not limited to, chemotherapy, radiation therapy, or both. [000765] In certain embodiments, the subject may exhibits acute or chronic microbial infections (e.g., bacterial infections). In certain embodiments, the subject may have received or may be receiving a therapy. In certain embodiments, the therapy may include, but is not limited to, radiotherapy, chemotherapy, steroids, ultraviolet radiation, or a combination thereof. In certain embodiments, the patient may suffer from a microvascular disorder. In some embodiments, the microvascular disorder may be diabetes. In certain embodiments, the patient may have a wound. In some embodiments, the wound may be an ulcer. In a specific embodiment, the wound may be a diabetic foot ulcer. In certain embodiments, the subject may have one or more burn wounds. In certain embodiments, the administration may be local or systemic. In certain

14165embodiments, the administration may be subcutaneous. In certain embodiments, the administration may be intravenous. In certain embodiments, the administration may be oral. In certain embodiments, the administration may be topical. In certain

14166embodiments, the administration may be by inhalation. In certain embodiments, the administration may be rectal. In certain embodiments, the administration may be vaginal.

14167[000766] Other aspects of the present disclosure relate to transplantation of cells containing polynucleotide, primary construct, or mmR A to a mammalian subject.

14168Administration of cells to mammalian subjects is known to those of ordinary skill in the art, and include, but is not limited to, local implantation (e.g., topical or subcutaneous administration), organ delivery or systemic injection (e.g., intravenous injection or inhalation), and the formulation of cells in pharmaceutically acceptable carrier. Such compositions containing polynucleotide, primary construct, or mmRNA can be formulated for administration intramuscularly, transarterially, intraperitoneally, intravenously, intranasally, subcutaneously, endoscopically, transdermally, or

14169intrathecally. In some embodiments, the composition may be formulated for extended release.

14170[000767] The subject to whom the therapeutic agent may be administered suffers from or may be at risk of developing a disease, disorder, or deleterious condition. Provided are methods of identifying, diagnosing, and classifying subjects on these bases, which may include clinical diagnosis, biomarker levels, genome-wide association studies (GWAS), and other methods known in the art. Wound Management

14171[000768] The polynucleotides, primary constructs or mmR A of the present invention may be used for wound treatment, e.g. of wounds exhibiting delayed healing. Provided herein are methods comprising the administration of polynucleotide, primary construct or mmRNA in order to manage the treatment of wounds. The methods herein may further comprise steps carried out either prior to, concurrent with or post administration of the polynucleotide, primary construct or mmRNA. For example, the wound bed may need to be cleaned and prepared in order to facilitate wound healing and hopefully obtain closure of the wound. Several strategies may be used in order to promote wound healing and achieve wound closure including, but not limited to: (i) debridement, optionally repeated, sharp debridement (surgical removal of dead or infected tissue from a wound), optionally including chemical debriding agents, such as enzymes, to remove necrotic tissue; (ii) wound dressings to provide the wound with a moist, warm environment and to promote tissue repair and healing.

14172[000769] Examples of materials that are used in formulating wound dressings include, but are not limited to: hydrogels (e.g., AQUASORB®; DUODERM®), hydrocolloids (e.g., AQUACEL®; COMFEEL®), foams (e.g., LYOFOAM®; SPYROSORB®), and alginates (e.g., ALGISITE®; CURASORB®); (iii) additional growth factors to stimulate cell division and proliferation and to promote wound healing e.g. becaplermin

14173(REGRANEX GEL®), a human recombinant platelet-derived growth factor that is approved by the FDA for the treatment of neuropathic foot ulcers; (iv) soft-tissue wound coverage, a skin graft may be necessary to obtain coverage of clean, non-healing wounds. Examples of skin grafts that may be used for soft-tissue coverage include, but are not limited to: autologous skin grafts, cadaveric skin graft, bioengineered skin substitutes (e.g., APLIGRAF®; DERMAGRAFT®).

14174[000770] In certain embodiments, the polynucleotide, primary construct or mmRNA of the present invention may further include hydrogels (e.g., AQUASORB®;

14175DUODERM®), hydrocolloids (e.g., AQUACEL®; COMFEEL®), foams (e.g.,

14176LYOFOAM®; SPYROSORB®), and/or alginates (e.g., ALGISITE®; CURASORB®). In certain embodiments, the polynucleotide, primary construct or mmRNA of the present invention may be used with skin grafts including, but not limited to, autologous skin grafts, cadaveric skin graft, or bioengineered skin substitutes (e.g., APLIGRAF®;

14177DERMAGRAFT®). In some embodiments, the polynucleotide, primary construct or mmRNA may be applied with would dressing formulations and/or skin grafts or they may be applied separately but methods such as, but not limited to, soaking or spraying.

14178[000771] In some embodiments, compositions for wound management may comprise a polynucleotide, primary construct or mmRNA encoding for an anti-microbial polypeptide (e.g., an anti-bacterial polypeptide) and/or an anti-viral polypeptide. A precursor or a partially or fully processed form of the anti-microbial polypeptide may be encoded. The composition may be formulated for administration using a bandage (e.g., an adhesive bandage). The anti-microbial polypeptide and/or the anti-viral polypeptide may be intermixed with the dressing compositions or may be applied separately, e.g., by soaking or spraying.

14179Production of Antibodies

14180[000772] In one embodiment of the invention, the polynucleotides, primary constructs or mmRNA may encode antibodies and fragments of such antibodies. These may be produced by any one of the methods described herein. The antibodies may be of any of the different subclasses or isotypes of immunoglobulin such as, but not limited to, IgA, IgG, or IgM, or any of the other subclasses. Exemplary antibody molecules and fragments that may be prepared according to the invention include, but are not limited to, immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that may contain the paratope. Such portion of antibodies that contain the paratope include, but are not limited to Fab, Fab', F(ab')2, F(v) and those portions known in the art.

14181[000773] The polynucleotides of the invention may encode variant antibody

14182polypeptides which may have a certain identity with a reference polypeptide sequence, or have a similar or dissimilar binding characteristic with the reference polypeptide sequence.

14183[000774] Antibodies obtained by the methods of the present invention may be chimeric antibodies comprising non-human antibody-derived variable region(s) sequences, derived from the immunized animals, and human antibody-derived constant region(s) sequences. In addition, they can also be humanized antibodies comprising complementary determining regions (CDRs) of non-human antibodies derived from the immunized animals and the framework regions (FRs) and constant regions derived from human antibodies. In another embodiment, the methods provided herein may be useful for enhancing antibody protein product yield in a cell culture process.

14184Managing Infection

14185[000775] In one embodiment, provided are methods for treating or preventing a microbial infection (e.g., a bacterial infection) and/or a disease, disorder, or condition associated with a microbial or viral infection, or a symptom thereof, in a subject, by administering a polynucleotide, primary construct or mmRNA encoding an anti-microbial polypeptide. Said administration may be in combination with an anti-microbial agent (e.g., an anti-bacterial agent), e.g., an anti-microbial polypeptide or a small molecule antimicrobial compound described herein. The anti-microbial agents include, but are not limited to, anti-bacterial agents, anti-viral agents, anti-fungal agents, anti-protozoal agents, anti-parasitic agents, and anti-prion agents.

14186[000776] The agents can be administered simultaneously, for example in a combined unit dose (e.g., providing simultaneous delivery of both agents). The agents can also be administered at a specified time interval, such as, but not limited to, an interval of minutes, hours, days or weeks. Generally, the agents may be concurrently bioavailable, e.g., detectable, in the subject. In some embodiments, the agents may be administered essentially simultaneously, for example two unit dosages administered at the same time, or a combined unit dosage of the two agents. In other embodiments, the agents may be delivered in separate unit dosages. The agents may be administered in any order, or as one or more preparations that includes two or more agents. In a preferred embodiment, at least one administration of one of the agents, e.g., the first agent, may be made within minutes, one, two, three, or four hours, or even within one or two days of the other agent, e.g., the second agent. In some embodiments, combinations can achieve synergistic results, e.g., greater than additive results, e.g., at least 25, 50, 75, 100, 200, 300, 400, or 500% greater than additive results.

14187Conditions associated with bacterial infection

14188[000777] Diseases, disorders, or conditions which may be associated with bacterial infections include, but are not limited to one or more of the following: abscesses, actinomycosis, acute prostatitis, aeromonas hydrophila, annual ryegrass toxicity, anthrax, bacillary peliosis, bacteremia, bacterial gastroenteritis, bacterial meningitis, bacterial pneumonia, bacterial vaginosis, bacterium-related cutaneous conditions, bartonellosis, BCG-oma, botryomycosis, botulism, Brazilian purpuric fever, Brodie abscess, brucellosis, Buruli ulcer, campylobacteriosis, caries, Carrion's disease, cat scratch disease, cellulitis, chlamydia infection, cholera, chronic bacterial prostatitis, chronic recurrent multifocal osteomyelitis, clostridial necrotizing enteritis, combined periodontic- endodontic lesions, contagious bovine pleuropneumonia, diphtheria, diphtheritic stomatitis, ehrlichiosis, erysipelas, piglottitis, erysipelas, Fitz-Hugh-Curtis syndrome, flea-borne spotted fever, foot rot (infectious pododermatitis), Garre's sclerosing osteomyelitis, Gonorrhea, Granuloma inguinale, human granulocytic anaplasmosis, human monocytotropic ehrlichiosis, hundred days' cough, impetigo, late congenital syphilitic oculopathy, legionellosis, Lemierre's syndrome, leprosy (Hansen's Disease), leptospirosis, listeriosis, Lyme disease, lymphadenitis, melioidosis, meningococcal disease, meningococcal septicaemia, methicillin-resistant Staphylococcus aureus

14189(MRSA) infection, mycobacterium avium-intracellulare (MAI), mycoplasma pneumonia, necrotizing fasciitis, nocardiosis, noma (cancrum oris or gangrenous stomatitis), omphalitis, orbital cellulitis, osteomyelitis, overwhelming post-splenectomy infection (OPSI), ovine brucellosis, pasteurellosis, periorbital cellulitis, pertussis (whooping cough), plague, pneumococcal pneumonia, Pott disease, proctitis, pseudomonas infection, psittacosis, pyaemia, pyomyositis, Q fever, relapsing fever (typhinia), rheumatic fever, Rocky Mountain spotted fever (RMSF), rickettsiosis, salmonellosis, scarlet fever, sepsis, serratia infection, shigellosis, southern tick-associated rash illness, staphylococcal scalded skin syndrome, streptococcal pharyngitis, swimming pool granuloma, swine brucellosis, syphilis, syphilitic aortitis, tetanus, toxic shock syndrome (TSS), trachoma, trench fever, tropical ulcer, tuberculosis, tularemia, typhoid fever, typhus, urogenital tuberculosis, urinary tract infections, vancomycin-resistant Staphylococcus aureus infection, Waterhouse-Friderichsen syndrome, pseudotuberculosis (Yersinia) disease, and yersiniosis. Other diseases, disorders, and/or conditions associated with bacterial infections can include, for example, Alzheimer's disease, anorexia nervosa, asthma, atherosclerosis, attention deficit hyperactivity disorder, autism, autoimmune diseases, bipolar disorder, cancer (e.g., colorectal cancer, gallbladder cancer, lung cancer, pancreatic cancer, and stomach cancer), chronic fatigue syndrome, chronic obstructive pulmonary disease, Crohn's disease, coronary heart disease, dementia, depression, Guillain-Barre syndrome, metabolic syndrome, multiple sclerosis, myocardial infarction, obesity, obsessive-compulsive disorder, panic disorder, psoriasis, rheumatoid arthritis, sarcoidosis, schizophrenia, stroke, thromboangiitis obliterans (Buerger's disease), and Tourette syndrome.

14190Bacterial Pathogens

14191[000778] The bacterium described herein can be a Gram-positive bacterium or a Gram- negative bacterium. Bacterial pathogens include, but are not limited to, Acinetobacter baumannii, Bacillus anthracis, Bacillus subtilis, Bordetella pertussis, Borrelia burgdorferi, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens,

14192Clostridium tetani, coagulase Negative Staphylococcus, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, enterotoxigenic

14193Escherichia coli (ETEC), enteropathogenic E. coli, E. coli 0157:H7, Enterobacter sp., Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Moraxella catarralis, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitides, Preteus mirabilis, Proteus sps., Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Salmonella typhimurium, Serratia marcesens, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum, Vibrio cholerae, and Yersinia pestis. Bacterial pathogens may also include bacteria that cause resistant bacterial infections, for example, clindamycin- resistant Clostridium difficile, fluoroquinolon-resistant Clostridium difficile, methicillin- resistant Staphylococcus aureus (MRSA), multidrug-resistant Enterococcus faecalis, multidrug-resistant Enterococcus faecium, multidrug-resistance Pseudomonas aeruginosa, multidrug-resistant Acinetobacter baumannii, and vancomycin-resistant Staphylococcus aureus (VRSA).

14194Antibiotic Combinations

14195[000779] In one embodiment, the modified mR A of the present invention may be administered in conjunction with one or more antibiotics. These include, but are not limited to Aknilox , Ambisome, Amoxycillin, Ampicillin, Augmentin, Avelox,

14196Azithromycin, Bactroban, Betadine, Betnovate, Blephamide, Cefaclor, Cefadroxil, Cefdinir, Cefepime, Cefix, Cefixime, Cefoxitin, Cefpodoxime, Cefprozil, Cefuroxime, Cefzil, Cephalexin, Cephazolin, Ceptaz, Chloramphenicol, Chlorhexidine,

14197Chloromycetin, Chlorsig, Ciprofloxacin, Clarithromycin, Clindagel, Clindamycin, Clindatech, Cloxacillin, Colistin, Co-trimoxazole, Demeclocycline, Diclocil,

14198Dicloxacillin, Doxycycline, Duricef, Erythromycin, Flamazine, Floxin, Framycetin, Fucidin, Furadantin, Fusidic, Gatifloxacin, Gemifloxacin, Gemifloxacin, Ilosone, Iodine, Levaquin, Levofloxacin, Lomefloxacin, Maxaquin, Mefoxin, Meronem, Minocycline, Moxifloxacin, Myambutol, Mycostatin, Neosporin, Netromycin, Nitrofurantoin,

14199Norfloxacin, Norilet, Ofloxacin, Omnicef, Ospamox, Oxytetracycline, Paraxin,

14200Penicillin, Pneumovax, Polyfax, Povidone, Rifadin, Rifampin, Rifaximin, Rifinah, Rimactane, Rocephin, Roxithromycin, Seromycin, Soframycin, Sparfloxacin, Staphlex, Targocid, Tetracycline, Tetradox, Tetralysal, tobramycin, Tobramycin, Trecator, Tygacil, Vancocin, Velosef, Vibramycin, Xifaxan, Zagam, Zitrotek, Zoderm, Zymar, and Zyvox. Antibacterial agents

14201[000780] Exemplary anti-bacterial agents include, but are not limited to,

14202aminoglycosides (e.g. , amikacin (AMIKIN®), gentamicin (GARAMYCIN®), kanamycin (KANTREX®), neomycin (M YCIFRADIN® ) , netilmicin (NETROMYCIN®), tobramycin (NEBCIN®), Paromomycin (HUMATIN®)), ansamycins (e.g.,

14203geldanamycin, herbimycin), carbacephem (e.g., loracarbef (LORABID®), Carbapenems (e.g., ertapenem (INVANZ®), doripenem (DORIBAX®), imipenem/cilastatin

14204(PRIMAXIN®), meropenem (MERREM®), cephalosporins (first generation) (e.g., cefadroxil (DURICEF®), cefazolin (ANCEF®), cefalotin or cefalothin (KEFLIN®), cefalexin (KEFLEX®), cephalosporins (second generation) (e.g., cefaclor (CECLOR®), cefamandole (MANDOL®), cefoxitin (MEFOXIN®), cefprozil (CEFZIL®), cefuroxime (CEFTIN®, ZINNAT®)), cephalosporins (third generation) (e.g., cefixime (SUPRAX®), cefdinir (OMNICEF®, CEFDIEL®), cefditoren (SPECTRACEF®), cefoperazone (CEFOBID®), cefotaxime (CLAFORAN®), cefpodoxime (VANTIN®), ceftazidime (FORTAZ®), ceftibuten (CEDAX®), ceftizoxime (CEFIZOX®), ceftriaxone

14205(ROCEPHIN®)), cephalosporins (fourth generation) (e.g., cefepime (MAXIPIME®)), cephalosporins (fifth generation) (e.g., ceftobiprole (ZEFTERA®)), glycopeptides (e.g., teicoplanin (TARGOCID®), vancomycin (VANCOCIN®), telavancin (VIBATIV®)), lincosamides (e.g., clindamycin (CLEOCIN®), lincomycin (LINCOCIN®)), lipopeptide (e.g., daptomycin (CUBICIN®)), macrolides (e.g., azithromycin (ZITHROMAX®, SUMAMED®, ZITROCIN®), clarithromycin (BIAXIN®), dirithromycin

14206(DYNABAC®), erythromycin (ERYTHOCIN®, ERYTHROPED®), roxithromycin, troleandomycin (TAO®), telithromycin (KETEK®), spectinomycin (TROBICIN®)), monobactams (e.g. , aztreonam (AZACTAM®)), nitrofurans (e.g. , furazolidone

14207(FUROXONE®), nitrofurantoin (MACRODANTIN®, MACROBID®)), penicillins (e.g., amoxicillin (NOVAMOX®, AMOXIL®), ampicillin (PRINCIPEN®), azlocillin, carbenicillin (GEOCILLIN®), cloxacillin (TEGOPEN®), dicloxacillin (DYNAPEN®), flucloxacillin (FLOXAPEN®), mezlocillin (MEZLIN®), methicillin (STAPHCILLIN®), nafcillin (UNIPEN®), oxacillin (PROSTAPHLIN®), penicillin G (PENTIDS®), penicillin V (PEN-VEE-K®), piperacillin (PIPRACIL®), temocillin (NEGABAN®), ticarcillin (TICAR®)), penicillin combinations (e.g., amoxicillin/clavulanate

14208(AUGMENTIN®), ampicillin/sulbactam (UNASYN®), piperacillin/tazobactam

14209(ZOSYN®), ticarcillin/clavulanate (TIMENTIN®)), polypeptides (e.g., bacitracin, colistin (COLY-MYCIN-S®), polymyxin B, quinolones (e.g., ciprofloxacin (CIPRO®, CIPROXIN®, CIPROBAY®), enoxacin (PENETREX®), gatifloxacin (TEQUIN®), levofloxacin (LEVAQUIN®), lomefloxacin (MAXAQUIN®), moxifloxacin

14210(AVELOX®), nalidixic acid (NEGGRAM®), norfloxacin (NOROXIN®), ofloxacin (FLOXIN®, OCUFLOX®), trovafloxacin (TROVAN®), grepafioxacin (RAXAR®), sparfloxacin (ZAGAM®), temafloxacin (OMNIFLOX®)), sulfonamides (e.g., mafenide (SULFAMYLON®), sulfonamidochrysoidine (PRONTOSIL®), sulfacetamide

14211(SULAMYD®, BLEPH-10®), sulfadiazine (MICRO-SULFON®), silver sulfadiazine (SILVADENE®), sulfamethizole (THIOSULFIL FORTE®), sulfamethoxazole (GANTANOL®), sulfanilamide, sulfasalazine ( AZULFIDINE® ) , sulfisoxazole

14212(GANTRISIN®), trimethoprim (PROLOPRIM®), TRIMPEX®), trimethoprim- sulfamethoxazole (co-trimoxazole) (TMP-SMX) (BACTRIM®, SEPTRA®)), tetracyclines (e.g., demeclocycline (DECLOMYCIN®), doxycycline (VIBRAMYCIN®), minocycline (MINOCIN®), oxytetracycline (TERRAMYCIN®), tetracycline

14213(SUMYCIN®, ACHROMYCIN® V, STECLIN®)), drugs against mycobacteria (e.g., clofazimine (LAMPRENE®), dapsone (AVLOSULFON®), capreomycin

14214(CAPASTAT®), cycloserine (SEROMYCIN®), ethambutol (MYAMBUTOL®), ethionamide (TRECATOR®), isoniazid (I.N.H.®), pyrazinamide (ALDIN AMIDE®), rifampin (RIFADIN®, RIMACTANE®), rifabutin (MYCOBUTIN®), rifapentine (PRIFTIN®), streptomycin), and others (e.g., arsphenamine (SALVARSAN®), chloramphenicol (CHLOROMYCETIN®), fosfomycin (MONUROL®), fusidic acid (FUCIDIN®), linezolid (ZYVOX®), metronidazole (FLAGYL®), mupirocin

14215(BACTROBAN®), platensimycin, quinupristin/dalfopristin (SYNERCID®), rifaximin (XIFAXAN®), thiamphenicol, tigecycline (TIGACYL®), imidazole (TINDAMAX®, FASIGYN®)).

14216Conditions associated with viral infection

14217[000781] In another embodiment, provided are methods for treating or preventing a viral infection and/or a disease, disorder, or condition associated with a viral infection, or a symptom thereof, in a subject, by administering a polynucleotide, primary construct or mmRNA encoding an anti-viral polypeptide, e.g., an anti-viral polypeptide described herein in combination with an anti-viral agent, e.g. , an anti-viral polypeptide or a small molecule anti-viral agent described herein.

14218[000782] Diseases, disorders, or conditions associated with viral infections include, but are not limited to, acute febrile pharyngitis, pharyngoconjunctival fever, epidemic keratoconjunctivitis, infantile gastroenteritis, Coxsackie infections, infectious

14219mononucleosis, Burkitt lymphoma, acute hepatitis, chronic hepatitis, hepatic cirrhosis, hepatocellular carcinoma, primary HSV-1 infection (e.g., gingivostomatitis in children, tonsillitis and pharyngitis in adults, keratoconjunctivitis), latent HSV-1 infection (e.g., herpes labialis and cold sores), primary HSV-2 infection, latent HSV-2 infection, aseptic meningitis, infectious mononucleosis, Cytomegalic inclusion disease, Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma, AIDS, influenza, Reye syndrome, measles, postinfectious encephalomyelitis, Mumps, hyperplastic epithelial lesions (e.g., common, flat, plantar and anogenital warts, laryngeal papillomas, epidermodysplasia verruciformis), cervical carcinoma, squamous cell carcinomas, croup, pneumonia, bronchiolitis, common cold, Poliomyelitis, Rabies, bronchiolitis, pneumonia, influenza-like syndrome, severe bronchiolitis with pneumonia, German measles, congenital rubella, Varicella, and herpes zoster.

14220Viral pathogens

14221[000783] Viral pathogens include, but are not limited to, adenovirus, coxsackievirus, dengue virus, encephalitis virus, Epstein-Barr virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus type 1, herpes simplex virus type 2,

14222cytomegalovirus, human herpesvirus type 8, human immunodeficiency virus, influenza virus, measles virus, mumps virus, human papillomavirus, parainfluenza virus, poliovirus, rabies virus, respiratory syncytial virus, rubella virus, varicella-zoster virus, West Nile virus, and yellow fever virus. Viral pathogens may also include viruses that cause resistant viral infections.

14223Antiviral agents

14224[000784] Exemplary anti-viral agents include, but are not limited to, abacavir

14225(ZIAGEN®), abacavir/lamivudine/zidovudine (trizivir®), aciclovir or acyclovir

14226(CYCLOVIR®, HERPEX®, ACIVIR®, ACIVIRAX®, ZOVIRAX®, ZOVIR®), adefovir (Preveon®, Hepsera®), amantadine (SYMMETREL®), amprenavir

14227(AGENERASE®), ampligen, arbidol, atazanavir (REYATAZ®), boceprevir, cidofovir, darunavir (PREZISTA®), delavirdine (RESCRIPTOR®), didanosine (VIDEX®), docosanol (ABREVA®), edoxudine, efavirenz (SUSTIVA®, STOCRIN®), emtricitabine (EMTRIVA®), emtricitabine/tenofovir/efavirenz (ATRIPLA®), enfuvirtide

14228(FUZEON®), entecavir (BARACLUDE®, ENTAVIR®), famciclovir (FAMVIR®), fomivirsen (VITRAVENE®), fosamprenavir (LEXIVA®, TELZIR®), foscarnet

14229(FOSCAVIR®), fosfonet, ganciclovir (CYTOVENE®, CYMEVENE®,

14230VITRASERT®), GS 9137 (ELVITEGRAVIR®), imiquimod (ALDARA®,

14231ZYCLARA®, BESELNA®), indinavir (CRIXIVAN®), inosine, inosine pranobex (IMUNOVIR®), interferon type I, interferon type II, interferon type III, kutapressin (NEXAVIR®), lamivudine (ZEFFIX®, HEPTOVIR®, EPIVIR®),

14232lamivudine/zidovudine (COMBIVIR®), lopinavir, loviride, maraviroc (SELZENTRY®, CELSENTRI®), methisazone, MK-2048, moroxydine, nelfmavir (VIRACEPT®), nevirapine (VIRAMUNE®), oseltamivir (TAMIFLU®), peginterferon alfa-2a

14233(PEGASYS®), penciclovir (DENAVIR®), peramivir, pleconaril, podophyllotoxin (CONDYLOX®), raltegravir (ISENTRESS®), ribavirin (COPEGUs®, REBETOL®, RIBASPHERE®, VILONA® AND VIRAZOLE®), rimantadine (FLUM ADINE® ) , ritonavir (NORVIR®), pyramidine, saquinavir (INVIRASE®, FORTOVASE®), stavudine, tea tree oil (melaleuca oil), tenofovir (VIREAD®), tenofovir/emtricitabine (TRUVADA®), tipranavir (APTIVUS®), trifiuridine (VIROPTIC®), tromantadine (VIRU-MERZ®), valaciclovir (VALTREX®), valganciclovir (VALCYTE®), vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir (RELENZA®), and zidovudine

14234(azidothymidine (AZT), RETROVIR®, RETRO VIS®).

14235Conditions associated with fungal infections

14236[000785] Diseases, disorders, or conditions associated with fungal infections include, but are not limited to, aspergilloses, blastomycosis, candidasis, coccidioidomycosis, cryptococcosis, histoplasmosis, mycetomas, paracoccidioidomycosis, and tinea pedis. Furthermore, persons with immuno-deficiencies are particularly susceptible to disease by fungal genera such as Aspergillus, Candida, Cryptoccocus, Histoplasma, and

14237Pneumocystis. Other fungi can attack eyes, nails, hair, and especially skin, the so-called dermatophyte fungi and keratinophilic fungi, and cause a variety of conditions, of which ringworms such as athlete's foot are common. Fungal spores are also a major cause of allergies, and a wide range of fungi from different taxonomic groups can evoke allergic reactions in some people.

14238Fungal pathogens

14239[000786] Fungal pathogens include, but are not limited to, Ascomycota (e.g., Fusarium oxysporum, Pneumocystis jirovecii, Aspergillus spp., Coccidioides immitis/posadasii, Candida albicans), Basidiomycota (e.g., Filobasidiella neoformans, Trichosporon), Microsporidia (e.g., Encephalitozoon cuniculi, Enterocytozoon bieneusi), and

14240Mucoromycotina (e.g., Mucor circinelloides, Rhizopus oryzae, Lichtheimia corymbifera). Anti-fungal agents

14241[000787] Exemplary anti-fungal agents include, but are not limited to, polyene antifungals {e.g., natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, hamycin), imidazole antifungals {e.g., miconazole (MICATIN®, DAKTARIN®), ketoconazole (NIZORAL®, FUNGORAL®, SEBIZOLE®), clotrimazole

14242(LOTRIMIN®, LOTRIMIN® AF, CANESTEN®), econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole (ERTACZO®), sulconazole, tioconazole), triazole antifungals {e.g., albaconazole fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole), thiazole antifungals {e.g., abafungin), allylamines {e.g., terbinafme (LAMISIL®), naftifme (NAFTIN®), butenafme (LOTRIMIN® Ultra)), echinocandins {e.g.,

14243anidulafungin, caspofungin, micafungin), and others {e.g., polygodial, benzoic acid, ciclopirox, tolnaftate (TINACTIN®, DESENEX®, AFTATE®), undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, haloprogin, sodium bicarbonate, allicin). Conditions associated with protozoal infection

14244[000788] Diseases, disorders, or conditions associated with protozoal infections include, but are not limited to, amoebiasis, giardiasis, trichomoniasis, African Sleeping Sickness, American Sleeping Sickness, leishmaniasis (Kala-Azar), balantidiasis, toxoplasmosis, malaria, acanthamoeba keratitis, and babesiosis.

14245Protozoan pathogens

14246[000789] Protozoal pathogens include, but are not limited to, Entamoeba histolytica, Giardia lambila, Trichomonas vaginalis, Trypanosoma brucei, T. cruzi, Leishmania donovani, Balantidium coli, Toxoplasma gondii, Plasmodium spp., and Babesia microti. Anti-protozoan agents

14247[000790] Exemplary anti-protozoal agents include, but are not limited to, eflornithine, furazolidone (FUROXONE®, DEPEND AL-M®), melarsoprol, metronidazole

14248(FLAGYL®), ornidazole, paromomycin sulfate (HUMATIN®), pentamidine,

14249pyrimethamine (DARAPRIM®), and imidazole (TINDAMAX®, FASIGYN®).

14250Conditions associated with parasitic infection

14251[000791] Diseases, disorders, or conditions associated with parasitic infections include, but are not limited to, acanthamoeba keratitis, amoebiasis, ascariasis, babesiosis, balantidiasis, baylisascariasis, chagas disease, clonorchiasis, cochliomyia, cryptosporidiosis, diphyllobothriasis, dracunculiasis, echinococcosis, elephantiasis, enterobiasis, fascioliasis, fasciolopsiasis, filariasis, giardiasis, gnathostomiasis, hymenolepiasis, isosporiasis, katayama fever, leishmaniasis, lyme disease, malaria, metagonimiasis, myiasis, onchocerciasis, pediculosis, scabies, schistosomiasis, sleeping sickness, strongyloidiasis, taeniasis, toxocariasis, toxoplasmosis, trichinosis, and trichuriasis.

14252Parasitic pathogens

14253[000792] Parasitic pathogens include, but are not limited to, Acanthamoeba, Anisakis, Ascaris lumbricoides, botfly, Balantidium coli, bedbug, Cestoda, chiggers, Cochliomyia hominivorax, Entamoeba histolytica, Fasciola hepatica, Giardia lamblia, hookworm, Leishmania, Linguatula serrata, liver fluke, Loa loa, Paragonimus, pinworm, Plasmodium falciparum, Schistosoma, Strongyloides stercoralis, mite, tapeworm, Toxoplasma gondii, Trypanosoma, whipworm, Wuchereria bancrofti.

14254Anti-parasitic agents

14255[000793] Exemplary anti-parasitic agents include, but are not limited to, antinematodes (e.g., mebendazole, pyrantel pamoate, thiabendazole, diethylcarbamazine, ivermectin), anticestodes (e.g., niclosamide, praziquantel, albendazole), antitrematodes (e.g., praziquantel), antiamoebics (e.g., rifampin, amphotericin B), and antiprotozoals (e.g., melarsoprol, eflornithine, metronidazole, imidazole).

14256Conditions associated with prion infection

14257[000794] Diseases, disorders, or conditions associated with prion infections include, but are not limited to Creutzfeldt-Jakob disease (CJD), iatrogenic Creutzfeldt-Jakob disease (iCJD), variant Creutzfeldt-Jakob disease (vCJD), familial Creutzfeldt-Jakob disease (fCJD), sporadic Creutzfeldt-Jakob disease (sCJD), Gerstmann-Straussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI), Kuru, Scrapie, bovine spongiform encephalopathy (BSE), mad cow disease, transmissible mink encephalopathy (TME), chronic wasting disease (CWD), feline spongiform encephalopathy (FSE), exotic ungulate encephalopathy (EUE), and spongiform encephalopathy.

14258Anti-prion agents [000795] Exemplary anti-prion agents include, but are not limited to, flupirtine, pentosan polysuphate, quinacrine, and tetracyclic compounds.

14259Modulation of the Immune Response

14260Avoidance of the immune response

14261[000796] As described herein, a useful feature of the polynucleotides, primary constructs or mmRNA of the invention is the capacity to reduce, evade or avoid the innate immune response of a cell. In one aspect, provided herein are polynucleotides, primary constructs or mmRNA encoding a polypeptide of interest which when delivered to cells, results in a reduced immune response from the host as compared to the response triggered by a reference compound, e.g. an unmodified polynucleotide corresponding to a polynucleotide, primary construct or mmRNA of the invention, or a different

14262polynucleotide, primary construct or mmRNA of the invention. As used herein, a "reference compound" is any molecule or substance which when administered to a mammal, results in an innate immune response having a known degree, level or amount of immune stimmulation. A reference compound need not be a nucleic acid molecule and it need not be any of the polynucleotides, primary constructs or mmRNA of the invention. Hence, the measure of a polynucleotides, primary constructs or mmRNA avoidance, evasion or failure to trigger an immune response can be expressed in terms relative to any compound or substance which is known to trigger such a response.

14263[000797] The term "innate immune response" includes a cellular response to exogenous single stranded nucleic acids, generally of viral or bacterial origin, which involves the induction of cytokine expression and release, particularly the interferons, and cell death. As used herein, the innate immune response or interferon response operates at the single cell level causing cytokine expression, cytokine release, global inhibition of protein synthesis, global destruction of cellular RNA, upregulation of major histocompatibility molecules, and/or induction of apoptotic death, induction of gene transcription of genes involved in apoptosis, anti-growth, and innate and adaptive immune cell activation. Some of the genes induced by type I IFNs include PKR, ADAR (adenosine deaminase acting on RNA), OAS (2',5'-oligoadenylate synthetase), RNase L, and Mx proteins. PKR and ADAR lead to inhibition of translation initiation and RNA editing, respectively. OAS is a dsRNA-dependent synthetase that activates the endoribonuclease R ase L to degrade ssR A.

14264[000798] In some embodiments, the innate immune response comprises expression of a Type I or Type II interferon, and the expression of the Type I or Type II interferon is not increased more than two-fold compared to a reference from a cell which has not been contacted with a polynucleotide, primary construct or mmR A of the invention.

14265[000799] In some embodiments, the innate immune response comprises expression of one or more IFN signature genes and where the expression of the one of more IFN signature genes is not increased more than three-fold compared to a reference from a cell which has not been contacted with the polynucleotide, primary construct or mmRNA of the invention.

14266[000800] While in some circumstances, it might be advantageous to eliminate the innate immune response in a cell, the invention provides polynucleotides, primary constructs and mmRNA that upon administration result in a substantially reduced (significantly less) the immune response, including interferon signaling, without entirely eliminating such a response.

14267[000801] In some embodiments, the immune response is lower by 10%, 20%>, 30%>, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, or greater than 99.9% as compared to the immune response induced by a reference compound. The immune response itself may be measured by determining the expression or activity level of Type 1 interferons or the expression of interferon-regulated genes such as the toll-like receptors (e.g., TLR7 and TLR8). Reduction of innate immune response can also be measured by measuring the level of decreased cell death following one or more administrations to a cell population; e.g., cell death is 10%, 25%, 50%, 75%, 85%, 90%, 95%, or over 95% less than the cell death frequency observed with a reference compound. Moreover, cell death may affect fewer than 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.1%, 0.01% or fewer than 0.01% of cells contacted with the polynucleotide, primary construct or mmRNA.

14268[000802] In another embodiment, the polynucleotide, primary construct or mmRNA of the present invention is significantly less immunogenic than an unmodified in vitro- synthesized RNA molecule polynucleotide, or primary construct with the same sequence or a reference compound. As used herein, "significantly less immunogenic" refers to a detectable decrease in immunogenicity. In another embodiment, the term refers to a fold decrease in immunogenicity. In another embodiment, the term refers to a decrease such that an effective amount of the polynucleotide, primary construct or mmR A can be administered without triggering a detectable immune response. In another embodiment, the term refers to a decrease such that the polynucleotide, primary construct or mmRNA can be repeatedly administered without eliciting an immune response sufficient to detectably reduce expression of the recombinant protein. In another embodiment, the decrease is such that the polynucleotide, primary construct or mmRNA can be repeatedly administered without eliciting an immune response sufficient to eliminate detectable expression of the recombinant protein.

14269[000803] In another embodiment, the polynucleotide, primary construct or mmRNA is 2-fold less immunogenic than its unmodified counterpart or reference compound. In another embodiment, immunogenicity is reduced by a 3 -fold factor. In another embodiment, immunogenicity is reduced by a 5 -fold factor. In another embodiment, immunogenicity is reduced by a 7-fold factor. In another embodiment, immunogenicity is reduced by a 10-fold factor. In another embodiment, immunogenicity is reduced by a 15- fold factor. In another embodiment, immunogenicity is reduced by a fold factor. In another embodiment, immunogenicity is reduced by a 50-fold factor. In another embodiment, immunogenicity is reduced by a 100-fold factor. In another embodiment, immunogenicity is reduced by a 200-fold factor. In another embodiment, immunogenicity is reduced by a 500-fold factor. In another embodiment, immunogenicity is reduced by a 1000-fold factor. In another embodiment, immunogenicity is reduced by a 2000-fold factor. In another embodiment, immunogenicity is reduced by another fold difference.

14270[000804] Methods of determining immunogenicity are well known in the art, and include, e.g. measuring secretion of cytokines (e.g. IL-12, IFNalpha, TNF-alpha, RANTES, MIP-1 alpha or beta, IL-6, IFN-beta, or IL-8), measuring expression of DC activation markers (e.g. CD83, HLA-DR, CD80 and CD86), or measuring ability to act as an adjuvant for an adaptive immune response.

14271[000805] The the polynucleotide, primary construct or mmRNA of the invention, including the combination of modifications taught herein may have superior properties making them more suitable as therapeutic modalities. [000806] It has been determined that the "all or none" model in the art is sorely insufficient to describe the biological phenomena associated with the therapeutic utility of modified mRNA. The present inventors have determined that to improve protein production, one may consider the nature of the modification, or combination of modifications, the percent modification and survey more than one cytokine or metric to determine the efficacy and risk profile of a particular modified mRNA.

14272[000807] In one aspect of the invention, methods of determining the effectiveness of a modified mRNA as compared to unmodified involves the measure and analysis of one or more cytokines whose expression is triggered by the administration of the exogenous nucleic acid of the invention. These values are compared to administration of an umodified nucleic acid or to a standard metric such as cytokine response, PolylC, R-848 or other standard known in the art.

14273[000808] One example of a standard metric developed herein is the measure of the ratio of the level or amount of encoded polypeptide (protein) produced in the cell, tissue or organism to the level or amount of one or more (or a panel) of cytokines whose expression is triggered in the cell, tissue or organism as a result of administration or contact with the modified nucleic acid. Such ratios are referred to herein as the

14274Protein: Cytokine Ratio or "PC" Ratio. The higher the PC ratio, the more efficacioius the modified nucleic acid (polynucleotide encoding the protein measured). Preferred PC Ratios, by cytokine, of the present invention may be greater than 1, greater than 10, greater than 100, greater than 1000, greater than 10,000 or more. Modified nucleic acids having higher PC Ratios than a modified nucleic acid of a different or unmodified construct are preferred.

14275[000809] The PC ratio may be further qualified by the percent modification present in the polynucleotide. For example, normalized to a 100% modified nucleic acid, the protein production as a function of cytokine (or risk) or cytokine profile can be determined.

14276[000810] In one embodiment, the present invention provides a method for determining, across chemistries, cytokines or percent modification, the relative efficacy of any particular modified the polynucleotide, primary construct or mmRNA by comparing the PC Ratio of the modified nucleic acid (polynucleotide, primary construct or mmRNA). [000811] mmRNA containing varying levels of nucleobase subsitutions could be produced that maintain increased protein production and decreased immunostimulatory potential. The relative percentage of any modified nucleotide to its naturally occurring nucleotide counterpart can be varied during the IVT reaction (for instance, 100, 50, 25, 10, 5, 2.5, 1, 0.1, 0.01% 5 methyl cytidine usage versus cytidine; 100, 50, 25, 10, 5, 2.5, 1, 0.1, 0.01% pseudouridine or Nl-methyl-pseudouridine usage versus uridine).

14277mmRNA can also be made that utilize different ratios using 2 or more different nucleotides to the same base (for instance, different ratios of pseudouridine and Nl- methyl-pseudouridine). mmRNA can also be made with mixed ratios at more than 1 "base" position, such as ratios of 5 methyl cytidine/cytidine and pseudouridine/Nl- methyl-pseudouridine/uridine at the same time. Use of modified mRNA with altered ratios of modified nucleotides can be beneficial in reducing potential exposure to chemically modified nucleotides. Lastly, positional introduction of modified nucleotides into the mmRNA which modulate either protein production or immunostimulatory potential or both is also possible. The ability of such mmRNA to demonstrate these improved properties can be assessed in vitro (using assays such as the PBMC assay described herein), and can also be assessed in vivo through measurement of both mmRNA-encoded protein production and mediators of innate immune recognition such as cytokines.

14278[000812] In another embodiment, the relative immunogenicity of the polynucleotide, primary construct or mmRNA and its unmodified counterpart are determined by determining the quantity of the polynucleotide, primary construct or mmRNA required to elicit one of the above responses to the same degree as a given quantity of the unmodified nucleotide or reference compound. For example, if twice as much polynucleotide, primary construct or mmRNA is required to elicit the same response, than the

14279polynucleotide, primary construct or mmRNA is two-fold less immunogenic than the unmodified nucleotide or the reference compound.

14280[000813] In another embodiment, the relative immunogenicity of the polynucleotide, primary construct or mmRNA and its unmodified counterpart are determined by determining the quantity of cytokine (e.g. IL-12, IFNalpha, TNF-alpha, RANTES, MIP- 1 alpha or beta, IL-6, IFN-beta, or IL-8) secreted in response to administration of the polynucleotide, primary construct or mmRNA, relative to the same quantity of the unmodified nucleotide or reference compound. For example, if one-half as much cytokine is secreted, than the polynucleotide, primary construct or mmRNA is two-fold less immunogenic than the unmodified nucleotide. In another embodiment, background levels of stimulation are subtracted before calculating the immunogenicity in the above methods.

14281[000814] Provided herein are also methods for performing the titration, reduction or elimination of the immune response in a cell or a population of cells. In some embodiments, the cell is contacted with varied doses of the same polynucleotides, primary constructs or mmRNA and dose response is evaluated. In some embodiments, a cell is contacted with a number of different polynucleotides, primary constructs or mmRNA at the same or different doses to determine the optimal composition for producing the desired effect. Regarding the immune response, the desired effect may be to avoid, evade or reduce the immune response of the cell. The desired effect may also be to alter the efficiency of protein production.

14282[000815] The polynucleotides, primary constructs and/or mmRNA of the present invention may be used to reduce the immune response using the method described in International Publication No. WO2013003475, herein incorporated by reference in its entirety.

14283Activation of the immune response: Vaccines

14284[000816] Additionally, certain modified nucleosides, or combinations thereof, when introduced into the polynucleotides, primary constructs or mmRNA of the invention will activate the innate immune response. Such activating molecules are useful as adjuvants when combined with polypeptides and/or other vaccines. In certain embodiments, the activating molecules contain a translatable region which encodes for a polypeptide sequence useful as a vaccine, thus providing the ability to be a self-adjuvant.

14285[000817] In one embodiment, the polynucleotides, primary constructs and/or mmRNA of the invention may encode an immunogen. The delivery of the polynucleotides, primary constructs and/or mmRNA encoding an immunogen may activate the immune response. As a non-limiting example, the polynucleotides, primary constructs and/or mmRNA encoding an immunogen may be delivered to cells to trigger multiple innate response pathways (see International Pub. No. WO2012006377; herein incorporated by reference in its entirety). As another non- limiting example, the polynucleotides, primary constructs and mmRNA of the present invention encoding an immunogen may be delivered to a vertebrate in a dose amount large enough to be immunogenic to the vertebrate (see International Pub. No. WO2012006372 and WO2012006369; each of which is herein incorporated by reference in their entirety).

14286[000818] The polynucleotides, primary constructs or mmRNA of invention may encode a polypeptide sequence for a vaccine and may further comprise an inhibitor. The inhibitor may impair antigen presentation and/or inhibit various pathways known in the art. As a non-limiting example, the polynucleotides, primary constructs or mmRNA of the invention may be used for a vaccine in combination with an inhibitor which can impair antigen presentation (see International Pub. No. WO2012089225 and WO2012089338; each of which is herein incorporated by reference in their entirety).

14287[000819] In one embodiment, the polynucleotides, primary constructs or mmRNA of the invention may be self-replicating RNA. Self-replicating RNA molecules can enhance efficiency of RNA delivery and expression of the enclosed gene product. In one embodiment, the polynucleotides, primary constructs or mmRNA may comprise at least one modification described herein and/or known in the art. In one embodiment, the self- replicating RNA can be designed so that the self-replicating RNA does not induce production of infectious viral particles. As a non-limiting example the self-replicating RNA may be designed by the methods described in US Pub. No. US20110300205 and International Pub. No. WO2011005799, each of which is herein incorporated by reference in their entirety.

14288[000820] In one embodiment, the self-replicating polynucleotides, primary constructs or mmRNA of the invention may encode a protein which may raise the immune response. As a non-limiting example, the polynucleotides, primary constructs or mmRNA may be self-replicating mRNA may encode at least one antigen (see US Pub. No.

14289US20110300205 and International Pub. Nos. WO2011005799, WO2013006838 and WO2013006842; each of which is herein incorporated by reference in their entirety).

14290[000821] In one embodiment, the self-replicating polynucleotides, primary constructs or mmRNA of the invention may be formulated using methods described herein or known in the art. As a non-limiting example, the self-replicating RNA may be formulated for delivery by the methods described in Geall et al (Nonviral delivery of self-amplifying RNA vaccines, PNAS 2012; PMID: 22908294).

14291[000822] In one embodiment, the polynucleotides, primary constructs or mmRNA of the present invention may encode amphipathic and/or immunogenic amphipathic peptides.

14292[000823] In on embodiment, a formulation of the polynucleotides, primary constructs or mmRNA of the present invention may further comprise an amphipathic and/or immunogenic amphipathic peptide. As a non-limiting example, the polynucleotides, primary constructs or mmRNA comprising an amphipathic and/or immunogenic amphipathic peptide may be formulated as described in US. Pub. No. US20110250237 and International Pub. Nos. WO2010009277 and WO2010009065; each of which is herein incorporated by reference in their entirety.

14293[000824] In one embodiment, the polynucleotides, primary constructs or mmRNA of the present invention may be immunostimultory. As a non-limiting example, the polynucleotides, primary constructs or mmRNA may encode all or a part of a positive- sense or a negative-sense stranded RNA virus genome (see International Pub No.

14294WO2012092569 and US Pub No. US20120177701, each of which is herein incorporated by reference in their entirety). In another non- limiting example, the immunostimultory polynucleotides, primary constructs or mmRNA of the present invention may be formulated with an excipient for administration as described herein and/or known in the art (see International Pub No. WO2012068295 and US Pub No. US20120213812, each of which is herein incorporated by reference in their entirety).

14295[000825] In one embodiment, the response of the vaccine formulated by the methods described herein may be enhanced by the addition of various compounds to induce the therapeutic effect. As a non-limiting example, the vaccine formulation may include a MHC II binding peptide or a peptide having a similar sequence to a MHC II binding peptide (see International Pub Nos. WO2012027365, WO2011031298 and US Pub No. US20120070493, US20110110965, each of which is herein incorporated by reference in their entirety). As another example, the vaccine formulations may comprise modified nicotinic compounds which may generate an antibody response to nicotine residue in a subject (see International Pub No. WO2012061717 and US Pub No. US20120114677, each of which is herein incorporated by reference in their entirety).

14296Naturally Occuring Mutants

14297[000826] In another embodiment, the polynucleotides, primary construct and/or mniRNA can be utilized to express variants of naturally occurring proteins that have an improved disease modifying activity, including increased biological activity, improved patient outcomes, or a protective function, etc. Many such modifier genes have been described in mammals (Nadeau, Current Opinion in Genetics & Development 2003 13:290-295; Hamilton and Yu, PLoS Genet. 2012;8:el002644; Corder et al, Nature Genetics 1994 7: 180 - 184; all herein incorporated by reference in their entireties).

14298Examples in humans include Apo E2 protein, Apo A-I variant proteins (Apo A-I Milano, Apo A-I Paris), hyperactive Factor IX protein (Factor IX Padua Arg338Lys),

14299transthyretin mutants (TTR Thrl 19Met). Expression of ApoE2 (cysl 12, cysl58) has been shown to confer protection relative to other ApoE iso forms (ApoE3 (cysl 12, argl58), and ApoE4 (argl 12, argl58)) by reducing susceptibility to Alzheimer's disease and possibly other conditions such as cardiovascular disease (Corder et al, Nature Genetics 1994 7: 180 - 184; Seripa et al, Rejuvenation Res. 2011 14:491-500; Liu et al. Nat Rev Neurol. 2013 9: 106-118; all herein incorporated by reference in their entireties). Expression of Apo A-I variants has been associated with reduced cholesterol (deGoma and Rader, 2011 Nature Rev Cardiol 8:266-271; Nissen et al, 2003 JAMA 290:2292- 2300; all herein incorporated by reference in its entirety). The amino acid sequence of ApoA-I in certain populations has been changed to cysteine in Apo A-I Milano (Arg 173 changed to Cys) and in Apo A-I Paris (Arg 151 changed to Cys). Factor IX mutation at position R338L (FIX Padua) results in a Factor IX protein that has ~ 10-fold increased activity (Simioni et al, N Engl J Med. 2009 361 : 1671-1675; Finn et al, Blood. 2012 120:4521-4523; Cantore et al, Blood. 2012 120:4517-20; all herein incorporated by reference in their entireties). Mutation of transthyretin at positions 104 or 119 (Arg 104 His, Thrl 19Met) has been shown to provide protection to patients also harboring the disease causing Va OMet mutations (Saraiva, Hum Mutat. 2001 17:493-503; DATA BASE ON TRANSTHYRETIN MUTATIONS

14300http://www.ibmc.up.pt/mjsaraiva/ttrmut.html; all herein incorporated by reference in its entirety). Differences in clinical presentation and severity of symptoms among

14301Portuguese and Japanese Met 30 patients carrying respectively the Met 119 and the His 104 mutations are observed with a clear protective effect exerted by the non pathogenic mutant (Coelho et al. 1996 Neuromuscular Disorders (Suppl) 6: S20;

14302Terazaki et al. 1999. Biochem Biophys Res Commun 264: 365-370; all herein

14303incorporated by reference in its entirety), which confer more stability to the molecule. A modified mRNA encoding these protective TTR alleles can be expressed in TTR amyloidosis patients, thereby reducing the effect of the pathogenic mutant TTR protein. Major Groove Interacting Partners

14304[000827] As described herein, the phrase "major groove interacting partner" refers to RNA recognition receptors that detect and respond to RNA ligands through interactions, e.g. binding, with the major groove face of a nucleotide or nucleic acid. As such, RNA ligands comprising modified nucleotides or nucleic acids such as the polynucleotide, primary construct or mmRNA as described herein decrease interactions with major groove binding partners, and therefore decrease an innate immune response.

14305[000828] Example major groove interacting, e.g. binding, partners include, but are not limited to the following nucleases and helicases. Within membranes, TLRs (Toll-like Receptors) 3, 7, and 8 can respond to single- and double-stranded RNAs. Within the cytoplasm, members of the superfamily 2 class of DE (D/H) helicases and ATPases can sense RNAs to initiate antiviral responses. These helicases include the RIG-I (retinoic acid-inducible gene I) and MDA5 (melanoma differentiation-associated gene 5). Other examples include laboratory of genetics and physiology 2 (LGP2), HIN-200 domain containing proteins, or Helicase-domain containing proteins.

14306Targeting of pathogenic organisms or diseased cells

14307[000829] Provided herein are methods for targeting pathogenic microorganisms, such as bacteria, yeast, protozoa, helminthes and the like, or diseased cells such as cancer cells using polynucleotides, primary constructs or mmRNA that encode cytostatic or cytotoxic polypeptides. Preferably the mRNA introduced contains modified nucleosides or other nucleic acid sequence modifications that are translated exclusively, or preferentially, in the target pathogenic organism, to reduce possible off-target effects of the therapeutic. Such methods are useful for removing pathogenic organisms or killing diseased cells found in any biological material, including blood, semen, eggs, and transplant materials including embryos, tissues, and organs.

14308Bioprocessing

14309[000830] The methods provided herein may be useful for enhancing protein product yield in a cell culture process. In a cell culture containing a plurality of host cells, introduction of a polynucleotide, primary construct or mmRNA described herein results in increased protein production efficiency relative to a corresponding unmodified nucleic acid. Such increased protein production efficiency can be demonstrated, e.g., by showing increased cell transfection, increased protein translation from the polynucleotide, primary construct or mmRNA, decreased nucleic acid degradation, and/or reduced innate immune response of the host cell. Protein production can be measured by enzyme-linked immunosorbent assay (ELISA), and protein activity can be measured by various functional assays known in the art. The protein production may be generated in a continuous or a batch-fed mammalian process.

14310[000831] Additionally, it is useful to optimize the expression of a specific polypeptide in a cell line or collection of cell lines of potential interest, particularly a polypeptide of interest such as a protein variant of a reference protein having a known activity. In one embodiment, provided is a method of optimizing expression of a polypeptide of interest in a target cell, by providing a plurality of target cell types, and independently contacting with each of the plurality of target cell types a polynucleotide, primary construct or mmRNA encoding a polypeptide of interest. The cells may be transfected with two or more polynucleotide, primary construct or mmRNA simultaneously or sequentially.

14311[000832] In certain embodiments, multiple rounds of the methods described herein may be used to obtain cells with increased expression of one or more nucleic acids or proteins of interest. For example, cells may be transfected with one or more polynucleotide, primary construct or mmRNA that encode a nucleic acid or protein of interest. The cells may be isolated according to methods described herein before being subjected to further rounds of transfections with one or more other nucleic acids which encode a nucleic acid or protein of interest before being isolated again. This method may be useful for generating cells with increased expression of a complex of proteins, nucleic acids or proteins in the same or related biological pathway, nucleic acids or proteins that act upstream or downstream of each other, nucleic acids or proteins that have a modulating, activating or repressing function to each other, nucleic acids or proteins that are dependent on each other for function or activity, or nucleic acids or proteins that share homology.

14312[000833] Additionally, culture conditions may be altered to increase protein production efficiency. Subsequently, the presence and/or level of the polypeptide of interest in the plurality of target cell types is detected and/or quantitated, allowing for the optimization of a polypeptide's expression by selection of an efficient target cell and cell culture conditions relating thereto. Such methods are particularly useful when the polypeptide contains one or more post-translational modifications or has substantial tertiary structure, situations which often complicate efficient protein production.

14313[000834] In one embodiment, the cells used in the methods of the present invention may be cultured. The cells may be cultured in suspension or as adherent cultures. The cells may be cultured in a varied of vessels including, but not limited to, bioreactors, cell bags, wave bags, culture plates, flasks and other vessels well known to those of ordinary skill in the art. Cells may be cultured in IMDM (Invitrogen, Catalog number 12440-53) or any other suitable media including, but not limited to, chemically defined media formulations. The ambient conditions which may be suitable for cell culture, such as temperature and atmospheric composition, are well known to those skilled in the art. The methods of the invention may be used with any cell that is suitable for use in protein production.

14314[000835] The invention provides for the repeated introduction (e.g., transfection) of modified nucleic acids into a target cell population, e.g., in vitro, ex vivo, in situ, or in vivo. For example, contacting the same cell population may be repeated one or more times (such as two, three, four, five or more than five times). In some embodiments, the step of contacting the cell population with the polynucleotides, primary constructs or mmRNA is repeated a number of times sufficient such that a predetermined efficiency of protein translation in the cell population is achieved. Given the often reduced cytotoxicity of the target cell population provided by the nucleic acid modifications, repeated transfections are achievable in a diverse array of cell types and within a variety of tissues, as provided herein. [000836] In one embodiment, the bioprocessing methods of the present invention may be used to produce antibodies or functional fragments thereof. The functional fragments may comprise a Fab, Fab', F(ab')2, an Fv domain, an scFv, or a diabody. They may be variable in any region including the complement determining region (CDR). In one embodiment, there is complete diversity in the CDR3 region. In another embodiment, the antibody is substantially conserved except in the CDR3 region.

14315[000837] Antibodies may be made which bind or associate with any biomolecule, whether human, pathogenic or non-human in origin. The pathogen may be present in a non-human mammal, a clinical specimen or from a commercial product such as a cosmetic or pharmaceutical material. They may also bind to any specimen or sample including clinical specimens or tissue samples from any organism.

14316[000838] In some embodiments, the contacting step is repeated multiple times at a frequency selected from the group consisting of: 6 hour, 12 hour, 24 hour, 36 hour, 48 hour, 72 hour, 84 hour, 96 hour, and 108 hour and at concentrations of less than 20 nM, less than 50 nM, less than 80 nM or less than 100 nM. Compositions may also be administered at less than ImM, less than 5mM, less than lOmM, less than lOOmM or less than 500 mM.

14317[000839] In some embodiments, the polynucleotides, primary constructs or mmRNA are added at an amount of 50 molecules per cell, 100 molecules/cell, 200 molecules/cell, 300 molecules/cell, 400 molecules/cell, 500 molecules/ cell, 600 molecules/cell, 700 molecules/ cell, 800 molecules/cell, 900 molecules/cell, 1000 molecules/cell, 2000 molecules/cell, or 5000 molecules/cell.

14318[000840] In other embodiments, the polynucleotides, primary constructs or mmRNA are added at a concentration selected from the group consisting of: 0.01 fmol/106 cells, 0.1 fmol/106 cells, 0.5 fmol/106 cells, 0.75 fmol/106 cells, 1 fmol/106 cells, 2 fmol/106 cells, 5 fmol/106 cells, 10 fmol/106 cells, 20 fmol/106 cells, 30 fmol/106 cells, 40 fmol/106 cells, 50 fmol/106 cells, 60 fmol/106 cells, 100 fmol/106 cells, 200 fmol/106 cells, 300 fmol/106 cells, 400 fmol/106 cells, 500 fmol/106 cells, 700 fmol/106 cells, 800 fmol/106 cells, 900 fmol/106 cells, and 1 pmol/106 cells.

14319[000841] In some embodiments, the production of a biological product upon is detected by monitoring one or more measurable bioprocess parameters, such as a parameter selected from the group consisting of: cell density, pH, oxygen levels, glucose levels, lactic acid levels, temperature, and protein production. Protein production can be measured as specific productivity (SP) (the concentration of a product, such as a heterologously expressed polypeptide, in solution) and can be expressed as mg/L or g/L; in the alternative, specific productivity can be expressed as pg/cell/day. An increase in SP can refer to an absolute or relative increase in the concentration of a product produced under two defined set of conditions (e.g., when compared with controls not treated with modified mRNA(s)).

14320Cells

14321[000842] In one embodiment, the cells are selected from the group consisting of mammalian cells, bacterial cells, plant, microbial, algal and fungal cells. In some embodiments, the cells are mammalian cells, such as, but not limited to, human, mouse, rat, goat, horse, rabbit, hamster or cow cells. In a further embodiment, the cells may be from an established cell line, including, but not limited to, HeLa, NSO, SP2/0, KEK 293T, Vero, Caco, Caco-2, MDCK, COS-1, COS-7, K562, Jurkat, CHO-K1, DG44, CHOKISV, CHO-S, Huvec, CV-1, Huh-7, NIH3T3, HEK293, 293, A549, HepG2, IMR- 90, MCF-7, U-20S, Per.C6, SF9, SF21 or Chinese Hamster Ovary (CHO) cells.

14322[000843] In certain embodiments, the cells are fungal cells, such as, but not limited to, Chrysosporium cells, Aspergillus cells, Trichoderma cells, Dictyostelium cells, Candida cells, Saccharomyces cells, Schizosaccharomyces cells, and Penicillium cells.

14323[000844] In certain embodiments, the cells are bacterial cells such as, but not limited to, E. coli, B. subtilis, or BL21 cells. Primary and secondary cells to be transfected by the methods of the invention can be obtained from a variety of tissues and include, but are not limited to, all cell types which can be maintained in culture. For examples, primary and secondary cells which can be transfected by the methods of the invention include, but are not limited to, fibroblasts, keratinocytes, epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells), endothelial cells, glial cells, neural cells, formed elements of the blood (e.g., lymphocytes, bone marrow cells), muscle cells and precursors of these somatic cell types. Primary cells may also be obtained from a donor of the same species or from another species (e.g., mouse, rat, rabbit, cat, dog, pig, cow, bird, sheep, goat, horse). Purification and Isolation

14324[000845] Those of ordinary skill in the art should be able to make a determination of the methods to use to purify or isolate of a protein of interest from cultured cells. Generally, this is done through a capture method using affinity binding or non-affinity purification. If the protein of interest is not secreted by the cultured cells, then a lysis of the cultured cells should be performed prior to purification or isolation. One may use unclarified cell culture fluid containing the protein of interest along with cell culture media components as well as cell culture additives, such as anti-foam compounds and other nutrients and supplements, cells, cellular debris, host cell proteins, DNA, viruses and the like in the present invention. The process may be conducted in the bioreactor itself. The fluid may either be preconditioned to a desired stimulus such as pH, temperature or other stimulus characteristic or the fluid can be conditioned upon the addition of polymer(s) or the polymer(s) can be added to a carrier liquid that is properly conditioned to the required parameter for the stimulus condition required for that polymer to be solubilized in the fluid. The polymer may be allowed to circulate thoroughly with the fluid and then the stimulus may be applied (change in pH, temperature, salt concentration, etc) and the desired protein and polymer(s) precipitate can out of the solution. The polymer and the desired protein(s) can be separated from the rest of the fluid and optionally washed one or more times to remove any trapped or loosely bound contaminants. The desired protein may then be recovered from the polymer(s) by, for example, elution and the like.

14325Preferably, the elution may be done under a set of conditions such that the polymer remains in its precipitated form and retains any impurities to it during the selected elution of the desired protein. The polymer and protein as well as any impurities may be solubilized in a new fluid such as water or a buffered solution and the protein may be recovered by a means such as affinity, ion exchanged, hydrophobic, or some other type of chromatography that has a preference and selectivity for the protein over that of the polymer or impurities. The eluted protein may then be recovered and may be subjected to additional processing steps, either batch like steps or continuous flow through steps if appropriate.

14326[000846] In another embodiment, it may be useful to optimize the expression of a specific polypeptide in a cell line or collection of cell lines of potential interest, particularly a polypeptide of interest such as a protein variant of a reference protein having a known activity. In one embodiment, provided is a method of optimizing expression of a polypeptide of interest in a target cell, by providing a plurality of target cell types, and independently contacting with each of the plurality of target cell types a modified mR A encoding a polypeptide. Additionally, culture conditions may be altered to increase protein production efficiency. Subsequently, the presence and/or level of the polypeptide of interest in the plurality of target cell types is detected and/or quantitated, allowing for the optimization of a polypeptide of interest's expression by selection of an efficient target cell and cell culture conditions relating thereto. Such methods may be useful when the polypeptide of interest contains one or more post-translational modifications or has substantial tertiary structure, which often complicate efficient protein production.

14327Protein recovery

14328[000847] The protein of interest may be preferably recovered from the culture medium as a secreted polypeptide, or it can be recovered from host cell lysates if expressed without a secretory signal. It may be necessary to purify the protein of interest from other recombinant proteins and host cell proteins in a way that substantially homogenous preparations of the protein of interest are obtained. The cells and/or particulate cell debris may be removed from the culture medium or lysate. The product of interest may then be purified from contaminant soluble proteins, polypeptides and nucleic acids by, for example, fractionation on immunoaffinity or ion-exchange columns, ethanol

14329precipitation, reverse phase HPLC (RP-HPLC), SEPHADEX® chromatography, chromatography on silica or on a cation exchange resin such as DEAE. Methods of purifying a protein heterologous expressed by a host cell are well known in the art.

14330[000848] Methods and compositions described herein may be used to produce proteins which are capable of attenuating or blocking the endogenous agonist biological response and/or antagonizing a receptor or signaling molecule in a mammalian subject. For example, IL-12 and IL-23 receptor signaling may be enhanced in chronic autoimmune disorders such as multiple sclerosis and inflammatory diseases such as rheumatoid arthritis, psoriasis, lupus erythematosus, ankylosing spondylitis and Chron's disease (Kikly K, Liu L, Na S, Sedgwich JD (2006) Cur. Opin. Immunol. 18(6): 670-5). In another embodiment, a nucleic acid encodes an antagonist for chemokine receptors. Chemokine receptors CXCR-4 and CCR-5 are required for HIV enry into host cells (Arenzana-Seisdedos F et al, (1996) Nature. Oct 3; 383 (6599):400).

14331Gene Silencing

14332[000849] The polynucleotides, primary constructs and mmRNA described herein are useful to silence (i.e., prevent or substantially reduce) expression of one or more target genes in a cell population. A polynucleotide, primary construct or mmRNA encoding a polypeptide of interest capable of directing sequence-specific histone H3 methylation is introduced into the cells in the population under conditions such that the polypeptide is translated and reduces gene transcription of a target gene via histone H3 methylation and subsequent heterochromatin formation. In some embodiments, the silencing mechanism is performed on a cell population present in a mammalian subject. By way of non- limiting example, a useful target gene is a mutated Janus Kinase-2 family member, wherein the mammalian subject expresses the mutant target gene suffers from a myeloproliferative disease resulting from aberrant kinase activity.

14333[000850] Co-administration of polynucleotides, primary constructs and mmRNA and RNAi agents are also provided herein.

14334Modulation of Biological Pathways

14335[000851] The rapid translation polynucleotides, primary constructs and mmRNA introduced into cells provides a desirable mechanism of modulating target biological pathways. Such modulation includes antagonism or agonism of a given pathway. In one embodiment, a method is provided for antagonizing a biological pathway in a cell by contacting the cell with an effective amount of a composition comprising a

14336polynucleotide, primary construct or mmRNA encoding a polypeptide of interest, under conditions such that the polynucleotides, primary constructs and mmRNA is localized into the cell and the polypeptide is capable of being translated in the cell from the polynucleotides, primary constructs and mmRNA, wherein the polypeptide inhibits the activity of a polypeptide functional in the biological pathway. Exemplary biological pathways are those defective in an autoimmune or inflammatory disorder such as multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, ankylosing spondylitis colitis, or Crohn's disease; in particular, antagonism of the IL-12 and IL-23 signaling pathways are of particular utility. (See Kikly K, Liu L, Na S, Sedgwick JD (2006) Curr. Opin. Immunol. 18 (6): 670-5).

14337[000852] Further, provided are polynucleotide, primary construct or mmRNA encoding an antagonist for chemokine receptors; chemokine receptors CXCR-4 and CCR-5 are required for, e.g., HIV entry into host cells (Arenzana-Seisdedos F et al, (1996)

14338Nature. Oct 3;383(6599):400).

14339[000853] Alternatively, provided are methods of agonizing a biological pathway in a cell by contacting the cell with an effective amount of a polynucleotide, primary construct or mmRNA encoding a recombinant polypeptide under conditions such that the nucleic acid is localized into the cell and the recombinant polypeptide is capable of being translated in the cell from the nucleic acid, and the recombinant polypeptide induces the activity of a polypeptide functional in the biological pathway. Exemplary agonized biological pathways include pathways that modulate cell fate determination. Such agonization is reversible or, alternatively, irreversible.

14340Expression of Ligand or Receptor on Cell Surface

14341[000854] In some aspects and embodiments of the aspects described herein, the polynucleotides, primary constructs or mmRNA described herein can be used to express a ligand or ligand receptor on the surface of a cell (e.g., a homing moiety). A ligand or ligand receptor moiety attached to a cell surface can permit the cell to have a desired biological interaction with a tissue or an agent in vivo. A ligand can be an antibody, an antibody fragment, an aptamer, a peptide, a vitamin, a carbohydrate, a protein or polypeptide, a receptor, e.g., cell-surface receptor, an adhesion molecule, a glycoprotein, a sugar residue, a therapeutic agent, a drug, a glycosaminoglycan, or any combination thereof. For example, a ligand can be an antibody that recognizes a cancer-cell specific antigen, rendering the cell capable of preferentially interacting with tumor cells to permit tumor-specific localization of a modified cell. A ligand can confer the ability of a cell composition to accumulate in a tissue to be treated, since a preferred ligand may be capable of interacting with a target molecule on the external face of a tissue to be treated. Ligands having limited cross-reactivity to other tissues are generally preferred.

14342[000855] In some cases, a ligand can act as a homing moiety which permits the cell to target to a specific tissue or interact with a specific ligand. Such homing moieties can include, but are not limited to, any member of a specific binding pair, antibodies, monoclonal antibodies, or derivatives or analogs thereof, including without limitation: Fv fragments, single chain Fv (scFv) fragments, Fab' fragments, F(ab')2 fragments, single domain antibodies, camelized antibodies and antibody fragments, humanized antibodies and antibody fragments, and multivalent versions of the foregoing; multivalent binding reagents including without limitation: monospecific or bispecific antibodies, such as disulfide stabilized Fv fragments, scFv tandems ((SCFV)2 fragments), diabodies, tribodies or tetrabodies, which typically are covalently linked or otherwise stabilized (i.e., leucine zipper or helix stabilized) scFv fragments; and other homing moieties include for example, aptamers, receptors, and fusion proteins.

14343[000856] In some embodiments, the homing moiety may be a surface-bound antibody, which can permit tuning of cell targeting specificity. This is especially useful since highly specific antibodies can be raised against an epitope of interest for the desired targeting site. In one embodiment, multiple antibodies are expressed on the surface of a cell, and each antibody can have a different specificity for a desired target. Such approaches can increase the avidity and specificity of homing interactions.

14344[000857] A skilled artisan can select any homing moiety based on the desired localization or function of the cell, for example an estrogen receptor ligand, such as tamoxifen, can target cells to estrogen-dependent breast cancer cells that have an increased number of estrogen receptors on the cell surface. Other non- limiting examples of ligand/receptor interactions include CCRI (e.g., for treatment of inflamed joint tissues or brain in rheumatoid arthritis, and/or multiple sclerosis), CCR7, CCR8 (e.g., targeting to lymph node tissue), CCR6, CCR9,CCR10 (e.g., to target to intestinal tissue), CCR4, CCR10 (e.g., for targeting to skin), CXCR4 (e.g., for general enhanced transmigration), HCELL (e.g., for treatment of inflammation and inflammatory disorders, bone marrow), Alpha4beta7 (e.g., for intestinal mucosa targeting), VLA-4/VC AM- 1 (e.g., targeting to endothelium). In general, any receptor involved in targeting (e.g., cancer metastasis) can be harnessed for use in the methods and compositions described herein.

14345Modulation of Cell Lineage

14346[000858] Provided are methods of inducing an alteration in cell fate in a target mammalian cell. The target mammalian cell may be a precursor cell and the alteration may involve driving differentiation into a lineage, or blocking such differentiation.

14347Alternatively, the target mammalian cell may be a differentiated cell, and the cell fate alteration includes driving de-differentiation into a pluripotent precursor cell, or blocking such de-differentiation, such as the dedifferentiation of cancer cells into cancer stem cells. In situations where a change in cell fate is desired, effective amounts of mR As encoding a cell fate inductive polypeptide is introduced into a target cell under conditions such that an alteration in cell fate is induced. In some embodiments, the modified mRNAs are useful to reprogram a subpopulation of cells from a first phenotype to a second phenotype. Such a reprogramming may be temporary or permanent.

14348Optionally, the reprogramming induces a target cell to adopt an intermediate phenotype.

14349[000859] Additionally, the methods of the present invention are particularly useful to generate induced pluripotent stem cells (iPS cells) because of the high efficiency of transfection, the ability to re-transfect cells, and the tenability of the amount of recombinant polypeptides produced in the target cells. Further, the use of iPS cells generated using the methods described herein is expected to have a reduced incidence of teratoma formation.

14350[000860] Also provided are methods of reducing cellular differentiation in a target cell population. For example, a target cell population containing one or more precursor cell types is contacted with a composition having an effective amount of a polynucleotides, primary constructs and mmRNA encoding a polypeptide, under conditions such that the polypeptide is translated and reduces the differentiation of the precursor cell. In non- limiting embodiments, the target cell population contains injured tissue in a mammalian subject or tissue affected by a surgical procedure. The precursor cell is, e.g., a stromal precursor cell, a neural precursor cell, or a mesenchymal precursor cell.

14351[000861] In a specific embodiment, provided are polynucleotide, primary construct or mmRNA that encode one or more differentiation factors Gata4, Mef2c and Tbx4. These mRNA-generated factors are introduced into fibroblasts and drive the reprogramming into cardiomyocytes. Such a reprogramming can be performed in vivo, by contacting an mRNA-containing patch or other material to damaged cardiac tissue to facilitate cardiac regeneration. Such a process promotes cardiomyocyte genesis as opposed to fibrosis. Mediation of cell death

14352[000862] In one embodiment, polynucleotides, primary constructs or mmRNA compositions can be used to induce apoptosis in a cell (e.g., a cancer cell) by increasing the expression of a death receptor, a death receptor ligand or a combination thereof. This method can be used to induce cell death in any desired cell and has particular usefulness in the treatment of cancer where cells escape natural apoptotic signals.

14353[000863] Apoptosis can be induced by multiple independent signaling pathways that converge upon a final effector mechanism consisting of multiple interactions between several "death receptors" and their ligands, which belong to the tumor necrosis factor (TNF) receptor/ligand superfamily. The best-characterized death receptors are CD95 ("Fas"), TNFRI (p55), death receptor 3 (DR3 or Apo3/TRAMO), DR4 and DR5 (apo2- TRAIL-R2). The final effector mechanism of apoptosis may be the activation of a series of proteinases designated as caspases. The activation of these caspases results in the cleavage of a series of vital cellular proteins and cell death. The molecular mechanism of death receptors/ligands-induced apoptosis is well known in the art. For example, Fas/FasL-mediated apoptosis is induced by binding of three FasL molecules which induces trimerization of Fas receptor via C-terminus death domains (DDs), which in turn recruits an adapter protein FADD (Fas-associated protein with death domain) and Caspase-8. The oligomerization of this trimolecular complex, Fas/FAIDD/caspase-8, results in proteolytic cleavage of proenzyme caspase-8 into active caspase-8 that, in turn, initiates the apoptosis process by activating other downstream caspases through proteolysis, including caspase-3. Death ligands in general are apoptotic when formed into trimers or higher order of structures. As monomers, they may serve as antiapoptotic agents by competing with the trimers for binding to the death receptors.

14354[000864] In one embodiment, the polynucleotides, primary constructs or mmRNA composition encodes for a death receptor (e.g., Fas, TRAIL, TRAMO, TNFR, TLR etc). Cells made to express a death receptor by transfection of polynucleotides, primary constructs and mmRNA become susceptible to death induced by the ligand that activates that receptor. Similarly, cells made to express a death ligand, e.g., on their surface, will induce death of cells with the receptor when the transfected cell contacts the target cell. In another embodiment, the polynucleotides, primary constructs and mmRNA composition encodes for a death receptor ligand (e.g., FasL, TNF, etc). In another embodiment, the polynucleotides, primary constructs and mmRNA composition encodes a caspase (e.g., caspase 3, caspase 8, caspase 9 etc). Where cancer cells often exhibit a failure to properly differentiate to a non-proliferative or controlled proliferative form, in another embodiment, the synthetic, polynucleotides, primary constructs and mmRNA composition encodes for both a death receptor and its appropriate activating ligand. In another embodiment, the synthetic, polynucleotides, primary constructs and mmRNA composition encodes for a differentiation factor that when expressed in the cancer cell, such as a cancer stem cell, will induce the cell to differentiate to a non-pathogenic or nonself-renewing phenotype (e.g., reduced cell growth rate, reduced cell division etc) or to induce the cell to enter a dormant cell phase (e.g., Go resting phase).

14355[000865] One of skill in the art will appreciate that the use of apoptosis-inducing techniques may require that the polynucleotides, primary constructs or mmRNA are appropriately targeted to e.g., tumor cells to prevent unwanted wide-spread cell death. Thus, one can use a delivery mechanism (e.g., attached ligand or antibody, targeted liposome etc) that recognizes a cancer antigen such that the polynucleotides, primary constructs or mmRNA are expressed only in cancer cells.

14356Cosmetic Applications

14357[000866] In one embodiment, the polynucleotides, primary constructs and/or mmRNA may be used in the treatment, amelioration or prophylaxis of cosmetic conditions. Such conditions include acne, rosacea, scarring, wrinkles, eczema, shingles, psoriasis, age spots, birth marks, dry skin, calluses, rash (e.g., diaper, heat), scabies, hives, warts, insect bites, vitiligo, dandruff, freckles, and general signs of aging.

14358VI. Kits and Devices

14359Kits

14360[000867] The invention provides a variety of kits for conveniently and/or effectively carrying out methods of the present invention. Typically kits will comprise sufficient amounts and/or numbers of components to allow a user to perform multiple treatments of a subject(s) and/or to perform multiple experiments. [000868] In one aspect, the present invention provides kits comprising the molecules (polynucleotides, primary constructs or mmRNA) of the invention. In one embodiment, the kit comprises one or more functional antibodies or function fragments thereof.

14361[000869] Said kits can be for protein production, comprising a first polynucleotide, primary construct or mmRNA comprising a translatable region. The kit may further comprise packaging and instructions and/or a delivery agent to form a formulation composition. The delivery agent may comprise a saline, a buffered solution, a lipidoid or any delivery agent disclosed herein.

14362[000870] In one embodiment, the buffer solution may include sodium chloride, calcium chloride, phosphate and/or EDTA. In another embodiment, the buffer solution may include, but is not limited to, saline, saline with 2mM calcium, 5% sucrose, 5% sucrose with 2mM calcium, 5% Mannitol, 5% Mannitol with 2mM calcium, Ringer's lactate, sodium chloride, sodium chloride with 2mM calcium and mannose (See e.g., U.S. Pub. No. 20120258046; herein incorporated by reference in its entirety). In a futher embodiment, the buffer solutions may be precipitated or it may be lyophilized. The amount of each component may be varied to enable consistent, reproducible higher concentration saline or simple buffer formulations. The components may also be varied in order to increase the stability of modified RNA in the buffer solution over a period of time and/or under a variety of conditions.In one aspect, the present invention provides kits for protein production, comprising: a polynucleotide, primary construct or mmRNA comprising a translatable region, provided in an amount effective to produce a desired amount of a protein encoded by the translatable region when introduced into a target cell; a second polynucleotide comprising an inhibitory nucleic acid, provided in an amount effective to substantially inhibit the innate immune response of the cell; and packaging and instructions.

14363[000871] In one aspect, the present invention provides kits for protein production, comprising a polynucleotide, primary construct or mmRNA comprising a translatable region, wherein the polynucleotide exhibits reduced degradation by a cellular nuclease, and packaging and instructions.

14364[000872] In one aspect, the present invention provides kits for protein production, comprising a polynucleotide, primary construct or mmRNA comprising a translatable region, wherein the polynucleotide exhibits reduced degradation by a cellular nuclease, and a mammalian cell suitable for translation of the translatable region of the first nucleic acid.

14365[000873] In one embodiment, the levels of Protein C may be measured by

14366immunoassay. The assay may be purchased and is available from any number of suppliers including BioMerieux, Inc. (Durham, NC), Abbott Laboratories (Abbott Park, IL), Siemens Medical Solutions USA, Inc. (Malvern, PA), BIOPORTO® Diagnostics A/S (Gentofte, Denmark), USCN® Life Science Inc. (Houston, TX) or Roche Diagnostic Corporation (Indianapolis, IN). In this embodiment, the assay may be used to assess levels of Protein C or its activated form or a variant delivered as or in response to administration of a modified mRNA molecule.

14367Devices

14368[000874] The present invention provides for devices which may incorporate

14369polynucleotides, primary constructs or mmRNA that encode polypeptides of interest. These devices contain in a stable formulation the reagents to synthesize a polynucleotide in a formulation available to be immediately delivered to a subject in need thereof, such as a human patient. Non-limiting examples of such a polypeptide of interest include a growth factor and/or angiogenesis stimulator for wound healing, a peptide antibiotic to facilitate infection control, and an antigen to rapidly stimulate an immune response to a newly identified virus.

14370[000875] Devices may also be used in conjunction with the present invention. In one embodiment, a device is used to assess levels of a protein which has been administered in the form of a modified mRNA. The device may comprise a blood, urine or other biofluidic test. It may be as large as to include an automated central lab platform or a small decentralized bench top device. It may be point of care or a handheld device. In this embodiment, for example, Protein C or APC may be quatitated before, during or after treatment with a modified mRNA encoding Protein C (its zymogen), APC or any variants thereof. Protein C, also known as autoprothrombin IIA and blood coagulation factor XIV is a zymogen, or precursor, of a serine protease which plays an important role in the regulation of blood coagulation and generation of fibrinolytic activity in vivo. It is synthesized in the liver as a single-chain polypeptide but undergoes posttranslational processing to give rise to a two-chain intermediate. The intermediate form of Protein C is converted via thrombin-mediated cleavage of a 12-residue peptide from the amino- terminus of the heavy chain to of the molecule to the active form, known as "activated protein C" (APC). The device may be useful in drug discovery efforts as a companion diagnostic test associated with Protein C, or APC treatment such as for sepsis or severe sepsis. In early studies it was suggested that APC had the ability to reduce mortality in severe sepsis. Following this line of work, clinical studies lead to the FDA approval of one compound, activated drotrecogin alfa (recombinant protein C). However, in late 2011, the drug was withdrawn from sale in all markets following results of the

14371PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The present invention provides modified mRNA molecules which may be used in the diagnosis and treatment of sepsis, severe sepsis and septicemia which overcome prior issues or problems associated with increasing protein expression efficiencies in mammals.

14372[000876] In some embodiments the device is self-contained, and is optionally capable of wireless remote access to obtain instructions for synthesis and/or analysis of the generated polynucleotide, primary construct or mmRNA. The device is capable of mobile synthesis of at least one polynucleotide, primary construct or mmRNA and preferably an unlimited number of different polynucleotides, primary constructs or mmRNA. In certain embodiments, the device is capable of being transported by one or a small number of individuals. In other embodiments, the device is scaled to fit on a benchtop or desk. In other embodiments, the device is scaled to fit into a suitcase, backpack or similarly sized object. In another embodiment, the device may be a point of care or handheld device. In further embodiments, the device is scaled to fit into a vehicle, such as a car, truck or ambulance, or a military vehicle such as a tank or personnel carrier. The information necessary to generate a modified mRNA encoding polypeptide of interest is present within a computer readable medium present in the device.

14373[000877] In one embodiment, a device may be used to assess levels of a protein which has been administered in the form of a polynucleotide, primary construct or mmRNA. The device may comprise a blood, urine or other biofluidic test. [000878] In some embodiments, the device is capable of communication (e.g., wireless communication) with a database of nucleic acid and polypeptide sequences. The device contains at least one sample block for insertion of one or more sample vessels. Such sample vessels are capable of accepting in liquid or other form any number of materials such as template DNA, nucleotides, enzymes, buffers, and other reagents. The sample vessels are also capable of being heated and cooled by contact with the sample block. The sample block is generally in communication with a device base with one or more electronic control units for the at least one sample block. The sample block preferably contains a heating module, such heating molecule capable of heating and/or cooling the sample vessels and contents thereof to temperatures between about -20C and above +100C. The device base is in communication with a voltage supply such as a battery or external voltage supply. The device also contains means for storing and distributing the materials for RNA synthesis.

14374[000879] Optionally, the sample block contains a module for separating the synthesized nucleic acids. Alternatively, the device contains a separation module operably linked to the sample block. Preferably the device contains a means for analysis of the synthesized nucleic acid. Such analysis includes sequence identity (demonstrated such as by hybridization), absence of non-desired sequences, measurement of integrity of synthesized mR A (such has by microfluidic viscometry combined with

14375spectrophotometry), and concentration and/or potency of modified RNA (such as by spectrophotometry).

14376[000880] In certain embodiments, the device is combined with a means for detection of pathogens present in a biological material obtained from a subject, e.g., the IBIS PLEX- ID system (Abbott, Abbott Park, IL) for microbial identification.

14377[000881] Suitable devices for use in delivering intradermal pharmaceutical

14378compositions described herein include short needle devices such as those described in U.S. Patents 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235;

143795,141,496; and 5,417,662; each of which is herein incorporated by reference in their entirety. Intradermal compositions may be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 (herein incorporated by reference in its entirety) and functional equivalents thereof. Jet injection devices which deliver liquid compositions to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Patents 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT publications WO 97/37705 and WO 97/13537; each of which are hrein incorporated by reference in their entirety. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes may be used in the classical mantoux method of intradermal administration.

14380[000882] In some embodiments, the device may be a pump or comprise a catheter for administration of compounds or compositions of the invention across the blood brain barrier. Such devices include but are not limited to a pressurized olfactory delivery device, iontophoresis devices, multi-layered microfluidic devices, and the like. Such devices may be portable or stationary. They may be implantable or externally tethered to the body or combinations thereof.

14381[000883] Devices for administration may be employed to deliver the polynucleotides, primary constructs or mmRNA of the present invention according to single, multi- or split-dosing regimens taught herein. Such devices are described below.

14382[000884] Method and devices known in the art for multi-administration to cells, organs and tissues are contemplated for use in conjunction with the methods and compositions disclosed herein as embodiments of the present invention. These include, for example, those methods and devices having multiple needles, hybrid devices employing for example lumens or catheters as well as devices utilizing heat, electric current or radiation driven mechanisms.

14383[000885] According to the present invention, these multi-administration devices may be utilized to deliver the single, multi- or split doses contemplated herein.

14384[000886] A method for delivering therapeutic agents to a solid tissue has been described by Bahrami et al. and is taught for example in US Patent Publication 20110230839, the contents of which are incorporated herein by reference in their entirety. According to Bahrami, an array of needles is incorporated into a device which delivers a substantially equal amount of fluid at any location in said solid tissue along each needle's length.

14385[000887] A device for delivery of biological material across the biological tissue has been described by Kodgule et al. and is taught for example in US Patent Publication 20110172610, the contents of which are incorporated herein by reference in their entirety. According to Kodgule, multiple hollow micro-needles made of one or more metals and having outer diameters from about 200 microns to about 350 microns and lengths of at least 100 microns are incorporated into the device which delivers peptides, proteins, carbohydrates, nucleic acid molecules, lipids and other pharmaceutically active ingredients or combinations thereof.

14386[000888] A delivery probe for delivering a therapeutic agent to a tissue has been described by Gunday et al. and is taught for example in US Patent Publication

1438720110270184, the contents of each of which are incorporated herein by reference in their entirety. According to Gunday, multiple needles are incorporated into the device which moves the attached capsules between an activated position and an inactivated position to force the agent out of the capsules through the needles.

14388[000889] A multiple-injection medical apparatus has been described by Assaf and is taught for example in US Patent Publication 20110218497, the contents of which are incorporated herein by reference in their entirety. According to Assaf, multiple needles are incorporated into the device which has a chamber connected to one or more of said needles and a means for continuously refilling the chamber with the medical fluid after each injection.

14389[000890] In one embodiment, the polynucleotide, primary construct, or mmRNA is administered subcutaneously or intramuscularly via at least 3 needles to three different, optionally adjacent, sites simultaneously, or within a 60 minutes period (e.g.,

14390administration to 4 ,5, 6, 7, 8, 9, or 10 sites simultaneously or within a 60 minute period). The split doses can be administered simultaneously to adjacent tissue using the devices described in U.S. Patent Publication Nos. 20110230839 and 20110218497, each of which is incorporated herein by reference in their entirety.

14391[000891] An at least partially implantable system for injecting a substance into a patient's body, in particular a penis erection stimulation system has been described by Forsell and is taught for example in US Patent Publication 20110196198, the contents of which are incorporated herein by reference in their entirety. According to Forsell, multiple needles are incorporated into the device which is implanted along with one or more housings adjacent the patient's left and right corpora cavernosa. A reservoir and a pump are also implanted to supply drugs through the needles.

14392[000892] A method for the transdermal delivery of a therapeutic effective amount of iron has been described by Berenson and is taught for example in US Patent Publication 20100130910, the contents of which are incorporated herein by reference in their entirety. According to Berenson, multiple needles may be used to create multiple micro channels in stratum corneum to enhance transdermal delivery of the ionic iron on an iontophoretic patch.

14393[000893] A method for delivery of biological material across the biological tissue has been described by Kodgule et al and is taught for example in US Patent Publication 20110196308, the contents of which are incorporated herein by reference in their entirety. According to Kodgule, multiple biodegradable microneedles containing a therapeutic active ingredient are incorporated in a device which delivers proteins, carbohydrates, nucleic acid molecules, lipids and other pharmaceutically active ingredients or combinations thereof.

14394[000894] A transdermal patch comprising a botulinum toxin composition has been described by Donovan and is taught for example in US Patent Publication 20080220020, the contents of which are incorporated herein by reference in their entirety. According to Donovan, multiple needles are incorporated into the patch which delivers botulinum toxin under stratum corneum through said needles which project through the stratum corneum of the skin without rupturing a blood vessel.

14395[000895] A small, disposable drug reservoir, or patch pump, which can hold

14396approximately 0.2 to 15 mL of liquid formulations can be placed on the skin and deliver the formulation continuously subcutaneously using a small bore needed (e.g., 26 to 34 gauge). As non-limiting examples, the patch pump may be 50 mm by 76 mm by 20 mm spring loaded having a 30 to 34 gauge needle (BD™ Microinfuser, Franklin Lakes NJ), 41 mm by 62 mm by 17 mm with a 2 mL reservoir used for drug delivery such as insulin (OMNIPOD®, Insulet Corporation Bedford, MA), or 43-60 mm diameter, 10 mm thick with a 0.5 to 10 mL reservoir (PATCHPUMP®, SteadyMed Therapeutics, San Francisco, CA). Further, the patch pump may be battery powered and/or rechargeable.

14397[000896] A cryoprobe for administration of an active agent to a location of cryogenic treatment has been described by Toubia and is taught for example in US Patent

14398Publication 20080140061, the contents of which are incorporated herein by reference in their entirety. According to Toubia, multiple needles are incorporated into the probe which receives the active agent into a chamber and administers the agent to the tissue.

14399[000897] A method for treating or preventing inflammation or promoting healthy joints has been described by Stock et al and is taught for example in US Patent Publication 20090155186, the contents of which are incorporated herein by reference in their entirety. According to Stock, multiple needles are incorporated in a device which administers compositions containing signal transduction modulator compounds.

14400[000898] A multi-site injection system has been described by Kimmell et al. and is taught for example in US Patent Publication 20100256594, the contents of which are incorporated herein by reference in their entirety. According to Kimmell, multiple needles are incorporated into a device which delivers a medication into a stratum corneum through the needles.

14401[000899] A method for delivering interferons to the intradermal compartment has been described by Dekker et al. and is taught for example in US Patent Publication

1440220050181033, the contents of which are incorporated herein by reference in their entirety. According to Dekker, multiple needles having an outlet with an exposed height between 0 and 1 mm are incorporated into a device which improves pharmacokinetics and bioavailability by delivering the substance at a depth between 0.3 mm and 2 mm.

14403[000900] A method for delivering genes, enzymes and biological agents to tissue cells has described by Desai and is taught for example in US Patent Publication 20030073908, the contents of which are incorporated herein by reference in their entirety. According to Desai, multiple needles are incorporated into a device which is inserted into a body and delivers a medication fluid through said needles.

14404[000901] A method for treating cardiac arrhythmias with fibroblast cells has been described by Lee et al and is taught for example in US Patent Publication 20040005295, the contents of which are incorporated herein by reference in their entirety. According to Lee, multiple needles are incorporated into the device which delivers fibroblast cells into the local region of the tissue.

14405[000902] A method using a magnetically controlled pump for treating a brain tumor has been described by Shachar et al. and is taught for example in US Patent 7799012

14406(method) and 7799016 (device), the contents of which are incorporated herein by reference in their entirety. According Shachar, multiple needles were incorporated into the pump which pushes a medicating agent through the needles at a controlled rate.

14407[000903] Methods of treating functional disorders of the bladder in mammalian females have been described by Versi et al. and are taught for example in US Patent 8,029,496, the contents of which are incorporated herein by reference in their entirety. According to Versi, an array of micro-needles is incorporated into a device which delivers a therapeutic agent through the needles directly into the trigone of the bladder.

14408[000904] A micro-needle transdermal transport device has been described by Angel et al and is taught for example in US Patent 7,364,568, the contents of which are incorporated herein by reference in their entirety. According to Angel, multiple needles are incorporated into the device which transports a substance into a body surface through the needles which are inserted into the surface from different directions. The microneedle transdermal transport device may be a solid micro-needle system or a hollow micro-needle system. As a non-limiting example, the solid micro-needle system may have up to a 0.5 mg capacity, with 300-1500 solid micro-needles per cm2 about 150-700 μιη tall coated with a drug. The micro-needles penetrate the stratum corneum and remain in the skin for short duration (e.g., 20 seconds to 15 minutes). In another example, the hollow micro-needle system has up to a 3 mL capacity to deliver liquid formulations using 15-20 microneedles per cm2 being approximately 950 μιη tall. The micro-needles penetrate the skin to allow the liquid formulations to flow from the device into the skin. The hollow micro-needle system may be worn from 1 to 30 minutes depending on the formulation volume and viscocity.

14409[000905] A device for subcutaneous infusion has been described by Dalton et al and is taught for example in US Patent 7,150,726, the contents of which are incorporated herein by reference in their entirety. According to Dalton, multiple needles are incorporated into the device which delivers fluid through the needles into a subcutaneous tissue. [000906] A device and a method for intradermal delivery of vaccines and gene therapeutic agents through microcannula have been described by Mikszta et al. and are taught for example in US Patent 7,473,247, the contents of which are incorporated herein by reference in their entirety. According to Mitszta, at least one hollow micro-needle is incorporated into the device which delivers the vaccines to the subject's skin to a depth of between 0.025 mm and 2 mm.

14410[000907] A method of delivering insulin has been described by Pettis et al and is taught for example in US Patent 7,722,595, the contents of which are incorporated herein by reference in their entirety. According to Pettis, two needles are incorporated into a device wherein both needles insert essentially simultaneously into the skin with the first at a depth of less than 2.5 mm to deliver insulin to intradermal compartment and the second at a depth of greater than 2.5 mm and less than 5.0 mm to deliver insulin to subcutaneous compartment.

14411[000908] Cutaneous injection delivery under suction has been described by Kochamba et al. and is taught for example in US Patent 6,896,666, the contents of which are incorporated herein by reference in their entirety. According to Kochamba, multiple needles in relative adjacency with each other are incorporated into a device which injects a fluid below the cutaneous layer.

14412[000909] A device for withdrawing or delivering a substance through the skin has been described by Down et al and is taught for example in US Patent 6,607,513, the contents of which are incorporated herein by reference in their entirety. According to Down, multiple skin penetrating members which are incorporated into the device have lengths of about 100 microns to about 2000 microns and are about 30 to 50 gauge.

14413[000910] A device for delivering a substance to the skin has been described by Palmer et al and is taught for example in US Patent 6,537,242, the contents of which are incorporated herein by reference in their entirety. According to Palmer, an array of micro-needles is incorporated into the device which uses a stretching assembly to enhance the contact of the needles with the skin and provides a more uniform delivery of the substance.

14414[000911] A perfusion device for localized drug delivery has been described by

14415Zamoyski and is taught for example in US Patent 6,468,247, the contents of which are incorporated herein by reference in their entirety. According to Zamoyski, multiple hypodermic needles are incorporated into the device which injects the contents of the hypodermics into a tissue as said hypodermics are being retracted.

14416[000912] A method for enhanced transport of drugs and biological molecules across tissue by improving the interaction between micro-needles and human skin has been described by Prausnitz et al. and is taught for example in US Patent 6,743,211, the contents of which are incorporated herein by reference in their entirety. According to Prausnitz, multiple micro-needles are incorporated into a device which is able to present a more rigid and less deformable surface to which the micro-needles are applied.

14417[000913] A device for intraorgan administration of medicinal agents has been described by Ting et al and is taught for example in US Patent 6,077,251, the contents of which are incorporated herein by reference in their entirety. According to Ting, multiple needles having side openings for enhanced administration are incorporated into a device which by extending and retracting said needles from and into the needle chamber forces a medicinal agent from a reservoir into said needles and injects said medicinal agent into a target organ.

14418[000914] A multiple needle holder and a subcutaneous multiple channel infusion port has been described by Brown and is taught for example in US Patent 4,695,273, the contents of which are incorporated herein by reference in their entirety. According to Brown, multiple needles on the needle holder are inserted through the septum of the infusion port and communicate with isolated chambers in said infusion port.

14419[000915] A dual hypodermic syringe has been described by Horn and is taught for example in US Patent 3,552,394, the contents of which are incorporated herein by reference in their entirety. According to Horn, two needles incorporated into the device are spaced apart less than 68 mm and may be of different styles and lengths, thus enabling injections to be made to different depths.

14420[000916] A syringe with multiple needles and multiple fluid compartments has been described by Hershberg and is taught for example in US Patent 3,572,336, the contents of which are incorporated herein by reference in their entirety. According to Hershberg, multiple needles are incorporated into the syringe which has multiple fluid compartments and is capable of simultaneously administering incompatible drugs which are not able to be mixed for one injection.

14421[000917] A surgical instrument for intradermal injection of fluids has been described by Eliscu et al. and is taught for example in US Patent 2,588,623, the contents of which are incorporated herein by reference in their entirety. According to Eliscu, multiple needles are incorporated into the instrument which injects fluids intradermally with a wider disperse.

14422[000918] An apparatus for simultaneous delivery of a substance to multiple breast milk ducts has been described by Hung and is taught for example in EP 1818017, the contents of which are incorporated herein by reference in their entirety. According to Hung, multiple lumens are incorporated into the device which inserts though the orifices of the ductal networks and delivers a fluid to the ductal networks.

14423[000919] A catheter for introduction of medications to the tissue of a heart or other organs has been described by Tkebuchava and is taught for example in WO2006138109, the contents of which are incorporated herein by reference in their entirety. According to Tkebuchava, two curved needles are incorporated which enter the organ wall in a flattened trajectory.

14424[000920] Devices for delivering medical agents have been described by Mckay et al. and are taught for example in WO2006118804, the content of which are incorporated herein by reference in their entirety. According to Mckay, multiple needles with multiple orifices on each needle are incorporated into the devices to facilitate regional delivery to a tissue, such as the interior disc space of a spinal disc.

14425[000921] A method for directly delivering an immunomodulatory substance into an intradermal space within a mammalian skin has been described by Pettis and is taught for example in WO2004020014, the contents of which are incorporated herein by reference in their entirety. According to Pettis, multiple needles are incorporated into a device which delivers the substance through the needles to a depth between 0.3 mm and 2 mm.

14426[000922] Methods and devices for administration of substances into at least two compartments in skin for systemic absorption and improved pharmacokinetics have been described by Pettis et al. and are taught for example in WO2003094995, the contents of which are incorporated herein by reference in their entirety. According to Pettis, multiple needles having lengths between about 300 μηι and about 5 mm are incorporated into a device which delivers to intradermal and subcutaneous tissue compartments

14427simultaneously.

14428[000923] A drug delivery device with needles and a roller has been described by Zimmerman et al. and is taught for example in WO2012006259, the contents of which are incorporated herein by reference in their entirety. According to Zimmerman, multiple hollow needles positioned in a roller are incorporated into the device which delivers the content in a reservoir through the needles as the roller rotates.

14429[000924] A drug delivery device such as a stent is known in the art and is taught for example in U.S. Pat. No. 8,333,799, U.S. Pub. Nos. US20060020329, US20040172127 and US20100161032; the contents of each of which are herein incorporated by reference in their entirety. Formulations of the polynucleotides, primary constructs, mmRNA described herein may be delivered using stents. Additionally, stents used herein may be able to deliver multiple polynucleotides, primary constructs and/or mmRNA and/or formulations at the same or varied rates of delivery. Non-limiting examples of manufacturers of stents include CORDIS® (Miami, FL) (CYPHER®), Boston Scientific Corporation (Natick, MA) (TAXUS®), Medtronic (Minneapolis, MN)

14430(ENDEAVOUR®) and Abbott (Abbott Park, IL) (XIENCE V®).

14431Methods and Devices utilizing catheters and/or lumens

14432[000925] Methods and devices using catheters and lumens may be employed to administer the mmRNA of the present invention on a single, multi- or split dosing schedule. Such methods and devices are described below.

14433[000926] A catheter-based delivery of skeletal myoblasts to the myocardium of damaged hearts has been described by Jacoby et al and is taught for example in US Patent Publication 20060263338, the contents of which are incorporated herein by reference in their entirety. According to Jacoby, multiple needles are incorporated into the device at least part of which is inserted into a blood vessel and delivers the cell composition through the needles into the localized region of the subject's heart.

14434[000927] An apparatus for treating asthma using neurotoxin has been described by Deem et al and is taught for example in US Patent Publication 20060225742, the contents of which are incorporated herein by reference in their entirety. According to Deem, multiple needles are incorporated into the device which delivers neurotoxin through the needles into the bronchial tissue.

14435[000928] A method for administering multiple-component therapies has been described by Nayak and is taught for example in US Patent 7,699,803, the contents of which are incorporated herein by reference in their entirety. According to Nayak, multiple injection cannulas may be incorporated into a device wherein depth slots may be included for controlling the depth at which the therapeutic substance is delivered within the tissue.

14436[000929] A surgical device for ablating a channel and delivering at least one therapeutic agent into a desired region of the tissue has been described by Mclntyre et al and is taught for example in US Patent 8,012,096, the contents of which are incorporated herein by reference in their entirety. According to Mclntyre, multiple needles are incorporated into the device which dispenses a therapeutic agent into a region of tissue surrounding the channel and is particularly well suited for transmyocardial revascularization operations.

14437[000930] Methods of treating functional disorders of the bladder in mammalian females have been described by Versi et al and are taught for example in US Patent 8,029,496, the contents of which are incorporated herein by reference in their entirety. According to Versi, an array of micro-needles is incorporated into a device which delivers a therapeutic agent through the needles directly into the trigone of the bladder.

14438[000931] A device and a method for delivering fluid into a flexible biological barrier have been described by Yeshurun et al. and are taught for example in US Patent

144397,998,119 (device) and 8,007,466 (method), the contents of which are incorporated herein by reference in their entirety. According to Yeshurun, the micro-needles on the device penetrate and extend into the flexible biological barrier and fluid is injected through the bore of the hollow micro-needles.

14440[000932] A method for epicardially injecting a substance into an area of tissue of a heart having an epicardial surface and disposed within a torso has been described by Bonner et al and is taught for example in US Patent 7,628,780, the contents of which are

14441incorporated herein by reference in their entirety. According to Bonner, the devices have elongate shafts and distal injection heads for driving needles into tissue and injecting medical agents into the tissue through the needles. [000933] A device for sealing a puncture has been described by Nielsen et al and is taught for example in US Patent 7,972,358, the contents of which are incorporated herein by reference in their entirety. According to Nielsen, multiple needles are incorporated into the device which delivers a closure agent into the tissue surrounding the puncture tract.

14442[000934] A method for myogenesis and angiogenesis has been described by Chiu et al. and is taught for example in US Patent 6,551,338, the contents of which are incorporated herein by reference in their entirety. According to Chiu, 5 to 15 needles having a maximum diameter of at least 1.25 mm and a length effective to provide a puncture depth of 6 to 20 mm are incorporated into a device which inserts into proximity with a myocardium and supplies an exogeneous angiogenic or myogenic factor to said myocardium through the conduits which are in at least some of said needles.

14443[000935] A method for the treatment of prostate tissue has been described by Bolmsj et al. and is taught for example in US Patent 6,524,270, the contents of which are incorporated herein by reference in their entirety. According to Bolmsj, a device comprising a catheter which is inserted through the urethra has at least one hollow tip extendible into the surrounding prostate tissue. An astringent and analgesic medicine is administered through said tip into said prostate tissue.

14444[000936] A method for infusing fluids to an intraosseous site has been described by Findlay et al. and is taught for example in US Patent 6,761,726, the contents of which are incorporated herein by reference in their entirety. According to Findlay, multiple needles are incorporated into a device which is capable of penetrating a hard shell of material covered by a layer of soft material and delivers a fluid at a predetermined distance below said hard shell of material.

14445[000937] A device for injecting medications into a vessel wall has been described by Vigil et al. and is taught for example in US Patent 5,713,863, the contents of which are incorporated herein by reference in their entirety. According to Vigil, multiple injectors are mounted on each of the flexible tubes in the device which introduces a medication fluid through a multi-lumen catheter, into said flexible tubes and out of said injectors for infusion into the vessel wall. [000938] A catheter for delivering therapeutic and/or diagnostic agents to the tissue surrounding a bodily passageway has been described by Faxon et al. and is taught for example in US Patent 5,464,395, the contents of which are incorporated herein by reference in their entirety. According to Faxon, at least one needle cannula is

14446incorporated into the catheter which delivers the desired agents to the tissue through said needles which project outboard of the catheter.

14447[000939] Balloon catheters for delivering therapeutic agents have been described by Orr and are taught for example in WO2010024871, the contents of which are incorporated herein by reference in their entirety. According to Orr, multiple needles are incorporated into the devices which deliver the therapeutic agents to different depths within the tissue. In another aspect, drug-eluting balloons may be used to deliver the formulations described herein. The drug-eluting balloons may be used in target lesion applications such as, but are not limited to, in-stent restenosis, treating lesion in tortuous vessels, bifurcation lesions, femoral/popliteal lesions and below the knee lesions.

14448[000940] A device for deliverying therapeutic agents (e.g., polynucleotides, primary constructs or mmRNA) to tissue disposed about a lumin has been described by Perry et al. and is taught for example in U.S. Pat. Pub. US20100125239, the contents of which are herein incorporated by reference in their entirety. According to Perry, the catheter has a balloon which may be coated with a therapeutic agent by methods known in the art and described in Perry. When the balloon expands, the therapeutic agent will contact the surrounding tissue. The device may additionally have a heat source to change the temperature of the coating on the balloon to release the thereapeutic agent to the tissue. Methods and Devices utilizing electrical current

14449[000941] Methods and devices utilizing electric current may be employed to deliver the mmRNA of the present invention according to the single, multi- or split dosing regimens taught herein. Such methods and devices are described below.

14450[000942] An electro collagen induction therapy device has been described by Marquez and is taught for example in US Patent Publication 20090137945, the contents of which are incorporated herein by reference in their entirety. According to Marquez, multiple needles are incorporated into the device which repeatedly pierce the skin and draw in the skin a portion of the substance which is applied to the skin first. [000943] An electrokinetic system has been described by Etheredge et al. and is taught for example in US Patent Publication 20070185432, the contents of which are incorporated herein by reference in their entirety. According to Etheredge, micro-needles are incorporated into a device which drives by an electrical current the medication through the needles into the targeted treatment site.

14451[000944] An iontophoresis device has been described by Matsumura et al. and is taught for example in US Patent 7,437,189, the contents of which are incorporated herein by reference in their entirety. According to Matsumura, multiple needles are incorporated into the device which is capable of delivering ionizable drug into a living body at higher speed or with higher efficiency.

14452[000945] Intradermal delivery of biologically active agents by needle-free injection and electroporation has been described by Hoffmann et al and is taught for example in US Patent 7,171,264, the contents of which are incorporated herein by reference in their entirety. According to Hoffmann, one or more needle-free injectors are incorporated into an electroporation device and the combination of needle-free injection and

14453electroporation is sufficient to introduce the agent into cells in skin, muscle or mucosa.

14454[000946] A method for electropermeabilization-mediated intracellular delivery has been described by Lundkvist et al. and is taught for example in US Patent 6,625,486, the contents of which are incorporated herein by reference in their entirety. According to Lundkvist, a pair of needle electrodes is incorporated into a catheter. Said catheter is positioned into a body lumen followed by extending said needle electrodes to penetrate into the tissue surrounding said lumen. Then the device introduces an agent through at least one of said needle electrodes and applies electric field by said pair of needle electrodes to allow said agent pass through the cell membranes into the cells at the treatment site.

14455[000947] A delivery system for transdermal immunization has been described by Levin et al. and is taught for example in WO2006003659, the contents of which are

14456incorporated herein by reference in their entirety. According to Levin, multiple electrodes are incorporated into the device which applies electrical energy between the electrodes to generate micro channels in the skin to facilitate transdermal delivery. [000948] A method for delivering RF energy into skin has been described by

14457Schomacker and is taught for example in WO2011163264, the contents of which are incorporated herein by reference in their entirety. According to Schomacker, multiple needles are incorporated into a device which applies vacuum to draw skin into contact with a plate so that needles insert into skin through the holes on the plate and deliver RF energy.

14458VII. Definitions

14459[000949] At various places in the present specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term "Ci_6 alkyl" is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.

14460[000950] About: As used herein, the term "about" means +/- 10% of the recited value.

14461[000951] Administered in combination: As used herein, the term "administered in combination" or "combined administration" means that two or more agents are administered to a subject at the same time or within an interval such that there may be an overlap of an effect of each agent on the patient. In some embodiments, they are administered within about 60, 30, 15, 10, 5, or 1 minute of one another. In some embodiments, the administrations of the agents are spaced sufficiently closely together such that a combinatorial {e.g., a synergistic) effect is achieved.

14462[000952] Animal: As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to humans at any stage of development. In some embodiments, "animal" refers to non-human animals at any stage of development. In certain embodiments, the non-human animal is a mammal {e.g. , a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and worms. In some embodiments, the animal is a transgenic animal, genetically-engineered animal, or a clone.

14463[000953] Antigens of interest or desired antigens: As used herein, the terms "antigens of interest" or "desired antigens" include those proteins and other biomolecules provided herein that are immunospecifically bound by the antibodies and fragments, mutants, variants, and alterations thereof described herein. Examples of antigens of interest include, but are not limited to, insulin, insulin-like growth factor, hGH, tPA, cytokines, such as interleukins (IL), e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, interferon (IFN) alpha, IFN beta, IFN gamma, IFN omega or IFN tau, tumor necrosis factor (TNF), such as TNF alpha and TNF beta, TNF gamma, TRAIL; G-CSF, GM-CSF, M-CSF, MCP-1 and VEGF.

14464[000954] Approximately: As used herein, the term "approximately" or "about," as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

14465[000955] Associated with: As used herein, the terms "associated with," "conjugated," "linked," "attached," and "tethered," when used with respect to two or more moieties, means that the moieties are physically associated or connected with one another, either directly or via one or more additional moieties that serves as a linking agent, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. An

14466"association" need not be strictly through direct covalent chemical bonding. It may also suggest ionic or hydrogen bonding or a hybridization based connectivity sufficiently stable such that the "associated" entities remain physically associated.

14467[000956] Bifunctional: As used herein, the term "bifunctional" refers to any substance, molecule or moiety which is capable of or maintains at least two functions. The functions may effect the same outcome or a different outcome. The structure that produces the function may be the same or different. For example, bifunctional modified RNAs of the present invention may encode a cytotoxic peptide (a first function) while those nucleosides which comprise the encoding RNA are, in and of themselves, cytotoxic (second function). In this example, delivery of the bifunctional modified RNA to a cancer cell would produce not only a peptide or protein molecule which may ameliorate or treat the cancer but would also deliver a cytotoxic payload of nucleosides to the cell should degradation, instead of translation of the modified RNA, occur.

14468[000957] Biocompatible: As used herein, the term "biocompatible" means compatible with living cells, tissues, organs or systems posing little to no risk of injury, toxicity or rejection by the immune system.

14469[000958] Biodegradable: As used herein, the term "biodegradable" means capable of being broken down into innocuous products by the action of living things.

14470[000959] Biologically active: As used herein, the phrase "biologically active" refers to a characteristic of any substance that has activity in a biological system and/or organism.

14471For instance, a substance that, when administered to an organism, has a biological effect on that organism, is considered to be biologically active. In particular embodiments, a polynucleotide, primary construct or mmRNA of the present invention may be considered biologically active if even a portion of the polynucleotide, primary construct or mmRNA is biologically active or mimics an activity considered biologically relevant.

14472[000960] Chemical terms: The following provides the definition of various chemical terms from "acyl" to "thiol."

14473[000961] The term "acyl," as used herein, represents a hydrogen or an alkyl group (e.g., a haloalkyl group), as defined herein, that is attached to the parent molecular group through a carbonyl group, as defined herein, and is exemplified by formyl (i.e., a carboxyaldehyde group), acetyl, propionyl, butanoyl and the like. Exemplary

14474unsubstituted acyl groups include from 1 to 7, from 1 to 11, or from 1 to 21 carbons. In some embodiments, the alkyl group is further substituted with 1, 2, 3, or 4 substituents as described herein.

14475[000962] The term "acylamino," as used herein, represents an acyl group, as defined herein, attached to the parent molecular group though an amino group, as defined herein (i.e., -N(RN1)-C(0)-R, where R is H or an optionally substituted C1-6, C1-10, or Ci_2o alkyl group and RN1 is as defined herein). Exemplary unsubstituted acylamino groups include from 1 to 41 carbons (e.g., from 1 to 7, from 1 to 13, from 1 to 21, from 2 to 7, from 2 to 13, from 2 to 21, or from 2 to 41 carbons). In some embodiments, the alkyl group is further substituted with 1, 2, 3, or 4 substituents as described herein, and/or the amino group is -NH2 or -NHR , wherein R is, independently, OH, N02, NH2, NR 2, S02ORN2, S02RN2, SORN2, alkyl, or aryl, and each RN2 can be H, alkyl, or aryl.

14476[000963] The term "acyloxy," as used herein, represents an acyl group, as defined herein, attached to the parent molecular group though an oxygen atom (i.e., -0-C(0)-R, where R is H or an optionally substituted Ci_6, Ci_i0, or Ci_20 alkyl group). Exemplary unsubstituted acyloxy groups include from 1 to 21 carbons (e.g., from 1 to 7 or from 1 to 1 1 carbons). In some embodiments, the alkyl group is further substituted with 1 , 2, 3, or 4 substituents as described herein, and/or the amino group is -NH2 or -NHRN1, wherein RN1 is, independently, OH, N02, NH2, NRN22, S02ORN2, S02RN2, SORN2, alkyl, or aryl, and each RN2 can be H, alkyl, or aryl.

14477[000964] The term "alkaryl," as used herein, represents an aryl group, as defined herein, attached to the parent molecular group through an alkylene group, as defined herein. Exemplary unsubstituted alkaryl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as Ci_6 alk-C6-io aryl, Ci_io alk-C6-io aryl, or Ci_2o alk-C6-io aryl). In some embodiments, the alkylene and the aryl each can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein for the respective groups. Other groups preceded by the prefix "alk-" are defined in the same manner, where "alk" refers to a Ci_6 alkylene, unless otherwise noted, and the attached chemical structure is as defined herein.

14478[000965] The term "alkcycloalkyl" represents a cycloalkyl group, as defined herein, attached to the parent molecular group through an alkylene group, as defined herein (e.g., an alkylene group of from 1 to 4, from 1 to 6, from 1 to 10, or form 1 to 20 carbons). In some embodiments, the alkylene and the cycloalkyl each can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein for the respective group.

14479[000966] The term "alkenyl," as used herein, represents monovalent straight or branched chain groups of, unless otherwise specified, from 2 to 20 carbons (e.g., from 2 to 6 or from 2 to 10 carbons) containing one or more carbon-carbon double bonds and is exemplified by ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, and the like. Alkenyls include both cis and trans isomers. Alkenyl groups may be optionally substituted with 1 , 2, 3, or 4 substituent groups that are selected, independently, from amino, aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein.

14480[000967] The term "alkenyloxy" represents a chemical substituent of formula -OR, where R is a C2-20 alkenyl group (e.g., C2-6 or C2-10 alkenyl), unless otherwise specified. Exemplary alkenyloxy groups include ethenyloxy, propenyloxy, and the like. In some embodiments, the alkenyl group can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein (e.g., a hydroxy group).

14481[000968] The term "alkheteroaryl" refers to a heteroaryl group, as defined herein, attached to the parent molecular group through an alkylene group, as defined herein. Exemplary unsubstituted alkheteroaryl groups are from 2 to 32 carbons (e.g., from 2 to 22, from 2 to 18, from 2 to 17, from 2 to 16, from 3 to 15, from 2 to 14, from 2 to 13, or from 2 to 12 carbons, such as Ci_6 alk-Ci_i2 heteroaryl, C1-10 alk-Ci_i2 heteroaryl, or Ci_2o alk-C i_i2 heteroaryl). In some embodiments, the alkylene and the heteroaryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective group. Alkheteroaryl groups are a subset of alkheterocyclyl groups.

14482[000969] The term "alkheterocyclyl" represents a heterocyclyl group, as defined herein, attached to the parent molecular group through an alkylene group, as defined herein. Exemplary unsubstituted alkheterocyclyl groups are from 2 to 32 carbons (e.g., from 2 to 22, from 2 to 18, from 2 to 17, from 2 to 16, from 3 to 15, from 2 to 14, from 2 to 13, or from 2 to 12 carbons, such as Ci_6 alk-Ci_i2 heterocyclyl, C1-10 alk-Ci_i2 heterocyclyl, or Ci_2o alk-Ci_i2 heterocyclyl). In some embodiments, the alkylene and the heterocyclyl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective group.

14483[000970] The term "alkoxy" represents a chemical substituent of formula -OR, where R is a Ci_2o alkyl group (e.g., Ci_6 or C1-10 alkyl), unless otherwise specified. Exemplary alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t- butoxy, and the like. In some embodiments, the alkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein (e.g., hydroxy or alkoxy).

14484[000971] The term "alkoxyalkoxy" represents an alkoxy group that is substituted with an alkoxy group. Exemplary unsubstituted alkoxyalkoxy groups include between 2 to 40 carbons (e.g., from 2 to 12 or from 2 to 20 carbons, such as Ci_6 alkoxy-Ci_6 alkoxy, C1-10 alkoxy-Ci_io alkoxy, or Ci_2o alkoxy-Ci_2o alkoxy). In some embodiments, the each alkoxy group can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein.

14485[000972] The term "alkoxyalkyl" represents an alkyl group that is substituted with an alkoxy group. Exemplary unsubstituted alkoxyalkyl groups include between 2 to 40 carbons (e.g., from 2 to 12 or from 2 to 20 carbons, such as Ci_6 alkoxy-Ci_6 alkyl, C1-10 alkoxy-Ci_io alkyl, or Ci_2o alkoxy-Ci_2o alkyl). In some embodiments, the alkyl and the alkoxy each can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein for the respective group.

14486[000973] The term "alkoxycarbonyl," as used herein, represents an alkoxy, as defined herein, attached to the parent molecular group through a carbonyl atom (e.g., -C(0)-OR, where R is H or an optionally substituted Ci_6, C1-10, or Ci_2o alkyl group). Exemplary unsubstituted alkoxycarbonyl include from 1 to 21 carbons (e.g., from 1 to 1 1 or from 1 to 7 carbons). In some embodiments, the alkoxy group is further substituted with 1 , 2, 3, or 4 substituents as described herein.

14487[000974] The term "alkoxycarbonylalkoxy," as used herein, represents an alkoxy group, as defined herein, that is substituted with an alkoxycarbonyl group, as defined herein (e.g., -0-alkyl-C(0)-OR, where R is an optionally substituted C1-6, C1-10, or Ci_2o alkyl group). Exemplary unsubstituted alkoxycarbonylalkoxy include from 3 to 41 carbons (e.g., from 3 to 10, from 3 to 13, from 3 to 17, from 3 to 21 , or from 3 to 31 carbons, such as Ci_6 alkoxycarbonyl-Ci_6 alkoxy, C1-10 alkoxycarbonyl-Ci_i0 alkoxy, or Ci_20

14488alkoxycarbonyl-Ci_2o alkoxy). In some embodiments, each alkoxy group is further independently substituted with 1 , 2, 3, or 4 substituents, as described herein (e.g., a hydroxy group).

14489[000975] The term "alkoxycarbonylalkyl," as used herein, represents an alkyl group, as defined herein, that is substituted with an alkoxycarbonyl group, as defined herein (e.g., - alkyl-C(0)-OR, where R is an optionally substituted Ci_2o, C1-10, or Ci_6 alkyl group). Exemplary unsubstituted alkoxycarbonylalkyl include from 3 to 41 carbons (e.g., from 3 to 10, from 3 to 13, from 3 to 17, from 3 to 21 , or from 3 to 31 carbons, such as Ci_6 alkoxycarbonyl-Ci_6 alkyl, C1-10 alkoxycarbonyl-Ci_io alkyl, or Ci_2o alkoxycarbonyl-Ci_2o alkyl). In some embodiments, each alkyl and alkoxy group is further independently substituted with 1, 2, 3, or 4 substituents as described herein (e.g., a hydroxy group).

14490[000976] The term "alkyl," as used herein, is inclusive of both straight chain and branched chain saturated groups from 1 to 20 carbons (e.g., from 1 to 10 or from 1 to 6), unless otherwise specified. Alkyl groups are exemplified by methyl, ethyl, n- and iso- propyl, n-, sec-, iso- and tert-butyl, neopentyl, and the like, and may be optionally substituted with one, two, three, or, in the case of alkyl groups of two carbons or more, four substituents independently selected from the group consisting of: (1) Ci_6 alkoxy; (2) Ci_6 alkylsulfinyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., -NH2) or a substituted amino (i.e., -N(RN1)2, where RN1 is as defined for amino); (4) C6-1o aryl-Ci_6 alkoxy; (5) azido; (6) halo; (7) (C2_9 heterocyclyl)oxy; (8) hydroxy; (9) nitro; (10) oxo (e.g., carboxyaldehyde or acyl); (11) Ci_7 spirocyclyl; (12) thioalkoxy; (13) thiol; (14) - C02RA , where RA is selected from the group consisting of (a) Ci_20 alkyl (e.g., Ci_6 alkyl), (b) C2_20 alkenyl (e.g., C2_6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) Ci_6 alk-C6-10 aryl, (f) amino-Ci_20 alkyl, (g) polyethylene glycol of -(CH2)s2(OCH2CH2)si(CH2)s3OR', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h) amino-polyethylene glycol of - NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; (15) -C(0)NR R , where each of R and R is, independently, selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6-io aryl, and (d) Ci_6 alk-C6-io aryl; (16) -S02RD , where RD is selected from the group consisting of (a) Ci_6 alkyl, (b) C6_io aryl, (c) Ci_6 alk-C6_io aryl, and (d) hydroxy; (17) -S02NRE RF , where each of RE and RF is, independently, selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6-io aryl and (d) Ci_6 alk-C6- io aryl; (18) -C(0)R , where R is selected from the group consisting of (a) Ci_2o alkyl (e.g., Ci_6 alkyl), (b) C2_20 alkenyl (e.g., C2_6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) Ci_6 alk-C6_io aryl, (f) amino-Ci_20 alkyl, (g) polyethylene glycol of -

14491(CH2)s2(OCH2CH2)si(CH2)s3OR', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3,

14492independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; (19) -NRH C(0)R! , wherein RH' is selected from the group consisting of (al) hydrogen and (bl) Ci_6 alkyl, and R1 is selected from the group consisting of (a2) Ci_20 alkyl (e.g., Ci_6 alkyl), (b2) C2_20 alkenyl (e.g., C2_6 alkenyl), (c2) C6-io aryl, (d2) hydrogen, (e2) Ci_6 alk-C6-io aryl, (f2) amino-Ci_20 alkyl, (g2)

14493polyethylene glycol of -(CH2)s2(OCH2CH2)si(CH2)S30R' , wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h2) amino-polyethylene glycol of -

14494NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; (20) -NRJ C(0)ORK , wherein RJ is selected from the group consisting of (al) hydrogen and (bl) Ci_6 alkyl, and RK is selected from the group consisting of (a2) Ci_2o alkyl (e.g., Ci_6 alkyl), (b2) C2_ 20 alkenyl (e.g., C2_6 alkenyl), (c2) C6-10 aryl, (d2) hydrogen, (e2) Ci_6 alk-C6_io aryl, (f2) amino-Ci_2o alkyl, (g2) polyethylene glycol of -(CH2)s2(OCH2CH2)si(CH2)s3OR', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h2) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; and (21) amidine. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a Ci-alkaryl can be further substituted with an oxo group to afford the respective aryloyl substituent.

14495[000977] The term "alkylene" and the prefix "alk-," as used herein, represent a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms, and is exemplified by methylene, ethylene, isopropylene, and the like. The term "Cx_y alkylene" and the prefix "Cx_y alk-" represent alkylene groups having between x and y carbons. Exemplary values for x are 1 , 2, 3, 4, 5, and 6, and exemplary values for y are 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 (e.g., Ci_6, Ci_io, C2_2o, C2_6, C2_io, or C2_2o alkylene). In some embodiments, the alkylene can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein for an alkyl group.

14496[000978] The term "alkylsulfmyl," as used herein, represents an alkyl group attached to the parent molecular group through an -S(O)- group. Exemplary unsubstituted alkylsulfmyl groups are from 1 to 6, from 1 to 10, or from 1 to 20 carbons. In some embodiments, the alkyl group can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein.

14497[000979] The term "alkylsulfinylalkyl," as used herein, represents an alkyl group, as defined herein, substituted by an alkylsulfmyl group. Exemplary unsubstituted alkylsulfinylalkyl groups are from 2 to 12, from 2 to 20, or from 2 to 40 carbons. In some embodiments, each alkyl group can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein.

14498[000980] The term "alkynyl," as used herein, represents monovalent straight or branched chain groups from 2 to 20 carbon atoms (e.g., from 2 to 4, from 2 to 6, or from 2 to 10 carbons) containing a carbon-carbon triple bond and is exemplified by ethynyl, 1- propynyl, and the like. Alkynyl groups may be optionally substituted with 1 , 2, 3, or 4 substituent groups that are selected, independently, from aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein.

14499[000981] The term "alkynyloxy" represents a chemical substituent of formula -OR, where R is a C2_2o alkynyl group (e.g., C2_6 or C2_io alkynyl), unless otherwise specified. Exemplary alkynyloxy groups include ethynyloxy, propynyloxy, and the like. In some embodiments, the alkynyl group can be further substituted with 1 , 2, 3, or 4 substituent groups as defined herein (e.g., a hydroxy group).

14500[000982] The term "amidine," as used herein, represents a -C(=NH)NH2 group.

14501[000983] The term "amino," as used herein, represents -N(RN1)2, wherein each RN1 is, independently, H, OH, N02, N(RN2)2, S02ORN2, S02RN2, SORN2, an N-protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, alkaryl, cycloalkyl, alkcycloalkyl, carboxyalkyl, sulfoalkyl, heterocyclyl (e.g., heteroaryl), or alkheterocyclyl (e.g., alkheteroaryl), wherein each of these recited RN1 groups can be optionally substituted, as defined herein for each group; or two RN1 combine to form a heterocyclyl or an N-protecting group, and wherein each RN2 is, independently, H, alkyl, or aryl. The amino groups of the invention can be an unsubstituted amino (i.e., -NH2) or a substituted amino (i.e., -N(RN1)2). In a preferred embodiment, amino is -NH2 or -NHRN1, wherein RN1 is, independently, OH, N02, NH2, NRN22, S02ORN2, S02RN2, SORN2, alkyl, carboxyalkyl, sulfoalkyl, or aryl, and each RN2 can be H, Ci_2o alkyl (e.g., Ci_6 alkyl), or C6-1o aryl.

14502[000984] The term "amino acid," as described herein, refers to a molecule having a side chain, an amino group, and an acid group (e.g., a carboxy group of-C02H or a sulfo group of -SO3H), wherein the amino acid is attached to the parent molecular group by the side chain, amino group, or acid group (e.g., the side chain). In some embodiments, the amino acid is attached to the parent molecular group by a carbonyl group, where the side chain or amino group is attached to the carbonyl group. Exemplary side chains include an optionally substituted alkyl, aryl, heterocyclyl, alkaryl, alkheterocyclyl, aminoalkyl, carbamoylalkyl, and carboxyalkyl. Exemplary amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, hydroxynorvaline, isoleucine, leucine, lysine, methionine, norvaline, ornithine, phenylalanine, proline, pyrrolysine, selenocysteine, serine, taurine, threonine, tryptophan, tyrosine, and valine. Amino acid groups may be optionally substituted with one, two, three, or, in the case of amino acid groups of two carbons or more, four substituents independently selected from the group consisting of: (1) Ci_6 alkoxy; (2) Ci_6

14503alkylsulfinyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., -NH2) or a substituted amino (i.e., -N(RN1)2, where RN1 is as defined for amino); (4) C6_io aryl-Ci_6 alkoxy; (5) azido; (6) halo; (7) (C2_9 heterocyclyl)oxy; (8) hydroxy; (9) nitro; (10) oxo (e.g., carboxyaldehyde or acyl); (11) Ci_7 spirocyclyl; (12) thioalkoxy; (13) thiol; (14) - C02RA , where RA is selected from the group consisting of (a) Ci_2o alkyl (e.g., Ci_6 alkyl), (b) C2_20 alkenyl (e.g., C2_6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) Ci_6 alk-C6-10 aryl, (f) amino-Ci_20 alkyl, (g) polyethylene glycol of -(CH2)s2(OCH2CH2)si(CH2)s3OR', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h) amino-polyethylene glycol of - NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; (15) -C(0)NR R , where each of R and R is, independently, selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6_io aryl, and (d) Ci_6 alk-C6_io aryl; (16) -S02RD , where RD is selected from the group consisting of (a) Ci_6 alkyl, (b) C6-io aryl, (c) Ci_6 alk-C6-io aryl, and (d) hydroxy; (17) -S02NRE RF , where each of RE and RF is, independently, selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6-io aryl and (d) Ci_6 alk-C6- io aryl; (18) -C(0)R , where R is selected from the group consisting of (a) Ci_20 alkyl (e.g., Ci_6 alkyl), (b) C2_20 alkenyl (e.g., C2_6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) Ci_6 alk-C6-io aryl, (f) amino-Ci_2o alkyl, (g) polyethylene glycol of -

14504(CH2)s2(OCH2CH2)si(CH2)s3OR', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3,

14505independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; (19) -NRH C(0)R! , wherein RH' is selected from the group consisting of (al) hydrogen and (bl) Ci_6 alkyl, and R1 is selected from the group consisting of (a2) Ci_2o alkyl (e.g., Ci_6 alkyl), (b2) C2_2o alkenyl (e.g., C2_6 alkenyl), (c2) C6-io aryl, (d2) hydrogen, (e2) Ci_6 alk-C6_io aryl, (f2) amino-Ci_20 alkyl, (g2)

14506polyethylene glycol of -(CH2)s2(OCH2CH2)si(CH2)s3OR', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h2) amino-poly ethylene glycol of -

14507NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; (20) -NRJ C(0)ORK , wherein RJ is selected from the group consisting of (al) hydrogen and (bl) Ci_6 alkyl, and RK is selected from the group consisting of (a2) Ci_2o alkyl (e.g., Ci_6 alkyl), (b2) C2_ 20 alkenyl (e.g., C2-e alkenyl), (c2) C6-10 aryl, (d2) hydrogen, (e2) Ci_6 alk-C6_io aryl, (f2) amino-Ci_2o alkyl, (g2) polyethylene glycol of -(CH2)S2(OCH2CH2)si(CH2)S30R', wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or Ci_2o alkyl, and (h2) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH20)si(CH2)s3NRN1, wherein si is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted Ci_6 alkyl; and (21) amidine. In some embodiments, each of these groups can be further substituted as described herein.

14508[000985] The term "aminoalkoxy," as used herein, represents an alkoxy group, as defined herein, substituted by an amino group, as defined herein. The alkyl and amino each can be further substituted with 1 , 2, 3, or 4 substituent groups as described herein for the respective group (e.g., CC"2RA , where RA is selected from the group consisting of (a) Ci_6 alkyl, (b) C6-io aryl, (c) hydrogen, and (d) Ci_6 alk-C6-io aryl, e.g., carboxy).

14509[000986] The term "aminoalkyl," as used herein, represents an alkyl group, as defined herein, substituted by an amino group, as defined herein. The alkyl and amino each can be further substituted with 1 , 2, 3, or 4 substituent groups as described herein for the respective group (e.g., CC"2RA , where RA is selected from the group consisting of (a) Ci_ 6 alkyl, (b) C6-io aryl, (c) hydrogen, and (d) Ci_6 alk-C6-io aryl, e.g., carboxy).

14510[000987] The term "aryl," as used herein, represents a mono-, bicyclic, or multicyclic carbocyclic ring system having one or two aromatic rings and is exemplified by phenyl, naphthyl, 1 ,2-dihydronaphthyl, 1 ,2,3,4-tetrahydronaphthyl, anthracenyl, phenanthrenyl, fluorenyl, indanyl, indenyl, and the like, and may be optionally substituted with 1 , 2, 3, 4, or 5 substituents independently selected from the group consisting of: (1) Ci_7 acyl (e.g., carboxyaldehyde); (2) Ci_2o alkyl (e.g., Ci_6 alkyl, Ci_6 alkoxy-Ci_6 alkyl, Ci_6

14511alkylsulfmyl-Ci_6 alkyl, amino-Ci_6 alkyl, azido-Ci_6 alkyl, (carboxyaldehyde)-Ci_6 alkyl, halo-Ci_6 alkyl (e.g., perfluoroalkyl), hydroxy-Ci_6 alkyl, nitro-Ci_6 alkyl, or Ci_6

14512thioalkoxy-Ci_6 alkyl); (3) Ci_2o alkoxy (e.g., Ci_6 alkoxy, such as perfluoroalkoxy); (4) Ci_6 alkylsulfinyl; (5) C6-1o aryl; (6) amino; (7) Ci_6 alk-C6-io aryl; (8) azido; (9) C3-8 cycloalkyl; (10) Ci_6 alk-C3_8 cycloalkyl; (1 1) halo; (12) C1-12 heterocyclyl (e.g., C1-12 heteroaryl); (13) (C1-12 heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) Ci_2o thioalkoxy (e.g., Ci_6 thioalkoxy); (17) -(CH2)qC02RA , where q is an integer from zero to four, and RA is selected from the group consisting of (a) Ci_6 alkyl, (b) C6-1o aryl, (c) hydrogen, and (d) Ci_6 alk-C6_io aryl; (18) -(CH2)qCONR R , where q is an integer from zero to four and where R and R are independently selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6_io aryl, and (d) Ci_6 alk-C6-io aryl; (19) -(CH2)qS02RD', where q is an integer from zero to four and where RD is selected from the group consisting of (a) alkyl, (b) C6_i0 aryl, and (c) alk-C6_i0 aryl; (20) -(CH2)qS02NRE'RF', where q is an integer from zero to four and where each of RE and RF is, independently, selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6-1o aryl, and (d) Ci_6 alk-C6-io aryl; (21) thiol; (22) C6-io aryloxy; (23) C3-8 cycloalkoxy; (24) C6-1o aryl-Ci_

145136 alkoxy; (25) Ci_6 alk-Ci_i2 heterocyclyl (e.g., Ci_6 alk-Ci_i2 heteroaryl); (26) C2_20 alkenyl; and (27) C2_2o alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a Ci-alkaryl or a Ci-alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.

14514[000988] The term "arylalkoxy," as used herein, represents an alkaryl group, as defined herein, attached to the parent molecular group through an oxygen atom. Exemplary unsubstituted alkoxyalkyl groups include from 7 to 30 carbons (e.g., from 7 to 16 or from

145157 to 20 carbons, such as C6-1o aryl-Ci_6 alkoxy, C6-io aryl-Ci_io alkoxy, or C6-1o aryl-Ci_2o alkoxy). In some embodiments, the arylalkoxy group can be substituted with 1 , 2, 3, or 4 substituents as defined herein [000989] The term "aryloxy" represents a chemical substituent of formula -OR', where R' is an aryl group of 6 to 18 carbons, unless otherwise specified. In some embodiments, the aryl group can be substituted with 1, 2, 3, or 4 substituents as defined herein.

14516[000990] The term "aryloyl," as used herein, represents an aryl group, as defined herein, that is attached to the parent molecular group through a carbonyl group. Exemplary unsubstituted aryloyl groups are of 7 to 11 carbons. In some embodiments, the aryl group can be substituted with 1, 2, 3, or 4 substituents as defined herein.

14517[000991] The term "azido" represents an -N3 group, which can also be represented as - N=N=N.

14518[000992] The term "bicyclic," as used herein, refer to a structure having two rings, which may be aromatic or non-aromatic. Bicyclic structures include spirocyclyl groups, as defined herein, and two rings that share one or more bridges, where such bridges can include one atom or a chain including two, three, or more atoms. Exemplary bicyclic groups include a bicyclic carbocyclyl group, where the first and second rings are carbocyclyl groups, as defined herein; a bicyclic aryl groups, where the first and second rings are aryl groups, as defined herein; bicyclic heterocyclyl groups, where the first ring is a heterocyclyl group and the second ring is a carbocyclyl (e.g., aryl) or heterocyclyl (e.g., heteroaryl) group; and bicyclic heteroaryl groups, where the first ring is a heteroaryl group and the second ring is a carbocyclyl (e.g., aryl) or heterocyclyl (e.g., heteroaryl) group. In some embodiments, the bicyclic group can be substituted with 1, 2, 3, or 4 substituents as defined herein for cycloalkyl, heterocyclyl, and aryl groups.

14519[000993] The terms "carbocyclic" and "carbocyclyl," as used herein, refer to an optionally substituted C3-12 monocyclic, bicyclic, or tricyclic structure in which the rings, which may be aromatic or non-aromatic, are formed by carbon atoms. Carbocyclic structures include cycloalkyl, cycloalkenyl, and aryl groups.

14520[000994] The term "carbamoyl," as used herein, represents -C(0)-N(RN1)2, where the meaning of each RN1 is found in the definition of "amino" provided herein.

14521[000995] The term "carbamoylalkyl," as used herein, represents an alkyl group, as defined herein, substituted by a carbamoyl group, as defined herein. The alkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein. [000996] The term "carbamyl," as used herein, refers to a carbamate group having the structure

14522-NRN1C(=0)OR or -OC(=0)N(RN1)2, where the meaning of each RN1 is found in the definition of "amino" provided herein, and R is alkyl, cycloalkyl , alkcycloalkyl, aryl, alkaryl, heterocyclyl (e.g., heteroaryl), or alkheterocyclyl (e.g., alkheteroaryl), as defined herein.

14523[000997] The term "carbonyl," as used herein, represents a C(O) group, which can also be represented as C=0.

14524[000998] The term "carboxyaldehyde" represents an acyl group having the structure - CHO.

14525[000999] The term "carboxy," as used herein, means -C02H.

14526[0001000] The term "carboxyalkoxy," as used herein, represents an alkoxy group, as defined herein, substituted by a carboxy group, as defined herein. The alkoxy group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for the alkyl group.

14527[0001001] The term "carboxyalkyl," as used herein, represents an alkyl group, as defined herein, substituted by a carboxy group, as defined herein. The alkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein.

14528[0001002] The term "cyano," as used herein, represents an -CN group.

14529[0001003] The term "cycloalkoxy" represents a chemical substituent of formula -OR, where R is a C3_8 cycloalkyl group, as defined herein, unless otherwise specified. The cycloalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein. Exemplary unsubstituted cycloalkoxy groups are from 3 to 8 carbons. In some embodiment, the cycloalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein.

14530[0001004] The term "cycloalkyl," as used herein represents a monovalent saturated or unsaturated non-aromatic cyclic hydrocarbon group from three to eight carbons, unless otherwise specified, and is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1.]heptyl, and the like. When the cycloalkyl group includes one carbon-carbon double bond, the cycloalkyl group can be referred to as a "cycloalkenyl" group. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, and the like. The cycloalkyl groups of this invention can be optionally substituted with: (1) Ci_7 acyl (e.g., carboxyaldehyde); (2) Ci_2o alkyl (e.g., Ci_6 alkyl, Ci_ 6 alkoxy-Ci_6 alkyl, Ci_6 alkylsulfinyl-Ci_6 alkyl, amino-Ci_6 alkyl, azido-Ci_6 alkyl, (carboxyaldehyde)-Ci_6 alkyl, halo-Ci_6 alkyl (e.g., perfluoroalkyl), hydroxy-Ci_6 alkyl, nitro-Ci_6 alkyl, or Ci_6 thioalkoxy-Ci_6 alkyl); (3) Ci_2o alkoxy (e.g., Ci_6 alkoxy, such as perfluoroalkoxy); (4) Ci_6 alkylsulfinyl; (5) C6-1o aryl; (6) amino; (7) Ci_6 alk-C6-io aryl; (8) azido; (9) C3_8 cycloalkyl; (10) Ci_6 alk-C3_8 cycloalkyl; (11) halo; (12) CM2 heterocyclyl (e.g., C1-12 heteroaryl); (13) (C1-12 heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) Ci_2o thioalkoxy (e.g., Ci_6 thioalkoxy); (17) -(CH2)qC02RA , where q is an integer from zero to four, and RA is selected from the group consisting of (a) Ci_6 alkyl,

14531(b) Ce-io aryl, (c) hydrogen, and (d) Ci_6 alk-Ce-io aryl; (18) -(CH2)qCONRB'Rc', where q is an integer from zero to four and where R and R are independently selected from the group consisting of (a) hydrogen, (b) C6_io alkyl, (c) C6_io aryl, and (d) Ci_6 alk-C6_io aryl; (19) -(CH2)qS02RD , where q is an integer from zero to four and where RD is selected from the group consisting of (a) C6-io alkyl, (b) C6-io aryl, and (c) Ci_6 alk-C6-io aryl; (20) -(CH2)qS02NRE RF , where q is an integer from zero to four and where each of RE and RF is, independently, selected from the group consisting of (a) hydrogen, (b) C6_io alkyl,

14532(c) C6-io aryl, and (d) Ci_6 alk-C6-10 aryl; (21) thiol; (22) C6-10 aryloxy; (23) C3_8 cycloalkoxy; (24) C6-io aryl-Ci_6 alkoxy; (25) Ci_6 alk-Ci_i2 heterocyclyl (e.g., Ci_6 alk-Ci_ 12 heteroaryl); (26) oxo; (27) C2_2o alkenyl; and (28) C2_2o alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a Ci-alkaryl or a Ci-alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.

14533[0001005] The term "diastereomer," as used herein means stereoisomers that are not mirror images of one another and are non-superimposable on one another.

14534[0001006] The term "effective amount" of an agent, as used herein, is that amount sufficient to effect beneficial or desired results, for example, clinical results, and, as such, an "effective amount" depends upon the context in which it is being applied. For example, in the context of administering an agent that treats cancer, an effective amount of an agent is, for example, an amount sufficient to achieve treatment, as defined herein, of cancer, as compared to the response obtained without administration of the agent. [0001007] The term "enantiomer," as used herein, means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e., at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.

14535[0001008] The term "halo," as used herein, represents a halogen selected from bromine, chlorine, iodine, or fluorine.

14536[0001009] The term "haloalkoxy," as used herein, represents an alkoxy group, as defined herein, substituted by a halogen group (i.e., F, CI, Br, or I). A haloalkoxy may be substituted with one, two, three, or, in the case of alkyl groups of two carbons or more, four halogens. Haloalkoxy groups include perfluoroalkoxys (e.g., -OCF3), -OCHF2, - OCH2F, -OCCl3, -OCH2CH2Br, -OCH2CH(CH2CH2Br)CH3, and -OCHICH3. In some embodiments, the haloalkoxy group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups.

14537[0001010] The term "haloalkyl," as used herein, represents an alkyl group, as defined herein, substituted by a halogen group (i.e., F, CI, Br, or I). A haloalkyl may be substituted with one, two, three, or, in the case of alkyl groups of two carbons or more, four halogens. Haloalkyl groups include perfluoroalkyls (e.g., -CF3), -CHF2, -CH2F, - CC13, -CH2CH2Br, -CH2CH(CH2CH2Br)CH3, and -CHICH3. In some embodiments, the haloalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups.

14538[0001011] The term "heteroalkylene," as used herein, refers to an alkylene group, as defined herein, in which one or two of the constituent carbon atoms have each been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkylene group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkylene groups.

14539[0001012] The term "heteroaryl," as used herein, represents that subset of heterocyclyls, as defined herein, which are aromatic: i.e., they contain 4n+2 pi electrons within the mono- or multicyclic ring system. Exemplary unsubstituted heteroaryl groups are of 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10, or 2 to 9) carbons. In some embodiment, the heteroaryl is substituted with 1, 2, 3, or 4 substituents groups as defined for a heterocyclyl group.

14540[0001013] The term "heterocyclyl," as used herein represents a 5-, 6- or 7-membered ring, unless otherwise specified, containing one, two, three, or four heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The 5- membered ring has zero to two double bonds, and the 6- and 7-membered rings have zero to three double bonds. Exemplary unsubstituted heterocyclyl groups are of 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10, or 2 to 9) carbons. The term

14541"heterocyclyl" also represents a heterocyclic compound having a bridged multicyclic structure in which one or more carbons and/or heteroatoms bridges two non-adjacent members of a monocyclic ring, e.g., a quinuclidinyl group. The term "heterocyclyl" includes bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one, two, or three carbocyclic rings, e.g., an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or another monocyclic heterocyclic ring, such as indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, benzothienyl and the like. Examples of fused heterocyclyls include tropanes and l,2,3,5,8,8a-hexahydroindolizine. Heterocyclics include pyrrolyl, pyrrolinyl,

14542pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl,

14543imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl,

14544pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidiniyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, dihydroquinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzothiadiazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl (e.g., 1,2,3- oxadiazolyl), purinyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl), tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, dihydroindolyl, dihydroquinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydroisoquinolyl, pyranyl, dihydropyranyl, dithiazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, and the like, including dihydro and tetrahydro forms thereof, where one or more double bonds are reduced and replaced with hydrogens. Still other exemplary heterocyclyls include: 2,3,4,5-tetrahydro-2-oxo- oxazolyl; 2,3-dihydro-2-oxo-lH-imidazolyl; 2,3,4,5-tetrahydro-5-oxo-lH-pyrazolyl (e.g., 2,3,4,5-tetrahydro-2-phenyl-5-oxo-lH-pyrazolyl); 2,3,4,5-tetrahydro-2,4-dioxo-lH- imidazolyl (e.g., 2,3,4,5-tetrahydro-2,4-dioxo-5-methyl-5-phenyl-lH-imidazolyl); 2,3- dihydro-2-thioxo-l,3,4-oxadiazolyl (e.g., 2,3-dihydro-2-thioxo-5-phenyl-l,3,4- oxadiazolyl); 4,5-dihydro-5-oxo-lH-triazolyl (e.g., 4,5-dihydro-3-methyl-4-amino 5-oxo- lH-triazolyl); l,2,3,4-tetrahydro-2,4-dioxopyridinyl (e.g., l,2,3,4-tetrahydro-2,4-dioxo- 3,3-diethylpyridinyl); 2,6-dioxo-piperidinyl (e.g., 2,6-dioxo-3-ethyl-3-phenylpiperidinyl); l,6-dihydro-6-oxopyridiminyl; l,6-dihydro-4-oxopyrimidinyl (e.g., 2-(methylthio)-l,6- dihydro-4-oxo-5-methylpyrimidin-l-yl); l,2,3,4-tetrahydro-2,4-dioxopyrimidinyl (e.g., 1 ,2,3,4-tetrahydro-2,4-dioxo-3-ethylpyrimidinyl); 1 ,6-dihydro-6-oxo-pyridazinyl (e.g., l,6-dihydro-6-oxo-3-ethylpyridazinyl); l,6-dihydro-6-oxo-l,2,4-triazinyl (e.g., 1,6- dihydro-5-isopropyl-6-oxo-l,2,4-triazinyl); 2,3-dihydro-2-oxo-lH-indolyl (e.g., 3,3- dimethyl-2,3-dihydro-2-oxo-lH-indolyl and 2,3-dihydro-2-oxo-3,3'-spiropropane-lH- indol- 1 -yl); 1 ,3-dihydro-l -oxo-2H-iso-indolyl; 1 ,3-dihydro- 1 ,3-dioxo-2H-iso-indolyl; lH-benzopyrazolyl (e.g., l-(ethoxycarbonyl)- lH-benzopyrazolyl); 2,3-dihydro-2-oxo- lH-benzimidazolyl (e.g., 3-ethyl-2,3-dihydro-2-oxo-lH-benzimidazolyl); 2,3-dihydro-2- oxo-benzoxazolyl (e.g., 5-chloro-2,3-dihydro-2-oxo-benzoxazolyl); 2,3-dihydro-2-oxo- benzoxazolyl; 2-oxo-2H-benzopyranyl; 1 ,4-benzodioxanyl; 1,3-benzodioxanyl; 2,3- dihydro-3-oxo,4H-l,3-benzothiazinyl; 3,4-dihydro-4-oxo-3H-quinazolinyl (e.g., 2- methyl-3 ,4-dihydro-4-oxo-3H-quinazolinyl); 1 ,2,3 ,4-tetrahydro-2,4-dioxo-3H-quinazolyl (e.g., 1 -ethyl- 1, 2,3, 4-tetrahydro-2,4-dioxo-3H-quinazolyl); l,2,3,6-tetrahydro-2,6-dioxo- 7H-purinyl (e.g., 1,2,3, 6-tetrahydro-l,3-dimethyl-2, 6-dioxo-7 H -purinyl); 1,2,3,6- tetrahydro-2,6-dioxo-l H-purinyl (e.g., l,2,3,6-tetrahydro-3,7-dimethyl-2,6-dioxo-l H - purinyl); 2-oxobenz[c,<i]indolyl; l,l-dioxo-2H-naphth[l,8-c,<i]isothiazolyl; and 1,8- naphthylenedicarboxamido. Additional heterocyclics include 3,3a,4,5,6,6a-hexahydro- pyrrolo[3,4-b]pyrrol-(2H)-yl, and 2,5-diazabicyclo[2.2.1]heptan-2-yl, homopiperazinyl (or diazepanyl), tetrahydropyranyl, dithiazolyl, benzofuranyl, benzothienyl, oxepanyl, thiepanyl, azocanyl, oxecanyl, and thiocanyl. Heterocyclic groups also include groups of the formula <img file="WO2013151663A1_D0156.tif" /> , where [0001014] E' is selected from the group consisting of -N- and -CH-; F' is selected from the group consisting of -N=CH-, -NH-CH2-, -NH-C(O)-, -NH-, -CH=N-, -CH2-NH-, - C(0)-NH-, -CH=CH-, -CH2-, -CH2CH2-, -CH20-, -OCH2-, -0-, and -S-; and G' is selected from the group consisting of -CH- and -N-. Any of the heterocyclyl groups mentioned herein may be optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of: (1) Ci_7 acyl (e.g., carboxyaldehyde ); (2) Ci_2o alkyl (e.g., Ci_6 alkyl, Ci_6 alkoxy-Ci_6 alkyl, Ci_6 alkylsulfmyl-Ci_6 alkyl, amino-Ci_6 alkyl, azido-Ci_6 alkyl, (carboxyaldehyde)-Ci_6 alkyl, halo-Ci_6 alkyl (e.g., perfluoroalkyl), hydroxy-Ci_6 alkyl, nitro-Ci_6 alkyl, or Ci_6 thioalkoxy-Ci_6 alkyl); (3) Ci_2o alkoxy (e.g., Ci_6 alkoxy, such as perfluoroalkoxy); (4) Ci_6 alkylsulfinyl; (5) C6-1o aryl; (6) amino; (7) Ci_6 alk-C6-io aryl; (8) azido; (9) C3-8 cycloalkyl; (10) Ci_6 alk-C3_g cycloalkyl; (11) halo; (12) C1-12 heterocyclyl (e.g., C2_i2 heteroaryl); (13) (C1-12 heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) Ci_20 thioalkoxy (e.g., Ci_6 thioalkoxy); (17) -(CH2)qC02RA , where q is an integer from zero to four, and RA is selected from the group consisting of (a) Ci_6 alkyl, (b) C6-1o aryl, (c) hydrogen, and (d) Ci_6 alk-C6-io aryl; (18) -(CH2)qCONR R , where q is an integer from zero to four and where R and R are independently selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6_io aryl, and (d) Ci_6 alk-C6-io aryl; (19) -(CH2)qS02RD', where q is an integer from zero to four and where RD is selected from the group consisting of (a) Ci_6 alkyl, (b) C6-io aryl, and (c) Ci_6 alk-C6-io aryl; (20) - (CH2)qS02NRE RF , where q is an integer from zero to four and where each of RE and RF is, independently, selected from the group consisting of (a) hydrogen, (b) Ci_6 alkyl, (c) C6-io aryl, and (d) Ci_6 alk-C6-io aryl; (21) thiol; (22) C6-io aryloxy; (23) C3-8 cycloalkoxy; (24) arylalkoxy; (25) Ci_6 alk-Ci_i2 heterocyclyl (e.g., Ci_6 alk-Ci_i2 heteroaryl); (26) oxo; (27) (C1-12 heterocyclyl)imino; (28) C2_20 alkenyl; and (29) C2_20 alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a Ci-alkaryl or a Ci-alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.

14545[0001015] The term "(heterocyclyl)imino," as used herein, represents a heterocyclyl group, as defined herein, attached to the parent molecular group through an imino group. In some embodiments, the heterocyclyl group can be substituted with 1, 2, 3, or 4 substituent groups as defined herein.

14546[0001016] The term "(heterocyclyl)oxy," as used herein, represents a heterocyclyl group, as defined herein, attached to the parent molecular group through an oxygen atom. In some embodiments, the heterocyclyl group can be substituted with 1, 2, 3, or 4 substituent groups as defined herein.

14547[0001017] The term "(heterocyclyl)oyl," as used herein, represents a heterocyclyl group, as defined herein, attached to the parent molecular group through a carbonyl group. In some embodiments, the heterocyclyl group can be substituted with 1, 2, 3, or 4 substituent groups as defined herein.

14548[0001018] The term "hydrocarbon," as used herein, represents a group consisting only of carbon and hydrogen atoms.

14549[0001019] The term "hydroxy," as used herein, represents an -OH group.

14550[0001020] The term "hydroxyalkenyl," as used herein, represents an alkenyl group, as defined herein, substituted by one to three hydroxy groups, with the proviso that no more than one hydroxy group may be attached to a single carbon atom of the alkyl group, and is exemplified by dihydroxypropenyl, hydroxyisopentenyl, and the like.

14551[0001021] The term "hydroxyalkyl," as used herein, represents an alkyl group, as defined herein, substituted by one to three hydroxy groups, with the proviso that no more than one hydroxy group may be attached to a single carbon atom of the alkyl group, and is exemplified by hydroxymethyl, dihydroxypropyl, and the like.

14552[0001022] The term "isomer," as used herein, means any tautomer, stereoisomer, enantiomer, or diastereomer of any compound of the invention. It is recognized that the compounds of the invention can have one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis/trans isomers).

14553According to the invention, the chemical structures depicted herein, and therefore the compounds of the invention, encompass all of the corresponding stereoisomers, that is, both the stereomerically pure form (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereoisomeric mixtures of compounds of the invention can typically be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and stereoisomers can also be obtained from stereomerically or enantiomerically pure intermediates, reagents, and catalysts by well- known asymmetric synthetic methods.

14554[0001023] The term "N-protected amino," as used herein, refers to an amino group, as defined herein, to which is attached one or two N-protecting groups, as defined herein.

14555[0001024] The term "N-protecting group," as used herein, represents those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999), which is incorporated herein by reference. N-protecting groups include acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, a- chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, phenylalanine, and the like; sulfonyl-containing groups such as benzenesulfonyl, p-toluenesulfonyl, and the like; carbamate forming groups such as benzyloxycarbonyl, p- chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2- nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3 ,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl,

145564-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl,

145573,4,5-trimethoxybenzyloxycarbonyl, l-(p-biphenylyl)-l-methylethoxycarbonyl, α,α- dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t- butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4- nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, and the like, alkaryl groups such as benzyl, triphenylmethyl, benzyloxymethyl, and the like and silyl groups, such as trimethylsilyl, and the like. Preferred N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

14558[0001025] The term "nitro," as used herein, represents an -N02 group.

14559[0001026] The term "oxo" as used herein, represents =0.

14560[0001027] The term "perfluoroalkyl," as used herein, represents an alkyl group, as defined herein, where each hydrogen radical bound to the alkyl group has been replaced by a fluoride radical. Perfluoroalkyl groups are exemplified by trifluoromethyl, pentafluoroethyl, and the like.

14561[0001028] The term "perfluoroalkoxy," as used herein, represents an alkoxy group, as defined herein, where each hydrogen radical bound to the alkoxy group has been replaced by a fluoride radical. Perfluoroalkoxy groups are exemplified by trifluoromethoxy, pentafluoroethoxy, and the like.

14562[0001029] The term "spirocyclyl," as used herein, represents a C2_7 alkylene diradical, both ends of which are bonded to the same carbon atom of the parent group to form a spirocyclic group, and also a Ci_6 heteroalkylene diradical, both ends of which are bonded to the same atom. The heteroalkylene radical forming the spirocyclyl group can containing one, two, three, or four heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the spirocyclyl group includes one to seven carbons, excluding the carbon atom to which the diradical is attached. The spirocyclyl groups of the invention may be optionally substituted with 1, 2, 3, or 4 substituents provided herein as optional substituents for cycloalkyl and/or heterocyclyl groups.

14563[0001030] The term "stereoisomer," as used herein, refers to all possible different isomeric as well as conformational forms which a compound may possess (e.g., a compound of any formula described herein), in particular all possible stereochemically and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds of the present invention may exist in different tautomeric forms, all of the latter being included within the scope of the present invention. [0001031] The term "sulfoalkyl," as used herein, represents an alkyl group, as defined herein, substituted by a sulfo group of -SO3H. In some embodiments, the alkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein.

14564[0001032] The term "sulfonyl," as used herein, represents an -S(0)2- group.

14565[0001033] The term "thioalkaryl," as used herein, represents a chemical substituent of formula -SR, where R is an alkaryl group. In some embodiments, the alkaryl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein.

14566[0001034] The term "thioalkheterocyclyl," as used herein, represents a chemical substituent of formula -SR, where R is an alkheterocyclyl group. In some embodiments, the alkheterocyclyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein.

14567[0001035] The term "thioalkoxy," as used herein, represents a chemical substituent of formula -SR, where R is an alkyl group, as defined herein. In some embodiments, the alkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein.

14568[0001036] The term "thiol" represents an -SH group.

14569[0001037] Compound: As used herein, the term "compound," is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted.

14570[0001038] The compounds described herein can be asymmetric {e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present disclosure that contain

14571asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms.

14572[0001039] Compounds of the present disclosure also include tautomeric forms.

14573Tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Examples prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

14574[0001040] Compounds of the present disclosure also include all of the isotopes of the atoms occurring in the intermediate or final compounds. "Isotopes" refers to atoms having the same atomic number but different mass numbers resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium.

14575[0001041] The compounds and salts of the present disclosure can be prepared in combination with solvent or water molecules to form solvates and hydrates by routine methods.

14576[0001042] Conserved: As used herein, the term "conserved" refers to nucleotides or amino acid residues of a polynucleotide sequence or polypeptide sequence, respectively, that are those that occur unaltered in the same position of two or more sequences being compared. Nucleotides or amino acids that are relatively conserved are those that are conserved amongst more related sequences than nucleotides or amino acids appearing elsewhere in the sequences.

14577[0001043] In some embodiments, two or more sequences are said to be "completely conserved" if they are 100% identical to one another. In some embodiments, two or more sequences are said to be "highly conserved" if they are at least 70%> identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some embodiments, two or more sequences are said to be "highly conserved" if they are about 70%) identical, about 80%> identical, about 90%> identical, about 95%, about 98%>, or about 99% identical to one another. In some embodiments, two or more sequences are said to be "conserved" if they are at least 30% identical, at least 40% identical, at least 50% identical, at least 60% identical, at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some embodiments, two or more sequences are said to be "conserved" if they are about 30%> identical, about 40%> identical, about 50%> identical, about 60%> identical, about 70%> identical, about 80%> identical, about 90%> identical, about 95% identical, about 98% identical, or about 99% identical to one another. Conservation of sequence may apply to the entire length of an oligonucleotide or polypeptide or may apply to a portion, region or feature thereof.

14578[0001044] Controlled Release: As used herein, the term "controlled release" refers to a pharmaceutical composition or compound release profile that conforms to a particular pattern of release to effect a therapeutic outcome.

14579[0001045] Cyclic or Cyclized: As used herein, the term "cyclic" refers to the presence of a continuous loop. Cyclic molecules need not be circular, only joined to form an unbroken chain of subunits. Cyclic molecules such as the engineered RNA or mRNA of the present invention may be single units or multimers or comprise one or more components of a complex or higher order structure.

14580[0001046] Cytostatic: As used herein, "cytostatic" refers to inhibiting, reducing, suppressing the growth, division, or multiplication of a cell {e.g., a mammalian cell {e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite, prion, or a combination thereof.

14581[0001047] Cytotoxic: As used herein, "cytotoxic" refers to killing or causing injurious, toxic, or deadly effect on a cell {e.g., a mammalian cell {e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite, prion, or a combination thereof.

14582[0001048] Delivery: As used herein, "delivery" refers to the act or manner of delivering a compound, substance, entity, moiety, cargo or payload.

14583[0001049] Delivery Agent: As used herein, "delivery agent" refers to any substance which facilitates, at least in part, the in vivo delivery of a polynucleotide, primary construct or mmRNA to targeted cells.

14584[0001050] Destabilized: As used herein, the term "destable," "destabilize," or

14585"destabilizing region" means a region or molecule that is less stable than a starting, wild- type or native form of the same region or molecule.

14586[0001051] Detectable label: As used herein, "detectable label" refers to one or more markers, signals, or moieties which are attached, incorporated or associated with another entity that is readily detected by methods known in the art including radiography, fluorescence, chemiluminescence, enzymatic activity, absorbance and the like. Detectable labels include radioisotopes, fluorophores, chromophores, enzymes, dyes, metal ions, ligands such as biotin, avidin, streptavidin and haptens, quantum dots, and the like.

14587Detectable labels may be located at any position in the peptides or proteins disclosed herein. They may be within the amino acids, the peptides, or proteins, or located at the N- or C- termini.

14588[0001052] Digest: As used herein, the term "digest" means to break apart into smaller pieces or components. When referring to polypeptides or proteins, digestion results in the production of peptides.

14589[0001053] Distal: As used herein, the term "distal" means situated away from the center or away from a point or region of interest.

14590[0001054] Dosing regimen: As used herein, a "dosing regimen" is a schedule of administration or physician determined regimen of treatment, prophylaxis, or palliative care.

14591[0001055] Dose splitting factor (DSF)-xd io of PUD of dose split treatment divided by PUD of total daily dose or single unit dose. The value is derived from comparison of dosing regimens groups.

14592[0001056] Encapsulate: As used herein, the term "encapsulate" means to enclose, surround or encase.

14593[0001057] Encoded protein cleavage signal: As used herein, "encoded protein cleavage signal" refers to the nucleotide sequence which encodes a protein cleavage signal.

14594[0001058] Engineered: As used herein, embodiments of the invention are "engineered" when they are designed to have a feature or property, whether structural or chemical, that varies from a starting point, wild type or native molecule.

14595[0001059] Exosome: As used herein, "exosome" is a vesicle secreted by mammalian cells or a complex involved in R A degradation.

14596[0001060] Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3' end processing); (3) translation of an R A into a polypeptide or protein; and (4) post-translational modification of a polypeptide or protein.

14597[0001061] Feature: As used herein, a "feature" refers to a characteristic, a property, or a distinctive element.

14598[0001062] Formulation: As used herein, a "formulation" includes at least a

14599polynucleotide, primary construct or mmR A and a delivery agent.

14600[0001063] Fragment: A "fragment," as used herein, refers to a portion. For example, fragments of proteins may comprise polypeptides obtained by digesting full-length protein isolated from cultured cells.

14601[0001064] Functional: As used herein, a "functional" biological molecule is a biological molecule in a form in which it exhibits a property and/or activity by which it is characterized.

14602[0001065] Homology: As used herein, the term "homology" refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules {e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical or similar. The term "homologous" necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences). In accordance with the invention, two polynucleotide sequences are considered to be homologous if the polypeptides they encode are at least about 50%>, 60%, 70%, 80%, 90%, 95%, or even 99% for at least one stretch of at least about 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. In accordance with the invention, two protein sequences are considered to be homologous if the proteins are at least about 50%>, 60%>, 70%>, 80%>, or 90%> identical for at least one stretch of at least about 20 amino acids.

14603[0001066] Identity: As used herein, the term "identity" refers to the overall relatedness between polymeric molecules, e.g., between oligonucleotide molecules {e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two polynucleotide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100%) of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988;

14604Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991 ; each of which is incorporated herein by reference. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 1 1-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

14605Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48: 1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et ah, Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol, 215, 403 (1990)).

14606[0001067] Inhibit expression of a gene: As used herein, the phrase "inhibit expression of a gene" means to cause a reduction in the amount of an expression product of the gene. The expression product can be an RNA transcribed from the gene {e.g. , an mRNA) or a polypeptide translated from an mRNA transcribed from the gene. Typically a reduction in the level of an mRNA results in a reduction in the level of a polypeptide translated therefrom. The level of expression may be determined using standard techniques for measuring mRNA or protein.

14607[0001068] In vitro: As used herein, the term "in vitro" refers to events that occur in an artificial environment, e.g. , in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism {e.g., animal, plant, or microbe).

14608[0001069] In vivo: As used herein, the term "in vivo" refers to events that occur within an organism {e.g., animal, plant, or microbe or cell or tissue thereof).

14609[0001070] Isolated: As used herein, the term "isolated" refers to a substance or entity that has been separated from at least some of the components with which it was associated (whether in nature or in an experimental setting). Isolated substances may have varying levels of purity in reference to the substances from which they have been associated. Isolated substances and/or entities may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, isolated agents are more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%), or more than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components. Substantially isolated: By "substantially isolated" is meant that the compound is substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compound of the present disclosure. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%>, at least about 90%>, at least about 95%, at least about 97%, or at least about 99% by weight of the compound of the present disclosure, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

14610[0001071] Linker: As used herein, a linker refers to a group of atoms, e.g., 10-1,000 atoms, and can be comprised of the atoms or groups such as, but not limited to, carbon, amino, alkylamino, oxygen, sulfur, sulfoxide, sulfonyl, carbonyl, and imine. The linker can be attached to a modified nucleoside or nucleotide on the nucleobase or sugar moiety at a first end, and to a payload, e.g., a detectable or therapeutic agent, at a second end. The linker may be of sufficient length as to not interfere with incorporation into a nucleic acid sequence. The linker can be used for any useful purpose, such as to form mmRNA multimers (e.g., through linkage of two or more polynucleotides, primary constructs, or mmRNA molecules) or mmRNA conjugates, as well as to administer a payload, as described herein. Examples of chemical groups that can be incorporated into the linker include, but are not limited to, alkyl, alkenyl, alkynyl, amido, amino, ether, thioether, ester, alkylene, heteroalkylene, aryl, or heterocyclyl, each of which can be optionally substituted, as described herein. Examples of linkers include, but are not limited to, unsaturated alkanes, polyethylene glycols (e.g., ethylene or propylene glycol monomeric units, e.g., diethylene glycol, dipropylene glycol, triethylene glycol, tripropylene glycol, tetraethylene glycol, or tetraethylene glycol), and dextran polymers and derivatives thereof, Other examples include, but are not limited to, cleavable moieties within the linker, such as, for example, a disulfide bond (-S-S-) or an azo bond (-N=N-), which can be cleaved using a reducing agent or photolysis. Non- limiting examples of a selectively cleavable bond include an amido bond can be cleaved for example by the use of tris(2- carboxyethyl)phosphine (TCEP), or other reducing agents, and/or photolysis, as well as an ester bond can be cleaved for example by acidic or basic hydrolysis.

14611[0001072] MicroRNA (miRNA) binding site: As used herein, a microRNA (miRNA) binding site represents a nucleotide location or region of a nucleic acid transcript to which at least the "seed" region of a miRNA binds.

14612[0001073] Modified: As used herein "modified" refers to a changed state or structure of a molecule of the invention. Molecules may be modified in many ways including chemically, structurally, and functionally. In one embodiment, the mR A molecules of the present invention are modified by the introduction of non-natural nucleosides and/or nucleotides, e.g., as it relates to the natural ribonucleotides A, U, G, and C. Noncanonical nucleotides such as the cap structures are not considered "modified" although they differ from the chemical structure of the A, C, G, U ribonucleotides.

14613[0001074] Mucus: As used herein, "mucus" refers to the natural substance that is viscous and comprises mucin glycoproteins.

14614[0001075] Naturally occurring: As used herein, "naturally occurring" means existing in nature without artificial aid.

14615[0001076] Non-human vertebrate: As used herein, a "non human vertebrate" includes all vertebrates except Homo sapiens, including wild and domesticated species. Examples of non-human vertebrates include, but are not limited to, mammals, such as alpaca, banteng, bison, camel, cat, cattle, deer, dog, donkey, gayal, goat, guinea pig, horse, llama, mule, pig, rabbit, reindeer, sheep water buffalo, and yak.

14616[0001077] Off-target: As used herein, "off target" refers to any unintended effect on any one or more target, gene, or cellular transcript.

14617[0001078] Open reading frame: As used herein, "open reading frame" or "ORF" refers to a sequence which does not contain a stop codon in a given reading frame.

14618[0001079] Operably linked: As used herein, the phrase "operably linked" refers to a functional connection between two or more molecules, constructs, transcripts, entities, moieties or the like.

14619[0001080] Optionally substituted: Herein a phrase of the form "optionally substituted X"

14620(e.g., optionally substituted alkyl) is intended to be equivalent to "X, wherein X is optionally substituted" (e.g., "alkyl, wherein said alkyl is optionally substituted"). It is not intended to mean that the feature "X" (e.g. alkyl) per se is optional.

14621[0001081] Peptide: As used herein, "peptide" is less than or equal to 50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

14622[0001082] Paratope: As used herein, a "paratope" refers to the antigen-binding site of an antibody. [0001083] Patient: As used herein, "patient" refers to a subject who may seek or be in need of treatment, requires treatment, is receiving treatment, will receive treatment, or a subject who is under care by a trained professional for a particular disease or condition.

14623[0001084] Pharmaceutically acceptable: The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

14624[0001085] Pharmaceutically acceptable excipients: The phrase "pharmaceutically acceptable excipient," as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and noninflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine,

14625methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

14626[0001086] Pharmaceutically acceptable salts: The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form (e.g., by reacting the free base group with a suitable organic acid).

14627Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate,

14628glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate,

14629toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection, and Use, P.H. Stahl and C.G. Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety. [0001087] Pharmaceutically acceptable solvate: The term "pharmaceutically acceptable solvate," as used herein, means a compound of the invention wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent is

14630physiologically tolerable at the dosage administered. For example, solvates may be prepared by crystallization, recrystallization, or precipitation from a solution that includes organic solvents, water, or a mixture thereof. Examples of suitable solvents are ethanol, water (for example, mono-, di-, and tri-hydrates), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), N,N'-dimethylformamide (DMF), N,N'-dimethylacetamide (DMAC), l,3-dimethyl-2-imidazolidinone (DMEU), l,3-dimethyl-3,4,5,6-tetrahydro-2- (lH)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, and the like. When water is the solvent, the solvate is referred to as a "hydrate."

14631[0001088] Pharmacokinetic: As used herein, "pharmacokinetic" refers to any one or more properties of a molecule or compound as it relates to the determination of the fate of substances administered to a living organism. Pharmacokinetics is divided into several areas including the extent and rate of absorption, distribution, metabolism and excretion. This is commonly referred to as ADME where: (A) Absorption is the process of a substance entering the blood circulation; (D) Distribution is the dispersion or

14632dissemination of substances throughout the fluids and tissues of the body; (M)

14633Metabolism (or Biotransformation) is the irreversible transformation of parent compounds into daughter metabolites; and (E) Excretion (or Elimination) refers to the elimination of the substances from the body. In rare cases, some drugs irreversibly accumulate in body tissue.

14634[0001089] Physicochemical: As used herein, "physicochemical" means of or relating to a physical and/or chemical property.

14635[0001090] Polypeptide per unit drug (PUD): As used herein, a PUD or product per unit drug, is defined as a subdivided portion of total daily dose, usually 1 mg, pg, kg, etc., of a product (such as a polypeptide) as measured in body fluid or tissue, usually defined in concentration such as pmol/mL, mmol/mL, etc divided by the measure in the body fluid.

14636[0001091] Preventing: As used herein, the term "preventing" refers to partially or completely delaying onset of an infection, disease, disorder and/or condition; partially or completely delaying onset of one or more symptoms, features, or clinical manifestations of a particular infection, disease, disorder, and/or condition; partially or completely delaying onset of one or more symptoms, features, or manifestations of a particular infection, disease, disorder, and/or condition; partially or completely delaying

14637progression from an infection, a particular disease, disorder and/or condition; and/or decreasing the risk of developing pathology associated with the infection, the disease, disorder, and/or condition.

14638[0001092] Prodrug: The present disclosure also includes prodrugs of the compounds described herein. As used herein, "prodrugs" refer to any substance, molecule or entity which is in a form predicate for that substance, molecule or entity to act as a therapeutic upon chemical or physical alteration. Prodrugs may by covalently bonded or sequestered in some way and which release or are converted into the active drug moiety prior to, upon or after administered to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery

14639Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and

14640Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.

14641[0001093] Proliferate: As used herein, the term "proliferate" means to grow, expand or increase or cause to grow, expand or increase rapidly. "Proliferative" means having the ability to proliferate. "Anti-proliferative" means having properties counter to or inapposite to proliferative properties.

14642[0001094] Protein cleavage site: As used herein, "protein cleavage site" refers to a site where controlled cleavage of the amino acid chain can be accomplished by chemical, enzymatic or photochemical means. [0001095] Protein cleavage signal: As used herein "protein cleavage signal" refers to at least one amino acid that flags or marks a polypeptide for cleavage.

14643[0001096] Protein of interest: As used herein, the terms "proteins of interest" or "desired proteins" include those provided herein and fragments, mutants, variants, and alterations thereof.

14644[0001097] Proximal: As used herein, the term "proximal" means situated nearer to the center or to a point or region of interest.

14645[0001098] Pseudouridine: As used herein, pseudouridine refers to the C-glycoside isomer of the nucleoside uridine. A "pseudouridine analog" is any modification, variant, isoform or derivative of pseudouridine. For example, pseudouridine analogs include but are not limited to 1-carboxymethyl-pseudouridine, 1-propynyl-pseudouridine, 1- taurinomethyl-pseudouridine, 1 -taurinomethyl-4-thio-pseudouridine, 1 - methylpseudouridine<img file="WO2013151663A1_D0157.tif" /> 4-thio-l-methyl- pseudouridine, 3-methyl-pseudouridine (m3\|/), 2-thio-l-methyl-pseudouridine, 1-methyl- 1-deaza-pseudouridine, 2-thio-l -methyl- 1-deaza-pseudouridine, dihydropseudouridine, 2- thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy- pseudouridine, 4-methoxy-2-thio-pseudouridine, Nl-methyl-pseudouridine, l-methyl-3- (3-amino-3-carboxypropyl)pseudouridine (acp3 ψ), and 2'-0-methyl-pseudouridine (\|/m).

14646[0001099] Purified: As used herein, "purify," "purified," "purification" means to make substantially pure or clear from unwanted components, material defilement, admixture or imperfection.

14647[0001100] Sample: As used herein, the term "sample" or "biological sample" refers to a subset of its tissues, cells or component parts (e.g. body fluids, including but not limited to blood, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid and semen). A sample further may include a homogenate, lysate or extract prepared from a whole organism or a subset of its tissues, cells or component parts, or a fraction or portion thereof, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs. A sample further refers to a medium, such as a nutrient broth or gel, which may contain cellular components, such as proteins or nucleic acid molecule. [0001101] Signal Sequences: As used herein, the phrase "signal sequences" refers to a sequence which can direct the transport or localization of a protein.

14648[0001102] Single unit dose: As used herein, a "single unit dose" is a dose of any therapeutic administed in one dose/at one time/single route/single point of contact, i.e., single administration event.

14649[0001103] Similarity: As used herein, the term "similarity" refers to the overall relatedness between polymeric molecules, e.g. between polynucleotide molecules {e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules.

14650Calculation of percent similarity of polymeric molecules to one another can be performed in the same manner as a calculation of percent identity, except that calculation of percent similarity takes into account conservative substitutions as is understood in the art.

14651[0001104] Split dose: As used herein, a "split dose" is the division of single unit dose or total daily dose into two or more doses.

14652[0001105] Stable: As used herein "stable" refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.

14653[0001106] Stabilized: As used herein, the term "stabilize", "stabilized," "stabilized region" means to make or become stable.

14654[0001107] Subject: As used herein, the term "subject" or "patient" refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals {e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and/or plants.

14655[0001108] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term "substantially" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena. [0001109] Substantially equal: As used herein as it relates to time differences between doses, the term means plus/minus 2%.

14656[0001110] Substantially simultaneously: As used herein and as it relates to plurality of doses, the term means within 2 seconds.

14657[0001111] Suffering from: An individual who is "suffering from" a disease, disorder, and/or condition has been diagnosed with or displays one or more symptoms of a disease, disorder, and/or condition.

14658[0001112] Susceptible to: An individual who is "susceptible to" a disease, disorder, and/or condition has not been diagnosed with and/or may not exhibit symptoms of the disease, disorder, and/or condition but harbors a propensity to develop a disease or its symptoms. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition (for example, cancer) may be characterized by one or more of the following: (1) a genetic mutation associated with development of the disease, disorder, and/or condition; (2) a genetic polymorphism associated with development of the disease, disorder, and/or condition; (3) increased and/or decreased expression and/or activity of a protein and/or nucleic acid associated with the disease, disorder, and/or condition; (4) habits and/or lifestyles associated with development of the disease, disorder, and/or condition; (5) a family history of the disease, disorder, and/or condition; and (6) exposure to and/or infection with a microbe associated with development of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.

14659[0001113] Sustained release: As used herein, the term "sustained release" refers to a pharmaceutical composition or compound release profile that conforms to a release rate over a specific period of time.

14660[0001114] Synthetic: The term "synthetic" means produced, prepared, and/or

14661manufactured by the hand of man. Synthesis of polynucleotides or polypeptides or other molecules of the present invention may be chemical or enzymatic.

14662[0001115] Targeted Cells: As used herein, "targeted cells" refers to any one or more cells of interest. The cells may be found in vitro, in vivo, in situ or in the tissue or organ of an organism. The organism may be an animal, preferably a mammal, more preferably a human and most preferably a patient.

14663[0001116] Therapeutic Agent: The term "therapeutic agent" refers to any agent that, when administered to a subject, has a therapeutic, diagnostic, and/or prophylactic effect and/or elicits a desired biological and/or pharmacological effect.

14664[0001117] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" means an amount of an agent to be delivered {e.g., nucleic acid, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition.

14665[0001118] Therapeutically effective outcome: As used herein, the term "therapeutically effective outcome" means an outcome that is sufficient in a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition.

14666[0001119] Total daily dose: As used herein, a "total daily dose" is an amount given or prescribed in 24 hr period. It may be administered as a single unit dose.

14667[0001120] Transcription factor: As used herein, the term "transcription factor" refers to a DNA-binding protein that regulates transcription of DNA into R A, for example, by activation or repression of transcription. Some transcription factors effect regulation of transcription alone, while others act in concert with other proteins. Some transcription factor can both activate and repress transcription under certain conditions. In general, transcription factors bind a specific target sequence or sequences highly similar to a specific consensus sequence in a regulatory region of a target gene. Transcription factors may regulate transcription of a target gene alone or in a complex with other molecules.

14668[0001121] Treating: As used herein, the term "treating" refers to partially or completely alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of a particular infection, disease, disorder, and/or condition. For example, "treating" cancer may refer to inhibiting survival, growth, and/or spread of a tumor. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.

14669[0001122] Unmodified: As used herein, "unmodified" refers to any substance, compound or molecule prior to being changed in any way. Unmodified may, but does not always, refer to the wild type or native form of a biomolecule. Molecules may undergo a series of modifications whereby each modified molecule may serve as the "unmodified" starting molecule for a subsequent modification.

14670Equivalents and Scope

14671[0001123] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the appended claims.

14672[0001124] In the claims, articles such as "a," "an," and "the" may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

14673[0001125] It is also noted that the term "comprising" is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term

14674"comprising" is used herein, the term "consisting of is thus also encompassed and disclosed.

14675[0001126] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

14676[0001127] In addition, it is to be understood that any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the compositions of the invention (e.g. , any nucleic acid or protein encoded thereby; any method of production; any method of use; etc.) can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.

14677[0001128] All cited sources, for example, references, publications, databases, database entries, and art cited herein, are incorporated into this application by reference, even if not expressly stated in the citation. In case of conflicting statements of a cited source and the instant application, the statement in the instant application shall control.

14678[0001129] Section and table headings are not intended to be limiting.

EXAMPLES

14680Example 1. Modified mRNA Production

14681[0001130] Modified mRNAs (mmRNA) according to the invention may be made using standard laboratory methods and materials. The open reading frame (ORF) of the gene of interest may be flanked by a 5' untranslated region (UTR) which may contain a strong Kozak translational initiation signal and/or an alpha-globin 3' UTR which may include an oligo(dT) sequence for templated addition of a poly-A tail. The modified mRNAs may be modified to reduce the cellular innate immune response. The modifications to reduce the cellular response may include pseudouridine (ψ) and 5-methyl-cytidine (5meC, 5mc or m5C). (See, Kariko K et al. Immunity 23: 165-75 (2005), Kariko K et al. Mol Ther 16: 1833-40 (2008), Anderson BR et al. NAR (2010); each of which are herein incorporated by reference in their entireties).

14682[0001131] The ORF may also include various upstream or downstream additions (such as, but not limited to, β-globin, tags, etc.) may be ordered from an optimization service such as, but limited to, DNA2.0 (Menlo Park, CA) and may contain multiple cloning sites which may have Xbal recognition. Upon receipt of the construct, it may be reconstituted and transformed into chemically competent E. coli.

14683[0001132] For the present invention, NEB DH5-alpha Competent E. coli are used.

14684Transformations are performed according to NEB instructions using 100 ng of plasmid. The protocol is as follows:

146851 Thaw a tube of NEB 5-alpha Competent E. coli cells on ice for 10 minutes.

146862 Add 1-5 μΐ containing 1 pg-100 ng of plasmid DNA to the cell mixture. Carefully flick the tube 4-5 times to mix cells and DNA. Do not vortex.

146873 Place the mixture on ice for 30 minutes. Do not mix.

146884 Heat shock at 42°C for exactly 30 seconds. Do not mix.

146895 Place on ice for 5 minutes. Do not mix.

146906 Pipette 950 μΐ of room temperature SOC into the mixture.

146917 Place at 37°C for 60 minutes. Shake vigorously (250 rpm) or rotate.

146928 Warm selection plates to 37°C.

146939 Mix the cells thoroughly by flicking the tube and inverting.

14694[0001133] Spread 50-100 μΐ of each dilution onto a selection plate and incubate overnight at 37°C. Alternatively, incubate at 30°C for 24-36 hours or 25°C for 48 hours.

14695[0001134] A single colony is then used to inoculate 5 ml of LB growth media using the appropriate antibiotic and then allowed to grow (250 RPM, 37° C) for 5 hours. This is then used to inoculate a 200 ml culture medium and allowed to grow overnight under the same conditions.

14696[0001135] To isolate the plasmid (up to 850 μg), a maxi prep is performed using the Invitrogen PURELINK™ HiPure Maxiprep Kit (Carlsbad, CA), following the manufacturer's instructions.

14697[0001136] In order to generate cDNA for In Vitro Transcription (IVT), the plasmid (an Example of which is shown in Figure 3) is first linearized using a restriction enzyme such as Xbal. A typical restriction digest with Xbal will comprise the following: Plasmid 1.0 μg; lOx Buffer 1.0 μΐ; Xbal 1.5 μΐ; dH20 up to 10 μΐ; incubated at 37° C for 1 hr. If performing at lab scale (< 5 ig), the reaction is cleaned up using Invitrogen' s

14698PURELINK™ PCR Micro Kit (Carlsbad, CA) per manufacturer's instructions. Larger scale purifications may need to be done with a product that has a larger load capacity such as Invitrogen's standard PURELINK™ PCR Kit (Carlsbad, CA). Following the cleanup, the linearized vector is quantified using the NanoDrop and analyzed to confirm linearization using agarose gel electrophoresis.

14699[0001137] The methods described herein to make modified mRNA may be used to produce molecules of all sizes including long molecules. Modified mRNA using the described methods has been made for different sized molecules including glucosidase, alpha; acid (GAA) (3.2 kb), cystic fibrosis transmembrane conductance regulator (CFTR) (4.7 kb), Factor VII (7.3 kb), lysosomal acid lipase (45.4kDa), glucocerebrosidase (59.7 kDa) and iduronate 2-sulfatase (76 kDa).

14700[0001138] As a non-limiting example, G-CSF may represent the polypeptide of interest. Sequences used in the steps outlined in Examples 1-5 are shown in Table 11. It should be noted that the start codon (ATG) has been underlined in each sequence of Table 11.

14701Table 11. G-CSF Sequences

14702<img file="WO2013151663A1_D0158.tif" /> CCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCT

TTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATCTCCCCCGA

GTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGC

CACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCC

TGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGC

GCCGGGCAGGAGGGGTCCTGGTTGCCTCCCATCTGCAGAGCTTCCTGG

AGGTGTCGTACCGCGTTCTACGCCACCTTGCCCAGCCCTGA

AGCGCTGCCTTCTGCGGGGCTTGCCTTCTGGCCATGCCCTTCTTCTCTC

CCTTGCACCTGTACCTCTTGGTCTTTGAATAAAGCCTGAGTAGGAAGG

CGGCCGCTCGAGCATGCATCTAGA

1471256151 Optimized sequence; containing T7 polymerase site, Afel and Xba restriction site

TAATACGACTCACTATA

GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCAC C

ATGGCCGGTCCCGCGACCCAAAGCCCCATGAAACTTATGGCCCTGCAG

TTGCTGCTTTGGCACTCGGCCCTCTGGACAGTCCAAGAAGCGACTCCT

CTCGGACCTGCCTCATCGTTGCCGCAGTCATTCCTTTTGAAGTGTCTGG

AGCAGGTGCGAAAGATTCAGGGCGATGGAGCCGCACTCCAAGAGAAG

CTCTGCGCGACATACAAACTTTGCCATCCCGAGGAGCTCGTACTGCTC

GGGCACAGCTTGGGGATTCCCTGGGCTCCTCTCTCGTCCTGTCCGTCGC

AGGCTTTGCAGTTGGCAGGGTGCCTTTCCCAGCTCCACTCCGGTTTGTT

CTTGTATCAGGGACTGCTGCAAGCCCTTGAGGGAATCTCGCCAGAATT

GGGCCCGACGCTGGACACGTTGCAGCTCGACGTGGCGGATTTCGCAAC

AACCATCTGGCAGCAGATGGAGGAACTGGGGATGGCACCCGCGCTGC

AGCCCACGCAGGGGGCAATGCCGGCCTTTGCGTCCGCGTTTCAGCGCA

GGGCGGGTGGAGTCCTCGTAGCGAGCCACCTTCAATCATTTTTGGAAG

TCTCGTACCGGGTGCTGAGACATCTTGCGCAGCCGTGA

AGCGCTGCCTTCTGCGGGGCTTGCCTTCTGGCCATGCCCTTCTTCTCTC

CCTTGCACCTGTACCTCTTGGTCTTTGAATAAAGCCTGAGTAGGAAGG

CGGCCGCTCGAGCATGCATCTAGA

1473156152 mRNA sequence (transcribed)

GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCA CC

AUGGCCGGUCCCGCGACCCAAAGCCCCAUGAAACUUAUGGCCCUGCA

GUUGCUGCUUUGGCACUCGGCCCUCUGGACAGUCCAAGAAGCGACU

CCUCUCGGACCUGCCUCAUCGUUGCCGCAGUCAUUCCUUUUGAAGU

GUCUGGAGCAGGUGCGAAAGAUUCAGGGCGAUGGAGCCGCACUCCA

AGAGAAGCUCUGCGCGACAUACAAACUUUGCCAUCCCGAGGAGCUC

GUACUGCUCGGGCACAGCUUGGGGAUUCCCUGGGCUCCUCUCUCGU

CCUGUCCGUCGCAGGCUUUGCAGUUGGCAGGGUGCCUUUCCCAGCU

CCACUCCGGUUUGUUCUUGUAUCAGGGACUGCUGCAAGCCCUUGAG

GGAAUCUCGCCAGAAUUGGGCCCGACGCUGGACACGUUGCAGCUCG

ACGUGGCGGAUUUCGCAACAACCAUCUGGCAGCAGAUGGAGGAACU

GGGGAUGGCACCCGCGCUGCAGCCCACGCAGGGGGCAAUGCCGGCC

14744UUUGCGUCCGCGUUUCAGCGCAGGGCGGGUGGAGUCCUCGUAGCGA GCCACCUUCAAUCAUUUUUGGAAGUCUCGUACCGGGUGCUGAGACA

UCUUGCGCAGCCGUGA

AGCGCUGCCUUCUGCGGGGCUUGCCUUCUGGCCAUGCCCUUCUUCUC

UCCCUUGCACCUGUACCUCUUGGUCUUUGAAUAAAGCCUGAGUAGG

AAG

14749Example 2: PCR for cDNA Production

14750[0001139] PCR procedures for the preparation of cDNA are performed using 2x KAPA HIFI™ HotStart Ready Mix by Kapa Biosystems (Woburn, MA). This system includes 2x KAPA ReadyMixl2.5 μΐ; Forward Primer (10 uM) 0.75 μΐ; Reverse Primer (10 uM) 0.75 μΐ; Template cDNA 100 ng; and dH20 diluted to 25.0 μΐ. The reaction conditions are at 95° C for 5 min. and 25 cycles of 98° C for 20 sec, then 58° C for 15 sec, then 72° C for 45 sec, then 72° C for 5 min. then 4° C to termination.

14751[0001140] The reverse primer of the instant invention incorporates a poly-Ti2o for a poly- Ai2o in the mRNA. Other reverse primers with longer or shorter poly(T) tracts can be used to adjust the length of the poly(A) tail in the mRNA.

14752[0001141] The reaction is cleaned up using Invitrogen's PURELINK™ PCR Micro Kit (Carlsbad, CA) per manufacturer's instructions (up to 5 μg). Larger reactions will require a cleanup using a product with a larger capacity. Following the cleanup, the cDNA is quantified using the NANODROP™ and analyzed by agarose gel electrophoresis to confirm the cDNA is the expected size. The cDNA is then submitted for sequencing analysis before proceeding to the in vitro transcription reaction.

14753Example 3. In vitro Transcription (TV )

14754[0001142] The in vitro transcription reaction generates mRNA containing modified nucleotides or modified RNA. The input nucleotide triphosphate (NTP) mix is made in- house using natural and un-natural NTPs.

14755[0001143] A typical in vitro transcription reaction includes the following:

147561 Template cDNA 1.0 μg

147572 lOx transcription buffer (400 mM Tris-HCl pH 8.0, 190 mM MgCl2, 50 mM

14758DTT, 10 mM Spermidine) 2.0 μΐ

147593 Custom NTPs (25mM each) 7.2 μΐ

147604 RNase Inhibitor 20 U

147615 T7 RNA polymerase 3000 U 6 dH20 Up to 20.0 μΐ. and

147627 Incubation at 37° C for 3 hr-5 hrs.

14763[0001144] The crude IVT mix may be stored at 4° C overnight for cleanup the next day. 1 U of RNase-free DNase is then used to digest the original template. After 15 minutes of incubation at 37° C, the mRNA is purified using Ambion's MEGACLEAR™ Kit (Austin, TX) following the manufacturer's instructions. This kit can purify up to 500 μg of RNA. Following the cleanup, the RNA is quantified using the NanoDrop and analyzed by agarose gel electrophoresis to confirm the RNA is the proper size and that no degradation of the RNA has occurred.

14764Example 4. Enzymatic Capping of mRNA

14765[0001145] Capping of the mRNA is performed as follows where the mixture includes: IVT RNA 60 μg-180μg and dH20 up to 72 μΐ. The mixture is incubated at 65° C for 5 minutes to denature RNA, and then is transferred immediately to ice.

14766[0001146] The protocol then involves the mixing of lOx Capping Buffer (0.5 M Tris-HCl (pH 8.0), 60 mM KC1, 12.5 mM MgCl2) (10.0 μΐ); 20 mM GTP (5.0 μΐ); 20 mM S- Adenosyl Methionine (2.5 μΐ); RNase Inhibitor (100 U); 2'-0-Methyltransferase (400U); Vaccinia capping enzyme (Guanylyl transferase) (40 U); dH20 (Up to 28 μΐ); and incubation at 37° C for 30 minutes for 60 μg RNA or up to 2 hours for 180 μg of RNA.

14767[0001147] The mRNA is then purified using Ambion's MEGACLEAR™ Kit (Austin, TX) following the manufacturer's instructions. Following the cleanup, the RNA is quantified using the NANODROP™ (ThermoFisher, Waltham, MA) and analyzed by agarose gel electrophoresis to confirm the RNA is the proper size and that no degradation of the RNA has occurred. The RNA product may also be sequenced by running a reverse-transcription-PCR to generate the cDNA for sequencing.

14768Example 5. Poly A Tailing Reaction

14769[0001148] Without a poly-T in the cDNA, a poly-A tailing reaction must be performed before cleaning the final product. This is done by mixing Capped IVT RNA (100 μΐ); RNase Inhibitor (20 U); lOx Tailing Buffer (0.5 M Tris-HCl (pH 8.0), 2.5 M NaCl, 100 mM MgCl2)(12.0 μΐ); 20 mM ATP (6.0 μΐ); Poly-A Polymerase (20 U); dH20 up to 123.5 μΐ and incubation at 37° C for 30 min. If the poly-A tail is already in the transcript, then the tailing reaction may be skipped and proceed directly to cleanup with Ambion's MEGACLEAR™ kit (Austin, TX) (up to 500 μg). Poly- A Polymerase is preferably a recombinant enzyme expressed in yeast.

14770[0001149] For studies performed and described herein, the poly-A tail is encoded in the IVT template to comprise 160 nucleotides in length. However, it should be understood that the processivity or integrity of the polyA tailing reaction may not always result in exactly 160 nucleotides. Hence polyA tails of approximately 160 nucleotides, e.g, about 150-165, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164 or 165 are within the scope of the invention.

14771Example 6. Natural 5f Caps and 5f Cap Analogues

14772[0001150] 5 '-capping of modified RNA may be completed concomitantly during the in vzYro-transcription reaction using the following chemical RNA cap analogs to generate the 5'-guanosine cap structure according to manufacturer protocols: 3 -O-Me- m7G(5*)ppp(5*) G [the ARCA cap];G(5*)ppp(5*)A; G(5*)ppp(5*)G; m7G(5*)ppp(5*)A; m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA). 5 '-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the "Cap 0" structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA). Cap 1 structure may be generated using both Vaccinia Virus Capping Enzyme and a 2'-0 methyl-transferase to generate: m7G(5')ppp(5')G-2'-0-methyl. Cap 2 structure may be generated from the Cap 1 structure followed by the 2'-0-methylation of the 5'- antepenultimate nucleotide using a 2'-0 methyl-transferase. Cap 3 structure may be generated from the Cap 2 structure followed by the 2'-0-methylation of the 5'- preantepenultimate nucleotide using a 2'-0 methyl-transferase. Enzymes are preferably derived from a recombinant source.

14773[0001151] When transfected into mammalian cells, the modified mRNAs have a stability of between 12-18 hours or more than 18 hours, e.g., 24, 36, 48, 60, 72 or greater than 72 hours.

14774Example 7. Capping

14775A. Protein Expression Assay

14776[0001152] Synthetic mRNAs encoding human G-CSF (cDNA shown in SEQ ID NO: 56149; mRNA sequence fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site shown in SEQ ID NO: 56152 with a polyA tail approximately 160 nucletodies in length not shown in sequence) containing the ARC A (3' 0-Me-m7G(5')ppp(5')G) cap analog or the Capl structure can be trans fected into human primary keratinocytes at equal concentrations. 6, 12, 24 and 36 hours post- transfection the amount of G-CSF secreted into the culture medium can be assayed by ELISA. Synthetic mRNAs that secrete higher levels of G-CSF into the medium would correspond to a synthetic mRNA with a higher translationally-competent Cap structure.

14777B. Purity Analysis Synthesis

14778[0001153] Synthetic mRNAs encoding human G-CSF (cDNA shown in SEQ ID NO: 56149; mRNA sequence fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site shown in SEQ ID NO: 56152 with a polyA tail approximately 160 nucletodies in length not shown in sequence) containing the ARC A cap analog or the Capl structure crude synthesis products can be compared for purity using denaturing Agarose-Urea gel electrophoresis or HPLC analysis. Synthetic mRNAs with a single, consolidated band by electrophoresis correspond to the higher purity product compared to a synthetic mRNA with multiple bands or streaking bands. Synthetic mRNAs with a single HPLC peak would also correspond to a higher purity product. The capping reaction with a higher efficiency would provide a more pure mRNA population.

14779C. Cytokine Analysis

14780[0001154] Synthetic mRNAs encoding human G-CSF (cDNA shown in SEQ ID NO: 56149; mRNA sequence fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site shown in SEQ ID NO: 56152 with a polyA tail approximately 160 nucletodies in length not shown in sequence) containing the ARC A cap analog or the Capl structure can be transfected into human primary keratinocytes at multiple concentrations. 6, 12, 24 and 36 hours post-transfection the amount of pro-inflammatory cytokines such as TNF-alpha and IFN-beta secreted into the culture medium can be assayed by ELISA. Synthetic mRNAs that secrete higher levels of pro-inflammatory cytokines into the medium would correspond to a synthetic mRNA containing an immune-activating cap structure.

14781D. Capping Reaction Efficiency [0001155] Synthetic mRNAs encoding human G-CSF (cDNA shown in SEQ ID NO: 56149; mRNA sequence fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site shown in SEQ ID NO: 56152 with a polyA tail approximately 160 nucletodies in length not shown in sequence) containing the ARC A cap analog or the Capl structure can be analyzed for capping reaction efficiency by LC-MS after capped mRNA nuclease treatment. Nuclease treatment of capped mRNAs would yield a mixture of free nucleotides and the capped 5 '-5 -triphosphate cap structure detectable by LC-MS. The amount of capped product on the LC-MS spectra can be expressed as a percent of total mRNA from the reaction and would correspond to capping reaction efficiency. The cap structure with higher capping reaction efficiency would have a higher amount of capped product by LC-MS.

14782Example 8. Agarose Gel Electrophoresis of Modified RNA or RT PCR Products

14783[0001156] Individual modified RNAs (200-400 ng in a 20 μΐ volume) or reverse transcribed PCR products (200-400 ng) are loaded into a well on a non-denaturing 1.2% Agarose E-Gel (Invitrogen, Carlsbad, CA) and run for 12-15 minutes according to the manufacturer protocol.

14784Example 9. Nanodrop Modified RNA Quantification and UV Spectral Data

14785[0001157] Modified RNAs in TE buffer (1 μΐ) are used for Nanodrop UV absorbance readings to quantitate the yield of each modified RNA from an in vitro transcription reaction.

14786Example 10. Formulation of Modified mRNA Using Lipidoids

14787[0001158] Modified mRNAs (mmRNA) are formulated for in vitro experiments by mixing the mmRNA with the lipidoid at a set ratio prior to addition to cells. In vivo formulation may require the addition of extra ingredients to facilitate circulation throughout the body. To test the ability of these lipidoids to form particles suitable for in vivo work, a standard formulation process used for siRNA-lipidoid formulations was used as a starting point. Initial mmRNA-lipidoid formulations may consist of particles composed of 42% lipidoid, 48% cholesterol and 10%> PEG, with further optimization of ratios possible. After formation of the particle, mmRNA is added and allowed to integrate with the complex. The encapsulation efficiency is determined using a standard dye exclusion assays. Materials and Methods for Examples 11-15

14788A. Lipid Synthesis

14789[0001159] Six lipids, DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200 and DLin-MC3-DMA, were synthesized by methods outlined in the art in order to be formulated with modified R A. DLin-DMA and precursorswere synthesized as described in Heyes et. al, J. Control Release, 2005, 107, 276-287. DLin-K-DMA and DLin-KC2-DMA and precursors were synthesized as described in Semple et. al, Nature Biotechnology, 2010, 28, 172-176. 98N12-5 and precursor were synthesized as described in Akinc et. al, Nature Biotechnology, 2008, 26, 561-569.

14790[0001160] CI 2-200 and precursors were synthesized according to the method outlined in Love et. al, PNAS, 2010, 107, 1864-1869. 2-epoxydodecane (5.10 g, 27.7 mmol, 8.2 eq) was added to a vial containing Amine 200 (0.723 g, 3.36 mmol, 1 eq) and a stirring bar. The vial was sealed and warmed to 80°C. The reaction was stirred for 4 days at 80°C. Then the mixture was purified by silica gel chromatography using a gradient from pure dichloromethane (DCM) to DCM:MeOH 98:2. The target compound was further purified by RP-HPLC to afford the desired compound.

14791[0001161] DLin-MC3-DMA and precursors were synthesized according to procedures described in WO 2010054401 herein incorporated by reference in its entirety. A mixture of dilinoleyl methanol (1.5 g, 2.8 mmol, 1 eq), Ν,Ν-dimethylaminobutyric acid (1.5 g, 2.8 mmol, leq), DIPEA (0.73 mL, 4.2 mmol, 1.5 eq) and TBTU(1.35 g, 4.2 mmol, 1.5 eq) in 10 mL of DMF was stirred for 10 h at room temperature. Then the reaction mixture was diluted in ether and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtrated and concentrated under reduced pressure. The crude product was purified by silica gel chromatography using a gradient DCM to DCM:MeOH 98:2.

14792Subsequently the target compound was subjected to an additional RP-HPLC purification which was done using a YMC - Pack C4 column to afford the target compound.

14793B. Formulation of Modified RNA Nanoparticles

14794[0001162] Solutions of synthesized lipid, 1 ,2-distearoyl-3 -phosphatidylcholine (DSPC) (Avanti Polar Lipids, Alabaster, AL), cholesterol (Sigma- Aldrich, Taufkirchen,

14795Germany), and a-[3'-(l ,2-dimyristoyl-3-propanoxy)-carboxamide-propyl]-ro-methoxy- polyoxyethylene (PEG-c-DOMG) (NOF, Bouwelven, Belgium) were prepared at concentrations of 50 mM in ethanol and stored at -20°C. The lipids were combined to yield molar ratio of 50: 10:38.5: 1.5 (Lipid: DSPC: Cholesterol: PEG-c-DOMG) and diluted with ethanol to a final lipid concentration of 25 mM. Solutions of modified mRNA at a concentration of 1-2 mg/mL in water were diluted in 50 mM sodium citrate buffer at a pH of 3 to form a stock modified mRNA solution. Formulations of the lipid and modified mRNA were prepared by combining the synthesized lipid solution with the modified mRNA solution at total lipid to modified mRNA weight ratio of l0: l, 15: 1, 20: 1 and 30: 1. The lipid ethanolic solution was rapidly injected into aqueous modified mRNA solution to afford a suspension containing 33% ethanol. The solutions were injected either manually (MI) or by the aid of a syringe pump (SP) (Harvard Pump 33 Dual Syringe Pump Harvard Apparatus Holliston, MA).

14796[0001163] To remove the ethanol and to achieve the buffer exhange, the formulations were dialyzed twice against phosphate buffered saline (PBS), pH 7.4 at volumes 200- times of the primary product using a Slide- A-Lyzer cassettes (Thermo Fisher Scientific Inc. Rockford, IL) with a molecular weight cutoff (MWCO) of 10 kD. The first dialysis was carried at room temperature for 3 hours and then the formulations were dialyzed overnight at 4°C. The resulting nanoparticle suspension was filtered through 0.2 μιη sterile filter (Sarstedt, Numbrecht, Germany) into glass vials and sealed with a crimp closure.

14797C. Characterization of formulations

14798[0001164] A Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) was used to determine the particle size, the polydispersity index (PDI) and the zeta potential of the modified mRNA nanoparticles in IX PBS in determining particle size and 15 mM PBS in determining zeta potential.

14799[0001165] Ultraviolet-visible spectroscopy was used to determine the concentration of modified mRNA nanoparticle formulation. 100 μΐ^ of the diluted formulation in IX PBS was added to 900 μΐ^ of a 4: 1 (v/v) mixture of methanol and chloroform. After mixing, the absorbance spectrum of the solution was recorded between 230 nm and 330 nm on a DU 800 spectrophotometer (Beckman Coulter, Beckman Coulter, Inc., Brea, CA). The modified RNA concentration in the nanoparicle formulation was calculated based on the extinction coefficient of the modified RNA used in the formulation and on the difference between the absorbance at a wavelength of 260 nm and the baseline value at a wavelength of 330 nm.

14800[0001166] QUANT-IT™ RIBOGREEN® RNA assay (Invitrogen Corporation Carlsbad, CA) was used to evaluate the encapsulation of modified RNA by the nanoparticle. The samples were diluted to a concentration of approximately 5 μg/mL in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). 50 of the diluted samples were transferred to a polystyrene 96 well plate, then either 50 of TE buffer or 50 of a 2% Triton X-100 solution was added. The plate was incubated at a temperature of 37°C for 15 minutes. The RIBOGREEN® reagent was diluted 1 : 100 in TE buffer, 100 μΕ of this solution was added to each well. The fluorescence intensity was measured using a fluorescence plate reader (Wallac Victor 1420 Multilablel Counter; Perkin Elmer, Waltham, MA) at an excitation wavelength of -480 nm and an emission wavelength of -520 nm. The fluorescence values of the reagent blank were subtracted from that of each of the samples and the percentage of free modified RNA was determined by dividing the fluorescence intensity of the intact sample (without addition of Triton X-100) by the fluorescence value of the disrupted sample (caused by the addition of Triton X-100).

14801D. In Vitro Incubation

14802[0001167] Human embryonic kidney epithelial (HEK293) and hepatocellular carcinoma epithelial (HepG2) cells (LGC standards GmbH, Wesel, Germany) were seeded on 96- well plates (Greiner Bio-one GmbH, Frickenhausen, Germany) and plates for HEK293 cells were precoated with collagen typel . HEK293 were seeded at a density of 30,000 and HepG2 were seeded at a density of 35,000 cells per well in 100 μΐ cell culture medium. For HEK293 the cell culture medium was DMEM, 10% FCS, adding 2mM L- Glutamine, 1 mM Sodiumpyruvate and lx non-essential amino acids (Biochrom AG, Berlin, Germany) and 1.2 mg/ml Sodiumbicarbonate (Sigma- Aldrich, Munich, Germany) and for HepG2 the culture medium was MEM (Gibco Life Technologies, Darmstadt, Germany), 10% FCS adding 2mM L-Glutamine, 1 mM Sodiumpyruvate and lx nonessential amino acids (Biochrom AG, Berlin, Germany. Formulations containing mCherry mRNA (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) were added in quadruplicates directly after seeding the cells and incubated. The mCherry cDNA with the T7 promoter, 5 'untranslated region (UTR) and 3' UTR used in in vitro transcription (IVT) is given in SEQ ID NO: 56154. The mCherry mRNA was modified with a 5meC at each cytosine and pseudouridine replacement at each uridine site.

14803[0001168] Cells were harvested by transferring the culture media supernatants to a 96- well Pro-Bind U-bottom plate (Beckton Dickinson GmbH, Heidelberg, Germany). Cells were trypsinized with ½ volume Trypsin/EDTA (Biochrom AG, Berlin, Germany), pooled with respective supernatants and fixed by adding one volume PBS/2%FCS (both Biochrom AG, Berlin, Germany)/0.5% formaldehyde (Merck, Darmstadt, Germany). Samples then were submitted to a flow cytometer measurement with a 532nm excitation laser and the 610/20 filter for PE-Texas Red in a LSRII cytometer (Beckton Dickinson GmbH, Heidelberg, Germany). The mean fluorescence intensity (MFI) of all events and the standard deviation of four independent wells are presented in for samples analyzed.

14804Example 11. Purification of Nanoparticle Formulations

14805[0001169] Nanoparticle formulations of DLin-KC2-DMA and 98N12-5 in HEK293 and HepG2 were tested to determine if the mean fluorescent intensity (MFI) was dependent on the lipid to modified RNA ratio and/or purification. Three formulations of DLin- KC2-DMA and two formulations of 98N12-5 were produced using a syringe pump to the specifications described in Table 12. Purified samples were purified by SEPHADEX™ G-25 DNA grade (GE Healthcare, Sweden). Each formulation before and after purification (aP) was tested at concentration of 250 ng modified RNA per well in a 24 well plate. The percentage of cells that are positive for the marker for FL4 channel (%FL4-positive) when analyzed by the flow cytometer for each formulation and the background sample, and the MFI of the marker for the FL4 channel for each formulation and the background sample are shown in Table 13. The formulations which had been purified had a slightly higher MFI than those formulations tested before purification.

14806Table 12. Formulations

14807<img file="WO2013151663A1_D0159.tif" /> NPA-003-1 DLin-KC2-DMA 20 114 nm

PDI: 0.08

14809NPA-003-1 aP DLin-KC2-DMA 20 104 nm

PDI: 0.06

14811NPA-005-1 98N12-5 15 127 nm

PDI: 0.12

14813NPA-005-1 aP 98N12-5 15 134 nm

PDI: 0.17

14815NPA-006-1 98N12 20 126 nm

PDI: 0.08

14817NPA-006-1 aP 98N12 20 118 nm

PDI: 0.13

14819Table 13. HEK293 and HepG2, 24-well, 250 ng Modified RNA/well

14820<img file="WO2013151663A1_D0160.tif" />

14821Example 12. Concentration Response Curve

14822[0001170] Nanoparticle formulations of 98N12-5 (NPA-005) and DLin-KC2-DMA (NPA-003) were tested at varying concentrations to determine the MFI of FL4 or mCherry (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5- methylcytosine and pseudouridine) over a range of doses. The formulations tested are outlined in Table 14. To determine the optimal concentration of nanoparticle

14823formulations of 98N12-5, varying concentrations of formulated modified RNA (100 ng, 10 ng, 1.0 ng, 0.1 ng and 0.01 ng per well) were tested in a 24-well plate of HEK293, and the results of the FL4 MFI of each dose are shown in Table 15. Likewise, to determine the optimal concentration of nanoparticle formulations of DLin-KC2-DMA, varying concentrations of formulated modified RNA (250 ng 100 ng, 10 ng, 1.0 ng, 0.1 ng and 0.01 ng per well) were tested in a 24-well plate of HEK293, and the results of the FL4 MFI of each dose are shown in Table 16. Nanoparticle formulations of DLin-KC2-DMA were also tested at varying concentrations of formulated modified RNA (250 ng, 100 ng and 30 ng per well) in a 24 well plate of HEK293, and the results of the FL4 MFI of each dose are shown in Table 17. A dose of 1 ng/well for 98N12-5 and a dose of 10 ng/well for DLin-KC2-DMA were found to resemble the FL4 MFI of the background.

14824[0001171] To determine how close the concentrations resembled the background, we utilized a flow cytometer with optimized filter sets for detection of mCherry expression, and were able to obtain results with increased sensitivity relative to background levels. Doses of 25 ng/well, 0.25 ng/well, 0.025 ng/well and 0.0025 ng/well were analyzed for 98N12-5 (NPA-005) and DLin-KC2-DMA (NPA-003) to determine the MFI of mCherry. As shown in Table 18, the concentration of 0.025 ng/well and lesser concentrations are similar to the background MFI level of mCherry which is about 386.125.

14825Table 14. Formulations

14826<img file="WO2013151663A1_D0161.tif" />

14827Table 15. HEK293, NPA-005, 24-well, n=4

14828<img file="WO2013151663A1_D0162.tif" />

14829Table 16. HEK293, NPA-003, 24-well, n=4

14830<img file="WO2013151663A1_D0163.tif" /> NPA-003 0.1 ng 0.34625

14831NPA-003 0.01 ng 0.3475

14832Table 17. HEK293, NPA-003, 24-well, n=4

14833<img file="WO2013151663A1_D0164.tif" />

14834Table 18. Concentration and MFI

14835<img file="WO2013151663A1_D0165.tif" />

14836Example 13. Manual Injection and Syringe Pump Formulations

14837[0001172] Two formulations of DLin-KC2-DMA and 98N12-5 were prepared by manual injection (MI) and syringe pump injection (SP) and analyzed along with a background sample to compare the MFI of mCherry (mR A sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) of the different formulations. Table 19 shows that the syringe pump formulations had a higher MFI as compared to the manual injection formulations of the same lipid and lipid/RNA ratio.

14838Table 19. Formulations and MFI

14839<img file="WO2013151663A1_D0166.tif" /> 106 nm

NPA-005-2 98N12-5 15 SP 9343.75

PDI: 0.07

14842126 nm

NPA-006 98N12-5 20 MI 11182.25

PDI: 0.08

1484593 nm

NPA-006-2 98N12-5 20 SP 5167

PDI: 0.08

14848Example 14. Lipid Nanoparticle Formulations

14849[0001173] Formulations of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200 and DLin-MC3-DMA were incubated at a concentration of 60 ng/well or 62.5 ng/well in a plate of HEK293 and 62.5 ng/well in a plate of HepG2 cells for 24 hours to determine the MFI of mCherry (m NA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) for each formulation. The formulations tested are outlined in Table 20 below. As shown in Table 21 for the 60 ng/well and Tables 22, 23, 24 and 25 for the 62.5 ng/well,the formulation of NPA-003 and NPA-018 have the highest mCherry MFI and the formulations of NPA-008, NPA-010 and NPA-013 are most the similar to the background sample mCherry MFI value.

14850Table 20. Formulations

14851Formulation Lipid Lipid/RNA wt/wt Mean size (nm)

14852#

14853NPA-001 DLin-KC2-DMA 10 155 nm

PDI: 0.08

14855NPA-002 DLin-KC2-DMA 15 140 nm

PDI: 0.11

14857NPA-002-2 DLin-KC2-DMA 15 105 nm

PDI: 0.04

14859NPA-003 DLin-KC2-DMA 20 114 nm

PDI: 0.08

14861NPA-003-2 DLin-KC2-DMA 20 95 nm

PDI: 0.02

14863NPA-005 98N12-5 15 127 nm

PDI: 0.12

14865NPA-006 98N12-5 20 126 nm

PDI: 0.08

14867NPA-007 DLin-DMA 15 148 nm

PDI: 0.09

14869NPA-008 DLin-K-DMA 15 121 nm

PDI: 0.08

14871NPA-009 C12-200 15 138 nm

PDI: 0.15

14873NPA-010 DLin-MC3-DMA 15 126 nm

PDI: 0.09

14875NPA-012 DLin-DMA 20 86 nm

14876PDI: 0.08 NPA-013 DLin-K-DMA 20 104 nm

PDI: 0.03

14878NPA-014 C12-200 20 101 nm

PDI: 0.06

14880NPA-015 DLin-MC3-DMA 20 109 nm

PDI: 0.07

14882Table 21. HEK293, 96-well, 60 ng Modified RNA/well

14883<img file="WO2013151663A1_D0167.tif" /> NPA-007 3504

NPA-012 8286

NPA-017 6128

NPA-003-2 17528

NPA-018 34142

NPA-010 1095

NPA-015 5859

NPA-019 3229

14891Table 24. HepG2, 62.5 ng /well

14892Formulation MFI mCherry

14893Untreated 649.94

NPA-001 6006.25

NPA-002 8705

NPA-002-2 15860.25

NPA-003 15059.25

NPA-003-2 28881

NPA-005 1676

NPA-006 1473

NPA-007 15678

NPA-008 2976.25

NPA-009 961.75

NPA-010 3301.75

NPA-012 18333.25

NPA-013 5853

NPA-014 2257

NPA-015 16225.75

14909Table 25. HepG2, 62.5 ng /well

14910Formulation MFI mCherry

14911Untreated control 656

NPA-007 16798

NPA-012 21993

NPA-017 20377

NPA-003-2 35651

NPA-018 40154

NPA-010 2496

NPA-015 19741

NPA-019 16373

14920Example 15. In vivo formulation studies

14921[0001174] Rodents (n=5) are administered intravenously, subcutaneously or

14922intramuscularly a single dose of a formulation containing a modified mRNA and a lipid. The modified mRNA administered to the rodents is selected from G-CSF (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl), erythropoietin (EPO) (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl), Factor IX (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) or mCherry (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl). The erythropoietin cDNA with the T7 promoter, 5 'untranslated region (UTR) and 3' UTR used in in vitro transcription (IVT) is given in SEQ ID NO: 56157 and SEQ ID NO: 56158.

14923[0001175] Each formulation also contains a lipid which is selected from one of DLin- DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3 -DMA, reLNP, ATUPLEX®, DACC and DBTC. The rodents are injected with lOOug, 10 ug or 1 ug of the formulated modified mRNA and samples are collected at specified time intervals.

14924[0001176] Serum from the rodents administered formulations containing human G-CSF modified mRNA are measured by specific G-CSF ELISA and serum from mice administered human factor IX modified RNA is analyzed by specific factor IX ELISA or chromogenic assay. The liver and spleen from the mice administered with mCherry modified mRNA are analyzed by immunohistochemistry (IHC) or fiuorescence-activated cell sorting (FACS). As a control, a group of mice are not injected with any formulation and their serum and tissue are collected analyzed by ELISA, FACS and/or IHC.

14925A. Time Course

14926[0001177] The rodents are administered formulations containing at least one modified mRNA to study the time course of protein expression for the administered formulation. The rodents are bled at specified time intervals prior to and after administration of the modified mRNA formulations to determine protein expression and complete blood count. Samples are also collected from the site of administration of rodents administered modified mRNA formulations subcutaneously and intramuscularly to determine the protein expression in the tissue.

14927B. Dose Response

14928[0001178] The rodents are administered formulations containing at least one modified mRNA to determine dose response of each formulation. The rodents are bled at specified time intervals prior to and after administration of the modified mRNA formulations to determine protein expression and complete blood count. The rodents are also sacrified to analyze the effect of the modified mRNA formulation on the internal tissue. Samples are also collected from the site of administration of rodents administered modified mRNA formulations subcutaneously and intramuscularly to determine the protein expression in the tissue.

14929C. Toxicity

14930[0001179] The rodents are administered formulations containing at least one modified mRNA to study toxicity of each formulation. The rodents are bled at specified time intervals prior to and after administration of the modified mRNA formulations to determine protein expression and complete blood count. The rodents are also sacrificedto analyze the effect of the modified mRNA formulation on the internal tissue. Samples are also collected from the site of administration of rodents administered modified mRNA formulations subcutaneously and intramuscularly to determine the protein expression in the tissue.

14931Example 16. PLGA Microsphere Formulations

14932[0001180] Optimization of parameters used in the formulation of PLGA microspheres may allow for tunable release rates and high encapsulation efficiencies while maintaining the integrity of the modified RNA encapsulated in the microspheres. Parameters such as, but not limited to, particle size, recovery rates and encapsulation efficiency may be optimized to achieve the optimal formulation.

14933A. Synthesis of PLGA microspheres

14934[0001181] Polylacticglycolic acid (PLGA) microspheres were synthesized using the water/oil/water double emulsification methods known in the art using PLGA (Lactel,

14935Cat# B6010-2, inherent viscosity 0.55-0.75, 50:50 LA:GA), polyvinylalcohol (PVA)

14936(Sigma, Cat# 348406-25G, MW 13-23k) dichloromethane and water. Briefly, 0.1 ml of water (Wl) was added to 2 ml of PLGA dissolved in dichloromethane (DCM) (01) at concentrations ranging from 50 - 200 mg/ml of PLGA. The Wl/Ol emulsion was homogenized (IKA Ultra-Turrax Homogenizer, T18) for 30 seconds at speed 4 (-15,000 rpm). The Wl/Ol emulsion was then added to 100 to 200 ml of 0.3 to 1% PVA (W2) and homogenized for 1 minute at varied speeds. Formulations were left to stir for 3 hours and then washed by centrifugation (20-25 min, 4,000 rpm, 4°C). The supernatant was discarded and the PLGA pellets were resuspended in 5-10 ml of water, which was repeated 2x. Average particle size (represents 20 -30 particles) for each formulation was determined by microscopy after washing. Table 26 shows that an increase in the PLGA concentration led to larger sized microspheres. A PLGA concentration of 200 mg/mL gave an average particle size of 14.8 μιη, 100 mg/mL was 8.7 μιη, and 50 mg/mL of

14937PLGA gave an average particle size of 4.0 μιη.

14938Table 26. Varied PLGA Concentration

14939<img file="WO2013151663A1_D0168.tif" />

14940[0001182] Table 27 shows that decreasing the homogenization speed from 5 (-20,000 rpm) to speed 4 (-15,000 rpm) led to an increase in particle size from 14.8 μιη to 29.7 μιη.

14941Table 27. Varied Homogenization Speed

14942<img file="WO2013151663A1_D0169.tif" />

14943[0001183] Table 28 shows that increasing the W2 volume (i.e. increasing the ratio of W2:01 from 50: 1 to 100: 1), decreased average particle size slightly. Altering the PVA concentration from 0.3 to 1 wt% had little impact on PLGA microsphere size.

14944Table 28. Varied W2 Volume and Concentration

14945<img file="WO2013151663A1_D0170.tif" /> B. Encapsulation of modified mRNA

14946[0001184] Modified G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) was dissolved in water at a concentration of 2 mg/ml (W3). Three batches of PLGA microsphere formulations were made as described above with the following parameters: 0.1 ml of W3 at 2 mg/ml, 1.6 ml of 01 at 200 mg/ml, 160 ml of W2 at 1%, and homogenized at a speed of 4 for the first emulsion (W3/01) and homogenized at a speed of 5 for the second emulstion

14947(W3/01/W2). After washing by centrifugation, the formulations were frozen in liquid nitrogen and then lyophilized for 3 days. To test the encapsulation efficiency of the formulations, the lyophilized material was deformulated in DCM for 6 hours followed by an overnight extraction in water. The modified RNA concentration in the samples was then determined by OD260. Encapsulation efficiency was calculated by taking the actual amount of modified RNA and dividing by the starting amount of modified RNA. In the three batches tested, there was an encapsulation efficiency of 59.2, 49.8 and 61.3.

14948C. Integrity of modified mRNA encapsulated in PLGA microspheres

14949[0001185] Modified Factor IX mRNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) was dissolved in water at varied concentrations (W4) to vary the weight percent loading in the formulation (mg modified

14950RNA/mg PLGA * 100) and to determine encapsulation efficiency. The parameters in

14951Table 29 were used to make four different batches of PLGA microsphere formulations with a homogenization speed of 4 for the first emulstion (W4/01) and a homogenization speed of 5 for the second emulsion (W4/01/W2).

14952Table 29. Factor IX PLGA Microsphere Formulation Parameters

14953<img file="WO2013151663A1_D0171.tif" /> [0001186] After lyophilization, PLGA microspheres were weighed out in 2 ml eppendorf tubes to correspond to ~ 10 ug of modified RNA. Lyophilization was found to not destroy the overall structure of the PLGA microspheres. To increase weight percent loading (wt%) for the PLGA microspheres, increasing amounts of modified RNA were added to the samples. PLGA microspheres were deformulated by adding 1.0 ml of DCM to each tube and then shaking the samples for 6 hours. For modified RNA extraction, 0.5 ml of water was added to each sample and the samples were shaken overnight before the concentration of modified RNA in the samples was determined by OD260. To determine the recovery of the extraction process, unformulated Factor IX modified RNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl ; fully modified with 5-methylcytosine and

14954pseudouridine) (deformulation control) was spiked into DCM and was subjected to the deformulation process. Table 30 shows the loading and encapsulation efficiency for the samples. All encapsulation efficiency samples were normalized to the deformulation control.

14955Table 30. Weight Percent Loading and Encapsulation Efficiency

14956<img file="WO2013151663A1_D0172.tif" />

14957D. Release study of modified mRNA encapsulated in PLGA microspheres

14958[0001187] PLGA microspheres formulated with Factor IX modified RNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl ; fully modified with 5-methylcytosine and

14959pseudouridine) were deformulated as described above and the integrity of the extracted modified RNA was determined by automated electrophoresis (Bio-Rad Experion). The extracted modified mRNA was compared against unformulated modified mRNA and the deformulation control in order to test the integrity of the encapsulated modified mRNA. As shown in Figure 4, the majority of modRNA was intact for batch ID A, B, C and D, for the deformulated control (Deform control) and the unformulated control (Unform control).

14960E. Protein Expression of modified mRNA encapsulated in PLGA microspheres

14961[0001188] PLGA microspheres formulated with Factor IX modified RNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and

14962pseudouridine) were deformulated as described above and the protein expression of the extracted modified RNA was determined by an in vitro transfection assay. HEK293 cells were reverse transfected with 250 ng of Factor IX modified RNA complexed with

14963RNAiMAX (Invitrogen) in triplicate.

14964[0001189] Factor IX modified RNA was diluted in nuclease-free water to a concentration of 25 ng/μΐ and RNAiMAX was diluted 13.3x in serum- free EMEM. Equal volumes of diluted modified RNA and diluted RNAiMAX were mixed together and were allowed to stand for 20 to 30 minutes at room temperature. Subsequently, 20 μΐ of the transfection mix containing 250 ng of Factor IX modified RNA was added to 80 μΐ of a cell suspension containing 30,000 cells. Cells were then incubated for 16h in a humidified 37°C/5% C02 cell culture incubator before harvesting the cell culture supernatant.

14965Factor IX protein expression in the cell supernatant was analyzed by an ELISA kit specific for Factor IX (Molecular Innovations, Cat # HFIXKT-TOT) and the protein expression is shown in Table 31 and Figure 5. In all PLGA microsphere batches tested, Factor IX modified RNA remained active and expressed Factor IX protein after formulation in PLGA microspheres and subsequent deformulation.

14966Table 31. Protein Expression

14967<img file="WO2013151663A1_D0173.tif" /> F. Release study of modified mRNA encapsulated in PLGA microspheres

14968[0001190] PLGA micropsheres formulated with Factor IX modified RNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and

14969pseudouridine) were resuspended in water to a PLGA microsphere concentration of 24 mg/ml. After resuspension, 150 ul of the PLGA microsphere suspension was aliquoted into eppendorf tubes. Samples were kept incubating and shaking at 37°C during the course of the study. Triplicate samples were pulled at 0.2, 1, 2, 8, 14, and 21 days. To determine the amount of modified RNA released from the PLGA microspheres, samples were centrifuged, the supernatant was removed, and the modified RNA concentration in the supernatant was determined by OD 260. The percent release, shown in Table 32, was calculated based on the total amount of modified RNA in each sample. After 31 days,

1497096% of the Factor IX modified RNA was released from the PLGA microsphere formulations.

14971Table 32. Percent Release

14972<img file="WO2013151663A1_D0174.tif" />

14973G. Particle size reproducibility of PLGA microspheres

14974[0001191] Three batches of Factor IX modified RNA (mRNA sequence shown in SEQ

14975ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence;

149765'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) PLGA

14977microspheres were made using the same conditions described for Batch D, shown in

14978Table 29, (0.4 ml of W4 at 4 mg/ml, 2.0 ml of 01 at 200 mg/ml, 200 ml of W2 at 1%, and homogenized at a speed of 5 for the W4/01/W2 emulsion). To improve the homogeneity of the PLGA microsphere suspension, filtration was incorporated prior to centrifugation. After stirring for 3 hours and before centrifuging, all formulated material was passed through a 100 μιη nylon mesh strainer (Fisherbrand Cell Strainer, Cat # 22- 363-549) to remove larger aggregates. After washing and resuspension with water, 100- 200 μΐ of a PLGA microspheres sample was used to measure particle size of the formulations by laser diffraction (Malvern Mastersizer2000). The particle size of the samples is shown in Table 33.

14979Table 33. Particle Size Summary

14980<img file="WO2013151663A1_D0175.tif" />

14981[0001192] Results of the 3 PLGA microsphere batches using filtration were compared to a PLGA microsphere batch made under the same conditions without filtration. The inclusion of a filtration step before washing reduced the mean particle size and demonstrated a consistent particle size distribution between 3 PLGA microsphere batches.

14982H. Serum Stability of Factor IX PLGA Microspheres

14983[0001193] Factor IX mRNA RNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl ; fully modified with 5-methylcytosine and pseudouridine) in buffer (TE) or 90% serum (Se), or Factor IX mRNA in PLGA in buffer, 90% serum or 1% serum was incubated in buffer, 90% serum or 1% serum at an mRNA concentration of 50 ng/ul in a total volume of 70 ul. The samples were removed at 0, 30, 60 or 120 minutes. RNases were inactivated with proteinase K digestion for 20 minutes at 55°C by adding 25 ul of 4x proteinase K buffer (0.4 ml 1M TRIS-HCl pH 7.5, 0.1 ml 0.5M EDTA, 0.12 ml 5M NaCl, and 0.4ml 10% SDS) and 8 ul of proteinase K at 20 mg/ml. The Factor IX mRNA was precipitated (add 250 ul 95% ethanol for 1 hour, centrifuge for 10 min at 13 k rpm and remove supernatant, add 200 ul 70% ethanol to the pellet, centrifuge again for 5 min at 13 k rpm and remove supernatant and resuspend the pellet in 70 ul water) or extracted from PLGA microspheres (centrifuge 5 min at 13k rpm and remove supernatant, wash pellet with 1 ml water, centrifuge 5 min at 13k rpm and remove supernatant, add 280 ul dichloromethane to the pellet and shake for 15 minutes, add 70 ul water and then shake for 2 hours and remove the aqueous phase) before being analyzed by bioanalyzer. PLGA microspheres protect Factor IX modified mRNA from degradation in 90% and 1% serum over 2 hours. Factor IX modified mRNA completely degrades in 90% serum at the initial time point.

14984Example 17. Lipid nanoparticle in vivo studies

14985[0001194] G-CSF (cDNA with the T7 promoter, 5' Untranslated region (UTR) and 3'UTR used in in vitro transcription is given in SEQ ID NO: 56151. mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Cap 1; fully modified with 5-methylcytosine and pseudouridine) and Factor IX (cDNA with the T7 promoter, 5' UTR and 3'UTR used in in vitro transcription is given in SEQ ID NO: 56159. mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Cap 1; fully modified with 5-methylcytosine and pseudouridine) modified mRNA were formulated as lipid nanoparticles (LNPs) using the syringe pump method. The LNPs were formulated at a 20:1 weight ratio of total lipid to modified mRNA with a final lipid molar ratio of 50: 10:38.5: 1.5 (DLin-KC2-DMA: DSPC: Cholesterol: PEG-c-DOMG). Formulations, listed in Table 34, were characterized by particle size, zeta potential, and encapsulation.

14986Table 34. Formulations

14987<img file="WO2013151663A1_D0176.tif" />

14988[0001195] LNP formulations were administered to mice (n=5) intravenously at a modified mRNA dose of 100, 10, or 1 ug. Mice were sacrificed at 8 hrs after dosing. Serum was collected by cardiac puncture from mice that were administered with G-CSF or Factor IX modified mR A formulations. Protein expression was determined by ELISA.

14989[0001196] There was no significant body weight loss (<5%) in the G-CSF or Factor IX dose groups. Protein expression for G-CSF or Factor IX dose groups was determined by ELISA from a standard curve. Serum samples were diluted (about 20-2500x for G-CSF and about 10-25 Ox for Factor IX) to ensure samples were within the linear range of the standard curve. As shown in Table 35, G-CSF protein expression determined by ELISA was approximately 17, 1200, and 4700 ng /ml for the 1, 10, and 100 ug dose groups, respectively. As shown in Table 36, Factor IX protein expression determined by ELISA was approximately 36, 380, and 3000-11000 ng/ml for the 1, 10, and 100 ug dose groups, respectively.

14990Table 35. G-CSF Protein Expression

14991<img file="WO2013151663A1_D0177.tif" />

14992Table 36. Factor IX Protein Expression

14993<img file="WO2013151663A1_D0178.tif" />

14994[0001197] As shown in Table 37, the LNP formulations described above have about a 10,000-100,000-fold increase in protein production compared to an administration of an intravenous (IV)-lipoplex formulation for the same dosage of modified mRNA and intramuscular (IM) or subcutaneous (SC) administration of the same dose of modified mRNA in saline. As used in Table 37, the symbol "~" means about.

14995Table 37. Protein Production <img file="WO2013151663A1_D0179.tif" />

14996Materials and Methods for Examples 18-23

14997[0001198] G-CSF (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nulceotides not shown in sequence; 5'cap, Cap 1; fully modified with 5-methylcytosine and pseudouridine) and EPO (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 160 nulceotides not shown in sequence; 5'cap, Cap 1; fully modified with 5-methylcytosine and pseudouridine) modified mRNA were formulated as lipid nanoparticles (LNPs) using the syringe pump method. The LNPs were formulated at a 20: 1 weight ratio of total lipid to modified mRNA with a final lipid molar ratio of 50: 10:38.5: 1.5 (DLin-KC2-DMA: DSPC: Cholesterol: PEG-c-DOMG). Formulations, listed in Table 38, were characterized by particle size, zeta potential, and encapsulation.

14998Table 38. Formulations

14999<img file="WO2013151663A1_D0180.tif" />

15000Example 18. Lipid nanoparticle in vivo studies with modified mRNA

15001[0001199] LNP formulations, shown in Table 38 (above), were administered to rats (n=5) intravenously (IV), intramuscularly (IM) or subcutaneously (SC) at a single modified mRNA dose of 0.05 mg/kg. A control group of rats (n=4) was untreated. The rats were bled at 2 hours, 8 hours, 24 hours, 48 hours and 96 hours and after they were administered with G-CSF or EPO modified mRNA formulations to determine protein expression using ELISA. The rats administered EPO modified mRNA intravenously were also bled at 7 days.

15002[0001200] As shown in Table 39, EPO protein expression in the rats intravenously administered modified EPO mRNA was detectable out to 5 days. G-CSF in the rats intravenously administered modified G-CSF mRNA was detectable to 7 days.

15003Subcutaneous and intramuscular administration of EPO modified mRNA was detectable to at least 24 hours and G-CSF modified mRNA was detectable to at least 8 hours. In Table 39, "OSC" refers to values that were outside the standard curve and "NT" means not tested.

15004Table 39. G-CSF and EPO Protein Expression

15005<img file="WO2013151663A1_D0181.tif" /> Example 19. Time course in vivo study

15006[0001201] LNP formulations, shown in Table 38 (above), were administered to mice (n=5) intravenously (IV) at a single modified mRNA dose of 0.5, 0.05 or 0.005 mg/kg. The mice were bled at 8 hours, 24 hours, 72 hours and 6 days after they were

15007administered with G-CSF or EPO modified mRNA formulations to determine protein expression using ELISA.

15008[0001202] As shown in Table 40, EPO and G-CSF protein expression in the mice administered with the modified mRNA intravenously was detectable out to 72 hours for the mice dosed with 0.005 mg/kg and 0.05 mg/kg of modified mRNA and out to 6 days for the mice administered the EPO modified mRNA. In Table 40, ">" means greater than and "ND" means not detected.

15009Table 40. Protein Expression

15010<img file="WO2013151663A1_D0182.tif" />

15011Example 20. LNP formulations in vivo study in rodents

15012A. LNP Formulations in Mice

15013[0001203] LNP formulations, shown in Table 38 (above), were administered to mice

15014(n=4) intravenously (IV) at a single modified mRNA dose 0.05 mg/kg or 0.005 mg/kg.

15015There was also 3 control groups of mice (n=4) that were untreated. The mice were bled at 2 hours, 8 hours, 24 hours, 48 hours and 72 hours after they were administered with G- CSF or EPO modified mRNA formulations to determine the protein expression. Protein expression of G-CSF and EPO were determined using ELISA.

15016[0001204] As shown in Table 41, EPO and G-CSF protein expression in the mice was detectable at least out to 48 hours for the mice that received a dose of 0.005 mg/kg modified RNA and 72 hours for the mice that received a dose of 0.05 mg/kg modified RNA. In Table 41, "OSC" refers to values that were outside the standard curve and "NT" means not tested.

15017Table 41. Protein Expression in Mice

15018<img file="WO2013151663A1_D0183.tif" />

15019B. LNP Formulations in Rodents

15020[0001205] LNP formulations, shown in Table 38 (above), are administered to rats (n=4) intravenously (IV) at a single modified mRNA dose 0.05 mg/kg. There is also a control group of rats (n=4) that are untreated. The rats are bled at 2 hours, 8 hours, 24 hours, 48 hours, 72 hours, 7 days and 14 days after they were administered with G-CSF or EPO modified mRNA formulations to determine the protein expression. Protein expression of

15021G-CSF and EPO are determined using ELISA.

15022Example 21. Early Time Course Study of LNPs [0001206] LNP formulations, shown in Table 38 (above), are administered to mammals intravenously (IV), intramuscularly (IM) or subcutaneously (SC) at a single modified mRNA dose of 0.5 mg/kg, 0.05 mg/kg or 0.005 mg/kg. A control group of mammals are not treated. The mammals are bled at 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours and/or 2 hours after they are administered with the modified mRNA LNP formulations to determine protein expression using ELISA. The mammals are also bled to determine the complete blood count such as the granulocyte levels and red blood cell count.

15023Example 22. Non-human primate in vivo study

15024[0001207] LNP formulations, shown in Table 38 (above), were administered to non- human primates (NHP) (cynomolgus monkey) (n=2) as a bolus intravenous injection (IV) over approximately 30 seconds using a hypodermic needle, which may be attached to a syringe/abbocath or butterfly if needed. The NHP were administered a single modified mRNA IV dose of 0.05mg/kg of EPO or G-CSF or 0.005 mg/kg of EPO in a dose volume of 0.5 mL/kg. The NHPs were bled 5-6 days before dosing with the modified mRNA LNP formulations to determine protein expression in the serum and a baseline complete blood count. After administration with the modified mRNA formulation the NHP were bled at 8, 24, 48 and 72 hours to determined protein expression. At 24 and 72 hours after administration the complete blood count of the NHP was also determined. Protein expression of G-CSF and EPO was determined by ELISA.Urine from the NHPs was collected over the course of the entire experiment and analyzed to evaluate clinical safety. Samples were collected from the NHPs after they were administered with G-CSF or EPO modified mRNA formulations to determine protein expression using ELISA. Clinical chemistry, hematology, urinalysis and cytokines of the non-human primates were also analyzed.

15025[0001208] As shown in Table 42, EPO protein expression in the NHPs administered 0.05 mg/kg is detectable out to 72 hours and the 0.005 mg/kg dosing of the EPO formulation is detectable out to 48 hours. In Table 42, the "<" means less than a given value. G-CSF protein expression was seen out to 24 hours after administration with the modified mRNA formulation. Preliminarily, there was an increase in granulocytes and reticulocytes levels seen in the NHP after administration with the modified mRNA formulations.

15026Table 42. Protein Expression in Non-Human Primates

15027<img file="WO2013151663A1_D0184.tif" />

15028Example 23. Non-human primate in vivo study for G-CSF and EPO

15029[0001209] LNP formulations, shown in Table 38 (above), were administered to non- human primates (NHP) (cynomolgus monkey) (n=2) as intravenous injection (IV). The NHP were administered a single modified mRNA IV dose of 0.5 mg/kg, 0.05mg/kg or 0.005 mg/kg of G-CSF or EPO in a dose volume of 0.5 mL/kg. The NHPs were bled before dosing with the modified mRNA LNP formulations to determine protein expression in the serum and a baseline complete blood count. After administration with the G-CSF modified mRNA formulation the NHP were bled at 8, 24, 48 and 72 hours to determined protein expression. After administration with the EPO modified mRNA formulation the NHP were bled at 8, 24, 48, 72 hours and 7 days to determined protein expression.

15030[0001210] Samples collected from the NHPs after they were administered with G-CSF or EPO modified mRNA formulations were analyzed by ELISA to determine protein expression. Neutrophil and reticulocyte count was also determined pre-dose, 24 hours, 3 days, 7 days, 14 days and 18 days after administration of the modified G-CSF or EPO formulation.

15031[0001211] As shown in Table 43, G-CSF protein expression was not detected beyond 72 hours. In Table 43, "<39" refers to a value below the lower limit of detection of 39 pg/ml.

15032Table 43. G-CSF Protein Expression

15033<img file="WO2013151663A1_D0185.tif" /> [0001212] As shown in Table 44, EPO protein expression was not detected beyond 7 days. In Table 44, "<7.8" refers to a value below the lower limit of detection of 7.8 pg/ml.

15034Table 44. EPO Protein Expression

15035<img file="WO2013151663A1_D0186.tif" />

15036[0001213] As shown in Table 45, there was an increase in neutrophils in all G-CSF groups relative to pre-dose levels.

15037Table 45. Pharmacologic Effect of G-CSF mRNA in NHP

15038<img file="WO2013151663A1_D0187.tif" /> Pre-dose 1.53 1.27 9.72 1.82

1503924 hours 14.92 13.96 7.5 11.85

150400.5 3 days 9.76 13.7 11.07 5.22

150417 days 2.74 3.81 11.8 2.85

1504214/18 days 2.58 1.98 7.16 2.36

15043Pre-dose 13.74 3.05 0.97 2.15

1504424 hours 19.92 29.91 2.51 2.63

150450.05 3 days 7.49 10.77 1.73 4.08

150467 days 4.13 3.8 1.23 2.77

1504714/18 days 3.59 1.82 1.53 1.27

15048Pre-dose 1.52 2.54 5.46 5.96

1504924 hours 16.44 8.6 5.37 2.59

150500.005 3 days 3.74 1.78 6.08 2.83

150517 days 7.28 2.27 3.51 2.23

1505214/18 days 4.31 2.28 1.52 2.54

15053[0001214] As shown in Table 46, there was an increase in reticulocytes in all EPO groups 3 days to 14/18 days after dosing relative to reticulocyte levels 24 hours after dosing.

15054Table 46. Pharmacologic Effect of EPO mRNA on Neutrophil Count

15055<img file="WO2013151663A1_D0188.tif" /> 14/18 days 0.107 0.06 0.067 0.055

15056Pre-dose 0.037 0.06 0.036 0.052

1505724 hours 0.037 0.07 0.034 0.061

150580.005 3 days 0.037 0.054 0.079 0.118

150597 days 0.046 0.066 0.049 0.087

1506014/18 days 0.069 0.057 0.037 0.06

15061[0001215] As shown in Tables 47-49, the administration of EPO modified RNA had an effect on other erythropoetic parameters including hemoglobin (HGB), hematocrit (HCT) and red blood cell (RBC) count.

15062<img file="WO2013151663A1_D0189.tif" /> 24 hours 0.37 0.38 0.4 0.36

150633 days 0.39 0.38 0.41 0.39

150647 days 0.39 0.38 0.45 0.45

1506514/18 days 0.34 0.37 0.48 0.46

15066Pre -dose 0.44 0.44 0.45 0.43

1506724 hours 0.39 0.4 0.43 0.39

150680.05 3 days 0.41 0.39 0.38 0.4

150697 days 0.42 0.4 0.45 0.41

1507014/18 days 0.44 0.4 0.46 0.43

15071Pre -dose 0.42 0.42 0.48 0.45

1507224 hours 0.4 0.42 0.42 0.43

150730.005 3 days 0.4 0.41 0.44 0.42

150747 days 0.39 0.42 0.41 0.42

1507514/18 days 0.41 0.42 0.42 0.42

15076Table 49. Pharmacologic Effect of EPO mRNA on Red Blood Cells

15077Male NHP (G- Female NHP (G- Female NHP

15078Dose Male NHP (EPO)

15079Time CSF) RBC CSF) RBC (EPO) RBC (mg/kg) RBC (1012/L)

15080(1012/L) (1012/L) (1012/L)

15081Pre -dose 5.57 5.57 5.43 5.26

1508224 hours 4.66 4.96 5.12 4.69

150830.5 3 days 4.91 4.97 5.13 5.15

150847 days 4.8 5.04 5.55 5.68

1508514/18 days 4.21 4.92 5.83 5.72

15086Pre -dose 5.68 5.64 5.57 5.84

1508724 hours 4.96 5.08 5.25 5.18

150880.05 3 days 5.13 5.04 4.81 5.16

150897 days 5.17 5.05 5.37 5.31

1509014/18 days 5.43 5.26 5.57 5.57

15091Pre -dose 5.67 5.36 6.15 5.72

1509224 hours 5.34 5.35 5.63 5.35

150930.005 3 days 5.32 5.24 5.77 5.42

150947 days 5.25 5.34 5.49 5.35

1509514/18 days 5.37 5.34 5.67 5.36 [0001216] As shown in Tables 50 and 51, the administration of modified RNA had an effect on serum chemistry parameters including alanine transaminase (ALT) and aspartate transaminase (AST).

15096<img file="WO2013151663A1_D0190.tif" />

15097Tab e 51. Pharmacolo ic Effect of EPO mRNA on As artate Transaminase

15098<img file="WO2013151663A1_D0191.tif" /> 7 days 62 52 53 78

1509914days 59 20 32 47

15100Pre -dose 35 54 39 40

151012 days 70 34 29 25

151020.005 4 days 39 36 43 55

151037 days 28 31 55 31

1510414days 39 20 35 54

15105[0001217] As shown in Table 52, the administration of lipid nanoparticle-formulated modified RNA at high doses (0.5 mg/kg) caused an increase in cytokines, interferon- alpha (IFN-alpha) after administration of modified mRNA.

15106<img file="WO2013151663A1_D0192.tif" />

15107Example 24. Study of Intramuscular and/or Subcutaneous Administration in Non- Human Primates

15108[0001218] Formulations containing modified EPO mRNA (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) or G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) in saline were administered to non-human primates (Cynomolgus monkey) (NHP) intramuscularly (IM) or subcutaneously (SC). The single modified mRNA dose of 0.05mg/kg or 0.005 mg/kg was in a dose volume of 0.5 mL/kg. The non- human primates are bled 5-6 days prior to dosing to determine serum protein

15109concentration and a baseline complete blood count. After administration with the modified mRNA formulation the NHP are bled at 8 hours, 24 hours, 48 hours, 72 hours, 7 days and 14 days to determined protein expression. Protein expression of G-CSF and EPO is determined by ELISA.At 24 hours, 72 hours, 7 days and 14 days after

15110administration the complete blood count of the NHP is also determined. Urine from the NHPs is collected over the course of the entire experiment and analyzed to evaluate clinical safety. Tissue near the injection site is also collected and analyzed to determine protein expression.

15111Example 25. Modified mRNA Trafficking

15112[0001219] In order to determine localization and/or trafficking of the modified mRNA, studies may be performed as follows.

15113[0001220] LNP formulations of siRNA and modified mRNA are formulated according to methods known in the art and/or described herein. The LNP formulations may include at least one modified mRNA which may encode a protein such as G-CSF, EPO, Factor VII, and/or any protein described herein. The formulations may be administered locally into muscle of mammals using intramuscular or subcutaneous injection. The dose of modified mRNA and the size of the LNP may be varied to determine the effect on trafficking in the body of the mammal and/or to assess the impact on a biologic reaction such as, but not limited to, inflammation. The mammal may be bled at different time points to determine the expression of protein encoded by the modified mRNA

15114administered present in the serum and/or to determine the complete blood count in the mammal.

15115[0001221] For example, modified mRNA encoding Factor VII, expressed in the liver and secreted into the serum, may be administered intramuscularly and/or subcutaneously. Coincident or prior to modified mRNA administration, siRNA is administered to knock out endogenous Factor VII. Factor VII arising from the intramuscular and/or

15116subcutaneous injection of modified mRNA is administered is measured in the blood. Also, the levels of Factor VII is measured in the tissues near the injection site. If Factor VII is expressed in blood then there is trafficking of the modified mRNA. If Factor VII is expressed in tissue and not in the blood than there is only local expression of Factor VII.

15117Example 26. Formulations of Multiple Modified mRNA

15118[0001222] LNP formulations of modified mRNA are formulated according to methods known in the art and/or described herein or known in the art. The LNP formulations may include at least one modified mRNA which may encode a protein such as G-CSF, EPO, thrombopoietin and/or any protein described herein. The at least one modified mRNA may include 1, 2, 3, 4 or 5 modified mRNA molecules. The formulations containing at least one modified mRNA may be administered intravenously, intramuscularly or subcutaneously in a single or multiple dosing regimens. Biological samples such as, but not limited to, blood and/or serum may be collected and analyzed at different time points before and/or after administration of the at least one modified mRNA formulation. An expression of a protein in a biological sample of 50-200 pg/ml after the mammal has been administered a formulation containing at least one modified mRNA encoding said protein would be considered biologically effective.

15119Example 27. Polyethylene Glycol Ratio Studies

15120A. Formulation and Characterization of PEG LNPs

15121[0001223] Lipid nanoparticles (LNPs) were formulated using the syringe pump method.

15122The LNPs were formulated at a 20: 1 weight ratio of total lipid to modified G-CSF mRNA

15123(mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine). The molar ratio ranges of the formulations are shown in Table 53.

15124Table 53. Molar Ratios <img file="WO2013151663A1_D0193.tif" />

15125[0001224] Two types of PEG lipid, 1 ,2-Dimyristoyl-sn-glycerol, methoxypolyethylene Glycol (PEG-DMG, NOF Cat # SUNBRIGHT® GM-020) and 1 ,2-Distearoyl-sn- glycerol, methoxypolyethylene Glycol (PEG-DSG, NOF Cat # SUNBRIGHT® GS-020), were tested at 1.5 or 3.0 mol%. After the formation of the LNPs and the encapsulation of the modified G-CSF mRNA, the LNP formulations were characterized by particle size, zeta potential and encapsulation percentage and the results are shown in Table 54.

15126Table 54. Characterization of LNP Formulations

15127<img file="WO2013151663A1_D0194.tif" />

15128B. In Vivo Screening of PEG LNPs

15129[0001225] Formulations of the PEG LNPs described in Table 55 were administered to mice (n=5) intravenously at a dose of 0.5 mg/kg. Serum was collected from the mice at 2 hours, 8 hours, 24 hours, 48 hours, 72 hours and 8 days after administration of the formulation. The serum was analyzed by ELISA to determine the protein expression of G-CSF and the expression levels are shown in Table 55. LNP formulations using PEG- DMG gave substantially higher levels of protein expression than LNP formulations with PEG-DSA.

15130Table 55. Protein Expression

15131<img file="WO2013151663A1_D0195.tif" /> 2 hours 3,193

151328 hours 6,162

1513324 hours 446

15134PEG-DSA, 1.5% NPA-073-1

1513548 hours 197

1513672 hours 124

151378 days 5

151382 hours 259

151398 hours 567

1514024 hours 258

15141PEG-DSA, 3% NPA-074-1

1514248 hours 160

1514372 hours 328

151448 days 33

15145Example 28. Cationic Lipid Formulation Studies

15146A. Formulation and Characterization of Cationic Lipid Nanoparticles

15147[0001226] Lipid nanoparticles (LNPs) were formulated using the syringe pump method.

15148The LNPs were formulated at a 20: 1 weight ratio of total lipid to modified mRNA. The final lipid molar ratio ranges of cationic lipid, DSPC, cholesterol and PEG-c-DOMG are outlined in Table 56.

15149Table 56. Molar Ratios <img file="WO2013151663A1_D0196.tif" />

15150[0001227] A 25 mM lipid solution in ethanol and modified RNA in 50mM citrate at a pH of 3 were mixed to create spontaneous vesicle formation. The vesicles were stabilized in ethanol before the ethanol was removed and there was a buffer exchange by dialysis. The LNPs were then characterized by particle size, zeta potential, and encapsulation percentage. Table 57 describes the characterization of LNPs encapsulating EPO modified mRNA (mRNA sequence shown in SEQ ID NO: 56155 polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl ; fully modified with 5-methylcytosine and pseudouridine) or G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotdies not shown in sequence; 5 'cap, Capl ; fully modified with 5-methylcytosine and pseudouridine) DLin-MC3 -DMA, DLin-DMA or CI 2-200 as the cationic lipid.

15151Table 57. Characterization of Cationic Lipid Formulations

15152<img file="WO2013151663A1_D0197.tif" />

15153B. In Vivo Screening of Cationic LNP Formulations

15154[0001228] Formulations of the cationic lipid formulations described in Table 57 were administered to mice (n=5) intravenously at a dose of 0.5 mg/kg. Serum was collected from the mice at 2 hours, 24 hours, 72 hours and/or 7 days after administration of the formulation. The serum was analyzed by ELISA to determine the protein expression of EPO or G-CSF and the expression levels are shown in Table 58.

15155Table 58. Protein Expression

15156<img file="WO2013151663A1_D0198.tif" />

15157[0001229] Toxcity was seen in the mice administered the LNPs formulations with the cationic lipid CI 2-200 (NPA-075-1 and NPA-076-1) and they were sacrificed at 24 hours because they showed symptoms such as scrubby fur, cowering behavior and weight loss of greater than 10%. CI 2-200 was expected to be more toxic but also had a high level of expression over a short period. The cationic lipid DLin-DMA (NPA-073-1 and NPA- 074-1) had the lowest expression out of the three cationic lipids tested. DLin-MC3-DMA (NPA-071-1 and NPA-072-1) showed good expression up to day three and was above the background sample out to day 7 for EPO formulations.

15158Example 29. Method of Screening for Protein Expression

15159A. Electrospray Ionization

15160[0001230] A biological sample which may contain proteins encoded by modified RNA administered to the subject is prepared and analyzed according to the manufacturer protocol for electrospray ionization (ESI) using 1, 2, 3 or 4 mass analyzers. A biologic sample may also be analyzed using a tandem ESI mass spectrometry system.

15161Patterns of protein fragments, or whole proteins, are compared to known controls for a given protein and identity is determined by comparison.

15162B. Matrix- Assisted Laser Desorption/Ionization

15163[0001231] A biological sample which may contain proteins encoded by modified RNA administered to the subject is prepared and analyzed according to the manufacturer protocol for matrix-assisted laser desorption/ionization (MALDI).

15164[0001232] Patterns of protein fragments, or whole proteins, are compared to known controls for a given protein and identity is determined by comparison.

15165C. Liquid Chromatography-Mass spectrometry-Mass spectrometry

15166[0001233] A biological sample, which may contain proteins encoded by modified RNA, may be treated with a trypsin enzyme to digest the proteins contained within. The resulting peptides are analyzed by liquid chromatography-mass spectrometry-mass spectrometry (LC/MS/MS). The peptides are fragmented in the mass spectrometer to yield diagnostic patterns that can be matched to protein sequence databases via computer algorithms. The digested sample may be diluted to achieve 1 ng or less starting material for a given protein. Biological samples containing a simple buffer background (e.g. water or volatile salts) are amenable to direct in-solution digest; more complex backgrounds (e.g. detergent, non-volatile salts, glycerol) require an additional clean-up step to facilitate the sample analysis. [0001234] Patterns of protein fragments, or whole proteins, are compared to known controls for a given protein and identity is determined by comparison.

15167Example 30. Lipid Nanoparticle in vivo studies

15168[0001235] mCherry mRNA (mRNA sequence shown in SEQ ID NO: 56160; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) was formulated as a lipid nanoparticle (LNP) using the syringe pump method. The LNP was formulated at a 20: 1 weight ratio of total lipid to modified mRNA with a final lipid molar ratio of 50: 10:38.5: 1.5 (DLin-KC2- DMA: DSPC: Cholesterol: PEG-c-DOMG). The mCherry formulation, listed in Table 59, was characterized by particle size, zeta potential, and encapsulation.

15169Table 59. mCherry Formulation

15170<img file="WO2013151663A1_D0199.tif" />

15171[0001236] The LNP formulation was administered to mice (n=5) intravenously at a modified mRNA dose of 100 ug. Mice were sacrificed at 24 hrs after dosing. The liver and spleen from the mice administered with mCherry modified mRNA formulations were analyzed by immunohistochemistry (IHC), western blot, or fluorescence-activated cell sorting (FACS).

15172[0001237] Histology of the liver showed uniform mCherry expression throughout the section, while untreated animals did not express mCherry. Western blots were also used to confirm mCherry expression in the treated animals, whereas mCherry was not detected in the untreated animals. Tubulin was used as a control marker and was detected in both treated and untreated mice, indicating that normal protein expression in hepatocytes was unaffected.

15173[0001238] FACS and IHC were also performed on the spleens of mCherry and untreated mice. All leukocyte cell populations were negative for mCherry expression by FACS analysis. By IHC, there were also no observable differences in the spleen in the spleen between mCherry treated and untreated mice.

15174Example 31. Syringe Pump in vivo studies

15175[0001239] mCherry modified mRNA (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) is formulated as a lipid nanoparticle (LNP) using the syringe pump method. The LNP is formulated at a 20: 1 weight ratio of total lipid to modified mRNA with a final lipid molar ratio of 50: 10:38.5: 1.5 (DLin-KC2-DMA: DSPC: Cholesterol: PEG-c-DOMG). The mCherry formulation is characterized by particle size, zeta potential, and encapsulation.

15176[0001240] The LNP formulation is administered to mice (n=5) intravenously at a modified mRNA dose of 10 or 100 ug. Mice are sacrificed at 24 hrs after dosing. The liver and spleen from the mice administered with mCherry modified mRNA formulations are analyzed by immunohistochemistry (IHC), western blot, and/or fluorescence- activated cell sorting (FACS).

15177Example 32. In vitro and in vivo Expression

15178A. In vitro Expression in Human Cells Using Lipidoid Formulations

15179[0001241] The ratio of mmRNA to lipidoid used to test for in vitro transfection is tested empirically at different lipidoid:mmRNA ratios. Previous work using siRNA and lipidoids have utilized 2.5:1, 5: 1, 10: 1, and 15: 1 lipidoid :siRN A w wt ratios. Given the longer length of mmRNA relative to siRNA, a lower wtwt ratio of lipidoid to mmRNA may be effective. In addition, for comparison mmRNA were also formulated using RNAIMAX™ (Invitrogen, Carlsbad, CA) or TRANSIT-mRNA (Minis Bio, Madison, WI) cationic lipid delivery vehicles.

15180[0001242] The ability of lipidoid-formulated Luciferase (IVT cDNA sequence as shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site), green fluorescent protein (GFP) (IVT cDNA sequence as shown in SEQ ID NO: 56163; mRNA sequence shown in SEQ ID NO: 56164, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site), G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl), and EPO mRNA (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl)to express the desired protein product can be confirmed by luminescence for luciferase expression, flow cytometry for GFP expression, and by ELISA for G-CSF and Erythropoietin (EPO) secretion.

15181B. In vivo Expression Following Intravenous Injection

15182[0001243] Systemic intravenous administration of the formulations are created using various different lipidoids including, but not limited to, 98N12-5, C 12-200, and MD1.

15183[0001244] Lipidoid formulations containing mmRNA are injected intravenously into animals. The expression of the modified mRNA (mmRNA)-encoded proteins are assessed in blood and/or other organs samples such as, but not limited to, the liver and spleen collected from the animal. Conducting single dose intravenous studies will also allow an assessment of the magnitude, dose responsiveness, and longevity of expression of the desired product.

15184[0001245] In one embodiment, lipidoid based formulations of 98N12-5, C12-200, MD1 and other lipidoids, are used to deliver luciferase, green fluorescent protein (GFP), mCherry fluorescent protein, secreted alkaline phosphatase (sAP), human G-CSF, human Factor IX, or human Erythropoietin (EPO) mmRNA into the animal. After formulating mmRNA with a lipid, as described previously, animals are divided into groups to receive either a saline formulation, or a lipidoid-formulation which contains one of a different mmRNA selected from luciferase, GFP, mCherry, sAP, human G-CSF, human Factor IX, and human EPO. Prior to injection into the animal, mmRNA-containing lipidoid formulations are diluted in PBS. Animals are then administered a single dose of formulated mmRNA ranging from a dose of 10 mg/kg to doses as low as 1 ng/kg, with a preferred range to be 10 mg/kg to 100 ng/kg, where the dose of mmRNA depends on the animal body weight such as a 20 gram mouse receiving a maximum formulation of 0.2 ml (dosing is based no mmRNA per kg body weight). After the administration of the mmRNA-lipidoid formulation, serum, tissues, and/or tissue lysates are obtained and the level of the mmRNA-encoded product is determined at a single and/or a range of time intervals. The ability of lipidoid- formulated Luciferase, GFP, mCherry, sAP, G-CSF, Factor IX, and EPO mmR A to express the desired protein product is confirmed by luminescence for the expression of Luciferase, flow cytometry for the expression of GFP and mCherry expression, by enzymatic activity for sAP, or by ELISA for the section of G-CSF, Factor IX and/or EPO.

15185[0001246] Further studies for a multi-dose regimen are also performed to determine the maximal expression of mmRNA, to evaluate the saturability of the mmRNA-driven expression (by giving a control and active mmRNA formulation in parallel or in sequence), and to determine the feasibility of repeat drug administration (by giving mmRNA in doses separated by weeks or months and then determining whether expression level is affected by factors such as immunogenicity). An assessment of the physiological function of proteins such as G-CSF and EPO are also determined through analyzing samples from the animal tested and detecting increases in granulocyte and red blood cell counts, respectively. . Activity of an expressed protein product such as Factor IX, in animals can also be assessed through analysis of Factor IX enzymatic activity (such as an activated partial thromboplastin time assay) and effect of clotting times.

15186C. In vitro Expression Following Intramuscular and/or Subcutaneous Injection

15187[0001247] The use of lipidoid formulations to deliver oligonucleotides, including mRNA, via an intramuscular route or a subcutaneous route of injection needs to be evaluated as it has not been previously reported. Intramuscular and/or subcutaneous injection of mmRNA are evaluated to determine if mmRNA-containing lipidoid formulations are capabable to produce both localized and systemic expression of a desired portiens.

15188[0001248] Lipidoid formulations of 98N12-5, C12-200, and MDlcontaining mmRNA selected from luciferase, green fluorescent protein (GFP), mCherry fluorescent protein, secreted alkaline phosphatase (sAP), human G-CSF, human factor IX, or human Erythropoietin (EPO) mmRNA are injected intramuscularly and/or subcutaneously into animals. The expression of mmRNA-encoded proteins are assessed both within the muscle or subcutaneous tissue and systemically in blood and other organs such as the liver and spleen. Single dose studies allow an assessment of the magnitude, dose responsiveness, and longevity of expression of the desired product. [0001249] Animals are divided into groups to receive either a saline formulation or a formulation containing modified mR A. Prior to injection mmR A-containing lipidoid formulations are diluted in PBS. Animals are administered a single intramuscular dose of formulated mmRNA ranging from 50 mg/kg to doses as low as 1 ng/kg with a preferred range to be 10 mg/kg to 100 ng/kg. A maximum dose for intramuscular administration, for a mouse, is roughly 1 mg mmRNA or as low as 0.02 ng mmRNA for an intramuscular injection into the hind limb of the mouse. For subcutaneous administration, the animals are administered a single subcutaneous dose of formulated mmRNA ranging from 400 mg/kg to doses as low as 1 ng/kg with a preferred range to be 80 mg/kg to 100 ng/kg. A maximum dose for subcutaneous administration, for a mouse, is roughly 8 mg mmRNA or as low as 0.02 ng mmRNA.

15189[0001250] For a 20 gram mouse the volume of a single intramuscular injection is maximally 0.025 ml and a single subcutaneous injection is maximally 0.2 ml. The optimal dose of mmRNA administered is calculated from the body weight of the animal. At various points in time points following the administration of the mmRNA-lipidoid, serum, tissues, and tissue lysates is obtained and the level of the mmRNA-encoded product is determined. The ability of lipidoid- formulated luciferase, green fluorescent protein (GFP), mCherry fluorescent protein, secreted alkaline phosphatase (sAP), human G-CSF, human factor IX, or human Erythropoietin (EPO) mmRNA to express the desired protein product is confirmed by luminescence for luciferase expression, flow cytometry for GFP and mCherry expression, by enzymatic activity for sAP, and by ELISA for G- CSF, Factor IX and Erythropoietin (EPO) secretion.

15190[0001251] Additional studies for a multi-dose regimen are also performed to determine the maximal expression using mmRNA, to evaluate the saturability of the mmRNA- driven expression (achieved by giving a control and active mmRNA formulation in parallel or in sequence), and to determine the feasibility of repeat drug administration (by giving mmRNA in doses separated by weeks or months and then determining whether expression level is affected by factors such as immunogenicity). Studies utilizing multiple subcutaneous or intramuscular injection sites at one time point, are also utilized to further increase mmRNA drug exposure and improve protein production. An assessment of the physiological function of proteins, such as GFP, mCherry, sAP, human G-CSF, human factor IX, and human EPO, are determined through analyzing samples from the tested animals and detecting a change in granulocyte and/or red blood cell counts. Activity of an expressed protein product such as Factor IX, in animals can also be assessed through analysis of Factor IX enzymatic activity (such as an activated partial thromboplastin time assay) and effect of clotting times.

15191Example 33. Bifunctional mmRNA

15192[0001252] Using the teachings and synthesis methods described herein, modified RNAs are designed and synthesized to be bifunctional, thereby encoding one or more cytotoxic protein molecules as well as be synthesized using cytotoxic nucleosides.

15193[0001253] Administration of the bifunctional modified mRNAs is effected using either saline or a lipid carrier. Once administered, the bifunctional modified mRNA is translated to produce the encoded cytotoxic peptide. Upon degradation of the delivered modified mRNA, the cytotoxic nucleosides are released which also effect therapeutic benefit to the subject.

15194Example 34. Modified mRNA Transfection

15195A. Reverse Transfection

15196[0001254] For experiments performed in a 24-well collagen-coated tissue culture plate, Keratinocytes are seeded at a cell density of 1 x 105. For experiments performed in a 96- well collagen-coated tissue culture plate, Keratinocytes are seeded at a cell density of 0.5 x 105. For each modified mRNA (mmRNA) to be transfected, modified mRNA:

15197RNAIMAX™ is prepared as described and mixed with the cells in the multi-well plate within a period of time, e.g., 6 hours, of cell seeding before cells had adhered to the tissue culture plate.

15198B. Forward Transfection

15199In a 24-well collagen-coated tissue culture plate, Keratinocytes are seeded at a cell density of 0.7 x 105. For experiments performed in a 96-well collagen-coated tissue culture plate, Keratinocytes are seeded at a cell density of 0.3 x 105. Keratinocytes are grown to a confluency of >70% for over 24 hours. For each modified mRNA (mmRNA) to be transfected, modified mRNA: RNAIMAX™ is prepared as described and transfected onto the cells in the multi-well plate over 24 hours after cell seeding and adherence to the tissue culture plate. C. Modified mRNA Translation Screen: G-CSF ELISA

15200[0001255] Keratinocytes are grown in EPILIFE medium with Supplement S7 from Invitrogen (Carlsbad, CA) at a confluence of >70%. One set of keratinocytes were reverse transfected with 300 ng of the chemically modified mRNA (mmRNA) complexed with RNAIMAX™ from Invitrogen. Another set of keratinocytes are forward transfected with 300 ng modified mRNA complexed with RNAIMAX™ from Invitrogen. The modified mRNA: RNAIMAX™ complex is formed by first incubating the RNA with Supplement-free EPILIFE® media in a 5X volumetric dilution for 10 minutes at room temperature.

15201[0001256] In a second vial, RNAIMAX™ reagent was incubated with Supplement-free EPILIFE® Media in 10X volumetric dilution for 10 minutes at room temperature. The RNA vial was then mixed with the RNAIMAX™ vial and incubated for 20-30 minutes at room temperature before being added to the cells in a drop-wise fashion. Secreted human Granulocyte-Colony Stimulating Factor (G-CSF) concentration in the culture medium is measured at 18 hours post-transfection for each of the chemically modified mRNA in triplicate.

15202[0001257] Secretion of Human G-CSF from transfected human keratinocytes is quantified using an ELISA kit from Invitrogen or R&D Systems (Minneapolis, MN) following the manufacturers recommended instructions.

15203D. Modified mRNA Dose and Duration: G-CSF ELISA

15204[0001258] Keratinocytes are grown in EPILIFE® medium with Supplement S7 from Invitrogen at a confluence of >70%. Keratinocytes are reverse transfected with either Ong, 46.875ng, 93.75ng, 187.5ng, 375ng, 750ng, or 1500ng modified mRNA complexed with the RNAIMAX™ from Invitrogen (Carlsbad, CA). The modified

15205mRNA:RNAIMAX™ complex is formed as described. Secreted human G-CSF concentration in the culture medium is measured at 0, 6, 12, 24, and 48 hours post- transfection for each concentration of each modified mRNA in triplicate. Secretion of human G-CSF from transfected human keratinocytes is quantified using an ELISA kit from Invitrogen or R&D Systems following the manufacturers recommended

15206instructions.

15207Example 35. Split dose studies [0001259] Studies utilizing multiple subcutaneous or intramuscular injection sites at one time point were designed and performed to investigate ways to increase mmRNA drug exposure and improve protein production. In addition to detection of the expressed protein product, an assessment of the physiological function of proteins was also determined through analyzing samples from the animal tested.

15208[0001260] Surprisingly, it has been determined that split dosing of mmRNA produces greater protein production and phenotypic responses than those produced by single unit dosing or multi-dosing schemes.

15209[0001261] The design of a single unit dose, multi-dose and split dose experiment involved using human erythropoietin (EPO) mmRNA (mRNA shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) administered in buffer alone. The dosing vehicle (F. buffer) consisted of 150mM NaCl, 2 mM CaCl2, 2 mM Na+-phosphate (1.4mM monobasic sodium phosphate; 0.6mM dibasic sodium phosphate), and 0.5 mM EDTA, pH 6.5. The pH was adjusted using sodium hydroxide and the final solution was filter sterilized. The mmRNA was modified with 5meC at each cytosine and pseudouridine replacement at each uridine site.

15210[0001262] Animals (n=5) were injected IM (intramuscular) for the single unit dose of 100 ug. For multi-dosing, two schedules were used, 3 doses of 100 ug and 6 doses of 100 ug. For the split dosing scheme, two schedules were used, 3 doses at 33.3 ug and 6 doses of 16.5 ug mmRNA. Control dosing involved use of buffer only at 6 doses. Control mmRNA involved the use of luciferase mmRNA (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5- methylcytosine at each cytosine and pseudouridine replacement at each uridine site) dosed 6 times at 100 ug. Blood and muscle tissue were evaluated 13 hrs post injection.

15211[0001263] Human EPO protein was measured in mouse serum 13h post I.M. single, multi- or split dosing of the EPO mmRNA in buffer. Seven groups of mice (n=5 mice per group) were treated and evaluated. The results are shown in Table 60.

15212Table 60. Split dose study <img file="WO2013151663A1_D0200.tif" /><img file="WO2013151663A1_D0201.tif" />

15213[0001264] The splitting factor is defined as the product per unit drug divided by the single dose product per unit drug (PUD). For example for treatment group 2 the value .28 or product (EPO) per unit drug (mmRNA) is divided by the single dose product per unit drug of 0.14. The result is 2. Likewise, for treatment group 4, the value 1.1 or product (EPO) per unit drug (mmRNA) is divided by the single dose product per unit drug of 0.14. The result is 7.9. Consequently, the dose splitting factor (DSF) may be used as an indicator of the efficacy of a split dose regimen. For any single administration of a total daily dose, the DSF should be equal to 1. Therefore any DSF greater than this value in a split dose regimen is an indication of increased efficacy.

15214[0001265] To determine the dose response trends, impact of injection site and impact of injection timing, studies are performed. In these studies, varied doses of lug, 5ug, 10 ug, 25 ug, 50 ug, and values in between are used to determine dose response outcomes. Split dosing for a 100 ug total dose includes three or six doses of 1.6 ug, 4.2 ug, 8.3 ug, 16.6 ug, or values and total doses equal to administration of the total dose selected.

15215[0001266] Injection sites are chosen from the limbs or any body surface presenting enough area suitable for injection. This may also include a selection of injection depth to target the dermis (Intradermal), epidermis (Epidermal), subcutaneous tissue (SC) or muscle (IM). Injection angle will vary based on targeted delivery site with injections targeting the intradermal site to be 10-15 degree angles from the plane of the surface of the skin, between 20-45 degrees from the plane of the surface of the skin for

15216subcutaneous injections and angles of between 60-90 degrees for injections substantially into the muscle.

15217Example 36. Quantification in Exosomes [0001267] The quantity and localization of the mmRNA of the present invention can be determined by measuring the amounts (initial, timecourse, or residual basis) in isolated exosomes. In this study, since the mmRNA are typically codon-optimized and distinct in sequence from endogenous mRNA, the levels of mmRNA are quantitated as compared to endogenous levels of native or wild type mRNA by using the methods of Gibbings, PCT/IB2009/005878, the contents of which are incorporated herein by reference in their entirety.

15218[0001268] In these studies, the method is performed by first isolating exosomes or vesicles preferably from a bodily fluid of a patient previously treated with a

15219polynucleotide, primary construct or mmRNA of the invention, then measuring, in said exosomes, the polynucleotide, primary construct or mmRNA levels by one of mRNA microarray, qRT-PCR, or other means for measuring RNA in the art including by suitable antibody or immunohistochemical methods.

15220Example 37. Effect of Modified mRNA on Cellular Viability, Cytotoxicity and Apoptosis

15221[0001269] This experiment demonstrates cellular viability, cytotoxicity and apoptosis for distinct modified mRNA in-vitro transfected Human Keratinocyte cells. Keratinocytes are grown in EPILIFE® medium with Human Keratinocyte Growth Supplement in the absence of hydrocortisone from Invitrogen (Carlsbad, CA) at a confluence of >70%. Keratinocytes are reverse transfected with Ong, 46.875ng, 93.75ng, 187.5ng, 375ng, 750ng, 1500ng, 3000ng, or 6000ng of modified mRNA complexed with RNAIMAX™ from Invitrogen. The modified mRNA:RNAIMAX™ complex is formed. Secreted human G-CSF concentration in the culture medium is measured at 0, 6, 12, 24, and 48 hours post-transfection for each concentration of each modified m RNA in triplicate. Secretion of human G-CSF from transfected human keratinocytes is quantified using an ELISA kit from Invitrogen or R&D Systems following the manufacturers recommended instructions.

15222[0001270] Cellular viability, cytotoxicity and apoptosis is measured at 0, 12, 48, 96, and 192 hours post-transfection using the APOTOX-GLO™ kit from Promega (Madison, WI) according to manufacturer instructions. Example 38. Detection of a Cellular Innate Immune Response to Modified mRNA Using an ELISA Assay

15223[0001271] An enzyme-linked immunosorbent assay (ELISA) for Human Tumor Necrosis Factor-a (TNF-a), Human Interferon-β (IFN-β) and Human Granulocyte-Colony

15224Stimulating Factor (G-CSF) secreted from in vzYro-transfected Human Keratinocyte cells is tested for the detection of a cellular innate immune response. Keratinocytes are grown in EPILIFE® medium with Human Keratinocyte Growth Supplement in the absence of hydrocortisone from Invitrogen (Carlsbad, CA) at a confluence of >70%. Secreted TNF- α keratinocytes are reverse transfected with Ong, 93.75ng, 1 87.5ng, 375ng, 750ng, 1500ng or 3000ng of the chemically modified mRNA (mmRNA) complexed with RNAIMAX™ from Invitrogen as described in triplicate. Secreted TNF-a in the culture medium is measured 24 hours post-transfection for each of the chemically modified mRNA using an ELISA kit from Invitrogen according to the manufacturer protocols.

15225[0001272] Secreted IFN-β in the same culture medium is measured 24 hours post- transfection for each of the chemically modified mRNA using an ELISA kit from

15226Invitrogen according to the manufacturer protocols. Secreted human G-CSF

15227concentration in the same culture medium is measured at 24 hours post-transfection for each of the chemically modified mRNA. Secretion of human G-CSF from transfected human keratinocytes is quantified using an ELISA kit from Invitrogen or R&D Systems (Minneapolis, MN) following the manufacturers recommended instructions. These data indicate which modified mRNA (mmRNA) are capable eliciting a reduced cellular innate immune response in comparison to natural and other chemically modified polynucleotides or reference compounds by measuring exemplary type 1 cytokines TNF- α and IFN-β.

15228Example 39. Human Granulocyte -Colony Stimulating Factor (G-CSF) Modified mRNA-induced Cell Proliferation Assay

15229[0001273] Human keratinocytes are grown in EPILIFE® medium with Supplement S7 from Invitrogen at a confluence of >70% in a 24-well collagen-coated TRANSWELL® (Coming, Lowell, MA) co-culture tissue culture plate. Keratinocytes are reverse transfected with 75 Ong of the indicated chemically modified mRNA (mmRNA) complexed with RNAIMAX from Invitrogen as described in triplicate. The modified mRNA :RN AIM AX complex is formed as described. Keratinocyte media is exchanged 6- 8 hours post-transfection. 42-hours post-transfection, the 24-well TRANSWELL® plate insert with a 0.4 μιη-pore semi-permeable polyester membrane is placed into the human G-CSF modified mRNA-transfected keratinocyte containing culture plate

15230[0001274] Human myeloblast cells, Kasumi-1 cells or KG- 1 (0.2 x 105 cells), are seeded into the insert well and cell proliferation is quantified 42 hours post-co-culture initiation using the CyQuant Direct Cell Proliferation Assay (Invitrogen, Carlsbad, CA) in a 100- 120μ1 volume in a 96-well plate. Modified mRNA-encoding human G-CSF-induced myeloblast cell proliferation is expressed as a percent cell proliferation normalized to untransfected keratinocyte/myeloblast co-culture control wells. Secreted human G-CSF concentration in both the keratinocyte and myeloblast insert co-culture wells is measured at 42 hours post-co-culture initiation for each modified mRNA in duplicate. Secretion of human G-CSF is quantified using an ELISA kit from Invitrogen following the manufacturer recommended instructions.

15231[0001275] Transfected human G-CSF modified mRNA in human keratinocyte feeder cells and untransfected human myeloblast cells are detected by RT -PCR. Total RNA from sample cells is extracted and lysed using RNEASY® kit (Qiagen, Valencia, CA) according to the manufacturer instructions. Extracted total RNA is submitted to RT-PCR for specific amplification of modified mRNA-G-CSF using PROTOSCRIPT® M-MuLV Taq RT-PCR kit (New England BioLabs, Ipswich, MA) according to the manufacturer instructions with human G-CSF-specific primers. RT-PCR products are visualized by 1.2% agarose gel electrophoresis.

15232Example 40: Co-Culture Assay

15233Modified mRNA comprised of chemically-distinct modified nucleotides encoding human Granulocyte-Colony Stimulating Factor (G-CSF) may stimulate the cellular proliferation of a transfection incompetent cell in a co-culture environment. The co-culture includes a highly transfectable cell type such as a human keratinocyte and a transfection

15234incompetent cell type such as a white blood cell (WBC). The modified mRNA encoding G-CSF are transfected into the highly transfectable cell allowing for the production and secretion of G-CSF protein into the extracellular environment where G-CSF acts in a paracrine-like manner to stimulate the white blood cell expressing the G-CSF receptor to proliferate. The expanded WBC population may be used to treat immune-compromised patients or partially reconstitute the WBC population of an immunosuppressed patient and thus reduce the risk of opportunistic infections.

15235In another example, a highly transfectable cell such as a fibroblast are transfected with certain growth factors support and simulate the growth, maintenance, or differentiation of poorly transfectable embryonic stem cells or induced pluripotent stem cells.

15236Example 41: Detection Assays of Human IgG Antibodies

15237A. ELISA Detection of Human IgG Antibodies

15238[0001276] This example describes an ELISA for Human IgG from Chinese Hamster Ovary's (CHO) and Human Embryonic Kidney (HEK, HER-2 Negative) 293 cells transfected with human IgG modified mRNA (mmRNA). The Human Embryonic Embryonic Kidney (HEK) 293 are grown in CD 293 Medium with Supplement of L- Glutamine from Invitrogen until they reach a confluence of 80-90%. The CHO cells are grown in CD CHO Medium with Supplement of L- Glutamine, Hypoxanthine and Thymidine. In one aspect, 2 x 106 cells are transfected with 24 μg modified mRNA complexed with RNAIMAXTM from Invitrogen in a 75cm2 culture flask from Corning in 7 ml of medium. In another aspect, 80,000 cells are transfected with 1 μg modified mRNA complexed with RNAIMAXTM from Invitrogen in a 24-well plate. The modified mRNA: RNAIMAXTM complex is formed by incubating in a vial the mmRNA with either the CD 293 or CD CHO medium in a 5X volumetric dilution for 10 minutes at room temperature. In a second vial, RNAIMAXTM reagent is incubated with CD 293 medium or CD CHO medium in a 10X volumetric dilution for 10 minutes at room temperature. The mmRNA vial is then mixed with the RNAIMAXTM vial and incubated for 20-30 minutes at room temperature before it isadded to the CHO or HEK cells in a drop-wise fashion. The culture supernatants are stored at 4 degrees Celsius. The concentration of the secreted human IgG in the culture medium in the 24 μg mmRNA transfections is measured at 12, 24, 36 hours post-transfection and the 1 μg mmRNA transfection is measured at 36 hours. Secretion of Trastuzumab from transfected HEK 293 cells is quantified using an ELISA kit from Abeam (Cambridge, MA) following the manufacturers recommended instructions. The data shows that a Humanized IgG antibody (such as Trastuzumab) mmRNA is capable of being translated in HEK Cells and that Trastuzumab is secreted out of the cells and released into the extracellular environment. Furthermore, the data demonstrate that transfection of cells with mmRNA encoding Trastuzumab for the production of secreted protein can be scaled up to a bioreactor or large cell culture conditions.

15239B. Western Detection of Modified mRNA Produced Human IgG Antibody

15240[0001277] A Western Blot of CHO-K1 cells is co-transfected with 1 μg each of Heavy and Light Chain of Trastuzumab modified mRNA (mmRNA). CHO cells are grown using standard protocols in 24-well plates. The cell supernatants or cell lysates are collected 24 hours post-transfection, separated on a 12% SDS-Page gel and transferred onto a nitrocellulose membrane using the IBOT® by Invitrogen (Carlsbad, CA). The cells are incubated with a first conjugation of a rabbit polyclonal antibody to Human IgG conjugated to DYLIGHT594 (ab96904, abeam, Cambridge, MA) and a second conjugation of a goat polyclonal antibody to Rb IgG which is conjugated to alkaline phosphatase. After incubation, the antibody is detected using No vex® alkaline phosphatase chromogenic substrate by Invitrogen (Carlsbad, CA).

15241C. Cell Immuno Staining of Modified mRNA Produced Trastuzumab and Rituximab

15242[0001278] CHO-K1 cells are co-transfected with 500 ng each of Heavy and Light Chain of either Trastuzumab or Rituximab. Cells are grown in F-12K Medium from GIBCO® (Grand Island, NY) and 10% FBS. Cells are fixed with 4% paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100 in PBS for 5-10 minutes at room temperature and cells are washed 3 times with room temperature PBS. Trastuzumab and Rituximab staining is performed using rabbit polyclonal antibody to Human IgG conjugated to DYLIGHT®594 (ab96904, abeam, Cambridge, MA) according to the manufacture's recommended dilutions. Nuclear DNA staining is performed with DAPI dye from Invitrogen (Carlsbad, CA). The protein for Trastuzumab and Rituximab is translated and localized to the cytoplasm upon modified mRNA transfections. Pictures are taken 13 hours post-transfection.

15243D. Binding Immunoblot Assay for Modified mRNA Produced Trastuzumab and Rituximab

15244[0001279] Trastuzumab and Rituximab are detected using a binding immunoblot detection assay. Varying concentrations (lOOng/ul to Ong/ul) of the ErB2 peptide (ab40048, abeam, Cambridge, MA), antigen for Trastuzumab and the CD20 peptide (ab97360, abeam, Cambridge, MA), antigen for Rituximab are run on a 12% SDS-Page gel and transferred onto a membrane using the iBlot from Invitrogen. The membranes are incubated for 1 hour with their respective cell supematants from CHO-Kl cells which are co-transfected with 500ng each of Heavy and Light Chain of either Trastuzumab or Rituximab. The membranes are blocked with 1% BSA and a secondary anti-human IgG antibody conjugated to alkaline phosphatase (abeam, Cambridge, MA) is added.

15245Antibody detection is conducted using the NO VEX alkaline phosphatase chromogenic substrate by Invitrogen (Carlsbad, CA). The data shows that a humanized IgG antibodies generated from modified mRNA is capable of recognizing and binding to their respective antigens.

15246E. Cell Proliferation Assay

15247[0001280] The SK-BR-3 cell line, an adherent cell line derived from a human breast adenocarcinoma, which overexpresses the HER2/neu receptor can be used to compare the anti-pro liferative properties of modified mRNA (mmRNA) generated Trastuzumab. Varying concentrations of purified Trastuzumab generated from modified mRNA and trastuzumab are be added to cell cultures, and their effects on cell growth are be assessed in triplicate cytotoxicity and viability assays.

15248Example 42: Bulk Transfection of Modified mRNA into Cell Culture

15249A. Cationic Lipid Delivery Vehicles

15250[0001281] RNA transfections are carried out using RNAIMAX™ (Invitrogen, Carlsbad, CA) or TRANSIT -mRNA (Minis Bio, Madison, WI) cationic lipid delivery vehicles. RNA and reagent are first diluted in Opti-MEM basal media (Invitrogen, Carlsbad, CA). 100 ng/uL RNA is diluted 5x and 5 of RNAIMax per μg of RNA is diluted lOx. The diluted components are pooled and incubated 15 minutes at room temperature before they are dispensed to culture media. For TRANSIT -mRNA transfections, 100 ng/uL RNA is diluted lOx in Opti-MEM and BOOST reagent is added (at a concentration of 2 μΕ per μg of RNA), TRANSIT -mRNA is added (at a concentration of 2 μΕ per μg of RNA), and then the RNA-lipid complexes are delivered to the culture media after a 2-minute incubation at room temperature. RNA transfections are performed in Nutristem xenofree hES media (Stemgent, Cambridge, MA) for RiPS derivations, Dermal Cell Basal Medium plus Keratinocyte Growth Kit (ATCC) for keratinocyte experiments, and Opti- MEM plus 2% FBS for all other experiments. Successful introduction of a modified mR A (mmR A) into host cells can be monitored using various known methods, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Successful transfection of a modified mRNA can also be determined by measuring the protein expression level of the target polypeptide by e.g., Western Blotting or

15251immunocytochemistry. Similar methods may be followed for large volume scale-up to multi-liter (5-10,000L) culture format following similar RNA-lipid complex ratios.

15252B. Electroporation Delivery of Exogenous Synthetic mRNA Transcripts

15253[0001282] Electroporation parameters are optimized by transfecting MRC-5 fibroblasts with in vitro synthetic modified mRNA (mmRNA) transcripts and measuring transfection efficiency by quantitative RT-PCR with primers designed to specifically detect the exogenous transcripts. Discharging a 150uF capacitor charged to F into 2.5xl06 cells suspended in 50 μΐ of Opti-MEM (Invitrogen, Carlsbad, CA) in a standard

15254electroporation cuvette with a 2mm gap is sufficient for repeated delivery in excess of 10,000 copies of modified mRNA transcripts per cell, as determined using the standard curve method, while maintaining high viability (>70%). Further experiments may reveal that the voltage required to efficiently transfect cells with mmRNA transcripts can depend on the cell density during electroporation. Cell density may vary from lxl 06 cell/50 μΐ to a density of 2.5xl06 ΰε1ΐ8/50μ1 and require from 110V to 145V to transfect cells with similar efficiencies measured in transcript copies per cell. Large multi-liter (5- 10,000 L) electroporation may be performed similar to large volume flow electroporation strategies similar to methods described with the above described constraints (Li et al, 2002; Geng et al, 2010).

15255Example 43: In Vivo Delivery Using Lipoplexes

15256A. Human EPO Modified RNA Lipoplex

15257[0001283] A formulation containing 100 μg of modified human erythropoietin mRNA( mRNA shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) (EPO; fully modified 5-methylcytosine; Nl-methyl- pseudouridine) was lipoplexed with 30% by volume of RNAIMAX™ (Lipoplex-h-Epo- 46; Generation 2 or Gen2) in 50-70 uL delivered intramuscularly to four C57/BL6 mice. Other groups consisted of mice receiving an injection of the lipoplexed modified luciferase mRNA (Lipoplex-luc) (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) which served as a control containing 100 μg of modified luciferase mRNA was lipoplexed with 30% by volume of RNAiMAX™ or mice receiving an injection of the formulation buffer as negative control at a dose volume of 65ul. 13 hours after the intramuscular injection, serum was collected from each mouse to measure the amount of human EPO protein in the mouse serum by human EPO ELISA and the results are shown in Table 61.

15258Table 61. Human EPO Production (IM Injection Route)

15259<img file="WO2013151663A1_D0202.tif" />

15260B. Human G-CSF Modified RNA Lipoplex

15261[0001284] A formulation containing 100 μg of one of two versions of modified human G-CSF mRNA(mRNA sequence shown in SEQ ID NO: 56152; polyA tail of

15262approximately 160 nucleotides not shown in sequence; 5'cap, Capl) (G-CSF fully modified with 5-methylcytosine and pseudouridine (G-CSF) or G-CSF fully modified with 5-methylcytosine and Nl-methyl-pseudouridine (G-CSF-N1) lipoplexed with 30% by volume of RNAIMAX™ and delivered in 150 uL intramuscularly (I.M), in 150 uL subcutaneously (S.C) and in 225uL intravenously (I.V) to C57/BL6 mice.

15263[0001285] Three control groups were administered either 100 μg of modified luciferase mRNA (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) intramuscularly (Luc-unsp I.M.) or 150 μg of modified luciferase mRNA intravenously (Luc-unsp I.V.) or 150 uL of the formulation buffer intramuscularly (Buffer I.M.). 6 hours after administration of a formulation, serum was collected from each mouse to measure the amount of human G-CSF protein in the mouse serum by human G-CSF ELISA and the results are shown in Table 62.

15264[0001286] These results demonstrate that both 5-methylcytosine/pseudouridine and 5- methylcytosine/Nl-methyl-pseudouridine modified human G-CSF mR A can result in specific human G-CSF protein expression in serum when delivered via I.V. or I.M. route of administration in a lipoplex formulation.

15265Table 62. Human G-CSF in Serum (I.M., I.V., S.C. Injection Route)

15266<img file="WO2013151663A1_D0203.tif" />

15267C. Human G-CSF Modified RNA Lipoplex Comparison

15268[0001287] A formulation containing 100 μg of either modified human G-CSF mRNA lipoplexed with 30% by volume of RN AIM AX™ with a 5-methylcytosine (5mc) and a pseudouridine (ψ) modification (G-CSF-Genl -Lipoplex), modified human G-CSF mRNA with a 5mc and ψ modification in saline (G-CSF-Genl -Saline), modified human G-CSF mRNA with a Nl -5-methylcytosine (Nl-5mc) and a ψ modification lipoplexed with 30% by volume of RNAIMAX™ (G-CSF-Gen2-Lipoplex), modified human G-CSF mRNA with a Nl-5mc and ψ modification in saline (G-CSF-Gen2-Saline), modified luciferase with a 5mc and ψ modification lipoplexed with 30% by volume of

15269RNAIMAX™ (Luc-Lipoplex), or modified luciferase mRNA with a a 5mc and ψ modification in saline (Luc-Saline) was delivered intramuscularly (I.M.) or

15270subcutaneously (S.C.) and a control group for each method of administration was giving a dose of 80uL of the formulation buffer (F. Buffer) to C57/BL6 mice. 13 hours post injection serum and tissue from the site of injection were collected from each mouse and analyzed by G-CSF ELISA to compare human G-CSF protein levels. The results of the human G-CSF protein in mouse serum from the intramuscular administration, and the subcutaneous administration results are shown in Table 63.

15271[0001288] These results demonstrate that 5-methylcytosine/pseudouridine and 5- methylcytosine/Nl-methyl-pseudouridine modified human G-CSF mR A can result in specific human G-CSF protein expression in serum when delivered via I.M. or S.C. route of administration whether in a saline formulation or in a lipoplex formulation. As shown in Table 63, 5-methylcytosine/Nl-methyl-pseudouridine modified human G-CSF mRNA generally demonstrates increased human G-CSF protein production relative to 5- methylcytosine/pseudouridine modified human G-CSF mRNA.

15272Table 63. Human G-CSF Protein in Mouse Serum

15273<img file="WO2013151663A1_D0204.tif" />

15274D. mCherry Modified RNA Lipoplex Comparison

15275Intramuscular and Subcutaneous Administration

15276[0001289] A formulation containing 100 μg of either modified mCherry mRNA (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) lipoplexed with 30% by volume of RNAIMAX™ or modified mCherry mRNA in saline is delivered intramuscularly and subcutaneously to mice. A formulation buffer is also administered to a control group of mice either intramuscularly or subcutaneously. The site of injection on the mice may be collected 17 hours post injection for sectioning to determine the cell type(s) responsible for producing protein.

15277Intravitreal Administration

15278[0001290] A formulation containing 10 μg of either modified mCherry mRNA lipoplexed with RNAIMAX™, modified mCherry mRNA in a formulation buffer, modified luciferase mRNA lipoplexed with RNAMAX™, modified luciferase mRNA in a formulation buffer can be administered by intravitreal injection (IVT) in rats in a dose volume of 5 μΐ/eye. A formulation buffer is also administrered by IVT to a control group of rats in a dose volume of 5 μΐ/eye. Eyes from treated rats can be collected after 18 hours post injection for sectioning and lysating to determine whether mmRNA can be effectively delivered in vivo to the eye and result in protein production, and to also determine the cell type(s) responsible for producing protein in vivo.

15279Intranasal Administration

15280[0001291] A formulation containing 100 μg of either modified mCherry mRNA lipoplexed with 30% by volume of RNAIMAX™, modified mCherry mRNA in saline, modified luciferase mRNA lipoplexed with 30% by volume of RNAIMAX™ or modified luciferase mRNA in saline is delivered intranasally. A formulation buffer is also administered to a control group intranasally. Lungs may be collected about 13 hours post instillation for sectioning (for those receiving mCherry mRNA) or homogenization (for those receiving luciferase mRNA). These samples will be used to determine whether mmRNA can be effectively delivered in vivo to the lungs and result in protein

15281production, and to also determine the cell type(s) responsible for producing protein in vivo.

15282Example 44: In Vivo Delivery Using Varying Lipid Ratios

15283[0001292] Modified mRNA was delivered to C57/BL6 mice to evaluate varying lipid ratios and the resulting protein expression. Formulations of 100μg modified human EPO mRNA (mRNA shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) lipoplexed with 10%, 30% or 50% RNAIMAX™, 100μg modified luciferase mRNA (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) lipoplexed with 10%>, 30%> or 50%> RNAIMAX™ or a formulation buffer were administered intramuscularly to mice in a single 70 μΐ dose. Serum was collected 13 hours post injection to undergo a human EPO ELISA to determine the human EPO protein level in each mouse. The results of the human EPO ELISA, shown in Table 64, show that modified human EPO expressed in the muscle is secreted into the serum for each of the different percentage of R AIMAX™.

15284Table 64. Human EPO Protein in Mouse Serum (IM Injection Route)

15285<img file="WO2013151663A1_D0205.tif" />

15286Example 45: Intramuscular and Subcutaneous In Vivo Delivery in Mammals

15287[0001293] Modified human EPO mRNA (mRNA sequence shown in SEQ ID NO:

1528856155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) formulated in formulation buffer was delivered to either C57/BL6 mice or Sprague-Dawley rats to evaluate the dose dependency on human EPO production. Rats were intramuscularlly injected with 50 μΐ of the modified human EPO mRNA (h-EPO), modified luciferase mRNA (Luc) (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) or the formulation buffer (F. Buffer) as described in the dosing chart Table 65.

15289[0001294] Mice were intramuscularly or subcutaneously injected with 50 μΐ of the modified human EPO mRNA (h-EPO), modified luciferase mRNA (Luc) or the formulation buffer (F. Buffer) as described in the dosing chart Table 66. 13 hours post injection blood was collected and serum was analyzed to determine the amount human EPO for each mouse or rat. The average and geometric mean in pg/ml for the rat study are also shown in Table 65.

15290Table 65. Rat Study <img file="WO2013151663A1_D0206.tif" /> h-EPO G#3 50 101.5 85.4 h-EPO G#4 10 46.3 31.2

15291h-EPO G#5 1 28.7 25.4

15292Luc G#6 100 24.5 22.4

15293F.Buffer G#7 - 18.7 18.5

15294Table 66. Mouse Study

15295<img file="WO2013151663A1_D0207.tif" />

15296Example 46: Duration of Activity after Intramuscular In Vivo Delivery

15297[0001295] Modified human EPO mRNA (mRNA sequence shown in SEQ ID NO:

1529856155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) formulated in formulation buffer was delivered to Sprague-Dawley rats to determine the duration of the dose response. Rats were intramuscularly injected with 50 μΐ of the modified human EPO mRNA (h-EPO), modified luciferase mRNA(IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) (Luc) or the formulation buffer (F.Buffer) as described in the dosing chart Table 67. The rats were bled 2, 6, 12, 24, 48 and 72 hours after the intramuscular injection to determine the concentration of human EPO in serum at a given time. The average and geometric mean in pg/ml for this study are also shown in Table 67.

15299Table 67. Dosing Chart <img file="WO2013151663A1_D0208.tif" /> h-EPO 6 hour 100 68.6 55.8

15300h-EPO 12 hour 100 87.4 84.5

15301h-EPO 24 hour 100 108.6 95.3

15302h-EPO 48 hour 100 77.9 77.0

15303h-EPO 72 hour 100 80.1 75.8

15304Luc 24, 48 and 72 hour 100 37.2 29.2

15305F. Buffer 24, 48 and 72 hour - 48.9 10.4

15306Example 47: Routes of Administration

15307[0001296] Further studies were performed to investigate dosing using different routes of administration. Following the protocol outlined in Example 35, 4 mice per group were dosed intramuscularly (I.M.), intravenously (IV) or subcutaneously (S.C.) by the dosing chart outlined in Table 68. Serum was collected 13 hours post injection from all mice, tissue was collected from the site of injection from the intramuscular and subcutaneous group and the spleen, liver and kidneys were collected from the intravenous group. The results from the intramuscular group and the subcutaneous group results are shown in

15308Table 69.

15309Table 68. Dosing Chart

15310<img file="WO2013151663A1_D0209.tif" />

15311Table 69. Human EPO Protein in Mouse Serum (I.M. Injection Route) <img file="WO2013151663A1_D0210.tif" />

15312Example 48. Rapidly eliminated Lipid Nanoparticle (reLNP) Studies

15313A. Formulation of Modified RNA reLNPs

15314[0001297] Solutions of synthesized lipid, 1 ,2-distearoyl-3 -phosphatidylcholine (DSPC)

15315(Avanti Polar Lipids, Alabaster, AL), cholesterol (Sigma- Aldrich, Taufkirchen,

15316Germany), and a-[3'-(l ,2-dimyristoyl-3-propanoxy)-carboxamide-propyl]-ro-methoxy- polyoxyethylene (PEG-c-DOMG) (NOF, Bouwelven, Belgium) are prepared and stored at -20°C. The synthesized lipid is selected from DLin-DMA with an internal ester, DLin- DMA with a terminal ester, DLin-MC 3 -DMA-internal ester, and DLin-MC3-DMA with a terminal ester. The reLNPs are combined to yield a molar ratio of 50: 10:38.5: 1.5 (reLNP: DSPC: Cholesterol: PEG-c-DOMG). Formulations of the reLNPs and modified mRNA are prepared by combining the lipid solution with the modified mRNA solution at total lipid to modified mRNA weight ratio of l0: l, 15: 1, 20: 1 and 30: 1.

15317B. Characterization of formulations

15318[0001298] A Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire,

15319UK) is used to determine the particle size, the polydispersity index (PDI) and the zeta potential of the modified mRNA nanoparticles in IX PBS in determining particle size and 15 mM PBS in determining zeta potential.

15320[0001299] Ultraviolet-visible spectroscopy is used to determine the concentration of modified mRNA nanoparticle formulation. After mixing, the absorbance spectrum of the solution is recorded between 230 nm and 330 nm on a DU 800 spectrophotometer (Beckman Coulter, Beckman Coulter, Inc., Brea, CA). The modified RNA concentration in the nanoparicle formulation is calculated based on the extinction coefficient of the modified RNA used in the formulation and on the difference between the absorbance at a wavelength of 260 nm and the baseline value at a wavelength of 330 nm.

15321[0001300] QUANT-IT™ RIBOGREEN® RNA assay (Invitrogen Corporation Carlsbad, CA) is used to evaluate the encapsulation of modified RNA by the nanoparticle. The samples are diluted, transferred to a polystyrene 96 well plate, then either a TE buffer or a 2% Triton X-100 solution is added. The plate is incubated and the RIBOGREEN® reagent is diluted in TE buffer, and of this solution is added to each well. The

15322fluorescence intensity is measured using a fluorescence plate reader (Wallac Victor 1420 Multilablel Counter; Perkin Elmer, Waltham, MA) The fluorescence values of the reagent blank are subtracted from each of the samples and the percentage of free modified RNA is determined by dividing the fluorescence intensity of the intact sample by the fluorescence value of the disrupted sample.

15323C. In Vitro Incubation

15324[0001301] Human embryonic kidney epithelial (HEK293) and hepatocellular carcinoma epithelial (HepG2) cells (LGC standards GmbH, Wesel, Germany) are seeded on 96-well plates (Greiner Bio-one GmbH, Frickenhausen, Germany) and plates for HEK293 cells are precoated with collagen typel . HEK293 are seeded at a density of about 30,000 and HepG2 are seeded at a density of about 35,000 cells per well in 100 μΐ cell culture medium. Formulations containing mCherry mRNA (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) are added directly after seeding the cells and incubated. The mCherry cDNA with the T7 promoter, 5 'untranslated region (UTR) and 3' UTR used in in vitro transcription (IVT) is given in SEQ ID NO: 56154.

15325[0001302] Cells are harvested by transferring the culture media supematants to a 96-well Pro-Bind U-bottom plate (Beckton Dickinson GmbH, Heidelberg, Germany). Cells are trypsinized with ½ volume Trypsin/EDTA (Biochrom AG, Berlin, Germany), pooled with respective supematants and fixed by adding one volume PBS/2%FCS (both

15326Biochrom AG, Berlin, Germany)/0.5% formaldehyde (Merck, Darmstadt, Germany). Samples are then submitted to a flow cytometer measurement with an excitation laser and a filter for PE-Texas Red in a LSRII cytometer (Beckton Dickinson GmbH, Heidelberg, Germany). The mean fluorescence intensity (MFI) of all events and the standard deviation of four independent wells are presented in for samples analyzed.

15327D. In Vivo Formulation Studies

15328[0001303] Mice are administered intravenously a single dose of a formulation containing a modified mRNA and a reLNP. The modified mRNA administered to the mice is selected from G-CSF (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl), Factor IX (mR A shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) or mCherry (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl).

15329[0001304] The mice are injected with lOOug, 10 ug or 1 ug of the formulated modified mRNA and are sacrificed 8 hours after they are administered the formulation. Serum from the mice administered formulations containing human G-CSF modified mRNA are measured by specific G-CSF ELISA and serum from mice administered human Factor IX modified RNA is analyzed by specific factor IX ELISA or chromogenic assay. The liver and spleen from the mice administered with mCherry modified mRNA are analyzed by immunohistochemistry (IHC) or fluorescence-activated cell sorting (FACS). As a control, a group of mice are not injected with any formulation and their serum and tissue are collected analyzed by ELISA, FACS and/or IHC.

15330Example 49. In Vitro Transfection of VEGF-A

15331[0001305] Human vascular endothelial growth factor-isoform A (VEGF-A) modified mRNA (mRNA sequence shown in SEQ ID NO: 56165; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) was transfected via reverse transfection in Human Keratinocyte cells in 24 multi-well plates. Human Keratinocytes cells were grown in EPILIFE® medium with Supplement S7 from Invitrogen (Carlsbad, CA) until they reached a confluence of 50-70%. The cells were transfected with 0, 46.875, 93.75, 187.5, 375, 750, and 1500 ng of modified mRNA (mmRNA) encoding VEGF-A which had been complexed with RNAIMAX™ from Invitrogen (Carlsbad, CA). The

15332RNA : RN AIM AX™ complex was formed by first incubating the RNA with Supplement- free EPILIFE® media in a 5X volumetric dilution for 10 minutes at room temperature. In a second vial, RNAIMAX™ reagent was incubated with Supplement- free EPILIFE® Media in a 10X volumetric dilution for 10 minutes at room temperature. The RNA vial was then mixed with the RNAIMAX™ vial and incubated for 20-30 minutes at room temperature before being added to the cells in a drop-wise fashion.

15333[0001306] The fully optimized mRNA encoding VEGF-A (mRNA sequence shown in SEQ ID NO: 56165; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) transfected with the Human Keratinocyte cells included modifications during translation such as natural nucleoside triphosphates (NTP), pseudouridine at each uridine site and 5-methylcytosine at each cytosine site (pseudo-U/5mC), and Nl-methyl- pseudouridine at each uridine site and 5-methylcytosine at each cytosine site (Nl-methyl- Pseudo-U/5mC). Cells were trans fected with the mmR A encoding VEGF-A and secreted VEGF-A concentration (pg/ml) in the culture medium was measured at 6, 12, 24, and 48 hours post-transfection for each of the concentrations using an ELISA kit from Invitrogen (Carlsbad, CA) following the manufacturers recommended instructions. These data, shown in Table 70 and Figures 6 A, 6B and 6C, show that modified mR A encoding VEGF-A is capable of being translated in Human Keratinocyte cells and that VEGF-A is transported out of the cells and released into the extracellular environment.

15334Table 70. VEGF-A Dosing and Protein Secretion

15335<img file="WO2013151663A1_D0211.tif" />

15336Example 50. In vivo studies of Factor IX [0001307] Human Factor IX mmRNA (Genl; fully modified 5-methycytosine and pseudouridine) formulated in formulation buffer was delivered to mice via intramuscular injection. The results demonstrate that Factor IX protein was elevated in serum as measured 13 hours after administration.

15337[0001308] In this study, mice (N=5 for Factor IX, N=3 for Luciferase or Buffer controls) were intramuscularly injected with 50 μΐ of the Factor IX mmRNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl), Luciferase (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) or the formulation buffer (F. Buffer) at 2x 100 ug/mouse. The mice were bled at 13 hours after the intramuscular injection to determine the concentration of human the polypeptide in serum in pg/mL. The results revealed that administration of Factor IX mmRNA resulted in levels of 1600 pg/mL at 13 hours as compared to less than 100 pg/mL of Factor IX for either Luciferase or buffer control administration.

15338Example 51. Multi-site administration: Intramuscular and Subcutaneous

15339[0001309] Human G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) modified as either Genl or Gen2 (5-methylcytosine (5mc) and a pseudouridine (ψ) modification, G-CSF-Genl; or Nl -5-methylcytosine (Nl-5mc) and a ψ modification, G- CSF-Gen2) and formulated in formulation buffer were delivered to mice via

15340intramuscular (IM) or subcutaneous (SC) injection. Injection of four doses or 2x 50ug (two sites) daily for three days (24 hrs interval) was performed. The fourth dose was administered 6 hrs before blood collection and CBC analysis. Controls included

15341Luciferase (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) or the formulation buffer (F. Buffer). The mice were bled at 72 hours after the first mRNA injection (6 hours after the last modified mRNA dose) to determine the effect of mRNA-encoded human G-CSF on the neutrophil count. The dosing regimen is shown in Table 71 as are the resulting neutrophil counts (thousands/uL). In Table 71, an asterisk^) indicates statistical significance at p<0.05.

15342[0001310] For intramuscular administration, the data reveal a four fold increase in neutrophil count above control at day 3 for the Genl G-CSF mRNA and a two fold increase for the Gen2 G-CSF mmRNA. For subcutaneous administration, the data reveal a two fold increase in neutrophil count above control at day 3 for the Gen2 G-CSF mRNA.

15343[0001311] These data demonstrate that both 5-methylcytidine/pseudouridine and 5- methylcytidine/Nl-methyl-pseudouridine -modified mRNA can be biologically active, as evidenced by specific increases in blood neutrophil counts.

15344Table 71. Dosing Regimen

15345<img file="WO2013151663A1_D0212.tif" />

15346Example 52. Intravenous administration

15347[0001312] Human G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) modified with 5-methylcytosine (5mc) and a pseudouridine (ψ) modification (Gen 1); or having no modifications and formulated in 10% lipoplex (RNAiMax) were delivered to mice at a dose of 50 ug RNA and in a volume of 100 ul via intravenous (IV) injection at days 0, 2 and 4. Neutrophils were measured at days 1, 5 and 8. Controls included nonspecific mammalian RNA or the formulation buffer alone (F.Buffer). The mice were bled at days 1, 5 and 8 to determine the effect of modified mRNA-encoded human G-CSF to increase neutrophil count. The dosing regimen is shown in Table 72 as are the resulting neutrophil counts (thousands/uL; K/uL).

15348[0001313] For intravenous administration, the data reveal a four to five fold increase in neutrophil count above control at day 5 with G-CSF modified mRNA but not with unmodified G-CSF mRNA or non-specific controls. Blood count returned to baseline four days after the final injection. No other changes in leukocyte populations were observed.

15349[0001314] In Table 72, an asterisk^*) indicates statistical significance at p<0.001 compared to buffer.

15350[0001315] These data demonstrate that lipoplex-formulated 5- methylcytidine/pseudouridine-modified mRNA can be biologically active, when delivered through an I.V. route of administration as evidenced by specific increases in blood neutrophil counts. No other cell subsets were significantly altered. Unmodified G- CSF mRNA similarly administered showed no pharmacologic effect on neutrophil counts.

15351Table 72. Dosing Regimen

15352<img file="WO2013151663A1_D0213.tif" />

15353Example 53. Saline formulation: Intramuscular Administration

15354A. Protein Expression [0001316] Human G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) and human EPO mmRNA (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl); G-CSF modified mRNA (modified with 5-methylcytosine (5mc) and pseudouridine (ψ)) and EPO modified mRNA (modified with Nl -5-methylcytosine (Nl-5mc) and ψ modification), were formulated in formulation buffer (150 mM sodium chloride, 2mM calcium chloride, 2mM phosphate, 0.5 mM EDTA at a pH of 6.5) and delivered to mice via intramuscular (IM) injection at a dose of 100 ug.

15355[0001317] Controls included Luciferase (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) or the formulation buffer (F. Buffer). The mice were bled at 13 hours after the injection to determine the concentration of the human polypeptide in serum in pg/mL. (G-CSF groups measured human G-CSF in mouse serum and EPO groups measured human EPO in mouse serum). The data are shown in Table 73.

15356Table 73. Dosing Regimen

15357<img file="WO2013151663A1_D0214.tif" />

15358B. Dose Response

15359[0001318] Human EPO modified mRNA (mRNA sequence shown in SEQ ID NO:

1536056155; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) were formulated in formulation buffer and delivered to mice via intramuscular (IM) injection. [0001319] Controls included Luciferase (rnRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5 'cap, Capl, fully modified with 5-methylcytosine and pseudouridine) or the formulation buffer (F.Buffer). The mice were bled at 13 hours after the injection to determine the concentration of the human polypeptide in serum in pg/mL. The dose and expression are shown in Table 74.

15361Table 74. Dosing Regimen and Expression

15362<img file="WO2013151663A1_D0215.tif" />

15363Example 54. EPO muti-dose/multi-administration

15364[0001320] Studies utilizing multiple intramuscular injection sites at one time point were designed and performed.

15365[0001321] The design of a single multi-dose experiment involved using human erythropoietin (EPO) mmRNA (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) or G-CSF mmRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) administered in formulation buffer. The dosing vehicle (F. buffer) was used as a control. The EPO and G-CSF modified mRNA were modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site.

15366[0001322] Animals (n=5), Sprague-Dawley rats, were injected IM (intramuscular) for the single unit dose of 100 ug (delivered to one thigh). For multi-dosing 6 doses of 100 ug (delivered to two thighs) were used for both EPO and G-CSF mmRNA. Control dosing involved use of buffer at a single dose. Human EPO blood levels were evaluated 13 hrs post injection. [0001323] Human EPO protein was measured in rat serum 13 hrs post intramuscular injection. Five groups of rats were treated and evaluated. The results are shown in Table 75.

15367Table 75. Multi-dose study

15368<img file="WO2013151663A1_D0216.tif" />

15369Example 55. Signal Sequence Exchange Study

15370[0001324] Several variants of mmRNAs encoding human Granulocyte colony stimulating factor (G-CSF) (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) were synthesized using modified nucleotides pseudouridine and 5-methylcytosine (pseudo-U/5mC). These variants included the G-CSF constructs encoding either the wild-type N terminal secretory signal peptide sequence (MAGPATQSPMKLMALQLLLWHSALWTVQEA; SEQ ID NO: 95), no secretory signal peptide sequence, or secretory signal peptide sequences taken from other mRNAs. These included sequences where the wild type G- CSF signal peptide sequence was replaced with the signal peptide sequence of either: human α-1-anti trypsin (AAT) (MMPSSVSWGILLLAGLCCLVPVSLA; SEQ ID NO: 94), human Factor IX (FIX)

15371(MQRVNMIMAESPSLITICLLGYLLSAECTVFLDHENANKILNRPKR; SEQ ID NO: 96), human Prolactin (Prolac) (MKGSLLLLLVSNLLLCQSVAP; SEQ ID NO: 97), or human Albumin (Alb) (MKWVTFISLLFLFSSAYSRGVFRR; SEQ ID NO: 98).

15372[0001325] 250ng of modified mRNA encoding each G-CSF variant was transfected into HEK293A (293 A in the table), mouse myoblast (MM in the table) (C2C12, CRL-1772, ATCC) and rat myoblast (RM in the table) (L6 line, CRL-1458, ATCC) cell lines in a 24 well plate using 1 ul of Lipofectamine 2000 (Life Technologies), each well containing 300,000 cells. The supernatants were harvested after 24 hrs and the secreted G-CSF protein was analyzed by ELISA using the Human G-CSF ELISA kit (Life Technologies). The data shown in Table 76 reveal that cells transfected with G-CSF mmRNA encoding the Albumin signal peptide secrete at least 12 fold more G-CSF protein than its wild type counterpart.

15373Table 76. Signal Peptide Exchange

15374<img file="WO2013151663A1_D0217.tif" />

15375Example 56. Cytokine Study: PBMC

15376A. PBMC isolation and Culture

15377[0001326] 50 mL of human blood from two donors was received from Research Blood Components (lots KP30928 and KP30931) in sodium heparin tubes. For each donor, the blood was pooled and diluted to 70 mL with DPBS (SAFC Bioscience 59331C, lot 071M8408) and split evenly between two 50 mL conical tubes. 10 mL of Ficoll Paque (GE Healthcare 17-5442-03, lot 10074400) was gently dispensed below the blood layer. The tubes were centrifuged at 2000 rpm for 30 minutes with low acceleration and braking. The tubes were removed and the buffy coat PBMC layers were gently transferred to a fresh 50 mL conical and washed with DPBS. The tubes were centrifuged at 1450 rpm for 10 minutes.

15378[0001327] The supernatant was aspirated and the PBMC pellets were resuspended and washed in 50 mL of DPBS. The tubes were centrifuged at 1250 rpm for 10 minutes. This wash step was repeated, and the PBMC pellets were resuspended in 19 mL of Optimem I (Gibco 11058, lot 1072088) and counted. The cell suspensions were adjusted to a concentration of 3.0 x 10A6 cells / mL live cells.

15379[0001328] These cells were then plated on five 96 well tissue culture treated round bottom plates (Costar 3799) per donor at 50 uL per well. Within 30 minutes, transfection mixtures were added to each well at a volume of 50 uL per well. After 4 hours post transfection, the media was supplemented with 10 uL of Fetal Bovine Serum (Gibco 10082, lot 1012368)

15380B. Transfection Preparation

15381[0001329] mmRNA encoding human G-CSF (mRNA sequence shown in SEQ ID NO:

1538256152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) (containing either (1) natural NTPs, (2) 100% substitution with 5-methyl cytidine and pseudouridine, or (3) 100% substitution with 5-methyl cytidine and Nl-methyl- pseudouridine; mmRNA encoding luciferase (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5- methylcytosine at each cytosine and pseudouridine replacement at each uridine site) (containing either (1) natural NTPs or (2) 100% substitution with 5-methyl cytidine and pseudouridine) and TLR agonist R848 (Invivogen tlrl-r848) were diluted to 38.4 ng / uL in a final volume of 2500 uL Optimem I.

15383[0001330] Separately, 432 uL of Lipofectamine 2000 (Invitrogen 11668-027, lot 1070962) was diluted with 13.1 mL Optimem I. In a 96 well plate nine aliquots of 135 uL of each mmRNA, positive control (R-848) or negative control (Optimem I) was added to 135 uL of the diluted Lipofectamine 2000. The plate containing the material to be transfected was incubated for 20 minutes. The transfection mixtures were then transferred to each of the human PBMC plates at 50 uL per well. The plates were then incubated at 37 C. At 2, 4, 8, 20, and 44 hours each plate was removed from the incubator, and the supernatants were frozen.

15384[0001331] After the last plate was removed, the supernatants were assayed using a human G-CSF ELISA kit (Invitrogen KHC2032) and human IFN-alpha ELISA kit (Thermo Scientific 41105-2). Each condition was done in duplicate.

15385C. Results

15386[0001332] The ability of unmodified and modified mRNA (mmRNAs) to produce the encoded protein was assessed (G-CSF production) over time as was the ability of the mRNA to trigger innate immune recognition as measured by interferon-alpha production. Use of in vitro PBMC cultures is an accepted way to measure the immunostimulatory potential of oligonucleotides (Robbins et al, Oligonucleotides 2009 19:89-102; herein incorporated by reference in its entirety). [0001333] Results were interpolated against the standard curve of each ELISA plate using a four parameter logistic curve fit. Shown in Tables 77 and 78 are the average from 2 separate PBMC donors of the G-CSF and IFN-alpha production over time as measured by specific ELISA.

15387[0001334] In the G-CSF ELISA, background signal from the Lipofectamine 2000 untreated condition was subtracted at each timepoint. The data demonstrated specific production of human G-CSF protein by human peripheral blood mononuclear is seen with G-CSF mRNA containing natural NTPs, 100% substitution with 5-methyl cytidine and pseudouridine, or 100% substitution with 5-methyl cytidine and Nl-methyl- pseudouridine. Production of G-CSF was significantly increased through the use of modified mRNA relative to unmodified mRNA, with the 5-methyl cytidine and Nl- methyl-pseudouridine containing G-CSF mmRNA showing the highest level of G-CSF production. With regards to innate immune recognition, unmodified mRNA resulted in substantial IFN-alpha production, while the modified mRNA largely prevented interferon-alpha production. G-CSF mRNA fully modified with 5-methyl cytidine and Nl-methyl-pseudouridine did not significantly increase cytokines whereas G-CSF mRNA fully modified with 5-methyl cytidine and pseudouridine induced IFN-alpha, TNF-alpha and IP 10. Many other cytokines were not affected by either modification.

15388Table 77. G-CSF Signal

15389<img file="WO2013151663A1_D0218.tif" />

15390Table 78. IFN-alpha signal

15391<img file="WO2013151663A1_D0219.tif" /> G-CSF(Natural) 0.0 2.1 23.3 74.9 119.7

15392Luciferase 0.4 0.4 4.7 1.0 2.4

15393(5mC/pseudouridine)

R-848 39.1 151.3 278.4 362.2 208.1

15395Lpf. 2000 control 0.8 17.2 16.5 0.7 3.1

15396Example 57. Chemical modification ranges of modified mRNA

15397[0001335] Modified nucleotides such as, but not limited to, the chemical modifications

153985-methylcytosine and pseudouridine have been shown to lower the innate immune response and increase expression of R A in mammalian cells. Surprisingly, and not previously known, the effects manifested by the chemical modifications can be titrated when the amount of chemical modification is less than 100%. Previously, it was believed that full modification was necessary and sufficient to elicit the beneficial effects of the chemical modifications and that less than 100% modification of an mRNA had little effect. However, it has now been shown that the benefits of chemical modification can be derived using less than complete modification and that the effects are target, concentration and modification dependent.

15399A. Modified RNA transfected in PBMC

15400[0001336] 960 ng of G-CSF mRNA modified with 5-methylcytosine (5mC) and pseudouridine (pseudoU) or unmodified G-CSF mRNA was transfected with 0.8 uL of

15401Lipofectamine 2000 into peripheral blood mononuclear cells (PBMC) from three normal blood donors (Dl , D2, D3). The G-CSF mRNA (mRNA sequence shown in SEQ ID

15402NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap,

15403Capl) was completely modified with 5mC and pseudoU (100% modification), not modified with 5mC and pseudoU (0% modification) or was partially modified with 5mC and pseudoU so the mRNA would contain 50%> modification, 25% modification, 10% modification, %5 modification, 1% modification or 0.1% modification. A control sample of Luciferase (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of

15404approximately 160 nucleotides not shown in sequence; 5 'cap, Capl ; fully modified 5meC and pseudoU) was also analyzed for G-CSF expression. For TNF-alpha and IFN-alpha control samples of Lipofectamine2000, LPS, R-848, Luciferase (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl ; fully modified 5mC and pseudo), and P(I)P(C) were also analyzed. The supernatant was harvested and run by ELISA 22 hours after transfection to determine the protein expression. The expression of G-CSF is shown in Table 79 and the expression of IFN-alpha and TNF-alpha is shown in Table 80. The expression of IFN- alpha and TNF-alpha may be a secondary effect from the transfection of the G-CSF mRNA. Tables 79 and 80 show that the amount of chemical modification of G-CSF, IFN- alpha and TNF-alpha is titratable when the mRNA is not fully modified and the titratable trend is not the same for each target.

15405Table 79. G-CSF Expression

15406<img file="WO2013151663A1_D0220.tif" />

15407Table 80. IFN-alpha and TNF-alpha Expression

15408<img file="WO2013151663A1_D0221.tif" /> B. Modified RNA transfected in HEK293

15409[0001337] Human embryonic kidney epithelial (HEK293) cells were seeded on 96-well plates at a density of 30,000 cells per well in 100 ul cell culture medium. 250 ng of modified G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) formulated with

15410RNAiMAX™ (Invitrogen, Carlsbad, CA) was added to a well. The G-CSF was completely modified with 5mC and pseudoU (100% modification), not modified with

154115mC and pseudoU (0% modification) or was partially modified with 5mC and pseudoU so the mRNA would contain 75% modification, 50% modification or 25% modification.

15412Control samples (AK 5/2, mCherry mRNA (mRNA sequence shown in SEQ ID NO:

1541356153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified 5mC and pseudoU) and untreated) were also analyzed. The half-life of G-

15414CSF mRNA fully modified with 5-methylcytosine and pseudouridine is approximately 8-

1541510 hours. The supematants were harvested after 16 hours and the secreted G-CSF protein was analyzed by ELISA. Table 81 shows that the amount of chemical modification of G-

15416CSF is titratable when the mRNA is not fully modified.

15417Table 81. G-CSF Expression

15418<img file="WO2013151663A1_D0222.tif" />

15419Example 58: In Vivo Delivery of Modified mRNA (mm RN A)

15420[0001338] Modified RNA was delivered to C57/BL6 mice intramuscularly,

15421subcutaneously, or intravenously to evaluate the bio-distribution of modified RNA using luciferase. A formulation buffer used with all delivery methods contained 150mM sodium chloride, 2mM calcium chloride, 2 mM Na+-phosphate which included 1.4mM monobasic sodium phosphate and 0.6 mM of dibasic sodium phosphate, and 0.5 mM ethylenediaminetetraacetic acid (EDTA) was adjusted using sodium hydroxide to reach a final H of 6.5 before being filtered and sterilized. A IX concentration was used as the delivery buffer. To create the lipoplexed solution delivered to the mice, in one vial 50 μg of RNA was equilibrated for 10 minutes at room temperature in the delivery buffer and in a second vial 10 μΐ RNAiMAX™ was equilibrated for 10 minutes at room temperature in the delivery buffer. After equilibrium, the vials were combined and delivery buffer was added to reach a final volume of 100 μΐ which was then incubated for 20 minutes at room temperature. Luciferin was administered by intraperitoneal injection (IP) at 150 mg/kg to each mouse prior to imaging during the plateau phase of the luciferin exposure curve which was between 15 and 30 minutes. To create luciferin, 1 g of D-luciferin potassium or sodium salt was dissolved in 66.6 ml of distilled phosphate buffer solution (DPBS), not containing Mg2+ or Ca2+, to make a 15 mg/ml solution. The solution was gently mixed and passed through a 0.2 μιη syringe filter, before being purged with nitrogen, aliquoted and frozen at -80°C while being protected from light as much as possible. The solution was thawed using a waterbath if luciferin was not dissolved, gently mixed and kept on ice on the day of dosing.

15422[0001339] Whole body images were taken of each mouse 2, 8 and 24 hours after dosing. Tissue images and serum was collected from each mouse 24 hours after dosing. Mice administered doses intravenously had their liver, spleen, kidneys, lungs, heart, peri-renal adipose tissue and thymus imaged. Mice administered doses intramuscularly or subcutaneously had their liver, spleen, kidneys, lungs, peri-renal adipose tissue, and muscle at the injection site. From the whole body images the bioluminescence was measured in photon per second for each route of administration and dosing regimen.

15423A. Intramuscular Administration

15424[0001340] Mice were intramuscularly (I.M.) administered either modified luciferase mRNA fully modified with 5-methylcytosine and pseudouridine (Naked-Luc), lipoplexed modified luciferase mRNA fully modified with 5-methylcytosine and pseudouridine (Lipoplex-luc) (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site), lipoplexed modified granulocyte colony- stimulating factor (G-CSF) mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) (Lipoplex-Cytokine) or the formation buffer at a single dose of 50 μg of modified RNA in an injection volume of 50μ1 for each formulation in the right hind limb and a single dose of 5 μg of modified RNA in an injection volume of 50 μΐ in the left hind limb. The bio luminescence average for the luciferase expression signals for each group at 2, 8 and 24 hours after dosing are shown in Table 82. The bio luminescence showed a positive signal at the injection site of the 5 μg and 50 μg modified RNA formulations containing and not containing lipoplex.

15425Table 82. In vivo Biophotoic Imaging (I.M. Injection Route)

15426<img file="WO2013151663A1_D0223.tif" />

15427B. Subcutaneous Administration

15428[0001341] Mice were subcutaneously (S.C.) administered either modified luciferase mRNA (Naked-Luc), lipoplexed modified luciferase mRNA (Lipoplex-luc), lipoplexed modified G-CSF mRNA (Lipoplex-G-CSF) or the formation buffer at a single dose of 50 μg of modified mRNA in an injection volume of 100 μΐ for each formulation. The bioluminescence average for the luciferase expression signals for each group at 2, 8 and 24 hours after dosing are shown in Table 83. The bioluminescence showed a positive signal at the injection site of the 50 μg modified mRNA formulations containing and not containing lipoplex.

15429Table 83. In vivo Biophotoic Imaging (S.C. Injection Route)

15430<img file="WO2013151663A1_D0224.tif" /> C. Intravenous Administration

15431[0001342] Mice were intravenously (I.V.) administered either modified luciferase mRNA (Naked-Luc), lipoplexed modified luciferase mRNA (Lipoplex-luc), lipoplexed modified G-CSF mRNA (Lipoplex-G-CSF) or the formation buffer at a single dose of 50 μg of modified mRNA in an injection volume of 100 μΐ for each formulation. The

15432bioluminescence average for the luciferase expression signal in the spleen from each group at 2 hours after dosing is shown in Table 84. The bioluminescence showed a positive signal in the spleen of the 50 μg modified mRNA formulations containing lipoplex.

15433Table 84. In vivo Biophotoic Imaging (I.V. Injection Route)

15434<img file="WO2013151663A1_D0225.tif" />

15435Example 59. Buffer Formulation Studies

15436[0001343] G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with Nl-pseudouridine and 5-methylcytosine) or Factor IX modified mRNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with Nl-pseudouridine and 5-methylcytosine) in a buffer solution is administered intramuscularly to rats in an injection volume of 50 μΐ (n=5) at a modified mRNA dose of 200 ug per rat as described in Table 85. The modified mRNA is lyophilized in water for 1-2 days. It is then reconstituted in the buffers listed below to a target concentration of 6 mg/ml.

15437Concentration is determined by OD 260. Samples are diluted to 4 mg/ml in the appropriate buffer before dosing.

15438[0001344] To precipitate the modified mRNA, 3M sodium acetate, pH 5.5 and pure ethanol are added at 1/10th the total volume and 4 times the total volume of modified mRNA, respectively. The material is placed at -80C for a minimum of 1 hour. The material is then centrifuged for 30 minutes at 4000 rpm, 4C. The supernatant is removed and the pellet is centrifuged and washed 3x with 75% ethanol. Finally, the pellet is reconstituted with buffer to a target concentration of 6 mg/ml. Concentration is determined by OD 260. Samples are diluted to 4 mg/ml in the appropriate buffer before dosing. All samples are prepared by lyophilization unless noted below.

15439Table 85. Buffer Dosing Groups

15440<img file="WO2013151663A1_D0226.tif" />

15441[0001345] Serum samples are collected from the rats at various time intervals and analyzed for G-CSF or Factor IX protein expression using G-CSF or Factor IX ELISA.

15442Example 60. Multi-Dose Study

15443[0001346] Sprague-Dawley rats (n=8) are injected intravenously eight times (twice a week) over 28 days. The rats are injected with 0.5 mg/kg, 0.05 mg/kg, 0.005 mg/kg or 0.0005 mg/kg of human G-CSF modified mRNA of luciferase modified mRNA formulated in a lipid nanoparticle, 0.5 mg/kg of human G-CSF modified mRNA in saline, 0.2 mg/kg of the human G-CSF protein Neupogen or non-translatable human G-CSF modified mRNA formulated in a lipid nanoparticle. Serum is collected during pre- determined time intervals to evaluate G-CSF protein expression (8, 24 and 72 hours after the first dose of the week), complete blood count and white blood count (24 and 72 hours after the first dose of the week) and clinical chemistry (24 and 72 hours after the first dose of the week). The rats are sacrificed at day 29, 4 days after the final dosing, to determine the complete blood count, white blood count, clinical chemistry, protein expression and to evaluate the effect on the major organs by histopathology and necropsy. Further, an antibody assay is performed on the rats on day 29.

15444Example 61. LNP in vivo study

15445[0001347] Luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence, 5' cap, Capl; fully modified with 5-methylcytosine and pseudouridine was formulated as a lipid nanoparticle (LNP) using the syringe pump method. The LNP was formulated at a 20: 1 weight ratio of total lipid to modified mRNA with a final lipid molar ratio of 50: 10:38.5: 1.5 (DLin- KC2-DMA: DSPC: Cholesterol: PEG-DMG). As shown in Table 86, the luciferase LNP formulation was characterized by particle size, zeta potential, and encapsulation.

15446Table 86. Luciferase Formulation

15447<img file="WO2013151663A1_D0227.tif" />

15448[0001348] As outlined in Table 87, the luciferase LNP formulation was administered to Balb-C mice (n=3) intramuscularly, intravenously and subcutaneously and a luciferase modified RNA formulated in PBS was administered to mice intravenously.

15449Table 87. Luciferase Formulations

15450<img file="WO2013151663A1_D0228.tif" /> [0001349] The mice administered the luciferase LNP formulation intravenously and intramuscularly were imaged at 2, 8, 24, 48, 120 and 192 hours and the mice

15451administered the luciferase LNP formulation subcutaneously were imaged at 2, 8, 24, 48 and 120 hours to determine the luciferase expression as shown in Table 88. In Table 88, "NT" means not tested. Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse.

15452Table 88. Luciferase Expression

15453<img file="WO2013151663A1_D0229.tif" />

15454[0001350] One mouse administered the LNP formulation intravenously was sacrificed at 8 hours to determine the luciferase expression in the liver and spleen. Also, one mouse administered the LNP formulation intramuscular was sacrificed at 8 hours to determine the luciferase expression of the muscle around the injection site and in the liver and spleen. As shown in Table 89, expression was seen in the both the liver and spleen after intravenous and intramuscular administration and in the muscle around the intramuscular injection site.

15455Table 89. Luciferase Expression in Tissue

15456<img file="WO2013151663A1_D0230.tif" />

15457Example 62. Cytokine Study: PBMC A. PBMC isolation and Culture

15458[0001351] 50 mL of human blood from two donors was received from Research Blood Components (lots KP30928 and KP30931) in sodium heparin tubes. For each donor, the blood was pooled and diluted to 70 mL with DPBS (SAFC Bioscience 59331C, lot 071M8408) and split evenly between two 50 mL conical tubes. 10 mL of Ficoll Paque (GE Healthcare 17-5442-03, lot 10074400) was gently dispensed below the blood layer. The tubes were centrifuged at 2000 rpm for 30 minutes with low acceleration and braking. The tubes were removed and the buffy coat PBMC layers were gently transferred to a fresh 50 mL conical and washed with DPBS. The tubes were centrifuged at 1450 rpm for 10 minutes.

15459[0001352] The supernatant was aspirated and the PBMC pellets were resuspended and washed in 50 mL of DPBS. The tubes were centrifuged at 1250 rpm for 10 minutes. This wash step was repeated, and the PBMC pellets were resuspended in 19 mL of Optimem I (Gibco 11058, lot 1072088) and counted. The cell suspensions were adjusted to a concentration of 3.0 x 10A6 cells / mL live cells.

15460[0001353] These cells were then plated on five 96 well tissue culture treated round bottom plates (Costar 3799) per donor at 50 uL per well. Within 30 minutes, transfection mixtures were added to each well at a volume of 50 uL per well. After 4 hours post transfection, the media was supplemented with 10 uL of Fetal Bovine Serum (Gibco 10082, lot 1012368).

15461B. Transfection Preparation

15462[0001354] Modified mRNA encoding human G-CSF (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) (containing either (1) natural NTPs, (2) 100% substitution with 5-methyl cytidine and pseudouridine, or (3) 100% substitution with 5-methyl cytidine and Nl- methyl-pseudouridine; mRNA encoding luciferase (IVT cDNA sequence shown in SEQ ID NO: 56161; mRNA sequence shown in SEQ ID NO: 56162, polyA tail of

15463approximately 160 nucleotides not shown in sequence, 5'cap, Capl, fully modified with 5-methylcytosine at each cytosine and pseudouridine replacement at each uridine site) (containing either (1) natural NTPs or (2) 100% substitution with 5-methyl cytidine and pseudouridine) and TLR agonist R848 (Invivogen tlrl-r848) were diluted to 38.4 ng / uL in a final volume of 2500 uL Optimem I.

15464[0001355] Separately, 110 uL of Lipofectamine 2000 (Invitrogen 11668-027, lot 1070962) was diluted with 6.76 mL Optimem I. In a 96 well plate nine aliquots of 135 uL of each mRNA, positive control (R-848) or negative control (Optimem I) was added to 135 uL of the diluted Lipofectamine 2000. The plate containing the material to be transfected was incubated for 20 minutes. The transfection mixtures were then transferred to each of the human PBMC plates at 50 uL per well. The plates were then incubated at 37°C. At 2, 4, 8, 20, and 44 hours each plate was removed from the incubator, and the supernatants were frozen.

15465[0001356] After the last plate was removed, the supernatants were assayed using a human G-CSF ELISA kit (Invitrogen KHC2032) and human IFN-alpha ELISA kit (Thermo Scientific 41105-2). Each condition was done in duplicate.

15466C. Protein and Innate Immune Response Analysis

15467[0001357] The ability of unmodified and modified mRNA to produce the encoded protein was assessed (G-CSF production) over time as was the ability of the mRNA to trigger innate immune recognition as measured by interferon-alpha production. Use of in vitro PBMC cultures is an accepted way to measure the immunostimulatory potential of oligonucleotides (Robbins et al, Oligonucleotides 2009 19:89-102).

15468[0001358] Results were interpolated against the standard curve of each ELISA plate using a four parameter logistic curve fit. Shown in Tables 90 and 91 are the average from 3 separate PBMC donors of the G-CSF, interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha) production over time as measured by specific ELISA.

15469[0001359] In the G-CSF ELISA, background signal from the Lipofectamine 2000 (LF2000) untreated condition was subtracted at each time point. The data demonstrated specific production of human G-CSF protein by human peripheral blood mononuclear is seen with G-CSF mRNA containing natural NTPs, 100% substitution with 5-methyl cytidine and pseudouridine, or 100% substitution with 5-methyl cytidine and Nl-methyl- pseudouridine. Production of G-CSF was significantly increased through the use of 5- methyl cytidine and Nl-methyl-pseudouridine modified mRNA relative to 5-methyl cytidine and pseudouridine modified mRNA. [0001360] With regards to innate immune recognition, while both modified mRNA chemistries largely prevented IFN-alpha and TNF-alpha production relative to positive controls (R848, p(I)p(C)), significant differences did exist between the chemistries. 5- methyl cytidine and pseudouridine modified mRNA resulted in low but detectable levels of IFN-alpha and TNF-alpha production, while 5 -methyl cytidine and Nl-methyl- pseudouridine modified mRNA resulted in no detectable IFN-alpha and TNF-alpha production.

15470[0001361] Consequently, it has been determined that, in addition to the need to review more than one cytokine marker of the activation of the innate immune response, it has surprisingly been found that combinations of modifications provide differing levels of cellular response (protein production and immune activation). The modification, Nl- methyl-pseudouridine, in this study has been shown to convey added protection over the standard combination of 5-methylcytidine/pseudouridine explored by others resulting in twice as much protein and almost 150 fold reduction in immune activation (TNF-alpha).

15471[0001362] Given that PBMC contain a large array of innate immune RNA recognition sensors and are also capable of protein translation, it offers a useful system to test the interdependency of these two pathways. It is known that mRNA translation can be negatively affected by activation of such innate immune pathways (Kariko et al.

15472Immunity (2005) 23: 165-175; Warren et al. Cell Stem Cell (2010) 7:618-630). Using PBMC as an in vitro assay system it is possible to establish a correlation between translation (in this case G-CSF protein production) and cytokine production (in this case exemplified by IFN-alpha and TNF-alpha protein production). Better protein production is correlated with lower induction of innate immune activation pathway, and new chemistries can be judged favorably based on this ratio (Table 92).

15473[0001363] In this study, the PC Ratio for the two chemical modifications, pseudouridine and Nl-methyl-pseudouridine, both with 5-methy cytosine was 4742/141=34 as compared to 9944/1=9944 for the cytokine IFN-alpha. For the cytokine, TNF-alpha, the two chemistries had PC Ratios of 153 and 1243, respectively suggesting that for either cytokine, the Nl-methyl-pseudouridine is the superior modification. In Tables 90 and 91, "NT" means not tested.

15474Table 90. G-CSF G-CSF: 3 Donor Average (pg/ml)

G-CSF 4742

154765-methylcytosine/

15477pseudouridine

G-CSF 9944

154795-methylcytosine/

15480N 1 -methyl-pseudouridine

15481Luciferase 18

LF2000 16

15483Table 91. IFN-alpha and TNF-alpha

15484<img file="WO2013151663A1_D0231.tif" />

15485<img file="WO2013151663A1_D0232.tif" />

15486Example 63. In Vitro PBMC Studies: Percent modification

15487[0001364] 480 ng of G-CSF mRNA modified with 5-methylcytosine (5mC) and pseudouridine (pseudoU) or unmodified G-CSF mRNA was transfected with 0.4 uL of Lipofectamine 2000 into peripheral blood mononuclear cells (PBMC) from three normal blood donors (Dl, D2, and D3). The G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) was completely modified with 5mC and pseudoU (100% modification), not modified with 5mC and pseudoU (0% modification) or was partially modified with 5mC and pseudoU so the mRNA would contain 75% modification, 50% modification or 25% modification. A control sample of Luciferase (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified 5meC and pseudoU) was also analyzed for G-CSF expression. For TNF- alpha and IFN-alpha control samples of Lipofectamine2000, LPS, R-848, Luciferase (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified 5mC and pseudo), and P(I)P(C) were also analyzed. The supernatant was harvested and run by ELISA 22 hours after transfection to determine the protein expression. The expression of G-CSF is shown in Table 93 and the expression of IFN-alpha and TNF-alpha is shown in Table 94. The expression of IFN-alpha and TNF-alpha may be a secondary effect from the transfection of the G-CSF mRNA. Tables 93 and 94 show that the amount of chemical modification of G-CSF, interferon alpha (IFN-alpha) and tumor necrosis factor-alpha (TNF-alpha) is titratable when the mRNA is not fully modified and the titratable trend is not the same for each target.

15488[0001365] By using PBMC as an in vitro assay system it is possible to establish a correlation between translation (in this case G-CSF protein production) and cytokine production (in this case exemplified by IFN-alpha protein production). Better protein production is correlated with lower induction of innate immune activation pathway, and the percentage modification of a chemistry can be judged favorably based on this ratio (Table 95). As calculated from Tables 93 and 94 and shown in Table 95, full

15489modification with 5-methylcytidine and pseudouridine shows a much better ratio of protein/cytokine production than without any modification (natural G-CSF mRNA) (100- fold for IFN-alpha and 27-fold for TNF-alpha). Partial modification shows a linear relationship with increasingly less modification resulting in a lower protein/cytokine ratio.

15490Table 93. G-CSF Expression

15491<img file="WO2013151663A1_D0233.tif" /> Table 94. IFN-alpha and TNF-alpha Expression

15492<img file="WO2013151663A1_D0234.tif" />

15493Table 95. PC Ratio and Effect of Percentage of Modification

15494<img file="WO2013151663A1_D0235.tif" />

15495Example 64. Modified RNA transfected in PBMC

15496[0001366] 500 ng of G-CSF mRNA modified with 5-methylcytosine (5mC) and pseudouridine (pseudoU) or unmodified G-CSF mRNA was transfected with 0.4 uL of Lipofectamine 2000 into peripheral blood mononuclear cells (PBMC) from three normal blood donors (Dl , D2, and D3). The G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) was completely modified with 5mC and pseudoU (100% modification), not modified with 5mC and pseudoU (0% modification) or was partially modified with 5mC and pseudoU so the mRNA would contain 50% modification, 25% modification, 10%> modification, %5 modification, 1% modification or 0.1% modification. A control sample of mCherry (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl ; fully modified 5meC and pseudouridine), G-CSF fully modified with 5-methylcytosine and pseudouridine (Control G-CSF) and an untreated control was also analyzed for expression of G-CSF, tumor necrosis factor-alpha (TNF-alpha) and interferon-alpha (IFN-alpha). The supernatant was harvested 6 hours and 18 hours after transfection and run by ELIS A to determine the protein expression. The expression of G-CSF, IFN-alpha, and TNF-alpha for Donor 1 is shown in Table 96, Donor 2 is shown in Table 97 and Donor 3 is shown in Table 98.

15497[0001367] Full 100% modification with 5-methylcytidine and pseudouridine resulted in the most protein translation (G-CSF) and the least amount of cytokine produced across all three human PBMC donors. Decreasing amounts of modification results in more cytokine production (IFN-alpha and TNF-alpha), thus further highlighting the importance of fully modification to reduce cytokines and to improve protein translation (as evidenced here by G-CSF production).

15498Table 96. Donor 1

15499<img file="WO2013151663A1_D0236.tif" />

15500Table 98. Donor 3 G-CSF (pg/mL) IFN-alpha (pg/mL) TNF-alpha (pg/mL)

155016 hours 18 hours 6 hours 18 hours 6 hours 18 hours

15502100% Mod 6086 7549 7 658 1 1 1 1

1550375% Mod 2479 2378 23 752 4 35

1550450% Mod 667 774 24 896 22 18

1550525% Mod 480 541 57 1557 43 1 15

1550610% Mod 838 956 159 2755 144 123 l% Mod 1 108 1 197 235 3415 88 270

155070.1% Mod 1338 1 177 191 2873 37 363

155080 % Mod 1463 1666 215 3793 74 429

15509Control G-CSF 3272 3603 16 1557 731 9066 mCherry 0 0 2 645 0 0

15510Untreated N/A N/A 1 1 0 8

15511Example 65. Innate Immune Response Study in BJ Fibroblasts

15512A. Single Transfection

15513[0001368] Human primary foreskin fibroblasts (BJ fibroblasts) were obtained from American Type Culture Collection (ATCC) (catalog # CRL-2522) and grown in Eagle's Minimum Essential Medium (ATCC, catalog # 30-2003) supplemented with 10% fetal bovine serum at 37°C, under 5% C02. BJ fibroblasts were seeded on a 24-well plate at a density of 300,000 cells per well in 0.5 ml of culture medium. 250 ng of modified G- CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of

15514approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (Genl) or fully modified with 5-methylcytosine and Nl-methyl-pseudouridine (Gen2) having CapO, Capl or no cap was transfected using Lipofectamine 2000 (Invitrogen, catalog # 11668-019), following manufacturer's protocol. Control samples of poly I:C (PIC), Lipofectamine 2000 (Lipo), natural luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) and natural G-CSF mRNA were also transfected. The cells were harvested after 18 hours, the total RNA was isolated and DNASE® treated using the RNeasy micro kit (catalog #74004) following the manufacturer's protocol. 100 ng of total RNA was used for cDNA synthesis using High Capacity cDNA Reverse Transcription kit (catalog #4368814) following the

15515manufacturer's protocol. The cDNA was then analyzed for the expression of innate immune response genes by quantitative real time PCR using SybrGreen in a Biorad CFX 384 instrument following manufacturer's protocol. Table 99 shows the expression level of innate immune response transcripts relative to house-keeping gene HPRT

15516(hypoxanthine phosphoribosytransferase) and is expressed as fold-induction relative to HPRT. In the table, the panel of standard metrics includes: RIG-I is retinoic acid inducible gene 1, IL6 is interleukin-6, OAS-1 is oligoadenylate synthetase 1, IFNb is interferon-beta, AIM2 is absent in melanoma-2, IFIT-1 is interferon-induced protein with tetratricopeptide repeats 1 , PKR is protein kinase R, TNFa is tumor necrosis factor alpha and IFNa is interferon alpha.

15517Table 99. Innate Immune Response Transcript Levels

15518<img file="WO2013151663A1_D0237.tif" />

15519B. Repeat Transfection

15520[0001369] Human primary foreskin fibroblasts (BJ fibroblasts) were obtained from American Type Culture Collection (ATCC) (catalog # CRL-2522) and grown in Eagle's Minimum Essential Medium (ATCC, catalog # 30-2003) supplemented with 10% fetal bovine serum at 37°C, under 5% C02. BJ fibroblasts were seeded on a 24-well plate at a density of 300,000 cells per well in 0.5 ml of culture medium. 250 ng of modified G- CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of

15521approximately 140 nucleotides not shown in sequence; 5'cap, Capl) unmodified, fully modified with 5-methylcytosine and pseudouridine (Genl) or fully modified with 5- methylcytosme and Nl-methyl-pseudouridine (Gen2) was transfected daily for 5 days following manufacturer's protocol. Control samples of Lipofectamine 2000 (L2000) and mCherry mRNA (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytidine and pseudouridine) were also transfected daily for 5 days. The results are shown in Table 100.

15522[0001370] Unmodified mRNA showed a cytokine response in interferon-beta (IFN-beta) and interleukin-6 (IL-6) after one day. mRNA modified with at least pseudouridine showed a cytokine response after 2-3 days whereas mRNA modified with 5- methylcytosine and Nl-methyl-pseudouridine showed a reduced response after 3-5 days.

15523Table 100. Cytokine Response

15524<img file="WO2013151663A1_D0238.tif" />

15525Example 66. In vivo detection of Innate Immune Response [0001371] In an effort to distringuish the importance of different chemical modification of mRNA on in vivo protein production and cytokine response in vivo, female BALB/C mice (n=5) are injected intramuscularly with G-CSF mRNA (G-CSF mRNA unmod) (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence;) with a 5 'cap of Capl , G-CSF mRNA fully modified with 5-methylcytosine and pseudouridine (G-CSF mRNA 5mc/pU), G-CSF mRNA fully modified with 5-methylcytosine and Nl-methyl-pseudouridine with (G-CSF mRNA 5mc/NlpU) or without a 5' cap (G-CSF mRNA 5mc/Nl pU no cap) or a control of either R848 or 5% sucrose as described in Table 101.

15526Table 101. Dosing Chart

15527<img file="WO2013151663A1_D0239.tif" />

15528[0001372] Blood is collected at 8 hours after dosing. Using ELISA the protein levels of G-CSF, TNF-alpha and IFN-alpha is determined by ELISA. 8 hours after dosing, muscle is collected from the injection site and quantitative real time polymerase chain reaction (QPCR) is used to determine the mRNA levels of RIG-I, PKR, AIM-2, IFIT-1, OAS-2, MDA-5, IFN-beta, TNF-alpha, IL-6, G-CSF, CD45 in the muscle.

15529Example 67. In vivo detection of Innate Immune Response Study

15530[0001373] Female BALB/C mice (n=5) were injected intramuscularly with G-CSF mRNA (G-CSF mRNA unmod) (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence;) with a 5 'cap of Capl , G- CSF mRNA fully modified with 5-methylcytosine and pseudouridine (G-CSF mRNA 5mc/pU), G-CSF mRNA fully modified with 5-methylcytosine and Nl-methyl- pseudouridine with (G-CSF mRNA 5mc/NlpU) or without a 5' cap (G-CSF mRNA 5mc/Nl pU no cap) or a control of either R848 or 5% sucrose as described in Table 102. Blood is collected at 8 hours after dosing and using ELISA the protein levels of G-CSF and interferon-alpha (IFN-alpha) is determined by ELISA and are shown in Table 102.

15531[0001374] As shown in Table 102, unmodified, 5mc/pU, and 5mc/NlpU modified G- CSF mRNA resulted in human G-CSF expression in mouse serum. The uncapped 5mC/NlpU modified G-CSF mRNA showed no human G-CSF expression in serum, highlighting the importance of having a 5' cap structure for protein translation.

15532[0001375] As expected, no human G-CSF protein was expressed in the R848, 5% sucrose only, and untreated groups. Importantly, significant differences were seen in cytokine production as measured by mouse IFN-alpha in the serum. As expected, unmodified G-CSF mRNA demonstrated a robust cytokine response in vivo (greater than the R848 positive control). The 5mc/pU modified G-CSF mRNA did show a low but detectable cytokine response in vivo, while the 5mc/NlpU modified mRNA showed no detectable IFN-alpha in the serum (and same as vehicle or untreated animals).

15533[0001376] Also, the response of 5mc/NlpU modified mRNA was the same regardless of whether it was capped or not. These in vivo results reinforce the conclusion that 1) that unmodified mRNA produce a robust innate immune response, 2) that this is reduced, but not abolished, through 100% incorporation of 5mc/pU modification, and 3) that incorporation of 5mc/NlpU modifications results in no detectable cytokine response.

15534[0001377] Lastly, given that these injections are in 5% sucrose (which has no effect by itself), these result should accurately reflect the immunostimulatory potential of these modifications.

15535[0001378] From the data it is evident that NlpU modified molecules produce more protein while concomitantly having little or no effect on IFN-alpha expression. It is also evident that capping is required for protein production for this chemical modification. The Protein: Cytokine Ratio of 748 as compared to the PC Ratio for the unmodified mRNA (PC=9) means that this chemical modification is far superior as related to the effects or biological implications associated with IFN-alpha.

15536Table 102. Human G-CSF and Mouse IFN-alpha in serum

15537<img file="WO2013151663A1_D0240.tif" /><img file="WO2013151663A1_D0241.tif" />

15538Example 68: In Vivo Delivery of Modified RNA

15539[0001379] Protein production of modified mRNA was evaluated by delivering modified G-CSF mRNA or modified Factor IX mRNA to female Sprague Dawley rats (n=6). Rats were injected with 400 ug in 100 ul of G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (G-CSF Genl), G- CSF mRNA fully modified with 5-methylcytosine and Nl-methyl-pseudouridine (G-CSF Gen2) or Factor IX mRNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (Factor IX Genl) reconstituted from the lyophilized form in 5% sucrose. Blood was collected 8 hours after injection and the G-CSF protein level in serum was measured by ELISA. Table 103 shows the G-CSF protein levels in serum after 8 hours.

15540[0001380] These results demonstrate that both G-CSF Gen 1 and G-CSF Gen 2 modified mRNA can produce human G-CSF protein in a rat following a single intramuscular injection, and that human G-CSF protein production is improved when using Gen 2 chemistry over Gen 1 chemistry.

15541Table 103. G-CSF Protein in Rat Serum (I.M. Injection Route) <img file="WO2013151663A1_D0242.tif" />

15542Example 69. Chemical Modification: In vitro studies

15543A. In vitro Screening in PBMC

15544[0001381] 500 ng of G-CSF (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) mRNA fully modified with the chemical modification outlined Tables 104 and 105 was transfected with 0.4 uL Lipofectamine 2000 into peripheral blood mononuclear cells (PBMC) from three normal blood donors. Control samples of LPS, R848, P(I)P(C) and mCherry (mR A sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence, 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) were also analyzed. The supernatant was harvested and stored frozen until analyzed by ELISA to determine the G-CSF protein expression, and the induction of the cytokines interferon-alpha (IFN-a) and tumor necrosis factor alpha (TNF-a). The protein expression of G-CSF is shown in Table 104, the expression of IFN-a and TNF-a is shown in Table 105.

15545[0001382] The data in Table 104 demonstrates that many, but not all, chemical modifications can be used to productively produce human G-CSF in PBMC. Of note, 100% Nl-methyl-pseudouridine substitution demonstrates the highest level of human G- CSF production (almost 10-fold higher than pseudouridine itself). When Nl-methyl- pseudouridine is used in combination with 5-methylcytidine a high level of human G- CSF protein is also produced (this is also higher than when pseudouridine is used in combination with 5 methylcytidine).

15546[0001383] Given the inverse relationship between protein production and cytokine production in PBMC, a similar trend is also seen in Table 105, where 100% substitution with Nl-methyl-pseudouridine results no cytokine induction (similar to transfection only controls) and pseudouridine shows detectable cytokine induction which is above background.

15547[0001384] Other modifications such as N6-methyladenosine and alpha-thiocytidine appear to increase cytokine stimulation.

15548Table 104. Chemical Modifications and G-CSF Protein Expression

15549<img file="WO2013151663A1_D0243.tif" />

15550<img file="WO2013151663A1_D0244.tif" />

15551Table 105. Chemical Modifications and Cytokine Expression

15552<img file="WO2013151663A1_D0245.tif" /><img file="WO2013151663A1_D0246.tif" />

15553B. In vitro Screening in HeLa Cells

15554[0001385] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas,

15555VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand

15556Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with

1555710%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas,

15558VA). The cells were grown at 37oG in 5% C02 atmosphere overnight. Next day, 83 ng of

15559Luciferase modified RNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) with the chemical modification described in Table 106, were diluted in lOul final volume of OPTI-MEM

15560(LifeTechnologies, Grand Island, NY).

15561[0001386] Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul were diluted in 10 ul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature.

15562[0001387] After 18 to 22 hours of incubation cells expressing luciferase were lysed with 100 ul of Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96- well plates (Corning, Manassas, VA) and combined with 100 ul complete luciferase assay solution (Promega, Madison, WI). The lysate volumes were adjusted or diluted until no more than 2 mio relative light units (RLU) per well were detected for the strongest signal producing samples and the RLUs for each chemistry tested are shown in Table 106. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT).The background signal of the plates without reagent was about 200 relative light units per well.

15563[0001388] These results demonstrate that many, but not all, chemical modifications can be used to productively produce human G-CSF in HeLa cells. Of note, 100% Nl-methyl- pseudouridine substitution demonstrates the highest level of human G-CSF production.

15564Table 106. Relative Light Units of Luciferase

15565<img file="WO2013151663A1_D0247.tif" /> 5-methyluridine 50,932

15566α-Thio-cytidine 26,358

155675-methylcytosine/pseudouridine, test B2 481,477

155685-methylcytosine/Nl-methyl-pseudouridine, test B2 271,989

155695-methylcytosine/pseudouridine, test A3 438,831

155705-methylcytosine/Nl-methyl-pseudouridine, test A3 277,499

15571Unmodified Luciferase 234,802

15572C. In vitro Screening in Rabbit Reticulocyte Lysates

15573[0001389] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) was modified with the chemical modification listed in Table 107 and were diluted in sterile nuclease- free water to a final amount of 250 ng in 10 ul. The diluted luciferase was added to 40 ul of freshly prepared Rabbit Reticulocyte Lysate and the in vitro translation reaction was done in a standard 1.5 mL polypropylene reaction tube (Thermo Fisher Scientific, Waltham, MA) at 30°C in a dry heating block. The translation assay was done with the Rabbit Reticulocyte Lysate (nuclease-treated) kit (Promega, Madison, WI) according to the manufacturer's instructions. The reaction buffer was supplemented with a one-to- one blend of provided amino acid stock solutions devoid of either Leucine or Methionine resulting in a reaction mix containing sufficient amounts of both amino acids to allow effective in vitro translation.

15574[0001390] After 60 minutes of incubation, the reaction was stopped by placing the reaction tubes on ice. Aliquots of the in vitro translation reaction containing luciferase modified RNA were transferred to white opaque polystyrene 96-well plates (Corning, Manassas, VA) and combined with lOOul complete luciferase assay solution (Promega, Madison, WI). The volumes of the in vitro translation reactions were adjusted or diluted until no more than 2 mio relative light units (RLUs) per well were detected for the strongest signal producing samples and the RLUs for each chemistry tested are shown in Table 107. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT).The background signal of the plates without reagent was about 200 relative light units per well.

15575[0001391] These cell-free translation results very nicely correlate with the protein production results in HeLa, with the same modifications generally working or not working in both systems. One notable exception is 5-formylcytidine modified luciferase mRNA which worked in the cell-free translation system, but not in the HeLa cell-based transfection system. A similar difference between the two assays was also seen with 5- formylcytidine modified G-CSF mRNA.

15576Table 107. Relative Light Units of Luciferase

15577<img file="WO2013151663A1_D0248.tif" />

15578Example 70. Chemical Modification: In vivo studies

15579A. In vivo Screening of G-CSF Modified mRNA

15580[0001392] Balb-C mice (n=4) are intramuscularly injected in each leg with modified G-

15581CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of

15582approximately 160 nucleotides not shown in sequence; 5'cap, Capl), fully modified with the chemical modifications outlined in Table 108, is formulated in IxPBS. A control of luciferase modified mR A (m NA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with pseudouridine and 5-methylcytosine) and a control of PBS are also tested. After 8 hours serum is collected to determine G-CSF protein levels cytokine levels by ELISA.

15583Table 108. G-CSF

15584<img file="WO2013151663A1_D0249.tif" />

15585B. In vivo Screening of Luciferase Modified mRNA

15586[0001393] Balb-C mice (n=4) were subcutaneously injected with 200ul containing 42 to

15587103 ug of modified luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl), fully modified with the chemical modifications outlined in Table 109, was formulated in

15588IxPBS. A control of PBS was also tested. The dosages of the modified luciferase mRNA is also outlined in Table 109. 8 hours after dosing the mice were imaged to determine luciferase expression. Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then

15589anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin

15590Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse.

15591[0001394] As demonstrated in Table 109, all luciferase mRNA modified chemistries demonstrated in vivo activity, with the exception of 2'-fluorouridine. In addition 1- methylpseudouridine modified mRNA demonstrated very high expression of luciferase (5 -fold greater expression than pseudouridine containing mRNA).

15592Table 109. Luciferase Screening

15593<img file="WO2013151663A1_D0250.tif" />

15594Example 71. In vivo Screening of Combination Luciferase Modified mRNA

15595[0001395] Balb-C mice (n=4) were subcutaneously injected with 200ul of 100 ug of modified luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl), fully modified with the chemical modifications outlined in Table 110, was formulated in lx PBS. A control of PBS was also tested. 8 hours after dosing the mice were imaged to determine luciferase expression. Twenty minutes prior to imaging, mice were injected

15596intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then

15597anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse.

15598[0001396] As demonstrated in Table 110, all luciferase mRNA modified chemistries (in combination) demonstrated in vivo activity. In addition the presence of Nl -methylpseudouridine in the modified mRNA (with N4-acetylcytidine or 5 methylcytidine) demonstrated higher expression than when the same combinations where tested using with pseudouridine. Taken together, these data demonstrate that Nl -methylpseudouridine containing luciferase mRNA results in improved protein expression in vivo whether used alone (Table 109) or when used in combination with other modified nulceotides (Table 110).

15599Table 110. Luciferase Screening Combinations

15600<img file="WO2013151663A1_D0251.tif" />

15601Example 72. Innate Immune Response in BJ Fibroblasts

15602[0001397] Human primary foreskin fibroblasts (BJ fibroblasts) are obtained from

15603American Type Culture Collection (ATCC) (catalog #CRL-2522) and grown in Eagle's Minimum Essential Medium (ATCC, cat# 30-2003) supplemented with 10% fetal bovine serum at 37°C, under 5% C02. BJ fibroblasts are seeded on a 24-well plate at a density of 130,000 cells per well in 0.5 ml of culture medium. 250 ng of modified G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (Genl) or fully modified with 5-methylcytosine and Nl -methyl- pseudouridine (Gen2) is transfected using Lipofectamine 2000 (Invitrogen, cat# 11668- 019), following manufacturer's protocol. Control samples of Lipofectamine 2000 and unmodified G-CSF mRNA (natural G-CSF) are also transfected. The cells are transfected for five consecutive days. The transfection complexes are removed four hours after each round of transfection.

15604[0001398] The culture supernatant is assayed for secreted G-CSF (R&D Systems, catalog #DCS50), tumor necrosis factor-alpha (TNF-alpha ) and interferon alpha (IFN-alpha by ELISA every day after transfection following manufacturer's protocols. The cells are analyzed for viability using CELL TITER GLO® (Promega, catalog #G7570) 6 hrs and 18 hrs after the first round of transfection and every alternate day following that. At the same time from the harvested cells, total RNA is isolated and treated with DNASE® using the RNAEASY micro kit (catalog #74004) following the manufacturer's protocol. 100 ng of total RNA is used for cDNA synthesis using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, cat #4368814) following the manufacturer's protocol. The cDNA is then analyzed for the expression of innate immune response genes by quantitative real time PCR using SybrGreen in a Biorad CFX 384 instrument following the manufacturer's protocol.

15605Example 73. In vitro Transcription with wild-type T7 polymerase

15606[0001399] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) and G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) were fully modified with different chemistries and chemistry combinations listed in Tables 111-114 using wild-type T7 polymerase as previously described.

15607[0001400] The yield of the translation reactions was determined by spectrophometric measurement (OD260) and the yield for Luciferase is shown in Table 111 and G-CSF is shown in Table 113.

15608[0001401] The luciferase and G-CSF modified mRNA were also subjected to an enzymatic capping reaction and each modified mRNA capping reaction was evaluated for yield by spectrophometic measurement (OD260) and correct size assessed using bioanalyzer. The yield from the capping reaction for luciferase is shown in Table 112 and G-CSF is shown in Table 114.

15609Table 111. In vitro transcription chemistry for Luciferase

15610<img file="WO2013151663A1_D0252.tif" /> α-Thio-cytidine 0.83

156115-Br-uridine (5Bru) 1.96

156125 (2 carbomethoxyvinyl) uridine 0.89

156135 (3- IE propenyl Amino) uridine 2.01

15614N4-acetylcytidine/pseudouridine 1.34

15615N4-acetylcytidine/N 1 -methyl-pseudouridine 1.26

156165 -methylcytidine/ 5 -methoxyuridine 1.38

156175 -methylcytidine/ 5 -bromouridine 0.12

156185 -methylcytidine/ 5 -methy luridine 2.97

156195 -methylcytidine/ half of the uridines are modified with 2-thiouridine 1.59

156205-methylcytidine/2-thiouridine 0.90

156215-methylcytidine/pseudouridine 1.83

156225-methylcytidine/N 1 -methyl-pseudouridine 1.33

15623Table 112. Capping chemistry and yield for Luciferase modified mRNA

15624<img file="WO2013151663A1_D0253.tif" />

15625Table 113. In vitro transcription chemistry and yield for G-CSF modified mRNA

15626<img file="WO2013151663A1_D0254.tif" /> N4-acetylcytidine 3.13

156275-formylcytidine 1.41

15628Pseudouridine 4.1

15629N 1 -methyl-pseudouridine 3.24

156302-thiouridine 3.46

156315 -methoxyuridine 2.57

156325-methyluridine 4.27

156334-thiouridine 1.45

156342'-F-uridine 0.96 a-Thio-cytidine 2.29

156352'-F-guanosine 0.6

15636N- 1 -methyladenosine 0.63

156375-Br-uridine (5Bru) 1.08

156385 (2 carbomethoxyvinyl) uridine 1.8

156395 (3- IE propenyl Amino) uridine 2.09

15640N4-acetylcytidine/pseudouridine 1.72

15641N4-acetylcytidine/N 1 -methyl-pseudouridine 1.37

156425 -methylcytidine/ 5 -methoxyuridine 1.85

156435 -methylcytidine/ 5 -methy luridine 1.56

156445 -methylcytidine/ half of the uridines are modified with 2-thiouridine 1.84

156455-methylcytidine/2-thiouridine 2.53

156465-methylcytidine/pseudouridine 0.63

15647N4-acetylcytidine/2-thiouridine 1.3

15648N4-acetylcytidine/5-bromouridine 1.37

156495-methylcytidine/N 1 -methyl-pseudouridine 1.25

15650N4-acetylcytidine/pseudouridine 2.24

15651Table 114. Capping chemistry and yield for G-CSF modified mRNA

15652<img file="WO2013151663A1_D0255.tif" /> 5 -methylcytidine/ 5 -methoxyuridine 0.91

156535 -methylcytidine/ 5 -methyluridine 0.61

156545 -methylcytidine/ half of the uridines are modified with 2-thiouridine 1.24

156555-methylcytidine/pseudouridine 1.08

15656N4-acetylcytidine/2-thiouridine 1.34

15657N4-acetylcytidine/5-bromouridine 1.22

156585-methylcytidine/N 1 -methyl-pseudouridine 1.56

15659Example 74. In vitro Transcription with mutant T7 polymerase

15660[0001402] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) and G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) were fully modified with different chemistries and chemistry combinations listed in Tables 115-118 using a mutant T7 polymerase (Durascribe® T7 Transcription kit (Cat. No. DS010925) (Epicentre®, Madison, WI).

15661[0001403] The yield of the translation reactions was determined by spectrophometric measurement (OD260) and the yield for Luciferase is shown in Tables 115 and G-CSF is shown in Tables 117.

15662[0001404] The luciferase and G-CSF modified mRNA were also subjected to an enzymatic capping reaction and each modified mRNA capping reaction was evaluated for yield by spectrophometic measurement (OD260) and correct size assessed using bioanalyzer. The yield from the capping reaction for luciferase is shown in Table 116 and G-CSF is shown in Table 118.

15663Table 115. In vitro transcription chemistry and yield for Luciferase modified mRNA

15664<img file="WO2013151663A1_D0256.tif" /><img file="WO2013151663A1_D0257.tif" />

156652 ' fluoroadenosine 190.98

15666Table 116. Capping chemistry and yield for Luciferase modified mRNA

15667<img file="WO2013151663A1_D0258.tif" />

156685-methylcytidine/Nl -methyl-pseudouridine, test B 44.4

15669Table 117. In vitro transcription chemistry and yield for G-CSF modified mRNA

15670<img file="WO2013151663A1_D0259.tif" /> 2-fluorocytosine/2-fluorouridine 93.9

156712-fluoroguanine/5-methylcytosine 97.3

156722-fluoroguanine/5-methylcytosine/pseudouridine 96.0

156732-fluoroguanine/5-methylcytidine/Nl-methyl-pseudouridine 82.0

156742-fluoroguanine/pseudouridine 68.0

156752-fluoroguanine/N 1 -methyl-pseudouridine 59.3

156765-methylcytidine/pseudouridine, test B 58,7

156775-methylcytidine/Nl -methyl-pseudouridine, test B 78.0

15678Table 118. Capping chemistry and yield for G-CSF modified mRNA

15679<img file="WO2013151663A1_D0260.tif" />

15680Example 75. 2'O-methyl and 2'Fluoro compounds

15681[0001405] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) were produced as fully modified versions with the chemistries in Table 119 and transcribed using mutant T7 polymerase (Durascribe® T7 Transcription kit (Cat. No. DS010925) (Epicentre®, Madison, WI). 2' fluoro-containing mRNA were made using Durascribe T7, however, 2'Omethyl-containing mRNA could not be transcribed using Durascribe T7.

15682[0001406] Incorporation of 2'Omethyl modified mRNA might possibly be accomplished using other mutant T7 polymerases (Nat Biotechnol. (2004) 22:1155-1160; Nucleic Acids Res. (2002) 30:el38) or US Patent 7,309,570, the contents of each of which are incorporated herein by reference in their entirety. Alternatively, 2'OMe modifications could be introduced post-transcriptionally using enzymatic means.

15683[0001407] Introduction of modifications on the 2' group of the sugar has many potential advantages. 2'OMe substitutions, like 2' fluoro substitutions are known to protect against nucleases and also have been shown to abolish innate immune recognition when incorporated into other nucleic acids such as siRNA and anti-sense (incorporated in its entirety, Crooke, ed. Antisense Drug Technology, 2nd edition; Boca Raton: CRC press).

15684[0001408] The 2'Fluoro-modified mRNA were then transfected into HeLa cells to assess protein production in a cell context and the same mRNA were also assessed in a cell-free rabbit reticulocyte system. A control of unmodified luciferase (natural luciferase) was used for both transcription experiments, a control of untreated and mock transfected (Lipofectamine 2000 alone) were also analyzed for the HeLa transfection and a control of no RNA was analyzed for the rabbit reticulysates.

15685[0001409] For the HeLa transfection experiments, the day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with

15686Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37oG in 5% C02 atmosphere overnight. Next day, 83 ng of the 2'fluoro-containing luciferase modified RNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) with the chemical modification described in Table 119, were diluted in lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul were diluted in 10 ul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature. After 18 to 22 hours of incubation cells expressing luciferase were lysed with 100 ul of Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96-well plates (Corning, Manassas, VA) and combined with 100 ul complete luciferase assay solution (Promega, Madison, WI). The lysate volumes were adjusted or diluted until no more than 2 mio relative light units (RLU) per well were detected for the strongest signal producing samples and the RLUs for each chemistry tested are shown in Table 119. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT).The background signal of the plates without reagent was about 200 relative light units per well.

15687[0001410] For the rabbit reticulocyte lysate assay, 2'-fluoro-containing luciferase mRNA were diluted in sterile nuclease-free water to a final amount of 250 ng in 10 ul and added to 40 ul of freshly prepared Rabbit Reticulocyte Lysate and the in vitro translation reaction was done in a standard 1.5 mL polypropylene reaction tube (Thermo Fisher Scientific, Waltham, MA) at 30°C in a dry heating block. The translation assay was done with the Rabbit Reticulocyte Lysate (nuclease-treated) kit (Promega, Madison, WI) according to the manufacturer's instructions. The reaction buffer was supplemented with a one-to-one blend of provided amino acid stock solutions devoid of either Leucine or Methionine resulting in a reaction mix containing sufficient amounts of both amino acids to allow effective in vitro translation. After 60 minutes of incubation, the reaction was stopped by placing the reaction tubes on ice.

15688[0001411] Aliquots of the in vitro translation reaction containing luciferase modified RNA were transferred to white opaque polystyrene 96-well plates (Corning, Manassas, VA) and combined with lOOul complete luciferase assay solution (Promega, Madison, WI). The volumes of the in vitro translation reactions were adjusted or diluted until no more than 2 mio relative light units (RLUs) per well were detected for the strongest signal producing samples and the RLUs for each chemistry tested are shown in Table 120. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT). The background signal of the plates without reagent was about 160 relative light units per well.

15689[0001412] As can be seen in Table 119 and 120, multiple 2'Fluoro-containing compounds are active in vitro and produce luciferase protein.

15690Table 119. HeLa Cells <img file="WO2013151663A1_D0261.tif" /> 2'Fluoroadenosine 381.96 500 190.98 388.5

156912'Fluorocytosine 654.56 500 327.28 2420

156922'Fluoroguanine 541,795 500 270.90 1 1,705.5

156932'Flurorouridine 944.005 500 472.00 6767.5

15694Natural luciferase N/A N/A N/A 133,853.5

15695Mock N/A N/A N/A 340

15696Untreated N/A N/A N/A 238

15697Table 120. Rabbit Reticulysates

15698<img file="WO2013151663A1_D0262.tif" />

15699Example 76. Luciferase in HeLa Cells using a combination of modifications

15700[0001413] To evaluate using of 2'fiuoro-modified mRNA in combination with other modification a series of mRNA were transcribed using either wild-type T7 polymerase (non-fluoro-containing compounds) or using mutant T7 polymerases (fluyoro-containing compounds) as described in Example 75. All modified mRNA were tested by in vitro transfection in HeLa cells.

15701[0001414] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37oG in 5% C02 atmosphere overnight. Next day, 83 ng of Luciferase modified RNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) with the chemical modification described in Table 121, were diluted in lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul were diluted in 10 ul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature. [0001415] After 18 to 22 hours of incubation cells expressing luciferase were lysed with 100 ul of Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96- well plates (Coming, Manassas, VA) and combined with 100 ul complete luciferase assay solution (Promega, Madison, WI). The lysate volumes were adjusted or diluted until no more than 2 mio relative light units (RLU) per well were detected for the strongest signal producing samples and the RLUs for each chemistry tested are shown in Table 121. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT).The background signal of the plates without reagent was about 200 relative light units per well.

15702[0001416] As evidenced in Table 121, most combinations of modifications resulted in mRNA which produced functional luciferase protein, including all the non-flouro containing compounds and many of the combinations containing 2'fluro modifications.

15703Table 121. Luciferase

15704<img file="WO2013151663A1_D0263.tif" /> Natural luciferase 30,801

15705Untreated 344

15706Mock 262

15707Example 77. G-CSF In Vitro Transcription

15708[0001417] To assess the activity of all our different chemical modifications in the context of a second open reading frame, we replicated experiments previously conducted using luciferase mRNA, with human G-CSF mRNA. G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) were fully modified with the chemistries in Tables 122 and 123 using wild-type T7 polymerase (for all non-fluoro-containing compounds) or mutant T7 polymerase (for all fluoro-containing compounds). The mutant T7 polymerase was obtained commercially (Durascribe® T7 Transcription kit (Cat. No. DS010925)

15709(Epicentre®, Madison, WI).

15710[0001418] The modified RNA in Tables 122 and 123 were transfected in vitro in HeLa cells or added to rabbit reticuly sates (250ng of modified mRNA) as indicated. A control of untreated, mock transfected (transfection reagent alone), G-CSF fully modified with 5- methylcytosine and Nl-methyl-pseudouridine or luciferase control (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl- pseudouridine were also analyzed. The expression of G-CSF protein was determined by ELISA and the values are shown in Tables 122 and 123. In Table 122, "NT" means not tested.

15711[0001419] As shown in Table 123, many, but not all, chemical modifications resulted in human G-CSF protein production. These results from cell-based and cell-free translation systems correlate very nicely with the same modifications generally working or not working in both systems. One notable exception is 5-formylcytidine modified G-CSF mRNA which worked in the cell-free translation system, but not in the HeLa cell-based transfection system. A similar difference between the two assays was also seen with 5- formylcytidine modified luciferase mRNA.

15712[0001420] As demonstrated in Table 123, many, but not all, G-CSF mRNA modified chemistries (when used in combination) demonstrated in vivo activity. In addition the presence of Nl-methyl-pseudouridine in the modified mRNA (with N4-acetylcytidine or 5 methylcytidine) demonstrated higher expression than when the same combinations where tested using with pseudouridine. Taken together, these data demonstrate that Nl- methyl-pseudouridine containing G-CSF mRNA results in improved protein expression in vitro.

15713Table 122. G-CSF Expression

15714<img file="WO2013151663A1_D0264.tif" />

15715Table 123. Combination Chemistries in HeLa cells Chemical Modification G-CSF protein

15716(pg/ml)

15717HeLa cells

15718N4-acetylcytidine/pseudouridine 537,273

15719N4-acetylcytidine/N 1 -methyl-pseudouridine 1,091,818

157205-methylcytidine/5-methoxyuridine 516,136

157215-memylcytidine/5-bromouridine 48,864

157225 -methylcytidine/ 5 -methyluridine 207,500

157235-methylcytidine/2-thiouridine 33,409

15724N4-acerylcytidine/5-bromouridine 21 1,591

15725N4-acetylcytidine/2-thiouridine 46,136

157265-methylcytosine/pseudouridine 301,364

157275-methylcytosine/N 1 -methyl-pseudouridine 1,017,727

15728N4-acetylcytidine/2'Fluorouridine triphosphate 62,273

157295-memylcytidine/2'Fluorouridine triphosphate 49,318

157302'Fluorocytosine triphosphate/pseudouridine 7,955

157312'Fluorocytosine triphosphate/N 1 -methyl-pseudouridine 1,364

157322'Fluorocytosine triphosphate/2-thiouridine 0

157332'Fluorocytosine triphosphate/5-bromouridine 1,818

157342'Fluorocytosine triphosphate/2'Fluorouridine triphosphate 909

157352'Fluoroguanine triphosphate/5-methylcytidine 0

157362'Fluoroguanine triphosphate/5-methylcytidine/pseudouridine 0

157372'Fluoroguanine triphosphate /5-methylcytidine/Nl 1,818

15738methylpseudouridine

157392'Fluoroguanine triphosphate/pseudouridine 1,136

157402'Fluoroguanine triphosphate/2 ' Fluorocytosine 0

15741triphosphate/N 1 -methyl-pseudouridine

157425-methylcytidine/pseudouridine 617,727

157435-methylcytidine/N 1 -methyl-pseudouridine 747,045

157445-methylcytidine/pseudouridine 475,455

157455-methylcytidine/N 1 -methyl-pseudouridine 689,091

157465-methylcytosine/N 1 -methyl-pseudouridine, Control 1 848,409

157475-methylcytosine/N 1 -methyl-pseudouridine, Control 2 581,818

15748Mock 682

15749Untreated 0

15750Luciferase 2'Fluorocytosine triphosphate 0

15751Luciferase 2'Fluorouridine triphosphate 0

15752Example 78. Screening of Chemistries

15753[0001421] The tables listed in below (Tables 124-126) summarize much of the in vitro and in vitro screening data with the different compounds presented in the previous examples. A good correlation exists between cell-based and cell-free translation assays. The same chemistry substitutions generally show good concordance whether tested in the context of luciferase or G-CSF mRNA. Lastly, Nl -methyl-pseudouridine containing mRNA show a very high level of protein expression with little to no detectable cytokine stimulation in vitro and in vivo, and is superior to mRNA containing pseudouridine both in vitro and in vivo.

15754[0001422] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) and G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) were modified with naturally and non- naturally occurring chemistries described in Tables 124 and 125 or combination chemistries described in Table 126 and tested using methods described herein.

15755[0001423] In Tables 125 and 126, "*" refers to in vitro transcription reaction using a mutant T7 polymerase (Durascribe® T7 Transcription kit (Cat. No. DS010925)

15756(Epicentre®, Madison, WI); refers to the second result in vitro transcription reaction using a mutant T7 polymerase (Durascribe® T7 Transcription kit (Cat. No. DS010925) (Epicentre®, Madison, WI); refers to production seen in cell free translations

15757(rabbit reticulocyte lysates); the protein production of HeLa is judged by "+," "+/-" and "-"; when referring to G-CSF PBMC "++++" means greater than 6,000 pg/ml G-CSF, "+++" means greater than 3,000 pg/ml G-CSF, "++" means greater than 1,500 pg/ml G- CSF, "+" means greater than 300 pg/ml G-CSF, "+/-" means 150-300 pg/ml G-CSF and the background was about 110 pg/ml; when referring to cytokine PBMC "++++" means greater than 1,000 pg/ml interferon-alpha (IFN-alpha), "+++" means greater than 600 pg/ml IFN-alpha, "++" means greater than 300 pg/ml IFN-alpha, "+" means greater than 100 pg/ml IFN-alpha, "-" means less than 100 pg/ml and the background was about 70 pg/ml; and "NT" means not tested. In Table 125, the protein production was evaluated using a mutant T7 polymerase (Durascribe® T7 Transcription kit (Cat. No. DS010925) (Epicentre®, Madison, WI).

15758Table 124. Naturally Occurring

15759<img file="WO2013151663A1_D0265.tif" />

15760<img file="WO2013151663A1_D0266.tif" />

15761Table 125. Non-Naturally Occurring<img file="WO2013151663A1_D0267.tif" />

15762<img file="WO2013151663A1_D0268.tif" /> 6-Chloro-purine NT NT NT NT NT NT NT NT a-Thio- NT NT NT NT NT NT NT NT adenosine

157637-Deaza- NT NT NT NT NT NT NT NT adenosine

157645-iodo-cytidine NT NT NT NT NT NT NT NT

15765[0001424] In Table 126, the protein production of HeLa is judged by "+," "+/-" and when referring to G-CSF PBMC "++++" means greater than 6,000 pg/ml G-CSF, "+++" means greater than 3,000 pg/ml G-CSF, "++" means greater than 1,500 pg/ml G-CSF, "+" means greater than 300 pg/ml G-CSF, "+/-" means 150-300 pg/ml G-CSF and the background was about 110 pg/ml; when referring to cytokine PBMC "++++" means greater than 1,000 pg/ml interferon-alpha (IFN-alpha), "+++" means greater than 600 pg/ml IFN-alpha, "++" means greater than 300 pg/ml IFN-alpha, "+" means greater than 100 pg/ml IFN-alpha, "-" means less than 100 pg/ml and the background was about 70 pg/ml; "WT" refers to the wild type T7 polymerase, "MT" refers to mutant T7 polymerase (Durascribe® T7 Transcription kit (Cat. No. DSO 10925) (Epicentre®, Madison, WI) and "NT" means not tested.

15766Table 126. Combination Chemistry

15767<img file="WO2013151663A1_D0269.tif" />

15768<img file="WO2013151663A1_D0270.tif" />

15769dine GTP Pass Pass NT NT NT 5- A,2

15770pseudouri

15771methylcyti Fluoro

15772dine

15773dine GTP Pass Pass NT NT NT

15774Nl- methyl- A,2

15775methylcyti

15776pseudouri Fluoro

15777dine

15778dine GTP Pass Pass +/- NT NT NT

157792

15780Fluorocyto

15781pseudouri

15782sine A,2

15783dine

15784triphosphat Fluoro

15785e GTP Pass Pass +/- NT NT NT

157862

15787Nl-

15788Fluorocyto

15789methyl- sine A,2

15790pseudouri

15791triphosphat Fluoro

15792dine

15793e GTP Pass Pass NT NT NT

15794Example 79. 2'Fluoro Chemistries in PBMC

15795[0001425] The ability of G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) to trigger innate an immune response was determined by measuring interferon- alpha (IFN-alpha) and tumor necrosis factor-alpha (TNF-alpha) production. Use of in vitro PBMC cultures is an accepted way to measure the immunostimulatory potential of oligonucleotides (Robbins et al, Oligonucleotides 2009 19:89-102) and transfection methods are described herein. Shown in Table 127 are the average from 2 or 3 separate PBMC donors of the interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF- alpha) production over time as measured by specific ELISA. Controls of R848, P(I)P(C), LPS and Lipofectamine 2000 (L2000) were also analyzed.

15796[0001426] With regards to innate immune recognition, while both modified mRNA chemistries largely prevented IFN-alpha and TNF-alpha production relative to positive controls (R848, P(I)P(C)), 2'fluoro compounds reduce IFN-alpha and TNF-alpha production even lower than other combinations and N4-acetylcytidine combinations raised the cytokine profile.

15797Table 127. IFN-alpha and TNF-alpha

15798<img file="WO2013151663A1_D0271.tif" /><img file="WO2013151663A1_D0272.tif" />

15799-met y cyt ne -met y -pseu ou ne

15800Example 80. Modified mRNA with a Tobacco Etch Virus 5'UTR

15801[0001427] A 5' untranslated region (UTR) may be provided as a flanking region.

15802Multiple 5' UTRs may be included in the flanking region and may be the same or of different sequences. Any portion of the flanking regions, including none, may be codon optimized and any may independently contain one or more different structural or chemical modifications, before and/or after codon optimization.

15803[0001428] The 5' UTR may comprise the 5'UTR from the tobacco etch virus (TEV). Variants of 5 ' UTRs may be utilized wherein one or more nucleotides are added or removed to the termini, including A, T, C or G.

15804Example 81. Expression of PLGA Formulated mRNA

15805A. Synthesis and Characterization of Luciferase PLGA Microspheres [0001429] Luciferase mRNA (mR A sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine, modified with 25% of uridine replaced with 2-thiouridine and 25% of cytosine replaced with 5-methylcytosine, fully modified with Nl-methyl-pseudouridine, or fully modified with pseudouridine was reconstituted in lx TE buffer and then formulated in PLGA microspheres. PLGA microspheres were synthesized using the water/oil/water double emulsification methods known in the art using PLGA-ester cap (Lactel, Cat# B6010-2, inherent viscosity 0.55- 0.75, 50:50 LA:GA), polyvinylalcohol (PVA) (Sigma, Cat# 348406-25G, MW 13-23k) dichloromethane and water. Briefly, 0.4 ml of mRNA in TE buffer at 4 mg/ml (Wl) was added to 2 ml of PLGA dissolved in dichloromethane (DCM) (01) at a concentration of 200 mg/ml of PLGA. The Wl/Ol emulsion was homogenized (IKA Ultra-Turrax Homogenizer, T18) for 30 seconds at speed 5 (-19,000 rpm). The Wl/Ol emulsion was then added to 250 ml 1% PVA (W2) and homogenized for 1 minute at speed 5 (-19,000 rpm). Formulations were left to stir for 3 hours, then passed through a 100 μιη nylon mesh strainer (Fisherbrand Cell Strainer, Cat # 22-363-549) to remove larger aggregates, and finally washed by centrifugation (10 min, 9,250 rpm, 4°C). The supernatant was discarded and the PLGA pellets were resuspended in 5-10 ml of water, which was repeated 2x. After washing and resuspension with water, 100-200 μΐ of a PLGA microspheres sample was used to measure particle size of the formulations by laser diffraction (Malvern Mastersizer2000). The washed formulations were frozen in liquid nitrogen and then lyophilized for 2-3 days.

15806[0001430] After lyophilization, -10 mg of PLGA MS were weighed out in 2 ml eppendorf tubes and deformulated by adding 1 ml of DCM and letting the samples shake for 2-6 hrs. The mRNA was extracted from the deformulated PLGA micropsheres by adding 0.5 ml of water and shaking the sample overnight. Unformulated luciferase mRNA in TE buffer (unformulated control) was spiked into DCM and went through the deformulation process (deformulation control) to be used as controls in the transfection assay. The encapsulation efficiency, weight percent loading and particle size are shown in Table 128. Encapsulation efficiency was calculated as mg of mRNA from

15807deformulation of PLGA microspheres divided by the initial amount of mRNA added to the formulation. Weight percent loading in the formulation was calculated as mg of mRNA from deformulation of PLGA microspheres divided by the initial amount of PLGA added to the formulation.

15808Table 128. PLGA Characteristics

15809<img file="WO2013151663A1_D0273.tif" />

15810B. Protein Expression of modified mRNA Encapsulated in PLGA Microspheres

15811[0001431] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas,

15812VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand

15813Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with

1581410%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas,

15815VA). The cells were grown at 37oC in a 5% C02 atmosphere overnight. The next day, 83 ng of the deformulated luciferase mRNA PLGA microsphere samples, deformulated luciferase mRNA control (Deform control), or unformulated luciferase mRNA control

15816(Unfomul control) was diluted in a lOul final volume of OPTI-MEM (LifeTechnologies,

15817Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as a transfection reagent and 0.2ul was diluted in a lOul final volume of OPTI-MEM.

15818After 5min of incubation at room temperature, both solutions were combined and incubated an additional 15min at room temperature. Then 20ul of the combined solution was added to lOOul of cell culture medium containing the HeLa cells. The plates were then incubated as described before.

15819[0001432] After an 18 to 22 hour incubation, cells expressing luciferase were lysed with lOOul Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96- well plates (Corning, Manassas, VA) and combined with lOOul complete luciferase assay solution (Promega, Madison, WI). The background signal of the plates without reagent was about 200 relative light units per well. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT).

15820[0001433] Cells were harvested and the bioluminescence (in relative light units, RLU) for each sample is shown in Table 129. Transfection of these samples confirmed that the varied chemistries of luciferase mR A is still able to express luciferase protein after PLGA microsphere formulation.

15821Table 129. Chemical Modifications

15822<img file="WO2013151663A1_D0274.tif" /> 43-68-3

15823Example 82. In vitro studies of Factor IX

15824A. Serum-Free Media

15825[0001434] Human Factor IX mRNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) was transfected in serum-free media. The cell culture supernatant was collected and subjected to trypsin digestion before undergoing 2-dimensional HPLC separation of the peptides. Matrix-assisted laser desorption/ionization was used to detect the peptides. 8 peptides were detected and 7 of the detected peptides are unique to Factor IX. These results indicate that the mRNA transfected in the serum-free media was able to express full-length Factor IX protein.

15826B. Human Embryonic Kidney (ΉΕΚ) 293A Cells

15827[0001435] 250 ng of codon optimized Human Factor IX mRNA (mRNA sequence shown in SEQ ID NO: 56156; fully modified with 5-methylcytosine and pseudouridine; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) was transfected into HEK 293A cells (150, 000 cells/well) using Lipofectamine 2000 in DMEM in presence of 10% FBS. The transfection complexes were removed 3 hours after transfection. Cells were harvested at 3, 6, 9, 12, 24, 48 and 72 hours after transfection. Total RNA was isolated and used for cDNA synthesis. The cDNA was subjected to analysis by quantitative Real-Time PCR using codon optimized Factor IX specific primer set. Human hypoxanthine phosphoribosyltransfersase 1 (HPRT) level was used for normalization. The data is plotted as a percent of detectable mRNA considering the mRNA level as 100% at the 3 hour time point. The half- life of Factor IX modified mRNA fully modified with 5-methylcytosine and pseudouridine in human embryonic kidney 293 (HEK293) cells is about 8-10 hours.

15828Example 83. Saline formulation: Subcutaneous Administration

15829[0001436] Human G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) and human EPO modified mRNA (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine), were formulated in saline and delivered to mice via intramuscular (IM) injection at a dose of 100 ug.

15830[0001437] Controls included Luciferase (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine)) or the formulation buffer (F.Buffer). The mice were bled at 13 hours after the injection to determine the concentration of the human polypeptide in serum in pg/mL. (G-CSF groups measured human G-CSF in mouse serum and EPO groups measured human EPO in mouse serum). The data are shown in Table 130.

15831[0001438] mRNA degrades rapidly in serum in the absence of formulation suggesting the best method to deliver mRNA to last longer in the system is by formulating the mRNA. As shown in Table 130, mRNA can be delivered subcutaneously using only a buffer formulation.

15832Table 130. Dosing Regimen

15833<img file="WO2013151663A1_D0275.tif" />

15834Example 84. Intravitreal Delivery

15835[0001439] mCherry modified mRNA (mRNA sequence shown in SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) and luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) formulated in saline was delivered intravitreally in rats as described in Table 131. The sample was compared against a control of saline only delivered intravitreally. Table 131. Dosing Chart

15836<img file="WO2013151663A1_D0276.tif" />

15837[0001440] The formulation will be administered to the left or right eye of each animal on day 1 while the animal is anesthetized. On the day prior to administration gentamicin ophthalmic ointment or solution was applied to both eyes twice. The gentamicin ophthalmic ointment or solution was also applied immediately following the injection and on the day following the injection.Prior to dosing, mydriatic drops (1% tropicamide and/or 2.5% phenylephrine) are applied to each eye.

15838[0001441] 18 hours post dosing the eyes receiving the dose of mCherry and delivery buffer are enucleated and each eye was separately placed in a tube containing 10 mL 4% paraformaldehyde at room temperature for overnight tissue fixation. The following day, eyes will be separately transferred to tubes containing 10 mL of 30%> sucurose and stored at 21°C until they were processed and sectioned. The slides prepared from different sections were evaluated under F-microscopy. Postive expression was seen in the slides prepared with the eyes administered mCherry modified mRNA and the control showed no expression.

15839Example 85. In Vivo Cytokine Expression Study

15840[0001442] Mice were injected intramuscularly with 200 ug of G-CSF modified mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence) which was unmodified with a 5'cap, Capl

15841(unmodified), fully modified with 5 -methyl cytosine and pseudouridine and a 5'cap, Capl (Genl) or fully modified with 5-methylcytosine and Nl-methyl-pseudouridine and a 5'cap, Capl (Gen2 cap) or no cap (Gen2 uncapped). Controls of R-848, 5% sucrose and untreated mice were also analyzed. After 8 hours serum was collected from the mice and analyzed for interferon-alpha (IFN-alpha) expression. The results are shown in Table 132. Table 132. IFN-alpha Expression

15842<img file="WO2013151663A1_D0277.tif" />

15843Example 86. In vitro expression of VEGF modified mRNA

15844[0001443] HEK293 cells were transfected with modified mRNA (mmRNA) VEGF-A (mRNA sequence shown in SEQ ID NO: 56165; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) which had been complexed with Lipofectamine2000 from Invitrogen (Carlsbad, CA) at the concentration shown in Table 133. The protein expression was detected by ELISA and the protein (pg/ml) is shown in Table 133 and Figure 7.

15845Table 134. Protein Expression <img file="WO2013151663A1_D0278.tif" />

15846Example 87. In vitro Screening in HeLa Cells of GFP

15847[0001444] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37°C in 5% C02 atmosphere overnight. Next day, 37.5 ng or 75 ng of Green Fluroescent protein (GFP) modified RNA (mRNA sequence shown in SEQ ID NO: 56164; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) with the chemical modification described in Table 134, were diluted in lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul were diluted in 10 ul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature.

15848[0001445] After an 18 to 22 hour incubation cells expressing luciferase were lysed with 100 ul of Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96- well plates (Corning, Manassas, VA) and combined with 100 ul complete luciferase assay solution (Promega, Madison, WI). The median fluorescence intensity (MFI) was determined for each chemistry and is shown in Table 134.

15849[0001446] These results demonstrate that GFP fully modified with Nl-methyl- pseudouridine and 5-methylcytosine produces more protein in HeLa cells compared to the other chemistry. Additionally the higher dose of GFP administered to the cells resulted in the highest MFI value.

15850Table 134. Mean Fluorescence Intensity

15851<img file="WO2013151663A1_D0279.tif" />

15852Example 88. Homogenization

15853[0001447] Different luciferase mRNA solutions (as described in Table 135 where "X" refers to the solution containing that component) (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) were evaluated to test the percent yield of the different solutions, the integrity of the mRNA by bioanalyzer, and the protein expression of the mRNA by in vitro transfection. The mRNA solutions were prepared in water, lx TE buffer at 4 mg/ml as indicated in Table 135, and added to either dichloromethane (DCM) or DCM containing 200 mg/ml of poly(lactic-co-glycolic acid) (PLGA) (Lactel, Cat# B6010-2, inherent viscosity 0.55-0.75, 50:50 LA:GA) to achieve a final mRNA concentration of 0.8 mg/ml. The solutions requiring homogenization were homogenized for 30 seconds at speed 5 (approximately 19,000 rpm) (IKA Ultra-Turrax Homogenizer, T18). The mRNA samples in water, dicloromethane and poly(lactic-co- glycolic acid) (PLGA) were not recoverable (NR). All samples, except the NR samples, maintained integrity of the mRNA as determined by bioanalyzer (Bio-rad Experion).

15854[0001448] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37oC in a 5% C02 atmosphere overnight. The next day, 250 ng of luciferase mRNA from the recoverable samples was diluted in a lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as a transfection reagent and 0.2ul was diluted in a lOul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minutes at room temperature. Then 20ul of the combined solution was added to lOOul of cell culture medium containing the HeLa cells. The plates were then incubated as described before. Controls luciferase mRNA (luciferase mRNA formulated in saline) (Control) and untreated cells (Untreat.) were also evaluated. Cells were harvested and the

15855bio luminescence average (in photons/second) (biolum. (p/s)) for each signal is also shown in Table 135. The recoverable samples all showed activity of luciferase mRNA when analyzed.

15856[0001449] After an 18 to 22 hour incubation, cells expressing luciferase were lysed with lOOul Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96- well plates (Corning, Manassas, VA) and combined with lOOul complete luciferase assay solution (Promega, Madison, WI). The background signal of the plates without reagent was about 200 relative light units per well. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT).

15857[0001450] Cells were harvested and the bioluminescence average (in relative light units, RLU) (biolum. (RLU)) for each signal is also shown in Table 135. The recoverable samples all showed activity of luciferase mRNA when analyzed.

15858Table 135. Solutions <img file="WO2013151663A1_D0280.tif" /> 1 X 96 5423780

2 X X 95 4911950

3 X X 92 2367230

4 X X 90 4349410

5 X X X 66 4145340

6 X X X 71 3834440

158647 X X X NR n/a

8 X X X 24 3182080

158669 X X NR n/a

10 X X 79 3276800

11 X X 79 5563550

12 X X 79 4919100

15870Control 2158060

15871Untreat. 3530

15872Example 89. TE Buffer and Water Evaluation

15873[0001451] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) was reconstituted in water or TE buffer as outlined in Table 136 and then formulated in PLGA microspheres. PLGA microspheres were synthesized using the water/oil/water double emulsification methods known in the art using PLGA (Lactel, Cat# B6010-2, inherent viscosity 0.55-0.75, 50:50 LA:GA), polyvinylalcohol (PVA) (Sigma, Cat# 348406-25G, MW 13-23k) dichloromethane and water. Briefly, 0.2 to 0.6 ml of mRNA in water or TE buffer at a concentration of 2 to 6 mg/ml (Wl) was added to 2 ml of PLGA dissolved in dichloromethane (DCM) (01) at a concentration of 100 mg/ml of PLGA. The Wl/Ol emulsion was homogenized (IKA Ultra-Turrax Homogenizer, T18) for 30 seconds at speed 5 (-19,000 rpm). The Wl/Ol emulsion was then added to 250 ml 1% PVA (W2) and homogenized for 1 minute at speed 5 (-19,000 rpm).

15874[0001452] Formulations were left to stir for 3 hours, then passed through a 100 μιη nylon mesh strainer (Fisherbrand Cell Strainer, Cat # 22-363-549) to remove larger aggregates, and finally washed by centrifugation (10 min, 9,250 rpm, 4°C). The supernatant was discarded and the PLGA pellets were resuspended in 5-10 ml of water, which was repeated 2x. The washed formulations were frozen in liquid nitrogen and then lyophilized for 2-3 days. After lyophilization, -10 mg of PLGA MS were weighed out in 2 ml eppendorf tubes and deformulated by adding 1 ml of DCM and letting the samples shake for 2-6 hrs. mRNA was extracted from the deformulated PLGA micropsheres by adding 0.5 ml of water and shaking the sample overnight. Unformulated luciferase mR A in water or TE buffer (deformulation controls) was spiked into DCM and went through the deformulation process to be used as controls in the transfection assay.

15875[0001453] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37oC in a 5% C02 atmosphere overnight. The next day, 100 ng of the deformulated luciferase mRNA samples was diluted in a lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000

15876(LifeTechnologies, Grand Island, NY) was used as a transfection reagent and 0.2ul was diluted in a lOul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minutes at room temperature. Then 20ul of the combined solution was added to lOOul of cell culture medium containing the HeLa cells. The plates were then incubated as described before.

15877[0001454] After 18 to 22 hour incubation, cells expressing luciferase were lysed with lOOul Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96- well plates (Corning, Manassas, VA) and combined with lOOul complete luciferase assay solution (Promega, Madison, WI). The background signal of the plates without reagent was about 200 relative light units per well. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT). To determine the activity of the luciferase mRNA from each formulation, the relative light units (RLU) for each formulation was divided by the RLU of the appropriate mRNA deformulation control (mRNA in water or TE buffer). Table 136 shows the activity of the luciferase mRNA. The activity of the luciferase mRNA in the PLGA microsphere formulations (Form.) was substantially improved by formulating in TE buffer versus water.

15878Table 136. Formulations

15879<img file="WO2013151663A1_D0281.tif" /> PLGA B 4 200 800 0.40 0.13 Water 1.3%

15880PLGA C 4 600 2400 1.20 0.13 Water 12.1%

15881PLGA D 2 400 800 0.40 0.07 Water 1.3%

15882PLGA E 6 400 2400 1.20 0.18 TE Buffer 38.9%

15883PLGA F 4 400 1600 0.80 0.16 TE Buffer 39.7%

15884PLGA G 4 400 1600 0.80 0.10 TE Buffer 26.6%

15885Example 90. Chemical Modifications on mRNA

15886[0001455] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (Life Technologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37°C in 5% C02 atmosphere overnight. The next day, 83 ng of Luciferase modified RNA (mRNA sequence shown SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) with the chemical modification described in Table 137, were diluted in lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000

15887(LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul were diluted in 10 ul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature.

15888[0001456] After 18 to 22 hours of incubation cells expressing luciferase were lysed with 100 ul of Passive Lysis Buffer (Promega, Madison, WI) according to manufacturer instructions. Aliquots of the lysates were transferred to white opaque polystyrene 96- well plates (Corning, Manassas, VA) and combined with 100 ul complete luciferase assay solution (Promega, Madison, WI). The lysate volumes were adjusted or diluted until no more than 2 mio relative light units (RLU) per well were detected for the strongest signal producing samples and the RLUs for each chemistry tested are shown in Table 137. The plate reader was a BioTek Synergy HI (BioTek, Winooski, VT).The background signal of the plates without reagent was about 200 relative light units per well.

15889Table 137. Chemical Modifications Sample RLU

15890Untreated 336

15891Unmodified Luciferase 33980

158925-methylcytosine and pseudouridine 1601234

158935-methylcytosine and Nl-methyl-pseudouridine 421 189

1589425% cytosines replaced with 5-methylcytosine and 25% of uridines 2221 14 replaced with 2-thiouridine

15895N 1 -methyl-pseudouridine 3068261

15896Pseudouridine 140234

15897N4-Acetylcytidine 1073251

158985 -methoxyuridine 219657

158995-Bromouridine 6787

15900N4- Acetylcytidineand N 1 -methyl-pseudouridine 976219

159015-methylcytosine and 5 -methoxyuridine 66621

159025-methylcytosine and 2'fluorouridine 1 1333

15903Example 91. Intramuscular and Subcutaneous Administration of Modified mRNA

15904[0001457] Luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5 'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (5mC/pU), fully modified with 5- methylcytosine and Nl-methyl-pseudouridine (5mC/NlmpU), fully modified with pseudouridine (pU), fully modified with Nl-methyl-pseudouridine (NlmpU) or modified where 25% of the cytosines replaced with 5-methylcytosine and 25% of the uridines replaced with 2-thiouridine (5mC/s2U) formulated in PBS (pH 7.4) was administered to Balb-C mice intramuscularly or subcutaneously at a dose of 2.5 mg/kg. The mice were imaged at 2 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours and 144 hours for intramuscular delivery and 2 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours and 120 hours for subcutaneous delivery. Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bio luminescence was measured as total flux (photons/second) of the entire mouse. The average total flux (photons/second) for intramuscular administration is shown in Table 138 and the average total flux (photons/second) for subcutaneous administration is shown in Table 139. The background signal was 3.79E+05 (p/s). The peak expression for intramuscular administration was seen between 24 and 48 hours for all chemistry and expression was still detected at 144 hours. For subcutaneous delivery the peak expression was seen at 2-8 hours and expression was detected at 72 hours.

15905Table 138. Intramuscular Administration

15906<img file="WO2013151663A1_D0282.tif" />

15907Example 92. Osmotic Pump Study

15908[0001458] Prior to implantation, an osmotic pump (ALZET® Osmotic Pump 2001D, DURECT Corp. Cupertino, CA) is loaded with the 0.2 ml of IX PBS (pH 7.4) (PBS loaded pump) or 0.2 ml of luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine) at 1 mg/ml in lx PBS (pH 7.4) (Luciferase loaded pump) and incubated overnight in lx PBS (pH 7.4) at 37°C.

15909[0001459] Balb-C mice (n=3) are implanted subcutaneously with either the PBS loaded pump or the luciferase loaded pump and imaged at 2 hours, 8 hours and 24 hours. As a control a PBS loaded pump is implanted subcutaneously and the mice are injected subcutaneously with luciferase modified mRNA in lx PBS (PBS loaded pump; SC Luciferase) or an osmotic pump is not implanted and the mice are injected subcutaneously with luciferase modified mR A in lx PBS (SC Luciferase). The luciferase formulations are outlined in Table 140.

15910Table 140. Luciferase Formulations

15911<img file="WO2013151663A1_D0283.tif" />

15912Example 93. External Osmotic Pump Study

15913[0001460] An external osmotic pump (ALZET® Osmotic Pump 2001D, DURECT Corp. Cupertino, CA) is loaded with the 0.2 ml of IX PBS (pH 7.4) (PBS loaded pump) or 0.2 ml of luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine) at 1 mg/ml in lx PBS (pH 7.4) (luciferase loaded pump) and incubated overnight in lx PBS (pH 7.4) at 37°C.

15914[0001461] Using a catheter connected to the external PBS loaded pump or the luciferase loaded pump Balb-C mice (n=3) are administered the formulation. The mice are imaged at 2 hours, 8 hours and 24 hours. As a control an external PBS loaded pump is used and the mice are injected subcutaneously with luciferase modified mRNA in lx PBS (PBS loaded pump; SC Luciferase) or the external pump is not used and the mice are only injected subcutaneously with luciferase modified mRNA in lx PBS (SC Luciferase). Twenty minutes prior to imaging, mice are injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals are then anesthetized and images are acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence is measured as total flux (photons/second) of the entire mouse. The luciferase formulations are outlined in Table 141 and the average total flux (photons/second).

15915Table 141. Luciferase Formulations <img file="WO2013151663A1_D0284.tif" /> Luciferase

15916Luciferase loaded pump PBS 1.00 - 200 10.0

15917PBS loaded pump PBS - - - -

15918SC Luciferase PBS 1.00 50 50 2.5

15919Example 94. Fibrin Sealant Study

15920[0001462] Fibrin sealant, such as Tisseel (Baxter Healthcare Corp., Deerfield, IL), is composed of fibrinogen and thrombin in a dual-barreled syringe. Upon mixing, fibrinogen is converted to fibrin to form a fibrin clot in about 10 to 30 seconds. This clot can mimic the natural clotting mechanism of the body. Additionally a fibrin hydrogel is a three dimensional structure that can potentially be used in sustained release delivery. Currently, fibrin sealant is approved for application in hemostasis and sealing to replace conventional surgical techniques such as suture, ligature and cautery.

15921[0001463] The thrombin and fibrinogen components were loaded separately into a dual barreled syringe. Balb-C mice (n=3) were injected subcutaneously with 50 ul of fibrinogen, 50 ul of thrombin and they were also injected at the same site with modified luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine) (Tisseel+Luciferase), 50 ul of fibrinogen and 50 ul thrombin (Tisseel) or modified luciferase mRNA (Luciferase). The injection of fibrinogen and thrombin was done simultaneously using the dual-barreled syringe. The SC injection of luciferase was done 15 minutes after the

15922fibrinogen/thrombin injection to allow the fibrin hydrogel to polymerize (Tisseel + Luciferase group). A control group of untreated mice were also evaluated. The mice were imaged at 5 hours and 24 hours. Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The luciferase formulations are outlined in Table 142 and the average total flux (photons/second) is shown in Table 143. The fibrin sealant was found to not interfere with imaging and the injection of luciferase and Tisseel showed expression of luciferase.

15923Table 142. Luciferase Formulations Group Vehicle Cone Inj. Vol. Amt Dose

15924(mg/ml) (ul) (ug) (mg/kg)

15925Tisseel+Luciferase PBS 1.00 50 50 2.5

15926Tisseel - - - - -

15927Luciferase PBS 1.00 50 50 2.5

15928Untreated - - - - -

15929Table 143. Total Flux

15930<img file="WO2013151663A1_D0285.tif" />

15931Example 95. Fibrin Containing mRNA Sealant Study

15932A. Modified mRNA and Calcium Chloride

15933[0001464] Prior to reconstitution, luciferase mRNA (mRNA sequence shown in SEQ ID

15934NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine or fully modified with Nl-methyl-pseudouridine is added to calcium chloride. The calcium chloride is then used to reconstitute thrombin. Fibrinogen is reconstituted with fibrinolysis inhibitor solution per the manufacturer's instructions. The reconstituted thrombin containing modified mRNA and fibrinogen is loaded into a dual barreled syringe. Mice are injected subcutaneously with 50 ul of fibrinogen and50 ul of thrombin containing modified mRNA or they were injected with 50 ul of PBS containing an equivalent dose of modified luciferase mRNA. A control group of untreated mice is also evaluated. The mice are imaged at predetermined intervals to determine the average total flux (photons/second).

15935B. Lipid Nanoparticle Formulated Modified mRNA and Calcium Chloride

15936[0001465] Prior to reconstitution, luciferase mRNA (mRNA sequence shown in SEQ ID

15937NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap,

15938Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine or fully modified with Nl-methyl-pseudouridine is formulated in a lipid nanoparticle is added to calcium chloride. The calcium chloride is then used to reconstitute thrombin. Fibrinogen is reconstituted with fibrinolysis inhibitor solution per the manufacturer's instructions. The reconstituted thrombin containing modified mRNA and fibrinogen is loaded into a dual barreled syringe. Mice are injected subcutaneously with 50 ul of fibrinogen and50 ul of thrombin containing modified mRNA or they were injected with 50 ul of PBS containing an equivalent dose of modified luciferase mRNA. A control group of untreated mice is also evaluated. The mice are imaged at predetermined intervals to determine the average total flux (photons/second).

15939C. Modified mRNA and Fibrinogen

15940[0001466] Prior to reconstitution, luciferase mRNA (mRNA sequence shown in SEQ ID

15941NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine or fully modified with Nl-methyl-pseudouridine is added to the fibrinolysis inhibitor solution. The fibrinolysis inhibitor solution is then used to reconstitute fibrinogen. Thrombin is reconstituted with the calcium chloride solution per the manufacturer's instructions. The reconstituted fibrinogen containing modified mRNA and thrombin is loaded into a dual barreled syringe. Mice are injected subcutaneously with 50 ul of thrombin and 50 ul of fibrinogen containing modified mRNA or they were injected with 50 ul of PBS containing an equivalent dose of modified luciferase mRNA. A control group of untreated mice is also evaluated. The mice are imaged at predetermined intervals to determine the average total flux (photons/second).

15942D. Lipid Nanoparticle Formualted Modified mRNA and Fibrinogen

15943[0001467] Prior to reconstitution, luciferase mRNA (mRNA sequence shown in SEQ ID

15944NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine or fully modified with Nl-methyl-pseudouridine is formulated in a lipid nanoparticle is added to the fibrinolysis inhibitor solution. The fibrinolysis inhibitor solution is then used to reconstitute fibrinogen. Thrombin is reconstituted with the calcium chloride solution per the manufacturer's instructions. The reconstituted fibrinogen containing modified mRNA and thrombin is loaded into a dual barreled syringe. Mice are injected subcutaneously with 50 ul of thrombin and 50 ul of fibrinogen containing modified mRNA or they were injected with 50 ul of PBS containing an equivalent dose of modified luciferase mRNA. A control group of untreated mice is also evaluated. The mice are imaged at predetermined intervals to determine the average total flux

15945(photons/second).

15946E. Modified mRNA and Thrombin

15947[0001468] Prior to reconstitution, luciferase mRNA (mRNA sequence shown in SEQ ID

15948NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine or fully modified with Nl-methyl-pseudouridine is added to the reconstituted thrombin after it is reconstituted with the calcium chloride per the manufactuer's instructions. The fibrinolysis inhibitor solution is then used to reconstitute fibrinogen per the

15949manufacturer's instructions. The reconstituted fibrinogen and thrombin containing modified mRNA is loaded into a dual barreled syringe. Mice are injected

15950subcutaneously with 50 ul of thrombin containing modified mRNA and 50 ul of fibrinogen or they were injected with 50 ul of PBS containing an equivalent dose of modified luciferase mRNA. A control group of untreated mice is also evaluated. The mice are imaged at predetermined intervals to determine the average total flux

15951(photons/second).

15952F. Lipid Nanoparticle Formualted Modified mRNA and Thrombin

15953[0001469] Prior to reconstitution, luciferase mRNA (mRNA sequence shown in SEQ ID

15954NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine or fully modified with Nl-methyl-pseudouridine is formulated in a lipid nanoparticle is added to the reconstituted thrombin after it is reconstituted with the calcium chloride per the manufactuer's instructions. The fibrinolysis inhibitor solution is then used to reconstitute fibrinogen per the manufacturer's instructions. The reconstituted fibrinogen and thrombin containing modified mRNA is loaded into a dual barreled syringe. Mice are injected subcutaneously with 50 ul of thrombin containing modified mRNA and 50 ul of fibrinogen or they were injected with 50 ul of PBS containing an equivalent dose of modified luciferase mRNA. A control group of untreated mice is also evaluated. The mice are imaged at predetermined intervals to determine the average total flux

15955(photons/second).

15956Example 96. Cationic Lipid Formulation of 5-Methylcytosine and Nl-Methyl- pseudouridine Modified mRNA [0001470] Luciferase mRNA (mR A sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine was formulated in the cationic lipids described in Table 144. The formulations were administered intravenously (I.V.), intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 0.05 mg/kg.

15957Table 144. Cationic Lipid Formulations

15958<img file="WO2013151663A1_D0286.tif" />

15959[0001471] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours and 24 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The

15960background flux was about 4.17E+05 p/s. The results of the imaging are shown

15961145. In Table 145, "NT" means not tested.

15962Table 145. Flux

15963<img file="WO2013151663A1_D0287.tif" /> s.c. 24 hrs 7.49E+07 2.47E+07 6.96E+06 6.50E+06 1.28E+06

15964Example 97. Lipid Nanoparticle Intravenous Study

15965[0001472] Luciferase mRNA (mR A sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) was formulated in a lipid nanoparticle containing 50% DLin-MC 3 -DMA OR DLin-KC2-DMA as described in Table 146, 38.5% cholesterol, 10% DSPC and 1.5% PEG. The formulation was administered intravenously (I.V.) to Balb-C mice at a dose of 0.5 mg/kg, 0.05 mg/kg, 0.005 mg/kg or 0.0005 mg/kg. Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bio luminescence was measured as total flux (photons/second) of the entire mouse.

15966Table 146. Formulations

15967<img file="WO2013151663A1_D0288.tif" />

15968[0001473] For DLin-KC2-DMA the mice were imaged at 2 hours, 8 hours, 24 hours, 72 hours, 96 hours and 168 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The background flux was about 3.66E+05 p/s. The results of the imaging are shown in Table 147. Organs were imaged at 8 hours and the average total flux (photons/second) was measured for the liver, spleen, lung and kidney. A control for each organ was also analyzed. The results are shown in Table 149. The peak signal for all dose levels was at 8 hours after administration. Also, distribution to the various organs (liver, spleen, lung, and kidney) may be able to be controlled by increasing or decreasing the LNP dose.

15969Table 147. Flux <img file="WO2013151663A1_D0289.tif" /> 2 hrs 3.54E+08 1.75E+07 2.30E+06 4.09E+05

159708 hrs 1.67E+09 1.71E+08 9.81E+06 7.84E+05

1597124 hrs 2.05E+08 2.67E+07 2.49E+06 5.51E+05

1597272 hrs 8.17E+07 1.43E+07 1.01E+06 3.75E+05

1597396 hrs 4.10E+07 9.15E+06 9.58E+05 4.29E+05

15974168 hrs 3.42E+07 9.15E+06 1.47E+06 5.29E+05

15975Table 148. Organ Flux

15976Liver Spleen Lung Kidney

15977Flux (p/s) Flux (p/s) Flux (p/s) Flux (p/s)

159780.5 mg/kg 1.42E+08 4.86E+07 1.90E+05 3.20E+05

159790.05 mg/kg 7.45E+06 4.62E+05 6.86E+04 9.1 1E+04

159800.005 mg/kg 3.32E+05 2.97E+04 1.42E+04 1.15E+04

159810.0005 mg/kg 2.34E+04 1.08E+04 1.87E+04 9.78E+03

15982Untreated 1.88E+04 1.02E+04 1.41E+04 9.20E+03

15983[0001474] For DLin-MC3-DMA the mice were imaged at 2 hours, 8 hours, 24 hours, 48 hours, 72 hours and 144 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The background flux was about 4.51E+05 p/s. The results of the imaging are shown in Table 149. Organs were imaged at 8 hours and the average total flux (photons/second) was measured for the liver, spleen, lung and kidney. A control for each organ was also analyzed. The results are shown in Table 150. The peak signal for all dose levels was at 8 hours after administration. Also, distribution to the various organs (liver, spleen, lung, and kidney) may be able to be controlled by increasing or decreasing the LNP dose.

15984Table 149. Flux

15985<img file="WO2013151663A1_D0290.tif" /> 0.005 mg/kg 3.58E+05 6.04E+04 1.33E+04 1.33E+04

159860.0005 mg/kg 2.25E+04 1.88E+04 2.05E+04 1.65E+04

15987Untreated 1.91E+04 1.66E+04 2.63E+04 2.14E+04

15988Example 98. Lipid Nanoparticle Subcutaneous Study

15989[0001475] Luciferase mRNA (mR A sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) was formulated in a lipid nanoparticle containing 50% DLin-KC2-DMA as described in Table 151, 385% cholesterol, 10% DSPC and 1.5% PEG. The formulation was administered subcutaneously (S.C.) to Balb- C mice at a dose of 0.5 mg/kg, 0.05 mg/kg or 0.005 mg/kg.

15990Table 151. DLin-KC2-DMA Formulation

15991<img file="WO2013151663A1_D0291.tif" />

15992[0001476] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours, 24 hours, 48 hours, 72 hours and 144 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The lower limit of detection was about 3E+05 p/s. The results of the imaging are shown in Table 152. Organs were imaged at 8 hours and the average total flux (photons/second) was measured for the liver, spleen, lung and kidney. A control for each organ was also analyzed. The results are shown in Table 153. The peak signal for all dose levels was at 8 hours after administration. Also, distribution to the various organs (liver, spleen, lung, and kidney) may be able to be controlled by increasing or decreasing the LNP dose. At high doses, the LNP formulations migrates outside of the subcutaneous injection site, as high levels of luciferase expression are detected liver, spleen, lung, and kidney.

15993Table 152. Flux

15994<img file="WO2013151663A1_D0292.tif" />

15995Example 99. Cationic Lipid Nanoparticle Subcutaneous Study

15996[0001477] Luciferase mRNA (mR A sequence shown in SEQ ID NO: 56162; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) is formulated in a lipid nanoparticle containing 50% DLin-MC3 -DMA, 38.5% cholesterol, 10% DSPC and 1.5% PEG. The formulation is administered subcutaneously (S.C.) to Balb-C mice at a dose of 0.5 mg/kg, 0.05 mg/kg or 0.005 mg/kg.

15997[0001478] The mice are imaged at 2 hours, 8 hours, 24 hours, 48 hours, 72 hours and 144 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. Organs are imaged at 8 hours and the average total flux (photons/second) is measured for the liver, spleen, lung and kidney. A control for each organ is also analyzed.

15998Example 100. Luciferase Lipoplex Study

15999[0001479] Lipoplexed luciferase mRNA (mRNA sequence shown in SEQ ID NO:

1600056162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (5mC/pU), fully modified with 5-methylcytosine and Nl-methyl-pseudouridine (5mC/NlmpU) or modified where 25% of the cytosines replaced with 5-methylcytosine and 25% of the uridines replaced with 2- thiouridine (5mC/s2U). The formulation was administered intravenously (I.V.), intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 0.10 mg/kg.

16001[0001480] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 8 hours, 24 hours and 48 hours after dosing and the average total flux (photons/second) was measured for each route of administration and chemical modification. The background signal was about 3.91E+05 p/s. The results of the imaging are shown in Table 154.

16002Organs were imaged at 6 hours and the average total flux (photons/second) was measured for the liver, spleen, lung and kidney. A control for each organ was also analyzed. The results are shown in Table 155.

16003Table 154. Flux

16004<img file="WO2013151663A1_D0293.tif" />

16005Table 155. Organ Flux

16006<img file="WO2013151663A1_D0294.tif" /> Untreated 2.59E+04 1.34E+04 1.26E+04 1.22E+04 n/a

16007Example 101. Cationic Lipid Formulation of Modified mRNA

16008[0001481] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5 'cap, Capl) modified where 25% of the cytosines replaced with 5-methylcytosine and 25% of the uridines replaced with 2-thiouridine (5mC/s2U) was formulated in the cationic lipids described in Table 156. The formulations were administered intravenously (I.V.), intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 0.05 mg/kg.

16009Table 156. Cationic Lipid Formulations

16010<img file="WO2013151663A1_D0295.tif" />

16011[0001482] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours and 24 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The

16012background flux was about 3.31E+05 p/s. The results of the imaging are shown in Table 157. In Table 157, "NT" means not tested. Untreated mice showed an average flux of 3.14E+05 at 2 hours, 3.33E+05 at 8 hours and 3.46E+05 at 24 hours. Peak expression was seen for all three routes tested at 8 hours. DLin-KC2-DMA has better expression than DLin-MC3-DMA and DODMA showed expression for all routes evaluated.

16013Table 157. Flux <img file="WO2013151663A1_D0296.tif" /> DMA DMA

16014Flux (p/s) Flux (p/s) Flux (p/s) Flux (p/s) Flux (p/s)

16015I.V. 2 hrs 9.88E+06 6.98E+07 9.18E+06 3.98E+06 5.79E+06

16016I.V. 8 hrs 1.21E+07 1.23E+08 1.02E+07 5.98E+06 6.14E+06

16017I.V. 24 hrs 2.02E+06 1.05E+07 1.25E+06 1.35E+06 5.72E+05

16018I.M. 2 hrs 6.72E+05 3.66E+06 3.25E+06 7.34E+05 4.42E+05

16019I.M. 8 hrs 7.78E+06 2.85E+07 4.29E+06 2.22E+06 1.38E+05

16020I.M. 24 hrs 4.22E+05 8.79E+05 5.95E+05 8.48E+05 4.80E+05

16021S.C. 2 hrs 2.37E+06 4.77E+06 4.44E+06 1.07E+06 1.05E+06 s.c. 8 hrs 3.65E+07 1.17E+08 3.71E+06 9.33E+06 2.57E+06

16022S.C. 24 hrs 4.47E+06 1.28E+07 6.39E+05 8.89E+05 4.27E+05

16023Example 102. Formulation of 5-Methylcytosine and Nl-Methyl-pseudouridine Modified mRNA

16024[0001483] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and Nl-methyl-pseudouridine was formulated in PBS (pH of 7.4). The formulations were administered intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 2.5 mg/kg.

16025[0001484] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 5 minutes, 30 minutes, 60 minutes and 120 minutes after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The background flux was about 3.78E+05 p/s. The results of the imaging are shown in Table 158. Expression of luciferase was already seen at 30 minutes with both routes of delivery. Peak expression from subcutaneous administration appears between 30 to 60 minutes. Intramuscular expression was still increasing at 120 minutes.

16026Table 158. Flux

16027<img file="WO2013151663A1_D0297.tif" /> s.c. 60 min 5.61E+06

16028s.c. 120 min 2.66E+06

16029Example 103. Intramuscular and Subcutaneous Administration of Chemically Modified mRNA

16030[0001485] Luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with N4-acetylcytidine, fully modified with 5-methoxyuridine, fully modified with N4-acetylcytidine and Nl-methyl-pseudouridine or fully modified 5-methylcytosine and 5-methoxyuridine formulated in PBS (pH 7.4) was administered to Balb-C mice intramuscularly or subcutaneously at a dose of 2.5 mg/kg. Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bio luminescence was measured as total flux

16031(photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours and 24 hours. The average total flux (photons/second) for intramuscular administration is shown in Table 159 and the average total flux (photons/second) for subcutaneous administration is shown in Table 160. The background signal was 3.84E+05 (p/s). The peak expression for intramuscular administration was seen between 24 and 48 hours for all chemistry and expression was still detected at 120 hours. For subcutaneous delivery the peak expression was seen at 2-8 hours and expression was detected at 72 hours.

16032Table 159. Intramuscular Administration

16033<img file="WO2013151663A1_D0298.tif" /> N4-acetylcytidine/ 7.12E+06 3.07E+06 1.03E+07

16034N 1 -methyl-pseudouridine

160355 -methylcytosine/ 5 - 7.15E+06 1.25E+07 1.11E+07 methoxyuridine

16036Example 104. In vivo study

16037[0001486] Luciferase modified mRNA containing at least one chemical modification is formulated as a lipid nanoparticle (LNP) using the syringe pump method and

16038characterized by particle size, zeta potential, and encapsulation.

16039[0001487] As outlined in Table 161, the luciferase LNP formulation is administered to Balb-C mice intramuscularly (I.M.), intravenously (I.V.) and subcutaneously (S.C.). As a control luciferase modified RNA formulated in PBS is administered intravenously to mice.

16040Table 161. Luciferase Formulations

16041<img file="WO2013151663A1_D0299.tif" />

16042[0001488] The mice are imaged at 2, 8, 24, 48, 120 and 192 hours to determine the bioluminescence (measured as total flux (photons/second) of the entire mouse). At 8 hours or 192 hours the liver, spleen, kidney and injection site for subcutaneous and intramuscular administration are imaged to determine the bioluminescence.

16043Example 105. Cationic Lipid Formulation Studies of Chemically Modified mRNA

16044[0001489] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (5mC/pU), pseudouridine (pU) or Nl-methyl- pseudouridine (NlmpU) was formulated in the cationic lipids described in Table 162. The formulations were administered intravenously (I.V.), intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 0.05 mg/kg.

16045Table 162. Cationic Lipid Formulations

16046<img file="WO2013151663A1_D0300.tif" />

16047[0001490] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours and 24 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The background flux was about 4.1 1E+05 p/s. The results of the imaging are shown in Table 163. Peak expression was seen for all three routes tested at 8 hours.

16048Table 163. Flux

16049<img file="WO2013151663A1_D0301.tif" /> Example 106. Studies of Chemical Modified mRNA

16050[0001491] Luciferase mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with N4-acetylcytidine (N4-acetyl), fully modified with 5-methoxyuridine (5meth), fully modified with N4-acetylcytidine and Nl-methyl-pseudouridine (N4-acetyl/NlmpU) or fully modified with 5-methylcytosine and 5-methoxyuridine (5mC/5-meth) was formulated in DLin-MC3-DMA as described in Table 164.

16051[0001492] The formulations were administered intravenously (I.V.), intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 0.05 mg/kg.

16052Table 164. Cationic Lipid Formulations

16053<img file="WO2013151663A1_D0302.tif" />

16054[0001493] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 6 hours and 24 hours after dosing and the average total flux (photons/second) was measured for each route of administration and cationic lipid formulation. The

16055background flux was about 2.70E+05 p/s. The results of the imaging are shown in Table 165.

16056Table 165. Flux <img file="WO2013151663A1_D0303.tif" /> Flux (p/s) Flux (p/s) Flux (p/s) Flux (p/s)

16057I.V. 2 hrs 9.17E+07 3.19E+06 4.21E+07 1.88E+06

16058IV. 6 hrs 7.70E+08 9.28E+06 2.34E+08 7.75E+06

16059IV. 24 hrs 6.84E+07 1.04E+06 3.55E+07 3.21E+06

16060I.M. 2 hrs 8.59E+06 7.86E+05 5.30E+06 5.1 1E+05

16061I.M. 6 hrs 1.27E+08 8.88E+06 3.82E+07 3.17E+06

16062I.M. 24 hrs 4.46E+07 1.38E+06 2.00E+07 1.39E+06

16063S.C. 2 hrs 1.83E+07 9.67E+05 4.45E+06 1.01E+06

16064s.c. 6 hrs 2.89E+08 1.78E+07 8.91E+07 1.29E+07

16065S.C. 24 hrs 6.09E+07 6.40E+06 2.08E+08 6.63E+06

16066Example 107. Lipid Nanoparticle Containing A Plurality of Modified mRNAs

16067[0001494] EPO mRNA (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine), G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl- pseudouridine) and Factor IX mRNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine), is formulated in DLin- MC3-DMA as described in Table 166. The formulations are administered intravenously (I.V.), intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 0.05 mg/kg. Control LNP formulations containing only one mRNA are also admininistered at an equivalent dose.

16068Table 166. DLin-MC3-DMA Formulation

16069<img file="WO2013151663A1_D0304.tif" />

16070[0001495] Serum is collected from the mice at 8 hours, 24 hours, 72 hours and/or 7 days after administration of the formulation. The serum is analyzed by ELISA to determine the protein expression of EPO, G-CSF, and Factor IX. Example 108. Cationic Lipid Formulation Studies of of 5-Methylcytosine and Nl- Methyl-pseudouridine Modified mRNA

16071[0001496] EPO mRNA (mRNA sequence shown in SEQ ID NO: 56155; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine) or G-CSF mRNA (mRNA sequence shown in SEQ ID NO: 56152; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl- pseudouridine) is formulated in DLin-MC3-DMA and DLin-KC2-DMA as described in Table 167. The formulations are administered intravenously (I.V) , intramuscularly (I.M.) or subcutaneously (S.C.) to Balb-C mice at a dose of 0.05 mg/kg.

16072Table 167. DLin-MC3-DMA and DLin-KC2-DMA Formulations

16073<img file="WO2013151663A1_D0305.tif" />

16074[0001497] Serum is collected from the mice at 8 hours, 24 hours, 72 hours and/or 7 days after administration of the formulation. The serum is analyzed by ELISA to determine the protein expression of EPO and G-CSF.

16075Example 109. In Vitro VEGF PBMC Study

16076[0001498] 500 ng of VEGF mRNA (mRNA sequence shown in SEQ ID NO: 56165 polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (VEGF 5mC/pU), fully modified with 5-methylcytosine and Nl-methyl-pseudouridine (VEGF 5mC/NlmpU) or unmodified (VEGF unmod) was transfected with 0.4 uL of Lipofectamine 2000 into peripheral blood mononuclear cells (PBMC) from three normal blood donors (Dl, D2, and D3). Cells were also untreated for each donor as a control. The supernatant was harvested and run by ELISA 22 hours after transfection to determine the protein expression and cytokine induction. The expression of VEGF and IFN-alpha induction is shown in Table 168 and Figures 8 A and 8B.

16077Table 168. Protein and Cytokine levels

16078<img file="WO2013151663A1_D0306.tif" />

16079Example 110. In vitro expression of modified mRNA

16080[0001499] HEK293 cells were transfected EPO modified mRNA (mRNA sequence shown in SEQ ID NO:56155; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine), HeLa cells were forward transfected with Transforming growth factor beta (TGF-beta) modified mRNA (mRNA sequence shown in SEQ ID NO: 56166; poly A tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) and HepG2 cells were transfected with

16081bactericidal/permeability-increasing protein (rBPI-21) modified mRNA (mRNA sequence shown in SEQ ID NO: 56167; poly A tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and

16082pseudouridine) which had been complexed with Lipofectamine2000 from Invitrogen (Carlsbad, CA) at the concentrations shown in Table 169, 170 and 171 using the procedures described herein. The protein expression was detected by ELISA and the protein (pg/ml) is also shown in Table 169, 170 and 171. In Table 169, ">" means greater than. For TGF-beta a control of untreated cells and a mock transfection of Lipofectamine2000 was also tested.

16083Table 169. EPO Protein Expression <img file="WO2013151663A1_D0307.tif" /> Table 170. TGF-beta Protein Expression <img file="WO2013151663A1_D0308.tif" />

16084Table 171. rBPI-21 Protein Expression <img file="WO2013151663A1_D0309.tif" />

16085Example 111. Bicistronic modified mRNA

16086[0001500] Human embryonic kidney epithelial (HEK293) were seeded on 96-well plates (Greiner Bio-one GmbH, Frickenhausen, Germany) HEK293 were seeded at a density of 30,000 in 100 μΐ cell culture medium (DMEM, 10% FCS, adding 2mM L-Glutamine, 1 mM Sodiumpyruvate and lx non-essential amino acids (Biochrom AG, Berlin, Germany) and 1.2 mg/ml Sodiumbicarbonate (Sigma- Aldrich, Munich, Germany)) 75 ng of the bicistronic modified mRNA (mCherry-2A-GFP) (SEQ ID NO: 56168; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine), mCherry modified mRNA (mRNA SEQ ID NO: 56153; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) or green fluorescent protein (GFP) modified mRNA (mRNA sequence shown in SEQ ID NO: 56164; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and pseudouridine) were added after seeding the cells and incubated. A control of untreated cells was also evaluated. mCherry-2A-GFP refers to a modified mRNA sequence comprising the coding region of mCherry, the 2A peptide and the coding region of GFP.

16087[0001501] Cells were harvested by transferring the culture media supernatants to a 96- well Pro-Bind U-bottom plate (Beckton Dickinson GmbH, Heidelberg, Germany). Cells were trypsinized with ½ volume Trypsin/EDTA (Biochrom AG, Berlin, Germany), pooled with respective supernatants and fixed by adding one volume PBS/2%FCS (both Biochrom AG, Berlin, Germany)/0.5% formaldehyde (Merck, Darmstadt, Germany). Samples then were submitted to a flow cytometer measurement with a 532nm excitation laser and the 610/20 filter for PE-Texas Red in a LSRII cytometer (Beckton Dickinson GmbH, Heidelberg, Germany). The mean fluorescence intensity (MFI) of all events is shown in Table 172. Cells transfected with the bi-cistronic modified mRNA were able to express both mCherry and GFP.

16088Table 172. MFI of Modified mRNA

16089<img file="WO2013151663A1_D0310.tif" />

16090Example 112. Cationic Lipid Formulation Studies of of 5-Methylcytosine and Nl- Methyl-pseudouridine Modified mRNA to Produce an Antibody

16091[0001502] Herceptin heavy chain (HC) mRNA (mRNA sequence shown in SEQ ID NO: 56169; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine) and Herceptin light chain (LC) modified mRNA (mRNA sequence shown in SEQ ID NO: 56170; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl; fully modified with 5-methylcytosine and Nl-methyl-pseudouridine) are formulated in DLin-MC3- DMA and DLin-KC2-DMA as described in Table 173. The formulations are

16092administered intravenously (I.V) to Balb-C mice at a dose of 0.500, 0.050, and 0.005 mg/kg.

16093Table 173. DLin-MC3-DMA and DLin-KC2-DMA Formulations

16094<img file="WO2013151663A1_D0311.tif" /> 129 nm 100 nm

16095Mean Size

PDI: 0.14 PDI: 0.10

16097Zeta at pH 7.4 0.9 mV 1.9 mV

16098Encaps. (RiboGr) 100% 100%

16099[0001503] Serum was collected from the mice at 8 hours, 24 hours, 72 hours and/or 7 days after administration of the formulation. The serum was analyzed by ELISA to determine the protein expression of Herceptin.

16100Example 113. Directed SAR of Pseudouridine and Nl-methyl-Pseudouridine

16101[0001504] With the recent focus on the pyrimidine nucleoside pseudouridine, a series of structure-activity studies were designed to investigate mRNA containing modifications to pseudouridine or Nl-methyl-pseudourdine.

16102[0001505] The study was designed to explore the effect of chain length, increased lipophilicity, presence of ring structures, and alteration of hydrophobic or hydrophilic interactions when modifications were made at the Nl position, C6 position, the 2- position, the 4-position and on the phosphate backbone. Stability is also investigated.

16103[0001506] To this end, modifications involving alkylation, cycloalkylation, alkyl- cycloalkylation, arylation, alkyl-arylation, alkylation moieties with amino groups, alkylation moieties with carboxylic acid groups, and alkylation moieties containing amino acid charged moieties are investigated. The degree of alkylation is generally Ci- C6. Examples of the chemistry modifications include those listed in Table 174 and Table 175.

16104Table 174. Pseudouridine and Nl-methylPseudouridine SAR

16105<img file="WO2013151663A1_D0312.tif" />

16106<img file="WO2013151663A1_D0313.tif" />

16107- e-a p a-t o-pseu o-

16108Table 175. Pseudouridine and Nl-methyl-Pseudouridine SAR

16109Compound Naturally

16110Chemistry Modification

16111# occurring

16112N 1 -Methyl-pseudo-UTP 1 Y

16113Nl-Butyl-pseudo-UTP 2 N

16114N 1 -tert-Butyl-pseudo-UTP 3 N

16115N 1 -Pentyl-pseudo-UTP 4 N

16116N 1 -Hexyl-pseudo-UTP 5 N

16117N 1 -Trifluoromethyl-pseudo-UTP 6 Y

16118N 1 -Cyclobutyl-pseudo-UTP 7 N

16119N 1 -Cyclopentyl-pseudo-UTP 8 N

16120N 1 -Cyclohexyl-pseudo-UTP 9 N

16121N 1 -Cycloheptyl-pseudo-UTP 10 N

16122N 1 -Cyclooctyl-pseudo-UTP 11 N

16123N 1 -Cyclobutylmethyl-pseudo-UTP 12 N

16124N 1 -Cyclopentylmethyl-pseudo-UTP 13 N

16125N 1 -Cyclohexylmethyl-pseudo-UTP 14 N

16126N 1 -Cycloheptylmethyl-pseudo-UTP 15 N

16127N 1 -Cyclooctylmethyl-pseudo-UTP 16 N

16128N 1 -p-tolyl-pseudo-UTP 17 N

16129N 1 -(2,4,6-Trimethyl-phenyl)pseudo-UTP 18 N

16130N 1 -(4-Methoxy-phenyl)pseudo-UTP 19 N N 1 -(4- Amino-phenyl)pseudo-UTP 20 N

16131N 1 (4-Nitro-phenyl)pseudo-UTP 21 N

16132Pseudo-UTP-N l-/?-benzoic acid 22 N

16133N 1 -(4-Methyl-benzyl)pseudo-UTP 24 N

16134N 1 -(2,4,6-Trimethyl-benzyl)pseudo-UTP 23 N

16135N 1 -(4-Methoxy-benzyl)pseudo-UTP 25 N

16136N 1 -(4- Amino-benzyl)pseudo-UTP 26 N

16137N 1 -(4-Nitro-benzyl)pseudo-UTP 27 N

16138Pseudo-UTP-N 1 -methyl-p-benzoic acid 28 N

16139N 1 -(2-Amino-ethyl)pseudo-UTP 29 N

16140N 1 -(3 - Amino-propyl)pseudo-UTP 30 N

16141N 1 -(4- Amino-butyl)pseudo-UTP 31 N

16142N 1 -(5 - Amino-pentyl)pseudo-UTP 32 N

16143N 1 -(6- Amino-hexyl)pseudo-UTP 33 N

16144Pseudo-UTP-N 1-3 -propionic acid 34 N

16145Pseudo-UTP-N 1-4-butanoic acid 35 N

16146Pseudo-UTP-N 1 -5 -pentanoic acid 36 N

16147Pseudo-UTP-N 1-6-hexanoic acid 37 N

16148Pseudo-UTP-N 1-7-heptanoic acid 38 N

16149N 1 -(2- Amino-2-carboxyethyl)pseudo-UTP 39 N

16150N 1 -(4- Amino-4-carboxybutyl)pseudo-UTP 40 N

16151N3-Alkyl-pseudo-UTP 41 N

161526-Ethyl-pseudo-UTP 42 N

161536-Propyl-pseudo-UTP 43 N

161546-iso-Propyl-pseudo-UTP 44 N

161556-Butyl-pseudo-UTP 45 N

161566-tert-Butyl-pseudo-UTP 46 N

161576-(2,2,2-Trifluoroethyl)-pseudo-UTP 47 N

161586-Ethoxy-pseudo-UTP 48 N

161596-Trifluoromethoxy-pseudo-UTP 49 N

161606-Phenyl-pseudo-UTP 50 N

161616-(Substituted-Phenyl)-pseudo-UTP 51 N

161626-Cyano-pseudo-UTP 52 N

161636-Azido-pseudo-UTP 53 N

161646-Amino-pseudo-UTP 54 N

161656-Ethylcarboxylate-pseudo-UTP 54b N

161666-Hydroxy-pseudo-UTP 55 N

161676-Methylamino-pseudo-UTP 55b N

161686-Dimethylamino-pseudo-UTP 57 N

161696-Hydroxyamino-pseudo-UTP 59 N

161706-Formyl-pseudo-UTP 60 N

161716-(4-Morpholino)-pseudo-UTP 61 N

161726-(4-Thiomorpholino)-pseudo-UTP 62 N N 1 -Me-4-thio-pseudo-UTP 63 N

16173N 1 -Me-2-thio-pseudo-UTP 64 N

161741 ,6-Dimethyl-pseudo-UTP 65 N l-Methyl-6-trifluoromethyl-pseudo-UTP 66 N

161751 -Methyl-6-ethyl-pseudo-UTP 67 N

161761 -Methyl-6-propyl-pseudo-UTP 68 N l-Methyl-6-iso-propyl-pseudo-UTP 69 N

161771 -Methyl-6-butyl-pseudo-UTP 70 N

161781 -Methyl-6-tert-butyl-pseudo-UTP 71 N l-Methyl-6-(2,2,2-Trifiuoroethyl)pseudo-UTP 72 N

161791 -Methyl-6-iodo-pseudo-UTP 73 N

161801 -Methyl-6-bromo-pseudo-UTP 74 N

161811 -Methyl-6-chloro-pseudo-UTP 75 N

161821 -Methyl-6-fluoro-pseudo-UTP 76 N

161831 -Methyl-6-methoxy-pseudo-UTP 77 N

161841 -Methyl-6-ethoxy-pseudo-UTP 78 N l-Methyl-6-trifluoromethoxy-pseudo-UTP 79 N

161851 -Methyl-6-phenyl-pseudo-UTP 80 N

161861 -Methyl-6-(substituted phenyl)pseudo-UTP 81 N

161871 -Methyl-6-cyano-pseudo-UTP 82 N

161881 -Methyl-6-azido-pseudo-UTP 83 N

161891 -Methyl-6-amino-pseudo-UTP 84 N l-Methyl-6-ethylcarboxylate-pseudo-UTP 85 N

161901 -Methyl-6-hydroxy-pseudo-UTP 86 N l-Methyl-6-methylamino-pseudo-UTP 87 N l-Methyl-6-dimethylamino-pseudo-UTP 88 N l-Methyl-6-hydroxyamino-pseudo-UTP 89 N

161911 -Methyl-6-formyl-pseudo-UTP 90 N l-Methyl-6-(4-morpholino)-pseudo-UTP 91 N l-Methyl-6-(4-thiomorpholino)-pseudo-UTP 92 N

161921 -Alkyl-6-vinyl-pseudo-UTP 93 N

161931 -Alkyl-6-allyl-pseudo-UTP 94 N

161941 -Alkyl-6-homoallyl-pseudo-UTP 95 N

161951 -Alkyl-6-ethynyl-pseudo-UTP 96 N l-Alkyl-6-(2-propynyl)-pseudo-UTP 97 N

161961 -Alkyl-6-(l -propynyl)-pseudo-UTP 98 N

16197Example 114. Incorporation of naturally and non-naturally occuring nucleosides

16198[0001507] Naturally and non-naturally occurring nucleosides are incorporated into mRNA encoding a polypeptide of interest. Examples of these are given in Tables 176 and 177. Certain commercially available nucleoside triphosphates (NTPs) are investigated in the polynucleotides of the invention. A selection of these are given in Table 176. The resultant mRNA are then examined for their ability to produce protein, induce cytokines, and/or produce a therapeutic outcome.

16199Table 176. Naturally and non-naturally occurring nucleosides

16200<img file="WO2013151663A1_D0314.tif" />

16201Table 177. Non-naturally occurring nucleoside triphosphates

16202<img file="WO2013151663A1_D0315.tif" /><img file="WO2013151663A1_D0316.tif" />

162032-Amino-riboside-TP 19 N

16204Example 115. Incorporation of modifications to the nucleobase and carbohydrate (sugar)

16205[0001508] Naturally and non-naturally occurring nucleosides are incorporated into mRNA encoding a polypeptide of interest. Commercially available nucleosides and NTPs having modifications to both the nucleobase and carbohydrate (sugar) are examined for their ability to be incorporated into mRNA and to produce protein, induce cytokines, and/or produce a therapeutic outcome. Examples of these nucleosides are given in Tables 178 and 179.

16206Table 178. Combination modifications

16207<img file="WO2013151663A1_D0317.tif" /> Table 179. Naturally occuring combinations

16208<img file="WO2013151663A1_D0318.tif" />

16209[0001509] In the tables "UTP" stands for uridine triphosphate, "GTP" stands for guanosine triphosphate, "ATP" stands for adenosine triphosphate, "CTP" stands for cytosine triphosphate, "TP" stands for triphosphate and "Bz" stands for benzyl.

16210Example 116. Protein Production of Vascular Endothelial Growth Factor in HeLa Cells

16211[0001510] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37°C in 5% C02 atmosphere overnight. The next day, 250 ng of vascular endothelial growth factor (VEGF) modified RNA (mRNA sequence shown in SEQ ID NO: 56165; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) with the chemical modification described in Table 180, was diluted in lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul of lipofectamine 2000 was diluted to 10 ul final volume of OPTI- MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature. A second set of HeLa cells was also evaluated with the VEGF mRNA according to the procedure set out above. A control of untreated cells and cells treated with just lipofecatamine 2000 was also analyzed for the first set of HeLa cells.

16212[0001511] After an 18 to 22 hour incubation cell culture supematants of cells expressing VEGF were collected and centrifuged at lO.OOOrcf for 2 minutes. The cleared supematants were then analyzed with a VEGF-specific ELISA kit (R & D Systems, Minneapolis, MN) according to the manufacturer instructions. All samples were diluted until the determined values were within the linear range of the ELISA standard curve. The amount of protein produced is shown in Table 180.

16213[0001512] These results demonstrate that VEGF fully modified with 1- methylpseudouridine produced more protein in HeLa cells compared to the other chemistry.

16214Table 180. Protein Production

16215<img file="WO2013151663A1_D0319.tif" /> Example 117. Comparison of Protein Production of Chemically Modified Vascular Endothelial Growth Factor in HeLa Cells

16216[0001513] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37°C in 5% C02 atmosphere overnight. Next day, 250 ng of vascular endothelial growth factor (VEGF) modified RNA (mRNA sequence shown in SEQ ID NO: 56165; polyA tail of approximately 160 nucleotides not shown in sequence; 5 'cap, Capl) with the chemical modification described in Table 181, were diluted in lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul of lipofectamine 2000 was diluted to 10 ul final volume of OPTI-MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature. A control of untreated cells was also analyzed.

16217[0001514] After an 18 to 22 hour incubation cell culture supernatants of cells expressing VEGF were collected and centrifuged at lO.OOOrcf for 2 minutes. The cleared

16218supernatants were then analyzed with a VEGF-specific ELISA kit (R & D Systems, Minneapolis, MN) according to the manufacturer instructions. All samples were diluted until the determined values were within the linear range of the ELISA standard curve. The amount of protein produced is shown in Table 181 and Figure 9.

16219[0001515] These results demonstrate that VEGF fully modified with 1- methylpseudouridine produced more protein in HeLa cells compared to the other chemistry.

16220Table 181. Protein Production <img file="WO2013151663A1_D0320.tif" /> 5-methylcytosine and 1-methylpsudouridine (5mC and ImpU) 760,000

162211-methylpseudouridine (ImpU) 1,393,824

16222Untreated 0

16223Example 118. Production of Vascular Endothelial Growth Factor Protein in

16224Mammals

16225[0001516] Lipoplexed vascular endothelial growth factor (VEGF) mRNA (m NA sequence shown in SEQ ID NO: 56165; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) unmodified, fully modified with 5-methylcytosine and pseudouridine (5mC/pU), fully modified with 5-methylcytosine and 1- methylpseudouridine (5mC/lmpU), modified where 25% of the cytosines replaced with 5-methylcytosine and 25% of the uridines replaced with 2-thiouridine (5mC/s2U), fully modified with 1-methylpseudouridine (ImpU) or fully modified with pseudouridine (pU). The formulation was administered intravenously to mice at a dose of 2 ug of mRNA per mouse. As a control, a group of mice were untreated. Serum from the mice is measured by specific VEGF ELISA 3 hours after administration for VEGF protein expression. The results are shown in Table 182 and Figure 10.

16226Table 182. Protein Production

16227<img file="WO2013151663A1_D0321.tif" />

16228Example 119. Protein Production of Granulocyte Colony Stimulating Factor in

16229HeLa Cells

16230[0001517] The day before transfection, 20,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin-EDTA solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul EMEM medium (supplemented with 10%FCS and lx Glutamax) per well in a 96-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37°C in 5% C02 atmosphere overnight. The next day, 250 ng of granulocyte colony stimulating factor (G-CSF) modified R A (mR A sequence shown in SEQ ID NO: 56152; polyA tail of approximately 160 nucleotides not shown in sequence; 5'cap, Capl) with the chemical modification described in Table 183, was diluted in lOul final volume of OPTI-MEM (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul of lipofectamine 2000 was diluted to 10 ul final volume of OPTI- MEM. After 5 minutes of incubation at room temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature. A control of untreated cells and cells treated with just lipofecatamine 2000 was also analyzed.

16231[0001518] After an 18 to 22 hour incubation cell culture supematants of cells expressing G-CSF were collected and centrifuged at lO.OOOrcf for 2 minutes. The cleared supematants were then analyzed with a G-CSF-specific ELISA kit (R & D Systems, Minneapolis, MN) according to the manufacturer instructions. All samples were diluted until the determined values were within the linear range of the ELISA standard curve. The amount of protein produced is shown in Table 183 and Figure 11.

16232Table 183. Protein Production

16233<img file="WO2013151663A1_D0322.tif" />

16234Example 120. Protein Production of Chemically Modified Factor IX in HeLa Cell Supernatant [0001519] The day before transfection, 15,000 HeLa cells (ATCC no. CCL-2; Manassas, VA) were harvested by treatment with Trypsin- Ethylenediaminetetraacetic acid (EDTA) solution (LifeTechnologies, Grand Island, NY) and seeded in a total volume of lOOul Eagle's minimal essential medium (EMEM) (supplemented with 10% fetal calf serum (FCS) and lx Glutamax) per well in a 24-well cell culture plate (Corning, Manassas, VA). The cells were grown at 37°C in 5% C02 atmosphere overnight. Next day, 250 ng of factor IX modified RNA (mRNA sequence shown in SEQ ID NO: 56156; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 5-methylcytosine and pseudouridine (5mC/pU), fully modified with 5- methylcytosine and 1-methylpseudouridine (5mC/lmpU), modified where 25% of the cytosines replaced with 5-methylcytosine and 25% of the uridines replaced with 2- thiouridine (s2U/5mC), fully modified with 1-methylpseudouridine (ImpU) or fully modified with pseudouridine (pU) were diluted in 10 ul final volume of OPTI-MEM® (LifeTechnologies, Grand Island, NY). Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) was used as transfection reagent and 0.2 ul of lipofectamine 2000 was diluted to 10 ul final volume of OPTI-MEM®. After 5 minutes of incubation at room

16235temperature, both solutions were combined and incubated an additional 15 minute at room temperature. Then the 20ul combined solution was added to the lOOul cell culture medium containing the HeLa cells and incubated at room temperature. A control of untreated was also analyzed.

16236[0001520] After an 18 hour incubation cell culture supematants of cells expressing factor IX were collected by lysing cells with immuno-precipitation (IP) buffer from Pierce Biotechnology (Thermo Scientific, Rockford, IL) and centrifuged at lO.OOOrcf for 2 minutes. The cleared supematants were diluted 1 :2 (1 ml lysate/2 wells/24 well plate) or 1 :5 (1 ml lysate/5 wells/24 well plate) then analyzed with a factor IX-specific ELISA kit according to the manufacturer instructions. All samples were diluted until the determined values were within the linear range of the ELISA standard curve. The amount of protein produced in both studies is shown in Table 184 and Figure 12.

16237Table 184. Protein Production <img file="WO2013151663A1_D0323.tif" /> 5 -methylcytosine and 1-methylpseudouridine (5mC/lmpU) 147.1

1623825% of the cytosines replaced with 5-methylcytosine and 25% of the 7.4 uridines replaced with 2-thiouridine (s2U/5mC)

16239Pseudouridine (pU) 17.0

162401-methylpseudouridine (ImpU) 32.0

16241Untreated 0

16242Example 121. Intranasal Lung Delivery of 1-methylpseudouridine or 5- methylcytosine and 1-methylpseudouridine Modified Luciferase mRNA Formulated in Cationic Lipid Nanoparticle

16243[0001521] Luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 1-methylpseudouridine (Luc-G5-LNP-KC2) or fully modified with 1- methylpseudouridine and 5-methylcytosine (Luc-G2-LNP-KC2) were formulated in the cationic Lipid Nanoparticle (LNP-KC2) as described in Table 185.

16244Table 185. Formulation

16245<img file="WO2013151663A1_D0324.tif" />

16246[0001522] The formulations were administered intranasally (I.N.) to Balb-C mice at a dose of 0.3 mg/kg. Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bio luminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours, 48, and 72 hours after dosing and the average total flux

16247(photons/second) was measured. The background flux was about 6.3+05 p/s. The results of the imaging of Luc-G5-LNP-KC2 or Luc-G5-LNP-KC2 vs. Vehicle are shown in the Table 186, "NT" means not tested.

16248Table 186. Luciferase expression after intranasal dosing Vehicle

16249Luc-G5-LNP-KC2 Luc-G2-LNP-KC2

16250Route Time Point (PBS)

16251Flux (p/s) Flux (p/s) Flux (p/s)

16252I.N. 2 hrs 1.53E+06 5.81E+05 3.87E+05

16253I.N. 8 hrs 1.09E+07 9.35E+05 5.57E+05

16254I.N. 24 hrs 5.93E+06 5.33E+05 4.89E+05

16255I.N. 28 hrs 1.22E+06 7.63E+05 8.81E+05

16256I.N. 72 hrs 8.43E+05 NT 8.17E+05

16257Example 122. Intranasal Lung Delivery of 1-methylpseudouridine or 5- methylcytosine and 1-methylpseudouridine Modified Luciferase mRNA lipoplexed in Lipofectamine 2000

16258[0001523] Luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5'cap, Capl) fully modified with 1-methylpseudouridine (Luc-G5-Lipoplex) or fully modified with 1- methylpseudouridine and 5-methylcytosine (Luc-G2-Lipoplex) were lipoplexed in two steps, first step was the dilution of 16.6ul from 3mg/ml of 1-methylpseudouridine or 1- methylpseudouridine and 5-methylcytosine modified luciferase mRNA in 108.5 ul DMEM and the second step was the dilution of lOOul LF2000 in 25ul DMEM then both mixed together gently to make 250ul total mixer which incubated 5-10 min at RT to form a Lipid-mRNA complex before injection. The lipoplex from both Luciferase mRNA fully modified with 1-methylpseudouridine or 1-methylpseudouridine and 5- methylcytosine were administered intranasally (I.N.) to Balb-C mice at a dose of 0.5 mg/kg.

16259[0001524] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours and 24 hours after dosing and the average total flux (photons/second) was measured. The background signal was about 4.8+05 p/s. The background flux was about 6.3+05 p/s. The results of the imaging of Luc-G5 -Lipoplex or Luc-G2-Lipoplex vs. Vehicle are shown in the Table 186. Table 186. Luciferase expression after intranasal dosing

16260<img file="WO2013151663A1_D0325.tif" />

16261Example 123. Intranasal Lung Delivery of 1-methylpseudouridine or 5- methylcytosine and 1-methylpseudouridine Modified Luciferase mRNA formulated in PBS

16262[0001525] Luciferase modified mRNA (mRNA sequence shown in SEQ ID NO: 56162; polyA tail of approximately 140 nucleotides not shown in sequence; 5 'cap, Capl) fully modified with 1-methylpseudouridine (Luc-G5-Buffer(PBS)) or fully modified with 1- methylpseudouridine and 5 -methylcytosine (Luc-G2-Buffer(PBS)) formulated in PBS (pH 7.4) were administered intranasally (I.N.) to Balb-C mice at a dose of 7.5 mg/kg.

16263[0001526] Twenty minutes prior to imaging, mice were injected intraperitoneally with a D-luciferin solution at 150 mg/kg. Animals were then anesthetized and images were acquired with an IVIS Lumina II imaging system (Perkin Elmer). Bioluminescence was measured as total flux (photons/second) of the entire mouse. The mice were imaged at 2 hours, 8 hours and 24 hours after dosing and the average total flux (photons/second) was measured. The background flux was about 4.8+05 p/s. The background flux was about 6.3+05 p/s. The results of the imaging of Luc-G5-in Buffer vs. Vehicle are shown in the Table 187.

16264Table 187. Luciferase expression after intranasal dosing

16265<img file="WO2013151663A1_D0326.tif" /> [0001527] It is to be understood that the words which have been used are words of description rather than limitation, and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the invention in its broader aspects.

16266[0001528] While the present invention has been described at some length and with some particularity with respect to the several described embodiments, it is not intended that it should be limited to any such particulars or embodiments or any particular embodiment, but it is to be construed with references to the appended claims so as to provide the broadest possible interpretation of such claims in view of the prior art and, therefore, to effectively encompass the intended scope of the invention.

16267[0001529] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, section headings, the materials, methods, and examples are illustrative only and not intended to be limiting.

Contents713

359 sheets

Sheet 1
Sheet 2
Sheet 3
Sheet 4
Sheet 5
Sheet 6
Sheet 7
Sheet 8
Sheet 9
Sheet 10
Sheet 11
Sheet 12
Sheet 13
Sheet 14
Sheet 15
Sheet 16
Sheet 17
Sheet 18
Sheet 19
Sheet 20
Sheet 21
Sheet 22
Sheet 23
Sheet 24
Sheet 25
Sheet 26
Sheet 27
Sheet 28
Sheet 29
Sheet 30
Sheet 31
Sheet 32
Sheet 33
Sheet 34
Sheet 35
Sheet 36
Sheet 37
Sheet 38
Sheet 39
Sheet 40
Sheet 41
Sheet 42
Sheet 43
Sheet 44
Sheet 45
Sheet 46
Sheet 47
Sheet 48
Sheet 49
Sheet 50
Sheet 51
Sheet 52
Sheet 53
Sheet 54
Sheet 55
Sheet 56
Sheet 57
Sheet 58
Sheet 59
Sheet 60
Sheet 61
Sheet 62
Sheet 63
Sheet 64
Sheet 65
Sheet 66
Sheet 67
Sheet 68
Sheet 69
Sheet 70
Sheet 71
Sheet 72
Sheet 73
Sheet 74
Sheet 75
Sheet 76
Sheet 77
Sheet 78
Sheet 79
Sheet 80
Sheet 81
Sheet 82
Sheet 83
Sheet 84
Sheet 85
Sheet 86
Sheet 87
Sheet 88
Sheet 89
Sheet 90
Sheet 91
Sheet 92
Sheet 93
Sheet 94
Sheet 95
Sheet 96
Sheet 97
Sheet 98
Sheet 99
Sheet 100
Sheet 101
Sheet 102
Sheet 103
Sheet 104
Sheet 105
Sheet 106
Sheet 107
Sheet 108
Sheet 109
Sheet 110
Sheet 111
Sheet 112
Sheet 113
Sheet 114
Sheet 115
Sheet 116
Sheet 117
Sheet 118
Sheet 119
Sheet 120
Sheet 121
Sheet 122
Sheet 123
Sheet 124
Sheet 125
Sheet 126
Sheet 127
Sheet 128
Sheet 129
Sheet 130
Sheet 131
Sheet 132
Sheet 133
Sheet 134
Sheet 135
Sheet 136
Sheet 137
Sheet 138
Sheet 139
Sheet 140
Sheet 141
Sheet 142
Sheet 143
Sheet 144
Sheet 145
Sheet 146
Sheet 147
Sheet 148
Sheet 149
Sheet 150
Sheet 151
Sheet 152
Sheet 153
Sheet 154
Sheet 155
Sheet 156
Sheet 157
Sheet 158
Sheet 159
Sheet 160
Sheet 161
Sheet 162
Sheet 163
Sheet 164
Sheet 165
Sheet 166
Sheet 167
Sheet 168
Sheet 169
Sheet 170
Sheet 171
Sheet 172
Sheet 173
Sheet 174
Sheet 175
Sheet 176
Sheet 177
Sheet 178
Sheet 179
Sheet 180
Sheet 181
Sheet 182
Sheet 183
Sheet 184
Sheet 185
Sheet 186
Sheet 187
Sheet 188
Sheet 189
Sheet 190
Sheet 191
Sheet 192
Sheet 193
Sheet 194
Sheet 195
Sheet 196
Sheet 197
Sheet 198
Sheet 199
Sheet 200
Sheet 201
Sheet 202
Sheet 203
Sheet 204
Sheet 205
Sheet 206
Sheet 207
Sheet 208
Sheet 209
Sheet 210
Sheet 211
Sheet 212
Sheet 213
Sheet 214
Sheet 215
Sheet 216
Sheet 217
Sheet 218
Sheet 219
Sheet 220
Sheet 221
Sheet 222
Sheet 223
Sheet 224
Sheet 225
Sheet 226
Sheet 227
Sheet 228
Sheet 229
Sheet 230
Sheet 231
Sheet 232
Sheet 233
Sheet 234
Sheet 235
Sheet 236
Sheet 237
Sheet 238
Sheet 239
Sheet 240
Sheet 241
Sheet 242
Sheet 243
Sheet 244
Sheet 245
Sheet 246
Sheet 247
Sheet 248
Sheet 249
Sheet 250
Sheet 251
Sheet 252
Sheet 253
Sheet 254
Sheet 255
Sheet 256
Sheet 257
Sheet 258
Sheet 259
Sheet 260
Sheet 261
Sheet 262
Sheet 263
Sheet 264
Sheet 265
Sheet 266
Sheet 267
Sheet 268
Sheet 269
Sheet 270
Sheet 271
Sheet 272
Sheet 273
Sheet 274
Sheet 275
Sheet 276
Sheet 277
Sheet 278
Sheet 279
Sheet 280
Sheet 281
Sheet 282
Sheet 283
Sheet 284
Sheet 285
Sheet 286
Sheet 287
Sheet 288
Sheet 289
Sheet 290
Sheet 291
Sheet 292
Sheet 293
Sheet 294
Sheet 295
Sheet 296
Sheet 297
Sheet 298
Sheet 299
Sheet 300
Sheet 301
Sheet 302
Sheet 303
Sheet 304
Sheet 305
Sheet 306
Sheet 307
Sheet 308
Sheet 309
Sheet 310
Sheet 311
Sheet 312
Sheet 313
Sheet 314
Sheet 315
Sheet 316
Sheet 317
Sheet 318
Sheet 319
Sheet 320
Sheet 321
Sheet 322
Sheet 323
Sheet 324
Sheet 325
Sheet 326
Sheet 327
Sheet 328
Sheet 329
Sheet 330
Sheet 331
Sheet 332
Sheet 333
Sheet 334
Sheet 335
Sheet 336
Sheet 337
Sheet 338
Sheet 339
Sheet 340
Sheet 341
Sheet 342
Sheet 343
Sheet 344
Sheet 345
Sheet 346
Sheet 347
Sheet 348
Sheet 349
Sheet 350
Sheet 351
Sheet 352
Sheet 353
Sheet 354
Sheet 355
Sheet 356
Sheet 357
Sheet 358
Sheet 359

Every citation, both ways

Citations
Document	Relation	Office	Cited during
US12385034B2	Cited by	United States of America	Applicant
US12084702B2	Cited by	United States of America	Applicant
DE202023106198U1	Cited by	Germany	Applicant
WO2023122080A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US9782462B2	Cited by	United States of America	Applicant
US10485884B2	Cited by	United States of America	Applicant
EP3762495A4	Cited by	European Patent Office (EPO)	Search report
US11504419B2	Cited by	United States of America	Applicant
US9782462B2	Cited by	United States of America	Applicant
US9771406B2	Cited by	United States of America	Applicant
US11318191B2	Cited by	United States of America	Applicant
US11377642B2	Cited by	United States of America	Applicant
US11298426B2	Cited by	United States of America	Applicant
US2022125723A1	Cited by	United States of America	Applicant
US10898574B2	Cited by	United States of America	Applicant
US10208295B2	Cited by	United States of America	Applicant
US12577554B2	Cited by	United States of America	Applicant
US10428349B2	Cited by	United States of America	Applicant
US10888605B2	Cited by	United States of America	Applicant
US11786467B2	Cited by	United States of America	Applicant
US11878060B2	Cited by	United States of America	Applicant
US12539309B2	Cited by	United States of America	Applicant
US10144942B2	Cited by	United States of America	Applicant
US11752198B2	Cited by	United States of America	Applicant
US9745360B2	Cited by	United States of America	Applicant
US10507249B2	Cited by	United States of America	Applicant
WO2026061971A1	Cited by	World Intellectual Property Organization (WIPO)	International search
US10413618B2	Cited by	United States of America	Applicant
WO2020001657A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US12533402B2	Cited by	United States of America	Applicant
US10077439B2	Cited by	United States of America	Applicant
US11884692B2	Cited by	United States of America	Applicant
US11248264B2	Cited by	United States of America	Applicant
US10584165B2	Cited by	United States of America	Applicant
WO2025233431A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US12364773B2	Cited by	United States of America	Applicant
US12220484B2	Cited by	United States of America	Applicant
US10286082B2	Cited by	United States of America	Applicant
US11638693B2	Cited by	United States of America	Applicant
US11696923B2	Cited by	United States of America	Applicant
US9670261B2	Cited by	United States of America	Applicant
US10576166B2	Cited by	United States of America	Applicant
US10350303B1	Cited by	United States of America	Applicant
US9814760B2	Cited by	United States of America	Applicant
US9827332B2	Cited by	United States of America	Applicant
US10245229B2	Cited by	United States of America	Applicant
US11377642B2	Cited by	United States of America	Applicant
EP3053585A1	Cited by	European Patent Office (EPO)	Applicant
US12246030B2	Cited by	United States of America	Applicant
US9828416B2	Cited by	United States of America	Applicant
WO2023144330A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US9713626B2	Cited by	United States of America	Applicant
EP4101930A1	Cited by	European Patent Office (EPO)	Applicant
US11913001B2	Cited by	United States of America	Applicant
US11174500B2	Cited by	United States of America	Applicant
US10772975B2	Cited by	United States of America	Applicant
US9932381B2	Cited by	United States of America	Applicant
EP4763287A2	Cited by	European Patent Office (EPO)	Applicant
US11185595B2	Cited by	United States of America	Applicant
WO2024184500A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US11712463B2	Cited by	United States of America	Applicant
US12509666B2	Cited by	United States of America	Applicant
US10780052B2	Cited by	United States of America	Applicant
WO2023031394A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
WO2024159172A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
WO2023073228A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
WO2025194138A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US11766401B2	Cited by	United States of America	Applicant
US9694053B2	Cited by	United States of America	Applicant
US10022455B2	Cited by	United States of America	Applicant
US10577403B2	Cited by	United States of America	Applicant
US12480117B2	Cited by	United States of America	Applicant
US11759475B2	Cited by	United States of America	Applicant
US12109274B2	Cited by	United States of America	Applicant
US12364763B2	Cited by	United States of America	Applicant
US11547764B2	Cited by	United States of America	Applicant
US11951180B2	Cited by	United States of America	Applicant
US11766401B2	Cited by	United States of America	Applicant
US12409218B2	Cited by	United States of America	Applicant
WO2023069498A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US11052159B2	Cited by	United States of America	Applicant
US11690863B2	Cited by	United States of America	Applicant
US11222711B2	Cited by	United States of America	Applicant
US12385049B2	Cited by	United States of America	Applicant
EP3134131B1	Cited by	European Patent Office (EPO)	Filed by opponent
EP3814492A4	Cited by	European Patent Office (EPO)	Search report
US11839686B2	Cited by	United States of America	Applicant
US11173190B2	Cited by	United States of America	Applicant
US11639370B2	Cited by	United States of America	Applicant
US12195505B2	Cited by	United States of America	Applicant
US12268754B2	Cited by	United States of America	Applicant
US11254936B2	Cited by	United States of America	Applicant
US11298426B2	Cited by	United States of America	Applicant
US9775904B2	Cited by	United States of America	Applicant
US9751926B2	Cited by	United States of America	Applicant
WO2023227608A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant
US11951179B2	Cited by	United States of America	Applicant
EP3134131B1	Cited by	European Patent Office (EPO)	Filed by opponent
US11730825B2	Cited by	United States of America	Applicant
WO2015034928A1	Cited by	World Intellectual Property Organization (WIPO)	Applicant

Showing 100 of 322

490 members in 29 offices

This recordMember, by publication date19 more offices are in the list below

Members490

Family members, oldest first
Document	Office	Kind
CA2850624A1	Canada	A1	2013-04-11
WO2013052523A1	World Intellectual Property Organization (WIPO)	A1	2013-04-11
US2013115272A1	United States of America	A1	2013-05-09
US2013123481A1	United States of America	A1	2013-05-16
CA2859387A1	Canada	A1	2013-06-20
CA3018046A1	Canada	A1	2013-06-20
US2013156849A1	United States of America	A1	2013-06-20
WO2013090648A1	World Intellectual Property Organization (WIPO)	A1	2013-06-20
US2013236974A1	United States of America	A1	2013-09-12
US2013237592A1	United States of America	A1	2013-09-12
US2013237593A1	United States of America	A1	2013-09-12
US2013237594A1	United States of America	A1	2013-09-12
US2013242738A1	United States of America	A1	2013-09-19
US2013244278A1	United States of America	A1	2013-09-19
US2013244279A1	United States of America	A1	2013-09-19
US2013245104A1	United States of America	A1	2013-09-19
US2013245105A1	United States of America	A1	2013-09-19
US2013245106A1	United States of America	A1	2013-09-19
US2013245107A1	United States of America	A1	2013-09-19
US2013252281A1	United States of America	A1	2013-09-26
US2013253043A1	United States of America	A1	2013-09-26
CA2866919A1	Canada	A1	2013-10-03
US2013257822A1	United States of America	A1	2013-10-03
US2013259923A1	United States of America	A1	2013-10-03
US2013259924A1	United States of America	A1	2013-10-03
WO2013142958A1	World Intellectual Property Organization (WIPO)	A1	2013-10-03
CA2868391A1	Canada	A1	2013-10-10
CA2868393A1	Canada	A1	2013-10-10
CA2868398A1	Canada	A1	2013-10-10
CA2868418A1	Canada	A1	2013-10-10
CA2868422A1	Canada	A1	2013-10-10
CA2868429A1	Canada	A1	2013-10-10
CA2868434A1	Canada	A1	2013-10-10
CA2868438A1	Canada	A1	2013-10-10
CA2868440A1	Canada	A1	2013-10-10
CA2868996A1	Canada	A1	2013-10-10
CA2869005A1	Canada	A1	2013-10-10
US2013266640A1	United States of America	A1	2013-10-10
WO2013151663A1This record	World Intellectual Property Organization (WIPO)	A1	2013-10-10
WO2013151664A1	World Intellectual Property Organization (WIPO)	A1	2013-10-10
WO2013151665A2	World Intellectual Property Organization (WIPO)	A2	2013-10-10
WO2013151666A2	World Intellectual Property Organization (WIPO)	A2	2013-10-10
WO2013151667A1	World Intellectual Property Organization (WIPO)	A1	2013-10-10
WO2013151668A2	World Intellectual Property Organization (WIPO)	A2	2013-10-10
WO2013151669A1	World Intellectual Property Organization (WIPO)	A1	2013-10-10
WO2013151670A2	World Intellectual Property Organization (WIPO)	A2	2013-10-10
WO2013151671A1	World Intellectual Property Organization (WIPO)	A1	2013-10-10
WO2013151672A2	World Intellectual Property Organization (WIPO)	A2	2013-10-10
WO2013151736A2	World Intellectual Property Organization (WIPO)	A2	2013-10-10
WO2013151668A3	World Intellectual Property Organization (WIPO)	A3	2013-12-19
WO2013151736A3	World Intellectual Property Organization (WIPO)	A3	2013-12-19
US2014010861A1	United States of America	A1	2014-01-09
WO2013151666A3	World Intellectual Property Organization (WIPO)	A3	2014-01-09
WO2013151665A3	World Intellectual Property Organization (WIPO)	A3	2014-02-20
WO2013151670A3	World Intellectual Property Organization (WIPO)	A3	2014-02-27
US8664194B2	United States of America	B2	2014-03-04
WO2013151672A3	World Intellectual Property Organization (WIPO)	A3	2014-03-13
US8680069B2	United States of America	B2	2014-03-25
US2014105964A1	United States of America	A1	2014-04-17
US2014105965A1	United States of America	A1	2014-04-17
US2014105966A1	United States of America	A1	2014-04-17
US2014107189A1	United States of America	A1	2014-04-17
AU2012318752A1	Australia	A1	2014-04-24
US2014113959A1	United States of America	A1	2014-04-24
US2014113960A1	United States of America	A1	2014-04-24
US2014141067A1	United States of America	A1	2014-05-22
US2014141068A1	United States of America	A1	2014-05-22
IL231808A0	Israel	A0	2014-05-28
IL231808D0	Israel	D0	2014-05-28
SG11201401196WA	Singapore	A	2014-05-29
US2014147432A1	United States of America	A1	2014-05-29
US2014147454A1	United States of America	A1	2014-05-29
US2014148502A1	United States of America	A1	2014-05-29
CA2892529A1	Canada	A1	2014-05-30
WO2014081507A1	World Intellectual Property Organization (WIPO)	A1	2014-05-30
KR20140068245A	Republic of Korea	A	2014-06-05
US2014155472A1	United States of America	A1	2014-06-05
US2014155473A1	United States of America	A1	2014-06-05
US2014155474A1	United States of America	A1	2014-06-05
US2014155475A1	United States of America	A1	2014-06-05
US2014161873A1	United States of America	A1	2014-06-12
US8754062B2	United States of America	B2	2014-06-17
CA2894462A1	Canada	A1	2014-06-19
US2014170594A1	United States of America	A1	2014-06-19
US2014171485A1	United States of America	A1	2014-06-19
WO2014093924A1	World Intellectual Property Organization (WIPO)	A1	2014-06-19
WO2014093926A1	World Intellectual Property Organization (WIPO)	A1	2014-06-19
US2014179771A1	United States of America	A1	2014-06-26
US2014186432A1	United States of America	A1	2014-07-03
US2014193482A1	United States of America	A1	2014-07-10
US2014194494A1	United States of America	A1	2014-07-10
US2014199371A1	United States of America	A1	2014-07-17
US2014200262A1	United States of America	A1	2014-07-17
US2014200263A1	United States of America	A1	2014-07-17
US2014200264A1	United States of America	A1	2014-07-17
US2014206755A1	United States of America	A1	2014-07-24
AU2012352180A1	Australia	A1	2014-07-31
IL232749A0	Israel	A0	2014-08-03
IL232749D0	Israel	D0	2014-08-03
CN103974724A	China	A	2014-08-06

Showing 100 of 490

Numbers

Publication: 2013/151663
Application: 30059

Titles2

English: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
French: POLYNUCLÉOTIDES MODIFIÉS POUR LA PRODUCTION DE PROTÉINES MEMBRANAIRES

Classification

CPC, 130: C12N15/85
A61K48/0066
C12Y603/02019
C12N9/93
C12N15/87
A61K38/45
A61K38/17
C07H21/02
C12N9/0069
C12N9/0091
C12N9/1241
C12N9/6435
C12N9/6437
C12N9/644
C12N9/6443
C12Y113/12007
C12Y116/03001
C12Y207/07012
C12Y304/21007
C12Y304/21022
C12Y304/21027
C12Y403/02001
A61K48/005
A61K38/1816
A61K38/1891
A61K38/191
A61K38/193
A61K38/212
A61K38/4846
A61P1/00
A61P1/04
A61P11/00
A61P13/00
A61P13/12
A61P15/00
A61P17/00
A61P17/02
A61P17/04
A61P17/06
A61P17/08
A61P17/14
A61P19/00
A61P19/02
A61P19/10
A61P21/00
A61P21/04
A61P25/00
A61P25/02
A61P25/14
A61P25/18
A61P25/24
A61P25/28
A61P25/30
A61P27/02
A61P29/00
A61P3/00
A61P31/00
A61P31/04
A61P31/10
A61P31/12
A61P31/14
A61P31/18
A61P35/00
A61P35/02
A61P3/06
A61P35/04
A61P37/00
A61P37/02
A61P37/06
A61P37/08
A61P43/00
A61P5/00
A61P7/00
A61P7/02
A61P7/04
A61P7/06
A61P9/00
A61P9/10
A61P3/10
Y02A50/30
C12N15/88
A61K48/0041
A61K9/0019
A61K9/5123
C07K14/4713
C07K14/62
A61K31/7115
C07K14/47
C12N9/88
A61K38/00
A61K9/1271
C12N15/11
C07K14/705
C07K14/505
C07K14/535
C12N9/6451
C12N9/1051
C12N9/2445
C07K14/4705
C12P13/04
C07K14/005
C12N9/16
C12N9/2402
C12N15/52
A61K38/177
C07K14/435
C12P21/00
A61K48/0033
C07K14/485
C07K14/43595
C07K14/4723
C07K14/4746
C07K14/475
C07K14/495
C07K14/525
C07K14/5418
C07K14/56
C07K14/61
C07K14/745
C07K16/2863
C07K16/2887
C07K16/40
A61K47/543
A61K9/145
A61K9/5146
A61K9/5153
A61K48/0075
C07K14/515
C07K16/00
C12P21/005
Filled: the office’s first classification
IPC, 2: C12N9 10
C07H21 04

Designated states145

Regional, 78: Botswana
Ghana
Gambia
Kenya
Liberia
Lesotho
Malawi
Mozambique
Namibia
Rwanda
Sudan
Sierra Leone
Eswatini
United Republic of Tanzania
Uganda
Zambia
Zimbabwe
Armenia
Azerbaijan
Belarus
Kyrgyzstan
Kazakhstan
Russian Federation
Tajikistan
and 54 moreShow fewer
Turkmenistan
Albania
Austria
Belgium
Bulgaria
Switzerland
Cyprus
Czechia
Germany
Denmark
Estonia
Spain
Finland
France
United Kingdom
Greece
Croatia
Hungary
Ireland
Iceland
Italy
Lithuania
Luxembourg
Latvia
Monaco
North Macedonia
Malta
Netherlands (Kingdom of the)
Norway
Poland
Portugal
Romania
Serbia
Sweden
Slovenia
Slovakia
San Marino
Türkiye
Burkina Faso
Benin
Central African Republic
Congo
Côte d’Ivoire
Cameroon
Gabon
Guinea
Equatorial Guinea
Guinea-Bissau
Mali
Mauritania
Niger
Senegal
Chad
Togo
National, 67: United Arab Emirates
Antigua and Barbuda
Angola
Australia
Bosnia and Herzegovina
Barbados
Bahrain
Brunei Darussalam
Brazil
Belize
Canada
Chile
China
Colombia
Costa Rica
Cuba
Dominica
Dominican Republic
Algeria
Ecuador
Egypt
Grenada
Georgia
Guatemala
and 43 moreShow fewer
Honduras
Indonesia
Israel
India
Japan
Comoros
Saint Kitts and Nevis
Democratic People’s Republic of Korea
Republic of Korea
Lao People’s Democratic Republic
Saint Lucia
Sri Lanka
Libya
Morocco
Republic of Moldova
Montenegro
Madagascar
Mongolia
Mexico
Malaysia
Nigeria
Nicaragua
New Zealand
Oman
Panama
Peru
Papua New Guinea
Philippines
Qatar
Seychelles
Singapore
Sao Tome and Principe
El Salvador
Syrian Arab Republic
Thailand
Tunisia
Trinidad and Tobago
Ukraine
United States of America
Uzbekistan
Saint Vincent and the Grenadines
Viet Nam
South Africa

Abstract

Term

MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE

PROTEINS

REFERENCE TO SEQUENCE LISTING

CROSS REFERENCE TO RELATED APPLICATIONS

FIELD OF THE INVENTION

SUMMARY OF THE INVENTION

BRIEF DESCRIPTION OF THE DRAWINGS

CACCCCAACCAGGAGCTCTAGTTAATGGA

GAGCTCCCAGCACACTCGGAGCTTGTGCT

TTGTCTCCACGCAAAGCGATAAATAAAAG

CATTGGTGGCCTTTGGTCTTTGAATAAAGC

CTGAGTAGGAAGTCTAGA

GCCCCTGCCGCTCCCACCCCCACCCATCTG

GGCCCCGGGTTCAAGAGAGAGCGGGGTCT

GATCTCGTGTAGCCATATAGAGTTTGCTTC

TGAGTGTCTGCTTTGTTTAGTAGAGGTGG

GCAGGAGGAGCTGAGGGGCTGGGGCTGG

GGTGTTGAAGTTGGCTTTGCATGCCCAGC

GATGCGCCTCCCTGTGGGATGTCATCACC

CTGGGAACCGGGAGTGGCCCTTGGCTCAC

TGTGTTCTGCATGGTTTGGATCTGAATTAA

TCTTCCAACCTCCAAACTGGCTGTAACCCC

AAATCCAAGCCATTAACTACACCTGACAG

TAGCAATTGTCTGATTAATCACTGGCCCCT

TGAAGACAGCAGAATGTCCCTTTGCAATG

AGGAGGAGATCTGGGCTGGGCGGGCCAG

CTGGGGAAGCATTTGACTATCTGGAACTT

GTGTGTGCCTCCTCAGGTATGGCAGTGAC

TCACCTGGTTTTAATAAAACAACCTGCAA

CATCTCATGGTCTTTGAATAAAGCCTGAG

TAGGAAGTCTAGA

ACACACTCCACCTCCAGCACGCGACTTCT

CAGGACGACGAATCTTCTCAATGGGGGGG

CGGCTGAGCTCCAGCCACCCCGCAGTCAC

TTTCTTTGTAACAACTTCCGTTGCTGCCAT

ACATACATTAACTTATTACCTCATTTTGTT

CATCACATTTAAAAGCATCTCAGCCTACC ATGAGAATAAGAGAAAGAAAATGAAGAT

GTTGGTGTAAAGCCAACACCCTGTCTAAA

AAACATAAATTTCTTTAATCATTTTGCCTC

TTTTCTCTGTGCTTCAATTAATAAAAAATG

UTR-004 GAAAGAATCTAATAGAGTGGTACAGCACT 8

GTTATTTTTCAAAGATGTGTTGCTATCCTG

AAAATTCTGTAGGTTCTGTGGAAGTTCCA

GTGTTCTCTCTTATTCCACTTCGGTAGAGG

ATTTCTAGTTTCTTGTGGGCTAATTAAATA

AATCATTAATACTCTTCTAATGGTCTTTGA

CTCTTGGTCTTTGAATAAAGCCTGAGTAG GAAGGCGGCCGCTCGAGCATGCATCTAGA

GCCAAGCCCTCCCCATCCCATGTATTTATC

TCTATTTAATATTTATGTCTATTTAAGCCT

CATATTTAAAGACAGGGAAGAGCAGAAC

GGAGCCCCAGGCCTCTGTGTCCTTCCCTGC

ATTTCTGAGTTTCATTCTCCTGCCTGTAGC

AGTGAGAAAAAGCTCCTGTCCTCCCATCC

CCTGGACTGGGAGGTAGATAGGTAAATAC

CAAGTATTTATTACTATGACTGCTCCCCAG

CCCTGGCTCTGCAATGGGCACTGGGATGA

GCCGCTGTGAGCCCCTGGTCCTGAGGGTC

CCCACCTGGGACCCTTGAGAGTATCAGGT

CTCCCACGTGGGAGACAAGAAATCCCTGT

TTAATATTTAAACAGCAGTGTTCCCCATCT

GGGTCCTTGCACCCCTCACTCTGGCCTCAG

CCGACTGCACAGCGGCCCCTGCATCCCCTUTR-006 G-CSF TGGCTGTGAGGCCCCTGGACAAGCAGAGG 10

TGGCCAGAGCTGGGAGGCATGGCCCTGGG

GTCCCACGAATTTGCTGGGGAATCTCGTTT

TTCTTCTTAAGACTTTTGGGACATGGTTTG

ACTCCCGAACATCACCGACGCGTCTCCTG

TGCCCCCACGAGGGTCAGGACTGTGACTC

TTGCCTTGCTGGACGGGGACTGGGGATGT

GGGAGGGAGCAGACAGGAGGAATCATGT

CAGGCCTGTGTGTGAAAGGAAGCTCCACT

GTCACCCTCCACCTCTTCACCCCCCACTCA

CCAGTGTCCCCTCCACTGTCACATTGTAAC

TGAACTTCAGGATAATAAAGTGTTTGCCT

CCATGGTCTTTGAATAAAGCCTGAGTAGG

AAGGCGGCCGCTCGAGCATGCATCTAGA

ACTCAATCTAAATTAAAAAAGAAAGAAAT

TTGAAAAAACTTTCTCTTTGCCATTTCTTC

TTCTTCTTTTTTAACTGAAAGCTGAATCCT